id	sid	tid	token	lemma	pos
cord-034340-3ksfpaf7	1	1	key	key	JJ
cord-034340-3ksfpaf7	1	2	:	:	:
cord-034340-3ksfpaf7	1	3	cord-034340	cord-034340	NN
cord-034340-3ksfpaf7	1	4	-	-	HYPH
cord-034340-3ksfpaf7	1	5	3ksfpaf7	3ksfpaf7	CD
cord-034340-3ksfpaf7	1	6	authors	author	NNS
cord-034340-3ksfpaf7	1	7	:	:	:
cord-034340-3ksfpaf7	2	1	nan	nan	NNP
cord-034340-3ksfpaf7	2	2	title	title	NN
cord-034340-3ksfpaf7	2	3	:	:	:
cord-034340-3ksfpaf7	2	4	Proceedings	proceeding	NNS
cord-034340-3ksfpaf7	2	5	of	of	IN
cord-034340-3ksfpaf7	2	6	the	the	DT
cord-034340-3ksfpaf7	2	7	26th	26th	JJ
cord-034340-3ksfpaf7	2	8	European	European	NNP
cord-034340-3ksfpaf7	2	9	Paediatric	Paediatric	NNP
cord-034340-3ksfpaf7	2	10	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	2	11	Congress	Congress	NNP
cord-034340-3ksfpaf7	2	12	:	:	:
cord-034340-3ksfpaf7	2	13	part	part	NN
cord-034340-3ksfpaf7	2	14	2	2	CD
cord-034340-3ksfpaf7	2	15	:	:	:
cord-034340-3ksfpaf7	2	16	Virtual	virtual	JJ
cord-034340-3ksfpaf7	2	17	.	.	.
cord-034340-3ksfpaf7	3	1	23	23	CD
cord-034340-3ksfpaf7	3	2	-	-	SYM
cord-034340-3ksfpaf7	3	3	26	26	CD
cord-034340-3ksfpaf7	3	4	September	September	NNP
cord-034340-3ksfpaf7	3	5	2020	2020	CD
cord-034340-3ksfpaf7	3	6	date	date	NN
cord-034340-3ksfpaf7	3	7	:	:	:
cord-034340-3ksfpaf7	3	8	2020	2020	CD
cord-034340-3ksfpaf7	3	9	-	-	SYM
cord-034340-3ksfpaf7	3	10	10	10	CD
cord-034340-3ksfpaf7	3	11	-	-	SYM
cord-034340-3ksfpaf7	3	12	28	28	CD
cord-034340-3ksfpaf7	3	13	journal	journal	NN
cord-034340-3ksfpaf7	3	14	:	:	:
cord-034340-3ksfpaf7	3	15	Pediatr	Pediatr	NNP
cord-034340-3ksfpaf7	3	16	Rheumatol	Rheumatol	NNP
cord-034340-3ksfpaf7	3	17	Online	Online	NNP
cord-034340-3ksfpaf7	3	18	J	J	NNP
cord-034340-3ksfpaf7	3	19	DOI	DOI	NNP
cord-034340-3ksfpaf7	3	20	:	:	:
cord-034340-3ksfpaf7	3	21	10.1186	10.1186	CD
cord-034340-3ksfpaf7	3	22	/	/	SYM
cord-034340-3ksfpaf7	3	23	s12969	s12969	NN
cord-034340-3ksfpaf7	3	24	-	-	HYPH
cord-034340-3ksfpaf7	3	25	020	020	CD
cord-034340-3ksfpaf7	3	26	-	-	HYPH
cord-034340-3ksfpaf7	3	27	00470	00470	CD
cord-034340-3ksfpaf7	3	28	-	-	SYM
cord-034340-3ksfpaf7	3	29	5	5	CD
cord-034340-3ksfpaf7	3	30	sha	sha	NN
cord-034340-3ksfpaf7	3	31	:	:	:
cord-034340-3ksfpaf7	3	32	2d0593befc72adc8d1988d31c4363322ed4faa93	2d0593befc72adc8d1988d31c4363322ed4faa93	NNP
cord-034340-3ksfpaf7	3	33	doc_id	doc_id	CD
cord-034340-3ksfpaf7	3	34	:	:	:
cord-034340-3ksfpaf7	3	35	34340	34340	CD
cord-034340-3ksfpaf7	3	36	cord_uid	cord_uid	NNS
cord-034340-3ksfpaf7	3	37	:	:	:
cord-034340-3ksfpaf7	3	38	3ksfpaf7	3ksfpaf7	CD
cord-034340-3ksfpaf7	3	39	nan	nan	NNP
cord-034340-3ksfpaf7	3	40	Introduction	introduction	NN
cord-034340-3ksfpaf7	3	41	:	:	:
cord-034340-3ksfpaf7	4	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	4	2	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	4	3	arthritis	arthritis	NN
cord-034340-3ksfpaf7	4	4	(	(	-LRB-
cord-034340-3ksfpaf7	4	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	4	6	)	)	-RRB-
cord-034340-3ksfpaf7	4	7	represents	represent	VBZ
cord-034340-3ksfpaf7	4	8	the	the	DT
cord-034340-3ksfpaf7	4	9	most	most	RBS
cord-034340-3ksfpaf7	4	10	common	common	JJ
cord-034340-3ksfpaf7	4	11	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	4	12	chronic	chronic	JJ
cord-034340-3ksfpaf7	4	13	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	4	14	disease	disease	NN
cord-034340-3ksfpaf7	4	15	.	.	.
cord-034340-3ksfpaf7	5	1	Children	child	NNS
cord-034340-3ksfpaf7	5	2	with	with	IN
cord-034340-3ksfpaf7	5	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	5	4	present	present	VBP
cord-034340-3ksfpaf7	5	5	an	an	DT
cord-034340-3ksfpaf7	5	6	increased	increase	VBN
cord-034340-3ksfpaf7	5	7	risk	risk	NN
cord-034340-3ksfpaf7	5	8	of	of	IN
cord-034340-3ksfpaf7	5	9	infections	infection	NNS
cord-034340-3ksfpaf7	5	10	,	,	,
cord-034340-3ksfpaf7	5	11	due	due	IN
cord-034340-3ksfpaf7	5	12	to	to	IN
cord-034340-3ksfpaf7	5	13	the	the	DT
cord-034340-3ksfpaf7	5	14	immune	immune	JJ
cord-034340-3ksfpaf7	5	15	-	-	HYPH
cord-034340-3ksfpaf7	5	16	regulatory	regulatory	JJ
cord-034340-3ksfpaf7	5	17	effects	effect	NNS
cord-034340-3ksfpaf7	5	18	of	of	IN
cord-034340-3ksfpaf7	5	19	disease	disease	NN
cord-034340-3ksfpaf7	5	20	modifying	modify	VBG
cord-034340-3ksfpaf7	5	21	antirheumatic	antirheumatic	JJ
cord-034340-3ksfpaf7	5	22	drugs	drug	NNS
cord-034340-3ksfpaf7	5	23	(	(	-LRB-
cord-034340-3ksfpaf7	5	24	DMARDs	dmard	NNS
cord-034340-3ksfpaf7	5	25	)	)	-RRB-
cord-034340-3ksfpaf7	5	26	;	;	:
cord-034340-3ksfpaf7	5	27	many	many	JJ
cord-034340-3ksfpaf7	5	28	of	of	IN
cord-034340-3ksfpaf7	5	29	these	these	DT
cord-034340-3ksfpaf7	5	30	infections	infection	NNS
cord-034340-3ksfpaf7	5	31	are	be	VBP
cord-034340-3ksfpaf7	5	32	vaccine	vaccine	NN
cord-034340-3ksfpaf7	5	33	-	-	HYPH
cord-034340-3ksfpaf7	5	34	preventable	preventable	JJ
cord-034340-3ksfpaf7	5	35	.	.	.
cord-034340-3ksfpaf7	6	1	Nevertheless	nevertheless	RB
cord-034340-3ksfpaf7	6	2	,	,	,
cord-034340-3ksfpaf7	6	3	suboptimal	suboptimal	JJ
cord-034340-3ksfpaf7	6	4	vaccinations	vaccination	NNS
cord-034340-3ksfpaf7	6	5	rates	rate	NNS
cord-034340-3ksfpaf7	6	6	are	be	VBP
cord-034340-3ksfpaf7	6	7	reported	report	VBN
cord-034340-3ksfpaf7	6	8	in	in	IN
cord-034340-3ksfpaf7	6	9	children	child	NNS
cord-034340-3ksfpaf7	6	10	with	with	IN
cord-034340-3ksfpaf7	6	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	6	12	.	.	.
cord-034340-3ksfpaf7	7	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	7	2	:	:	:
cord-034340-3ksfpaf7	7	3	To	to	TO
cord-034340-3ksfpaf7	7	4	evaluate	evaluate	VB
cord-034340-3ksfpaf7	7	5	vaccination	vaccination	NN
cord-034340-3ksfpaf7	7	6	coverage	coverage	NN
cord-034340-3ksfpaf7	7	7	in	in	IN
cord-034340-3ksfpaf7	7	8	a	a	DT
cord-034340-3ksfpaf7	7	9	population	population	NN
cord-034340-3ksfpaf7	7	10	of	of	IN
cord-034340-3ksfpaf7	7	11	children	child	NNS
cord-034340-3ksfpaf7	7	12	with	with	IN
cord-034340-3ksfpaf7	7	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	7	14	and	and	CC
cord-034340-3ksfpaf7	7	15	to	to	TO
cord-034340-3ksfpaf7	7	16	describe	describe	VB
cord-034340-3ksfpaf7	7	17	the	the	DT
cord-034340-3ksfpaf7	7	18	prevalence	prevalence	NN
cord-034340-3ksfpaf7	7	19	of	of	IN
cord-034340-3ksfpaf7	7	20	the	the	DT
cord-034340-3ksfpaf7	7	21	adverse	adverse	JJ
cord-034340-3ksfpaf7	7	22	events	event	NNS
cord-034340-3ksfpaf7	7	23	following	follow	VBG
cord-034340-3ksfpaf7	7	24	immunization	immunization	NN
cord-034340-3ksfpaf7	7	25	(	(	-LRB-
cord-034340-3ksfpaf7	7	26	AEFIs	aefi	NNS
cord-034340-3ksfpaf7	7	27	)	)	-RRB-
cord-034340-3ksfpaf7	7	28	in	in	IN
cord-034340-3ksfpaf7	7	29	our	-PRON-	PRP$
cord-034340-3ksfpaf7	7	30	cohort	cohort	NN
cord-034340-3ksfpaf7	7	31	.	.	.
cord-034340-3ksfpaf7	8	1	Methods	method	NNS
cord-034340-3ksfpaf7	8	2	:	:	:
cord-034340-3ksfpaf7	9	1	A	a	DT
cord-034340-3ksfpaf7	9	2	single	single	JJ
cord-034340-3ksfpaf7	9	3	-	-	HYPH
cord-034340-3ksfpaf7	9	4	centre	centre	NN
cord-034340-3ksfpaf7	9	5	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	9	6	study	study	NN
cord-034340-3ksfpaf7	9	7	was	be	VBD
cord-034340-3ksfpaf7	9	8	conducted	conduct	VBN
cord-034340-3ksfpaf7	9	9	by	by	IN
cord-034340-3ksfpaf7	9	10	reviewing	review	VBG
cord-034340-3ksfpaf7	9	11	medical	medical	JJ
cord-034340-3ksfpaf7	9	12	records	record	NNS
cord-034340-3ksfpaf7	9	13	of	of	IN
cord-034340-3ksfpaf7	9	14	all	all	DT
cord-034340-3ksfpaf7	9	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	9	16	patients	patient	NNS
cord-034340-3ksfpaf7	9	17	,	,	,
cord-034340-3ksfpaf7	9	18	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	9	19	according	accord	VBG
cord-034340-3ksfpaf7	9	20	to	to	IN
cord-034340-3ksfpaf7	9	21	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	9	22	criteria	criterion	NNS
cord-034340-3ksfpaf7	9	23	,	,	,
cord-034340-3ksfpaf7	9	24	admitted	admit	VBN
cord-034340-3ksfpaf7	9	25	to	to	IN
cord-034340-3ksfpaf7	9	26	the	the	DT
cord-034340-3ksfpaf7	9	27	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	9	28	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	9	29	Unit	Unit	NNP
cord-034340-3ksfpaf7	9	30	of	of	IN
cord-034340-3ksfpaf7	9	31	University	University	NNP
cord-034340-3ksfpaf7	9	32	of	of	IN
cord-034340-3ksfpaf7	9	33	Naples	Naples	NNP
cord-034340-3ksfpaf7	9	34	Federico	Federico	NNP
cord-034340-3ksfpaf7	9	35	II	II	NNP
cord-034340-3ksfpaf7	9	36	from	from	IN
cord-034340-3ksfpaf7	9	37	January	January	NNP
cord-034340-3ksfpaf7	9	38	to	to	IN
cord-034340-3ksfpaf7	9	39	December	December	NNP
cord-034340-3ksfpaf7	9	40	2019	2019	CD
cord-034340-3ksfpaf7	9	41	.	.	.
cord-034340-3ksfpaf7	10	1	Parents	parent	NNS
cord-034340-3ksfpaf7	10	2	were	be	VBD
cord-034340-3ksfpaf7	10	3	asked	ask	VBN
cord-034340-3ksfpaf7	10	4	to	to	TO
cord-034340-3ksfpaf7	10	5	provide	provide	VB
cord-034340-3ksfpaf7	10	6	the	the	DT
cord-034340-3ksfpaf7	10	7	vaccinations	vaccination	NNS
cord-034340-3ksfpaf7	10	8	records	record	NNS
cord-034340-3ksfpaf7	10	9	in	in	IN
cord-034340-3ksfpaf7	10	10	form	form	NN
cord-034340-3ksfpaf7	10	11	of	of	IN
cord-034340-3ksfpaf7	10	12	the	the	DT
cord-034340-3ksfpaf7	10	13	vaccination	vaccination	NN
cord-034340-3ksfpaf7	10	14	booklet	booklet	NN
cord-034340-3ksfpaf7	10	15	.	.	.
cord-034340-3ksfpaf7	11	1	The	the	DT
cord-034340-3ksfpaf7	11	2	occurrence	occurrence	NN
cord-034340-3ksfpaf7	11	3	of	of	IN
cord-034340-3ksfpaf7	11	4	AEFIs	aefi	NNS
cord-034340-3ksfpaf7	11	5	was	be	VBD
cord-034340-3ksfpaf7	11	6	explored	explore	VBN
cord-034340-3ksfpaf7	11	7	by	by	IN
cord-034340-3ksfpaf7	11	8	telephone	telephone	NN
cord-034340-3ksfpaf7	11	9	interviews	interview	NNS
cord-034340-3ksfpaf7	11	10	.	.	.
cord-034340-3ksfpaf7	12	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	12	2	:	:	:
cord-034340-3ksfpaf7	13	1	Intrarticular	Intrarticular	NNP
cord-034340-3ksfpaf7	13	2	corticosteroid	corticosteroid	NN
cord-034340-3ksfpaf7	13	3	injections	injection	NNS
cord-034340-3ksfpaf7	13	4	(	(	-LRB-
cord-034340-3ksfpaf7	13	5	IACI	IACI	NNP
cord-034340-3ksfpaf7	13	6	)	)	-RRB-
cord-034340-3ksfpaf7	13	7	are	be	VBP
cord-034340-3ksfpaf7	13	8	widely	widely	RB
cord-034340-3ksfpaf7	13	9	used	use	VBN
cord-034340-3ksfpaf7	13	10	in	in	IN
cord-034340-3ksfpaf7	13	11	the	the	DT
cord-034340-3ksfpaf7	13	12	management	management	NN
cord-034340-3ksfpaf7	13	13	of	of	IN
cord-034340-3ksfpaf7	13	14	patients	patient	NNS
cord-034340-3ksfpaf7	13	15	with	with	IN
cord-034340-3ksfpaf7	13	16	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	13	17	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	13	18	arthritis	arthritis	NN
cord-034340-3ksfpaf7	13	19	(	(	-LRB-
cord-034340-3ksfpaf7	13	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	13	21	)	)	-RRB-
cord-034340-3ksfpaf7	13	22	.	.	.
cord-034340-3ksfpaf7	14	1	General	general	JJ
cord-034340-3ksfpaf7	14	2	anesthesia	anesthesia	NN
cord-034340-3ksfpaf7	14	3	can	can	MD
cord-034340-3ksfpaf7	14	4	be	be	VB
cord-034340-3ksfpaf7	14	5	avoided	avoid	VBN
cord-034340-3ksfpaf7	14	6	in	in	IN
cord-034340-3ksfpaf7	14	7	case	case	NN
cord-034340-3ksfpaf7	14	8	of	of	IN
cord-034340-3ksfpaf7	14	9	a	a	DT
cord-034340-3ksfpaf7	14	10	small	small	JJ
cord-034340-3ksfpaf7	14	11	number	number	NN
cord-034340-3ksfpaf7	14	12	of	of	IN
cord-034340-3ksfpaf7	14	13	joints	joint	NNS
cord-034340-3ksfpaf7	14	14	to	to	TO
cord-034340-3ksfpaf7	14	15	inject	inject	VB
cord-034340-3ksfpaf7	14	16	or	or	CC
cord-034340-3ksfpaf7	14	17	in	in	IN
cord-034340-3ksfpaf7	14	18	older	old	JJR
cord-034340-3ksfpaf7	14	19	children	child	NNS
cord-034340-3ksfpaf7	14	20	.	.	.
cord-034340-3ksfpaf7	15	1	However	however	RB
cord-034340-3ksfpaf7	15	2	,	,	,
cord-034340-3ksfpaf7	15	3	pain	pain	NN
cord-034340-3ksfpaf7	15	4	and	and	CC
cord-034340-3ksfpaf7	15	5	anxiety	anxiety	NN
cord-034340-3ksfpaf7	15	6	may	may	MD
cord-034340-3ksfpaf7	15	7	reduce	reduce	VB
cord-034340-3ksfpaf7	15	8	the	the	DT
cord-034340-3ksfpaf7	15	9	patient	patient	JJ
cord-034340-3ksfpaf7	15	10	compliance	compliance	NN
cord-034340-3ksfpaf7	15	11	to	to	IN
cord-034340-3ksfpaf7	15	12	IACI	IACI	NNP
cord-034340-3ksfpaf7	15	13	,	,	,
cord-034340-3ksfpaf7	15	14	and	and	CC
cord-034340-3ksfpaf7	15	15	may	may	MD
cord-034340-3ksfpaf7	15	16	compromise	compromise	VB
cord-034340-3ksfpaf7	15	17	the	the	DT
cord-034340-3ksfpaf7	15	18	accuracy	accuracy	NN
cord-034340-3ksfpaf7	15	19	of	of	IN
cord-034340-3ksfpaf7	15	20	the	the	DT
cord-034340-3ksfpaf7	15	21	procedure	procedure	NN
cord-034340-3ksfpaf7	15	22	.	.	.
cord-034340-3ksfpaf7	16	1	In	in	IN
cord-034340-3ksfpaf7	16	2	order	order	NN
cord-034340-3ksfpaf7	16	3	to	to	TO
cord-034340-3ksfpaf7	16	4	overcame	overcome	VBD
cord-034340-3ksfpaf7	16	5	such	such	JJ
cord-034340-3ksfpaf7	16	6	problems	problem	NNS
cord-034340-3ksfpaf7	16	7	,	,	,
cord-034340-3ksfpaf7	16	8	the	the	DT
cord-034340-3ksfpaf7	16	9	use	use	NN
cord-034340-3ksfpaf7	16	10	of	of	IN
cord-034340-3ksfpaf7	16	11	appropriate	appropriate	JJ
cord-034340-3ksfpaf7	16	12	methods	method	NNS
cord-034340-3ksfpaf7	16	13	of	of	IN
cord-034340-3ksfpaf7	16	14	pain	pain	NN
cord-034340-3ksfpaf7	16	15	and	and	CC
cord-034340-3ksfpaf7	16	16	anxiety	anxiety	NN
cord-034340-3ksfpaf7	16	17	control	control	NN
cord-034340-3ksfpaf7	16	18	is	be	VBZ
cord-034340-3ksfpaf7	16	19	advisable	advisable	JJ
cord-034340-3ksfpaf7	16	20	.	.	.
cord-034340-3ksfpaf7	17	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	17	2	:	:	:
cord-034340-3ksfpaf7	17	3	To	to	TO
cord-034340-3ksfpaf7	17	4	assess	assess	VB
cord-034340-3ksfpaf7	17	5	the	the	DT
cord-034340-3ksfpaf7	17	6	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	17	7	and	and	CC
cord-034340-3ksfpaf7	17	8	satisfaction	satisfaction	NN
cord-034340-3ksfpaf7	17	9	of	of	IN
cord-034340-3ksfpaf7	17	10	patients	patient	NNS
cord-034340-3ksfpaf7	17	11	undergoing	undergo	VBG
cord-034340-3ksfpaf7	17	12	IACI	IACI	NNP
cord-034340-3ksfpaf7	17	13	with	with	IN
cord-034340-3ksfpaf7	17	14	the	the	DT
cord-034340-3ksfpaf7	17	15	use	use	NN
cord-034340-3ksfpaf7	17	16	of	of	IN
cord-034340-3ksfpaf7	17	17	topical	topical	JJ
cord-034340-3ksfpaf7	17	18	numbing	numb	VBG
cord-034340-3ksfpaf7	17	19	agent	agent	NN
cord-034340-3ksfpaf7	17	20	or	or	CC
cord-034340-3ksfpaf7	17	21	under	under	IN
cord-034340-3ksfpaf7	17	22	minimal	minimal	JJ
cord-034340-3ksfpaf7	17	23	sedation	sedation	NN
cord-034340-3ksfpaf7	17	24	.	.	.
cord-034340-3ksfpaf7	18	1	Methods	method	NNS
cord-034340-3ksfpaf7	18	2	:	:	:
cord-034340-3ksfpaf7	18	3	Patients	patient	NNS
cord-034340-3ksfpaf7	18	4	with	with	IN
cord-034340-3ksfpaf7	18	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	18	6	who	who	WP
cord-034340-3ksfpaf7	18	7	underwent	undergo	VBD
cord-034340-3ksfpaf7	18	8	an	an	DT
cord-034340-3ksfpaf7	18	9	IACI	IACI	NNP
cord-034340-3ksfpaf7	18	10	of	of	IN
cord-034340-3ksfpaf7	18	11	up	up	IN
cord-034340-3ksfpaf7	18	12	to	to	TO
cord-034340-3ksfpaf7	18	13	3	3	CD
cord-034340-3ksfpaf7	18	14	joints	joint	NNS
cord-034340-3ksfpaf7	18	15	were	be	VBD
cord-034340-3ksfpaf7	18	16	recruited	recruit	VBN
cord-034340-3ksfpaf7	18	17	.	.	.
cord-034340-3ksfpaf7	19	1	Depending	depend	VBG
cord-034340-3ksfpaf7	19	2	on	on	IN
cord-034340-3ksfpaf7	19	3	age	age	NN
cord-034340-3ksfpaf7	19	4	and	and	CC
cord-034340-3ksfpaf7	19	5	number	number	NN
cord-034340-3ksfpaf7	19	6	of	of	IN
cord-034340-3ksfpaf7	19	7	joints	joint	NNS
cord-034340-3ksfpaf7	19	8	to	to	TO
cord-034340-3ksfpaf7	19	9	treat	treat	VB
cord-034340-3ksfpaf7	19	10	,	,	,
cord-034340-3ksfpaf7	19	11	a	a	DT
cord-034340-3ksfpaf7	19	12	group	group	NN
cord-034340-3ksfpaf7	19	13	of	of	IN
cord-034340-3ksfpaf7	19	14	patients	patient	NNS
cord-034340-3ksfpaf7	19	15	(	(	-LRB-
cord-034340-3ksfpaf7	19	16	group	group	NN
cord-034340-3ksfpaf7	19	17	A	A	NNP
cord-034340-3ksfpaf7	19	18	)	)	-RRB-
cord-034340-3ksfpaf7	19	19	were	be	VBD
cord-034340-3ksfpaf7	19	20	injected	inject	VBN
cord-034340-3ksfpaf7	19	21	with	with	IN
cord-034340-3ksfpaf7	19	22	the	the	DT
cord-034340-3ksfpaf7	19	23	application	application	NN
cord-034340-3ksfpaf7	19	24	30	30	CD
cord-034340-3ksfpaf7	19	25	minutes	minute	NNS
cord-034340-3ksfpaf7	19	26	prior	prior	IN
cord-034340-3ksfpaf7	19	27	the	the	DT
cord-034340-3ksfpaf7	19	28	procedure	procedure	NN
cord-034340-3ksfpaf7	19	29	of	of	IN
cord-034340-3ksfpaf7	19	30	a	a	DT
cord-034340-3ksfpaf7	19	31	topical	topical	JJ
cord-034340-3ksfpaf7	19	32	numbing	numb	VBG
cord-034340-3ksfpaf7	19	33	agent	agent	NN
cord-034340-3ksfpaf7	19	34	(	(	-LRB-
cord-034340-3ksfpaf7	19	35	prilocaine+lidocaine	prilocaine+lidocaine	NNP
cord-034340-3ksfpaf7	19	36	)	)	-RRB-
cord-034340-3ksfpaf7	19	37	to	to	IN
cord-034340-3ksfpaf7	19	38	the	the	DT
cord-034340-3ksfpaf7	19	39	skin	skin	NN
cord-034340-3ksfpaf7	19	40	over	over	IN
cord-034340-3ksfpaf7	19	41	the	the	DT
cord-034340-3ksfpaf7	19	42	injection	injection	NN
cord-034340-3ksfpaf7	19	43	site	site	NN
cord-034340-3ksfpaf7	19	44	.	.	.
cord-034340-3ksfpaf7	20	1	Another	another	DT
cord-034340-3ksfpaf7	20	2	group	group	NN
cord-034340-3ksfpaf7	20	3	of	of	IN
cord-034340-3ksfpaf7	20	4	patients	patient	NNS
cord-034340-3ksfpaf7	20	5	(	(	-LRB-
cord-034340-3ksfpaf7	20	6	group	group	NN
cord-034340-3ksfpaf7	20	7	B	B	NNP
cord-034340-3ksfpaf7	20	8	)	)	-RRB-
cord-034340-3ksfpaf7	20	9	were	be	VBD
cord-034340-3ksfpaf7	20	10	treated	treat	VBN
cord-034340-3ksfpaf7	20	11	under	under	IN
cord-034340-3ksfpaf7	20	12	minimal	minimal	JJ
cord-034340-3ksfpaf7	20	13	sedation	sedation	NN
cord-034340-3ksfpaf7	20	14	(	(	-LRB-
cord-034340-3ksfpaf7	20	15	Ketorolac	Ketorolac	NNP
cord-034340-3ksfpaf7	20	16	/	/	SYM
cord-034340-3ksfpaf7	20	17	Tramadol	Tramadol	NNP
cord-034340-3ksfpaf7	20	18	or	or	CC
cord-034340-3ksfpaf7	20	19	Morphine	Morphine	NNP
cord-034340-3ksfpaf7	20	20	+	+	CC
cord-034340-3ksfpaf7	20	21	Midazolam	Midazolam	NNP
cord-034340-3ksfpaf7	20	22	)	)	-RRB-
cord-034340-3ksfpaf7	20	23	.	.	.
cord-034340-3ksfpaf7	21	1	The	the	DT
cord-034340-3ksfpaf7	21	2	physician	physician	NN
cord-034340-3ksfpaf7	21	3	was	be	VBD
cord-034340-3ksfpaf7	21	4	asked	ask	VBN
cord-034340-3ksfpaf7	21	5	to	to	TO
cord-034340-3ksfpaf7	21	6	record	record	VB
cord-034340-3ksfpaf7	21	7	the	the	DT
cord-034340-3ksfpaf7	21	8	degree	degree	NN
cord-034340-3ksfpaf7	21	9	of	of	IN
cord-034340-3ksfpaf7	21	10	motion	motion	NN
cord-034340-3ksfpaf7	21	11	and	and	CC
cord-034340-3ksfpaf7	21	12	pain	pain	NN
cord-034340-3ksfpaf7	21	13	of	of	IN
cord-034340-3ksfpaf7	21	14	the	the	DT
cord-034340-3ksfpaf7	21	15	patient	patient	NN
cord-034340-3ksfpaf7	21	16	during	during	IN
cord-034340-3ksfpaf7	21	17	the	the	DT
cord-034340-3ksfpaf7	21	18	procedure	procedure	NN
cord-034340-3ksfpaf7	21	19	and	and	CC
cord-034340-3ksfpaf7	21	20	the	the	DT
cord-034340-3ksfpaf7	21	21	patient	patient	NN
cord-034340-3ksfpaf7	21	22	(	(	-LRB-
cord-034340-3ksfpaf7	21	23	or	or	CC
cord-034340-3ksfpaf7	21	24	parents	parent	NNS
cord-034340-3ksfpaf7	21	25	for	for	IN
cord-034340-3ksfpaf7	21	26	patients	patient	NNS
cord-034340-3ksfpaf7	21	27	aged	age	VBN
cord-034340-3ksfpaf7	21	28	less	less	JJR
cord-034340-3ksfpaf7	21	29	than	than	IN
cord-034340-3ksfpaf7	21	30	4	4	CD
cord-034340-3ksfpaf7	21	31	years	year	NNS
cord-034340-3ksfpaf7	21	32	)	)	-RRB-
cord-034340-3ksfpaf7	21	33	was	be	VBD
cord-034340-3ksfpaf7	21	34	asked	ask	VBN
cord-034340-3ksfpaf7	21	35	to	to	TO
cord-034340-3ksfpaf7	21	36	report	report	VB
cord-034340-3ksfpaf7	21	37	the	the	DT
cord-034340-3ksfpaf7	21	38	degree	degree	NN
cord-034340-3ksfpaf7	21	39	of	of	IN
cord-034340-3ksfpaf7	21	40	pain	pain	NN
cord-034340-3ksfpaf7	21	41	and	and	CC
cord-034340-3ksfpaf7	21	42	satisfaction	satisfaction	NN
cord-034340-3ksfpaf7	21	43	on	on	IN
cord-034340-3ksfpaf7	21	44	a	a	DT
cord-034340-3ksfpaf7	21	45	Visual	visual	JJ
cord-034340-3ksfpaf7	21	46	Analogue	analogue	NN
cord-034340-3ksfpaf7	21	47	Scale	scale	NN
cord-034340-3ksfpaf7	21	48	(	(	-LRB-
cord-034340-3ksfpaf7	21	49	VAS	VAS	NNP
cord-034340-3ksfpaf7	21	50	)	)	-RRB-
cord-034340-3ksfpaf7	21	51	from	from	IN
cord-034340-3ksfpaf7	21	52	0	0	CD
cord-034340-3ksfpaf7	21	53	to	to	IN
cord-034340-3ksfpaf7	21	54	10	10	CD
cord-034340-3ksfpaf7	21	55	.	.	.
cord-034340-3ksfpaf7	22	1	Results	result	NNS
cord-034340-3ksfpaf7	22	2	:	:	:
cord-034340-3ksfpaf7	23	1	Twenty	twenty	CD
cord-034340-3ksfpaf7	23	2	-	-	HYPH
cord-034340-3ksfpaf7	23	3	seven	seven	CD
cord-034340-3ksfpaf7	23	4	patients	patient	NNS
cord-034340-3ksfpaf7	23	5	were	be	VBD
cord-034340-3ksfpaf7	23	6	enrolled	enrol	VBN
cord-034340-3ksfpaf7	23	7	for	for	IN
cord-034340-3ksfpaf7	23	8	a	a	DT
cord-034340-3ksfpaf7	23	9	total	total	NN
cord-034340-3ksfpaf7	23	10	of	of	IN
cord-034340-3ksfpaf7	23	11	30	30	CD
cord-034340-3ksfpaf7	23	12	procedures	procedure	NNS
cord-034340-3ksfpaf7	23	13	,	,	,
cord-034340-3ksfpaf7	23	14	17	17	CD
cord-034340-3ksfpaf7	23	15	and	and	CC
cord-034340-3ksfpaf7	23	16	13	13	CD
cord-034340-3ksfpaf7	23	17	of	of	IN
cord-034340-3ksfpaf7	23	18	them	-PRON-	PRP
cord-034340-3ksfpaf7	23	19	in	in	IN
cord-034340-3ksfpaf7	23	20	group	group	NN
cord-034340-3ksfpaf7	23	21	A	A	NNP
cord-034340-3ksfpaf7	23	22	and	and	CC
cord-034340-3ksfpaf7	23	23	B	b	NN
cord-034340-3ksfpaf7	23	24	,	,	,
cord-034340-3ksfpaf7	23	25	respectively	respectively	RB
cord-034340-3ksfpaf7	23	26	.	.	.
cord-034340-3ksfpaf7	24	1	The	the	DT
cord-034340-3ksfpaf7	24	2	median	median	JJ
cord-034340-3ksfpaf7	24	3	age	age	NN
cord-034340-3ksfpaf7	24	4	at	at	IN
cord-034340-3ksfpaf7	24	5	the	the	DT
cord-034340-3ksfpaf7	24	6	procedure	procedure	NN
cord-034340-3ksfpaf7	24	7	was	be	VBD
cord-034340-3ksfpaf7	24	8	10	10	CD
cord-034340-3ksfpaf7	24	9	years	year	NNS
cord-034340-3ksfpaf7	24	10	for	for	IN
cord-034340-3ksfpaf7	24	11	group	group	NN
cord-034340-3ksfpaf7	24	12	A	a	NN
cord-034340-3ksfpaf7	24	13	and	and	CC
cord-034340-3ksfpaf7	24	14	11	11	CD
cord-034340-3ksfpaf7	24	15	years	year	NNS
cord-034340-3ksfpaf7	24	16	for	for	IN
cord-034340-3ksfpaf7	24	17	group	group	NN
cord-034340-3ksfpaf7	24	18	B.	B.	NNP
cord-034340-3ksfpaf7	24	19	For	for	IN
cord-034340-3ksfpaf7	24	20	group	group	NN
cord-034340-3ksfpaf7	25	1	A	a	DT
cord-034340-3ksfpaf7	25	2	median	median	JJ
cord-034340-3ksfpaf7	25	3	pain	pain	NN
cord-034340-3ksfpaf7	25	4	scores	score	NNS
cord-034340-3ksfpaf7	25	5	for	for	IN
cord-034340-3ksfpaf7	25	6	patients	patient	NNS
cord-034340-3ksfpaf7	25	7	,	,	,
cord-034340-3ksfpaf7	25	8	parents	parent	NNS
cord-034340-3ksfpaf7	25	9	and	and	CC
cord-034340-3ksfpaf7	25	10	physicians	physician	NNS
cord-034340-3ksfpaf7	25	11	were	be	VBD
cord-034340-3ksfpaf7	25	12	2	2	CD
cord-034340-3ksfpaf7	25	13	,	,	,
cord-034340-3ksfpaf7	25	14	2	2	CD
cord-034340-3ksfpaf7	25	15	and	and	CC
cord-034340-3ksfpaf7	25	16	1.5	1.5	CD
cord-034340-3ksfpaf7	25	17	,	,	,
cord-034340-3ksfpaf7	25	18	respectively	respectively	RB
cord-034340-3ksfpaf7	25	19	.	.	.
cord-034340-3ksfpaf7	26	1	In	in	IN
cord-034340-3ksfpaf7	26	2	patients	patient	NNS
cord-034340-3ksfpaf7	26	3	of	of	IN
cord-034340-3ksfpaf7	26	4	group	group	NN
cord-034340-3ksfpaf7	26	5	B	B	NNP
cord-034340-3ksfpaf7	26	6	who	who	WP
cord-034340-3ksfpaf7	26	7	underwent	undergo	VBD
cord-034340-3ksfpaf7	26	8	the	the	DT
cord-034340-3ksfpaf7	26	9	IACI	IACI	NNP
cord-034340-3ksfpaf7	26	10	under	under	IN
cord-034340-3ksfpaf7	26	11	Ketorolac	Ketorolac	NNP
cord-034340-3ksfpaf7	26	12	/	/	SYM
cord-034340-3ksfpaf7	26	13	Tramadol	Tramadol	NNP
cord-034340-3ksfpaf7	26	14	the	the	DT
cord-034340-3ksfpaf7	26	15	median	median	JJ
cord-034340-3ksfpaf7	26	16	pain	pain	NN
cord-034340-3ksfpaf7	26	17	scores	score	NNS
cord-034340-3ksfpaf7	26	18	for	for	IN
cord-034340-3ksfpaf7	26	19	patients	patient	NNS
cord-034340-3ksfpaf7	26	20	,	,	,
cord-034340-3ksfpaf7	26	21	parents	parent	NNS
cord-034340-3ksfpaf7	26	22	and	and	CC
cord-034340-3ksfpaf7	26	23	physicians	physician	NNS
cord-034340-3ksfpaf7	26	24	were	be	VBD
cord-034340-3ksfpaf7	26	25	3	3	CD
cord-034340-3ksfpaf7	26	26	,	,	,
cord-034340-3ksfpaf7	26	27	5.25	5.25	CD
cord-034340-3ksfpaf7	26	28	and	and	CC
cord-034340-3ksfpaf7	26	29	2.5	2.5	CD
cord-034340-3ksfpaf7	26	30	,	,	,
cord-034340-3ksfpaf7	26	31	whereas	whereas	IN
cord-034340-3ksfpaf7	26	32	in	in	IN
cord-034340-3ksfpaf7	26	33	patients	patient	NNS
cord-034340-3ksfpaf7	26	34	treated	treat	VBN
cord-034340-3ksfpaf7	26	35	with	with	IN
cord-034340-3ksfpaf7	26	36	Morphine	Morphine	NNP
cord-034340-3ksfpaf7	26	37	median	median	JJ
cord-034340-3ksfpaf7	26	38	pain	pain	NN
cord-034340-3ksfpaf7	26	39	scores	score	NNS
cord-034340-3ksfpaf7	26	40	were	be	VBD
cord-034340-3ksfpaf7	26	41	6	6	CD
cord-034340-3ksfpaf7	26	42	,	,	,
cord-034340-3ksfpaf7	26	43	6	6	CD
cord-034340-3ksfpaf7	26	44	and	and	CC
cord-034340-3ksfpaf7	26	45	2	2	CD
cord-034340-3ksfpaf7	26	46	,	,	,
cord-034340-3ksfpaf7	26	47	respectively	respectively	RB
cord-034340-3ksfpaf7	26	48	.	.	.
cord-034340-3ksfpaf7	27	1	Overall	overall	RB
cord-034340-3ksfpaf7	27	2	,	,	,
cord-034340-3ksfpaf7	27	3	we	-PRON-	PRP
cord-034340-3ksfpaf7	27	4	found	find	VBD
cord-034340-3ksfpaf7	27	5	that	that	DT
cord-034340-3ksfpaf7	27	6	pain	pain	NN
cord-034340-3ksfpaf7	27	7	as	as	IN
cord-034340-3ksfpaf7	27	8	reported	report	VBN
cord-034340-3ksfpaf7	27	9	by	by	IN
cord-034340-3ksfpaf7	27	10	the	the	DT
cord-034340-3ksfpaf7	27	11	patient	patient	NN
cord-034340-3ksfpaf7	27	12	/	/	SYM
cord-034340-3ksfpaf7	27	13	parent	parent	NN
cord-034340-3ksfpaf7	27	14	were	be	VBD
cord-034340-3ksfpaf7	27	15	higher	high	JJR
cord-034340-3ksfpaf7	27	16	with	with	IN
cord-034340-3ksfpaf7	27	17	increase	increase	NN
cord-034340-3ksfpaf7	27	18	in	in	IN
cord-034340-3ksfpaf7	27	19	the	the	DT
cord-034340-3ksfpaf7	27	20	number	number	NN
cord-034340-3ksfpaf7	27	21	of	of	IN
cord-034340-3ksfpaf7	27	22	sites	site	NNS
cord-034340-3ksfpaf7	27	23	injected	inject	VBN
cord-034340-3ksfpaf7	27	24	(	(	-LRB-
cord-034340-3ksfpaf7	27	25	and	and	CC
cord-034340-3ksfpaf7	27	26	,	,	,
cord-034340-3ksfpaf7	27	27	consequently	consequently	RB
cord-034340-3ksfpaf7	27	28	,	,	,
cord-034340-3ksfpaf7	27	29	duration	duration	NN
cord-034340-3ksfpaf7	27	30	of	of	IN
cord-034340-3ksfpaf7	27	31	procedure	procedure	NN
cord-034340-3ksfpaf7	27	32	)	)	-RRB-
cord-034340-3ksfpaf7	27	33	and	and	CC
cord-034340-3ksfpaf7	27	34	age	age	NN
cord-034340-3ksfpaf7	27	35	of	of	IN
cord-034340-3ksfpaf7	27	36	patient	patient	NN
cord-034340-3ksfpaf7	27	37	.	.	.
cord-034340-3ksfpaf7	28	1	Amount	amount	NN
cord-034340-3ksfpaf7	28	2	of	of	IN
cord-034340-3ksfpaf7	28	3	motion	motion	NN
cord-034340-3ksfpaf7	28	4	during	during	IN
cord-034340-3ksfpaf7	28	5	procedures	procedure	NNS
cord-034340-3ksfpaf7	28	6	was	be	VBD
cord-034340-3ksfpaf7	28	7	overall	overall	RB
cord-034340-3ksfpaf7	28	8	negligible	negligible	JJ
cord-034340-3ksfpaf7	28	9	.	.	.
cord-034340-3ksfpaf7	29	1	The	the	DT
cord-034340-3ksfpaf7	29	2	majority	majority	NN
cord-034340-3ksfpaf7	29	3	of	of	IN
cord-034340-3ksfpaf7	29	4	patients	patient	NNS
cord-034340-3ksfpaf7	29	5	/	/	SYM
cord-034340-3ksfpaf7	29	6	parents	parent	NNS
cord-034340-3ksfpaf7	29	7	was	be	VBD
cord-034340-3ksfpaf7	29	8	satisfied	satisfied	JJ
cord-034340-3ksfpaf7	29	9	for	for	IN
cord-034340-3ksfpaf7	29	10	the	the	DT
cord-034340-3ksfpaf7	29	11	procedures	procedure	NNS
cord-034340-3ksfpaf7	29	12	.	.	.
cord-034340-3ksfpaf7	30	1	Only	only	RB
cord-034340-3ksfpaf7	30	2	2	2	CD
cord-034340-3ksfpaf7	30	3	patients	patient	NNS
cord-034340-3ksfpaf7	30	4	treated	treat	VBN
cord-034340-3ksfpaf7	30	5	with	with	IN
cord-034340-3ksfpaf7	30	6	Midazolam	Midazolam	NNP
cord-034340-3ksfpaf7	30	7	had	have	VBD
cord-034340-3ksfpaf7	30	8	psychomotor	psychomotor	JJ
cord-034340-3ksfpaf7	30	9	agitation	agitation	NN
cord-034340-3ksfpaf7	30	10	during	during	IN
cord-034340-3ksfpaf7	30	11	the	the	DT
cord-034340-3ksfpaf7	30	12	IACI	IACI	NNP
cord-034340-3ksfpaf7	30	13	.	.	.
cord-034340-3ksfpaf7	31	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	31	2	:	:	:
cord-034340-3ksfpaf7	31	3	IACI	IACI	NNP
cord-034340-3ksfpaf7	31	4	in	in	IN
cord-034340-3ksfpaf7	31	5	a	a	DT
cord-034340-3ksfpaf7	31	6	small	small	JJ
cord-034340-3ksfpaf7	31	7	number	number	NN
cord-034340-3ksfpaf7	31	8	of	of	IN
cord-034340-3ksfpaf7	31	9	sites	site	NNS
cord-034340-3ksfpaf7	31	10	without	without	IN
cord-034340-3ksfpaf7	31	11	the	the	DT
cord-034340-3ksfpaf7	31	12	use	use	NN
cord-034340-3ksfpaf7	31	13	of	of	IN
cord-034340-3ksfpaf7	31	14	general	general	JJ
cord-034340-3ksfpaf7	31	15	anesthesia	anesthesia	NN
cord-034340-3ksfpaf7	31	16	is	be	VBZ
cord-034340-3ksfpaf7	31	17	well	well	RB
cord-034340-3ksfpaf7	31	18	tolerated	tolerate	VBN
cord-034340-3ksfpaf7	31	19	by	by	IN
cord-034340-3ksfpaf7	31	20	patients	patient	NNS
cord-034340-3ksfpaf7	31	21	.	.	.
cord-034340-3ksfpaf7	32	1	The	the	DT
cord-034340-3ksfpaf7	32	2	level	level	NN
cord-034340-3ksfpaf7	32	3	of	of	IN
cord-034340-3ksfpaf7	32	4	pain	pain	NN
cord-034340-3ksfpaf7	32	5	perceived	perceive	VBN
cord-034340-3ksfpaf7	32	6	from	from	IN
cord-034340-3ksfpaf7	32	7	patients	patient	NNS
cord-034340-3ksfpaf7	32	8	is	be	VBZ
cord-034340-3ksfpaf7	32	9	irrespective	irrespective	JJ
cord-034340-3ksfpaf7	32	10	of	of	IN
cord-034340-3ksfpaf7	32	11	the	the	DT
cord-034340-3ksfpaf7	32	12	power	power	NN
cord-034340-3ksfpaf7	32	13	of	of	IN
cord-034340-3ksfpaf7	32	14	the	the	DT
cord-034340-3ksfpaf7	32	15	painkiller	painkiller	NN
cord-034340-3ksfpaf7	32	16	used	use	VBN
cord-034340-3ksfpaf7	32	17	,	,	,
cord-034340-3ksfpaf7	32	18	but	but	CC
cord-034340-3ksfpaf7	32	19	seems	seem	VBZ
cord-034340-3ksfpaf7	32	20	to	to	TO
cord-034340-3ksfpaf7	32	21	correlate	correlate	VB
cord-034340-3ksfpaf7	32	22	with	with	IN
cord-034340-3ksfpaf7	32	23	the	the	DT
cord-034340-3ksfpaf7	32	24	duration	duration	NN
cord-034340-3ksfpaf7	32	25	of	of	IN
cord-034340-3ksfpaf7	32	26	the	the	DT
cord-034340-3ksfpaf7	32	27	procedures	procedure	NNS
cord-034340-3ksfpaf7	32	28	.	.	.
cord-034340-3ksfpaf7	33	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	33	2	is	be	VBZ
cord-034340-3ksfpaf7	33	3	possible	possible	JJ
cord-034340-3ksfpaf7	33	4	that	that	IN
cord-034340-3ksfpaf7	33	5	,	,	,
cord-034340-3ksfpaf7	33	6	in	in	IN
cord-034340-3ksfpaf7	33	7	the	the	DT
cord-034340-3ksfpaf7	33	8	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	33	9	age	age	NN
cord-034340-3ksfpaf7	33	10	,	,	,
cord-034340-3ksfpaf7	33	11	the	the	DT
cord-034340-3ksfpaf7	33	12	psychoemotional	psychoemotional	JJ
cord-034340-3ksfpaf7	33	13	component	component	NN
cord-034340-3ksfpaf7	33	14	seems	seem	VBZ
cord-034340-3ksfpaf7	33	15	to	to	TO
cord-034340-3ksfpaf7	33	16	be	be	VB
cord-034340-3ksfpaf7	33	17	decisive	decisive	JJ
cord-034340-3ksfpaf7	33	18	,	,	,
cord-034340-3ksfpaf7	33	19	with	with	IN
cord-034340-3ksfpaf7	33	20	a	a	DT
cord-034340-3ksfpaf7	33	21	progressive	progressive	JJ
cord-034340-3ksfpaf7	33	22	loss	loss	NN
cord-034340-3ksfpaf7	33	23	of	of	IN
cord-034340-3ksfpaf7	33	24	tolerance	tolerance	NN
cord-034340-3ksfpaf7	33	25	with	with	IN
cord-034340-3ksfpaf7	33	26	the	the	DT
cord-034340-3ksfpaf7	33	27	increase	increase	NN
cord-034340-3ksfpaf7	33	28	in	in	IN
cord-034340-3ksfpaf7	33	29	the	the	DT
cord-034340-3ksfpaf7	33	30	number	number	NN
cord-034340-3ksfpaf7	33	31	of	of	IN
cord-034340-3ksfpaf7	33	32	injected	inject	VBN
cord-034340-3ksfpaf7	33	33	joints	joint	NNS
cord-034340-3ksfpaf7	33	34	.	.	.
cord-034340-3ksfpaf7	34	1	for	for	IN
cord-034340-3ksfpaf7	34	2	GC	GC	NNP
cord-034340-3ksfpaf7	34	3	-	-	HYPH
cord-034340-3ksfpaf7	34	4	MS	MS	NNP
cord-034340-3ksfpaf7	34	5	analysis	analysis	NN
cord-034340-3ksfpaf7	34	6	of	of	IN
cord-034340-3ksfpaf7	34	7	the	the	DT
cord-034340-3ksfpaf7	34	8	steroid	steroid	NN
cord-034340-3ksfpaf7	34	9	hormone	hormone	NN
cord-034340-3ksfpaf7	34	10	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	34	11	age	age	NN
cord-034340-3ksfpaf7	34	12	and	and	CC
cord-034340-3ksfpaf7	34	13	sexmatched	sexmatche	VBN
cord-034340-3ksfpaf7	34	14	healthy	healthy	JJ
cord-034340-3ksfpaf7	34	15	controls	control	NNS
cord-034340-3ksfpaf7	34	16	were	be	VBD
cord-034340-3ksfpaf7	34	17	matched	match	VBN
cord-034340-3ksfpaf7	34	18	to	to	IN
cord-034340-3ksfpaf7	34	19	each	each	DT
cord-034340-3ksfpaf7	34	20	patient	patient	NN
cord-034340-3ksfpaf7	34	21	.	.	.
cord-034340-3ksfpaf7	35	1	Patients	patient	NNS
cord-034340-3ksfpaf7	35	2	were	be	VBD
cord-034340-3ksfpaf7	35	3	excluded	exclude	VBN
cord-034340-3ksfpaf7	35	4	if	if	IN
cord-034340-3ksfpaf7	35	5	they	-PRON-	PRP
cord-034340-3ksfpaf7	35	6	were	be	VBD
cord-034340-3ksfpaf7	35	7	treated	treat	VBN
cord-034340-3ksfpaf7	35	8	with	with	IN
cord-034340-3ksfpaf7	35	9	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	35	10	in	in	IN
cord-034340-3ksfpaf7	35	11	the	the	DT
cord-034340-3ksfpaf7	35	12	preceding	precede	VBG
cord-034340-3ksfpaf7	35	13	3	3	CD
cord-034340-3ksfpaf7	35	14	months	month	NNS
cord-034340-3ksfpaf7	35	15	.	.	.
cord-034340-3ksfpaf7	36	1	Results	result	NNS
cord-034340-3ksfpaf7	36	2	:	:	:
cord-034340-3ksfpaf7	37	1	Of	of	IN
cord-034340-3ksfpaf7	37	2	the	the	DT
cord-034340-3ksfpaf7	37	3	35	35	CD
cord-034340-3ksfpaf7	37	4	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	37	5	measured	measure	VBN
cord-034340-3ksfpaf7	37	6	,	,	,
cord-034340-3ksfpaf7	37	7	23	23	CD
cord-034340-3ksfpaf7	37	8	were	be	VBD
cord-034340-3ksfpaf7	37	9	significantly	significantly	RB
cord-034340-3ksfpaf7	37	10	lower	low	JJR
cord-034340-3ksfpaf7	37	11	in	in	IN
cord-034340-3ksfpaf7	37	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	37	13	patients	patient	NNS
cord-034340-3ksfpaf7	37	14	before	before	IN
cord-034340-3ksfpaf7	37	15	the	the	DT
cord-034340-3ksfpaf7	37	16	Etanercept	Etanercept	NNP
cord-034340-3ksfpaf7	37	17	treatment	treatment	NN
cord-034340-3ksfpaf7	37	18	compared	compare	VBN
cord-034340-3ksfpaf7	37	19	to	to	IN
cord-034340-3ksfpaf7	37	20	the	the	DT
cord-034340-3ksfpaf7	37	21	healthy	healthy	JJ
cord-034340-3ksfpaf7	37	22	control	control	NN
cord-034340-3ksfpaf7	37	23	group	group	NN
cord-034340-3ksfpaf7	37	24	.	.	.
cord-034340-3ksfpaf7	38	1	One	one	CD
cord-034340-3ksfpaf7	38	2	day	day	NN
cord-034340-3ksfpaf7	38	3	after	after	IN
cord-034340-3ksfpaf7	38	4	the	the	DT
cord-034340-3ksfpaf7	38	5	injection	injection	NN
cord-034340-3ksfpaf7	38	6	only	only	RB
cord-034340-3ksfpaf7	38	7	5	5	CD
cord-034340-3ksfpaf7	38	8	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	38	9	were	be	VBD
cord-034340-3ksfpaf7	38	10	still	still	RB
cord-034340-3ksfpaf7	38	11	significantly	significantly	RB
cord-034340-3ksfpaf7	38	12	lower	low	JJR
cord-034340-3ksfpaf7	38	13	in	in	IN
cord-034340-3ksfpaf7	38	14	the	the	DT
cord-034340-3ksfpaf7	38	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	38	16	patients	patient	NNS
cord-034340-3ksfpaf7	38	17	and	and	CC
cord-034340-3ksfpaf7	38	18	all	all	PDT
cord-034340-3ksfpaf7	38	19	the	the	DT
cord-034340-3ksfpaf7	38	20	other	other	JJ
cord-034340-3ksfpaf7	38	21	30	30	CD
cord-034340-3ksfpaf7	38	22	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	38	23	normalized	normalize	VBN
cord-034340-3ksfpaf7	38	24	and	and	CC
cord-034340-3ksfpaf7	38	25	were	be	VBD
cord-034340-3ksfpaf7	38	26	similar	similar	JJ
cord-034340-3ksfpaf7	38	27	to	to	IN
cord-034340-3ksfpaf7	38	28	the	the	DT
cord-034340-3ksfpaf7	38	29	control	control	NN
cord-034340-3ksfpaf7	38	30	group	group	NN
cord-034340-3ksfpaf7	38	31	.	.	.
cord-034340-3ksfpaf7	39	1	Urine	urine	NN
cord-034340-3ksfpaf7	39	2	metabolite	metabolite	NN
cord-034340-3ksfpaf7	39	3	ratios	ratio	NNS
cord-034340-3ksfpaf7	39	4	reflecting	reflect	VBG
cord-034340-3ksfpaf7	39	5	CYP21	CYP21	NNP
cord-034340-3ksfpaf7	39	6	and	and	CC
cord-034340-3ksfpaf7	39	7	11β	11β	NNS
cord-034340-3ksfpaf7	39	8	-	-	SYM
cord-034340-3ksfpaf7	39	9	HSD2	hsd2	JJ
cord-034340-3ksfpaf7	39	10	enzymatic	enzymatic	JJ
cord-034340-3ksfpaf7	39	11	activity	activity	NN
cord-034340-3ksfpaf7	39	12	indicate	indicate	VBP
cord-034340-3ksfpaf7	39	13	that	that	IN
cord-034340-3ksfpaf7	39	14	these	these	DT
cord-034340-3ksfpaf7	39	15	two	two	CD
cord-034340-3ksfpaf7	39	16	enzyme	enzyme	NN
cord-034340-3ksfpaf7	39	17	activities	activity	NNS
cord-034340-3ksfpaf7	39	18	were	be	VBD
cord-034340-3ksfpaf7	39	19	lower	low	JJR
cord-034340-3ksfpaf7	39	20	in	in	IN
cord-034340-3ksfpaf7	39	21	JIA	JIA	NNP
cord-034340-3ksfpaf7	39	22	patients	patient	NNS
cord-034340-3ksfpaf7	39	23	.	.	.
cord-034340-3ksfpaf7	40	1	The	the	DT
cord-034340-3ksfpaf7	40	2	slowest	slow	JJS
cord-034340-3ksfpaf7	40	3	recoveries	recovery	NNS
cord-034340-3ksfpaf7	40	4	noted	note	VBN
cord-034340-3ksfpaf7	40	5	were	be	VBD
cord-034340-3ksfpaf7	40	6	for	for	IN
cord-034340-3ksfpaf7	40	7	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	40	8	of	of	IN
cord-034340-3ksfpaf7	40	9	DHEAS	DHEAS	NNP
cord-034340-3ksfpaf7	40	10	and	and	CC
cord-034340-3ksfpaf7	40	11	17	17	CD
cord-034340-3ksfpaf7	40	12	OH	OH	NNP
cord-034340-3ksfpaf7	40	13	pregnenolone	pregnenolone	NN
cord-034340-3ksfpaf7	40	14	.	.	.
cord-034340-3ksfpaf7	41	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	41	2	:	:	:
cord-034340-3ksfpaf7	41	3	Prior	prior	RB
cord-034340-3ksfpaf7	41	4	to	to	IN
cord-034340-3ksfpaf7	41	5	Etanercept	Etanercept	NNP
cord-034340-3ksfpaf7	41	6	treatment	treatment	NN
cord-034340-3ksfpaf7	41	7	almost	almost	RB
cord-034340-3ksfpaf7	41	8	all	all	DT
cord-034340-3ksfpaf7	41	9	urine	urine	NN
cord-034340-3ksfpaf7	41	10	adrenal	adrenal	JJ
cord-034340-3ksfpaf7	41	11	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	41	12	were	be	VBD
cord-034340-3ksfpaf7	41	13	significantly	significantly	RB
cord-034340-3ksfpaf7	41	14	lower	low	JJR
cord-034340-3ksfpaf7	41	15	mainly	mainly	RB
cord-034340-3ksfpaf7	41	16	due	due	IN
cord-034340-3ksfpaf7	41	17	to	to	IN
cord-034340-3ksfpaf7	41	18	the	the	DT
cord-034340-3ksfpaf7	41	19	active	active	JJ
cord-034340-3ksfpaf7	41	20	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	41	21	process	process	NN
cord-034340-3ksfpaf7	41	22	.	.	.
cord-034340-3ksfpaf7	42	1	Immediately	immediately	RB
cord-034340-3ksfpaf7	42	2	after	after	IN
cord-034340-3ksfpaf7	42	3	the	the	DT
cord-034340-3ksfpaf7	42	4	treatment	treatment	NN
cord-034340-3ksfpaf7	43	1	many	many	JJ
cord-034340-3ksfpaf7	43	2	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	43	3	raised	raise	VBN
cord-034340-3ksfpaf7	43	4	to	to	IN
cord-034340-3ksfpaf7	43	5	normal	normal	JJ
cord-034340-3ksfpaf7	43	6	values	value	NNS
cord-034340-3ksfpaf7	43	7	as	as	IN
cord-034340-3ksfpaf7	43	8	in	in	IN
cord-034340-3ksfpaf7	43	9	the	the	DT
cord-034340-3ksfpaf7	43	10	control	control	NN
cord-034340-3ksfpaf7	43	11	group	group	NN
cord-034340-3ksfpaf7	43	12	.	.	.
cord-034340-3ksfpaf7	44	1	The	the	DT
cord-034340-3ksfpaf7	44	2	two	two	CD
cord-034340-3ksfpaf7	44	3	adrenal	adrenal	JJ
cord-034340-3ksfpaf7	44	4	enzymes	enzyme	NNS
cord-034340-3ksfpaf7	44	5	that	that	WDT
cord-034340-3ksfpaf7	44	6	were	be	VBD
cord-034340-3ksfpaf7	44	7	found	find	VBN
cord-034340-3ksfpaf7	44	8	to	to	TO
cord-034340-3ksfpaf7	44	9	be	be	VB
cord-034340-3ksfpaf7	44	10	affected	affect	VBN
cord-034340-3ksfpaf7	44	11	in	in	IN
cord-034340-3ksfpaf7	44	12	JIR	JIR	NNP
cord-034340-3ksfpaf7	44	13	are	be	VBP
cord-034340-3ksfpaf7	44	14	CYP21	CYP21	NNP
cord-034340-3ksfpaf7	44	15	and	and	CC
cord-034340-3ksfpaf7	44	16	11β	11β	NNS
cord-034340-3ksfpaf7	44	17	-	-	SYM
cord-034340-3ksfpaf7	44	18	HSD2	HSD2	NNS
cord-034340-3ksfpaf7	44	19	.	.	.
cord-034340-3ksfpaf7	45	1	Blocking	block	VBG
cord-034340-3ksfpaf7	45	2	TN	TN	NNP
cord-034340-3ksfpaf7	45	3	alpha	alpha	NN
cord-034340-3ksfpaf7	45	4	immediately	immediately	RB
cord-034340-3ksfpaf7	45	5	restore	restore	VBP
cord-034340-3ksfpaf7	45	6	adrenal	adrenal	JJ
cord-034340-3ksfpaf7	45	7	function	function	NN
cord-034340-3ksfpaf7	45	8	in	in	IN
cord-034340-3ksfpaf7	45	9	JIA	JIA	NNP
cord-034340-3ksfpaf7	45	10	.	.	.
cord-034340-3ksfpaf7	46	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	46	2	:	:	:
cord-034340-3ksfpaf7	47	1	Patients	patient	NNS
cord-034340-3ksfpaf7	47	2	with	with	IN
cord-034340-3ksfpaf7	47	3	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	47	4	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	47	5	arthritis	arthritis	NN
cord-034340-3ksfpaf7	47	6	(	(	-LRB-
cord-034340-3ksfpaf7	47	7	JIA	JIA	NNP
cord-034340-3ksfpaf7	47	8	)	)	-RRB-
cord-034340-3ksfpaf7	47	9	receive	receive	VBP
cord-034340-3ksfpaf7	47	10	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	47	11	treatment	treatment	NN
cord-034340-3ksfpaf7	47	12	.	.	.
cord-034340-3ksfpaf7	48	1	Adalimumab	Adalimumab	NNS
cord-034340-3ksfpaf7	48	2	is	be	VBZ
cord-034340-3ksfpaf7	48	3	a	a	DT
cord-034340-3ksfpaf7	48	4	monoclonal	monoclonal	JJ
cord-034340-3ksfpaf7	48	5	antibody	antibody	NN
cord-034340-3ksfpaf7	48	6	that	that	WDT
cord-034340-3ksfpaf7	48	7	blocks	block	VBZ
cord-034340-3ksfpaf7	48	8	TNF	TNF	NNP
cord-034340-3ksfpaf7	48	9	-	-	HYPH
cord-034340-3ksfpaf7	48	10	α	α	NNP
cord-034340-3ksfpaf7	48	11	and	and	CC
cord-034340-3ksfpaf7	48	12	is	be	VBZ
cord-034340-3ksfpaf7	48	13	structurally	structurally	RB
cord-034340-3ksfpaf7	48	14	and	and	CC
cord-034340-3ksfpaf7	48	15	functionally	functionally	RB
cord-034340-3ksfpaf7	48	16	similar	similar	JJ
cord-034340-3ksfpaf7	48	17	to	to	IN
cord-034340-3ksfpaf7	48	18	human	human	JJ
cord-034340-3ksfpaf7	48	19	IgG	IgG	NNP
cord-034340-3ksfpaf7	48	20	1	1	CD
cord-034340-3ksfpaf7	48	21	.	.	.
cord-034340-3ksfpaf7	49	1	Nevertheless	nevertheless	RB
cord-034340-3ksfpaf7	49	2	,	,	,
cord-034340-3ksfpaf7	49	3	there	there	EX
cord-034340-3ksfpaf7	49	4	are	be	VBP
cord-034340-3ksfpaf7	49	5	reports	report	NNS
cord-034340-3ksfpaf7	49	6	of	of	IN
cord-034340-3ksfpaf7	49	7	the	the	DT
cord-034340-3ksfpaf7	49	8	development	development	NN
cord-034340-3ksfpaf7	49	9	of	of	IN
cord-034340-3ksfpaf7	49	10	anti	anti	JJ
cord-034340-3ksfpaf7	49	11	-	-	JJ
cord-034340-3ksfpaf7	49	12	drug	drug	JJ
cord-034340-3ksfpaf7	49	13	antibodies	antibody	NNS
cord-034340-3ksfpaf7	49	14	.	.	.
cord-034340-3ksfpaf7	50	1	The	the	DT
cord-034340-3ksfpaf7	50	2	production	production	NN
cord-034340-3ksfpaf7	50	3	of	of	IN
cord-034340-3ksfpaf7	50	4	these	these	DT
cord-034340-3ksfpaf7	50	5	antibodies	antibody	NNS
cord-034340-3ksfpaf7	50	6	may	may	MD
cord-034340-3ksfpaf7	50	7	be	be	VB
cord-034340-3ksfpaf7	50	8	associated	associate	VBN
cord-034340-3ksfpaf7	50	9	with	with	IN
cord-034340-3ksfpaf7	50	10	treatment	treatment	NN
cord-034340-3ksfpaf7	50	11	failures	failure	NNS
cord-034340-3ksfpaf7	50	12	(	(	-LRB-
cord-034340-3ksfpaf7	50	13	a	a	DT
cord-034340-3ksfpaf7	50	14	decrease	decrease	NN
cord-034340-3ksfpaf7	50	15	in	in	IN
cord-034340-3ksfpaf7	50	16	the	the	DT
cord-034340-3ksfpaf7	50	17	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	50	18	of	of	IN
cord-034340-3ksfpaf7	50	19	therapy	therapy	NN
cord-034340-3ksfpaf7	50	20	or	or	CC
cord-034340-3ksfpaf7	50	21	drug	drug	NN
cord-034340-3ksfpaf7	50	22	inefficiency	inefficiency	NN
cord-034340-3ksfpaf7	50	23	that	that	WDT
cord-034340-3ksfpaf7	50	24	developed	develop	VBD
cord-034340-3ksfpaf7	50	25	over	over	IN
cord-034340-3ksfpaf7	50	26	time	time	NN
cord-034340-3ksfpaf7	50	27	)	)	-RRB-
cord-034340-3ksfpaf7	50	28	and	and	CC
cord-034340-3ksfpaf7	50	29	hypersensitivity	hypersensitivity	NN
cord-034340-3ksfpaf7	50	30	reactions	reaction	NNS
cord-034340-3ksfpaf7	50	31	.	.	.
cord-034340-3ksfpaf7	51	1	To	to	IN
cord-034340-3ksfpaf7	51	2	our	-PRON-	PRP$
cord-034340-3ksfpaf7	51	3	knowledge	knowledge	NN
cord-034340-3ksfpaf7	51	4	,	,	,
cord-034340-3ksfpaf7	51	5	there	there	EX
cord-034340-3ksfpaf7	51	6	is	be	VBZ
cord-034340-3ksfpaf7	51	7	currently	currently	RB
cord-034340-3ksfpaf7	51	8	limited	limited	JJ
cord-034340-3ksfpaf7	51	9	information	information	NN
cord-034340-3ksfpaf7	51	10	on	on	IN
cord-034340-3ksfpaf7	51	11	the	the	DT
cord-034340-3ksfpaf7	51	12	availability	availability	NN
cord-034340-3ksfpaf7	51	13	of	of	IN
cord-034340-3ksfpaf7	51	14	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	51	15	antibodies	antibody	NNS
cord-034340-3ksfpaf7	51	16	(	(	-LRB-
cord-034340-3ksfpaf7	51	17	AAA	AAA	NNP
cord-034340-3ksfpaf7	51	18	)	)	-RRB-
cord-034340-3ksfpaf7	51	19	in	in	IN
cord-034340-3ksfpaf7	51	20	patients	patient	NNS
cord-034340-3ksfpaf7	51	21	with	with	IN
cord-034340-3ksfpaf7	51	22	JIA	JIA	NNP
cord-034340-3ksfpaf7	51	23	.	.	.
cord-034340-3ksfpaf7	52	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	52	2	:	:	:
cord-034340-3ksfpaf7	52	3	to	to	TO
cord-034340-3ksfpaf7	52	4	evaluate	evaluate	VB
cord-034340-3ksfpaf7	52	5	the	the	DT
cord-034340-3ksfpaf7	52	6	prevalence	prevalence	NN
cord-034340-3ksfpaf7	52	7	rate	rate	NN
cord-034340-3ksfpaf7	52	8	and	and	CC
cord-034340-3ksfpaf7	52	9	the	the	DT
cord-034340-3ksfpaf7	52	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	52	11	significance	significance	NN
cord-034340-3ksfpaf7	52	12	of	of	IN
cord-034340-3ksfpaf7	52	13	AAA	AAA	NNP
cord-034340-3ksfpaf7	52	14	in	in	IN
cord-034340-3ksfpaf7	52	15	patients	patient	NNS
cord-034340-3ksfpaf7	52	16	with	with	IN
cord-034340-3ksfpaf7	52	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	52	18	on	on	IN
cord-034340-3ksfpaf7	52	19	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	52	20	treatment	treatment	NN
cord-034340-3ksfpaf7	52	21	.	.	.
cord-034340-3ksfpaf7	53	1	Methods	method	NNS
cord-034340-3ksfpaf7	53	2	:	:	:
cord-034340-3ksfpaf7	54	1	26	26	CD
cord-034340-3ksfpaf7	54	2	patients	patient	NNS
cord-034340-3ksfpaf7	54	3	with	with	IN
cord-034340-3ksfpaf7	54	4	JIA	JIA	NNP
cord-034340-3ksfpaf7	54	5	were	be	VBD
cord-034340-3ksfpaf7	54	6	examined	examine	VBN
cord-034340-3ksfpaf7	54	7	,	,	,
cord-034340-3ksfpaf7	54	8	17	17	CD
cord-034340-3ksfpaf7	54	9	of	of	IN
cord-034340-3ksfpaf7	54	10	whom	whom	WP
cord-034340-3ksfpaf7	54	11	had	have	VBD
cord-034340-3ksfpaf7	54	12	the	the	DT
cord-034340-3ksfpaf7	54	13	oligoarticular	oligoarticular	JJ
cord-034340-3ksfpaf7	54	14	form	form	NN
cord-034340-3ksfpaf7	54	15	of	of	IN
cord-034340-3ksfpaf7	54	16	the	the	DT
cord-034340-3ksfpaf7	54	17	disease	disease	NN
cord-034340-3ksfpaf7	54	18	,	,	,
cord-034340-3ksfpaf7	54	19	7	7	CD
cord-034340-3ksfpaf7	54	20	of	of	IN
cord-034340-3ksfpaf7	54	21	them	-PRON-	PRP
cord-034340-3ksfpaf7	54	22	with	with	IN
cord-034340-3ksfpaf7	54	23	uveitis	uveitis	NN
cord-034340-3ksfpaf7	54	24	,	,	,
cord-034340-3ksfpaf7	54	25	and	and	CC
cord-034340-3ksfpaf7	54	26	9	9	CD
cord-034340-3ksfpaf7	54	27	patients	patient	NNS
cord-034340-3ksfpaf7	54	28	had	have	VBD
cord-034340-3ksfpaf7	54	29	the	the	DT
cord-034340-3ksfpaf7	54	30	polyarticular	polyarticular	JJ
cord-034340-3ksfpaf7	54	31	form	form	NN
cord-034340-3ksfpaf7	54	32	of	of	IN
cord-034340-3ksfpaf7	54	33	the	the	DT
cord-034340-3ksfpaf7	54	34	disease	disease	NN
cord-034340-3ksfpaf7	54	35	,	,	,
cord-034340-3ksfpaf7	54	36	3	3	CD
cord-034340-3ksfpaf7	54	37	of	of	IN
cord-034340-3ksfpaf7	54	38	them	-PRON-	PRP
cord-034340-3ksfpaf7	54	39	with	with	IN
cord-034340-3ksfpaf7	54	40	uveitis	uveitis	NN
cord-034340-3ksfpaf7	54	41	.	.	.
cord-034340-3ksfpaf7	55	1	Among	among	IN
cord-034340-3ksfpaf7	55	2	them	-PRON-	PRP
cord-034340-3ksfpaf7	55	3	,	,	,
cord-034340-3ksfpaf7	55	4	there	there	EX
cord-034340-3ksfpaf7	55	5	were	be	VBD
cord-034340-3ksfpaf7	55	6	13	13	CD
cord-034340-3ksfpaf7	55	7	(	(	-LRB-
cord-034340-3ksfpaf7	55	8	50	50	CD
cord-034340-3ksfpaf7	55	9	%	%	NN
cord-034340-3ksfpaf7	55	10	)	)	-RRB-
cord-034340-3ksfpaf7	55	11	girls	girl	NNS
cord-034340-3ksfpaf7	55	12	and	and	CC
cord-034340-3ksfpaf7	55	13	13	13	CD
cord-034340-3ksfpaf7	55	14	(	(	-LRB-
cord-034340-3ksfpaf7	55	15	50	50	CD
cord-034340-3ksfpaf7	55	16	%	%	NN
cord-034340-3ksfpaf7	55	17	)	)	-RRB-
cord-034340-3ksfpaf7	55	18	boys	boy	NNS
cord-034340-3ksfpaf7	55	19	.	.	.
cord-034340-3ksfpaf7	56	1	The	the	DT
cord-034340-3ksfpaf7	56	2	mean	mean	JJ
cord-034340-3ksfpaf7	56	3	age	age	NN
cord-034340-3ksfpaf7	56	4	was	be	VBD
cord-034340-3ksfpaf7	56	5	11.0	11.0	CD
cord-034340-3ksfpaf7	56	6	±	±	NNP
cord-034340-3ksfpaf7	56	7	3.4	3.4	CD
cord-034340-3ksfpaf7	56	8	years	year	NNS
cord-034340-3ksfpaf7	56	9	;	;	:
cord-034340-3ksfpaf7	56	10	the	the	DT
cord-034340-3ksfpaf7	56	11	mean	mean	JJ
cord-034340-3ksfpaf7	56	12	disease	disease	NN
cord-034340-3ksfpaf7	56	13	duration	duration	NN
cord-034340-3ksfpaf7	56	14	was	be	VBD
cord-034340-3ksfpaf7	56	15	4.1	4.1	CD
cord-034340-3ksfpaf7	56	16	±	±	CD
cord-034340-3ksfpaf7	56	17	2.2	2.2	CD
cord-034340-3ksfpaf7	56	18	years	year	NNS
cord-034340-3ksfpaf7	56	19	.	.	.
cord-034340-3ksfpaf7	57	1	Patients	patient	NNS
cord-034340-3ksfpaf7	57	2	received	receive	VBD
cord-034340-3ksfpaf7	57	3	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	57	4	(	(	-LRB-
cord-034340-3ksfpaf7	57	5	at	at	IN
cord-034340-3ksfpaf7	57	6	least	least	JJS
cord-034340-3ksfpaf7	57	7	1	1	CD
cord-034340-3ksfpaf7	57	8	year	year	NN
cord-034340-3ksfpaf7	57	9	before	before	IN
cord-034340-3ksfpaf7	57	10	the	the	DT
cord-034340-3ksfpaf7	57	11	study	study	NN
cord-034340-3ksfpaf7	57	12	)	)	-RRB-
cord-034340-3ksfpaf7	57	13	with	with	IN
cord-034340-3ksfpaf7	57	14	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	57	15	administration	administration	NN
cord-034340-3ksfpaf7	57	16	of	of	IN
cord-034340-3ksfpaf7	57	17	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	57	18	(	(	-LRB-
cord-034340-3ksfpaf7	57	19	MTX	MTX	NNP
cord-034340-3ksfpaf7	57	20	)	)	-RRB-
cord-034340-3ksfpaf7	57	21	or	or	CC
cord-034340-3ksfpaf7	57	22	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	57	23	only	only	RB
cord-034340-3ksfpaf7	57	24	-13	-13	CD
cord-034340-3ksfpaf7	57	25	children	child	NNS
cord-034340-3ksfpaf7	57	26	who	who	WP
cord-034340-3ksfpaf7	57	27	did	do	VBD
cord-034340-3ksfpaf7	57	28	not	not	RB
cord-034340-3ksfpaf7	57	29	receive	receive	VB
cord-034340-3ksfpaf7	57	30	MTX	MTX	NNP
cord-034340-3ksfpaf7	57	31	for	for	IN
cord-034340-3ksfpaf7	57	32	at	at	RB
cord-034340-3ksfpaf7	57	33	least	least	JJS
cord-034340-3ksfpaf7	57	34	3	3	CD
cord-034340-3ksfpaf7	57	35	months	month	NNS
cord-034340-3ksfpaf7	57	36	prior	prior	RB
cord-034340-3ksfpaf7	57	37	to	to	IN
cord-034340-3ksfpaf7	57	38	the	the	DT
cord-034340-3ksfpaf7	57	39	study	study	NN
cord-034340-3ksfpaf7	57	40	as	as	IN
cord-034340-3ksfpaf7	57	41	a	a	DT
cord-034340-3ksfpaf7	57	42	result	result	NN
cord-034340-3ksfpaf7	57	43	of	of	IN
cord-034340-3ksfpaf7	57	44	either	either	CC
cord-034340-3ksfpaf7	57	45	adverse	adverse	JJ
cord-034340-3ksfpaf7	57	46	events	event	NNS
cord-034340-3ksfpaf7	57	47	of	of	IN
cord-034340-3ksfpaf7	57	48	MTX	MTX	NNP
cord-034340-3ksfpaf7	57	49	administration	administration	NN
cord-034340-3ksfpaf7	57	50	(	(	-LRB-
cord-034340-3ksfpaf7	57	51	5	5	CD
cord-034340-3ksfpaf7	57	52	patients	patient	NNS
cord-034340-3ksfpaf7	57	53	)	)	-RRB-
cord-034340-3ksfpaf7	57	54	or	or	CC
cord-034340-3ksfpaf7	57	55	permanent	permanent	JJ
cord-034340-3ksfpaf7	57	56	drug	drug	NN
cord-034340-3ksfpaf7	57	57	remission	remission	NN
cord-034340-3ksfpaf7	57	58	(	(	-LRB-
cord-034340-3ksfpaf7	57	59	8	8	CD
cord-034340-3ksfpaf7	57	60	patients	patient	NNS
cord-034340-3ksfpaf7	57	61	)	)	-RRB-
cord-034340-3ksfpaf7	57	62	.	.	.
cord-034340-3ksfpaf7	58	1	Before	before	IN
cord-034340-3ksfpaf7	58	2	starting	start	VBG
cord-034340-3ksfpaf7	58	3	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	58	4	therapy	therapy	NN
cord-034340-3ksfpaf7	58	5	,	,	,
cord-034340-3ksfpaf7	58	6	all	all	DT
cord-034340-3ksfpaf7	58	7	participants	participant	NNS
cord-034340-3ksfpaf7	58	8	were	be	VBD
cord-034340-3ksfpaf7	58	9	treated	treat	VBN
cord-034340-3ksfpaf7	58	10	with	with	IN
cord-034340-3ksfpaf7	58	11	MTX	MTX	NNP
cord-034340-3ksfpaf7	58	12	.	.	.
cord-034340-3ksfpaf7	59	1	The	the	DT
cord-034340-3ksfpaf7	59	2	mean	mean	JJ
cord-034340-3ksfpaf7	59	3	duration	duration	NN
cord-034340-3ksfpaf7	59	4	of	of	IN
cord-034340-3ksfpaf7	59	5	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	59	6	treatment	treatment	NN
cord-034340-3ksfpaf7	59	7	for	for	IN
cord-034340-3ksfpaf7	59	8	these	these	DT
cord-034340-3ksfpaf7	59	9	patients	patient	NNS
cord-034340-3ksfpaf7	59	10	was	be	VBD
cord-034340-3ksfpaf7	59	11	1.8	1.8	CD
cord-034340-3ksfpaf7	59	12	±	±	CD
cord-034340-3ksfpaf7	59	13	1.0	1.0	CD
cord-034340-3ksfpaf7	59	14	years	year	NNS
cord-034340-3ksfpaf7	59	15	.	.	.
cord-034340-3ksfpaf7	60	1	The	the	DT
cord-034340-3ksfpaf7	60	2	serum	serum	NN
cord-034340-3ksfpaf7	60	3	AAA	aaa	NN
cord-034340-3ksfpaf7	60	4	level	level	NN
cord-034340-3ksfpaf7	60	5	of	of	IN
cord-034340-3ksfpaf7	60	6	antibodies	antibody	NNS
cord-034340-3ksfpaf7	60	7	was	be	VBD
cord-034340-3ksfpaf7	60	8	determined	determine	VBN
cord-034340-3ksfpaf7	60	9	using	use	VBG
cord-034340-3ksfpaf7	60	10	the	the	DT
cord-034340-3ksfpaf7	60	11	enzyme	enzyme	NN
cord-034340-3ksfpaf7	60	12	immunoassay	immunoassay	NN
cord-034340-3ksfpaf7	60	13	(	(	-LRB-
cord-034340-3ksfpaf7	60	14	EIA	EIA	NNP
cord-034340-3ksfpaf7	60	15	)	)	-RRB-
cord-034340-3ksfpaf7	60	16	method	method	NN
cord-034340-3ksfpaf7	60	17	.	.	.
cord-034340-3ksfpaf7	61	1	This	this	DT
cord-034340-3ksfpaf7	61	2	method	method	NN
cord-034340-3ksfpaf7	61	3	determines	determine	VBZ
cord-034340-3ksfpaf7	61	4	both	both	CC
cord-034340-3ksfpaf7	61	5	free	free	JJ
cord-034340-3ksfpaf7	61	6	and	and	CC
cord-034340-3ksfpaf7	61	7	bound	bind	VBN
cord-034340-3ksfpaf7	61	8	antibodies	antibody	NNS
cord-034340-3ksfpaf7	61	9	to	to	IN
cord-034340-3ksfpaf7	61	10	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	61	11	at	at	IN
cord-034340-3ksfpaf7	61	12	reference	reference	NN
cord-034340-3ksfpaf7	61	13	values	value	NNS
cord-034340-3ksfpaf7	62	1	less	less	JJR
cord-034340-3ksfpaf7	62	2	than	than	IN
cord-034340-3ksfpaf7	62	3	10	10	CD
cord-034340-3ksfpaf7	62	4	AU	AU	NNP
cord-034340-3ksfpaf7	62	5	/	/	SYM
cord-034340-3ksfpaf7	62	6	ml	ml	NN
cord-034340-3ksfpaf7	62	7	.	.	.
cord-034340-3ksfpaf7	63	1	a	a	LS
cord-034340-3ksfpaf7	64	1	and	and	CC
cord-034340-3ksfpaf7	64	2	was	be	VBD
cord-034340-3ksfpaf7	64	3	used	use	VBN
cord-034340-3ksfpaf7	64	4	every	every	DT
cord-034340-3ksfpaf7	64	5	2	2	CD
cord-034340-3ksfpaf7	64	6	weeks	week	NNS
cord-034340-3ksfpaf7	64	7	for	for	IN
cord-034340-3ksfpaf7	64	8	3	3	CD
cord-034340-3ksfpaf7	64	9	months	month	NNS
cord-034340-3ksfpaf7	64	10	.	.	.
cord-034340-3ksfpaf7	65	1	The	the	DT
cord-034340-3ksfpaf7	65	2	values	value	NNS
cord-034340-3ksfpaf7	65	3	were	be	VBD
cord-034340-3ksfpaf7	65	4	presented	present	VBN
cord-034340-3ksfpaf7	65	5	as	as	IN
cord-034340-3ksfpaf7	65	6	mean	mean	JJ
cord-034340-3ksfpaf7	65	7	±	±	NNP
cord-034340-3ksfpaf7	65	8	standard	standard	JJ
cord-034340-3ksfpaf7	65	9	deviation	deviation	NN
cord-034340-3ksfpaf7	65	10	.	.	.
cord-034340-3ksfpaf7	66	1	Data	data	NN
cord-034340-3ksfpaf7	66	2	processing	processing	NN
cord-034340-3ksfpaf7	66	3	and	and	CC
cord-034340-3ksfpaf7	66	4	analysis	analysis	NN
cord-034340-3ksfpaf7	66	5	were	be	VBD
cord-034340-3ksfpaf7	66	6	carried	carry	VBN
cord-034340-3ksfpaf7	66	7	out	out	RP
cord-034340-3ksfpaf7	66	8	using	use	VBG
cord-034340-3ksfpaf7	66	9	Pearson	Pearson	NNP
cord-034340-3ksfpaf7	66	10	's	's	POS
cord-034340-3ksfpaf7	66	11	chi	chi	JJ
cord-034340-3ksfpaf7	66	12	-	-	JJ
cord-034340-3ksfpaf7	66	13	squared	squared	JJ
cord-034340-3ksfpaf7	66	14	test	test	NN
cord-034340-3ksfpaf7	66	15	and	and	CC
cord-034340-3ksfpaf7	66	16	Spearman	Spearman	NNP
cord-034340-3ksfpaf7	66	17	's	's	POS
cord-034340-3ksfpaf7	66	18	correlation	correlation	NN
cord-034340-3ksfpaf7	66	19	test	test	NN
cord-034340-3ksfpaf7	66	20	.	.	.
cord-034340-3ksfpaf7	67	1	Results	result	NNS
cord-034340-3ksfpaf7	67	2	:	:	:
cord-034340-3ksfpaf7	67	3	8	8	CD
cord-034340-3ksfpaf7	67	4	(	(	-LRB-
cord-034340-3ksfpaf7	67	5	31	31	CD
cord-034340-3ksfpaf7	67	6	%	%	NN
cord-034340-3ksfpaf7	67	7	)	)	-RRB-
cord-034340-3ksfpaf7	67	8	of	of	IN
cord-034340-3ksfpaf7	67	9	the	the	DT
cord-034340-3ksfpaf7	67	10	26	26	CD
cord-034340-3ksfpaf7	67	11	patients	patient	NNS
cord-034340-3ksfpaf7	67	12	enrolled	enrol	VBN
cord-034340-3ksfpaf7	67	13	in	in	IN
cord-034340-3ksfpaf7	67	14	the	the	DT
cord-034340-3ksfpaf7	67	15	study	study	NN
cord-034340-3ksfpaf7	67	16	had	have	VBD
cord-034340-3ksfpaf7	67	17	AAApositive	aaapositive	JJ
cord-034340-3ksfpaf7	67	18	results	result	NNS
cord-034340-3ksfpaf7	67	19	.	.	.
cord-034340-3ksfpaf7	68	1	The	the	DT
cord-034340-3ksfpaf7	68	2	mean	mean	JJ
cord-034340-3ksfpaf7	68	3	AAA	aaa	NN
cord-034340-3ksfpaf7	68	4	level	level	NN
cord-034340-3ksfpaf7	68	5	in	in	IN
cord-034340-3ksfpaf7	68	6	positive	positive	JJ
cord-034340-3ksfpaf7	68	7	patients	patient	NNS
cord-034340-3ksfpaf7	68	8	was	be	VBD
cord-034340-3ksfpaf7	68	9	40.8	40.8	CD
cord-034340-3ksfpaf7	68	10	±	±	CD
cord-034340-3ksfpaf7	68	11	20.1	20.1	CD
cord-034340-3ksfpaf7	68	12	AU	AU	NNP
cord-034340-3ksfpaf7	68	13	/	/	SYM
cord-034340-3ksfpaf7	68	14	ml	ml	NN
cord-034340-3ksfpaf7	68	15	.	.	.
cord-034340-3ksfpaf7	69	1	Further	further	JJ
cord-034340-3ksfpaf7	69	2	disease	disease	NN
cord-034340-3ksfpaf7	69	3	relapses	relapse	NNS
cord-034340-3ksfpaf7	69	4	tended	tend	VBD
cord-034340-3ksfpaf7	69	5	to	to	TO
cord-034340-3ksfpaf7	69	6	occur	occur	VB
cord-034340-3ksfpaf7	69	7	significantly	significantly	RB
cord-034340-3ksfpaf7	69	8	more	more	RBR
cord-034340-3ksfpaf7	69	9	often	often	RB
cord-034340-3ksfpaf7	69	10	in	in	IN
cord-034340-3ksfpaf7	69	11	AAA	aaa	NN
cord-034340-3ksfpaf7	69	12	-	-	HYPH
cord-034340-3ksfpaf7	69	13	positive	positive	JJ
cord-034340-3ksfpaf7	69	14	patients	patient	NNS
cord-034340-3ksfpaf7	69	15	than	than	IN
cord-034340-3ksfpaf7	69	16	in	in	IN
cord-034340-3ksfpaf7	69	17	AAA	aaa	NN
cord-034340-3ksfpaf7	69	18	-	-	HYPH
cord-034340-3ksfpaf7	69	19	negative	negative	JJ
cord-034340-3ksfpaf7	69	20	ones	one	NNS
cord-034340-3ksfpaf7	69	21	(	(	-LRB-
cord-034340-3ksfpaf7	69	22	χ2	χ2	NNP
cord-034340-3ksfpaf7	69	23	=	=	SYM
cord-034340-3ksfpaf7	69	24	5.46	5.46	CD
cord-034340-3ksfpaf7	69	25	,	,	,
cord-034340-3ksfpaf7	69	26	p	p	NN
cord-034340-3ksfpaf7	69	27	=	=	SYM
cord-034340-3ksfpaf7	69	28	0.019	0.019	CD
cord-034340-3ksfpaf7	69	29	)	)	-RRB-
cord-034340-3ksfpaf7	69	30	.	.	.
cord-034340-3ksfpaf7	70	1	Thus	thus	RB
cord-034340-3ksfpaf7	70	2	,	,	,
cord-034340-3ksfpaf7	70	3	5	5	CD
cord-034340-3ksfpaf7	70	4	of	of	IN
cord-034340-3ksfpaf7	70	5	8	8	CD
cord-034340-3ksfpaf7	70	6	(	(	-LRB-
cord-034340-3ksfpaf7	70	7	62.5	62.5	CD
cord-034340-3ksfpaf7	70	8	%	%	NN
cord-034340-3ksfpaf7	70	9	)	)	-RRB-
cord-034340-3ksfpaf7	70	10	AAA	aaa	NN
cord-034340-3ksfpaf7	70	11	-	-	HYPH
cord-034340-3ksfpaf7	70	12	positive	positive	JJ
cord-034340-3ksfpaf7	70	13	children	child	NNS
cord-034340-3ksfpaf7	70	14	had	have	VBD
cord-034340-3ksfpaf7	70	15	at	at	RB
cord-034340-3ksfpaf7	70	16	least	least	JJS
cord-034340-3ksfpaf7	70	17	1	1	CD
cord-034340-3ksfpaf7	70	18	exacerbation	exacerbation	NN
cord-034340-3ksfpaf7	70	19	of	of	IN
cord-034340-3ksfpaf7	70	20	the	the	DT
cord-034340-3ksfpaf7	70	21	disease	disease	NN
cord-034340-3ksfpaf7	70	22	within	within	IN
cord-034340-3ksfpaf7	70	23	3	3	CD
cord-034340-3ksfpaf7	70	24	months	month	NNS
cord-034340-3ksfpaf7	70	25	,	,	,
cord-034340-3ksfpaf7	70	26	compared	compare	VBN
cord-034340-3ksfpaf7	70	27	with	with	IN
cord-034340-3ksfpaf7	70	28	3	3	CD
cord-034340-3ksfpaf7	70	29	of	of	IN
cord-034340-3ksfpaf7	70	30	18	18	CD
cord-034340-3ksfpaf7	70	31	(	(	-LRB-
cord-034340-3ksfpaf7	70	32	16.7	16.7	CD
cord-034340-3ksfpaf7	70	33	%	%	NN
cord-034340-3ksfpaf7	70	34	)	)	-RRB-
cord-034340-3ksfpaf7	70	35	in	in	IN
cord-034340-3ksfpaf7	70	36	AAA	aaa	NN
cord-034340-3ksfpaf7	70	37	-	-	HYPH
cord-034340-3ksfpaf7	70	38	negative	negative	JJ
cord-034340-3ksfpaf7	70	39	ones	one	NNS
cord-034340-3ksfpaf7	70	40	.	.	.
cord-034340-3ksfpaf7	71	1	7	7	CD
cord-034340-3ksfpaf7	71	2	out	out	IN
cord-034340-3ksfpaf7	71	3	of	of	IN
cord-034340-3ksfpaf7	71	4	8	8	CD
cord-034340-3ksfpaf7	71	5	(	(	-LRB-
cord-034340-3ksfpaf7	71	6	87.5	87.5	CD
cord-034340-3ksfpaf7	71	7	%	%	NN
cord-034340-3ksfpaf7	71	8	)	)	-RRB-
cord-034340-3ksfpaf7	72	1	AAApositives	aaapositive	NNS
cord-034340-3ksfpaf7	72	2	did	do	VBD
cord-034340-3ksfpaf7	72	3	not	not	RB
cord-034340-3ksfpaf7	72	4	take	take	VB
cord-034340-3ksfpaf7	72	5	MTX	MTX	NNP
cord-034340-3ksfpaf7	72	6	for	for	IN
cord-034340-3ksfpaf7	72	7	at	at	RB
cord-034340-3ksfpaf7	72	8	least	least	JJS
cord-034340-3ksfpaf7	72	9	3	3	CD
cord-034340-3ksfpaf7	72	10	months	month	NNS
cord-034340-3ksfpaf7	72	11	compared	compare	VBN
cord-034340-3ksfpaf7	72	12	to	to	IN
cord-034340-3ksfpaf7	72	13	6	6	CD
cord-034340-3ksfpaf7	72	14	out	out	IN
cord-034340-3ksfpaf7	72	15	of	of	IN
cord-034340-3ksfpaf7	72	16	18	18	CD
cord-034340-3ksfpaf7	72	17	(	(	-LRB-
cord-034340-3ksfpaf7	72	18	33.3	33.3	CD
cord-034340-3ksfpaf7	72	19	%	%	NN
cord-034340-3ksfpaf7	72	20	)	)	-RRB-
cord-034340-3ksfpaf7	72	21	in	in	IN
cord-034340-3ksfpaf7	72	22	AAA	aaa	NN
cord-034340-3ksfpaf7	72	23	-	-	HYPH
cord-034340-3ksfpaf7	72	24	negative	negative	JJ
cord-034340-3ksfpaf7	72	25	ones	one	NNS
cord-034340-3ksfpaf7	72	26	.	.	.
cord-034340-3ksfpaf7	73	1	Thus	thus	RB
cord-034340-3ksfpaf7	73	2	,	,	,
cord-034340-3ksfpaf7	73	3	AAAs	AAAs	NNP
cord-034340-3ksfpaf7	73	4	are	be	VBP
cord-034340-3ksfpaf7	73	5	found	find	VBN
cord-034340-3ksfpaf7	73	6	to	to	TO
cord-034340-3ksfpaf7	73	7	be	be	VB
cord-034340-3ksfpaf7	73	8	significantly	significantly	RB
cord-034340-3ksfpaf7	73	9	more	more	RBR
cord-034340-3ksfpaf7	73	10	frequent	frequent	JJ
cord-034340-3ksfpaf7	73	11	without	without	IN
cord-034340-3ksfpaf7	73	12	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	73	13	administration	administration	NN
cord-034340-3ksfpaf7	73	14	of	of	IN
cord-034340-3ksfpaf7	73	15	MTX	MTX	NNP
cord-034340-3ksfpaf7	73	16	in	in	IN
cord-034340-3ksfpaf7	73	17	the	the	DT
cord-034340-3ksfpaf7	73	18	treatment	treatment	NN
cord-034340-3ksfpaf7	73	19	of	of	IN
cord-034340-3ksfpaf7	73	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	73	21	(	(	-LRB-
cord-034340-3ksfpaf7	73	22	χ2	χ2	NNP
cord-034340-3ksfpaf7	73	23	=	=	SYM
cord-034340-3ksfpaf7	73	24	6.5	6.5	CD
cord-034340-3ksfpaf7	73	25	,	,	,
cord-034340-3ksfpaf7	73	26	p	p	NN
cord-034340-3ksfpaf7	73	27	=	=	SYM
cord-034340-3ksfpaf7	73	28	0.01	0.01	CD
cord-034340-3ksfpaf7	73	29	)	)	-RRB-
cord-034340-3ksfpaf7	73	30	.	.	.
cord-034340-3ksfpaf7	74	1	There	there	EX
cord-034340-3ksfpaf7	74	2	were	be	VBD
cord-034340-3ksfpaf7	74	3	no	no	DT
cord-034340-3ksfpaf7	74	4	observed	observed	JJ
cord-034340-3ksfpaf7	74	5	adverse	adverse	JJ
cord-034340-3ksfpaf7	74	6	events	event	NNS
cord-034340-3ksfpaf7	74	7	or	or	CC
cord-034340-3ksfpaf7	74	8	side	side	NN
cord-034340-3ksfpaf7	74	9	effects	effect	NNS
cord-034340-3ksfpaf7	74	10	during	during	IN
cord-034340-3ksfpaf7	74	11	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	74	12	therapy	therapy	NN
cord-034340-3ksfpaf7	74	13	.	.	.
cord-034340-3ksfpaf7	75	1	No	no	DT
cord-034340-3ksfpaf7	75	2	significant	significant	JJ
cord-034340-3ksfpaf7	75	3	correlation	correlation	NN
cord-034340-3ksfpaf7	75	4	was	be	VBD
cord-034340-3ksfpaf7	75	5	found	find	VBN
cord-034340-3ksfpaf7	75	6	between	between	IN
cord-034340-3ksfpaf7	75	7	the	the	DT
cord-034340-3ksfpaf7	75	8	presence	presence	NN
cord-034340-3ksfpaf7	75	9	of	of	IN
cord-034340-3ksfpaf7	75	10	AAA	AAA	NNP
cord-034340-3ksfpaf7	75	11	and	and	CC
cord-034340-3ksfpaf7	75	12	sex	sex	NN
cord-034340-3ksfpaf7	75	13	,	,	,
cord-034340-3ksfpaf7	75	14	Introduction	introduction	NN
cord-034340-3ksfpaf7	75	15	:	:	:
cord-034340-3ksfpaf7	75	16	Advances	advance	NNS
cord-034340-3ksfpaf7	75	17	on	on	IN
cord-034340-3ksfpaf7	75	18	molecular	molecular	JJ
cord-034340-3ksfpaf7	75	19	medicine	medicine	NN
cord-034340-3ksfpaf7	75	20	,	,	,
cord-034340-3ksfpaf7	75	21	illumination	illumination	NN
cord-034340-3ksfpaf7	75	22	of	of	IN
cord-034340-3ksfpaf7	75	23	the	the	DT
cord-034340-3ksfpaf7	75	24	cytokine	cytokine	NN
cord-034340-3ksfpaf7	75	25	network	network	NN
cord-034340-3ksfpaf7	75	26	and	and	CC
cord-034340-3ksfpaf7	76	1	the	the	DT
cord-034340-3ksfpaf7	76	2	immune	immune	JJ
cord-034340-3ksfpaf7	76	3	pathways	pathway	NNS
cord-034340-3ksfpaf7	76	4	shed	shed	VBP
cord-034340-3ksfpaf7	76	5	light	light	NN
cord-034340-3ksfpaf7	76	6	on	on	IN
cord-034340-3ksfpaf7	76	7	the	the	DT
cord-034340-3ksfpaf7	76	8	etiopathogenesis	etiopathogenesis	NN
cord-034340-3ksfpaf7	76	9	for	for	IN
cord-034340-3ksfpaf7	76	10	a	a	DT
cord-034340-3ksfpaf7	76	11	better	well	JJR
cord-034340-3ksfpaf7	76	12	understanding	understanding	NN
cord-034340-3ksfpaf7	76	13	of	of	IN
cord-034340-3ksfpaf7	76	14	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	76	15	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	76	16	arthritis	arthritis	NN
cord-034340-3ksfpaf7	76	17	(	(	-LRB-
cord-034340-3ksfpaf7	76	18	JIA	JIA	NNP
cord-034340-3ksfpaf7	76	19	)	)	-RRB-
cord-034340-3ksfpaf7	76	20	.	.	.
cord-034340-3ksfpaf7	77	1	However	however	RB
cord-034340-3ksfpaf7	77	2	,	,	,
cord-034340-3ksfpaf7	77	3	the	the	DT
cord-034340-3ksfpaf7	77	4	fact	fact	NN
cord-034340-3ksfpaf7	77	5	that	that	IN
cord-034340-3ksfpaf7	77	6	the	the	DT
cord-034340-3ksfpaf7	77	7	course	course	NN
cord-034340-3ksfpaf7	77	8	of	of	IN
cord-034340-3ksfpaf7	77	9	the	the	DT
cord-034340-3ksfpaf7	77	10	disease	disease	NN
cord-034340-3ksfpaf7	77	11	differs	differ	VBZ
cord-034340-3ksfpaf7	77	12	individually	individually	RB
cord-034340-3ksfpaf7	77	13	strongly	strongly	RB
cord-034340-3ksfpaf7	77	14	suggests	suggest	VBZ
cord-034340-3ksfpaf7	77	15	the	the	DT
cord-034340-3ksfpaf7	77	16	effect	effect	NN
cord-034340-3ksfpaf7	77	17	of	of	IN
cord-034340-3ksfpaf7	77	18	external	external	JJ
cord-034340-3ksfpaf7	77	19	factors	factor	NNS
cord-034340-3ksfpaf7	77	20	.	.	.
cord-034340-3ksfpaf7	78	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	78	2	:	:	:
cord-034340-3ksfpaf7	78	3	The	the	DT
cord-034340-3ksfpaf7	78	4	current	current	JJ
cord-034340-3ksfpaf7	78	5	study	study	NN
cord-034340-3ksfpaf7	78	6	was	be	VBD
cord-034340-3ksfpaf7	78	7	undertaken	undertake	VBN
cord-034340-3ksfpaf7	78	8	to	to	TO
cord-034340-3ksfpaf7	78	9	evaluate	evaluate	VB
cord-034340-3ksfpaf7	78	10	sociodemographic	sociodemographic	JJ
cord-034340-3ksfpaf7	78	11	and	and	CC
cord-034340-3ksfpaf7	78	12	sociocultural	sociocultural	JJ
cord-034340-3ksfpaf7	78	13	features	feature	NNS
cord-034340-3ksfpaf7	78	14	,	,	,
cord-034340-3ksfpaf7	78	15	parent	parent	NN
cord-034340-3ksfpaf7	78	16	behavior	behavior	NN
cord-034340-3ksfpaf7	78	17	,	,	,
cord-034340-3ksfpaf7	78	18	the	the	DT
cord-034340-3ksfpaf7	78	19	gestation	gestation	NN
cord-034340-3ksfpaf7	78	20	and	and	CC
cord-034340-3ksfpaf7	78	21	breastfeeding	breastfeeding	NN
cord-034340-3ksfpaf7	78	22	period	period	NN
cord-034340-3ksfpaf7	78	23	,	,	,
cord-034340-3ksfpaf7	78	24	nutritional	nutritional	JJ
cord-034340-3ksfpaf7	78	25	status	status	NN
cord-034340-3ksfpaf7	78	26	of	of	IN
cord-034340-3ksfpaf7	78	27	early	early	JJ
cord-034340-3ksfpaf7	78	28	childhood	childhood	NN
cord-034340-3ksfpaf7	78	29	in	in	IN
cord-034340-3ksfpaf7	78	30	our	-PRON-	PRP$
cord-034340-3ksfpaf7	78	31	patients	patient	NNS
cord-034340-3ksfpaf7	78	32	with	with	IN
cord-034340-3ksfpaf7	78	33	JIA	JIA	NNP
cord-034340-3ksfpaf7	78	34	,	,	,
cord-034340-3ksfpaf7	78	35	and	and	CC
cord-034340-3ksfpaf7	78	36	to	to	TO
cord-034340-3ksfpaf7	78	37	determine	determine	VB
cord-034340-3ksfpaf7	78	38	their	-PRON-	PRP$
cord-034340-3ksfpaf7	78	39	relationship	relationship	NN
cord-034340-3ksfpaf7	78	40	with	with	IN
cord-034340-3ksfpaf7	78	41	disease	disease	NN
cord-034340-3ksfpaf7	78	42	activity	activity	NN
cord-034340-3ksfpaf7	78	43	,	,	,
cord-034340-3ksfpaf7	78	44	damage	damage	NN
cord-034340-3ksfpaf7	78	45	index	index	NN
cord-034340-3ksfpaf7	78	46	,	,	,
cord-034340-3ksfpaf7	78	47	remission	remission	NN
cord-034340-3ksfpaf7	78	48	time	time	NN
cord-034340-3ksfpaf7	78	49	,	,	,
cord-034340-3ksfpaf7	78	50	and	and	CC
cord-034340-3ksfpaf7	78	51	relapse	relapse	NN
cord-034340-3ksfpaf7	78	52	rate	rate	NN
cord-034340-3ksfpaf7	78	53	.	.	.
cord-034340-3ksfpaf7	79	1	Methods	method	NNS
cord-034340-3ksfpaf7	79	2	:	:	:
cord-034340-3ksfpaf7	79	3	The	the	DT
cord-034340-3ksfpaf7	79	4	study	study	NN
cord-034340-3ksfpaf7	79	5	was	be	VBD
cord-034340-3ksfpaf7	79	6	conducted	conduct	VBN
cord-034340-3ksfpaf7	79	7	with	with	IN
cord-034340-3ksfpaf7	79	8	a	a	DT
cord-034340-3ksfpaf7	79	9	face	face	NN
cord-034340-3ksfpaf7	79	10	-	-	HYPH
cord-034340-3ksfpaf7	79	11	to	to	IN
cord-034340-3ksfpaf7	79	12	-	-	HYPH
cord-034340-3ksfpaf7	79	13	face	face	NN
cord-034340-3ksfpaf7	79	14	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	79	15	method	method	NN
cord-034340-3ksfpaf7	79	16	with	with	IN
cord-034340-3ksfpaf7	79	17	the	the	DT
cord-034340-3ksfpaf7	79	18	parents	parent	NNS
cord-034340-3ksfpaf7	79	19	of	of	IN
cord-034340-3ksfpaf7	79	20	171	171	CD
cord-034340-3ksfpaf7	79	21	patients	patient	NNS
cord-034340-3ksfpaf7	79	22	with	with	IN
cord-034340-3ksfpaf7	79	23	JIA	JIA	NNP
cord-034340-3ksfpaf7	79	24	and	and	CC
cord-034340-3ksfpaf7	79	25	183	183	CD
cord-034340-3ksfpaf7	79	26	healthy	healthy	JJ
cord-034340-3ksfpaf7	79	27	children	child	NNS
cord-034340-3ksfpaf7	79	28	.	.	.
cord-034340-3ksfpaf7	80	1	The	the	DT
cord-034340-3ksfpaf7	80	2	medical	medical	JJ
cord-034340-3ksfpaf7	80	3	patient	patient	NN
cord-034340-3ksfpaf7	80	4	records	record	NNS
cord-034340-3ksfpaf7	80	5	were	be	VBD
cord-034340-3ksfpaf7	80	6	reviewed	review	VBN
cord-034340-3ksfpaf7	80	7	.	.	.
cord-034340-3ksfpaf7	81	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	81	2	Arthritis	arthritis	NN
cord-034340-3ksfpaf7	81	3	Disease	Disease	NNP
cord-034340-3ksfpaf7	81	4	Activity	Activity	NNP
cord-034340-3ksfpaf7	81	5	Score	Score	NNP
cord-034340-3ksfpaf7	81	6	(	(	-LRB-
cord-034340-3ksfpaf7	81	7	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	81	8	)	)	-RRB-
cord-034340-3ksfpaf7	81	9	27	27	CD
cord-034340-3ksfpaf7	81	10	,	,	,
cord-034340-3ksfpaf7	81	11	Wallace	Wallace	NNP
cord-034340-3ksfpaf7	81	12	clinical	clinical	JJ
cord-034340-3ksfpaf7	81	13	inactive	inactive	JJ
cord-034340-3ksfpaf7	81	14	disease	disease	NN
cord-034340-3ksfpaf7	81	15	criteria	criterion	NNS
cord-034340-3ksfpaf7	81	16	,	,	,
cord-034340-3ksfpaf7	81	17	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	81	18	Arthritis	Arthritis	NNP
cord-034340-3ksfpaf7	81	19	Damage	Damage	NNP
cord-034340-3ksfpaf7	81	20	Index	Index	NNP
cord-034340-3ksfpaf7	81	21	(	(	-LRB-
cord-034340-3ksfpaf7	81	22	JADI	JADI	NNP
cord-034340-3ksfpaf7	81	23	)	)	-RRB-
cord-034340-3ksfpaf7	81	24	,	,	,
cord-034340-3ksfpaf7	81	25	and	and	CC
cord-034340-3ksfpaf7	81	26	relapse	relapse	NN
cord-034340-3ksfpaf7	81	27	rates	rate	NNS
cord-034340-3ksfpaf7	81	28	were	be	VBD
cord-034340-3ksfpaf7	81	29	used	use	VBN
cord-034340-3ksfpaf7	81	30	to	to	TO
cord-034340-3ksfpaf7	81	31	assess	assess	VB
cord-034340-3ksfpaf7	81	32	the	the	DT
cord-034340-3ksfpaf7	81	33	general	general	JJ
cord-034340-3ksfpaf7	81	34	medical	medical	JJ
cord-034340-3ksfpaf7	81	35	condition	condition	NN
cord-034340-3ksfpaf7	81	36	of	of	IN
cord-034340-3ksfpaf7	81	37	each	each	DT
cord-034340-3ksfpaf7	81	38	patient	patient	NN
cord-034340-3ksfpaf7	81	39	.	.	.
cord-034340-3ksfpaf7	82	1	Results	result	NNS
cord-034340-3ksfpaf7	82	2	:	:	:
cord-034340-3ksfpaf7	83	1	The	the	DT
cord-034340-3ksfpaf7	83	2	median	median	JJ
cord-034340-3ksfpaf7	83	3	age	age	NN
cord-034340-3ksfpaf7	83	4	of	of	IN
cord-034340-3ksfpaf7	83	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	83	6	patients	patient	NNS
cord-034340-3ksfpaf7	83	7	(	(	-LRB-
cord-034340-3ksfpaf7	83	8	n	n	NN
cord-034340-3ksfpaf7	83	9	=	=	SYM
cord-034340-3ksfpaf7	83	10	171	171	CD
cord-034340-3ksfpaf7	83	11	)	)	-RRB-
cord-034340-3ksfpaf7	83	12	was	be	VBD
cord-034340-3ksfpaf7	83	13	13	13	CD
cord-034340-3ksfpaf7	83	14	(	(	-LRB-
cord-034340-3ksfpaf7	83	15	3	3	CD
cord-034340-3ksfpaf7	83	16	)	)	-RRB-
cord-034340-3ksfpaf7	84	1	(	(	-LRB-
cord-034340-3ksfpaf7	84	2	4	4	LS
cord-034340-3ksfpaf7	84	3	)	)	-RRB-
cord-034340-3ksfpaf7	84	4	(	(	-LRB-
cord-034340-3ksfpaf7	84	5	5	5	LS
cord-034340-3ksfpaf7	84	6	)	)	-RRB-
cord-034340-3ksfpaf7	84	7	(	(	-LRB-
cord-034340-3ksfpaf7	84	8	6	6	LS
cord-034340-3ksfpaf7	84	9	)	)	-RRB-
cord-034340-3ksfpaf7	84	10	(	(	-LRB-
cord-034340-3ksfpaf7	84	11	7	7	LS
cord-034340-3ksfpaf7	84	12	)	)	-RRB-
cord-034340-3ksfpaf7	84	13	(	(	-LRB-
cord-034340-3ksfpaf7	84	14	8)	8)	NNP
cord-034340-3ksfpaf7	84	15	(	(	-LRB-
cord-034340-3ksfpaf7	84	16	9	9	CD
cord-034340-3ksfpaf7	84	17	)	)	-RRB-
cord-034340-3ksfpaf7	84	18	(	(	-LRB-
cord-034340-3ksfpaf7	84	19	10	10	CD
cord-034340-3ksfpaf7	84	20	)	)	-RRB-
cord-034340-3ksfpaf7	84	21	(	(	-LRB-
cord-034340-3ksfpaf7	84	22	11	11	CD
cord-034340-3ksfpaf7	84	23	)	)	-RRB-
cord-034340-3ksfpaf7	84	24	(	(	-LRB-
cord-034340-3ksfpaf7	84	25	12	12	CD
cord-034340-3ksfpaf7	84	26	)	)	-RRB-
cord-034340-3ksfpaf7	84	27	(	(	-LRB-
cord-034340-3ksfpaf7	84	28	13	13	CD
cord-034340-3ksfpaf7	84	29	)	)	-RRB-
cord-034340-3ksfpaf7	84	30	(	(	-LRB-
cord-034340-3ksfpaf7	84	31	14	14	CD
cord-034340-3ksfpaf7	84	32	)	)	-RRB-
cord-034340-3ksfpaf7	84	33	(	(	-LRB-
cord-034340-3ksfpaf7	84	34	15	15	CD
cord-034340-3ksfpaf7	84	35	)	)	-RRB-
cord-034340-3ksfpaf7	84	36	(	(	-LRB-
cord-034340-3ksfpaf7	84	37	16	16	CD
cord-034340-3ksfpaf7	84	38	)	)	-RRB-
cord-034340-3ksfpaf7	84	39	(	(	-LRB-
cord-034340-3ksfpaf7	84	40	17	17	CD
cord-034340-3ksfpaf7	84	41	)	)	-RRB-
cord-034340-3ksfpaf7	84	42	(	(	-LRB-
cord-034340-3ksfpaf7	84	43	18	18	CD
cord-034340-3ksfpaf7	84	44	)	)	-RRB-
cord-034340-3ksfpaf7	84	45	(	(	-LRB-
cord-034340-3ksfpaf7	84	46	19	19	CD
cord-034340-3ksfpaf7	84	47	)	)	-RRB-
cord-034340-3ksfpaf7	84	48	(	(	-LRB-
cord-034340-3ksfpaf7	84	49	20	20	CD
cord-034340-3ksfpaf7	84	50	)	)	-RRB-
cord-034340-3ksfpaf7	84	51	,	,	,
cord-034340-3ksfpaf7	84	52	with	with	IN
cord-034340-3ksfpaf7	84	53	a	a	DT
cord-034340-3ksfpaf7	84	54	female	female	JJ
cord-034340-3ksfpaf7	84	55	ratio	ratio	NN
cord-034340-3ksfpaf7	84	56	of	of	IN
cord-034340-3ksfpaf7	84	57	59,1	59,1	CD
cord-034340-3ksfpaf7	84	58	%	%	NN
cord-034340-3ksfpaf7	84	59	.	.	.
cord-034340-3ksfpaf7	85	1	Age	age	NN
cord-034340-3ksfpaf7	85	2	at	at	IN
cord-034340-3ksfpaf7	85	3	disease	disease	NN
cord-034340-3ksfpaf7	85	4	onset	onset	NN
cord-034340-3ksfpaf7	85	5	was	be	VBD
cord-034340-3ksfpaf7	85	6	7	7	CD
cord-034340-3ksfpaf7	85	7	(	(	-LRB-
cord-034340-3ksfpaf7	85	8	1	1	CD
cord-034340-3ksfpaf7	85	9	)	)	-RRB-
cord-034340-3ksfpaf7	85	10	(	(	-LRB-
cord-034340-3ksfpaf7	85	11	2	2	LS
cord-034340-3ksfpaf7	85	12	)	)	-RRB-
cord-034340-3ksfpaf7	85	13	(	(	-LRB-
cord-034340-3ksfpaf7	85	14	3	3	LS
cord-034340-3ksfpaf7	85	15	)	)	-RRB-
cord-034340-3ksfpaf7	85	16	(	(	-LRB-
cord-034340-3ksfpaf7	85	17	4	4	LS
cord-034340-3ksfpaf7	85	18	)	)	-RRB-
cord-034340-3ksfpaf7	85	19	(	(	-LRB-
cord-034340-3ksfpaf7	85	20	5	5	LS
cord-034340-3ksfpaf7	85	21	)	)	-RRB-
cord-034340-3ksfpaf7	85	22	(	(	-LRB-
cord-034340-3ksfpaf7	85	23	6	6	LS
cord-034340-3ksfpaf7	85	24	)	)	-RRB-
cord-034340-3ksfpaf7	85	25	(	(	-LRB-
cord-034340-3ksfpaf7	85	26	7	7	LS
cord-034340-3ksfpaf7	85	27	)	)	-RRB-
cord-034340-3ksfpaf7	85	28	(	(	-LRB-
cord-034340-3ksfpaf7	85	29	8)	8)	NNP
cord-034340-3ksfpaf7	85	30	(	(	-LRB-
cord-034340-3ksfpaf7	85	31	9	9	CD
cord-034340-3ksfpaf7	85	32	)	)	-RRB-
cord-034340-3ksfpaf7	85	33	(	(	-LRB-
cord-034340-3ksfpaf7	85	34	10	10	CD
cord-034340-3ksfpaf7	85	35	)	)	-RRB-
cord-034340-3ksfpaf7	85	36	(	(	-LRB-
cord-034340-3ksfpaf7	85	37	11	11	CD
cord-034340-3ksfpaf7	85	38	)	)	-RRB-
cord-034340-3ksfpaf7	85	39	(	(	-LRB-
cord-034340-3ksfpaf7	85	40	12	12	CD
cord-034340-3ksfpaf7	85	41	)	)	-RRB-
cord-034340-3ksfpaf7	85	42	(	(	-LRB-
cord-034340-3ksfpaf7	85	43	13	13	CD
cord-034340-3ksfpaf7	85	44	)	)	-RRB-
cord-034340-3ksfpaf7	85	45	(	(	-LRB-
cord-034340-3ksfpaf7	85	46	14	14	CD
cord-034340-3ksfpaf7	85	47	)	)	-RRB-
cord-034340-3ksfpaf7	85	48	(	(	-LRB-
cord-034340-3ksfpaf7	85	49	15	15	CD
cord-034340-3ksfpaf7	85	50	)	)	-RRB-
cord-034340-3ksfpaf7	85	51	(	(	-LRB-
cord-034340-3ksfpaf7	85	52	16	16	CD
cord-034340-3ksfpaf7	85	53	)	)	-RRB-
cord-034340-3ksfpaf7	85	54	years	year	NNS
cord-034340-3ksfpaf7	85	55	.	.	.
cord-034340-3ksfpaf7	86	1	The	the	DT
cord-034340-3ksfpaf7	86	2	first	first	JJ
cord-034340-3ksfpaf7	86	3	remission	remission	NN
cord-034340-3ksfpaf7	86	4	time	time	NN
cord-034340-3ksfpaf7	86	5	was	be	VBD
cord-034340-3ksfpaf7	86	6	5(1	5(1	NNP
cord-034340-3ksfpaf7	86	7	-	-	SYM
cord-034340-3ksfpaf7	86	8	17	17	CD
cord-034340-3ksfpaf7	86	9	)	)	-RRB-
cord-034340-3ksfpaf7	86	10	months	month	NNS
cord-034340-3ksfpaf7	86	11	.	.	.
cord-034340-3ksfpaf7	87	1	The	the	DT
cord-034340-3ksfpaf7	87	2	patients	patient	NNS
cord-034340-3ksfpaf7	87	3	were	be	VBD
cord-034340-3ksfpaf7	87	4	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	87	5	according	accord	VBG
cord-034340-3ksfpaf7	87	6	to	to	IN
cord-034340-3ksfpaf7	87	7	disease	disease	NN
cord-034340-3ksfpaf7	87	8	subtypes	subtype	NNS
cord-034340-3ksfpaf7	87	9	and	and	CC
cord-034340-3ksfpaf7	87	10	treatment	treatment	NN
cord-034340-3ksfpaf7	87	11	modalities	modality	NNS
cord-034340-3ksfpaf7	87	12	.	.	.
cord-034340-3ksfpaf7	88	1	There	there	EX
cord-034340-3ksfpaf7	88	2	was	be	VBD
cord-034340-3ksfpaf7	88	3	no	no	DT
cord-034340-3ksfpaf7	88	4	difference	difference	NN
cord-034340-3ksfpaf7	88	5	in	in	IN
cord-034340-3ksfpaf7	88	6	the	the	DT
cord-034340-3ksfpaf7	88	7	duration	duration	NN
cord-034340-3ksfpaf7	88	8	of	of	IN
cord-034340-3ksfpaf7	88	9	breastfeeding	breastfeeding	NN
cord-034340-3ksfpaf7	88	10	according	accord	VBG
cord-034340-3ksfpaf7	88	11	to	to	IN
cord-034340-3ksfpaf7	88	12	the	the	DT
cord-034340-3ksfpaf7	88	13	distribution	distribution	NN
cord-034340-3ksfpaf7	88	14	of	of	IN
cord-034340-3ksfpaf7	88	15	the	the	DT
cord-034340-3ksfpaf7	88	16	subtypes	subtype	NNS
cord-034340-3ksfpaf7	88	17	(	(	-LRB-
cord-034340-3ksfpaf7	88	18	p	p	NN
cord-034340-3ksfpaf7	88	19	=	=	SYM
cord-034340-3ksfpaf7	88	20	0,97	0,97	CD
cord-034340-3ksfpaf7	88	21	)	)	-RRB-
cord-034340-3ksfpaf7	88	22	.	.	.
cord-034340-3ksfpaf7	89	1	When	when	WRB
cord-034340-3ksfpaf7	89	2	the	the	DT
cord-034340-3ksfpaf7	89	3	breastfed	breastfed	JJ
cord-034340-3ksfpaf7	89	4	and	and	CC
cord-034340-3ksfpaf7	89	5	formula	formula	NN
cord-034340-3ksfpaf7	89	6	-	-	HYPH
cord-034340-3ksfpaf7	89	7	fed	feed	VBN
cord-034340-3ksfpaf7	89	8	patients	patient	NNS
cord-034340-3ksfpaf7	89	9	were	be	VBD
cord-034340-3ksfpaf7	89	10	compared	compare	VBN
cord-034340-3ksfpaf7	89	11	,	,	,
cord-034340-3ksfpaf7	89	12	there	there	EX
cord-034340-3ksfpaf7	89	13	was	be	VBD
cord-034340-3ksfpaf7	89	14	a	a	DT
cord-034340-3ksfpaf7	89	15	marginally	marginally	RB
cord-034340-3ksfpaf7	89	16	significant	significant	JJ
cord-034340-3ksfpaf7	89	17	difference	difference	NN
cord-034340-3ksfpaf7	89	18	in	in	IN
cord-034340-3ksfpaf7	89	19	terms	term	NNS
cord-034340-3ksfpaf7	89	20	of	of	IN
cord-034340-3ksfpaf7	89	21	first	first	JJ
cord-034340-3ksfpaf7	89	22	remission	remission	NN
cord-034340-3ksfpaf7	89	23	time	time	NN
cord-034340-3ksfpaf7	89	24	(	(	-LRB-
cord-034340-3ksfpaf7	89	25	p	p	NN
cord-034340-3ksfpaf7	89	26	=	=	SYM
cord-034340-3ksfpaf7	89	27	0,05	0,05	NN
cord-034340-3ksfpaf7	89	28	)	)	-RRB-
cord-034340-3ksfpaf7	89	29	,	,	,
cord-034340-3ksfpaf7	89	30	whereas	whereas	IN
cord-034340-3ksfpaf7	89	31	there	there	EX
cord-034340-3ksfpaf7	89	32	was	be	VBD
cord-034340-3ksfpaf7	89	33	a	a	DT
cord-034340-3ksfpaf7	89	34	significant	significant	JJ
cord-034340-3ksfpaf7	89	35	difference	difference	NN
cord-034340-3ksfpaf7	89	36	in	in	IN
cord-034340-3ksfpaf7	89	37	relapse	relapse	NN
cord-034340-3ksfpaf7	89	38	rate	rate	NN
cord-034340-3ksfpaf7	89	39	in	in	IN
cord-034340-3ksfpaf7	89	40	patients	patient	NNS
cord-034340-3ksfpaf7	89	41	who	who	WP
cord-034340-3ksfpaf7	89	42	introduced	introduce	VBD
cord-034340-3ksfpaf7	89	43	to	to	TO
cord-034340-3ksfpaf7	89	44	cow	cow	VB
cord-034340-3ksfpaf7	89	45	milk	milk	NN
cord-034340-3ksfpaf7	89	46	early	early	RB
cord-034340-3ksfpaf7	89	47	(	(	-LRB-
cord-034340-3ksfpaf7	89	48	<	<	NNP
cord-034340-3ksfpaf7	89	49	12	12	CD
cord-034340-3ksfpaf7	89	50	months	month	NNS
cord-034340-3ksfpaf7	89	51	)	)	-RRB-
cord-034340-3ksfpaf7	90	1	(	(	-LRB-
cord-034340-3ksfpaf7	90	2	p	p	NN
cord-034340-3ksfpaf7	90	3	=	=	SYM
cord-034340-3ksfpaf7	90	4	0,019	0,019	CD
cord-034340-3ksfpaf7	90	5	)	)	-RRB-
cord-034340-3ksfpaf7	90	6	.	.	.
cord-034340-3ksfpaf7	91	1	The	the	DT
cord-034340-3ksfpaf7	91	2	early	early	JJ
cord-034340-3ksfpaf7	91	3	risk	risk	NN
cord-034340-3ksfpaf7	91	4	factors	factor	NNS
cord-034340-3ksfpaf7	91	5	and	and	CC
cord-034340-3ksfpaf7	91	6	their	-PRON-	PRP$
cord-034340-3ksfpaf7	91	7	relationship	relationship	NN
cord-034340-3ksfpaf7	91	8	with	with	IN
cord-034340-3ksfpaf7	91	9	the	the	DT
cord-034340-3ksfpaf7	91	10	disease	disease	NN
cord-034340-3ksfpaf7	91	11	are	be	VBP
cord-034340-3ksfpaf7	91	12	presented	present	VBN
cord-034340-3ksfpaf7	91	13	in	in	IN
cord-034340-3ksfpaf7	91	14	Table	Table	NNP
cord-034340-3ksfpaf7	91	15	1	1	CD
cord-034340-3ksfpaf7	91	16	.	.	.
cord-034340-3ksfpaf7	92	1	Both	both	DT
cord-034340-3ksfpaf7	92	2	breastfeeding	breastfeeding	NN
cord-034340-3ksfpaf7	92	3	durations	duration	NNS
cord-034340-3ksfpaf7	92	4	and	and	CC
cord-034340-3ksfpaf7	92	5	maternal	maternal	JJ
cord-034340-3ksfpaf7	92	6	literacy	literacy	NN
cord-034340-3ksfpaf7	92	7	levels	level	NNS
cord-034340-3ksfpaf7	92	8	showed	show	VBD
cord-034340-3ksfpaf7	92	9	a	a	DT
cord-034340-3ksfpaf7	92	10	significant	significant	JJ
cord-034340-3ksfpaf7	92	11	difference	difference	NN
cord-034340-3ksfpaf7	92	12	in	in	IN
cord-034340-3ksfpaf7	92	13	terms	term	NNS
cord-034340-3ksfpaf7	92	14	of	of	IN
cord-034340-3ksfpaf7	92	15	relapse	relapse	NN
cord-034340-3ksfpaf7	92	16	rates	rate	NNS
cord-034340-3ksfpaf7	92	17	(	(	-LRB-
cord-034340-3ksfpaf7	92	18	p	p	NN
cord-034340-3ksfpaf7	92	19	=	=	SYM
cord-034340-3ksfpaf7	92	20	0,01	0,01	NN
cord-034340-3ksfpaf7	92	21	;	;	:
cord-034340-3ksfpaf7	92	22	p=0,03	p=0,03	XX
cord-034340-3ksfpaf7	92	23	,	,	,
cord-034340-3ksfpaf7	92	24	respectively	respectively	RB
cord-034340-3ksfpaf7	92	25	)	)	-RRB-
cord-034340-3ksfpaf7	92	26	.	.	.
cord-034340-3ksfpaf7	93	1	There	there	EX
cord-034340-3ksfpaf7	93	2	was	be	VBD
cord-034340-3ksfpaf7	93	3	no	no	DT
cord-034340-3ksfpaf7	93	4	significant	significant	JJ
cord-034340-3ksfpaf7	93	5	difference	difference	NN
cord-034340-3ksfpaf7	93	6	in	in	IN
cord-034340-3ksfpaf7	93	7	breastfeeding	breastfeeding	NN
cord-034340-3ksfpaf7	93	8	durations	duration	NNS
cord-034340-3ksfpaf7	93	9	and	and	CC
cord-034340-3ksfpaf7	93	10	gestational	gestational	JJ
cord-034340-3ksfpaf7	93	11	risks	risk	NNS
cord-034340-3ksfpaf7	93	12	between	between	IN
cord-034340-3ksfpaf7	93	13	the	the	DT
cord-034340-3ksfpaf7	93	14	patients	patient	NNS
cord-034340-3ksfpaf7	93	15	and	and	CC
cord-034340-3ksfpaf7	93	16	the	the	DT
cord-034340-3ksfpaf7	93	17	healthy	healthy	JJ
cord-034340-3ksfpaf7	93	18	group	group	NN
cord-034340-3ksfpaf7	93	19	(	(	-LRB-
cord-034340-3ksfpaf7	93	20	p	p	NN
cord-034340-3ksfpaf7	93	21	=	=	SYM
cord-034340-3ksfpaf7	93	22	0,1	0,1	XX
cord-034340-3ksfpaf7	93	23	;	;	:
cord-034340-3ksfpaf7	93	24	p=	p=	VB
cord-034340-3ksfpaf7	93	25	0,65	0,65	CD
cord-034340-3ksfpaf7	93	26	)	)	-RRB-
cord-034340-3ksfpaf7	93	27	,	,	,
cord-034340-3ksfpaf7	93	28	respectively	respectively	RB
cord-034340-3ksfpaf7	93	29	.	.	.
cord-034340-3ksfpaf7	94	1	However	however	RB
cord-034340-3ksfpaf7	94	2	,	,	,
cord-034340-3ksfpaf7	94	3	the	the	DT
cord-034340-3ksfpaf7	94	4	smoking	smoking	NN
cord-034340-3ksfpaf7	94	5	rate	rate	NN
cord-034340-3ksfpaf7	94	6	among	among	IN
cord-034340-3ksfpaf7	94	7	family	family	NN
cord-034340-3ksfpaf7	94	8	members	member	NNS
cord-034340-3ksfpaf7	94	9	was	be	VBD
cord-034340-3ksfpaf7	94	10	significantly	significantly	RB
cord-034340-3ksfpaf7	94	11	higher	high	JJR
cord-034340-3ksfpaf7	94	12	in	in	IN
cord-034340-3ksfpaf7	94	13	the	the	DT
cord-034340-3ksfpaf7	94	14	patient	patient	NN
cord-034340-3ksfpaf7	94	15	group	group	NN
cord-034340-3ksfpaf7	94	16	(	(	-LRB-
cord-034340-3ksfpaf7	94	17	p	p	NN
cord-034340-3ksfpaf7	94	18	=	=	SYM
cord-034340-3ksfpaf7	94	19	0,03	0,03	CD
cord-034340-3ksfpaf7	94	20	)	)	-RRB-
cord-034340-3ksfpaf7	94	21	.	.	.
cord-034340-3ksfpaf7	95	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	95	2	:	:	:
cord-034340-3ksfpaf7	96	1	In	in	IN
cord-034340-3ksfpaf7	96	2	patients	patient	NNS
cord-034340-3ksfpaf7	96	3	with	with	IN
cord-034340-3ksfpaf7	96	4	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	96	5	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	96	6	arthritis	arthritis	NN
cord-034340-3ksfpaf7	96	7	,	,	,
cord-034340-3ksfpaf7	96	8	breastfeeding	breastfeeding	NN
cord-034340-3ksfpaf7	96	9	rate	rate	NN
cord-034340-3ksfpaf7	96	10	and	and	CC
cord-034340-3ksfpaf7	96	11	duration	duration	NN
cord-034340-3ksfpaf7	96	12	did	do	VBD
cord-034340-3ksfpaf7	96	13	not	not	RB
cord-034340-3ksfpaf7	96	14	differ	differ	VB
cord-034340-3ksfpaf7	96	15	when	when	WRB
cord-034340-3ksfpaf7	96	16	compared	compare	VBN
cord-034340-3ksfpaf7	96	17	to	to	IN
cord-034340-3ksfpaf7	96	18	healthy	healthy	JJ
cord-034340-3ksfpaf7	96	19	controls	control	NNS
cord-034340-3ksfpaf7	96	20	.	.	.
cord-034340-3ksfpaf7	97	1	However	however	RB
cord-034340-3ksfpaf7	97	2	,	,	,
cord-034340-3ksfpaf7	97	3	breastfeeding	breastfeed	VBG
cord-034340-3ksfpaf7	97	4	duration	duration	NN
cord-034340-3ksfpaf7	97	5	,	,	,
cord-034340-3ksfpaf7	97	6	cow	cow	NN
cord-034340-3ksfpaf7	97	7	's	's	POS
cord-034340-3ksfpaf7	97	8	milk	milk	NN
cord-034340-3ksfpaf7	97	9	commence	commence	NN
cord-034340-3ksfpaf7	97	10	age	age	NN
cord-034340-3ksfpaf7	97	11	,	,	,
cord-034340-3ksfpaf7	97	12	and	and	CC
cord-034340-3ksfpaf7	97	13	maternal	maternal	JJ
cord-034340-3ksfpaf7	97	14	literacy	literacy	NN
cord-034340-3ksfpaf7	97	15	appeared	appear	VBD
cord-034340-3ksfpaf7	97	16	to	to	TO
cord-034340-3ksfpaf7	97	17	be	be	VB
cord-034340-3ksfpaf7	97	18	relevant	relevant	JJ
cord-034340-3ksfpaf7	97	19	to	to	IN
cord-034340-3ksfpaf7	97	20	the	the	DT
cord-034340-3ksfpaf7	97	21	relapse	relapse	NN
cord-034340-3ksfpaf7	97	22	rates	rate	NNS
cord-034340-3ksfpaf7	97	23	.	.	.
cord-034340-3ksfpaf7	98	1	Going	go	VBG
cord-034340-3ksfpaf7	98	2	to	to	IN
cord-034340-3ksfpaf7	98	3	preschool	preschool	VB
cord-034340-3ksfpaf7	98	4	both	both	DT
cord-034340-3ksfpaf7	98	5	influence	influence	VB
cord-034340-3ksfpaf7	98	6	the	the	DT
cord-034340-3ksfpaf7	98	7	remission	remission	NN
cord-034340-3ksfpaf7	98	8	time	time	NN
cord-034340-3ksfpaf7	98	9	and	and	CC
cord-034340-3ksfpaf7	98	10	relapse	relapse	NN
cord-034340-3ksfpaf7	98	11	rate	rate	NN
cord-034340-3ksfpaf7	98	12	.	.	.
cord-034340-3ksfpaf7	99	1	These	these	DT
cord-034340-3ksfpaf7	99	2	findings	finding	NNS
cord-034340-3ksfpaf7	99	3	suggest	suggest	VBP
cord-034340-3ksfpaf7	99	4	a	a	DT
cord-034340-3ksfpaf7	99	5	role	role	NN
cord-034340-3ksfpaf7	99	6	for	for	IN
cord-034340-3ksfpaf7	99	7	parental	parental	JJ
cord-034340-3ksfpaf7	99	8	attitude	attitude	NN
cord-034340-3ksfpaf7	99	9	and	and	CC
cord-034340-3ksfpaf7	99	10	nutritional	nutritional	JJ
cord-034340-3ksfpaf7	99	11	status	status	NN
cord-034340-3ksfpaf7	99	12	during	during	IN
cord-034340-3ksfpaf7	99	13	early	early	JJ
cord-034340-3ksfpaf7	99	14	childhood	childhood	NN
cord-034340-3ksfpaf7	99	15	in	in	IN
cord-034340-3ksfpaf7	99	16	the	the	DT
cord-034340-3ksfpaf7	99	17	course	course	NN
cord-034340-3ksfpaf7	99	18	of	of	IN
cord-034340-3ksfpaf7	99	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	99	20	.	.	.
cord-034340-3ksfpaf7	100	1	None	none	NN
cord-034340-3ksfpaf7	100	2	declared	declare	VBD
cord-034340-3ksfpaf7	100	3	Introduction	introduction	NN
cord-034340-3ksfpaf7	100	4	:	:	:
cord-034340-3ksfpaf7	100	5	Immunogenicity	immunogenicity	NN
cord-034340-3ksfpaf7	100	6	and	and	CC
cord-034340-3ksfpaf7	100	7	low	low	JJ
cord-034340-3ksfpaf7	100	8	trough	trough	NN
cord-034340-3ksfpaf7	100	9	concentrations	concentration	NNS
cord-034340-3ksfpaf7	100	10	have	have	VBP
cord-034340-3ksfpaf7	100	11	been	be	VBN
cord-034340-3ksfpaf7	100	12	associated	associate	VBN
cord-034340-3ksfpaf7	100	13	with	with	IN
cord-034340-3ksfpaf7	100	14	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	100	15	treatment	treatment	NN
cord-034340-3ksfpaf7	100	16	failure	failure	NN
cord-034340-3ksfpaf7	100	17	in	in	IN
cord-034340-3ksfpaf7	100	18	several	several	JJ
cord-034340-3ksfpaf7	100	19	studies	study	NNS
cord-034340-3ksfpaf7	100	20	of	of	IN
cord-034340-3ksfpaf7	100	21	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	100	22	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	100	23	diseases	disease	NNS
cord-034340-3ksfpaf7	100	24	,	,	,
cord-034340-3ksfpaf7	100	25	indicating	indicate	VBG
cord-034340-3ksfpaf7	100	26	the	the	DT
cord-034340-3ksfpaf7	100	27	possible	possible	JJ
cord-034340-3ksfpaf7	100	28	value	value	NN
cord-034340-3ksfpaf7	100	29	of	of	IN
cord-034340-3ksfpaf7	100	30	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	100	31	drug	drug	NN
cord-034340-3ksfpaf7	100	32	monitoring	monitoring	NN
cord-034340-3ksfpaf7	100	33	(	(	-LRB-
cord-034340-3ksfpaf7	100	34	TDM	TDM	NNP
cord-034340-3ksfpaf7	100	35	)	)	-RRB-
cord-034340-3ksfpaf7	100	36	.	.	.
cord-034340-3ksfpaf7	101	1	Adalimumab	Adalimumab	NNS
cord-034340-3ksfpaf7	101	2	efficacy	efficacy	NN
cord-034340-3ksfpaf7	101	3	may	may	MD
cord-034340-3ksfpaf7	101	4	be	be	VB
cord-034340-3ksfpaf7	101	5	improved	improve	VBN
cord-034340-3ksfpaf7	101	6	by	by	IN
cord-034340-3ksfpaf7	101	7	changing	change	VBG
cord-034340-3ksfpaf7	101	8	dose	dose	NN
cord-034340-3ksfpaf7	101	9	or	or	CC
cord-034340-3ksfpaf7	101	10	treatment	treatment	NN
cord-034340-3ksfpaf7	101	11	intervals	interval	NNS
cord-034340-3ksfpaf7	101	12	based	base	VBN
cord-034340-3ksfpaf7	101	13	on	on	IN
cord-034340-3ksfpaf7	101	14	drug	drug	NN
cord-034340-3ksfpaf7	101	15	concentrations	concentration	NNS
cord-034340-3ksfpaf7	101	16	.	.	.
cord-034340-3ksfpaf7	102	1	However	however	RB
cord-034340-3ksfpaf7	102	2	,	,	,
cord-034340-3ksfpaf7	102	3	lack	lack	NN
cord-034340-3ksfpaf7	102	4	of	of	IN
cord-034340-3ksfpaf7	102	5	standardization	standardization	NN
cord-034340-3ksfpaf7	102	6	,	,	,
cord-034340-3ksfpaf7	102	7	assay	assay	NN
cord-034340-3ksfpaf7	102	8	heterogeneity	heterogeneity	NN
cord-034340-3ksfpaf7	102	9	,	,	,
cord-034340-3ksfpaf7	102	10	and	and	CC
cord-034340-3ksfpaf7	102	11	paucity	paucity	NN
cord-034340-3ksfpaf7	102	12	of	of	IN
cord-034340-3ksfpaf7	102	13	research	research	NN
cord-034340-3ksfpaf7	102	14	hinder	hinder	VBP
cord-034340-3ksfpaf7	102	15	the	the	DT
cord-034340-3ksfpaf7	102	16	implementation	implementation	NN
cord-034340-3ksfpaf7	102	17	of	of	IN
cord-034340-3ksfpaf7	102	18	TDM	tdm	NN
cord-034340-3ksfpaf7	102	19	in	in	IN
cord-034340-3ksfpaf7	102	20	clinical	clinical	JJ
cord-034340-3ksfpaf7	102	21	practice	practice	NN
cord-034340-3ksfpaf7	102	22	.	.	.
cord-034340-3ksfpaf7	103	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	103	2	:	:	:
cord-034340-3ksfpaf7	103	3	To	to	TO
cord-034340-3ksfpaf7	103	4	assess	assess	VB
cord-034340-3ksfpaf7	103	5	the	the	DT
cord-034340-3ksfpaf7	103	6	relationship	relationship	NN
cord-034340-3ksfpaf7	103	7	of	of	IN
cord-034340-3ksfpaf7	103	8	trough	trough	NN
cord-034340-3ksfpaf7	103	9	concentrations	concentration	NNS
cord-034340-3ksfpaf7	103	10	,	,	,
cord-034340-3ksfpaf7	103	11	immunogenicity	immunogenicity	NN
cord-034340-3ksfpaf7	103	12	and	and	CC
cord-034340-3ksfpaf7	103	13	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	103	14	response	response	NN
cord-034340-3ksfpaf7	103	15	in	in	IN
cord-034340-3ksfpaf7	103	16	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	103	17	patients	patient	NNS
cord-034340-3ksfpaf7	103	18	with	with	IN
cord-034340-3ksfpaf7	103	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	103	20	.	.	.
cord-034340-3ksfpaf7	104	1	Methods	method	NNS
cord-034340-3ksfpaf7	104	2	:	:	:
cord-034340-3ksfpaf7	105	1	Monocentric	monocentric	JJ
cord-034340-3ksfpaf7	105	2	cohort	cohort	NN
cord-034340-3ksfpaf7	105	3	study	study	NN
cord-034340-3ksfpaf7	105	4	of	of	IN
cord-034340-3ksfpaf7	105	5	patients	patient	NNS
cord-034340-3ksfpaf7	105	6	≤18	≤18	XX
cord-034340-3ksfpaf7	106	1	years	year	NNS
cord-034340-3ksfpaf7	106	2	with	with	IN
cord-034340-3ksfpaf7	106	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	106	4	treated	treat	VBD
cord-034340-3ksfpaf7	106	5	with	with	IN
cord-034340-3ksfpaf7	106	6	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	106	7	due	due	JJ
cord-034340-3ksfpaf7	106	8	to	to	IN
cord-034340-3ksfpaf7	106	9	active	active	JJ
cord-034340-3ksfpaf7	106	10	arthritis	arthritis	NN
cord-034340-3ksfpaf7	106	11	.	.	.
cord-034340-3ksfpaf7	107	1	Clinical	clinical	JJ
cord-034340-3ksfpaf7	107	2	data	datum	NNS
cord-034340-3ksfpaf7	107	3	and	and	CC
cord-034340-3ksfpaf7	107	4	plasma	plasma	NN
cord-034340-3ksfpaf7	107	5	samples	sample	NNS
cord-034340-3ksfpaf7	107	6	were	be	VBD
cord-034340-3ksfpaf7	107	7	collected	collect	VBN
cord-034340-3ksfpaf7	107	8	during	during	IN
cord-034340-3ksfpaf7	107	9	routine	routine	JJ
cord-034340-3ksfpaf7	107	10	follow	follow	NN
cord-034340-3ksfpaf7	107	11	-	-	HYPH
cord-034340-3ksfpaf7	107	12	up	up	NN
cord-034340-3ksfpaf7	107	13	.	.	.
cord-034340-3ksfpaf7	108	1	Adalimumab	Adalimumab	NNS
cord-034340-3ksfpaf7	108	2	trough	trough	NN
cord-034340-3ksfpaf7	108	3	concentrations	concentration	NNS
cord-034340-3ksfpaf7	108	4	were	be	VBD
cord-034340-3ksfpaf7	108	5	measured	measure	VBN
cord-034340-3ksfpaf7	108	6	by	by	IN
cord-034340-3ksfpaf7	108	7	liquid	liquid	JJ
cord-034340-3ksfpaf7	108	8	chromatographytandem	chromatographytandem	JJ
cord-034340-3ksfpaf7	108	9	mass	mass	NN
cord-034340-3ksfpaf7	108	10	spectrometry	spectrometry	NNP
cord-034340-3ksfpaf7	108	11	(	(	-LRB-
cord-034340-3ksfpaf7	108	12	LC	LC	NNP
cord-034340-3ksfpaf7	108	13	-	-	HYPH
cord-034340-3ksfpaf7	108	14	MS	MS	NNP
cord-034340-3ksfpaf7	108	15	/	/	SYM
cord-034340-3ksfpaf7	108	16	MS	MS	NNP
cord-034340-3ksfpaf7	108	17	)	)	-RRB-
cord-034340-3ksfpaf7	108	18	.	.	.
cord-034340-3ksfpaf7	109	1	Anti	Anti	NNP
cord-034340-3ksfpaf7	109	2	-	-	JJ
cord-034340-3ksfpaf7	109	3	adalimumab	adalimumab	JJ
cord-034340-3ksfpaf7	109	4	antibodies	antibody	NNS
cord-034340-3ksfpaf7	109	5	were	be	VBD
cord-034340-3ksfpaf7	109	6	measured	measure	VBN
cord-034340-3ksfpaf7	109	7	in	in	IN
cord-034340-3ksfpaf7	109	8	samples	sample	NNS
cord-034340-3ksfpaf7	109	9	with	with	IN
cord-034340-3ksfpaf7	109	10	trough	trough	NN
cord-034340-3ksfpaf7	109	11	concentrations	concentration	NNS
cord-034340-3ksfpaf7	109	12	<	<	XX
cord-034340-3ksfpaf7	110	1	5mg	5mg	NNP
cord-034340-3ksfpaf7	110	2	/	/	SYM
cord-034340-3ksfpaf7	110	3	l	l	NN
cord-034340-3ksfpaf7	110	4	.	.	.
cord-034340-3ksfpaf7	111	1	Disease	disease	NN
cord-034340-3ksfpaf7	111	2	activity	activity	NN
cord-034340-3ksfpaf7	111	3	was	be	VBD
cord-034340-3ksfpaf7	111	4	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	111	5	using	use	VBG
cord-034340-3ksfpaf7	111	6	the	the	DT
cord-034340-3ksfpaf7	111	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	111	8	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	111	9	Arthritis	Arthritis	NNP
cord-034340-3ksfpaf7	111	10	Disease	Disease	NNP
cord-034340-3ksfpaf7	111	11	Activity	Activity	NNP
cord-034340-3ksfpaf7	111	12	Score	Score	NNP
cord-034340-3ksfpaf7	111	13	with	with	IN
cord-034340-3ksfpaf7	111	14	71	71	CD
cord-034340-3ksfpaf7	111	15	joint	joint	JJ
cord-034340-3ksfpaf7	111	16	count	count	NN
cord-034340-3ksfpaf7	111	17	(	(	-LRB-
cord-034340-3ksfpaf7	111	18	cJADAS71	cJADAS71	NNP
cord-034340-3ksfpaf7	111	19	)	)	-RRB-
cord-034340-3ksfpaf7	111	20	.	.	.
cord-034340-3ksfpaf7	112	1	Response	response	NN
cord-034340-3ksfpaf7	112	2	to	to	IN
cord-034340-3ksfpaf7	112	3	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	112	4	was	be	VBD
cord-034340-3ksfpaf7	112	5	defined	define	VBN
cord-034340-3ksfpaf7	112	6	as	as	IN
cord-034340-3ksfpaf7	112	7	at	at	RB
cord-034340-3ksfpaf7	112	8	least	least	JJS
cord-034340-3ksfpaf7	112	9	50	50	CD
cord-034340-3ksfpaf7	112	10	%	%	NN
cord-034340-3ksfpaf7	112	11	reduction	reduction	NN
cord-034340-3ksfpaf7	112	12	of	of	IN
cord-034340-3ksfpaf7	112	13	disease	disease	NN
cord-034340-3ksfpaf7	112	14	activity	activity	NN
cord-034340-3ksfpaf7	112	15	within	within	IN
cord-034340-3ksfpaf7	112	16	3	3	CD
cord-034340-3ksfpaf7	112	17	months	month	NNS
cord-034340-3ksfpaf7	112	18	of	of	IN
cord-034340-3ksfpaf7	112	19	therapy	therapy	NN
cord-034340-3ksfpaf7	112	20	followed	follow	VBN
cord-034340-3ksfpaf7	112	21	by	by	IN
cord-034340-3ksfpaf7	112	22	clinical	clinical	JJ
cord-034340-3ksfpaf7	112	23	inactive	inactive	JJ
cord-034340-3ksfpaf7	112	24	disease	disease	NN
cord-034340-3ksfpaf7	112	25	or	or	CC
cord-034340-3ksfpaf7	112	26	minimal	minimal	JJ
cord-034340-3ksfpaf7	112	27	disease	disease	NN
cord-034340-3ksfpaf7	112	28	activity	activity	NN
cord-034340-3ksfpaf7	112	29	after	after	IN
cord-034340-3ksfpaf7	112	30	6	6	CD
cord-034340-3ksfpaf7	112	31	months	month	NNS
cord-034340-3ksfpaf7	112	32	.	.	.
cord-034340-3ksfpaf7	113	1	The	the	DT
cord-034340-3ksfpaf7	113	2	latter	latter	JJ
cord-034340-3ksfpaf7	113	3	was	be	VBD
cord-034340-3ksfpaf7	113	4	defined	define	VBN
cord-034340-3ksfpaf7	113	5	as	as	IN
cord-034340-3ksfpaf7	113	6	cJADAS71	cJADAS71	NNP
cord-034340-3ksfpaf7	113	7	≤1.5	≤1.5	NNP
cord-034340-3ksfpaf7	113	8	and	and	CC
cord-034340-3ksfpaf7	113	9	≤2.5	≤2.5	NNP
cord-034340-3ksfpaf7	113	10	,	,	,
cord-034340-3ksfpaf7	113	11	for	for	IN
cord-034340-3ksfpaf7	113	12	oligoarthritis	oligoarthritis	NNP
cord-034340-3ksfpaf7	113	13	and	and	CC
cord-034340-3ksfpaf7	113	14	polyarthritis	polyarthritis	NNP
cord-034340-3ksfpaf7	113	15	,	,	,
cord-034340-3ksfpaf7	113	16	respectively	respectively	RB
cord-034340-3ksfpaf7	113	17	,	,	,
cord-034340-3ksfpaf7	113	18	or	or	CC
cord-034340-3ksfpaf7	113	19	an	an	DT
cord-034340-3ksfpaf7	113	20	active	active	JJ
cord-034340-3ksfpaf7	113	21	joint	joint	JJ
cord-034340-3ksfpaf7	113	22	count	count	NN
cord-034340-3ksfpaf7	113	23	equal	equal	JJ
cord-034340-3ksfpaf7	113	24	to	to	IN
cord-034340-3ksfpaf7	113	25	zero	zero	CD
cord-034340-3ksfpaf7	113	26	when	when	WRB
cord-034340-3ksfpaf7	113	27	cJADAS71	cJADAS71	NNP
cord-034340-3ksfpaf7	113	28	was	be	VBD
cord-034340-3ksfpaf7	113	29	unavailable	unavailable	JJ
cord-034340-3ksfpaf7	113	30	.	.	.
cord-034340-3ksfpaf7	114	1	Results	result	NNS
cord-034340-3ksfpaf7	114	2	:	:	:
cord-034340-3ksfpaf7	115	1	36	36	CD
cord-034340-3ksfpaf7	115	2	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	115	3	trough	trough	NN
cord-034340-3ksfpaf7	115	4	samples	sample	NNS
cord-034340-3ksfpaf7	115	5	were	be	VBD
cord-034340-3ksfpaf7	115	6	available	available	JJ
cord-034340-3ksfpaf7	115	7	from	from	IN
cord-034340-3ksfpaf7	115	8	35	35	CD
cord-034340-3ksfpaf7	115	9	JIA	JIA	NNP
cord-034340-3ksfpaf7	115	10	patients	patient	NNS
cord-034340-3ksfpaf7	115	11	.	.	.
cord-034340-3ksfpaf7	116	1	Although	although	IN
cord-034340-3ksfpaf7	116	2	there	there	EX
cord-034340-3ksfpaf7	116	3	was	be	VBD
cord-034340-3ksfpaf7	116	4	no	no	DT
cord-034340-3ksfpaf7	116	5	significant	significant	JJ
cord-034340-3ksfpaf7	116	6	difference	difference	NN
cord-034340-3ksfpaf7	116	7	in	in	IN
cord-034340-3ksfpaf7	116	8	median	median	JJ
cord-034340-3ksfpaf7	116	9	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	116	10	dose	dose	VBP
cord-034340-3ksfpaf7	116	11	,	,	,
cord-034340-3ksfpaf7	116	12	trough	trough	NN
cord-034340-3ksfpaf7	116	13	concentrations	concentration	NNS
cord-034340-3ksfpaf7	116	14	were	be	VBD
cord-034340-3ksfpaf7	116	15	significantly	significantly	RB
cord-034340-3ksfpaf7	116	16	lower	low	JJR
cord-034340-3ksfpaf7	116	17	in	in	IN
cord-034340-3ksfpaf7	116	18	patients	patient	NNS
cord-034340-3ksfpaf7	116	19	with	with	IN
cord-034340-3ksfpaf7	116	20	secondary	secondary	JJ
cord-034340-3ksfpaf7	116	21	failure	failure	NN
cord-034340-3ksfpaf7	116	22	compared	compare	VBN
cord-034340-3ksfpaf7	116	23	to	to	IN
cord-034340-3ksfpaf7	116	24	primary	primary	JJ
cord-034340-3ksfpaf7	116	25	failure	failure	NN
cord-034340-3ksfpaf7	116	26	or	or	CC
cord-034340-3ksfpaf7	116	27	an	an	DT
cord-034340-3ksfpaf7	116	28	adequate	adequate	JJ
cord-034340-3ksfpaf7	116	29	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	116	30	response	response	NN
cord-034340-3ksfpaf7	116	31	(	(	-LRB-
cord-034340-3ksfpaf7	116	32	p	p	NN
cord-034340-3ksfpaf7	116	33	-	-	HYPH
cord-034340-3ksfpaf7	116	34	values	value	NNS
cord-034340-3ksfpaf7	116	35	<	<	XX
cord-034340-3ksfpaf7	116	36	0.01	0.01	CD
cord-034340-3ksfpaf7	116	37	)	)	-RRB-
cord-034340-3ksfpaf7	116	38	.	.	.
cord-034340-3ksfpaf7	117	1	In	in	IN
cord-034340-3ksfpaf7	117	2	addition	addition	NN
cord-034340-3ksfpaf7	117	3	,	,	,
cord-034340-3ksfpaf7	117	4	there	there	EX
cord-034340-3ksfpaf7	117	5	were	be	VBD
cord-034340-3ksfpaf7	117	6	11	11	CD
cord-034340-3ksfpaf7	117	7	samples	sample	NNS
cord-034340-3ksfpaf7	117	8	with	with	IN
cord-034340-3ksfpaf7	117	9	trough	trough	NN
cord-034340-3ksfpaf7	117	10	concentrations	concentration	NNS
cord-034340-3ksfpaf7	117	11	<	<	XX
cord-034340-3ksfpaf7	117	12	5mg	5mg	NNP
cord-034340-3ksfpaf7	117	13	/	/	SYM
cord-034340-3ksfpaf7	117	14	l	l	NNP
cord-034340-3ksfpaf7	117	15	,	,	,
cord-034340-3ksfpaf7	117	16	9	9	CD
cord-034340-3ksfpaf7	117	17	in	in	IN
cord-034340-3ksfpaf7	117	18	the	the	DT
cord-034340-3ksfpaf7	117	19	group	group	NN
cord-034340-3ksfpaf7	117	20	with	with	IN
cord-034340-3ksfpaf7	117	21	secondary	secondary	JJ
cord-034340-3ksfpaf7	117	22	failure	failure	NN
cord-034340-3ksfpaf7	117	23	and	and	CC
cord-034340-3ksfpaf7	117	24	2	2	CD
cord-034340-3ksfpaf7	117	25	in	in	IN
cord-034340-3ksfpaf7	117	26	the	the	DT
cord-034340-3ksfpaf7	117	27	group	group	NN
cord-034340-3ksfpaf7	117	28	with	with	IN
cord-034340-3ksfpaf7	117	29	adequate	adequate	JJ
cord-034340-3ksfpaf7	117	30	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	117	31	response	response	NN
cord-034340-3ksfpaf7	117	32	(	(	-LRB-
cord-034340-3ksfpaf7	117	33	Table	table	NN
cord-034340-3ksfpaf7	117	34	1	1	CD
cord-034340-3ksfpaf7	117	35	)	)	-RRB-
cord-034340-3ksfpaf7	117	36	.	.	.
cord-034340-3ksfpaf7	118	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	118	2	:	:	:
cord-034340-3ksfpaf7	119	1	Adalimumab	Adalimumab	NNS
cord-034340-3ksfpaf7	119	2	trough	trough	NN
cord-034340-3ksfpaf7	119	3	concentrations	concentration	NNS
cord-034340-3ksfpaf7	119	4	were	be	VBD
cord-034340-3ksfpaf7	119	5	significantly	significantly	RB
cord-034340-3ksfpaf7	119	6	lower	low	JJR
cord-034340-3ksfpaf7	119	7	in	in	IN
cord-034340-3ksfpaf7	119	8	JIA	JIA	NNP
cord-034340-3ksfpaf7	119	9	patients	patient	NNS
cord-034340-3ksfpaf7	119	10	with	with	IN
cord-034340-3ksfpaf7	119	11	secondary	secondary	JJ
cord-034340-3ksfpaf7	119	12	failure	failure	NN
cord-034340-3ksfpaf7	119	13	compared	compare	VBN
cord-034340-3ksfpaf7	119	14	to	to	IN
cord-034340-3ksfpaf7	119	15	primary	primary	JJ
cord-034340-3ksfpaf7	119	16	failure	failure	NN
cord-034340-3ksfpaf7	119	17	or	or	CC
cord-034340-3ksfpaf7	119	18	an	an	DT
cord-034340-3ksfpaf7	119	19	adequate	adequate	JJ
cord-034340-3ksfpaf7	119	20	response	response	NN
cord-034340-3ksfpaf7	119	21	to	to	IN
cord-034340-3ksfpaf7	119	22	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	119	23	.	.	.
cord-034340-3ksfpaf7	120	1	Anti	Anti	NNP
cord-034340-3ksfpaf7	120	2	-	-	JJ
cord-034340-3ksfpaf7	120	3	adalimumab	adalimumab	JJ
cord-034340-3ksfpaf7	120	4	antibodies	antibody	NNS
cord-034340-3ksfpaf7	120	5	were	be	VBD
cord-034340-3ksfpaf7	120	6	present	present	JJ
cord-034340-3ksfpaf7	120	7	in	in	IN
cord-034340-3ksfpaf7	120	8	8	8	CD
cord-034340-3ksfpaf7	120	9	out	out	IN
cord-034340-3ksfpaf7	120	10	of	of	IN
cord-034340-3ksfpaf7	120	11	11	11	CD
cord-034340-3ksfpaf7	120	12	samples	sample	NNS
cord-034340-3ksfpaf7	120	13	with	with	IN
cord-034340-3ksfpaf7	120	14	trough	trough	NN
cord-034340-3ksfpaf7	120	15	concentrations	concentration	NNS
cord-034340-3ksfpaf7	120	16	<	<	XX
cord-034340-3ksfpaf7	121	1	5mg	5mg	NNP
cord-034340-3ksfpaf7	121	2	/	/	SYM
cord-034340-3ksfpaf7	121	3	l	l	NN
cord-034340-3ksfpaf7	121	4	.	.	.
cord-034340-3ksfpaf7	122	1	Adalimumab	Adalimumab	NNS
cord-034340-3ksfpaf7	122	2	trough	trough	IN
cord-034340-3ksfpaf7	122	3	concentration	concentration	NN
cord-034340-3ksfpaf7	122	4	measurements	measurement	NNS
cord-034340-3ksfpaf7	122	5	may	may	MD
cord-034340-3ksfpaf7	122	6	identify	identify	VB
cord-034340-3ksfpaf7	122	7	JIA	JIA	NNP
cord-034340-3ksfpaf7	122	8	patients	patient	NNS
cord-034340-3ksfpaf7	122	9	that	that	WDT
cord-034340-3ksfpaf7	122	10	would	would	MD
cord-034340-3ksfpaf7	122	11	benefit	benefit	VB
cord-034340-3ksfpaf7	122	12	from	from	IN
cord-034340-3ksfpaf7	122	13	increased	increase	VBN
cord-034340-3ksfpaf7	122	14	doses	dose	NNS
cord-034340-3ksfpaf7	122	15	or	or	CC
cord-034340-3ksfpaf7	122	16	shorter	short	JJR
cord-034340-3ksfpaf7	122	17	treatment	treatment	NN
cord-034340-3ksfpaf7	122	18	intervals	interval	NNS
cord-034340-3ksfpaf7	122	19	.	.	.
cord-034340-3ksfpaf7	123	1	In	in	IN
cord-034340-3ksfpaf7	123	2	addition	addition	NN
cord-034340-3ksfpaf7	123	3	,	,	,
cord-034340-3ksfpaf7	123	4	JIA	JIA	NNP
cord-034340-3ksfpaf7	123	5	patients	patient	NNS
cord-034340-3ksfpaf7	123	6	with	with	IN
cord-034340-3ksfpaf7	123	7	primary	primary	JJ
cord-034340-3ksfpaf7	123	8	failure	failure	NN
cord-034340-3ksfpaf7	123	9	and	and	CC
cord-034340-3ksfpaf7	123	10	adequate	adequate	JJ
cord-034340-3ksfpaf7	123	11	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	123	12	trough	trough	IN
cord-034340-3ksfpaf7	123	13	concentrations	concentration	NNS
cord-034340-3ksfpaf7	123	14	may	may	MD
cord-034340-3ksfpaf7	123	15	respond	respond	VB
cord-034340-3ksfpaf7	123	16	better	better	RB
cord-034340-3ksfpaf7	123	17	to	to	IN
cord-034340-3ksfpaf7	123	18	biologic	biologic	JJ
cord-034340-3ksfpaf7	123	19	agents	agent	NNS
cord-034340-3ksfpaf7	123	20	with	with	IN
cord-034340-3ksfpaf7	123	21	other	other	JJ
cord-034340-3ksfpaf7	123	22	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	123	23	targets	target	NNS
cord-034340-3ksfpaf7	123	24	.	.	.
cord-034340-3ksfpaf7	124	1	Although	although	IN
cord-034340-3ksfpaf7	124	2	biologic	biologic	JJ
cord-034340-3ksfpaf7	124	3	agents	agent	NNS
cord-034340-3ksfpaf7	124	4	have	have	VBP
cord-034340-3ksfpaf7	124	5	improved	improve	VBN
cord-034340-3ksfpaf7	124	6	disease	disease	NN
cord-034340-3ksfpaf7	124	7	outcome	outcome	NN
cord-034340-3ksfpaf7	124	8	of	of	IN
cord-034340-3ksfpaf7	124	9	patients	patient	NNS
cord-034340-3ksfpaf7	124	10	with	with	IN
cord-034340-3ksfpaf7	124	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	124	12	,	,	,
cord-034340-3ksfpaf7	124	13	concentration	concentration	NN
cord-034340-3ksfpaf7	124	14	measurements	measurement	NNS
cord-034340-3ksfpaf7	124	15	using	use	VBG
cord-034340-3ksfpaf7	124	16	reliable	reliable	JJ
cord-034340-3ksfpaf7	124	17	and	and	CC
cord-034340-3ksfpaf7	124	18	cost	cost	NN
cord-034340-3ksfpaf7	124	19	-	-	HYPH
cord-034340-3ksfpaf7	124	20	effective	effective	JJ
cord-034340-3ksfpaf7	124	21	methods	method	NNS
cord-034340-3ksfpaf7	124	22	,	,	,
cord-034340-3ksfpaf7	124	23	such	such	JJ
cord-034340-3ksfpaf7	124	24	as	as	IN
cord-034340-3ksfpaf7	124	25	LC	LC	NNP
cord-034340-3ksfpaf7	124	26	-	-	HYPH
cord-034340-3ksfpaf7	124	27	MS	MS	NNP
cord-034340-3ksfpaf7	124	28	/	/	SYM
cord-034340-3ksfpaf7	124	29	MS	MS	NNP
cord-034340-3ksfpaf7	124	30	,	,	,
cord-034340-3ksfpaf7	124	31	could	could	MD
cord-034340-3ksfpaf7	124	32	further	further	RB
cord-034340-3ksfpaf7	124	33	improve	improve	VB
cord-034340-3ksfpaf7	124	34	efficacy	efficacy	NN
cord-034340-3ksfpaf7	124	35	of	of	IN
cord-034340-3ksfpaf7	124	36	biologic	biologic	JJ
cord-034340-3ksfpaf7	124	37	agents	agent	NNS
cord-034340-3ksfpaf7	124	38	and	and	CC
cord-034340-3ksfpaf7	124	39	guide	guide	VB
cord-034340-3ksfpaf7	124	40	treat	treat	VB
cord-034340-3ksfpaf7	124	41	-	-	HYPH
cord-034340-3ksfpaf7	124	42	to	to	IN
cord-034340-3ksfpaf7	124	43	-	-	HYPH
cord-034340-3ksfpaf7	124	44	target	target	NN
cord-034340-3ksfpaf7	124	45	strategies	strategy	NNS
cord-034340-3ksfpaf7	124	46	.	.	.
cord-034340-3ksfpaf7	125	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	125	2	:	:	:
cord-034340-3ksfpaf7	126	1	Most	Most	JJS
cord-034340-3ksfpaf7	126	2	studies	study	NNS
cord-034340-3ksfpaf7	126	3	of	of	IN
cord-034340-3ksfpaf7	126	4	physical	physical	JJ
cord-034340-3ksfpaf7	126	5	fitness	fitness	NN
cord-034340-3ksfpaf7	126	6	(	(	-LRB-
cord-034340-3ksfpaf7	126	7	PF	PF	NNP
cord-034340-3ksfpaf7	126	8	)	)	-RRB-
cord-034340-3ksfpaf7	126	9	in	in	IN
cord-034340-3ksfpaf7	126	10	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	126	11	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	126	12	arthritis	arthritis	NN
cord-034340-3ksfpaf7	126	13	(	(	-LRB-
cord-034340-3ksfpaf7	126	14	JIA	JIA	NNP
cord-034340-3ksfpaf7	126	15	)	)	-RRB-
cord-034340-3ksfpaf7	126	16	have	have	VBP
cord-034340-3ksfpaf7	126	17	shown	show	VBN
cord-034340-3ksfpaf7	126	18	decreased	decrease	VBN
cord-034340-3ksfpaf7	126	19	levels	level	NNS
cord-034340-3ksfpaf7	126	20	of	of	IN
cord-034340-3ksfpaf7	126	21	maximal	maximal	JJ
cord-034340-3ksfpaf7	126	22	oxygen	oxygen	NN
cord-034340-3ksfpaf7	126	23	consumption	consumption	NN
cord-034340-3ksfpaf7	126	24	(	(	-LRB-
cord-034340-3ksfpaf7	126	25	VO	VO	NNP
cord-034340-3ksfpaf7	126	26	2	2	CD
cord-034340-3ksfpaf7	126	27	max	max	NNP
cord-034340-3ksfpaf7	126	28	)	)	-RRB-
cord-034340-3ksfpaf7	126	29	compared	compare	VBN
cord-034340-3ksfpaf7	126	30	to	to	IN
cord-034340-3ksfpaf7	126	31	healthy	healthy	JJ
cord-034340-3ksfpaf7	126	32	peers	peer	NNS
cord-034340-3ksfpaf7	126	33	.	.	.
cord-034340-3ksfpaf7	127	1	In	in	IN
cord-034340-3ksfpaf7	127	2	JIA	JIA	NNP
cord-034340-3ksfpaf7	127	3	,	,	,
cord-034340-3ksfpaf7	127	4	boys	boy	NNS
cord-034340-3ksfpaf7	127	5	have	have	VBP
cord-034340-3ksfpaf7	127	6	higher	high	JJR
cord-034340-3ksfpaf7	127	7	PF	pf	NN
cord-034340-3ksfpaf7	127	8	-	-	HYPH
cord-034340-3ksfpaf7	127	9	levels	level	NNS
cord-034340-3ksfpaf7	127	10	than	than	IN
cord-034340-3ksfpaf7	127	11	girls	girl	NNS
cord-034340-3ksfpaf7	127	12	and	and	CC
cord-034340-3ksfpaf7	127	13	younger	young	JJR
cord-034340-3ksfpaf7	127	14	children	child	NNS
cord-034340-3ksfpaf7	127	15	have	have	VBP
cord-034340-3ksfpaf7	127	16	higher	high	JJR
cord-034340-3ksfpaf7	127	17	levels	level	NNS
cord-034340-3ksfpaf7	127	18	than	than	IN
cord-034340-3ksfpaf7	127	19	adolescents	adolescent	NNS
cord-034340-3ksfpaf7	127	20	,	,	,
cord-034340-3ksfpaf7	127	21	congruently	congruently	RB
cord-034340-3ksfpaf7	127	22	with	with	IN
cord-034340-3ksfpaf7	127	23	data	datum	NNS
cord-034340-3ksfpaf7	127	24	of	of	IN
cord-034340-3ksfpaf7	127	25	healthy	healthy	JJ
cord-034340-3ksfpaf7	127	26	peers	peer	NNS
cord-034340-3ksfpaf7	127	27	.	.	.
cord-034340-3ksfpaf7	128	1	Previously	previously	RB
cord-034340-3ksfpaf7	128	2	,	,	,
cord-034340-3ksfpaf7	128	3	we	-PRON-	PRP
cord-034340-3ksfpaf7	128	4	have	have	VBP
cord-034340-3ksfpaf7	128	5	shown	show	VBN
cord-034340-3ksfpaf7	128	6	that	that	IN
cord-034340-3ksfpaf7	128	7	more	more	JJR
cord-034340-3ksfpaf7	128	8	than	than	IN
cord-034340-3ksfpaf7	128	9	half	half	NN
cord-034340-3ksfpaf7	128	10	of	of	IN
cord-034340-3ksfpaf7	128	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	128	12	-	-	HYPH
cord-034340-3ksfpaf7	128	13	patients	patient	NNS
cord-034340-3ksfpaf7	128	14	had	have	VBD
cord-034340-3ksfpaf7	128	15	below	below	IN
cord-034340-3ksfpaf7	128	16	normative	normative	JJ
cord-034340-3ksfpaf7	128	17	average	average	NN
cord-034340-3ksfpaf7	128	18	of	of	IN
cord-034340-3ksfpaf7	128	19	VO	VO	NNP
cord-034340-3ksfpaf7	128	20	2	2	CD
cord-034340-3ksfpaf7	128	21	max	max	NNP
cord-034340-3ksfpaf7	128	22	.	.	.
cord-034340-3ksfpaf7	129	1	However	however	RB
cord-034340-3ksfpaf7	129	2	,	,	,
cord-034340-3ksfpaf7	129	3	monitoring	monitor	VBG
cord-034340-3ksfpaf7	129	4	physical	physical	JJ
cord-034340-3ksfpaf7	129	5	activity	activity	NN
cord-034340-3ksfpaf7	129	6	(	(	-LRB-
cord-034340-3ksfpaf7	129	7	PA	PA	NNP
cord-034340-3ksfpaf7	129	8	)	)	-RRB-
cord-034340-3ksfpaf7	129	9	using	use	VBG
cord-034340-3ksfpaf7	129	10	accelerometry	accelerometry	NN
cord-034340-3ksfpaf7	129	11	,	,	,
cord-034340-3ksfpaf7	129	12	68	68	CD
cord-034340-3ksfpaf7	129	13	%	%	NN
cord-034340-3ksfpaf7	129	14	of	of	IN
cord-034340-3ksfpaf7	129	15	boys	boy	NNS
cord-034340-3ksfpaf7	129	16	and	and	CC
cord-034340-3ksfpaf7	129	17	39	39	CD
cord-034340-3ksfpaf7	129	18	%	%	NN
cord-034340-3ksfpaf7	129	19	of	of	IN
cord-034340-3ksfpaf7	129	20	girls	girl	NNS
cord-034340-3ksfpaf7	129	21	with	with	IN
cord-034340-3ksfpaf7	129	22	JIA	JIA	NNP
cord-034340-3ksfpaf7	129	23	fulfilled	fulfil	VBD
cord-034340-3ksfpaf7	129	24	the	the	DT
cord-034340-3ksfpaf7	129	25	recommendations	recommendation	NNS
cord-034340-3ksfpaf7	129	26	of	of	IN
cord-034340-3ksfpaf7	129	27	WHO	who	WP
cord-034340-3ksfpaf7	129	28	of	of	IN
cord-034340-3ksfpaf7	129	29	≥1	≥1	NNP
cord-034340-3ksfpaf7	129	30	hour	hour	NN
cord-034340-3ksfpaf7	129	31	of	of	IN
cord-034340-3ksfpaf7	129	32	PA	PA	NNP
cord-034340-3ksfpaf7	129	33	per	per	IN
cord-034340-3ksfpaf7	129	34	day	day	NN
cord-034340-3ksfpaf7	129	35	,	,	,
cord-034340-3ksfpaf7	129	36	which	which	WDT
cord-034340-3ksfpaf7	129	37	was	be	VBD
cord-034340-3ksfpaf7	129	38	comparable	comparable	JJ
cord-034340-3ksfpaf7	129	39	to	to	IN
cord-034340-3ksfpaf7	129	40	normative	normative	JJ
cord-034340-3ksfpaf7	129	41	values	value	NNS
cord-034340-3ksfpaf7	129	42	(	(	-LRB-
cord-034340-3ksfpaf7	129	43	61%/39	61%/39	CD
cord-034340-3ksfpaf7	129	44	%	%	NN
cord-034340-3ksfpaf7	129	45	)	)	-RRB-
cord-034340-3ksfpaf7	129	46	.	.	.
cord-034340-3ksfpaf7	130	1	Moreover	moreover	RB
cord-034340-3ksfpaf7	130	2	,	,	,
cord-034340-3ksfpaf7	130	3	patients	patient	NNS
cord-034340-3ksfpaf7	130	4	reporting	report	VBG
cord-034340-3ksfpaf7	130	5	engagement	engagement	NN
cord-034340-3ksfpaf7	130	6	more	more	JJR
cord-034340-3ksfpaf7	130	7	than	than	IN
cord-034340-3ksfpaf7	130	8	7	7	CD
cord-034340-3ksfpaf7	130	9	hours	hour	NNS
cord-034340-3ksfpaf7	130	10	per	per	IN
cord-034340-3ksfpaf7	130	11	week	week	NN
cord-034340-3ksfpaf7	130	12	in	in	IN
cord-034340-3ksfpaf7	130	13	club	club	NN
cord-034340-3ksfpaf7	130	14	-	-	HYPH
cord-034340-3ksfpaf7	130	15	sports	sport	NNS
cord-034340-3ksfpaf7	130	16	exceeded	exceed	VBD
cord-034340-3ksfpaf7	130	17	accelerometry	accelerometry	NN
cord-034340-3ksfpaf7	130	18	values	value	NNS
cord-034340-3ksfpaf7	130	19	of	of	IN
cord-034340-3ksfpaf7	130	20	healthy	healthy	JJ
cord-034340-3ksfpaf7	130	21	peers	peer	NNS
cord-034340-3ksfpaf7	130	22	.	.	.
cord-034340-3ksfpaf7	131	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	131	2	:	:	:
cord-034340-3ksfpaf7	132	1	To	to	TO
cord-034340-3ksfpaf7	132	2	explore	explore	VB
cord-034340-3ksfpaf7	132	3	the	the	DT
cord-034340-3ksfpaf7	132	4	association	association	NN
cord-034340-3ksfpaf7	132	5	between	between	IN
cord-034340-3ksfpaf7	132	6	PF	PF	NNP
cord-034340-3ksfpaf7	132	7	and	and	CC
cord-034340-3ksfpaf7	132	8	specific	specific	JJ
cord-034340-3ksfpaf7	132	9	sport	sport	NN
cord-034340-3ksfpaf7	132	10	habits	habit	NNS
cord-034340-3ksfpaf7	132	11	in	in	IN
cord-034340-3ksfpaf7	132	12	10	10	CD
cord-034340-3ksfpaf7	132	13	to	to	TO
cord-034340-3ksfpaf7	132	14	16-year	16-year	JJ
cord-034340-3ksfpaf7	132	15	-	-	HYPH
cord-034340-3ksfpaf7	132	16	old	old	JJ
cord-034340-3ksfpaf7	132	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	132	18	-	-	HYPH
cord-034340-3ksfpaf7	132	19	patients	patient	NNS
cord-034340-3ksfpaf7	132	20	,	,	,
cord-034340-3ksfpaf7	132	21	related	relate	VBN
cord-034340-3ksfpaf7	132	22	to	to	IN
cord-034340-3ksfpaf7	132	23	gender	gender	NN
cord-034340-3ksfpaf7	132	24	,	,	,
cord-034340-3ksfpaf7	132	25	BMI	BMI	NNP
cord-034340-3ksfpaf7	132	26	,	,	,
cord-034340-3ksfpaf7	132	27	disease	disease	NN
cord-034340-3ksfpaf7	132	28	activity	activity	NN
cord-034340-3ksfpaf7	132	29	,	,	,
cord-034340-3ksfpaf7	132	30	and	and	CC
cord-034340-3ksfpaf7	132	31	pain	pain	NN
cord-034340-3ksfpaf7	132	32	,	,	,
cord-034340-3ksfpaf7	132	33	and	and	CC
cord-034340-3ksfpaf7	132	34	comparing	compare	VBG
cord-034340-3ksfpaf7	132	35	the	the	DT
cord-034340-3ksfpaf7	132	36	most	most	RBS
cord-034340-3ksfpaf7	132	37	fit	fit	JJ
cord-034340-3ksfpaf7	132	38	quartile	quartile	NN
cord-034340-3ksfpaf7	132	39	(	(	-LRB-
cord-034340-3ksfpaf7	132	40	Q4	Q4	NNP
cord-034340-3ksfpaf7	132	41	)	)	-RRB-
cord-034340-3ksfpaf7	132	42	of	of	IN
cord-034340-3ksfpaf7	132	43	patients	patient	NNS
cord-034340-3ksfpaf7	132	44	(	(	-LRB-
cord-034340-3ksfpaf7	132	45	respectively	respectively	RB
cord-034340-3ksfpaf7	132	46	boys	boy	NNS
cord-034340-3ksfpaf7	132	47	and	and	CC
cord-034340-3ksfpaf7	132	48	girls	girl	NNS
cord-034340-3ksfpaf7	132	49	)	)	-RRB-
cord-034340-3ksfpaf7	132	50	to	to	IN
cord-034340-3ksfpaf7	132	51	the	the	DT
cord-034340-3ksfpaf7	132	52	least	least	JJS
cord-034340-3ksfpaf7	132	53	fit	fit	JJ
cord-034340-3ksfpaf7	132	54	quartile	quartile	NN
cord-034340-3ksfpaf7	132	55	(	(	-LRB-
cord-034340-3ksfpaf7	132	56	Q1	Q1	NNP
cord-034340-3ksfpaf7	132	57	)	)	-RRB-
cord-034340-3ksfpaf7	132	58	.	.	.
cord-034340-3ksfpaf7	133	1	Methods	method	NNS
cord-034340-3ksfpaf7	133	2	:	:	:
cord-034340-3ksfpaf7	133	3	Sixty	sixty	CD
cord-034340-3ksfpaf7	133	4	patients	patient	NNS
cord-034340-3ksfpaf7	133	5	with	with	IN
cord-034340-3ksfpaf7	133	6	JIA	JIA	NNP
cord-034340-3ksfpaf7	133	7	performed	perform	VBD
cord-034340-3ksfpaf7	133	8	an	an	DT
cord-034340-3ksfpaf7	133	9	indirect	indirect	JJ
cord-034340-3ksfpaf7	133	10	ergometertest	ergometertest	NN
cord-034340-3ksfpaf7	133	11	of	of	IN
cord-034340-3ksfpaf7	133	12	VO	VO	NNP
cord-034340-3ksfpaf7	133	13	2	2	CD
cord-034340-3ksfpaf7	133	14	max	max	NNP
cord-034340-3ksfpaf7	133	15	(	(	-LRB-
cord-034340-3ksfpaf7	133	16	Watt	Watt	NNP
cord-034340-3ksfpaf7	133	17	max	max	NN
cord-034340-3ksfpaf7	133	18	test	test	NN
cord-034340-3ksfpaf7	133	19	)	)	-RRB-
cord-034340-3ksfpaf7	133	20	and	and	CC
cord-034340-3ksfpaf7	133	21	answered	answer	VBD
cord-034340-3ksfpaf7	133	22	the	the	DT
cord-034340-3ksfpaf7	133	23	Physical	Physical	NNP
cord-034340-3ksfpaf7	133	24	Activity	Activity	NNP
cord-034340-3ksfpaf7	133	25	and	and	CC
cord-034340-3ksfpaf7	133	26	Sport	Sport	NNP
cord-034340-3ksfpaf7	133	27	Questionnaire	Questionnaire	NNP
cord-034340-3ksfpaf7	133	28	(	(	-LRB-
cord-034340-3ksfpaf7	133	29	PASQ	PASQ	NNP
cord-034340-3ksfpaf7	133	30	)	)	-RRB-
cord-034340-3ksfpaf7	133	31	.	.	.
cord-034340-3ksfpaf7	134	1	Objective	Objective	NNP
cord-034340-3ksfpaf7	134	2	PA	PA	NNP
cord-034340-3ksfpaf7	134	3	-	-	:
cord-034340-3ksfpaf7	134	4	monitoring	monitor	VBG
cord-034340-3ksfpaf7	134	5	for	for	IN
cord-034340-3ksfpaf7	134	6	one	one	CD
cord-034340-3ksfpaf7	134	7	week	week	NN
cord-034340-3ksfpaf7	134	8	was	be	VBD
cord-034340-3ksfpaf7	134	9	conducted	conduct	VBN
cord-034340-3ksfpaf7	134	10	using	use	VBG
cord-034340-3ksfpaf7	134	11	the	the	DT
cord-034340-3ksfpaf7	134	12	GT1	GT1	NNP
cord-034340-3ksfpaf7	134	13	M	M	NNP
cord-034340-3ksfpaf7	134	14	accelerometer	accelerometer	NN
cord-034340-3ksfpaf7	134	15	.	.	.
cord-034340-3ksfpaf7	135	1	Cut	cut	VB
cord-034340-3ksfpaf7	135	2	-	-	HYPH
cord-034340-3ksfpaf7	135	3	offs	off	NNS
cord-034340-3ksfpaf7	135	4	for	for	IN
cord-034340-3ksfpaf7	135	5	moderate	moderate	JJ
cord-034340-3ksfpaf7	135	6	-	-	HYPH
cord-034340-3ksfpaf7	135	7	high	high	JJ
cord-034340-3ksfpaf7	135	8	and	and	CC
cord-034340-3ksfpaf7	135	9	high	high	JJ
cord-034340-3ksfpaf7	135	10	intensity	intensity	NN
cord-034340-3ksfpaf7	135	11	PA	PA	NNP
cord-034340-3ksfpaf7	135	12	were	be	VBD
cord-034340-3ksfpaf7	135	13	set	set	VBN
cord-034340-3ksfpaf7	135	14	to	to	IN
cord-034340-3ksfpaf7	135	15	>	>	XX
cord-034340-3ksfpaf7	135	16	1000	1000	CD
cord-034340-3ksfpaf7	135	17	and	and	CC
cord-034340-3ksfpaf7	135	18	>	>	XX
cord-034340-3ksfpaf7	135	19	2500	2500	CD
cord-034340-3ksfpaf7	135	20	counts	count	NNS
cord-034340-3ksfpaf7	135	21	per	per	IN
cord-034340-3ksfpaf7	135	22	minute	minute	NN
cord-034340-3ksfpaf7	135	23	,	,	,
cord-034340-3ksfpaf7	135	24	respectively	respectively	RB
cord-034340-3ksfpaf7	135	25	.	.	.
cord-034340-3ksfpaf7	136	1	Disease	disease	NN
cord-034340-3ksfpaf7	136	2	activity	activity	NN
cord-034340-3ksfpaf7	136	3	was	be	VBD
cord-034340-3ksfpaf7	136	4	assessed	assess	VBN
cord-034340-3ksfpaf7	136	5	with	with	IN
cord-034340-3ksfpaf7	136	6	the	the	DT
cord-034340-3ksfpaf7	136	7	JADAS-27	jadas-27	NN
cord-034340-3ksfpaf7	136	8	,	,	,
cord-034340-3ksfpaf7	136	9	current	current	JJ
cord-034340-3ksfpaf7	136	10	pain	pain	NN
cord-034340-3ksfpaf7	136	11	and	and	CC
cord-034340-3ksfpaf7	136	12	worst	bad	JJS
cord-034340-3ksfpaf7	136	13	pain	pain	NN
cord-034340-3ksfpaf7	136	14	last	last	JJ
cord-034340-3ksfpaf7	136	15	week	week	NN
cord-034340-3ksfpaf7	136	16	were	be	VBD
cord-034340-3ksfpaf7	136	17	measured	measure	VBN
cord-034340-3ksfpaf7	136	18	on	on	IN
cord-034340-3ksfpaf7	136	19	visual	visual	JJ
cord-034340-3ksfpaf7	136	20	analogue	analogue	NN
cord-034340-3ksfpaf7	136	21	scales	scale	NNS
cord-034340-3ksfpaf7	136	22	(	(	-LRB-
cord-034340-3ksfpaf7	136	23	VAS	VAS	NNP
cord-034340-3ksfpaf7	136	24	)	)	-RRB-
cord-034340-3ksfpaf7	136	25	and	and	CC
cord-034340-3ksfpaf7	136	26	in	in	IN
cord-034340-3ksfpaf7	136	27	a	a	DT
cord-034340-3ksfpaf7	136	28	one	one	CD
cord-034340-3ksfpaf7	136	29	-	-	HYPH
cord-034340-3ksfpaf7	136	30	week	week	NN
cord-034340-3ksfpaf7	136	31	pain	pain	NN
cord-034340-3ksfpaf7	136	32	diary	diary	NN
cord-034340-3ksfpaf7	136	33	using	use	VBG
cord-034340-3ksfpaf7	136	34	the	the	DT
cord-034340-3ksfpaf7	136	35	Faces	Faces	NNPS
cord-034340-3ksfpaf7	136	36	Pain	Pain	NNP
cord-034340-3ksfpaf7	136	37	Scale	scale	NN
cord-034340-3ksfpaf7	136	38	-	-	HYPH
cord-034340-3ksfpaf7	136	39	Revised	revise	VBN
cord-034340-3ksfpaf7	136	40	(	(	-LRB-
cord-034340-3ksfpaf7	136	41	FPS	FPS	NNP
cord-034340-3ksfpaf7	136	42	-	-	HYPH
cord-034340-3ksfpaf7	136	43	R	R	NNP
cord-034340-3ksfpaf7	136	44	)	)	-RRB-
cord-034340-3ksfpaf7	136	45	.	.	.
cord-034340-3ksfpaf7	137	1	Results	result	NNS
cord-034340-3ksfpaf7	137	2	:	:	:
cord-034340-3ksfpaf7	138	1	Girls	girl	NNS
cord-034340-3ksfpaf7	138	2	with	with	IN
cord-034340-3ksfpaf7	138	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	139	1	(	(	-LRB-
cord-034340-3ksfpaf7	139	2	n=36	n=36	NNP
cord-034340-3ksfpaf7	139	3	)	)	-RRB-
cord-034340-3ksfpaf7	139	4	had	have	VBD
cord-034340-3ksfpaf7	139	5	lower	low	JJR
cord-034340-3ksfpaf7	139	6	mean	mean	JJ
cord-034340-3ksfpaf7	139	7	PF	pf	NN
cord-034340-3ksfpaf7	139	8	than	than	IN
cord-034340-3ksfpaf7	139	9	the	the	DT
cord-034340-3ksfpaf7	139	10	boys	boy	NNS
cord-034340-3ksfpaf7	139	11	(	(	-LRB-
cord-034340-3ksfpaf7	139	12	n=	n=	NNP
cord-034340-3ksfpaf7	139	13	24	24	CD
cord-034340-3ksfpaf7	139	14	)	)	-RRB-
cord-034340-3ksfpaf7	140	1	(	(	-LRB-
cord-034340-3ksfpaf7	140	2	36.5±8.2/43.4±6.73	36.5±8.2/43.4±6.73	CD
cord-034340-3ksfpaf7	140	3	ml	ml	NNS
cord-034340-3ksfpaf7	140	4	/	/	SYM
cord-034340-3ksfpaf7	140	5	kg	kg	NNP
cord-034340-3ksfpaf7	140	6	/	/	SYM
cord-034340-3ksfpaf7	140	7	min	min	NNP
cord-034340-3ksfpaf7	140	8	)	)	-RRB-
cord-034340-3ksfpaf7	140	9	,	,	,
cord-034340-3ksfpaf7	140	10	being	be	VBG
cord-034340-3ksfpaf7	140	11	below	below	IN
cord-034340-3ksfpaf7	140	12	normative	normative	JJ
cord-034340-3ksfpaf7	140	13	values	value	NNS
cord-034340-3ksfpaf7	140	14	,	,	,
cord-034340-3ksfpaf7	140	15	respectively	respectively	RB
cord-034340-3ksfpaf7	140	16	.	.	.
cord-034340-3ksfpaf7	141	1	In	in	IN
cord-034340-3ksfpaf7	141	2	both	both	DT
cord-034340-3ksfpaf7	141	3	genders	gender	NNS
cord-034340-3ksfpaf7	141	4	the	the	DT
cord-034340-3ksfpaf7	141	5	most	most	RBS
cord-034340-3ksfpaf7	141	6	fit	fit	JJ
cord-034340-3ksfpaf7	141	7	boys	boy	NNS
cord-034340-3ksfpaf7	141	8	and	and	CC
cord-034340-3ksfpaf7	141	9	girls	girl	NNS
cord-034340-3ksfpaf7	141	10	(	(	-LRB-
cord-034340-3ksfpaf7	141	11	Q4	Q4	NNP
cord-034340-3ksfpaf7	141	12	;	;	:
cord-034340-3ksfpaf7	141	13	49.3	49.3	CD
cord-034340-3ksfpaf7	141	14	-	-	HYPH
cord-034340-3ksfpaf7	141	15	57/	57/	CD
cord-034340-3ksfpaf7	141	16	40.9	40.9	CD
cord-034340-3ksfpaf7	141	17	-	-	SYM
cord-034340-3ksfpaf7	141	18	54	54	CD
cord-034340-3ksfpaf7	141	19	)	)	-RRB-
cord-034340-3ksfpaf7	141	20	had	have	VBD
cord-034340-3ksfpaf7	141	21	average	average	JJ
cord-034340-3ksfpaf7	141	22	to	to	IN
cord-034340-3ksfpaf7	141	23	well	well	RB
cord-034340-3ksfpaf7	141	24	-	-	HYPH
cord-034340-3ksfpaf7	141	25	above	above	JJ
cord-034340-3ksfpaf7	141	26	normative	normative	JJ
cord-034340-3ksfpaf7	141	27	average	average	JJ
cord-034340-3ksfpaf7	141	28	PF	pf	NN
cord-034340-3ksfpaf7	141	29	.	.	.
cord-034340-3ksfpaf7	142	1	The	the	DT
cord-034340-3ksfpaf7	142	2	least	least	JJS
cord-034340-3ksfpaf7	142	3	fit	fit	JJ
cord-034340-3ksfpaf7	142	4	boys	boy	NNS
cord-034340-3ksfpaf7	142	5	(	(	-LRB-
cord-034340-3ksfpaf7	142	6	Q1	Q1	NNP
cord-034340-3ksfpaf7	142	7	;	;	:
cord-034340-3ksfpaf7	142	8	33.5	33.5	CD
cord-034340-3ksfpaf7	142	9	-	-	HYPH
cord-034340-3ksfpaf7	142	10	37.4	37.4	CD
cord-034340-3ksfpaf7	142	11	)	)	-RRB-
cord-034340-3ksfpaf7	142	12	all	all	DT
cord-034340-3ksfpaf7	142	13	had	have	VBD
cord-034340-3ksfpaf7	142	14	PF	pf	NN
cord-034340-3ksfpaf7	142	15	-	-	HYPH
cord-034340-3ksfpaf7	142	16	levels	level	NNS
cord-034340-3ksfpaf7	142	17	well	well	RB
cord-034340-3ksfpaf7	142	18	-	-	HYPH
cord-034340-3ksfpaf7	142	19	below	below	IN
cord-034340-3ksfpaf7	142	20	normative	normative	JJ
cord-034340-3ksfpaf7	142	21	average	average	NN
cord-034340-3ksfpaf7	142	22	.	.	.
cord-034340-3ksfpaf7	143	1	In	in	IN
cord-034340-3ksfpaf7	143	2	girls	girl	NNS
cord-034340-3ksfpaf7	143	3	Q1-levels	Q1-levels	.
cord-034340-3ksfpaf7	144	1	(	(	-LRB-
cord-034340-3ksfpaf7	144	2	18.7	18.7	CD
cord-034340-3ksfpaf7	144	3	-	-	HYPH
cord-034340-3ksfpaf7	144	4	30.9	30.9	CD
cord-034340-3ksfpaf7	144	5	)	)	-RRB-
cord-034340-3ksfpaf7	144	6	were	be	VBD
cord-034340-3ksfpaf7	144	7	well	well	RB
cord-034340-3ksfpaf7	144	8	-	-	HYPH
cord-034340-3ksfpaf7	144	9	below	below	RB
cord-034340-3ksfpaf7	144	10	to	to	IN
cord-034340-3ksfpaf7	144	11	below	below	IN
cord-034340-3ksfpaf7	144	12	normative	normative	JJ
cord-034340-3ksfpaf7	144	13	average	average	NN
cord-034340-3ksfpaf7	144	14	.	.	.
cord-034340-3ksfpaf7	145	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	145	2	found	find	VBD
cord-034340-3ksfpaf7	145	3	significant	significant	JJ
cord-034340-3ksfpaf7	145	4	differences	difference	NNS
cord-034340-3ksfpaf7	145	5	between	between	IN
cord-034340-3ksfpaf7	145	6	most	most	JJS
cord-034340-3ksfpaf7	145	7	fit	fit	JJ
cord-034340-3ksfpaf7	145	8	(	(	-LRB-
cord-034340-3ksfpaf7	145	9	Q4	Q4	NNP
cord-034340-3ksfpaf7	145	10	)	)	-RRB-
cord-034340-3ksfpaf7	145	11	and	and	CC
cord-034340-3ksfpaf7	145	12	least	least	JJS
cord-034340-3ksfpaf7	145	13	fit	fit	JJ
cord-034340-3ksfpaf7	145	14	(	(	-LRB-
cord-034340-3ksfpaf7	145	15	Q1	Q1	NNP
cord-034340-3ksfpaf7	145	16	)	)	-RRB-
cord-034340-3ksfpaf7	145	17	patients	patient	NNS
cord-034340-3ksfpaf7	145	18	regarding	regard	VBG
cord-034340-3ksfpaf7	145	19	patient´s	patient´s	NNP
cord-034340-3ksfpaf7	145	20	global	global	JJ
cord-034340-3ksfpaf7	145	21	wellbeing	wellbeing	NN
cord-034340-3ksfpaf7	145	22	(	(	-LRB-
cord-034340-3ksfpaf7	145	23	p=0.040	p=0.040	NNP
cord-034340-3ksfpaf7	145	24	)	)	-RRB-
cord-034340-3ksfpaf7	145	25	and	and	CC
cord-034340-3ksfpaf7	145	26	pain	pain	NN
cord-034340-3ksfpaf7	145	27	diary	diary	NN
cord-034340-3ksfpaf7	145	28	(	(	-LRB-
cord-034340-3ksfpaf7	145	29	p=0.026	p=0.026	NNP
cord-034340-3ksfpaf7	145	30	)	)	-RRB-
cord-034340-3ksfpaf7	145	31	.	.	.
cord-034340-3ksfpaf7	146	1	These	these	DT
cord-034340-3ksfpaf7	146	2	differences	difference	NNS
cord-034340-3ksfpaf7	146	3	were	be	VBD
cord-034340-3ksfpaf7	146	4	not	not	RB
cord-034340-3ksfpaf7	146	5	significant	significant	JJ
cord-034340-3ksfpaf7	146	6	when	when	WRB
cord-034340-3ksfpaf7	146	7	separating	separate	VBG
cord-034340-3ksfpaf7	146	8	genders	gender	NNS
cord-034340-3ksfpaf7	146	9	,	,	,
cord-034340-3ksfpaf7	146	10	though	though	IN
cord-034340-3ksfpaf7	146	11	differences	difference	NNS
cord-034340-3ksfpaf7	146	12	were	be	VBD
cord-034340-3ksfpaf7	146	13	more	more	RBR
cord-034340-3ksfpaf7	146	14	pronounced	pronounced	JJ
cord-034340-3ksfpaf7	146	15	in	in	IN
cord-034340-3ksfpaf7	146	16	girls	girl	NNS
cord-034340-3ksfpaf7	146	17	.	.	.
cord-034340-3ksfpaf7	147	1	The	the	DT
cord-034340-3ksfpaf7	147	2	least	least	JJS
cord-034340-3ksfpaf7	147	3	fit	fit	JJ
cord-034340-3ksfpaf7	147	4	girls	girl	NNS
cord-034340-3ksfpaf7	147	5	(	(	-LRB-
cord-034340-3ksfpaf7	147	6	Q1	Q1	NNP
cord-034340-3ksfpaf7	147	7	)	)	-RRB-
cord-034340-3ksfpaf7	147	8	had	have	VBD
cord-034340-3ksfpaf7	147	9	significantly	significantly	RB
cord-034340-3ksfpaf7	147	10	higher	high	JJR
cord-034340-3ksfpaf7	147	11	disease	disease	NN
cord-034340-3ksfpaf7	147	12	activity	activity	NN
cord-034340-3ksfpaf7	147	13	(	(	-LRB-
cord-034340-3ksfpaf7	147	14	JADAS-27	JADAS-27	NFP
cord-034340-3ksfpaf7	147	15	)	)	-RRB-
cord-034340-3ksfpaf7	147	16	than	than	IN
cord-034340-3ksfpaf7	147	17	the	the	DT
cord-034340-3ksfpaf7	147	18	most	most	RBS
cord-034340-3ksfpaf7	147	19	fit	fit	JJ
cord-034340-3ksfpaf7	147	20	girls	girl	NNS
cord-034340-3ksfpaf7	147	21	(	(	-LRB-
cord-034340-3ksfpaf7	147	22	Q4)(p=0.019	q4)(p=0.019	NN
cord-034340-3ksfpaf7	147	23	)	)	-RRB-
cord-034340-3ksfpaf7	147	24	.	.	.
cord-034340-3ksfpaf7	148	1	The	the	DT
cord-034340-3ksfpaf7	148	2	most	most	RBS
cord-034340-3ksfpaf7	148	3	fit	fit	JJ
cord-034340-3ksfpaf7	148	4	boys	boy	NNS
cord-034340-3ksfpaf7	148	5	and	and	CC
cord-034340-3ksfpaf7	148	6	girls	girl	NNS
cord-034340-3ksfpaf7	148	7	(	(	-LRB-
cord-034340-3ksfpaf7	148	8	Q4	Q4	NNP
cord-034340-3ksfpaf7	148	9	)	)	-RRB-
cord-034340-3ksfpaf7	148	10	engaged	engage	VBD
cord-034340-3ksfpaf7	148	11	equally	equally	RB
cord-034340-3ksfpaf7	148	12	in	in	IN
cord-034340-3ksfpaf7	148	13	high	high	JJ
cord-034340-3ksfpaf7	148	14	intensity	intensity	NN
cord-034340-3ksfpaf7	148	15	sports	sport	NNS
cord-034340-3ksfpaf7	148	16	(	(	-LRB-
cord-034340-3ksfpaf7	148	17	soccer	soccer	NN
cord-034340-3ksfpaf7	148	18	:	:	:
cord-034340-3ksfpaf7	148	19	3/24	3/24	CD
cord-034340-3ksfpaf7	148	20	;	;	:
cord-034340-3ksfpaf7	148	21	2/36	2/36	CD
cord-034340-3ksfpaf7	148	22	,	,	,
cord-034340-3ksfpaf7	148	23	handball	handball	NN
cord-034340-3ksfpaf7	148	24	:	:	:
cord-034340-3ksfpaf7	148	25	0/24	0/24	CD
cord-034340-3ksfpaf7	148	26	;	;	:
cord-034340-3ksfpaf7	148	27	2/36	2/36	CD
cord-034340-3ksfpaf7	148	28	,	,	,
cord-034340-3ksfpaf7	148	29	gymnastics	gymnastic	NNS
cord-034340-3ksfpaf7	148	30	:	:	:
cord-034340-3ksfpaf7	148	31	2/24	2/24	CD
cord-034340-3ksfpaf7	148	32	;	;	:
cord-034340-3ksfpaf7	148	33	4/	4/	CD
cord-034340-3ksfpaf7	148	34	36	36	CD
cord-034340-3ksfpaf7	148	35	,	,	,
cord-034340-3ksfpaf7	148	36	rowing	rowing	NN
cord-034340-3ksfpaf7	148	37	:	:	:
cord-034340-3ksfpaf7	148	38	1/24	1/24	CD
cord-034340-3ksfpaf7	148	39	;	;	:
cord-034340-3ksfpaf7	148	40	0/36	0/36	CD
cord-034340-3ksfpaf7	148	41	)	)	-RRB-
cord-034340-3ksfpaf7	148	42	.	.	.
cord-034340-3ksfpaf7	149	1	However	however	RB
cord-034340-3ksfpaf7	149	2	,	,	,
cord-034340-3ksfpaf7	149	3	more	more	JJR
cord-034340-3ksfpaf7	149	4	boys	boy	NNS
cord-034340-3ksfpaf7	149	5	than	than	IN
cord-034340-3ksfpaf7	149	6	girls	girl	NNS
cord-034340-3ksfpaf7	149	7	played	play	VBD
cord-034340-3ksfpaf7	149	8	soccer	soccer	NN
cord-034340-3ksfpaf7	149	9	(	(	-LRB-
cord-034340-3ksfpaf7	149	10	11/24	11/24	CD
cord-034340-3ksfpaf7	149	11	;	;	:
cord-034340-3ksfpaf7	149	12	3/36	3/36	CD
cord-034340-3ksfpaf7	149	13	)	)	-RRB-
cord-034340-3ksfpaf7	149	14	,	,	,
cord-034340-3ksfpaf7	149	15	whereas	whereas	IN
cord-034340-3ksfpaf7	149	16	more	more	JJR
cord-034340-3ksfpaf7	149	17	girls	girl	NNS
cord-034340-3ksfpaf7	149	18	preferred	prefer	VBN
cord-034340-3ksfpaf7	149	19	sports	sport	NNS
cord-034340-3ksfpaf7	149	20	of	of	IN
cord-034340-3ksfpaf7	149	21	lower	low	JJR
cord-034340-3ksfpaf7	149	22	intensity	intensity	NN
cord-034340-3ksfpaf7	149	23	(	(	-LRB-
cord-034340-3ksfpaf7	149	24	riding	ride	VBG
cord-034340-3ksfpaf7	149	25	:	:	:
cord-034340-3ksfpaf7	149	26	8/36	8/36	CD
cord-034340-3ksfpaf7	149	27	;	;	:
cord-034340-3ksfpaf7	149	28	0/24	0/24	CD
cord-034340-3ksfpaf7	149	29	)	)	-RRB-
cord-034340-3ksfpaf7	149	30	.	.	.
cord-034340-3ksfpaf7	150	1	Eight	eight	CD
cord-034340-3ksfpaf7	150	2	of	of	IN
cord-034340-3ksfpaf7	150	3	11	11	CD
cord-034340-3ksfpaf7	150	4	boys	boy	NNS
cord-034340-3ksfpaf7	150	5	in	in	IN
cord-034340-3ksfpaf7	150	6	soccer	soccer	NN
cord-034340-3ksfpaf7	150	7	and	and	CC
cord-034340-3ksfpaf7	150	8	2	2	CD
cord-034340-3ksfpaf7	150	9	boys	boy	NNS
cord-034340-3ksfpaf7	150	10	in	in	IN
cord-034340-3ksfpaf7	150	11	gymnastics	gymnastic	NNS
cord-034340-3ksfpaf7	150	12	or	or	CC
cord-034340-3ksfpaf7	150	13	rowing	rowing	NN
cord-034340-3ksfpaf7	150	14	had	have	VBD
cord-034340-3ksfpaf7	150	15	below	below	IN
cord-034340-3ksfpaf7	150	16	average	average	NN
cord-034340-3ksfpaf7	150	17	to	to	IN
cord-034340-3ksfpaf7	150	18	well	well	RB
cord-034340-3ksfpaf7	150	19	-	-	HYPH
cord-034340-3ksfpaf7	150	20	above	above	JJ
cord-034340-3ksfpaf7	150	21	normative	normative	JJ
cord-034340-3ksfpaf7	150	22	average	average	NN
cord-034340-3ksfpaf7	150	23	of	of	IN
cord-034340-3ksfpaf7	150	24	PF	pf	NN
cord-034340-3ksfpaf7	150	25	(	(	-LRB-
cord-034340-3ksfpaf7	150	26	Q3+Q4	Q3+Q4	NNP
cord-034340-3ksfpaf7	150	27	:	:	:
cord-034340-3ksfpaf7	150	28	41.6	41.6	CD
cord-034340-3ksfpaf7	150	29	-	-	SYM
cord-034340-3ksfpaf7	150	30	57	57	CD
cord-034340-3ksfpaf7	150	31	)	)	-RRB-
cord-034340-3ksfpaf7	150	32	.	.	.
cord-034340-3ksfpaf7	151	1	Three	three	CD
cord-034340-3ksfpaf7	151	2	girls	girl	NNS
cord-034340-3ksfpaf7	151	3	in	in	IN
cord-034340-3ksfpaf7	151	4	gymnastics	gymnastic	NNS
cord-034340-3ksfpaf7	151	5	,	,	,
cord-034340-3ksfpaf7	151	6	2	2	CD
cord-034340-3ksfpaf7	151	7	girls	girl	NNS
cord-034340-3ksfpaf7	151	8	in	in	IN
cord-034340-3ksfpaf7	151	9	soccer	soccer	NN
cord-034340-3ksfpaf7	151	10	,	,	,
cord-034340-3ksfpaf7	151	11	and	and	CC
cord-034340-3ksfpaf7	151	12	2	2	CD
cord-034340-3ksfpaf7	151	13	girls	girl	NNS
cord-034340-3ksfpaf7	151	14	in	in	IN
cord-034340-3ksfpaf7	151	15	handball	handball	NN
cord-034340-3ksfpaf7	151	16	were	be	VBD
cord-034340-3ksfpaf7	151	17	in	in	IN
cord-034340-3ksfpaf7	151	18	Q4	Q4	NNP
cord-034340-3ksfpaf7	151	19	(	(	-LRB-
cord-034340-3ksfpaf7	151	20	40.9	40.9	CD
cord-034340-3ksfpaf7	151	21	-	-	SYM
cord-034340-3ksfpaf7	151	22	54	54	CD
cord-034340-3ksfpaf7	151	23	)	)	-RRB-
cord-034340-3ksfpaf7	151	24	with	with	IN
cord-034340-3ksfpaf7	151	25	levels	level	NNS
cord-034340-3ksfpaf7	151	26	of	of	IN
cord-034340-3ksfpaf7	151	27	average	average	NN
cord-034340-3ksfpaf7	151	28	to	to	IN
cord-034340-3ksfpaf7	151	29	well	well	RB
cord-034340-3ksfpaf7	151	30	-	-	HYPH
cord-034340-3ksfpaf7	151	31	above	above	JJ
cord-034340-3ksfpaf7	151	32	average	average	JJ
cord-034340-3ksfpaf7	151	33	PF	pf	NN
cord-034340-3ksfpaf7	151	34	.	.	.
cord-034340-3ksfpaf7	152	1	The	the	DT
cord-034340-3ksfpaf7	152	2	third	third	JJ
cord-034340-3ksfpaf7	152	3	girl	girl	NN
cord-034340-3ksfpaf7	152	4	in	in	IN
cord-034340-3ksfpaf7	152	5	soccer	soccer	NN
cord-034340-3ksfpaf7	152	6	was	be	VBD
cord-034340-3ksfpaf7	152	7	in	in	IN
cord-034340-3ksfpaf7	152	8	Q2	Q2	NNP
cord-034340-3ksfpaf7	152	9	(	(	-LRB-
cord-034340-3ksfpaf7	152	10	31	31	CD
cord-034340-3ksfpaf7	152	11	-	-	SYM
cord-034340-3ksfpaf7	152	12	36.3	36.3	CD
cord-034340-3ksfpaf7	152	13	)	)	-RRB-
cord-034340-3ksfpaf7	152	14	with	with	IN
cord-034340-3ksfpaf7	152	15	levels	level	NNS
cord-034340-3ksfpaf7	152	16	of	of	IN
cord-034340-3ksfpaf7	152	17	well	well	RB
cord-034340-3ksfpaf7	152	18	-	-	HYPH
cord-034340-3ksfpaf7	152	19	below	below	RB
cord-034340-3ksfpaf7	152	20	to	to	IN
cord-034340-3ksfpaf7	152	21	below	below	IN
cord-034340-3ksfpaf7	152	22	normative	normative	JJ
cord-034340-3ksfpaf7	152	23	average	average	NN
cord-034340-3ksfpaf7	152	24	.	.	.
cord-034340-3ksfpaf7	153	1	None	none	NN
cord-034340-3ksfpaf7	153	2	of	of	IN
cord-034340-3ksfpaf7	153	3	the	the	DT
cord-034340-3ksfpaf7	153	4	riding	ride	VBG
cord-034340-3ksfpaf7	153	5	girls	girl	NNS
cord-034340-3ksfpaf7	153	6	were	be	VBD
cord-034340-3ksfpaf7	153	7	in	in	IN
cord-034340-3ksfpaf7	153	8	Q4	Q4	NNP
cord-034340-3ksfpaf7	153	9	and	and	CC
cord-034340-3ksfpaf7	153	10	only	only	RB
cord-034340-3ksfpaf7	153	11	1	1	CD
cord-034340-3ksfpaf7	153	12	was	be	VBD
cord-034340-3ksfpaf7	153	13	in	in	IN
cord-034340-3ksfpaf7	153	14	Q3	Q3	NNP
cord-034340-3ksfpaf7	153	15	(	(	-LRB-
cord-034340-3ksfpaf7	153	16	36.3	36.3	CD
cord-034340-3ksfpaf7	153	17	-	-	SYM
cord-034340-3ksfpaf7	153	18	40.8	40.8	CD
cord-034340-3ksfpaf7	153	19	)	)	-RRB-
cord-034340-3ksfpaf7	153	20	(	(	-LRB-
cord-034340-3ksfpaf7	153	21	Below	below	IN
cord-034340-3ksfpaf7	153	22	to	to	IN
cord-034340-3ksfpaf7	153	23	average	average	JJ
cord-034340-3ksfpaf7	153	24	normative	normative	JJ
cord-034340-3ksfpaf7	153	25	PF	pf	NN
cord-034340-3ksfpaf7	153	26	)	)	-RRB-
cord-034340-3ksfpaf7	153	27	.	.	.
cord-034340-3ksfpaf7	154	1	Comparing	compare	VBG
cord-034340-3ksfpaf7	154	2	accelerometer	accelerometer	RB
cord-034340-3ksfpaf7	154	3	-	-	HYPH
cord-034340-3ksfpaf7	154	4	monitored	monitor	VBN
cord-034340-3ksfpaf7	154	5	values	value	NNS
cord-034340-3ksfpaf7	154	6	of	of	IN
cord-034340-3ksfpaf7	154	7	PA	PA	NNP
cord-034340-3ksfpaf7	154	8	-	-	HYPH
cord-034340-3ksfpaf7	154	9	intensity	intensity	NN
cord-034340-3ksfpaf7	154	10	in	in	IN
cord-034340-3ksfpaf7	154	11	girls	girl	NNS
cord-034340-3ksfpaf7	154	12	with	with	IN
cord-034340-3ksfpaf7	154	13	low	low	JJ
cord-034340-3ksfpaf7	154	14	(	(	-LRB-
cord-034340-3ksfpaf7	154	15	Q1	Q1	NNP
cord-034340-3ksfpaf7	154	16	)	)	-RRB-
cord-034340-3ksfpaf7	154	17	and	and	CC
cord-034340-3ksfpaf7	154	18	high	high	JJ
cord-034340-3ksfpaf7	154	19	(	(	-LRB-
cord-034340-3ksfpaf7	154	20	Q4	Q4	NNP
cord-034340-3ksfpaf7	154	21	)	)	-RRB-
cord-034340-3ksfpaf7	154	22	PF	PF	NNP
cord-034340-3ksfpaf7	154	23	,	,	,
cord-034340-3ksfpaf7	154	24	PAvalues	PAvalues	NNPS
cord-034340-3ksfpaf7	154	25	of	of	IN
cord-034340-3ksfpaf7	154	26	Q1	Q1	NNP
cord-034340-3ksfpaf7	154	27	were	be	VBD
cord-034340-3ksfpaf7	154	28	significantly	significantly	RB
cord-034340-3ksfpaf7	154	29	lower	low	JJR
cord-034340-3ksfpaf7	154	30	than	than	IN
cord-034340-3ksfpaf7	154	31	in	in	IN
cord-034340-3ksfpaf7	154	32	Q4	Q4	NNP
cord-034340-3ksfpaf7	154	33	.	.	.
cord-034340-3ksfpaf7	155	1	The	the	DT
cord-034340-3ksfpaf7	155	2	same	same	JJ
cord-034340-3ksfpaf7	155	3	tendency	tendency	NN
cord-034340-3ksfpaf7	155	4	was	be	VBD
cord-034340-3ksfpaf7	155	5	observed	observe	VBN
cord-034340-3ksfpaf7	155	6	in	in	IN
cord-034340-3ksfpaf7	155	7	boys	boy	NNS
cord-034340-3ksfpaf7	155	8	,	,	,
cord-034340-3ksfpaf7	155	9	but	but	CC
cord-034340-3ksfpaf7	155	10	not	not	RB
cord-034340-3ksfpaf7	155	11	to	to	TO
cord-034340-3ksfpaf7	155	12	significance	significance	VB
cord-034340-3ksfpaf7	155	13	.	.	.
cord-034340-3ksfpaf7	156	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	156	2	:	:	:
cord-034340-3ksfpaf7	157	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	157	2	results	result	NNS
cord-034340-3ksfpaf7	157	3	are	be	VBP
cord-034340-3ksfpaf7	157	4	in	in	IN
cord-034340-3ksfpaf7	157	5	accordance	accordance	NN
cord-034340-3ksfpaf7	157	6	with	with	IN
cord-034340-3ksfpaf7	157	7	most	most	JJS
cord-034340-3ksfpaf7	157	8	other	other	JJ
cord-034340-3ksfpaf7	157	9	studies	study	NNS
cord-034340-3ksfpaf7	157	10	of	of	IN
cord-034340-3ksfpaf7	157	11	PF	PF	NNP
cord-034340-3ksfpaf7	157	12	in	in	IN
cord-034340-3ksfpaf7	157	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	157	14	,	,	,
cord-034340-3ksfpaf7	157	15	adding	add	VBG
cord-034340-3ksfpaf7	157	16	to	to	IN
cord-034340-3ksfpaf7	157	17	the	the	DT
cord-034340-3ksfpaf7	157	18	knowledge	knowledge	NN
cord-034340-3ksfpaf7	157	19	of	of	IN
cord-034340-3ksfpaf7	157	20	gender	gender	NN
cord-034340-3ksfpaf7	157	21	-	-	HYPH
cord-034340-3ksfpaf7	157	22	specific	specific	JJ
cord-034340-3ksfpaf7	157	23	differences	difference	NNS
cord-034340-3ksfpaf7	157	24	in	in	IN
cord-034340-3ksfpaf7	157	25	PF	pf	NN
cord-034340-3ksfpaf7	157	26	and	and	CC
cord-034340-3ksfpaf7	157	27	type	type	NN
cord-034340-3ksfpaf7	157	28	and	and	CC
cord-034340-3ksfpaf7	157	29	behavior	behavior	NN
cord-034340-3ksfpaf7	157	30	in	in	IN
cord-034340-3ksfpaf7	157	31	sport	sport	NN
cord-034340-3ksfpaf7	157	32	activities	activity	NNS
cord-034340-3ksfpaf7	157	33	.	.	.
cord-034340-3ksfpaf7	158	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	158	2	emphasizes	emphasize	VBZ
cord-034340-3ksfpaf7	158	3	the	the	DT
cord-034340-3ksfpaf7	158	4	need	need	NN
cord-034340-3ksfpaf7	158	5	of	of	IN
cord-034340-3ksfpaf7	158	6	regular	regular	JJ
cord-034340-3ksfpaf7	158	7	PF	pf	NN
cord-034340-3ksfpaf7	158	8	-	-	HYPH
cord-034340-3ksfpaf7	158	9	testing	testing	NN
cord-034340-3ksfpaf7	158	10	and	and	CC
cord-034340-3ksfpaf7	158	11	guidance	guidance	NN
cord-034340-3ksfpaf7	158	12	in	in	IN
cord-034340-3ksfpaf7	158	13	high	high	JJ
cord-034340-3ksfpaf7	158	14	intensity	intensity	NN
cord-034340-3ksfpaf7	158	15	PA	PA	NNP
cord-034340-3ksfpaf7	158	16	and	and	CC
cord-034340-3ksfpaf7	158	17	sport	sport	NN
cord-034340-3ksfpaf7	158	18	in	in	IN
cord-034340-3ksfpaf7	158	19	order	order	NN
cord-034340-3ksfpaf7	158	20	to	to	TO
cord-034340-3ksfpaf7	158	21	improve	improve	VB
cord-034340-3ksfpaf7	158	22	PF	PF	NNP
cord-034340-3ksfpaf7	158	23	and	and	CC
cord-034340-3ksfpaf7	158	24	avoid	avoid	VB
cord-034340-3ksfpaf7	158	25	the	the	DT
cord-034340-3ksfpaf7	158	26	risks	risk	NNS
cord-034340-3ksfpaf7	158	27	of	of	IN
cord-034340-3ksfpaf7	158	28	inactivity	inactivity	NN
cord-034340-3ksfpaf7	158	29	and	and	CC
cord-034340-3ksfpaf7	158	30	lifestyle	lifestyle	NN
cord-034340-3ksfpaf7	158	31	diseases	disease	NNS
cord-034340-3ksfpaf7	158	32	in	in	IN
cord-034340-3ksfpaf7	158	33	JIA	JIA	NNP
cord-034340-3ksfpaf7	158	34	.	.	.
cord-034340-3ksfpaf7	159	1	pg	pg	NNP
cord-034340-3ksfpaf7	159	2	/	/	SYM
cord-034340-3ksfpaf7	159	3	ml	ml	NNP
cord-034340-3ksfpaf7	159	4	)	)	-RRB-
cord-034340-3ksfpaf7	159	5	,	,	,
cord-034340-3ksfpaf7	159	6	which	which	WDT
cord-034340-3ksfpaf7	159	7	also	also	RB
cord-034340-3ksfpaf7	159	8	showed	show	VBD
cord-034340-3ksfpaf7	159	9	the	the	DT
cord-034340-3ksfpaf7	159	10	highest	high	JJS
cord-034340-3ksfpaf7	159	11	the	the	DT
cord-034340-3ksfpaf7	159	12	frequency	frequency	NN
cord-034340-3ksfpaf7	159	13	of	of	IN
cord-034340-3ksfpaf7	159	14	detection	detection	NN
cord-034340-3ksfpaf7	159	15	of	of	IN
cord-034340-3ksfpaf7	159	16	its	-PRON-	PRP$
cord-034340-3ksfpaf7	159	17	increase	increase	NN
cord-034340-3ksfpaf7	159	18	.	.	.
cord-034340-3ksfpaf7	160	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	160	2	was	be	VBD
cord-034340-3ksfpaf7	160	3	absent	absent	JJ
cord-034340-3ksfpaf7	160	4	in	in	IN
cord-034340-3ksfpaf7	160	5	sJIA	sjia	NN
cord-034340-3ksfpaf7	161	1	(	(	-LRB-
cord-034340-3ksfpaf7	161	2	7.52±4.74	7.52±4.74	CD
cord-034340-3ksfpaf7	161	3	pg	pg	NNP
cord-034340-3ksfpaf7	161	4	/	/	SYM
cord-034340-3ksfpaf7	161	5	ml	ml	NNP
cord-034340-3ksfpaf7	161	6	)	)	-RRB-
cord-034340-3ksfpaf7	161	7	.	.	.
cord-034340-3ksfpaf7	162	1	The	the	DT
cord-034340-3ksfpaf7	162	2	highest	high	JJS
cord-034340-3ksfpaf7	162	3	values	value	NNS
cord-034340-3ksfpaf7	162	4	of	of	IN
cord-034340-3ksfpaf7	162	5	IL-17R	IL-17R	NNP
cord-034340-3ksfpaf7	162	6	(	(	-LRB-
cord-034340-3ksfpaf7	162	7	1849836.4±176751	1849836.4±176751	CD
cord-034340-3ksfpaf7	162	8	pg	pg	NNP
cord-034340-3ksfpaf7	162	9	/	/	SYM
cord-034340-3ksfpaf7	162	10	ml	ml	NNP
cord-034340-3ksfpaf7	162	11	)	)	-RRB-
cord-034340-3ksfpaf7	162	12	were	be	VBD
cord-034340-3ksfpaf7	162	13	in	in	IN
cord-034340-3ksfpaf7	162	14	the	the	DT
cord-034340-3ksfpaf7	162	15	middle	middle	JJ
cord-034340-3ksfpaf7	162	16	age	age	NN
cord-034340-3ksfpaf7	162	17	group	group	NN
cord-034340-3ksfpaf7	162	18	.	.	.
cord-034340-3ksfpaf7	163	1	The	the	DT
cord-034340-3ksfpaf7	163	2	data	datum	NNS
cord-034340-3ksfpaf7	163	3	obtained	obtain	VBN
cord-034340-3ksfpaf7	163	4	suggest	suggest	VBP
cord-034340-3ksfpaf7	163	5	the	the	DT
cord-034340-3ksfpaf7	163	6	compensatory	compensatory	JJ
cord-034340-3ksfpaf7	163	7	value	value	NN
cord-034340-3ksfpaf7	163	8	of	of	IN
cord-034340-3ksfpaf7	163	9	increasing	increase	VBG
cord-034340-3ksfpaf7	163	10	IL-17R	IL-17R	NNP
cord-034340-3ksfpaf7	163	11	and	and	CC
cord-034340-3ksfpaf7	163	12	the	the	DT
cord-034340-3ksfpaf7	163	13	simultaneous	simultaneous	JJ
cord-034340-3ksfpaf7	163	14	initiation	initiation	NN
cord-034340-3ksfpaf7	163	15	of	of	IN
cord-034340-3ksfpaf7	163	16	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	163	17	and	and	CC
cord-034340-3ksfpaf7	163	18	anti	anti	JJ
cord-034340-3ksfpaf7	163	19	-	-	JJ
cord-034340-3ksfpaf7	163	20	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	163	21	processes	process	NNS
cord-034340-3ksfpaf7	163	22	during	during	IN
cord-034340-3ksfpaf7	163	23	exacerbation	exacerbation	NN
cord-034340-3ksfpaf7	163	24	of	of	IN
cord-034340-3ksfpaf7	163	25	JIA	JIA	NNP
cord-034340-3ksfpaf7	163	26	.	.	.
cord-034340-3ksfpaf7	164	1	Assessment	assessment	NN
cord-034340-3ksfpaf7	164	2	of	of	IN
cord-034340-3ksfpaf7	164	3	the	the	DT
cord-034340-3ksfpaf7	164	4	ratios	ratio	NNS
cord-034340-3ksfpaf7	164	5	of	of	IN
cord-034340-3ksfpaf7	164	6	stimulating	stimulate	VBG
cord-034340-3ksfpaf7	164	7	and	and	CC
cord-034340-3ksfpaf7	164	8	inhibiting	inhibit	VBG
cord-034340-3ksfpaf7	164	9	cytokines	cytokine	NNS
cord-034340-3ksfpaf7	164	10	showed	show	VBD
cord-034340-3ksfpaf7	164	11	in	in	IN
cord-034340-3ksfpaf7	164	12	patients	patient	NNS
cord-034340-3ksfpaf7	164	13	with	with	IN
cord-034340-3ksfpaf7	164	14	uveitis	uveitis	NN
cord-034340-3ksfpaf7	164	15	,	,	,
cord-034340-3ksfpaf7	164	16	the	the	DT
cord-034340-3ksfpaf7	164	17	ratio	ratio	NN
cord-034340-3ksfpaf7	164	18	of	of	IN
cord-034340-3ksfpaf7	164	19	IFN	IFN	NNP
cord-034340-3ksfpaf7	164	20	-	-	HYPH
cord-034340-3ksfpaf7	164	21	γ	γ	NNP
cord-034340-3ksfpaf7	164	22	/	/	SYM
cord-034340-3ksfpaf7	164	23	IL-1β	IL-1β	NNP
cord-034340-3ksfpaf7	164	24	(	(	-LRB-
cord-034340-3ksfpaf7	164	25	4379.29	4379.29	CD
cord-034340-3ksfpaf7	164	26	±476.83	±476.83	NN
cord-034340-3ksfpaf7	164	27	)	)	-RRB-
cord-034340-3ksfpaf7	164	28	was	be	VBD
cord-034340-3ksfpaf7	164	29	higher	high	JJR
cord-034340-3ksfpaf7	164	30	than	than	IN
cord-034340-3ksfpaf7	164	31	with	with	IN
cord-034340-3ksfpaf7	164	32	other	other	JJ
cord-034340-3ksfpaf7	164	33	JIA	JIA	NNP
cord-034340-3ksfpaf7	164	34	(	(	-LRB-
cord-034340-3ksfpaf7	164	35	from	from	IN
cord-034340-3ksfpaf7	164	36	60.84	60.84	CD
cord-034340-3ksfpaf7	164	37	±	±	CD
cord-034340-3ksfpaf7	164	38	14.92	14.92	CD
cord-034340-3ksfpaf7	164	39	in	in	IN
cord-034340-3ksfpaf7	164	40	oJIA	ojia	NN
cord-034340-3ksfpaf7	164	41	to	to	IN
cord-034340-3ksfpaf7	164	42	105.20±	105.20±	CD
cord-034340-3ksfpaf7	164	43	66.01	66.01	CD
cord-034340-3ksfpaf7	164	44	in	in	IN
cord-034340-3ksfpaf7	164	45	pJIA	pjia	NN
cord-034340-3ksfpaf7	164	46	)	)	-RRB-
cord-034340-3ksfpaf7	165	1	and	and	CC
cord-034340-3ksfpaf7	165	2	IFN	IFN	NNP
cord-034340-3ksfpaf7	165	3	-	-	HYPH
cord-034340-3ksfpaf7	165	4	γ	γ	NNP
cord-034340-3ksfpaf7	166	1	/IL-17R	/IL-17R	NFP
cord-034340-3ksfpaf7	166	2	(	(	-LRB-
cord-034340-3ksfpaf7	166	3	4474.01	4474.01	CD
cord-034340-3ksfpaf7	166	4	±3899.19	±3899.19	NN
cord-034340-3ksfpaf7	166	5	versus	versus	NN
cord-034340-3ksfpaf7	166	6	from	from	IN
cord-034340-3ksfpaf7	166	7	20.14±	20.14±	CD
cord-034340-3ksfpaf7	166	8	11.48	11.48	CD
cord-034340-3ksfpaf7	166	9	in	in	IN
cord-034340-3ksfpaf7	166	10	oJIA	ojia	NN
cord-034340-3ksfpaf7	166	11	to	to	IN
cord-034340-3ksfpaf7	166	12	934.55±931.37	934.55±931.37	CD
cord-034340-3ksfpaf7	166	13	in	in	IN
cord-034340-3ksfpaf7	166	14	sJIA	sjia	NN
cord-034340-3ksfpaf7	166	15	)	)	-RRB-
cord-034340-3ksfpaf7	166	16	.	.	.
cord-034340-3ksfpaf7	167	1	An	an	DT
cord-034340-3ksfpaf7	167	2	increase	increase	NN
cord-034340-3ksfpaf7	167	3	of	of	IN
cord-034340-3ksfpaf7	167	4	IL-1β	IL-1β	NNS
cord-034340-3ksfpaf7	167	5	/	/	SYM
cord-034340-3ksfpaf7	167	6	IL-17R	IL-17R	NNP
cord-034340-3ksfpaf7	167	7	ratio	ratio	NN
cord-034340-3ksfpaf7	167	8	was	be	VBD
cord-034340-3ksfpaf7	167	9	characteristic	characteristic	JJ
cord-034340-3ksfpaf7	167	10	only	only	RB
cord-034340-3ksfpaf7	167	11	for	for	IN
cord-034340-3ksfpaf7	167	12	sJIA	sjia	NN
cord-034340-3ksfpaf7	168	1	(	(	-LRB-
cord-034340-3ksfpaf7	168	2	34.12±26.17	34.12±26.17	CD
cord-034340-3ksfpaf7	168	3	)	)	-RRB-
cord-034340-3ksfpaf7	168	4	.	.	.
cord-034340-3ksfpaf7	169	1	All	all	DT
cord-034340-3ksfpaf7	169	2	of	of	IN
cord-034340-3ksfpaf7	169	3	these	these	DT
cord-034340-3ksfpaf7	169	4	ratios	ratio	NNS
cord-034340-3ksfpaf7	169	5	increased	increase	VBD
cord-034340-3ksfpaf7	169	6	with	with	IN
cord-034340-3ksfpaf7	169	7	disease	disease	NN
cord-034340-3ksfpaf7	169	8	activity	activity	NN
cord-034340-3ksfpaf7	169	9	(	(	-LRB-
cord-034340-3ksfpaf7	169	10	r=0.22	r=0.22	NNP
cord-034340-3ksfpaf7	169	11	-	-	HYPH
cord-034340-3ksfpaf7	169	12	0.37	0.37	CD
cord-034340-3ksfpaf7	169	13	)	)	-RRB-
cord-034340-3ksfpaf7	169	14	&	&	CC
cord-034340-3ksfpaf7	169	15	they	-PRON-	PRP
cord-034340-3ksfpaf7	169	16	did	do	VBD
cord-034340-3ksfpaf7	169	17	not	not	RB
cord-034340-3ksfpaf7	169	18	reflect	reflect	VB
cord-034340-3ksfpaf7	169	19	the	the	DT
cord-034340-3ksfpaf7	169	20	unpleasant	unpleasant	JJ
cord-034340-3ksfpaf7	169	21	course	course	NN
cord-034340-3ksfpaf7	169	22	of	of	IN
cord-034340-3ksfpaf7	169	23	the	the	DT
cord-034340-3ksfpaf7	169	24	disease	disease	NN
cord-034340-3ksfpaf7	169	25	.	.	.
cord-034340-3ksfpaf7	170	1	Methods	method	NNS
cord-034340-3ksfpaf7	170	2	:	:	:
cord-034340-3ksfpaf7	170	3	In	in	IN
cord-034340-3ksfpaf7	170	4	this	this	DT
cord-034340-3ksfpaf7	170	5	multicenter	multicenter	NN
cord-034340-3ksfpaf7	170	6	,	,	,
cord-034340-3ksfpaf7	170	7	case	case	NN
cord-034340-3ksfpaf7	170	8	-	-	HYPH
cord-034340-3ksfpaf7	170	9	control	control	NN
cord-034340-3ksfpaf7	170	10	study	study	NN
cord-034340-3ksfpaf7	170	11	,	,	,
cord-034340-3ksfpaf7	170	12	113	113	CD
cord-034340-3ksfpaf7	170	13	fecal	fecal	JJ
cord-034340-3ksfpaf7	170	14	samples	sample	NNS
cord-034340-3ksfpaf7	170	15	were	be	VBD
cord-034340-3ksfpaf7	170	16	collected	collect	VBN
cord-034340-3ksfpaf7	170	17	from	from	IN
cord-034340-3ksfpaf7	170	18	91	91	CD
cord-034340-3ksfpaf7	170	19	children	child	NNS
cord-034340-3ksfpaf7	170	20	with	with	IN
cord-034340-3ksfpaf7	170	21	JIA	JIA	NNP
cord-034340-3ksfpaf7	170	22	,	,	,
cord-034340-3ksfpaf7	170	23	with	with	IN
cord-034340-3ksfpaf7	170	24	72	72	CD
cord-034340-3ksfpaf7	170	25	of	of	IN
cord-034340-3ksfpaf7	170	26	these	these	DT
cord-034340-3ksfpaf7	170	27	samples	sample	NNS
cord-034340-3ksfpaf7	170	28	collected	collect	VBN
cord-034340-3ksfpaf7	170	29	from	from	IN
cord-034340-3ksfpaf7	170	30	untreated	untreated	JJ
cord-034340-3ksfpaf7	170	31	children	child	NNS
cord-034340-3ksfpaf7	170	32	(	(	-LRB-
cord-034340-3ksfpaf7	170	33	67	67	CD
cord-034340-3ksfpaf7	170	34	of	of	IN
cord-034340-3ksfpaf7	170	35	whom	whom	WP
cord-034340-3ksfpaf7	170	36	were	be	VBD
cord-034340-3ksfpaf7	170	37	treatment	treatment	NN
cord-034340-3ksfpaf7	170	38	-	-	HYPH
cord-034340-3ksfpaf7	170	39	naïve	naïve	JJ
cord-034340-3ksfpaf7	170	40	children	child	NNS
cord-034340-3ksfpaf7	170	41	)	)	-RRB-
cord-034340-3ksfpaf7	170	42	.	.	.
cord-034340-3ksfpaf7	171	1	Samples	sample	NNS
cord-034340-3ksfpaf7	171	2	from	from	IN
cord-034340-3ksfpaf7	171	3	28	28	CD
cord-034340-3ksfpaf7	171	4	children	child	NNS
cord-034340-3ksfpaf7	171	5	with	with	IN
cord-034340-3ksfpaf7	171	6	JIA	JIA	NNP
cord-034340-3ksfpaf7	171	7	were	be	VBD
cord-034340-3ksfpaf7	171	8	collected	collect	VBN
cord-034340-3ksfpaf7	171	9	during	during	IN
cord-034340-3ksfpaf7	171	10	treatment	treatment	NN
cord-034340-3ksfpaf7	171	11	with	with	IN
cord-034340-3ksfpaf7	171	12	MTX	MTX	NNP
cord-034340-3ksfpaf7	171	13	as	as	IN
cord-034340-3ksfpaf7	171	14	single	single	JJ
cord-034340-3ksfpaf7	171	15	treatment	treatment	NN
cord-034340-3ksfpaf7	171	16	and	and	CC
cord-034340-3ksfpaf7	171	17	samples	sample	NNS
cord-034340-3ksfpaf7	171	18	from	from	IN
cord-034340-3ksfpaf7	171	19	13	13	CD
cord-034340-3ksfpaf7	171	20	children	child	NNS
cord-034340-3ksfpaf7	171	21	during	during	IN
cord-034340-3ksfpaf7	171	22	treatment	treatment	NN
cord-034340-3ksfpaf7	171	23	with	with	IN
cord-034340-3ksfpaf7	171	24	ETN	ETN	NNP
cord-034340-3ksfpaf7	171	25	.	.	.
cord-034340-3ksfpaf7	172	1	Of	of	IN
cord-034340-3ksfpaf7	172	2	those	those	DT
cord-034340-3ksfpaf7	172	3	13	13	CD
cord-034340-3ksfpaf7	172	4	children	child	NNS
cord-034340-3ksfpaf7	172	5	,	,	,
cord-034340-3ksfpaf7	172	6	four	four	CD
cord-034340-3ksfpaf7	172	7	were	be	VBD
cord-034340-3ksfpaf7	172	8	treated	treat	VBN
cord-034340-3ksfpaf7	172	9	with	with	IN
cord-034340-3ksfpaf7	172	10	ETN	ETN	NNP
cord-034340-3ksfpaf7	172	11	as	as	IN
cord-034340-3ksfpaf7	172	12	single	single	JJ
cord-034340-3ksfpaf7	172	13	treatment	treatment	NN
cord-034340-3ksfpaf7	172	14	and	and	CC
cord-034340-3ksfpaf7	172	15	nine	nine	CD
cord-034340-3ksfpaf7	172	16	had	have	VBD
cord-034340-3ksfpaf7	172	17	a	a	DT
cord-034340-3ksfpaf7	172	18	combination	combination	NN
cord-034340-3ksfpaf7	172	19	of	of	IN
cord-034340-3ksfpaf7	172	20	ETN	ETN	NNP
cord-034340-3ksfpaf7	172	21	and	and	CC
cord-034340-3ksfpaf7	172	22	MTX	MTX	NNP
cord-034340-3ksfpaf7	172	23	.	.	.
cord-034340-3ksfpaf7	173	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	173	2	compared	compare	VBD
cord-034340-3ksfpaf7	173	3	28	28	CD
cord-034340-3ksfpaf7	173	4	children	child	NNS
cord-034340-3ksfpaf7	173	5	on	on	IN
cord-034340-3ksfpaf7	173	6	single	single	JJ
cord-034340-3ksfpaf7	173	7	treatment	treatment	NN
cord-034340-3ksfpaf7	173	8	with	with	IN
cord-034340-3ksfpaf7	173	9	MTX	MTX	NNP
cord-034340-3ksfpaf7	173	10	with	with	IN
cord-034340-3ksfpaf7	173	11	57	57	CD
cord-034340-3ksfpaf7	173	12	untreated	untreated	JJ
cord-034340-3ksfpaf7	173	13	children	child	NNS
cord-034340-3ksfpaf7	173	14	(	(	-LRB-
cord-034340-3ksfpaf7	173	15	52	52	CD
cord-034340-3ksfpaf7	173	16	treatment	treatment	NN
cord-034340-3ksfpaf7	173	17	-	-	HYPH
cord-034340-3ksfpaf7	173	18	naïve	naïve	JJ
cord-034340-3ksfpaf7	173	19	)	)	-RRB-
cord-034340-3ksfpaf7	173	20	,	,	,
cord-034340-3ksfpaf7	173	21	and	and	CC
cord-034340-3ksfpaf7	173	22	13	13	CD
cord-034340-3ksfpaf7	173	23	children	child	NNS
cord-034340-3ksfpaf7	173	24	on	on	IN
cord-034340-3ksfpaf7	173	25	treatment	treatment	NN
cord-034340-3ksfpaf7	173	26	with	with	IN
cord-034340-3ksfpaf7	173	27	ETN	ETN	NNP
cord-034340-3ksfpaf7	173	28	(	(	-LRB-
cord-034340-3ksfpaf7	173	29	nine	nine	CD
cord-034340-3ksfpaf7	173	30	in	in	IN
cord-034340-3ksfpaf7	173	31	combination	combination	NN
cord-034340-3ksfpaf7	173	32	with	with	IN
cord-034340-3ksfpaf7	173	33	MTX	MTX	NNP
cord-034340-3ksfpaf7	173	34	)	)	-RRB-
cord-034340-3ksfpaf7	173	35	with	with	IN
cord-034340-3ksfpaf7	173	36	62	62	CD
cord-034340-3ksfpaf7	173	37	untreated	untreated	JJ
cord-034340-3ksfpaf7	173	38	children	child	NNS
cord-034340-3ksfpaf7	173	39	(	(	-LRB-
cord-034340-3ksfpaf7	173	40	57	57	CD
cord-034340-3ksfpaf7	173	41	treatment	treatment	NN
cord-034340-3ksfpaf7	173	42	-	-	HYPH
cord-034340-3ksfpaf7	173	43	naïve	naïve	JJ
cord-034340-3ksfpaf7	173	44	)	)	-RRB-
cord-034340-3ksfpaf7	173	45	.	.	.
cord-034340-3ksfpaf7	174	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	174	2	also	also	RB
cord-034340-3ksfpaf7	174	3	did	do	VBD
cord-034340-3ksfpaf7	174	4	pairwise	pairwise	JJ
cord-034340-3ksfpaf7	174	5	comparisons	comparison	NNS
cord-034340-3ksfpaf7	174	6	of	of	IN
cord-034340-3ksfpaf7	174	7	samples	sample	NNS
cord-034340-3ksfpaf7	174	8	taken	take	VBN
cord-034340-3ksfpaf7	174	9	before	before	IN
cord-034340-3ksfpaf7	174	10	any	any	DT
cord-034340-3ksfpaf7	174	11	medication	medication	NN
cord-034340-3ksfpaf7	174	12	was	be	VBD
cord-034340-3ksfpaf7	174	13	given	give	VBN
cord-034340-3ksfpaf7	174	14	(	(	-LRB-
cord-034340-3ksfpaf7	174	15	n	n	NN
cord-034340-3ksfpaf7	174	16	=	=	SYM
cord-034340-3ksfpaf7	174	17	22	22	CD
cord-034340-3ksfpaf7	174	18	)	)	-RRB-
cord-034340-3ksfpaf7	174	19	and	and	CC
cord-034340-3ksfpaf7	174	20	samples	sample	NNS
cord-034340-3ksfpaf7	174	21	taken	take	VBN
cord-034340-3ksfpaf7	174	22	during	during	IN
cord-034340-3ksfpaf7	174	23	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	174	24	treatment	treatment	NN
cord-034340-3ksfpaf7	174	25	with	with	IN
cord-034340-3ksfpaf7	174	26	MTX	MTX	NNP
cord-034340-3ksfpaf7	174	27	(	(	-LRB-
cord-034340-3ksfpaf7	174	28	n	n	NN
cord-034340-3ksfpaf7	174	29	=	=	SYM
cord-034340-3ksfpaf7	174	30	14	14	CD
cord-034340-3ksfpaf7	174	31	)	)	-RRB-
cord-034340-3ksfpaf7	174	32	or	or	CC
cord-034340-3ksfpaf7	174	33	ETN	ETN	NNP
cord-034340-3ksfpaf7	174	34	(	(	-LRB-
cord-034340-3ksfpaf7	174	35	n	n	NN
cord-034340-3ksfpaf7	174	36	=	=	SYM
cord-034340-3ksfpaf7	174	37	8	8	CD
cord-034340-3ksfpaf7	174	38	,	,	,
cord-034340-3ksfpaf7	174	39	four	four	CD
cord-034340-3ksfpaf7	174	40	in	in	IN
cord-034340-3ksfpaf7	174	41	combination	combination	NN
cord-034340-3ksfpaf7	174	42	with	with	IN
cord-034340-3ksfpaf7	174	43	MTX	MTX	NNP
cord-034340-3ksfpaf7	174	44	)	)	-RRB-
cord-034340-3ksfpaf7	174	45	.	.	.
cord-034340-3ksfpaf7	175	1	The	the	DT
cord-034340-3ksfpaf7	175	2	microbiota	microbiota	NN
cord-034340-3ksfpaf7	175	3	was	be	VBD
cord-034340-3ksfpaf7	175	4	characterized	characterize	VBN
cord-034340-3ksfpaf7	175	5	by	by	IN
cord-034340-3ksfpaf7	175	6	sequencing	sequence	VBG
cord-034340-3ksfpaf7	175	7	amplicons	amplicon	NNS
cord-034340-3ksfpaf7	175	8	from	from	IN
cord-034340-3ksfpaf7	175	9	the	the	DT
cord-034340-3ksfpaf7	175	10	V3	V3	NNP
cord-034340-3ksfpaf7	175	11	and	and	CC
cord-034340-3ksfpaf7	175	12	V4	v4	NN
cord-034340-3ksfpaf7	175	13	regions	region	NNS
cord-034340-3ksfpaf7	175	14	of	of	IN
cord-034340-3ksfpaf7	175	15	the	the	DT
cord-034340-3ksfpaf7	175	16	16S	16S	NNP
cord-034340-3ksfpaf7	175	17	rRNA	rRNA	NNP
cord-034340-3ksfpaf7	175	18	gene	gene	NN
cord-034340-3ksfpaf7	175	19	.	.	.
cord-034340-3ksfpaf7	176	1	Alpha	alpha	NN
cord-034340-3ksfpaf7	176	2	diversity	diversity	NN
cord-034340-3ksfpaf7	176	3	of	of	IN
cord-034340-3ksfpaf7	176	4	the	the	DT
cord-034340-3ksfpaf7	176	5	fecal	fecal	JJ
cord-034340-3ksfpaf7	176	6	samples	sample	NNS
cord-034340-3ksfpaf7	176	7	was	be	VBD
cord-034340-3ksfpaf7	176	8	measured	measure	VBN
cord-034340-3ksfpaf7	176	9	using	use	VBG
cord-034340-3ksfpaf7	176	10	the	the	DT
cord-034340-3ksfpaf7	176	11	Chao-1	Chao-1	NNP
cord-034340-3ksfpaf7	176	12	index	index	NN
cord-034340-3ksfpaf7	176	13	and	and	CC
cord-034340-3ksfpaf7	176	14	the	the	DT
cord-034340-3ksfpaf7	176	15	Shannon	Shannon	NNP
cord-034340-3ksfpaf7	176	16	diversity	diversity	NN
cord-034340-3ksfpaf7	176	17	index	index	NN
cord-034340-3ksfpaf7	176	18	.	.	.
cord-034340-3ksfpaf7	177	1	To	to	TO
cord-034340-3ksfpaf7	177	2	compare	compare	VB
cord-034340-3ksfpaf7	177	3	these	these	DT
cord-034340-3ksfpaf7	177	4	indices	index	NNS
cord-034340-3ksfpaf7	177	5	between	between	IN
cord-034340-3ksfpaf7	177	6	treated	treat	VBN
cord-034340-3ksfpaf7	177	7	children	child	NNS
cord-034340-3ksfpaf7	177	8	and	and	CC
cord-034340-3ksfpaf7	177	9	untreated	untreated	JJ
cord-034340-3ksfpaf7	177	10	children	child	NNS
cord-034340-3ksfpaf7	177	11	,	,	,
cord-034340-3ksfpaf7	177	12	we	-PRON-	PRP
cord-034340-3ksfpaf7	177	13	used	use	VBD
cord-034340-3ksfpaf7	177	14	a	a	DT
cord-034340-3ksfpaf7	177	15	logistic	logistic	JJ
cord-034340-3ksfpaf7	177	16	regression	regression	NN
cord-034340-3ksfpaf7	177	17	model	model	NN
cord-034340-3ksfpaf7	177	18	with	with	IN
cord-034340-3ksfpaf7	177	19	age	age	NN
cord-034340-3ksfpaf7	177	20	at	at	IN
cord-034340-3ksfpaf7	177	21	sampling	sampling	NN
cord-034340-3ksfpaf7	177	22	as	as	IN
cord-034340-3ksfpaf7	177	23	a	a	DT
cord-034340-3ksfpaf7	177	24	covariate	covariate	NN
cord-034340-3ksfpaf7	177	25	.	.	.
cord-034340-3ksfpaf7	178	1	For	for	IN
cord-034340-3ksfpaf7	178	2	pairwise	pairwise	JJ
cord-034340-3ksfpaf7	178	3	analyses	analysis	NNS
cord-034340-3ksfpaf7	178	4	,	,	,
cord-034340-3ksfpaf7	178	5	we	-PRON-	PRP
cord-034340-3ksfpaf7	178	6	used	use	VBD
cord-034340-3ksfpaf7	178	7	the	the	DT
cord-034340-3ksfpaf7	178	8	Wilcoxon	Wilcoxon	NNP
cord-034340-3ksfpaf7	178	9	signed	sign	VBN
cord-034340-3ksfpaf7	178	10	-	-	HYPH
cord-034340-3ksfpaf7	178	11	rank	rank	NN
cord-034340-3ksfpaf7	178	12	test	test	NN
cord-034340-3ksfpaf7	178	13	.	.	.
cord-034340-3ksfpaf7	179	1	To	to	TO
cord-034340-3ksfpaf7	179	2	analyze	analyze	VB
cord-034340-3ksfpaf7	179	3	the	the	DT
cord-034340-3ksfpaf7	179	4	community	community	NN
cord-034340-3ksfpaf7	179	5	composition	composition	NN
cord-034340-3ksfpaf7	179	6	of	of	IN
cord-034340-3ksfpaf7	179	7	the	the	DT
cord-034340-3ksfpaf7	179	8	microbiota	microbiota	NN
cord-034340-3ksfpaf7	179	9	,	,	,
cord-034340-3ksfpaf7	179	10	principal	principal	JJ
cord-034340-3ksfpaf7	179	11	coordinate	coordinate	VB
cord-034340-3ksfpaf7	179	12	analysis	analysis	NN
cord-034340-3ksfpaf7	179	13	(	(	-LRB-
cord-034340-3ksfpaf7	179	14	PCoA	PCoA	NNP
cord-034340-3ksfpaf7	179	15	)	)	-RRB-
cord-034340-3ksfpaf7	179	16	plots	plot	NNS
cord-034340-3ksfpaf7	179	17	based	base	VBN
cord-034340-3ksfpaf7	179	18	on	on	IN
cord-034340-3ksfpaf7	179	19	Bray	Bray	NNP
cord-034340-3ksfpaf7	179	20	-	-	HYPH
cord-034340-3ksfpaf7	179	21	Curtis	Curtis	NNP
cord-034340-3ksfpaf7	179	22	distances	distance	NNS
cord-034340-3ksfpaf7	179	23	were	be	VBD
cord-034340-3ksfpaf7	179	24	generated	generate	VBN
cord-034340-3ksfpaf7	179	25	for	for	IN
cord-034340-3ksfpaf7	179	26	visual	visual	JJ
cord-034340-3ksfpaf7	179	27	comparisons	comparison	NNS
cord-034340-3ksfpaf7	179	28	,	,	,
cord-034340-3ksfpaf7	179	29	and	and	CC
cord-034340-3ksfpaf7	179	30	analysis	analysis	NN
cord-034340-3ksfpaf7	179	31	of	of	IN
cord-034340-3ksfpaf7	179	32	similarity	similarity	NN
cord-034340-3ksfpaf7	179	33	(	(	-LRB-
cord-034340-3ksfpaf7	179	34	ANOSIM	ANOSIM	NNP
cord-034340-3ksfpaf7	179	35	)	)	-RRB-
cord-034340-3ksfpaf7	179	36	was	be	VBD
cord-034340-3ksfpaf7	179	37	used	use	VBN
cord-034340-3ksfpaf7	179	38	to	to	TO
cord-034340-3ksfpaf7	179	39	test	test	VB
cord-034340-3ksfpaf7	179	40	for	for	IN
cord-034340-3ksfpaf7	179	41	differences	difference	NNS
cord-034340-3ksfpaf7	179	42	.	.	.
cord-034340-3ksfpaf7	180	1	Analyses	analysis	NNS
cord-034340-3ksfpaf7	180	2	for	for	IN
cord-034340-3ksfpaf7	180	3	relative	relative	JJ
cord-034340-3ksfpaf7	180	4	abundances	abundance	NNS
cord-034340-3ksfpaf7	180	5	of	of	IN
cord-034340-3ksfpaf7	180	6	taxa	taxon	NNS
cord-034340-3ksfpaf7	180	7	were	be	VBD
cord-034340-3ksfpaf7	180	8	performed	perform	VBN
cord-034340-3ksfpaf7	180	9	at	at	IN
cord-034340-3ksfpaf7	180	10	three	three	CD
cord-034340-3ksfpaf7	180	11	taxonomic	taxonomic	JJ
cord-034340-3ksfpaf7	180	12	levels	level	NNS
cord-034340-3ksfpaf7	180	13	(	(	-LRB-
cord-034340-3ksfpaf7	180	14	phyla	phylum	NNS
cord-034340-3ksfpaf7	180	15	,	,	,
cord-034340-3ksfpaf7	180	16	families	family	NNS
cord-034340-3ksfpaf7	180	17	,	,	,
cord-034340-3ksfpaf7	180	18	and	and	CC
cord-034340-3ksfpaf7	180	19	genera	genera	NNPS
cord-034340-3ksfpaf7	180	20	)	)	-RRB-
cord-034340-3ksfpaf7	180	21	,	,	,
cord-034340-3ksfpaf7	180	22	and	and	CC
cord-034340-3ksfpaf7	180	23	logistic	logistic	JJ
cord-034340-3ksfpaf7	180	24	regression	regression	NN
cord-034340-3ksfpaf7	180	25	with	with	IN
cord-034340-3ksfpaf7	180	26	age	age	NN
cord-034340-3ksfpaf7	180	27	as	as	IN
cord-034340-3ksfpaf7	180	28	a	a	DT
cord-034340-3ksfpaf7	180	29	covariate	covariate	NN
cord-034340-3ksfpaf7	180	30	was	be	VBD
cord-034340-3ksfpaf7	180	31	used	use	VBN
cord-034340-3ksfpaf7	180	32	for	for	IN
cord-034340-3ksfpaf7	180	33	calculations	calculation	NNS
cord-034340-3ksfpaf7	180	34	of	of	IN
cord-034340-3ksfpaf7	180	35	differences	difference	NNS
cord-034340-3ksfpaf7	180	36	between	between	IN
cord-034340-3ksfpaf7	180	37	treated	treated	JJ
cord-034340-3ksfpaf7	180	38	and	and	CC
cord-034340-3ksfpaf7	180	39	untreated	untreated	JJ
cord-034340-3ksfpaf7	180	40	children	child	NNS
cord-034340-3ksfpaf7	180	41	,	,	,
cord-034340-3ksfpaf7	180	42	while	while	IN
cord-034340-3ksfpaf7	180	43	the	the	DT
cord-034340-3ksfpaf7	180	44	Wilcoxon	Wilcoxon	NNP
cord-034340-3ksfpaf7	180	45	signedrank	signedrank	NN
cord-034340-3ksfpaf7	180	46	test	test	NN
cord-034340-3ksfpaf7	180	47	was	be	VBD
cord-034340-3ksfpaf7	180	48	used	use	VBN
cord-034340-3ksfpaf7	180	49	for	for	IN
cord-034340-3ksfpaf7	180	50	pairwise	pairwise	JJ
cord-034340-3ksfpaf7	180	51	comparisons	comparison	NNS
cord-034340-3ksfpaf7	180	52	.	.	.
cord-034340-3ksfpaf7	181	1	Significance	significance	NN
cord-034340-3ksfpaf7	181	2	was	be	VBD
cord-034340-3ksfpaf7	181	3	set	set	VBN
cord-034340-3ksfpaf7	181	4	to	to	IN
cord-034340-3ksfpaf7	181	5	p	p	NN
cord-034340-3ksfpaf7	181	6	<	<	XX
cord-034340-3ksfpaf7	181	7	0.05	0.05	CD
cord-034340-3ksfpaf7	181	8	and	and	CC
cord-034340-3ksfpaf7	181	9	corrections	correction	NNS
cord-034340-3ksfpaf7	181	10	for	for	IN
cord-034340-3ksfpaf7	181	11	multiple	multiple	JJ
cord-034340-3ksfpaf7	181	12	comparisons	comparison	NNS
cord-034340-3ksfpaf7	181	13	were	be	VBD
cord-034340-3ksfpaf7	181	14	made	make	VBN
cord-034340-3ksfpaf7	181	15	using	use	VBG
cord-034340-3ksfpaf7	181	16	the	the	DT
cord-034340-3ksfpaf7	181	17	Benjamini	Benjamini	NNP
cord-034340-3ksfpaf7	181	18	-	-	HYPH
cord-034340-3ksfpaf7	181	19	Hochberg	Hochberg	NNP
cord-034340-3ksfpaf7	181	20	method	method	NN
cord-034340-3ksfpaf7	181	21	.	.	.
cord-034340-3ksfpaf7	182	1	Results	result	NNS
cord-034340-3ksfpaf7	182	2	:	:	:
cord-034340-3ksfpaf7	183	1	Analyses	analysis	NNS
cord-034340-3ksfpaf7	183	2	showed	show	VBD
cord-034340-3ksfpaf7	183	3	no	no	DT
cord-034340-3ksfpaf7	183	4	significant	significant	JJ
cord-034340-3ksfpaf7	183	5	differences	difference	NNS
cord-034340-3ksfpaf7	183	6	in	in	IN
cord-034340-3ksfpaf7	183	7	α	α	NN
cord-034340-3ksfpaf7	183	8	-	-	HYPH
cord-034340-3ksfpaf7	183	9	diversity	diversity	NN
cord-034340-3ksfpaf7	183	10	between	between	IN
cord-034340-3ksfpaf7	183	11	children	child	NNS
cord-034340-3ksfpaf7	183	12	treated	treat	VBN
cord-034340-3ksfpaf7	183	13	with	with	IN
cord-034340-3ksfpaf7	183	14	MTX	MTX	NNP
cord-034340-3ksfpaf7	183	15	or	or	CC
cord-034340-3ksfpaf7	183	16	ETN	ETN	NNP
cord-034340-3ksfpaf7	183	17	and	and	CC
cord-034340-3ksfpaf7	183	18	untreated	untreated	JJ
cord-034340-3ksfpaf7	183	19	children	child	NNS
cord-034340-3ksfpaf7	183	20	,	,	,
cord-034340-3ksfpaf7	183	21	and	and	CC
cord-034340-3ksfpaf7	183	22	pairwise	pairwise	JJ
cord-034340-3ksfpaf7	183	23	comparisons	comparison	NNS
cord-034340-3ksfpaf7	183	24	of	of	IN
cord-034340-3ksfpaf7	183	25	samples	sample	NNS
cord-034340-3ksfpaf7	183	26	before	before	RB
cord-034340-3ksfpaf7	183	27	and	and	CC
cord-034340-3ksfpaf7	183	28	during	during	IN
cord-034340-3ksfpaf7	183	29	treatment	treatment	NN
cord-034340-3ksfpaf7	183	30	with	with	IN
cord-034340-3ksfpaf7	183	31	MTX	MTX	NNP
cord-034340-3ksfpaf7	183	32	or	or	CC
cord-034340-3ksfpaf7	183	33	ETN	ETN	NNP
cord-034340-3ksfpaf7	183	34	also	also	RB
cord-034340-3ksfpaf7	183	35	showed	show	VBD
cord-034340-3ksfpaf7	183	36	no	no	DT
cord-034340-3ksfpaf7	183	37	differences	difference	NNS
cord-034340-3ksfpaf7	183	38	.	.	.
cord-034340-3ksfpaf7	184	1	PCoA	pcoa	JJ
cord-034340-3ksfpaf7	184	2	plots	plot	VBZ
cord-034340-3ksfpaf7	184	3	for	for	IN
cord-034340-3ksfpaf7	184	4	children	child	NNS
cord-034340-3ksfpaf7	184	5	treated	treat	VBN
cord-034340-3ksfpaf7	184	6	with	with	IN
cord-034340-3ksfpaf7	184	7	MTX	MTX	NNP
cord-034340-3ksfpaf7	184	8	or	or	CC
cord-034340-3ksfpaf7	184	9	ETN	ETN	NNP
cord-034340-3ksfpaf7	184	10	,	,	,
cord-034340-3ksfpaf7	184	11	in	in	IN
cord-034340-3ksfpaf7	184	12	comparison	comparison	NN
cord-034340-3ksfpaf7	184	13	with	with	IN
cord-034340-3ksfpaf7	184	14	untreated	untreated	JJ
cord-034340-3ksfpaf7	184	15	children	child	NNS
cord-034340-3ksfpaf7	184	16	,	,	,
cord-034340-3ksfpaf7	184	17	did	do	VBD
cord-034340-3ksfpaf7	184	18	not	not	RB
cord-034340-3ksfpaf7	184	19	show	show	VB
cord-034340-3ksfpaf7	184	20	any	any	DT
cord-034340-3ksfpaf7	184	21	clustering	clustering	NN
cord-034340-3ksfpaf7	184	22	.	.	.
cord-034340-3ksfpaf7	185	1	ANOSIM	ANOSIM	NNP
cord-034340-3ksfpaf7	185	2	showed	show	VBD
cord-034340-3ksfpaf7	185	3	no	no	DT
cord-034340-3ksfpaf7	185	4	significant	significant	JJ
cord-034340-3ksfpaf7	185	5	differences	difference	NNS
cord-034340-3ksfpaf7	185	6	between	between	IN
cord-034340-3ksfpaf7	185	7	treated	treated	JJ
cord-034340-3ksfpaf7	185	8	and	and	CC
cord-034340-3ksfpaf7	185	9	untreated	untreated	JJ
cord-034340-3ksfpaf7	185	10	children	child	NNS
cord-034340-3ksfpaf7	185	11	.	.	.
cord-034340-3ksfpaf7	186	1	PCoA	pcoa	JJ
cord-034340-3ksfpaf7	186	2	plots	plot	NNS
cord-034340-3ksfpaf7	186	3	were	be	VBD
cord-034340-3ksfpaf7	186	4	also	also	RB
cord-034340-3ksfpaf7	186	5	made	make	VBN
cord-034340-3ksfpaf7	186	6	for	for	IN
cord-034340-3ksfpaf7	186	7	the	the	DT
cord-034340-3ksfpaf7	186	8	pairwise	pairwise	JJ
cord-034340-3ksfpaf7	186	9	comparisons	comparison	NNS
cord-034340-3ksfpaf7	186	10	of	of	IN
cord-034340-3ksfpaf7	186	11	children	child	NNS
cord-034340-3ksfpaf7	186	12	sampled	sample	VBN
cord-034340-3ksfpaf7	186	13	before	before	IN
cord-034340-3ksfpaf7	186	14	and	and	CC
cord-034340-3ksfpaf7	186	15	during	during	IN
cord-034340-3ksfpaf7	186	16	treatment	treatment	NN
cord-034340-3ksfpaf7	186	17	,	,	,
cord-034340-3ksfpaf7	186	18	and	and	CC
cord-034340-3ksfpaf7	186	19	according	accord	VBG
cord-034340-3ksfpaf7	186	20	to	to	IN
cord-034340-3ksfpaf7	186	21	that	that	DT
cord-034340-3ksfpaf7	186	22	analysis	analysis	NN
cord-034340-3ksfpaf7	186	23	the	the	DT
cord-034340-3ksfpaf7	186	24	community	community	NN
cord-034340-3ksfpaf7	186	25	compositions	composition	NNS
cord-034340-3ksfpaf7	186	26	of	of	IN
cord-034340-3ksfpaf7	186	27	microbiota	microbiota	NN
cord-034340-3ksfpaf7	186	28	did	do	VBD
cord-034340-3ksfpaf7	186	29	not	not	RB
cord-034340-3ksfpaf7	186	30	change	change	VB
cord-034340-3ksfpaf7	186	31	in	in	IN
cord-034340-3ksfpaf7	186	32	any	any	DT
cord-034340-3ksfpaf7	186	33	uniform	uniform	JJ
cord-034340-3ksfpaf7	186	34	way	way	NN
cord-034340-3ksfpaf7	186	35	during	during	IN
cord-034340-3ksfpaf7	186	36	treatment	treatment	NN
cord-034340-3ksfpaf7	186	37	with	with	IN
cord-034340-3ksfpaf7	186	38	either	either	CC
cord-034340-3ksfpaf7	186	39	MTX	MTX	NNP
cord-034340-3ksfpaf7	186	40	or	or	CC
cord-034340-3ksfpaf7	186	41	ETN	ETN	NNP
cord-034340-3ksfpaf7	186	42	.	.	.
cord-034340-3ksfpaf7	187	1	Furthermor	Furthermor	NNP
cord-034340-3ksfpaf7	187	2	,	,	,
cord-034340-3ksfpaf7	187	3	analyses	analysis	NNS
cord-034340-3ksfpaf7	187	4	of	of	IN
cord-034340-3ksfpaf7	187	5	relative	relative	JJ
cord-034340-3ksfpaf7	187	6	abundances	abundance	NNS
cord-034340-3ksfpaf7	187	7	of	of	IN
cord-034340-3ksfpaf7	187	8	specific	specific	JJ
cord-034340-3ksfpaf7	187	9	taxa	taxon	NNS
cord-034340-3ksfpaf7	187	10	did	do	VBD
cord-034340-3ksfpaf7	187	11	not	not	RB
cord-034340-3ksfpaf7	187	12	reveal	reveal	VB
cord-034340-3ksfpaf7	187	13	any	any	DT
cord-034340-3ksfpaf7	187	14	significant	significant	JJ
cord-034340-3ksfpaf7	187	15	results	result	NNS
cord-034340-3ksfpaf7	187	16	in	in	IN
cord-034340-3ksfpaf7	187	17	any	any	DT
cord-034340-3ksfpaf7	187	18	of	of	IN
cord-034340-3ksfpaf7	187	19	the	the	DT
cord-034340-3ksfpaf7	187	20	comparisons	comparison	NNS
cord-034340-3ksfpaf7	187	21	,	,	,
cord-034340-3ksfpaf7	187	22	after	after	IN
cord-034340-3ksfpaf7	187	23	adjustment	adjustment	NN
cord-034340-3ksfpaf7	187	24	for	for	IN
cord-034340-3ksfpaf7	187	25	multiple	multiple	JJ
cord-034340-3ksfpaf7	187	26	analyses	analysis	NNS
cord-034340-3ksfpaf7	187	27	.	.	.
cord-034340-3ksfpaf7	188	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	188	2	:	:	:
cord-034340-3ksfpaf7	189	1	Treatment	treatment	NN
cord-034340-3ksfpaf7	189	2	with	with	IN
cord-034340-3ksfpaf7	189	3	MTX	MTX	NNP
cord-034340-3ksfpaf7	189	4	or	or	CC
cord-034340-3ksfpaf7	189	5	ETN	ETN	NNP
cord-034340-3ksfpaf7	189	6	did	do	VBD
cord-034340-3ksfpaf7	189	7	not	not	RB
cord-034340-3ksfpaf7	189	8	alter	alter	VB
cord-034340-3ksfpaf7	189	9	the	the	DT
cord-034340-3ksfpaf7	189	10	composition	composition	NN
cord-034340-3ksfpaf7	189	11	of	of	IN
cord-034340-3ksfpaf7	189	12	fecal	fecal	JJ
cord-034340-3ksfpaf7	189	13	microbiota	microbiota	NN
cord-034340-3ksfpaf7	189	14	in	in	IN
cord-034340-3ksfpaf7	189	15	children	child	NNS
cord-034340-3ksfpaf7	189	16	with	with	IN
cord-034340-3ksfpaf7	189	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	189	18	.	.	.
cord-034340-3ksfpaf7	190	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	190	2	:	:	:
cord-034340-3ksfpaf7	191	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	191	2	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	191	3	arthritis	arthritis	NN
cord-034340-3ksfpaf7	191	4	(	(	-LRB-
cord-034340-3ksfpaf7	191	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	191	6	)	)	-RRB-
cord-034340-3ksfpaf7	191	7	is	be	VBZ
cord-034340-3ksfpaf7	191	8	the	the	DT
cord-034340-3ksfpaf7	191	9	most	most	RBS
cord-034340-3ksfpaf7	191	10	common	common	JJ
cord-034340-3ksfpaf7	191	11	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	191	12	disease	disease	NN
cord-034340-3ksfpaf7	191	13	in	in	IN
cord-034340-3ksfpaf7	191	14	childhood	childhood	NN
cord-034340-3ksfpaf7	191	15	and	and	CC
cord-034340-3ksfpaf7	191	16	an	an	DT
cord-034340-3ksfpaf7	191	17	important	important	JJ
cord-034340-3ksfpaf7	191	18	cause	cause	NN
cord-034340-3ksfpaf7	191	19	of	of	IN
cord-034340-3ksfpaf7	191	20	shortterm	shortterm	JJ
cord-034340-3ksfpaf7	191	21	and	and	CC
cord-034340-3ksfpaf7	191	22	long	long	JJ
cord-034340-3ksfpaf7	191	23	-	-	HYPH
cord-034340-3ksfpaf7	191	24	term	term	NN
cord-034340-3ksfpaf7	191	25	disability	disability	NN
cord-034340-3ksfpaf7	191	26	if	if	IN
cord-034340-3ksfpaf7	191	27	patients	patient	NNS
cord-034340-3ksfpaf7	191	28	are	be	VBP
cord-034340-3ksfpaf7	191	29	not	not	RB
cord-034340-3ksfpaf7	191	30	treated	treat	VBN
cord-034340-3ksfpaf7	191	31	appropriately	appropriately	RB
cord-034340-3ksfpaf7	191	32	.	.	.
cord-034340-3ksfpaf7	192	1	By	by	IN
cord-034340-3ksfpaf7	192	2	definition	definition	NN
cord-034340-3ksfpaf7	192	3	,	,	,
cord-034340-3ksfpaf7	192	4	JIA	JIA	NNP
cord-034340-3ksfpaf7	192	5	clinically	clinically	RB
cord-034340-3ksfpaf7	192	6	presents	present	VBZ
cord-034340-3ksfpaf7	192	7	with	with	IN
cord-034340-3ksfpaf7	192	8	peripheral	peripheral	JJ
cord-034340-3ksfpaf7	192	9	joint	joint	JJ
cord-034340-3ksfpaf7	192	10	inflammation	inflammation	NN
cord-034340-3ksfpaf7	192	11	of	of	IN
cord-034340-3ksfpaf7	192	12	unknown	unknown	JJ
cord-034340-3ksfpaf7	192	13	origin	origin	NN
cord-034340-3ksfpaf7	192	14	,	,	,
cord-034340-3ksfpaf7	192	15	persisting	persist	VBG
cord-034340-3ksfpaf7	192	16	for	for	IN
cord-034340-3ksfpaf7	192	17	at	at	RB
cord-034340-3ksfpaf7	192	18	least	least	JJS
cord-034340-3ksfpaf7	192	19	six	six	CD
cord-034340-3ksfpaf7	192	20	consecutive	consecutive	JJ
cord-034340-3ksfpaf7	192	21	weeks	week	NNS
cord-034340-3ksfpaf7	192	22	and	and	CC
cord-034340-3ksfpaf7	192	23	starting	start	VBG
cord-034340-3ksfpaf7	192	24	before	before	IN
cord-034340-3ksfpaf7	192	25	the	the	DT
cord-034340-3ksfpaf7	192	26	age	age	NN
cord-034340-3ksfpaf7	192	27	of	of	IN
cord-034340-3ksfpaf7	192	28	16	16	CD
cord-034340-3ksfpaf7	192	29	years	year	NNS
cord-034340-3ksfpaf7	192	30	.	.	.
cord-034340-3ksfpaf7	193	1	The	the	DT
cord-034340-3ksfpaf7	193	2	predominant	predominant	JJ
cord-034340-3ksfpaf7	193	3	subtypes	subtype	NNS
cord-034340-3ksfpaf7	193	4	,	,	,
cord-034340-3ksfpaf7	193	5	i.e.	i.e.	FW
cord-034340-3ksfpaf7	193	6	oligoarticular	oligoarticular	FW
cord-034340-3ksfpaf7	193	7	(	(	-LRB-
cord-034340-3ksfpaf7	193	8	oligo	oligo	NNP
cord-034340-3ksfpaf7	193	9	)	)	-RRB-
cord-034340-3ksfpaf7	193	10	and	and	CC
cord-034340-3ksfpaf7	193	11	polyarticular	polyarticular	JJ
cord-034340-3ksfpaf7	193	12	(	(	-LRB-
cord-034340-3ksfpaf7	193	13	poly	poly	NNP
cord-034340-3ksfpaf7	193	14	)	)	-RRB-
cord-034340-3ksfpaf7	193	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	193	16	,	,	,
cord-034340-3ksfpaf7	193	17	have	have	VBP
cord-034340-3ksfpaf7	193	18	long	long	RB
cord-034340-3ksfpaf7	193	19	been	be	VBN
cord-034340-3ksfpaf7	193	20	assumed	assume	VBN
cord-034340-3ksfpaf7	193	21	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	193	22	diseases	disease	NNS
cord-034340-3ksfpaf7	193	23	caused	cause	VBN
cord-034340-3ksfpaf7	193	24	by	by	IN
cord-034340-3ksfpaf7	193	25	dysregulation	dysregulation	NN
cord-034340-3ksfpaf7	193	26	of	of	IN
cord-034340-3ksfpaf7	193	27	the	the	DT
cord-034340-3ksfpaf7	193	28	adaptive	adaptive	JJ
cord-034340-3ksfpaf7	193	29	immune	immune	JJ
cord-034340-3ksfpaf7	193	30	system	system	NN
cord-034340-3ksfpaf7	193	31	,	,	,
cord-034340-3ksfpaf7	193	32	with	with	IN
cord-034340-3ksfpaf7	193	33	a	a	DT
cord-034340-3ksfpaf7	193	34	central	central	JJ
cord-034340-3ksfpaf7	193	35	role	role	NN
cord-034340-3ksfpaf7	193	36	for	for	IN
cord-034340-3ksfpaf7	193	37	autoreactive	autoreactive	JJ
cord-034340-3ksfpaf7	193	38	T	t	NN
cord-034340-3ksfpaf7	193	39	cells	cell	NNS
cord-034340-3ksfpaf7	193	40	belonging	belong	VBG
cord-034340-3ksfpaf7	193	41	to	to	IN
cord-034340-3ksfpaf7	193	42	the	the	DT
cord-034340-3ksfpaf7	193	43	Th1	th1	CD
cord-034340-3ksfpaf7	193	44	and	and	CC
cord-034340-3ksfpaf7	193	45	Th17	th17	CD
cord-034340-3ksfpaf7	193	46	lineages	lineage	NNS
cord-034340-3ksfpaf7	193	47	and	and	CC
cord-034340-3ksfpaf7	193	48	autoantigens	autoantigens	NNP
cord-034340-3ksfpaf7	193	49	that	that	WDT
cord-034340-3ksfpaf7	193	50	may	may	MD
cord-034340-3ksfpaf7	193	51	include	include	VB
cord-034340-3ksfpaf7	193	52	aggrecan	aggrecan	NNP
cord-034340-3ksfpaf7	193	53	,	,	,
cord-034340-3ksfpaf7	193	54	fibrillin	fibrillin	NNP
cord-034340-3ksfpaf7	193	55	,	,	,
cord-034340-3ksfpaf7	193	56	matrix	matrix	NN
cord-034340-3ksfpaf7	193	57	metalloproteinase	metalloproteinase	NN
cord-034340-3ksfpaf7	193	58	(	(	-LRB-
cord-034340-3ksfpaf7	193	59	MMP)-3	mmp)-3	NN
cord-034340-3ksfpaf7	193	60	and	and	CC
cord-034340-3ksfpaf7	193	61	heat	heat	NN
cord-034340-3ksfpaf7	193	62	shock	shock	NN
cord-034340-3ksfpaf7	193	63	proteins	protein	NNS
cord-034340-3ksfpaf7	193	64	.	.	.
cord-034340-3ksfpaf7	194	1	Nevertheless	nevertheless	RB
cord-034340-3ksfpaf7	194	2	,	,	,
cord-034340-3ksfpaf7	194	3	the	the	DT
cord-034340-3ksfpaf7	194	4	original	original	JJ
cord-034340-3ksfpaf7	194	5	T	T	NNP
cord-034340-3ksfpaf7	194	6	cell	cell	NN
cord-034340-3ksfpaf7	194	7	-	-	HYPH
cord-034340-3ksfpaf7	194	8	centered	center	VBN
cord-034340-3ksfpaf7	194	9	hypothesis	hypothesis	NN
cord-034340-3ksfpaf7	194	10	has	have	VBZ
cord-034340-3ksfpaf7	194	11	been	be	VBN
cord-034340-3ksfpaf7	194	12	challenged	challenge	VBN
cord-034340-3ksfpaf7	194	13	since	since	IN
cord-034340-3ksfpaf7	194	14	it	-PRON-	PRP
cord-034340-3ksfpaf7	194	15	does	do	VBZ
cord-034340-3ksfpaf7	194	16	not	not	RB
cord-034340-3ksfpaf7	194	17	cover	cover	VB
cord-034340-3ksfpaf7	194	18	nor	nor	CC
cord-034340-3ksfpaf7	194	19	completely	completely	RB
cord-034340-3ksfpaf7	194	20	explain	explain	VB
cord-034340-3ksfpaf7	194	21	the	the	DT
cord-034340-3ksfpaf7	194	22	full	full	JJ
cord-034340-3ksfpaf7	194	23	spectrum	spectrum	NN
cord-034340-3ksfpaf7	194	24	of	of	IN
cord-034340-3ksfpaf7	194	25	immune	immune	JJ
cord-034340-3ksfpaf7	194	26	-	-	HYPH
cord-034340-3ksfpaf7	194	27	pathological	pathological	JJ
cord-034340-3ksfpaf7	194	28	phenomena	phenomenon	NNS
cord-034340-3ksfpaf7	194	29	observed	observe	VBN
cord-034340-3ksfpaf7	194	30	in	in	IN
cord-034340-3ksfpaf7	194	31	patients	patient	NNS
cord-034340-3ksfpaf7	194	32	.	.	.
cord-034340-3ksfpaf7	195	1	lien.desomer@uzleuven.b	lien.desomer@uzleuven.b	NNP
cord-034340-3ksfpaf7	195	2	Objectives	objective	NNS
cord-034340-3ksfpaf7	195	3	:	:	:
cord-034340-3ksfpaf7	196	1	Emerging	emerge	VBG
cord-034340-3ksfpaf7	196	2	evidence	evidence	NN
cord-034340-3ksfpaf7	196	3	suggests	suggest	VBZ
cord-034340-3ksfpaf7	196	4	a	a	DT
cord-034340-3ksfpaf7	196	5	potentially	potentially	RB
cord-034340-3ksfpaf7	196	6	important	important	JJ
cord-034340-3ksfpaf7	196	7	role	role	NN
cord-034340-3ksfpaf7	196	8	for	for	IN
cord-034340-3ksfpaf7	196	9	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	196	10	in	in	IN
cord-034340-3ksfpaf7	196	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	196	12	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	196	13	.	.	.
cord-034340-3ksfpaf7	197	1	Here	here	RB
cord-034340-3ksfpaf7	197	2	,	,	,
cord-034340-3ksfpaf7	197	3	we	-PRON-	PRP
cord-034340-3ksfpaf7	197	4	investigated	investigate	VBD
cord-034340-3ksfpaf7	197	5	extensively	extensively	RB
cord-034340-3ksfpaf7	197	6	the	the	DT
cord-034340-3ksfpaf7	197	7	phenotypical	phenotypical	JJ
cord-034340-3ksfpaf7	197	8	features	feature	NNS
cord-034340-3ksfpaf7	197	9	of	of	IN
cord-034340-3ksfpaf7	197	10	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	197	11	present	present	JJ
cord-034340-3ksfpaf7	197	12	in	in	IN
cord-034340-3ksfpaf7	197	13	the	the	DT
cord-034340-3ksfpaf7	197	14	peripheral	peripheral	JJ
cord-034340-3ksfpaf7	197	15	blood	blood	NN
cord-034340-3ksfpaf7	197	16	and	and	CC
cord-034340-3ksfpaf7	197	17	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	197	18	joints	joint	NNS
cord-034340-3ksfpaf7	197	19	of	of	IN
cord-034340-3ksfpaf7	197	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	197	21	patients	patient	NNS
cord-034340-3ksfpaf7	197	22	.	.	.
cord-034340-3ksfpaf7	198	1	Methods	method	NNS
cord-034340-3ksfpaf7	198	2	:	:	:
cord-034340-3ksfpaf7	198	3	Synovial	synovial	JJ
cord-034340-3ksfpaf7	198	4	fluids	fluid	NNS
cord-034340-3ksfpaf7	198	5	and	and	CC
cord-034340-3ksfpaf7	198	6	parallel	parallel	JJ
cord-034340-3ksfpaf7	198	7	blood	blood	NN
cord-034340-3ksfpaf7	198	8	samples	sample	NNS
cord-034340-3ksfpaf7	198	9	from	from	IN
cord-034340-3ksfpaf7	198	10	patients	patient	NNS
cord-034340-3ksfpaf7	198	11	with	with	IN
cord-034340-3ksfpaf7	198	12	oligo	oligo	NN
cord-034340-3ksfpaf7	198	13	-	-	:
cord-034340-3ksfpaf7	198	14	or	or	CC
cord-034340-3ksfpaf7	198	15	polyJIA	polyjia	NN
cord-034340-3ksfpaf7	198	16	and	and	CC
cord-034340-3ksfpaf7	198	17	blood	blood	NN
cord-034340-3ksfpaf7	198	18	samples	sample	NNS
cord-034340-3ksfpaf7	198	19	from	from	IN
cord-034340-3ksfpaf7	198	20	healthy	healthy	JJ
cord-034340-3ksfpaf7	198	21	children	child	NNS
cord-034340-3ksfpaf7	198	22	were	be	VBD
cord-034340-3ksfpaf7	198	23	collected	collect	VBN
cord-034340-3ksfpaf7	198	24	.	.	.
cord-034340-3ksfpaf7	199	1	Multicolor	multicolor	JJ
cord-034340-3ksfpaf7	199	2	flow	flow	NN
cord-034340-3ksfpaf7	199	3	cytometry	cytometry	NN
cord-034340-3ksfpaf7	199	4	panels	panel	NNS
cord-034340-3ksfpaf7	199	5	allowed	allow	VBN
cord-034340-3ksfpaf7	199	6	for	for	IN
cord-034340-3ksfpaf7	199	7	in	in	IN
cord-034340-3ksfpaf7	199	8	-	-	HYPH
cord-034340-3ksfpaf7	199	9	depth	depth	NN
cord-034340-3ksfpaf7	199	10	phenotypical	phenotypical	JJ
cord-034340-3ksfpaf7	199	11	analysis	analysis	NN
cord-034340-3ksfpaf7	199	12	of	of	IN
cord-034340-3ksfpaf7	199	13	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	199	14	,	,	,
cord-034340-3ksfpaf7	199	15	focusing	focus	VBG
cord-034340-3ksfpaf7	199	16	on	on	IN
cord-034340-3ksfpaf7	199	17	the	the	DT
cord-034340-3ksfpaf7	199	18	surface	surface	NN
cord-034340-3ksfpaf7	199	19	expression	expression	NN
cord-034340-3ksfpaf7	199	20	of	of	IN
cord-034340-3ksfpaf7	199	21	adhesion	adhesion	NN
cord-034340-3ksfpaf7	199	22	molecules	molecule	NNS
cord-034340-3ksfpaf7	199	23	,	,	,
cord-034340-3ksfpaf7	199	24	activation	activation	NN
cord-034340-3ksfpaf7	199	25	and	and	CC
cord-034340-3ksfpaf7	199	26	maturation	maturation	NN
cord-034340-3ksfpaf7	199	27	markers	marker	NNS
cord-034340-3ksfpaf7	199	28	,	,	,
cord-034340-3ksfpaf7	199	29	chemoattractant	chemoattractant	NN
cord-034340-3ksfpaf7	199	30	-	-	:
cord-034340-3ksfpaf7	199	31	and	and	CC
cord-034340-3ksfpaf7	199	32	Toll	Toll	NNP
cord-034340-3ksfpaf7	199	33	-	-	HYPH
cord-034340-3ksfpaf7	199	34	like	like	JJ
cord-034340-3ksfpaf7	199	35	receptors	receptor	NNS
cord-034340-3ksfpaf7	199	36	.	.	.
cord-034340-3ksfpaf7	200	1	Multiplex	multiplex	NN
cord-034340-3ksfpaf7	200	2	technology	technology	NN
cord-034340-3ksfpaf7	200	3	was	be	VBD
cord-034340-3ksfpaf7	200	4	exploited	exploit	VBN
cord-034340-3ksfpaf7	200	5	to	to	TO
cord-034340-3ksfpaf7	200	6	quantify	quantify	VB
cord-034340-3ksfpaf7	200	7	pro	pro	JJ
cord-034340-3ksfpaf7	200	8	-	-	JJ
cord-034340-3ksfpaf7	200	9	and	and	CC
cord-034340-3ksfpaf7	200	10	anti	anti	JJ
cord-034340-3ksfpaf7	200	11	-	-	JJ
cord-034340-3ksfpaf7	200	12	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	200	13	cytokines	cytokine	NNS
cord-034340-3ksfpaf7	200	14	in	in	IN
cord-034340-3ksfpaf7	200	15	plasma	plasma	NN
cord-034340-3ksfpaf7	200	16	and	and	CC
cord-034340-3ksfpaf7	200	17	synovial	synovial	JJ
cord-034340-3ksfpaf7	200	18	fluids	fluid	NNS
cord-034340-3ksfpaf7	200	19	.	.	.
cord-034340-3ksfpaf7	201	1	Results	result	NNS
cord-034340-3ksfpaf7	201	2	:	:	:
cord-034340-3ksfpaf7	202	1	The	the	DT
cord-034340-3ksfpaf7	202	2	vast	vast	JJ
cord-034340-3ksfpaf7	202	3	majority	majority	NN
cord-034340-3ksfpaf7	202	4	of	of	IN
cord-034340-3ksfpaf7	202	5	synovial	synovial	JJ
cord-034340-3ksfpaf7	202	6	fluid	fluid	JJ
cord-034340-3ksfpaf7	202	7	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	202	8	displayed	display	VBD
cord-034340-3ksfpaf7	202	9	a	a	DT
cord-034340-3ksfpaf7	202	10	strongly	strongly	RB
cord-034340-3ksfpaf7	202	11	activated	activate	VBN
cord-034340-3ksfpaf7	202	12	,	,	,
cord-034340-3ksfpaf7	202	13	hypersegmented	hypersegmented	JJ
cord-034340-3ksfpaf7	202	14	phenotype	phenotype	NN
cord-034340-3ksfpaf7	202	15	with	with	IN
cord-034340-3ksfpaf7	202	16	decreased	decrease	VBN
cord-034340-3ksfpaf7	202	17	Lselectin	Lselectin	NNP
cord-034340-3ksfpaf7	202	18	(	(	-LRB-
cord-034340-3ksfpaf7	202	19	CD62L	cd62l	NN
cord-034340-3ksfpaf7	202	20	)	)	-RRB-
cord-034340-3ksfpaf7	202	21	expression	expression	NN
cord-034340-3ksfpaf7	202	22	and	and	CC
cord-034340-3ksfpaf7	202	23	increased	increase	VBN
cord-034340-3ksfpaf7	202	24	numbers	number	NNS
cord-034340-3ksfpaf7	202	25	of	of	IN
cord-034340-3ksfpaf7	202	26	nuclear	nuclear	JJ
cord-034340-3ksfpaf7	202	27	lobes	lobe	NNS
cord-034340-3ksfpaf7	202	28	,	,	,
cord-034340-3ksfpaf7	202	29	upregulation	upregulation	NN
cord-034340-3ksfpaf7	202	30	of	of	IN
cord-034340-3ksfpaf7	202	31	adhesion	adhesion	NN
cord-034340-3ksfpaf7	202	32	molecules	molecule	NNS
cord-034340-3ksfpaf7	202	33	CD66b	CD66b	NNS
cord-034340-3ksfpaf7	202	34	,	,	,
cord-034340-3ksfpaf7	202	35	CD11b	CD11b	NNPS
cord-034340-3ksfpaf7	202	36	and	and	CC
cord-034340-3ksfpaf7	202	37	CD15	CD15	NNP
cord-034340-3ksfpaf7	202	38	and	and	CC
cord-034340-3ksfpaf7	202	39	downregulation	downregulation	NN
cord-034340-3ksfpaf7	202	40	of	of	IN
cord-034340-3ksfpaf7	202	41	chemokine	chemokine	NN
cord-034340-3ksfpaf7	202	42	receptors	receptor	NNS
cord-034340-3ksfpaf7	202	43	CXCR1/2	CXCR1/2	NNP
cord-034340-3ksfpaf7	202	44	.	.	.
cord-034340-3ksfpaf7	203	1	An	an	DT
cord-034340-3ksfpaf7	203	2	elevated	elevated	JJ
cord-034340-3ksfpaf7	203	3	percentage	percentage	NN
cord-034340-3ksfpaf7	203	4	of	of	IN
cord-034340-3ksfpaf7	203	5	CXCR4-expressing	cxcr4-expresse	VBG
cord-034340-3ksfpaf7	203	6	aged	aged	JJ
cord-034340-3ksfpaf7	203	7	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	203	8	was	be	VBD
cord-034340-3ksfpaf7	203	9	detected	detect	VBN
cord-034340-3ksfpaf7	203	10	in	in	IN
cord-034340-3ksfpaf7	203	11	synovial	synovial	JJ
cord-034340-3ksfpaf7	203	12	fluids	fluid	NNS
cord-034340-3ksfpaf7	203	13	from	from	IN
cord-034340-3ksfpaf7	203	14	patients	patient	NNS
cord-034340-3ksfpaf7	203	15	.	.	.
cord-034340-3ksfpaf7	204	1	Strikingly	strikingly	RB
cord-034340-3ksfpaf7	204	2	,	,	,
cord-034340-3ksfpaf7	204	3	significant	significant	JJ
cord-034340-3ksfpaf7	204	4	percentages	percentage	NNS
cord-034340-3ksfpaf7	204	5	of	of	IN
cord-034340-3ksfpaf7	204	6	synovial	synovial	JJ
cord-034340-3ksfpaf7	204	7	fluid	fluid	JJ
cord-034340-3ksfpaf7	204	8	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	204	9	showed	show	VBD
cord-034340-3ksfpaf7	204	10	a	a	DT
cord-034340-3ksfpaf7	204	11	profound	profound	JJ
cord-034340-3ksfpaf7	204	12	upregulation	upregulation	NN
cord-034340-3ksfpaf7	204	13	of	of	IN
cord-034340-3ksfpaf7	204	14	atypical	atypical	JJ
cord-034340-3ksfpaf7	204	15	neutrophil	neutrophil	NN
cord-034340-3ksfpaf7	204	16	markers	marker	NNS
cord-034340-3ksfpaf7	204	17	,	,	,
cord-034340-3ksfpaf7	204	18	including	include	VBG
cord-034340-3ksfpaf7	204	19	CXCR3	cxcr3	NN
cord-034340-3ksfpaf7	204	20	,	,	,
cord-034340-3ksfpaf7	204	21	ICAM-1	ICAM-1	NNP
cord-034340-3ksfpaf7	204	22	and	and	CC
cord-034340-3ksfpaf7	204	23	HLA	HLA	NNP
cord-034340-3ksfpaf7	204	24	-	-	HYPH
cord-034340-3ksfpaf7	204	25	DR	DR	NNP
cord-034340-3ksfpaf7	204	26	.	.	.
cord-034340-3ksfpaf7	205	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	205	2	:	:	:
cord-034340-3ksfpaf7	206	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	206	2	data	datum	NNS
cord-034340-3ksfpaf7	206	3	indicate	indicate	VBP
cord-034340-3ksfpaf7	206	4	that	that	IN
cord-034340-3ksfpaf7	206	5	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	206	6	present	present	JJ
cord-034340-3ksfpaf7	206	7	in	in	IN
cord-034340-3ksfpaf7	206	8	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	206	9	joints	joint	NNS
cord-034340-3ksfpaf7	206	10	of	of	IN
cord-034340-3ksfpaf7	206	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	206	12	patients	patient	NNS
cord-034340-3ksfpaf7	206	13	are	be	VBP
cord-034340-3ksfpaf7	206	14	strongly	strongly	RB
cord-034340-3ksfpaf7	206	15	activated	activate	VBN
cord-034340-3ksfpaf7	206	16	cells	cell	NNS
cord-034340-3ksfpaf7	206	17	with	with	IN
cord-034340-3ksfpaf7	206	18	elevated	elevated	JJ
cord-034340-3ksfpaf7	206	19	proinflammatory	proinflammatory	JJ
cord-034340-3ksfpaf7	206	20	and	and	CC
cord-034340-3ksfpaf7	206	21	antigen	antigen	NN
cord-034340-3ksfpaf7	206	22	presenting	present	VBG
cord-034340-3ksfpaf7	206	23	potential	potential	NN
cord-034340-3ksfpaf7	206	24	.	.	.
cord-034340-3ksfpaf7	207	1	This	this	DT
cord-034340-3ksfpaf7	207	2	detailed	detailed	JJ
cord-034340-3ksfpaf7	207	3	molecular	molecular	JJ
cord-034340-3ksfpaf7	207	4	analysis	analysis	NN
cord-034340-3ksfpaf7	207	5	supports	support	VBZ
cord-034340-3ksfpaf7	207	6	the	the	DT
cord-034340-3ksfpaf7	207	7	notion	notion	NN
cord-034340-3ksfpaf7	207	8	that	that	IN
cord-034340-3ksfpaf7	207	9	a	a	DT
cord-034340-3ksfpaf7	207	10	complex	complex	JJ
cord-034340-3ksfpaf7	207	11	intertwining	intertwine	VBG
cord-034340-3ksfpaf7	207	12	between	between	IN
cord-034340-3ksfpaf7	207	13	these	these	DT
cord-034340-3ksfpaf7	207	14	innate	innate	JJ
cord-034340-3ksfpaf7	207	15	immune	immune	JJ
cord-034340-3ksfpaf7	207	16	cells	cell	NNS
cord-034340-3ksfpaf7	207	17	and	and	CC
cord-034340-3ksfpaf7	207	18	adaptive	adaptive	JJ
cord-034340-3ksfpaf7	207	19	immune	immune	JJ
cord-034340-3ksfpaf7	207	20	events	event	NNS
cord-034340-3ksfpaf7	207	21	drives	drive	VBZ
cord-034340-3ksfpaf7	207	22	JIA	JIA	NNP
cord-034340-3ksfpaf7	207	23	.	.	.
cord-034340-3ksfpaf7	208	1	None	none	NN
cord-034340-3ksfpaf7	208	2	declared	declare	VBD
cord-034340-3ksfpaf7	208	3	The	the	DT
cord-034340-3ksfpaf7	208	4	main	main	JJ
cord-034340-3ksfpaf7	208	5	factors	factor	NNS
cord-034340-3ksfpaf7	208	6	,	,	,
cord-034340-3ksfpaf7	208	7	associated	associate	VBN
cord-034340-3ksfpaf7	208	8	with	with	IN
cord-034340-3ksfpaf7	208	9	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	208	10	vaccination	vaccination	NN
cord-034340-3ksfpaf7	208	11	againts	againts	IN
cord-034340-3ksfpaf7	208	12	measels	measel	NNS
cord-034340-3ksfpaf7	208	13	,	,	,
cord-034340-3ksfpaf7	208	14	parotitis	parotitis	NNP
cord-034340-3ksfpaf7	208	15	,	,	,
cord-034340-3ksfpaf7	208	16	rubella	rubella	NN
cord-034340-3ksfpaf7	208	17	and	and	CC
cord-034340-3ksfpaf7	208	18	diphtheria	diphtheria	NN
cord-034340-3ksfpaf7	208	19	in	in	IN
cord-034340-3ksfpaf7	208	20	170	170	CD
cord-034340-3ksfpaf7	208	21	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	208	22	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	208	23	arthritis	arthritis	NN
cord-034340-3ksfpaf7	208	24	patients	patient	NNS
cord-034340-3ksfpaf7	208	25	N.	N.	NNP
cord-034340-3ksfpaf7	208	26	Lyubimova	Lyubimova	NNP
cord-034340-3ksfpaf7	208	27	1	1	CD
cord-034340-3ksfpaf7	208	28	,	,	,
cord-034340-3ksfpaf7	208	29	I.	I.	NNP
cord-034340-3ksfpaf7	208	30	Objectives	Objectives	NNP
cord-034340-3ksfpaf7	208	31	:	:	:
cord-034340-3ksfpaf7	209	1	The	the	DT
cord-034340-3ksfpaf7	209	2	aim	aim	NN
cord-034340-3ksfpaf7	209	3	of	of	IN
cord-034340-3ksfpaf7	209	4	our	-PRON-	PRP$
cord-034340-3ksfpaf7	209	5	study	study	NN
cord-034340-3ksfpaf7	209	6	was	be	VBD
cord-034340-3ksfpaf7	209	7	to	to	TO
cord-034340-3ksfpaf7	209	8	evaluate	evaluate	VB
cord-034340-3ksfpaf7	209	9	the	the	DT
cord-034340-3ksfpaf7	209	10	rate	rate	NN
cord-034340-3ksfpaf7	209	11	and	and	CC
cord-034340-3ksfpaf7	209	12	the	the	DT
cord-034340-3ksfpaf7	209	13	main	main	JJ
cord-034340-3ksfpaf7	209	14	factors	factor	NNS
cord-034340-3ksfpaf7	209	15	of	of	IN
cord-034340-3ksfpaf7	209	16	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	209	17	vaccination	vaccination	NN
cord-034340-3ksfpaf7	209	18	against	against	IN
cord-034340-3ksfpaf7	209	19	measels	measel	NNS
cord-034340-3ksfpaf7	209	20	,	,	,
cord-034340-3ksfpaf7	209	21	parotitis	parotitis	NNP
cord-034340-3ksfpaf7	209	22	,	,	,
cord-034340-3ksfpaf7	209	23	rubella	rubella	NN
cord-034340-3ksfpaf7	209	24	(	(	-LRB-
cord-034340-3ksfpaf7	209	25	MMR	MMR	NNP
cord-034340-3ksfpaf7	209	26	)	)	-RRB-
cord-034340-3ksfpaf7	209	27	and	and	CC
cord-034340-3ksfpaf7	209	28	diphtheria	diphtheria	NN
cord-034340-3ksfpaf7	209	29	in	in	IN
cord-034340-3ksfpaf7	209	30	JIA	JIA	NNP
cord-034340-3ksfpaf7	209	31	patients	patient	NNS
cord-034340-3ksfpaf7	209	32	.	.	.
cord-034340-3ksfpaf7	210	1	Methods	method	NNS
cord-034340-3ksfpaf7	210	2	:	:	:
cord-034340-3ksfpaf7	210	3	In	in	IN
cord-034340-3ksfpaf7	210	4	the	the	DT
cord-034340-3ksfpaf7	210	5	present	present	JJ
cord-034340-3ksfpaf7	210	6	study	study	NN
cord-034340-3ksfpaf7	210	7	were	be	VBD
cord-034340-3ksfpaf7	210	8	included	include	VBN
cord-034340-3ksfpaf7	210	9	data	datum	NNS
cord-034340-3ksfpaf7	210	10	170	170	CD
cord-034340-3ksfpaf7	210	11	JIA(55	jia(55	NN
cord-034340-3ksfpaf7	210	12	boys	boy	NNS
cord-034340-3ksfpaf7	210	13	and	and	CC
cord-034340-3ksfpaf7	210	14	115	115	CD
cord-034340-3ksfpaf7	210	15	girls)aged	girls)aged	NNP
cord-034340-3ksfpaf7	210	16	from	from	IN
cord-034340-3ksfpaf7	210	17	2	2	CD
cord-034340-3ksfpaf7	210	18	to	to	TO
cord-034340-3ksfpaf7	210	19	17	17	CD
cord-034340-3ksfpaf7	210	20	years	year	NNS
cord-034340-3ksfpaf7	210	21	,	,	,
cord-034340-3ksfpaf7	210	22	who	who	WP
cord-034340-3ksfpaf7	210	23	received	receive	VBD
cord-034340-3ksfpaf7	210	24	scheduled	scheduled	JJ
cord-034340-3ksfpaf7	210	25	vaccination	vaccination	NN
cord-034340-3ksfpaf7	210	26	before	before	IN
cord-034340-3ksfpaf7	210	27	the	the	DT
cord-034340-3ksfpaf7	210	28	age	age	NN
cord-034340-3ksfpaf7	210	29	of	of	IN
cord-034340-3ksfpaf7	210	30	2	2	CD
cord-034340-3ksfpaf7	210	31	years	year	NNS
cord-034340-3ksfpaf7	210	32	and	and	CC
cord-034340-3ksfpaf7	210	33	before	before	IN
cord-034340-3ksfpaf7	210	34	JIA	JIA	NNP
cord-034340-3ksfpaf7	210	35	onset	onset	NN
cord-034340-3ksfpaf7	210	36	against	against	IN
cord-034340-3ksfpaf7	210	37	measles	measle	NNS
cord-034340-3ksfpaf7	210	38	,	,	,
cord-034340-3ksfpaf7	210	39	parotitis	parotitis	NNP
cord-034340-3ksfpaf7	210	40	,	,	,
cord-034340-3ksfpaf7	210	41	diphtheria	diphtheria	NN
cord-034340-3ksfpaf7	210	42	and	and	CC
cord-034340-3ksfpaf7	210	43	rubella	rubella	NN
cord-034340-3ksfpaf7	210	44	.	.	.
cord-034340-3ksfpaf7	211	1	Incomplete	incomplete	JJ
cord-034340-3ksfpaf7	211	2	vaccination	vaccination	NN
cord-034340-3ksfpaf7	211	3	means	mean	VBZ
cord-034340-3ksfpaf7	211	4	the	the	DT
cord-034340-3ksfpaf7	211	5	reduced	reduced	JJ
cord-034340-3ksfpaf7	211	6	number	number	NN
cord-034340-3ksfpaf7	211	7	of	of	IN
cord-034340-3ksfpaf7	211	8	vaccine	vaccine	NN
cord-034340-3ksfpaf7	211	9	to	to	IN
cord-034340-3ksfpaf7	211	10	age	age	NN
cord-034340-3ksfpaf7	211	11	.	.	.
cord-034340-3ksfpaf7	212	1	In	in	IN
cord-034340-3ksfpaf7	212	2	all	all	DT
cord-034340-3ksfpaf7	212	3	patients	patient	NNS
cord-034340-3ksfpaf7	212	4	the	the	DT
cord-034340-3ksfpaf7	212	5	Ig	Ig	NNP
cord-034340-3ksfpaf7	212	6	G	G	NNP
cord-034340-3ksfpaf7	212	7	anti	anti	JJ
cord-034340-3ksfpaf7	212	8	-	-	JJ
cord-034340-3ksfpaf7	212	9	vaccine	vaccine	JJ
cord-034340-3ksfpaf7	212	10	antibodies	antibody	NNS
cord-034340-3ksfpaf7	212	11	levels	level	NNS
cord-034340-3ksfpaf7	212	12	were	be	VBD
cord-034340-3ksfpaf7	212	13	detected	detect	VBN
cord-034340-3ksfpaf7	212	14	with	with	IN
cord-034340-3ksfpaf7	212	15	ELISA.JIA	elisa.jia	JJ
cord-034340-3ksfpaf7	212	16	categories	category	NNS
cord-034340-3ksfpaf7	212	17	were	be	VBD
cord-034340-3ksfpaf7	212	18	:	:	:
cord-034340-3ksfpaf7	212	19	oligoarthritis	oligoarthritis	NNP
cord-034340-3ksfpaf7	212	20	-73,polyarthritis	-73,polyarthritis	.
cord-034340-3ksfpaf7	213	1	-61,systemic-16	-61,systemic-16	RB
cord-034340-3ksfpaf7	214	1	and	and	CC
cord-034340-3ksfpaf7	214	2	enthesitisrelated	enthesitisrelate	VBD
cord-034340-3ksfpaf7	214	3	arthritis-20.Data	arthritis-20.data	NN
cord-034340-3ksfpaf7	214	4	presented	present	VBN
cord-034340-3ksfpaf7	214	5	with	with	IN
cord-034340-3ksfpaf7	214	6	median	median	NN
cord-034340-3ksfpaf7	214	7	and	and	CC
cord-034340-3ksfpaf7	214	8	25%>75	25%>75	CD
cord-034340-3ksfpaf7	214	9	%	%	NN
cord-034340-3ksfpaf7	214	10	Results	result	NNS
cord-034340-3ksfpaf7	214	11	:	:	:
cord-034340-3ksfpaf7	214	12	Incomplete	incomplete	JJ
cord-034340-3ksfpaf7	214	13	vaccination	vaccination	NN
cord-034340-3ksfpaf7	214	14	against	against	IN
cord-034340-3ksfpaf7	214	15	MMR	MMR	NNP
cord-034340-3ksfpaf7	214	16	was	be	VBD
cord-034340-3ksfpaf7	214	17	in	in	IN
cord-034340-3ksfpaf7	214	18	50	50	CD
cord-034340-3ksfpaf7	215	1	(	(	-LRB-
cord-034340-3ksfpaf7	215	2	42%)diphtheria	42%)diphtheria	CD
cord-034340-3ksfpaf7	215	3	in	in	IN
cord-034340-3ksfpaf7	215	4	85	85	CD
cord-034340-3ksfpaf7	215	5	(	(	-LRB-
cord-034340-3ksfpaf7	215	6	50	50	CD
cord-034340-3ksfpaf7	215	7	%	%	NN
cord-034340-3ksfpaf7	215	8	)	)	-RRB-
cord-034340-3ksfpaf7	215	9	of	of	IN
cord-034340-3ksfpaf7	215	10	the	the	DT
cord-034340-3ksfpaf7	215	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	215	12	patients	patient	NNS
cord-034340-3ksfpaf7	215	13	.	.	.
cord-034340-3ksfpaf7	216	1	The	the	DT
cord-034340-3ksfpaf7	216	2	main	main	JJ
cord-034340-3ksfpaf7	216	3	differences	difference	NNS
cord-034340-3ksfpaf7	216	4	in	in	IN
cord-034340-3ksfpaf7	216	5	the	the	DT
cord-034340-3ksfpaf7	216	6	studied	study	VBN
cord-034340-3ksfpaf7	216	7	groups	group	NNS
cord-034340-3ksfpaf7	216	8	are	be	VBP
cord-034340-3ksfpaf7	216	9	in	in	IN
cord-034340-3ksfpaf7	216	10	the	the	DT
cord-034340-3ksfpaf7	216	11	table	table	NN
cord-034340-3ksfpaf7	216	12	.	.	.
cord-034340-3ksfpaf7	217	1	There	there	EX
cord-034340-3ksfpaf7	217	2	were	be	VBD
cord-034340-3ksfpaf7	217	3	no	no	DT
cord-034340-3ksfpaf7	217	4	differences	difference	NNS
cord-034340-3ksfpaf7	217	5	in	in	IN
cord-034340-3ksfpaf7	217	6	sex	sex	NN
cord-034340-3ksfpaf7	217	7	,	,	,
cord-034340-3ksfpaf7	217	8	JIA	JIA	NNP
cord-034340-3ksfpaf7	217	9	categories	category	NNS
cord-034340-3ksfpaf7	217	10	and	and	CC
cord-034340-3ksfpaf7	217	11	treatment	treatment	NN
cord-034340-3ksfpaf7	217	12	,	,	,
cord-034340-3ksfpaf7	217	13	except	except	IN
cord-034340-3ksfpaf7	217	14	biologics	biologic	NNS
cord-034340-3ksfpaf7	217	15	compare	compare	VBP
cord-034340-3ksfpaf7	217	16	to	to	TO
cord-034340-3ksfpaf7	217	17	complete	complete	VB
cord-034340-3ksfpaf7	217	18	and	and	CC
cord-034340-3ksfpaf7	217	19	complete	complete	JJ
cord-034340-3ksfpaf7	217	20	vaccination	vaccination	NN
cord-034340-3ksfpaf7	217	21	in	in	IN
cord-034340-3ksfpaf7	217	22	all	all	DT
cord-034340-3ksfpaf7	217	23	vaccines	vaccine	NNS
cord-034340-3ksfpaf7	217	24	.	.	.
cord-034340-3ksfpaf7	218	1	No	no	DT
cord-034340-3ksfpaf7	218	2	differences	difference	NNS
cord-034340-3ksfpaf7	218	3	in	in	IN
cord-034340-3ksfpaf7	218	4	antimeasels(p=0.18),antiparotitis	antimeasels(p=0.18),antiparotitis	NNP
cord-034340-3ksfpaf7	218	5	(	(	-LRB-
cord-034340-3ksfpaf7	218	6	p=0.1	p=0.1	NNP
cord-034340-3ksfpaf7	218	7	)	)	-RRB-
cord-034340-3ksfpaf7	218	8	and	and	CC
cord-034340-3ksfpaf7	218	9	anti	anti	JJ
cord-034340-3ksfpaf7	218	10	-	-	JJ
cord-034340-3ksfpaf7	218	11	rubella(p=0.17)vaccination	rubella(p=0.17)vaccination	NN
cord-034340-3ksfpaf7	218	12	between	between	IN
cord-034340-3ksfpaf7	218	13	complete	complete	JJ
cord-034340-3ksfpaf7	218	14	and	and	CC
cord-034340-3ksfpaf7	218	15	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	218	16	vaccination	vaccination	NN
cord-034340-3ksfpaf7	218	17	group	group	NN
cord-034340-3ksfpaf7	218	18	.	.	.
cord-034340-3ksfpaf7	219	1	Number	number	NN
cord-034340-3ksfpaf7	219	2	of	of	IN
cord-034340-3ksfpaf7	219	3	patients	patient	NNS
cord-034340-3ksfpaf7	219	4	with	with	IN
cord-034340-3ksfpaf7	219	5	protective	protective	JJ
cord-034340-3ksfpaf7	219	6	level	level	NN
cord-034340-3ksfpaf7	219	7	of	of	IN
cord-034340-3ksfpaf7	219	8	anti	anti	JJ
cord-034340-3ksfpaf7	219	9	-	-	JJ
cord-034340-3ksfpaf7	219	10	vaccine	vaccine	JJ
cord-034340-3ksfpaf7	219	11	antibodies	antibody	NNS
cord-034340-3ksfpaf7	219	12	was	be	VBD
cord-034340-3ksfpaf7	219	13	similar	similar	JJ
cord-034340-3ksfpaf7	219	14	,	,	,
cord-034340-3ksfpaf7	219	15	except	except	IN
cord-034340-3ksfpaf7	219	16	parotitis(70	parotitis(70	JJ
cord-034340-3ksfpaf7	219	17	%	%	NN
cord-034340-3ksfpaf7	219	18	vs	vs	IN
cord-034340-3ksfpaf7	219	19	84.2	84.2	CD
cord-034340-3ksfpaf7	219	20	%	%	NN
cord-034340-3ksfpaf7	219	21	,	,	,
cord-034340-3ksfpaf7	219	22	p=0.035).The	p=0.035).The	NNP
cord-034340-3ksfpaf7	219	23	anti	anti	JJ
cord-034340-3ksfpaf7	219	24	-	-	JJ
cord-034340-3ksfpaf7	219	25	diphtheria	diphtheria	JJ
cord-034340-3ksfpaf7	219	26	antibodies	antibody	NNS
cord-034340-3ksfpaf7	219	27	IgG	igg	NN
cord-034340-3ksfpaf7	219	28	level	level	NN
cord-034340-3ksfpaf7	219	29	was	be	VBD
cord-034340-3ksfpaf7	219	30	lower	low	JJR
cord-034340-3ksfpaf7	219	31	in	in	IN
cord-034340-3ksfpaf7	219	32	the	the	DT
cord-034340-3ksfpaf7	219	33	patients	patient	NNS
cord-034340-3ksfpaf7	219	34	with	with	IN
cord-034340-3ksfpaf7	219	35	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	219	36	vaccination	vaccination	NN
cord-034340-3ksfpaf7	219	37	group	group	NN
cord-034340-3ksfpaf7	219	38	(	(	-LRB-
cord-034340-3ksfpaf7	219	39	0.07	0.07	CD
cord-034340-3ksfpaf7	219	40	IU	IU	NNP
cord-034340-3ksfpaf7	219	41	/	/	SYM
cord-034340-3ksfpaf7	219	42	ml	ml	NN
cord-034340-3ksfpaf7	219	43	[	[	-LRB-
cord-034340-3ksfpaf7	219	44	95%CI:0.03	95%ci:0.03	CD
cord-034340-3ksfpaf7	219	45	;	;	:
cord-034340-3ksfpaf7	219	46	0.22	0.22	CD
cord-034340-3ksfpaf7	219	47	]	]	-RRB-
cord-034340-3ksfpaf7	220	1	vs	vs	IN
cord-034340-3ksfpaf7	220	2	0.2	0.2	CD
cord-034340-3ksfpaf7	220	3	[	[	-LRB-
cord-034340-3ksfpaf7	220	4	95%CI:0.06	95%CI:0.06	NNS
cord-034340-3ksfpaf7	220	5	;	;	:
cord-034340-3ksfpaf7	220	6	0.4	0.4	CD
cord-034340-3ksfpaf7	220	7	]	]	-RRB-
cord-034340-3ksfpaf7	220	8	,	,	,
cord-034340-3ksfpaf7	220	9	p=0.001)as	p=0.001)a	VBN
cord-034340-3ksfpaf7	220	10	well	well	RB
cord-034340-3ksfpaf7	220	11	as	as	IN
cord-034340-3ksfpaf7	220	12	number	number	NN
cord-034340-3ksfpaf7	220	13	of	of	IN
cord-034340-3ksfpaf7	220	14	patients	patient	NNS
cord-034340-3ksfpaf7	220	15	with	with	IN
cord-034340-3ksfpaf7	220	16	protective	protective	JJ
cord-034340-3ksfpaf7	220	17	level(34	level(34	NNP
cord-034340-3ksfpaf7	220	18	%	%	NN
cord-034340-3ksfpaf7	220	19	vs	vs	IN
cord-034340-3ksfpaf7	220	20	54	54	CD
cord-034340-3ksfpaf7	220	21	%	%	NN
cord-034340-3ksfpaf7	220	22	,	,	,
cord-034340-3ksfpaf7	220	23	p=0.002	p=0.002	NNP
cord-034340-3ksfpaf7	220	24	)	)	-RRB-
cord-034340-3ksfpaf7	220	25	.	.	.
cord-034340-3ksfpaf7	221	1	In	in	IN
cord-034340-3ksfpaf7	221	2	the	the	DT
cord-034340-3ksfpaf7	221	3	multiple	multiple	JJ
cord-034340-3ksfpaf7	221	4	regression	regression	NN
cord-034340-3ksfpaf7	221	5	model	model	NN
cord-034340-3ksfpaf7	221	6	only	only	RB
cord-034340-3ksfpaf7	221	7	JIA	JIA	NNP
cord-034340-3ksfpaf7	221	8	onset	onset	NN
cord-034340-3ksfpaf7	222	1	age(p=0.00001)and	age(p=0.00001)and	NNP
cord-034340-3ksfpaf7	222	2	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	222	3	treatment	treatment	NN
cord-034340-3ksfpaf7	222	4	duration(p=0.003	duration(p=0.003	NNP
cord-034340-3ksfpaf7	222	5	)	)	-RRB-
cord-034340-3ksfpaf7	222	6	were	be	VBD
cord-034340-3ksfpaf7	222	7	predictors	predictor	NNS
cord-034340-3ksfpaf7	222	8	of	of	IN
cord-034340-3ksfpaf7	222	9	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	222	10	vaccination	vaccination	NN
cord-034340-3ksfpaf7	222	11	against	against	IN
cord-034340-3ksfpaf7	222	12	MMR	MMR	NNP
cord-034340-3ksfpaf7	222	13	and	and	CC
cord-034340-3ksfpaf7	222	14	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	222	15	treatment	treatment	NN
cord-034340-3ksfpaf7	222	16	duration(p=0.005	duration(p=0.005	NNP
cord-034340-3ksfpaf7	222	17	)	)	-RRB-
cord-034340-3ksfpaf7	222	18	and	and	CC
cord-034340-3ksfpaf7	222	19	biologic	biologic	JJ
cord-034340-3ksfpaf7	222	20	treatment(p=0.05	treatment(p=0.05	CD
cord-034340-3ksfpaf7	222	21	)	)	-RRB-
cord-034340-3ksfpaf7	222	22	for	for	IN
cord-034340-3ksfpaf7	222	23	diphtheria	diphtheria	NN
cord-034340-3ksfpaf7	222	24	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	222	25	vaccination	vaccination	NN
cord-034340-3ksfpaf7	222	26	.	.	.
cord-034340-3ksfpaf7	223	1	Incomplete	incomplete	JJ
cord-034340-3ksfpaf7	223	2	MMR	MMR	NNP
cord-034340-3ksfpaf7	223	3	vaccination	vaccination	NN
cord-034340-3ksfpaf7	223	4	influence	influence	NN
cord-034340-3ksfpaf7	223	5	on	on	IN
cord-034340-3ksfpaf7	223	6	the	the	DT
cord-034340-3ksfpaf7	223	7	maintenance	maintenance	NN
cord-034340-3ksfpaf7	223	8	of	of	IN
cord-034340-3ksfpaf7	223	9	the	the	DT
cord-034340-3ksfpaf7	223	10	protective	protective	JJ
cord-034340-3ksfpaf7	223	11	anti	anti	JJ
cord-034340-3ksfpaf7	223	12	-	-	JJ
cord-034340-3ksfpaf7	223	13	parotitis	parotitis	JJ
cord-034340-3ksfpaf7	223	14	level(p=0.036)in	level(p=0.036)in	NNP
cord-034340-3ksfpaf7	223	15	regression	regression	NN
cord-034340-3ksfpaf7	223	16	model	model	NN
cord-034340-3ksfpaf7	223	17	.	.	.
cord-034340-3ksfpaf7	224	1	In	in	IN
cord-034340-3ksfpaf7	224	2	correlation	correlation	NN
cord-034340-3ksfpaf7	224	3	analysis	analysis	NN
cord-034340-3ksfpaf7	224	4	the	the	DT
cord-034340-3ksfpaf7	224	5	number	number	NN
cord-034340-3ksfpaf7	224	6	of	of	IN
cord-034340-3ksfpaf7	224	7	vaccination	vaccination	NN
cord-034340-3ksfpaf7	224	8	influences	influence	NNS
cord-034340-3ksfpaf7	224	9	on	on	IN
cord-034340-3ksfpaf7	224	10	anti	anti	JJ
cord-034340-3ksfpaf7	224	11	-	-	JJ
cord-034340-3ksfpaf7	224	12	diphtheria	diphtheria	JJ
cord-034340-3ksfpaf7	224	13	antibodies	antibody	NNS
cord-034340-3ksfpaf7	224	14	level(p=0.017)and	level(p=0.017)and	NNP
cord-034340-3ksfpaf7	224	15	number	number	NN
cord-034340-3ksfpaf7	224	16	of	of	IN
cord-034340-3ksfpaf7	224	17	patients	patient	NNS
cord-034340-3ksfpaf7	224	18	with	with	IN
cord-034340-3ksfpaf7	224	19	protective	protective	JJ
cord-034340-3ksfpaf7	224	20	level	level	NN
cord-034340-3ksfpaf7	224	21	of	of	IN
cord-034340-3ksfpaf7	224	22	anti	anti	JJ
cord-034340-3ksfpaf7	224	23	-	-	JJ
cord-034340-3ksfpaf7	224	24	diphtheria	diphtheria	JJ
cord-034340-3ksfpaf7	224	25	antibodies(p=0.017	antibodies(p=0.017	-RRB-
cord-034340-3ksfpaf7	224	26	)	)	-RRB-
cord-034340-3ksfpaf7	224	27	.	.	.
cord-034340-3ksfpaf7	225	1	The	the	DT
cord-034340-3ksfpaf7	225	2	main	main	JJ
cord-034340-3ksfpaf7	225	3	predictors	predictor	NNS
cord-034340-3ksfpaf7	225	4	in	in	IN
cord-034340-3ksfpaf7	225	5	logistic	logistic	JJ
cord-034340-3ksfpaf7	225	6	regression	regression	NN
cord-034340-3ksfpaf7	225	7	for	for	IN
cord-034340-3ksfpaf7	225	8	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	225	9	vaccination	vaccination	NN
cord-034340-3ksfpaf7	225	10	for	for	IN
cord-034340-3ksfpaf7	225	11	MMR	MMR	NNP
cord-034340-3ksfpaf7	225	12	were	be	VBD
cord-034340-3ksfpaf7	225	13	:	:	:
cord-034340-3ksfpaf7	225	14	onset	onset	NN
cord-034340-3ksfpaf7	225	15	age<6	age<6	ADD
cord-034340-3ksfpaf7	226	1	years(OR=7	years(OR=7	NNP
cord-034340-3ksfpaf7	226	2	.	.	.
cord-034340-3ksfpaf7	227	1	8	8	CD
cord-034340-3ksfpaf7	228	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	228	2	:	:	:
cord-034340-3ksfpaf7	229	1	Younger	young	JJR
cord-034340-3ksfpaf7	229	2	onset	onset	NN
cord-034340-3ksfpaf7	229	3	of	of	IN
cord-034340-3ksfpaf7	229	4	JIA	JIA	NNP
cord-034340-3ksfpaf7	229	5	age	age	NN
cord-034340-3ksfpaf7	229	6	,	,	,
cord-034340-3ksfpaf7	229	7	longer	long	JJR
cord-034340-3ksfpaf7	229	8	duration	duration	NN
cord-034340-3ksfpaf7	229	9	of	of	IN
cord-034340-3ksfpaf7	229	10	JIA	JIA	NNP
cord-034340-3ksfpaf7	229	11	and	and	CC
cord-034340-3ksfpaf7	229	12	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	229	13	treatment	treatment	NN
cord-034340-3ksfpaf7	229	14	,	,	,
cord-034340-3ksfpaf7	229	15	biologics	biologic	NNS
cord-034340-3ksfpaf7	229	16	and	and	CC
cord-034340-3ksfpaf7	229	17	more	more	JJR
cord-034340-3ksfpaf7	229	18	than	than	IN
cord-034340-3ksfpaf7	229	19	1	1	CD
cord-034340-3ksfpaf7	229	20	biologics	biologic	NNS
cord-034340-3ksfpaf7	229	21	are	be	VBP
cord-034340-3ksfpaf7	229	22	the	the	DT
cord-034340-3ksfpaf7	229	23	main	main	JJ
cord-034340-3ksfpaf7	229	24	predictors	predictor	NNS
cord-034340-3ksfpaf7	229	25	of	of	IN
cord-034340-3ksfpaf7	229	26	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	229	27	vaccination	vaccination	NN
cord-034340-3ksfpaf7	229	28	againt	againt	IN
cord-034340-3ksfpaf7	229	29	MMR	MMR	NNP
cord-034340-3ksfpaf7	229	30	and	and	CC
cord-034340-3ksfpaf7	229	31	diphtheria	diphtheria	NN
cord-034340-3ksfpaf7	229	32	.	.	.
cord-034340-3ksfpaf7	230	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	230	2	:	:	:
cord-034340-3ksfpaf7	231	1	The	the	DT
cord-034340-3ksfpaf7	231	2	prevalence	prevalence	NN
cord-034340-3ksfpaf7	231	3	of	of	IN
cord-034340-3ksfpaf7	231	4	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	231	5	thyroid	thyroid	NN
cord-034340-3ksfpaf7	231	6	disorders	disorder	NNS
cord-034340-3ksfpaf7	231	7	(	(	-LRB-
cord-034340-3ksfpaf7	231	8	AITD	AITD	NNP
cord-034340-3ksfpaf7	231	9	)	)	-RRB-
cord-034340-3ksfpaf7	231	10	has	have	VBZ
cord-034340-3ksfpaf7	231	11	been	be	VBN
cord-034340-3ksfpaf7	231	12	reported	report	VBN
cord-034340-3ksfpaf7	231	13	to	to	TO
cord-034340-3ksfpaf7	231	14	be	be	VB
cord-034340-3ksfpaf7	231	15	higher	high	JJR
cord-034340-3ksfpaf7	231	16	in	in	IN
cord-034340-3ksfpaf7	231	17	patients	patient	NNS
cord-034340-3ksfpaf7	231	18	with	with	IN
cord-034340-3ksfpaf7	231	19	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	231	20	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	231	21	arthritis	arthritis	NN
cord-034340-3ksfpaf7	231	22	(	(	-LRB-
cord-034340-3ksfpaf7	231	23	JIA	JIA	NNP
cord-034340-3ksfpaf7	231	24	)	)	-RRB-
cord-034340-3ksfpaf7	231	25	in	in	IN
cord-034340-3ksfpaf7	231	26	comparison	comparison	NN
cord-034340-3ksfpaf7	231	27	to	to	IN
cord-034340-3ksfpaf7	231	28	the	the	DT
cord-034340-3ksfpaf7	231	29	general	general	JJ
cord-034340-3ksfpaf7	231	30	population	population	NN
cord-034340-3ksfpaf7	231	31	.	.	.
cord-034340-3ksfpaf7	232	1	Nevertheless	nevertheless	RB
cord-034340-3ksfpaf7	232	2	,	,	,
cord-034340-3ksfpaf7	232	3	there	there	EX
cord-034340-3ksfpaf7	232	4	is	be	VBZ
cord-034340-3ksfpaf7	232	5	a	a	DT
cord-034340-3ksfpaf7	232	6	lack	lack	NN
cord-034340-3ksfpaf7	232	7	of	of	IN
cord-034340-3ksfpaf7	232	8	studies	study	NNS
cord-034340-3ksfpaf7	232	9	investigating	investigate	VBG
cord-034340-3ksfpaf7	232	10	risk	risk	NN
cord-034340-3ksfpaf7	232	11	factors	factor	NNS
cord-034340-3ksfpaf7	232	12	for	for	IN
cord-034340-3ksfpaf7	232	13	AITD	AITD	NNP
cord-034340-3ksfpaf7	232	14	development	development	NN
cord-034340-3ksfpaf7	232	15	in	in	IN
cord-034340-3ksfpaf7	232	16	children	child	NNS
cord-034340-3ksfpaf7	232	17	with	with	IN
cord-034340-3ksfpaf7	232	18	JIA	JIA	NNP
cord-034340-3ksfpaf7	232	19	.	.	.
cord-034340-3ksfpaf7	233	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	233	2	:	:	:
cord-034340-3ksfpaf7	233	3	To	to	TO
cord-034340-3ksfpaf7	233	4	investigate	investigate	VB
cord-034340-3ksfpaf7	233	5	the	the	DT
cord-034340-3ksfpaf7	233	6	co	co	NN
cord-034340-3ksfpaf7	233	7	-	-	NN
cord-034340-3ksfpaf7	233	8	occurrence	occurrence	NN
cord-034340-3ksfpaf7	233	9	of	of	IN
cord-034340-3ksfpaf7	233	10	JIA	JIA	NNP
cord-034340-3ksfpaf7	233	11	and	and	CC
cord-034340-3ksfpaf7	233	12	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	233	13	thyroiditis	thyroiditis	NN
cord-034340-3ksfpaf7	233	14	in	in	IN
cord-034340-3ksfpaf7	233	15	southern	southern	JJ
cord-034340-3ksfpaf7	233	16	Italy	Italy	NNP
cord-034340-3ksfpaf7	233	17	and	and	CC
cord-034340-3ksfpaf7	233	18	to	to	TO
cord-034340-3ksfpaf7	233	19	identify	identify	VB
cord-034340-3ksfpaf7	233	20	potential	potential	JJ
cord-034340-3ksfpaf7	233	21	predisposing	predispose	VBG
cord-034340-3ksfpaf7	233	22	factors	factor	NNS
cord-034340-3ksfpaf7	233	23	to	to	IN
cord-034340-3ksfpaf7	233	24	anti	anti	JJ
cord-034340-3ksfpaf7	233	25	-	-	JJ
cord-034340-3ksfpaf7	233	26	thyroid	thyroid	JJ
cord-034340-3ksfpaf7	233	27	antibodies	antibody	NNS
cord-034340-3ksfpaf7	233	28	(	(	-LRB-
cord-034340-3ksfpaf7	233	29	ATA	ATA	NNP
cord-034340-3ksfpaf7	233	30	)	)	-RRB-
cord-034340-3ksfpaf7	233	31	positivity	positivity	NN
cord-034340-3ksfpaf7	233	32	in	in	IN
cord-034340-3ksfpaf7	233	33	a	a	DT
cord-034340-3ksfpaf7	233	34	JIA	JIA	NNP
cord-034340-3ksfpaf7	233	35	population	population	NN
cord-034340-3ksfpaf7	233	36	.	.	.
cord-034340-3ksfpaf7	234	1	Methods	method	NNS
cord-034340-3ksfpaf7	234	2	:	:	:
cord-034340-3ksfpaf7	235	1	A	a	DT
cord-034340-3ksfpaf7	235	2	single	single	JJ
cord-034340-3ksfpaf7	235	3	-	-	HYPH
cord-034340-3ksfpaf7	235	4	centre	centre	NN
cord-034340-3ksfpaf7	235	5	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	235	6	study	study	NN
cord-034340-3ksfpaf7	235	7	was	be	VBD
cord-034340-3ksfpaf7	235	8	conducted	conduct	VBN
cord-034340-3ksfpaf7	235	9	.	.	.
cord-034340-3ksfpaf7	236	1	All	all	DT
cord-034340-3ksfpaf7	236	2	JIA	JIA	NNP
cord-034340-3ksfpaf7	236	3	patients	patient	NNS
cord-034340-3ksfpaf7	236	4	admitted	admit	VBD
cord-034340-3ksfpaf7	236	5	to	to	IN
cord-034340-3ksfpaf7	236	6	the	the	DT
cord-034340-3ksfpaf7	236	7	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	236	8	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	236	9	Unit	Unit	NNP
cord-034340-3ksfpaf7	236	10	of	of	IN
cord-034340-3ksfpaf7	236	11	the	the	DT
cord-034340-3ksfpaf7	236	12	University	University	NNP
cord-034340-3ksfpaf7	236	13	of	of	IN
cord-034340-3ksfpaf7	236	14	Naples	Naples	NNP
cord-034340-3ksfpaf7	236	15	Federico	Federico	NNP
cord-034340-3ksfpaf7	236	16	II	II	NNP
cord-034340-3ksfpaf7	236	17	,	,	,
cord-034340-3ksfpaf7	236	18	from	from	IN
cord-034340-3ksfpaf7	236	19	January	January	NNP
cord-034340-3ksfpaf7	236	20	2001	2001	CD
cord-034340-3ksfpaf7	236	21	to	to	IN
cord-034340-3ksfpaf7	236	22	December	December	NNP
cord-034340-3ksfpaf7	236	23	2019	2019	CD
cord-034340-3ksfpaf7	236	24	,	,	,
cord-034340-3ksfpaf7	236	25	tested	test	VBN
cord-034340-3ksfpaf7	236	26	for	for	IN
cord-034340-3ksfpaf7	236	27	ATA	ATA	NNP
cord-034340-3ksfpaf7	236	28	at	at	IN
cord-034340-3ksfpaf7	236	29	least	least	JJS
cord-034340-3ksfpaf7	236	30	once	once	RB
cord-034340-3ksfpaf7	236	31	and	and	CC
cord-034340-3ksfpaf7	236	32	with	with	IN
cord-034340-3ksfpaf7	236	33	a	a	DT
cord-034340-3ksfpaf7	236	34	minimum	minimum	NN
cord-034340-3ksfpaf7	236	35	of	of	IN
cord-034340-3ksfpaf7	236	36	6-months	6-months	CD
cord-034340-3ksfpaf7	236	37	follow	follow	NN
cord-034340-3ksfpaf7	236	38	-	-	HYPH
cord-034340-3ksfpaf7	236	39	up	up	NN
cord-034340-3ksfpaf7	236	40	,	,	,
cord-034340-3ksfpaf7	236	41	were	be	VBD
cord-034340-3ksfpaf7	236	42	included	include	VBN
cord-034340-3ksfpaf7	236	43	.	.	.
cord-034340-3ksfpaf7	237	1	For	for	IN
cord-034340-3ksfpaf7	237	2	each	each	DT
cord-034340-3ksfpaf7	237	3	patient	patient	JJ
cord-034340-3ksfpaf7	237	4	,	,	,
cord-034340-3ksfpaf7	237	5	demographic	demographic	JJ
cord-034340-3ksfpaf7	237	6	,	,	,
cord-034340-3ksfpaf7	237	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	237	8	and	and	CC
cord-034340-3ksfpaf7	237	9	laboratory	laboratory	NN
cord-034340-3ksfpaf7	237	10	data	datum	NNS
cord-034340-3ksfpaf7	237	11	were	be	VBD
cord-034340-3ksfpaf7	237	12	extracted	extract	VBN
cord-034340-3ksfpaf7	237	13	from	from	IN
cord-034340-3ksfpaf7	237	14	clinical	clinical	JJ
cord-034340-3ksfpaf7	237	15	charts	chart	NNS
cord-034340-3ksfpaf7	237	16	.	.	.
cord-034340-3ksfpaf7	238	1	Differences	difference	NNS
cord-034340-3ksfpaf7	238	2	between	between	IN
cord-034340-3ksfpaf7	238	3	patients	patient	NNS
cord-034340-3ksfpaf7	238	4	affected	affect	VBN
cord-034340-3ksfpaf7	238	5	by	by	IN
cord-034340-3ksfpaf7	238	6	JIA	JIA	NNP
cord-034340-3ksfpaf7	238	7	with	with	IN
cord-034340-3ksfpaf7	238	8	or	or	CC
cord-034340-3ksfpaf7	238	9	without	without	IN
cord-034340-3ksfpaf7	238	10	ATA	ATA	NNP
cord-034340-3ksfpaf7	238	11	were	be	VBD
cord-034340-3ksfpaf7	238	12	analyzed	analyze	VBN
cord-034340-3ksfpaf7	238	13	.	.	.
cord-034340-3ksfpaf7	239	1	Results	result	NNS
cord-034340-3ksfpaf7	239	2	:	:	:
cord-034340-3ksfpaf7	240	1	Three	three	CD
cord-034340-3ksfpaf7	240	2	hundred	hundred	CD
cord-034340-3ksfpaf7	240	3	thirty	thirty	CD
cord-034340-3ksfpaf7	240	4	JIA	JIA	NNP
cord-034340-3ksfpaf7	240	5	patients	patient	NNS
cord-034340-3ksfpaf7	240	6	(	(	-LRB-
cord-034340-3ksfpaf7	240	7	247	247	CD
cord-034340-3ksfpaf7	240	8	females	female	NNS
cord-034340-3ksfpaf7	240	9	;	;	:
cord-034340-3ksfpaf7	240	10	median	median	JJ
cord-034340-3ksfpaf7	240	11	age	age	NN
cord-034340-3ksfpaf7	240	12	12.5	12.5	CD
cord-034340-3ksfpaf7	240	13	years	year	NNS
cord-034340-3ksfpaf7	240	14	,	,	,
cord-034340-3ksfpaf7	240	15	IQR	IQR	NNP
cord-034340-3ksfpaf7	240	16	9.1	9.1	CD
cord-034340-3ksfpaf7	240	17	-	-	HYPH
cord-034340-3ksfpaf7	240	18	16.1	16.1	CD
cord-034340-3ksfpaf7	240	19	)	)	-RRB-
cord-034340-3ksfpaf7	240	20	were	be	VBD
cord-034340-3ksfpaf7	240	21	included	include	VBN
cord-034340-3ksfpaf7	240	22	in	in	IN
cord-034340-3ksfpaf7	240	23	study	study	NN
cord-034340-3ksfpaf7	240	24	.	.	.
cord-034340-3ksfpaf7	241	1	Median	median	JJ
cord-034340-3ksfpaf7	241	2	age	age	NN
cord-034340-3ksfpaf7	241	3	at	at	IN
cord-034340-3ksfpaf7	241	4	JIA	JIA	NNP
cord-034340-3ksfpaf7	241	5	onset	onset	NN
cord-034340-3ksfpaf7	241	6	was	be	VBD
cord-034340-3ksfpaf7	241	7	4	4	CD
cord-034340-3ksfpaf7	241	8	years	year	NNS
cord-034340-3ksfpaf7	242	1	(	(	-LRB-
cord-034340-3ksfpaf7	242	2	IQR	iqr	NN
cord-034340-3ksfpaf7	242	3	:	:	:
cord-034340-3ksfpaf7	242	4	2.2	2.2	CD
cord-034340-3ksfpaf7	242	5	-	-	SYM
cord-034340-3ksfpaf7	242	6	7.8	7.8	CD
cord-034340-3ksfpaf7	242	7	)	)	-RRB-
cord-034340-3ksfpaf7	242	8	.	.	.
cord-034340-3ksfpaf7	243	1	Twenty	twenty	CD
cord-034340-3ksfpaf7	243	2	-	-	HYPH
cord-034340-3ksfpaf7	243	3	three	three	CD
cord-034340-3ksfpaf7	243	4	patients	patient	NNS
cord-034340-3ksfpaf7	243	5	[	[	-LRB-
cord-034340-3ksfpaf7	243	6	7	7	CD
cord-034340-3ksfpaf7	243	7	%	%	NN
cord-034340-3ksfpaf7	243	8	(	(	-LRB-
cord-034340-3ksfpaf7	243	9	95	95	CD
cord-034340-3ksfpaf7	243	10	%	%	NN
cord-034340-3ksfpaf7	243	11	CI	CI	NNP
cord-034340-3ksfpaf7	243	12	4.5	4.5	CD
cord-034340-3ksfpaf7	243	13	-	-	SYM
cord-034340-3ksfpaf7	243	14	10	10	CD
cord-034340-3ksfpaf7	243	15	.	.	.
cord-034340-3ksfpaf7	243	16	3	3	LS
cord-034340-3ksfpaf7	243	17	)	)	-RRB-
cord-034340-3ksfpaf7	243	18	]	]	-RRB-
cord-034340-3ksfpaf7	243	19	presented	present	VBN
cord-034340-3ksfpaf7	243	20	ATA	ATA	NNP
cord-034340-3ksfpaf7	243	21	positivity	positivity	NN
cord-034340-3ksfpaf7	243	22	.	.	.
cord-034340-3ksfpaf7	244	1	Twenty	twenty	CD
cord-034340-3ksfpaf7	244	2	-	-	HYPH
cord-034340-3ksfpaf7	244	3	one	one	CD
cord-034340-3ksfpaf7	244	4	of	of	IN
cord-034340-3ksfpaf7	244	5	them	-PRON-	PRP
cord-034340-3ksfpaf7	244	6	(	(	-LRB-
cord-034340-3ksfpaf7	244	7	91.3	91.3	CD
cord-034340-3ksfpaf7	244	8	%	%	NN
cord-034340-3ksfpaf7	244	9	)	)	-RRB-
cord-034340-3ksfpaf7	244	10	were	be	VBD
cord-034340-3ksfpaf7	244	11	females	female	NNS
cord-034340-3ksfpaf7	244	12	.	.	.
cord-034340-3ksfpaf7	245	1	Anti	anti	JJ
cord-034340-3ksfpaf7	245	2	-	-	NN
cord-034340-3ksfpaf7	245	3	thyroperoxidase	thyroperoxidase	NNP
cord-034340-3ksfpaf7	245	4	was	be	VBD
cord-034340-3ksfpaf7	245	5	positive	positive	JJ
cord-034340-3ksfpaf7	245	6	in	in	IN
cord-034340-3ksfpaf7	245	7	18/23	18/23	CD
cord-034340-3ksfpaf7	245	8	patients	patient	NNS
cord-034340-3ksfpaf7	245	9	(	(	-LRB-
cord-034340-3ksfpaf7	245	10	78.2	78.2	CD
cord-034340-3ksfpaf7	245	11	%	%	NN
cord-034340-3ksfpaf7	245	12	)	)	-RRB-
cord-034340-3ksfpaf7	245	13	while	while	IN
cord-034340-3ksfpaf7	245	14	12	12	CD
cord-034340-3ksfpaf7	245	15	patients	patient	NNS
cord-034340-3ksfpaf7	245	16	presented	present	VBD
cord-034340-3ksfpaf7	245	17	anti	anti	JJ
cord-034340-3ksfpaf7	245	18	-	-	JJ
cord-034340-3ksfpaf7	245	19	thyroglobulin	thyroglobulin	JJ
cord-034340-3ksfpaf7	245	20	positivity	positivity	NN
cord-034340-3ksfpaf7	245	21	(	(	-LRB-
cord-034340-3ksfpaf7	245	22	52.1	52.1	CD
cord-034340-3ksfpaf7	245	23	%	%	NN
cord-034340-3ksfpaf7	245	24	)	)	-RRB-
cord-034340-3ksfpaf7	245	25	.	.	.
cord-034340-3ksfpaf7	246	1	Both	both	DT
cord-034340-3ksfpaf7	246	2	antibodies	antibody	NNS
cord-034340-3ksfpaf7	246	3	were	be	VBD
cord-034340-3ksfpaf7	246	4	present	present	JJ
cord-034340-3ksfpaf7	246	5	in	in	IN
cord-034340-3ksfpaf7	246	6	8/23	8/23	CD
cord-034340-3ksfpaf7	246	7	(	(	-LRB-
cord-034340-3ksfpaf7	246	8	34.8	34.8	CD
cord-034340-3ksfpaf7	246	9	%	%	NN
cord-034340-3ksfpaf7	246	10	)	)	-RRB-
cord-034340-3ksfpaf7	246	11	.	.	.
cord-034340-3ksfpaf7	247	1	19	19	CD
cord-034340-3ksfpaf7	247	2	patients	patient	NNS
cord-034340-3ksfpaf7	247	3	showed	show	VBD
cord-034340-3ksfpaf7	247	4	the	the	DT
cord-034340-3ksfpaf7	247	5	typical	typical	JJ
cord-034340-3ksfpaf7	247	6	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	247	7	findings	finding	NNS
cord-034340-3ksfpaf7	247	8	of	of	IN
cord-034340-3ksfpaf7	247	9	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	247	10	thyroiditis	thyroiditis	NN
cord-034340-3ksfpaf7	247	11	,	,	,
cord-034340-3ksfpaf7	247	12	resulting	result	VBG
cord-034340-3ksfpaf7	247	13	in	in	IN
cord-034340-3ksfpaf7	247	14	a	a	DT
cord-034340-3ksfpaf7	247	15	prevalence	prevalence	NN
cord-034340-3ksfpaf7	247	16	of	of	IN
cord-034340-3ksfpaf7	247	17	Hashimoto	Hashimoto	NNP
cord-034340-3ksfpaf7	247	18	's	's	POS
cord-034340-3ksfpaf7	247	19	thyroiditis	thyroiditis	NN
cord-034340-3ksfpaf7	247	20	of	of	IN
cord-034340-3ksfpaf7	247	21	5.7	5.7	CD
cord-034340-3ksfpaf7	247	22	%	%	NN
cord-034340-3ksfpaf7	247	23	(	(	-LRB-
cord-034340-3ksfpaf7	247	24	95	95	CD
cord-034340-3ksfpaf7	247	25	%	%	NN
cord-034340-3ksfpaf7	247	26	CI	CI	NNP
cord-034340-3ksfpaf7	247	27	3.5	3.5	CD
cord-034340-3ksfpaf7	247	28	-	-	HYPH
cord-034340-3ksfpaf7	247	29	8.8	8.8	CD
cord-034340-3ksfpaf7	247	30	)	)	-RRB-
cord-034340-3ksfpaf7	247	31	in	in	IN
cord-034340-3ksfpaf7	247	32	our	-PRON-	PRP$
cord-034340-3ksfpaf7	247	33	cohort	cohort	NN
cord-034340-3ksfpaf7	247	34	.	.	.
cord-034340-3ksfpaf7	248	1	Three	three	CD
cord-034340-3ksfpaf7	248	2	female	female	JJ
cord-034340-3ksfpaf7	248	3	patients	patient	NNS
cord-034340-3ksfpaf7	248	4	developed	develop	VBD
cord-034340-3ksfpaf7	248	5	subclinical	subclinical	JJ
cord-034340-3ksfpaf7	248	6	hypothyroidism	hypothyroidism	NN
cord-034340-3ksfpaf7	248	7	,	,	,
cord-034340-3ksfpaf7	248	8	whereas	whereas	IN
cord-034340-3ksfpaf7	248	9	one	one	CD
cord-034340-3ksfpaf7	248	10	male	male	JJ
cord-034340-3ksfpaf7	248	11	patient	patient	NN
cord-034340-3ksfpaf7	248	12	presented	present	VBD
cord-034340-3ksfpaf7	248	13	subclinical	subclinical	JJ
cord-034340-3ksfpaf7	248	14	hyperthyroidism	hyperthyroidism	NN
cord-034340-3ksfpaf7	248	15	.	.	.
cord-034340-3ksfpaf7	249	1	The	the	DT
cord-034340-3ksfpaf7	249	2	remaining	remain	VBG
cord-034340-3ksfpaf7	249	3	19	19	CD
cord-034340-3ksfpaf7	249	4	patients	patient	NNS
cord-034340-3ksfpaf7	249	5	were	be	VBD
cord-034340-3ksfpaf7	249	6	euthyroid	euthyroid	JJ
cord-034340-3ksfpaf7	249	7	.	.	.
cord-034340-3ksfpaf7	250	1	No	no	DT
cord-034340-3ksfpaf7	250	2	statistically	statistically	RB
cord-034340-3ksfpaf7	250	3	significant	significant	JJ
cord-034340-3ksfpaf7	250	4	difference	difference	NN
cord-034340-3ksfpaf7	250	5	was	be	VBD
cord-034340-3ksfpaf7	250	6	observed	observe	VBN
cord-034340-3ksfpaf7	250	7	in	in	IN
cord-034340-3ksfpaf7	250	8	regard	regard	NN
cord-034340-3ksfpaf7	250	9	to	to	IN
cord-034340-3ksfpaf7	250	10	age	age	NN
cord-034340-3ksfpaf7	250	11	of	of	IN
cord-034340-3ksfpaf7	250	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	250	13	onset	onset	NN
cord-034340-3ksfpaf7	250	14	,	,	,
cord-034340-3ksfpaf7	250	15	follow	follow	NN
cord-034340-3ksfpaf7	250	16	-	-	HYPH
cord-034340-3ksfpaf7	250	17	up	up	NN
cord-034340-3ksfpaf7	250	18	duration	duration	NN
cord-034340-3ksfpaf7	250	19	and	and	CC
cord-034340-3ksfpaf7	251	1	JIA	JIA	NNP
cord-034340-3ksfpaf7	251	2	subtype	subtype	NN
cord-034340-3ksfpaf7	251	3	between	between	IN
cord-034340-3ksfpaf7	251	4	the	the	DT
cord-034340-3ksfpaf7	251	5	patients	patient	NNS
cord-034340-3ksfpaf7	251	6	with	with	IN
cord-034340-3ksfpaf7	251	7	or	or	CC
cord-034340-3ksfpaf7	251	8	without	without	IN
cord-034340-3ksfpaf7	251	9	ATA	ATA	NNP
cord-034340-3ksfpaf7	251	10	.	.	.
cord-034340-3ksfpaf7	252	1	The	the	DT
cord-034340-3ksfpaf7	252	2	proportion	proportion	NN
cord-034340-3ksfpaf7	252	3	of	of	IN
cord-034340-3ksfpaf7	252	4	females	female	NNS
cord-034340-3ksfpaf7	252	5	was	be	VBD
cord-034340-3ksfpaf7	252	6	marginally	marginally	RB
cord-034340-3ksfpaf7	252	7	significantly	significantly	RB
cord-034340-3ksfpaf7	252	8	higher	high	JJR
cord-034340-3ksfpaf7	252	9	(	(	-LRB-
cord-034340-3ksfpaf7	252	10	p=0.059	p=0.059	NNS
cord-034340-3ksfpaf7	252	11	)	)	-RRB-
cord-034340-3ksfpaf7	252	12	in	in	IN
cord-034340-3ksfpaf7	252	13	the	the	DT
cord-034340-3ksfpaf7	252	14	group	group	NN
cord-034340-3ksfpaf7	252	15	with	with	IN
cord-034340-3ksfpaf7	252	16	ATA	ATA	NNP
cord-034340-3ksfpaf7	252	17	positivity	positivity	NN
cord-034340-3ksfpaf7	252	18	compared	compare	VBN
cord-034340-3ksfpaf7	252	19	to	to	IN
cord-034340-3ksfpaf7	252	20	children	child	NNS
cord-034340-3ksfpaf7	252	21	without	without	IN
cord-034340-3ksfpaf7	252	22	thyroid	thyroid	NN
cord-034340-3ksfpaf7	252	23	antibodies	antibody	NNS
cord-034340-3ksfpaf7	252	24	(	(	-LRB-
cord-034340-3ksfpaf7	252	25	91.3	91.3	CD
cord-034340-3ksfpaf7	252	26	%	%	NN
cord-034340-3ksfpaf7	252	27	vs	vs	IN
cord-034340-3ksfpaf7	252	28	73.6	73.6	CD
cord-034340-3ksfpaf7	252	29	%	%	NN
cord-034340-3ksfpaf7	252	30	,	,	,
cord-034340-3ksfpaf7	252	31	respectively	respectively	RB
cord-034340-3ksfpaf7	252	32	)	)	-RRB-
cord-034340-3ksfpaf7	252	33	.	.	.
cord-034340-3ksfpaf7	253	1	56.5	56.5	CD
cord-034340-3ksfpaf7	253	2	%	%	NN
cord-034340-3ksfpaf7	253	3	of	of	IN
cord-034340-3ksfpaf7	253	4	patients	patient	NNS
cord-034340-3ksfpaf7	253	5	with	with	IN
cord-034340-3ksfpaf7	253	6	ATA	ATA	NNP
cord-034340-3ksfpaf7	253	7	showed	show	VBD
cord-034340-3ksfpaf7	253	8	ANA	ANA	NNP
cord-034340-3ksfpaf7	253	9	positivity	positivity	NN
cord-034340-3ksfpaf7	253	10	compared	compare	VBN
cord-034340-3ksfpaf7	253	11	to	to	IN
cord-034340-3ksfpaf7	253	12	37.5	37.5	CD
cord-034340-3ksfpaf7	253	13	%	%	NN
cord-034340-3ksfpaf7	253	14	of	of	IN
cord-034340-3ksfpaf7	253	15	patients	patient	NNS
cord-034340-3ksfpaf7	253	16	without	without	IN
cord-034340-3ksfpaf7	253	17	ATA	ATA	NNP
cord-034340-3ksfpaf7	253	18	(	(	-LRB-
cord-034340-3ksfpaf7	253	19	p=0.07	p=0.07	NNP
cord-034340-3ksfpaf7	253	20	)	)	-RRB-
cord-034340-3ksfpaf7	253	21	.	.	.
cord-034340-3ksfpaf7	254	1	Family	family	NN
cord-034340-3ksfpaf7	254	2	history	history	NN
cord-034340-3ksfpaf7	254	3	for	for	IN
cord-034340-3ksfpaf7	254	4	AITD	AITD	NNP
cord-034340-3ksfpaf7	254	5	was	be	VBD
cord-034340-3ksfpaf7	254	6	significantly	significantly	RB
cord-034340-3ksfpaf7	254	7	higher	high	JJR
cord-034340-3ksfpaf7	254	8	in	in	IN
cord-034340-3ksfpaf7	254	9	children	child	NNS
cord-034340-3ksfpaf7	254	10	with	with	IN
cord-034340-3ksfpaf7	254	11	thyroid	thyroid	JJ
cord-034340-3ksfpaf7	254	12	antibodies	antibody	NNS
cord-034340-3ksfpaf7	254	13	positivity	positivity	NN
cord-034340-3ksfpaf7	254	14	(	(	-LRB-
cord-034340-3ksfpaf7	254	15	p=	p=	NNP
cord-034340-3ksfpaf7	254	16	0.01	0.01	CD
cord-034340-3ksfpaf7	254	17	)	)	-RRB-
cord-034340-3ksfpaf7	254	18	.	.	.
cord-034340-3ksfpaf7	255	1	Anti	Anti	NNP
cord-034340-3ksfpaf7	255	2	-	-	JJ
cord-034340-3ksfpaf7	255	3	TNF	tnf	NN
cord-034340-3ksfpaf7	255	4	-	-	HYPH
cord-034340-3ksfpaf7	255	5	alpha	alpha	NN
cord-034340-3ksfpaf7	255	6	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	255	7	were	be	VBD
cord-034340-3ksfpaf7	255	8	administered	administer	VBN
cord-034340-3ksfpaf7	255	9	in	in	IN
cord-034340-3ksfpaf7	255	10	only	only	RB
cord-034340-3ksfpaf7	255	11	3	3	CD
cord-034340-3ksfpaf7	255	12	children	child	NNS
cord-034340-3ksfpaf7	255	13	(	(	-LRB-
cord-034340-3ksfpaf7	255	14	13	13	CD
cord-034340-3ksfpaf7	255	15	%	%	NN
cord-034340-3ksfpaf7	255	16	)	)	-RRB-
cord-034340-3ksfpaf7	255	17	with	with	IN
cord-034340-3ksfpaf7	255	18	thyroid	thyroid	JJ
cord-034340-3ksfpaf7	255	19	antibodies	antibody	NNS
cord-034340-3ksfpaf7	255	20	before	before	IN
cord-034340-3ksfpaf7	255	21	their	-PRON-	PRP$
cord-034340-3ksfpaf7	255	22	detection	detection	NN
cord-034340-3ksfpaf7	255	23	compared	compare	VBN
cord-034340-3ksfpaf7	255	24	to	to	IN
cord-034340-3ksfpaf7	255	25	35	35	CD
cord-034340-3ksfpaf7	255	26	.5	.5	CD
cord-034340-3ksfpaf7	255	27	%	%	NN
cord-034340-3ksfpaf7	255	28	of	of	IN
cord-034340-3ksfpaf7	255	29	patients	patient	NNS
cord-034340-3ksfpaf7	255	30	without	without	IN
cord-034340-3ksfpaf7	255	31	thyroid	thyroid	NN
cord-034340-3ksfpaf7	255	32	antibodies	antibody	NNS
cord-034340-3ksfpaf7	255	33	(	(	-LRB-
cord-034340-3ksfpaf7	255	34	p=0.028	p=0.028	NNP
cord-034340-3ksfpaf7	255	35	)	)	-RRB-
cord-034340-3ksfpaf7	255	36	.	.	.
cord-034340-3ksfpaf7	256	1	Multivariate	multivariate	JJ
cord-034340-3ksfpaf7	256	2	regression	regression	NN
cord-034340-3ksfpaf7	256	3	analysis	analysis	NN
cord-034340-3ksfpaf7	256	4	showed	show	VBD
cord-034340-3ksfpaf7	256	5	that	that	IN
cord-034340-3ksfpaf7	256	6	patients	patient	NNS
cord-034340-3ksfpaf7	256	7	with	with	IN
cord-034340-3ksfpaf7	256	8	a	a	DT
cord-034340-3ksfpaf7	256	9	family	family	NN
cord-034340-3ksfpaf7	256	10	history	history	NN
cord-034340-3ksfpaf7	256	11	for	for	IN
cord-034340-3ksfpaf7	256	12	AITD	AITD	NNP
cord-034340-3ksfpaf7	256	13	were	be	VBD
cord-034340-3ksfpaf7	256	14	about	about	RB
cord-034340-3ksfpaf7	256	15	four	four	CD
cord-034340-3ksfpaf7	256	16	times	time	NNS
cord-034340-3ksfpaf7	256	17	more	more	RBR
cord-034340-3ksfpaf7	256	18	likely	likely	JJ
cord-034340-3ksfpaf7	256	19	to	to	TO
cord-034340-3ksfpaf7	256	20	develop	develop	VB
cord-034340-3ksfpaf7	256	21	ATA	ATA	NNP
cord-034340-3ksfpaf7	256	22	(	(	-LRB-
cord-034340-3ksfpaf7	256	23	OR	or	CC
cord-034340-3ksfpaf7	256	24	3.75	3.75	CD
cord-034340-3ksfpaf7	256	25	,	,	,
cord-034340-3ksfpaf7	256	26	95	95	CD
cord-034340-3ksfpaf7	256	27	%	%	NN
cord-034340-3ksfpaf7	256	28	CI	CI	NNP
cord-034340-3ksfpaf7	256	29	1.401	1.401	CD
cord-034340-3ksfpaf7	256	30	-	-	SYM
cord-034340-3ksfpaf7	256	31	10.017	10.017	CD
cord-034340-3ksfpaf7	256	32	,	,	,
cord-034340-3ksfpaf7	256	33	p=0.008	p=0.008	NNP
cord-034340-3ksfpaf7	256	34	)	)	-RRB-
cord-034340-3ksfpaf7	256	35	and	and	CC
cord-034340-3ksfpaf7	256	36	confirmed	confirm	VBD
cord-034340-3ksfpaf7	256	37	that	that	IN
cord-034340-3ksfpaf7	256	38	ATA	ATA	NNP
cord-034340-3ksfpaf7	256	39	positivity	positivity	NN
cord-034340-3ksfpaf7	256	40	is	be	VBZ
cord-034340-3ksfpaf7	256	41	less	less	RBR
cord-034340-3ksfpaf7	256	42	likely	likely	JJ
cord-034340-3ksfpaf7	256	43	to	to	TO
cord-034340-3ksfpaf7	256	44	occur	occur	VB
cord-034340-3ksfpaf7	256	45	in	in	IN
cord-034340-3ksfpaf7	256	46	patients	patient	NNS
cord-034340-3ksfpaf7	256	47	undergone	undergo	VBN
cord-034340-3ksfpaf7	256	48	anti	anti	JJ
cord-034340-3ksfpaf7	256	49	-	-	JJ
cord-034340-3ksfpaf7	256	50	TNF	tnf	JJ
cord-034340-3ksfpaf7	256	51	-	-	HYPH
cord-034340-3ksfpaf7	256	52	alpha	alpha	NN
cord-034340-3ksfpaf7	256	53	therapy	therapy	NN
cord-034340-3ksfpaf7	256	54	(	(	-LRB-
cord-034340-3ksfpaf7	256	55	OR	OR	NNP
cord-034340-3ksfpaf7	256	56	0.127	0.127	CD
cord-034340-3ksfpaf7	256	57	,	,	,
cord-034340-3ksfpaf7	256	58	95	95	CD
cord-034340-3ksfpaf7	256	59	%	%	NN
cord-034340-3ksfpaf7	256	60	CI	CI	NNP
cord-034340-3ksfpaf7	256	61	0.031	0.031	CD
cord-034340-3ksfpaf7	256	62	-	-	SYM
cord-034340-3ksfpaf7	256	63	0.518	0.518	CD
cord-034340-3ksfpaf7	256	64	,	,	,
cord-034340-3ksfpaf7	256	65	p=0.004	p=0.004	NNP
cord-034340-3ksfpaf7	256	66	)	)	-RRB-
cord-034340-3ksfpaf7	256	67	.	.	.
cord-034340-3ksfpaf7	257	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	257	2	:	:	:
cord-034340-3ksfpaf7	258	1	A	a	DT
cord-034340-3ksfpaf7	258	2	high	high	JJ
cord-034340-3ksfpaf7	258	3	prevalence	prevalence	NN
cord-034340-3ksfpaf7	258	4	of	of	IN
cord-034340-3ksfpaf7	258	5	ATA	ATA	NNP
cord-034340-3ksfpaf7	258	6	positivity	positivity	NN
cord-034340-3ksfpaf7	258	7	and	and	CC
cord-034340-3ksfpaf7	258	8	Hashimoto	Hashimoto	NNP
cord-034340-3ksfpaf7	258	9	's	's	POS
cord-034340-3ksfpaf7	258	10	thyroiditis	thyroiditis	NN
cord-034340-3ksfpaf7	258	11	in	in	IN
cord-034340-3ksfpaf7	258	12	patients	patient	NNS
cord-034340-3ksfpaf7	258	13	with	with	IN
cord-034340-3ksfpaf7	258	14	JIA	JIA	NNP
cord-034340-3ksfpaf7	258	15	was	be	VBD
cord-034340-3ksfpaf7	258	16	found	find	VBN
cord-034340-3ksfpaf7	258	17	in	in	IN
cord-034340-3ksfpaf7	258	18	our	-PRON-	PRP$
cord-034340-3ksfpaf7	258	19	wide	wide	JJ
cord-034340-3ksfpaf7	258	20	southern	southern	JJ
cord-034340-3ksfpaf7	258	21	Italian	italian	JJ
cord-034340-3ksfpaf7	258	22	cohort	cohort	NN
cord-034340-3ksfpaf7	258	23	.	.	.
cord-034340-3ksfpaf7	259	1	As	as	IN
cord-034340-3ksfpaf7	259	2	expected	expect	VBN
cord-034340-3ksfpaf7	259	3	,	,	,
cord-034340-3ksfpaf7	259	4	a	a	DT
cord-034340-3ksfpaf7	259	5	positive	positive	JJ
cord-034340-3ksfpaf7	259	6	family	family	NN
cord-034340-3ksfpaf7	259	7	history	history	NN
cord-034340-3ksfpaf7	259	8	of	of	IN
cord-034340-3ksfpaf7	259	9	AITD	AITD	NNP
cord-034340-3ksfpaf7	259	10	was	be	VBD
cord-034340-3ksfpaf7	259	11	found	find	VBN
cord-034340-3ksfpaf7	259	12	to	to	TO
cord-034340-3ksfpaf7	259	13	be	be	VB
cord-034340-3ksfpaf7	259	14	associated	associate	VBN
cord-034340-3ksfpaf7	259	15	with	with	IN
cord-034340-3ksfpaf7	259	16	a	a	DT
cord-034340-3ksfpaf7	259	17	higher	high	JJR
cord-034340-3ksfpaf7	259	18	risk	risk	NN
cord-034340-3ksfpaf7	259	19	to	to	IN
cord-034340-3ksfpaf7	259	20	ATA	ATA	NNP
cord-034340-3ksfpaf7	259	21	development	development	NN
cord-034340-3ksfpaf7	259	22	during	during	IN
cord-034340-3ksfpaf7	259	23	the	the	DT
cord-034340-3ksfpaf7	259	24	follow	follow	NN
cord-034340-3ksfpaf7	259	25	-	-	HYPH
cord-034340-3ksfpaf7	259	26	up	up	NN
cord-034340-3ksfpaf7	259	27	.	.	.
cord-034340-3ksfpaf7	260	1	This	this	DT
cord-034340-3ksfpaf7	260	2	finding	finding	NN
cord-034340-3ksfpaf7	260	3	supports	support	VBZ
cord-034340-3ksfpaf7	260	4	the	the	DT
cord-034340-3ksfpaf7	260	5	usefulness	usefulness	NN
cord-034340-3ksfpaf7	260	6	of	of	IN
cord-034340-3ksfpaf7	260	7	an	an	DT
cord-034340-3ksfpaf7	260	8	active	active	JJ
cord-034340-3ksfpaf7	260	9	screening	screening	NN
cord-034340-3ksfpaf7	260	10	for	for	IN
cord-034340-3ksfpaf7	260	11	AITD	AITD	NNP
cord-034340-3ksfpaf7	260	12	in	in	IN
cord-034340-3ksfpaf7	260	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	260	14	children	child	NNS
cord-034340-3ksfpaf7	260	15	,	,	,
cord-034340-3ksfpaf7	260	16	in	in	IN
cord-034340-3ksfpaf7	260	17	particular	particular	JJ
cord-034340-3ksfpaf7	260	18	in	in	IN
cord-034340-3ksfpaf7	260	19	patients	patient	NNS
cord-034340-3ksfpaf7	260	20	with	with	IN
cord-034340-3ksfpaf7	260	21	relatives	relative	NNS
cord-034340-3ksfpaf7	260	22	affected	affect	VBN
cord-034340-3ksfpaf7	260	23	by	by	IN
cord-034340-3ksfpaf7	260	24	thyroid	thyroid	JJ
cord-034340-3ksfpaf7	260	25	disorders	disorder	NNS
cord-034340-3ksfpaf7	260	26	.	.	.
cord-034340-3ksfpaf7	261	1	Notably	notably	RB
cord-034340-3ksfpaf7	261	2	,	,	,
cord-034340-3ksfpaf7	261	3	patients	patient	NNS
cord-034340-3ksfpaf7	261	4	treated	treat	VBN
cord-034340-3ksfpaf7	261	5	with	with	IN
cord-034340-3ksfpaf7	261	6	TNF	TNF	NNP
cord-034340-3ksfpaf7	261	7	-	-	HYPH
cord-034340-3ksfpaf7	261	8	alpha	alpha	NN
cord-034340-3ksfpaf7	261	9	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	261	10	resulted	result	VBD
cord-034340-3ksfpaf7	261	11	less	less	RBR
cord-034340-3ksfpaf7	261	12	likely	likely	JJ
cord-034340-3ksfpaf7	261	13	to	to	TO
cord-034340-3ksfpaf7	261	14	develop	develop	VB
cord-034340-3ksfpaf7	261	15	thyroid	thyroid	JJ
cord-034340-3ksfpaf7	261	16	antibodies	antibody	NNS
cord-034340-3ksfpaf7	261	17	.	.	.
cord-034340-3ksfpaf7	262	1	Further	further	JJ
cord-034340-3ksfpaf7	262	2	studies	study	NNS
cord-034340-3ksfpaf7	262	3	are	be	VBP
cord-034340-3ksfpaf7	262	4	needed	need	VBN
cord-034340-3ksfpaf7	262	5	to	to	TO
cord-034340-3ksfpaf7	262	6	investigate	investigate	VB
cord-034340-3ksfpaf7	262	7	the	the	DT
cord-034340-3ksfpaf7	262	8	effect	effect	NN
cord-034340-3ksfpaf7	262	9	of	of	IN
cord-034340-3ksfpaf7	262	10	anti	anti	JJ
cord-034340-3ksfpaf7	262	11	-	-	JJ
cord-034340-3ksfpaf7	262	12	TNF	tnf	JJ
cord-034340-3ksfpaf7	262	13	-	-	HYPH
cord-034340-3ksfpaf7	262	14	alpha	alpha	NN
cord-034340-3ksfpaf7	262	15	therapy	therapy	NN
cord-034340-3ksfpaf7	262	16	on	on	IN
cord-034340-3ksfpaf7	262	17	thyroid	thyroid	NN
cord-034340-3ksfpaf7	262	18	autoimmunity	autoimmunity	NN
cord-034340-3ksfpaf7	262	19	in	in	IN
cord-034340-3ksfpaf7	262	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	262	21	.	.	.
cord-034340-3ksfpaf7	263	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	263	2	:	:	:
cord-034340-3ksfpaf7	264	1	The	the	DT
cord-034340-3ksfpaf7	264	2	knee	knee	NN
cord-034340-3ksfpaf7	264	3	is	be	VBZ
cord-034340-3ksfpaf7	264	4	considered	consider	VBN
cord-034340-3ksfpaf7	264	5	by	by	IN
cord-034340-3ksfpaf7	264	6	far	far	RB
cord-034340-3ksfpaf7	264	7	the	the	DT
cord-034340-3ksfpaf7	264	8	joint	joint	NN
cord-034340-3ksfpaf7	264	9	most	most	RBS
cord-034340-3ksfpaf7	264	10	frequently	frequently	RB
cord-034340-3ksfpaf7	264	11	affected	affect	VBN
cord-034340-3ksfpaf7	264	12	at	at	IN
cord-034340-3ksfpaf7	264	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	264	14	onset	onset	NN
cord-034340-3ksfpaf7	264	15	.	.	.
cord-034340-3ksfpaf7	265	1	Nonetheless	nonetheless	RB
cord-034340-3ksfpaf7	265	2	,	,	,
cord-034340-3ksfpaf7	265	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	265	4	onset	onset	NN
cord-034340-3ksfpaf7	265	5	may	may	MD
cord-034340-3ksfpaf7	265	6	present	present	VB
cord-034340-3ksfpaf7	265	7	with	with	IN
cord-034340-3ksfpaf7	265	8	unusual	unusual	JJ
cord-034340-3ksfpaf7	265	9	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	265	10	involvement	involvement	NN
cord-034340-3ksfpaf7	265	11	,	,	,
cord-034340-3ksfpaf7	265	12	eventually	eventually	RB
cord-034340-3ksfpaf7	265	13	leading	lead	VBG
cord-034340-3ksfpaf7	265	14	to	to	IN
cord-034340-3ksfpaf7	265	15	a	a	DT
cord-034340-3ksfpaf7	265	16	delay	delay	NN
cord-034340-3ksfpaf7	265	17	in	in	IN
cord-034340-3ksfpaf7	265	18	the	the	DT
cord-034340-3ksfpaf7	265	19	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	265	20	and	and	CC
cord-034340-3ksfpaf7	265	21	treatment	treatment	NN
cord-034340-3ksfpaf7	265	22	.	.	.
cord-034340-3ksfpaf7	266	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	266	2	:	:	:
cord-034340-3ksfpaf7	266	3	To	to	TO
cord-034340-3ksfpaf7	266	4	identify	identify	VB
cord-034340-3ksfpaf7	266	5	the	the	DT
cord-034340-3ksfpaf7	266	6	type	type	NN
cord-034340-3ksfpaf7	266	7	and	and	CC
cord-034340-3ksfpaf7	266	8	number	number	NN
cord-034340-3ksfpaf7	266	9	of	of	IN
cord-034340-3ksfpaf7	266	10	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	266	11	sites	site	NNS
cord-034340-3ksfpaf7	266	12	affected	affect	VBN
cord-034340-3ksfpaf7	266	13	at	at	IN
cord-034340-3ksfpaf7	266	14	JIA	JIA	NNP
cord-034340-3ksfpaf7	266	15	onset	onset	NN
cord-034340-3ksfpaf7	266	16	in	in	IN
cord-034340-3ksfpaf7	266	17	consecutive	consecutive	JJ
cord-034340-3ksfpaf7	266	18	patients	patient	NNS
cord-034340-3ksfpaf7	266	19	seen	see	VBN
cord-034340-3ksfpaf7	266	20	at	at	IN
cord-034340-3ksfpaf7	266	21	the	the	DT
cord-034340-3ksfpaf7	266	22	study	study	NN
cord-034340-3ksfpaf7	266	23	center	center	NN
cord-034340-3ksfpaf7	266	24	in	in	IN
cord-034340-3ksfpaf7	266	25	an	an	DT
cord-034340-3ksfpaf7	266	26	8	8	CD
cord-034340-3ksfpaf7	266	27	years	year	NNS
cord-034340-3ksfpaf7	266	28	period	period	NN
cord-034340-3ksfpaf7	266	29	.	.	.
cord-034340-3ksfpaf7	267	1	Methods	method	NNS
cord-034340-3ksfpaf7	267	2	:	:	:
cord-034340-3ksfpaf7	267	3	Records	record	NNS
cord-034340-3ksfpaf7	267	4	of	of	IN
cord-034340-3ksfpaf7	267	5	patients	patient	NNS
cord-034340-3ksfpaf7	267	6	with	with	IN
cord-034340-3ksfpaf7	267	7	new	new	JJ
cord-034340-3ksfpaf7	267	8	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	267	9	of	of	IN
cord-034340-3ksfpaf7	267	10	JIA	JIA	NNP
cord-034340-3ksfpaf7	267	11	from	from	IN
cord-034340-3ksfpaf7	267	12	June	June	NNP
cord-034340-3ksfpaf7	267	13	2012	2012	CD
cord-034340-3ksfpaf7	267	14	to	to	IN
cord-034340-3ksfpaf7	267	15	May	May	NNP
cord-034340-3ksfpaf7	267	16	2020	2020	CD
cord-034340-3ksfpaf7	267	17	available	available	JJ
cord-034340-3ksfpaf7	267	18	information	information	NN
cord-034340-3ksfpaf7	267	19	in	in	IN
cord-034340-3ksfpaf7	267	20	the	the	DT
cord-034340-3ksfpaf7	267	21	medical	medical	JJ
cord-034340-3ksfpaf7	267	22	history	history	NN
cord-034340-3ksfpaf7	267	23	and	and	CC
cord-034340-3ksfpaf7	267	24	standardized	standardized	JJ
cord-034340-3ksfpaf7	267	25	joint	joint	JJ
cord-034340-3ksfpaf7	267	26	assessment	assessment	NN
cord-034340-3ksfpaf7	267	27	at	at	IN
cord-034340-3ksfpaf7	267	28	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	267	29	,	,	,
cord-034340-3ksfpaf7	267	30	were	be	VBD
cord-034340-3ksfpaf7	267	31	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	267	32	reviewed	review	VBN
cord-034340-3ksfpaf7	267	33	.	.	.
cord-034340-3ksfpaf7	268	1	Systemic	systemic	JJ
cord-034340-3ksfpaf7	268	2	JIA	JIA	NNP
cord-034340-3ksfpaf7	268	3	subtype	subtype	NN
cord-034340-3ksfpaf7	268	4	according	accord	VBG
cord-034340-3ksfpaf7	268	5	to	to	IN
cord-034340-3ksfpaf7	268	6	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	268	7	classification	classification	NN
cord-034340-3ksfpaf7	268	8	criteria	criterion	NNS
cord-034340-3ksfpaf7	268	9	were	be	VBD
cord-034340-3ksfpaf7	268	10	excluded	exclude	VBN
cord-034340-3ksfpaf7	268	11	.	.	.
cord-034340-3ksfpaf7	269	1	Demographic	demographic	JJ
cord-034340-3ksfpaf7	269	2	and	and	CC
cord-034340-3ksfpaf7	269	3	clinical	clinical	JJ
cord-034340-3ksfpaf7	269	4	features	feature	NNS
cord-034340-3ksfpaf7	269	5	,	,	,
cord-034340-3ksfpaf7	269	6	including	include	VBG
cord-034340-3ksfpaf7	269	7	the	the	DT
cord-034340-3ksfpaf7	269	8	type	type	NN
cord-034340-3ksfpaf7	269	9	and	and	CC
cord-034340-3ksfpaf7	269	10	number	number	NN
cord-034340-3ksfpaf7	269	11	of	of	IN
cord-034340-3ksfpaf7	269	12	joints	joint	NNS
cord-034340-3ksfpaf7	269	13	at	at	IN
cord-034340-3ksfpaf7	269	14	disease	disease	NN
cord-034340-3ksfpaf7	269	15	onset	onset	NN
cord-034340-3ksfpaf7	269	16	and	and	CC
cord-034340-3ksfpaf7	269	17	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	269	18	,	,	,
cord-034340-3ksfpaf7	269	19	were	be	VBD
cord-034340-3ksfpaf7	269	20	registered	register	VBN
cord-034340-3ksfpaf7	269	21	.	.	.
cord-034340-3ksfpaf7	270	1	Data	datum	NNS
cord-034340-3ksfpaf7	270	2	were	be	VBD
cord-034340-3ksfpaf7	270	3	analyzed	analyze	VBN
cord-034340-3ksfpaf7	270	4	through	through	IN
cord-034340-3ksfpaf7	270	5	descriptive	descriptive	JJ
cord-034340-3ksfpaf7	270	6	statistics	statistic	NNS
cord-034340-3ksfpaf7	270	7	.	.	.
cord-034340-3ksfpaf7	271	1	Results	result	NNS
cord-034340-3ksfpaf7	271	2	:	:	:
cord-034340-3ksfpaf7	272	1	Of	of	IN
cord-034340-3ksfpaf7	272	2	a	a	DT
cord-034340-3ksfpaf7	272	3	total	total	NN
cord-034340-3ksfpaf7	272	4	of	of	IN
cord-034340-3ksfpaf7	272	5	333	333	CD
cord-034340-3ksfpaf7	272	6	Caucasian	caucasian	JJ
cord-034340-3ksfpaf7	272	7	patients	patient	NNS
cord-034340-3ksfpaf7	272	8	included	include	VBN
cord-034340-3ksfpaf7	272	9	in	in	IN
cord-034340-3ksfpaf7	272	10	the	the	DT
cord-034340-3ksfpaf7	272	11	study	study	NN
cord-034340-3ksfpaf7	272	12	(	(	-LRB-
cord-034340-3ksfpaf7	272	13	75.7	75.7	CD
cord-034340-3ksfpaf7	272	14	%	%	NN
cord-034340-3ksfpaf7	272	15	females	female	NNS
cord-034340-3ksfpaf7	272	16	)	)	-RRB-
cord-034340-3ksfpaf7	272	17	,	,	,
cord-034340-3ksfpaf7	272	18	241	241	CD
cord-034340-3ksfpaf7	272	19	patients	patient	NNS
cord-034340-3ksfpaf7	272	20	(	(	-LRB-
cord-034340-3ksfpaf7	272	21	72.4	72.4	CD
cord-034340-3ksfpaf7	272	22	%	%	NN
cord-034340-3ksfpaf7	272	23	)	)	-RRB-
cord-034340-3ksfpaf7	272	24	had	have	VBD
cord-034340-3ksfpaf7	272	25	oligoarthritis	oligoarthritis	NNP
cord-034340-3ksfpaf7	272	26	,	,	,
cord-034340-3ksfpaf7	272	27	79	79	CD
cord-034340-3ksfpaf7	272	28	(	(	-LRB-
cord-034340-3ksfpaf7	272	29	23.7	23.7	CD
cord-034340-3ksfpaf7	272	30	%	%	NN
cord-034340-3ksfpaf7	272	31	)	)	-RRB-
cord-034340-3ksfpaf7	273	1	RF	rf	NN
cord-034340-3ksfpaf7	273	2	-	-	HYPH
cord-034340-3ksfpaf7	273	3	negative	negative	JJ
cord-034340-3ksfpaf7	273	4	polyarthritis	polyarthritis	NN
cord-034340-3ksfpaf7	273	5	,	,	,
cord-034340-3ksfpaf7	273	6	7	7	CD
cord-034340-3ksfpaf7	273	7	(	(	-LRB-
cord-034340-3ksfpaf7	273	8	2.1	2.1	CD
cord-034340-3ksfpaf7	273	9	%	%	NN
cord-034340-3ksfpaf7	273	10	)	)	-RRB-
cord-034340-3ksfpaf7	273	11	RF	rf	NN
cord-034340-3ksfpaf7	273	12	-	-	HYPH
cord-034340-3ksfpaf7	273	13	positive	positive	JJ
cord-034340-3ksfpaf7	273	14	polyarthritis	polyarthritis	NN
cord-034340-3ksfpaf7	273	15	,	,	,
cord-034340-3ksfpaf7	273	16	1	1	CD
cord-034340-3ksfpaf7	273	17	(	(	-LRB-
cord-034340-3ksfpaf7	273	18	0.3	0.3	CD
cord-034340-3ksfpaf7	273	19	%	%	NN
cord-034340-3ksfpaf7	273	20	)	)	-RRB-
cord-034340-3ksfpaf7	273	21	psoriatic	psoriatic	JJ
cord-034340-3ksfpaf7	273	22	arthritis	arthritis	NN
cord-034340-3ksfpaf7	273	23	,	,	,
cord-034340-3ksfpaf7	273	24	5	5	CD
cord-034340-3ksfpaf7	273	25	(	(	-LRB-
cord-034340-3ksfpaf7	273	26	1.5	1.5	CD
cord-034340-3ksfpaf7	273	27	%	%	NN
cord-034340-3ksfpaf7	273	28	)	)	-RRB-
cord-034340-3ksfpaf7	273	29	enthesitis	enthesitis	NN
cord-034340-3ksfpaf7	273	30	-	-	HYPH
cord-034340-3ksfpaf7	273	31	related	relate	VBN
cord-034340-3ksfpaf7	273	32	arthritis	arthritis	NN
cord-034340-3ksfpaf7	273	33	(	(	-LRB-
cord-034340-3ksfpaf7	273	34	ERA	ERA	NNP
cord-034340-3ksfpaf7	273	35	)	)	-RRB-
cord-034340-3ksfpaf7	273	36	.	.	.
cord-034340-3ksfpaf7	274	1	Antinuclear	antinuclear	JJ
cord-034340-3ksfpaf7	274	2	antibody	antibody	NN
cord-034340-3ksfpaf7	274	3	(	(	-LRB-
cord-034340-3ksfpaf7	274	4	ANA	ANA	NNP
cord-034340-3ksfpaf7	274	5	)	)	-RRB-
cord-034340-3ksfpaf7	274	6	were	be	VBD
cord-034340-3ksfpaf7	274	7	positive	positive	JJ
cord-034340-3ksfpaf7	274	8	in	in	IN
cord-034340-3ksfpaf7	274	9	188	188	CD
cord-034340-3ksfpaf7	274	10	patients	patient	NNS
cord-034340-3ksfpaf7	274	11	(	(	-LRB-
cord-034340-3ksfpaf7	274	12	56.5	56.5	CD
cord-034340-3ksfpaf7	274	13	%	%	NN
cord-034340-3ksfpaf7	274	14	)	)	-RRB-
cord-034340-3ksfpaf7	274	15	.	.	.
cord-034340-3ksfpaf7	275	1	The	the	DT
cord-034340-3ksfpaf7	275	2	median	median	JJ
cord-034340-3ksfpaf7	275	3	age	age	NN
cord-034340-3ksfpaf7	275	4	at	at	IN
cord-034340-3ksfpaf7	275	5	onset	onset	NN
cord-034340-3ksfpaf7	275	6	was	be	VBD
cord-034340-3ksfpaf7	275	7	4.8	4.8	CD
cord-034340-3ksfpaf7	275	8	years	year	NNS
cord-034340-3ksfpaf7	275	9	(	(	-LRB-
cord-034340-3ksfpaf7	275	10	IQR	IQR	NNP
cord-034340-3ksfpaf7	275	11	2.3	2.3	CD
cord-034340-3ksfpaf7	275	12	-	-	SYM
cord-034340-3ksfpaf7	275	13	9.3	9.3	CD
cord-034340-3ksfpaf7	275	14	)	)	-RRB-
cord-034340-3ksfpaf7	275	15	.	.	.
cord-034340-3ksfpaf7	276	1	At	at	IN
cord-034340-3ksfpaf7	276	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	276	3	103	103	CD
cord-034340-3ksfpaf7	276	4	(	(	-LRB-
cord-034340-3ksfpaf7	276	5	30.9	30.9	CD
cord-034340-3ksfpaf7	276	6	%	%	NN
cord-034340-3ksfpaf7	276	7	)	)	-RRB-
cord-034340-3ksfpaf7	276	8	patients	patient	NNS
cord-034340-3ksfpaf7	276	9	had	have	VBD
cord-034340-3ksfpaf7	276	10	only	only	RB
cord-034340-3ksfpaf7	276	11	1	1	CD
cord-034340-3ksfpaf7	276	12	active	active	JJ
cord-034340-3ksfpaf7	276	13	joint	joint	NN
cord-034340-3ksfpaf7	276	14	,	,	,
cord-034340-3ksfpaf7	276	15	143	143	CD
cord-034340-3ksfpaf7	276	16	(	(	-LRB-
cord-034340-3ksfpaf7	276	17	43.0	43.0	CD
cord-034340-3ksfpaf7	276	18	%	%	NN
cord-034340-3ksfpaf7	276	19	)	)	-RRB-
cord-034340-3ksfpaf7	276	20	had	have	VBD
cord-034340-3ksfpaf7	276	21	2	2	CD
cord-034340-3ksfpaf7	276	22	-	-	SYM
cord-034340-3ksfpaf7	276	23	4	4	CD
cord-034340-3ksfpaf7	276	24	active	active	JJ
cord-034340-3ksfpaf7	276	25	joints	joint	NNS
cord-034340-3ksfpaf7	276	26	,	,	,
cord-034340-3ksfpaf7	276	27	87	87	CD
cord-034340-3ksfpaf7	276	28	(	(	-LRB-
cord-034340-3ksfpaf7	276	29	26.1	26.1	CD
cord-034340-3ksfpaf7	276	30	%	%	NN
cord-034340-3ksfpaf7	276	31	)	)	-RRB-
cord-034340-3ksfpaf7	276	32	had	have	VBD
cord-034340-3ksfpaf7	276	33	≥	≥	CD
cord-034340-3ksfpaf7	276	34	5	5	CD
cord-034340-3ksfpaf7	276	35	.	.	.
cord-034340-3ksfpaf7	277	1	As	as	IN
cord-034340-3ksfpaf7	277	2	expected	expect	VBN
cord-034340-3ksfpaf7	277	3	the	the	DT
cord-034340-3ksfpaf7	277	4	knee	knee	NN
cord-034340-3ksfpaf7	277	5	,	,	,
cord-034340-3ksfpaf7	277	6	the	the	DT
cord-034340-3ksfpaf7	277	7	tibiotalar	tibiotalar	NNP
cord-034340-3ksfpaf7	277	8	and	and	CC
cord-034340-3ksfpaf7	277	9	the	the	DT
cord-034340-3ksfpaf7	277	10	wrist	wrist	NN
cord-034340-3ksfpaf7	277	11	were	be	VBD
cord-034340-3ksfpaf7	277	12	the	the	DT
cord-034340-3ksfpaf7	277	13	most	most	RBS
cord-034340-3ksfpaf7	277	14	frequently	frequently	RB
cord-034340-3ksfpaf7	277	15	affected	affect	VBN
cord-034340-3ksfpaf7	277	16	joints	joint	NNS
cord-034340-3ksfpaf7	277	17	(	(	-LRB-
cord-034340-3ksfpaf7	277	18	77.2	77.2	CD
cord-034340-3ksfpaf7	277	19	%	%	NN
cord-034340-3ksfpaf7	277	20	,	,	,
cord-034340-3ksfpaf7	277	21	41.1	41.1	CD
cord-034340-3ksfpaf7	277	22	%	%	NN
cord-034340-3ksfpaf7	277	23	,	,	,
cord-034340-3ksfpaf7	277	24	21.0	21.0	CD
cord-034340-3ksfpaf7	277	25	%	%	NN
cord-034340-3ksfpaf7	277	26	,	,	,
cord-034340-3ksfpaf7	277	27	respectively	respectively	RB
cord-034340-3ksfpaf7	277	28	)	)	-RRB-
cord-034340-3ksfpaf7	277	29	;	;	,
cord-034340-3ksfpaf7	277	30	cervical	cervical	JJ
cord-034340-3ksfpaf7	277	31	spine	spine	NN
cord-034340-3ksfpaf7	277	32	was	be	VBD
cord-034340-3ksfpaf7	277	33	involved	involve	VBN
cord-034340-3ksfpaf7	277	34	only	only	RB
cord-034340-3ksfpaf7	277	35	in	in	IN
cord-034340-3ksfpaf7	277	36	patients	patient	NNS
cord-034340-3ksfpaf7	277	37	with	with	IN
cord-034340-3ksfpaf7	277	38	polyarthritis	polyarthritis	NNP
cord-034340-3ksfpaf7	277	39	(	(	-LRB-
cord-034340-3ksfpaf7	277	40	n=13	n=13	NNP
cord-034340-3ksfpaf7	277	41	)	)	-RRB-
cord-034340-3ksfpaf7	277	42	.	.	.
cord-034340-3ksfpaf7	278	1	Notably	notably	RB
cord-034340-3ksfpaf7	278	2	,	,	,
cord-034340-3ksfpaf7	278	3	of	of	IN
cord-034340-3ksfpaf7	278	4	103	103	CD
cord-034340-3ksfpaf7	278	5	patients	patient	NNS
cord-034340-3ksfpaf7	278	6	with	with	IN
cord-034340-3ksfpaf7	278	7	monoarthritis	monoarthritis	NNP
cord-034340-3ksfpaf7	278	8	at	at	IN
cord-034340-3ksfpaf7	278	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	278	10	98	98	CD
cord-034340-3ksfpaf7	278	11	presented	present	VBN
cord-034340-3ksfpaf7	278	12	with	with	IN
cord-034340-3ksfpaf7	278	13	large	large	JJ
cord-034340-3ksfpaf7	278	14	joints	joint	NNS
cord-034340-3ksfpaf7	278	15	involvement	involvement	NN
cord-034340-3ksfpaf7	278	16	,	,	,
cord-034340-3ksfpaf7	278	17	among	among	IN
cord-034340-3ksfpaf7	278	18	which	which	WDT
cord-034340-3ksfpaf7	278	19	n=2	n=2	NNS
cord-034340-3ksfpaf7	278	20	isolated	isolate	VBN
cord-034340-3ksfpaf7	278	21	elbow	elbow	NN
cord-034340-3ksfpaf7	278	22	and	and	CC
cord-034340-3ksfpaf7	278	23	n=2	n=2	NNS
cord-034340-3ksfpaf7	278	24	isolated	isolate	VBN
cord-034340-3ksfpaf7	278	25	wrist	wrist	NN
cord-034340-3ksfpaf7	278	26	,	,	,
cord-034340-3ksfpaf7	278	27	and	and	CC
cord-034340-3ksfpaf7	278	28	5	5	CD
cord-034340-3ksfpaf7	278	29	with	with	IN
cord-034340-3ksfpaf7	278	30	small	small	JJ
cord-034340-3ksfpaf7	278	31	joints	joint	NNS
cord-034340-3ksfpaf7	278	32	involvement	involvement	NN
cord-034340-3ksfpaf7	278	33	(	(	-LRB-
cord-034340-3ksfpaf7	278	34	Table	table	NN
cord-034340-3ksfpaf7	278	35	1	1	CD
cord-034340-3ksfpaf7	278	36	)	)	-RRB-
cord-034340-3ksfpaf7	278	37	.	.	.
cord-034340-3ksfpaf7	279	1	No	no	DT
cord-034340-3ksfpaf7	279	2	sufficient	sufficient	JJ
cord-034340-3ksfpaf7	279	3	data	datum	NNS
cord-034340-3ksfpaf7	279	4	were	be	VBD
cord-034340-3ksfpaf7	279	5	available	available	JJ
cord-034340-3ksfpaf7	279	6	regarding	regard	VBG
cord-034340-3ksfpaf7	279	7	the	the	DT
cord-034340-3ksfpaf7	279	8	involvement	involvement	NN
cord-034340-3ksfpaf7	279	9	of	of	IN
cord-034340-3ksfpaf7	279	10	tendons	tendon	NNS
cord-034340-3ksfpaf7	279	11	and	and	CC
cord-034340-3ksfpaf7	279	12	bursae	bursae	NN
cord-034340-3ksfpaf7	279	13	,	,	,
cord-034340-3ksfpaf7	279	14	since	since	IN
cord-034340-3ksfpaf7	279	15	the	the	DT
cord-034340-3ksfpaf7	279	16	standard	standard	JJ
cord-034340-3ksfpaf7	279	17	joint	joint	JJ
cord-034340-3ksfpaf7	279	18	assessment	assessment	NN
cord-034340-3ksfpaf7	279	19	form	form	NN
cord-034340-3ksfpaf7	279	20	did	do	VBD
cord-034340-3ksfpaf7	279	21	not	not	RB
cord-034340-3ksfpaf7	279	22	include	include	VB
cord-034340-3ksfpaf7	279	23	them	-PRON-	PRP
cord-034340-3ksfpaf7	279	24	.	.	.
cord-034340-3ksfpaf7	280	1	Nonetheless	nonetheless	RB
cord-034340-3ksfpaf7	280	2	,	,	,
cord-034340-3ksfpaf7	280	3	additional	additional	JJ
cord-034340-3ksfpaf7	280	4	4	4	CD
cord-034340-3ksfpaf7	280	5	patients	patient	NNS
cord-034340-3ksfpaf7	280	6	,	,	,
cord-034340-3ksfpaf7	280	7	not	not	RB
cord-034340-3ksfpaf7	280	8	included	include	VBN
cord-034340-3ksfpaf7	280	9	in	in	IN
cord-034340-3ksfpaf7	280	10	the	the	DT
cord-034340-3ksfpaf7	280	11	sample	sample	NN
cord-034340-3ksfpaf7	280	12	analysis	analysis	NN
cord-034340-3ksfpaf7	280	13	,	,	,
cord-034340-3ksfpaf7	280	14	had	have	VBD
cord-034340-3ksfpaf7	280	15	isolated	isolate	VBN
cord-034340-3ksfpaf7	280	16	tenosynovitis	tenosynovitis	JJ
cord-034340-3ksfpaf7	280	17	involvement	involvement	NN
cord-034340-3ksfpaf7	280	18	at	at	IN
cord-034340-3ksfpaf7	280	19	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	280	20	(	(	-LRB-
cord-034340-3ksfpaf7	280	21	n=1	n=1	PDT
cord-034340-3ksfpaf7	280	22	both	both	RB
cord-034340-3ksfpaf7	280	23	-	-	HYPH
cord-034340-3ksfpaf7	280	24	sided	sided	JJ
cord-034340-3ksfpaf7	280	25	ulnar	ulnar	JJ
cord-034340-3ksfpaf7	280	26	extensor	extensor	NN
cord-034340-3ksfpaf7	280	27	tendons	tendon	NNS
cord-034340-3ksfpaf7	280	28	;	;	:
cord-034340-3ksfpaf7	280	29	n=2	n=2	NNS
cord-034340-3ksfpaf7	280	30	isolated	isolate	VBN
cord-034340-3ksfpaf7	280	31	tenosynovitis	tenosynovitis	NNP
cord-034340-3ksfpaf7	280	32	of	of	IN
cord-034340-3ksfpaf7	280	33	the	the	DT
cord-034340-3ksfpaf7	280	34	flexor	flexor	NN
cord-034340-3ksfpaf7	280	35	digiti	digiti	NNP
cord-034340-3ksfpaf7	280	36	proprius	proprius	NN
cord-034340-3ksfpaf7	280	37	;	;	:
cord-034340-3ksfpaf7	280	38	n=1	n=1	NNP
cord-034340-3ksfpaf7	280	39	tenosynovitis	tenosynovitis	NNP
cord-034340-3ksfpaf7	280	40	of	of	IN
cord-034340-3ksfpaf7	280	41	2	2	CD
cord-034340-3ksfpaf7	280	42	flexors	flexor	NNS
cord-034340-3ksfpaf7	280	43	digiti	digiti	NNP
cord-034340-3ksfpaf7	280	44	proprii	proprii	NNP
cord-034340-3ksfpaf7	280	45	)	)	-RRB-
cord-034340-3ksfpaf7	280	46	.	.	.
cord-034340-3ksfpaf7	281	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	281	2	:	:	:
cord-034340-3ksfpaf7	282	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	282	2	study	study	NN
cord-034340-3ksfpaf7	282	3	confirms	confirm	VBZ
cord-034340-3ksfpaf7	282	4	the	the	DT
cord-034340-3ksfpaf7	282	5	knee	knee	NN
cord-034340-3ksfpaf7	282	6	,	,	,
cord-034340-3ksfpaf7	282	7	the	the	DT
cord-034340-3ksfpaf7	282	8	tibiotalar	tibiotalar	NNP
cord-034340-3ksfpaf7	282	9	and	and	CC
cord-034340-3ksfpaf7	282	10	the	the	DT
cord-034340-3ksfpaf7	282	11	wrist	wrist	NN
cord-034340-3ksfpaf7	282	12	as	as	IN
cord-034340-3ksfpaf7	282	13	the	the	DT
cord-034340-3ksfpaf7	282	14	most	most	RBS
cord-034340-3ksfpaf7	282	15	frequently	frequently	RB
cord-034340-3ksfpaf7	282	16	affected	affect	VBN
cord-034340-3ksfpaf7	282	17	joints	joint	NNS
cord-034340-3ksfpaf7	282	18	at	at	IN
cord-034340-3ksfpaf7	282	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	282	20	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	282	21	.	.	.
cord-034340-3ksfpaf7	283	1	On	on	IN
cord-034340-3ksfpaf7	283	2	the	the	DT
cord-034340-3ksfpaf7	283	3	other	other	JJ
cord-034340-3ksfpaf7	283	4	hand	hand	NN
cord-034340-3ksfpaf7	283	5	,	,	,
cord-034340-3ksfpaf7	283	6	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	283	7	sites	site	NNS
cord-034340-3ksfpaf7	283	8	,	,	,
cord-034340-3ksfpaf7	283	9	such	such	JJ
cord-034340-3ksfpaf7	283	10	as	as	IN
cord-034340-3ksfpaf7	283	11	small	small	JJ
cord-034340-3ksfpaf7	283	12	joints	joint	NNS
cord-034340-3ksfpaf7	283	13	of	of	IN
cord-034340-3ksfpaf7	283	14	hands	hand	NNS
cord-034340-3ksfpaf7	283	15	and	and	CC
cord-034340-3ksfpaf7	283	16	feet	foot	NNS
cord-034340-3ksfpaf7	283	17	,	,	,
cord-034340-3ksfpaf7	283	18	the	the	DT
cord-034340-3ksfpaf7	283	19	hip	hip	NN
cord-034340-3ksfpaf7	283	20	and	and	CC
cord-034340-3ksfpaf7	283	21	the	the	DT
cord-034340-3ksfpaf7	283	22	shoulder	shoulder	NN
cord-034340-3ksfpaf7	283	23	,	,	,
cord-034340-3ksfpaf7	283	24	usually	usually	RB
cord-034340-3ksfpaf7	283	25	involved	involve	VBN
cord-034340-3ksfpaf7	283	26	in	in	IN
cord-034340-3ksfpaf7	283	27	polyarticular	polyarticular	JJ
cord-034340-3ksfpaf7	283	28	JIA	JIA	NNP
cord-034340-3ksfpaf7	283	29	,	,	,
cord-034340-3ksfpaf7	283	30	can	can	MD
cord-034340-3ksfpaf7	283	31	be	be	VB
cord-034340-3ksfpaf7	283	32	the	the	DT
cord-034340-3ksfpaf7	283	33	site	site	NN
cord-034340-3ksfpaf7	283	34	of	of	IN
cord-034340-3ksfpaf7	283	35	disease	disease	NN
cord-034340-3ksfpaf7	283	36	presentation	presentation	NN
cord-034340-3ksfpaf7	283	37	in	in	IN
cord-034340-3ksfpaf7	283	38	oligo	oligo	NN
cord-034340-3ksfpaf7	283	39	-	-	:
cord-034340-3ksfpaf7	283	40	and	and	CC
cord-034340-3ksfpaf7	283	41	also	also	RB
cord-034340-3ksfpaf7	283	42	mono	mono	JJ
cord-034340-3ksfpaf7	283	43	-	-	HYPH
cord-034340-3ksfpaf7	283	44	articular	articular	JJ
cord-034340-3ksfpaf7	283	45	JIA	JIA	NNP
cord-034340-3ksfpaf7	283	46	.	.	.
cord-034340-3ksfpaf7	284	1	Further	further	RB
cord-034340-3ksfpaf7	284	2	,	,	,
cord-034340-3ksfpaf7	284	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	284	4	may	may	MD
cord-034340-3ksfpaf7	284	5	present	present	VB
cord-034340-3ksfpaf7	284	6	with	with	IN
cord-034340-3ksfpaf7	284	7	isolated	isolate	VBN
cord-034340-3ksfpaf7	284	8	tendon	tendon	NN
cord-034340-3ksfpaf7	284	9	involvement	involvement	NN
cord-034340-3ksfpaf7	284	10	.	.	.
cord-034340-3ksfpaf7	285	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	285	2	results	result	NNS
cord-034340-3ksfpaf7	285	3	foster	foster	VBP
cord-034340-3ksfpaf7	285	4	not	not	RB
cord-034340-3ksfpaf7	285	5	to	to	TO
cord-034340-3ksfpaf7	285	6	delay	delay	VB
cord-034340-3ksfpaf7	285	7	JIA	JIA	NNP
cord-034340-3ksfpaf7	285	8	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	285	9	in	in	IN
cord-034340-3ksfpaf7	285	10	persistent	persistent	JJ
cord-034340-3ksfpaf7	285	11	synovitis	synovitis	NN
cord-034340-3ksfpaf7	285	12	occurring	occur	VBG
cord-034340-3ksfpaf7	285	13	in	in	IN
cord-034340-3ksfpaf7	285	14	infrequent	infrequent	JJ
cord-034340-3ksfpaf7	285	15	joints	joint	NNS
cord-034340-3ksfpaf7	285	16	and	and	CC
cord-034340-3ksfpaf7	285	17	to	to	TO
cord-034340-3ksfpaf7	285	18	include	include	VB
cord-034340-3ksfpaf7	285	19	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	285	20	sites	site	NNS
cord-034340-3ksfpaf7	285	21	,	,	,
cord-034340-3ksfpaf7	285	22	other	other	JJ
cord-034340-3ksfpaf7	285	23	than	than	IN
cord-034340-3ksfpaf7	285	24	joints	joint	NNS
cord-034340-3ksfpaf7	285	25	,	,	,
cord-034340-3ksfpaf7	285	26	in	in	IN
cord-034340-3ksfpaf7	285	27	the	the	DT
cord-034340-3ksfpaf7	285	28	standard	standard	JJ
cord-034340-3ksfpaf7	285	29	articular	articular	JJ
cord-034340-3ksfpaf7	285	30	evaluation	evaluation	NN
cord-034340-3ksfpaf7	285	31	.	.	.
cord-034340-3ksfpaf7	286	1	This	this	DT
cord-034340-3ksfpaf7	286	2	could	could	MD
cord-034340-3ksfpaf7	286	3	be	be	VB
cord-034340-3ksfpaf7	286	4	realized	realize	VBN
cord-034340-3ksfpaf7	286	5	by	by	IN
cord-034340-3ksfpaf7	286	6	merging	merge	VBG
cord-034340-3ksfpaf7	286	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	286	8	and	and	CC
cord-034340-3ksfpaf7	286	9	imaging	image	VBG
cord-034340-3ksfpaf7	286	10	(	(	-LRB-
cord-034340-3ksfpaf7	286	11	i.e.	i.e.	FW
cord-034340-3ksfpaf7	286	12	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	286	13	)	)	-RRB-
cord-034340-3ksfpaf7	286	14	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	286	15	examinations	examination	NNS
cord-034340-3ksfpaf7	286	16	in	in	IN
cord-034340-3ksfpaf7	286	17	the	the	DT
cord-034340-3ksfpaf7	286	18	same	same	JJ
cord-034340-3ksfpaf7	286	19	assessment	assessment	NN
cord-034340-3ksfpaf7	286	20	.	.	.
cord-034340-3ksfpaf7	287	1	None	none	NN
cord-034340-3ksfpaf7	287	2	declared	declare	VBD
cord-034340-3ksfpaf7	287	3	Introduction	introduction	NN
cord-034340-3ksfpaf7	287	4	:	:	:
cord-034340-3ksfpaf7	287	5	Treatment	treatment	NN
cord-034340-3ksfpaf7	287	6	response	response	NN
cord-034340-3ksfpaf7	287	7	in	in	IN
cord-034340-3ksfpaf7	287	8	JIA	JIA	NNP
cord-034340-3ksfpaf7	287	9	is	be	VBZ
cord-034340-3ksfpaf7	287	10	currently	currently	RB
cord-034340-3ksfpaf7	287	11	viewed	view	VBN
cord-034340-3ksfpaf7	287	12	as	as	IN
cord-034340-3ksfpaf7	287	13	a	a	DT
cord-034340-3ksfpaf7	287	14	binary	binary	JJ
cord-034340-3ksfpaf7	287	15	outcome	outcome	NN
cord-034340-3ksfpaf7	287	16	:	:	:
cord-034340-3ksfpaf7	287	17	response	response	NN
cord-034340-3ksfpaf7	287	18	or	or	CC
cord-034340-3ksfpaf7	287	19	non	non	JJ
cord-034340-3ksfpaf7	287	20	-	-	JJ
cord-034340-3ksfpaf7	287	21	response	response	NN
cord-034340-3ksfpaf7	287	22	.	.	.
cord-034340-3ksfpaf7	288	1	However	however	RB
cord-034340-3ksfpaf7	288	2	,	,	,
cord-034340-3ksfpaf7	288	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	288	4	is	be	VBZ
cord-034340-3ksfpaf7	288	5	a	a	DT
cord-034340-3ksfpaf7	288	6	heterogeneous	heterogeneous	JJ
cord-034340-3ksfpaf7	288	7	disease	disease	NN
cord-034340-3ksfpaf7	288	8	and	and	CC
cord-034340-3ksfpaf7	288	9	it	-PRON-	PRP
cord-034340-3ksfpaf7	288	10	is	be	VBZ
cord-034340-3ksfpaf7	288	11	likely	likely	JJ
cord-034340-3ksfpaf7	288	12	that	that	RB
cord-034340-3ksfpaf7	288	13	different	different	JJ
cord-034340-3ksfpaf7	288	14	,	,	,
cord-034340-3ksfpaf7	288	15	identifiable	identifiable	JJ
cord-034340-3ksfpaf7	288	16	subgroups	subgroup	NNS
cord-034340-3ksfpaf7	288	17	of	of	IN
cord-034340-3ksfpaf7	288	18	children	child	NNS
cord-034340-3ksfpaf7	288	19	and	and	CC
cord-034340-3ksfpaf7	288	20	young	young	JJ
cord-034340-3ksfpaf7	288	21	people	people	NNS
cord-034340-3ksfpaf7	288	22	(	(	-LRB-
cord-034340-3ksfpaf7	288	23	CYP	CYP	NNP
cord-034340-3ksfpaf7	288	24	)	)	-RRB-
cord-034340-3ksfpaf7	288	25	may	may	MD
cord-034340-3ksfpaf7	288	26	demonstrate	demonstrate	VB
cord-034340-3ksfpaf7	288	27	different	different	JJ
cord-034340-3ksfpaf7	288	28	patterns	pattern	NNS
cord-034340-3ksfpaf7	288	29	of	of	IN
cord-034340-3ksfpaf7	288	30	disease	disease	NN
cord-034340-3ksfpaf7	288	31	following	follow	VBG
cord-034340-3ksfpaf7	288	32	treatment	treatment	NN
cord-034340-3ksfpaf7	288	33	.	.	.
cord-034340-3ksfpaf7	289	1	Identifying	identify	VBG
cord-034340-3ksfpaf7	289	2	these	these	DT
cord-034340-3ksfpaf7	289	3	response	response	NN
cord-034340-3ksfpaf7	289	4	subgroups	subgroup	NNS
cord-034340-3ksfpaf7	289	5	can	can	MD
cord-034340-3ksfpaf7	289	6	assist	assist	VB
cord-034340-3ksfpaf7	289	7	the	the	DT
cord-034340-3ksfpaf7	289	8	tailoring	tailoring	NN
cord-034340-3ksfpaf7	289	9	of	of	IN
cord-034340-3ksfpaf7	289	10	stratified	stratified	JJ
cord-034340-3ksfpaf7	289	11	treatment	treatment	NN
cord-034340-3ksfpaf7	289	12	approaches	approach	NNS
cord-034340-3ksfpaf7	289	13	in	in	IN
cord-034340-3ksfpaf7	289	14	JIA	JIA	NNP
cord-034340-3ksfpaf7	289	15	.	.	.
cord-034340-3ksfpaf7	290	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	290	2	:	:	:
cord-034340-3ksfpaf7	290	3	To	to	TO
cord-034340-3ksfpaf7	290	4	identify	identify	VB
cord-034340-3ksfpaf7	290	5	subgroups	subgroup	NNS
cord-034340-3ksfpaf7	290	6	of	of	IN
cord-034340-3ksfpaf7	290	7	CYP	CYP	NNP
cord-034340-3ksfpaf7	290	8	defined	define	VBN
cord-034340-3ksfpaf7	290	9	by	by	IN
cord-034340-3ksfpaf7	290	10	different	different	JJ
cord-034340-3ksfpaf7	290	11	trajectories	trajectory	NNS
cord-034340-3ksfpaf7	290	12	of	of	IN
cord-034340-3ksfpaf7	290	13	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	290	14	arthritis	arthritis	NN
cord-034340-3ksfpaf7	290	15	disease	disease	NN
cord-034340-3ksfpaf7	290	16	activity	activity	NN
cord-034340-3ksfpaf7	290	17	score	score	NN
cord-034340-3ksfpaf7	290	18	(	(	-LRB-
cord-034340-3ksfpaf7	290	19	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	290	20	)	)	-RRB-
cord-034340-3ksfpaf7	290	21	components	component	NNS
cord-034340-3ksfpaf7	290	22	following	follow	VBG
cord-034340-3ksfpaf7	290	23	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	290	24	(	(	-LRB-
cord-034340-3ksfpaf7	290	25	MTX	MTX	NNP
cord-034340-3ksfpaf7	290	26	)	)	-RRB-
cord-034340-3ksfpaf7	290	27	initiation	initiation	NN
cord-034340-3ksfpaf7	290	28	for	for	IN
cord-034340-3ksfpaf7	290	29	JIA	JIA	NNP
cord-034340-3ksfpaf7	290	30	.	.	.
cord-034340-3ksfpaf7	291	1	Methods	method	NNS
cord-034340-3ksfpaf7	291	2	:	:	:
cord-034340-3ksfpaf7	291	3	MTX	mtx	NN
cord-034340-3ksfpaf7	291	4	-	-	HYPH
cord-034340-3ksfpaf7	291	5	naïve	naïve	JJ
cord-034340-3ksfpaf7	291	6	CYP	CYP	NNP
cord-034340-3ksfpaf7	291	7	with	with	IN
cord-034340-3ksfpaf7	291	8	JIA	JIA	NNP
cord-034340-3ksfpaf7	291	9	were	be	VBD
cord-034340-3ksfpaf7	291	10	selected	select	VBN
cord-034340-3ksfpaf7	291	11	if	if	IN
cord-034340-3ksfpaf7	291	12	enrolled	enrol	VBN
cord-034340-3ksfpaf7	291	13	prior	prior	RB
cord-034340-3ksfpaf7	291	14	to	to	IN
cord-034340-3ksfpaf7	291	15	January	January	NNP
cord-034340-3ksfpaf7	291	16	2018	2018	CD
cord-034340-3ksfpaf7	291	17	in	in	IN
cord-034340-3ksfpaf7	291	18	the	the	DT
cord-034340-3ksfpaf7	291	19	BSPAR	BSPAR	NNP
cord-034340-3ksfpaf7	291	20	Etanercept	Etanercept	NNP
cord-034340-3ksfpaf7	291	21	Cohort	Cohort	NNP
cord-034340-3ksfpaf7	291	22	Register	Register	NNP
cord-034340-3ksfpaf7	291	23	or	or	CC
cord-034340-3ksfpaf7	291	24	the	the	DT
cord-034340-3ksfpaf7	291	25	Biologics	Biologics	NNPS
cord-034340-3ksfpaf7	291	26	for	for	IN
cord-034340-3ksfpaf7	291	27	Children	child	NNS
cord-034340-3ksfpaf7	291	28	with	with	IN
cord-034340-3ksfpaf7	291	29	Rheumatic	Rheumatic	NNP
cord-034340-3ksfpaf7	291	30	Diseases	Diseases	NNPS
cord-034340-3ksfpaf7	291	31	Study	Study	NNP
cord-034340-3ksfpaf7	291	32	at	at	IN
cord-034340-3ksfpaf7	291	33	point	point	NN
cord-034340-3ksfpaf7	291	34	of	of	IN
cord-034340-3ksfpaf7	291	35	starting	start	VBG
cord-034340-3ksfpaf7	291	36	MTX	MTX	NNP
cord-034340-3ksfpaf7	291	37	.	.	.
cord-034340-3ksfpaf7	292	1	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	292	2	components	component	NNS
cord-034340-3ksfpaf7	292	3	(	(	-LRB-
cord-034340-3ksfpaf7	292	4	active	active	JJ
cord-034340-3ksfpaf7	292	5	joint	joint	JJ
cord-034340-3ksfpaf7	292	6	count	count	NN
cord-034340-3ksfpaf7	292	7	,	,	,
cord-034340-3ksfpaf7	292	8	physician	physician	NN
cord-034340-3ksfpaf7	292	9	's	's	POS
cord-034340-3ksfpaf7	292	10	global	global	JJ
cord-034340-3ksfpaf7	292	11	assessment	assessment	NN
cord-034340-3ksfpaf7	292	12	(	(	-LRB-
cord-034340-3ksfpaf7	292	13	PGA	PGA	NNP
cord-034340-3ksfpaf7	292	14	,	,	,
cord-034340-3ksfpaf7	292	15	0	0	CD
cord-034340-3ksfpaf7	292	16	-	-	SYM
cord-034340-3ksfpaf7	292	17	10	10	CD
cord-034340-3ksfpaf7	292	18	cm	cm	NNS
cord-034340-3ksfpaf7	292	19	)	)	-RRB-
cord-034340-3ksfpaf7	292	20	,	,	,
cord-034340-3ksfpaf7	292	21	parental	parental	JJ
cord-034340-3ksfpaf7	292	22	global	global	JJ
cord-034340-3ksfpaf7	292	23	evaluation	evaluation	NN
cord-034340-3ksfpaf7	292	24	(	(	-LRB-
cord-034340-3ksfpaf7	292	25	PGE	PGE	NNP
cord-034340-3ksfpaf7	292	26	,	,	,
cord-034340-3ksfpaf7	292	27	0	0	CD
cord-034340-3ksfpaf7	292	28	-	-	SYM
cord-034340-3ksfpaf7	292	29	10	10	CD
cord-034340-3ksfpaf7	292	30	cm	cm	NNS
cord-034340-3ksfpaf7	292	31	)	)	-RRB-
cord-034340-3ksfpaf7	292	32	and	and	CC
cord-034340-3ksfpaf7	292	33	standardised	standardise	VBN
cord-034340-3ksfpaf7	292	34	ESR	ESR	NNP
cord-034340-3ksfpaf7	292	35	(	(	-LRB-
cord-034340-3ksfpaf7	292	36	0	0	CD
cord-034340-3ksfpaf7	292	37	-	-	SYM
cord-034340-3ksfpaf7	292	38	10	10	CD
cord-034340-3ksfpaf7	292	39	)	)	-RRB-
cord-034340-3ksfpaf7	292	40	were	be	VBD
cord-034340-3ksfpaf7	292	41	calculated	calculate	VBN
cord-034340-3ksfpaf7	292	42	based	base	VBN
cord-034340-3ksfpaf7	292	43	on	on	IN
cord-034340-3ksfpaf7	292	44	data	datum	NNS
cord-034340-3ksfpaf7	292	45	collected	collect	VBN
cord-034340-3ksfpaf7	292	46	in	in	IN
cord-034340-3ksfpaf7	292	47	the	the	DT
cord-034340-3ksfpaf7	292	48	year	year	NN
cord-034340-3ksfpaf7	292	49	following	follow	VBG
cord-034340-3ksfpaf7	292	50	MTX	MTX	NNP
cord-034340-3ksfpaf7	292	51	initiation	initiation	NN
cord-034340-3ksfpaf7	292	52	.	.	.
cord-034340-3ksfpaf7	293	1	Multivariate	multivariate	JJ
cord-034340-3ksfpaf7	293	2	group	group	NN
cord-034340-3ksfpaf7	293	3	-	-	HYPH
cord-034340-3ksfpaf7	293	4	based	base	VBN
cord-034340-3ksfpaf7	293	5	trajectory	trajectory	NN
cord-034340-3ksfpaf7	293	6	models	model	NNS
cord-034340-3ksfpaf7	293	7	were	be	VBD
cord-034340-3ksfpaf7	293	8	used	use	VBN
cord-034340-3ksfpaf7	293	9	to	to	TO
cord-034340-3ksfpaf7	293	10	explore	explore	VB
cord-034340-3ksfpaf7	293	11	MTX	MTX	NNP
cord-034340-3ksfpaf7	293	12	response	response	NN
cord-034340-3ksfpaf7	293	13	clusters	cluster	NNS
cord-034340-3ksfpaf7	293	14	across	across	IN
cord-034340-3ksfpaf7	293	15	the	the	DT
cord-034340-3ksfpaf7	293	16	different	different	JJ
cord-034340-3ksfpaf7	293	17	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	293	18	components	component	NNS
cord-034340-3ksfpaf7	293	19	,	,	,
cord-034340-3ksfpaf7	293	20	which	which	WDT
cord-034340-3ksfpaf7	293	21	were	be	VBD
cord-034340-3ksfpaf7	293	22	log1p	log1p	VBN
cord-034340-3ksfpaf7	293	23	transformed	transform	VBN
cord-034340-3ksfpaf7	293	24	for	for	IN
cord-034340-3ksfpaf7	293	25	analysis	analysis	NN
cord-034340-3ksfpaf7	293	26	.	.	.
cord-034340-3ksfpaf7	294	1	Optimal	optimal	JJ
cord-034340-3ksfpaf7	294	2	models	model	NNS
cord-034340-3ksfpaf7	294	3	were	be	VBD
cord-034340-3ksfpaf7	294	4	selected	select	VBN
cord-034340-3ksfpaf7	294	5	based	base	VBN
cord-034340-3ksfpaf7	294	6	on	on	IN
cord-034340-3ksfpaf7	294	7	a	a	DT
cord-034340-3ksfpaf7	294	8	combination	combination	NN
cord-034340-3ksfpaf7	294	9	of	of	IN
cord-034340-3ksfpaf7	294	10	model	model	NN
cord-034340-3ksfpaf7	294	11	fit	fit	JJ
cord-034340-3ksfpaf7	294	12	(	(	-LRB-
cord-034340-3ksfpaf7	294	13	BIC	BIC	NNP
cord-034340-3ksfpaf7	294	14	,	,	,
cord-034340-3ksfpaf7	294	15	relative	relative	JJ
cord-034340-3ksfpaf7	294	16	entropy	entropy	NN
cord-034340-3ksfpaf7	294	17	,	,	,
cord-034340-3ksfpaf7	294	18	average	average	JJ
cord-034340-3ksfpaf7	294	19	posterior	posterior	JJ
cord-034340-3ksfpaf7	294	20	probabilities	probability	NNS
cord-034340-3ksfpaf7	294	21	)	)	-RRB-
cord-034340-3ksfpaf7	294	22	,	,	,
cord-034340-3ksfpaf7	294	23	parsimony	parsimony	NN
cord-034340-3ksfpaf7	294	24	and	and	CC
cord-034340-3ksfpaf7	294	25	clinical	clinical	JJ
cord-034340-3ksfpaf7	294	26	plausibility	plausibility	NN
cord-034340-3ksfpaf7	294	27	.	.	.
cord-034340-3ksfpaf7	295	1	Clinical	clinical	JJ
cord-034340-3ksfpaf7	295	2	and	and	CC
cord-034340-3ksfpaf7	295	3	demographic	demographic	JJ
cord-034340-3ksfpaf7	295	4	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	295	5	and	and	CC
cord-034340-3ksfpaf7	295	6	achievement	achievement	NN
cord-034340-3ksfpaf7	295	7	of	of	IN
cord-034340-3ksfpaf7	295	8	ACR	ACR	NNP
cord-034340-3ksfpaf7	295	9	Pedi	Pedi	NNP
cord-034340-3ksfpaf7	295	10	30/90	30/90	CD
cord-034340-3ksfpaf7	295	11	by	by	IN
cord-034340-3ksfpaf7	295	12	six	six	CD
cord-034340-3ksfpaf7	295	13	months	month	NNS
cord-034340-3ksfpaf7	295	14	were	be	VBD
cord-034340-3ksfpaf7	295	15	compared	compare	VBN
cord-034340-3ksfpaf7	295	16	across	across	IN
cord-034340-3ksfpaf7	295	17	identified	identify	VBN
cord-034340-3ksfpaf7	295	18	groups	group	NNS
cord-034340-3ksfpaf7	295	19	.	.	.
cord-034340-3ksfpaf7	296	1	Results	result	NNS
cord-034340-3ksfpaf7	296	2	:	:	:
cord-034340-3ksfpaf7	297	1	Of	of	IN
cord-034340-3ksfpaf7	297	2	658	658	CD
cord-034340-3ksfpaf7	297	3	CYP	CYP	NNP
cord-034340-3ksfpaf7	297	4	selected	select	VBN
cord-034340-3ksfpaf7	297	5	,	,	,
cord-034340-3ksfpaf7	297	6	the	the	DT
cord-034340-3ksfpaf7	297	7	majority	majority	NN
cord-034340-3ksfpaf7	297	8	were	be	VBD
cord-034340-3ksfpaf7	297	9	female	female	JJ
cord-034340-3ksfpaf7	297	10	(	(	-LRB-
cord-034340-3ksfpaf7	297	11	68	68	CD
cord-034340-3ksfpaf7	297	12	%	%	NN
cord-034340-3ksfpaf7	297	13	)	)	-RRB-
cord-034340-3ksfpaf7	297	14	and	and	CC
cord-034340-3ksfpaf7	297	15	of	of	IN
cord-034340-3ksfpaf7	297	16	white	white	JJ
cord-034340-3ksfpaf7	297	17	ethnicity	ethnicity	NN
cord-034340-3ksfpaf7	297	18	(	(	-LRB-
cord-034340-3ksfpaf7	297	19	86	86	CD
cord-034340-3ksfpaf7	297	20	%	%	NN
cord-034340-3ksfpaf7	297	21	)	)	-RRB-
cord-034340-3ksfpaf7	297	22	,	,	,
cord-034340-3ksfpaf7	297	23	with	with	IN
cord-034340-3ksfpaf7	297	24	RF	rf	NN
cord-034340-3ksfpaf7	297	25	-	-	HYPH
cord-034340-3ksfpaf7	297	26	negative	negative	JJ
cord-034340-3ksfpaf7	297	27	JIA	JIA	NNP
cord-034340-3ksfpaf7	297	28	the	the	DT
cord-034340-3ksfpaf7	297	29	most	most	RBS
cord-034340-3ksfpaf7	297	30	common	common	JJ
cord-034340-3ksfpaf7	297	31	disease	disease	NN
cord-034340-3ksfpaf7	297	32	category	category	NN
cord-034340-3ksfpaf7	297	33	(	(	-LRB-
cord-034340-3ksfpaf7	297	34	35	35	CD
cord-034340-3ksfpaf7	297	35	%	%	NN
cord-034340-3ksfpaf7	297	36	)	)	-RRB-
cord-034340-3ksfpaf7	297	37	.	.	.
cord-034340-3ksfpaf7	298	1	Six	six	CD
cord-034340-3ksfpaf7	298	2	subgroups	subgroup	NNS
cord-034340-3ksfpaf7	298	3	of	of	IN
cord-034340-3ksfpaf7	298	4	CYP	CYP	NNP
cord-034340-3ksfpaf7	298	5	were	be	VBD
cord-034340-3ksfpaf7	298	6	identified	identify	VBN
cord-034340-3ksfpaf7	298	7	with	with	IN
cord-034340-3ksfpaf7	298	8	differing	differ	VBG
cord-034340-3ksfpaf7	298	9	patterns	pattern	NNS
cord-034340-3ksfpaf7	298	10	of	of	IN
cord-034340-3ksfpaf7	298	11	disease	disease	NN
cord-034340-3ksfpaf7	298	12	activity	activity	NN
cord-034340-3ksfpaf7	298	13	following	follow	VBG
cord-034340-3ksfpaf7	298	14	MTX	MTX	NNP
cord-034340-3ksfpaf7	298	15	initiation	initiation	NN
cord-034340-3ksfpaf7	298	16	.	.	.
cord-034340-3ksfpaf7	299	1	Two	two	CD
cord-034340-3ksfpaf7	299	2	groups	group	NNS
cord-034340-3ksfpaf7	299	3	improved	improve	VBD
cord-034340-3ksfpaf7	299	4	across	across	IN
cord-034340-3ksfpaf7	299	5	all	all	DT
cord-034340-3ksfpaf7	299	6	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	299	7	components	component	NNS
cord-034340-3ksfpaf7	299	8	:	:	:
cord-034340-3ksfpaf7	299	9	Fast	fast	JJ
cord-034340-3ksfpaf7	299	10	improvers	improver	NNS
cord-034340-3ksfpaf7	299	11	(	(	-LRB-
cord-034340-3ksfpaf7	299	12	11	11	CD
cord-034340-3ksfpaf7	299	13	%	%	NN
cord-034340-3ksfpaf7	299	14	)	)	-RRB-
cord-034340-3ksfpaf7	299	15	,	,	,
cord-034340-3ksfpaf7	299	16	and	and	CC
cord-034340-3ksfpaf7	299	17	Slow	Slow	NNP
cord-034340-3ksfpaf7	299	18	improvers	improver	NNS
cord-034340-3ksfpaf7	299	19	(	(	-LRB-
cord-034340-3ksfpaf7	299	20	16	16	CD
cord-034340-3ksfpaf7	299	21	%	%	NN
cord-034340-3ksfpaf7	299	22	)	)	-RRB-
cord-034340-3ksfpaf7	299	23	.	.	.
cord-034340-3ksfpaf7	300	1	Persistent	Persistent	NNP
cord-034340-3ksfpaf7	300	2	PGA	PGA	NNP
cord-034340-3ksfpaf7	300	3	(	(	-LRB-
cord-034340-3ksfpaf7	300	4	8	8	CD
cord-034340-3ksfpaf7	300	5	%	%	NN
cord-034340-3ksfpaf7	300	6	)	)	-RRB-
cord-034340-3ksfpaf7	300	7	,	,	,
cord-034340-3ksfpaf7	300	8	and	and	CC
cord-034340-3ksfpaf7	300	9	Persistent	Persistent	NNP
cord-034340-3ksfpaf7	300	10	PGE	PGE	NNP
cord-034340-3ksfpaf7	300	11	(	(	-LRB-
cord-034340-3ksfpaf7	300	12	13	13	CD
cord-034340-3ksfpaf7	300	13	%	%	NN
cord-034340-3ksfpaf7	300	14	)	)	-RRB-
cord-034340-3ksfpaf7	300	15	groups	group	NNS
cord-034340-3ksfpaf7	300	16	maintained	maintain	VBD
cord-034340-3ksfpaf7	300	17	one	one	CD
cord-034340-3ksfpaf7	300	18	persistent	persistent	JJ
cord-034340-3ksfpaf7	300	19	disease	disease	NN
cord-034340-3ksfpaf7	300	20	feature	feature	NN
cord-034340-3ksfpaf7	300	21	but	but	CC
cord-034340-3ksfpaf7	300	22	otherwise	otherwise	RB
cord-034340-3ksfpaf7	300	23	improved	improve	VBN
cord-034340-3ksfpaf7	300	24	.	.	.
cord-034340-3ksfpaf7	301	1	One	one	CD
cord-034340-3ksfpaf7	301	2	group	group	NN
cord-034340-3ksfpaf7	301	3	relapsed	relapse	VBD
cord-034340-3ksfpaf7	301	4	(	(	-LRB-
cord-034340-3ksfpaf7	301	5	7	7	CD
cord-034340-3ksfpaf7	301	6	%	%	NN
cord-034340-3ksfpaf7	301	7	)	)	-RRB-
cord-034340-3ksfpaf7	301	8	and	and	CC
cord-034340-3ksfpaf7	301	9	a	a	DT
cord-034340-3ksfpaf7	301	10	final	final	JJ
cord-034340-3ksfpaf7	301	11	group	group	NN
cord-034340-3ksfpaf7	301	12	had	have	VBD
cord-034340-3ksfpaf7	301	13	persistent	persistent	JJ
cord-034340-3ksfpaf7	301	14	disease	disease	NN
cord-034340-3ksfpaf7	301	15	overall	overall	RB
cord-034340-3ksfpaf7	301	16	(	(	-LRB-
cord-034340-3ksfpaf7	301	17	44	44	CD
cord-034340-3ksfpaf7	301	18	%	%	NN
cord-034340-3ksfpaf7	301	19	)	)	-RRB-
cord-034340-3ksfpaf7	301	20	.	.	.
cord-034340-3ksfpaf7	302	1	There	there	EX
cord-034340-3ksfpaf7	302	2	were	be	VBD
cord-034340-3ksfpaf7	302	3	no	no	DT
cord-034340-3ksfpaf7	302	4	differences	difference	NNS
cord-034340-3ksfpaf7	302	5	in	in	IN
cord-034340-3ksfpaf7	302	6	active	active	JJ
cord-034340-3ksfpaf7	302	7	joint	joint	JJ
cord-034340-3ksfpaf7	302	8	counts	count	NNS
cord-034340-3ksfpaf7	302	9	at	at	IN
cord-034340-3ksfpaf7	302	10	MTX	MTX	NNP
cord-034340-3ksfpaf7	302	11	initiation	initiation	NN
cord-034340-3ksfpaf7	302	12	between	between	IN
cord-034340-3ksfpaf7	302	13	subgroups	subgroup	NNS
cord-034340-3ksfpaf7	302	14	and	and	CC
cord-034340-3ksfpaf7	302	15	all	all	DT
cord-034340-3ksfpaf7	302	16	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	302	17	categories	category	NNS
cord-034340-3ksfpaf7	302	18	were	be	VBD
cord-034340-3ksfpaf7	302	19	represented	represent	VBN
cord-034340-3ksfpaf7	302	20	across	across	IN
cord-034340-3ksfpaf7	302	21	each	each	DT
cord-034340-3ksfpaf7	302	22	subgroup	subgroup	NN
cord-034340-3ksfpaf7	302	23	.	.	.
cord-034340-3ksfpaf7	303	1	However	however	RB
cord-034340-3ksfpaf7	303	2	,	,	,
cord-034340-3ksfpaf7	303	3	CYP	CYP	NNP
cord-034340-3ksfpaf7	303	4	in	in	IN
cord-034340-3ksfpaf7	303	5	persistent	persistent	JJ
cord-034340-3ksfpaf7	303	6	disease	disease	NN
cord-034340-3ksfpaf7	303	7	and	and	CC
cord-034340-3ksfpaf7	303	8	slow	slow	JJ
cord-034340-3ksfpaf7	303	9	improver	improver	NN
cord-034340-3ksfpaf7	303	10	groups	group	NNS
cord-034340-3ksfpaf7	303	11	had	have	VBD
cord-034340-3ksfpaf7	303	12	higher	high	JJR
cord-034340-3ksfpaf7	303	13	CHAQ	CHAQ	NNP
cord-034340-3ksfpaf7	303	14	,	,	,
cord-034340-3ksfpaf7	303	15	PGA	PGA	NNP
cord-034340-3ksfpaf7	303	16	and	and	CC
cord-034340-3ksfpaf7	303	17	PGE	PGE	NNP
cord-034340-3ksfpaf7	303	18	scores	score	NNS
cord-034340-3ksfpaf7	303	19	at	at	IN
cord-034340-3ksfpaf7	303	20	MTX	MTX	NNP
cord-034340-3ksfpaf7	303	21	initiation	initiation	NN
cord-034340-3ksfpaf7	303	22	.	.	.
cord-034340-3ksfpaf7	304	1	Those	those	DT
cord-034340-3ksfpaf7	304	2	with	with	IN
cord-034340-3ksfpaf7	304	3	persistent	persistent	JJ
cord-034340-3ksfpaf7	304	4	disease	disease	NN
cord-034340-3ksfpaf7	304	5	were	be	VBD
cord-034340-3ksfpaf7	304	6	also	also	RB
cord-034340-3ksfpaf7	304	7	older	old	JJR
cord-034340-3ksfpaf7	304	8	at	at	IN
cord-034340-3ksfpaf7	304	9	MTX	MTX	NNP
cord-034340-3ksfpaf7	304	10	initiation	initiation	NN
cord-034340-3ksfpaf7	304	11	.	.	.
cord-034340-3ksfpaf7	305	1	The	the	DT
cord-034340-3ksfpaf7	305	2	majority	majority	NN
cord-034340-3ksfpaf7	305	3	of	of	IN
cord-034340-3ksfpaf7	305	4	CYP	CYP	NNP
cord-034340-3ksfpaf7	305	5	fulfilled	fulfil	VBD
cord-034340-3ksfpaf7	305	6	ACR	ACR	NNP
cord-034340-3ksfpaf7	305	7	Pedi	Pedi	NNP
cord-034340-3ksfpaf7	305	8	30	30	CD
cord-034340-3ksfpaf7	305	9	response	response	NN
cord-034340-3ksfpaf7	305	10	(	(	-LRB-
cord-034340-3ksfpaf7	305	11	>	>	NFP
cord-034340-3ksfpaf7	305	12	60	60	CD
cord-034340-3ksfpaf7	305	13	%	%	NN
cord-034340-3ksfpaf7	305	14	across	across	IN
cord-034340-3ksfpaf7	305	15	every	every	DT
cord-034340-3ksfpaf7	305	16	group	group	NN
cord-034340-3ksfpaf7	305	17	)	)	-RRB-
cord-034340-3ksfpaf7	305	18	.	.	.
cord-034340-3ksfpaf7	306	1	ACR	ACR	NNP
cord-034340-3ksfpaf7	306	2	Pedi	Pedi	NNP
cord-034340-3ksfpaf7	306	3	90	90	CD
cord-034340-3ksfpaf7	306	4	achievement	achievement	NN
cord-034340-3ksfpaf7	306	5	was	be	VBD
cord-034340-3ksfpaf7	306	6	low	low	JJ
cord-034340-3ksfpaf7	306	7	at	at	IN
cord-034340-3ksfpaf7	306	8	6	6	CD
cord-034340-3ksfpaf7	306	9	months	month	NNS
cord-034340-3ksfpaf7	306	10	for	for	IN
cord-034340-3ksfpaf7	306	11	slow	slow	JJ
cord-034340-3ksfpaf7	306	12	improvers	improver	NNS
cord-034340-3ksfpaf7	306	13	(	(	-LRB-
cord-034340-3ksfpaf7	306	14	30	30	CD
cord-034340-3ksfpaf7	306	15	%	%	NN
cord-034340-3ksfpaf7	306	16	)	)	-RRB-
cord-034340-3ksfpaf7	306	17	and	and	CC
cord-034340-3ksfpaf7	306	18	high	high	JJ
cord-034340-3ksfpaf7	306	19	in	in	IN
cord-034340-3ksfpaf7	306	20	the	the	DT
cord-034340-3ksfpaf7	306	21	relapse	relapse	NN
cord-034340-3ksfpaf7	306	22	group	group	NN
cord-034340-3ksfpaf7	306	23	(	(	-LRB-
cord-034340-3ksfpaf7	306	24	68	68	CD
cord-034340-3ksfpaf7	306	25	%	%	NN
cord-034340-3ksfpaf7	306	26	)	)	-RRB-
cord-034340-3ksfpaf7	306	27	.	.	.
cord-034340-3ksfpaf7	307	1	Between	between	IN
cord-034340-3ksfpaf7	307	2	41	41	CD
cord-034340-3ksfpaf7	307	3	%	%	NN
cord-034340-3ksfpaf7	307	4	and	and	CC
cord-034340-3ksfpaf7	307	5	73	73	CD
cord-034340-3ksfpaf7	307	6	%	%	NN
cord-034340-3ksfpaf7	307	7	achieved	achieve	VBD
cord-034340-3ksfpaf7	307	8	ACR	ACR	NNP
cord-034340-3ksfpaf7	307	9	Pedi	Pedi	NNP
cord-034340-3ksfpaf7	307	10	90	90	CD
cord-034340-3ksfpaf7	307	11	response	response	NN
cord-034340-3ksfpaf7	307	12	in	in	IN
cord-034340-3ksfpaf7	307	13	groups	group	NNS
cord-034340-3ksfpaf7	307	14	with	with	IN
cord-034340-3ksfpaf7	307	15	persistent	persistent	JJ
cord-034340-3ksfpaf7	307	16	disease	disease	NN
cord-034340-3ksfpaf7	307	17	in	in	IN
cord-034340-3ksfpaf7	307	18	one	one	CD
cord-034340-3ksfpaf7	307	19	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	307	20	component	component	NN
cord-034340-3ksfpaf7	307	21	.	.	.
cord-034340-3ksfpaf7	308	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	308	2	identify	identify	VBP
cord-034340-3ksfpaf7	308	3	different	different	JJ
cord-034340-3ksfpaf7	308	4	patterns	pattern	NNS
cord-034340-3ksfpaf7	308	5	of	of	IN
cord-034340-3ksfpaf7	308	6	disease	disease	NN
cord-034340-3ksfpaf7	308	7	activity	activity	NN
cord-034340-3ksfpaf7	308	8	within	within	IN
cord-034340-3ksfpaf7	308	9	CYP	CYP	NNP
cord-034340-3ksfpaf7	308	10	initiating	initiate	VBG
cord-034340-3ksfpaf7	308	11	MTX	MTX	NNP
cord-034340-3ksfpaf7	308	12	,	,	,
cord-034340-3ksfpaf7	308	13	suggesting	suggest	VBG
cord-034340-3ksfpaf7	308	14	a	a	DT
cord-034340-3ksfpaf7	308	15	simple	simple	JJ
cord-034340-3ksfpaf7	308	16	responder	responder	NN
cord-034340-3ksfpaf7	308	17	/	/	SYM
cord-034340-3ksfpaf7	308	18	non	non	JJ
cord-034340-3ksfpaf7	308	19	-	-	JJ
cord-034340-3ksfpaf7	308	20	responder	responder	JJ
cord-034340-3ksfpaf7	308	21	analysis	analysis	NN
cord-034340-3ksfpaf7	308	22	at	at	IN
cord-034340-3ksfpaf7	308	23	a	a	DT
cord-034340-3ksfpaf7	308	24	set	set	NN
cord-034340-3ksfpaf7	308	25	point	point	NN
cord-034340-3ksfpaf7	308	26	may	may	MD
cord-034340-3ksfpaf7	308	27	be	be	VB
cord-034340-3ksfpaf7	308	28	over	over	RB
cord-034340-3ksfpaf7	308	29	-	-	HYPH
cord-034340-3ksfpaf7	308	30	simplistic	simplistic	JJ
cord-034340-3ksfpaf7	308	31	.	.	.
cord-034340-3ksfpaf7	309	1	Commonly	commonly	RB
cord-034340-3ksfpaf7	309	2	used	use	VBN
cord-034340-3ksfpaf7	309	3	response	response	NN
cord-034340-3ksfpaf7	309	4	measures	measure	NNS
cord-034340-3ksfpaf7	309	5	did	do	VBD
cord-034340-3ksfpaf7	309	6	not	not	RB
cord-034340-3ksfpaf7	309	7	adequately	adequately	RB
cord-034340-3ksfpaf7	309	8	describe	describe	VB
cord-034340-3ksfpaf7	309	9	these	these	DT
cord-034340-3ksfpaf7	309	10	heterogeneous	heterogeneous	JJ
cord-034340-3ksfpaf7	309	11	response	response	NN
cord-034340-3ksfpaf7	309	12	patterns	pattern	NNS
cord-034340-3ksfpaf7	309	13	.	.	.
cord-034340-3ksfpaf7	310	1	Understanding	understand	VBG
cord-034340-3ksfpaf7	310	2	both	both	DT
cord-034340-3ksfpaf7	310	3	clinical	clinical	JJ
cord-034340-3ksfpaf7	310	4	factors	factor	NNS
cord-034340-3ksfpaf7	310	5	associated	associate	VBN
cord-034340-3ksfpaf7	310	6	with	with	IN
cord-034340-3ksfpaf7	310	7	,	,	,
cord-034340-3ksfpaf7	310	8	and	and	CC
cord-034340-3ksfpaf7	310	9	biological	biological	JJ
cord-034340-3ksfpaf7	310	10	mechanisms	mechanism	NNS
cord-034340-3ksfpaf7	310	11	underpinning	underpin	VBG
cord-034340-3ksfpaf7	310	12	,	,	,
cord-034340-3ksfpaf7	310	13	these	these	DT
cord-034340-3ksfpaf7	310	14	subgroups	subgroup	NNS
cord-034340-3ksfpaf7	310	15	would	would	MD
cord-034340-3ksfpaf7	310	16	aid	aid	VB
cord-034340-3ksfpaf7	310	17	stratified	stratified	JJ
cord-034340-3ksfpaf7	310	18	medicine	medicine	NN
cord-034340-3ksfpaf7	310	19	in	in	IN
cord-034340-3ksfpaf7	310	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	310	21	.	.	.
cord-034340-3ksfpaf7	311	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	311	2	:	:	:
cord-034340-3ksfpaf7	312	1	Despite	despite	IN
cord-034340-3ksfpaf7	312	2	modern	modern	JJ
cord-034340-3ksfpaf7	312	3	treatment	treatment	NN
cord-034340-3ksfpaf7	312	4	and	and	CC
cord-034340-3ksfpaf7	312	5	improved	improved	JJ
cord-034340-3ksfpaf7	312	6	disease	disease	NN
cord-034340-3ksfpaf7	312	7	control	control	NN
cord-034340-3ksfpaf7	312	8	,	,	,
cord-034340-3ksfpaf7	312	9	pain	pain	NN
cord-034340-3ksfpaf7	312	10	is	be	VBZ
cord-034340-3ksfpaf7	312	11	the	the	DT
cord-034340-3ksfpaf7	312	12	most	most	RBS
cord-034340-3ksfpaf7	312	13	common	common	JJ
cord-034340-3ksfpaf7	312	14	complaint	complaint	NN
cord-034340-3ksfpaf7	312	15	in	in	IN
cord-034340-3ksfpaf7	312	16	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	312	17	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	312	18	arthritis	arthritis	NN
cord-034340-3ksfpaf7	312	19	(	(	-LRB-
cord-034340-3ksfpaf7	312	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	312	21	)	)	-RRB-
cord-034340-3ksfpaf7	312	22	.	.	.
cord-034340-3ksfpaf7	313	1	Knowledge	knowledge	NN
cord-034340-3ksfpaf7	313	2	about	about	IN
cord-034340-3ksfpaf7	313	3	pain	pain	NN
cord-034340-3ksfpaf7	313	4	thresholds	threshold	NNS
cord-034340-3ksfpaf7	313	5	and	and	CC
cord-034340-3ksfpaf7	313	6	pain	pain	NN
cord-034340-3ksfpaf7	313	7	sensitivity	sensitivity	NN
cord-034340-3ksfpaf7	313	8	among	among	IN
cord-034340-3ksfpaf7	313	9	young	young	JJ
cord-034340-3ksfpaf7	313	10	adults	adult	NNS
cord-034340-3ksfpaf7	313	11	with	with	IN
cord-034340-3ksfpaf7	313	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	313	13	is	be	VBZ
cord-034340-3ksfpaf7	313	14	sparse	sparse	JJ
cord-034340-3ksfpaf7	313	15	.	.	.
cord-034340-3ksfpaf7	314	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	314	2	:	:	:
cord-034340-3ksfpaf7	314	3	To	to	TO
cord-034340-3ksfpaf7	314	4	study	study	VB
cord-034340-3ksfpaf7	314	5	pressure	pressure	NN
cord-034340-3ksfpaf7	314	6	pain	pain	NN
cord-034340-3ksfpaf7	314	7	thresholds	threshold	NNS
cord-034340-3ksfpaf7	314	8	(	(	-LRB-
cord-034340-3ksfpaf7	314	9	PPTs	ppt	NNS
cord-034340-3ksfpaf7	314	10	)	)	-RRB-
cord-034340-3ksfpaf7	314	11	in	in	IN
cord-034340-3ksfpaf7	314	12	young	young	JJ
cord-034340-3ksfpaf7	314	13	adults	adult	NNS
cord-034340-3ksfpaf7	314	14	with	with	IN
cord-034340-3ksfpaf7	314	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	314	16	,	,	,
cord-034340-3ksfpaf7	314	17	16	16	CD
cord-034340-3ksfpaf7	314	18	years	year	NNS
cord-034340-3ksfpaf7	314	19	after	after	IN
cord-034340-3ksfpaf7	314	20	disease	disease	NN
cord-034340-3ksfpaf7	314	21	onset	onset	NN
cord-034340-3ksfpaf7	314	22	compared	compare	VBN
cord-034340-3ksfpaf7	314	23	with	with	IN
cord-034340-3ksfpaf7	314	24	controls	control	NNS
cord-034340-3ksfpaf7	314	25	.	.	.
cord-034340-3ksfpaf7	315	1	Methods	method	NNS
cord-034340-3ksfpaf7	315	2	:	:	:
cord-034340-3ksfpaf7	315	3	Consecutive	consecutive	JJ
cord-034340-3ksfpaf7	315	4	newly	newly	RB
cord-034340-3ksfpaf7	315	5	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	315	6	children	child	NNS
cord-034340-3ksfpaf7	315	7	with	with	IN
cord-034340-3ksfpaf7	315	8	JIA	JIA	NNP
cord-034340-3ksfpaf7	315	9	and	and	CC
cord-034340-3ksfpaf7	315	10	a	a	DT
cord-034340-3ksfpaf7	315	11	disease	disease	NN
cord-034340-3ksfpaf7	315	12	onset	onset	NN
cord-034340-3ksfpaf7	315	13	between	between	IN
cord-034340-3ksfpaf7	315	14	1997	1997	CD
cord-034340-3ksfpaf7	315	15	-	-	SYM
cord-034340-3ksfpaf7	315	16	2004	2004	CD
cord-034340-3ksfpaf7	315	17	from	from	IN
cord-034340-3ksfpaf7	315	18	Central	Central	NNP
cord-034340-3ksfpaf7	315	19	Norway	Norway	NNP
cord-034340-3ksfpaf7	315	20	,	,	,
cord-034340-3ksfpaf7	315	21	were	be	VBD
cord-034340-3ksfpaf7	315	22	included	include	VBN
cord-034340-3ksfpaf7	315	23	in	in	IN
cord-034340-3ksfpaf7	315	24	this	this	DT
cord-034340-3ksfpaf7	315	25	prospective	prospective	JJ
cord-034340-3ksfpaf7	315	26	population	population	NN
cord-034340-3ksfpaf7	315	27	-	-	HYPH
cord-034340-3ksfpaf7	315	28	based	base	VBN
cord-034340-3ksfpaf7	315	29	long	long	JJ
cord-034340-3ksfpaf7	315	30	-	-	HYPH
cord-034340-3ksfpaf7	315	31	term	term	NN
cord-034340-3ksfpaf7	315	32	follow	follow	NN
cord-034340-3ksfpaf7	315	33	-	-	HYPH
cord-034340-3ksfpaf7	315	34	up	up	NN
cord-034340-3ksfpaf7	315	35	study	study	NN
cord-034340-3ksfpaf7	315	36	.	.	.
cord-034340-3ksfpaf7	316	1	Children	child	NNS
cord-034340-3ksfpaf7	316	2	with	with	IN
cord-034340-3ksfpaf7	316	3	onset	onset	NN
cord-034340-3ksfpaf7	316	4	1997	1997	CD
cord-034340-3ksfpaf7	316	5	-	-	SYM
cord-034340-3ksfpaf7	316	6	2000	2000	CD
cord-034340-3ksfpaf7	316	7	were	be	VBD
cord-034340-3ksfpaf7	316	8	part	part	NN
cord-034340-3ksfpaf7	316	9	of	of	IN
cord-034340-3ksfpaf7	316	10	the	the	DT
cord-034340-3ksfpaf7	316	11	Nordic	Nordic	NNP
cord-034340-3ksfpaf7	316	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	316	13	cohort	cohort	NN
cord-034340-3ksfpaf7	316	14	1,2	1,2	CD
cord-034340-3ksfpaf7	316	15	.	.	.
cord-034340-3ksfpaf7	317	1	Age	age	NN
cord-034340-3ksfpaf7	317	2	-	-	HYPH
cord-034340-3ksfpaf7	317	3	and	and	CC
cord-034340-3ksfpaf7	317	4	sex	sex	NN
cord-034340-3ksfpaf7	317	5	-	-	HYPH
cord-034340-3ksfpaf7	317	6	matched	match	VBN
cord-034340-3ksfpaf7	317	7	controls	control	NNS
cord-034340-3ksfpaf7	317	8	were	be	VBD
cord-034340-3ksfpaf7	317	9	drawn	draw	VBN
cord-034340-3ksfpaf7	317	10	from	from	IN
cord-034340-3ksfpaf7	317	11	the	the	DT
cord-034340-3ksfpaf7	317	12	National	National	NNP
cord-034340-3ksfpaf7	317	13	Population	Population	NNP
cord-034340-3ksfpaf7	317	14	Register	Register	NNP
cord-034340-3ksfpaf7	317	15	of	of	IN
cord-034340-3ksfpaf7	317	16	Norway	Norway	NNP
cord-034340-3ksfpaf7	317	17	.	.	.
cord-034340-3ksfpaf7	318	1	Inactive	inactive	JJ
cord-034340-3ksfpaf7	318	2	disease	disease	NN
cord-034340-3ksfpaf7	318	3	and	and	CC
cord-034340-3ksfpaf7	318	4	remission	remission	NN
cord-034340-3ksfpaf7	318	5	were	be	VBD
cord-034340-3ksfpaf7	318	6	defined	define	VBN
cord-034340-3ksfpaf7	318	7	according	accord	VBG
cord-034340-3ksfpaf7	318	8	to	to	IN
cord-034340-3ksfpaf7	318	9	Wallace	Wallace	NNP
cord-034340-3ksfpaf7	318	10	3	3	CD
cord-034340-3ksfpaf7	318	11	,	,	,
cord-034340-3ksfpaf7	318	12	4	4	CD
cord-034340-3ksfpaf7	318	13	.	.	.
cord-034340-3ksfpaf7	319	1	At	at	IN
cord-034340-3ksfpaf7	319	2	the	the	DT
cord-034340-3ksfpaf7	319	3	follow	follow	NN
cord-034340-3ksfpaf7	319	4	-	-	HYPH
cord-034340-3ksfpaf7	319	5	up	up	NN
cord-034340-3ksfpaf7	319	6	between	between	IN
cord-034340-3ksfpaf7	319	7	2015	2015	CD
cord-034340-3ksfpaf7	319	8	-	-	SYM
cord-034340-3ksfpaf7	319	9	17	17	CD
cord-034340-3ksfpaf7	319	10	,	,	,
cord-034340-3ksfpaf7	319	11	data	datum	NNS
cord-034340-3ksfpaf7	319	12	from	from	IN
cord-034340-3ksfpaf7	319	13	a	a	DT
cord-034340-3ksfpaf7	319	14	clinical	clinical	JJ
cord-034340-3ksfpaf7	319	15	examination	examination	NN
cord-034340-3ksfpaf7	319	16	and	and	CC
cord-034340-3ksfpaf7	319	17	blood	blood	NN
cord-034340-3ksfpaf7	319	18	tests	test	NNS
cord-034340-3ksfpaf7	319	19	were	be	VBD
cord-034340-3ksfpaf7	319	20	included	include	VBN
cord-034340-3ksfpaf7	319	21	in	in	IN
cord-034340-3ksfpaf7	319	22	addition	addition	NN
cord-034340-3ksfpaf7	319	23	to	to	IN
cord-034340-3ksfpaf7	319	24	an	an	DT
cord-034340-3ksfpaf7	319	25	investigator	investigator	NN
cord-034340-3ksfpaf7	319	26	-	-	HYPH
cord-034340-3ksfpaf7	319	27	blinded	blind	VBN
cord-034340-3ksfpaf7	319	28	quantification	quantification	NN
cord-034340-3ksfpaf7	319	29	of	of	IN
cord-034340-3ksfpaf7	319	30	PPTs	ppt	NNS
cord-034340-3ksfpaf7	319	31	.	.	.
cord-034340-3ksfpaf7	320	1	A	a	DT
cord-034340-3ksfpaf7	320	2	digital	digital	JJ
cord-034340-3ksfpaf7	320	3	algometer	algometer	NN
cord-034340-3ksfpaf7	320	4	was	be	VBD
cord-034340-3ksfpaf7	320	5	used	use	VBN
cord-034340-3ksfpaf7	320	6	to	to	TO
cord-034340-3ksfpaf7	320	7	manually	manually	RB
cord-034340-3ksfpaf7	320	8	apply	apply	VB
cord-034340-3ksfpaf7	320	9	pressure	pressure	NN
cord-034340-3ksfpaf7	320	10	three	three	CD
cord-034340-3ksfpaf7	320	11	times	time	NNS
cord-034340-3ksfpaf7	320	12	with	with	IN
cord-034340-3ksfpaf7	320	13	an	an	DT
cord-034340-3ksfpaf7	320	14	even	even	JJ
cord-034340-3ksfpaf7	320	15	rate	rate	NN
cord-034340-3ksfpaf7	320	16	at	at	IN
cord-034340-3ksfpaf7	320	17	the	the	DT
cord-034340-3ksfpaf7	320	18	upper	upper	JJ
cord-034340-3ksfpaf7	320	19	and	and	CC
cord-034340-3ksfpaf7	320	20	lower	low	JJR
cord-034340-3ksfpaf7	320	21	limb	limb	NN
cord-034340-3ksfpaf7	320	22	.	.	.
cord-034340-3ksfpaf7	321	1	PPTs	ppt	NNS
cord-034340-3ksfpaf7	321	2	from	from	IN
cord-034340-3ksfpaf7	321	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	321	4	and	and	CC
cord-034340-3ksfpaf7	321	5	controls	control	VBZ
cord-034340-3ksfpaf7	321	6	,	,	,
cord-034340-3ksfpaf7	321	7	and	and	CC
cord-034340-3ksfpaf7	321	8	from	from	IN
cord-034340-3ksfpaf7	321	9	subgroups	subgroup	NNS
cord-034340-3ksfpaf7	321	10	of	of	IN
cord-034340-3ksfpaf7	321	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	321	12	defined	define	VBN
cord-034340-3ksfpaf7	321	13	by	by	IN
cord-034340-3ksfpaf7	321	14	disease	disease	NN
cord-034340-3ksfpaf7	321	15	status	status	NN
cord-034340-3ksfpaf7	321	16	,	,	,
cord-034340-3ksfpaf7	321	17	were	be	VBD
cord-034340-3ksfpaf7	321	18	compared	compare	VBN
cord-034340-3ksfpaf7	321	19	with	with	IN
cord-034340-3ksfpaf7	321	20	multilevel	multilevel	JJ
cord-034340-3ksfpaf7	321	21	models	model	NNS
cord-034340-3ksfpaf7	321	22	in	in	IN
cord-034340-3ksfpaf7	321	23	STATA	STATA	NNP
cord-034340-3ksfpaf7	321	24	.	.	.
cord-034340-3ksfpaf7	322	1	Results	result	NNS
cord-034340-3ksfpaf7	322	2	:	:	:
cord-034340-3ksfpaf7	323	1	Among	among	IN
cord-034340-3ksfpaf7	323	2	the	the	DT
cord-034340-3ksfpaf7	323	3	96	96	CD
cord-034340-3ksfpaf7	323	4	participants	participant	NNS
cord-034340-3ksfpaf7	323	5	with	with	IN
cord-034340-3ksfpaf7	323	6	JIA	JIA	NNP
cord-034340-3ksfpaf7	323	7	,	,	,
cord-034340-3ksfpaf7	323	8	71	71	CD
cord-034340-3ksfpaf7	323	9	%	%	NN
cord-034340-3ksfpaf7	323	10	were	be	VBD
cord-034340-3ksfpaf7	323	11	female	female	JJ
cord-034340-3ksfpaf7	323	12	,	,	,
cord-034340-3ksfpaf7	323	13	median	median	JJ
cord-034340-3ksfpaf7	323	14	age	age	NN
cord-034340-3ksfpaf7	323	15	was	be	VBD
cord-034340-3ksfpaf7	323	16	22.7	22.7	CD
cord-034340-3ksfpaf7	324	1	(	(	-LRB-
cord-034340-3ksfpaf7	324	2	IQR	IQR	NNP
cord-034340-3ksfpaf7	324	3	18.7	18.7	CD
cord-034340-3ksfpaf7	324	4	-	-	HYPH
cord-034340-3ksfpaf7	324	5	26.2	26.2	CD
cord-034340-3ksfpaf7	324	6	)	)	-RRB-
cord-034340-3ksfpaf7	324	7	years	year	NNS
cord-034340-3ksfpaf7	324	8	,	,	,
cord-034340-3ksfpaf7	324	9	median	median	JJ
cord-034340-3ksfpaf7	324	10	disease	disease	NN
cord-034340-3ksfpaf7	324	11	duration	duration	NN
cord-034340-3ksfpaf7	324	12	was	be	VBD
cord-034340-3ksfpaf7	324	13	16.1	16.1	CD
cord-034340-3ksfpaf7	325	1	(	(	-LRB-
cord-034340-3ksfpaf7	325	2	IQR	IQR	NNP
cord-034340-3ksfpaf7	325	3	14.2	14.2	CD
cord-034340-3ksfpaf7	325	4	-	-	HYPH
cord-034340-3ksfpaf7	325	5	17.1	17.1	CD
cord-034340-3ksfpaf7	325	6	)	)	-RRB-
cord-034340-3ksfpaf7	325	7	years	year	NNS
cord-034340-3ksfpaf7	325	8	,	,	,
cord-034340-3ksfpaf7	325	9	47	47	CD
cord-034340-3ksfpaf7	325	10	%	%	NN
cord-034340-3ksfpaf7	325	11	had	have	VBD
cord-034340-3ksfpaf7	325	12	an	an	DT
cord-034340-3ksfpaf7	325	13	oligoarticular	oligoarticular	JJ
cord-034340-3ksfpaf7	325	14	disease	disease	NN
cord-034340-3ksfpaf7	325	15	(	(	-LRB-
cord-034340-3ksfpaf7	325	16	persistent	persistent	JJ
cord-034340-3ksfpaf7	325	17	or	or	CC
cord-034340-3ksfpaf7	325	18	extended	extended	JJ
cord-034340-3ksfpaf7	325	19	)	)	-RRB-
cord-034340-3ksfpaf7	325	20	,	,	,
cord-034340-3ksfpaf7	325	21	and	and	CC
cord-034340-3ksfpaf7	325	22	45	45	CD
cord-034340-3ksfpaf7	325	23	%	%	NN
cord-034340-3ksfpaf7	325	24	were	be	VBD
cord-034340-3ksfpaf7	325	25	in	in	IN
cord-034340-3ksfpaf7	325	26	remission	remission	NN
cord-034340-3ksfpaf7	325	27	off	off	IN
cord-034340-3ksfpaf7	325	28	medication	medication	NN
cord-034340-3ksfpaf7	325	29	.	.	.
cord-034340-3ksfpaf7	326	1	In	in	IN
cord-034340-3ksfpaf7	326	2	the	the	DT
cord-034340-3ksfpaf7	326	3	control	control	NN
cord-034340-3ksfpaf7	326	4	group	group	NN
cord-034340-3ksfpaf7	326	5	,	,	,
cord-034340-3ksfpaf7	326	6	71	71	CD
cord-034340-3ksfpaf7	326	7	%	%	NN
cord-034340-3ksfpaf7	326	8	were	be	VBD
cord-034340-3ksfpaf7	326	9	female	female	JJ
cord-034340-3ksfpaf7	326	10	and	and	CC
cord-034340-3ksfpaf7	326	11	median	median	JJ
cord-034340-3ksfpaf7	326	12	age	age	NN
cord-034340-3ksfpaf7	326	13	was	be	VBD
cord-034340-3ksfpaf7	326	14	23.5	23.5	CD
cord-034340-3ksfpaf7	326	15	(	(	-LRB-
cord-034340-3ksfpaf7	326	16	IQR	IQR	NNP
cord-034340-3ksfpaf7	326	17	20.2	20.2	CD
cord-034340-3ksfpaf7	326	18	-	-	HYPH
cord-034340-3ksfpaf7	326	19	26.7	26.7	CD
cord-034340-3ksfpaf7	326	20	)	)	-RRB-
cord-034340-3ksfpaf7	326	21	years	year	NNS
cord-034340-3ksfpaf7	326	22	.	.	.
cord-034340-3ksfpaf7	327	1	Results	result	NNS
cord-034340-3ksfpaf7	327	2	from	from	IN
cord-034340-3ksfpaf7	327	3	the	the	DT
cord-034340-3ksfpaf7	327	4	multilevel	multilevel	JJ
cord-034340-3ksfpaf7	327	5	regression	regression	NN
cord-034340-3ksfpaf7	327	6	model	model	NN
cord-034340-3ksfpaf7	327	7	showed	show	VBD
cord-034340-3ksfpaf7	327	8	significantly	significantly	RB
cord-034340-3ksfpaf7	327	9	lower	low	JJR
cord-034340-3ksfpaf7	327	10	PPTs	ppt	NNS
cord-034340-3ksfpaf7	327	11	among	among	IN
cord-034340-3ksfpaf7	327	12	participants	participant	NNS
cord-034340-3ksfpaf7	327	13	with	with	IN
cord-034340-3ksfpaf7	327	14	JIA	JIA	NNP
cord-034340-3ksfpaf7	327	15	compared	compare	VBD
cord-034340-3ksfpaf7	327	16	to	to	IN
cord-034340-3ksfpaf7	327	17	controls	control	NNS
cord-034340-3ksfpaf7	327	18	(	(	-LRB-
cord-034340-3ksfpaf7	327	19	Table	table	NN
cord-034340-3ksfpaf7	327	20	1	1	CD
cord-034340-3ksfpaf7	327	21	)	)	-RRB-
cord-034340-3ksfpaf7	327	22	.	.	.
cord-034340-3ksfpaf7	328	1	In	in	IN
cord-034340-3ksfpaf7	328	2	the	the	DT
cord-034340-3ksfpaf7	328	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	328	4	group	group	NN
cord-034340-3ksfpaf7	328	5	,	,	,
cord-034340-3ksfpaf7	328	6	participants	participant	NNS
cord-034340-3ksfpaf7	328	7	with	with	IN
cord-034340-3ksfpaf7	328	8	inactive	inactive	JJ
cord-034340-3ksfpaf7	328	9	disease	disease	NN
cord-034340-3ksfpaf7	328	10	had	have	VBD
cord-034340-3ksfpaf7	328	11	lower	low	JJR
cord-034340-3ksfpaf7	328	12	PPTs	ppt	NNS
cord-034340-3ksfpaf7	328	13	than	than	IN
cord-034340-3ksfpaf7	328	14	both	both	CC
cord-034340-3ksfpaf7	328	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	328	16	in	in	IN
cord-034340-3ksfpaf7	328	17	remission	remission	NN
cord-034340-3ksfpaf7	328	18	off	off	IN
cord-034340-3ksfpaf7	328	19	medication	medication	NN
cord-034340-3ksfpaf7	328	20	and	and	CC
cord-034340-3ksfpaf7	328	21	JIA	JIA	NNP
cord-034340-3ksfpaf7	328	22	with	with	IN
cord-034340-3ksfpaf7	328	23	active	active	JJ
cord-034340-3ksfpaf7	328	24	disease	disease	NN
cord-034340-3ksfpaf7	328	25	(	(	-LRB-
cord-034340-3ksfpaf7	328	26	Table	table	NN
cord-034340-3ksfpaf7	328	27	1	1	CD
cord-034340-3ksfpaf7	328	28	)	)	-RRB-
cord-034340-3ksfpaf7	328	29	.	.	.
cord-034340-3ksfpaf7	329	1	The	the	DT
cord-034340-3ksfpaf7	329	2	results	result	NNS
cord-034340-3ksfpaf7	329	3	were	be	VBD
cord-034340-3ksfpaf7	329	4	consistent	consistent	JJ
cord-034340-3ksfpaf7	329	5	for	for	IN
cord-034340-3ksfpaf7	329	6	both	both	CC
cord-034340-3ksfpaf7	329	7	upper	upper	JJ
cord-034340-3ksfpaf7	329	8	and	and	CC
cord-034340-3ksfpaf7	329	9	lower	low	JJR
cord-034340-3ksfpaf7	329	10	limb	limb	NN
cord-034340-3ksfpaf7	329	11	.	.	.
cord-034340-3ksfpaf7	330	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	330	2	:	:	:
cord-034340-3ksfpaf7	331	1	In	in	IN
cord-034340-3ksfpaf7	331	2	this	this	DT
cord-034340-3ksfpaf7	331	3	long	long	JJ
cord-034340-3ksfpaf7	331	4	-	-	HYPH
cord-034340-3ksfpaf7	331	5	term	term	NN
cord-034340-3ksfpaf7	331	6	follow	follow	NN
cord-034340-3ksfpaf7	331	7	-	-	HYPH
cord-034340-3ksfpaf7	331	8	up	up	NN
cord-034340-3ksfpaf7	331	9	study	study	NN
cord-034340-3ksfpaf7	331	10	of	of	IN
cord-034340-3ksfpaf7	331	11	young	young	JJ
cord-034340-3ksfpaf7	331	12	adults	adult	NNS
cord-034340-3ksfpaf7	331	13	with	with	IN
cord-034340-3ksfpaf7	331	14	JIA	JIA	NNP
cord-034340-3ksfpaf7	331	15	,	,	,
cord-034340-3ksfpaf7	331	16	we	-PRON-	PRP
cord-034340-3ksfpaf7	331	17	found	find	VBD
cord-034340-3ksfpaf7	331	18	significantly	significantly	RB
cord-034340-3ksfpaf7	331	19	lower	low	JJR
cord-034340-3ksfpaf7	331	20	PPTs	ppt	NNS
cord-034340-3ksfpaf7	331	21	compared	compare	VBN
cord-034340-3ksfpaf7	331	22	to	to	IN
cord-034340-3ksfpaf7	331	23	controls	control	NNS
cord-034340-3ksfpaf7	331	24	.	.	.
cord-034340-3ksfpaf7	332	1	This	this	DT
cord-034340-3ksfpaf7	332	2	may	may	MD
cord-034340-3ksfpaf7	332	3	indicate	indicate	VB
cord-034340-3ksfpaf7	332	4	that	that	IN
cord-034340-3ksfpaf7	332	5	young	young	JJ
cord-034340-3ksfpaf7	332	6	adults	adult	NNS
cord-034340-3ksfpaf7	332	7	with	with	IN
cord-034340-3ksfpaf7	332	8	JIA	JIA	NNP
cord-034340-3ksfpaf7	332	9	have	have	VBP
cord-034340-3ksfpaf7	332	10	altered	alter	VBN
cord-034340-3ksfpaf7	332	11	pain	pain	NN
cord-034340-3ksfpaf7	332	12	sensitivity	sensitivity	NN
cord-034340-3ksfpaf7	332	13	possibly	possibly	RB
cord-034340-3ksfpaf7	332	14	due	due	JJ
cord-034340-3ksfpaf7	332	15	to	to	IN
cord-034340-3ksfpaf7	332	16	accumulated	accumulate	VBN
cord-034340-3ksfpaf7	332	17	earlier	early	JJR
cord-034340-3ksfpaf7	332	18	pain	pain	NN
cord-034340-3ksfpaf7	332	19	experiences	experience	NNS
cord-034340-3ksfpaf7	332	20	.	.	.
cord-034340-3ksfpaf7	333	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	333	2	:	:	:
cord-034340-3ksfpaf7	334	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	334	2	Idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	334	3	Arthritis	arthritis	NN
cord-034340-3ksfpaf7	334	4	(	(	-LRB-
cord-034340-3ksfpaf7	334	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	334	6	)	)	-RRB-
cord-034340-3ksfpaf7	334	7	represents	represent	VBZ
cord-034340-3ksfpaf7	334	8	the	the	DT
cord-034340-3ksfpaf7	334	9	most	most	RBS
cord-034340-3ksfpaf7	334	10	common	common	JJ
cord-034340-3ksfpaf7	334	11	chronic	chronic	JJ
cord-034340-3ksfpaf7	334	12	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	334	13	disease	disease	NN
cord-034340-3ksfpaf7	334	14	in	in	IN
cord-034340-3ksfpaf7	334	15	childhood	childhood	NN
cord-034340-3ksfpaf7	334	16	.	.	.
cord-034340-3ksfpaf7	335	1	Non	non	JJ
cord-034340-3ksfpaf7	335	2	-	-	JJ
cord-034340-3ksfpaf7	335	3	steroidal	steroidal	JJ
cord-034340-3ksfpaf7	335	4	antiinflammatory	antiinflammatory	JJ
cord-034340-3ksfpaf7	335	5	drugs	drug	NNS
cord-034340-3ksfpaf7	335	6	(	(	-LRB-
cord-034340-3ksfpaf7	335	7	NSAIDs	NSAIDs	NNP
cord-034340-3ksfpaf7	335	8	)	)	-RRB-
cord-034340-3ksfpaf7	335	9	and	and	CC
cord-034340-3ksfpaf7	335	10	intra	intra	JJ
cord-034340-3ksfpaf7	335	11	-	-	JJ
cord-034340-3ksfpaf7	335	12	articular	articular	JJ
cord-034340-3ksfpaf7	335	13	steroids	steroid	NNS
cord-034340-3ksfpaf7	335	14	are	be	VBP
cord-034340-3ksfpaf7	335	15	the	the	DT
cord-034340-3ksfpaf7	335	16	first	first	JJ
cord-034340-3ksfpaf7	335	17	line	line	NN
cord-034340-3ksfpaf7	335	18	treatment	treatment	NN
cord-034340-3ksfpaf7	335	19	for	for	IN
cord-034340-3ksfpaf7	335	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	335	21	.	.	.
cord-034340-3ksfpaf7	336	1	Systemic	systemic	JJ
cord-034340-3ksfpaf7	336	2	steroids	steroid	NNS
cord-034340-3ksfpaf7	336	3	,	,	,
cord-034340-3ksfpaf7	336	4	disease	disease	NN
cord-034340-3ksfpaf7	336	5	modifying	modify	VBG
cord-034340-3ksfpaf7	336	6	antirheumatic	antirheumatic	JJ
cord-034340-3ksfpaf7	336	7	drugs	drug	NNS
cord-034340-3ksfpaf7	336	8	(	(	-LRB-
cord-034340-3ksfpaf7	336	9	DMARDs	dmard	NNS
cord-034340-3ksfpaf7	336	10	)	)	-RRB-
cord-034340-3ksfpaf7	336	11	and	and	CC
cord-034340-3ksfpaf7	336	12	biologic	biologic	JJ
cord-034340-3ksfpaf7	336	13	drugs	drug	NNS
cord-034340-3ksfpaf7	336	14	are	be	VBP
cord-034340-3ksfpaf7	336	15	used	use	VBN
cord-034340-3ksfpaf7	336	16	in	in	IN
cord-034340-3ksfpaf7	336	17	children	child	NNS
cord-034340-3ksfpaf7	336	18	with	with	IN
cord-034340-3ksfpaf7	336	19	severe	severe	JJ
cord-034340-3ksfpaf7	336	20	disease	disease	NN
cord-034340-3ksfpaf7	336	21	.	.	.
cord-034340-3ksfpaf7	337	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	337	2	is	be	VBZ
cord-034340-3ksfpaf7	337	3	not	not	RB
cord-034340-3ksfpaf7	337	4	possible	possible	JJ
cord-034340-3ksfpaf7	337	5	at	at	IN
cord-034340-3ksfpaf7	337	6	onset	onset	NN
cord-034340-3ksfpaf7	337	7	of	of	IN
cord-034340-3ksfpaf7	337	8	disease	disease	NN
cord-034340-3ksfpaf7	337	9	to	to	TO
cord-034340-3ksfpaf7	337	10	predict	predict	VB
cord-034340-3ksfpaf7	337	11	when	when	WRB
cord-034340-3ksfpaf7	337	12	a	a	DT
cord-034340-3ksfpaf7	337	13	child	child	NN
cord-034340-3ksfpaf7	337	14	can	can	MD
cord-034340-3ksfpaf7	337	15	suspend	suspend	VB
cord-034340-3ksfpaf7	337	16	pharmacological	pharmacological	JJ
cord-034340-3ksfpaf7	337	17	treatment	treatment	NN
cord-034340-3ksfpaf7	337	18	,	,	,
cord-034340-3ksfpaf7	337	19	so	so	IN
cord-034340-3ksfpaf7	337	20	children	child	NNS
cord-034340-3ksfpaf7	337	21	affected	affect	VBN
cord-034340-3ksfpaf7	337	22	from	from	IN
cord-034340-3ksfpaf7	337	23	JIA	JIA	NNP
cord-034340-3ksfpaf7	337	24	have	have	VBP
cord-034340-3ksfpaf7	337	25	to	to	TO
cord-034340-3ksfpaf7	337	26	continue	continue	VB
cord-034340-3ksfpaf7	337	27	pharmacological	pharmacological	JJ
cord-034340-3ksfpaf7	337	28	treatment	treatment	NN
cord-034340-3ksfpaf7	337	29	for	for	IN
cord-034340-3ksfpaf7	337	30	several	several	JJ
cord-034340-3ksfpaf7	337	31	months	month	NNS
cord-034340-3ksfpaf7	337	32	or	or	CC
cord-034340-3ksfpaf7	337	33	years	year	NNS
cord-034340-3ksfpaf7	337	34	.	.	.
cord-034340-3ksfpaf7	338	1	Anecdotal	anecdotal	JJ
cord-034340-3ksfpaf7	338	2	reports	report	NNS
cord-034340-3ksfpaf7	338	3	showed	show	VBD
cord-034340-3ksfpaf7	338	4	that	that	IN
cord-034340-3ksfpaf7	338	5	rarely	rarely	RB
cord-034340-3ksfpaf7	338	6	JIA	JIA	NNP
cord-034340-3ksfpaf7	338	7	could	could	MD
cord-034340-3ksfpaf7	338	8	present	present	VB
cord-034340-3ksfpaf7	338	9	renal	renal	JJ
cord-034340-3ksfpaf7	338	10	involvement	involvement	NN
cord-034340-3ksfpaf7	338	11	due	due	IN
cord-034340-3ksfpaf7	338	12	to	to	IN
cord-034340-3ksfpaf7	338	13	uncontrolled	uncontrolled	JJ
cord-034340-3ksfpaf7	338	14	inflammation	inflammation	NN
cord-034340-3ksfpaf7	338	15	or	or	CC
cord-034340-3ksfpaf7	338	16	to	to	IN
cord-034340-3ksfpaf7	338	17	long	long	JJ
cord-034340-3ksfpaf7	338	18	exposure	exposure	NN
cord-034340-3ksfpaf7	338	19	to	to	IN
cord-034340-3ksfpaf7	338	20	drugs	drug	NNS
cord-034340-3ksfpaf7	338	21	.	.	.
cord-034340-3ksfpaf7	339	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	339	2	:	:	:
cord-034340-3ksfpaf7	339	3	Because	because	IN
cord-034340-3ksfpaf7	339	4	no	no	DT
cord-034340-3ksfpaf7	339	5	cohort	cohort	NN
cord-034340-3ksfpaf7	339	6	studies	study	NNS
cord-034340-3ksfpaf7	339	7	investigating	investigate	VBG
cord-034340-3ksfpaf7	339	8	renal	renal	JJ
cord-034340-3ksfpaf7	339	9	injury	injury	NN
cord-034340-3ksfpaf7	339	10	in	in	IN
cord-034340-3ksfpaf7	339	11	children	child	NNS
cord-034340-3ksfpaf7	339	12	with	with	IN
cord-034340-3ksfpaf7	339	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	339	14	are	be	VBP
cord-034340-3ksfpaf7	339	15	available	available	JJ
cord-034340-3ksfpaf7	340	1	,	,	,
cord-034340-3ksfpaf7	340	2	we	-PRON-	PRP
cord-034340-3ksfpaf7	340	3	designed	design	VBD
cord-034340-3ksfpaf7	340	4	this	this	DT
cord-034340-3ksfpaf7	340	5	kind	kind	NN
cord-034340-3ksfpaf7	340	6	of	of	IN
cord-034340-3ksfpaf7	340	7	study	study	NN
cord-034340-3ksfpaf7	340	8	in	in	IN
cord-034340-3ksfpaf7	340	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	340	10	population	population	NN
cord-034340-3ksfpaf7	340	11	.	.	.
cord-034340-3ksfpaf7	341	1	Methods	method	NNS
cord-034340-3ksfpaf7	341	2	:	:	:
cord-034340-3ksfpaf7	341	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	341	4	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	341	5	evaluated	evaluate	VBD
cord-034340-3ksfpaf7	341	6	110	110	CD
cord-034340-3ksfpaf7	341	7	patients	patient	NNS
cord-034340-3ksfpaf7	341	8	suffering	suffer	VBG
cord-034340-3ksfpaf7	341	9	from	from	IN
cord-034340-3ksfpaf7	341	10	JIA	JIA	NNP
cord-034340-3ksfpaf7	341	11	.	.	.
cord-034340-3ksfpaf7	342	1	JIA	JIA	NNP
cord-034340-3ksfpaf7	342	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	342	3	was	be	VBD
cord-034340-3ksfpaf7	342	4	made	make	VBN
cord-034340-3ksfpaf7	342	5	according	accord	VBG
cord-034340-3ksfpaf7	342	6	to	to	IN
cord-034340-3ksfpaf7	342	7	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	342	8	criteria	criterion	NNS
cord-034340-3ksfpaf7	342	9	,	,	,
cord-034340-3ksfpaf7	342	10	treatment	treatment	NN
cord-034340-3ksfpaf7	342	11	was	be	VBD
cord-034340-3ksfpaf7	342	12	assigned	assign	VBN
cord-034340-3ksfpaf7	342	13	with	with	IN
cord-034340-3ksfpaf7	342	14	ACR	ACR	NNP
cord-034340-3ksfpaf7	342	15	recommendations	recommendation	NNS
cord-034340-3ksfpaf7	342	16	.	.	.
cord-034340-3ksfpaf7	343	1	For	for	IN
cord-034340-3ksfpaf7	343	2	each	each	DT
cord-034340-3ksfpaf7	343	3	patient	patient	NN
cord-034340-3ksfpaf7	343	4	we	-PRON-	PRP
cord-034340-3ksfpaf7	343	5	recorded	record	VBD
cord-034340-3ksfpaf7	343	6	the	the	DT
cord-034340-3ksfpaf7	343	7	type	type	NN
cord-034340-3ksfpaf7	343	8	and	and	CC
cord-034340-3ksfpaf7	343	9	the	the	DT
cord-034340-3ksfpaf7	343	10	duration	duration	NN
cord-034340-3ksfpaf7	343	11	of	of	IN
cord-034340-3ksfpaf7	343	12	pharmacological	pharmacological	JJ
cord-034340-3ksfpaf7	343	13	treatment	treatment	NN
cord-034340-3ksfpaf7	343	14	and	and	CC
cord-034340-3ksfpaf7	343	15	the	the	DT
cord-034340-3ksfpaf7	343	16	presence	presence	NN
cord-034340-3ksfpaf7	343	17	of	of	IN
cord-034340-3ksfpaf7	343	18	renal	renal	JJ
cord-034340-3ksfpaf7	343	19	injury	injury	NN
cord-034340-3ksfpaf7	343	20	.	.	.
cord-034340-3ksfpaf7	344	1	Renal	renal	JJ
cord-034340-3ksfpaf7	344	2	injury	injury	NN
cord-034340-3ksfpaf7	344	3	was	be	VBD
cord-034340-3ksfpaf7	344	4	defined	define	VBN
cord-034340-3ksfpaf7	344	5	by	by	IN
cord-034340-3ksfpaf7	344	6	the	the	DT
cord-034340-3ksfpaf7	344	7	presence	presence	NN
cord-034340-3ksfpaf7	344	8	of	of	IN
cord-034340-3ksfpaf7	344	9	hypertension	hypertension	NN
cord-034340-3ksfpaf7	344	10	(	(	-LRB-
cord-034340-3ksfpaf7	344	11	systolic	systolic	JJ
cord-034340-3ksfpaf7	344	12	and/or	and/or	CC
cord-034340-3ksfpaf7	344	13	diastolic	diastolic	JJ
cord-034340-3ksfpaf7	344	14	blood	blood	NN
cord-034340-3ksfpaf7	344	15	pressure	pressure	NN
cord-034340-3ksfpaf7	344	16	>	>	XX
cord-034340-3ksfpaf7	344	17	95	95	CD
cord-034340-3ksfpaf7	344	18	th	th	XX
cord-034340-3ksfpaf7	344	19	percentile	percentile	NN
cord-034340-3ksfpaf7	344	20	for	for	IN
cord-034340-3ksfpaf7	344	21	age	age	NN
cord-034340-3ksfpaf7	344	22	,	,	,
cord-034340-3ksfpaf7	344	23	sex	sex	NN
cord-034340-3ksfpaf7	344	24	and	and	CC
cord-034340-3ksfpaf7	344	25	height	height	NN
cord-034340-3ksfpaf7	344	26	)	)	-RRB-
cord-034340-3ksfpaf7	344	27	,	,	,
cord-034340-3ksfpaf7	344	28	proteinuria	proteinuria	NN
cord-034340-3ksfpaf7	344	29	(	(	-LRB-
cord-034340-3ksfpaf7	344	30	persistentconfirmation	persistentconfirmation	NN
cord-034340-3ksfpaf7	344	31	within	within	IN
cord-034340-3ksfpaf7	344	32	3	3	CD
cord-034340-3ksfpaf7	344	33	months	month	NNS
cord-034340-3ksfpaf7	344	34	-	-	HYPH
cord-034340-3ksfpaf7	344	35	urinary	urinary	JJ
cord-034340-3ksfpaf7	344	36	protein	protein	NN
cord-034340-3ksfpaf7	344	37	/	/	SYM
cord-034340-3ksfpaf7	344	38	creatinine	creatinine	NN
cord-034340-3ksfpaf7	344	39	ratio>0.5	ratio>0.5	NNP
cord-034340-3ksfpaf7	345	1	mg	mg	NNP
cord-034340-3ksfpaf7	345	2	/	/	SYM
cord-034340-3ksfpaf7	345	3	mg	mg	NNP
cord-034340-3ksfpaf7	345	4	for	for	IN
cord-034340-3ksfpaf7	345	5	children	child	NNS
cord-034340-3ksfpaf7	345	6	<	<	XX
cord-034340-3ksfpaf7	345	7	2	2	CD
cord-034340-3ksfpaf7	345	8	years	year	NNS
cord-034340-3ksfpaf7	345	9	old	old	JJ
cord-034340-3ksfpaf7	345	10	and	and	CC
cord-034340-3ksfpaf7	345	11	>	>	XX
cord-034340-3ksfpaf7	345	12	0	0	CD
cord-034340-3ksfpaf7	345	13	.	.	.
cord-034340-3ksfpaf7	345	14	2	2	CD
cord-034340-3ksfpaf7	345	15	Introduction	introduction	NN
cord-034340-3ksfpaf7	345	16	:	:	:
cord-034340-3ksfpaf7	345	17	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	345	18	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	345	19	arthritis	arthritis	NN
cord-034340-3ksfpaf7	345	20	(	(	-LRB-
cord-034340-3ksfpaf7	345	21	JIA	JIA	NNP
cord-034340-3ksfpaf7	345	22	)	)	-RRB-
cord-034340-3ksfpaf7	345	23	is	be	VBZ
cord-034340-3ksfpaf7	345	24	a	a	DT
cord-034340-3ksfpaf7	345	25	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	345	26	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	345	27	disease	disease	NN
cord-034340-3ksfpaf7	345	28	with	with	IN
cord-034340-3ksfpaf7	345	29	partially	partially	RB
cord-034340-3ksfpaf7	345	30	unknown	unknown	JJ
cord-034340-3ksfpaf7	345	31	etiology	etiology	NN
cord-034340-3ksfpaf7	345	32	and	and	CC
cord-034340-3ksfpaf7	345	33	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	345	34	.	.	.
cord-034340-3ksfpaf7	346	1	Neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	346	2	are	be	VBP
cord-034340-3ksfpaf7	346	3	the	the	DT
cord-034340-3ksfpaf7	346	4	most	most	RBS
cord-034340-3ksfpaf7	346	5	common	common	JJ
cord-034340-3ksfpaf7	346	6	immune	immune	JJ
cord-034340-3ksfpaf7	346	7	cell	cell	NN
cord-034340-3ksfpaf7	346	8	present	present	JJ
cord-034340-3ksfpaf7	346	9	in	in	IN
cord-034340-3ksfpaf7	346	10	synovial	synovial	JJ
cord-034340-3ksfpaf7	346	11	fluid	fluid	NN
cord-034340-3ksfpaf7	346	12	from	from	IN
cord-034340-3ksfpaf7	346	13	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	346	14	joints	joint	NNS
cord-034340-3ksfpaf7	346	15	in	in	IN
cord-034340-3ksfpaf7	346	16	oligoarticular	oligoarticular	JJ
cord-034340-3ksfpaf7	346	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	346	18	,	,	,
cord-034340-3ksfpaf7	346	19	but	but	CC
cord-034340-3ksfpaf7	346	20	the	the	DT
cord-034340-3ksfpaf7	346	21	role	role	NN
cord-034340-3ksfpaf7	346	22	of	of	IN
cord-034340-3ksfpaf7	346	23	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	346	24	in	in	IN
cord-034340-3ksfpaf7	346	25	the	the	DT
cord-034340-3ksfpaf7	346	26	immunopathogenesis	immunopathogenesis	NNP
cord-034340-3ksfpaf7	346	27	of	of	IN
cord-034340-3ksfpaf7	346	28	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	346	29	JIA	JIA	NNP
cord-034340-3ksfpaf7	346	30	has	have	VBZ
cord-034340-3ksfpaf7	346	31	not	not	RB
cord-034340-3ksfpaf7	346	32	been	be	VBN
cord-034340-3ksfpaf7	346	33	investigated	investigate	VBN
cord-034340-3ksfpaf7	346	34	.	.	.
cord-034340-3ksfpaf7	347	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	347	2	:	:	:
cord-034340-3ksfpaf7	347	3	To	to	TO
cord-034340-3ksfpaf7	347	4	characterize	characterize	VB
cord-034340-3ksfpaf7	347	5	neutrophil	neutrophil	NN
cord-034340-3ksfpaf7	347	6	phenotypes	phenotype	NNS
cord-034340-3ksfpaf7	347	7	and	and	CC
cord-034340-3ksfpaf7	347	8	effector	effector	NN
cord-034340-3ksfpaf7	347	9	functions	function	NNS
cord-034340-3ksfpaf7	347	10	in	in	IN
cord-034340-3ksfpaf7	347	11	the	the	DT
cord-034340-3ksfpaf7	347	12	circulation	circulation	NN
cord-034340-3ksfpaf7	347	13	and	and	CC
cord-034340-3ksfpaf7	347	14	in	in	IN
cord-034340-3ksfpaf7	347	15	the	the	DT
cord-034340-3ksfpaf7	347	16	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	347	17	joint	joint	NN
cord-034340-3ksfpaf7	347	18	during	during	IN
cord-034340-3ksfpaf7	347	19	active	active	JJ
cord-034340-3ksfpaf7	347	20	arthritis	arthritis	NN
cord-034340-3ksfpaf7	347	21	in	in	IN
cord-034340-3ksfpaf7	347	22	children	child	NNS
cord-034340-3ksfpaf7	347	23	with	with	IN
cord-034340-3ksfpaf7	347	24	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	347	25	JIA	JIA	NNP
cord-034340-3ksfpaf7	347	26	.	.	.
cord-034340-3ksfpaf7	348	1	Methods	method	NNS
cord-034340-3ksfpaf7	348	2	:	:	:
cord-034340-3ksfpaf7	349	1	Paired	paired	JJ
cord-034340-3ksfpaf7	349	2	samples	sample	NNS
cord-034340-3ksfpaf7	349	3	of	of	IN
cord-034340-3ksfpaf7	349	4	blood	blood	NN
cord-034340-3ksfpaf7	349	5	and	and	CC
cord-034340-3ksfpaf7	349	6	synovial	synovial	JJ
cord-034340-3ksfpaf7	349	7	fluid	fluid	NN
cord-034340-3ksfpaf7	349	8	from	from	IN
cord-034340-3ksfpaf7	349	9	17	17	CD
cord-034340-3ksfpaf7	349	10	children	child	NNS
cord-034340-3ksfpaf7	349	11	with	with	IN
cord-034340-3ksfpaf7	349	12	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	349	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	349	14	were	be	VBD
cord-034340-3ksfpaf7	349	15	investigated	investigate	VBN
cord-034340-3ksfpaf7	349	16	regarding	regard	VBG
cord-034340-3ksfpaf7	349	17	surface	surface	NN
cord-034340-3ksfpaf7	349	18	markers	marker	NNS
cord-034340-3ksfpaf7	349	19	,	,	,
cord-034340-3ksfpaf7	349	20	phagocytic	phagocytic	JJ
cord-034340-3ksfpaf7	349	21	ability	ability	NN
cord-034340-3ksfpaf7	349	22	and	and	CC
cord-034340-3ksfpaf7	349	23	oxidative	oxidative	JJ
cord-034340-3ksfpaf7	349	24	burst	burst	NN
cord-034340-3ksfpaf7	349	25	.	.	.
cord-034340-3ksfpaf7	350	1	Healthy	healthy	JJ
cord-034340-3ksfpaf7	350	2	blood	blood	NN
cord-034340-3ksfpaf7	350	3	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	350	4	exposed	expose	VBN
cord-034340-3ksfpaf7	350	5	to	to	IN
cord-034340-3ksfpaf7	350	6	cell	cell	NN
cord-034340-3ksfpaf7	350	7	-	-	HYPH
cord-034340-3ksfpaf7	350	8	free	free	JJ
cord-034340-3ksfpaf7	350	9	JIA	JIA	NNP
cord-034340-3ksfpaf7	350	10	synovial	synovial	JJ
cord-034340-3ksfpaf7	350	11	fluid	fluid	NN
cord-034340-3ksfpaf7	350	12	and	and	CC
cord-034340-3ksfpaf7	350	13	healthy	healthy	JJ
cord-034340-3ksfpaf7	350	14	oral	oral	JJ
cord-034340-3ksfpaf7	350	15	cavity	cavity	NN
cord-034340-3ksfpaf7	350	16	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	350	17	were	be	VBD
cord-034340-3ksfpaf7	350	18	studied	study	VBN
cord-034340-3ksfpaf7	350	19	as	as	IN
cord-034340-3ksfpaf7	350	20	controls	control	NNS
cord-034340-3ksfpaf7	350	21	for	for	IN
cord-034340-3ksfpaf7	350	22	synovial	synovial	JJ
cord-034340-3ksfpaf7	350	23	fluid	fluid	JJ
cord-034340-3ksfpaf7	350	24	exposure	exposure	NN
cord-034340-3ksfpaf7	350	25	and	and	CC
cord-034340-3ksfpaf7	350	26	transmigration	transmigration	NN
cord-034340-3ksfpaf7	350	27	respectively	respectively	RB
cord-034340-3ksfpaf7	350	28	.	.	.
cord-034340-3ksfpaf7	351	1	Results	result	NNS
cord-034340-3ksfpaf7	351	2	:	:	:
cord-034340-3ksfpaf7	352	1	Synovial	synovial	JJ
cord-034340-3ksfpaf7	352	2	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	352	3	had	have	VBD
cord-034340-3ksfpaf7	352	4	a	a	DT
cord-034340-3ksfpaf7	352	5	shifted	shift	VBN
cord-034340-3ksfpaf7	352	6	phenotype	phenotype	NN
cord-034340-3ksfpaf7	352	7	,	,	,
cord-034340-3ksfpaf7	352	8	characterized	characterize	VBN
cord-034340-3ksfpaf7	352	9	by	by	IN
cord-034340-3ksfpaf7	352	10	high	high	JJ
cord-034340-3ksfpaf7	352	11	surface	surface	NN
cord-034340-3ksfpaf7	352	12	levels	level	NNS
cord-034340-3ksfpaf7	352	13	of	of	IN
cord-034340-3ksfpaf7	352	14	neutrophil	neutrophil	NN
cord-034340-3ksfpaf7	352	15	activation	activation	NN
cord-034340-3ksfpaf7	352	16	markers	marker	NNS
cord-034340-3ksfpaf7	352	17	CD11b	CD11b	NNS
cord-034340-3ksfpaf7	352	18	and	and	CC
cord-034340-3ksfpaf7	352	19	CD66b	cd66b	NN
cord-034340-3ksfpaf7	352	20	,	,	,
cord-034340-3ksfpaf7	352	21	and	and	CC
cord-034340-3ksfpaf7	352	22	mannose	mannose	NN
cord-034340-3ksfpaf7	352	23	receptor	receptor	NN
cord-034340-3ksfpaf7	353	1	CD206	CD206	NNP
cord-034340-3ksfpaf7	354	1	and	and	CC
cord-034340-3ksfpaf7	354	2	decreased	decrease	VBD
cord-034340-3ksfpaf7	354	3	levels	level	NNS
cord-034340-3ksfpaf7	354	4	of	of	IN
cord-034340-3ksfpaf7	354	5	adhesion	adhesion	NN
cord-034340-3ksfpaf7	354	6	molecule	molecule	NN
cord-034340-3ksfpaf7	354	7	CD62L	cd62l	NN
cord-034340-3ksfpaf7	354	8	compared	compare	VBN
cord-034340-3ksfpaf7	354	9	to	to	IN
cord-034340-3ksfpaf7	354	10	circulating	circulate	VBG
cord-034340-3ksfpaf7	354	11	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	354	12	.	.	.
cord-034340-3ksfpaf7	355	1	In	in	IN
cord-034340-3ksfpaf7	355	2	comparison	comparison	NN
cord-034340-3ksfpaf7	355	3	to	to	IN
cord-034340-3ksfpaf7	355	4	oral	oral	JJ
cord-034340-3ksfpaf7	355	5	cavity	cavity	NN
cord-034340-3ksfpaf7	355	6	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	355	7	,	,	,
cord-034340-3ksfpaf7	355	8	synovial	synovial	JJ
cord-034340-3ksfpaf7	355	9	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	355	10	had	have	VBD
cord-034340-3ksfpaf7	355	11	higher	high	JJR
cord-034340-3ksfpaf7	355	12	levels	level	NNS
cord-034340-3ksfpaf7	355	13	of	of	IN
cord-034340-3ksfpaf7	355	14	CD11b	CD11b	NNS
cord-034340-3ksfpaf7	355	15	and	and	CC
cord-034340-3ksfpaf7	355	16	a	a	DT
cord-034340-3ksfpaf7	355	17	different	different	JJ
cord-034340-3ksfpaf7	355	18	overall	overall	JJ
cord-034340-3ksfpaf7	355	19	phenotype	phenotype	NN
cord-034340-3ksfpaf7	355	20	,	,	,
cord-034340-3ksfpaf7	355	21	suggesting	suggest	VBG
cord-034340-3ksfpaf7	355	22	that	that	IN
cord-034340-3ksfpaf7	355	23	the	the	DT
cord-034340-3ksfpaf7	355	24	phenotype	phenotype	NN
cord-034340-3ksfpaf7	355	25	shift	shift	NN
cord-034340-3ksfpaf7	355	26	in	in	IN
cord-034340-3ksfpaf7	355	27	synovial	synovial	JJ
cord-034340-3ksfpaf7	355	28	compared	compare	VBN
cord-034340-3ksfpaf7	355	29	to	to	IN
cord-034340-3ksfpaf7	355	30	circulating	circulate	VBG
cord-034340-3ksfpaf7	355	31	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	355	32	is	be	VBZ
cord-034340-3ksfpaf7	355	33	not	not	RB
cord-034340-3ksfpaf7	355	34	dependent	dependent	JJ
cord-034340-3ksfpaf7	355	35	on	on	IN
cord-034340-3ksfpaf7	355	36	transmigration	transmigration	NN
cord-034340-3ksfpaf7	355	37	alone	alone	RB
cord-034340-3ksfpaf7	355	38	.	.	.
cord-034340-3ksfpaf7	356	1	JIA	JIA	NNP
cord-034340-3ksfpaf7	356	2	synovial	synovial	JJ
cord-034340-3ksfpaf7	356	3	fluid	fluid	NN
cord-034340-3ksfpaf7	356	4	in	in	IN
cord-034340-3ksfpaf7	356	5	itself	-PRON-	PRP
cord-034340-3ksfpaf7	356	6	induced	induce	VBN
cord-034340-3ksfpaf7	356	7	activation	activation	NN
cord-034340-3ksfpaf7	356	8	of	of	IN
cord-034340-3ksfpaf7	356	9	healthy	healthy	JJ
cord-034340-3ksfpaf7	356	10	blood	blood	NN
cord-034340-3ksfpaf7	356	11	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	356	12	,	,	,
cord-034340-3ksfpaf7	356	13	measured	measure	VBN
cord-034340-3ksfpaf7	356	14	as	as	IN
cord-034340-3ksfpaf7	356	15	increased	increase	VBN
cord-034340-3ksfpaf7	356	16	CD11b	CD11b	NNS
cord-034340-3ksfpaf7	356	17	levels	level	NNS
cord-034340-3ksfpaf7	356	18	.	.	.
cord-034340-3ksfpaf7	357	1	Synovial	synovial	JJ
cord-034340-3ksfpaf7	357	2	fluid	fluid	JJ
cord-034340-3ksfpaf7	357	3	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	357	4	had	have	VBD
cord-034340-3ksfpaf7	357	5	impaired	impair	VBN
cord-034340-3ksfpaf7	357	6	ability	ability	NN
cord-034340-3ksfpaf7	357	7	to	to	TO
cord-034340-3ksfpaf7	357	8	phagocytose	phagocytose	VB
cord-034340-3ksfpaf7	357	9	opsonized	opsonize	VBN
cord-034340-3ksfpaf7	357	10	E.	E.	NNP
cord-034340-3ksfpaf7	357	11	coli	coli	NNS
cord-034340-3ksfpaf7	357	12	and	and	CC
cord-034340-3ksfpaf7	357	13	to	to	TO
cord-034340-3ksfpaf7	357	14	produce	produce	VB
cord-034340-3ksfpaf7	357	15	oxygen	oxygen	NN
cord-034340-3ksfpaf7	357	16	radicals	radical	NNS
cord-034340-3ksfpaf7	357	17	upon	upon	IN
cord-034340-3ksfpaf7	357	18	neutrophil	neutrophil	NN
cord-034340-3ksfpaf7	357	19	activation	activation	NN
cord-034340-3ksfpaf7	357	20	with	with	IN
cord-034340-3ksfpaf7	357	21	phorbol	phorbol	NNP
cord-034340-3ksfpaf7	357	22	-	-	HYPH
cord-034340-3ksfpaf7	357	23	myristateacetate	myristateacetate	NNP
cord-034340-3ksfpaf7	357	24	(	(	-LRB-
cord-034340-3ksfpaf7	357	25	PMA	PMA	NNP
cord-034340-3ksfpaf7	357	26	)	)	-RRB-
cord-034340-3ksfpaf7	357	27	compared	compare	VBN
cord-034340-3ksfpaf7	357	28	to	to	IN
cord-034340-3ksfpaf7	357	29	circulating	circulate	VBG
cord-034340-3ksfpaf7	357	30	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	357	31	.	.	.
cord-034340-3ksfpaf7	358	1	The	the	DT
cord-034340-3ksfpaf7	358	2	impaired	impaired	JJ
cord-034340-3ksfpaf7	358	3	effector	effector	NN
cord-034340-3ksfpaf7	358	4	functions	function	NNS
cord-034340-3ksfpaf7	358	5	in	in	IN
cord-034340-3ksfpaf7	358	6	synovial	synovial	JJ
cord-034340-3ksfpaf7	358	7	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	358	8	was	be	VBD
cord-034340-3ksfpaf7	358	9	not	not	RB
cord-034340-3ksfpaf7	358	10	dependent	dependent	JJ
cord-034340-3ksfpaf7	358	11	on	on	IN
cord-034340-3ksfpaf7	358	12	the	the	DT
cord-034340-3ksfpaf7	358	13	synovial	synovial	JJ
cord-034340-3ksfpaf7	358	14	fluid	fluid	NN
cord-034340-3ksfpaf7	358	15	alone	alone	RB
cord-034340-3ksfpaf7	358	16	,	,	,
cord-034340-3ksfpaf7	358	17	as	as	IN
cord-034340-3ksfpaf7	358	18	addition	addition	NN
cord-034340-3ksfpaf7	358	19	of	of	IN
cord-034340-3ksfpaf7	358	20	cell	cell	NN
cord-034340-3ksfpaf7	358	21	-	-	HYPH
cord-034340-3ksfpaf7	358	22	free	free	JJ
cord-034340-3ksfpaf7	358	23	synovial	synovial	JJ
cord-034340-3ksfpaf7	358	24	fluid	fluid	NN
cord-034340-3ksfpaf7	358	25	to	to	IN
cord-034340-3ksfpaf7	358	26	blood	blood	NN
cord-034340-3ksfpaf7	358	27	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	358	28	did	do	VBD
cord-034340-3ksfpaf7	358	29	not	not	RB
cord-034340-3ksfpaf7	358	30	alter	alter	VB
cord-034340-3ksfpaf7	358	31	phagocytosis	phagocytosis	NN
cord-034340-3ksfpaf7	358	32	and	and	CC
cord-034340-3ksfpaf7	358	33	oxidative	oxidative	JJ
cord-034340-3ksfpaf7	358	34	burst	burst	NN
cord-034340-3ksfpaf7	358	35	.	.	.
cord-034340-3ksfpaf7	359	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	359	2	:	:	:
cord-034340-3ksfpaf7	359	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	359	4	synovial	synovial	JJ
cord-034340-3ksfpaf7	359	5	fluid	fluid	JJ
cord-034340-3ksfpaf7	359	6	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	359	7	are	be	VBP
cord-034340-3ksfpaf7	359	8	activated	activate	VBN
cord-034340-3ksfpaf7	359	9	,	,	,
cord-034340-3ksfpaf7	359	10	have	have	VBP
cord-034340-3ksfpaf7	359	11	a	a	DT
cord-034340-3ksfpaf7	359	12	"	"	``
cord-034340-3ksfpaf7	359	13	polarized	polarized	JJ
cord-034340-3ksfpaf7	359	14	"	"	''
cord-034340-3ksfpaf7	359	15	phenotype	phenotype	NN
cord-034340-3ksfpaf7	359	16	and	and	CC
cord-034340-3ksfpaf7	359	17	impaired	impaired	JJ
cord-034340-3ksfpaf7	359	18	effector	effector	NN
cord-034340-3ksfpaf7	359	19	functions	function	NNS
cord-034340-3ksfpaf7	359	20	compared	compare	VBN
cord-034340-3ksfpaf7	359	21	to	to	IN
cord-034340-3ksfpaf7	359	22	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	359	23	in	in	IN
cord-034340-3ksfpaf7	359	24	the	the	DT
cord-034340-3ksfpaf7	359	25	circulation	circulation	NN
cord-034340-3ksfpaf7	359	26	.	.	.
cord-034340-3ksfpaf7	360	1	This	this	DT
cord-034340-3ksfpaf7	360	2	study	study	NN
cord-034340-3ksfpaf7	360	3	will	will	MD
cord-034340-3ksfpaf7	360	4	help	help	VB
cord-034340-3ksfpaf7	360	5	bridge	bridge	VB
cord-034340-3ksfpaf7	360	6	the	the	DT
cord-034340-3ksfpaf7	360	7	current	current	JJ
cord-034340-3ksfpaf7	360	8	knowledge	knowledge	NN
cord-034340-3ksfpaf7	360	9	-	-	HYPH
cord-034340-3ksfpaf7	360	10	gap	gap	NN
cord-034340-3ksfpaf7	360	11	regarding	regard	VBG
cord-034340-3ksfpaf7	360	12	the	the	DT
cord-034340-3ksfpaf7	360	13	role	role	NN
cord-034340-3ksfpaf7	360	14	of	of	IN
cord-034340-3ksfpaf7	360	15	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	360	16	in	in	IN
cord-034340-3ksfpaf7	360	17	the	the	DT
cord-034340-3ksfpaf7	360	18	immunopathogenesis	immunopathogenesis	NN
cord-034340-3ksfpaf7	360	19	in	in	IN
cord-034340-3ksfpaf7	360	20	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	360	21	JIA	JIA	NNP
cord-034340-3ksfpaf7	360	22	.	.	.
cord-034340-3ksfpaf7	361	1	Methods	method	NNS
cord-034340-3ksfpaf7	361	2	:	:	:
cord-034340-3ksfpaf7	361	3	A	a	DT
cord-034340-3ksfpaf7	361	4	case	case	NN
cord-034340-3ksfpaf7	361	5	report	report	NN
cord-034340-3ksfpaf7	361	6	is	be	VBZ
cord-034340-3ksfpaf7	361	7	described	describe	VBN
cord-034340-3ksfpaf7	361	8	.	.	.
cord-034340-3ksfpaf7	362	1	Data	datum	NNS
cord-034340-3ksfpaf7	362	2	was	be	VBD
cord-034340-3ksfpaf7	362	3	extracted	extract	VBN
cord-034340-3ksfpaf7	362	4	from	from	IN
cord-034340-3ksfpaf7	362	5	the	the	DT
cord-034340-3ksfpaf7	362	6	medical	medical	JJ
cord-034340-3ksfpaf7	362	7	chart	chart	NN
cord-034340-3ksfpaf7	362	8	of	of	IN
cord-034340-3ksfpaf7	362	9	the	the	DT
cord-034340-3ksfpaf7	362	10	patient	patient	NN
cord-034340-3ksfpaf7	362	11	and	and	CC
cord-034340-3ksfpaf7	362	12	a	a	DT
cord-034340-3ksfpaf7	362	13	literature	literature	NN
cord-034340-3ksfpaf7	362	14	review	review	NN
cord-034340-3ksfpaf7	362	15	was	be	VBD
cord-034340-3ksfpaf7	362	16	undertaken	undertake	VBN
cord-034340-3ksfpaf7	362	17	.	.	.
cord-034340-3ksfpaf7	363	1	Results	result	NNS
cord-034340-3ksfpaf7	363	2	:	:	:
cord-034340-3ksfpaf7	364	1	A	a	DT
cord-034340-3ksfpaf7	364	2	7-year	7-year	JJ
cord-034340-3ksfpaf7	364	3	-	-	HYPH
cord-034340-3ksfpaf7	364	4	old	old	JJ
cord-034340-3ksfpaf7	364	5	girl	girl	NN
cord-034340-3ksfpaf7	364	6	was	be	VBD
cord-034340-3ksfpaf7	364	7	transferred	transfer	VBN
cord-034340-3ksfpaf7	364	8	to	to	IN
cord-034340-3ksfpaf7	364	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	364	10	tertiary	tertiary	JJ
cord-034340-3ksfpaf7	364	11	center	center	NN
cord-034340-3ksfpaf7	364	12	after	after	IN
cord-034340-3ksfpaf7	364	13	being	be	VBG
cord-034340-3ksfpaf7	364	14	admitted	admit	VBN
cord-034340-3ksfpaf7	364	15	for	for	IN
cord-034340-3ksfpaf7	364	16	prolonged	prolong	VBN
cord-034340-3ksfpaf7	364	17	intermittent	intermittent	JJ
cord-034340-3ksfpaf7	364	18	fevers	fever	NNS
cord-034340-3ksfpaf7	364	19	,	,	,
cord-034340-3ksfpaf7	364	20	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	364	21	pain	pain	NN
cord-034340-3ksfpaf7	364	22	,	,	,
cord-034340-3ksfpaf7	364	23	fatigue	fatigue	NN
cord-034340-3ksfpaf7	364	24	and	and	CC
cord-034340-3ksfpaf7	364	25	polyarthralgias	polyarthralgias	NNP
cord-034340-3ksfpaf7	364	26	.	.	.
cord-034340-3ksfpaf7	365	1	On	on	IN
cord-034340-3ksfpaf7	365	2	examination	examination	NN
cord-034340-3ksfpaf7	365	3	,	,	,
cord-034340-3ksfpaf7	365	4	there	there	EX
cord-034340-3ksfpaf7	365	5	was	be	VBD
cord-034340-3ksfpaf7	365	6	symmetrical	symmetrical	JJ
cord-034340-3ksfpaf7	365	7	proximal	proximal	JJ
cord-034340-3ksfpaf7	365	8	muscle	muscle	NN
cord-034340-3ksfpaf7	365	9	weakness	weakness	NN
cord-034340-3ksfpaf7	365	10	,	,	,
cord-034340-3ksfpaf7	365	11	a	a	DT
cord-034340-3ksfpaf7	365	12	vasculitic	vasculitic	JJ
cord-034340-3ksfpaf7	365	13	lower	low	JJR
cord-034340-3ksfpaf7	365	14	limb	limb	NN
cord-034340-3ksfpaf7	365	15	rash	rash	NN
cord-034340-3ksfpaf7	365	16	,	,	,
cord-034340-3ksfpaf7	365	17	facial	facial	JJ
cord-034340-3ksfpaf7	365	18	erythema	erythema	NN
cord-034340-3ksfpaf7	365	19	with	with	IN
cord-034340-3ksfpaf7	365	20	eyelid	eyelid	NN
cord-034340-3ksfpaf7	365	21	edema	edema	NN
cord-034340-3ksfpaf7	365	22	(	(	-LRB-
cord-034340-3ksfpaf7	365	23	Fig	Fig	NNP
cord-034340-3ksfpaf7	365	24	.	.	.
cord-034340-3ksfpaf7	365	25	1	1	CD
cord-034340-3ksfpaf7	365	26	)	)	-RRB-
cord-034340-3ksfpaf7	365	27	and	and	CC
cord-034340-3ksfpaf7	365	28	oral	oral	JJ
cord-034340-3ksfpaf7	365	29	mucositis	mucositis	NNP
cord-034340-3ksfpaf7	365	30	.	.	.
cord-034340-3ksfpaf7	366	1	Initial	initial	JJ
cord-034340-3ksfpaf7	366	2	laboratory	laboratory	NN
cord-034340-3ksfpaf7	366	3	exams	exam	NNS
cord-034340-3ksfpaf7	366	4	revealed	reveal	VBD
cord-034340-3ksfpaf7	366	5	pancytopenia	pancytopenia	NNP
cord-034340-3ksfpaf7	366	6	,	,	,
cord-034340-3ksfpaf7	366	7	high	high	JJ
cord-034340-3ksfpaf7	366	8	muscle	muscle	NN
cord-034340-3ksfpaf7	366	9	enzymes	enzyme	NNS
cord-034340-3ksfpaf7	366	10	,	,	,
cord-034340-3ksfpaf7	366	11	increased	increase	VBN
cord-034340-3ksfpaf7	366	12	erythrocyte	erythrocyte	NN
cord-034340-3ksfpaf7	366	13	sedimentation	sedimentation	NN
cord-034340-3ksfpaf7	366	14	rate	rate	NN
cord-034340-3ksfpaf7	366	15	with	with	IN
cord-034340-3ksfpaf7	366	16	moderately	moderately	RB
cord-034340-3ksfpaf7	366	17	elevated	elevated	JJ
cord-034340-3ksfpaf7	366	18	reactive	reactive	JJ
cord-034340-3ksfpaf7	366	19	C	c	NN
cord-034340-3ksfpaf7	366	20	-	-	HYPH
cord-034340-3ksfpaf7	366	21	protein	protein	NN
cord-034340-3ksfpaf7	366	22	,	,	,
cord-034340-3ksfpaf7	366	23	and	and	CC
cord-034340-3ksfpaf7	366	24	hypocomplementemia	hypocomplementemia	NNP
cord-034340-3ksfpaf7	366	25	.	.	.
cord-034340-3ksfpaf7	367	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	367	2	also	also	RB
cord-034340-3ksfpaf7	367	3	had	have	VBD
cord-034340-3ksfpaf7	367	4	non	non	JJ
cord-034340-3ksfpaf7	367	5	-	-	JJ
cord-034340-3ksfpaf7	367	6	nephrotic	nephrotic	JJ
cord-034340-3ksfpaf7	367	7	proteinuria	proteinuria	NN
cord-034340-3ksfpaf7	367	8	,	,	,
cord-034340-3ksfpaf7	367	9	without	without	IN
cord-034340-3ksfpaf7	367	10	hematuria	hematuria	NN
cord-034340-3ksfpaf7	367	11	.	.	.
cord-034340-3ksfpaf7	368	1	Further	further	JJ
cord-034340-3ksfpaf7	368	2	investigations	investigation	NNS
cord-034340-3ksfpaf7	368	3	showed	show	VBD
cord-034340-3ksfpaf7	368	4	a	a	DT
cord-034340-3ksfpaf7	368	5	positive	positive	JJ
cord-034340-3ksfpaf7	368	6	direct	direct	JJ
cord-034340-3ksfpaf7	368	7	antiglobulin	antiglobulin	NN
cord-034340-3ksfpaf7	368	8	test	test	NN
cord-034340-3ksfpaf7	368	9	,	,	,
cord-034340-3ksfpaf7	368	10	antinuclear	antinuclear	JJ
cord-034340-3ksfpaf7	368	11	antibodies	antibody	NNS
cord-034340-3ksfpaf7	368	12	,	,	,
cord-034340-3ksfpaf7	368	13	antidouble	antidouble	RB
cord-034340-3ksfpaf7	368	14	-	-	HYPH
cord-034340-3ksfpaf7	368	15	stranded	strand	VBN
cord-034340-3ksfpaf7	368	16	DNA	dna	NN
cord-034340-3ksfpaf7	368	17	,	,	,
cord-034340-3ksfpaf7	368	18	anti	anti	JJ
cord-034340-3ksfpaf7	368	19	-	-	NNP
cord-034340-3ksfpaf7	368	20	Mi	Mi	NNP
cord-034340-3ksfpaf7	368	21	2	2	CD
cord-034340-3ksfpaf7	368	22	and	and	CC
cord-034340-3ksfpaf7	368	23	anti	anti	NNS
cord-034340-3ksfpaf7	368	24	-	-	NNP
cord-034340-3ksfpaf7	368	25	Ku	Ku	NNP
cord-034340-3ksfpaf7	368	26	.	.	.
cord-034340-3ksfpaf7	369	1	Serositis	Serositis	NNP
cord-034340-3ksfpaf7	369	2	(	(	-LRB-
cord-034340-3ksfpaf7	369	3	pericardial	pericardial	JJ
cord-034340-3ksfpaf7	369	4	and	and	CC
cord-034340-3ksfpaf7	369	5	pleural	pleural	JJ
cord-034340-3ksfpaf7	369	6	effusions	effusion	NNS
cord-034340-3ksfpaf7	369	7	,	,	,
cord-034340-3ksfpaf7	369	8	ascitis	ascitis	NNP
cord-034340-3ksfpaf7	369	9	)	)	-RRB-
cord-034340-3ksfpaf7	369	10	and	and	CC
cord-034340-3ksfpaf7	369	11	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-034340-3ksfpaf7	369	12	were	be	VBD
cord-034340-3ksfpaf7	369	13	present	present	JJ
cord-034340-3ksfpaf7	369	14	.	.	.
cord-034340-3ksfpaf7	370	1	Lower	low	JJR
cord-034340-3ksfpaf7	370	2	limb	limb	NN
cord-034340-3ksfpaf7	370	3	MRI	MRI	NNP
cord-034340-3ksfpaf7	370	4	documented	document	VBD
cord-034340-3ksfpaf7	370	5	diffuse	diffuse	JJ
cord-034340-3ksfpaf7	370	6	muscle	muscle	NN
cord-034340-3ksfpaf7	370	7	edema	edema	NN
cord-034340-3ksfpaf7	370	8	.	.	.
cord-034340-3ksfpaf7	371	1	The	the	DT
cord-034340-3ksfpaf7	371	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	371	3	of	of	IN
cord-034340-3ksfpaf7	371	4	an	an	DT
cord-034340-3ksfpaf7	371	5	overlap	overlap	NN
cord-034340-3ksfpaf7	371	6	syndrome	syndrome	NN
cord-034340-3ksfpaf7	371	7	of	of	IN
cord-034340-3ksfpaf7	371	8	jSLE	jSLE	NNP
cord-034340-3ksfpaf7	371	9	and	and	CC
cord-034340-3ksfpaf7	371	10	IIM	IIM	NNP
cord-034340-3ksfpaf7	371	11	was	be	VBD
cord-034340-3ksfpaf7	371	12	established	establish	VBN
cord-034340-3ksfpaf7	371	13	.	.	.
cord-034340-3ksfpaf7	372	1	While	while	IN
cord-034340-3ksfpaf7	372	2	being	be	VBG
cord-034340-3ksfpaf7	372	3	treated	treat	VBN
cord-034340-3ksfpaf7	372	4	for	for	IN
cord-034340-3ksfpaf7	372	5	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	372	6	bacteremia	bacteremia	NN
cord-034340-3ksfpaf7	372	7	,	,	,
cord-034340-3ksfpaf7	372	8	the	the	DT
cord-034340-3ksfpaf7	372	9	patient	patient	NN
cord-034340-3ksfpaf7	372	10	became	become	VBD
cord-034340-3ksfpaf7	372	11	ill	ill	RB
cord-034340-3ksfpaf7	372	12	-	-	HYPH
cord-034340-3ksfpaf7	372	13	appearing	appear	VBG
cord-034340-3ksfpaf7	372	14	,	,	,
cord-034340-3ksfpaf7	372	15	with	with	IN
cord-034340-3ksfpaf7	372	16	persistent	persistent	JJ
cord-034340-3ksfpaf7	372	17	fevers	fever	NNS
cord-034340-3ksfpaf7	372	18	,	,	,
cord-034340-3ksfpaf7	372	19	worsened	worsen	VBD
cord-034340-3ksfpaf7	372	20	cytopenias	cytopenia	NNS
cord-034340-3ksfpaf7	372	21	,	,	,
cord-034340-3ksfpaf7	372	22	low	low	JJ
cord-034340-3ksfpaf7	372	23	fibrinogen	fibrinogen	NN
cord-034340-3ksfpaf7	372	24	and	and	CC
cord-034340-3ksfpaf7	372	25	high	high	JJ
cord-034340-3ksfpaf7	372	26	ferritin	ferritin	NN
cord-034340-3ksfpaf7	372	27	and	and	CC
cord-034340-3ksfpaf7	372	28	triglycerides	triglyceride	NNS
cord-034340-3ksfpaf7	372	29	,	,	,
cord-034340-3ksfpaf7	372	30	and	and	CC
cord-034340-3ksfpaf7	372	31	a	a	DT
cord-034340-3ksfpaf7	372	32	Macrophage	Macrophage	NNP
cord-034340-3ksfpaf7	372	33	Activation	Activation	NNP
cord-034340-3ksfpaf7	372	34	Syndrome	Syndrome	NNP
cord-034340-3ksfpaf7	372	35	(	(	-LRB-
cord-034340-3ksfpaf7	372	36	MAS	MAS	NNP
cord-034340-3ksfpaf7	372	37	)	)	-RRB-
cord-034340-3ksfpaf7	372	38	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	372	39	was	be	VBD
cord-034340-3ksfpaf7	372	40	assumed	assume	VBN
cord-034340-3ksfpaf7	372	41	.	.	.
cord-034340-3ksfpaf7	373	1	The	the	DT
cord-034340-3ksfpaf7	373	2	patient	patient	NN
cord-034340-3ksfpaf7	373	3	received	receive	VBD
cord-034340-3ksfpaf7	373	4	antibiotics	antibiotic	NNS
cord-034340-3ksfpaf7	373	5	and	and	CC
cord-034340-3ksfpaf7	373	6	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	373	7	immunoglobulin	immunoglobulin	NN
cord-034340-3ksfpaf7	373	8	,	,	,
cord-034340-3ksfpaf7	373	9	followed	follow	VBN
cord-034340-3ksfpaf7	373	10	by	by	IN
cord-034340-3ksfpaf7	373	11	methylprednisolone	methylprednisolone	NNP
cord-034340-3ksfpaf7	373	12	pulses	pulse	NNS
cord-034340-3ksfpaf7	373	13	,	,	,
cord-034340-3ksfpaf7	373	14	IV	IV	NNP
cord-034340-3ksfpaf7	373	15	cyclosporine	cyclosporine	NN
cord-034340-3ksfpaf7	373	16	(	(	-LRB-
cord-034340-3ksfpaf7	373	17	CYC	CYC	NNP
cord-034340-3ksfpaf7	373	18	)	)	-RRB-
cord-034340-3ksfpaf7	373	19	,	,	,
cord-034340-3ksfpaf7	373	20	hydroxychloroquine	hydroxychloroquine	NNP
cord-034340-3ksfpaf7	373	21	and	and	CC
cord-034340-3ksfpaf7	373	22	supportive	supportive	JJ
cord-034340-3ksfpaf7	373	23	therapy	therapy	NN
cord-034340-3ksfpaf7	373	24	with	with	IN
cord-034340-3ksfpaf7	373	25	progressive	progressive	JJ
cord-034340-3ksfpaf7	373	26	improvement	improvement	NN
cord-034340-3ksfpaf7	373	27	.	.	.
cord-034340-3ksfpaf7	374	1	Due	due	IN
cord-034340-3ksfpaf7	374	2	to	to	IN
cord-034340-3ksfpaf7	374	3	hypertension	hypertension	NN
cord-034340-3ksfpaf7	374	4	(	(	-LRB-
cord-034340-3ksfpaf7	374	5	possibly	possibly	RB
cord-034340-3ksfpaf7	374	6	related	related	JJ
cord-034340-3ksfpaf7	374	7	to	to	IN
cord-034340-3ksfpaf7	374	8	CYC	CYC	NNP
cord-034340-3ksfpaf7	374	9	)	)	-RRB-
cord-034340-3ksfpaf7	374	10	and	and	CC
cord-034340-3ksfpaf7	374	11	persistent	persistent	JJ
cord-034340-3ksfpaf7	374	12	proteinuria	proteinuria	NN
cord-034340-3ksfpaf7	374	13	a	a	DT
cord-034340-3ksfpaf7	374	14	renal	renal	JJ
cord-034340-3ksfpaf7	374	15	biopsy	biopsy	NN
cord-034340-3ksfpaf7	374	16	was	be	VBD
cord-034340-3ksfpaf7	374	17	performed	perform	VBN
cord-034340-3ksfpaf7	374	18	showing	show	VBG
cord-034340-3ksfpaf7	374	19	class	class	NN
cord-034340-3ksfpaf7	374	20	IV	IV	NNP
cord-034340-3ksfpaf7	374	21	lupus	lupus	NN
cord-034340-3ksfpaf7	374	22	nephritis	nephritis	NN
cord-034340-3ksfpaf7	374	23	.	.	.
cord-034340-3ksfpaf7	375	1	After	after	IN
cord-034340-3ksfpaf7	375	2	achieving	achieve	VBG
cord-034340-3ksfpaf7	375	3	clinical	clinical	JJ
cord-034340-3ksfpaf7	375	4	stability	stability	NN
cord-034340-3ksfpaf7	375	5	,	,	,
cord-034340-3ksfpaf7	375	6	CYC	CYC	NNP
cord-034340-3ksfpaf7	375	7	was	be	VBD
cord-034340-3ksfpaf7	375	8	switched	switch	VBN
cord-034340-3ksfpaf7	375	9	to	to	IN
cord-034340-3ksfpaf7	375	10	mycophenolate	mycophenolate	NNP
cord-034340-3ksfpaf7	375	11	mofetil	mofetil	NNP
cord-034340-3ksfpaf7	375	12	as	as	IN
cord-034340-3ksfpaf7	375	13	an	an	DT
cord-034340-3ksfpaf7	375	14	induction	induction	NN
cord-034340-3ksfpaf7	375	15	treatment	treatment	NN
cord-034340-3ksfpaf7	375	16	,	,	,
cord-034340-3ksfpaf7	375	17	which	which	WDT
cord-034340-3ksfpaf7	375	18	is	be	VBZ
cord-034340-3ksfpaf7	375	19	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	375	20	.	.	.
cord-034340-3ksfpaf7	376	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	376	2	:	:	:
cord-034340-3ksfpaf7	376	3	IMM	IMM	NNP
cord-034340-3ksfpaf7	376	4	with	with	IN
cord-034340-3ksfpaf7	376	5	SLE	SLE	NNP
cord-034340-3ksfpaf7	376	6	OS	OS	NNP
cord-034340-3ksfpaf7	376	7	is	be	VBZ
cord-034340-3ksfpaf7	376	8	uncommon	uncommon	JJ
cord-034340-3ksfpaf7	376	9	,	,	,
cord-034340-3ksfpaf7	376	10	and	and	CC
cord-034340-3ksfpaf7	376	11	has	have	VBZ
cord-034340-3ksfpaf7	376	12	seldom	seldom	RB
cord-034340-3ksfpaf7	376	13	been	be	VBN
cord-034340-3ksfpaf7	376	14	described	describe	VBN
cord-034340-3ksfpaf7	376	15	in	in	IN
cord-034340-3ksfpaf7	376	16	children	child	NNS
cord-034340-3ksfpaf7	376	17	.	.	.
cord-034340-3ksfpaf7	377	1	In	in	IN
cord-034340-3ksfpaf7	377	2	addition	addition	NN
cord-034340-3ksfpaf7	377	3	to	to	IN
cord-034340-3ksfpaf7	377	4	fulfilling	fulfil	VBG
cord-034340-3ksfpaf7	377	5	SLE	SLE	NNP
cord-034340-3ksfpaf7	377	6	criteria	criterion	NNS
cord-034340-3ksfpaf7	377	7	,	,	,
cord-034340-3ksfpaf7	377	8	our	-PRON-	PRP$
cord-034340-3ksfpaf7	377	9	patient	patient	NN
cord-034340-3ksfpaf7	377	10	had	have	VBD
cord-034340-3ksfpaf7	377	11	clinical	clinical	JJ
cord-034340-3ksfpaf7	377	12	,	,	,
cord-034340-3ksfpaf7	377	13	laboratory	laboratory	NN
cord-034340-3ksfpaf7	377	14	and	and	CC
cord-034340-3ksfpaf7	377	15	imagiologic	imagiologic	JJ
cord-034340-3ksfpaf7	377	16	evidence	evidence	NN
cord-034340-3ksfpaf7	377	17	of	of	IN
cord-034340-3ksfpaf7	377	18	IMM	IMM	NNP
cord-034340-3ksfpaf7	377	19	.	.	.
cord-034340-3ksfpaf7	378	1	The	the	DT
cord-034340-3ksfpaf7	378	2	presence	presence	NN
cord-034340-3ksfpaf7	378	3	of	of	IN
cord-034340-3ksfpaf7	378	4	myositis	myositis	NN
cord-034340-3ksfpaf7	378	5	specific	specific	JJ
cord-034340-3ksfpaf7	378	6	antibodies	antibody	NNS
cord-034340-3ksfpaf7	378	7	(	(	-LRB-
cord-034340-3ksfpaf7	378	8	especially	especially	RB
cord-034340-3ksfpaf7	378	9	anti	anti	JJ
cord-034340-3ksfpaf7	378	10	-	-	JJ
cord-034340-3ksfpaf7	378	11	Mi	Mi	NNP
cord-034340-3ksfpaf7	378	12	2	2	CD
cord-034340-3ksfpaf7	378	13	)	)	-RRB-
cord-034340-3ksfpaf7	378	14	further	further	RB
cord-034340-3ksfpaf7	378	15	supports	support	VBZ
cord-034340-3ksfpaf7	378	16	the	the	DT
cord-034340-3ksfpaf7	378	17	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	378	18	of	of	IN
cord-034340-3ksfpaf7	378	19	an	an	DT
cord-034340-3ksfpaf7	378	20	OS	OS	NNP
cord-034340-3ksfpaf7	378	21	rather	rather	RB
cord-034340-3ksfpaf7	378	22	than	than	IN
cord-034340-3ksfpaf7	378	23	an	an	DT
cord-034340-3ksfpaf7	378	24	atypical	atypical	JJ
cord-034340-3ksfpaf7	378	25	presentation	presentation	NN
cord-034340-3ksfpaf7	378	26	of	of	IN
cord-034340-3ksfpaf7	378	27	a	a	DT
cord-034340-3ksfpaf7	378	28	lupus	lupus	NN
cord-034340-3ksfpaf7	378	29	myopathy	myopathy	NN
cord-034340-3ksfpaf7	378	30	.	.	.
cord-034340-3ksfpaf7	379	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	379	2	dermatomyositis	dermatomyositis	NN
cord-034340-3ksfpaf7	379	3	appears	appear	VBZ
cord-034340-3ksfpaf7	379	4	to	to	TO
cord-034340-3ksfpaf7	379	5	be	be	VB
cord-034340-3ksfpaf7	379	6	the	the	DT
cord-034340-3ksfpaf7	379	7	IMM	IMM	NNP
cord-034340-3ksfpaf7	379	8	subtype	subtype	NN
cord-034340-3ksfpaf7	379	9	-it	-it	.
cord-034340-3ksfpaf7	380	1	is	be	VBZ
cord-034340-3ksfpaf7	380	2	associated	associate	VBN
cord-034340-3ksfpaf7	380	3	with	with	IN
cord-034340-3ksfpaf7	380	4	anti	anti	JJ
cord-034340-3ksfpaf7	380	5	-	-	JJ
cord-034340-3ksfpaf7	380	6	Mi	Mi	NNP
cord-034340-3ksfpaf7	380	7	2	2	CD
cord-034340-3ksfpaf7	380	8	,	,	,
cord-034340-3ksfpaf7	380	9	and	and	CC
cord-034340-3ksfpaf7	380	10	mild	mild	JJ
cord-034340-3ksfpaf7	380	11	heliotrope	heliotrope	NN
cord-034340-3ksfpaf7	380	12	and	and	CC
cord-034340-3ksfpaf7	380	13	eyelid	eyelid	NN
cord-034340-3ksfpaf7	380	14	edema	edema	NN
cord-034340-3ksfpaf7	380	15	are	be	VBP
cord-034340-3ksfpaf7	380	16	compatible	compatible	JJ
cord-034340-3ksfpaf7	380	17	.	.	.
cord-034340-3ksfpaf7	381	1	Facial	facial	JJ
cord-034340-3ksfpaf7	381	2	rash	rash	NN
cord-034340-3ksfpaf7	381	3	sparing	spare	VBG
cord-034340-3ksfpaf7	381	4	the	the	DT
cord-034340-3ksfpaf7	381	5	nasolabial	nasolabial	NN
cord-034340-3ksfpaf7	381	6	folds	fold	NNS
cord-034340-3ksfpaf7	381	7	is	be	VBZ
cord-034340-3ksfpaf7	381	8	more	more	RBR
cord-034340-3ksfpaf7	381	9	suggestive	suggestive	JJ
cord-034340-3ksfpaf7	381	10	of	of	IN
cord-034340-3ksfpaf7	381	11	SLE	SLE	NNP
cord-034340-3ksfpaf7	381	12	.	.	.
cord-034340-3ksfpaf7	382	1	MAS	MAS	NNP
cord-034340-3ksfpaf7	382	2	is	be	VBZ
cord-034340-3ksfpaf7	382	3	a	a	DT
cord-034340-3ksfpaf7	382	4	rare	rare	JJ
cord-034340-3ksfpaf7	382	5	but	but	CC
cord-034340-3ksfpaf7	382	6	life	life	NN
cord-034340-3ksfpaf7	382	7	-	-	HYPH
cord-034340-3ksfpaf7	382	8	threatening	threaten	VBG
cord-034340-3ksfpaf7	382	9	condition	condition	NN
cord-034340-3ksfpaf7	382	10	that	that	WDT
cord-034340-3ksfpaf7	382	11	should	should	MD
cord-034340-3ksfpaf7	382	12	be	be	VB
cord-034340-3ksfpaf7	382	13	suspected	suspect	VBN
cord-034340-3ksfpaf7	382	14	in	in	IN
cord-034340-3ksfpaf7	382	15	rheumatologic	rheumatologic	JJ
cord-034340-3ksfpaf7	382	16	conditions	condition	NNS
cord-034340-3ksfpaf7	382	17	and	and	CC
cord-034340-3ksfpaf7	382	18	might	may	MD
cord-034340-3ksfpaf7	382	19	be	be	VB
cord-034340-3ksfpaf7	382	20	triggered	trigger	VBN
cord-034340-3ksfpaf7	382	21	by	by	IN
cord-034340-3ksfpaf7	382	22	infections	infection	NNS
cord-034340-3ksfpaf7	382	23	or	or	CC
cord-034340-3ksfpaf7	382	24	disease	disease	NN
cord-034340-3ksfpaf7	382	25	flares	flare	NNS
cord-034340-3ksfpaf7	382	26	.	.	.
cord-034340-3ksfpaf7	383	1	Its	-PRON-	PRP$
cord-034340-3ksfpaf7	383	2	identification	identification	NN
cord-034340-3ksfpaf7	383	3	may	may	MD
cord-034340-3ksfpaf7	383	4	be	be	VB
cord-034340-3ksfpaf7	383	5	particularly	particularly	RB
cord-034340-3ksfpaf7	383	6	challenging	challenge	VBG
cord-034340-3ksfpaf7	383	7	at	at	IN
cord-034340-3ksfpaf7	383	8	presentation	presentation	NN
cord-034340-3ksfpaf7	383	9	,	,	,
cord-034340-3ksfpaf7	383	10	especially	especially	RB
cord-034340-3ksfpaf7	383	11	in	in	IN
cord-034340-3ksfpaf7	383	12	SLE	SLE	NNP
cord-034340-3ksfpaf7	383	13	where	where	WRB
cord-034340-3ksfpaf7	383	14	cytopenias	cytopenias	NNP
cord-034340-3ksfpaf7	383	15	are	be	VBP
cord-034340-3ksfpaf7	383	16	common	common	JJ
cord-034340-3ksfpaf7	383	17	.	.	.
cord-034340-3ksfpaf7	384	1	The	the	DT
cord-034340-3ksfpaf7	384	2	reported	report	VBN
cord-034340-3ksfpaf7	384	3	prevalence	prevalence	NN
cord-034340-3ksfpaf7	384	4	in	in	IN
cord-034340-3ksfpaf7	384	5	adult	adult	NN
cord-034340-3ksfpaf7	384	6	SLE	SLE	NNP
cord-034340-3ksfpaf7	384	7	ranges	range	VBZ
cord-034340-3ksfpaf7	384	8	from	from	IN
cord-034340-3ksfpaf7	384	9	0.9	0.9	CD
cord-034340-3ksfpaf7	384	10	%	%	NN
cord-034340-3ksfpaf7	384	11	to	to	IN
cord-034340-3ksfpaf7	384	12	4.6	4.6	CD
cord-034340-3ksfpaf7	384	13	%	%	NN
cord-034340-3ksfpaf7	384	14	;	;	,
cord-034340-3ksfpaf7	384	15	disease	disease	NN
cord-034340-3ksfpaf7	384	16	-	-	HYPH
cord-034340-3ksfpaf7	384	17	specific	specific	JJ
cord-034340-3ksfpaf7	384	18	criteria	criterion	NNS
cord-034340-3ksfpaf7	384	19	have	have	VBP
cord-034340-3ksfpaf7	384	20	been	be	VBN
cord-034340-3ksfpaf7	384	21	proposed	propose	VBN
cord-034340-3ksfpaf7	384	22	.	.	.
cord-034340-3ksfpaf7	385	1	MAS	MAS	NNP
cord-034340-3ksfpaf7	385	2	has	have	VBZ
cord-034340-3ksfpaf7	385	3	occasionally	occasionally	RB
cord-034340-3ksfpaf7	385	4	been	be	VBN
cord-034340-3ksfpaf7	385	5	described	describe	VBN
cord-034340-3ksfpaf7	385	6	in	in	IN
cord-034340-3ksfpaf7	385	7	IIM	IIM	NNP
cord-034340-3ksfpaf7	385	8	.	.	.
cord-034340-3ksfpaf7	386	1	In	in	IN
cord-034340-3ksfpaf7	386	2	a	a	DT
cord-034340-3ksfpaf7	386	3	patient	patient	NN
cord-034340-3ksfpaf7	386	4	with	with	IN
cord-034340-3ksfpaf7	386	5	a	a	DT
cord-034340-3ksfpaf7	386	6	predisposing	predisposing	JJ
cord-034340-3ksfpaf7	386	7	condition	condition	NN
cord-034340-3ksfpaf7	386	8	,	,	,
cord-034340-3ksfpaf7	386	9	persistent	persistent	JJ
cord-034340-3ksfpaf7	386	10	fevers	fever	NNS
cord-034340-3ksfpaf7	386	11	and	and	CC
cord-034340-3ksfpaf7	386	12	illappearance	illappearance	NN
cord-034340-3ksfpaf7	386	13	must	must	MD
cord-034340-3ksfpaf7	386	14	always	always	RB
cord-034340-3ksfpaf7	386	15	prompt	prompt	VB
cord-034340-3ksfpaf7	386	16	a	a	DT
cord-034340-3ksfpaf7	386	17	MAS	MAS	NNP
cord-034340-3ksfpaf7	386	18	workup	workup	NN
cord-034340-3ksfpaf7	386	19	,	,	,
cord-034340-3ksfpaf7	386	20	since	since	IN
cord-034340-3ksfpaf7	386	21	early	early	JJ
cord-034340-3ksfpaf7	386	22	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	386	23	and	and	CC
cord-034340-3ksfpaf7	386	24	treatment	treatment	NN
cord-034340-3ksfpaf7	386	25	are	be	VBP
cord-034340-3ksfpaf7	386	26	paramount	paramount	JJ
cord-034340-3ksfpaf7	386	27	.	.	.
cord-034340-3ksfpaf7	387	1	Due	due	IN
cord-034340-3ksfpaf7	387	2	to	to	IN
cord-034340-3ksfpaf7	387	3	an	an	DT
cord-034340-3ksfpaf7	387	4	early	early	JJ
cord-034340-3ksfpaf7	387	5	referral	referral	NN
cord-034340-3ksfpaf7	387	6	to	to	IN
cord-034340-3ksfpaf7	387	7	a	a	DT
cord-034340-3ksfpaf7	387	8	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	387	9	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	387	10	center	center	NN
cord-034340-3ksfpaf7	387	11	,	,	,
cord-034340-3ksfpaf7	387	12	the	the	DT
cord-034340-3ksfpaf7	387	13	patient	patient	NN
cord-034340-3ksfpaf7	387	14	received	receive	VBD
cord-034340-3ksfpaf7	387	15	a	a	DT
cord-034340-3ksfpaf7	387	16	prompt	prompt	JJ
cord-034340-3ksfpaf7	387	17	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	387	18	and	and	CC
cord-034340-3ksfpaf7	387	19	treatment	treatment	NN
cord-034340-3ksfpaf7	387	20	,	,	,
cord-034340-3ksfpaf7	387	21	which	which	WDT
cord-034340-3ksfpaf7	387	22	probably	probably	RB
cord-034340-3ksfpaf7	387	23	improved	improve	VBD
cord-034340-3ksfpaf7	387	24	her	-PRON-	PRP$
cord-034340-3ksfpaf7	387	25	prognosis	prognosis	NN
cord-034340-3ksfpaf7	387	26	.	.	.
cord-034340-3ksfpaf7	388	1	Results	result	NNS
cord-034340-3ksfpaf7	388	2	:	:	:
cord-034340-3ksfpaf7	389	1	Four	four	CD
cord-034340-3ksfpaf7	389	2	of	of	IN
cord-034340-3ksfpaf7	389	3	the	the	DT
cord-034340-3ksfpaf7	389	4	five	five	CD
cord-034340-3ksfpaf7	389	5	patients	patient	NNS
cord-034340-3ksfpaf7	389	6	were	be	VBD
cord-034340-3ksfpaf7	389	7	female	female	JJ
cord-034340-3ksfpaf7	389	8	(	(	-LRB-
cord-034340-3ksfpaf7	389	9	80	80	CD
cord-034340-3ksfpaf7	389	10	%	%	NN
cord-034340-3ksfpaf7	389	11	)	)	-RRB-
cord-034340-3ksfpaf7	389	12	and	and	CC
cord-034340-3ksfpaf7	389	13	all	all	DT
cord-034340-3ksfpaf7	389	14	aged	aged	JJ
cord-034340-3ksfpaf7	389	15	between	between	IN
cord-034340-3ksfpaf7	389	16	6	6	CD
cord-034340-3ksfpaf7	389	17	and	and	CC
cord-034340-3ksfpaf7	389	18	10	10	CD
cord-034340-3ksfpaf7	389	19	years	year	NNS
cord-034340-3ksfpaf7	389	20	.	.	.
cord-034340-3ksfpaf7	390	1	Four	four	CD
cord-034340-3ksfpaf7	390	2	of	of	IN
cord-034340-3ksfpaf7	390	3	them	-PRON-	PRP
cord-034340-3ksfpaf7	390	4	had	have	VBD
cord-034340-3ksfpaf7	390	5	calcinosis	calcinosis	NN
cord-034340-3ksfpaf7	390	6	at	at	IN
cord-034340-3ksfpaf7	390	7	the	the	DT
cord-034340-3ksfpaf7	390	8	time	time	NN
cord-034340-3ksfpaf7	390	9	of	of	IN
cord-034340-3ksfpaf7	390	10	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	390	11	,	,	,
cord-034340-3ksfpaf7	390	12	although	although	IN
cord-034340-3ksfpaf7	390	13	they	-PRON-	PRP
cord-034340-3ksfpaf7	390	14	may	may	MD
cord-034340-3ksfpaf7	390	15	have	have	VB
cord-034340-3ksfpaf7	390	16	had	have	VBN
cord-034340-3ksfpaf7	390	17	symptoms	symptom	NNS
cord-034340-3ksfpaf7	390	18	for	for	IN
cord-034340-3ksfpaf7	390	19	12	12	CD
cord-034340-3ksfpaf7	390	20	to	to	TO
cord-034340-3ksfpaf7	390	21	18	18	CD
cord-034340-3ksfpaf7	390	22	months	month	NNS
cord-034340-3ksfpaf7	390	23	prior	prior	RB
cord-034340-3ksfpaf7	390	24	to	to	IN
cord-034340-3ksfpaf7	390	25	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	390	26	.	.	.
cord-034340-3ksfpaf7	391	1	Skin	skin	NN
cord-034340-3ksfpaf7	391	2	involvement	involvement	NN
cord-034340-3ksfpaf7	391	3	was	be	VBD
cord-034340-3ksfpaf7	391	4	severe	severe	JJ
cord-034340-3ksfpaf7	391	5	requiring	require	VBG
cord-034340-3ksfpaf7	391	6	multiple	multiple	JJ
cord-034340-3ksfpaf7	391	7	systemic	systemic	JJ
cord-034340-3ksfpaf7	391	8	and	and	CC
cord-034340-3ksfpaf7	391	9	topical	topical	JJ
cord-034340-3ksfpaf7	391	10	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	391	11	agents	agent	NNS
cord-034340-3ksfpaf7	391	12	in	in	IN
cord-034340-3ksfpaf7	391	13	four	four	CD
cord-034340-3ksfpaf7	391	14	out	out	IN
cord-034340-3ksfpaf7	391	15	of	of	IN
cord-034340-3ksfpaf7	391	16	the	the	DT
cord-034340-3ksfpaf7	391	17	five	five	CD
cord-034340-3ksfpaf7	391	18	patients	patient	NNS
cord-034340-3ksfpaf7	391	19	-significantly	-significantly	RBS
cord-034340-3ksfpaf7	391	20	more	more	RBR
cord-034340-3ksfpaf7	391	21	affected	affected	JJ
cord-034340-3ksfpaf7	391	22	than	than	IN
cord-034340-3ksfpaf7	391	23	the	the	DT
cord-034340-3ksfpaf7	391	24	muscles	muscle	NNS
cord-034340-3ksfpaf7	391	25	.	.	.
cord-034340-3ksfpaf7	392	1	One	one	CD
cord-034340-3ksfpaf7	392	2	patient	patient	NN
cord-034340-3ksfpaf7	392	3	had	have	VBD
cord-034340-3ksfpaf7	392	4	amyopathic	amyopathic	JJ
cord-034340-3ksfpaf7	392	5	subtype	subtype	NN
cord-034340-3ksfpaf7	392	6	with	with	IN
cord-034340-3ksfpaf7	392	7	normal	normal	JJ
cord-034340-3ksfpaf7	392	8	Childhood	Childhood	NNP
cord-034340-3ksfpaf7	392	9	Myositis	Myositis	NNP
cord-034340-3ksfpaf7	392	10	Assessment	Assessment	NNP
cord-034340-3ksfpaf7	392	11	Score	Score	NNP
cord-034340-3ksfpaf7	392	12	(	(	-LRB-
cord-034340-3ksfpaf7	392	13	CMAS	CMAS	NNP
cord-034340-3ksfpaf7	392	14	)	)	-RRB-
cord-034340-3ksfpaf7	392	15	throughout	throughout	IN
cord-034340-3ksfpaf7	392	16	.	.	.
cord-034340-3ksfpaf7	393	1	None	none	NN
cord-034340-3ksfpaf7	393	2	of	of	IN
cord-034340-3ksfpaf7	393	3	them	-PRON-	PRP
cord-034340-3ksfpaf7	393	4	had	have	VBD
cord-034340-3ksfpaf7	393	5	cardiac	cardiac	JJ
cord-034340-3ksfpaf7	393	6	involvement	involvement	NN
cord-034340-3ksfpaf7	393	7	.	.	.
cord-034340-3ksfpaf7	394	1	All	all	DT
cord-034340-3ksfpaf7	394	2	had	have	VBD
cord-034340-3ksfpaf7	394	3	weakly	weakly	RB
cord-034340-3ksfpaf7	394	4	positive	positive	JJ
cord-034340-3ksfpaf7	394	5	Anti	Anti	NNP
cord-034340-3ksfpaf7	394	6	-	-	NNP
cord-034340-3ksfpaf7	394	7	Nuclear	Nuclear	NNP
cord-034340-3ksfpaf7	394	8	Antibodies	Antibodies	NNPS
cord-034340-3ksfpaf7	394	9	(	(	-LRB-
cord-034340-3ksfpaf7	394	10	ANA	ANA	NNP
cord-034340-3ksfpaf7	394	11	)	)	-RRB-
cord-034340-3ksfpaf7	394	12	;	;	:
cord-034340-3ksfpaf7	394	13	but	but	CC
cord-034340-3ksfpaf7	394	14	were	be	VBD
cord-034340-3ksfpaf7	394	15	negative	negative	JJ
cord-034340-3ksfpaf7	394	16	for	for	IN
cord-034340-3ksfpaf7	394	17	myositis	myositis	NN
cord-034340-3ksfpaf7	394	18	antibodies	antibody	NNS
cord-034340-3ksfpaf7	394	19	except	except	IN
cord-034340-3ksfpaf7	394	20	the	the	DT
cord-034340-3ksfpaf7	394	21	patient	patient	NN
cord-034340-3ksfpaf7	394	22	with	with	IN
cord-034340-3ksfpaf7	394	23	most	most	JJS
cord-034340-3ksfpaf7	394	24	severe	severe	JJ
cord-034340-3ksfpaf7	394	25	skin	skin	NN
cord-034340-3ksfpaf7	394	26	involvement	involvement	NN
cord-034340-3ksfpaf7	394	27	and	and	CC
cord-034340-3ksfpaf7	394	28	calcinosis	calcinosis	NN
cord-034340-3ksfpaf7	394	29	(	(	-LRB-
cord-034340-3ksfpaf7	394	30	patient	patient	NNP
cord-034340-3ksfpaf7	394	31	2	2	CD
cord-034340-3ksfpaf7	394	32	)	)	-RRB-
cord-034340-3ksfpaf7	394	33	,	,	,
cord-034340-3ksfpaf7	394	34	who	who	WP
cord-034340-3ksfpaf7	394	35	was	be	VBD
cord-034340-3ksfpaf7	394	36	positive	positive	JJ
cord-034340-3ksfpaf7	394	37	for	for	IN
cord-034340-3ksfpaf7	394	38	Anti	Anti	NNP
cord-034340-3ksfpaf7	394	39	-	-	JJ
cord-034340-3ksfpaf7	394	40	TIF1gamma	tif1gamma	JJ
cord-034340-3ksfpaf7	394	41	antibodies	antibody	NNS
cord-034340-3ksfpaf7	394	42	.	.	.
cord-034340-3ksfpaf7	395	1	Two	two	CD
cord-034340-3ksfpaf7	395	2	of	of	IN
cord-034340-3ksfpaf7	395	3	the	the	DT
cord-034340-3ksfpaf7	395	4	three	three	CD
cord-034340-3ksfpaf7	395	5	patients	patient	NNS
cord-034340-3ksfpaf7	395	6	with	with	IN
cord-034340-3ksfpaf7	395	7	calcinosis	calcinosis	NNP
cord-034340-3ksfpaf7	395	8	at	at	IN
cord-034340-3ksfpaf7	395	9	onset	onset	NN
cord-034340-3ksfpaf7	395	10	had	have	VBD
cord-034340-3ksfpaf7	395	11	Cyclophosphamide	Cyclophosphamide	NNP
cord-034340-3ksfpaf7	395	12	as	as	IN
cord-034340-3ksfpaf7	395	13	the	the	DT
cord-034340-3ksfpaf7	395	14	second	second	JJ
cord-034340-3ksfpaf7	395	15	line	line	NN
cord-034340-3ksfpaf7	395	16	agent	agent	NN
cord-034340-3ksfpaf7	395	17	(	(	-LRB-
cord-034340-3ksfpaf7	395	18	chosen	choose	VBN
cord-034340-3ksfpaf7	395	19	due	due	IN
cord-034340-3ksfpaf7	395	20	to	to	IN
cord-034340-3ksfpaf7	395	21	calcinosis	calcinosis	NN
cord-034340-3ksfpaf7	395	22	)	)	-RRB-
cord-034340-3ksfpaf7	395	23	following	follow	VBG
cord-034340-3ksfpaf7	395	24	systemic	systemic	JJ
cord-034340-3ksfpaf7	395	25	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	395	26	with	with	IN
cord-034340-3ksfpaf7	395	27	complete	complete	JJ
cord-034340-3ksfpaf7	395	28	resolution	resolution	NN
cord-034340-3ksfpaf7	395	29	of	of	IN
cord-034340-3ksfpaf7	395	30	the	the	DT
cord-034340-3ksfpaf7	395	31	lesions	lesion	NNS
cord-034340-3ksfpaf7	395	32	after	after	IN
cord-034340-3ksfpaf7	395	33	six	six	CD
cord-034340-3ksfpaf7	395	34	cycles	cycle	NNS
cord-034340-3ksfpaf7	395	35	at	at	IN
cord-034340-3ksfpaf7	395	36	500mg	500mg	NNP
cord-034340-3ksfpaf7	395	37	/	/	SYM
cord-034340-3ksfpaf7	395	38	m2	m2	NNP
cord-034340-3ksfpaf7	395	39	.	.	.
cord-034340-3ksfpaf7	396	1	One	one	CD
cord-034340-3ksfpaf7	396	2	patient	patient	NN
cord-034340-3ksfpaf7	396	3	responded	respond	VBD
cord-034340-3ksfpaf7	396	4	to	to	IN
cord-034340-3ksfpaf7	396	5	Infliximab	Infliximab	NNP
cord-034340-3ksfpaf7	396	6	,	,	,
cord-034340-3ksfpaf7	396	7	which	which	WDT
cord-034340-3ksfpaf7	396	8	failed	fail	VBD
cord-034340-3ksfpaf7	396	9	to	to	TO
cord-034340-3ksfpaf7	396	10	work	work	VB
cord-034340-3ksfpaf7	396	11	after	after	IN
cord-034340-3ksfpaf7	396	12	20	20	CD
cord-034340-3ksfpaf7	396	13	months	month	NNS
cord-034340-3ksfpaf7	396	14	,	,	,
cord-034340-3ksfpaf7	396	15	following	follow	VBG
cord-034340-3ksfpaf7	396	16	which	which	WDT
cord-034340-3ksfpaf7	396	17	Cyclophosphamide	Cyclophosphamide	NNP
cord-034340-3ksfpaf7	396	18	was	be	VBD
cord-034340-3ksfpaf7	396	19	tried	try	VBN
cord-034340-3ksfpaf7	396	20	with	with	IN
cord-034340-3ksfpaf7	396	21	good	good	JJ
cord-034340-3ksfpaf7	396	22	response	response	NN
cord-034340-3ksfpaf7	396	23	.	.	.
cord-034340-3ksfpaf7	397	1	The	the	DT
cord-034340-3ksfpaf7	397	2	other	other	JJ
cord-034340-3ksfpaf7	397	3	two	two	CD
cord-034340-3ksfpaf7	397	4	patients	patient	NNS
cord-034340-3ksfpaf7	397	5	were	be	VBD
cord-034340-3ksfpaf7	397	6	given	give	VBN
cord-034340-3ksfpaf7	397	7	Cyclophosphamide	Cyclophosphamide	NNP
cord-034340-3ksfpaf7	397	8	after	after	IN
cord-034340-3ksfpaf7	397	9	they	-PRON-	PRP
cord-034340-3ksfpaf7	397	10	failed	fail	VBD
cord-034340-3ksfpaf7	397	11	to	to	TO
cord-034340-3ksfpaf7	397	12	respond	respond	VB
cord-034340-3ksfpaf7	397	13	to	to	IN
cord-034340-3ksfpaf7	397	14	Rituximab	Rituximab	NNP
cord-034340-3ksfpaf7	397	15	,	,	,
cord-034340-3ksfpaf7	397	16	which	which	WDT
cord-034340-3ksfpaf7	397	17	did	do	VBD
cord-034340-3ksfpaf7	397	18	work	work	NN
cord-034340-3ksfpaf7	397	19	for	for	IN
cord-034340-3ksfpaf7	397	20	muscle	muscle	NN
cord-034340-3ksfpaf7	397	21	disease	disease	NN
cord-034340-3ksfpaf7	397	22	.	.	.
cord-034340-3ksfpaf7	398	1	One	one	CD
cord-034340-3ksfpaf7	398	2	patient	patient	NN
cord-034340-3ksfpaf7	398	3	had	have	VBD
cord-034340-3ksfpaf7	398	4	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	398	5	episodes	episode	NNS
cord-034340-3ksfpaf7	398	6	of	of	IN
cord-034340-3ksfpaf7	398	7	calcinosis	calcinosis	NN
cord-034340-3ksfpaf7	398	8	needing	need	VBG
cord-034340-3ksfpaf7	398	9	surgical	surgical	JJ
cord-034340-3ksfpaf7	398	10	curettage	curettage	NN
cord-034340-3ksfpaf7	398	11	despite	despite	IN
cord-034340-3ksfpaf7	398	12	initial	initial	JJ
cord-034340-3ksfpaf7	398	13	response	response	NN
cord-034340-3ksfpaf7	398	14	to	to	IN
cord-034340-3ksfpaf7	398	15	Cyclophosphamide	Cyclophosphamide	NNP
cord-034340-3ksfpaf7	398	16	and	and	CC
cord-034340-3ksfpaf7	398	17	later	later	RB
cord-034340-3ksfpaf7	398	18	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	398	19	.	.	.
cord-034340-3ksfpaf7	399	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	399	2	:	:	:
cord-034340-3ksfpaf7	400	1	Systemic	systemic	JJ
cord-034340-3ksfpaf7	400	2	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	400	3	Idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	400	4	Arthritis	arthritis	NN
cord-034340-3ksfpaf7	400	5	(	(	-LRB-
cord-034340-3ksfpaf7	400	6	sJIA	sjia	NN
cord-034340-3ksfpaf7	400	7	)	)	-RRB-
cord-034340-3ksfpaf7	400	8	is	be	VBZ
cord-034340-3ksfpaf7	400	9	a	a	DT
cord-034340-3ksfpaf7	400	10	unique	unique	JJ
cord-034340-3ksfpaf7	400	11	form	form	NN
cord-034340-3ksfpaf7	400	12	of	of	IN
cord-034340-3ksfpaf7	400	13	childhood	childhood	NN
cord-034340-3ksfpaf7	400	14	arthritis	arthritis	NN
cord-034340-3ksfpaf7	400	15	.	.	.
cord-034340-3ksfpaf7	401	1	According	accord	VBG
cord-034340-3ksfpaf7	401	2	to	to	IN
cord-034340-3ksfpaf7	401	3	current	current	JJ
cord-034340-3ksfpaf7	401	4	understanding	understanding	NN
cord-034340-3ksfpaf7	401	5	sJIA	sjia	NN
cord-034340-3ksfpaf7	401	6	is	be	VBZ
cord-034340-3ksfpaf7	401	7	primarily	primarily	RB
cord-034340-3ksfpaf7	401	8	driven	drive	VBN
cord-034340-3ksfpaf7	401	9	by	by	IN
cord-034340-3ksfpaf7	401	10	innate	innate	JJ
cord-034340-3ksfpaf7	401	11	immune	immune	JJ
cord-034340-3ksfpaf7	401	12	mechanisms	mechanism	NNS
cord-034340-3ksfpaf7	401	13	at	at	IN
cord-034340-3ksfpaf7	401	14	disease	disease	NN
cord-034340-3ksfpaf7	401	15	onset	onset	NN
cord-034340-3ksfpaf7	401	16	,	,	,
cord-034340-3ksfpaf7	401	17	but	but	CC
cord-034340-3ksfpaf7	401	18	can	can	MD
cord-034340-3ksfpaf7	401	19	progress	progress	VB
cord-034340-3ksfpaf7	401	20	towards	towards	IN
cord-034340-3ksfpaf7	401	21	chronic	chronic	JJ
cord-034340-3ksfpaf7	401	22	destructive	destructive	JJ
cord-034340-3ksfpaf7	401	23	arthritis	arthritis	NN
cord-034340-3ksfpaf7	401	24	,	,	,
cord-034340-3ksfpaf7	401	25	which	which	WDT
cord-034340-3ksfpaf7	401	26	can	can	MD
cord-034340-3ksfpaf7	401	27	involve	involve	VB
cord-034340-3ksfpaf7	401	28	T	T	NNP
cord-034340-3ksfpaf7	401	29	cellular	cellular	JJ
cord-034340-3ksfpaf7	401	30	immunity	immunity	NN
cord-034340-3ksfpaf7	401	31	.	.	.
cord-034340-3ksfpaf7	402	1	For	for	IN
cord-034340-3ksfpaf7	402	2	yet	yet	CC
cord-034340-3ksfpaf7	402	3	incompletely	incompletely	RB
cord-034340-3ksfpaf7	402	4	understood	understand	VBN
cord-034340-3ksfpaf7	402	5	reasons	reason	NNS
cord-034340-3ksfpaf7	402	6	,	,	,
cord-034340-3ksfpaf7	402	7	sJIA	sjia	NN
cord-034340-3ksfpaf7	402	8	can	can	MD
cord-034340-3ksfpaf7	402	9	be	be	VB
cord-034340-3ksfpaf7	402	10	complicated	complicate	VBN
cord-034340-3ksfpaf7	402	11	by	by	IN
cord-034340-3ksfpaf7	402	12	Macrophage	Macrophage	NNP
cord-034340-3ksfpaf7	402	13	Activation	Activation	NNP
cord-034340-3ksfpaf7	402	14	Syndrome	Syndrome	NNP
cord-034340-3ksfpaf7	402	15	(	(	-LRB-
cord-034340-3ksfpaf7	402	16	MAS	MAS	NNP
cord-034340-3ksfpaf7	402	17	)	)	-RRB-
cord-034340-3ksfpaf7	402	18	,	,	,
cord-034340-3ksfpaf7	402	19	a	a	DT
cord-034340-3ksfpaf7	402	20	severe	severe	JJ
cord-034340-3ksfpaf7	402	21	hyperinflammatory	hyperinflammatory	JJ
cord-034340-3ksfpaf7	402	22	condition	condition	NN
cord-034340-3ksfpaf7	402	23	characterized	characterize	VBN
cord-034340-3ksfpaf7	402	24	by	by	IN
cord-034340-3ksfpaf7	402	25	a	a	DT
cord-034340-3ksfpaf7	402	26	catastrophic	catastrophic	JJ
cord-034340-3ksfpaf7	402	27	cytokine	cytokine	NN
cord-034340-3ksfpaf7	402	28	storm	storm	NN
cord-034340-3ksfpaf7	402	29	resulting	result	VBG
cord-034340-3ksfpaf7	402	30	in	in	IN
cord-034340-3ksfpaf7	402	31	multiple	multiple	JJ
cord-034340-3ksfpaf7	402	32	organ	organ	NN
cord-034340-3ksfpaf7	402	33	failure	failure	NN
cord-034340-3ksfpaf7	402	34	and	and	CC
cord-034340-3ksfpaf7	402	35	high	high	JJ
cord-034340-3ksfpaf7	402	36	mortality	mortality	NN
cord-034340-3ksfpaf7	402	37	.	.	.
cord-034340-3ksfpaf7	403	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	403	2	:	:	:
cord-034340-3ksfpaf7	404	1	The	the	DT
cord-034340-3ksfpaf7	404	2	sJIA	sjia	JJ
cord-034340-3ksfpaf7	404	3	/	/	SYM
cord-034340-3ksfpaf7	404	4	MAS	MAS	NNP
cord-034340-3ksfpaf7	404	5	Working	Working	NNP
cord-034340-3ksfpaf7	404	6	Party	Party	NNP
cord-034340-3ksfpaf7	404	7	(	(	-LRB-
cord-034340-3ksfpaf7	404	8	WP	WP	NNP
cord-034340-3ksfpaf7	404	9	)	)	-RRB-
cord-034340-3ksfpaf7	404	10	aims	aim	VBZ
cord-034340-3ksfpaf7	404	11	to	to	TO
cord-034340-3ksfpaf7	404	12	promote	promote	VB
cord-034340-3ksfpaf7	404	13	knowledge	knowledge	NN
cord-034340-3ksfpaf7	404	14	and	and	CC
cord-034340-3ksfpaf7	404	15	international	international	JJ
cord-034340-3ksfpaf7	404	16	multidisciplinary	multidisciplinary	JJ
cord-034340-3ksfpaf7	404	17	collaboration	collaboration	NN
cord-034340-3ksfpaf7	404	18	among	among	IN
cord-034340-3ksfpaf7	404	19	experts	expert	NNS
cord-034340-3ksfpaf7	404	20	in	in	IN
cord-034340-3ksfpaf7	404	21	the	the	DT
cord-034340-3ksfpaf7	404	22	field	field	NN
cord-034340-3ksfpaf7	404	23	of	of	IN
cord-034340-3ksfpaf7	404	24	MAS	MAS	NNP
cord-034340-3ksfpaf7	404	25	and	and	CC
cord-034340-3ksfpaf7	404	26	sJIA	sjia	NN
cord-034340-3ksfpaf7	404	27	and	and	CC
cord-034340-3ksfpaf7	404	28	to	to	TO
cord-034340-3ksfpaf7	404	29	foster	foster	VB
cord-034340-3ksfpaf7	404	30	translational	translational	JJ
cord-034340-3ksfpaf7	404	31	research	research	NN
cord-034340-3ksfpaf7	404	32	in	in	IN
cord-034340-3ksfpaf7	404	33	order	order	NN
cord-034340-3ksfpaf7	404	34	to	to	TO
cord-034340-3ksfpaf7	404	35	improve	improve	VB
cord-034340-3ksfpaf7	404	36	the	the	DT
cord-034340-3ksfpaf7	404	37	care	care	NN
cord-034340-3ksfpaf7	404	38	and	and	CC
cord-034340-3ksfpaf7	404	39	outcome	outcome	NN
cord-034340-3ksfpaf7	404	40	of	of	IN
cord-034340-3ksfpaf7	404	41	these	these	DT
cord-034340-3ksfpaf7	404	42	patients	patient	NNS
cord-034340-3ksfpaf7	404	43	Methods	method	NNS
cord-034340-3ksfpaf7	404	44	:	:	:
cord-034340-3ksfpaf7	404	45	Currently	currently	RB
cord-034340-3ksfpaf7	404	46	60	60	CD
cord-034340-3ksfpaf7	404	47	PReS	pres	JJ
cord-034340-3ksfpaf7	404	48	members	member	NNS
cord-034340-3ksfpaf7	404	49	participate	participate	VBP
cord-034340-3ksfpaf7	404	50	to	to	IN
cord-034340-3ksfpaf7	404	51	the	the	DT
cord-034340-3ksfpaf7	404	52	MAS	MAS	NNP
cord-034340-3ksfpaf7	404	53	/	/	SYM
cord-034340-3ksfpaf7	404	54	sJIA	sjia	JJ
cord-034340-3ksfpaf7	404	55	WP	WP	NNP
cord-034340-3ksfpaf7	404	56	.	.	.
cord-034340-3ksfpaf7	405	1	The	the	DT
cord-034340-3ksfpaf7	405	2	WP	WP	NNP
cord-034340-3ksfpaf7	405	3	arranges	arrange	VBZ
cord-034340-3ksfpaf7	405	4	an	an	DT
cord-034340-3ksfpaf7	405	5	annual	annual	JJ
cord-034340-3ksfpaf7	405	6	meeting	meeting	NN
cord-034340-3ksfpaf7	405	7	during	during	IN
cord-034340-3ksfpaf7	405	8	the	the	DT
cord-034340-3ksfpaf7	405	9	PReS	PReS	NNP
cord-034340-3ksfpaf7	405	10	Congress	Congress	NNP
cord-034340-3ksfpaf7	405	11	,	,	,
cord-034340-3ksfpaf7	405	12	open	open	JJ
cord-034340-3ksfpaf7	405	13	to	to	IN
cord-034340-3ksfpaf7	405	14	all	all	DT
cord-034340-3ksfpaf7	405	15	members	member	NNS
cord-034340-3ksfpaf7	405	16	activities	activity	NNS
cord-034340-3ksfpaf7	405	17	.	.	.
cord-034340-3ksfpaf7	406	1	The	the	DT
cord-034340-3ksfpaf7	406	2	MAS	MAS	NNP
cord-034340-3ksfpaf7	406	3	/	/	SYM
cord-034340-3ksfpaf7	406	4	sJIA	sjia	JJ
cord-034340-3ksfpaf7	406	5	WP	WP	NNP
cord-034340-3ksfpaf7	406	6	core	core	NN
cord-034340-3ksfpaf7	406	7	team	team	NN
cord-034340-3ksfpaf7	406	8	frequently	frequently	RB
cord-034340-3ksfpaf7	406	9	report	report	VBP
cord-034340-3ksfpaf7	406	10	about	about	IN
cord-034340-3ksfpaf7	406	11	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	406	12	activities	activity	NNS
cord-034340-3ksfpaf7	406	13	by	by	IN
cord-034340-3ksfpaf7	406	14	email	email	NN
cord-034340-3ksfpaf7	406	15	.	.	.
cord-034340-3ksfpaf7	407	1	Results	result	NNS
cord-034340-3ksfpaf7	407	2	:	:	:
cord-034340-3ksfpaf7	408	1	Several	several	JJ
cord-034340-3ksfpaf7	408	2	studies	study	NNS
cord-034340-3ksfpaf7	408	3	are	be	VBP
cord-034340-3ksfpaf7	408	4	currently	currently	RB
cord-034340-3ksfpaf7	408	5	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	408	6	.	.	.
cord-034340-3ksfpaf7	409	1	A	a	DT
cord-034340-3ksfpaf7	409	2	project	project	NN
cord-034340-3ksfpaf7	409	3	aimed	aim	VBN
cord-034340-3ksfpaf7	409	4	to	to	TO
cord-034340-3ksfpaf7	409	5	establish	establish	VB
cord-034340-3ksfpaf7	409	6	and	and	CC
cord-034340-3ksfpaf7	409	7	validate	validate	VB
cord-034340-3ksfpaf7	409	8	a	a	DT
cord-034340-3ksfpaf7	409	9	risk	risk	NN
cord-034340-3ksfpaf7	409	10	score	score	NN
cord-034340-3ksfpaf7	409	11	for	for	IN
cord-034340-3ksfpaf7	409	12	MAS	MAS	NNP
cord-034340-3ksfpaf7	409	13	in	in	IN
cord-034340-3ksfpaf7	409	14	sJIA	sjia	JJ
cord-034340-3ksfpaf7	409	15	patients	patient	NNS
cord-034340-3ksfpaf7	409	16	using	use	VBG
cord-034340-3ksfpaf7	409	17	routine	routine	JJ
cord-034340-3ksfpaf7	409	18	laboratory	laboratory	NN
cord-034340-3ksfpaf7	409	19	parameters	parameter	NNS
cord-034340-3ksfpaf7	409	20	of	of	IN
cord-034340-3ksfpaf7	409	21	disease	disease	NN
cord-034340-3ksfpaf7	409	22	activity	activity	NN
cord-034340-3ksfpaf7	409	23	and	and	CC
cord-034340-3ksfpaf7	409	24	severity	severity	NN
cord-034340-3ksfpaf7	409	25	has	have	VBZ
cord-034340-3ksfpaf7	409	26	already	already	RB
cord-034340-3ksfpaf7	409	27	completed	complete	VBN
cord-034340-3ksfpaf7	409	28	the	the	DT
cord-034340-3ksfpaf7	409	29	construction	construction	NN
cord-034340-3ksfpaf7	409	30	phase	phase	NN
cord-034340-3ksfpaf7	409	31	.	.	.
cord-034340-3ksfpaf7	410	1	Recently	recently	RB
cord-034340-3ksfpaf7	410	2	,	,	,
cord-034340-3ksfpaf7	410	3	building	build	VBG
cord-034340-3ksfpaf7	410	4	of	of	IN
cord-034340-3ksfpaf7	410	5	a	a	DT
cord-034340-3ksfpaf7	410	6	validation	validation	NN
cord-034340-3ksfpaf7	410	7	cohort	cohort	NN
cord-034340-3ksfpaf7	410	8	comprising	comprise	VBG
cord-034340-3ksfpaf7	410	9	data	datum	NNS
cord-034340-3ksfpaf7	410	10	form	form	NN
cord-034340-3ksfpaf7	410	11	182	182	CD
cord-034340-3ksfpaf7	410	12	patients	patient	NNS
cord-034340-3ksfpaf7	410	13	from	from	IN
cord-034340-3ksfpaf7	410	14	10	10	CD
cord-034340-3ksfpaf7	410	15	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	410	16	rheumatologic	rheumatologic	JJ
cord-034340-3ksfpaf7	410	17	centers	center	NNS
cord-034340-3ksfpaf7	410	18	has	have	VBZ
cord-034340-3ksfpaf7	410	19	been	be	VBN
cord-034340-3ksfpaf7	410	20	accomplished	accomplish	VBN
cord-034340-3ksfpaf7	410	21	and	and	CC
cord-034340-3ksfpaf7	410	22	is	be	VBZ
cord-034340-3ksfpaf7	410	23	awaiting	await	VBG
cord-034340-3ksfpaf7	410	24	analysis	analysis	NN
cord-034340-3ksfpaf7	410	25	(	(	-LRB-
cord-034340-3ksfpaf7	410	26	Claudia	Claudia	NNP
cord-034340-3ksfpaf7	410	27	Bracaglia	Bracaglia	NNP
cord-034340-3ksfpaf7	410	28	)	)	-RRB-
cord-034340-3ksfpaf7	410	29	.	.	.
cord-034340-3ksfpaf7	411	1	A	a	DT
cord-034340-3ksfpaf7	411	2	second	second	JJ
cord-034340-3ksfpaf7	411	3	project	project	NN
cord-034340-3ksfpaf7	411	4	focused	focus	VBN
cord-034340-3ksfpaf7	411	5	on	on	IN
cord-034340-3ksfpaf7	411	6	MAS	MAS	NNP
cord-034340-3ksfpaf7	411	7	patients	patient	NNS
cord-034340-3ksfpaf7	411	8	with	with	IN
cord-034340-3ksfpaf7	411	9	systemic	systemic	JJ
cord-034340-3ksfpaf7	411	10	thrombotic	thrombotic	JJ
cord-034340-3ksfpaf7	411	11	microangiopathy	microangiopathy	NN
cord-034340-3ksfpaf7	411	12	(	(	-LRB-
cord-034340-3ksfpaf7	411	13	TMA	TMA	NNP
cord-034340-3ksfpaf7	411	14	)	)	-RRB-
cord-034340-3ksfpaf7	411	15	has	have	VBZ
cord-034340-3ksfpaf7	411	16	just	just	RB
cord-034340-3ksfpaf7	411	17	completed	complete	VBN
cord-034340-3ksfpaf7	411	18	the	the	DT
cord-034340-3ksfpaf7	411	19	collection	collection	NN
cord-034340-3ksfpaf7	411	20	of	of	IN
cord-034340-3ksfpaf7	411	21	27	27	CD
cord-034340-3ksfpaf7	411	22	patients	patient	NNS
cord-034340-3ksfpaf7	411	23	with	with	IN
cord-034340-3ksfpaf7	411	24	MAS	MAS	NNP
cord-034340-3ksfpaf7	411	25	and	and	CC
cord-034340-3ksfpaf7	411	26	TMA	TMA	NNP
cord-034340-3ksfpaf7	411	27	from	from	IN
cord-034340-3ksfpaf7	411	28	18	18	CD
cord-034340-3ksfpaf7	411	29	centers	center	NNS
cord-034340-3ksfpaf7	411	30	in	in	IN
cord-034340-3ksfpaf7	411	31	9	9	CD
cord-034340-3ksfpaf7	411	32	countries	country	NNS
cord-034340-3ksfpaf7	411	33	and	and	CC
cord-034340-3ksfpaf7	411	34	results	result	NNS
cord-034340-3ksfpaf7	411	35	will	will	MD
cord-034340-3ksfpaf7	411	36	soon	soon	RB
cord-034340-3ksfpaf7	411	37	be	be	VB
cord-034340-3ksfpaf7	411	38	published	publish	VBN
cord-034340-3ksfpaf7	411	39	(	(	-LRB-
cord-034340-3ksfpaf7	411	40	Francesca	Francesca	NNP
cord-034340-3ksfpaf7	411	41	Minoia	Minoia	NNP
cord-034340-3ksfpaf7	411	42	)	)	-RRB-
cord-034340-3ksfpaf7	411	43	.	.	.
cord-034340-3ksfpaf7	412	1	Furthermore	furthermore	RB
cord-034340-3ksfpaf7	412	2	,	,	,
cord-034340-3ksfpaf7	412	3	the	the	DT
cord-034340-3ksfpaf7	412	4	MAS	MAS	NNP
cord-034340-3ksfpaf7	412	5	/	/	SYM
cord-034340-3ksfpaf7	412	6	sJIA	sjia	JJ
cord-034340-3ksfpaf7	412	7	WP	WP	NNP
cord-034340-3ksfpaf7	412	8	participated	participate	VBD
cord-034340-3ksfpaf7	412	9	in	in	IN
cord-034340-3ksfpaf7	412	10	the	the	DT
cord-034340-3ksfpaf7	412	11	data	data	NN
cord-034340-3ksfpaf7	412	12	collection	collection	NN
cord-034340-3ksfpaf7	412	13	phase	phase	NN
cord-034340-3ksfpaf7	412	14	of	of	IN
cord-034340-3ksfpaf7	412	15	a	a	DT
cord-034340-3ksfpaf7	412	16	project	project	NN
cord-034340-3ksfpaf7	412	17	on	on	IN
cord-034340-3ksfpaf7	412	18	the	the	DT
cord-034340-3ksfpaf7	412	19	development	development	NN
cord-034340-3ksfpaf7	412	20	of	of	IN
cord-034340-3ksfpaf7	412	21	new	new	JJ
cord-034340-3ksfpaf7	412	22	criteria	criterion	NNS
cord-034340-3ksfpaf7	412	23	for	for	IN
cord-034340-3ksfpaf7	412	24	primary	primary	JJ
cord-034340-3ksfpaf7	412	25	HLH	HLH	NNP
cord-034340-3ksfpaf7	413	1	(	(	-LRB-
cord-034340-3ksfpaf7	413	2	Jan	Jan	NNP
cord-034340-3ksfpaf7	413	3	-	-	HYPH
cord-034340-3ksfpaf7	413	4	Inge	Inge	NNP
cord-034340-3ksfpaf7	413	5	Henter	Henter	NNP
cord-034340-3ksfpaf7	413	6	and	and	CC
cord-034340-3ksfpaf7	413	7	AnnaCarin	AnnaCarin	NNP
cord-034340-3ksfpaf7	413	8	Horne	Horne	NNP
cord-034340-3ksfpaf7	413	9	Introduction	introduction	NN
cord-034340-3ksfpaf7	413	10	:	:	:
cord-034340-3ksfpaf7	414	1	Hemophagocytic	hemophagocytic	JJ
cord-034340-3ksfpaf7	414	2	lymphohistiocytosis	lymphohistiocytosis	NN
cord-034340-3ksfpaf7	414	3	(	(	-LRB-
cord-034340-3ksfpaf7	414	4	HLH	HLH	NNP
cord-034340-3ksfpaf7	414	5	)	)	-RRB-
cord-034340-3ksfpaf7	414	6	is	be	VBZ
cord-034340-3ksfpaf7	414	7	an	an	DT
cord-034340-3ksfpaf7	414	8	immunological	immunological	JJ
cord-034340-3ksfpaf7	414	9	disorder	disorder	NN
cord-034340-3ksfpaf7	414	10	characterized	characterize	VBN
cord-034340-3ksfpaf7	414	11	by	by	IN
cord-034340-3ksfpaf7	414	12	clinical	clinical	JJ
cord-034340-3ksfpaf7	414	13	signs	sign	NNS
cord-034340-3ksfpaf7	414	14	and	and	CC
cord-034340-3ksfpaf7	414	15	symptoms	symptom	NNS
cord-034340-3ksfpaf7	414	16	of	of	IN
cord-034340-3ksfpaf7	414	17	severe	severe	JJ
cord-034340-3ksfpaf7	414	18	uncontrolled	uncontrolled	JJ
cord-034340-3ksfpaf7	414	19	inflammation	inflammation	NN
cord-034340-3ksfpaf7	414	20	,	,	,
cord-034340-3ksfpaf7	414	21	due	due	IN
cord-034340-3ksfpaf7	414	22	to	to	IN
cord-034340-3ksfpaf7	414	23	massive	massive	JJ
cord-034340-3ksfpaf7	414	24	release	release	NN
cord-034340-3ksfpaf7	414	25	of	of	IN
cord-034340-3ksfpaf7	414	26	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	414	27	cytokines	cytokine	NNS
cord-034340-3ksfpaf7	414	28	.	.	.
cord-034340-3ksfpaf7	415	1	A	a	DT
cord-034340-3ksfpaf7	415	2	delay	delay	NN
cord-034340-3ksfpaf7	415	3	in	in	IN
cord-034340-3ksfpaf7	415	4	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	415	5	is	be	VBZ
cord-034340-3ksfpaf7	415	6	common	common	JJ
cord-034340-3ksfpaf7	415	7	,	,	,
cord-034340-3ksfpaf7	415	8	and	and	CC
cord-034340-3ksfpaf7	415	9	is	be	VBZ
cord-034340-3ksfpaf7	415	10	one	one	CD
cord-034340-3ksfpaf7	415	11	of	of	IN
cord-034340-3ksfpaf7	415	12	the	the	DT
cord-034340-3ksfpaf7	415	13	factors	factor	NNS
cord-034340-3ksfpaf7	415	14	that	that	WDT
cord-034340-3ksfpaf7	415	15	determine	determine	VBP
cord-034340-3ksfpaf7	415	16	the	the	DT
cord-034340-3ksfpaf7	415	17	poor	poor	JJ
cord-034340-3ksfpaf7	415	18	outcome	outcome	NN
cord-034340-3ksfpaf7	415	19	.	.	.
cord-034340-3ksfpaf7	416	1	HLH	HLH	NNP
cord-034340-3ksfpaf7	416	2	is	be	VBZ
cord-034340-3ksfpaf7	416	3	classified	classify	VBN
cord-034340-3ksfpaf7	416	4	into	into	IN
cord-034340-3ksfpaf7	416	5	primary	primary	JJ
cord-034340-3ksfpaf7	416	6	(	(	-LRB-
cord-034340-3ksfpaf7	416	7	pHLH	phlh	JJ
cord-034340-3ksfpaf7	416	8	)	)	-RRB-
cord-034340-3ksfpaf7	416	9	and	and	CC
cord-034340-3ksfpaf7	416	10	secondary	secondary	JJ
cord-034340-3ksfpaf7	416	11	(	(	-LRB-
cord-034340-3ksfpaf7	416	12	sHLH	shlh	JJ
cord-034340-3ksfpaf7	416	13	)	)	-RRB-
cord-034340-3ksfpaf7	416	14	.	.	.
cord-034340-3ksfpaf7	417	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	417	2	is	be	VBZ
cord-034340-3ksfpaf7	417	3	important	important	JJ
cord-034340-3ksfpaf7	417	4	to	to	TO
cord-034340-3ksfpaf7	417	5	differentiate	differentiate	VB
cord-034340-3ksfpaf7	417	6	between	between	IN
cord-034340-3ksfpaf7	417	7	the	the	DT
cord-034340-3ksfpaf7	417	8	two	two	CD
cord-034340-3ksfpaf7	417	9	as	as	IN
cord-034340-3ksfpaf7	417	10	management	management	NN
cord-034340-3ksfpaf7	417	11	differs	differ	VBZ
cord-034340-3ksfpaf7	417	12	.	.	.
cord-034340-3ksfpaf7	418	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	418	2	:	:	:
cord-034340-3ksfpaf7	418	3	To	to	TO
cord-034340-3ksfpaf7	418	4	describe	describe	VB
cord-034340-3ksfpaf7	418	5	the	the	DT
cord-034340-3ksfpaf7	418	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	418	7	and	and	CC
cord-034340-3ksfpaf7	418	8	laboratory	laboratory	NN
cord-034340-3ksfpaf7	418	9	profile	profile	NN
cord-034340-3ksfpaf7	418	10	of	of	IN
cord-034340-3ksfpaf7	418	11	HLH	HLH	NNP
cord-034340-3ksfpaf7	418	12	in	in	IN
cord-034340-3ksfpaf7	418	13	infancy	infancy	NN
cord-034340-3ksfpaf7	418	14	.	.	.
cord-034340-3ksfpaf7	419	1	Methods	method	NNS
cord-034340-3ksfpaf7	419	2	:	:	:
cord-034340-3ksfpaf7	420	1	The	the	DT
cord-034340-3ksfpaf7	420	2	electronic	electronic	JJ
cord-034340-3ksfpaf7	420	3	case	case	NN
cord-034340-3ksfpaf7	420	4	files	file	NNS
cord-034340-3ksfpaf7	420	5	of	of	IN
cord-034340-3ksfpaf7	420	6	children	child	NNS
cord-034340-3ksfpaf7	420	7	(	(	-LRB-
cord-034340-3ksfpaf7	420	8	age<1	age<1	NN
cord-034340-3ksfpaf7	420	9	year	year	NN
cord-034340-3ksfpaf7	420	10	)	)	-RRB-
cord-034340-3ksfpaf7	420	11	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	420	12	with	with	IN
cord-034340-3ksfpaf7	420	13	HLH	HLH	NNP
cord-034340-3ksfpaf7	420	14	at	at	IN
cord-034340-3ksfpaf7	420	15	the	the	DT
cord-034340-3ksfpaf7	420	16	AIMS	aim	NNS
cord-034340-3ksfpaf7	420	17	,	,	,
cord-034340-3ksfpaf7	420	18	Kochi	Kochi	NNP
cord-034340-3ksfpaf7	420	19	,	,	,
cord-034340-3ksfpaf7	420	20	Kerala	Kerala	NNP
cord-034340-3ksfpaf7	420	21	,	,	,
cord-034340-3ksfpaf7	420	22	between	between	IN
cord-034340-3ksfpaf7	420	23	January	January	NNP
cord-034340-3ksfpaf7	420	24	2012	2012	CD
cord-034340-3ksfpaf7	420	25	and	and	CC
cord-034340-3ksfpaf7	420	26	December	December	NNP
cord-034340-3ksfpaf7	420	27	2019	2019	CD
cord-034340-3ksfpaf7	420	28	,	,	,
cord-034340-3ksfpaf7	420	29	was	be	VBD
cord-034340-3ksfpaf7	420	30	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	420	31	reviewed	review	VBN
cord-034340-3ksfpaf7	420	32	and	and	CC
cord-034340-3ksfpaf7	420	33	described	describe	VBN
cord-034340-3ksfpaf7	420	34	.	.	.
cord-034340-3ksfpaf7	421	1	Results	result	NNS
cord-034340-3ksfpaf7	421	2	:	:	:
cord-034340-3ksfpaf7	421	3	Eight	eight	CD
cord-034340-3ksfpaf7	421	4	infants	infant	NNS
cord-034340-3ksfpaf7	421	5	,	,	,
cord-034340-3ksfpaf7	421	6	with	with	IN
cord-034340-3ksfpaf7	421	7	age	age	NN
cord-034340-3ksfpaf7	421	8	range	range	VBP
cord-034340-3ksfpaf7	421	9	1.5	1.5	CD
cord-034340-3ksfpaf7	421	10	months	month	NNS
cord-034340-3ksfpaf7	421	11	to	to	IN
cord-034340-3ksfpaf7	421	12	7	7	CD
cord-034340-3ksfpaf7	421	13	months	month	NNS
cord-034340-3ksfpaf7	421	14	,	,	,
cord-034340-3ksfpaf7	421	15	were	be	VBD
cord-034340-3ksfpaf7	421	16	clinically	clinically	RB
cord-034340-3ksfpaf7	421	17	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	421	18	with	with	IN
cord-034340-3ksfpaf7	421	19	HLH	HLH	NNP
cord-034340-3ksfpaf7	421	20	.	.	.
cord-034340-3ksfpaf7	422	1	All	all	DT
cord-034340-3ksfpaf7	422	2	were	be	VBD
cord-034340-3ksfpaf7	422	3	immunised	immunise	VBN
cord-034340-3ksfpaf7	422	4	and	and	CC
cord-034340-3ksfpaf7	422	5	had	have	VBD
cord-034340-3ksfpaf7	422	6	normal	normal	JJ
cord-034340-3ksfpaf7	422	7	development	development	NN
cord-034340-3ksfpaf7	422	8	for	for	IN
cord-034340-3ksfpaf7	422	9	age	age	NN
cord-034340-3ksfpaf7	422	10	.	.	.
cord-034340-3ksfpaf7	423	1	None	none	NN
cord-034340-3ksfpaf7	423	2	had	have	VBD
cord-034340-3ksfpaf7	423	3	a	a	DT
cord-034340-3ksfpaf7	423	4	family	family	NN
cord-034340-3ksfpaf7	423	5	history	history	NN
cord-034340-3ksfpaf7	423	6	suggestive	suggestive	JJ
cord-034340-3ksfpaf7	423	7	of	of	IN
cord-034340-3ksfpaf7	423	8	HLH	HLH	NNP
cord-034340-3ksfpaf7	423	9	.	.	.
cord-034340-3ksfpaf7	424	1	Third	third	JJ
cord-034340-3ksfpaf7	424	2	degree	degree	NN
cord-034340-3ksfpaf7	424	3	consanguinity	consanguinity	NN
cord-034340-3ksfpaf7	424	4	was	be	VBD
cord-034340-3ksfpaf7	424	5	present	present	JJ
cord-034340-3ksfpaf7	424	6	in	in	IN
cord-034340-3ksfpaf7	424	7	parents	parent	NNS
cord-034340-3ksfpaf7	424	8	of	of	IN
cord-034340-3ksfpaf7	424	9	patient	patient	JJ
cord-034340-3ksfpaf7	424	10	no.5	no.5	NN
cord-034340-3ksfpaf7	424	11	and	and	CC
cord-034340-3ksfpaf7	424	12	second	second	JJ
cord-034340-3ksfpaf7	424	13	degree	degree	NN
cord-034340-3ksfpaf7	424	14	for	for	IN
cord-034340-3ksfpaf7	424	15	patient	patient	JJ
cord-034340-3ksfpaf7	424	16	no.7	no.7	NNP
cord-034340-3ksfpaf7	424	17	.	.	.
cord-034340-3ksfpaf7	425	1	Duration	duration	NN
cord-034340-3ksfpaf7	425	2	of	of	IN
cord-034340-3ksfpaf7	425	3	symptoms	symptom	NNS
cord-034340-3ksfpaf7	425	4	before	before	IN
cord-034340-3ksfpaf7	425	5	presentation	presentation	NN
cord-034340-3ksfpaf7	425	6	ranged	range	VBD
cord-034340-3ksfpaf7	425	7	from	from	IN
cord-034340-3ksfpaf7	425	8	2	2	CD
cord-034340-3ksfpaf7	425	9	days	day	NNS
cord-034340-3ksfpaf7	425	10	to	to	IN
cord-034340-3ksfpaf7	425	11	68	68	CD
cord-034340-3ksfpaf7	425	12	days	day	NNS
cord-034340-3ksfpaf7	425	13	.	.	.
cord-034340-3ksfpaf7	426	1	Duration	duration	NN
cord-034340-3ksfpaf7	426	2	of	of	IN
cord-034340-3ksfpaf7	426	3	follow	follow	NN
cord-034340-3ksfpaf7	426	4	up	up	RP
cord-034340-3ksfpaf7	426	5	with	with	IN
cord-034340-3ksfpaf7	426	6	us	-PRON-	PRP
cord-034340-3ksfpaf7	426	7	ranged	range	VBD
cord-034340-3ksfpaf7	426	8	from	from	IN
cord-034340-3ksfpaf7	426	9	12	12	CD
cord-034340-3ksfpaf7	426	10	days	day	NNS
cord-034340-3ksfpaf7	426	11	to	to	IN
cord-034340-3ksfpaf7	426	12	192	192	CD
cord-034340-3ksfpaf7	426	13	days	day	NNS
cord-034340-3ksfpaf7	426	14	,	,	,
cord-034340-3ksfpaf7	426	15	for	for	IN
cord-034340-3ksfpaf7	426	16	those	those	DT
cord-034340-3ksfpaf7	426	17	who	who	WP
cord-034340-3ksfpaf7	426	18	expired	expire	VBD
cord-034340-3ksfpaf7	426	19	.	.	.
cord-034340-3ksfpaf7	427	1	All	all	DT
cord-034340-3ksfpaf7	427	2	,	,	,
cord-034340-3ksfpaf7	427	3	eight	eight	CD
cord-034340-3ksfpaf7	427	4	of	of	IN
cord-034340-3ksfpaf7	427	5	them	-PRON-	PRP
cord-034340-3ksfpaf7	427	6	,	,	,
cord-034340-3ksfpaf7	427	7	had	have	VBD
cord-034340-3ksfpaf7	427	8	fever	fever	NN
cord-034340-3ksfpaf7	427	9	,	,	,
cord-034340-3ksfpaf7	427	10	anemia	anemia	NN
cord-034340-3ksfpaf7	427	11	,	,	,
cord-034340-3ksfpaf7	427	12	thrombocytopenia	thrombocytopenia	NN
cord-034340-3ksfpaf7	427	13	,	,	,
cord-034340-3ksfpaf7	427	14	hyperferritinemia	hyperferritinemia	NNP
cord-034340-3ksfpaf7	427	15	,	,	,
cord-034340-3ksfpaf7	427	16	transaminitis	transaminitis	NNP
cord-034340-3ksfpaf7	427	17	,	,	,
cord-034340-3ksfpaf7	427	18	raised	raise	VBD
cord-034340-3ksfpaf7	427	19	LDH	LDH	NNP
cord-034340-3ksfpaf7	427	20	and	and	CC
cord-034340-3ksfpaf7	427	21	CRP	CRP	NNP
cord-034340-3ksfpaf7	427	22	.	.	.
cord-034340-3ksfpaf7	428	1	Lymphadenopathy	Lymphadenopathy	NNP
cord-034340-3ksfpaf7	428	2	was	be	VBD
cord-034340-3ksfpaf7	428	3	present	present	JJ
cord-034340-3ksfpaf7	428	4	only	only	RB
cord-034340-3ksfpaf7	428	5	in	in	IN
cord-034340-3ksfpaf7	428	6	patient	patient	JJ
cord-034340-3ksfpaf7	428	7	no.4	no.4	NNP
cord-034340-3ksfpaf7	428	8	.	.	.
cord-034340-3ksfpaf7	429	1	Before	before	IN
cord-034340-3ksfpaf7	429	2	starting	start	VBG
cord-034340-3ksfpaf7	429	3	specific	specific	JJ
cord-034340-3ksfpaf7	429	4	treatment	treatment	NN
cord-034340-3ksfpaf7	429	5	patient	patient	NN
cord-034340-3ksfpaf7	429	6	no	no	NN
cord-034340-3ksfpaf7	429	7	.	.	NN
cord-034340-3ksfpaf7	429	8	7	7	CD
cord-034340-3ksfpaf7	429	9	had	have	VBD
cord-034340-3ksfpaf7	429	10	Pseudomonas	Pseudomonas	NNP
cord-034340-3ksfpaf7	429	11	sepsis	sepsis	NN
cord-034340-3ksfpaf7	429	12	,	,	,
cord-034340-3ksfpaf7	429	13	patient	patient	JJ
cord-034340-3ksfpaf7	429	14	no.5	no.5	NN
cord-034340-3ksfpaf7	429	15	had	have	VBD
cord-034340-3ksfpaf7	429	16	Roseomonas	Roseomonas	NNP
cord-034340-3ksfpaf7	429	17	gilardii	gilardii	NNP
cord-034340-3ksfpaf7	429	18	infection	infection	NN
cord-034340-3ksfpaf7	429	19	;	;	:
cord-034340-3ksfpaf7	429	20	patient	patient	JJ
cord-034340-3ksfpaf7	429	21	no.3	no.3	NN
cord-034340-3ksfpaf7	429	22	and	and	CC
cord-034340-3ksfpaf7	429	23	4	4	CD
cord-034340-3ksfpaf7	429	24	were	be	VBD
cord-034340-3ksfpaf7	429	25	IgM	IgM	NNP
cord-034340-3ksfpaf7	429	26	CMV	CMV	NNP
cord-034340-3ksfpaf7	429	27	positive	positive	JJ
cord-034340-3ksfpaf7	429	28	but	but	CC
cord-034340-3ksfpaf7	429	29	their	-PRON-	PRP$
cord-034340-3ksfpaf7	429	30	PCR	PCR	NNP
cord-034340-3ksfpaf7	429	31	was	be	VBD
cord-034340-3ksfpaf7	429	32	negative	negative	JJ
cord-034340-3ksfpaf7	429	33	.	.	.
cord-034340-3ksfpaf7	430	1	Both	both	DT
cord-034340-3ksfpaf7	430	2	of	of	IN
cord-034340-3ksfpaf7	430	3	them	-PRON-	PRP
cord-034340-3ksfpaf7	430	4	had	have	VBD
cord-034340-3ksfpaf7	430	5	received	receive	VBN
cord-034340-3ksfpaf7	430	6	prior	prior	JJ
cord-034340-3ksfpaf7	430	7	blood	blood	NN
cord-034340-3ksfpaf7	430	8	transfusion	transfusion	NN
cord-034340-3ksfpaf7	430	9	.	.	.
cord-034340-3ksfpaf7	431	1	Before	before	IN
cord-034340-3ksfpaf7	431	2	making	make	VBG
cord-034340-3ksfpaf7	431	3	a	a	DT
cord-034340-3ksfpaf7	431	4	definitive	definitive	JJ
cord-034340-3ksfpaf7	431	5	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	431	6	of	of	IN
cord-034340-3ksfpaf7	431	7	HLH	HLH	NNP
cord-034340-3ksfpaf7	431	8	patients	patient	NNS
cord-034340-3ksfpaf7	431	9	were	be	VBD
cord-034340-3ksfpaf7	431	10	treated	treat	VBN
cord-034340-3ksfpaf7	431	11	for	for	IN
cord-034340-3ksfpaf7	431	12	PUO	PUO	NNP
cord-034340-3ksfpaf7	431	13	,	,	,
cord-034340-3ksfpaf7	431	14	sepsis	sepsis	NN
cord-034340-3ksfpaf7	431	15	?	?	.
cord-034340-3ksfpaf7	432	1	cause	cause	VB
cord-034340-3ksfpaf7	432	2	and	and	CC
cord-034340-3ksfpaf7	432	3	acute	acute	JJ
cord-034340-3ksfpaf7	432	4	liver	liver	NN
cord-034340-3ksfpaf7	432	5	failure	failure	NN
cord-034340-3ksfpaf7	432	6	.	.	.
cord-034340-3ksfpaf7	433	1	There	there	EX
cord-034340-3ksfpaf7	433	2	was	be	VBD
cord-034340-3ksfpaf7	433	3	a	a	DT
cord-034340-3ksfpaf7	433	4	delay	delay	NN
cord-034340-3ksfpaf7	433	5	in	in	IN
cord-034340-3ksfpaf7	433	6	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	433	7	for	for	IN
cord-034340-3ksfpaf7	433	8	all	all	DT
cord-034340-3ksfpaf7	433	9	patients	patient	NNS
cord-034340-3ksfpaf7	433	10	except	except	IN
cord-034340-3ksfpaf7	433	11	patient	patient	JJ
cord-034340-3ksfpaf7	433	12	no.7	no.7	NNP
cord-034340-3ksfpaf7	433	13	.	.	.
cord-034340-3ksfpaf7	434	1	All	all	DT
cord-034340-3ksfpaf7	434	2	of	of	IN
cord-034340-3ksfpaf7	434	3	them	-PRON-	PRP
cord-034340-3ksfpaf7	434	4	were	be	VBD
cord-034340-3ksfpaf7	434	5	treated	treat	VBN
cord-034340-3ksfpaf7	434	6	with	with	IN
cord-034340-3ksfpaf7	434	7	HLH	HLH	NNP
cord-034340-3ksfpaf7	434	8	2004	2004	CD
cord-034340-3ksfpaf7	434	9	protocol	protocol	NN
cord-034340-3ksfpaf7	434	10	with	with	IN
cord-034340-3ksfpaf7	434	11	modification	modification	NN
cord-034340-3ksfpaf7	434	12	according	accord	VBG
cord-034340-3ksfpaf7	434	13	to	to	IN
cord-034340-3ksfpaf7	434	14	clinical	clinical	JJ
cord-034340-3ksfpaf7	434	15	status	status	NN
cord-034340-3ksfpaf7	434	16	of	of	IN
cord-034340-3ksfpaf7	434	17	the	the	DT
cord-034340-3ksfpaf7	434	18	patient	patient	NN
cord-034340-3ksfpaf7	434	19	.	.	.
cord-034340-3ksfpaf7	435	1	Later	later	RB
cord-034340-3ksfpaf7	435	2	,	,	,
cord-034340-3ksfpaf7	435	3	broad	broad	JJ
cord-034340-3ksfpaf7	435	4	spectrum	spectrum	NN
cord-034340-3ksfpaf7	435	5	antibiotics	antibiotic	NNS
cord-034340-3ksfpaf7	435	6	,	,	,
cord-034340-3ksfpaf7	435	7	antifungals	antifungal	NNS
cord-034340-3ksfpaf7	435	8	and	and	CC
cord-034340-3ksfpaf7	435	9	antivirals	antiviral	NNS
cord-034340-3ksfpaf7	435	10	were	be	VBD
cord-034340-3ksfpaf7	435	11	used	use	VBN
cord-034340-3ksfpaf7	435	12	for	for	IN
cord-034340-3ksfpaf7	435	13	all	all	DT
cord-034340-3ksfpaf7	435	14	.	.	.
cord-034340-3ksfpaf7	436	1	Anakinra	Anakinra	NNP
cord-034340-3ksfpaf7	436	2	was	be	VBD
cord-034340-3ksfpaf7	436	3	tried	try	VBN
cord-034340-3ksfpaf7	436	4	for	for	IN
cord-034340-3ksfpaf7	436	5	patient	patient	JJ
cord-034340-3ksfpaf7	436	6	no.5	no.5	NN
cord-034340-3ksfpaf7	436	7	.	.	.
cord-034340-3ksfpaf7	437	1	Five	five	CD
cord-034340-3ksfpaf7	437	2	patients	patient	NNS
cord-034340-3ksfpaf7	437	3	(	(	-LRB-
cord-034340-3ksfpaf7	437	4	pHLH	phlh	JJ
cord-034340-3ksfpaf7	437	5	)	)	-RRB-
cord-034340-3ksfpaf7	437	6	succumbed	succumb	VBD
cord-034340-3ksfpaf7	437	7	to	to	IN
cord-034340-3ksfpaf7	437	8	sepsis	sepsis	NN
cord-034340-3ksfpaf7	437	9	and	and	CC
cord-034340-3ksfpaf7	437	10	MODS	mod	NNS
cord-034340-3ksfpaf7	437	11	and	and	CC
cord-034340-3ksfpaf7	437	12	three	three	CD
cord-034340-3ksfpaf7	437	13	(	(	-LRB-
cord-034340-3ksfpaf7	437	14	one	one	CD
cord-034340-3ksfpaf7	437	15	pHLH	phlh	NN
cord-034340-3ksfpaf7	437	16	and	and	CC
cord-034340-3ksfpaf7	437	17	two	two	CD
cord-034340-3ksfpaf7	437	18	sHLH	shlh	JJ
cord-034340-3ksfpaf7	437	19	)	)	-RRB-
cord-034340-3ksfpaf7	437	20	are	be	VBP
cord-034340-3ksfpaf7	437	21	continuing	continue	VBG
cord-034340-3ksfpaf7	437	22	follow	follow	NN
cord-034340-3ksfpaf7	437	23	up	up	RP
cord-034340-3ksfpaf7	437	24	.	.	.
cord-034340-3ksfpaf7	438	1	HSCT	HSCT	NNP
cord-034340-3ksfpaf7	438	2	was	be	VBD
cord-034340-3ksfpaf7	438	3	not	not	RB
cord-034340-3ksfpaf7	438	4	done	do	VBN
cord-034340-3ksfpaf7	438	5	in	in	IN
cord-034340-3ksfpaf7	438	6	any	any	DT
cord-034340-3ksfpaf7	438	7	of	of	IN
cord-034340-3ksfpaf7	438	8	them	-PRON-	PRP
cord-034340-3ksfpaf7	438	9	.	.	.
cord-034340-3ksfpaf7	439	1	Other	other	JJ
cord-034340-3ksfpaf7	439	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	439	3	features	feature	NNS
cord-034340-3ksfpaf7	439	4	are	be	VBP
cord-034340-3ksfpaf7	439	5	shown	show	VBN
cord-034340-3ksfpaf7	439	6	in	in	IN
cord-034340-3ksfpaf7	439	7	Table	Table	NNP
cord-034340-3ksfpaf7	439	8	1	1	CD
cord-034340-3ksfpaf7	439	9	.	.	.
cord-034340-3ksfpaf7	440	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	440	2	:	:	:
cord-034340-3ksfpaf7	440	3	Making	make	VBG
cord-034340-3ksfpaf7	440	4	a	a	DT
cord-034340-3ksfpaf7	440	5	timely	timely	JJ
cord-034340-3ksfpaf7	440	6	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	440	7	of	of	IN
cord-034340-3ksfpaf7	440	8	HLH	HLH	NNP
cord-034340-3ksfpaf7	440	9	is	be	VBZ
cord-034340-3ksfpaf7	440	10	difficult	difficult	JJ
cord-034340-3ksfpaf7	440	11	.	.	.
cord-034340-3ksfpaf7	441	1	Differentiating	differentiate	VBG
cord-034340-3ksfpaf7	441	2	pHLH	phlh	JJ
cord-034340-3ksfpaf7	441	3	from	from	IN
cord-034340-3ksfpaf7	441	4	sHLH	sHLH	NNP
cord-034340-3ksfpaf7	441	5	is	be	VBZ
cord-034340-3ksfpaf7	441	6	very	very	RB
cord-034340-3ksfpaf7	441	7	important	important	JJ
cord-034340-3ksfpaf7	441	8	as	as	IN
cord-034340-3ksfpaf7	441	9	the	the	DT
cord-034340-3ksfpaf7	441	10	management	management	NN
cord-034340-3ksfpaf7	441	11	differs	differ	VBZ
cord-034340-3ksfpaf7	441	12	.	.	.
cord-034340-3ksfpaf7	442	1	Genetic	genetic	JJ
cord-034340-3ksfpaf7	442	2	testing	testing	NN
cord-034340-3ksfpaf7	442	3	should	should	MD
cord-034340-3ksfpaf7	442	4	be	be	VB
cord-034340-3ksfpaf7	442	5	done	do	VBN
cord-034340-3ksfpaf7	442	6	for	for	IN
cord-034340-3ksfpaf7	442	7	all	all	DT
cord-034340-3ksfpaf7	442	8	infants	infant	NNS
cord-034340-3ksfpaf7	442	9	with	with	IN
cord-034340-3ksfpaf7	442	10	HLH	HLH	NNP
cord-034340-3ksfpaf7	442	11	.	.	.
cord-034340-3ksfpaf7	443	1	Negative	negative	JJ
cord-034340-3ksfpaf7	443	2	genetic	genetic	JJ
cord-034340-3ksfpaf7	443	3	study	study	NN
cord-034340-3ksfpaf7	443	4	does	do	VBZ
cord-034340-3ksfpaf7	443	5	n't	not	RB
cord-034340-3ksfpaf7	443	6	rule	rule	VB
cord-034340-3ksfpaf7	443	7	out	out	RP
cord-034340-3ksfpaf7	443	8	pHLH	phlh	NN
cord-034340-3ksfpaf7	443	9	.	.	.
cord-034340-3ksfpaf7	444	1	The	the	DT
cord-034340-3ksfpaf7	444	2	only	only	JJ
cord-034340-3ksfpaf7	444	3	curative	curative	JJ
cord-034340-3ksfpaf7	444	4	treatment	treatment	NN
cord-034340-3ksfpaf7	444	5	for	for	IN
cord-034340-3ksfpaf7	444	6	pHLH	phlh	NN
cord-034340-3ksfpaf7	444	7	is	be	VBZ
cord-034340-3ksfpaf7	444	8	HSCT	HSCT	NNP
cord-034340-3ksfpaf7	444	9	.	.	.
cord-034340-3ksfpaf7	445	1	sHLH	shlh	JJ
cord-034340-3ksfpaf7	445	2	infants	infant	NNS
cord-034340-3ksfpaf7	445	3	,	,	,
cord-034340-3ksfpaf7	445	4	once	once	IN
cord-034340-3ksfpaf7	445	5	their	-PRON-	PRP$
cord-034340-3ksfpaf7	445	6	primary	primary	JJ
cord-034340-3ksfpaf7	445	7	condition	condition	NN
cord-034340-3ksfpaf7	445	8	is	be	VBZ
cord-034340-3ksfpaf7	445	9	treated	treat	VBN
cord-034340-3ksfpaf7	445	10	,	,	,
cord-034340-3ksfpaf7	445	11	can	can	MD
cord-034340-3ksfpaf7	445	12	have	have	VB
cord-034340-3ksfpaf7	445	13	normal	normal	JJ
cord-034340-3ksfpaf7	445	14	survival	survival	NN
cord-034340-3ksfpaf7	445	15	.	.	.
cord-034340-3ksfpaf7	446	1	Hyperbilirubinemia	Hyperbilirubinemia	NNP
cord-034340-3ksfpaf7	446	2	,	,	,
cord-034340-3ksfpaf7	446	3	splenomegaly	splenomegaly	NN
cord-034340-3ksfpaf7	446	4	,	,	,
cord-034340-3ksfpaf7	446	5	neutropenia	neutropenia	NN
cord-034340-3ksfpaf7	446	6	,	,	,
cord-034340-3ksfpaf7	446	7	hepatomegaly	hepatomegaly	NNP
cord-034340-3ksfpaf7	446	8	,	,	,
cord-034340-3ksfpaf7	446	9	tissue	tissue	NN
cord-034340-3ksfpaf7	446	10	hemophagocytes	hemophagocytes	NNP
cord-034340-3ksfpaf7	446	11	and	and	CC
cord-034340-3ksfpaf7	446	12	hypertriglyceridemia	hypertriglyceridemia	NNP
cord-034340-3ksfpaf7	446	13	were	be	VBD
cord-034340-3ksfpaf7	446	14	more	more	RBR
cord-034340-3ksfpaf7	446	15	common	common	JJ
cord-034340-3ksfpaf7	446	16	in	in	IN
cord-034340-3ksfpaf7	446	17	pHLH	phlh	NN
cord-034340-3ksfpaf7	446	18	.	.	.
cord-034340-3ksfpaf7	447	1	Health	Health	NNP
cord-034340-3ksfpaf7	447	2	,	,	,
cord-034340-3ksfpaf7	447	3	Kolkata	Kolkata	NNP
cord-034340-3ksfpaf7	447	4	diagnosed	diagnose	VBD
cord-034340-3ksfpaf7	447	5	as	as	IN
cord-034340-3ksfpaf7	447	6	having	have	VBG
cord-034340-3ksfpaf7	447	7	MAS	MAS	NNP
cord-034340-3ksfpaf7	447	8	,	,	,
cord-034340-3ksfpaf7	447	9	admitted	admit	VBN
cord-034340-3ksfpaf7	447	10	between	between	IN
cord-034340-3ksfpaf7	447	11	July	July	NNP
cord-034340-3ksfpaf7	447	12	2008	2008	CD
cord-034340-3ksfpaf7	447	13	and	and	CC
cord-034340-3ksfpaf7	447	14	April	April	NNP
cord-034340-3ksfpaf7	447	15	2020	2020	CD
cord-034340-3ksfpaf7	447	16	was	be	VBD
cord-034340-3ksfpaf7	447	17	tabulated	tabulate	VBN
cord-034340-3ksfpaf7	447	18	and	and	CC
cord-034340-3ksfpaf7	447	19	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	447	20	analyzed	analyze	VBN
cord-034340-3ksfpaf7	447	21	.	.	.
cord-034340-3ksfpaf7	448	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	448	2	:	:	:
cord-034340-3ksfpaf7	448	3	To	to	TO
cord-034340-3ksfpaf7	448	4	evaluate	evaluate	VB
cord-034340-3ksfpaf7	448	5	the	the	DT
cord-034340-3ksfpaf7	448	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	448	7	features	feature	NNS
cord-034340-3ksfpaf7	448	8	,	,	,
cord-034340-3ksfpaf7	448	9	laboratory	laboratory	NN
cord-034340-3ksfpaf7	448	10	findings	finding	NNS
cord-034340-3ksfpaf7	448	11	and	and	CC
cord-034340-3ksfpaf7	448	12	outcomes	outcome	NNS
cord-034340-3ksfpaf7	448	13	in	in	IN
cord-034340-3ksfpaf7	448	14	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	448	15	MAS	MAS	NNP
cord-034340-3ksfpaf7	448	16	,	,	,
cord-034340-3ksfpaf7	448	17	assess	assess	VB
cord-034340-3ksfpaf7	448	18	the	the	DT
cord-034340-3ksfpaf7	448	19	response	response	NN
cord-034340-3ksfpaf7	448	20	to	to	IN
cord-034340-3ksfpaf7	448	21	different	different	JJ
cord-034340-3ksfpaf7	448	22	pharmacological	pharmacological	JJ
cord-034340-3ksfpaf7	448	23	therapies	therapy	NNS
cord-034340-3ksfpaf7	448	24	,	,	,
cord-034340-3ksfpaf7	448	25	and	and	CC
cord-034340-3ksfpaf7	448	26	finally	finally	RB
cord-034340-3ksfpaf7	448	27	to	to	TO
cord-034340-3ksfpaf7	448	28	identify	identify	VB
cord-034340-3ksfpaf7	448	29	possible	possible	JJ
cord-034340-3ksfpaf7	448	30	factors	factor	NNS
cord-034340-3ksfpaf7	448	31	associated	associate	VBN
cord-034340-3ksfpaf7	448	32	with	with	IN
cord-034340-3ksfpaf7	448	33	an	an	DT
cord-034340-3ksfpaf7	448	34	unfavourable	unfavourable	JJ
cord-034340-3ksfpaf7	448	35	outcome	outcome	NN
cord-034340-3ksfpaf7	448	36	.	.	.
cord-034340-3ksfpaf7	449	1	Methods	method	NNS
cord-034340-3ksfpaf7	449	2	:	:	:
cord-034340-3ksfpaf7	450	1	The	the	DT
cord-034340-3ksfpaf7	450	2	data	datum	NNS
cord-034340-3ksfpaf7	450	3	of	of	IN
cord-034340-3ksfpaf7	450	4	patients	patient	NNS
cord-034340-3ksfpaf7	450	5	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	450	6	with	with	IN
cord-034340-3ksfpaf7	450	7	MAS	MAS	NNP
cord-034340-3ksfpaf7	450	8	over	over	IN
cord-034340-3ksfpaf7	450	9	the	the	DT
cord-034340-3ksfpaf7	450	10	study	study	NN
cord-034340-3ksfpaf7	450	11	period	period	NN
cord-034340-3ksfpaf7	450	12	was	be	VBD
cord-034340-3ksfpaf7	450	13	analyzed	analyze	VBN
cord-034340-3ksfpaf7	450	14	for	for	IN
cord-034340-3ksfpaf7	450	15	the	the	DT
cord-034340-3ksfpaf7	450	16	clinical	clinical	JJ
cord-034340-3ksfpaf7	450	17	and	and	CC
cord-034340-3ksfpaf7	450	18	laboratory	laboratory	NN
cord-034340-3ksfpaf7	450	19	features	feature	NNS
cord-034340-3ksfpaf7	450	20	,	,	,
cord-034340-3ksfpaf7	450	21	treatment	treatment	NN
cord-034340-3ksfpaf7	450	22	details	detail	NNS
cord-034340-3ksfpaf7	450	23	,	,	,
cord-034340-3ksfpaf7	450	24	response	response	NN
cord-034340-3ksfpaf7	450	25	to	to	IN
cord-034340-3ksfpaf7	450	26	therapy	therapy	NN
cord-034340-3ksfpaf7	450	27	and	and	CC
cord-034340-3ksfpaf7	450	28	outcome	outcome	NN
cord-034340-3ksfpaf7	450	29	.	.	.
cord-034340-3ksfpaf7	451	1	Results	result	NNS
cord-034340-3ksfpaf7	451	2	:	:	:
cord-034340-3ksfpaf7	451	3	35	35	CD
cord-034340-3ksfpaf7	451	4	patients	patient	NNS
cord-034340-3ksfpaf7	451	5	were	be	VBD
cord-034340-3ksfpaf7	451	6	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	451	7	as	as	IN
cord-034340-3ksfpaf7	451	8	having	have	VBG
cord-034340-3ksfpaf7	451	9	MAS	MAS	NNP
cord-034340-3ksfpaf7	451	10	.	.	.
cord-034340-3ksfpaf7	452	1	Primary	primary	JJ
cord-034340-3ksfpaf7	452	2	illness	illness	NN
cord-034340-3ksfpaf7	452	3	was	be	VBD
cord-034340-3ksfpaf7	452	4	sJIA	sjia	JJ
cord-034340-3ksfpaf7	453	1	in	in	IN
cord-034340-3ksfpaf7	453	2	29	29	CD
cord-034340-3ksfpaf7	453	3	(	(	-LRB-
cord-034340-3ksfpaf7	453	4	82	82	CD
cord-034340-3ksfpaf7	453	5	%	%	NN
cord-034340-3ksfpaf7	453	6	)	)	-RRB-
cord-034340-3ksfpaf7	453	7	,	,	,
cord-034340-3ksfpaf7	453	8	SLE	SLE	NNP
cord-034340-3ksfpaf7	453	9	in	in	IN
cord-034340-3ksfpaf7	453	10	5	5	CD
cord-034340-3ksfpaf7	453	11	(	(	-LRB-
cord-034340-3ksfpaf7	453	12	14	14	CD
cord-034340-3ksfpaf7	453	13	%	%	NN
cord-034340-3ksfpaf7	453	14	)	)	-RRB-
cord-034340-3ksfpaf7	453	15	and	and	CC
cord-034340-3ksfpaf7	453	16	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	453	17	Disease	Disease	NNP
cord-034340-3ksfpaf7	453	18	(	(	-LRB-
cord-034340-3ksfpaf7	453	19	KD	KD	NNP
cord-034340-3ksfpaf7	453	20	)	)	-RRB-
cord-034340-3ksfpaf7	453	21	in	in	IN
cord-034340-3ksfpaf7	453	22	1(4	1(4	CD
cord-034340-3ksfpaf7	453	23	%	%	NN
cord-034340-3ksfpaf7	453	24	)	)	-RRB-
cord-034340-3ksfpaf7	453	25	.	.	.
cord-034340-3ksfpaf7	454	1	All	all	DT
cord-034340-3ksfpaf7	454	2	had	have	VBD
cord-034340-3ksfpaf7	454	3	fever	fever	NN
cord-034340-3ksfpaf7	454	4	with	with	IN
cord-034340-3ksfpaf7	454	5	varying	vary	VBG
cord-034340-3ksfpaf7	454	6	degrees	degree	NNS
cord-034340-3ksfpaf7	454	7	of	of	IN
cord-034340-3ksfpaf7	454	8	multi	multi	JJ
cord-034340-3ksfpaf7	454	9	systemic	systemic	JJ
cord-034340-3ksfpaf7	454	10	involvement	involvement	NN
cord-034340-3ksfpaf7	454	11	.	.	.
cord-034340-3ksfpaf7	455	1	Hyperferritinemia	Hyperferritinemia	NNP
cord-034340-3ksfpaf7	455	2	was	be	VBD
cord-034340-3ksfpaf7	455	3	universally	universally	RB
cord-034340-3ksfpaf7	455	4	present	present	JJ
cord-034340-3ksfpaf7	455	5	.	.	.
cord-034340-3ksfpaf7	456	1	In	in	IN
cord-034340-3ksfpaf7	456	2	the	the	DT
cord-034340-3ksfpaf7	456	3	absence	absence	NN
cord-034340-3ksfpaf7	456	4	of	of	IN
cord-034340-3ksfpaf7	456	5	Anakinra	Anakinra	NNP
cord-034340-3ksfpaf7	456	6	in	in	IN
cord-034340-3ksfpaf7	456	7	India	India	NNP
cord-034340-3ksfpaf7	456	8	,	,	,
cord-034340-3ksfpaf7	456	9	pulse	pulse	NN
cord-034340-3ksfpaf7	456	10	methylprednisolone	methylprednisolone	NN
cord-034340-3ksfpaf7	456	11	with	with	IN
cord-034340-3ksfpaf7	456	12	Cyclosporine	Cyclosporine	NNP
cord-034340-3ksfpaf7	456	13	was	be	VBD
cord-034340-3ksfpaf7	456	14	used	use	VBN
cord-034340-3ksfpaf7	456	15	for	for	IN
cord-034340-3ksfpaf7	456	16	treating	treat	VBG
cord-034340-3ksfpaf7	456	17	the	the	DT
cord-034340-3ksfpaf7	456	18	majority.10	majority.10	NNP
cord-034340-3ksfpaf7	456	19	patients	patient	NNS
cord-034340-3ksfpaf7	456	20	(	(	-LRB-
cord-034340-3ksfpaf7	456	21	28.5	28.5	CD
cord-034340-3ksfpaf7	456	22	%	%	NN
cord-034340-3ksfpaf7	456	23	)	)	-RRB-
cord-034340-3ksfpaf7	456	24	expired	expire	VBD
cord-034340-3ksfpaf7	456	25	.	.	.
cord-034340-3ksfpaf7	457	1	Patients	patient	NNS
cord-034340-3ksfpaf7	457	2	on	on	IN
cord-034340-3ksfpaf7	457	3	biologics	biologic	NNS
cord-034340-3ksfpaf7	457	4	and	and	CC
cord-034340-3ksfpaf7	457	5	steroids	steroid	NNS
cord-034340-3ksfpaf7	457	6	can	can	MD
cord-034340-3ksfpaf7	457	7	present	present	VB
cord-034340-3ksfpaf7	457	8	with	with	IN
cord-034340-3ksfpaf7	457	9	a	a	DT
cord-034340-3ksfpaf7	457	10	silent	silent	JJ
cord-034340-3ksfpaf7	457	11	MAS	MAS	NNP
cord-034340-3ksfpaf7	457	12	which	which	WDT
cord-034340-3ksfpaf7	457	13	may	may	MD
cord-034340-3ksfpaf7	457	14	be	be	VB
cord-034340-3ksfpaf7	457	15	difficult	difficult	JJ
cord-034340-3ksfpaf7	457	16	to	to	TO
cord-034340-3ksfpaf7	457	17	diagnose	diagnose	VB
cord-034340-3ksfpaf7	457	18	.	.	.
cord-034340-3ksfpaf7	458	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	458	2	:	:	:
cord-034340-3ksfpaf7	458	3	MAS	MAS	NNP
cord-034340-3ksfpaf7	458	4	is	be	VBZ
cord-034340-3ksfpaf7	458	5	a	a	DT
cord-034340-3ksfpaf7	458	6	near	near	JJ
cord-034340-3ksfpaf7	458	7	fatal	fatal	JJ
cord-034340-3ksfpaf7	458	8	complication	complication	NN
cord-034340-3ksfpaf7	458	9	with	with	IN
cord-034340-3ksfpaf7	458	10	protean	protean	JJ
cord-034340-3ksfpaf7	458	11	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	458	12	and	and	CC
cord-034340-3ksfpaf7	458	13	multi	multi	JJ
cord-034340-3ksfpaf7	458	14	organ	organ	NN
cord-034340-3ksfpaf7	458	15	dysfunction	dysfunction	NN
cord-034340-3ksfpaf7	458	16	.	.	.
cord-034340-3ksfpaf7	459	1	Hyperferritinemia	Hyperferritinemia	NNP
cord-034340-3ksfpaf7	459	2	is	be	VBZ
cord-034340-3ksfpaf7	459	3	characteristic	characteristic	JJ
cord-034340-3ksfpaf7	459	4	,	,	,
cord-034340-3ksfpaf7	459	5	higher	high	JJR
cord-034340-3ksfpaf7	459	6	values	value	NNS
cord-034340-3ksfpaf7	459	7	being	be	VBG
cord-034340-3ksfpaf7	459	8	associated	associate	VBN
cord-034340-3ksfpaf7	459	9	with	with	IN
cord-034340-3ksfpaf7	459	10	increased	increase	VBN
cord-034340-3ksfpaf7	459	11	mortality	mortality	NN
cord-034340-3ksfpaf7	459	12	.	.	.
cord-034340-3ksfpaf7	460	1	Patients	patient	NNS
cord-034340-3ksfpaf7	460	2	resistant	resistant	JJ
cord-034340-3ksfpaf7	460	3	to	to	IN
cord-034340-3ksfpaf7	460	4	steroids	steroid	NNS
cord-034340-3ksfpaf7	460	5	and	and	CC
cord-034340-3ksfpaf7	460	6	cyclosporine	cyclosporine	NN
cord-034340-3ksfpaf7	460	7	had	have	VBD
cord-034340-3ksfpaf7	460	8	a	a	DT
cord-034340-3ksfpaf7	460	9	poor	poor	JJ
cord-034340-3ksfpaf7	460	10	prognosis	prognosis	NN
cord-034340-3ksfpaf7	460	11	.	.	.
cord-034340-3ksfpaf7	461	1	Early	early	JJ
cord-034340-3ksfpaf7	461	2	recognition	recognition	NN
cord-034340-3ksfpaf7	461	3	with	with	IN
cord-034340-3ksfpaf7	461	4	aggresive	aggresive	JJ
cord-034340-3ksfpaf7	461	5	management	management	NN
cord-034340-3ksfpaf7	461	6	forms	form	VBZ
cord-034340-3ksfpaf7	461	7	the	the	DT
cord-034340-3ksfpaf7	461	8	backbone	backbone	NN
cord-034340-3ksfpaf7	461	9	of	of	IN
cord-034340-3ksfpaf7	461	10	a	a	DT
cord-034340-3ksfpaf7	461	11	successful	successful	JJ
cord-034340-3ksfpaf7	461	12	outcome	outcome	NN
cord-034340-3ksfpaf7	461	13	as	as	IN
cord-034340-3ksfpaf7	461	14	reflected	reflect	VBN
cord-034340-3ksfpaf7	461	15	by	by	IN
cord-034340-3ksfpaf7	461	16	improved	improved	JJ
cord-034340-3ksfpaf7	461	17	prognosis	prognosis	NN
cord-034340-3ksfpaf7	461	18	over	over	IN
cord-034340-3ksfpaf7	461	19	successive	successive	JJ
cord-034340-3ksfpaf7	461	20	years	year	NNS
cord-034340-3ksfpaf7	461	21	.	.	.
cord-034340-3ksfpaf7	462	1	Late	late	JJ
cord-034340-3ksfpaf7	462	2	presentations	presentation	NNS
cord-034340-3ksfpaf7	462	3	with	with	IN
cord-034340-3ksfpaf7	462	4	multiorgan	multiorgan	NNP
cord-034340-3ksfpaf7	462	5	dysfunction	dysfunction	NN
cord-034340-3ksfpaf7	462	6	are	be	VBP
cord-034340-3ksfpaf7	462	7	associated	associate	VBN
cord-034340-3ksfpaf7	462	8	with	with	IN
cord-034340-3ksfpaf7	462	9	the	the	DT
cord-034340-3ksfpaf7	462	10	poorest	poor	JJS
cord-034340-3ksfpaf7	462	11	outcomes	outcome	NNS
cord-034340-3ksfpaf7	462	12	.	.	.
cord-034340-3ksfpaf7	463	1	Methods	method	NNS
cord-034340-3ksfpaf7	463	2	:	:	:
cord-034340-3ksfpaf7	464	1	Case	case	NN
cord-034340-3ksfpaf7	464	2	report	report	NN
cord-034340-3ksfpaf7	464	3	's	's	POS
cord-034340-3ksfpaf7	464	4	description	description	NN
cord-034340-3ksfpaf7	464	5	Results	result	VBZ
cord-034340-3ksfpaf7	464	6	:	:	:
cord-034340-3ksfpaf7	465	1	A	a	DT
cord-034340-3ksfpaf7	465	2	two	two	CD
cord-034340-3ksfpaf7	465	3	-	-	HYPH
cord-034340-3ksfpaf7	465	4	year	year	NN
cord-034340-3ksfpaf7	465	5	-	-	HYPH
cord-034340-3ksfpaf7	465	6	old	old	JJ
cord-034340-3ksfpaf7	465	7	boy	boy	NN
cord-034340-3ksfpaf7	465	8	presented	present	VBN
cord-034340-3ksfpaf7	465	9	with	with	IN
cord-034340-3ksfpaf7	465	10	one	one	CD
cord-034340-3ksfpaf7	465	11	month	month	NN
cord-034340-3ksfpaf7	465	12	history	history	NN
cord-034340-3ksfpaf7	465	13	of	of	IN
cord-034340-3ksfpaf7	465	14	fever	fever	NN
cord-034340-3ksfpaf7	465	15	associated	associate	VBN
cord-034340-3ksfpaf7	465	16	with	with	IN
cord-034340-3ksfpaf7	465	17	limping	limp	VBG
cord-034340-3ksfpaf7	465	18	gait	gait	NN
cord-034340-3ksfpaf7	465	19	,	,	,
cord-034340-3ksfpaf7	465	20	cervical	cervical	JJ
cord-034340-3ksfpaf7	465	21	lymphadenopathy	lymphadenopathy	NN
cord-034340-3ksfpaf7	465	22	and	and	CC
cord-034340-3ksfpaf7	465	23	skin	skin	NN
cord-034340-3ksfpaf7	465	24	rash	rash	NN
cord-034340-3ksfpaf7	465	25	.	.	.
cord-034340-3ksfpaf7	466	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	466	2	tests	test	NNS
cord-034340-3ksfpaf7	466	3	showed	show	VBD
cord-034340-3ksfpaf7	466	4	elevation	elevation	NN
cord-034340-3ksfpaf7	466	5	of	of	IN
cord-034340-3ksfpaf7	466	6	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	466	7	markers	marker	NNS
cord-034340-3ksfpaf7	466	8	and	and	CC
cord-034340-3ksfpaf7	466	9	ferritin	ferritin	NN
cord-034340-3ksfpaf7	466	10	.	.	.
cord-034340-3ksfpaf7	467	1	By	by	IN
cord-034340-3ksfpaf7	467	2	exclusion	exclusion	NN
cord-034340-3ksfpaf7	467	3	criteria	criterion	NNS
cord-034340-3ksfpaf7	467	4	,	,	,
cord-034340-3ksfpaf7	467	5	sJIA	sjia	NN
cord-034340-3ksfpaf7	467	6	was	be	VBD
cord-034340-3ksfpaf7	467	7	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	467	8	and	and	CC
cord-034340-3ksfpaf7	467	9	steroid	steroid	NN
cord-034340-3ksfpaf7	467	10	therapy	therapy	NN
cord-034340-3ksfpaf7	467	11	started	start	VBD
cord-034340-3ksfpaf7	467	12	.	.	.
cord-034340-3ksfpaf7	468	1	After	after	IN
cord-034340-3ksfpaf7	468	2	a	a	DT
cord-034340-3ksfpaf7	468	3	soft	soft	JJ
cord-034340-3ksfpaf7	468	4	tissue	tissue	NN
cord-034340-3ksfpaf7	468	5	bacterial	bacterial	JJ
cord-034340-3ksfpaf7	468	6	infection	infection	NN
cord-034340-3ksfpaf7	468	7	,	,	,
cord-034340-3ksfpaf7	468	8	fever	fever	NN
cord-034340-3ksfpaf7	468	9	relapsed	relapse	VBN
cord-034340-3ksfpaf7	468	10	and	and	CC
cord-034340-3ksfpaf7	468	11	laboratory	laboratory	NN
cord-034340-3ksfpaf7	468	12	tests	test	NNS
cord-034340-3ksfpaf7	468	13	were	be	VBD
cord-034340-3ksfpaf7	468	14	consistent	consistent	JJ
cord-034340-3ksfpaf7	468	15	with	with	IN
cord-034340-3ksfpaf7	468	16	MAS	MAS	NNP
cord-034340-3ksfpaf7	468	17	(	(	-LRB-
cord-034340-3ksfpaf7	468	18	day	day	NN
cord-034340-3ksfpaf7	468	19	1	1	CD
cord-034340-3ksfpaf7	468	20	)	)	-RRB-
cord-034340-3ksfpaf7	468	21	:	:	:
cord-034340-3ksfpaf7	469	1	Hb	Hb	NNP
cord-034340-3ksfpaf7	469	2	8.5	8.5	CD
cord-034340-3ksfpaf7	469	3	g	g	NN
cord-034340-3ksfpaf7	469	4	/	/	SYM
cord-034340-3ksfpaf7	469	5	dL	dl	NN
cord-034340-3ksfpaf7	469	6	,	,	,
cord-034340-3ksfpaf7	469	7	PLT	PLT	NNP
cord-034340-3ksfpaf7	469	8	44000	44000	CD
cord-034340-3ksfpaf7	469	9	/	/	SYM
cord-034340-3ksfpaf7	469	10	mm3	mm3	NNS
cord-034340-3ksfpaf7	469	11	;	;	:
cord-034340-3ksfpaf7	469	12	FDP	FDP	NNP
cord-034340-3ksfpaf7	469	13	1522	1522	CD
cord-034340-3ksfpaf7	469	14	ug	ug	NNP
cord-034340-3ksfpaf7	469	15	/	/	SYM
cord-034340-3ksfpaf7	469	16	L	L	NNP
cord-034340-3ksfpaf7	469	17	,	,	,
cord-034340-3ksfpaf7	469	18	CRP	CRP	NNP
cord-034340-3ksfpaf7	469	19	100	100	CD
cord-034340-3ksfpaf7	469	20	mg	mg	NNP
cord-034340-3ksfpaf7	469	21	/	/	SYM
cord-034340-3ksfpaf7	469	22	L	L	NNP
cord-034340-3ksfpaf7	469	23	,	,	,
cord-034340-3ksfpaf7	469	24	ferritin	ferritin	NN
cord-034340-3ksfpaf7	469	25	2200	2200	CD
cord-034340-3ksfpaf7	470	1	ug	ug	NNP
cord-034340-3ksfpaf7	470	2	/	/	SYM
cord-034340-3ksfpaf7	470	3	L.	L.	NNP
cord-034340-3ksfpaf7	470	4	High	High	NNP
cord-034340-3ksfpaf7	470	5	doses	dose	NNS
cord-034340-3ksfpaf7	470	6	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	470	7	metilprednisolone	metilprednisolone	NN
cord-034340-3ksfpaf7	470	8	and	and	CC
cord-034340-3ksfpaf7	470	9	oral	oral	JJ
cord-034340-3ksfpaf7	470	10	Cyclosporin	Cyclosporin	NNP
cord-034340-3ksfpaf7	470	11	A	A	NNP
cord-034340-3ksfpaf7	470	12	(	(	-LRB-
cord-034340-3ksfpaf7	470	13	CSA	CSA	NNP
cord-034340-3ksfpaf7	470	14	)	)	-RRB-
cord-034340-3ksfpaf7	470	15	were	be	VBD
cord-034340-3ksfpaf7	470	16	started	start	VBN
cord-034340-3ksfpaf7	470	17	.	.	.
cord-034340-3ksfpaf7	471	1	On	on	IN
cord-034340-3ksfpaf7	471	2	day	day	NN
cord-034340-3ksfpaf7	471	3	2	2	CD
cord-034340-3ksfpaf7	471	4	he	-PRON-	PRP
cord-034340-3ksfpaf7	471	5	presented	present	VBD
cord-034340-3ksfpaf7	471	6	a	a	DT
cord-034340-3ksfpaf7	471	7	Systemic	Systemic	NNP
cord-034340-3ksfpaf7	471	8	Capillary	capillary	JJ
cord-034340-3ksfpaf7	471	9	Leak	leak	NN
cord-034340-3ksfpaf7	471	10	Syndrome	syndrome	NN
cord-034340-3ksfpaf7	471	11	and	and	CC
cord-034340-3ksfpaf7	471	12	acute	acute	JJ
cord-034340-3ksfpaf7	471	13	myocarditis	myocarditis	NN
cord-034340-3ksfpaf7	471	14	.	.	.
cord-034340-3ksfpaf7	472	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	472	2	was	be	VBD
cord-034340-3ksfpaf7	472	3	admitted	admit	VBN
cord-034340-3ksfpaf7	472	4	into	into	IN
cord-034340-3ksfpaf7	472	5	the	the	DT
cord-034340-3ksfpaf7	472	6	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	472	7	intensive	intensive	JJ
cord-034340-3ksfpaf7	472	8	care	care	NN
cord-034340-3ksfpaf7	472	9	unit	unit	NN
cord-034340-3ksfpaf7	472	10	(	(	-LRB-
cord-034340-3ksfpaf7	472	11	PICU	PICU	NNP
cord-034340-3ksfpaf7	472	12	)	)	-RRB-
cord-034340-3ksfpaf7	472	13	where	where	WRB
cord-034340-3ksfpaf7	472	14	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	472	15	immunoglobulin	immunoglobulin	NN
cord-034340-3ksfpaf7	472	16	and	and	CC
cord-034340-3ksfpaf7	472	17	subcutaneous	subcutaneous	JJ
cord-034340-3ksfpaf7	472	18	Anakinra	Anakinra	NNP
cord-034340-3ksfpaf7	472	19	(	(	-LRB-
cord-034340-3ksfpaf7	472	20	ANA	ANA	NNP
cord-034340-3ksfpaf7	472	21	)	)	-RRB-
cord-034340-3ksfpaf7	472	22	were	be	VBD
cord-034340-3ksfpaf7	472	23	added	add	VBN
cord-034340-3ksfpaf7	472	24	.	.	.
cord-034340-3ksfpaf7	473	1	On	on	IN
cord-034340-3ksfpaf7	473	2	day	day	NN
cord-034340-3ksfpaf7	473	3	4	4	CD
cord-034340-3ksfpaf7	473	4	,	,	,
cord-034340-3ksfpaf7	473	5	due	due	IN
cord-034340-3ksfpaf7	473	6	to	to	IN
cord-034340-3ksfpaf7	473	7	an	an	DT
cord-034340-3ksfpaf7	473	8	Introduction	introduction	NN
cord-034340-3ksfpaf7	473	9	:	:	:
cord-034340-3ksfpaf7	473	10	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	473	11	's	's	POS
cord-034340-3ksfpaf7	473	12	syndrome	syndrome	NN
cord-034340-3ksfpaf7	473	13	is	be	VBZ
cord-034340-3ksfpaf7	473	14	a	a	DT
cord-034340-3ksfpaf7	473	15	systemic	systemic	JJ
cord-034340-3ksfpaf7	473	16	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	473	17	disease	disease	NN
cord-034340-3ksfpaf7	473	18	characterized	characterize	VBN
cord-034340-3ksfpaf7	473	19	by	by	IN
cord-034340-3ksfpaf7	473	20	dry	dry	JJ
cord-034340-3ksfpaf7	473	21	syndrome	syndrome	NN
cord-034340-3ksfpaf7	473	22	and	and	CC
cord-034340-3ksfpaf7	473	23	lymphocytic	lymphocytic	JJ
cord-034340-3ksfpaf7	473	24	infiltration	infiltration	NN
cord-034340-3ksfpaf7	473	25	of	of	IN
cord-034340-3ksfpaf7	473	26	the	the	DT
cord-034340-3ksfpaf7	473	27	exocrine	exocrine	JJ
cord-034340-3ksfpaf7	473	28	and	and	CC
cord-034340-3ksfpaf7	473	29	extraglandular	extraglandular	JJ
cord-034340-3ksfpaf7	473	30	glands	gland	NNS
cord-034340-3ksfpaf7	473	31	.	.	.
cord-034340-3ksfpaf7	474	1	Pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	474	2	involvement	involvement	NN
cord-034340-3ksfpaf7	474	3	in	in	IN
cord-034340-3ksfpaf7	474	4	primary	primary	JJ
cord-034340-3ksfpaf7	474	5	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	474	6	's	's	POS
cord-034340-3ksfpaf7	474	7	syndrome	syndrome	NN
cord-034340-3ksfpaf7	474	8	occurs	occur	VBZ
cord-034340-3ksfpaf7	474	9	in	in	IN
cord-034340-3ksfpaf7	474	10	9	9	CD
cord-034340-3ksfpaf7	474	11	-	-	SYM
cord-034340-3ksfpaf7	474	12	20	20	CD
cord-034340-3ksfpaf7	474	13	%	%	NN
cord-034340-3ksfpaf7	474	14	of	of	IN
cord-034340-3ksfpaf7	474	15	patients	patient	NNS
cord-034340-3ksfpaf7	474	16	,	,	,
cord-034340-3ksfpaf7	474	17	with	with	IN
cord-034340-3ksfpaf7	474	18	very	very	RB
cord-034340-3ksfpaf7	474	19	heterogeneous	heterogeneous	JJ
cord-034340-3ksfpaf7	474	20	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	474	21	,	,	,
cord-034340-3ksfpaf7	474	22	and	and	CC
cord-034340-3ksfpaf7	474	23	occasionally	occasionally	RB
cord-034340-3ksfpaf7	474	24	as	as	IN
cord-034340-3ksfpaf7	474	25	an	an	DT
cord-034340-3ksfpaf7	474	26	initial	initial	JJ
cord-034340-3ksfpaf7	474	27	mani	mani	NN
cord-034340-3ksfpaf7	474	28	-	-	HYPH
cord-034340-3ksfpaf7	474	29	festation¹.	festation¹.	JJ
cord-034340-3ksfpaf7	474	30	Diffuse	Diffuse	NNP
cord-034340-3ksfpaf7	474	31	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	474	32	lung	lung	NN
cord-034340-3ksfpaf7	474	33	involvement	involvement	NN
cord-034340-3ksfpaf7	474	34	is	be	VBZ
cord-034340-3ksfpaf7	474	35	one	one	CD
cord-034340-3ksfpaf7	474	36	of	of	IN
cord-034340-3ksfpaf7	474	37	the	the	DT
cord-034340-3ksfpaf7	474	38	most	most	RBS
cord-034340-3ksfpaf7	474	39	characteristic	characteristic	JJ
cord-034340-3ksfpaf7	474	40	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	474	41	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	474	42	and	and	CC
cord-034340-3ksfpaf7	474	43	the	the	DT
cord-034340-3ksfpaf7	474	44	most	most	RBS
cord-034340-3ksfpaf7	474	45	frequent	frequent	JJ
cord-034340-3ksfpaf7	474	46	subtypes	subtype	NNS
cord-034340-3ksfpaf7	474	47	in	in	IN
cord-034340-3ksfpaf7	474	48	lung	lung	NN
cord-034340-3ksfpaf7	474	49	biopsy	biopsy	NN
cord-034340-3ksfpaf7	474	50	are	be	VBP
cord-034340-3ksfpaf7	474	51	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	474	52	lymphocytic	lymphocytic	JJ
cord-034340-3ksfpaf7	474	53	pneumonia	pneumonia	NN
cord-034340-3ksfpaf7	474	54	and	and	CC
cord-034340-3ksfpaf7	474	55	nonspecific	nonspecific	JJ
cord-034340-3ksfpaf7	474	56	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	474	57	pneumonia²	pneumonia²	NN
cord-034340-3ksfpaf7	474	58	.	.	.
cord-034340-3ksfpaf7	475	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	475	2	:	:	:
cord-034340-3ksfpaf7	475	3	14-year	14-year	JJ
cord-034340-3ksfpaf7	475	4	-	-	HYPH
cord-034340-3ksfpaf7	475	5	old	old	JJ
cord-034340-3ksfpaf7	475	6	girl	girl	NN
cord-034340-3ksfpaf7	475	7	presented	present	VBN
cord-034340-3ksfpaf7	475	8	to	to	IN
cord-034340-3ksfpaf7	475	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	475	10	hospital	hospital	NN
cord-034340-3ksfpaf7	475	11	because	because	IN
cord-034340-3ksfpaf7	475	12	of	of	IN
cord-034340-3ksfpaf7	475	13	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	475	14	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	475	15	involvement	involvement	NN
cord-034340-3ksfpaf7	475	16	with	with	IN
cord-034340-3ksfpaf7	475	17	ground	ground	NN
cord-034340-3ksfpaf7	475	18	glass	glass	NN
cord-034340-3ksfpaf7	475	19	areas	area	NNS
cord-034340-3ksfpaf7	475	20	in	in	IN
cord-034340-3ksfpaf7	475	21	lower	low	JJR
cord-034340-3ksfpaf7	475	22	lobes	lobe	NNS
cord-034340-3ksfpaf7	475	23	of	of	IN
cord-034340-3ksfpaf7	475	24	both	both	DT
cord-034340-3ksfpaf7	475	25	lungs	lung	NNS
cord-034340-3ksfpaf7	475	26	on	on	IN
cord-034340-3ksfpaf7	475	27	thorax	thorax	NN
cord-034340-3ksfpaf7	475	28	and	and	CC
cord-034340-3ksfpaf7	475	29	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	475	30	CT	CT	NNP
cord-034340-3ksfpaf7	475	31	scan	scan	NN
cord-034340-3ksfpaf7	475	32	after	after	IN
cord-034340-3ksfpaf7	475	33	for	for	IN
cord-034340-3ksfpaf7	475	34	kidney	kidney	NN
cord-034340-3ksfpaf7	475	35	stones	stone	NNS
cord-034340-3ksfpaf7	475	36	follow	follow	NN
cord-034340-3ksfpaf7	475	37	-	-	HYPH
cord-034340-3ksfpaf7	475	38	up	up	NN
cord-034340-3ksfpaf7	475	39	.	.	.
cord-034340-3ksfpaf7	476	1	The	the	DT
cord-034340-3ksfpaf7	476	2	patient	patient	NN
cord-034340-3ksfpaf7	476	3	had	have	VBD
cord-034340-3ksfpaf7	476	4	grade	grade	NN
cord-034340-3ksfpaf7	476	5	1	1	CD
cord-034340-3ksfpaf7	476	6	mMRC	mMRC	NNS
cord-034340-3ksfpaf7	476	7	dyspnoea	dyspnoea	NNS
cord-034340-3ksfpaf7	476	8	and	and	CC
cord-034340-3ksfpaf7	476	9	dry	dry	JJ
cord-034340-3ksfpaf7	476	10	cough	cough	NN
cord-034340-3ksfpaf7	476	11	but	but	CC
cord-034340-3ksfpaf7	476	12	denied	deny	VBN
cord-034340-3ksfpaf7	476	13	having	have	VBG
cord-034340-3ksfpaf7	476	14	symptoms	symptom	NNS
cord-034340-3ksfpaf7	476	15	of	of	IN
cord-034340-3ksfpaf7	476	16	arthralgia	arthralgia	NN
cord-034340-3ksfpaf7	476	17	or	or	CC
cord-034340-3ksfpaf7	476	18	arthritis	arthritis	NN
cord-034340-3ksfpaf7	476	19	,	,	,
cord-034340-3ksfpaf7	476	20	photosensitivity	photosensitivity	NN
cord-034340-3ksfpaf7	476	21	,	,	,
cord-034340-3ksfpaf7	476	22	oral	oral	JJ
cord-034340-3ksfpaf7	476	23	and	and	CC
cord-034340-3ksfpaf7	476	24	genital	genital	JJ
cord-034340-3ksfpaf7	476	25	ulcers	ulcer	NNS
cord-034340-3ksfpaf7	476	26	,	,	,
cord-034340-3ksfpaf7	476	27	Raynaud	Raynaud	NNP
cord-034340-3ksfpaf7	476	28	's	's	POS
cord-034340-3ksfpaf7	476	29	phenomenon	phenomenon	NN
cord-034340-3ksfpaf7	476	30	or	or	CC
cord-034340-3ksfpaf7	476	31	episodes	episode	NNS
cord-034340-3ksfpaf7	476	32	of	of	IN
cord-034340-3ksfpaf7	476	33	dry	dry	JJ
cord-034340-3ksfpaf7	476	34	mucosa	mucosa	NN
cord-034340-3ksfpaf7	476	35	.	.	.
cord-034340-3ksfpaf7	477	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	477	2	had	have	VBD
cord-034340-3ksfpaf7	477	3	no	no	DT
cord-034340-3ksfpaf7	477	4	history	history	NN
cord-034340-3ksfpaf7	477	5	of	of	IN
cord-034340-3ksfpaf7	477	6	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	477	7	disease	disease	NN
cord-034340-3ksfpaf7	477	8	nor	nor	CC
cord-034340-3ksfpaf7	477	9	family	family	NN
cord-034340-3ksfpaf7	477	10	antecedents	antecedent	NNS
cord-034340-3ksfpaf7	477	11	of	of	IN
cord-034340-3ksfpaf7	477	12	any	any	DT
cord-034340-3ksfpaf7	477	13	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	477	14	disease	disease	NN
cord-034340-3ksfpaf7	477	15	.	.	.
cord-034340-3ksfpaf7	478	1	A	a	DT
cord-034340-3ksfpaf7	478	2	physical	physical	JJ
cord-034340-3ksfpaf7	478	3	examination	examination	NN
cord-034340-3ksfpaf7	478	4	disclosed	disclose	VBD
cord-034340-3ksfpaf7	478	5	no	no	DT
cord-034340-3ksfpaf7	478	6	finger	finger	NN
cord-034340-3ksfpaf7	478	7	clubbing	clubbing	NN
cord-034340-3ksfpaf7	478	8	or	or	CC
cord-034340-3ksfpaf7	478	9	swollen	swollen	JJ
cord-034340-3ksfpaf7	478	10	superficial	superficial	JJ
cord-034340-3ksfpaf7	478	11	lymph	lymph	NN
cord-034340-3ksfpaf7	478	12	nodes	node	NNS
cord-034340-3ksfpaf7	478	13	but	but	CC
cord-034340-3ksfpaf7	478	14	indicated	indicate	VBD
cord-034340-3ksfpaf7	478	15	crackles	crackle	NNS
cord-034340-3ksfpaf7	478	16	on	on	IN
cord-034340-3ksfpaf7	478	17	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	478	18	auscultation	auscultation	NN
cord-034340-3ksfpaf7	478	19	.	.	.
cord-034340-3ksfpaf7	479	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	479	2	work	work	NN
cord-034340-3ksfpaf7	479	3	showed	show	VBD
cord-034340-3ksfpaf7	479	4	elevated	elevated	JJ
cord-034340-3ksfpaf7	479	5	acute	acute	JJ
cord-034340-3ksfpaf7	479	6	phase	phase	NN
cord-034340-3ksfpaf7	479	7	reactants	reactant	NNS
cord-034340-3ksfpaf7	479	8	,	,	,
cord-034340-3ksfpaf7	479	9	positive	positive	JJ
cord-034340-3ksfpaf7	479	10	rheumatoid	rheumatoid	NN
cord-034340-3ksfpaf7	479	11	factor	factor	NN
cord-034340-3ksfpaf7	479	12	,	,	,
cord-034340-3ksfpaf7	479	13	positive	positive	JJ
cord-034340-3ksfpaf7	479	14	antinuclear	antinuclear	JJ
cord-034340-3ksfpaf7	479	15	antibodies	antibody	NNS
cord-034340-3ksfpaf7	479	16	(	(	-LRB-
cord-034340-3ksfpaf7	479	17	1/	1/	CD
cord-034340-3ksfpaf7	479	18	40	40	CD
cord-034340-3ksfpaf7	479	19	)	)	-RRB-
cord-034340-3ksfpaf7	479	20	,	,	,
cord-034340-3ksfpaf7	479	21	positive	positive	JJ
cord-034340-3ksfpaf7	479	22	cytoplasmic	cytoplasmic	JJ
cord-034340-3ksfpaf7	479	23	antineutrophil	antineutrophil	NNP
cord-034340-3ksfpaf7	479	24	antibodies	antibody	NNS
cord-034340-3ksfpaf7	479	25	(	(	-LRB-
cord-034340-3ksfpaf7	479	26	1/320	1/320	CD
cord-034340-3ksfpaf7	479	27	)	)	-RRB-
cord-034340-3ksfpaf7	479	28	and	and	CC
cord-034340-3ksfpaf7	479	29	IgG	IgG	NNP
cord-034340-3ksfpaf7	479	30	and	and	CC
cord-034340-3ksfpaf7	479	31	IgA	IgA	NNP
cord-034340-3ksfpaf7	479	32	hypergammaglobulinemia	hypergammaglobulinemia	NNP
cord-034340-3ksfpaf7	479	33	.	.	.
cord-034340-3ksfpaf7	480	1	An	an	DT
cord-034340-3ksfpaf7	480	2	examination	examination	NN
cord-034340-3ksfpaf7	480	3	for	for	IN
cord-034340-3ksfpaf7	480	4	autoantibodies	autoantibody	NNS
cord-034340-3ksfpaf7	480	5	were	be	VBD
cord-034340-3ksfpaf7	480	6	negative	negative	JJ
cord-034340-3ksfpaf7	480	7	for	for	IN
cord-034340-3ksfpaf7	480	8	anti	anti	JJ
cord-034340-3ksfpaf7	480	9	-	-	JJ
cord-034340-3ksfpaf7	480	10	SS	SS	NNP
cord-034340-3ksfpaf7	480	11	-	-	HYPH
cord-034340-3ksfpaf7	480	12	A	A	NNP
cord-034340-3ksfpaf7	480	13	,	,	,
cord-034340-3ksfpaf7	480	14	anti	anti	JJ
cord-034340-3ksfpaf7	480	15	-	-	JJ
cord-034340-3ksfpaf7	480	16	SS	SS	NNP
cord-034340-3ksfpaf7	480	17	-	-	HYPH
cord-034340-3ksfpaf7	480	18	B	B	NNP
cord-034340-3ksfpaf7	480	19	,	,	,
cord-034340-3ksfpaf7	480	20	anti	anti	NNP
cord-034340-3ksfpaf7	480	21	Jo-1	Jo-1	NNP
cord-034340-3ksfpaf7	480	22	,	,	,
cord-034340-3ksfpaf7	480	23	anticentromere	anticentromere	NN
cord-034340-3ksfpaf7	480	24	and	and	CC
cord-034340-3ksfpaf7	480	25	anti	anti	JJ
cord-034340-3ksfpaf7	480	26	-	-	JJ
cord-034340-3ksfpaf7	480	27	scl-70	scl-70	JJ
cord-034340-3ksfpaf7	480	28	antibodies	antibody	NNS
cord-034340-3ksfpaf7	480	29	.	.	.
cord-034340-3ksfpaf7	481	1	Iontophoresis	iontophoresis	NN
cord-034340-3ksfpaf7	481	2	with	with	IN
cord-034340-3ksfpaf7	481	3	pilocarpine	pilocarpine	NNP
cord-034340-3ksfpaf7	481	4	and	and	CC
cord-034340-3ksfpaf7	481	5	6-minute	6-minute	CD
cord-034340-3ksfpaf7	481	6	walk	walk	NN
cord-034340-3ksfpaf7	481	7	test	test	NN
cord-034340-3ksfpaf7	481	8	was	be	VBD
cord-034340-3ksfpaf7	481	9	also	also	RB
cord-034340-3ksfpaf7	481	10	normal	normal	JJ
cord-034340-3ksfpaf7	481	11	.	.	.
cord-034340-3ksfpaf7	482	1	Pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	482	2	function	function	NN
cord-034340-3ksfpaf7	482	3	tests	test	NNS
cord-034340-3ksfpaf7	482	4	demonstrated	demonstrate	VBD
cord-034340-3ksfpaf7	482	5	a	a	DT
cord-034340-3ksfpaf7	482	6	mild	mild	JJ
cord-034340-3ksfpaf7	482	7	restrictive	restrictive	JJ
cord-034340-3ksfpaf7	482	8	impairment	impairment	NN
cord-034340-3ksfpaf7	482	9	and	and	CC
cord-034340-3ksfpaf7	482	10	a	a	DT
cord-034340-3ksfpaf7	482	11	reduced	reduced	JJ
cord-034340-3ksfpaf7	482	12	percent	percent	NN
cord-034340-3ksfpaf7	482	13	diffusion	diffusion	NN
cord-034340-3ksfpaf7	482	14	capacity	capacity	NN
cord-034340-3ksfpaf7	482	15	for	for	IN
cord-034340-3ksfpaf7	482	16	carbon	carbon	NN
cord-034340-3ksfpaf7	482	17	monoxide	monoxide	NN
cord-034340-3ksfpaf7	482	18	of	of	IN
cord-034340-3ksfpaf7	482	19	55	55	CD
cord-034340-3ksfpaf7	482	20	%	%	NN
cord-034340-3ksfpaf7	482	21	.	.	.
cord-034340-3ksfpaf7	483	1	Fibreoptic	fibreoptic	JJ
cord-034340-3ksfpaf7	483	2	bronchoscopy	bronchoscopy	NN
cord-034340-3ksfpaf7	483	3	showed	show	VBD
cord-034340-3ksfpaf7	483	4	acute	acute	JJ
cord-034340-3ksfpaf7	483	5	inflammation	inflammation	NN
cord-034340-3ksfpaf7	483	6	in	in	IN
cord-034340-3ksfpaf7	483	7	bronchial	bronchial	JJ
cord-034340-3ksfpaf7	483	8	mucosa	mucosa	NN
cord-034340-3ksfpaf7	483	9	.	.	.
cord-034340-3ksfpaf7	484	1	Flow	flow	NN
cord-034340-3ksfpaf7	484	2	cytometry	cytometry	NN
cord-034340-3ksfpaf7	484	3	of	of	IN
cord-034340-3ksfpaf7	484	4	bronchoalveolar	bronchoalveolar	NNP
cord-034340-3ksfpaf7	484	5	lavage	lavage	NN
cord-034340-3ksfpaf7	484	6	and	and	CC
cord-034340-3ksfpaf7	484	7	cytology	cytology	NN
cord-034340-3ksfpaf7	484	8	showed	show	VBD
cord-034340-3ksfpaf7	484	9	lymphocytosis	lymphocytosis	NN
cord-034340-3ksfpaf7	484	10	with	with	IN
cord-034340-3ksfpaf7	484	11	a	a	DT
cord-034340-3ksfpaf7	484	12	15	15	CD
cord-034340-3ksfpaf7	484	13	%	%	NN
cord-034340-3ksfpaf7	484	14	of	of	IN
cord-034340-3ksfpaf7	484	15	CD4	CD4	NNP
cord-034340-3ksfpaf7	484	16	and	and	CC
cord-034340-3ksfpaf7	484	17	85	85	CD
cord-034340-3ksfpaf7	484	18	%	%	NN
cord-034340-3ksfpaf7	484	19	of	of	IN
cord-034340-3ksfpaf7	484	20	CD8	CD8	NNP
cord-034340-3ksfpaf7	484	21	lymphocytes	lymphocyte	NNS
cord-034340-3ksfpaf7	484	22	in	in	IN
cord-034340-3ksfpaf7	484	23	bronchoalveolar	bronchoalveolar	NNP
cord-034340-3ksfpaf7	484	24	lavage	lavage	NN
cord-034340-3ksfpaf7	484	25	fluid	fluid	NN
cord-034340-3ksfpaf7	484	26	.	.	.
cord-034340-3ksfpaf7	485	1	Finally	finally	RB
cord-034340-3ksfpaf7	485	2	,	,	,
cord-034340-3ksfpaf7	485	3	a	a	DT
cord-034340-3ksfpaf7	485	4	transbronchial	transbronchial	JJ
cord-034340-3ksfpaf7	485	5	lung	lung	NN
cord-034340-3ksfpaf7	485	6	biopsy	biopsy	NN
cord-034340-3ksfpaf7	485	7	lead	lead	VB
cord-034340-3ksfpaf7	485	8	to	to	IN
cord-034340-3ksfpaf7	485	9	a	a	DT
cord-034340-3ksfpaf7	485	10	definitive	definitive	JJ
cord-034340-3ksfpaf7	485	11	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	485	12	,	,	,
cord-034340-3ksfpaf7	485	13	showing	show	VBG
cord-034340-3ksfpaf7	485	14	mixed	mixed	JJ
cord-034340-3ksfpaf7	485	15	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	485	16	inflammation	inflammation	NN
cord-034340-3ksfpaf7	485	17	and	and	CC
cord-034340-3ksfpaf7	485	18	lymphocytic	lymphocytic	JJ
cord-034340-3ksfpaf7	485	19	follicular	follicular	JJ
cord-034340-3ksfpaf7	485	20	hyperplasia	hyperplasia	NN
cord-034340-3ksfpaf7	485	21	with	with	IN
cord-034340-3ksfpaf7	485	22	formation	formation	NN
cord-034340-3ksfpaf7	485	23	of	of	IN
cord-034340-3ksfpaf7	485	24	germinal	germinal	JJ
cord-034340-3ksfpaf7	485	25	centers	center	NNS
cord-034340-3ksfpaf7	485	26	,	,	,
cord-034340-3ksfpaf7	485	27	suggestive	suggestive	JJ
cord-034340-3ksfpaf7	485	28	of	of	IN
cord-034340-3ksfpaf7	485	29	a	a	DT
cord-034340-3ksfpaf7	485	30	lymphoid	lymphoid	JJ
cord-034340-3ksfpaf7	485	31	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	485	32	pneumonia	pneumonia	NN
cord-034340-3ksfpaf7	485	33	of	of	IN
cord-034340-3ksfpaf7	485	34	unreleased	unreleased	JJ
cord-034340-3ksfpaf7	485	35	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	485	36	etiology	etiology	NN
cord-034340-3ksfpaf7	485	37	.	.	.
cord-034340-3ksfpaf7	486	1	Throughout	throughout	IN
cord-034340-3ksfpaf7	486	2	time	time	NN
cord-034340-3ksfpaf7	486	3	,	,	,
cord-034340-3ksfpaf7	486	4	the	the	DT
cord-034340-3ksfpaf7	486	5	patient	patient	NN
cord-034340-3ksfpaf7	486	6	reported	report	VBD
cord-034340-3ksfpaf7	486	7	progression	progression	NN
cord-034340-3ksfpaf7	486	8	of	of	IN
cord-034340-3ksfpaf7	486	9	her	-PRON-	PRP$
cord-034340-3ksfpaf7	486	10	symptoms	symptom	NNS
cord-034340-3ksfpaf7	486	11	with	with	IN
cord-034340-3ksfpaf7	486	12	increasing	increase	VBG
cord-034340-3ksfpaf7	486	13	dyspnoea	dyspnoea	NNS
cord-034340-3ksfpaf7	486	14	,	,	,
cord-034340-3ksfpaf7	486	15	persistent	persistent	JJ
cord-034340-3ksfpaf7	486	16	dry	dry	JJ
cord-034340-3ksfpaf7	486	17	cough	cough	NN
cord-034340-3ksfpaf7	486	18	,	,	,
cord-034340-3ksfpaf7	486	19	xerostomia	xerostomia	NN
cord-034340-3ksfpaf7	486	20	and	and	CC
cord-034340-3ksfpaf7	486	21	arthralgia	arthralgia	NNP
cord-034340-3ksfpaf7	486	22	.	.	.
cord-034340-3ksfpaf7	487	1	Schirmer	Schirmer	NNP
cord-034340-3ksfpaf7	487	2	and	and	CC
cord-034340-3ksfpaf7	487	3	Rose	Rose	NNP
cord-034340-3ksfpaf7	487	4	Bengal	Bengal	NNP
cord-034340-3ksfpaf7	487	5	dye	dye	NN
cord-034340-3ksfpaf7	487	6	test	test	NN
cord-034340-3ksfpaf7	487	7	were	be	VBD
cord-034340-3ksfpaf7	487	8	negative	negative	JJ
cord-034340-3ksfpaf7	487	9	,	,	,
cord-034340-3ksfpaf7	487	10	and	and	CC
cord-034340-3ksfpaf7	487	11	a	a	DT
cord-034340-3ksfpaf7	487	12	salivary	salivary	NN
cord-034340-3ksfpaf7	487	13	gland	gland	NN
cord-034340-3ksfpaf7	487	14	biopsy	biopsy	NN
cord-034340-3ksfpaf7	487	15	showed	show	VBD
cord-034340-3ksfpaf7	487	16	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	487	17	plasmacytosis	plasmacytosis	NN
cord-034340-3ksfpaf7	487	18	and	and	CC
cord-034340-3ksfpaf7	487	19	no	no	DT
cord-034340-3ksfpaf7	487	20	IgG4	igg4	JJ
cord-034340-3ksfpaf7	487	21	plasma	plasma	NN
cord-034340-3ksfpaf7	487	22	cells	cell	NNS
cord-034340-3ksfpaf7	487	23	expression	expression	NN
cord-034340-3ksfpaf7	487	24	which	which	WDT
cord-034340-3ksfpaf7	487	25	suggested	suggest	VBD
cord-034340-3ksfpaf7	487	26	Sjogren	Sjogren	NNP
cord-034340-3ksfpaf7	487	27	's	's	POS
cord-034340-3ksfpaf7	487	28	disease	disease	NN
cord-034340-3ksfpaf7	487	29	.	.	.
cord-034340-3ksfpaf7	488	1	A	a	DT
cord-034340-3ksfpaf7	488	2	high	high	JJ
cord-034340-3ksfpaf7	488	3	resolution	resolution	NN
cord-034340-3ksfpaf7	488	4	computerized	computerize	VBN
cord-034340-3ksfpaf7	488	5	axial	axial	JJ
cord-034340-3ksfpaf7	488	6	tomography	tomography	NN
cord-034340-3ksfpaf7	488	7	was	be	VBD
cord-034340-3ksfpaf7	488	8	requested	request	VBN
cord-034340-3ksfpaf7	488	9	,	,	,
cord-034340-3ksfpaf7	488	10	suggesting	suggest	VBG
cord-034340-3ksfpaf7	488	11	organizing	organize	VBG
cord-034340-3ksfpaf7	488	12	pneumonia	pneumonia	NN
cord-034340-3ksfpaf7	488	13	in	in	IN
cord-034340-3ksfpaf7	488	14	the	the	DT
cord-034340-3ksfpaf7	488	15	context	context	NN
cord-034340-3ksfpaf7	488	16	of	of	IN
cord-034340-3ksfpaf7	488	17	Sjogren	Sjogren	NNP
cord-034340-3ksfpaf7	488	18	's	's	POS
cord-034340-3ksfpaf7	488	19	disease	disease	NN
cord-034340-3ksfpaf7	488	20	.	.	.
cord-034340-3ksfpaf7	489	1	Methods	method	NNS
cord-034340-3ksfpaf7	489	2	:	:	:
cord-034340-3ksfpaf7	489	3	Several	several	JJ
cord-034340-3ksfpaf7	489	4	studies	study	NNS
cord-034340-3ksfpaf7	489	5	indicate	indicate	VBP
cord-034340-3ksfpaf7	489	6	that	that	IN
cord-034340-3ksfpaf7	489	7	lung	lung	NN
cord-034340-3ksfpaf7	489	8	involvement	involvement	NN
cord-034340-3ksfpaf7	489	9	in	in	IN
cord-034340-3ksfpaf7	489	10	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	489	11	is	be	VBZ
cord-034340-3ksfpaf7	489	12	more	more	RBR
cord-034340-3ksfpaf7	489	13	frequent	frequent	JJ
cord-034340-3ksfpaf7	489	14	in	in	IN
cord-034340-3ksfpaf7	489	15	advanced	advanced	JJ
cord-034340-3ksfpaf7	489	16	stages	stage	NNS
cord-034340-3ksfpaf7	489	17	of	of	IN
cord-034340-3ksfpaf7	489	18	the	the	DT
cord-034340-3ksfpaf7	489	19	disease	disease	NN
cord-034340-3ksfpaf7	489	20	and	and	CC
cord-034340-3ksfpaf7	489	21	rarely	rarely	RB
cord-034340-3ksfpaf7	489	22	as	as	IN
cord-034340-3ksfpaf7	489	23	an	an	DT
cord-034340-3ksfpaf7	489	24	initial	initial	JJ
cord-034340-3ksfpaf7	489	25	manifestation	manifestation	NN
cord-034340-3ksfpaf7	489	26	.	.	.
cord-034340-3ksfpaf7	490	1	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	490	2	's	's	POS
cord-034340-3ksfpaf7	490	3	syndrome	syndrome	NN
cord-034340-3ksfpaf7	490	4	in	in	IN
cord-034340-3ksfpaf7	490	5	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	490	6	age	age	NN
cord-034340-3ksfpaf7	490	7	is	be	VBZ
cord-034340-3ksfpaf7	490	8	rare	rare	JJ
cord-034340-3ksfpaf7	490	9	and	and	CC
cord-034340-3ksfpaf7	490	10	the	the	DT
cord-034340-3ksfpaf7	490	11	subtype	subtype	NN
cord-034340-3ksfpaf7	490	12	of	of	IN
cord-034340-3ksfpaf7	490	13	secondary	secondary	JJ
cord-034340-3ksfpaf7	490	14	Sjogren	Sjogren	NNP
cord-034340-3ksfpaf7	490	15	's	's	POS
cord-034340-3ksfpaf7	490	16	is	be	VBZ
cord-034340-3ksfpaf7	490	17	the	the	DT
cord-034340-3ksfpaf7	490	18	most	most	RBS
cord-034340-3ksfpaf7	490	19	common	common	JJ
cord-034340-3ksfpaf7	490	20	.	.	.
cord-034340-3ksfpaf7	491	1	The	the	DT
cord-034340-3ksfpaf7	491	2	course	course	NN
cord-034340-3ksfpaf7	491	3	is	be	VBZ
cord-034340-3ksfpaf7	491	4	longer	long	JJR
cord-034340-3ksfpaf7	491	5	,	,	,
cord-034340-3ksfpaf7	491	6	and	and	CC
cord-034340-3ksfpaf7	491	7	the	the	DT
cord-034340-3ksfpaf7	491	8	symptoms	symptom	NNS
cord-034340-3ksfpaf7	491	9	are	be	VBP
cord-034340-3ksfpaf7	491	10	more	more	RBR
cord-034340-3ksfpaf7	491	11	heterogeneous	heterogeneous	JJ
cord-034340-3ksfpaf7	491	12	than	than	IN
cord-034340-3ksfpaf7	491	13	in	in	IN
cord-034340-3ksfpaf7	491	14	adulthood	adulthood	NN
cord-034340-3ksfpaf7	491	15	5	5	CD
cord-034340-3ksfpaf7	491	16	.	.	.
cord-034340-3ksfpaf7	492	1	The	the	DT
cord-034340-3ksfpaf7	492	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	492	3	in	in	IN
cord-034340-3ksfpaf7	492	4	children	child	NNS
cord-034340-3ksfpaf7	492	5	is	be	VBZ
cord-034340-3ksfpaf7	492	6	delayed	delay	VBN
cord-034340-3ksfpaf7	492	7	,	,	,
cord-034340-3ksfpaf7	492	8	because	because	IN
cord-034340-3ksfpaf7	492	9	children	child	NNS
cord-034340-3ksfpaf7	492	10	less	less	RBR
cord-034340-3ksfpaf7	492	11	frequently	frequently	RB
cord-034340-3ksfpaf7	492	12	report	report	VBP
cord-034340-3ksfpaf7	492	13	dryness	dryness	NN
cord-034340-3ksfpaf7	492	14	and	and	CC
cord-034340-3ksfpaf7	492	15	frequently	frequently	RB
cord-034340-3ksfpaf7	492	16	present	present	JJ
cord-034340-3ksfpaf7	492	17	with	with	IN
cord-034340-3ksfpaf7	492	18	extraglandular	extraglandular	JJ
cord-034340-3ksfpaf7	492	19	clinical	clinical	JJ
cord-034340-3ksfpaf7	492	20	features	feature	NNS
cord-034340-3ksfpaf7	492	21	suggestive	suggestive	JJ
cord-034340-3ksfpaf7	492	22	of	of	IN
cord-034340-3ksfpaf7	492	23	other	other	JJ
cord-034340-3ksfpaf7	492	24	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	492	25	diseases	disease	NNS
cord-034340-3ksfpaf7	492	26	.	.	.
cord-034340-3ksfpaf7	493	1	A	a	DT
cord-034340-3ksfpaf7	493	2	systematic	systematic	JJ
cord-034340-3ksfpaf7	493	3	review	review	NN
cord-034340-3ksfpaf7	493	4	on	on	IN
cord-034340-3ksfpaf7	493	5	primary	primary	JJ
cord-034340-3ksfpaf7	493	6	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	493	7	's	's	POS
cord-034340-3ksfpaf7	493	8	syndrome	syndrome	NN
cord-034340-3ksfpaf7	493	9	in	in	IN
cord-034340-3ksfpaf7	493	10	male	male	JJ
cord-034340-3ksfpaf7	493	11	and	and	CC
cord-034340-3ksfpaf7	493	12	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	493	13	population	population	NN
cord-034340-3ksfpaf7	493	14	reported	report	VBD
cord-034340-3ksfpaf7	493	15	a	a	DT
cord-034340-3ksfpaf7	493	16	2.4	2.4	CD
cord-034340-3ksfpaf7	493	17	%	%	NN
cord-034340-3ksfpaf7	493	18	of	of	IN
cord-034340-3ksfpaf7	493	19	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	493	20	involvement	involvement	NN
cord-034340-3ksfpaf7	493	21	in	in	IN
cord-034340-3ksfpaf7	493	22	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	493	23	patients	patient	NNS
cord-034340-3ksfpaf7	493	24	.	.	.
cord-034340-3ksfpaf7	494	1	6	6	CD
cord-034340-3ksfpaf7	494	2	Pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	494	3	involvement	involvement	NN
cord-034340-3ksfpaf7	494	4	is	be	VBZ
cord-034340-3ksfpaf7	494	5	associated	associate	VBN
cord-034340-3ksfpaf7	494	6	with	with	IN
cord-034340-3ksfpaf7	494	7	an	an	DT
cord-034340-3ksfpaf7	494	8	increase	increase	NN
cord-034340-3ksfpaf7	494	9	in	in	IN
cord-034340-3ksfpaf7	494	10	the	the	DT
cord-034340-3ksfpaf7	494	11	mortality	mortality	NN
cord-034340-3ksfpaf7	494	12	of	of	IN
cord-034340-3ksfpaf7	494	13	patients	patient	NNS
cord-034340-3ksfpaf7	494	14	with	with	IN
cord-034340-3ksfpaf7	494	15	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	494	16	's	's	POS
cord-034340-3ksfpaf7	494	17	,	,	,
cord-034340-3ksfpaf7	494	18	therefore	therefore	RB
cord-034340-3ksfpaf7	494	19	,	,	,
cord-034340-3ksfpaf7	494	20	it	-PRON-	PRP
cord-034340-3ksfpaf7	494	21	is	be	VBZ
cord-034340-3ksfpaf7	494	22	essential	essential	JJ
cord-034340-3ksfpaf7	494	23	to	to	TO
cord-034340-3ksfpaf7	494	24	periodically	periodically	RB
cord-034340-3ksfpaf7	494	25	monitor	monitor	VB
cord-034340-3ksfpaf7	494	26	patients	patient	NNS
cord-034340-3ksfpaf7	494	27	with	with	IN
cord-034340-3ksfpaf7	494	28	respiratory	respiratory	JJ
cord-034340-3ksfpaf7	494	29	symptoms	symptom	NNS
cord-034340-3ksfpaf7	494	30	,	,	,
cord-034340-3ksfpaf7	494	31	making	make	VBG
cord-034340-3ksfpaf7	494	32	an	an	DT
cord-034340-3ksfpaf7	494	33	early	early	JJ
cord-034340-3ksfpaf7	494	34	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	494	35	and	and	CC
cord-034340-3ksfpaf7	494	36	treatment	treatment	NN
cord-034340-3ksfpaf7	494	37	of	of	IN
cord-034340-3ksfpaf7	494	38	the	the	DT
cord-034340-3ksfpaf7	494	39	disease	disease	NN
cord-034340-3ksfpaf7	494	40	.	.	.
cord-034340-3ksfpaf7	495	1	Results	result	NNS
cord-034340-3ksfpaf7	495	2	:	:	:
cord-034340-3ksfpaf7	496	1	-Conclusion	-conclusion	NN
cord-034340-3ksfpaf7	496	2	:	:	:
cord-034340-3ksfpaf7	497	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	497	2	present	present	VBP
cord-034340-3ksfpaf7	497	3	a	a	DT
cord-034340-3ksfpaf7	497	4	case	case	NN
cord-034340-3ksfpaf7	497	5	of	of	IN
cord-034340-3ksfpaf7	497	6	a	a	DT
cord-034340-3ksfpaf7	497	7	patient	patient	NN
cord-034340-3ksfpaf7	497	8	with	with	IN
cord-034340-3ksfpaf7	497	9	childhood	childhood	NN
cord-034340-3ksfpaf7	497	10	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	497	11	's	's	POS
cord-034340-3ksfpaf7	497	12	disease	disease	NN
cord-034340-3ksfpaf7	497	13	with	with	IN
cord-034340-3ksfpaf7	497	14	atypical	atypical	JJ
cord-034340-3ksfpaf7	497	15	onset	onset	NN
cord-034340-3ksfpaf7	497	16	of	of	IN
cord-034340-3ksfpaf7	497	17	disease	disease	NN
cord-034340-3ksfpaf7	497	18	with	with	IN
cord-034340-3ksfpaf7	497	19	lung	lung	NN
cord-034340-3ksfpaf7	497	20	involvement	involvement	NN
cord-034340-3ksfpaf7	497	21	.	.	.
cord-034340-3ksfpaf7	498	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	498	2	:	:	:
cord-034340-3ksfpaf7	498	3	Sarcoidosis	Sarcoidosis	NNP
cord-034340-3ksfpaf7	498	4	is	be	VBZ
cord-034340-3ksfpaf7	498	5	a	a	DT
cord-034340-3ksfpaf7	498	6	multi	multi	JJ
cord-034340-3ksfpaf7	498	7	-	-	JJ
cord-034340-3ksfpaf7	498	8	system	system	JJ
cord-034340-3ksfpaf7	498	9	disorder	disorder	NN
cord-034340-3ksfpaf7	498	10	.	.	.
cord-034340-3ksfpaf7	499	1	Little	little	JJ
cord-034340-3ksfpaf7	499	2	is	be	VBZ
cord-034340-3ksfpaf7	499	3	known	know	VBN
cord-034340-3ksfpaf7	499	4	about	about	IN
cord-034340-3ksfpaf7	499	5	its	-PRON-	PRP$
cord-034340-3ksfpaf7	499	6	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	499	7	.	.	.
cord-034340-3ksfpaf7	500	1	In	in	IN
cord-034340-3ksfpaf7	500	2	children	child	NNS
cord-034340-3ksfpaf7	500	3	,	,	,
cord-034340-3ksfpaf7	500	4	the	the	DT
cord-034340-3ksfpaf7	500	5	early	early	JJ
cord-034340-3ksfpaf7	500	6	onset	onset	NN
cord-034340-3ksfpaf7	500	7	sarcoidosis	sarcoidosis	NN
cord-034340-3ksfpaf7	500	8	phenotype	phenotype	NN
cord-034340-3ksfpaf7	500	9	including	include	VBG
cord-034340-3ksfpaf7	500	10	Blau	Blau	NNP
cord-034340-3ksfpaf7	500	11	syndrome	syndrome	NN
cord-034340-3ksfpaf7	500	12	is	be	VBZ
cord-034340-3ksfpaf7	500	13	more	more	RBR
cord-034340-3ksfpaf7	500	14	often	often	RB
cord-034340-3ksfpaf7	500	15	seen	see	VBN
cord-034340-3ksfpaf7	500	16	.	.	.
cord-034340-3ksfpaf7	501	1	1	1	CD
cord-034340-3ksfpaf7	501	2	,	,	,
cord-034340-3ksfpaf7	501	3	2	2	CD
cord-034340-3ksfpaf7	502	1	The	the	DT
cord-034340-3ksfpaf7	502	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	502	3	of	of	IN
cord-034340-3ksfpaf7	502	4	sarcoidosis	sarcoidosis	NNP
cord-034340-3ksfpaf7	502	5	is	be	VBZ
cord-034340-3ksfpaf7	502	6	confirmed	confirm	VBN
cord-034340-3ksfpaf7	502	7	by	by	IN
cord-034340-3ksfpaf7	502	8	demonstrating	demonstrate	VBG
cord-034340-3ksfpaf7	502	9	a	a	DT
cord-034340-3ksfpaf7	502	10	typical	typical	JJ
cord-034340-3ksfpaf7	502	11	non	non	JJ
cord-034340-3ksfpaf7	502	12	-	-	JJ
cord-034340-3ksfpaf7	502	13	caseating	caseating	JJ
cord-034340-3ksfpaf7	502	14	granuloma	granuloma	NN
cord-034340-3ksfpaf7	502	15	on	on	IN
cord-034340-3ksfpaf7	502	16	a	a	DT
cord-034340-3ksfpaf7	502	17	biopsy	biopsy	NN
cord-034340-3ksfpaf7	502	18	specimen	specimen	NN
cord-034340-3ksfpaf7	502	19	.	.	.
cord-034340-3ksfpaf7	503	1	Other	other	JJ
cord-034340-3ksfpaf7	503	2	granulomatous	granulomatous	JJ
cord-034340-3ksfpaf7	503	3	diseases	disease	NNS
cord-034340-3ksfpaf7	503	4	should	should	MD
cord-034340-3ksfpaf7	503	5	be	be	VB
cord-034340-3ksfpaf7	503	6	excluded	exclude	VBN
cord-034340-3ksfpaf7	503	7	,	,	,
cord-034340-3ksfpaf7	503	8	in	in	IN
cord-034340-3ksfpaf7	503	9	particular	particular	JJ
cord-034340-3ksfpaf7	503	10	mycobacterial	mycobacterial	JJ
cord-034340-3ksfpaf7	503	11	infections	infection	NNS
cord-034340-3ksfpaf7	503	12	,	,	,
cord-034340-3ksfpaf7	503	13	Crohn	Crohn	NNP
cord-034340-3ksfpaf7	503	14	's	's	POS
cord-034340-3ksfpaf7	503	15	disease	disease	NN
cord-034340-3ksfpaf7	503	16	and	and	CC
cord-034340-3ksfpaf7	503	17	immunodeficiencies	immunodeficiency	NNS
cord-034340-3ksfpaf7	503	18	.	.	.
cord-034340-3ksfpaf7	504	1	The	the	DT
cord-034340-3ksfpaf7	504	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	504	3	presentation	presentation	NN
cord-034340-3ksfpaf7	504	4	may	may	MD
cord-034340-3ksfpaf7	504	5	vary	vary	VB
cord-034340-3ksfpaf7	504	6	depending	depend	VBG
cord-034340-3ksfpaf7	504	7	on	on	IN
cord-034340-3ksfpaf7	504	8	the	the	DT
cord-034340-3ksfpaf7	504	9	organs	organ	NNS
cord-034340-3ksfpaf7	504	10	involved	involve	VBN
cord-034340-3ksfpaf7	504	11	and	and	CC
cord-034340-3ksfpaf7	504	12	the	the	DT
cord-034340-3ksfpaf7	504	13	age	age	NN
cord-034340-3ksfpaf7	504	14	of	of	IN
cord-034340-3ksfpaf7	504	15	the	the	DT
cord-034340-3ksfpaf7	504	16	patient	patient	NN
cord-034340-3ksfpaf7	504	17	.	.	.
cord-034340-3ksfpaf7	505	1	3	3	LS
cord-034340-3ksfpaf7	505	2	,	,	,
cord-034340-3ksfpaf7	505	3	4	4	CD
cord-034340-3ksfpaf7	505	4	Objectives	objective	NNS
cord-034340-3ksfpaf7	505	5	:	:	:
cord-034340-3ksfpaf7	506	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	506	2	are	be	VBP
cord-034340-3ksfpaf7	506	3	reporting	report	VBG
cord-034340-3ksfpaf7	506	4	the	the	DT
cord-034340-3ksfpaf7	506	5	case	case	NN
cord-034340-3ksfpaf7	506	6	of	of	IN
cord-034340-3ksfpaf7	506	7	a	a	DT
cord-034340-3ksfpaf7	506	8	boy	boy	NN
cord-034340-3ksfpaf7	506	9	with	with	IN
cord-034340-3ksfpaf7	506	10	a	a	DT
cord-034340-3ksfpaf7	506	11	presentation	presentation	NN
cord-034340-3ksfpaf7	506	12	of	of	IN
cord-034340-3ksfpaf7	506	13	bone	bone	NN
cord-034340-3ksfpaf7	506	14	sarcoidosis	sarcoidosis	NN
cord-034340-3ksfpaf7	506	15	at	at	IN
cord-034340-3ksfpaf7	506	16	a	a	DT
cord-034340-3ksfpaf7	506	17	young	young	JJ
cord-034340-3ksfpaf7	506	18	age	age	NN
cord-034340-3ksfpaf7	506	19	.	.	.
cord-034340-3ksfpaf7	507	1	This	this	DT
cord-034340-3ksfpaf7	507	2	is	be	VBZ
cord-034340-3ksfpaf7	507	3	a	a	DT
cord-034340-3ksfpaf7	507	4	rare	rare	JJ
cord-034340-3ksfpaf7	507	5	phenotype	phenotype	NN
cord-034340-3ksfpaf7	507	6	in	in	IN
cord-034340-3ksfpaf7	507	7	children	child	NNS
cord-034340-3ksfpaf7	507	8	.	.	.
cord-034340-3ksfpaf7	508	1	Methods	method	NNS
cord-034340-3ksfpaf7	508	2	:	:	:
cord-034340-3ksfpaf7	508	3	Clinical	clinical	JJ
cord-034340-3ksfpaf7	508	4	details	detail	NNS
cord-034340-3ksfpaf7	508	5	were	be	VBD
cord-034340-3ksfpaf7	508	6	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	508	7	collated	collate	VBN
cord-034340-3ksfpaf7	508	8	using	use	VBG
cord-034340-3ksfpaf7	508	9	routine	routine	JJ
cord-034340-3ksfpaf7	508	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	508	11	records	record	NNS
cord-034340-3ksfpaf7	508	12	.	.	.
cord-034340-3ksfpaf7	509	1	Confirmation	confirmation	NN
cord-034340-3ksfpaf7	509	2	of	of	IN
cord-034340-3ksfpaf7	509	3	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	509	4	was	be	VBD
cord-034340-3ksfpaf7	509	5	confirmed	confirm	VBN
cord-034340-3ksfpaf7	509	6	with	with	IN
cord-034340-3ksfpaf7	509	7	bone	bone	NN
cord-034340-3ksfpaf7	509	8	biopsy	biopsy	NN
cord-034340-3ksfpaf7	509	9	.	.	.
cord-034340-3ksfpaf7	510	1	Results	result	NNS
cord-034340-3ksfpaf7	510	2	:	:	:
cord-034340-3ksfpaf7	511	1	A	a	DT
cord-034340-3ksfpaf7	511	2	5	5	CD
cord-034340-3ksfpaf7	511	3	year	year	NN
cord-034340-3ksfpaf7	511	4	old	old	JJ
cord-034340-3ksfpaf7	511	5	non	non	JJ
cord-034340-3ksfpaf7	511	6	-	-	JJ
cord-034340-3ksfpaf7	511	7	identical	identical	JJ
cord-034340-3ksfpaf7	511	8	twin	twin	JJ
cord-034340-3ksfpaf7	511	9	boy	boy	NN
cord-034340-3ksfpaf7	511	10	of	of	IN
cord-034340-3ksfpaf7	511	11	Ghanaian	ghanaian	JJ
cord-034340-3ksfpaf7	511	12	descent	descent	NN
cord-034340-3ksfpaf7	511	13	born	bear	VBN
cord-034340-3ksfpaf7	511	14	in	in	IN
cord-034340-3ksfpaf7	511	15	the	the	DT
cord-034340-3ksfpaf7	511	16	UK	UK	NNP
cord-034340-3ksfpaf7	511	17	had	have	VBD
cord-034340-3ksfpaf7	511	18	a	a	DT
cord-034340-3ksfpaf7	511	19	slowly	slowly	RB
cord-034340-3ksfpaf7	511	20	growing	grow	VBG
cord-034340-3ksfpaf7	511	21	,	,	,
cord-034340-3ksfpaf7	511	22	painless	painless	JJ
cord-034340-3ksfpaf7	511	23	frontal	frontal	JJ
cord-034340-3ksfpaf7	511	24	bone	bone	NN
cord-034340-3ksfpaf7	511	25	mass	mass	NN
cord-034340-3ksfpaf7	511	26	which	which	WDT
cord-034340-3ksfpaf7	511	27	started	start	VBD
cord-034340-3ksfpaf7	511	28	to	to	TO
cord-034340-3ksfpaf7	511	29	develop	develop	VB
cord-034340-3ksfpaf7	511	30	from	from	IN
cord-034340-3ksfpaf7	511	31	7	7	CD
cord-034340-3ksfpaf7	511	32	months	month	NNS
cord-034340-3ksfpaf7	511	33	of	of	IN
cord-034340-3ksfpaf7	511	34	age	age	NN
cord-034340-3ksfpaf7	511	35	.	.	.
cord-034340-3ksfpaf7	512	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	512	2	was	be	VBD
cord-034340-3ksfpaf7	512	3	developmentally	developmentally	RB
cord-034340-3ksfpaf7	512	4	normal	normal	JJ
cord-034340-3ksfpaf7	512	5	,	,	,
cord-034340-3ksfpaf7	512	6	with	with	IN
cord-034340-3ksfpaf7	512	7	no	no	DT
cord-034340-3ksfpaf7	512	8	history	history	NN
cord-034340-3ksfpaf7	512	9	of	of	IN
cord-034340-3ksfpaf7	512	10	fever	fever	NN
cord-034340-3ksfpaf7	512	11	,	,	,
cord-034340-3ksfpaf7	512	12	rashes	rash	NNS
cord-034340-3ksfpaf7	512	13	or	or	CC
cord-034340-3ksfpaf7	512	14	joint	joint	JJ
cord-034340-3ksfpaf7	512	15	pains	pain	NNS
cord-034340-3ksfpaf7	512	16	.	.	.
cord-034340-3ksfpaf7	513	1	Examination	examination	NN
cord-034340-3ksfpaf7	513	2	findings	finding	NNS
cord-034340-3ksfpaf7	513	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	513	4	frontal	frontal	JJ
cord-034340-3ksfpaf7	513	5	bossing	bossing	NN
cord-034340-3ksfpaf7	513	6	while	while	IN
cord-034340-3ksfpaf7	513	7	the	the	DT
cord-034340-3ksfpaf7	513	8	remainder	remainder	NN
cord-034340-3ksfpaf7	513	9	of	of	IN
cord-034340-3ksfpaf7	513	10	the	the	DT
cord-034340-3ksfpaf7	513	11	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	513	12	examination	examination	NN
cord-034340-3ksfpaf7	513	13	was	be	VBD
cord-034340-3ksfpaf7	513	14	normal	normal	JJ
cord-034340-3ksfpaf7	513	15	.	.	.
cord-034340-3ksfpaf7	514	1	There	there	EX
cord-034340-3ksfpaf7	514	2	was	be	VBD
cord-034340-3ksfpaf7	514	3	no	no	DT
cord-034340-3ksfpaf7	514	4	evidence	evidence	NN
cord-034340-3ksfpaf7	514	5	of	of	IN
cord-034340-3ksfpaf7	514	6	rashes	rash	NNS
cord-034340-3ksfpaf7	514	7	,	,	,
cord-034340-3ksfpaf7	514	8	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-034340-3ksfpaf7	514	9	and	and	CC
cord-034340-3ksfpaf7	514	10	ocular	ocular	JJ
cord-034340-3ksfpaf7	514	11	examination	examination	NN
cord-034340-3ksfpaf7	514	12	was	be	VBD
cord-034340-3ksfpaf7	514	13	normal	normal	JJ
cord-034340-3ksfpaf7	514	14	.	.	.
cord-034340-3ksfpaf7	515	1	The	the	DT
cord-034340-3ksfpaf7	515	2	patient	patient	NN
cord-034340-3ksfpaf7	515	3	was	be	VBD
cord-034340-3ksfpaf7	515	4	initially	initially	RB
cord-034340-3ksfpaf7	515	5	referred	refer	VBN
cord-034340-3ksfpaf7	515	6	for	for	IN
cord-034340-3ksfpaf7	515	7	neurosurgical	neurosurgical	JJ
cord-034340-3ksfpaf7	515	8	review	review	NN
cord-034340-3ksfpaf7	515	9	with	with	IN
cord-034340-3ksfpaf7	515	10	suspected	suspect	VBN
cord-034340-3ksfpaf7	515	11	fibrous	fibrous	JJ
cord-034340-3ksfpaf7	515	12	dysplasia	dysplasia	NN
cord-034340-3ksfpaf7	515	13	,	,	,
cord-034340-3ksfpaf7	515	14	after	after	IN
cord-034340-3ksfpaf7	515	15	an	an	DT
cord-034340-3ksfpaf7	515	16	initial	initial	JJ
cord-034340-3ksfpaf7	515	17	MRI	MRI	NNP
cord-034340-3ksfpaf7	515	18	scan	scan	NN
cord-034340-3ksfpaf7	515	19	of	of	IN
cord-034340-3ksfpaf7	515	20	the	the	DT
cord-034340-3ksfpaf7	515	21	head	head	NN
cord-034340-3ksfpaf7	515	22	revealed	reveal	VBD
cord-034340-3ksfpaf7	515	23	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	515	24	marrow	marrow	NN
cord-034340-3ksfpaf7	515	25	signal	signal	NN
cord-034340-3ksfpaf7	515	26	and	and	CC
cord-034340-3ksfpaf7	515	27	expansion	expansion	NN
cord-034340-3ksfpaf7	515	28	of	of	IN
cord-034340-3ksfpaf7	515	29	the	the	DT
cord-034340-3ksfpaf7	515	30	frontal	frontal	JJ
cord-034340-3ksfpaf7	515	31	bone	bone	NN
cord-034340-3ksfpaf7	515	32	,	,	,
cord-034340-3ksfpaf7	515	33	with	with	IN
cord-034340-3ksfpaf7	515	34	no	no	DT
cord-034340-3ksfpaf7	515	35	soft	soft	JJ
cord-034340-3ksfpaf7	515	36	tissue	tissue	NN
cord-034340-3ksfpaf7	515	37	swelling	swelling	NN
cord-034340-3ksfpaf7	515	38	.	.	.
cord-034340-3ksfpaf7	516	1	However	however	RB
cord-034340-3ksfpaf7	516	2	,	,	,
cord-034340-3ksfpaf7	516	3	the	the	DT
cord-034340-3ksfpaf7	516	4	CT	CT	NNP
cord-034340-3ksfpaf7	516	5	scan	scan	NN
cord-034340-3ksfpaf7	516	6	of	of	IN
cord-034340-3ksfpaf7	516	7	the	the	DT
cord-034340-3ksfpaf7	516	8	calvarium	calvarium	NN
cord-034340-3ksfpaf7	516	9	was	be	VBD
cord-034340-3ksfpaf7	516	10	not	not	RB
cord-034340-3ksfpaf7	516	11	suggestive	suggestive	JJ
cord-034340-3ksfpaf7	516	12	of	of	IN
cord-034340-3ksfpaf7	516	13	fibrous	fibrous	JJ
cord-034340-3ksfpaf7	516	14	dysplasia	dysplasia	NN
cord-034340-3ksfpaf7	516	15	.	.	.
cord-034340-3ksfpaf7	517	1	Consequently	consequently	RB
cord-034340-3ksfpaf7	517	2	,	,	,
cord-034340-3ksfpaf7	517	3	bone	bone	NN
cord-034340-3ksfpaf7	517	4	biopsy	biopsy	NN
cord-034340-3ksfpaf7	517	5	was	be	VBD
cord-034340-3ksfpaf7	517	6	performed	perform	VBN
cord-034340-3ksfpaf7	517	7	demonstrating	demonstrate	VBG
cord-034340-3ksfpaf7	517	8	inflammation	inflammation	NN
cord-034340-3ksfpaf7	517	9	with	with	IN
cord-034340-3ksfpaf7	517	10	granuloma	granuloma	NN
cord-034340-3ksfpaf7	517	11	formation	formation	NN
cord-034340-3ksfpaf7	517	12	.	.	.
cord-034340-3ksfpaf7	518	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	518	2	was	be	VBD
cord-034340-3ksfpaf7	518	3	referred	refer	VBN
cord-034340-3ksfpaf7	518	4	to	to	IN
cord-034340-3ksfpaf7	518	5	Infectious	Infectious	NNP
cord-034340-3ksfpaf7	518	6	Diseases	Diseases	NNPS
cord-034340-3ksfpaf7	518	7	and	and	CC
cord-034340-3ksfpaf7	518	8	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	518	9	.	.	.
cord-034340-3ksfpaf7	519	1	There	there	EX
cord-034340-3ksfpaf7	519	2	was	be	VBD
cord-034340-3ksfpaf7	519	3	no	no	DT
cord-034340-3ksfpaf7	519	4	travel	travel	NN
cord-034340-3ksfpaf7	519	5	history	history	NN
cord-034340-3ksfpaf7	519	6	and	and	CC
cord-034340-3ksfpaf7	519	7	no	no	DT
cord-034340-3ksfpaf7	519	8	TB	TB	NNP
cord-034340-3ksfpaf7	519	9	contact	contact	NN
cord-034340-3ksfpaf7	519	10	.	.	.
cord-034340-3ksfpaf7	520	1	QuantiFERON	QuantiFERON	NNP
cord-034340-3ksfpaf7	520	2	TB	TB	NNP
cord-034340-3ksfpaf7	520	3	was	be	VBD
cord-034340-3ksfpaf7	520	4	negative	negative	JJ
cord-034340-3ksfpaf7	520	5	.	.	.
cord-034340-3ksfpaf7	521	1	Infectious	infectious	JJ
cord-034340-3ksfpaf7	521	2	work	work	NN
cord-034340-3ksfpaf7	521	3	-	-	HYPH
cord-034340-3ksfpaf7	521	4	up	up	NN
cord-034340-3ksfpaf7	521	5	was	be	VBD
cord-034340-3ksfpaf7	521	6	negative	negative	JJ
cord-034340-3ksfpaf7	521	7	especially	especially	RB
cord-034340-3ksfpaf7	521	8	for	for	IN
cord-034340-3ksfpaf7	521	9	mycobacterial	mycobacterial	JJ
cord-034340-3ksfpaf7	521	10	infections	infection	NNS
cord-034340-3ksfpaf7	521	11	.	.	.
cord-034340-3ksfpaf7	522	1	Rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	522	2	work	work	NN
cord-034340-3ksfpaf7	522	3	-	-	HYPH
cord-034340-3ksfpaf7	522	4	up	up	NN
cord-034340-3ksfpaf7	522	5	identified	identify	VBN
cord-034340-3ksfpaf7	522	6	on	on	IN
cord-034340-3ksfpaf7	522	7	skeletal	skeletal	JJ
cord-034340-3ksfpaf7	522	8	survey	survey	NN
cord-034340-3ksfpaf7	522	9	another	another	DT
cord-034340-3ksfpaf7	522	10	bone	bone	NN
cord-034340-3ksfpaf7	522	11	location	location	NN
cord-034340-3ksfpaf7	522	12	:	:	:
cord-034340-3ksfpaf7	522	13	a	a	DT
cord-034340-3ksfpaf7	522	14	well	well	RB
cord-034340-3ksfpaf7	522	15	-	-	HYPH
cord-034340-3ksfpaf7	522	16	defined	define	VBN
cord-034340-3ksfpaf7	522	17	lytic	lytic	JJ
cord-034340-3ksfpaf7	522	18	lesion	lesion	NN
cord-034340-3ksfpaf7	522	19	in	in	IN
cord-034340-3ksfpaf7	522	20	the	the	DT
cord-034340-3ksfpaf7	522	21	right	right	JJ
cord-034340-3ksfpaf7	522	22	distal	distal	JJ
cord-034340-3ksfpaf7	522	23	fibula	fibula	NN
cord-034340-3ksfpaf7	522	24	that	that	WDT
cord-034340-3ksfpaf7	522	25	was	be	VBD
cord-034340-3ksfpaf7	522	26	biopsied	biopsie	VBN
cord-034340-3ksfpaf7	522	27	.	.	.
cord-034340-3ksfpaf7	523	1	Infection	infection	NN
cord-034340-3ksfpaf7	523	2	cultures	culture	NNS
cord-034340-3ksfpaf7	523	3	and	and	CC
cord-034340-3ksfpaf7	523	4	PCR	PCR	NNP
cord-034340-3ksfpaf7	523	5	were	be	VBD
cord-034340-3ksfpaf7	523	6	negative	negative	JJ
cord-034340-3ksfpaf7	523	7	.	.	.
cord-034340-3ksfpaf7	524	1	Histopathology	Histopathology	NNP
cord-034340-3ksfpaf7	524	2	identified	identify	VBD
cord-034340-3ksfpaf7	524	3	fibrous	fibrous	JJ
cord-034340-3ksfpaf7	524	4	tissue	tissue	NN
cord-034340-3ksfpaf7	524	5	and	and	CC
cord-034340-3ksfpaf7	524	6	poorly	poorly	RB
cord-034340-3ksfpaf7	524	7	formed	form	VBN
cord-034340-3ksfpaf7	524	8	granulomas	granuloma	NNS
cord-034340-3ksfpaf7	524	9	.	.	.
cord-034340-3ksfpaf7	525	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	525	2	investigations	investigation	NNS
cord-034340-3ksfpaf7	525	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	525	4	a	a	DT
cord-034340-3ksfpaf7	525	5	mild	mild	JJ
cord-034340-3ksfpaf7	525	6	microcytic	microcytic	JJ
cord-034340-3ksfpaf7	525	7	anaemia	anaemia	NN
cord-034340-3ksfpaf7	525	8	with	with	IN
cord-034340-3ksfpaf7	525	9	iron	iron	NN
cord-034340-3ksfpaf7	525	10	deficiency	deficiency	NN
cord-034340-3ksfpaf7	525	11	and	and	CC
cord-034340-3ksfpaf7	525	12	eosinophilia	eosinophilia	NN
cord-034340-3ksfpaf7	525	13	.	.	.
cord-034340-3ksfpaf7	526	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	526	2	had	have	VBD
cord-034340-3ksfpaf7	526	3	normal	normal	JJ
cord-034340-3ksfpaf7	526	4	serum	serum	NN
cord-034340-3ksfpaf7	526	5	calcium	calcium	NN
cord-034340-3ksfpaf7	526	6	and	and	CC
cord-034340-3ksfpaf7	526	7	vitamin	vitamin	NN
cord-034340-3ksfpaf7	526	8	D	d	NN
cord-034340-3ksfpaf7	526	9	and	and	CC
cord-034340-3ksfpaf7	526	10	his	-PRON-	PRP$
cord-034340-3ksfpaf7	526	11	ESR	ESR	NNP
cord-034340-3ksfpaf7	526	12	was	be	VBD
cord-034340-3ksfpaf7	526	13	25	25	CD
cord-034340-3ksfpaf7	526	14	mm	mm	NNP
cord-034340-3ksfpaf7	526	15	/	/	SYM
cord-034340-3ksfpaf7	526	16	hr	hr	NN
cord-034340-3ksfpaf7	526	17	.	.	.
cord-034340-3ksfpaf7	527	1	ANA	ANA	NNP
cord-034340-3ksfpaf7	527	2	,	,	,
cord-034340-3ksfpaf7	527	3	ANCA	ANCA	NNP
cord-034340-3ksfpaf7	527	4	and	and	CC
cord-034340-3ksfpaf7	527	5	rheumatoid	rheumatoid	NN
cord-034340-3ksfpaf7	527	6	factor	factor	NN
cord-034340-3ksfpaf7	527	7	were	be	VBD
cord-034340-3ksfpaf7	527	8	negative	negative	JJ
cord-034340-3ksfpaf7	527	9	,	,	,
cord-034340-3ksfpaf7	527	10	and	and	CC
cord-034340-3ksfpaf7	527	11	complement	complement	VB
cord-034340-3ksfpaf7	527	12	C3	C3	NNP
cord-034340-3ksfpaf7	527	13	and	and	CC
cord-034340-3ksfpaf7	527	14	C4	C4	NNP
cord-034340-3ksfpaf7	527	15	were	be	VBD
cord-034340-3ksfpaf7	527	16	normal	normal	JJ
cord-034340-3ksfpaf7	527	17	.	.	.
cord-034340-3ksfpaf7	528	1	His	-PRON-	PRP$
cord-034340-3ksfpaf7	528	2	serum	serum	NN
cord-034340-3ksfpaf7	528	3	Angiotensin	Angiotensin	NNP
cord-034340-3ksfpaf7	528	4	Converting	Converting	NNP
cord-034340-3ksfpaf7	528	5	Enzyme	Enzyme	NNP
cord-034340-3ksfpaf7	528	6	(	(	-LRB-
cord-034340-3ksfpaf7	528	7	ACE	ace	NN
cord-034340-3ksfpaf7	528	8	)	)	-RRB-
cord-034340-3ksfpaf7	528	9	level	level	NN
cord-034340-3ksfpaf7	528	10	was	be	VBD
cord-034340-3ksfpaf7	528	11	raised	raise	VBN
cord-034340-3ksfpaf7	528	12	at	at	IN
cord-034340-3ksfpaf7	528	13	125	125	CD
cord-034340-3ksfpaf7	528	14	nmol/	nmol/	CD
cord-034340-3ksfpaf7	529	1	ml	ml	NNP
cord-034340-3ksfpaf7	529	2	/	/	SYM
cord-034340-3ksfpaf7	529	3	min	min	NNP
cord-034340-3ksfpaf7	529	4	(	(	-LRB-
cord-034340-3ksfpaf7	529	5	normal	normal	JJ
cord-034340-3ksfpaf7	529	6	<	<	XX
cord-034340-3ksfpaf7	529	7	40	40	CD
cord-034340-3ksfpaf7	529	8	nmol	nmol	JJ
cord-034340-3ksfpaf7	529	9	/	/	SYM
cord-034340-3ksfpaf7	529	10	ml	ml	NN
cord-034340-3ksfpaf7	529	11	/	/	SYM
cord-034340-3ksfpaf7	529	12	min	min	NNP
cord-034340-3ksfpaf7	529	13	)	)	-RRB-
cord-034340-3ksfpaf7	529	14	.	.	.
cord-034340-3ksfpaf7	530	1	Investigations	investigation	NNS
cord-034340-3ksfpaf7	530	2	revealed	reveal	VBD
cord-034340-3ksfpaf7	530	3	mild	mild	JJ
cord-034340-3ksfpaf7	530	4	renal	renal	JJ
cord-034340-3ksfpaf7	530	5	impairment	impairment	NN
cord-034340-3ksfpaf7	530	6	with	with	IN
cord-034340-3ksfpaf7	530	7	normal	normal	JJ
cord-034340-3ksfpaf7	530	8	urinary	urinary	JJ
cord-034340-3ksfpaf7	530	9	tests	test	NNS
cord-034340-3ksfpaf7	530	10	including	include	VBG
cord-034340-3ksfpaf7	530	11	normal	normal	JJ
cord-034340-3ksfpaf7	530	12	calcium	calcium	NN
cord-034340-3ksfpaf7	530	13	,	,	,
cord-034340-3ksfpaf7	530	14	protein	protein	NN
cord-034340-3ksfpaf7	530	15	and	and	CC
cord-034340-3ksfpaf7	530	16	tubular	tubular	JJ
cord-034340-3ksfpaf7	530	17	proteins	protein	NNS
cord-034340-3ksfpaf7	530	18	.	.	.
cord-034340-3ksfpaf7	531	1	Ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	531	2	of	of	IN
cord-034340-3ksfpaf7	531	3	the	the	DT
cord-034340-3ksfpaf7	531	4	kidneys	kidney	NNS
cord-034340-3ksfpaf7	531	5	was	be	VBD
cord-034340-3ksfpaf7	531	6	normal	normal	JJ
cord-034340-3ksfpaf7	531	7	.	.	.
cord-034340-3ksfpaf7	532	1	Chest	chest	NN
cord-034340-3ksfpaf7	532	2	X	x	NN
cord-034340-3ksfpaf7	532	3	-	-	NN
cord-034340-3ksfpaf7	532	4	ray	ray	NN
cord-034340-3ksfpaf7	532	5	was	be	VBD
cord-034340-3ksfpaf7	532	6	normal	normal	JJ
cord-034340-3ksfpaf7	532	7	.	.	.
cord-034340-3ksfpaf7	533	1	Lung	lung	NN
cord-034340-3ksfpaf7	533	2	function	function	NN
cord-034340-3ksfpaf7	533	3	was	be	VBD
cord-034340-3ksfpaf7	533	4	performed	perform	VBN
cord-034340-3ksfpaf7	533	5	and	and	CC
cord-034340-3ksfpaf7	533	6	was	be	VBD
cord-034340-3ksfpaf7	533	7	normal	normal	JJ
cord-034340-3ksfpaf7	533	8	.	.	.
cord-034340-3ksfpaf7	534	1	DLCO	DLCO	NNP
cord-034340-3ksfpaf7	534	2	could	could	MD
cord-034340-3ksfpaf7	534	3	n't	not	RB
cord-034340-3ksfpaf7	534	4	be	be	VB
cord-034340-3ksfpaf7	534	5	performed	perform	VBN
cord-034340-3ksfpaf7	534	6	due	due	IN
cord-034340-3ksfpaf7	534	7	to	to	IN
cord-034340-3ksfpaf7	534	8	low	low	JJ
cord-034340-3ksfpaf7	534	9	lung	lung	NN
cord-034340-3ksfpaf7	534	10	volume	volume	NN
cord-034340-3ksfpaf7	534	11	.	.	.
cord-034340-3ksfpaf7	535	1	Vascular	vascular	JJ
cord-034340-3ksfpaf7	535	2	and	and	CC
cord-034340-3ksfpaf7	535	3	inflammation	inflammation	NN
cord-034340-3ksfpaf7	535	4	genetic	genetic	JJ
cord-034340-3ksfpaf7	535	5	panel	panel	NN
cord-034340-3ksfpaf7	535	6	identified	identify	VBD
cord-034340-3ksfpaf7	535	7	a	a	DT
cord-034340-3ksfpaf7	535	8	variant	variant	NN
cord-034340-3ksfpaf7	535	9	in	in	IN
cord-034340-3ksfpaf7	535	10	the	the	DT
cord-034340-3ksfpaf7	535	11	NEMO	NEMO	NNP
cord-034340-3ksfpaf7	535	12	gene	gene	NN
cord-034340-3ksfpaf7	535	13	.	.	.
cord-034340-3ksfpaf7	536	1	Functional	functional	JJ
cord-034340-3ksfpaf7	536	2	studies	study	NNS
cord-034340-3ksfpaf7	536	3	excluded	exclude	VBD
cord-034340-3ksfpaf7	536	4	NEMO	NEMO	NNP
cord-034340-3ksfpaf7	536	5	deficiency	deficiency	NN
cord-034340-3ksfpaf7	536	6	and	and	CC
cord-034340-3ksfpaf7	536	7	patient	patient	NN
cord-034340-3ksfpaf7	536	8	did	do	VBD
cord-034340-3ksfpaf7	536	9	not	not	RB
cord-034340-3ksfpaf7	536	10	display	display	VB
cord-034340-3ksfpaf7	536	11	any	any	DT
cord-034340-3ksfpaf7	536	12	of	of	IN
cord-034340-3ksfpaf7	536	13	the	the	DT
cord-034340-3ksfpaf7	536	14	clinical	clinical	JJ
cord-034340-3ksfpaf7	536	15	features	feature	NNS
cord-034340-3ksfpaf7	536	16	.	.	.
cord-034340-3ksfpaf7	537	1	However	however	RB
cord-034340-3ksfpaf7	537	2	,	,	,
cord-034340-3ksfpaf7	537	3	a	a	DT
cord-034340-3ksfpaf7	537	4	pattern	pattern	NN
cord-034340-3ksfpaf7	537	5	of	of	IN
cord-034340-3ksfpaf7	537	6	dysregulated	dysregulate	VBN
cord-034340-3ksfpaf7	537	7	T	T	NNP
cord-034340-3ksfpaf7	537	8	cells	cell	NNS
cord-034340-3ksfpaf7	537	9	response	response	NN
cord-034340-3ksfpaf7	537	10	was	be	VBD
cord-034340-3ksfpaf7	537	11	identified	identify	VBN
cord-034340-3ksfpaf7	537	12	.	.	.
cord-034340-3ksfpaf7	538	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	538	2	was	be	VBD
cord-034340-3ksfpaf7	538	3	treated	treat	VBN
cord-034340-3ksfpaf7	538	4	with	with	IN
cord-034340-3ksfpaf7	538	5	oral	oral	JJ
cord-034340-3ksfpaf7	538	6	steroids	steroid	NNS
cord-034340-3ksfpaf7	538	7	and	and	CC
cord-034340-3ksfpaf7	538	8	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	538	9	.	.	.
cord-034340-3ksfpaf7	539	1	The	the	DT
cord-034340-3ksfpaf7	539	2	oral	oral	JJ
cord-034340-3ksfpaf7	539	3	steroids	steroid	NNS
cord-034340-3ksfpaf7	539	4	were	be	VBD
cord-034340-3ksfpaf7	539	5	successfully	successfully	RB
cord-034340-3ksfpaf7	539	6	weaned	wean	VBN
cord-034340-3ksfpaf7	539	7	off	off	RP
cord-034340-3ksfpaf7	539	8	.	.	.
cord-034340-3ksfpaf7	540	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	540	2	has	have	VBZ
cord-034340-3ksfpaf7	540	3	been	be	VBN
cord-034340-3ksfpaf7	540	4	successfully	successfully	RB
cord-034340-3ksfpaf7	540	5	treated	treat	VBN
cord-034340-3ksfpaf7	540	6	with	with	IN
cord-034340-3ksfpaf7	540	7	Methotrexate	Methotrexate	NNP
cord-034340-3ksfpaf7	540	8	10	10	CD
cord-034340-3ksfpaf7	540	9	mg	mg	NNP
cord-034340-3ksfpaf7	540	10	s	s	NNP
cord-034340-3ksfpaf7	540	11	/	/	SYM
cord-034340-3ksfpaf7	540	12	c	c	NN
cord-034340-3ksfpaf7	540	13	to	to	TO
cord-034340-3ksfpaf7	540	14	initially	initially	RB
cord-034340-3ksfpaf7	540	15	stabilise	stabilise	VB
cord-034340-3ksfpaf7	540	16	disease	disease	NN
cord-034340-3ksfpaf7	540	17	with	with	IN
cord-034340-3ksfpaf7	540	18	no	no	DT
cord-034340-3ksfpaf7	540	19	bone	bone	NN
cord-034340-3ksfpaf7	540	20	growth	growth	NN
cord-034340-3ksfpaf7	540	21	,	,	,
cord-034340-3ksfpaf7	540	22	and	and	CC
cord-034340-3ksfpaf7	540	23	had	have	VBD
cord-034340-3ksfpaf7	540	24	no	no	DT
cord-034340-3ksfpaf7	540	25	significant	significant	JJ
cord-034340-3ksfpaf7	540	26	side	side	NN
cord-034340-3ksfpaf7	540	27	effects	effect	NNS
cord-034340-3ksfpaf7	540	28	.	.	.
cord-034340-3ksfpaf7	541	1	Repeat	repeat	NN
cord-034340-3ksfpaf7	541	2	MRI	MRI	NNP
cord-034340-3ksfpaf7	541	3	2	2	CD
cord-034340-3ksfpaf7	541	4	years	year	NNS
cord-034340-3ksfpaf7	541	5	later	later	RB
cord-034340-3ksfpaf7	541	6	showed	show	VBD
cord-034340-3ksfpaf7	541	7	increased	increase	VBN
cord-034340-3ksfpaf7	541	8	burden	burden	NN
cord-034340-3ksfpaf7	541	9	of	of	IN
cord-034340-3ksfpaf7	541	10	disease	disease	NN
cord-034340-3ksfpaf7	541	11	with	with	IN
cord-034340-3ksfpaf7	541	12	other	other	JJ
cord-034340-3ksfpaf7	541	13	newly	newly	RB
cord-034340-3ksfpaf7	541	14	affected	affect	VBN
cord-034340-3ksfpaf7	541	15	sites	site	NNS
cord-034340-3ksfpaf7	541	16	however	however	RB
cord-034340-3ksfpaf7	541	17	,	,	,
cord-034340-3ksfpaf7	541	18	including	include	VBG
cord-034340-3ksfpaf7	541	19	the	the	DT
cord-034340-3ksfpaf7	541	20	right	right	JJ
cord-034340-3ksfpaf7	541	21	femoral	femoral	JJ
cord-034340-3ksfpaf7	541	22	diaphysis	diaphysis	NN
cord-034340-3ksfpaf7	541	23	and	and	CC
cord-034340-3ksfpaf7	541	24	signal	signal	NN
cord-034340-3ksfpaf7	541	25	changes	change	NNS
cord-034340-3ksfpaf7	541	26	in	in	IN
cord-034340-3ksfpaf7	541	27	the	the	DT
cord-034340-3ksfpaf7	541	28	left	left	JJ
cord-034340-3ksfpaf7	541	29	tibial	tibial	NN
cord-034340-3ksfpaf7	541	30	metaphysis	metaphysis	NN
cord-034340-3ksfpaf7	541	31	.	.	.
cord-034340-3ksfpaf7	542	1	Based	base	VBN
cord-034340-3ksfpaf7	542	2	on	on	IN
cord-034340-3ksfpaf7	542	3	the	the	DT
cord-034340-3ksfpaf7	542	4	MRI	MRI	NNP
cord-034340-3ksfpaf7	542	5	and	and	CC
cord-034340-3ksfpaf7	542	6	increasing	increase	VBG
cord-034340-3ksfpaf7	542	7	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	542	8	pain	pain	NN
cord-034340-3ksfpaf7	542	9	,	,	,
cord-034340-3ksfpaf7	542	10	decision	decision	NN
cord-034340-3ksfpaf7	542	11	was	be	VBD
cord-034340-3ksfpaf7	542	12	made	make	VBN
cord-034340-3ksfpaf7	542	13	to	to	TO
cord-034340-3ksfpaf7	542	14	escalate	escalate	VB
cord-034340-3ksfpaf7	542	15	to	to	IN
cord-034340-3ksfpaf7	542	16	anti	anti	JJ
cord-034340-3ksfpaf7	542	17	-	-	JJ
cord-034340-3ksfpaf7	542	18	TNF	TNF	NNP
cord-034340-3ksfpaf7	542	19	(	(	-LRB-
cord-034340-3ksfpaf7	542	20	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	542	21	)	)	-RRB-
cord-034340-3ksfpaf7	542	22	with	with	IN
cord-034340-3ksfpaf7	542	23	good	good	JJ
cord-034340-3ksfpaf7	542	24	clinical	clinical	JJ
cord-034340-3ksfpaf7	542	25	response	response	NN
cord-034340-3ksfpaf7	542	26	.	.	.
cord-034340-3ksfpaf7	543	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	543	2	:	:	:
cord-034340-3ksfpaf7	544	1	Bone	bone	NN
cord-034340-3ksfpaf7	544	2	sarcoidoisis	sarcoidoisis	NN
cord-034340-3ksfpaf7	544	3	is	be	VBZ
cord-034340-3ksfpaf7	544	4	rare	rare	JJ
cord-034340-3ksfpaf7	544	5	in	in	IN
cord-034340-3ksfpaf7	544	6	children	child	NNS
cord-034340-3ksfpaf7	544	7	but	but	CC
cord-034340-3ksfpaf7	544	8	this	this	DT
cord-034340-3ksfpaf7	544	9	should	should	MD
cord-034340-3ksfpaf7	544	10	be	be	VB
cord-034340-3ksfpaf7	544	11	considered	consider	VBN
cord-034340-3ksfpaf7	544	12	in	in	IN
cord-034340-3ksfpaf7	544	13	the	the	DT
cord-034340-3ksfpaf7	544	14	differential	differential	JJ
cord-034340-3ksfpaf7	544	15	diagnoses	diagnosis	NNS
cord-034340-3ksfpaf7	544	16	when	when	WRB
cord-034340-3ksfpaf7	544	17	granulomatous	granulomatous	JJ
cord-034340-3ksfpaf7	544	18	inflammation	inflammation	NN
cord-034340-3ksfpaf7	544	19	is	be	VBZ
cord-034340-3ksfpaf7	544	20	identified	identify	VBN
cord-034340-3ksfpaf7	544	21	on	on	IN
cord-034340-3ksfpaf7	544	22	histopathology	histopathology	NN
cord-034340-3ksfpaf7	544	23	.	.	.
cord-034340-3ksfpaf7	545	1	Response	response	NN
cord-034340-3ksfpaf7	545	2	to	to	IN
cord-034340-3ksfpaf7	545	3	steroids	steroid	NNS
cord-034340-3ksfpaf7	545	4	and	and	CC
cord-034340-3ksfpaf7	545	5	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	545	6	is	be	VBZ
cord-034340-3ksfpaf7	545	7	usually	usually	RB
cord-034340-3ksfpaf7	545	8	good	good	JJ
cord-034340-3ksfpaf7	545	9	but	but	CC
cord-034340-3ksfpaf7	545	10	some	some	DT
cord-034340-3ksfpaf7	545	11	patients	patient	NNS
cord-034340-3ksfpaf7	545	12	will	will	MD
cord-034340-3ksfpaf7	545	13	need	need	VB
cord-034340-3ksfpaf7	545	14	escalation	escalation	NN
cord-034340-3ksfpaf7	545	15	to	to	IN
cord-034340-3ksfpaf7	545	16	anti	anti	JJ
cord-034340-3ksfpaf7	545	17	-	-	JJ
cord-034340-3ksfpaf7	545	18	TNF	TNF	NNP
cord-034340-3ksfpaf7	545	19	.	.	.
cord-034340-3ksfpaf7	546	1	The	the	DT
cord-034340-3ksfpaf7	546	2	most	most	RBS
cord-034340-3ksfpaf7	546	3	worrisome	worrisome	JJ
cord-034340-3ksfpaf7	546	4	non	non	JJ
cord-034340-3ksfpaf7	546	5	-	-	JJ
cord-034340-3ksfpaf7	546	6	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	546	7	condition	condition	NN
cord-034340-3ksfpaf7	546	8	causing	cause	VBG
cord-034340-3ksfpaf7	546	9	persistent	persistent	JJ
cord-034340-3ksfpaf7	546	10	night	night	NN
cord-034340-3ksfpaf7	546	11	pain	pain	NN
cord-034340-3ksfpaf7	546	12	in	in	IN
cord-034340-3ksfpaf7	546	13	children	child	NNS
cord-034340-3ksfpaf7	547	1	which	which	WDT
cord-034340-3ksfpaf7	547	2	closely	closely	RB
cord-034340-3ksfpaf7	547	3	mimics	mimic	VBZ
cord-034340-3ksfpaf7	547	4	arthritis	arthritis	NN
cord-034340-3ksfpaf7	547	5	is	be	VBZ
cord-034340-3ksfpaf7	547	6	malignancy	malignancy	NN
cord-034340-3ksfpaf7	547	7	1	1	CD
cord-034340-3ksfpaf7	547	8	,	,	,
cord-034340-3ksfpaf7	547	9	4	4	CD
cord-034340-3ksfpaf7	547	10	.	.	.
cord-034340-3ksfpaf7	548	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	548	2	is	be	VBZ
cord-034340-3ksfpaf7	548	3	vital	vital	JJ
cord-034340-3ksfpaf7	548	4	to	to	TO
cord-034340-3ksfpaf7	548	5	pick	pick	VB
cord-034340-3ksfpaf7	548	6	up	up	RP
cord-034340-3ksfpaf7	548	7	subtle	subtle	JJ
cord-034340-3ksfpaf7	548	8	clues	clue	NNS
cord-034340-3ksfpaf7	548	9	at	at	IN
cord-034340-3ksfpaf7	548	10	an	an	DT
cord-034340-3ksfpaf7	548	11	early	early	JJ
cord-034340-3ksfpaf7	548	12	stage	stage	NN
cord-034340-3ksfpaf7	548	13	especially	especially	RB
cord-034340-3ksfpaf7	548	14	in	in	IN
cord-034340-3ksfpaf7	548	15	absence	absence	NN
cord-034340-3ksfpaf7	548	16	of	of	IN
cord-034340-3ksfpaf7	548	17	hematological	hematological	JJ
cord-034340-3ksfpaf7	548	18	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	548	19	,	,	,
cord-034340-3ksfpaf7	548	20	organomegaly	organomegaly	NNS
cord-034340-3ksfpaf7	548	21	and	and	CC
cord-034340-3ksfpaf7	548	22	lymphadenopathy	lymphadenopathy	JJ
cord-034340-3ksfpaf7	548	23	.	.	.
cord-034340-3ksfpaf7	549	1	To	to	TO
cord-034340-3ksfpaf7	549	2	reveal	reveal	VB
cord-034340-3ksfpaf7	549	3	early	early	JJ
cord-034340-3ksfpaf7	549	4	clinical	clinical	JJ
cord-034340-3ksfpaf7	549	5	clues	clue	NNS
cord-034340-3ksfpaf7	549	6	in	in	IN
cord-034340-3ksfpaf7	549	7	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	549	8	patients	patient	NNS
cord-034340-3ksfpaf7	549	9	with	with	IN
cord-034340-3ksfpaf7	549	10	predominant	predominant	JJ
cord-034340-3ksfpaf7	549	11	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	549	12	(	(	-LRB-
cord-034340-3ksfpaf7	549	13	MSK	MSK	NNP
cord-034340-3ksfpaf7	549	14	)	)	-RRB-
cord-034340-3ksfpaf7	549	15	night	night	NN
cord-034340-3ksfpaf7	549	16	pains	pain	NNS
cord-034340-3ksfpaf7	549	17	who	who	WP
cord-034340-3ksfpaf7	549	18	were	be	VBD
cord-034340-3ksfpaf7	549	19	initially	initially	RB
cord-034340-3ksfpaf7	549	20	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	549	21	as	as	IN
cord-034340-3ksfpaf7	549	22	suffering	suffer	VBG
cord-034340-3ksfpaf7	549	23	from	from	IN
cord-034340-3ksfpaf7	549	24	some	some	DT
cord-034340-3ksfpaf7	549	25	form	form	NN
cord-034340-3ksfpaf7	549	26	of	of	IN
cord-034340-3ksfpaf7	549	27	chronic	chronic	JJ
cord-034340-3ksfpaf7	549	28	arthritis	arthritis	NN
cord-034340-3ksfpaf7	549	29	but	but	CC
cord-034340-3ksfpaf7	549	30	ultimately	ultimately	RB
cord-034340-3ksfpaf7	549	31	turned	turn	VBD
cord-034340-3ksfpaf7	549	32	out	out	RP
cord-034340-3ksfpaf7	549	33	to	to	TO
cord-034340-3ksfpaf7	549	34	be	be	VB
cord-034340-3ksfpaf7	549	35	affected	affect	VBN
cord-034340-3ksfpaf7	549	36	by	by	IN
cord-034340-3ksfpaf7	549	37	malignancy	malignancy	NN
cord-034340-3ksfpaf7	549	38	.	.	.
cord-034340-3ksfpaf7	550	1	Methods	method	NNS
cord-034340-3ksfpaf7	551	1	I	-PRON-	PRP
cord-034340-3ksfpaf7	551	2	gathered	gather	VBD
cord-034340-3ksfpaf7	551	3	a	a	DT
cord-034340-3ksfpaf7	551	4	data	data	NN
cord-034340-3ksfpaf7	551	5	of	of	IN
cord-034340-3ksfpaf7	551	6	five	five	CD
cord-034340-3ksfpaf7	551	7	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	551	8	patients	patient	NNS
cord-034340-3ksfpaf7	551	9	fulfilling	fulfil	VBG
cord-034340-3ksfpaf7	551	10	above	above	RB
cord-034340-3ksfpaf7	551	11	mentioned	mention	VBN
cord-034340-3ksfpaf7	551	12	criteria	criterion	NNS
cord-034340-3ksfpaf7	551	13	who	who	WP
cord-034340-3ksfpaf7	551	14	were	be	VBD
cord-034340-3ksfpaf7	551	15	seen	see	VBN
cord-034340-3ksfpaf7	551	16	at	at	IN
cord-034340-3ksfpaf7	551	17	Dev	Dev	NNP
cord-034340-3ksfpaf7	551	18	Children	Children	NNP
cord-034340-3ksfpaf7	551	19	's	's	POS
cord-034340-3ksfpaf7	551	20	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	551	21	between	between	IN
cord-034340-3ksfpaf7	551	22	January	January	NNP
cord-034340-3ksfpaf7	551	23	2019	2019	CD
cord-034340-3ksfpaf7	551	24	and	and	CC
cord-034340-3ksfpaf7	551	25	March	March	NNP
cord-034340-3ksfpaf7	551	26	2020	2020	CD
cord-034340-3ksfpaf7	551	27	.	.	.
cord-034340-3ksfpaf7	552	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	552	2	included	include	VBD
cord-034340-3ksfpaf7	552	3	demographics	demographic	NNS
cord-034340-3ksfpaf7	552	4	,	,	,
cord-034340-3ksfpaf7	552	5	clinical	clinical	JJ
cord-034340-3ksfpaf7	552	6	presentation	presentation	NN
cord-034340-3ksfpaf7	552	7	and	and	CC
cord-034340-3ksfpaf7	552	8	laboratory	laboratory	NN
cord-034340-3ksfpaf7	552	9	results	result	NNS
cord-034340-3ksfpaf7	552	10	.	.	.
cord-034340-3ksfpaf7	553	1	All	all	DT
cord-034340-3ksfpaf7	553	2	above	above	IN
cord-034340-3ksfpaf7	553	3	cases	case	NNS
cord-034340-3ksfpaf7	553	4	reemphasize	reemphasize	VBP
cord-034340-3ksfpaf7	553	5	the	the	DT
cord-034340-3ksfpaf7	553	6	need	need	NN
cord-034340-3ksfpaf7	553	7	for	for	IN
cord-034340-3ksfpaf7	553	8	an	an	DT
cord-034340-3ksfpaf7	553	9	extremely	extremely	RB
cord-034340-3ksfpaf7	553	10	detailed	detailed	JJ
cord-034340-3ksfpaf7	553	11	history	history	NN
cord-034340-3ksfpaf7	553	12	pertaining	pertain	VBG
cord-034340-3ksfpaf7	553	13	to	to	IN
cord-034340-3ksfpaf7	553	14	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	553	15	of	of	IN
cord-034340-3ksfpaf7	553	16	pain	pain	NN
cord-034340-3ksfpaf7	553	17	&	&	CC
cord-034340-3ksfpaf7	553	18	pattern	pattern	NN
cord-034340-3ksfpaf7	553	19	recognition	recognition	NN
cord-034340-3ksfpaf7	553	20	in	in	IN
cord-034340-3ksfpaf7	553	21	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	553	22	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	553	23	.	.	.
cord-034340-3ksfpaf7	554	1	Prolonged	prolonged	JJ
cord-034340-3ksfpaf7	554	2	fever	fever	NN
cord-034340-3ksfpaf7	554	3	,	,	,
cord-034340-3ksfpaf7	554	4	persistent	persistent	JJ
cord-034340-3ksfpaf7	554	5	MSK	MSK	NNP
cord-034340-3ksfpaf7	554	6	night	night	NN
cord-034340-3ksfpaf7	554	7	pain	pain	NN
cord-034340-3ksfpaf7	554	8	,	,	,
cord-034340-3ksfpaf7	554	9	persistent	persistent	JJ
cord-034340-3ksfpaf7	554	10	limp	limp	JJ
cord-034340-3ksfpaf7	554	11	,	,	,
cord-034340-3ksfpaf7	554	12	upper	upper	JJ
cord-034340-3ksfpaf7	554	13	limb	limb	NN
cord-034340-3ksfpaf7	554	14	and	and	CC
cord-034340-3ksfpaf7	554	15	hip	hip	NN
cord-034340-3ksfpaf7	554	16	joint	joint	JJ
cord-034340-3ksfpaf7	554	17	involvement	involvement	NN
cord-034340-3ksfpaf7	554	18	which	which	WDT
cord-034340-3ksfpaf7	554	19	is	be	VBZ
cord-034340-3ksfpaf7	554	20	unlikely	unlikely	JJ
cord-034340-3ksfpaf7	554	21	for	for	IN
cord-034340-3ksfpaf7	554	22	JIA	JIA	NNP
cord-034340-3ksfpaf7	554	23	at	at	IN
cord-034340-3ksfpaf7	554	24	onset	onset	NN
cord-034340-3ksfpaf7	554	25	are	be	VBP
cord-034340-3ksfpaf7	554	26	proven	prove	VBN
cord-034340-3ksfpaf7	554	27	to	to	TO
cord-034340-3ksfpaf7	554	28	be	be	VB
cord-034340-3ksfpaf7	554	29	the	the	DT
cord-034340-3ksfpaf7	554	30	earliest	early	JJS
cord-034340-3ksfpaf7	554	31	subtle	subtle	JJ
cord-034340-3ksfpaf7	554	32	clues	clue	NNS
cord-034340-3ksfpaf7	554	33	which	which	WDT
cord-034340-3ksfpaf7	554	34	should	should	MD
cord-034340-3ksfpaf7	554	35	not	not	RB
cord-034340-3ksfpaf7	554	36	be	be	VB
cord-034340-3ksfpaf7	554	37	missed	miss	VBN
cord-034340-3ksfpaf7	554	38	.	.	.
cord-034340-3ksfpaf7	555	1	1	1	LS
cord-034340-3ksfpaf7	556	1	Other	other	JJ
cord-034340-3ksfpaf7	556	2	constitutional	constitutional	JJ
cord-034340-3ksfpaf7	556	3	symptoms	symptom	NNS
cord-034340-3ksfpaf7	556	4	,	,	,
cord-034340-3ksfpaf7	556	5	respiratory	respiratory	JJ
cord-034340-3ksfpaf7	556	6	,	,	,
cord-034340-3ksfpaf7	556	7	cardiovascular	cardiovascular	JJ
cord-034340-3ksfpaf7	556	8	,	,	,
cord-034340-3ksfpaf7	556	9	ophthalmologic	ophthalmologic	NNP
cord-034340-3ksfpaf7	556	10	or	or	CC
cord-034340-3ksfpaf7	556	11	osteoarticular	osteoarticular	JJ
cord-034340-3ksfpaf7	556	12	involvement	involvement	NN
cord-034340-3ksfpaf7	556	13	were	be	VBD
cord-034340-3ksfpaf7	556	14	absent	absent	JJ
cord-034340-3ksfpaf7	556	15	.	.	.
cord-034340-3ksfpaf7	557	1	Growth	growth	NN
cord-034340-3ksfpaf7	557	2	was	be	VBD
cord-034340-3ksfpaf7	557	3	unaffected	unaffected	JJ
cord-034340-3ksfpaf7	557	4	.	.	.
cord-034340-3ksfpaf7	558	1	Auditory	auditory	JJ
cord-034340-3ksfpaf7	558	2	tests	test	NNS
cord-034340-3ksfpaf7	558	3	were	be	VBD
cord-034340-3ksfpaf7	558	4	normal	normal	JJ
cord-034340-3ksfpaf7	558	5	.	.	.
cord-034340-3ksfpaf7	559	1	Systemic	systemic	JJ
cord-034340-3ksfpaf7	559	2	antibiotic	antibiotic	JJ
cord-034340-3ksfpaf7	559	3	treatment	treatment	NN
cord-034340-3ksfpaf7	559	4	and	and	CC
cord-034340-3ksfpaf7	559	5	local	local	JJ
cord-034340-3ksfpaf7	559	6	steroids	steroid	NNS
cord-034340-3ksfpaf7	559	7	were	be	VBD
cord-034340-3ksfpaf7	559	8	ineffective	ineffective	JJ
cord-034340-3ksfpaf7	559	9	.	.	.
cord-034340-3ksfpaf7	560	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	560	2	findings	finding	NNS
cord-034340-3ksfpaf7	560	3	were	be	VBD
cord-034340-3ksfpaf7	560	4	unremarkable	unremarkable	JJ
cord-034340-3ksfpaf7	560	5	,	,	,
cord-034340-3ksfpaf7	560	6	with	with	IN
cord-034340-3ksfpaf7	560	7	only	only	JJ
cord-034340-3ksfpaf7	560	8	mild	mild	JJ
cord-034340-3ksfpaf7	560	9	elevation	elevation	NN
cord-034340-3ksfpaf7	560	10	of	of	IN
cord-034340-3ksfpaf7	560	11	ESR	ESR	NNP
cord-034340-3ksfpaf7	560	12	(	(	-LRB-
cord-034340-3ksfpaf7	560	13	28mm/1	28mm/1	NNP
cord-034340-3ksfpaf7	560	14	st	st	NNP
cord-034340-3ksfpaf7	560	15	hr	hr	NNP
cord-034340-3ksfpaf7	560	16	)	)	-RRB-
cord-034340-3ksfpaf7	560	17	.	.	.
cord-034340-3ksfpaf7	561	1	ANA	ANA	NNP
cord-034340-3ksfpaf7	561	2	and	and	CC
cord-034340-3ksfpaf7	561	3	ANCA	ANCA	NNP
cord-034340-3ksfpaf7	561	4	were	be	VBD
cord-034340-3ksfpaf7	561	5	absent	absent	JJ
cord-034340-3ksfpaf7	561	6	in	in	IN
cord-034340-3ksfpaf7	561	7	repeat	repeat	NN
cord-034340-3ksfpaf7	561	8	meausrements	meausrement	NNS
cord-034340-3ksfpaf7	561	9	(	(	-LRB-
cord-034340-3ksfpaf7	561	10	3	3	CD
cord-034340-3ksfpaf7	561	11	months	month	NNS
cord-034340-3ksfpaf7	561	12	intervals	interval	NNS
cord-034340-3ksfpaf7	561	13	)	)	-RRB-
cord-034340-3ksfpaf7	561	14	.	.	.
cord-034340-3ksfpaf7	562	1	Cardiovascular	cardiovascular	JJ
cord-034340-3ksfpaf7	562	2	disease	disease	NN
cord-034340-3ksfpaf7	562	3	was	be	VBD
cord-034340-3ksfpaf7	562	4	excluded	exclude	VBN
cord-034340-3ksfpaf7	562	5	.	.	.
cord-034340-3ksfpaf7	563	1	Abdominal	abdominal	JJ
cord-034340-3ksfpaf7	563	2	US	US	NNP
cord-034340-3ksfpaf7	563	3	was	be	VBD
cord-034340-3ksfpaf7	563	4	normal	normal	JJ
cord-034340-3ksfpaf7	563	5	.	.	.
cord-034340-3ksfpaf7	564	1	On	on	IN
cord-034340-3ksfpaf7	564	2	the	the	DT
cord-034340-3ksfpaf7	564	3	basis	basis	NN
cord-034340-3ksfpaf7	564	4	of	of	IN
cord-034340-3ksfpaf7	564	5	relapsing	relapse	VBG
cord-034340-3ksfpaf7	564	6	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	564	7	auricular	auricular	JJ
cord-034340-3ksfpaf7	564	8	chondritis	chondritis	NN
cord-034340-3ksfpaf7	564	9	and	and	CC
cord-034340-3ksfpaf7	564	10	confirmatory	confirmatory	JJ
cord-034340-3ksfpaf7	564	11	histological	histological	JJ
cord-034340-3ksfpaf7	564	12	findings	finding	NNS
cord-034340-3ksfpaf7	564	13	revealing	reveal	VBG
cord-034340-3ksfpaf7	564	14	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	564	15	cartilage	cartilage	NN
cord-034340-3ksfpaf7	564	16	from	from	IN
cord-034340-3ksfpaf7	564	17	the	the	DT
cord-034340-3ksfpaf7	564	18	pinna	pinna	NN
cord-034340-3ksfpaf7	564	19	of	of	IN
cord-034340-3ksfpaf7	564	20	the	the	DT
cord-034340-3ksfpaf7	564	21	ear	ear	NN
cord-034340-3ksfpaf7	564	22	with	with	IN
cord-034340-3ksfpaf7	564	23	chondrocyte	chondrocyte	NNP
cord-034340-3ksfpaf7	564	24	degeneration	degeneration	NN
cord-034340-3ksfpaf7	564	25	,	,	,
cord-034340-3ksfpaf7	564	26	perichondrial	perichondrial	NNP
cord-034340-3ksfpaf7	564	27	infiltrates	infiltrate	VBZ
cord-034340-3ksfpaf7	564	28	of	of	IN
cord-034340-3ksfpaf7	564	29	lymphocytes	lymphocyte	NNS
cord-034340-3ksfpaf7	564	30	,	,	,
cord-034340-3ksfpaf7	564	31	plasma	plasma	NN
cord-034340-3ksfpaf7	564	32	and	and	CC
cord-034340-3ksfpaf7	564	33	polymorphonuclear	polymorphonuclear	NN
cord-034340-3ksfpaf7	564	34	cells	cell	NNS
cord-034340-3ksfpaf7	564	35	and	and	CC
cord-034340-3ksfpaf7	564	36	replacement	replacement	NN
cord-034340-3ksfpaf7	564	37	of	of	IN
cord-034340-3ksfpaf7	564	38	cartilage	cartilage	NN
cord-034340-3ksfpaf7	564	39	with	with	IN
cord-034340-3ksfpaf7	564	40	fibrous	fibrous	JJ
cord-034340-3ksfpaf7	564	41	tissue	tissue	NN
cord-034340-3ksfpaf7	564	42	perivascular	perivascular	NNP
cord-034340-3ksfpaf7	564	43	infiltrates	infiltrate	VBZ
cord-034340-3ksfpaf7	564	44	of	of	IN
cord-034340-3ksfpaf7	564	45	polymorphonuclear	polymorphonuclear	JJ
cord-034340-3ksfpaf7	564	46	cells	cell	NNS
cord-034340-3ksfpaf7	564	47	and	and	CC
cord-034340-3ksfpaf7	564	48	lymphocytes	lymphocyte	NNS
cord-034340-3ksfpaf7	564	49	,	,	,
cord-034340-3ksfpaf7	564	50	relapsing	relapse	VBG
cord-034340-3ksfpaf7	564	51	polychondritis	polychondritis	NNP
cord-034340-3ksfpaf7	564	52	was	be	VBD
cord-034340-3ksfpaf7	564	53	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	564	54	.	.	.
cord-034340-3ksfpaf7	565	1	One	one	CD
cord-034340-3ksfpaf7	565	2	month	month	NN
cord-034340-3ksfpaf7	565	3	NSAIDS	NSAIDS	NNP
cord-034340-3ksfpaf7	565	4	trial	trial	NN
cord-034340-3ksfpaf7	565	5	,	,	,
cord-034340-3ksfpaf7	565	6	pending	pende	VBG
cord-034340-3ksfpaf7	565	7	histology	histology	NN
cord-034340-3ksfpaf7	565	8	results	result	NNS
cord-034340-3ksfpaf7	565	9	was	be	VBD
cord-034340-3ksfpaf7	565	10	ineffective	ineffective	JJ
cord-034340-3ksfpaf7	565	11	.	.	.
cord-034340-3ksfpaf7	566	1	Methotrexate	Methotrexate	NNP
cord-034340-3ksfpaf7	566	2	SC	SC	NNP
cord-034340-3ksfpaf7	566	3	and	and	CC
cord-034340-3ksfpaf7	566	4	steroids	steroid	NNS
cord-034340-3ksfpaf7	566	5	1mg/	1mg/	CD
cord-034340-3ksfpaf7	567	1	kg	kg	NNP
cord-034340-3ksfpaf7	567	2	/	/	SYM
cord-034340-3ksfpaf7	567	3	d	d	XX
cord-034340-3ksfpaf7	567	4	gradually	gradually	RB
cord-034340-3ksfpaf7	567	5	tapered	taper	VBD
cord-034340-3ksfpaf7	567	6	over	over	IN
cord-034340-3ksfpaf7	567	7	a	a	DT
cord-034340-3ksfpaf7	567	8	3-month	3-month	CD
cord-034340-3ksfpaf7	567	9	period	period	NN
cord-034340-3ksfpaf7	567	10	were	be	VBD
cord-034340-3ksfpaf7	567	11	given	give	VBN
cord-034340-3ksfpaf7	567	12	with	with	IN
cord-034340-3ksfpaf7	567	13	significant	significant	JJ
cord-034340-3ksfpaf7	567	14	improvement	improvement	NN
cord-034340-3ksfpaf7	567	15	of	of	IN
cord-034340-3ksfpaf7	567	16	auricular	auricular	JJ
cord-034340-3ksfpaf7	567	17	inflammation	inflammation	NN
cord-034340-3ksfpaf7	567	18	and	and	CC
cord-034340-3ksfpaf7	567	19	normalization	normalization	NN
cord-034340-3ksfpaf7	567	20	of	of	IN
cord-034340-3ksfpaf7	567	21	markers	marker	NNS
cord-034340-3ksfpaf7	567	22	of	of	IN
cord-034340-3ksfpaf7	567	23	inflammation	inflammation	NN
cord-034340-3ksfpaf7	567	24	.	.	.
cord-034340-3ksfpaf7	568	1	Auricular	Auricular	NNP
cord-034340-3ksfpaf7	568	2	chondritis	chondritis	NN
cord-034340-3ksfpaf7	568	3	worsened	worsen	VBD
cord-034340-3ksfpaf7	568	4	after	after	IN
cord-034340-3ksfpaf7	568	5	steroid	steroid	NN
cord-034340-3ksfpaf7	568	6	withdrawal	withdrawal	NN
cord-034340-3ksfpaf7	568	7	and	and	CC
cord-034340-3ksfpaf7	568	8	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	568	9	was	be	VBD
cord-034340-3ksfpaf7	568	10	added	add	VBN
cord-034340-3ksfpaf7	568	11	to	to	IN
cord-034340-3ksfpaf7	568	12	treatment	treatment	NN
cord-034340-3ksfpaf7	568	13	with	with	IN
cord-034340-3ksfpaf7	568	14	significant	significant	JJ
cord-034340-3ksfpaf7	568	15	improvement	improvement	NN
cord-034340-3ksfpaf7	568	16	of	of	IN
cord-034340-3ksfpaf7	568	17	auricular	auricular	JJ
cord-034340-3ksfpaf7	568	18	inflammation	inflammation	NN
cord-034340-3ksfpaf7	568	19	in	in	IN
cord-034340-3ksfpaf7	568	20	2	2	CD
cord-034340-3ksfpaf7	568	21	months	month	NNS
cord-034340-3ksfpaf7	568	22	.	.	.
cord-034340-3ksfpaf7	569	1	In	in	IN
cord-034340-3ksfpaf7	569	2	the	the	DT
cord-034340-3ksfpaf7	569	3	following	following	JJ
cord-034340-3ksfpaf7	569	4	8	8	CD
cord-034340-3ksfpaf7	569	5	months	month	NNS
cord-034340-3ksfpaf7	569	6	auricular	auricular	NNP
cord-034340-3ksfpaf7	569	7	chondritis	chondritis	NNP
cord-034340-3ksfpaf7	569	8	relapsed	relapse	VBD
cord-034340-3ksfpaf7	569	9	during	during	IN
cord-034340-3ksfpaf7	569	10	URIs	uri	NNS
cord-034340-3ksfpaf7	569	11	with	with	IN
cord-034340-3ksfpaf7	569	12	mild	mild	JJ
cord-034340-3ksfpaf7	569	13	elevation	elevation	NN
cord-034340-3ksfpaf7	569	14	of	of	IN
cord-034340-3ksfpaf7	569	15	ESR	ESR	NNP
cord-034340-3ksfpaf7	569	16	(	(	-LRB-
cord-034340-3ksfpaf7	569	17	25	25	CD
cord-034340-3ksfpaf7	569	18	mm	mm	NNP
cord-034340-3ksfpaf7	569	19	1st	1st	NNP
cord-034340-3ksfpaf7	569	20	hr	hr	NN
cord-034340-3ksfpaf7	569	21	)	)	-RRB-
cord-034340-3ksfpaf7	569	22	and	and	CC
cord-034340-3ksfpaf7	569	23	CRP	CRP	NNP
cord-034340-3ksfpaf7	569	24	(	(	-LRB-
cord-034340-3ksfpaf7	569	25	13	13	CD
cord-034340-3ksfpaf7	569	26	mg	mg	NNP
cord-034340-3ksfpaf7	569	27	/	/	SYM
cord-034340-3ksfpaf7	569	28	l	l	NN
cord-034340-3ksfpaf7	569	29	)	)	-RRB-
cord-034340-3ksfpaf7	569	30	.	.	.
cord-034340-3ksfpaf7	570	1	After	after	IN
cord-034340-3ksfpaf7	570	2	15	15	CD
cord-034340-3ksfpaf7	570	3	months	month	NNS
cord-034340-3ksfpaf7	570	4	of	of	IN
cord-034340-3ksfpaf7	570	5	treatment	treatment	NN
cord-034340-3ksfpaf7	570	6	,	,	,
cord-034340-3ksfpaf7	570	7	in	in	IN
cord-034340-3ksfpaf7	570	8	an	an	DT
cord-034340-3ksfpaf7	570	9	effort	effort	NN
cord-034340-3ksfpaf7	570	10	to	to	TO
cord-034340-3ksfpaf7	570	11	prolong	prolong	VB
cord-034340-3ksfpaf7	570	12	the	the	DT
cord-034340-3ksfpaf7	570	13	intervals	interval	NNS
cord-034340-3ksfpaf7	570	14	of	of	IN
cord-034340-3ksfpaf7	570	15	adalimumab	adalimumab	NNP
cord-034340-3ksfpaf7	570	16	administration	administration	NN
cord-034340-3ksfpaf7	570	17	,	,	,
cord-034340-3ksfpaf7	570	18	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	570	19	auricular	auricular	NNP
cord-034340-3ksfpaf7	570	20	chondritis	chondritis	NNP
cord-034340-3ksfpaf7	570	21	relapsed	relapse	VBD
cord-034340-3ksfpaf7	570	22	.	.	.
cord-034340-3ksfpaf7	571	1	After	after	IN
cord-034340-3ksfpaf7	571	2	24	24	CD
cord-034340-3ksfpaf7	571	3	months	month	NNS
cord-034340-3ksfpaf7	571	4	of	of	IN
cord-034340-3ksfpaf7	571	5	MTX	MTX	NNP
cord-034340-3ksfpaf7	571	6	and	and	CC
cord-034340-3ksfpaf7	571	7	21	21	CD
cord-034340-3ksfpaf7	571	8	months	month	NNS
cord-034340-3ksfpaf7	571	9	of	of	IN
cord-034340-3ksfpaf7	571	10	adalimumab	adalimumab	NNP
cord-034340-3ksfpaf7	571	11	administration	administration	NN
cord-034340-3ksfpaf7	571	12	inflammation	inflammation	NN
cord-034340-3ksfpaf7	571	13	was	be	VBD
cord-034340-3ksfpaf7	571	14	put	put	VBN
cord-034340-3ksfpaf7	571	15	in	in	IN
cord-034340-3ksfpaf7	571	16	complete	complete	JJ
cord-034340-3ksfpaf7	571	17	remission	remission	NN
cord-034340-3ksfpaf7	571	18	.	.	.
cord-034340-3ksfpaf7	572	1	The	the	DT
cord-034340-3ksfpaf7	572	2	following	following	JJ
cord-034340-3ksfpaf7	572	3	year	year	NN
cord-034340-3ksfpaf7	572	4	no	no	DT
cord-034340-3ksfpaf7	572	5	flares	flare	NNS
cord-034340-3ksfpaf7	572	6	or	or	CC
cord-034340-3ksfpaf7	572	7	involvement	involvement	NN
cord-034340-3ksfpaf7	572	8	of	of	IN
cord-034340-3ksfpaf7	572	9	other	other	JJ
cord-034340-3ksfpaf7	572	10	systems	system	NNS
cord-034340-3ksfpaf7	572	11	were	be	VBD
cord-034340-3ksfpaf7	572	12	observed	observe	VBN
cord-034340-3ksfpaf7	572	13	,	,	,
cord-034340-3ksfpaf7	572	14	under	under	IN
cord-034340-3ksfpaf7	572	15	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	572	16	and	and	CC
cord-034340-3ksfpaf7	572	17	adalimumab	adalimumab	NNP
cord-034340-3ksfpaf7	572	18	treatment	treatment	NN
cord-034340-3ksfpaf7	572	19	.	.	.
cord-034340-3ksfpaf7	573	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	573	2	:	:	:
cord-034340-3ksfpaf7	574	1	In	in	IN
cord-034340-3ksfpaf7	574	2	this	this	DT
cord-034340-3ksfpaf7	574	3	patient	patient	NN
cord-034340-3ksfpaf7	574	4	isolated	isolate	VBN
cord-034340-3ksfpaf7	574	5	auricular	auricular	NNP
cord-034340-3ksfpaf7	574	6	relapsing	relapse	VBG
cord-034340-3ksfpaf7	574	7	polychondritis	polychondritis	NNP
cord-034340-3ksfpaf7	574	8	was	be	VBD
cord-034340-3ksfpaf7	574	9	unresponsive	unresponsive	JJ
cord-034340-3ksfpaf7	574	10	to	to	IN
cord-034340-3ksfpaf7	574	11	NSAIDs	NSAIDs	NNP
cord-034340-3ksfpaf7	574	12	.	.	.
cord-034340-3ksfpaf7	575	1	Steroids	steroid	NNS
cord-034340-3ksfpaf7	575	2	and	and	CC
cord-034340-3ksfpaf7	575	3	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	575	4	greatly	greatly	RB
cord-034340-3ksfpaf7	575	5	improved	improve	VBD
cord-034340-3ksfpaf7	575	6	inflammation	inflammation	NN
cord-034340-3ksfpaf7	575	7	but	but	CC
cord-034340-3ksfpaf7	575	8	did	do	VBD
cord-034340-3ksfpaf7	575	9	not	not	RB
cord-034340-3ksfpaf7	575	10	induce	induce	VB
cord-034340-3ksfpaf7	575	11	complete	complete	JJ
cord-034340-3ksfpaf7	575	12	remission	remission	NN
cord-034340-3ksfpaf7	575	13	.	.	.
cord-034340-3ksfpaf7	576	1	Complete	complete	JJ
cord-034340-3ksfpaf7	576	2	remission	remission	NN
cord-034340-3ksfpaf7	576	3	was	be	VBD
cord-034340-3ksfpaf7	576	4	achieved	achieve	VBN
cord-034340-3ksfpaf7	576	5	by	by	IN
cord-034340-3ksfpaf7	576	6	addition	addition	NN
cord-034340-3ksfpaf7	576	7	of	of	IN
cord-034340-3ksfpaf7	576	8	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	576	9	to	to	IN
cord-034340-3ksfpaf7	576	10	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	576	11	treatment	treatment	NN
cord-034340-3ksfpaf7	576	12	,	,	,
cord-034340-3ksfpaf7	576	13	which	which	WDT
cord-034340-3ksfpaf7	576	14	also	also	RB
cord-034340-3ksfpaf7	576	15	allowed	allow	VBD
cord-034340-3ksfpaf7	576	16	for	for	IN
cord-034340-3ksfpaf7	576	17	steroids	steroid	NNS
cord-034340-3ksfpaf7	576	18	discontinuation	discontinuation	NN
cord-034340-3ksfpaf7	576	19	.	.	.
cord-034340-3ksfpaf7	577	1	None	none	NN
cord-034340-3ksfpaf7	577	2	declared	declare	VBD
cord-034340-3ksfpaf7	577	3	First	first	RB
cord-034340-3ksfpaf7	577	4	ever	ever	RB
cord-034340-3ksfpaf7	577	5	single	single	JJ
cord-034340-3ksfpaf7	577	6	center	center	NN
cord-034340-3ksfpaf7	577	7	study	study	NN
cord-034340-3ksfpaf7	577	8	revealing	reveal	VBG
cord-034340-3ksfpaf7	577	9	spectrum	spectrum	NN
cord-034340-3ksfpaf7	577	10	of	of	IN
cord-034340-3ksfpaf7	577	11	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	577	12	diseases	disease	NNS
cord-034340-3ksfpaf7	577	13	in	in	IN
cord-034340-3ksfpaf7	577	14	114	114	CD
cord-034340-3ksfpaf7	577	15	children	child	NNS
cord-034340-3ksfpaf7	577	16	from	from	IN
cord-034340-3ksfpaf7	577	17	an	an	DT
cord-034340-3ksfpaf7	577	18	Indian	indian	JJ
cord-034340-3ksfpaf7	577	19	State	State	NNP
cord-034340-3ksfpaf7	577	20	of	of	IN
cord-034340-3ksfpaf7	577	21	Gujarat	Gujarat	NNP
cord-034340-3ksfpaf7	577	22	D.	D.	NNP
cord-034340-3ksfpaf7	577	23	B.	B.	NNP
cord-034340-3ksfpaf7	577	24	Pandya	Pandya	NNP
cord-034340-3ksfpaf7	577	25	,	,	,
cord-034340-3ksfpaf7	577	26	on	on	IN
cord-034340-3ksfpaf7	577	27	behalf	behalf	NN
cord-034340-3ksfpaf7	577	28	of	of	IN
cord-034340-3ksfpaf7	577	29	Dr	Dr	NNP
cord-034340-3ksfpaf7	577	30	Mehul	Mehul	NNP
cord-034340-3ksfpaf7	577	31	Mitra	Mitra	NNP
cord-034340-3ksfpaf7	577	32	,	,	,
cord-034340-3ksfpaf7	577	33	Pankaj	Pankaj	NNP
cord-034340-3ksfpaf7	577	34	Buch	Buch	NNP
cord-034340-3ksfpaf7	577	35	,	,	,
cord-034340-3ksfpaf7	577	36	Sonal	Sonal	NNP
cord-034340-3ksfpaf7	577	37	Shah	Shah	NNP
cord-034340-3ksfpaf7	578	1	,	,	,
cord-034340-3ksfpaf7	578	2	There	there	EX
cord-034340-3ksfpaf7	578	3	is	be	VBZ
cord-034340-3ksfpaf7	578	4	very	very	RB
cord-034340-3ksfpaf7	578	5	limited	limited	JJ
cord-034340-3ksfpaf7	578	6	information	information	NN
cord-034340-3ksfpaf7	578	7	and	and	CC
cord-034340-3ksfpaf7	578	8	awareness	awareness	NN
cord-034340-3ksfpaf7	578	9	about	about	IN
cord-034340-3ksfpaf7	578	10	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	578	11	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	578	12	and	and	CC
cord-034340-3ksfpaf7	578	13	immunodeficiency	immunodeficiency	NN
cord-034340-3ksfpaf7	578	14	diseases	disease	NNS
cord-034340-3ksfpaf7	578	15	amongst	amongst	IN
cord-034340-3ksfpaf7	578	16	primary	primary	JJ
cord-034340-3ksfpaf7	578	17	physicians	physician	NNS
cord-034340-3ksfpaf7	578	18	1	1	CD
cord-034340-3ksfpaf7	578	19	,	,	,
cord-034340-3ksfpaf7	578	20	2	2	CD
cord-034340-3ksfpaf7	578	21	,	,	,
cord-034340-3ksfpaf7	578	22	3	3	CD
cord-034340-3ksfpaf7	578	23	in	in	IN
cord-034340-3ksfpaf7	578	24	Gujarat	Gujarat	NNP
cord-034340-3ksfpaf7	578	25	and	and	CC
cord-034340-3ksfpaf7	578	26	to	to	TO
cord-034340-3ksfpaf7	578	27	make	make	VB
cord-034340-3ksfpaf7	578	28	this	this	DT
cord-034340-3ksfpaf7	578	29	matter	matter	NN
cord-034340-3ksfpaf7	578	30	even	even	RB
cord-034340-3ksfpaf7	578	31	worse	worse	RBR
cord-034340-3ksfpaf7	578	32	,	,	,
cord-034340-3ksfpaf7	578	33	we	-PRON-	PRP
cord-034340-3ksfpaf7	578	34	are	be	VBP
cord-034340-3ksfpaf7	578	35	not	not	RB
cord-034340-3ksfpaf7	578	36	having	have	VBG
cord-034340-3ksfpaf7	578	37	a	a	DT
cord-034340-3ksfpaf7	578	38	single	single	JJ
cord-034340-3ksfpaf7	578	39	exclusive	exclusive	JJ
cord-034340-3ksfpaf7	578	40	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	578	41	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	578	42	and	and	CC
cord-034340-3ksfpaf7	578	43	immunology	immunology	NN
cord-034340-3ksfpaf7	578	44	centre	centre	NN
cord-034340-3ksfpaf7	578	45	for	for	IN
cord-034340-3ksfpaf7	578	46	a	a	DT
cord-034340-3ksfpaf7	578	47	population	population	NN
cord-034340-3ksfpaf7	578	48	of	of	IN
cord-034340-3ksfpaf7	578	49	around	around	RB
cord-034340-3ksfpaf7	578	50	60	60	CD
cord-034340-3ksfpaf7	578	51	million	million	CD
cord-034340-3ksfpaf7	578	52	.	.	.
cord-034340-3ksfpaf7	579	1	To	to	TO
cord-034340-3ksfpaf7	579	2	guesstimate	guesstimate	VB
cord-034340-3ksfpaf7	579	3	a	a	DT
cord-034340-3ksfpaf7	579	4	status	status	NN
cord-034340-3ksfpaf7	579	5	of	of	IN
cord-034340-3ksfpaf7	579	6	children	child	NNS
cord-034340-3ksfpaf7	579	7	with	with	IN
cord-034340-3ksfpaf7	579	8	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	579	9	and	and	CC
cord-034340-3ksfpaf7	579	10	immunodeficiency	immunodeficiency	NN
cord-034340-3ksfpaf7	579	11	diseases	disease	NNS
cord-034340-3ksfpaf7	579	12	in	in	IN
cord-034340-3ksfpaf7	579	13	Gujarat	Gujarat	NNP
cord-034340-3ksfpaf7	579	14	and	and	CC
cord-034340-3ksfpaf7	579	15	spectrum	spectrum	NN
cord-034340-3ksfpaf7	579	16	of	of	IN
cord-034340-3ksfpaf7	579	17	these	these	DT
cord-034340-3ksfpaf7	579	18	diseases	disease	NNS
cord-034340-3ksfpaf7	579	19	at	at	IN
cord-034340-3ksfpaf7	579	20	Dev	Dev	NNP
cord-034340-3ksfpaf7	579	21	Children	Children	NNP
cord-034340-3ksfpaf7	579	22	's	's	POS
cord-034340-3ksfpaf7	579	23	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	579	24	.	.	.
cord-034340-3ksfpaf7	580	1	Methods	method	NNS
cord-034340-3ksfpaf7	581	1	I	-PRON-	PRP
cord-034340-3ksfpaf7	581	2	gathered	gather	VBD
cord-034340-3ksfpaf7	581	3	a	a	DT
cord-034340-3ksfpaf7	581	4	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	581	5	data	datum	NNS
cord-034340-3ksfpaf7	581	6	of	of	IN
cord-034340-3ksfpaf7	581	7	174	174	CD
cord-034340-3ksfpaf7	581	8	patients	patient	NNS
cord-034340-3ksfpaf7	581	9	who	who	WP
cord-034340-3ksfpaf7	581	10	attended	attend	VBD
cord-034340-3ksfpaf7	581	11	Dev	Dev	NNP
cord-034340-3ksfpaf7	581	12	Children	Children	NNP
cord-034340-3ksfpaf7	581	13	's	's	POS
cord-034340-3ksfpaf7	581	14	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	581	15	between	between	IN
cord-034340-3ksfpaf7	581	16	January	January	NNP
cord-034340-3ksfpaf7	581	17	2019	2019	CD
cord-034340-3ksfpaf7	581	18	and	and	CC
cord-034340-3ksfpaf7	581	19	January	January	NNP
cord-034340-3ksfpaf7	581	20	2020	2020	CD
cord-034340-3ksfpaf7	581	21	.	.	.
cord-034340-3ksfpaf7	582	1	Out	out	IN
cord-034340-3ksfpaf7	582	2	of	of	IN
cord-034340-3ksfpaf7	582	3	these	these	DT
cord-034340-3ksfpaf7	582	4	,	,	,
cord-034340-3ksfpaf7	582	5	114	114	CD
cord-034340-3ksfpaf7	582	6	children	child	NNS
cord-034340-3ksfpaf7	582	7	with	with	IN
cord-034340-3ksfpaf7	582	8	confirmed	confirmed	JJ
cord-034340-3ksfpaf7	582	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	582	10	of	of	IN
cord-034340-3ksfpaf7	582	11	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	582	12	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	582	13	diseases	disease	NNS
cord-034340-3ksfpaf7	582	14	and	and	CC
cord-034340-3ksfpaf7	582	15	suspected	suspect	VBN
cord-034340-3ksfpaf7	582	16	primary	primary	JJ
cord-034340-3ksfpaf7	582	17	immunodeficiencies	immunodeficiency	NNS
cord-034340-3ksfpaf7	582	18	were	be	VBD
cord-034340-3ksfpaf7	582	19	included	include	VBN
cord-034340-3ksfpaf7	582	20	.	.	.
cord-034340-3ksfpaf7	583	1	Patients	patient	NNS
cord-034340-3ksfpaf7	583	2	with	with	IN
cord-034340-3ksfpaf7	583	3	non	non	JJ
cord-034340-3ksfpaf7	583	4	-	-	JJ
cord-034340-3ksfpaf7	583	5	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	583	6	musculoskeletal(MSK	musculoskeletal(MSK	NNS
cord-034340-3ksfpaf7	583	7	)	)	-RRB-
cord-034340-3ksfpaf7	583	8	pains	pain	NNS
cord-034340-3ksfpaf7	583	9	and	and	CC
cord-034340-3ksfpaf7	583	10	non	non	JJ
cord-034340-3ksfpaf7	583	11	-	-	JJ
cord-034340-3ksfpaf7	583	12	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	583	13	diseases	disease	NNS
cord-034340-3ksfpaf7	583	14	causing	cause	VBG
cord-034340-3ksfpaf7	583	15	MSK	MSK	NNP
cord-034340-3ksfpaf7	583	16	pains	pain	NNS
cord-034340-3ksfpaf7	583	17	were	be	VBD
cord-034340-3ksfpaf7	583	18	excluded	exclude	VBN
cord-034340-3ksfpaf7	583	19	.	.	.
cord-034340-3ksfpaf7	584	1	My	-PRON-	PRP$
cord-034340-3ksfpaf7	584	2	collected	collect	VBN
cord-034340-3ksfpaf7	584	3	data	datum	NNS
cord-034340-3ksfpaf7	584	4	included	include	VBD
cord-034340-3ksfpaf7	584	5	referral	referral	JJ
cord-034340-3ksfpaf7	584	6	details	detail	NNS
cord-034340-3ksfpaf7	584	7	,	,	,
cord-034340-3ksfpaf7	584	8	demographics	demographic	NNS
cord-034340-3ksfpaf7	584	9	,	,	,
cord-034340-3ksfpaf7	584	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	584	11	presentation	presentation	NN
cord-034340-3ksfpaf7	584	12	,	,	,
cord-034340-3ksfpaf7	584	13	laboratory	laboratory	NN
cord-034340-3ksfpaf7	584	14	results	result	NNS
cord-034340-3ksfpaf7	584	15	and	and	CC
cord-034340-3ksfpaf7	584	16	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	584	17	.	.	.
cord-034340-3ksfpaf7	585	1	Majority	majority	NN
cord-034340-3ksfpaf7	585	2	of	of	IN
cord-034340-3ksfpaf7	585	3	the	the	DT
cord-034340-3ksfpaf7	585	4	cases	case	NNS
cord-034340-3ksfpaf7	585	5	were	be	VBD
cord-034340-3ksfpaf7	585	6	referred	refer	VBN
cord-034340-3ksfpaf7	585	7	by	by	IN
cord-034340-3ksfpaf7	585	8	pediatricians	pediatrician	NNS
cord-034340-3ksfpaf7	585	9	,	,	,
cord-034340-3ksfpaf7	585	10	orthopedicians	orthopedicians	NNP
cord-034340-3ksfpaf7	585	11	,	,	,
cord-034340-3ksfpaf7	585	12	hemato	hemato	NN
cord-034340-3ksfpaf7	585	13	-	-	HYPH
cord-034340-3ksfpaf7	585	14	oncologist	oncologist	NN
cord-034340-3ksfpaf7	585	15	and	and	CC
cord-034340-3ksfpaf7	585	16	general	general	JJ
cord-034340-3ksfpaf7	585	17	physicians	physician	NNS
cord-034340-3ksfpaf7	585	18	.	.	.
cord-034340-3ksfpaf7	586	1	Main	main	JJ
cord-034340-3ksfpaf7	586	2	reasons	reason	NNS
cord-034340-3ksfpaf7	586	3	for	for	IN
cord-034340-3ksfpaf7	586	4	referral	referral	NN
cord-034340-3ksfpaf7	586	5	were	be	VBD
cord-034340-3ksfpaf7	586	6	joint	joint	JJ
cord-034340-3ksfpaf7	586	7	involvement	involvement	NN
cord-034340-3ksfpaf7	586	8	,	,	,
cord-034340-3ksfpaf7	586	9	undiagnosed	undiagnosed	JJ
cord-034340-3ksfpaf7	586	10	fever	fever	NN
cord-034340-3ksfpaf7	586	11	,	,	,
cord-034340-3ksfpaf7	586	12	multisystem	multisystem	JJ
cord-034340-3ksfpaf7	586	13	disease	disease	NN
cord-034340-3ksfpaf7	586	14	and	and	CC
cord-034340-3ksfpaf7	586	15	elevated	elevated	JJ
cord-034340-3ksfpaf7	586	16	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	586	17	markers	marker	NNS
cord-034340-3ksfpaf7	586	18	.	.	.
cord-034340-3ksfpaf7	587	1	Many	many	JJ
cord-034340-3ksfpaf7	587	2	physicians	physician	NNS
cord-034340-3ksfpaf7	587	3	had	have	VBD
cord-034340-3ksfpaf7	587	4	put	put	VBN
cord-034340-3ksfpaf7	587	5	a	a	DT
cord-034340-3ksfpaf7	587	6	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	587	7	like	like	IN
cord-034340-3ksfpaf7	587	8	rheumatoid	rheumatoid	NN
cord-034340-3ksfpaf7	587	9	/	/	SYM
cord-034340-3ksfpaf7	587	10	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	587	11	arthritis	arthritis	NN
cord-034340-3ksfpaf7	587	12	,	,	,
cord-034340-3ksfpaf7	587	13	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	587	14	disease	disease	NN
cord-034340-3ksfpaf7	587	15	or	or	CC
cord-034340-3ksfpaf7	587	16	connective	connective	JJ
cord-034340-3ksfpaf7	587	17	tissue	tissue	NN
cord-034340-3ksfpaf7	587	18	disease	disease	NN
cord-034340-3ksfpaf7	587	19	.	.	.
cord-034340-3ksfpaf7	588	1	Almost	almost	RB
cord-034340-3ksfpaf7	588	2	80	80	CD
cord-034340-3ksfpaf7	588	3	%	%	NN
cord-034340-3ksfpaf7	588	4	of	of	IN
cord-034340-3ksfpaf7	588	5	patients	patient	NNS
cord-034340-3ksfpaf7	588	6	had	have	VBD
cord-034340-3ksfpaf7	588	7	been	be	VBN
cord-034340-3ksfpaf7	588	8	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	588	9	with	with	IN
cord-034340-3ksfpaf7	588	10	RF	RF	NNP
cord-034340-3ksfpaf7	588	11	,	,	,
cord-034340-3ksfpaf7	588	12	ASO	ASO	NNP
cord-034340-3ksfpaf7	588	13	titer	titer	NN
cord-034340-3ksfpaf7	588	14	,	,	,
cord-034340-3ksfpaf7	588	15	ANA	ANA	NNP
cord-034340-3ksfpaf7	588	16	and	and	CC
cord-034340-3ksfpaf7	588	17	joint	joint	JJ
cord-034340-3ksfpaf7	588	18	imaging	imaging	NN
cord-034340-3ksfpaf7	588	19	irrespective	irrespective	RB
cord-034340-3ksfpaf7	588	20	of	of	IN
cord-034340-3ksfpaf7	588	21	clinical	clinical	JJ
cord-034340-3ksfpaf7	588	22	pattern	pattern	NN
cord-034340-3ksfpaf7	588	23	by	by	IN
cord-034340-3ksfpaf7	588	24	their	-PRON-	PRP$
cord-034340-3ksfpaf7	588	25	primary	primary	JJ
cord-034340-3ksfpaf7	588	26	physicians	physician	NNS
cord-034340-3ksfpaf7	588	27	before	before	IN
cord-034340-3ksfpaf7	588	28	referral	referral	NN
cord-034340-3ksfpaf7	588	29	.	.	.
cord-034340-3ksfpaf7	589	1	Fever	Fever	NNP
cord-034340-3ksfpaf7	589	2	,	,	,
cord-034340-3ksfpaf7	589	3	MSK	MSK	NNP
cord-034340-3ksfpaf7	589	4	involvement	involvement	NN
cord-034340-3ksfpaf7	589	5	,	,	,
cord-034340-3ksfpaf7	589	6	extreme	extreme	JJ
cord-034340-3ksfpaf7	589	7	fatigue	fatigue	NN
cord-034340-3ksfpaf7	589	8	,	,	,
cord-034340-3ksfpaf7	589	9	constitutional	constitutional	JJ
cord-034340-3ksfpaf7	589	10	symptoms	symptom	NNS
cord-034340-3ksfpaf7	589	11	,	,	,
cord-034340-3ksfpaf7	589	12	skin	skin	NN
cord-034340-3ksfpaf7	589	13	and	and	CC
cord-034340-3ksfpaf7	589	14	mucosal	mucosal	JJ
cord-034340-3ksfpaf7	589	15	involvement	involvement	NN
cord-034340-3ksfpaf7	589	16	were	be	VBD
cord-034340-3ksfpaf7	589	17	prominent	prominent	JJ
cord-034340-3ksfpaf7	589	18	complaints	complaint	NNS
cord-034340-3ksfpaf7	589	19	noted	note	VBN
cord-034340-3ksfpaf7	589	20	by	by	IN
cord-034340-3ksfpaf7	589	21	me	-PRON-	PRP
cord-034340-3ksfpaf7	589	22	.	.	.
cord-034340-3ksfpaf7	590	1	Family	family	NN
cord-034340-3ksfpaf7	590	2	history	history	NN
cord-034340-3ksfpaf7	590	3	of	of	IN
cord-034340-3ksfpaf7	590	4	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	590	5	,	,	,
cord-034340-3ksfpaf7	590	6	primary	primary	JJ
cord-034340-3ksfpaf7	590	7	immunodeficiency	immunodeficiency	NN
cord-034340-3ksfpaf7	590	8	(	(	-LRB-
cord-034340-3ksfpaf7	590	9	PID	PID	NNP
cord-034340-3ksfpaf7	590	10	)	)	-RRB-
cord-034340-3ksfpaf7	590	11	or	or	CC
cord-034340-3ksfpaf7	590	12	consanguinity	consanguinity	NN
cord-034340-3ksfpaf7	590	13	was	be	VBD
cord-034340-3ksfpaf7	590	14	found	find	VBN
cord-034340-3ksfpaf7	590	15	in	in	IN
cord-034340-3ksfpaf7	590	16	1/3	1/3	CD
cord-034340-3ksfpaf7	590	17	of	of	IN
cord-034340-3ksfpaf7	590	18	patients	patient	NNS
cord-034340-3ksfpaf7	590	19	.	.	.
cord-034340-3ksfpaf7	591	1	Anemia	anemia	NN
cord-034340-3ksfpaf7	591	2	of	of	IN
cord-034340-3ksfpaf7	591	3	chronic	chronic	JJ
cord-034340-3ksfpaf7	591	4	disease	disease	NN
cord-034340-3ksfpaf7	591	5	,	,	,
cord-034340-3ksfpaf7	591	6	elevated	elevate	VBN
cord-034340-3ksfpaf7	591	7	ESR	ESR	NNP
cord-034340-3ksfpaf7	591	8	and	and	CC
cord-034340-3ksfpaf7	591	9	thrombocytosis	thrombocytosis	NNP
cord-034340-3ksfpaf7	591	10	were	be	VBD
cord-034340-3ksfpaf7	591	11	almost	almost	RB
cord-034340-3ksfpaf7	591	12	universal	universal	JJ
cord-034340-3ksfpaf7	591	13	laboratory	laboratory	NN
cord-034340-3ksfpaf7	591	14	findings	finding	NNS
cord-034340-3ksfpaf7	591	15	in	in	IN
cord-034340-3ksfpaf7	591	16	our	-PRON-	PRP$
cord-034340-3ksfpaf7	591	17	cohort	cohort	NN
cord-034340-3ksfpaf7	591	18	.	.	.
cord-034340-3ksfpaf7	592	1	Rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	592	2	diseases	disease	NNS
cord-034340-3ksfpaf7	592	3	in	in	IN
cord-034340-3ksfpaf7	592	4	children	child	NNS
cord-034340-3ksfpaf7	592	5	are	be	VBP
cord-034340-3ksfpaf7	592	6	not	not	RB
cord-034340-3ksfpaf7	592	7	anymore	anymore	RB
cord-034340-3ksfpaf7	592	8	rare	rare	JJ
cord-034340-3ksfpaf7	592	9	but	but	CC
cord-034340-3ksfpaf7	592	10	due	due	IN
cord-034340-3ksfpaf7	592	11	to	to	IN
cord-034340-3ksfpaf7	592	12	lack	lack	NN
cord-034340-3ksfpaf7	592	13	of	of	IN
cord-034340-3ksfpaf7	592	14	expertise	expertise	NN
cord-034340-3ksfpaf7	592	15	and	and	CC
cord-034340-3ksfpaf7	592	16	awareness	awareness	NN
cord-034340-3ksfpaf7	592	17	,	,	,
cord-034340-3ksfpaf7	592	18	these	these	DT
cord-034340-3ksfpaf7	592	19	children	child	NNS
cord-034340-3ksfpaf7	592	20	are	be	VBP
cord-034340-3ksfpaf7	592	21	not	not	RB
cord-034340-3ksfpaf7	592	22	getting	get	VBG
cord-034340-3ksfpaf7	592	23	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	592	24	.	.	.
cord-034340-3ksfpaf7	593	1	Many	many	JJ
cord-034340-3ksfpaf7	593	2	cases	case	NNS
cord-034340-3ksfpaf7	593	3	were	be	VBD
cord-034340-3ksfpaf7	593	4	advised	advise	VBN
cord-034340-3ksfpaf7	593	5	unnecessary	unnecessary	JJ
cord-034340-3ksfpaf7	593	6	rheumatological	rheumatological	JJ
cord-034340-3ksfpaf7	593	7	investigations	investigation	NNS
cord-034340-3ksfpaf7	593	8	even	even	RB
cord-034340-3ksfpaf7	593	9	before	before	IN
cord-034340-3ksfpaf7	593	10	referral	referral	NN
cord-034340-3ksfpaf7	593	11	.	.	.
cord-034340-3ksfpaf7	594	1	Results	result	NNS
cord-034340-3ksfpaf7	594	2	:	:	:
cord-034340-3ksfpaf7	595	1	A	a	DT
cord-034340-3ksfpaf7	595	2	10-year	10-year	CD
cord-034340-3ksfpaf7	595	3	-	-	HYPH
cord-034340-3ksfpaf7	595	4	old	old	JJ
cord-034340-3ksfpaf7	595	5	female	female	JJ
cord-034340-3ksfpaf7	595	6	patient	patient	NN
cord-034340-3ksfpaf7	595	7	was	be	VBD
cord-034340-3ksfpaf7	595	8	referred	refer	VBN
cord-034340-3ksfpaf7	595	9	to	to	IN
cord-034340-3ksfpaf7	595	10	the	the	DT
cord-034340-3ksfpaf7	595	11	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	595	12	clinic	clinic	NN
cord-034340-3ksfpaf7	595	13	at	at	IN
cord-034340-3ksfpaf7	595	14	our	-PRON-	PRP$
cord-034340-3ksfpaf7	595	15	hospital	hospital	NN
cord-034340-3ksfpaf7	595	16	with	with	IN
cord-034340-3ksfpaf7	595	17	a	a	DT
cord-034340-3ksfpaf7	595	18	previous	previous	JJ
cord-034340-3ksfpaf7	595	19	history	history	NN
cord-034340-3ksfpaf7	595	20	of	of	IN
cord-034340-3ksfpaf7	595	21	fever	fever	NN
cord-034340-3ksfpaf7	595	22	of	of	IN
cord-034340-3ksfpaf7	595	23	39	39	CD
cord-034340-3ksfpaf7	595	24	°	°	NN
cord-034340-3ksfpaf7	595	25	C	c	NN
cord-034340-3ksfpaf7	595	26	(	(	-LRB-
cord-034340-3ksfpaf7	595	27	102.2ºC	102.2ºc	CD
cord-034340-3ksfpaf7	595	28	)	)	-RRB-
cord-034340-3ksfpaf7	595	29	,	,	,
cord-034340-3ksfpaf7	595	30	loss	loss	NN
cord-034340-3ksfpaf7	595	31	of	of	IN
cord-034340-3ksfpaf7	595	32	appetite	appetite	NN
cord-034340-3ksfpaf7	595	33	,	,	,
cord-034340-3ksfpaf7	595	34	and	and	CC
cord-034340-3ksfpaf7	595	35	acute	acute	JJ
cord-034340-3ksfpaf7	595	36	polyarthritis	polyarthritis	NN
cord-034340-3ksfpaf7	595	37	of	of	IN
cord-034340-3ksfpaf7	595	38	wrist	wrist	NN
cord-034340-3ksfpaf7	595	39	,	,	,
cord-034340-3ksfpaf7	595	40	knees	knee	NNS
cord-034340-3ksfpaf7	595	41	,	,	,
cord-034340-3ksfpaf7	595	42	and	and	CC
cord-034340-3ksfpaf7	595	43	ankles	ankle	NNS
cord-034340-3ksfpaf7	595	44	.	.	.
cord-034340-3ksfpaf7	596	1	At	at	IN
cord-034340-3ksfpaf7	596	2	that	that	DT
cord-034340-3ksfpaf7	596	3	time	time	NN
cord-034340-3ksfpaf7	596	4	,	,	,
cord-034340-3ksfpaf7	596	5	laboratory	laboratory	NN
cord-034340-3ksfpaf7	596	6	exams	exam	NNS
cord-034340-3ksfpaf7	596	7	revealed	reveal	VBD
cord-034340-3ksfpaf7	596	8	a	a	DT
cord-034340-3ksfpaf7	596	9	hemoglobin	hemoglobin	NN
cord-034340-3ksfpaf7	596	10	of	of	IN
cord-034340-3ksfpaf7	596	11	11.1	11.1	CD
cord-034340-3ksfpaf7	596	12	g	g	NN
cord-034340-3ksfpaf7	596	13	/	/	SYM
cord-034340-3ksfpaf7	596	14	dL	dl	NN
cord-034340-3ksfpaf7	596	15	,	,	,
cord-034340-3ksfpaf7	596	16	C	C	NNP
cord-034340-3ksfpaf7	596	17	reactive	reactive	JJ
cord-034340-3ksfpaf7	596	18	protein	protein	NN
cord-034340-3ksfpaf7	596	19	78.6	78.6	CD
cord-034340-3ksfpaf7	596	20	mg	mg	NNP
cord-034340-3ksfpaf7	596	21	/	/	SYM
cord-034340-3ksfpaf7	596	22	L	L	NNP
cord-034340-3ksfpaf7	596	23	,	,	,
cord-034340-3ksfpaf7	596	24	and	and	CC
cord-034340-3ksfpaf7	596	25	antistreptolysin	antistreptolysin	NNP
cord-034340-3ksfpaf7	596	26	O	o	NN
cord-034340-3ksfpaf7	596	27	titers	titer	NNS
cord-034340-3ksfpaf7	596	28	of	of	IN
cord-034340-3ksfpaf7	596	29	400	400	CD
cord-034340-3ksfpaf7	596	30	UI	UI	NNP
cord-034340-3ksfpaf7	596	31	/	/	SYM
cord-034340-3ksfpaf7	596	32	mL	ml	NN
cord-034340-3ksfpaf7	596	33	(	(	-LRB-
cord-034340-3ksfpaf7	596	34	normal	normal	JJ
cord-034340-3ksfpaf7	596	35	range	range	NN
cord-034340-3ksfpaf7	596	36	<	<	XX
cord-034340-3ksfpaf7	596	37	200UI	200UI	NNP
cord-034340-3ksfpaf7	596	38	/	/	SYM
cord-034340-3ksfpaf7	596	39	ml	ml	NN
cord-034340-3ksfpaf7	596	40	.	.	.
cord-034340-3ksfpaf7	597	1	Clinical	clinical	JJ
cord-034340-3ksfpaf7	597	2	symptoms	symptom	NNS
cord-034340-3ksfpaf7	597	3	were	be	VBD
cord-034340-3ksfpaf7	597	4	relieved	relieve	VBN
cord-034340-3ksfpaf7	597	5	only	only	RB
cord-034340-3ksfpaf7	597	6	after	after	IN
cord-034340-3ksfpaf7	597	7	using	use	VBG
cord-034340-3ksfpaf7	597	8	NSAIDs	NSAIDs	NNP
cord-034340-3ksfpaf7	597	9	.	.	.
cord-034340-3ksfpaf7	598	1	After	after	IN
cord-034340-3ksfpaf7	598	2	6	6	CD
cord-034340-3ksfpaf7	598	3	months	month	NNS
cord-034340-3ksfpaf7	598	4	,	,	,
cord-034340-3ksfpaf7	598	5	the	the	DT
cord-034340-3ksfpaf7	598	6	patient	patient	NN
cord-034340-3ksfpaf7	598	7	returned	return	VBD
cord-034340-3ksfpaf7	598	8	to	to	IN
cord-034340-3ksfpaf7	598	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	598	10	hospital	hospital	NN
cord-034340-3ksfpaf7	598	11	with	with	IN
cord-034340-3ksfpaf7	598	12	a	a	DT
cord-034340-3ksfpaf7	598	13	7-month	7-month	NNP
cord-034340-3ksfpaf7	598	14	history	history	NN
cord-034340-3ksfpaf7	598	15	of	of	IN
cord-034340-3ksfpaf7	598	16	weight	weight	NN
cord-034340-3ksfpaf7	598	17	loss	loss	NN
cord-034340-3ksfpaf7	598	18	and	and	CC
cord-034340-3ksfpaf7	598	19	claudication	claudication	NN
cord-034340-3ksfpaf7	598	20	related	relate	VBN
cord-034340-3ksfpaf7	598	21	to	to	IN
cord-034340-3ksfpaf7	598	22	pain	pain	NN
cord-034340-3ksfpaf7	598	23	and	and	CC
cord-034340-3ksfpaf7	598	24	daily	daily	JJ
cord-034340-3ksfpaf7	598	25	morning	morning	NN
cord-034340-3ksfpaf7	598	26	stiffness	stiffness	NN
cord-034340-3ksfpaf7	598	27	(	(	-LRB-
cord-034340-3ksfpaf7	598	28	15	15	CD
cord-034340-3ksfpaf7	598	29	minutes	minute	NNS
cord-034340-3ksfpaf7	598	30	)	)	-RRB-
cord-034340-3ksfpaf7	598	31	on	on	IN
cord-034340-3ksfpaf7	598	32	her	-PRON-	PRP$
cord-034340-3ksfpaf7	598	33	right	right	JJ
cord-034340-3ksfpaf7	598	34	ankle	ankle	NN
cord-034340-3ksfpaf7	598	35	.	.	.
cord-034340-3ksfpaf7	599	1	New	new	JJ
cord-034340-3ksfpaf7	599	2	laboratory	laboratory	NN
cord-034340-3ksfpaf7	599	3	findings	finding	NNS
cord-034340-3ksfpaf7	599	4	demonstrated	demonstrate	VBD
cord-034340-3ksfpaf7	599	5	positive	positive	JJ
cord-034340-3ksfpaf7	599	6	antinuclear	antinuclear	JJ
cord-034340-3ksfpaf7	599	7	antibodies	antibody	NNS
cord-034340-3ksfpaf7	599	8	1:320	1:320	CD
cord-034340-3ksfpaf7	599	9	,	,	,
cord-034340-3ksfpaf7	599	10	negative	negative	JJ
cord-034340-3ksfpaf7	599	11	rheumatoid	rheumatoid	NN
cord-034340-3ksfpaf7	599	12	factor	factor	NN
cord-034340-3ksfpaf7	599	13	,	,	,
cord-034340-3ksfpaf7	599	14	and	and	CC
cord-034340-3ksfpaf7	599	15	alpha-1-acid	alpha-1-acid	NNP
cord-034340-3ksfpaf7	599	16	glycoprotein	glycoprotein	NN
cord-034340-3ksfpaf7	599	17	of	of	IN
cord-034340-3ksfpaf7	599	18	171	171	CD
cord-034340-3ksfpaf7	599	19	mg	mg	NNP
cord-034340-3ksfpaf7	599	20	/	/	SYM
cord-034340-3ksfpaf7	599	21	dL	dl	NN
cord-034340-3ksfpaf7	600	1	(	(	-LRB-
cord-034340-3ksfpaf7	600	2	normal	normal	JJ
cord-034340-3ksfpaf7	600	3	range	range	NN
cord-034340-3ksfpaf7	600	4	:	:	:
cord-034340-3ksfpaf7	600	5	44	44	CD
cord-034340-3ksfpaf7	600	6	-	-	HYPH
cord-034340-3ksfpaf7	600	7	113mg	113mg	NNP
cord-034340-3ksfpaf7	600	8	/	/	SYM
cord-034340-3ksfpaf7	600	9	dL	dl	NN
cord-034340-3ksfpaf7	600	10	)	)	-RRB-
cord-034340-3ksfpaf7	600	11	.	.	.
cord-034340-3ksfpaf7	601	1	Clinical	clinical	JJ
cord-034340-3ksfpaf7	601	2	signs	sign	NNS
cord-034340-3ksfpaf7	601	3	suggestive	suggestive	JJ
cord-034340-3ksfpaf7	601	4	of	of	IN
cord-034340-3ksfpaf7	601	5	chronic	chronic	JJ
cord-034340-3ksfpaf7	601	6	arthritis	arthritis	NN
cord-034340-3ksfpaf7	601	7	with	with	IN
cord-034340-3ksfpaf7	601	8	exuberant	exuberant	JJ
cord-034340-3ksfpaf7	601	9	swelling	swelling	NN
cord-034340-3ksfpaf7	601	10	of	of	IN
cord-034340-3ksfpaf7	601	11	the	the	DT
cord-034340-3ksfpaf7	601	12	ankles	ankle	NNS
cord-034340-3ksfpaf7	601	13	were	be	VBD
cord-034340-3ksfpaf7	601	14	observed	observe	VBN
cord-034340-3ksfpaf7	601	15	on	on	IN
cord-034340-3ksfpaf7	601	16	physical	physical	JJ
cord-034340-3ksfpaf7	601	17	examination	examination	NN
cord-034340-3ksfpaf7	601	18	(	(	-LRB-
cord-034340-3ksfpaf7	601	19	figure	figure	VB
cord-034340-3ksfpaf7	601	20	A	a	NN
cord-034340-3ksfpaf7	601	21	)	)	-RRB-
cord-034340-3ksfpaf7	601	22	.	.	.
cord-034340-3ksfpaf7	602	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	602	2	was	be	VBD
cord-034340-3ksfpaf7	602	3	screened	screen	VBN
cord-034340-3ksfpaf7	602	4	for	for	IN
cord-034340-3ksfpaf7	602	5	tuberculosis	tuberculosis	NN
cord-034340-3ksfpaf7	602	6	(	(	-LRB-
cord-034340-3ksfpaf7	602	7	TB	TB	NNP
cord-034340-3ksfpaf7	602	8	)	)	-RRB-
cord-034340-3ksfpaf7	602	9	and	and	CC
cord-034340-3ksfpaf7	602	10	had	have	VBD
cord-034340-3ksfpaf7	602	11	a	a	DT
cord-034340-3ksfpaf7	602	12	positive	positive	JJ
cord-034340-3ksfpaf7	602	13	(	(	-LRB-
cord-034340-3ksfpaf7	602	14	18	18	CD
cord-034340-3ksfpaf7	602	15	mm	mm	NN
cord-034340-3ksfpaf7	602	16	)	)	-RRB-
cord-034340-3ksfpaf7	602	17	tuberculin	tuberculin	NN
cord-034340-3ksfpaf7	602	18	skin	skin	NN
cord-034340-3ksfpaf7	602	19	test	test	NN
cord-034340-3ksfpaf7	602	20	(	(	-LRB-
cord-034340-3ksfpaf7	602	21	figure	figure	NN
cord-034340-3ksfpaf7	602	22	B	B	NNP
cord-034340-3ksfpaf7	602	23	)	)	-RRB-
cord-034340-3ksfpaf7	602	24	.	.	.
cord-034340-3ksfpaf7	603	1	Chest	Chest	NNP
cord-034340-3ksfpaf7	603	2	CT	CT	NNP
cord-034340-3ksfpaf7	603	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	603	4	infiltrative	infiltrative	JJ
cord-034340-3ksfpaf7	603	5	soft	soft	JJ
cord-034340-3ksfpaf7	603	6	tissue	tissue	NN
cord-034340-3ksfpaf7	603	7	mass	mass	NN
cord-034340-3ksfpaf7	603	8	in	in	IN
cord-034340-3ksfpaf7	603	9	the	the	DT
cord-034340-3ksfpaf7	603	10	posterior	posterior	JJ
cord-034340-3ksfpaf7	603	11	mediastinum	mediastinum	NN
cord-034340-3ksfpaf7	603	12	,	,	,
cord-034340-3ksfpaf7	603	13	with	with	IN
cord-034340-3ksfpaf7	603	14	homogeneous	homogeneous	JJ
cord-034340-3ksfpaf7	603	15	contrast	contrast	NN
cord-034340-3ksfpaf7	603	16	enhancement	enhancement	NN
cord-034340-3ksfpaf7	603	17	(	(	-LRB-
cord-034340-3ksfpaf7	603	18	figure	figure	NN
cord-034340-3ksfpaf7	603	19	C	C	NNP
cord-034340-3ksfpaf7	603	20	)	)	-RRB-
cord-034340-3ksfpaf7	603	21	.	.	.
cord-034340-3ksfpaf7	604	1	Magnetic	magnetic	JJ
cord-034340-3ksfpaf7	604	2	resonance	resonance	NN
cord-034340-3ksfpaf7	604	3	imaging	imaging	NN
cord-034340-3ksfpaf7	604	4	of	of	IN
cord-034340-3ksfpaf7	604	5	both	both	DT
cord-034340-3ksfpaf7	604	6	ankles	ankle	NNS
cord-034340-3ksfpaf7	604	7	was	be	VBD
cord-034340-3ksfpaf7	604	8	performed	perform	VBN
cord-034340-3ksfpaf7	604	9	and	and	CC
cord-034340-3ksfpaf7	604	10	demonstrated	demonstrate	VBN
cord-034340-3ksfpaf7	604	11	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	604	12	and	and	CC
cord-034340-3ksfpaf7	604	13	symmetrical	symmetrical	JJ
cord-034340-3ksfpaf7	604	14	tibiotalar	tibiotalar	JJ
cord-034340-3ksfpaf7	604	15	arthritis	arthritis	NN
cord-034340-3ksfpaf7	604	16	and	and	CC
cord-034340-3ksfpaf7	604	17	prominent	prominent	JJ
cord-034340-3ksfpaf7	604	18	tenosynovitis	tenosynovitis	NN
cord-034340-3ksfpaf7	604	19	of	of	IN
cord-034340-3ksfpaf7	604	20	extensors	extensor	NNS
cord-034340-3ksfpaf7	604	21	,	,	,
cord-034340-3ksfpaf7	604	22	flexors	flexor	NNS
cord-034340-3ksfpaf7	604	23	,	,	,
cord-034340-3ksfpaf7	604	24	and	and	CC
cord-034340-3ksfpaf7	604	25	fibularis	fibularis	JJ
cord-034340-3ksfpaf7	604	26	tendons	tendon	NNS
cord-034340-3ksfpaf7	604	27	(	(	-LRB-
cord-034340-3ksfpaf7	604	28	figure	figure	NN
cord-034340-3ksfpaf7	604	29	D	D	NNP
cord-034340-3ksfpaf7	604	30	)	)	-RRB-
cord-034340-3ksfpaf7	604	31	.	.	.
cord-034340-3ksfpaf7	605	1	Right	right	JJ
cord-034340-3ksfpaf7	605	2	ankle	ankle	JJ
cord-034340-3ksfpaf7	605	3	synovial	synovial	JJ
cord-034340-3ksfpaf7	605	4	biopsy	biopsy	NN
cord-034340-3ksfpaf7	605	5	revealed	reveal	VBD
cord-034340-3ksfpaf7	605	6	no	no	DT
cord-034340-3ksfpaf7	605	7	granulomas	granuloma	NNS
cord-034340-3ksfpaf7	605	8	and	and	CC
cord-034340-3ksfpaf7	605	9	joint	joint	JJ
cord-034340-3ksfpaf7	605	10	fluid	fluid	JJ
cord-034340-3ksfpaf7	605	11	culture	culture	NN
cord-034340-3ksfpaf7	605	12	was	be	VBD
cord-034340-3ksfpaf7	605	13	negative	negative	JJ
cord-034340-3ksfpaf7	605	14	for	for	IN
cord-034340-3ksfpaf7	605	15	Mycobacterium	Mycobacterium	NNP
cord-034340-3ksfpaf7	605	16	tuberculosis	tuberculosis	NN
cord-034340-3ksfpaf7	605	17	,	,	,
cord-034340-3ksfpaf7	605	18	confirming	confirm	VBG
cord-034340-3ksfpaf7	605	19	reactive	reactive	JJ
cord-034340-3ksfpaf7	605	20	arthritis	arthritis	NN
cord-034340-3ksfpaf7	605	21	(	(	-LRB-
cord-034340-3ksfpaf7	605	22	Poncet	Poncet	NNP
cord-034340-3ksfpaf7	605	23	's	's	POS
cord-034340-3ksfpaf7	605	24	)	)	-RRB-
cord-034340-3ksfpaf7	605	25	and	and	CC
cord-034340-3ksfpaf7	605	26	tenosynovitis	tenosynovitis	NNP
cord-034340-3ksfpaf7	605	27	,	,	,
cord-034340-3ksfpaf7	605	28	that	that	WDT
cord-034340-3ksfpaf7	605	29	may	may	MD
cord-034340-3ksfpaf7	605	30	follow	follow	VB
cord-034340-3ksfpaf7	605	31	mycobacterial	mycobacterial	JJ
cord-034340-3ksfpaf7	605	32	infection	infection	NN
cord-034340-3ksfpaf7	605	33	with	with	IN
cord-034340-3ksfpaf7	605	34	no	no	DT
cord-034340-3ksfpaf7	605	35	infective	infective	JJ
cord-034340-3ksfpaf7	605	36	agent	agent	NN
cord-034340-3ksfpaf7	605	37	in	in	IN
cord-034340-3ksfpaf7	605	38	the	the	DT
cord-034340-3ksfpaf7	605	39	joints	joint	NNS
cord-034340-3ksfpaf7	605	40	.	.	.
cord-034340-3ksfpaf7	606	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	606	2	:	:	:
cord-034340-3ksfpaf7	607	1	To	to	IN
cord-034340-3ksfpaf7	607	2	our	-PRON-	PRP$
cord-034340-3ksfpaf7	607	3	knowledge	knowledge	NN
cord-034340-3ksfpaf7	607	4	,	,	,
cord-034340-3ksfpaf7	607	5	there	there	EX
cord-034340-3ksfpaf7	607	6	is	be	VBZ
cord-034340-3ksfpaf7	607	7	no	no	DT
cord-034340-3ksfpaf7	607	8	report	report	NN
cord-034340-3ksfpaf7	607	9	of	of	IN
cord-034340-3ksfpaf7	607	10	Poncet	Poncet	NNP
cord-034340-3ksfpaf7	607	11	's	's	POS
cord-034340-3ksfpaf7	607	12	disease	disease	NN
cord-034340-3ksfpaf7	607	13	associated	associate	VBN
cord-034340-3ksfpaf7	607	14	with	with	IN
cord-034340-3ksfpaf7	607	15	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	607	16	tenosynovitis	tenosynovitis	NN
cord-034340-3ksfpaf7	607	17	,	,	,
cord-034340-3ksfpaf7	607	18	showing	show	VBG
cord-034340-3ksfpaf7	607	19	the	the	DT
cord-034340-3ksfpaf7	607	20	particularity	particularity	NN
cord-034340-3ksfpaf7	607	21	of	of	IN
cord-034340-3ksfpaf7	607	22	this	this	DT
cord-034340-3ksfpaf7	607	23	case	case	NN
cord-034340-3ksfpaf7	607	24	.	.	.
cord-034340-3ksfpaf7	608	1	The	the	DT
cord-034340-3ksfpaf7	608	2	patient	patient	NN
cord-034340-3ksfpaf7	608	3	's	's	POS
cord-034340-3ksfpaf7	608	4	symptoms	symptom	NNS
cord-034340-3ksfpaf7	608	5	resolved	resolve	VBN
cord-034340-3ksfpaf7	608	6	after	after	IN
cord-034340-3ksfpaf7	608	7	two	two	CD
cord-034340-3ksfpaf7	608	8	months	month	NNS
cord-034340-3ksfpaf7	608	9	of	of	IN
cord-034340-3ksfpaf7	608	10	anti	anti	JJ
cord-034340-3ksfpaf7	608	11	-	-	JJ
cord-034340-3ksfpaf7	608	12	TB	tb	JJ
cord-034340-3ksfpaf7	608	13	therapy	therapy	NN
cord-034340-3ksfpaf7	608	14	.	.	.
cord-034340-3ksfpaf7	609	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	609	2	:	:	:
cord-034340-3ksfpaf7	610	1	CACP	CACP	NNP
cord-034340-3ksfpaf7	610	2	is	be	VBZ
cord-034340-3ksfpaf7	610	3	characterized	characterize	VBN
cord-034340-3ksfpaf7	610	4	by	by	IN
cord-034340-3ksfpaf7	610	5	congenital	congenital	JJ
cord-034340-3ksfpaf7	610	6	or	or	CC
cord-034340-3ksfpaf7	610	7	early	early	JJ
cord-034340-3ksfpaf7	610	8	-	-	HYPH
cord-034340-3ksfpaf7	610	9	onset	onset	NN
cord-034340-3ksfpaf7	610	10	camptodactyly	camptodactyly	NNP
cord-034340-3ksfpaf7	610	11	(	(	-LRB-
cord-034340-3ksfpaf7	610	12	usually	usually	RB
cord-034340-3ksfpaf7	610	13	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	610	14	)	)	-RRB-
cord-034340-3ksfpaf7	610	15	;	;	:
cord-034340-3ksfpaf7	610	16	non	non	JJ
cord-034340-3ksfpaf7	610	17	-	-	JJ
cord-034340-3ksfpaf7	610	18	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	610	19	arthropathy	arthropathy	NN
cord-034340-3ksfpaf7	610	20	(	(	-LRB-
cord-034340-3ksfpaf7	610	21	more	more	RBR
cord-034340-3ksfpaf7	610	22	frequently	frequently	RB
cord-034340-3ksfpaf7	610	23	in	in	IN
cord-034340-3ksfpaf7	610	24	the	the	DT
cord-034340-3ksfpaf7	610	25	wrists	wrist	NNS
cord-034340-3ksfpaf7	610	26	,	,	,
cord-034340-3ksfpaf7	610	27	knees	knee	NNS
cord-034340-3ksfpaf7	610	28	,	,	,
cord-034340-3ksfpaf7	610	29	ankles	ankle	NNS
cord-034340-3ksfpaf7	610	30	,	,	,
cord-034340-3ksfpaf7	610	31	elbows	elbow	NNS
cord-034340-3ksfpaf7	610	32	,	,	,
cord-034340-3ksfpaf7	610	33	and	and	CC
cord-034340-3ksfpaf7	610	34	hips	hip	NNS
cord-034340-3ksfpaf7	610	35	)	)	-RRB-
cord-034340-3ksfpaf7	610	36	;	;	:
cord-034340-3ksfpaf7	610	37	coxa	coxa	NNP
cord-034340-3ksfpaf7	610	38	vara	vara	NNP
cord-034340-3ksfpaf7	610	39	(	(	-LRB-
cord-034340-3ksfpaf7	610	40	reduction	reduction	NN
cord-034340-3ksfpaf7	610	41	of	of	IN
cord-034340-3ksfpaf7	610	42	the	the	DT
cord-034340-3ksfpaf7	610	43	angle	angle	NN
cord-034340-3ksfpaf7	610	44	between	between	IN
cord-034340-3ksfpaf7	610	45	the	the	DT
cord-034340-3ksfpaf7	610	46	neck	neck	NN
cord-034340-3ksfpaf7	610	47	and	and	CC
cord-034340-3ksfpaf7	610	48	shaft	shaft	NN
cord-034340-3ksfpaf7	610	49	of	of	IN
cord-034340-3ksfpaf7	610	50	the	the	DT
cord-034340-3ksfpaf7	610	51	femur	femur	NN
cord-034340-3ksfpaf7	610	52	)	)	-RRB-
cord-034340-3ksfpaf7	610	53	;	;	:
cord-034340-3ksfpaf7	610	54	and	and	CC
cord-034340-3ksfpaf7	610	55	non	non	JJ
cord-034340-3ksfpaf7	610	56	-	-	JJ
cord-034340-3ksfpaf7	610	57	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	610	58	pericardial	pericardial	JJ
cord-034340-3ksfpaf7	610	59	effusion	effusion	NN
cord-034340-3ksfpaf7	610	60	(	(	-LRB-
cord-034340-3ksfpaf7	610	61	a	a	DT
cord-034340-3ksfpaf7	610	62	late	late	JJ
cord-034340-3ksfpaf7	610	63	manifestation	manifestation	NN
cord-034340-3ksfpaf7	610	64	,	,	,
cord-034340-3ksfpaf7	610	65	less	less	RBR
cord-034340-3ksfpaf7	610	66	frequently	frequently	RB
cord-034340-3ksfpaf7	610	67	reported	report	VBN
cord-034340-3ksfpaf7	610	68	)	)	-RRB-
cord-034340-3ksfpaf7	610	69	.	.	.
cord-034340-3ksfpaf7	611	1	Recognizing	recognize	VBG
cord-034340-3ksfpaf7	611	2	the	the	DT
cord-034340-3ksfpaf7	611	3	radiological	radiological	JJ
cord-034340-3ksfpaf7	611	4	aspects	aspect	NNS
cord-034340-3ksfpaf7	611	5	of	of	IN
cord-034340-3ksfpaf7	611	6	this	this	DT
cord-034340-3ksfpaf7	611	7	syndrome	syndrome	NN
cord-034340-3ksfpaf7	611	8	and	and	CC
cord-034340-3ksfpaf7	611	9	differentiating	differentiate	VBG
cord-034340-3ksfpaf7	611	10	it	-PRON-	PRP
cord-034340-3ksfpaf7	611	11	from	from	IN
cord-034340-3ksfpaf7	611	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	611	13	is	be	VBZ
cord-034340-3ksfpaf7	611	14	crucial	crucial	JJ
cord-034340-3ksfpaf7	611	15	since	since	IN
cord-034340-3ksfpaf7	611	16	CACP	CACP	NNP
cord-034340-3ksfpaf7	611	17	has	have	VBZ
cord-034340-3ksfpaf7	611	18	no	no	DT
cord-034340-3ksfpaf7	611	19	effective	effective	JJ
cord-034340-3ksfpaf7	611	20	treatment	treatment	NN
cord-034340-3ksfpaf7	611	21	and	and	CC
cord-034340-3ksfpaf7	611	22	JIA	JIA	NNP
cord-034340-3ksfpaf7	611	23	is	be	VBZ
cord-034340-3ksfpaf7	611	24	usually	usually	RB
cord-034340-3ksfpaf7	611	25	treated	treat	VBN
cord-034340-3ksfpaf7	611	26	with	with	IN
cord-034340-3ksfpaf7	611	27	NSAIDs	NSAIDs	NNP
cord-034340-3ksfpaf7	611	28	and	and	CC
cord-034340-3ksfpaf7	611	29	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	611	30	(	(	-LRB-
cord-034340-3ksfpaf7	611	31	2	2	CD
cord-034340-3ksfpaf7	611	32	,	,	,
cord-034340-3ksfpaf7	611	33	3	3	CD
cord-034340-3ksfpaf7	611	34	)	)	-RRB-
cord-034340-3ksfpaf7	611	35	.	.	.
cord-034340-3ksfpaf7	612	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	612	2	:	:	:
cord-034340-3ksfpaf7	612	3	To	to	TO
cord-034340-3ksfpaf7	612	4	report	report	VB
cord-034340-3ksfpaf7	612	5	a	a	DT
cord-034340-3ksfpaf7	612	6	rare	rare	JJ
cord-034340-3ksfpaf7	612	7	case	case	NN
cord-034340-3ksfpaf7	612	8	of	of	IN
cord-034340-3ksfpaf7	612	9	CACP	CACP	NNP
cord-034340-3ksfpaf7	612	10	syndrome	syndrome	NN
cord-034340-3ksfpaf7	612	11	mimicking	mimic	VBG
cord-034340-3ksfpaf7	612	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	612	13	.	.	.
cord-034340-3ksfpaf7	613	1	Methods	method	NNS
cord-034340-3ksfpaf7	613	2	:	:	:
cord-034340-3ksfpaf7	614	1	Case	case	NN
cord-034340-3ksfpaf7	614	2	report	report	NN
cord-034340-3ksfpaf7	614	3	and	and	CC
cord-034340-3ksfpaf7	614	4	literature	literature	NN
cord-034340-3ksfpaf7	614	5	review	review	NN
cord-034340-3ksfpaf7	614	6	.	.	.
cord-034340-3ksfpaf7	615	1	Results	result	NNS
cord-034340-3ksfpaf7	615	2	:	:	:
cord-034340-3ksfpaf7	616	1	A	a	DT
cord-034340-3ksfpaf7	616	2	5-year	5-year	CD
cord-034340-3ksfpaf7	616	3	-	-	HYPH
cord-034340-3ksfpaf7	616	4	old	old	JJ
cord-034340-3ksfpaf7	616	5	male	male	JJ
cord-034340-3ksfpaf7	616	6	patient	patient	NN
cord-034340-3ksfpaf7	616	7	presented	present	VBN
cord-034340-3ksfpaf7	616	8	with	with	IN
cord-034340-3ksfpaf7	616	9	arthropathy	arthropathy	NNP
cord-034340-3ksfpaf7	616	10	characterized	characterize	VBN
cord-034340-3ksfpaf7	616	11	by	by	IN
cord-034340-3ksfpaf7	616	12	painless	painless	JJ
cord-034340-3ksfpaf7	616	13	progressive	progressive	JJ
cord-034340-3ksfpaf7	616	14	swelling	swelling	NN
cord-034340-3ksfpaf7	616	15	and	and	CC
cord-034340-3ksfpaf7	616	16	restricted	restricted	JJ
cord-034340-3ksfpaf7	616	17	movement	movement	NN
cord-034340-3ksfpaf7	616	18	of	of	IN
cord-034340-3ksfpaf7	616	19	the	the	DT
cord-034340-3ksfpaf7	616	20	hands	hand	NNS
cord-034340-3ksfpaf7	616	21	,	,	,
cord-034340-3ksfpaf7	616	22	hips	hip	NNS
cord-034340-3ksfpaf7	616	23	,	,	,
cord-034340-3ksfpaf7	616	24	knees	knee	NNS
cord-034340-3ksfpaf7	616	25	,	,	,
cord-034340-3ksfpaf7	616	26	and	and	CC
cord-034340-3ksfpaf7	616	27	ankles	ankle	NNS
cord-034340-3ksfpaf7	616	28	since	since	IN
cord-034340-3ksfpaf7	616	29	the	the	DT
cord-034340-3ksfpaf7	616	30	first	first	JJ
cord-034340-3ksfpaf7	616	31	year	year	NN
cord-034340-3ksfpaf7	616	32	of	of	IN
cord-034340-3ksfpaf7	616	33	life	life	NN
cord-034340-3ksfpaf7	616	34	.	.	.
cord-034340-3ksfpaf7	617	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	617	2	had	have	VBD
cord-034340-3ksfpaf7	617	3	a	a	DT
cord-034340-3ksfpaf7	617	4	family	family	NN
cord-034340-3ksfpaf7	617	5	history	history	NN
cord-034340-3ksfpaf7	617	6	of	of	IN
cord-034340-3ksfpaf7	617	7	camptodactyly	camptodactyly	NNP
cord-034340-3ksfpaf7	617	8	from	from	IN
cord-034340-3ksfpaf7	617	9	his	-PRON-	PRP$
cord-034340-3ksfpaf7	617	10	paternal	paternal	JJ
cord-034340-3ksfpaf7	617	11	grandfather	grandfather	NN
cord-034340-3ksfpaf7	617	12	.	.	.
cord-034340-3ksfpaf7	618	1	On	on	IN
cord-034340-3ksfpaf7	618	2	physical	physical	JJ
cord-034340-3ksfpaf7	618	3	examination	examination	NN
cord-034340-3ksfpaf7	618	4	,	,	,
cord-034340-3ksfpaf7	618	5	symmetric	symmetric	JJ
cord-034340-3ksfpaf7	618	6	camptodactyly	camptodactyly	NN
cord-034340-3ksfpaf7	618	7	of	of	IN
cord-034340-3ksfpaf7	618	8	the	the	DT
cord-034340-3ksfpaf7	618	9	hands	hand	NNS
cord-034340-3ksfpaf7	618	10	and	and	CC
cord-034340-3ksfpaf7	618	11	feet	foot	NNS
cord-034340-3ksfpaf7	618	12	was	be	VBD
cord-034340-3ksfpaf7	618	13	observed	observe	VBN
cord-034340-3ksfpaf7	618	14	(	(	-LRB-
cord-034340-3ksfpaf7	618	15	A	a	NN
cord-034340-3ksfpaf7	618	16	)	)	-RRB-
cord-034340-3ksfpaf7	618	17	.	.	.
cord-034340-3ksfpaf7	619	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	619	2	had	have	VBD
cord-034340-3ksfpaf7	619	3	no	no	DT
cord-034340-3ksfpaf7	619	4	history	history	NN
cord-034340-3ksfpaf7	619	5	of	of	IN
cord-034340-3ksfpaf7	619	6	rash	rash	JJ
cord-034340-3ksfpaf7	619	7	or	or	CC
cord-034340-3ksfpaf7	619	8	weight	weight	NN
cord-034340-3ksfpaf7	619	9	loss	loss	NN
cord-034340-3ksfpaf7	619	10	and	and	CC
cord-034340-3ksfpaf7	619	11	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	619	12	markers	marker	NNS
cord-034340-3ksfpaf7	619	13	were	be	VBD
cord-034340-3ksfpaf7	619	14	unremarkable	unremarkable	JJ
cord-034340-3ksfpaf7	619	15	.	.	.
cord-034340-3ksfpaf7	620	1	The	the	DT
cord-034340-3ksfpaf7	620	2	echocardiogram	echocardiogram	NN
cord-034340-3ksfpaf7	620	3	was	be	VBD
cord-034340-3ksfpaf7	620	4	normal	normal	JJ
cord-034340-3ksfpaf7	620	5	.	.	.
cord-034340-3ksfpaf7	621	1	The	the	DT
cord-034340-3ksfpaf7	621	2	pelvic	pelvic	JJ
cord-034340-3ksfpaf7	621	3	radiograph	radiograph	NN
cord-034340-3ksfpaf7	621	4	showed	show	VBD
cord-034340-3ksfpaf7	621	5	a	a	DT
cord-034340-3ksfpaf7	621	6	widening	widening	NN
cord-034340-3ksfpaf7	621	7	of	of	IN
cord-034340-3ksfpaf7	621	8	the	the	DT
cord-034340-3ksfpaf7	621	9	joint	joint	JJ
cord-034340-3ksfpaf7	621	10	space	space	NN
cord-034340-3ksfpaf7	621	11	and	and	CC
cord-034340-3ksfpaf7	621	12	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	621	13	coxa	coxa	NNP
cord-034340-3ksfpaf7	621	14	vara	vara	NNP
cord-034340-3ksfpaf7	621	15	.	.	.
cord-034340-3ksfpaf7	622	1	Magnetic	magnetic	JJ
cord-034340-3ksfpaf7	622	2	resonance	resonance	NN
cord-034340-3ksfpaf7	622	3	imaging	imaging	NN
cord-034340-3ksfpaf7	622	4	(	(	-LRB-
cord-034340-3ksfpaf7	622	5	MRI	MRI	NNP
cord-034340-3ksfpaf7	622	6	)	)	-RRB-
cord-034340-3ksfpaf7	622	7	of	of	IN
cord-034340-3ksfpaf7	622	8	the	the	DT
cord-034340-3ksfpaf7	622	9	hips	hip	NNS
cord-034340-3ksfpaf7	622	10	(	(	-LRB-
cord-034340-3ksfpaf7	622	11	B	b	NN
cord-034340-3ksfpaf7	622	12	)	)	-RRB-
cord-034340-3ksfpaf7	622	13	and	and	CC
cord-034340-3ksfpaf7	622	14	knees	knee	NNS
cord-034340-3ksfpaf7	622	15	(	(	-LRB-
cord-034340-3ksfpaf7	622	16	C	C	NNP
cord-034340-3ksfpaf7	622	17	)	)	-RRB-
cord-034340-3ksfpaf7	622	18	was	be	VBD
cord-034340-3ksfpaf7	622	19	performed	perform	VBN
cord-034340-3ksfpaf7	622	20	and	and	CC
cord-034340-3ksfpaf7	622	21	depicted	depict	VBD
cord-034340-3ksfpaf7	622	22	large	large	JJ
cord-034340-3ksfpaf7	622	23	joint	joint	JJ
cord-034340-3ksfpaf7	622	24	effusions	effusion	NNS
cord-034340-3ksfpaf7	622	25	(	(	-LRB-
cord-034340-3ksfpaf7	622	26	arrows	arrow	NNS
cord-034340-3ksfpaf7	622	27	,	,	,
cord-034340-3ksfpaf7	622	28	B	b	NN
cord-034340-3ksfpaf7	622	29	and	and	CC
cord-034340-3ksfpaf7	622	30	C	C	NNP
cord-034340-3ksfpaf7	622	31	)	)	-RRB-
cord-034340-3ksfpaf7	622	32	with	with	IN
cord-034340-3ksfpaf7	622	33	normal	normal	JJ
cord-034340-3ksfpaf7	622	34	synovial	synovial	JJ
cord-034340-3ksfpaf7	622	35	thickness	thickness	NN
cord-034340-3ksfpaf7	622	36	and	and	CC
cord-034340-3ksfpaf7	622	37	mild	mild	JJ
cord-034340-3ksfpaf7	622	38	synovial	synovial	JJ
cord-034340-3ksfpaf7	622	39	enhancement	enhancement	NN
cord-034340-3ksfpaf7	622	40	in	in	IN
cord-034340-3ksfpaf7	622	41	all	all	DT
cord-034340-3ksfpaf7	622	42	joints	joint	NNS
cord-034340-3ksfpaf7	622	43	,	,	,
cord-034340-3ksfpaf7	622	44	without	without	IN
cord-034340-3ksfpaf7	622	45	bone	bone	NN
cord-034340-3ksfpaf7	622	46	marrow	marrow	NN
cord-034340-3ksfpaf7	622	47	edema	edema	NN
cord-034340-3ksfpaf7	622	48	-	-	HYPH
cord-034340-3ksfpaf7	622	49	like	like	JJ
cord-034340-3ksfpaf7	622	50	signal	signal	NN
cord-034340-3ksfpaf7	622	51	.	.	.
cord-034340-3ksfpaf7	623	1	A	a	DT
cord-034340-3ksfpaf7	623	2	synovial	synovial	JJ
cord-034340-3ksfpaf7	623	3	biopsy	biopsy	NN
cord-034340-3ksfpaf7	623	4	of	of	IN
cord-034340-3ksfpaf7	623	5	the	the	DT
cord-034340-3ksfpaf7	623	6	knee	knee	NN
cord-034340-3ksfpaf7	623	7	was	be	VBD
cord-034340-3ksfpaf7	623	8	performed	perform	VBN
cord-034340-3ksfpaf7	623	9	and	and	CC
cord-034340-3ksfpaf7	623	10	revealed	reveal	VBN
cord-034340-3ksfpaf7	623	11	mild	mild	JJ
cord-034340-3ksfpaf7	623	12	synovial	synovial	JJ
cord-034340-3ksfpaf7	623	13	hyperplasia	hyperplasia	NN
cord-034340-3ksfpaf7	623	14	without	without	IN
cord-034340-3ksfpaf7	623	15	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	623	16	cells	cell	NNS
cord-034340-3ksfpaf7	623	17	.	.	.
cord-034340-3ksfpaf7	624	1	The	the	DT
cord-034340-3ksfpaf7	624	2	patient	patient	NN
cord-034340-3ksfpaf7	624	3	was	be	VBD
cord-034340-3ksfpaf7	624	4	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	624	5	with	with	IN
cord-034340-3ksfpaf7	624	6	camptodactyly	camptodactyly	NNP
cord-034340-3ksfpaf7	624	7	-	-	HYPH
cord-034340-3ksfpaf7	624	8	arthropathy	arthropathy	NNP
cord-034340-3ksfpaf7	624	9	-	-	HYPH
cord-034340-3ksfpaf7	624	10	coxa	coxa	NNP
cord-034340-3ksfpaf7	624	11	vara	vara	NNP
cord-034340-3ksfpaf7	624	12	-	-	HYPH
cord-034340-3ksfpaf7	624	13	pericarditis	pericarditis	NN
cord-034340-3ksfpaf7	624	14	syndrome	syndrome	NN
cord-034340-3ksfpaf7	624	15	(	(	-LRB-
cord-034340-3ksfpaf7	624	16	CACP	CACP	NNP
cord-034340-3ksfpaf7	624	17	-OMIM	-OMIM	.
cord-034340-3ksfpaf7	625	1	208250	208250	CD
cord-034340-3ksfpaf7	625	2	)	)	-RRB-
cord-034340-3ksfpaf7	625	3	,	,	,
cord-034340-3ksfpaf7	625	4	a	a	DT
cord-034340-3ksfpaf7	625	5	recently	recently	RB
cord-034340-3ksfpaf7	625	6	described	describe	VBN
cord-034340-3ksfpaf7	625	7	genetic	genetic	JJ
cord-034340-3ksfpaf7	625	8	disorder	disorder	NN
cord-034340-3ksfpaf7	625	9	with	with	IN
cord-034340-3ksfpaf7	625	10	no	no	DT
cord-034340-3ksfpaf7	625	11	gender	gender	NN
cord-034340-3ksfpaf7	625	12	predominance	predominance	NN
cord-034340-3ksfpaf7	625	13	identified	identify	VBN
cord-034340-3ksfpaf7	625	14	to	to	IN
cord-034340-3ksfpaf7	625	15	date	date	NN
cord-034340-3ksfpaf7	625	16	(	(	-LRB-
cord-034340-3ksfpaf7	625	17	1	1	CD
cord-034340-3ksfpaf7	625	18	)	)	-RRB-
cord-034340-3ksfpaf7	625	19	.	.	.
cord-034340-3ksfpaf7	626	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	626	2	:	:	:
cord-034340-3ksfpaf7	627	1	An	an	DT
cord-034340-3ksfpaf7	627	2	important	important	JJ
cord-034340-3ksfpaf7	627	3	differential	differential	JJ
cord-034340-3ksfpaf7	627	4	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	627	5	of	of	IN
cord-034340-3ksfpaf7	627	6	CACP	CACP	NNP
cord-034340-3ksfpaf7	627	7	is	be	VBZ
cord-034340-3ksfpaf7	627	8	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	627	9	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	627	10	arthritis	arthritis	NN
cord-034340-3ksfpaf7	627	11	(	(	-LRB-
cord-034340-3ksfpaf7	627	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	627	13	)	)	-RRB-
cord-034340-3ksfpaf7	627	14	,	,	,
cord-034340-3ksfpaf7	627	15	a	a	DT
cord-034340-3ksfpaf7	627	16	painful	painful	JJ
cord-034340-3ksfpaf7	627	17	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	627	18	chronic	chronic	JJ
cord-034340-3ksfpaf7	627	19	arthritis	arthritis	NN
cord-034340-3ksfpaf7	627	20	that	that	WDT
cord-034340-3ksfpaf7	627	21	can	can	MD
cord-034340-3ksfpaf7	627	22	cause	cause	VB
cord-034340-3ksfpaf7	627	23	not	not	RB
cord-034340-3ksfpaf7	627	24	only	only	RB
cord-034340-3ksfpaf7	627	25	joint	joint	JJ
cord-034340-3ksfpaf7	627	26	effusions	effusion	NNS
cord-034340-3ksfpaf7	627	27	due	due	IN
cord-034340-3ksfpaf7	627	28	to	to	IN
cord-034340-3ksfpaf7	627	29	synovial	synovial	JJ
cord-034340-3ksfpaf7	627	30	inflammation	inflammation	NN
cord-034340-3ksfpaf7	627	31	,	,	,
cord-034340-3ksfpaf7	627	32	but	but	CC
cord-034340-3ksfpaf7	627	33	Arthritis	arthritis	NN
cord-034340-3ksfpaf7	627	34	was	be	VBD
cord-034340-3ksfpaf7	627	35	the	the	DT
cord-034340-3ksfpaf7	627	36	most	most	RBS
cord-034340-3ksfpaf7	627	37	frequent	frequent	JJ
cord-034340-3ksfpaf7	627	38	extraglandular	extraglandular	JJ
cord-034340-3ksfpaf7	627	39	manifestation	manifestation	NN
cord-034340-3ksfpaf7	627	40	.	.	.
cord-034340-3ksfpaf7	628	1	Renal	renal	JJ
cord-034340-3ksfpaf7	628	2	tubular	tubular	JJ
cord-034340-3ksfpaf7	628	3	acidosis	acidosis	NN
cord-034340-3ksfpaf7	628	4	represented	represent	VBD
cord-034340-3ksfpaf7	628	5	the	the	DT
cord-034340-3ksfpaf7	628	6	typical	typical	JJ
cord-034340-3ksfpaf7	628	7	expression	expression	NN
cord-034340-3ksfpaf7	628	8	of	of	IN
cord-034340-3ksfpaf7	628	9	renal	renal	JJ
cord-034340-3ksfpaf7	628	10	involvement	involvement	NN
cord-034340-3ksfpaf7	628	11	(	(	-LRB-
cord-034340-3ksfpaf7	628	12	19	19	CD
cord-034340-3ksfpaf7	628	13	cases	case	NNS
cord-034340-3ksfpaf7	628	14	)	)	-RRB-
cord-034340-3ksfpaf7	628	15	.	.	.
cord-034340-3ksfpaf7	629	1	Neuromyelitis	Neuromyelitis	NNP
cord-034340-3ksfpaf7	629	2	optica	optica	NN
cord-034340-3ksfpaf7	629	3	and	and	CC
cord-034340-3ksfpaf7	629	4	aseptic	aseptic	JJ
cord-034340-3ksfpaf7	629	5	meningoencephalitis	meningoencephalitis	NNP
cord-034340-3ksfpaf7	629	6	(	(	-LRB-
cord-034340-3ksfpaf7	629	7	6	6	CD
cord-034340-3ksfpaf7	629	8	and	and	CC
cord-034340-3ksfpaf7	629	9	9	9	CD
cord-034340-3ksfpaf7	629	10	cases	case	NNS
cord-034340-3ksfpaf7	629	11	,	,	,
cord-034340-3ksfpaf7	629	12	respectively	respectively	RB
cord-034340-3ksfpaf7	629	13	)	)	-RRB-
cord-034340-3ksfpaf7	629	14	were	be	VBD
cord-034340-3ksfpaf7	629	15	the	the	DT
cord-034340-3ksfpaf7	629	16	most	most	RBS
cord-034340-3ksfpaf7	629	17	typical	typical	JJ
cord-034340-3ksfpaf7	629	18	neurologic	neurologic	JJ
cord-034340-3ksfpaf7	629	19	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	629	20	.	.	.
cord-034340-3ksfpaf7	630	1	Two	two	CD
cord-034340-3ksfpaf7	630	2	cases	case	NNS
cord-034340-3ksfpaf7	630	3	of	of	IN
cord-034340-3ksfpaf7	630	4	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	630	5	lung	lung	NN
cord-034340-3ksfpaf7	630	6	disease	disease	NN
cord-034340-3ksfpaf7	630	7	and	and	CC
cord-034340-3ksfpaf7	630	8	one	one	CD
cord-034340-3ksfpaf7	630	9	of	of	IN
cord-034340-3ksfpaf7	630	10	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	630	11	hypertension	hypertension	NN
cord-034340-3ksfpaf7	630	12	were	be	VBD
cord-034340-3ksfpaf7	630	13	reported	report	VBN
cord-034340-3ksfpaf7	630	14	.	.	.
cord-034340-3ksfpaf7	631	1	Almost	almost	RB
cord-034340-3ksfpaf7	631	2	all	all	DT
cord-034340-3ksfpaf7	631	3	patients	patient	NNS
cord-034340-3ksfpaf7	631	4	had	have	VBD
cord-034340-3ksfpaf7	631	5	autoantibodies	autoantibody	NNS
cord-034340-3ksfpaf7	631	6	,	,	,
cord-034340-3ksfpaf7	631	7	mostly	mostly	RB
cord-034340-3ksfpaf7	631	8	ANA	ANA	NNP
cord-034340-3ksfpaf7	631	9	(	(	-LRB-
cord-034340-3ksfpaf7	631	10	200/224	200/224	CD
cord-034340-3ksfpaf7	631	11	patients	patient	NNS
cord-034340-3ksfpaf7	631	12	)	)	-RRB-
cord-034340-3ksfpaf7	631	13	and	and	CC
cord-034340-3ksfpaf7	631	14	anti	anti	JJ
cord-034340-3ksfpaf7	631	15	-	-	JJ
cord-034340-3ksfpaf7	631	16	SSA	ssa	JJ
cord-034340-3ksfpaf7	631	17	/	/	SYM
cord-034340-3ksfpaf7	631	18	Ro	Ro	NNP
cord-034340-3ksfpaf7	631	19	(	(	-LRB-
cord-034340-3ksfpaf7	631	20	170/208	170/208	CD
cord-034340-3ksfpaf7	631	21	patients	patient	NNS
cord-034340-3ksfpaf7	631	22	)	)	-RRB-
cord-034340-3ksfpaf7	631	23	.	.	.
cord-034340-3ksfpaf7	632	1	The	the	DT
cord-034340-3ksfpaf7	632	2	Schirmer	Schirmer	NNP
cord-034340-3ksfpaf7	632	3	test	test	NN
cord-034340-3ksfpaf7	632	4	was	be	VBD
cord-034340-3ksfpaf7	632	5	performed	perform	VBN
cord-034340-3ksfpaf7	632	6	in	in	IN
cord-034340-3ksfpaf7	632	7	less	less	JJR
cord-034340-3ksfpaf7	632	8	than	than	IN
cord-034340-3ksfpaf7	632	9	half	half	NN
cord-034340-3ksfpaf7	632	10	of	of	IN
cord-034340-3ksfpaf7	632	11	the	the	DT
cord-034340-3ksfpaf7	632	12	patients	patient	NNS
cord-034340-3ksfpaf7	632	13	,	,	,
cord-034340-3ksfpaf7	632	14	of	of	IN
cord-034340-3ksfpaf7	632	15	whom	whom	WP
cord-034340-3ksfpaf7	632	16	62	62	CD
cord-034340-3ksfpaf7	632	17	%	%	NN
cord-034340-3ksfpaf7	632	18	tested	test	VBD
cord-034340-3ksfpaf7	632	19	positive	positive	JJ
cord-034340-3ksfpaf7	632	20	.	.	.
cord-034340-3ksfpaf7	633	1	A	a	DT
cord-034340-3ksfpaf7	633	2	positive	positive	JJ
cord-034340-3ksfpaf7	633	3	result	result	NN
cord-034340-3ksfpaf7	633	4	of	of	IN
cord-034340-3ksfpaf7	633	5	minor	minor	JJ
cord-034340-3ksfpaf7	633	6	salivary	salivary	NN
cord-034340-3ksfpaf7	633	7	biopsy	biopsy	NN
cord-034340-3ksfpaf7	633	8	was	be	VBD
cord-034340-3ksfpaf7	633	9	reported	report	VBN
cord-034340-3ksfpaf7	633	10	in	in	IN
cord-034340-3ksfpaf7	633	11	129/140	129/140	CD
cord-034340-3ksfpaf7	633	12	cases	case	NNS
cord-034340-3ksfpaf7	633	13	with	with	IN
cord-034340-3ksfpaf7	633	14	available	available	JJ
cord-034340-3ksfpaf7	633	15	data	datum	NNS
cord-034340-3ksfpaf7	633	16	.	.	.
cord-034340-3ksfpaf7	634	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	634	2	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	634	3	arthritis	arthritis	NN
cord-034340-3ksfpaf7	634	4	was	be	VBD
cord-034340-3ksfpaf7	634	5	the	the	DT
cord-034340-3ksfpaf7	634	6	most	most	RBS
cord-034340-3ksfpaf7	634	7	frequently	frequently	RB
cord-034340-3ksfpaf7	634	8	associated	associate	VBN
cord-034340-3ksfpaf7	634	9	disease	disease	NN
cord-034340-3ksfpaf7	634	10	,	,	,
cord-034340-3ksfpaf7	634	11	followed	follow	VBN
cord-034340-3ksfpaf7	634	12	by	by	IN
cord-034340-3ksfpaf7	634	13	systemic	systemic	JJ
cord-034340-3ksfpaf7	634	14	lupus	lupus	NN
cord-034340-3ksfpaf7	634	15	erythematosus	erythematosus	NN
cord-034340-3ksfpaf7	634	16	(	(	-LRB-
cord-034340-3ksfpaf7	634	17	16	16	CD
cord-034340-3ksfpaf7	634	18	and	and	CC
cord-034340-3ksfpaf7	634	19	8	8	CD
cord-034340-3ksfpaf7	634	20	cases	case	NNS
cord-034340-3ksfpaf7	634	21	,	,	,
cord-034340-3ksfpaf7	634	22	respectively	respectively	RB
cord-034340-3ksfpaf7	634	23	)	)	-RRB-
cord-034340-3ksfpaf7	634	24	.	.	.
cord-034340-3ksfpaf7	635	1	No	no	DT
cord-034340-3ksfpaf7	635	2	significant	significant	JJ
cord-034340-3ksfpaf7	635	3	differences	difference	NNS
cord-034340-3ksfpaf7	635	4	between	between	IN
cord-034340-3ksfpaf7	635	5	patients	patient	NNS
cord-034340-3ksfpaf7	635	6	with	with	IN
cord-034340-3ksfpaf7	635	7	or	or	CC
cord-034340-3ksfpaf7	635	8	without	without	IN
cord-034340-3ksfpaf7	635	9	parotitis	parotitis	NNP
cord-034340-3ksfpaf7	635	10	were	be	VBD
cord-034340-3ksfpaf7	635	11	found	find	VBN
cord-034340-3ksfpaf7	635	12	except	except	IN
cord-034340-3ksfpaf7	635	13	that	that	IN
cord-034340-3ksfpaf7	635	14	patients	patient	NNS
cord-034340-3ksfpaf7	635	15	with	with	IN
cord-034340-3ksfpaf7	635	16	parotitis	parotitis	NNP
cord-034340-3ksfpaf7	635	17	showed	show	VBD
cord-034340-3ksfpaf7	635	18	increased	increase	VBN
cord-034340-3ksfpaf7	635	19	levels	level	NNS
cord-034340-3ksfpaf7	635	20	of	of	IN
cord-034340-3ksfpaf7	635	21	CRP	CRP	NNP
cord-034340-3ksfpaf7	635	22	more	more	RBR
cord-034340-3ksfpaf7	635	23	frequently	frequently	RB
cord-034340-3ksfpaf7	635	24	than	than	IN
cord-034340-3ksfpaf7	635	25	those	those	DT
cord-034340-3ksfpaf7	635	26	without	without	IN
cord-034340-3ksfpaf7	635	27	it	-PRON-	PRP
cord-034340-3ksfpaf7	635	28	(	(	-LRB-
cord-034340-3ksfpaf7	635	29	p=	p=	NNP
cord-034340-3ksfpaf7	635	30	0.00	0.00	CD
cord-034340-3ksfpaf7	635	31	)	)	-RRB-
cord-034340-3ksfpaf7	635	32	.	.	.
cord-034340-3ksfpaf7	636	1	Patients	patient	NNS
cord-034340-3ksfpaf7	636	2	with	with	IN
cord-034340-3ksfpaf7	636	3	anti	anti	JJ
cord-034340-3ksfpaf7	636	4	-	-	JJ
cord-034340-3ksfpaf7	636	5	SSA	SSA	NNP
cord-034340-3ksfpaf7	636	6	/	/	SYM
cord-034340-3ksfpaf7	636	7	Ro	Ro	NNP
cord-034340-3ksfpaf7	636	8	had	have	VBD
cord-034340-3ksfpaf7	636	9	more	more	RBR
cord-034340-3ksfpaf7	636	10	frequently	frequently	RB
cord-034340-3ksfpaf7	636	11	a	a	DT
cord-034340-3ksfpaf7	636	12	positive	positive	JJ
cord-034340-3ksfpaf7	636	13	Schirmer	Schirmer	NNP
cord-034340-3ksfpaf7	636	14	test	test	NN
cord-034340-3ksfpaf7	636	15	(	(	-LRB-
cord-034340-3ksfpaf7	636	16	p=	p=	NNP
cord-034340-3ksfpaf7	636	17	0.04	0.04	CD
cord-034340-3ksfpaf7	636	18	)	)	-RRB-
cord-034340-3ksfpaf7	636	19	.	.	.
cord-034340-3ksfpaf7	637	1	The	the	DT
cord-034340-3ksfpaf7	637	2	presence	presence	NN
cord-034340-3ksfpaf7	637	3	of	of	IN
cord-034340-3ksfpaf7	637	4	RF	RF	NNP
cord-034340-3ksfpaf7	637	5	was	be	VBD
cord-034340-3ksfpaf7	637	6	significantly	significantly	RB
cord-034340-3ksfpaf7	637	7	associated	associate	VBN
cord-034340-3ksfpaf7	637	8	with	with	IN
cord-034340-3ksfpaf7	637	9	dry	dry	JJ
cord-034340-3ksfpaf7	637	10	mouth	mouth	NN
cord-034340-3ksfpaf7	637	11	(	(	-LRB-
cord-034340-3ksfpaf7	637	12	p=	p=	NN
cord-034340-3ksfpaf7	637	13	0.00	0.00	CD
cord-034340-3ksfpaf7	637	14	)	)	-RRB-
cord-034340-3ksfpaf7	637	15	,	,	,
cord-034340-3ksfpaf7	637	16	arthritis	arthritis	NN
cord-034340-3ksfpaf7	637	17	(	(	-LRB-
cord-034340-3ksfpaf7	637	18	p=	p=	NNP
cord-034340-3ksfpaf7	637	19	0.00	0.00	CD
cord-034340-3ksfpaf7	637	20	)	)	-RRB-
cord-034340-3ksfpaf7	637	21	,	,	,
cord-034340-3ksfpaf7	637	22	and	and	CC
cord-034340-3ksfpaf7	637	23	rash	rash	JJ
cord-034340-3ksfpaf7	637	24	(	(	-LRB-
cord-034340-3ksfpaf7	637	25	p=	p=	JJ
cord-034340-3ksfpaf7	637	26	0.04	0.04	CD
cord-034340-3ksfpaf7	637	27	)	)	-RRB-
cord-034340-3ksfpaf7	637	28	.	.	.
cord-034340-3ksfpaf7	638	1	A	a	DT
cord-034340-3ksfpaf7	638	2	positive	positive	JJ
cord-034340-3ksfpaf7	638	3	minor	minor	JJ
cord-034340-3ksfpaf7	638	4	salivary	salivary	NN
cord-034340-3ksfpaf7	638	5	biopsy	biopsy	NN
cord-034340-3ksfpaf7	638	6	was	be	VBD
cord-034340-3ksfpaf7	638	7	more	more	RBR
cord-034340-3ksfpaf7	638	8	common	common	JJ
cord-034340-3ksfpaf7	638	9	in	in	IN
cord-034340-3ksfpaf7	638	10	children	child	NNS
cord-034340-3ksfpaf7	638	11	with	with	IN
cord-034340-3ksfpaf7	638	12	dry	dry	JJ
cord-034340-3ksfpaf7	638	13	eyes	eye	NNS
cord-034340-3ksfpaf7	638	14	than	than	IN
cord-034340-3ksfpaf7	638	15	in	in	IN
cord-034340-3ksfpaf7	638	16	those	those	DT
cord-034340-3ksfpaf7	638	17	without	without	IN
cord-034340-3ksfpaf7	638	18	this	this	DT
cord-034340-3ksfpaf7	638	19	clinical	clinical	JJ
cord-034340-3ksfpaf7	638	20	feature	feature	NN
cord-034340-3ksfpaf7	638	21	(	(	-LRB-
cord-034340-3ksfpaf7	638	22	p=	p=	NNP
cord-034340-3ksfpaf7	638	23	0.02	0.02	CD
cord-034340-3ksfpaf7	638	24	)	)	-RRB-
cord-034340-3ksfpaf7	638	25	.	.	.
cord-034340-3ksfpaf7	639	1	Arthritis	arthritis	NN
cord-034340-3ksfpaf7	639	2	was	be	VBD
cord-034340-3ksfpaf7	639	3	more	more	RBR
cord-034340-3ksfpaf7	639	4	frequent	frequent	JJ
cord-034340-3ksfpaf7	639	5	in	in	IN
cord-034340-3ksfpaf7	639	6	patients	patient	NNS
cord-034340-3ksfpaf7	639	7	with	with	IN
cord-034340-3ksfpaf7	639	8	other	other	JJ
cord-034340-3ksfpaf7	639	9	diseases	disease	NNS
cord-034340-3ksfpaf7	639	10	than	than	IN
cord-034340-3ksfpaf7	639	11	in	in	IN
cord-034340-3ksfpaf7	639	12	those	those	DT
cord-034340-3ksfpaf7	639	13	with	with	IN
cord-034340-3ksfpaf7	639	14	primary	primary	JJ
cord-034340-3ksfpaf7	639	15	SS	SS	NNP
cord-034340-3ksfpaf7	639	16	(	(	-LRB-
cord-034340-3ksfpaf7	639	17	p=	p=	NNP
cord-034340-3ksfpaf7	639	18	0.00	0.00	CD
cord-034340-3ksfpaf7	639	19	)	)	-RRB-
cord-034340-3ksfpaf7	639	20	.	.	.
cord-034340-3ksfpaf7	640	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	640	2	further	further	RB
cord-034340-3ksfpaf7	640	3	investigated	investigate	VBD
cord-034340-3ksfpaf7	640	4	SS	SS	NNP
cord-034340-3ksfpaf7	640	5	features	feature	NNS
cord-034340-3ksfpaf7	640	6	according	accord	VBG
cord-034340-3ksfpaf7	640	7	to	to	IN
cord-034340-3ksfpaf7	640	8	the	the	DT
cord-034340-3ksfpaf7	640	9	age	age	NN
cord-034340-3ksfpaf7	640	10	groups	group	NNS
cord-034340-3ksfpaf7	640	11	(	(	-LRB-
cord-034340-3ksfpaf7	640	12	≤	≤	NNP
cord-034340-3ksfpaf7	640	13	6	6	CD
cord-034340-3ksfpaf7	640	14	years	year	NNS
cord-034340-3ksfpaf7	640	15	,	,	,
cord-034340-3ksfpaf7	640	16	7	7	CD
cord-034340-3ksfpaf7	640	17	-	-	SYM
cord-034340-3ksfpaf7	640	18	11	11	CD
cord-034340-3ksfpaf7	640	19	years	year	NNS
cord-034340-3ksfpaf7	640	20	,	,	,
cord-034340-3ksfpaf7	640	21	≥	≥	CD
cord-034340-3ksfpaf7	640	22	12	12	CD
cord-034340-3ksfpaf7	640	23	years	year	NNS
cord-034340-3ksfpaf7	640	24	)	)	-RRB-
cord-034340-3ksfpaf7	640	25	.	.	.
cord-034340-3ksfpaf7	641	1	Parotid	Parotid	NNP
cord-034340-3ksfpaf7	641	2	involvement	involvement	NN
cord-034340-3ksfpaf7	641	3	was	be	VBD
cord-034340-3ksfpaf7	641	4	inversely	inversely	RB
cord-034340-3ksfpaf7	641	5	proportional	proportional	JJ
cord-034340-3ksfpaf7	641	6	to	to	IN
cord-034340-3ksfpaf7	641	7	the	the	DT
cord-034340-3ksfpaf7	641	8	age	age	NN
cord-034340-3ksfpaf7	641	9	and	and	CC
cord-034340-3ksfpaf7	641	10	occurred	occur	VBD
cord-034340-3ksfpaf7	641	11	more	more	RBR
cord-034340-3ksfpaf7	641	12	frequently	frequently	RB
cord-034340-3ksfpaf7	641	13	in	in	IN
cord-034340-3ksfpaf7	641	14	younger	young	JJR
cord-034340-3ksfpaf7	641	15	patients	patient	NNS
cord-034340-3ksfpaf7	641	16	(	(	-LRB-
cord-034340-3ksfpaf7	641	17	79	79	CD
cord-034340-3ksfpaf7	641	18	%	%	NN
cord-034340-3ksfpaf7	641	19	of	of	IN
cord-034340-3ksfpaf7	641	20	those	those	DT
cord-034340-3ksfpaf7	641	21	≤	≤	NNS
cord-034340-3ksfpaf7	641	22	6	6	CD
cord-034340-3ksfpaf7	641	23	years	year	NNS
cord-034340-3ksfpaf7	641	24	;	;	:
cord-034340-3ksfpaf7	641	25	p=	p=	NN
cord-034340-3ksfpaf7	641	26	0.03	0.03	CD
cord-034340-3ksfpaf7	641	27	)	)	-RRB-
cord-034340-3ksfpaf7	641	28	.	.	.
cord-034340-3ksfpaf7	642	1	Interestingly	interestingly	RB
cord-034340-3ksfpaf7	642	2	,	,	,
cord-034340-3ksfpaf7	642	3	the	the	DT
cord-034340-3ksfpaf7	642	4	rate	rate	NN
cord-034340-3ksfpaf7	642	5	of	of	IN
cord-034340-3ksfpaf7	642	6	anti	anti	JJ
cord-034340-3ksfpaf7	642	7	-	-	JJ
cord-034340-3ksfpaf7	642	8	SSA	ssa	JJ
cord-034340-3ksfpaf7	642	9	/	/	SYM
cord-034340-3ksfpaf7	642	10	Ro	Ro	NNP
cord-034340-3ksfpaf7	642	11	positivity	positivity	NN
cord-034340-3ksfpaf7	642	12	increased	increase	VBD
cord-034340-3ksfpaf7	642	13	with	with	IN
cord-034340-3ksfpaf7	642	14	age	age	NN
cord-034340-3ksfpaf7	642	15	(	(	-LRB-
cord-034340-3ksfpaf7	642	16	97	97	CD
cord-034340-3ksfpaf7	642	17	%	%	NN
cord-034340-3ksfpaf7	642	18	of	of	IN
cord-034340-3ksfpaf7	642	19	those	those	DT
cord-034340-3ksfpaf7	642	20	≥	≥	CD
cord-034340-3ksfpaf7	642	21	12	12	CD
cord-034340-3ksfpaf7	642	22	years	year	NNS
cord-034340-3ksfpaf7	642	23	;	;	:
cord-034340-3ksfpaf7	642	24	p=	p=	NN
cord-034340-3ksfpaf7	642	25	0.00	0.00	CD
cord-034340-3ksfpaf7	642	26	)	)	-RRB-
cord-034340-3ksfpaf7	642	27	.	.	.
cord-034340-3ksfpaf7	643	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	643	2	:	:	:
cord-034340-3ksfpaf7	643	3	Even	even	RB
cord-034340-3ksfpaf7	643	4	though	though	IN
cord-034340-3ksfpaf7	643	5	parotitis	parotitis	NNP
cord-034340-3ksfpaf7	643	6	was	be	VBD
cord-034340-3ksfpaf7	643	7	the	the	DT
cord-034340-3ksfpaf7	643	8	most	most	RBS
cord-034340-3ksfpaf7	643	9	frequently	frequently	RB
cord-034340-3ksfpaf7	643	10	reported	report	VBN
cord-034340-3ksfpaf7	643	11	feature	feature	NN
cord-034340-3ksfpaf7	643	12	,	,	,
cord-034340-3ksfpaf7	643	13	a	a	DT
cord-034340-3ksfpaf7	643	14	wide	wide	JJ
cord-034340-3ksfpaf7	643	15	range	range	NN
cord-034340-3ksfpaf7	643	16	of	of	IN
cord-034340-3ksfpaf7	643	17	clinical	clinical	JJ
cord-034340-3ksfpaf7	643	18	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	643	19	in	in	IN
cord-034340-3ksfpaf7	643	20	children	child	NNS
cord-034340-3ksfpaf7	643	21	with	with	IN
cord-034340-3ksfpaf7	643	22	SS	SS	NNP
cord-034340-3ksfpaf7	643	23	has	have	VBZ
cord-034340-3ksfpaf7	643	24	been	be	VBN
cord-034340-3ksfpaf7	643	25	reported	report	VBN
cord-034340-3ksfpaf7	643	26	so	so	RB
cord-034340-3ksfpaf7	643	27	far	far	RB
cord-034340-3ksfpaf7	643	28	.	.	.
cord-034340-3ksfpaf7	644	1	A	a	DT
cord-034340-3ksfpaf7	644	2	better	well	JJR
cord-034340-3ksfpaf7	644	3	knowledge	knowledge	NN
cord-034340-3ksfpaf7	644	4	of	of	IN
cord-034340-3ksfpaf7	644	5	cSS	cSS	NNP
cord-034340-3ksfpaf7	644	6	features	feature	NNS
cord-034340-3ksfpaf7	644	7	will	will	MD
cord-034340-3ksfpaf7	644	8	help	help	VB
cord-034340-3ksfpaf7	644	9	to	to	TO
cord-034340-3ksfpaf7	644	10	pave	pave	VB
cord-034340-3ksfpaf7	644	11	the	the	DT
cord-034340-3ksfpaf7	644	12	way	way	NN
cord-034340-3ksfpaf7	644	13	for	for	IN
cord-034340-3ksfpaf7	644	14	the	the	DT
cord-034340-3ksfpaf7	644	15	development	development	NN
cord-034340-3ksfpaf7	644	16	of	of	IN
cord-034340-3ksfpaf7	644	17	cSS	css	FW
cord-034340-3ksfpaf7	644	18	specific	specific	JJ
cord-034340-3ksfpaf7	644	19	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	644	20	criteria	criterion	NNS
cord-034340-3ksfpaf7	644	21	.	.	.
cord-034340-3ksfpaf7	645	1	None	none	NN
cord-034340-3ksfpaf7	645	2	declared	declare	VBD
cord-034340-3ksfpaf7	645	3	Introduction	introduction	NN
cord-034340-3ksfpaf7	645	4	:	:	:
cord-034340-3ksfpaf7	645	5	Pachydermodactyly	Pachydermodactyly	NNP
cord-034340-3ksfpaf7	645	6	(	(	-LRB-
cord-034340-3ksfpaf7	645	7	PDD	PDD	NNP
cord-034340-3ksfpaf7	645	8	)	)	-RRB-
cord-034340-3ksfpaf7	645	9	is	be	VBZ
cord-034340-3ksfpaf7	645	10	a	a	DT
cord-034340-3ksfpaf7	645	11	rare	rare	JJ
cord-034340-3ksfpaf7	645	12	benign	benign	JJ
cord-034340-3ksfpaf7	645	13	fibromatosis	fibromatosis	NN
cord-034340-3ksfpaf7	645	14	,	,	,
cord-034340-3ksfpaf7	645	15	characterized	characterize	VBN
cord-034340-3ksfpaf7	645	16	by	by	IN
cord-034340-3ksfpaf7	645	17	progressive	progressive	JJ
cord-034340-3ksfpaf7	645	18	painless	painless	JJ
cord-034340-3ksfpaf7	645	19	swelling	swelling	NN
cord-034340-3ksfpaf7	645	20	of	of	IN
cord-034340-3ksfpaf7	645	21	soft	soft	JJ
cord-034340-3ksfpaf7	645	22	tissue	tissue	NN
cord-034340-3ksfpaf7	645	23	of	of	IN
cord-034340-3ksfpaf7	645	24	proximal	proximal	JJ
cord-034340-3ksfpaf7	645	25	interphalangeal	interphalangeal	NN
cord-034340-3ksfpaf7	645	26	(	(	-LRB-
cord-034340-3ksfpaf7	645	27	PIP	PIP	NNP
cord-034340-3ksfpaf7	645	28	)	)	-RRB-
cord-034340-3ksfpaf7	645	29	joints	joint	NNS
cord-034340-3ksfpaf7	645	30	without	without	IN
cord-034340-3ksfpaf7	645	31	inflammation	inflammation	NN
cord-034340-3ksfpaf7	645	32	signs	sign	NNS
cord-034340-3ksfpaf7	645	33	.	.	.
cord-034340-3ksfpaf7	646	1	Generally	generally	RB
cord-034340-3ksfpaf7	646	2	PDD	PDD	NNP
cord-034340-3ksfpaf7	646	3	affects	affect	VBZ
cord-034340-3ksfpaf7	646	4	PIP	PIP	NNP
cord-034340-3ksfpaf7	646	5	joints	joint	NNS
cord-034340-3ksfpaf7	646	6	of	of	IN
cord-034340-3ksfpaf7	646	7	the	the	DT
cord-034340-3ksfpaf7	646	8	fingers	finger	NNS
cord-034340-3ksfpaf7	646	9	,	,	,
cord-034340-3ksfpaf7	646	10	rarely	rarely	RB
cord-034340-3ksfpaf7	646	11	of	of	IN
cord-034340-3ksfpaf7	646	12	the	the	DT
cord-034340-3ksfpaf7	646	13	thumb	thumb	NN
cord-034340-3ksfpaf7	646	14	.	.	.
cord-034340-3ksfpaf7	647	1	The	the	DT
cord-034340-3ksfpaf7	647	2	involvement	involvement	NN
cord-034340-3ksfpaf7	647	3	is	be	VBZ
cord-034340-3ksfpaf7	647	4	typically	typically	RB
cord-034340-3ksfpaf7	647	5	symmetrical	symmetrical	JJ
cord-034340-3ksfpaf7	647	6	,	,	,
cord-034340-3ksfpaf7	647	7	in	in	IN
cord-034340-3ksfpaf7	647	8	few	few	JJ
cord-034340-3ksfpaf7	647	9	cases	case	NNS
cord-034340-3ksfpaf7	647	10	unilateral	unilateral	JJ
cord-034340-3ksfpaf7	647	11	.	.	.
cord-034340-3ksfpaf7	648	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	648	2	usually	usually	RB
cord-034340-3ksfpaf7	648	3	occurs	occur	VBZ
cord-034340-3ksfpaf7	648	4	more	more	RBR
cord-034340-3ksfpaf7	648	5	frequently	frequently	RB
cord-034340-3ksfpaf7	648	6	in	in	IN
cord-034340-3ksfpaf7	648	7	young	young	JJ
cord-034340-3ksfpaf7	648	8	males	male	NNS
cord-034340-3ksfpaf7	648	9	.	.	.
cord-034340-3ksfpaf7	649	1	Etiology	etiology	NN
cord-034340-3ksfpaf7	649	2	is	be	VBZ
cord-034340-3ksfpaf7	649	3	unknown	unknown	JJ
cord-034340-3ksfpaf7	649	4	,	,	,
cord-034340-3ksfpaf7	649	5	but	but	CC
cord-034340-3ksfpaf7	649	6	it	-PRON-	PRP
cord-034340-3ksfpaf7	649	7	arises	arise	VBZ
cord-034340-3ksfpaf7	649	8	from	from	IN
cord-034340-3ksfpaf7	649	9	mechanical	mechanical	JJ
cord-034340-3ksfpaf7	649	10	stimulation	stimulation	NN
cord-034340-3ksfpaf7	649	11	of	of	IN
cord-034340-3ksfpaf7	649	12	periarticular	periarticular	JJ
cord-034340-3ksfpaf7	649	13	skin	skin	NN
cord-034340-3ksfpaf7	649	14	(	(	-LRB-
cord-034340-3ksfpaf7	649	15	i.e	i.e	CC
cord-034340-3ksfpaf7	649	16	repetitive	repetitive	JJ
cord-034340-3ksfpaf7	649	17	rubbing	rubbing	NN
cord-034340-3ksfpaf7	649	18	,	,	,
cord-034340-3ksfpaf7	649	19	interlacing	interlacing	NN
cord-034340-3ksfpaf7	649	20	,	,	,
cord-034340-3ksfpaf7	649	21	and	and	CC
cord-034340-3ksfpaf7	649	22	cracking	cracking	NN
cord-034340-3ksfpaf7	649	23	of	of	IN
cord-034340-3ksfpaf7	649	24	fingers	finger	NNS
cord-034340-3ksfpaf7	649	25	)	)	-RRB-
cord-034340-3ksfpaf7	649	26	.	.	.
cord-034340-3ksfpaf7	650	1	PDD	PDD	NNP
cord-034340-3ksfpaf7	650	2	has	have	VBZ
cord-034340-3ksfpaf7	650	3	to	to	TO
cord-034340-3ksfpaf7	650	4	be	be	VB
cord-034340-3ksfpaf7	650	5	considered	consider	VBN
cord-034340-3ksfpaf7	650	6	in	in	IN
cord-034340-3ksfpaf7	650	7	the	the	DT
cord-034340-3ksfpaf7	650	8	differential	differential	JJ
cord-034340-3ksfpaf7	650	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	650	10	of	of	IN
cord-034340-3ksfpaf7	650	11	arthritis	arthritis	NN
cord-034340-3ksfpaf7	650	12	(	(	-LRB-
cord-034340-3ksfpaf7	650	13	i.e.	i.e.	FW
cord-034340-3ksfpaf7	650	14	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	650	15	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	650	16	arthritis	arthritis	NN
cord-034340-3ksfpaf7	650	17	,	,	,
cord-034340-3ksfpaf7	650	18	JIA	JIA	NNP
cord-034340-3ksfpaf7	650	19	)	)	-RRB-
cord-034340-3ksfpaf7	650	20	and	and	CC
cord-034340-3ksfpaf7	650	21	many	many	JJ
cord-034340-3ksfpaf7	650	22	syndromes	syndrome	NNS
cord-034340-3ksfpaf7	650	23	(	(	-LRB-
cord-034340-3ksfpaf7	650	24	i.e.	i.e.	FW
cord-034340-3ksfpaf7	650	25	progressive	progressive	JJ
cord-034340-3ksfpaf7	650	26	pseudorheumatoid	pseudorheumatoid	FW
cord-034340-3ksfpaf7	650	27	dysplasia	dysplasia	NN
cord-034340-3ksfpaf7	650	28	)	)	-RRB-
cord-034340-3ksfpaf7	650	29	.	.	.
cord-034340-3ksfpaf7	651	1	Prognosis	prognosis	NN
cord-034340-3ksfpaf7	651	2	is	be	VBZ
cord-034340-3ksfpaf7	651	3	good	good	JJ
cord-034340-3ksfpaf7	651	4	with	with	IN
cord-034340-3ksfpaf7	651	5	cessation	cessation	NN
cord-034340-3ksfpaf7	651	6	of	of	IN
cord-034340-3ksfpaf7	651	7	mechanical	mechanical	JJ
cord-034340-3ksfpaf7	651	8	stimulation	stimulation	NN
cord-034340-3ksfpaf7	651	9	1	1	CD
cord-034340-3ksfpaf7	652	1	The	the	DT
cord-034340-3ksfpaf7	652	2	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	652	3	paroxysmal	paroxysmal	JJ
cord-034340-3ksfpaf7	652	4	appearance	appearance	NN
cord-034340-3ksfpaf7	652	5	of	of	IN
cord-034340-3ksfpaf7	652	6	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	652	7	lumps	lump	NNS
cord-034340-3ksfpaf7	652	8	(	(	-LRB-
cord-034340-3ksfpaf7	652	9	local	local	JJ
cord-034340-3ksfpaf7	652	10	erythematous	erythematous	JJ
cord-034340-3ksfpaf7	652	11	tender	tender	NN
cord-034340-3ksfpaf7	652	12	swellings	swelling	NNS
cord-034340-3ksfpaf7	652	13	,	,	,
cord-034340-3ksfpaf7	652	14	which	which	WDT
cord-034340-3ksfpaf7	652	15	partially	partially	RB
cord-034340-3ksfpaf7	652	16	respond	respond	VBP
cord-034340-3ksfpaf7	652	17	to	to	IN
cord-034340-3ksfpaf7	652	18	antiinflammatory	antiinflammatory	JJ
cord-034340-3ksfpaf7	652	19	agents	agent	NNS
cord-034340-3ksfpaf7	652	20	)	)	-RRB-
cord-034340-3ksfpaf7	652	21	,	,	,
cord-034340-3ksfpaf7	652	22	accompanied	accompany	VBN
cord-034340-3ksfpaf7	652	23	by	by	IN
cord-034340-3ksfpaf7	652	24	elevated	elevated	JJ
cord-034340-3ksfpaf7	652	25	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	652	26	markers	marker	NNS
cord-034340-3ksfpaf7	652	27	during	during	IN
cord-034340-3ksfpaf7	652	28	flares	flare	NNS
cord-034340-3ksfpaf7	652	29	,	,	,
cord-034340-3ksfpaf7	652	30	suggest	suggest	VBP
cord-034340-3ksfpaf7	652	31	that	that	IN
cord-034340-3ksfpaf7	652	32	FOP	FOP	NNP
cord-034340-3ksfpaf7	652	33	may	may	MD
cord-034340-3ksfpaf7	652	34	be	be	VB
cord-034340-3ksfpaf7	652	35	an	an	DT
cord-034340-3ksfpaf7	652	36	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	652	37	disease	disease	NN
cord-034340-3ksfpaf7	652	38	.	.	.
cord-034340-3ksfpaf7	653	1	The	the	DT
cord-034340-3ksfpaf7	653	2	episodic	episodic	JJ
cord-034340-3ksfpaf7	653	3	formation	formation	NN
cord-034340-3ksfpaf7	653	4	of	of	IN
cord-034340-3ksfpaf7	653	5	bone	bone	NN
cord-034340-3ksfpaf7	653	6	,	,	,
cord-034340-3ksfpaf7	653	7	often	often	RB
cord-034340-3ksfpaf7	653	8	following	follow	VBG
cord-034340-3ksfpaf7	653	9	a	a	DT
cord-034340-3ksfpaf7	653	10	trivial	trivial	JJ
cord-034340-3ksfpaf7	653	11	injury	injury	NN
cord-034340-3ksfpaf7	653	12	,	,	,
cord-034340-3ksfpaf7	653	13	suggests	suggest	VBZ
cord-034340-3ksfpaf7	653	14	that	that	IN
cord-034340-3ksfpaf7	653	15	innate	innate	JJ
cord-034340-3ksfpaf7	653	16	immune	immune	NN
cord-034340-3ksfpaf7	653	17	-	-	HYPH
cord-034340-3ksfpaf7	653	18	related	relate	VBN
cord-034340-3ksfpaf7	653	19	triggers	trigger	NNS
cord-034340-3ksfpaf7	653	20	induce	induce	VBP
cord-034340-3ksfpaf7	653	21	tissue	tissue	NN
cord-034340-3ksfpaf7	653	22	transformation	transformation	NN
cord-034340-3ksfpaf7	653	23	through	through	IN
cord-034340-3ksfpaf7	653	24	the	the	DT
cord-034340-3ksfpaf7	653	25	BMP	BMP	NNP
cord-034340-3ksfpaf7	653	26	pathway	pathway	NN
cord-034340-3ksfpaf7	653	27	.	.	.
cord-034340-3ksfpaf7	654	1	Moreover	moreover	RB
cord-034340-3ksfpaf7	654	2	,	,	,
cord-034340-3ksfpaf7	654	3	interleukin-1β	interleukin-1β	NNP
cord-034340-3ksfpaf7	654	4	(	(	-LRB-
cord-034340-3ksfpaf7	654	5	IL-1β	IL-1β	NNP
cord-034340-3ksfpaf7	654	6	)	)	-RRB-
cord-034340-3ksfpaf7	654	7	,	,	,
cord-034340-3ksfpaf7	654	8	a	a	DT
cord-034340-3ksfpaf7	654	9	well	well	RB
cord-034340-3ksfpaf7	654	10	-	-	HYPH
cord-034340-3ksfpaf7	654	11	known	know	VBN
cord-034340-3ksfpaf7	654	12	mediator	mediator	NN
cord-034340-3ksfpaf7	654	13	of	of	IN
cord-034340-3ksfpaf7	654	14	the	the	DT
cord-034340-3ksfpaf7	654	15	innate	innate	JJ
cord-034340-3ksfpaf7	654	16	immune	immune	JJ
cord-034340-3ksfpaf7	654	17	system	system	NN
cord-034340-3ksfpaf7	654	18	,	,	,
cord-034340-3ksfpaf7	654	19	has	have	VBZ
cord-034340-3ksfpaf7	654	20	been	be	VBN
cord-034340-3ksfpaf7	654	21	linked	link	VBN
cord-034340-3ksfpaf7	654	22	to	to	IN
cord-034340-3ksfpaf7	654	23	HO	HO	NNP
cord-034340-3ksfpaf7	654	24	and	and	CC
cord-034340-3ksfpaf7	654	25	mineralization	mineralization	NN
cord-034340-3ksfpaf7	654	26	in	in	IN
cord-034340-3ksfpaf7	654	27	mesenchymal	mesenchymal	JJ
cord-034340-3ksfpaf7	654	28	stem	stem	NN
cord-034340-3ksfpaf7	654	29	cell	cell	NN
cord-034340-3ksfpaf7	654	30	cultures	culture	NNS
cord-034340-3ksfpaf7	654	31	derived	derive	VBN
cord-034340-3ksfpaf7	654	32	from	from	IN
cord-034340-3ksfpaf7	654	33	human	human	JJ
cord-034340-3ksfpaf7	654	34	bone	bone	NN
cord-034340-3ksfpaf7	654	35	marrow	marrow	NN
cord-034340-3ksfpaf7	654	36	.	.	.
cord-034340-3ksfpaf7	655	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	655	2	hypothesized	hypothesize	VBD
cord-034340-3ksfpaf7	655	3	that	that	IN
cord-034340-3ksfpaf7	655	4	treating	treat	VBG
cord-034340-3ksfpaf7	655	5	FOP	fop	NN
cord-034340-3ksfpaf7	655	6	patients	patient	NNS
cord-034340-3ksfpaf7	655	7	with	with	IN
cord-034340-3ksfpaf7	655	8	anti	anti	JJ
cord-034340-3ksfpaf7	655	9	-	-	JJ
cord-034340-3ksfpaf7	655	10	IL-1	il-1	JJ
cord-034340-3ksfpaf7	655	11	agents	agent	NNS
cord-034340-3ksfpaf7	655	12	could	could	MD
cord-034340-3ksfpaf7	655	13	help	help	VB
cord-034340-3ksfpaf7	655	14	ameliorate	ameliorate	VB
cord-034340-3ksfpaf7	655	15	the	the	DT
cord-034340-3ksfpaf7	655	16	progression	progression	NN
cord-034340-3ksfpaf7	655	17	of	of	IN
cord-034340-3ksfpaf7	655	18	this	this	DT
cord-034340-3ksfpaf7	655	19	devastating	devastating	JJ
cord-034340-3ksfpaf7	655	20	disease	disease	NN
cord-034340-3ksfpaf7	655	21	.	.	.
cord-034340-3ksfpaf7	656	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	656	2	report	report	VBP
cord-034340-3ksfpaf7	656	3	our	-PRON-	PRP$
cord-034340-3ksfpaf7	656	4	experience	experience	NN
cord-034340-3ksfpaf7	656	5	treating	treat	VBG
cord-034340-3ksfpaf7	656	6	two	two	CD
cord-034340-3ksfpaf7	656	7	FOP	FOP	NNP
cord-034340-3ksfpaf7	656	8	patients	patient	NNS
cord-034340-3ksfpaf7	656	9	with	with	IN
cord-034340-3ksfpaf7	656	10	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	656	11	and	and	CC
cord-034340-3ksfpaf7	656	12	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	656	13	.	.	.
cord-034340-3ksfpaf7	657	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	657	2	:	:	:
cord-034340-3ksfpaf7	657	3	To	to	TO
cord-034340-3ksfpaf7	657	4	decrease	decrease	VB
cord-034340-3ksfpaf7	657	5	the	the	DT
cord-034340-3ksfpaf7	657	6	frequency	frequency	NN
cord-034340-3ksfpaf7	657	7	of	of	IN
cord-034340-3ksfpaf7	657	8	FOP	fop	NN
cord-034340-3ksfpaf7	657	9	paroxysms	paroxysm	NNS
cord-034340-3ksfpaf7	657	10	,	,	,
cord-034340-3ksfpaf7	657	11	and/or	and/or	CC
cord-034340-3ksfpaf7	657	12	limit	limit	VB
cord-034340-3ksfpaf7	657	13	the	the	DT
cord-034340-3ksfpaf7	657	14	symptoms	symptom	NNS
cord-034340-3ksfpaf7	657	15	and	and	CC
cord-034340-3ksfpaf7	657	16	extent	extent	NN
cord-034340-3ksfpaf7	657	17	of	of	IN
cord-034340-3ksfpaf7	657	18	residual	residual	JJ
cord-034340-3ksfpaf7	657	19	lesions	lesion	NNS
cord-034340-3ksfpaf7	657	20	,	,	,
cord-034340-3ksfpaf7	657	21	by	by	IN
cord-034340-3ksfpaf7	657	22	using	use	VBG
cord-034340-3ksfpaf7	657	23	anti	anti	JJ
cord-034340-3ksfpaf7	657	24	-	-	JJ
cord-034340-3ksfpaf7	657	25	IL-1	il-1	JJ
cord-034340-3ksfpaf7	657	26	agents	agent	NNS
cord-034340-3ksfpaf7	657	27	.	.	.
cord-034340-3ksfpaf7	658	1	Methods	method	NNS
cord-034340-3ksfpaf7	658	2	:	:	:
cord-034340-3ksfpaf7	659	1	Patients	patient	NNS
cord-034340-3ksfpaf7	659	2	'	'	POS
cord-034340-3ksfpaf7	659	3	data	datum	NNS
cord-034340-3ksfpaf7	659	4	and	and	CC
cord-034340-3ksfpaf7	659	5	blood	blood	NN
cord-034340-3ksfpaf7	659	6	IL-1	IL-1	NNP
cord-034340-3ksfpaf7	659	7	levels	level	NNS
cord-034340-3ksfpaf7	659	8	were	be	VBD
cord-034340-3ksfpaf7	659	9	analyzed	analyze	VBN
cord-034340-3ksfpaf7	659	10	to	to	TO
cord-034340-3ksfpaf7	659	11	characterize	characterize	VB
cord-034340-3ksfpaf7	659	12	the	the	DT
cord-034340-3ksfpaf7	659	13	efficacy	efficacy	NN
cord-034340-3ksfpaf7	659	14	of	of	IN
cord-034340-3ksfpaf7	659	15	anti	anti	JJ
cord-034340-3ksfpaf7	659	16	-	-	JJ
cord-034340-3ksfpaf7	659	17	IL-1	il-1	JJ
cord-034340-3ksfpaf7	659	18	treatments	treatment	NNS
cord-034340-3ksfpaf7	659	19	in	in	IN
cord-034340-3ksfpaf7	659	20	ameliorating	ameliorate	VBG
cord-034340-3ksfpaf7	659	21	the	the	DT
cord-034340-3ksfpaf7	659	22	natural	natural	JJ
cord-034340-3ksfpaf7	659	23	progression	progression	NN
cord-034340-3ksfpaf7	659	24	of	of	IN
cord-034340-3ksfpaf7	659	25	FOP	fop	NN
cord-034340-3ksfpaf7	659	26	.	.	.
cord-034340-3ksfpaf7	660	1	Results	result	NNS
cord-034340-3ksfpaf7	660	2	:	:	:
cord-034340-3ksfpaf7	661	1	A	a	DT
cord-034340-3ksfpaf7	661	2	13.5	13.5	CD
cord-034340-3ksfpaf7	661	3	year	year	NN
cord-034340-3ksfpaf7	661	4	old	old	JJ
cord-034340-3ksfpaf7	661	5	boy	boy	NN
cord-034340-3ksfpaf7	661	6	and	and	CC
cord-034340-3ksfpaf7	661	7	a	a	DT
cord-034340-3ksfpaf7	661	8	5	5	CD
cord-034340-3ksfpaf7	661	9	year	year	NN
cord-034340-3ksfpaf7	661	10	old	old	JJ
cord-034340-3ksfpaf7	661	11	girl	girl	NN
cord-034340-3ksfpaf7	661	12	were	be	VBD
cord-034340-3ksfpaf7	661	13	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	661	14	with	with	IN
cord-034340-3ksfpaf7	661	15	FOP	FOP	NNP
cord-034340-3ksfpaf7	661	16	,	,	,
cord-034340-3ksfpaf7	661	17	both	both	DT
cord-034340-3ksfpaf7	661	18	clinically	clinically	RB
cord-034340-3ksfpaf7	661	19	and	and	CC
cord-034340-3ksfpaf7	661	20	genetically	genetically	RB
cord-034340-3ksfpaf7	661	21	(	(	-LRB-
cord-034340-3ksfpaf7	661	22	the	the	DT
cord-034340-3ksfpaf7	661	23	typical	typical	JJ
cord-034340-3ksfpaf7	661	24	R206H	r206h	NN
cord-034340-3ksfpaf7	661	25	mutation	mutation	NN
cord-034340-3ksfpaf7	661	26	was	be	VBD
cord-034340-3ksfpaf7	661	27	found	find	VBN
cord-034340-3ksfpaf7	661	28	)	)	-RRB-
cord-034340-3ksfpaf7	661	29	.	.	.
cord-034340-3ksfpaf7	662	1	Various	various	JJ
cord-034340-3ksfpaf7	662	2	treatments	treatment	NNS
cord-034340-3ksfpaf7	662	3	,	,	,
cord-034340-3ksfpaf7	662	4	including	include	VBG
cord-034340-3ksfpaf7	662	5	high	high	JJ
cord-034340-3ksfpaf7	662	6	-	-	HYPH
cord-034340-3ksfpaf7	662	7	dose	dose	NN
cord-034340-3ksfpaf7	662	8	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	662	9	,	,	,
cord-034340-3ksfpaf7	662	10	pamidronate	pamidronate	JJ
cord-034340-3ksfpaf7	662	11	infusions	infusion	NNS
cord-034340-3ksfpaf7	662	12	,	,	,
cord-034340-3ksfpaf7	662	13	celecoxib	celecoxib	NNP
cord-034340-3ksfpaf7	662	14	,	,	,
cord-034340-3ksfpaf7	662	15	monteleukast	monteleukast	NNP
cord-034340-3ksfpaf7	662	16	and	and	CC
cord-034340-3ksfpaf7	662	17	sirolimus	sirolimus	NNP
cord-034340-3ksfpaf7	662	18	,	,	,
cord-034340-3ksfpaf7	662	19	did	do	VBD
cord-034340-3ksfpaf7	662	20	not	not	RB
cord-034340-3ksfpaf7	662	21	change	change	VB
cord-034340-3ksfpaf7	662	22	the	the	DT
cord-034340-3ksfpaf7	662	23	course	course	NN
cord-034340-3ksfpaf7	662	24	of	of	IN
cord-034340-3ksfpaf7	662	25	the	the	DT
cord-034340-3ksfpaf7	662	26	disease	disease	NN
cord-034340-3ksfpaf7	662	27	.	.	.
cord-034340-3ksfpaf7	663	1	Both	both	DT
cord-034340-3ksfpaf7	663	2	patients	patient	NNS
cord-034340-3ksfpaf7	663	3	are	be	VBP
cord-034340-3ksfpaf7	663	4	receiving	receive	VBG
cord-034340-3ksfpaf7	663	5	canakinumab	canakinumab	NNS
cord-034340-3ksfpaf7	663	6	(	(	-LRB-
cord-034340-3ksfpaf7	663	7	the	the	DT
cord-034340-3ksfpaf7	663	8	male	male	JJ
cord-034340-3ksfpaf7	663	9	patient	patient	NN
cord-034340-3ksfpaf7	663	10	was	be	VBD
cord-034340-3ksfpaf7	663	11	initially	initially	RB
cord-034340-3ksfpaf7	663	12	treated	treat	VBN
cord-034340-3ksfpaf7	663	13	with	with	IN
cord-034340-3ksfpaf7	663	14	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	663	15	)	)	-RRB-
cord-034340-3ksfpaf7	663	16	.	.	.
cord-034340-3ksfpaf7	664	1	The	the	DT
cord-034340-3ksfpaf7	664	2	male	male	JJ
cord-034340-3ksfpaf7	664	3	patient	patient	NN
cord-034340-3ksfpaf7	664	4	has	have	VBZ
cord-034340-3ksfpaf7	664	5	been	be	VBN
cord-034340-3ksfpaf7	664	6	treated	treat	VBN
cord-034340-3ksfpaf7	664	7	for	for	IN
cord-034340-3ksfpaf7	664	8	over	over	IN
cord-034340-3ksfpaf7	664	9	2	2	CD
cord-034340-3ksfpaf7	664	10	years	year	NNS
cord-034340-3ksfpaf7	664	11	.	.	.
cord-034340-3ksfpaf7	665	1	Flare	flare	NN
cord-034340-3ksfpaf7	665	2	rate	rate	NN
cord-034340-3ksfpaf7	665	3	was	be	VBD
cord-034340-3ksfpaf7	665	4	markedly	markedly	RB
cord-034340-3ksfpaf7	665	5	reduced	reduce	VBN
cord-034340-3ksfpaf7	665	6	from	from	IN
cord-034340-3ksfpaf7	665	7	one	one	CD
cord-034340-3ksfpaf7	665	8	new	new	JJ
cord-034340-3ksfpaf7	665	9	lump	lump	NN
cord-034340-3ksfpaf7	665	10	every	every	DT
cord-034340-3ksfpaf7	665	11	8	8	CD
cord-034340-3ksfpaf7	665	12	days	day	NNS
cord-034340-3ksfpaf7	665	13	to	to	IN
cord-034340-3ksfpaf7	665	14	approximately	approximately	RB
cord-034340-3ksfpaf7	665	15	one	one	CD
cord-034340-3ksfpaf7	665	16	every	every	DT
cord-034340-3ksfpaf7	665	17	25	25	CD
cord-034340-3ksfpaf7	665	18	days	day	NNS
cord-034340-3ksfpaf7	665	19	(	(	-LRB-
cord-034340-3ksfpaf7	665	20	Figure	figure	NN
cord-034340-3ksfpaf7	665	21	1	1	CD
cord-034340-3ksfpaf7	665	22	)	)	-RRB-
cord-034340-3ksfpaf7	665	23	.	.	.
cord-034340-3ksfpaf7	666	1	The	the	DT
cord-034340-3ksfpaf7	666	2	lumps	lump	NNS
cord-034340-3ksfpaf7	666	3	involved	involve	VBN
cord-034340-3ksfpaf7	666	4	in	in	IN
cord-034340-3ksfpaf7	666	5	almost	almost	RB
cord-034340-3ksfpaf7	666	6	all	all	DT
cord-034340-3ksfpaf7	666	7	of	of	IN
cord-034340-3ksfpaf7	666	8	these	these	DT
cord-034340-3ksfpaf7	666	9	flares	flare	NNS
cord-034340-3ksfpaf7	666	10	are	be	VBP
cord-034340-3ksfpaf7	666	11	the	the	DT
cord-034340-3ksfpaf7	666	12	same	same	JJ
cord-034340-3ksfpaf7	666	13	:	:	:
cord-034340-3ksfpaf7	666	14	at	at	IN
cord-034340-3ksfpaf7	666	15	the	the	DT
cord-034340-3ksfpaf7	666	16	left	left	JJ
cord-034340-3ksfpaf7	666	17	scapular	scapular	JJ
cord-034340-3ksfpaf7	666	18	base	base	NN
cord-034340-3ksfpaf7	666	19	and	and	CC
cord-034340-3ksfpaf7	666	20	within	within	IN
cord-034340-3ksfpaf7	666	21	the	the	DT
cord-034340-3ksfpaf7	666	22	sternocleidomastoid	sternocleidomastoid	JJ
cord-034340-3ksfpaf7	666	23	muscle	muscle	NN
cord-034340-3ksfpaf7	666	24	.	.	.
cord-034340-3ksfpaf7	667	1	The	the	DT
cord-034340-3ksfpaf7	667	2	female	female	JJ
cord-034340-3ksfpaf7	667	3	patient	patient	NN
cord-034340-3ksfpaf7	667	4	has	have	VBZ
cord-034340-3ksfpaf7	667	5	been	be	VBN
cord-034340-3ksfpaf7	667	6	treated	treat	VBN
cord-034340-3ksfpaf7	667	7	for	for	IN
cord-034340-3ksfpaf7	667	8	a	a	DT
cord-034340-3ksfpaf7	667	9	year	year	NN
cord-034340-3ksfpaf7	667	10	,	,	,
cord-034340-3ksfpaf7	667	11	and	and	CC
cord-034340-3ksfpaf7	667	12	has	have	VBZ
cord-034340-3ksfpaf7	667	13	not	not	RB
cord-034340-3ksfpaf7	667	14	experienced	experience	VBN
cord-034340-3ksfpaf7	667	15	any	any	DT
cord-034340-3ksfpaf7	667	16	HO	HO	NNP
cord-034340-3ksfpaf7	667	17	flares	flare	NNS
cord-034340-3ksfpaf7	667	18	during	during	IN
cord-034340-3ksfpaf7	667	19	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	667	20	treatment	treatment	NN
cord-034340-3ksfpaf7	667	21	.	.	.
cord-034340-3ksfpaf7	668	1	Temporarily	temporarily	RB
cord-034340-3ksfpaf7	668	2	withholding	withhold	VBG
cord-034340-3ksfpaf7	668	3	canakinumab	canakinumab	NNS
cord-034340-3ksfpaf7	668	4	in	in	IN
cord-034340-3ksfpaf7	668	5	both	both	DT
cord-034340-3ksfpaf7	668	6	patients	patient	NNS
cord-034340-3ksfpaf7	668	7	,	,	,
cord-034340-3ksfpaf7	668	8	led	lead	VBD
cord-034340-3ksfpaf7	668	9	to	to	IN
cord-034340-3ksfpaf7	668	10	serious	serious	JJ
cord-034340-3ksfpaf7	668	11	flares	flare	NNS
cord-034340-3ksfpaf7	668	12	8	8	CD
cord-034340-3ksfpaf7	668	13	weeks	week	NNS
cord-034340-3ksfpaf7	668	14	after	after	IN
cord-034340-3ksfpaf7	668	15	the	the	DT
cord-034340-3ksfpaf7	668	16	last	last	JJ
cord-034340-3ksfpaf7	668	17	dose	dose	NN
cord-034340-3ksfpaf7	668	18	.	.	.
cord-034340-3ksfpaf7	669	1	Notably	notably	RB
cord-034340-3ksfpaf7	669	2	,	,	,
cord-034340-3ksfpaf7	669	3	while	while	IN
cord-034340-3ksfpaf7	669	4	undetectable	undetectable	JJ
cord-034340-3ksfpaf7	669	5	levels	level	NNS
cord-034340-3ksfpaf7	669	6	of	of	IN
cord-034340-3ksfpaf7	669	7	IL-1β	il-1β	NN
cord-034340-3ksfpaf7	669	8	(	(	-LRB-
cord-034340-3ksfpaf7	669	9	<	<	XX
cord-034340-3ksfpaf7	669	10	0.125	0.125	CD
cord-034340-3ksfpaf7	669	11	pg	pg	NN
cord-034340-3ksfpaf7	669	12	/	/	SYM
cord-034340-3ksfpaf7	669	13	ml	ml	NN
cord-034340-3ksfpaf7	669	14	)	)	-RRB-
cord-034340-3ksfpaf7	669	15	were	be	VBD
cord-034340-3ksfpaf7	669	16	found	find	VBN
cord-034340-3ksfpaf7	669	17	in	in	IN
cord-034340-3ksfpaf7	669	18	the	the	DT
cord-034340-3ksfpaf7	669	19	three	three	CD
cord-034340-3ksfpaf7	669	20	plasma	plasma	NN
cord-034340-3ksfpaf7	669	21	samples	sample	NNS
cord-034340-3ksfpaf7	669	22	obtained	obtain	VBN
cord-034340-3ksfpaf7	669	23	from	from	IN
cord-034340-3ksfpaf7	669	24	the	the	DT
cord-034340-3ksfpaf7	669	25	male	male	JJ
cord-034340-3ksfpaf7	669	26	patient	patient	NN
cord-034340-3ksfpaf7	669	27	during	during	IN
cord-034340-3ksfpaf7	669	28	treatment	treatment	NN
cord-034340-3ksfpaf7	669	29	with	with	IN
cord-034340-3ksfpaf7	669	30	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	669	31	or	or	CC
cord-034340-3ksfpaf7	669	32	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	669	33	,	,	,
cord-034340-3ksfpaf7	669	34	high	high	JJ
cord-034340-3ksfpaf7	669	35	levels	level	NNS
cord-034340-3ksfpaf7	669	36	(	(	-LRB-
cord-034340-3ksfpaf7	669	37	up	up	IN
cord-034340-3ksfpaf7	669	38	to	to	IN
cord-034340-3ksfpaf7	669	39	21.52	21.52	CD
cord-034340-3ksfpaf7	669	40	pg	pg	NN
cord-034340-3ksfpaf7	669	41	/	/	SYM
cord-034340-3ksfpaf7	669	42	ml	ml	XX
cord-034340-3ksfpaf7	669	43	,	,	,
cord-034340-3ksfpaf7	669	44	about	about	IN
cord-034340-3ksfpaf7	669	45	90-fold	90-fold	CD
cord-034340-3ksfpaf7	669	46	higher	high	JJR
cord-034340-3ksfpaf7	669	47	compared	compare	VBN
cord-034340-3ksfpaf7	669	48	to	to	IN
cord-034340-3ksfpaf7	669	49	average	average	JJ
cord-034340-3ksfpaf7	669	50	levels	level	NNS
cord-034340-3ksfpaf7	669	51	measured	measure	VBN
cord-034340-3ksfpaf7	669	52	in	in	IN
cord-034340-3ksfpaf7	669	53	healthy	healthy	JJ
cord-034340-3ksfpaf7	669	54	controls	control	NNS
cord-034340-3ksfpaf7	669	55	)	)	-RRB-
cord-034340-3ksfpaf7	669	56	were	be	VBD
cord-034340-3ksfpaf7	669	57	found	find	VBN
cord-034340-3ksfpaf7	669	58	in	in	IN
cord-034340-3ksfpaf7	669	59	his	-PRON-	PRP$
cord-034340-3ksfpaf7	669	60	plasma	plasma	NN
cord-034340-3ksfpaf7	669	61	samples	sample	NNS
cord-034340-3ksfpaf7	669	62	collected	collect	VBN
cord-034340-3ksfpaf7	669	63	during	during	IN
cord-034340-3ksfpaf7	669	64	the	the	DT
cord-034340-3ksfpaf7	669	65	flare	flare	NN
cord-034340-3ksfpaf7	669	66	(	(	-LRB-
cord-034340-3ksfpaf7	669	67	Figure	figure	NN
cord-034340-3ksfpaf7	669	68	2	2	CD
cord-034340-3ksfpaf7	669	69	)	)	-RRB-
cord-034340-3ksfpaf7	669	70	.	.	.
cord-034340-3ksfpaf7	670	1	In	in	IN
cord-034340-3ksfpaf7	670	2	contrast	contrast	NN
cord-034340-3ksfpaf7	670	3	,	,	,
cord-034340-3ksfpaf7	670	4	IL-18	IL-18	NNP
cord-034340-3ksfpaf7	670	5	and	and	CC
cord-034340-3ksfpaf7	670	6	IL-6	IL-6	NNP
cord-034340-3ksfpaf7	670	7	plasma	plasma	NN
cord-034340-3ksfpaf7	670	8	levels	level	NNS
cord-034340-3ksfpaf7	670	9	,	,	,
cord-034340-3ksfpaf7	670	10	measured	measure	VBN
cord-034340-3ksfpaf7	670	11	before	before	RB
cord-034340-3ksfpaf7	670	12	,	,	,
cord-034340-3ksfpaf7	670	13	during	during	IN
cord-034340-3ksfpaf7	670	14	and	and	CC
cord-034340-3ksfpaf7	670	15	after	after	IN
cord-034340-3ksfpaf7	670	16	withholding	withhold	VBG
cord-034340-3ksfpaf7	670	17	treatment	treatment	NN
cord-034340-3ksfpaf7	670	18	,	,	,
cord-034340-3ksfpaf7	670	19	were	be	VBD
cord-034340-3ksfpaf7	670	20	comparable	comparable	JJ
cord-034340-3ksfpaf7	670	21	or	or	CC
cord-034340-3ksfpaf7	670	22	slightly	slightly	RB
cord-034340-3ksfpaf7	670	23	higher	high	JJR
cord-034340-3ksfpaf7	670	24	than	than	IN
cord-034340-3ksfpaf7	670	25	those	those	DT
cord-034340-3ksfpaf7	670	26	observed	observe	VBN
cord-034340-3ksfpaf7	670	27	in	in	IN
cord-034340-3ksfpaf7	670	28	healthy	healthy	JJ
cord-034340-3ksfpaf7	670	29	controls	control	NNS
cord-034340-3ksfpaf7	670	30	(	(	-LRB-
cord-034340-3ksfpaf7	670	31	Figure	figure	NN
cord-034340-3ksfpaf7	670	32	3A	3a	NN
cord-034340-3ksfpaf7	670	33	,	,	,
cord-034340-3ksfpaf7	670	34	B	b	NN
cord-034340-3ksfpaf7	670	35	)	)	-RRB-
cord-034340-3ksfpaf7	670	36	.	.	.
cord-034340-3ksfpaf7	671	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	671	2	:	:	:
cord-034340-3ksfpaf7	671	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	671	4	report	report	VBP
cord-034340-3ksfpaf7	671	5	here	here	RB
cord-034340-3ksfpaf7	671	6	,	,	,
cord-034340-3ksfpaf7	671	7	for	for	IN
cord-034340-3ksfpaf7	671	8	the	the	DT
cord-034340-3ksfpaf7	671	9	first	first	JJ
cord-034340-3ksfpaf7	671	10	time	time	NN
cord-034340-3ksfpaf7	671	11	,	,	,
cord-034340-3ksfpaf7	671	12	that	that	IN
cord-034340-3ksfpaf7	671	13	anti	anti	JJ
cord-034340-3ksfpaf7	671	14	-	-	JJ
cord-034340-3ksfpaf7	671	15	IL-1	il-1	JJ
cord-034340-3ksfpaf7	671	16	agents	agent	NNS
cord-034340-3ksfpaf7	671	17	were	be	VBD
cord-034340-3ksfpaf7	671	18	found	find	VBN
cord-034340-3ksfpaf7	671	19	efficacious	efficacious	JJ
cord-034340-3ksfpaf7	671	20	in	in	IN
cord-034340-3ksfpaf7	671	21	treating	treat	VBG
cord-034340-3ksfpaf7	671	22	two	two	CD
cord-034340-3ksfpaf7	671	23	FOP	FOP	NNP
cord-034340-3ksfpaf7	671	24	patients	patient	NNS
cord-034340-3ksfpaf7	671	25	.	.	.
cord-034340-3ksfpaf7	672	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	672	2	also	also	RB
cord-034340-3ksfpaf7	672	3	found	find	VBD
cord-034340-3ksfpaf7	672	4	markedly	markedly	RB
cord-034340-3ksfpaf7	672	5	increased	increase	VBN
cord-034340-3ksfpaf7	672	6	IL-1β	IL-1β	JJR
cord-034340-3ksfpaf7	672	7	levels	level	NNS
cord-034340-3ksfpaf7	672	8	during	during	IN
cord-034340-3ksfpaf7	672	9	flares	flare	NNS
cord-034340-3ksfpaf7	672	10	,	,	,
cord-034340-3ksfpaf7	672	11	which	which	WDT
cord-034340-3ksfpaf7	672	12	normalized	normalize	VBD
cord-034340-3ksfpaf7	672	13	following	follow	VBG
cord-034340-3ksfpaf7	672	14	the	the	DT
cord-034340-3ksfpaf7	672	15	treatment	treatment	NN
cord-034340-3ksfpaf7	672	16	.	.	.
cord-034340-3ksfpaf7	673	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	673	2	suggest	suggest	VBP
cord-034340-3ksfpaf7	673	3	a	a	DT
cord-034340-3ksfpaf7	673	4	role	role	NN
cord-034340-3ksfpaf7	673	5	for	for	IN
cord-034340-3ksfpaf7	673	6	IL-1β	il-1β	ADD
cord-034340-3ksfpaf7	673	7	in	in	IN
cord-034340-3ksfpaf7	673	8	the	the	DT
cord-034340-3ksfpaf7	673	9	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	673	10	of	of	IN
cord-034340-3ksfpaf7	673	11	this	this	DT
cord-034340-3ksfpaf7	673	12	disease	disease	NN
cord-034340-3ksfpaf7	673	13	.	.	.
cord-034340-3ksfpaf7	674	1	Although	although	IN
cord-034340-3ksfpaf7	674	2	it	-PRON-	PRP
cord-034340-3ksfpaf7	674	3	is	be	VBZ
cord-034340-3ksfpaf7	674	4	too	too	RB
cord-034340-3ksfpaf7	674	5	soon	soon	RB
cord-034340-3ksfpaf7	674	6	to	to	TO
cord-034340-3ksfpaf7	674	7	conclude	conclude	VB
cord-034340-3ksfpaf7	674	8	whether	whether	IN
cord-034340-3ksfpaf7	674	9	FOP	FOP	NNP
cord-034340-3ksfpaf7	674	10	may	may	MD
cord-034340-3ksfpaf7	674	11	be	be	VB
cord-034340-3ksfpaf7	674	12	included	include	VBN
cord-034340-3ksfpaf7	674	13	under	under	IN
cord-034340-3ksfpaf7	674	14	the	the	DT
cord-034340-3ksfpaf7	674	15	umbrella	umbrella	NN
cord-034340-3ksfpaf7	674	16	of	of	IN
cord-034340-3ksfpaf7	674	17	auto	auto	NN
cord-034340-3ksfpaf7	674	18	-	-	HYPH
cord-034340-3ksfpaf7	674	19	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	674	20	syndromes	syndrome	NNS
cord-034340-3ksfpaf7	674	21	,	,	,
cord-034340-3ksfpaf7	674	22	anti	anti	JJ
cord-034340-3ksfpaf7	674	23	-	-	JJ
cord-034340-3ksfpaf7	674	24	IL-1	il-1	JJ
cord-034340-3ksfpaf7	674	25	agents	agent	NNS
cord-034340-3ksfpaf7	674	26	can	can	MD
cord-034340-3ksfpaf7	674	27	be	be	VB
cord-034340-3ksfpaf7	674	28	effective	effective	JJ
cord-034340-3ksfpaf7	674	29	in	in	IN
cord-034340-3ksfpaf7	674	30	ameliorating	ameliorate	VBG
cord-034340-3ksfpaf7	674	31	the	the	DT
cord-034340-3ksfpaf7	674	32	natural	natural	JJ
cord-034340-3ksfpaf7	674	33	progression	progression	NN
cord-034340-3ksfpaf7	674	34	of	of	IN
cord-034340-3ksfpaf7	674	35	FOP	fop	NN
cord-034340-3ksfpaf7	674	36	.	.	.
cord-034340-3ksfpaf7	675	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	675	2	:	:	:
cord-034340-3ksfpaf7	676	1	Musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	676	2	symptoms	symptom	NNS
cord-034340-3ksfpaf7	676	3	are	be	VBP
cord-034340-3ksfpaf7	676	4	one	one	CD
cord-034340-3ksfpaf7	676	5	of	of	IN
cord-034340-3ksfpaf7	676	6	the	the	DT
cord-034340-3ksfpaf7	676	7	common	common	JJ
cord-034340-3ksfpaf7	676	8	reasons	reason	NNS
cord-034340-3ksfpaf7	676	9	for	for	IN
cord-034340-3ksfpaf7	676	10	applying	apply	VBG
cord-034340-3ksfpaf7	676	11	to	to	IN
cord-034340-3ksfpaf7	676	12	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	676	13	departments	department	NNS
cord-034340-3ksfpaf7	676	14	in	in	IN
cord-034340-3ksfpaf7	676	15	general	general	JJ
cord-034340-3ksfpaf7	676	16	practice	practice	NN
cord-034340-3ksfpaf7	676	17	1	1	CD
cord-034340-3ksfpaf7	676	18	.	.	.
cord-034340-3ksfpaf7	677	1	Although	although	IN
cord-034340-3ksfpaf7	677	2	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	677	3	causes	cause	NNS
cord-034340-3ksfpaf7	677	4	are	be	VBP
cord-034340-3ksfpaf7	677	5	generally	generally	RB
cord-034340-3ksfpaf7	677	6	considered	consider	VBN
cord-034340-3ksfpaf7	677	7	in	in	IN
cord-034340-3ksfpaf7	677	8	the	the	DT
cord-034340-3ksfpaf7	677	9	foreground	foreground	NN
cord-034340-3ksfpaf7	677	10	,	,	,
cord-034340-3ksfpaf7	677	11	it	-PRON-	PRP
cord-034340-3ksfpaf7	677	12	is	be	VBZ
cord-034340-3ksfpaf7	677	13	known	know	VBN
cord-034340-3ksfpaf7	677	14	that	that	IN
cord-034340-3ksfpaf7	677	15	non	non	JJ
cord-034340-3ksfpaf7	677	16	-	-	JJ
cord-034340-3ksfpaf7	677	17	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	677	18	causes	cause	NNS
cord-034340-3ksfpaf7	677	19	including	include	VBG
cord-034340-3ksfpaf7	677	20	genetic	genetic	JJ
cord-034340-3ksfpaf7	677	21	diseases	disease	NNS
cord-034340-3ksfpaf7	677	22	may	may	MD
cord-034340-3ksfpaf7	677	23	also	also	RB
cord-034340-3ksfpaf7	677	24	be	be	VB
cord-034340-3ksfpaf7	677	25	responsible	responsible	JJ
cord-034340-3ksfpaf7	677	26	.	.	.
cord-034340-3ksfpaf7	678	1	The	the	DT
cord-034340-3ksfpaf7	678	2	absence	absence	NN
cord-034340-3ksfpaf7	678	3	of	of	IN
cord-034340-3ksfpaf7	678	4	signs	sign	NNS
cord-034340-3ksfpaf7	678	5	of	of	IN
cord-034340-3ksfpaf7	678	6	inflammation	inflammation	NN
cord-034340-3ksfpaf7	678	7	(	(	-LRB-
cord-034340-3ksfpaf7	678	8	morning	morning	NN
cord-034340-3ksfpaf7	678	9	stiffness	stiffness	NN
cord-034340-3ksfpaf7	678	10	,	,	,
cord-034340-3ksfpaf7	678	11	redness	redness	NN
cord-034340-3ksfpaf7	678	12	,	,	,
cord-034340-3ksfpaf7	678	13	tenderness	tenderness	NN
cord-034340-3ksfpaf7	678	14	)	)	-RRB-
cord-034340-3ksfpaf7	678	15	and	and	CC
cord-034340-3ksfpaf7	678	16	normal	normal	JJ
cord-034340-3ksfpaf7	678	17	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	678	18	markers	marker	NNS
cord-034340-3ksfpaf7	678	19	in	in	IN
cord-034340-3ksfpaf7	678	20	laboratory	laboratory	NN
cord-034340-3ksfpaf7	678	21	findings	finding	NNS
cord-034340-3ksfpaf7	678	22	may	may	MD
cord-034340-3ksfpaf7	678	23	support	support	VB
cord-034340-3ksfpaf7	678	24	nonrheumatologic	nonrheumatologic	JJ
cord-034340-3ksfpaf7	678	25	diseases	disease	NNS
cord-034340-3ksfpaf7	678	26	2	2	CD
cord-034340-3ksfpaf7	678	27	.	.	.
cord-034340-3ksfpaf7	679	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	679	2	:	:	:
cord-034340-3ksfpaf7	680	1	To	to	TO
cord-034340-3ksfpaf7	680	2	present	present	VB
cord-034340-3ksfpaf7	680	3	genetic	genetic	JJ
cord-034340-3ksfpaf7	680	4	disorders	disorder	NNS
cord-034340-3ksfpaf7	680	5	that	that	WDT
cord-034340-3ksfpaf7	680	6	can	can	MD
cord-034340-3ksfpaf7	680	7	mimic	mimic	VB
cord-034340-3ksfpaf7	680	8	rheumatologic	rheumatologic	JJ
cord-034340-3ksfpaf7	680	9	symptoms	symptom	NNS
cord-034340-3ksfpaf7	680	10	and	and	CC
cord-034340-3ksfpaf7	680	11	to	to	TO
cord-034340-3ksfpaf7	680	12	answer	answer	VB
cord-034340-3ksfpaf7	680	13	when	when	WRB
cord-034340-3ksfpaf7	680	14	genetic	genetic	JJ
cord-034340-3ksfpaf7	680	15	diseases	disease	NNS
cord-034340-3ksfpaf7	680	16	should	should	MD
cord-034340-3ksfpaf7	680	17	be	be	VB
cord-034340-3ksfpaf7	680	18	considered	consider	VBN
cord-034340-3ksfpaf7	680	19	in	in	IN
cord-034340-3ksfpaf7	680	20	the	the	DT
cord-034340-3ksfpaf7	680	21	differential	differential	JJ
cord-034340-3ksfpaf7	680	22	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	680	23	in	in	IN
cord-034340-3ksfpaf7	680	24	patients	patient	NNS
cord-034340-3ksfpaf7	680	25	presenting	present	VBG
cord-034340-3ksfpaf7	680	26	with	with	IN
cord-034340-3ksfpaf7	680	27	rheumatological	rheumatological	JJ
cord-034340-3ksfpaf7	680	28	complaints	complaint	NNS
cord-034340-3ksfpaf7	680	29	.	.	.
cord-034340-3ksfpaf7	681	1	Methods	method	NNS
cord-034340-3ksfpaf7	681	2	:	:	:
cord-034340-3ksfpaf7	681	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	681	4	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	681	5	evaluated	evaluate	VBD
cord-034340-3ksfpaf7	681	6	60	60	CD
cord-034340-3ksfpaf7	681	7	patients	patient	NNS
cord-034340-3ksfpaf7	681	8	who	who	WP
cord-034340-3ksfpaf7	681	9	applied	apply	VBD
cord-034340-3ksfpaf7	681	10	to	to	IN
cord-034340-3ksfpaf7	681	11	Hacettepe	Hacettepe	NNP
cord-034340-3ksfpaf7	681	12	University	University	NNP
cord-034340-3ksfpaf7	681	13	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	681	14	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	681	15	department	department	NN
cord-034340-3ksfpaf7	681	16	with	with	IN
cord-034340-3ksfpaf7	681	17	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	681	18	compliants	compliant	NNS
cord-034340-3ksfpaf7	681	19	between	between	IN
cord-034340-3ksfpaf7	681	20	January	January	NNP
cord-034340-3ksfpaf7	681	21	2015	2015	CD
cord-034340-3ksfpaf7	681	22	and	and	CC
cord-034340-3ksfpaf7	681	23	December	December	NNP
cord-034340-3ksfpaf7	681	24	2019	2019	CD
cord-034340-3ksfpaf7	681	25	and	and	CC
cord-034340-3ksfpaf7	681	26	had	have	VBD
cord-034340-3ksfpaf7	681	27	been	be	VBN
cord-034340-3ksfpaf7	681	28	consulted	consult	VBN
cord-034340-3ksfpaf7	681	29	to	to	IN
cord-034340-3ksfpaf7	681	30	genetics	genetics	NN
cord-034340-3ksfpaf7	681	31	departmant	departmant	JJ
cord-034340-3ksfpaf7	681	32	.	.	.
cord-034340-3ksfpaf7	682	1	The	the	DT
cord-034340-3ksfpaf7	682	2	rate	rate	NN
cord-034340-3ksfpaf7	682	3	and	and	CC
cord-034340-3ksfpaf7	682	4	degree	degree	NN
cord-034340-3ksfpaf7	682	5	of	of	IN
cord-034340-3ksfpaf7	682	6	consanguinity	consanguinity	NN
cord-034340-3ksfpaf7	682	7	,	,	,
cord-034340-3ksfpaf7	682	8	clinical	clinical	JJ
cord-034340-3ksfpaf7	682	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	682	10	,	,	,
cord-034340-3ksfpaf7	682	11	indication	indication	NN
cord-034340-3ksfpaf7	682	12	for	for	IN
cord-034340-3ksfpaf7	682	13	consultation	consultation	NN
cord-034340-3ksfpaf7	682	14	,	,	,
cord-034340-3ksfpaf7	682	15	accompanying	accompany	VBG
cord-034340-3ksfpaf7	682	16	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	682	17	and	and	CC
cord-034340-3ksfpaf7	682	18	other	other	JJ
cord-034340-3ksfpaf7	682	19	findings	finding	NNS
cord-034340-3ksfpaf7	682	20	had	have	VBD
cord-034340-3ksfpaf7	682	21	been	be	VBN
cord-034340-3ksfpaf7	682	22	recorded	record	VBN
cord-034340-3ksfpaf7	682	23	.	.	.
cord-034340-3ksfpaf7	683	1	The	the	DT
cord-034340-3ksfpaf7	683	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	683	3	of	of	IN
cord-034340-3ksfpaf7	683	4	genetic	genetic	JJ
cord-034340-3ksfpaf7	683	5	diseases	disease	NNS
cord-034340-3ksfpaf7	683	6	were	be	VBD
cord-034340-3ksfpaf7	683	7	based	base	VBN
cord-034340-3ksfpaf7	683	8	on	on	IN
cord-034340-3ksfpaf7	683	9	physical	physical	JJ
cord-034340-3ksfpaf7	683	10	examination	examination	NN
cord-034340-3ksfpaf7	683	11	,	,	,
cord-034340-3ksfpaf7	683	12	radiological	radiological	JJ
cord-034340-3ksfpaf7	683	13	evaluations	evaluation	NNS
cord-034340-3ksfpaf7	683	14	and	and	CC
cord-034340-3ksfpaf7	683	15	genetic	genetic	JJ
cord-034340-3ksfpaf7	683	16	analysis	analysis	NN
cord-034340-3ksfpaf7	683	17	.	.	.
cord-034340-3ksfpaf7	684	1	Results	result	NNS
cord-034340-3ksfpaf7	684	2	:	:	:
cord-034340-3ksfpaf7	685	1	A	a	DT
cord-034340-3ksfpaf7	685	2	total	total	NN
cord-034340-3ksfpaf7	685	3	of	of	IN
cord-034340-3ksfpaf7	685	4	60	60	CD
cord-034340-3ksfpaf7	685	5	patients	patient	NNS
cord-034340-3ksfpaf7	685	6	,	,	,
cord-034340-3ksfpaf7	685	7	19	19	CD
cord-034340-3ksfpaf7	685	8	boys	boy	NNS
cord-034340-3ksfpaf7	685	9	(	(	-LRB-
cord-034340-3ksfpaf7	685	10	31.6	31.6	CD
cord-034340-3ksfpaf7	685	11	%	%	NN
cord-034340-3ksfpaf7	685	12	)	)	-RRB-
cord-034340-3ksfpaf7	685	13	,	,	,
cord-034340-3ksfpaf7	685	14	with	with	IN
cord-034340-3ksfpaf7	685	15	a	a	DT
cord-034340-3ksfpaf7	685	16	mean	mean	JJ
cord-034340-3ksfpaf7	685	17	age	age	NN
cord-034340-3ksfpaf7	685	18	12.46	12.46	CD
cord-034340-3ksfpaf7	685	19	±	±	CD
cord-034340-3ksfpaf7	685	20	1.41	1.41	CD
cord-034340-3ksfpaf7	685	21	years	year	NNS
cord-034340-3ksfpaf7	685	22	were	be	VBD
cord-034340-3ksfpaf7	685	23	included	include	VBN
cord-034340-3ksfpaf7	685	24	in	in	IN
cord-034340-3ksfpaf7	685	25	the	the	DT
cord-034340-3ksfpaf7	685	26	study	study	NN
cord-034340-3ksfpaf7	685	27	.	.	.
cord-034340-3ksfpaf7	686	1	The	the	DT
cord-034340-3ksfpaf7	686	2	rate	rate	NN
cord-034340-3ksfpaf7	686	3	of	of	IN
cord-034340-3ksfpaf7	686	4	consanguinity	consanguinity	NN
cord-034340-3ksfpaf7	686	5	was	be	VBD
cord-034340-3ksfpaf7	686	6	25.0	25.0	CD
cord-034340-3ksfpaf7	686	7	%	%	NN
cord-034340-3ksfpaf7	686	8	.	.	.
cord-034340-3ksfpaf7	687	1	The	the	DT
cord-034340-3ksfpaf7	687	2	most	most	RBS
cord-034340-3ksfpaf7	687	3	frequent	frequent	JJ
cord-034340-3ksfpaf7	687	4	referral	referral	NN
cord-034340-3ksfpaf7	687	5	to	to	IN
cord-034340-3ksfpaf7	687	6	the	the	DT
cord-034340-3ksfpaf7	687	7	genetic	genetic	JJ
cord-034340-3ksfpaf7	687	8	department	department	NN
cord-034340-3ksfpaf7	687	9	was	be	VBD
cord-034340-3ksfpaf7	687	10	the	the	DT
cord-034340-3ksfpaf7	687	11	presence	presence	NN
cord-034340-3ksfpaf7	687	12	of	of	IN
cord-034340-3ksfpaf7	687	13	skeletal	skeletal	JJ
cord-034340-3ksfpaf7	687	14	anomalies	anomaly	NNS
cord-034340-3ksfpaf7	687	15	(	(	-LRB-
cord-034340-3ksfpaf7	687	16	n:12	n:12	RB
cord-034340-3ksfpaf7	687	17	)	)	-RRB-
cord-034340-3ksfpaf7	687	18	such	such	JJ
cord-034340-3ksfpaf7	687	19	as	as	IN
cord-034340-3ksfpaf7	687	20	camptodactyly	camptodactyly	NNP
cord-034340-3ksfpaf7	687	21	,	,	,
cord-034340-3ksfpaf7	687	22	clinodactyly	clinodactyly	NNP
cord-034340-3ksfpaf7	687	23	,	,	,
cord-034340-3ksfpaf7	687	24	and	and	CC
cord-034340-3ksfpaf7	687	25	bone	bone	NN
cord-034340-3ksfpaf7	687	26	shortness	shortness	NN
cord-034340-3ksfpaf7	687	27	accompanying	accompany	VBG
cord-034340-3ksfpaf7	687	28	joint	joint	JJ
cord-034340-3ksfpaf7	687	29	findings	finding	NNS
cord-034340-3ksfpaf7	687	30	.	.	.
cord-034340-3ksfpaf7	688	1	Other	other	JJ
cord-034340-3ksfpaf7	688	2	causes	cause	NNS
cord-034340-3ksfpaf7	688	3	include	include	VBP
cord-034340-3ksfpaf7	688	4	short	short	JJ
cord-034340-3ksfpaf7	688	5	stature	stature	NN
cord-034340-3ksfpaf7	688	6	(	(	-LRB-
cord-034340-3ksfpaf7	688	7	n:4	n:4	NNP
cord-034340-3ksfpaf7	688	8	)	)	-RRB-
cord-034340-3ksfpaf7	688	9	,	,	,
cord-034340-3ksfpaf7	688	10	joint	joint	JJ
cord-034340-3ksfpaf7	688	11	deformity	deformity	NN
cord-034340-3ksfpaf7	688	12	(	(	-LRB-
cord-034340-3ksfpaf7	688	13	n:5	n:5	NNP
cord-034340-3ksfpaf7	688	14	)	)	-RRB-
cord-034340-3ksfpaf7	688	15	,	,	,
cord-034340-3ksfpaf7	688	16	joint	joint	JJ
cord-034340-3ksfpaf7	688	17	hyperlaxicity	hyperlaxicity	NN
cord-034340-3ksfpaf7	688	18	(	(	-LRB-
cord-034340-3ksfpaf7	688	19	n:10	n:10	ADD
cord-034340-3ksfpaf7	688	20	)	)	-RRB-
cord-034340-3ksfpaf7	688	21	,	,	,
cord-034340-3ksfpaf7	688	22	dysmorphic	dysmorphic	JJ
cord-034340-3ksfpaf7	688	23	findings	finding	NNS
cord-034340-3ksfpaf7	688	24	such	such	JJ
cord-034340-3ksfpaf7	688	25	as	as	IN
cord-034340-3ksfpaf7	688	26	atypic	atypic	JJ
cord-034340-3ksfpaf7	688	27	facial	facial	JJ
cord-034340-3ksfpaf7	688	28	appearance	appearance	NN
cord-034340-3ksfpaf7	688	29	(	(	-LRB-
cord-034340-3ksfpaf7	688	30	n:9	n:9	NNP
cord-034340-3ksfpaf7	688	31	)	)	-RRB-
cord-034340-3ksfpaf7	688	32	,	,	,
cord-034340-3ksfpaf7	688	33	accompanying	accompany	VBG
cord-034340-3ksfpaf7	688	34	diseases	disease	NNS
cord-034340-3ksfpaf7	688	35	that	that	WDT
cord-034340-3ksfpaf7	688	36	may	may	MD
cord-034340-3ksfpaf7	688	37	be	be	VB
cord-034340-3ksfpaf7	688	38	part	part	NN
cord-034340-3ksfpaf7	688	39	of	of	IN
cord-034340-3ksfpaf7	688	40	a	a	DT
cord-034340-3ksfpaf7	688	41	syndrome	syndrome	NN
cord-034340-3ksfpaf7	688	42	(	(	-LRB-
cord-034340-3ksfpaf7	688	43	n:11	n:11	CD
cord-034340-3ksfpaf7	688	44	)	)	-RRB-
cord-034340-3ksfpaf7	688	45	,	,	,
cord-034340-3ksfpaf7	688	46	genetic	genetic	JJ
cord-034340-3ksfpaf7	688	47	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	688	48	suspicion	suspicion	NN
cord-034340-3ksfpaf7	688	49	according	accord	VBG
cord-034340-3ksfpaf7	688	50	to	to	IN
cord-034340-3ksfpaf7	688	51	the	the	DT
cord-034340-3ksfpaf7	688	52	results	result	NNS
cord-034340-3ksfpaf7	688	53	of	of	IN
cord-034340-3ksfpaf7	688	54	radiological	radiological	JJ
cord-034340-3ksfpaf7	688	55	examination	examination	NN
cord-034340-3ksfpaf7	688	56	(	(	-LRB-
cord-034340-3ksfpaf7	688	57	n:4	n:4	NNP
cord-034340-3ksfpaf7	688	58	)	)	-RRB-
cord-034340-3ksfpaf7	688	59	and	and	CC
cord-034340-3ksfpaf7	688	60	joint	joint	JJ
cord-034340-3ksfpaf7	688	61	findings	finding	NNS
cord-034340-3ksfpaf7	688	62	without	without	IN
cord-034340-3ksfpaf7	688	63	clinical	clinical	JJ
cord-034340-3ksfpaf7	688	64	and	and	CC
cord-034340-3ksfpaf7	688	65	laboratory	laboratory	NN
cord-034340-3ksfpaf7	688	66	signs	sign	NNS
cord-034340-3ksfpaf7	688	67	of	of	IN
cord-034340-3ksfpaf7	688	68	inflammation	inflammation	NN
cord-034340-3ksfpaf7	688	69	(	(	-LRB-
cord-034340-3ksfpaf7	688	70	n:5	n:5	NNP
cord-034340-3ksfpaf7	688	71	)	)	-RRB-
cord-034340-3ksfpaf7	688	72	.	.	.
cord-034340-3ksfpaf7	689	1	Distribution	distribution	NN
cord-034340-3ksfpaf7	689	2	of	of	IN
cord-034340-3ksfpaf7	689	3	joint	joint	JJ
cord-034340-3ksfpaf7	689	4	involvement	involvement	NN
cord-034340-3ksfpaf7	689	5	in	in	IN
cord-034340-3ksfpaf7	689	6	20	20	CD
cord-034340-3ksfpaf7	689	7	patients	patient	NNS
cord-034340-3ksfpaf7	689	8	with	with	IN
cord-034340-3ksfpaf7	689	9	genetic	genetic	JJ
cord-034340-3ksfpaf7	689	10	disease	disease	NN
cord-034340-3ksfpaf7	689	11	were	be	VBD
cord-034340-3ksfpaf7	689	12	hands	hand	NNS
cord-034340-3ksfpaf7	689	13	,	,	,
cord-034340-3ksfpaf7	689	14	knees	knee	NNS
cord-034340-3ksfpaf7	689	15	,	,	,
cord-034340-3ksfpaf7	689	16	and	and	CC
cord-034340-3ksfpaf7	689	17	hips	hip	NNS
cord-034340-3ksfpaf7	689	18	respectively	respectively	RB
cord-034340-3ksfpaf7	689	19	.	.	.
cord-034340-3ksfpaf7	690	1	In	in	IN
cord-034340-3ksfpaf7	690	2	the	the	DT
cord-034340-3ksfpaf7	690	3	laboratory	laboratory	NN
cord-034340-3ksfpaf7	690	4	evaluation	evaluation	NN
cord-034340-3ksfpaf7	690	5	of	of	IN
cord-034340-3ksfpaf7	690	6	patients	patient	NNS
cord-034340-3ksfpaf7	690	7	presenting	present	VBG
cord-034340-3ksfpaf7	690	8	with	with	IN
cord-034340-3ksfpaf7	690	9	joint	joint	JJ
cord-034340-3ksfpaf7	690	10	swelling	swelling	NN
cord-034340-3ksfpaf7	690	11	and	and	CC
cord-034340-3ksfpaf7	690	12	arthralgia	arthralgia	NN
cord-034340-3ksfpaf7	690	13	,	,	,
cord-034340-3ksfpaf7	690	14	acute	acute	JJ
cord-034340-3ksfpaf7	690	15	phase	phase	NN
cord-034340-3ksfpaf7	690	16	reactants	reactant	NNS
cord-034340-3ksfpaf7	690	17	(	(	-LRB-
cord-034340-3ksfpaf7	690	18	erythrocyte	erythrocyte	NN
cord-034340-3ksfpaf7	690	19	sedimentation	sedimentation	NN
cord-034340-3ksfpaf7	690	20	rate	rate	NN
cord-034340-3ksfpaf7	690	21	and	and	CC
cord-034340-3ksfpaf7	690	22	C	c	NN
cord-034340-3ksfpaf7	690	23	-	-	HYPH
cord-034340-3ksfpaf7	690	24	reactive	reactive	JJ
cord-034340-3ksfpaf7	690	25	protein	protein	NN
cord-034340-3ksfpaf7	690	26	concentrations	concentration	NNS
cord-034340-3ksfpaf7	690	27	)	)	-RRB-
cord-034340-3ksfpaf7	690	28	were	be	VBD
cord-034340-3ksfpaf7	690	29	within	within	IN
cord-034340-3ksfpaf7	690	30	normal	normal	JJ
cord-034340-3ksfpaf7	690	31	reference	reference	NN
cord-034340-3ksfpaf7	690	32	values	value	NNS
cord-034340-3ksfpaf7	690	33	.	.	.
cord-034340-3ksfpaf7	691	1	One	one	CD
cord-034340-3ksfpaf7	691	2	third	third	NN
cord-034340-3ksfpaf7	691	3	of	of	IN
cord-034340-3ksfpaf7	691	4	the	the	DT
cord-034340-3ksfpaf7	691	5	patients	patient	NNS
cord-034340-3ksfpaf7	691	6	(	(	-LRB-
cord-034340-3ksfpaf7	691	7	33.3	33.3	CD
cord-034340-3ksfpaf7	691	8	%	%	NN
cord-034340-3ksfpaf7	691	9	)	)	-RRB-
cord-034340-3ksfpaf7	691	10	had	have	VBD
cord-034340-3ksfpaf7	691	11	a	a	DT
cord-034340-3ksfpaf7	691	12	final	final	JJ
cord-034340-3ksfpaf7	691	13	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	691	14	of	of	IN
cord-034340-3ksfpaf7	691	15	a	a	DT
cord-034340-3ksfpaf7	691	16	genetic	genetic	JJ
cord-034340-3ksfpaf7	691	17	disease	disease	NN
cord-034340-3ksfpaf7	691	18	.	.	.
cord-034340-3ksfpaf7	692	1	The	the	DT
cord-034340-3ksfpaf7	692	2	diagnoses	diagnosis	NNS
cord-034340-3ksfpaf7	692	3	of	of	IN
cord-034340-3ksfpaf7	692	4	these	these	DT
cord-034340-3ksfpaf7	692	5	patients	patient	NNS
cord-034340-3ksfpaf7	692	6	were	be	VBD
cord-034340-3ksfpaf7	692	7	as	as	IN
cord-034340-3ksfpaf7	692	8	follows	follow	VBZ
cord-034340-3ksfpaf7	692	9	;	;	:
cord-034340-3ksfpaf7	692	10	CACP	CACP	NNP
cord-034340-3ksfpaf7	692	11	(	(	-LRB-
cord-034340-3ksfpaf7	692	12	camptodactyly	camptodactyly	NNP
cord-034340-3ksfpaf7	692	13	,	,	,
cord-034340-3ksfpaf7	692	14	arthropathy	arthropathy	NNP
cord-034340-3ksfpaf7	692	15	,	,	,
cord-034340-3ksfpaf7	692	16	coxa	coxa	NNP
cord-034340-3ksfpaf7	692	17	vara	vara	NNP
cord-034340-3ksfpaf7	692	18	deformity	deformity	NN
cord-034340-3ksfpaf7	692	19	and	and	CC
cord-034340-3ksfpaf7	692	20	pericarditis	pericarditis	NN
cord-034340-3ksfpaf7	692	21	)	)	-RRB-
cord-034340-3ksfpaf7	692	22	syndrome	syndrome	NN
cord-034340-3ksfpaf7	692	23	(	(	-LRB-
cord-034340-3ksfpaf7	692	24	n:3	n:3	NNP
cord-034340-3ksfpaf7	692	25	)	)	-RRB-
cord-034340-3ksfpaf7	692	26	,	,	,
cord-034340-3ksfpaf7	692	27	trichorhinophalangeal	trichorhinophalangeal	NNP
cord-034340-3ksfpaf7	692	28	syndrome	syndrome	NN
cord-034340-3ksfpaf7	692	29	(	(	-LRB-
cord-034340-3ksfpaf7	692	30	n:1	n:1	NNP
cord-034340-3ksfpaf7	692	31	)	)	-RRB-
cord-034340-3ksfpaf7	692	32	,	,	,
cord-034340-3ksfpaf7	692	33	progressive	progressive	JJ
cord-034340-3ksfpaf7	692	34	pseudoromatoid	pseudoromatoid	NN
cord-034340-3ksfpaf7	692	35	dysplasia	dysplasia	NN
cord-034340-3ksfpaf7	692	36	(	(	-LRB-
cord-034340-3ksfpaf7	692	37	n:2	n:2	ADD
cord-034340-3ksfpaf7	692	38	)	)	-RRB-
cord-034340-3ksfpaf7	692	39	,	,	,
cord-034340-3ksfpaf7	692	40	LIG4	LIG4	NNP
cord-034340-3ksfpaf7	692	41	syndrome	syndrome	NN
cord-034340-3ksfpaf7	692	42	(	(	-LRB-
cord-034340-3ksfpaf7	692	43	n:1	n:1	NNP
cord-034340-3ksfpaf7	692	44	)	)	-RRB-
cord-034340-3ksfpaf7	692	45	,	,	.
cord-034340-3ksfpaf7	693	1	3	3	LS
cord-034340-3ksfpaf7	693	2	M	M	NNP
cord-034340-3ksfpaf7	693	3	syndrome	syndrome	NN
cord-034340-3ksfpaf7	693	4	(	(	-LRB-
cord-034340-3ksfpaf7	693	5	n:1	n:1	NNP
cord-034340-3ksfpaf7	693	6	)	)	-RRB-
cord-034340-3ksfpaf7	693	7	,	,	,
cord-034340-3ksfpaf7	693	8	H	h	NN
cord-034340-3ksfpaf7	693	9	syndrome	syndrome	NN
cord-034340-3ksfpaf7	693	10	(	(	-LRB-
cord-034340-3ksfpaf7	693	11	n:1	n:1	NNP
cord-034340-3ksfpaf7	693	12	)	)	-RRB-
cord-034340-3ksfpaf7	693	13	,	,	,
cord-034340-3ksfpaf7	693	14	SPENCD	SPENCD	NNP
cord-034340-3ksfpaf7	693	15	(	(	-LRB-
cord-034340-3ksfpaf7	693	16	spondyloenchondrodysplasia	spondyloenchondrodysplasia	NNP
cord-034340-3ksfpaf7	693	17	,	,	,
cord-034340-3ksfpaf7	693	18	n:3	n:3	NNP
cord-034340-3ksfpaf7	693	19	)	)	-RRB-
cord-034340-3ksfpaf7	693	20	,	,	,
cord-034340-3ksfpaf7	693	21	and	and	CC
cord-034340-3ksfpaf7	693	22	nonspecific	nonspecific	JJ
cord-034340-3ksfpaf7	693	23	connective	connective	JJ
cord-034340-3ksfpaf7	693	24	tissue	tissue	NN
cord-034340-3ksfpaf7	693	25	disease	disease	NN
cord-034340-3ksfpaf7	693	26	(	(	-LRB-
cord-034340-3ksfpaf7	693	27	n:8	n:8	NNP
cord-034340-3ksfpaf7	693	28	)	)	-RRB-
cord-034340-3ksfpaf7	693	29	.	.	.
cord-034340-3ksfpaf7	694	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	694	2	:	:	:
cord-034340-3ksfpaf7	695	1	Genetic	genetic	JJ
cord-034340-3ksfpaf7	695	2	syndromes	syndrome	NNS
cord-034340-3ksfpaf7	695	3	with	with	IN
cord-034340-3ksfpaf7	695	4	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	695	5	findings	finding	NNS
cord-034340-3ksfpaf7	695	6	are	be	VBP
cord-034340-3ksfpaf7	695	7	often	often	RB
cord-034340-3ksfpaf7	695	8	unrecognized	unrecognized	JJ
cord-034340-3ksfpaf7	695	9	and	and	CC
cord-034340-3ksfpaf7	695	10	misdiagnosed	misdiagnose	VBN
cord-034340-3ksfpaf7	695	11	as	as	IN
cord-034340-3ksfpaf7	695	12	rheumatologic	rheumatologic	JJ
cord-034340-3ksfpaf7	695	13	diseases	disease	NNS
cord-034340-3ksfpaf7	695	14	leading	lead	VBG
cord-034340-3ksfpaf7	695	15	to	to	IN
cord-034340-3ksfpaf7	695	16	unnecessary	unnecessary	JJ
cord-034340-3ksfpaf7	695	17	procedures	procedure	NNS
cord-034340-3ksfpaf7	695	18	and	and	CC
cord-034340-3ksfpaf7	695	19	treatments	treatment	NNS
cord-034340-3ksfpaf7	695	20	.	.	.
cord-034340-3ksfpaf7	696	1	Summarizing	summarize	VBG
cord-034340-3ksfpaf7	696	2	the	the	DT
cord-034340-3ksfpaf7	696	3	genetic	genetic	JJ
cord-034340-3ksfpaf7	696	4	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	696	5	spectrum	spectrum	NN
cord-034340-3ksfpaf7	696	6	that	that	WDT
cord-034340-3ksfpaf7	696	7	can	can	MD
cord-034340-3ksfpaf7	696	8	be	be	VB
cord-034340-3ksfpaf7	696	9	detected	detect	VBN
cord-034340-3ksfpaf7	696	10	in	in	IN
cord-034340-3ksfpaf7	696	11	these	these	DT
cord-034340-3ksfpaf7	696	12	patients	patient	NNS
cord-034340-3ksfpaf7	696	13	will	will	MD
cord-034340-3ksfpaf7	696	14	increase	increase	VB
cord-034340-3ksfpaf7	696	15	the	the	DT
cord-034340-3ksfpaf7	696	16	awareness	awareness	NN
cord-034340-3ksfpaf7	696	17	of	of	IN
cord-034340-3ksfpaf7	696	18	physicians	physician	NNS
cord-034340-3ksfpaf7	696	19	.	.	.
cord-034340-3ksfpaf7	697	1	Results	result	NNS
cord-034340-3ksfpaf7	697	2	:	:	:
cord-034340-3ksfpaf7	698	1	According	accord	VBG
cord-034340-3ksfpaf7	698	2	to	to	IN
cord-034340-3ksfpaf7	698	3	the	the	DT
cord-034340-3ksfpaf7	698	4	results	result	NNS
cord-034340-3ksfpaf7	698	5	of	of	IN
cord-034340-3ksfpaf7	698	6	observation	observation	NN
cord-034340-3ksfpaf7	698	7	,	,	,
cord-034340-3ksfpaf7	698	8	the	the	DT
cord-034340-3ksfpaf7	698	9	disease	disease	NN
cord-034340-3ksfpaf7	698	10	was	be	VBD
cord-034340-3ksfpaf7	698	11	more	more	RBR
cord-034340-3ksfpaf7	698	12	common	common	JJ
cord-034340-3ksfpaf7	698	13	in	in	IN
cord-034340-3ksfpaf7	698	14	the	the	DT
cord-034340-3ksfpaf7	698	15	age	age	NN
cord-034340-3ksfpaf7	698	16	group	group	NN
cord-034340-3ksfpaf7	698	17	of	of	IN
cord-034340-3ksfpaf7	698	18	7	7	CD
cord-034340-3ksfpaf7	698	19	-	-	SYM
cord-034340-3ksfpaf7	698	20	11	11	CD
cord-034340-3ksfpaf7	698	21	years	year	NNS
cord-034340-3ksfpaf7	698	22	(	(	-LRB-
cord-034340-3ksfpaf7	698	23	65	65	CD
cord-034340-3ksfpaf7	698	24	%	%	NN
cord-034340-3ksfpaf7	698	25	)	)	-RRB-
cord-034340-3ksfpaf7	698	26	,	,	,
cord-034340-3ksfpaf7	698	27	to	to	IN
cord-034340-3ksfpaf7	698	28	a	a	DT
cord-034340-3ksfpaf7	698	29	lesser	less	JJR
cord-034340-3ksfpaf7	698	30	extent	extent	NN
cord-034340-3ksfpaf7	698	31	among	among	IN
cord-034340-3ksfpaf7	698	32	children	child	NNS
cord-034340-3ksfpaf7	698	33	in	in	IN
cord-034340-3ksfpaf7	698	34	the	the	DT
cord-034340-3ksfpaf7	698	35	group	group	NN
cord-034340-3ksfpaf7	698	36	of	of	IN
cord-034340-3ksfpaf7	698	37	12	12	CD
cord-034340-3ksfpaf7	698	38	-	-	SYM
cord-034340-3ksfpaf7	698	39	15	15	CD
cord-034340-3ksfpaf7	698	40	years	year	NNS
cord-034340-3ksfpaf7	698	41	(	(	-LRB-
cord-034340-3ksfpaf7	698	42	35	35	CD
cord-034340-3ksfpaf7	698	43	%	%	NN
cord-034340-3ksfpaf7	698	44	)	)	-RRB-
cord-034340-3ksfpaf7	698	45	,	,	,
cord-034340-3ksfpaf7	698	46	less	less	RBR
cord-034340-3ksfpaf7	698	47	often	often	RB
cord-034340-3ksfpaf7	698	48	in	in	IN
cord-034340-3ksfpaf7	698	49	the	the	DT
cord-034340-3ksfpaf7	698	50	group	group	NN
cord-034340-3ksfpaf7	698	51	of	of	IN
cord-034340-3ksfpaf7	698	52	3	3	CD
cord-034340-3ksfpaf7	698	53	-	-	SYM
cord-034340-3ksfpaf7	698	54	7	7	CD
cord-034340-3ksfpaf7	698	55	years	year	NNS
cord-034340-3ksfpaf7	698	56	(	(	-LRB-
cord-034340-3ksfpaf7	698	57	5	5	CD
cord-034340-3ksfpaf7	698	58	%	%	NN
cord-034340-3ksfpaf7	698	59	)	)	-RRB-
cord-034340-3ksfpaf7	698	60	.	.	.
cord-034340-3ksfpaf7	699	1	When	when	WRB
cord-034340-3ksfpaf7	699	2	examining	examine	VBG
cord-034340-3ksfpaf7	699	3	infectious	infectious	JJ
cord-034340-3ksfpaf7	699	4	agents	agent	NNS
cord-034340-3ksfpaf7	699	5	,	,	,
cord-034340-3ksfpaf7	699	6	zoonotic	zoonotic	JJ
cord-034340-3ksfpaf7	699	7	infection	infection	NN
cord-034340-3ksfpaf7	699	8	was	be	VBD
cord-034340-3ksfpaf7	699	9	detected	detect	VBN
cord-034340-3ksfpaf7	699	10	in	in	IN
cord-034340-3ksfpaf7	699	11	41	41	CD
cord-034340-3ksfpaf7	699	12	%	%	NN
cord-034340-3ksfpaf7	699	13	(	(	-LRB-
cord-034340-3ksfpaf7	699	14	Listeria	Listeria	NNP
cord-034340-3ksfpaf7	699	15	monozytogenes	monozytogene	NNS
cord-034340-3ksfpaf7	699	16	,	,	,
cord-034340-3ksfpaf7	699	17	Yersinia	Yersinia	NNP
cord-034340-3ksfpaf7	699	18	enterocolitica	enterocolitica	NNP
cord-034340-3ksfpaf7	699	19	)	)	-RRB-
cord-034340-3ksfpaf7	699	20	.	.	.
cord-034340-3ksfpaf7	700	1	Clinical	clinical	JJ
cord-034340-3ksfpaf7	700	2	course	course	NN
cord-034340-3ksfpaf7	700	3	of	of	IN
cord-034340-3ksfpaf7	700	4	nodular	nodular	JJ
cord-034340-3ksfpaf7	700	5	erythema	erythema	NN
cord-034340-3ksfpaf7	700	6	in	in	IN
cord-034340-3ksfpaf7	700	7	this	this	DT
cord-034340-3ksfpaf7	700	8	group	group	NN
cord-034340-3ksfpaf7	700	9	was	be	VBD
cord-034340-3ksfpaf7	700	10	characterized	characterize	VBN
cord-034340-3ksfpaf7	700	11	by	by	IN
cord-034340-3ksfpaf7	700	12	an	an	DT
cord-034340-3ksfpaf7	700	13	expressed	express	VBN
cord-034340-3ksfpaf7	700	14	activity	activity	NN
cord-034340-3ksfpaf7	700	15	of	of	IN
cord-034340-3ksfpaf7	700	16	the	the	DT
cord-034340-3ksfpaf7	700	17	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	700	18	process	process	NN
cord-034340-3ksfpaf7	700	19	with	with	IN
cord-034340-3ksfpaf7	700	20	multiple	multiple	JJ
cord-034340-3ksfpaf7	700	21	elements	element	NNS
cord-034340-3ksfpaf7	700	22	in	in	IN
cord-034340-3ksfpaf7	700	23	the	the	DT
cord-034340-3ksfpaf7	700	24	lower	low	JJR
cord-034340-3ksfpaf7	700	25	and	and	CC
cord-034340-3ksfpaf7	700	26	upper	upper	JJ
cord-034340-3ksfpaf7	700	27	extremities	extremity	NNS
cord-034340-3ksfpaf7	700	28	,	,	,
cord-034340-3ksfpaf7	700	29	joint	joint	JJ
cord-034340-3ksfpaf7	700	30	syndrome	syndrome	NN
cord-034340-3ksfpaf7	700	31	,	,	,
cord-034340-3ksfpaf7	700	32	increased	increase	VBD
cord-034340-3ksfpaf7	700	33	ESR	ESR	NNP
cord-034340-3ksfpaf7	700	34	to	to	IN
cord-034340-3ksfpaf7	700	35	45±	45±	CD
cord-034340-3ksfpaf7	700	36	3.8	3.8	CD
cord-034340-3ksfpaf7	700	37	mm	mm	NN
cord-034340-3ksfpaf7	700	38	per	per	IN
cord-034340-3ksfpaf7	700	39	hour	hour	NN
cord-034340-3ksfpaf7	700	40	,	,	,
cord-034340-3ksfpaf7	700	41	CRP	CRP	NNP
cord-034340-3ksfpaf7	700	42	28±	28±	CD
cord-034340-3ksfpaf7	700	43	2.5	2.5	CD
cord-034340-3ksfpaf7	700	44	mg\l	mg\l	NNS
cord-034340-3ksfpaf7	700	45	.	.	.
cord-034340-3ksfpaf7	701	1	The	the	DT
cord-034340-3ksfpaf7	701	2	disease	disease	NN
cord-034340-3ksfpaf7	701	3	was	be	VBD
cord-034340-3ksfpaf7	701	4	preceded	precede	VBN
cord-034340-3ksfpaf7	701	5	by	by	IN
cord-034340-3ksfpaf7	701	6	an	an	DT
cord-034340-3ksfpaf7	701	7	episode	episode	NN
cord-034340-3ksfpaf7	701	8	of	of	IN
cord-034340-3ksfpaf7	701	9	acute	acute	JJ
cord-034340-3ksfpaf7	701	10	infection	infection	NN
cord-034340-3ksfpaf7	701	11	with	with	IN
cord-034340-3ksfpaf7	701	12	an	an	DT
cord-034340-3ksfpaf7	701	13	increase	increase	NN
cord-034340-3ksfpaf7	701	14	in	in	IN
cord-034340-3ksfpaf7	701	15	body	body	NN
cord-034340-3ksfpaf7	701	16	temperature	temperature	NN
cord-034340-3ksfpaf7	701	17	,	,	,
cord-034340-3ksfpaf7	701	18	intoxication	intoxication	NN
cord-034340-3ksfpaf7	701	19	,	,	,
cord-034340-3ksfpaf7	701	20	in	in	IN
cord-034340-3ksfpaf7	701	21	some	some	DT
cord-034340-3ksfpaf7	701	22	cases	case	NNS
cord-034340-3ksfpaf7	701	23	with	with	IN
cord-034340-3ksfpaf7	701	24	short	short	JJ
cord-034340-3ksfpaf7	701	25	-	-	HYPH
cord-034340-3ksfpaf7	701	26	term	term	NN
cord-034340-3ksfpaf7	701	27	intestinal	intestinal	JJ
cord-034340-3ksfpaf7	701	28	syndrome	syndrome	NN
cord-034340-3ksfpaf7	701	29	,	,	,
cord-034340-3ksfpaf7	701	30	pharyngitis	pharyngitis	NN
cord-034340-3ksfpaf7	701	31	.	.	.
cord-034340-3ksfpaf7	702	1	The	the	DT
cord-034340-3ksfpaf7	702	2	rashes	rash	NNS
cord-034340-3ksfpaf7	702	3	were	be	VBD
cord-034340-3ksfpaf7	702	4	persistent	persistent	JJ
cord-034340-3ksfpaf7	702	5	and	and	CC
cord-034340-3ksfpaf7	702	6	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	702	7	,	,	,
cord-034340-3ksfpaf7	702	8	with	with	IN
cord-034340-3ksfpaf7	702	9	a	a	DT
cord-034340-3ksfpaf7	702	10	slow	slow	JJ
cord-034340-3ksfpaf7	702	11	regression	regression	NN
cord-034340-3ksfpaf7	702	12	of	of	IN
cord-034340-3ksfpaf7	702	13	laboratory	laboratory	NN
cord-034340-3ksfpaf7	702	14	activity	activity	NN
cord-034340-3ksfpaf7	702	15	.	.	.
cord-034340-3ksfpaf7	703	1	Streptococcal	streptococcal	JJ
cord-034340-3ksfpaf7	703	2	etiology	etiology	NN
cord-034340-3ksfpaf7	703	3	of	of	IN
cord-034340-3ksfpaf7	703	4	nodular	nodular	JJ
cord-034340-3ksfpaf7	703	5	erythema	erythema	NN
cord-034340-3ksfpaf7	703	6	was	be	VBD
cord-034340-3ksfpaf7	703	7	detected	detect	VBN
cord-034340-3ksfpaf7	703	8	in	in	IN
cord-034340-3ksfpaf7	703	9	37	37	CD
cord-034340-3ksfpaf7	703	10	%	%	NN
cord-034340-3ksfpaf7	703	11	of	of	IN
cord-034340-3ksfpaf7	703	12	cases	case	NNS
cord-034340-3ksfpaf7	703	13	.	.	.
cord-034340-3ksfpaf7	704	1	There	there	EX
cord-034340-3ksfpaf7	704	2	was	be	VBD
cord-034340-3ksfpaf7	704	3	an	an	DT
cord-034340-3ksfpaf7	704	4	increase	increase	NN
cord-034340-3ksfpaf7	704	5	in	in	IN
cord-034340-3ksfpaf7	704	6	ESR	ESR	NNP
cord-034340-3ksfpaf7	704	7	to	to	IN
cord-034340-3ksfpaf7	704	8	25±3.8	25±3.8	CD
cord-034340-3ksfpaf7	704	9	mm	mm	CD
cord-034340-3ksfpaf7	704	10	per	per	IN
cord-034340-3ksfpaf7	704	11	hour	hour	NN
cord-034340-3ksfpaf7	704	12	,	,	,
cord-034340-3ksfpaf7	704	13	CRP	CRP	NNP
cord-034340-3ksfpaf7	704	14	15±	15±	CD
cord-034340-3ksfpaf7	705	1	2.7	2.7	CD
cord-034340-3ksfpaf7	705	2	mg	mg	NNP
cord-034340-3ksfpaf7	705	3	/	/	SYM
cord-034340-3ksfpaf7	705	4	l	l	NNP
cord-034340-3ksfpaf7	705	5	,	,	,
cord-034340-3ksfpaf7	705	6	a	a	DT
cord-034340-3ksfpaf7	705	7	significant	significant	JJ
cord-034340-3ksfpaf7	705	8	increase	increase	NN
cord-034340-3ksfpaf7	705	9	in	in	IN
cord-034340-3ksfpaf7	705	10	antistreptolysin	antistreptolysin	NNP
cord-034340-3ksfpaf7	705	11	on	on	IN
cord-034340-3ksfpaf7	705	12	average	average	JJ
cord-034340-3ksfpaf7	705	13	480±	480±	CD
cord-034340-3ksfpaf7	705	14	34	34	CD
cord-034340-3ksfpaf7	705	15	%	%	NN
cord-034340-3ksfpaf7	705	16	IU	IU	NNP
cord-034340-3ksfpaf7	705	17	/	/	,
cord-034340-3ksfpaf7	705	18	ml	ml	NN
cord-034340-3ksfpaf7	705	19	.	.	.
cord-034340-3ksfpaf7	706	1	with	with	IN
cord-034340-3ksfpaf7	706	2	an	an	DT
cord-034340-3ksfpaf7	706	3	increase	increase	NN
cord-034340-3ksfpaf7	706	4	in	in	IN
cord-034340-3ksfpaf7	706	5	individual	individual	JJ
cord-034340-3ksfpaf7	706	6	cases	case	NNS
cord-034340-3ksfpaf7	706	7	to	to	IN
cord-034340-3ksfpaf7	706	8	870	870	CD
cord-034340-3ksfpaf7	706	9	IU	IU	NNP
cord-034340-3ksfpaf7	706	10	/	/	,
cord-034340-3ksfpaf7	706	11	ml	ml	NN
cord-034340-3ksfpaf7	706	12	.	.	.
cord-034340-3ksfpaf7	707	1	In	in	IN
cord-034340-3ksfpaf7	707	2	13	13	CD
cord-034340-3ksfpaf7	707	3	%	%	NN
cord-034340-3ksfpaf7	707	4	of	of	IN
cord-034340-3ksfpaf7	707	5	cases	case	NNS
cord-034340-3ksfpaf7	707	6	,	,	,
cord-034340-3ksfpaf7	707	7	erythema	erythema	NNP
cord-034340-3ksfpaf7	707	8	nodosum	nodosum	NNP
cord-034340-3ksfpaf7	707	9	developed	develop	VBN
cord-034340-3ksfpaf7	707	10	after	after	IN
cord-034340-3ksfpaf7	707	11	an	an	DT
cord-034340-3ksfpaf7	707	12	intestinal	intestinal	JJ
cord-034340-3ksfpaf7	707	13	infection	infection	NN
cord-034340-3ksfpaf7	707	14	.	.	.
cord-034340-3ksfpaf7	708	1	Among	among	IN
cord-034340-3ksfpaf7	708	2	the	the	DT
cord-034340-3ksfpaf7	708	3	pathogens	pathogen	NNS
cord-034340-3ksfpaf7	708	4	were	be	VBD
cord-034340-3ksfpaf7	708	5	identified	identify	VBN
cord-034340-3ksfpaf7	708	6	Sh	Sh	NNP
cord-034340-3ksfpaf7	708	7	.	.	.
cord-034340-3ksfpaf7	709	1	disenteria	disenteria	NNP
cord-034340-3ksfpaf7	709	2	,	,	,
cord-034340-3ksfpaf7	709	3	E.	E.	NNP
cord-034340-3ksfpaf7	709	4	coli	coli	NNS
cord-034340-3ksfpaf7	709	5	,	,	,
cord-034340-3ksfpaf7	709	6	Yersinia	Yersinia	NNP
cord-034340-3ksfpaf7	709	7	enterocolitica	enterocolitica	NNP
cord-034340-3ksfpaf7	709	8	,	,	,
cord-034340-3ksfpaf7	709	9	enterovirus	enterovirus	NN
cord-034340-3ksfpaf7	709	10	.	.	.
cord-034340-3ksfpaf7	710	1	The	the	DT
cord-034340-3ksfpaf7	710	2	disease	disease	NN
cord-034340-3ksfpaf7	710	3	was	be	VBD
cord-034340-3ksfpaf7	710	4	characterized	characterize	VBN
cord-034340-3ksfpaf7	710	5	by	by	IN
cord-034340-3ksfpaf7	710	6	moderate	moderate	JJ
cord-034340-3ksfpaf7	710	7	activity	activity	NN
cord-034340-3ksfpaf7	710	8	,	,	,
cord-034340-3ksfpaf7	710	9	a	a	DT
cord-034340-3ksfpaf7	710	10	good	good	JJ
cord-034340-3ksfpaf7	710	11	response	response	NN
cord-034340-3ksfpaf7	710	12	to	to	IN
cord-034340-3ksfpaf7	710	13	etiological	etiological	JJ
cord-034340-3ksfpaf7	710	14	therapy	therapy	NN
cord-034340-3ksfpaf7	710	15	and	and	CC
cord-034340-3ksfpaf7	710	16	a	a	DT
cord-034340-3ksfpaf7	710	17	short	short	JJ
cord-034340-3ksfpaf7	710	18	course	course	NN
cord-034340-3ksfpaf7	710	19	of	of	IN
cord-034340-3ksfpaf7	710	20	NSAIDs	nsaid	NNS
cord-034340-3ksfpaf7	710	21	.	.	.
cord-034340-3ksfpaf7	711	1	An	an	DT
cord-034340-3ksfpaf7	711	2	interesting	interesting	JJ
cord-034340-3ksfpaf7	711	3	fact	fact	NN
cord-034340-3ksfpaf7	711	4	was	be	VBD
cord-034340-3ksfpaf7	711	5	the	the	DT
cord-034340-3ksfpaf7	711	6	development	development	NN
cord-034340-3ksfpaf7	711	7	of	of	IN
cord-034340-3ksfpaf7	711	8	nodular	nodular	JJ
cord-034340-3ksfpaf7	711	9	erythema	erythema	NN
cord-034340-3ksfpaf7	711	10	in	in	IN
cord-034340-3ksfpaf7	711	11	4	4	CD
cord-034340-3ksfpaf7	711	12	%	%	NN
cord-034340-3ksfpaf7	711	13	of	of	IN
cord-034340-3ksfpaf7	711	14	cases	case	NNS
cord-034340-3ksfpaf7	711	15	caused	cause	VBN
cord-034340-3ksfpaf7	711	16	by	by	IN
cord-034340-3ksfpaf7	711	17	the	the	DT
cord-034340-3ksfpaf7	711	18	Epstein	Epstein	NNP
cord-034340-3ksfpaf7	711	19	-	-	HYPH
cord-034340-3ksfpaf7	711	20	Barr	Barr	NNP
cord-034340-3ksfpaf7	711	21	virus	virus	NN
cord-034340-3ksfpaf7	711	22	in	in	IN
cord-034340-3ksfpaf7	711	23	groups	group	NNS
cord-034340-3ksfpaf7	711	24	of	of	IN
cord-034340-3ksfpaf7	711	25	children	child	NNS
cord-034340-3ksfpaf7	711	26	from	from	IN
cord-034340-3ksfpaf7	711	27	3	3	CD
cord-034340-3ksfpaf7	711	28	to	to	TO
cord-034340-3ksfpaf7	711	29	7	7	CD
cord-034340-3ksfpaf7	711	30	years	year	NNS
cord-034340-3ksfpaf7	711	31	and	and	CC
cord-034340-3ksfpaf7	711	32	7	7	CD
cord-034340-3ksfpaf7	711	33	-	-	SYM
cord-034340-3ksfpaf7	711	34	9	9	CD
cord-034340-3ksfpaf7	711	35	years	year	NNS
cord-034340-3ksfpaf7	711	36	.	.	.
cord-034340-3ksfpaf7	712	1	They	-PRON-	PRP
cord-034340-3ksfpaf7	712	2	had	have	VBD
cord-034340-3ksfpaf7	712	3	clinic	clinic	NN
cord-034340-3ksfpaf7	712	4	picture	picture	NN
cord-034340-3ksfpaf7	712	5	with	with	IN
cord-034340-3ksfpaf7	712	6	normothermia	normothermia	NN
cord-034340-3ksfpaf7	712	7	,	,	,
cord-034340-3ksfpaf7	712	8	no	no	DT
cord-034340-3ksfpaf7	712	9	symptoms	symptom	NNS
cord-034340-3ksfpaf7	712	10	of	of	IN
cord-034340-3ksfpaf7	712	11	intoxication	intoxication	NN
cord-034340-3ksfpaf7	712	12	,	,	,
cord-034340-3ksfpaf7	712	13	periodically	periodically	RB
cord-034340-3ksfpaf7	712	14	occurring	occur	VBG
cord-034340-3ksfpaf7	712	15	elements	element	NNS
cord-034340-3ksfpaf7	712	16	of	of	IN
cord-034340-3ksfpaf7	712	17	nodular	nodular	JJ
cord-034340-3ksfpaf7	712	18	erythema	erythema	NN
cord-034340-3ksfpaf7	712	19	on	on	IN
cord-034340-3ksfpaf7	712	20	the	the	DT
cord-034340-3ksfpaf7	712	21	shins	shin	NNS
cord-034340-3ksfpaf7	712	22	,	,	,
cord-034340-3ksfpaf7	712	23	no	no	DT
cord-034340-3ksfpaf7	712	24	blood	blood	NN
cord-034340-3ksfpaf7	712	25	changes	change	NNS
cord-034340-3ksfpaf7	712	26	.	.	.
cord-034340-3ksfpaf7	713	1	Therapy	therapy	NN
cord-034340-3ksfpaf7	713	2	aimed	aim	VBN
cord-034340-3ksfpaf7	713	3	at	at	IN
cord-034340-3ksfpaf7	713	4	eliminating	eliminate	VBG
cord-034340-3ksfpaf7	713	5	the	the	DT
cord-034340-3ksfpaf7	713	6	virus	virus	NN
cord-034340-3ksfpaf7	713	7	gave	give	VBD
cord-034340-3ksfpaf7	713	8	a	a	DT
cord-034340-3ksfpaf7	713	9	positive	positive	JJ
cord-034340-3ksfpaf7	713	10	result	result	NN
cord-034340-3ksfpaf7	713	11	and	and	CC
cord-034340-3ksfpaf7	713	12	did	do	VBD
cord-034340-3ksfpaf7	713	13	not	not	RB
cord-034340-3ksfpaf7	713	14	require	require	VB
cord-034340-3ksfpaf7	713	15	specific	specific	JJ
cord-034340-3ksfpaf7	713	16	anti	anti	JJ
cord-034340-3ksfpaf7	713	17	-	-	JJ
cord-034340-3ksfpaf7	713	18	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	713	19	therapy	therapy	NN
cord-034340-3ksfpaf7	713	20	.	.	.
cord-034340-3ksfpaf7	714	1	In	in	IN
cord-034340-3ksfpaf7	714	2	5	5	CD
cord-034340-3ksfpaf7	714	3	%	%	NN
cord-034340-3ksfpaf7	714	4	of	of	IN
cord-034340-3ksfpaf7	714	5	cases	case	NNS
cord-034340-3ksfpaf7	714	6	,	,	,
cord-034340-3ksfpaf7	714	7	the	the	DT
cord-034340-3ksfpaf7	714	8	etiology	etiology	NN
cord-034340-3ksfpaf7	714	9	of	of	IN
cord-034340-3ksfpaf7	714	10	nodular	nodular	JJ
cord-034340-3ksfpaf7	714	11	erythema	erythema	NN
cord-034340-3ksfpaf7	714	12	was	be	VBD
cord-034340-3ksfpaf7	714	13	not	not	RB
cord-034340-3ksfpaf7	714	14	defined	define	VBN
cord-034340-3ksfpaf7	714	15	.	.	.
cord-034340-3ksfpaf7	715	1	The	the	DT
cord-034340-3ksfpaf7	715	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	715	3	course	course	NN
cord-034340-3ksfpaf7	715	4	of	of	IN
cord-034340-3ksfpaf7	715	5	nodular	nodular	JJ
cord-034340-3ksfpaf7	715	6	erythema	erythema	NN
cord-034340-3ksfpaf7	715	7	in	in	IN
cord-034340-3ksfpaf7	715	8	children	child	NNS
cord-034340-3ksfpaf7	715	9	depends	depend	VBZ
cord-034340-3ksfpaf7	715	10	on	on	IN
cord-034340-3ksfpaf7	715	11	the	the	DT
cord-034340-3ksfpaf7	715	12	infectious	infectious	JJ
cord-034340-3ksfpaf7	715	13	agent	agent	NN
cord-034340-3ksfpaf7	715	14	that	that	WDT
cord-034340-3ksfpaf7	715	15	was	be	VBD
cord-034340-3ksfpaf7	715	16	the	the	DT
cord-034340-3ksfpaf7	715	17	trigger	trigger	NN
cord-034340-3ksfpaf7	715	18	of	of	IN
cord-034340-3ksfpaf7	715	19	the	the	DT
cord-034340-3ksfpaf7	715	20	pathological	pathological	JJ
cord-034340-3ksfpaf7	715	21	process	process	NN
cord-034340-3ksfpaf7	715	22	.	.	.
cord-034340-3ksfpaf7	716	1	The	the	DT
cord-034340-3ksfpaf7	716	2	higher	high	JJR
cord-034340-3ksfpaf7	716	3	activity	activity	NN
cord-034340-3ksfpaf7	716	4	and	and	CC
cord-034340-3ksfpaf7	716	5	duration	duration	NN
cord-034340-3ksfpaf7	716	6	of	of	IN
cord-034340-3ksfpaf7	716	7	the	the	DT
cord-034340-3ksfpaf7	716	8	disease	disease	NN
cord-034340-3ksfpaf7	716	9	is	be	VBZ
cord-034340-3ksfpaf7	716	10	caused	cause	VBN
cord-034340-3ksfpaf7	716	11	by	by	IN
cord-034340-3ksfpaf7	716	12	zoonotic	zoonotic	JJ
cord-034340-3ksfpaf7	716	13	infection	infection	NN
cord-034340-3ksfpaf7	716	14	,	,	,
cord-034340-3ksfpaf7	716	15	which	which	WDT
cord-034340-3ksfpaf7	716	16	requires	require	VBZ
cord-034340-3ksfpaf7	716	17	more	more	RBR
cord-034340-3ksfpaf7	716	18	active	active	JJ
cord-034340-3ksfpaf7	716	19	antiinflammatory	antiinflammatory	JJ
cord-034340-3ksfpaf7	716	20	therapy	therapy	NN
cord-034340-3ksfpaf7	716	21	with	with	IN
cord-034340-3ksfpaf7	716	22	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	716	23	,	,	,
cord-034340-3ksfpaf7	716	24	which	which	WDT
cord-034340-3ksfpaf7	716	25	may	may	MD
cord-034340-3ksfpaf7	716	26	be	be	VB
cord-034340-3ksfpaf7	716	27	associated	associate	VBN
cord-034340-3ksfpaf7	716	28	with	with	IN
cord-034340-3ksfpaf7	716	29	the	the	DT
cord-034340-3ksfpaf7	716	30	activation	activation	NN
cord-034340-3ksfpaf7	716	31	of	of	IN
cord-034340-3ksfpaf7	716	32	autoimmunity	autoimmunity	NN
cord-034340-3ksfpaf7	716	33	.	.	.
cord-034340-3ksfpaf7	717	1	This	this	DT
cord-034340-3ksfpaf7	717	2	group	group	NN
cord-034340-3ksfpaf7	717	3	of	of	IN
cord-034340-3ksfpaf7	717	4	children	child	NNS
cord-034340-3ksfpaf7	717	5	was	be	VBD
cord-034340-3ksfpaf7	717	6	taken	take	VBN
cord-034340-3ksfpaf7	717	7	for	for	IN
cord-034340-3ksfpaf7	717	8	further	further	JJ
cord-034340-3ksfpaf7	717	9	observation	observation	NN
cord-034340-3ksfpaf7	717	10	as	as	IN
cord-034340-3ksfpaf7	717	11	a	a	DT
cord-034340-3ksfpaf7	717	12	group	group	NN
cord-034340-3ksfpaf7	717	13	at	at	IN
cord-034340-3ksfpaf7	717	14	risk	risk	NN
cord-034340-3ksfpaf7	717	15	of	of	IN
cord-034340-3ksfpaf7	717	16	developing	develop	VBG
cord-034340-3ksfpaf7	717	17	systemic	systemic	JJ
cord-034340-3ksfpaf7	717	18	connective	connective	JJ
cord-034340-3ksfpaf7	717	19	tissue	tissue	NN
cord-034340-3ksfpaf7	717	20	disease	disease	NN
cord-034340-3ksfpaf7	717	21	.	.	.
cord-034340-3ksfpaf7	718	1	Changes	change	NNS
cord-034340-3ksfpaf7	718	2	in	in	IN
cord-034340-3ksfpaf7	718	3	the	the	DT
cord-034340-3ksfpaf7	718	4	etiological	etiological	JJ
cord-034340-3ksfpaf7	718	5	structure	structure	NN
cord-034340-3ksfpaf7	718	6	of	of	IN
cord-034340-3ksfpaf7	718	7	nodular	nodular	JJ
cord-034340-3ksfpaf7	718	8	erythema	erythema	NN
cord-034340-3ksfpaf7	718	9	and	and	CC
cord-034340-3ksfpaf7	718	10	treatment	treatment	NN
cord-034340-3ksfpaf7	718	11	tactics	tactic	NNS
cord-034340-3ksfpaf7	718	12	require	require	VBP
cord-034340-3ksfpaf7	718	13	further	further	JJ
cord-034340-3ksfpaf7	718	14	study	study	NN
cord-034340-3ksfpaf7	718	15	.	.	.
cord-034340-3ksfpaf7	719	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	719	2	:	:	:
cord-034340-3ksfpaf7	720	1	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	720	2	syndrome	syndrome	NN
cord-034340-3ksfpaf7	720	3	(	(	-LRB-
cord-034340-3ksfpaf7	720	4	SS	SS	NNP
cord-034340-3ksfpaf7	720	5	)	)	-RRB-
cord-034340-3ksfpaf7	720	6	is	be	VBZ
cord-034340-3ksfpaf7	720	7	a	a	DT
cord-034340-3ksfpaf7	720	8	chronic	chronic	JJ
cord-034340-3ksfpaf7	720	9	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	720	10	disorder	disorder	NN
cord-034340-3ksfpaf7	720	11	characterized	characterize	VBN
cord-034340-3ksfpaf7	720	12	by	by	IN
cord-034340-3ksfpaf7	720	13	inflammation	inflammation	NN
cord-034340-3ksfpaf7	720	14	of	of	IN
cord-034340-3ksfpaf7	720	15	the	the	DT
cord-034340-3ksfpaf7	720	16	lacrimal	lacrimal	NN
cord-034340-3ksfpaf7	720	17	and	and	CC
cord-034340-3ksfpaf7	720	18	salivary	salivary	NN
cord-034340-3ksfpaf7	720	19	glands	gland	NNS
cord-034340-3ksfpaf7	720	20	leading	lead	VBG
cord-034340-3ksfpaf7	720	21	to	to	IN
cord-034340-3ksfpaf7	720	22	oral	oral	JJ
cord-034340-3ksfpaf7	720	23	and	and	CC
cord-034340-3ksfpaf7	720	24	ocular	ocular	JJ
cord-034340-3ksfpaf7	720	25	dryness	dryness	NN
cord-034340-3ksfpaf7	720	26	.	.	.
cord-034340-3ksfpaf7	721	1	Childhood	Childhood	NNP
cord-034340-3ksfpaf7	721	2	SS	SS	NNP
cord-034340-3ksfpaf7	721	3	is	be	VBZ
cord-034340-3ksfpaf7	721	4	rare	rare	JJ
cord-034340-3ksfpaf7	721	5	and	and	CC
cord-034340-3ksfpaf7	721	6	poorly	poorly	RB
cord-034340-3ksfpaf7	721	7	defined	define	VBN
cord-034340-3ksfpaf7	721	8	and	and	CC
cord-034340-3ksfpaf7	721	9	underdiagnosed	underdiagnosed	JJ
cord-034340-3ksfpaf7	721	10	owing	owe	VBG
cord-034340-3ksfpaf7	721	11	to	to	IN
cord-034340-3ksfpaf7	721	12	the	the	DT
cord-034340-3ksfpaf7	721	13	lack	lack	NN
cord-034340-3ksfpaf7	721	14	of	of	IN
cord-034340-3ksfpaf7	721	15	childspecific	childspecific	NNP
cord-034340-3ksfpaf7	721	16	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	721	17	or	or	CC
cord-034340-3ksfpaf7	721	18	classification	classification	NN
cord-034340-3ksfpaf7	721	19	criteria	criterion	NNS
cord-034340-3ksfpaf7	721	20	.	.	.
cord-034340-3ksfpaf7	722	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	722	2	:	:	:
cord-034340-3ksfpaf7	722	3	The	the	DT
cord-034340-3ksfpaf7	722	4	purpose	purpose	NN
cord-034340-3ksfpaf7	722	5	of	of	IN
cord-034340-3ksfpaf7	722	6	this	this	DT
cord-034340-3ksfpaf7	722	7	study	study	NN
cord-034340-3ksfpaf7	722	8	is	be	VBZ
cord-034340-3ksfpaf7	722	9	to	to	TO
cord-034340-3ksfpaf7	722	10	describe	describe	VB
cord-034340-3ksfpaf7	722	11	12	12	CD
cord-034340-3ksfpaf7	722	12	cases	case	NNS
cord-034340-3ksfpaf7	722	13	with	with	IN
cord-034340-3ksfpaf7	722	14	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	722	15	SS	SS	NNP
cord-034340-3ksfpaf7	722	16	in	in	IN
cord-034340-3ksfpaf7	722	17	order	order	NN
cord-034340-3ksfpaf7	722	18	to	to	TO
cord-034340-3ksfpaf7	722	19	better	better	RB
cord-034340-3ksfpaf7	722	20	clarify	clarify	VB
cord-034340-3ksfpaf7	722	21	the	the	DT
cord-034340-3ksfpaf7	722	22	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	722	23	of	of	IN
cord-034340-3ksfpaf7	722	24	the	the	DT
cord-034340-3ksfpaf7	722	25	disease	disease	NN
cord-034340-3ksfpaf7	722	26	in	in	IN
cord-034340-3ksfpaf7	722	27	the	the	DT
cord-034340-3ksfpaf7	722	28	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	722	29	age	age	NN
cord-034340-3ksfpaf7	722	30	.	.	.
cord-034340-3ksfpaf7	723	1	Methods	method	NNS
cord-034340-3ksfpaf7	723	2	:	:	:
cord-034340-3ksfpaf7	724	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	724	2	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	724	3	reviewed	review	VBD
cord-034340-3ksfpaf7	724	4	medical	medical	JJ
cord-034340-3ksfpaf7	724	5	records	record	NNS
cord-034340-3ksfpaf7	724	6	of	of	IN
cord-034340-3ksfpaf7	724	7	patients	patient	NNS
cord-034340-3ksfpaf7	724	8	(	(	-LRB-
cord-034340-3ksfpaf7	724	9	pts	pt	NNS
cord-034340-3ksfpaf7	724	10	)	)	-RRB-
cord-034340-3ksfpaf7	724	11	with	with	IN
cord-034340-3ksfpaf7	724	12	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	724	13	SS	SS	NNP
cord-034340-3ksfpaf7	724	14	referring	refer	VBG
cord-034340-3ksfpaf7	724	15	to	to	IN
cord-034340-3ksfpaf7	724	16	three	three	CD
cord-034340-3ksfpaf7	724	17	Italian	italian	JJ
cord-034340-3ksfpaf7	724	18	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	724	19	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	724	20	centers	center	NNS
cord-034340-3ksfpaf7	724	21	.	.	.
cord-034340-3ksfpaf7	725	1	Due	due	IN
cord-034340-3ksfpaf7	725	2	to	to	IN
cord-034340-3ksfpaf7	725	3	lack	lack	NN
cord-034340-3ksfpaf7	725	4	of	of	IN
cord-034340-3ksfpaf7	725	5	childhood	childhood	NN
cord-034340-3ksfpaf7	725	6	validated	validate	VBN
cord-034340-3ksfpaf7	725	7	SS	ss	NN
cord-034340-3ksfpaf7	725	8	-	-	HYPH
cord-034340-3ksfpaf7	725	9	specific	specific	JJ
cord-034340-3ksfpaf7	725	10	criteria	criterion	NNS
cord-034340-3ksfpaf7	725	11	,	,	,
cord-034340-3ksfpaf7	725	12	physician	physician	NN
cord-034340-3ksfpaf7	725	13	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	725	14	was	be	VBD
cord-034340-3ksfpaf7	725	15	the	the	DT
cord-034340-3ksfpaf7	725	16	only	only	JJ
cord-034340-3ksfpaf7	725	17	inclusion	inclusion	NN
cord-034340-3ksfpaf7	725	18	criteria	criterion	NNS
cord-034340-3ksfpaf7	725	19	.	.	.
cord-034340-3ksfpaf7	726	1	Results	result	NNS
cord-034340-3ksfpaf7	726	2	:	:	:
cord-034340-3ksfpaf7	727	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	727	2	collected	collect	VBD
cord-034340-3ksfpaf7	727	3	data	datum	NNS
cord-034340-3ksfpaf7	727	4	on	on	IN
cord-034340-3ksfpaf7	727	5	12	12	CD
cord-034340-3ksfpaf7	727	6	pts	pt	NNS
cord-034340-3ksfpaf7	727	7	(	(	-LRB-
cord-034340-3ksfpaf7	727	8	9	9	CD
cord-034340-3ksfpaf7	727	9	females	female	NNS
cord-034340-3ksfpaf7	727	10	)	)	-RRB-
cord-034340-3ksfpaf7	727	11	.	.	.
cord-034340-3ksfpaf7	728	1	The	the	DT
cord-034340-3ksfpaf7	728	2	mean	mean	JJ
cord-034340-3ksfpaf7	728	3	age	age	NN
cord-034340-3ksfpaf7	728	4	of	of	IN
cord-034340-3ksfpaf7	728	5	disease	disease	NN
cord-034340-3ksfpaf7	728	6	onset	onset	NN
cord-034340-3ksfpaf7	728	7	is	be	VBZ
cord-034340-3ksfpaf7	728	8	10.0	10.0	CD
cord-034340-3ksfpaf7	728	9	yrs	yr	NNS
cord-034340-3ksfpaf7	728	10	(	(	-LRB-
cord-034340-3ksfpaf7	728	11	median	median	NN
cord-034340-3ksfpaf7	728	12	10.2	10.2	CD
cord-034340-3ksfpaf7	728	13	,	,	,
cord-034340-3ksfpaf7	728	14	range	range	NNP
cord-034340-3ksfpaf7	728	15	4	4	CD
cord-034340-3ksfpaf7	728	16	-	-	SYM
cord-034340-3ksfpaf7	728	17	17	17	CD
cord-034340-3ksfpaf7	728	18	)	)	-RRB-
cord-034340-3ksfpaf7	728	19	.	.	.
cord-034340-3ksfpaf7	729	1	The	the	DT
cord-034340-3ksfpaf7	729	2	mean	mean	JJ
cord-034340-3ksfpaf7	729	3	age	age	NN
cord-034340-3ksfpaf7	729	4	of	of	IN
cord-034340-3ksfpaf7	729	5	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	729	6	is	be	VBZ
cord-034340-3ksfpaf7	729	7	11.83	11.83	CD
cord-034340-3ksfpaf7	729	8	(	(	-LRB-
cord-034340-3ksfpaf7	729	9	median	median	NN
cord-034340-3ksfpaf7	729	10	11.45	11.45	CD
cord-034340-3ksfpaf7	729	11	,	,	,
cord-034340-3ksfpaf7	729	12	range	range	NNP
cord-034340-3ksfpaf7	729	13	6	6	CD
cord-034340-3ksfpaf7	729	14	-	-	SYM
cord-034340-3ksfpaf7	729	15	18	18	CD
cord-034340-3ksfpaf7	729	16	)	)	-RRB-
cord-034340-3ksfpaf7	729	17	.	.	.
cord-034340-3ksfpaf7	730	1	The	the	DT
cord-034340-3ksfpaf7	730	2	follow	follow	NN
cord-034340-3ksfpaf7	730	3	up	up	RP
cord-034340-3ksfpaf7	730	4	period	period	NN
cord-034340-3ksfpaf7	730	5	varied	varied	JJ
cord-034340-3ksfpaf7	730	6	from	from	IN
cord-034340-3ksfpaf7	730	7	0.1	0.1	CD
cord-034340-3ksfpaf7	730	8	to	to	IN
cord-034340-3ksfpaf7	730	9	9.3	9.3	CD
cord-034340-3ksfpaf7	730	10	yrs	yr	NNS
cord-034340-3ksfpaf7	730	11	(	(	-LRB-
cord-034340-3ksfpaf7	730	12	mean	mean	VBP
cord-034340-3ksfpaf7	730	13	3.95	3.95	CD
cord-034340-3ksfpaf7	730	14	,	,	,
cord-034340-3ksfpaf7	730	15	median	median	JJ
cord-034340-3ksfpaf7	730	16	5.0	5.0	CD
cord-034340-3ksfpaf7	730	17	)	)	-RRB-
cord-034340-3ksfpaf7	730	18	.	.	.
cord-034340-3ksfpaf7	731	1	The	the	DT
cord-034340-3ksfpaf7	731	2	most	most	RBS
cord-034340-3ksfpaf7	731	3	common	common	JJ
cord-034340-3ksfpaf7	731	4	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	731	5	were	be	VBD
cord-034340-3ksfpaf7	731	6	articular	articular	JJ
cord-034340-3ksfpaf7	731	7	involvement	involvement	NN
cord-034340-3ksfpaf7	731	8	(	(	-LRB-
cord-034340-3ksfpaf7	731	9	mainly	mainly	RB
cord-034340-3ksfpaf7	731	10	with	with	IN
cord-034340-3ksfpaf7	731	11	arthralgia	arthralgia	NNP
cord-034340-3ksfpaf7	731	12	)	)	-RRB-
cord-034340-3ksfpaf7	732	1	(	(	-LRB-
cord-034340-3ksfpaf7	732	2	9/12	9/12	CD
cord-034340-3ksfpaf7	732	3	pts	pts	CD
cord-034340-3ksfpaf7	732	4	)	)	-RRB-
cord-034340-3ksfpaf7	732	5	and	and	CC
cord-034340-3ksfpaf7	733	1	parotid	parotid	JJ
cord-034340-3ksfpaf7	733	2	/	/	SYM
cord-034340-3ksfpaf7	733	3	salivary	salivary	NN
cord-034340-3ksfpaf7	733	4	glands	gland	NNS
cord-034340-3ksfpaf7	733	5	swelling	swell	VBG
cord-034340-3ksfpaf7	733	6	(	(	-LRB-
cord-034340-3ksfpaf7	733	7	8/12	8/12	CD
cord-034340-3ksfpaf7	733	8	pts	pts	NN
cord-034340-3ksfpaf7	733	9	)	)	-RRB-
cord-034340-3ksfpaf7	733	10	.	.	.
cord-034340-3ksfpaf7	734	1	Xerostomia	Xerostomia	NNP
cord-034340-3ksfpaf7	734	2	and	and	CC
cord-034340-3ksfpaf7	734	3	xerophthalmia	xerophthalmia	NNP
cord-034340-3ksfpaf7	734	4	were	be	VBD
cord-034340-3ksfpaf7	734	5	found	find	VBN
cord-034340-3ksfpaf7	734	6	in	in	IN
cord-034340-3ksfpaf7	734	7	6/12	6/12	CD
cord-034340-3ksfpaf7	734	8	pts	pt	NNS
cord-034340-3ksfpaf7	734	9	and	and	CC
cord-034340-3ksfpaf7	734	10	in	in	IN
cord-034340-3ksfpaf7	734	11	4/12	4/12	CD
cord-034340-3ksfpaf7	734	12	respectively	respectively	RB
cord-034340-3ksfpaf7	734	13	.	.	.
cord-034340-3ksfpaf7	735	1	Vaginal	vaginal	JJ
cord-034340-3ksfpaf7	735	2	dryness	dryness	NN
cord-034340-3ksfpaf7	735	3	was	be	VBD
cord-034340-3ksfpaf7	735	4	reported	report	VBN
cord-034340-3ksfpaf7	735	5	only	only	RB
cord-034340-3ksfpaf7	735	6	by	by	IN
cord-034340-3ksfpaf7	735	7	one	one	CD
cord-034340-3ksfpaf7	735	8	pt	pt	NN
cord-034340-3ksfpaf7	735	9	.	.	.
cord-034340-3ksfpaf7	736	1	Fever	fever	NN
cord-034340-3ksfpaf7	736	2	and	and	CC
cord-034340-3ksfpaf7	736	3	fatigue	fatigue	NN
cord-034340-3ksfpaf7	736	4	occurred	occur	VBD
cord-034340-3ksfpaf7	736	5	in	in	IN
cord-034340-3ksfpaf7	736	6	3/12	3/12	CD
cord-034340-3ksfpaf7	736	7	and	and	CC
cord-034340-3ksfpaf7	736	8	7/12	7/12	CD
cord-034340-3ksfpaf7	736	9	pts	pts	NN
cord-034340-3ksfpaf7	736	10	respectively	respectively	RB
cord-034340-3ksfpaf7	736	11	.	.	.
cord-034340-3ksfpaf7	737	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	737	2	also	also	RB
cord-034340-3ksfpaf7	737	3	recorded	record	VBD
cord-034340-3ksfpaf7	737	4	3	3	CD
cord-034340-3ksfpaf7	737	5	cases	case	NNS
cord-034340-3ksfpaf7	737	6	of	of	IN
cord-034340-3ksfpaf7	737	7	circulating	circulate	VBG
cord-034340-3ksfpaf7	737	8	immune	immune	JJ
cord-034340-3ksfpaf7	737	9	complexes	complex	NNS
cord-034340-3ksfpaf7	737	10	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	737	11	in	in	IN
cord-034340-3ksfpaf7	737	12	3	3	CD
cord-034340-3ksfpaf7	737	13	pts	pt	NNS
cord-034340-3ksfpaf7	737	14	,	,	,
cord-034340-3ksfpaf7	737	15	purpura	purpura	NN
cord-034340-3ksfpaf7	737	16	(	(	-LRB-
cord-034340-3ksfpaf7	737	17	n=2	n=2	NNS
cord-034340-3ksfpaf7	737	18	)	)	-RRB-
cord-034340-3ksfpaf7	737	19	and	and	CC
cord-034340-3ksfpaf7	737	20	glomerulonephritis	glomerulonephritis	NN
cord-034340-3ksfpaf7	737	21	(	(	-LRB-
cord-034340-3ksfpaf7	737	22	n=1	n=1	FW
cord-034340-3ksfpaf7	737	23	)	)	-RRB-
cord-034340-3ksfpaf7	737	24	.	.	.
cord-034340-3ksfpaf7	738	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	738	2	observed	observe	VBD
cord-034340-3ksfpaf7	738	3	an	an	DT
cord-034340-3ksfpaf7	738	4	endocrine	endocrine	JJ
cord-034340-3ksfpaf7	738	5	involvement	involvement	NN
cord-034340-3ksfpaf7	738	6	in	in	IN
cord-034340-3ksfpaf7	738	7	3	3	CD
cord-034340-3ksfpaf7	738	8	pts	pts	NN
cord-034340-3ksfpaf7	738	9	(	(	-LRB-
cord-034340-3ksfpaf7	738	10	1	1	CD
cord-034340-3ksfpaf7	738	11	metabolic	metabolic	JJ
cord-034340-3ksfpaf7	738	12	syndrome	syndrome	NN
cord-034340-3ksfpaf7	738	13	,	,	,
cord-034340-3ksfpaf7	738	14	2	2	CD
cord-034340-3ksfpaf7	738	15	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	738	16	thyroiditis	thyroiditis	NN
cord-034340-3ksfpaf7	738	17	)	)	-RRB-
cord-034340-3ksfpaf7	738	18	.	.	.
cord-034340-3ksfpaf7	739	1	Abdominal	abdominal	JJ
cord-034340-3ksfpaf7	739	2	pain	pain	NN
cord-034340-3ksfpaf7	739	3	was	be	VBD
cord-034340-3ksfpaf7	739	4	found	find	VBN
cord-034340-3ksfpaf7	739	5	in	in	IN
cord-034340-3ksfpaf7	739	6	4/12	4/12	CD
cord-034340-3ksfpaf7	739	7	pts	pt	NNS
cord-034340-3ksfpaf7	739	8	.	.	.
cord-034340-3ksfpaf7	740	1	All	all	DT
cord-034340-3ksfpaf7	740	2	pts	pt	NNS
cord-034340-3ksfpaf7	740	3	were	be	VBD
cord-034340-3ksfpaf7	740	4	positive	positive	JJ
cord-034340-3ksfpaf7	740	5	for	for	IN
cord-034340-3ksfpaf7	740	6	autoantibodies	autoantibody	NNS
cord-034340-3ksfpaf7	740	7	(	(	-LRB-
cord-034340-3ksfpaf7	740	8	positivity	positivity	NN
cord-034340-3ksfpaf7	740	9	for	for	IN
cord-034340-3ksfpaf7	740	10	ANA	ANA	NNP
cord-034340-3ksfpaf7	740	11	or	or	CC
cord-034340-3ksfpaf7	740	12	anti	anti	JJ
cord-034340-3ksfpaf7	740	13	-	-	JJ
cord-034340-3ksfpaf7	740	14	SSA	ssa	JJ
cord-034340-3ksfpaf7	740	15	or	or	CC
cord-034340-3ksfpaf7	740	16	anti	anti	JJ
cord-034340-3ksfpaf7	740	17	-	-	JJ
cord-034340-3ksfpaf7	740	18	SSB	SSB	NNP
cord-034340-3ksfpaf7	740	19	or	or	CC
cord-034340-3ksfpaf7	740	20	FR	FR	NNP
cord-034340-3ksfpaf7	740	21	)	)	-RRB-
cord-034340-3ksfpaf7	740	22	at	at	IN
cord-034340-3ksfpaf7	740	23	presentation	presentation	NN
cord-034340-3ksfpaf7	740	24	.	.	.
cord-034340-3ksfpaf7	741	1	RF	rf	NN
cord-034340-3ksfpaf7	741	2	test	test	NN
cord-034340-3ksfpaf7	741	3	results	result	NNS
cord-034340-3ksfpaf7	741	4	were	be	VBD
cord-034340-3ksfpaf7	741	5	available	available	JJ
cord-034340-3ksfpaf7	741	6	in	in	IN
cord-034340-3ksfpaf7	741	7	8	8	CD
cord-034340-3ksfpaf7	741	8	pts	pt	NNS
cord-034340-3ksfpaf7	741	9	,	,	,
cord-034340-3ksfpaf7	741	10	all	all	DT
cord-034340-3ksfpaf7	741	11	positive	positive	JJ
cord-034340-3ksfpaf7	741	12	.	.	.
cord-034340-3ksfpaf7	742	1	Positive	positive	JJ
cord-034340-3ksfpaf7	742	2	ANA	ANA	NNP
cord-034340-3ksfpaf7	742	3	(	(	-LRB-
cord-034340-3ksfpaf7	742	4	titer>1/320	titer>1/320	NN
cord-034340-3ksfpaf7	742	5	)	)	-RRB-
cord-034340-3ksfpaf7	742	6	and	and	CC
cord-034340-3ksfpaf7	742	7	anti	anti	JJ
cord-034340-3ksfpaf7	742	8	-	-	JJ
cord-034340-3ksfpaf7	742	9	SSA	SSA	NNP
cord-034340-3ksfpaf7	742	10	were	be	VBD
cord-034340-3ksfpaf7	742	11	present	present	JJ
cord-034340-3ksfpaf7	742	12	in	in	IN
cord-034340-3ksfpaf7	742	13	10/12	10/12	CD
cord-034340-3ksfpaf7	742	14	pts	pt	NNS
cord-034340-3ksfpaf7	742	15	and	and	CC
cord-034340-3ksfpaf7	742	16	in	in	IN
cord-034340-3ksfpaf7	742	17	9/12	9/12	CD
cord-034340-3ksfpaf7	742	18	respectively	respectively	RB
cord-034340-3ksfpaf7	742	19	.	.	.
cord-034340-3ksfpaf7	743	1	Hypergammaglobulinemia	Hypergammaglobulinemia	NNP
cord-034340-3ksfpaf7	743	2	(	(	-LRB-
cord-034340-3ksfpaf7	743	3	range	range	VBP
cord-034340-3ksfpaf7	743	4	1,6	1,6	CD
cord-034340-3ksfpaf7	743	5	-	-	HYPH
cord-034340-3ksfpaf7	743	6	8.04	8.04	CD
cord-034340-3ksfpaf7	743	7	g	g	NN
cord-034340-3ksfpaf7	743	8	/	/	SYM
cord-034340-3ksfpaf7	743	9	dl	dl	NN
cord-034340-3ksfpaf7	743	10	)	)	-RRB-
cord-034340-3ksfpaf7	743	11	was	be	VBD
cord-034340-3ksfpaf7	743	12	found	find	VBN
cord-034340-3ksfpaf7	743	13	in	in	IN
cord-034340-3ksfpaf7	743	14	8/11	8/11	CD
cord-034340-3ksfpaf7	743	15	pts	pt	NNS
cord-034340-3ksfpaf7	743	16	(	(	-LRB-
cord-034340-3ksfpaf7	743	17	1	1	CD
cord-034340-3ksfpaf7	743	18	NA	NA	NNP
cord-034340-3ksfpaf7	743	19	)	)	-RRB-
cord-034340-3ksfpaf7	743	20	.	.	.
cord-034340-3ksfpaf7	744	1	Abnormal	abnormal	JJ
cord-034340-3ksfpaf7	744	2	Schirmer	Schirmer	NNP
cord-034340-3ksfpaf7	744	3	test	test	NN
cord-034340-3ksfpaf7	744	4	was	be	VBD
cord-034340-3ksfpaf7	744	5	observed	observe	VBN
cord-034340-3ksfpaf7	744	6	in	in	IN
cord-034340-3ksfpaf7	744	7	the	the	DT
cord-034340-3ksfpaf7	744	8	half	half	NN
cord-034340-3ksfpaf7	744	9	of	of	IN
cord-034340-3ksfpaf7	744	10	cases	case	NNS
cord-034340-3ksfpaf7	744	11	(	(	-LRB-
cord-034340-3ksfpaf7	744	12	6/12	6/12	CD
cord-034340-3ksfpaf7	744	13	)	)	-RRB-
cord-034340-3ksfpaf7	744	14	.	.	.
cord-034340-3ksfpaf7	745	1	Minor	minor	JJ
cord-034340-3ksfpaf7	745	2	salivary	salivary	NN
cord-034340-3ksfpaf7	745	3	gland	gland	NN
cord-034340-3ksfpaf7	745	4	biopsy	biopsy	NN
cord-034340-3ksfpaf7	745	5	was	be	VBD
cord-034340-3ksfpaf7	745	6	performed	perform	VBN
cord-034340-3ksfpaf7	745	7	in	in	IN
cord-034340-3ksfpaf7	745	8	10	10	CD
cord-034340-3ksfpaf7	745	9	pts	pt	NNS
cord-034340-3ksfpaf7	745	10	resulting	result	VBG
cord-034340-3ksfpaf7	745	11	in	in	IN
cord-034340-3ksfpaf7	745	12	histological	histological	JJ
cord-034340-3ksfpaf7	745	13	evidence	evidence	NN
cord-034340-3ksfpaf7	745	14	of	of	IN
cord-034340-3ksfpaf7	745	15	focal	focal	JJ
cord-034340-3ksfpaf7	745	16	lymphocytic	lymphocytic	JJ
cord-034340-3ksfpaf7	745	17	sialadenitis	sialadenitis	NN
cord-034340-3ksfpaf7	745	18	in	in	IN
cord-034340-3ksfpaf7	745	19	9/10	9/10	CD
cord-034340-3ksfpaf7	745	20	.	.	.
cord-034340-3ksfpaf7	746	1	Sonographic	sonographic	JJ
cord-034340-3ksfpaf7	746	2	evaluation	evaluation	NN
cord-034340-3ksfpaf7	746	3	of	of	IN
cord-034340-3ksfpaf7	746	4	salivary	salivary	JJ
cord-034340-3ksfpaf7	746	5	glands	gland	NNS
cord-034340-3ksfpaf7	746	6	was	be	VBD
cord-034340-3ksfpaf7	746	7	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	746	8	in	in	IN
cord-034340-3ksfpaf7	746	9	all	all	DT
cord-034340-3ksfpaf7	746	10	of	of	IN
cord-034340-3ksfpaf7	746	11	the	the	DT
cord-034340-3ksfpaf7	746	12	patients	patient	NNS
cord-034340-3ksfpaf7	746	13	(	(	-LRB-
cord-034340-3ksfpaf7	746	14	10/10	10/10	CD
cord-034340-3ksfpaf7	746	15	)	)	-RRB-
cord-034340-3ksfpaf7	746	16	.	.	.
cord-034340-3ksfpaf7	747	1	With	with	IN
cord-034340-3ksfpaf7	747	2	regard	regard	NN
cord-034340-3ksfpaf7	747	3	to	to	IN
cord-034340-3ksfpaf7	747	4	treatment	treatment	NN
cord-034340-3ksfpaf7	747	5	,	,	,
cord-034340-3ksfpaf7	747	6	6/12	6/12	CD
cord-034340-3ksfpaf7	747	7	pts	pts	NN
cord-034340-3ksfpaf7	747	8	received	receive	VBD
cord-034340-3ksfpaf7	747	9	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	747	10	and	and	CC
cord-034340-3ksfpaf7	747	11	eight	eight	CD
cord-034340-3ksfpaf7	747	12	were	be	VBD
cord-034340-3ksfpaf7	747	13	also	also	RB
cord-034340-3ksfpaf7	747	14	treated	treat	VBN
cord-034340-3ksfpaf7	747	15	with	with	IN
cord-034340-3ksfpaf7	747	16	one	one	CD
cord-034340-3ksfpaf7	747	17	or	or	CC
cord-034340-3ksfpaf7	747	18	more	more	JJR
cord-034340-3ksfpaf7	747	19	DMARDs	dmard	NNS
cord-034340-3ksfpaf7	747	20	such	such	PDT
cord-034340-3ksfpaf7	747	21	a	a	DT
cord-034340-3ksfpaf7	747	22	hydroxychloroquine	hydroxychloroquine	NN
cord-034340-3ksfpaf7	747	23	(	(	-LRB-
cord-034340-3ksfpaf7	747	24	n=8	n=8	NNP
cord-034340-3ksfpaf7	747	25	)	)	-RRB-
cord-034340-3ksfpaf7	747	26	,	,	,
cord-034340-3ksfpaf7	747	27	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	747	28	(	(	-LRB-
cord-034340-3ksfpaf7	747	29	n=3	n=3	NN
cord-034340-3ksfpaf7	747	30	)	)	-RRB-
cord-034340-3ksfpaf7	747	31	,	,	,
cord-034340-3ksfpaf7	747	32	azathioprine	azathioprine	JJ
cord-034340-3ksfpaf7	747	33	(	(	-LRB-
cord-034340-3ksfpaf7	747	34	n=1	n=1	CD
cord-034340-3ksfpaf7	747	35	)	)	-RRB-
cord-034340-3ksfpaf7	747	36	,	,	,
cord-034340-3ksfpaf7	747	37	leflunomide	leflunomide	NNP
cord-034340-3ksfpaf7	747	38	(	(	-LRB-
cord-034340-3ksfpaf7	747	39	n=1	n=1	NN
cord-034340-3ksfpaf7	747	40	)	)	-RRB-
cord-034340-3ksfpaf7	747	41	.	.	.
cord-034340-3ksfpaf7	748	1	Biological	biological	JJ
cord-034340-3ksfpaf7	748	2	therapy	therapy	NN
cord-034340-3ksfpaf7	748	3	was	be	VBD
cord-034340-3ksfpaf7	748	4	used	use	VBN
cord-034340-3ksfpaf7	748	5	in	in	IN
cord-034340-3ksfpaf7	748	6	3	3	CD
cord-034340-3ksfpaf7	748	7	patients	patient	NNS
cord-034340-3ksfpaf7	748	8	for	for	IN
cord-034340-3ksfpaf7	748	9	systemic	systemic	JJ
cord-034340-3ksfpaf7	748	10	involvement	involvement	NN
cord-034340-3ksfpaf7	748	11	:	:	:
cord-034340-3ksfpaf7	748	12	1	1	CD
cord-034340-3ksfpaf7	748	13	received	receive	VBN
cord-034340-3ksfpaf7	748	14	belimumab	belimumab	NNP
cord-034340-3ksfpaf7	748	15	and	and	CC
cord-034340-3ksfpaf7	748	16	then	then	RB
cord-034340-3ksfpaf7	748	17	rituximab	rituximab	VBD
cord-034340-3ksfpaf7	748	18	,	,	,
cord-034340-3ksfpaf7	748	19	while	while	IN
cord-034340-3ksfpaf7	748	20	the	the	DT
cord-034340-3ksfpaf7	748	21	other	other	JJ
cord-034340-3ksfpaf7	748	22	patients	patient	NNS
cord-034340-3ksfpaf7	748	23	received	receive	VBD
cord-034340-3ksfpaf7	748	24	rituximab	rituximab	NN
cord-034340-3ksfpaf7	748	25	.	.	.
cord-034340-3ksfpaf7	749	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	749	2	:	:	:
cord-034340-3ksfpaf7	750	1	Xerostomia	Xerostomia	NNP
cord-034340-3ksfpaf7	750	2	and	and	CC
cord-034340-3ksfpaf7	750	3	keratoconjunctivitis	keratoconjunctivitis	NNP
cord-034340-3ksfpaf7	750	4	sicca	sicca	NNP
cord-034340-3ksfpaf7	750	5	were	be	VBD
cord-034340-3ksfpaf7	750	6	not	not	RB
cord-034340-3ksfpaf7	750	7	common	common	JJ
cord-034340-3ksfpaf7	750	8	in	in	IN
cord-034340-3ksfpaf7	750	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	750	10	series	series	NN
cord-034340-3ksfpaf7	750	11	while	while	IN
cord-034340-3ksfpaf7	750	12	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	750	13	parotid	parotid	JJ
cord-034340-3ksfpaf7	750	14	swellings	swelling	NNS
cord-034340-3ksfpaf7	750	15	were	be	VBD
cord-034340-3ksfpaf7	750	16	more	more	RBR
cord-034340-3ksfpaf7	750	17	frequent	frequent	JJ
cord-034340-3ksfpaf7	750	18	than	than	IN
cord-034340-3ksfpaf7	750	19	what	what	WP
cord-034340-3ksfpaf7	750	20	reported	report	VBD
cord-034340-3ksfpaf7	750	21	in	in	IN
cord-034340-3ksfpaf7	750	22	adults	adult	NNS
cord-034340-3ksfpaf7	750	23	.	.	.
cord-034340-3ksfpaf7	751	1	Pediatric	pediatric	JJ
cord-034340-3ksfpaf7	751	2	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	751	3	parotitis	parotitis	NN
cord-034340-3ksfpaf7	751	4	should	should	MD
cord-034340-3ksfpaf7	751	5	increase	increase	VB
cord-034340-3ksfpaf7	751	6	the	the	DT
cord-034340-3ksfpaf7	751	7	suspicion	suspicion	NN
cord-034340-3ksfpaf7	751	8	for	for	IN
cord-034340-3ksfpaf7	751	9	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	751	10	syndrome	syndrome	NN
cord-034340-3ksfpaf7	751	11	.	.	.
cord-034340-3ksfpaf7	752	1	Current	current	JJ
cord-034340-3ksfpaf7	752	2	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	752	3	criteria	criterion	NNS
cord-034340-3ksfpaf7	752	4	for	for	IN
cord-034340-3ksfpaf7	752	5	SS	SS	NNP
cord-034340-3ksfpaf7	752	6	do	do	VBP
cord-034340-3ksfpaf7	752	7	not	not	RB
cord-034340-3ksfpaf7	752	8	include	include	VB
cord-034340-3ksfpaf7	752	9	parotitis	parotitis	NN
cord-034340-3ksfpaf7	752	10	and	and	CC
cord-034340-3ksfpaf7	752	11	therefore	therefore	RB
cord-034340-3ksfpaf7	752	12	,	,	,
cord-034340-3ksfpaf7	752	13	the	the	DT
cord-034340-3ksfpaf7	752	14	incidence	incidence	NN
cord-034340-3ksfpaf7	752	15	of	of	IN
cord-034340-3ksfpaf7	752	16	SS	SS	NNP
cord-034340-3ksfpaf7	752	17	may	may	MD
cord-034340-3ksfpaf7	752	18	be	be	VB
cord-034340-3ksfpaf7	752	19	under	under	RB
cord-034340-3ksfpaf7	752	20	-	-	HYPH
cord-034340-3ksfpaf7	752	21	recognized	recognize	VBN
cord-034340-3ksfpaf7	752	22	in	in	IN
cord-034340-3ksfpaf7	752	23	childhood	childhood	NN
cord-034340-3ksfpaf7	752	24	.	.	.
cord-034340-3ksfpaf7	753	1	The	the	DT
cord-034340-3ksfpaf7	753	2	disease	disease	NN
cord-034340-3ksfpaf7	753	3	is	be	VBZ
cord-034340-3ksfpaf7	753	4	not	not	RB
cord-034340-3ksfpaf7	753	5	always	always	RB
cord-034340-3ksfpaf7	753	6	benign	benign	JJ
cord-034340-3ksfpaf7	753	7	and	and	CC
cord-034340-3ksfpaf7	753	8	patients	patient	NNS
cord-034340-3ksfpaf7	753	9	with	with	IN
cord-034340-3ksfpaf7	753	10	severe	severe	JJ
cord-034340-3ksfpaf7	753	11	course	course	NN
cord-034340-3ksfpaf7	753	12	may	may	MD
cord-034340-3ksfpaf7	753	13	need	need	VB
cord-034340-3ksfpaf7	753	14	second	second	JJ
cord-034340-3ksfpaf7	753	15	line	line	NN
cord-034340-3ksfpaf7	753	16	treatment	treatment	NN
cord-034340-3ksfpaf7	753	17	including	include	VBG
cord-034340-3ksfpaf7	753	18	immunosuppressant	immunosuppressant	JJ
cord-034340-3ksfpaf7	753	19	and	and	CC
cord-034340-3ksfpaf7	753	20	biologics	biologic	NNS
cord-034340-3ksfpaf7	753	21	.	.	.
cord-034340-3ksfpaf7	754	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	754	2	:	:	:
cord-034340-3ksfpaf7	754	3	Improving	improve	VBG
cord-034340-3ksfpaf7	754	4	our	-PRON-	PRP$
cord-034340-3ksfpaf7	754	5	understanding	understanding	NN
cord-034340-3ksfpaf7	754	6	of	of	IN
cord-034340-3ksfpaf7	754	7	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	754	8	rheumatological	rheumatological	JJ
cord-034340-3ksfpaf7	754	9	(	(	-LRB-
cord-034340-3ksfpaf7	754	10	PR	PR	NNP
cord-034340-3ksfpaf7	754	11	)	)	-RRB-
cord-034340-3ksfpaf7	754	12	patient	patient	JJ
cord-034340-3ksfpaf7	754	13	population	population	NN
cord-034340-3ksfpaf7	754	14	is	be	VBZ
cord-034340-3ksfpaf7	754	15	crucial	crucial	JJ
cord-034340-3ksfpaf7	754	16	for	for	IN
cord-034340-3ksfpaf7	754	17	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	754	18	rheumatologists	rheumatologist	NNS
cord-034340-3ksfpaf7	754	19	to	to	TO
cord-034340-3ksfpaf7	754	20	know	know	VB
cord-034340-3ksfpaf7	754	21	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	754	22	disease	disease	NN
cord-034340-3ksfpaf7	754	23	epidemiology	epidemiology	NN
cord-034340-3ksfpaf7	754	24	and	and	CC
cord-034340-3ksfpaf7	754	25	to	to	TO
cord-034340-3ksfpaf7	754	26	raise	raise	VB
cord-034340-3ksfpaf7	754	27	awareness	awareness	NN
cord-034340-3ksfpaf7	754	28	leading	lead	VBG
cord-034340-3ksfpaf7	754	29	to	to	IN
cord-034340-3ksfpaf7	754	30	early	early	JJ
cord-034340-3ksfpaf7	754	31	detection	detection	NN
cord-034340-3ksfpaf7	754	32	.	.	.
cord-034340-3ksfpaf7	755	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	755	2	did	do	VBD
cord-034340-3ksfpaf7	755	3	n't	not	RB
cord-034340-3ksfpaf7	755	4	find	find	VB
cord-034340-3ksfpaf7	755	5	studies	study	NNS
cord-034340-3ksfpaf7	755	6	of	of	IN
cord-034340-3ksfpaf7	755	7	PR	PR	NNP
cord-034340-3ksfpaf7	755	8	disorders	disorder	NNS
cord-034340-3ksfpaf7	755	9	presenting	present	VBG
cord-034340-3ksfpaf7	755	10	in	in	IN
cord-034340-3ksfpaf7	755	11	the	the	DT
cord-034340-3ksfpaf7	755	12	first	first	JJ
cord-034340-3ksfpaf7	755	13	year	year	NN
cord-034340-3ksfpaf7	755	14	of	of	IN
cord-034340-3ksfpaf7	755	15	life	life	NN
cord-034340-3ksfpaf7	755	16	.	.	.
cord-034340-3ksfpaf7	756	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	756	2	:	:	:
cord-034340-3ksfpaf7	757	1	The	the	DT
cord-034340-3ksfpaf7	757	2	aim	aim	NN
cord-034340-3ksfpaf7	757	3	of	of	IN
cord-034340-3ksfpaf7	757	4	this	this	DT
cord-034340-3ksfpaf7	757	5	study	study	NN
cord-034340-3ksfpaf7	757	6	is	be	VBZ
cord-034340-3ksfpaf7	757	7	to	to	TO
cord-034340-3ksfpaf7	757	8	assess	assess	VB
cord-034340-3ksfpaf7	757	9	the	the	DT
cord-034340-3ksfpaf7	757	10	prevalence	prevalence	NN
cord-034340-3ksfpaf7	757	11	of	of	IN
cord-034340-3ksfpaf7	757	12	PR	PR	NNP
cord-034340-3ksfpaf7	757	13	disorders	disorder	NNS
cord-034340-3ksfpaf7	757	14	with	with	IN
cord-034340-3ksfpaf7	757	15	onset	onset	NN
cord-034340-3ksfpaf7	757	16	in	in	IN
cord-034340-3ksfpaf7	757	17	the	the	DT
cord-034340-3ksfpaf7	757	18	first	first	JJ
cord-034340-3ksfpaf7	757	19	year	year	NN
cord-034340-3ksfpaf7	757	20	of	of	IN
cord-034340-3ksfpaf7	757	21	life	life	NN
cord-034340-3ksfpaf7	757	22	.	.	.
cord-034340-3ksfpaf7	758	1	Methods	method	NNS
cord-034340-3ksfpaf7	758	2	:	:	:
cord-034340-3ksfpaf7	758	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	758	4	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	758	5	studied	study	VBD
cord-034340-3ksfpaf7	758	6	patients	patient	NNS
cord-034340-3ksfpaf7	758	7	observed	observe	VBN
cord-034340-3ksfpaf7	758	8	in	in	IN
cord-034340-3ksfpaf7	758	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	758	10	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	758	11	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	758	12	Unit	Unit	NNP
cord-034340-3ksfpaf7	758	13	between	between	IN
cord-034340-3ksfpaf7	758	14	January	January	NNP
cord-034340-3ksfpaf7	758	15	1	1	CD
cord-034340-3ksfpaf7	758	16	st	st	NNP
cord-034340-3ksfpaf7	758	17	of	of	IN
cord-034340-3ksfpaf7	758	18	1987	1987	CD
cord-034340-3ksfpaf7	758	19	and	and	CC
cord-034340-3ksfpaf7	758	20	December	December	NNP
cord-034340-3ksfpaf7	758	21	31	31	CD
cord-034340-3ksfpaf7	758	22	st	st	NNS
cord-034340-3ksfpaf7	758	23	of	of	IN
cord-034340-3ksfpaf7	758	24	2019	2019	CD
cord-034340-3ksfpaf7	758	25	.	.	.
cord-034340-3ksfpaf7	759	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	759	2	defined	define	VBD
cord-034340-3ksfpaf7	759	3	acute	acute	JJ
cord-034340-3ksfpaf7	759	4	(	(	-LRB-
cord-034340-3ksfpaf7	759	5	<	<	NNP
cord-034340-3ksfpaf7	759	6	2	2	CD
cord-034340-3ksfpaf7	759	7	weeks	week	NNS
cord-034340-3ksfpaf7	759	8	)	)	-RRB-
cord-034340-3ksfpaf7	759	9	,	,	,
cord-034340-3ksfpaf7	759	10	subacute	subacute	JJ
cord-034340-3ksfpaf7	759	11	(	(	-LRB-
cord-034340-3ksfpaf7	759	12	≥2	≥2	NNP
cord-034340-3ksfpaf7	759	13	and	and	CC
cord-034340-3ksfpaf7	759	14	<	<	NNP
cord-034340-3ksfpaf7	759	15	6	6	CD
cord-034340-3ksfpaf7	759	16	weeks	week	NNS
cord-034340-3ksfpaf7	759	17	)	)	-RRB-
cord-034340-3ksfpaf7	759	18	and	and	CC
cord-034340-3ksfpaf7	759	19	chronic	chronic	JJ
cord-034340-3ksfpaf7	759	20	(	(	-LRB-
cord-034340-3ksfpaf7	759	21	≥6	≥6	NN
cord-034340-3ksfpaf7	759	22	weeks	week	NNS
cord-034340-3ksfpaf7	759	23	)	)	-RRB-
cord-034340-3ksfpaf7	759	24	.	.	.
cord-034340-3ksfpaf7	760	1	Results	result	NNS
cord-034340-3ksfpaf7	760	2	:	:	:
cord-034340-3ksfpaf7	761	1	A	a	DT
cord-034340-3ksfpaf7	761	2	total	total	NN
cord-034340-3ksfpaf7	761	3	of	of	IN
cord-034340-3ksfpaf7	761	4	3751	3751	CD
cord-034340-3ksfpaf7	761	5	patients	patient	NNS
cord-034340-3ksfpaf7	761	6	were	be	VBD
cord-034340-3ksfpaf7	761	7	observed	observe	VBN
cord-034340-3ksfpaf7	761	8	in	in	IN
cord-034340-3ksfpaf7	761	9	32	32	CD
cord-034340-3ksfpaf7	761	10	years	year	NNS
cord-034340-3ksfpaf7	761	11	.	.	.
cord-034340-3ksfpaf7	762	1	Diseases	disease	NNS
cord-034340-3ksfpaf7	762	2	'	'	POS
cord-034340-3ksfpaf7	762	3	onset	onset	NN
cord-034340-3ksfpaf7	762	4	occurred	occur	VBD
cord-034340-3ksfpaf7	762	5	in	in	IN
cord-034340-3ksfpaf7	762	6	the	the	DT
cord-034340-3ksfpaf7	762	7	first	first	JJ
cord-034340-3ksfpaf7	762	8	decade	decade	NN
cord-034340-3ksfpaf7	762	9	of	of	IN
cord-034340-3ksfpaf7	762	10	life	life	NN
cord-034340-3ksfpaf7	762	11	in	in	IN
cord-034340-3ksfpaf7	762	12	2290	2290	CD
cord-034340-3ksfpaf7	762	13	patients	patient	NNS
cord-034340-3ksfpaf7	762	14	(	(	-LRB-
cord-034340-3ksfpaf7	762	15	61	61	CD
cord-034340-3ksfpaf7	762	16	%	%	NN
cord-034340-3ksfpaf7	762	17	)	)	-RRB-
cord-034340-3ksfpaf7	762	18	and	and	CC
cord-034340-3ksfpaf7	762	19	in	in	IN
cord-034340-3ksfpaf7	762	20	the	the	DT
cord-034340-3ksfpaf7	762	21	first	first	JJ
cord-034340-3ksfpaf7	762	22	year	year	NN
cord-034340-3ksfpaf7	762	23	of	of	IN
cord-034340-3ksfpaf7	762	24	life	life	NN
cord-034340-3ksfpaf7	762	25	in	in	IN
cord-034340-3ksfpaf7	762	26	158	158	CD
cord-034340-3ksfpaf7	762	27	(	(	-LRB-
cord-034340-3ksfpaf7	762	28	4,2	4,2	CD
cord-034340-3ksfpaf7	762	29	%	%	NN
cord-034340-3ksfpaf7	762	30	)	)	-RRB-
cord-034340-3ksfpaf7	762	31	.	.	.
cord-034340-3ksfpaf7	763	1	Among	among	IN
cord-034340-3ksfpaf7	763	2	the	the	DT
cord-034340-3ksfpaf7	763	3	latest	late	JJS
cord-034340-3ksfpaf7	763	4	group	group	NN
cord-034340-3ksfpaf7	763	5	,	,	,
cord-034340-3ksfpaf7	763	6	chronic	chronic	JJ
cord-034340-3ksfpaf7	763	7	inflammation	inflammation	NN
cord-034340-3ksfpaf7	763	8	was	be	VBD
cord-034340-3ksfpaf7	763	9	the	the	DT
cord-034340-3ksfpaf7	763	10	most	most	RBS
cord-034340-3ksfpaf7	763	11	frequent	frequent	JJ
cord-034340-3ksfpaf7	763	12	group	group	NN
cord-034340-3ksfpaf7	763	13	of	of	IN
cord-034340-3ksfpaf7	763	14	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	763	15	(	(	-LRB-
cord-034340-3ksfpaf7	763	16	30	30	CD
cord-034340-3ksfpaf7	763	17	%	%	NN
cord-034340-3ksfpaf7	763	18	)	)	-RRB-
cord-034340-3ksfpaf7	763	19	,	,	,
cord-034340-3ksfpaf7	763	20	followed	follow	VBN
cord-034340-3ksfpaf7	763	21	by	by	IN
cord-034340-3ksfpaf7	763	22	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	763	23	inflammation	inflammation	NN
cord-034340-3ksfpaf7	763	24	(	(	-LRB-
cord-034340-3ksfpaf7	763	25	23	23	CD
cord-034340-3ksfpaf7	763	26	%	%	NN
cord-034340-3ksfpaf7	763	27	)	)	-RRB-
cord-034340-3ksfpaf7	763	28	,	,	,
cord-034340-3ksfpaf7	763	29	acute	acute	JJ
cord-034340-3ksfpaf7	763	30	inflammation	inflammation	NN
cord-034340-3ksfpaf7	763	31	(	(	-LRB-
cord-034340-3ksfpaf7	763	32	11	11	CD
cord-034340-3ksfpaf7	763	33	%	%	NN
cord-034340-3ksfpaf7	763	34	)	)	-RRB-
cord-034340-3ksfpaf7	763	35	,	,	,
cord-034340-3ksfpaf7	763	36	infection	infection	NN
cord-034340-3ksfpaf7	763	37	(	(	-LRB-
cord-034340-3ksfpaf7	763	38	9	9	CD
cord-034340-3ksfpaf7	763	39	%	%	NN
cord-034340-3ksfpaf7	763	40	)	)	-RRB-
cord-034340-3ksfpaf7	763	41	,	,	,
cord-034340-3ksfpaf7	763	42	infiltrative/	infiltrative/	ADD
cord-034340-3ksfpaf7	763	43	degenerative	degenerative	JJ
cord-034340-3ksfpaf7	763	44	disorders	disorder	NNS
cord-034340-3ksfpaf7	763	45	(	(	-LRB-
cord-034340-3ksfpaf7	763	46	8	8	CD
cord-034340-3ksfpaf7	763	47	%	%	NN
cord-034340-3ksfpaf7	763	48	)	)	-RRB-
cord-034340-3ksfpaf7	763	49	and	and	CC
cord-034340-3ksfpaf7	763	50	subacute	subacute	JJ
cord-034340-3ksfpaf7	763	51	inflammation	inflammation	NN
cord-034340-3ksfpaf7	763	52	(	(	-LRB-
cord-034340-3ksfpaf7	763	53	3	3	CD
cord-034340-3ksfpaf7	763	54	%	%	NN
cord-034340-3ksfpaf7	763	55	)	)	-RRB-
cord-034340-3ksfpaf7	763	56	.	.	.
cord-034340-3ksfpaf7	764	1	The	the	DT
cord-034340-3ksfpaf7	764	2	remaining	remain	VBG
cord-034340-3ksfpaf7	764	3	patients	patient	NNS
cord-034340-3ksfpaf7	764	4	(	(	-LRB-
cord-034340-3ksfpaf7	764	5	16	16	CD
cord-034340-3ksfpaf7	764	6	%	%	NN
cord-034340-3ksfpaf7	764	7	)	)	-RRB-
cord-034340-3ksfpaf7	764	8	were	be	VBD
cord-034340-3ksfpaf7	764	9	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	764	10	with	with	IN
cord-034340-3ksfpaf7	764	11	other	other	JJ
cord-034340-3ksfpaf7	764	12	disorders	disorder	NNS
cord-034340-3ksfpaf7	764	13	classified	classify	VBN
cord-034340-3ksfpaf7	764	14	as	as	IN
cord-034340-3ksfpaf7	764	15	miscellaneous	miscellaneous	JJ
cord-034340-3ksfpaf7	764	16	.	.	.
cord-034340-3ksfpaf7	765	1	Among	among	IN
cord-034340-3ksfpaf7	765	2	chronic	chronic	JJ
cord-034340-3ksfpaf7	765	3	inflammation	inflammation	NN
cord-034340-3ksfpaf7	765	4	group	group	NN
cord-034340-3ksfpaf7	765	5	,	,	,
cord-034340-3ksfpaf7	765	6	14	14	CD
cord-034340-3ksfpaf7	765	7	patients	patient	NNS
cord-034340-3ksfpaf7	765	8	were	be	VBD
cord-034340-3ksfpaf7	765	9	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	765	10	with	with	IN
cord-034340-3ksfpaf7	765	11	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	765	12	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	765	13	arthritis	arthritis	NN
cord-034340-3ksfpaf7	765	14	(	(	-LRB-
cord-034340-3ksfpaf7	765	15	4	4	CD
cord-034340-3ksfpaf7	765	16	systemic	systemic	JJ
cord-034340-3ksfpaf7	765	17	)	)	-RRB-
cord-034340-3ksfpaf7	765	18	;	;	:
cord-034340-3ksfpaf7	765	19	14	14	CD
cord-034340-3ksfpaf7	765	20	had	have	VBD
cord-034340-3ksfpaf7	765	21	neonatal	neonatal	JJ
cord-034340-3ksfpaf7	765	22	lupus	lupus	NN
cord-034340-3ksfpaf7	765	23	and	and	CC
cord-034340-3ksfpaf7	765	24	one	one	CD
cord-034340-3ksfpaf7	765	25	patient	patient	NN
cord-034340-3ksfpaf7	766	1	had	have	VBD
cord-034340-3ksfpaf7	766	2	polyarteritis	polyarteritis	NN
cord-034340-3ksfpaf7	766	3	nodosa	nodosa	RB
cord-034340-3ksfpaf7	766	4	.	.	.
cord-034340-3ksfpaf7	767	1	Among	among	IN
cord-034340-3ksfpaf7	767	2	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	767	3	inflammation	inflammation	NN
cord-034340-3ksfpaf7	767	4	group	group	NN
cord-034340-3ksfpaf7	767	5	,	,	,
cord-034340-3ksfpaf7	767	6	13	13	CD
cord-034340-3ksfpaf7	767	7	patients	patient	NNS
cord-034340-3ksfpaf7	767	8	were	be	VBD
cord-034340-3ksfpaf7	767	9	later	later	RB
cord-034340-3ksfpaf7	767	10	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	767	11	with	with	IN
cord-034340-3ksfpaf7	767	12	PFAPA	PFAPA	NNP
cord-034340-3ksfpaf7	767	13	(	(	-LRB-
cord-034340-3ksfpaf7	767	14	periodic	periodic	JJ
cord-034340-3ksfpaf7	767	15	fever	fever	NN
cord-034340-3ksfpaf7	767	16	,	,	,
cord-034340-3ksfpaf7	767	17	aphthous	aphthous	JJ
cord-034340-3ksfpaf7	767	18	stomatitis	stomatitis	NN
cord-034340-3ksfpaf7	767	19	,	,	,
cord-034340-3ksfpaf7	767	20	pharyngitis	pharyngitis	NN
cord-034340-3ksfpaf7	767	21	and	and	CC
cord-034340-3ksfpaf7	767	22	adenitis	adenitis	NNP
cord-034340-3ksfpaf7	767	23	)	)	-RRB-
cord-034340-3ksfpaf7	767	24	,	,	,
cord-034340-3ksfpaf7	767	25	8	8	CD
cord-034340-3ksfpaf7	767	26	were	be	VBD
cord-034340-3ksfpaf7	767	27	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	767	28	with	with	IN
cord-034340-3ksfpaf7	767	29	Behçet	Behçet	NNP
cord-034340-3ksfpaf7	767	30	disease	disease	NN
cord-034340-3ksfpaf7	767	31	and	and	CC
cord-034340-3ksfpaf7	767	32	6	6	CD
cord-034340-3ksfpaf7	767	33	had	have	VBD
cord-034340-3ksfpaf7	767	34	an	an	DT
cord-034340-3ksfpaf7	767	35	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	767	36	disorder	disorder	NN
cord-034340-3ksfpaf7	767	37	.	.	.
cord-034340-3ksfpaf7	768	1	Acute	acute	JJ
cord-034340-3ksfpaf7	768	2	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	768	3	was	be	VBD
cord-034340-3ksfpaf7	768	4	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	768	5	in	in	IN
cord-034340-3ksfpaf7	768	6	13	13	CD
cord-034340-3ksfpaf7	768	7	patients	patient	NNS
cord-034340-3ksfpaf7	768	8	(	(	-LRB-
cord-034340-3ksfpaf7	768	9	9	9	CD
cord-034340-3ksfpaf7	768	10	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	768	11	disease	disease	NN
cord-034340-3ksfpaf7	768	12	and	and	CC
cord-034340-3ksfpaf7	768	13	4	4	CD
cord-034340-3ksfpaf7	768	14	acute	acute	JJ
cord-034340-3ksfpaf7	768	15	hemorrhagic	hemorrhagic	JJ
cord-034340-3ksfpaf7	768	16	edema	edema	NN
cord-034340-3ksfpaf7	768	17	of	of	IN
cord-034340-3ksfpaf7	768	18	infancy	infancy	NN
cord-034340-3ksfpaf7	768	19	)	)	-RRB-
cord-034340-3ksfpaf7	768	20	.	.	.
cord-034340-3ksfpaf7	769	1	Among	among	IN
cord-034340-3ksfpaf7	769	2	infectious	infectious	JJ
cord-034340-3ksfpaf7	769	3	diseases	disease	NNS
cord-034340-3ksfpaf7	769	4	group	group	NN
cord-034340-3ksfpaf7	769	5	,	,	,
cord-034340-3ksfpaf7	769	6	there	there	EX
cord-034340-3ksfpaf7	769	7	were	be	VBD
cord-034340-3ksfpaf7	769	8	two	two	CD
cord-034340-3ksfpaf7	769	9	cases	case	NNS
cord-034340-3ksfpaf7	769	10	of	of	IN
cord-034340-3ksfpaf7	769	11	congenital	congenital	JJ
cord-034340-3ksfpaf7	769	12	syphilis	syphili	NNS
cord-034340-3ksfpaf7	769	13	with	with	IN
cord-034340-3ksfpaf7	769	14	arthritis	arthritis	NN
cord-034340-3ksfpaf7	769	15	and	and	CC
cord-034340-3ksfpaf7	769	16	two	two	CD
cord-034340-3ksfpaf7	769	17	cases	case	NNS
cord-034340-3ksfpaf7	769	18	of	of	IN
cord-034340-3ksfpaf7	769	19	osteomyelitis	osteomyelitis	NN
cord-034340-3ksfpaf7	769	20	secondary	secondary	JJ
cord-034340-3ksfpaf7	769	21	to	to	IN
cord-034340-3ksfpaf7	769	22	BCG	BCG	NNP
cord-034340-3ksfpaf7	769	23	vaccination	vaccination	NN
cord-034340-3ksfpaf7	769	24	.	.	.
cord-034340-3ksfpaf7	770	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	770	2	:	:	:
cord-034340-3ksfpaf7	770	3	Rheumatological	Rheumatological	NNP
cord-034340-3ksfpaf7	770	4	diseases	disease	NNS
cord-034340-3ksfpaf7	770	5	presenting	present	VBG
cord-034340-3ksfpaf7	770	6	in	in	IN
cord-034340-3ksfpaf7	770	7	the	the	DT
cord-034340-3ksfpaf7	770	8	first	first	JJ
cord-034340-3ksfpaf7	770	9	year	year	NN
cord-034340-3ksfpaf7	770	10	of	of	IN
cord-034340-3ksfpaf7	770	11	life	life	NN
cord-034340-3ksfpaf7	770	12	are	be	VBP
cord-034340-3ksfpaf7	770	13	not	not	RB
cord-034340-3ksfpaf7	770	14	exceptional	exceptional	JJ
cord-034340-3ksfpaf7	770	15	.	.	.
cord-034340-3ksfpaf7	771	1	Although	although	IN
cord-034340-3ksfpaf7	771	2	many	many	JJ
cord-034340-3ksfpaf7	771	3	patients	patient	NNS
cord-034340-3ksfpaf7	771	4	did	do	VBD
cord-034340-3ksfpaf7	771	5	n't	not	RB
cord-034340-3ksfpaf7	771	6	have	have	VB
cord-034340-3ksfpaf7	771	7	a	a	DT
cord-034340-3ksfpaf7	771	8	definitive	definitive	JJ
cord-034340-3ksfpaf7	771	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	771	10	at	at	IN
cord-034340-3ksfpaf7	771	11	the	the	DT
cord-034340-3ksfpaf7	771	12	beginning	beginning	NN
cord-034340-3ksfpaf7	771	13	of	of	IN
cord-034340-3ksfpaf7	771	14	the	the	DT
cord-034340-3ksfpaf7	771	15	symptoms	symptom	NNS
cord-034340-3ksfpaf7	771	16	,	,	,
cord-034340-3ksfpaf7	771	17	many	many	JJ
cord-034340-3ksfpaf7	771	18	of	of	IN
cord-034340-3ksfpaf7	771	19	them	-PRON-	PRP
cord-034340-3ksfpaf7	771	20	were	be	VBD
cord-034340-3ksfpaf7	771	21	later	later	RB
cord-034340-3ksfpaf7	771	22	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	771	23	with	with	IN
cord-034340-3ksfpaf7	771	24	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	771	25	disorders	disorder	NNS
cord-034340-3ksfpaf7	771	26	,	,	,
cord-034340-3ksfpaf7	771	27	mostly	mostly	RB
cord-034340-3ksfpaf7	771	28	chronic	chronic	JJ
cord-034340-3ksfpaf7	771	29	inflammation	inflammation	NN
cord-034340-3ksfpaf7	771	30	(	(	-LRB-
cord-034340-3ksfpaf7	771	31	30	30	CD
cord-034340-3ksfpaf7	771	32	%	%	NN
cord-034340-3ksfpaf7	771	33	)	)	-RRB-
cord-034340-3ksfpaf7	771	34	,	,	,
cord-034340-3ksfpaf7	771	35	which	which	WDT
cord-034340-3ksfpaf7	771	36	requires	require	VBZ
cord-034340-3ksfpaf7	771	37	early	early	JJ
cord-034340-3ksfpaf7	771	38	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	771	39	,	,	,
cord-034340-3ksfpaf7	771	40	specific	specific	JJ
cord-034340-3ksfpaf7	771	41	treatment	treatment	NN
cord-034340-3ksfpaf7	771	42	and	and	CC
cord-034340-3ksfpaf7	771	43	long	long	JJ
cord-034340-3ksfpaf7	771	44	-	-	HYPH
cord-034340-3ksfpaf7	771	45	term	term	NN
cord-034340-3ksfpaf7	771	46	follow	follow	NN
cord-034340-3ksfpaf7	771	47	-	-	HYPH
cord-034340-3ksfpaf7	771	48	up	up	NN
cord-034340-3ksfpaf7	771	49	.	.	.
cord-034340-3ksfpaf7	772	1	Rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	772	2	diseases	disease	NNS
cord-034340-3ksfpaf7	772	3	must	must	MD
cord-034340-3ksfpaf7	772	4	be	be	VB
cord-034340-3ksfpaf7	772	5	considered	consider	VBN
cord-034340-3ksfpaf7	772	6	as	as	IN
cord-034340-3ksfpaf7	772	7	differential	differential	JJ
cord-034340-3ksfpaf7	772	8	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	772	9	in	in	IN
cord-034340-3ksfpaf7	772	10	the	the	DT
cord-034340-3ksfpaf7	772	11	first	first	JJ
cord-034340-3ksfpaf7	772	12	year	year	NN
cord-034340-3ksfpaf7	772	13	of	of	IN
cord-034340-3ksfpaf7	772	14	life	life	NN
cord-034340-3ksfpaf7	772	15	in	in	IN
cord-034340-3ksfpaf7	772	16	order	order	NN
cord-034340-3ksfpaf7	772	17	to	to	TO
cord-034340-3ksfpaf7	772	18	avoid	avoid	VB
cord-034340-3ksfpaf7	772	19	delayed	delay	VBN
cord-034340-3ksfpaf7	772	20	intervention	intervention	NN
cord-034340-3ksfpaf7	772	21	and	and	CC
cord-034340-3ksfpaf7	772	22	long	long	JJ
cord-034340-3ksfpaf7	772	23	term	term	NN
cord-034340-3ksfpaf7	772	24	disabilities	disability	NNS
cord-034340-3ksfpaf7	772	25	and	and	CC
cord-034340-3ksfpaf7	772	26	sequelae	sequela	NNS
cord-034340-3ksfpaf7	772	27	.	.	.
cord-034340-3ksfpaf7	773	1	(	(	-LRB-
cord-034340-3ksfpaf7	773	2	1	1	CD
cord-034340-3ksfpaf7	773	3	)	)	-RRB-
cord-034340-3ksfpaf7	773	4	,	,	,
cord-034340-3ksfpaf7	773	5	on	on	IN
cord-034340-3ksfpaf7	773	6	the	the	DT
cord-034340-3ksfpaf7	773	7	other	other	JJ
cord-034340-3ksfpaf7	773	8	side	side	NN
cord-034340-3ksfpaf7	773	9	measles	measle	NNS
cord-034340-3ksfpaf7	773	10	-	-	HYPH
cord-034340-3ksfpaf7	773	11	induced	induce	VBN
cord-034340-3ksfpaf7	773	12	MAS	MAS	NNP
cord-034340-3ksfpaf7	773	13	has	have	VBZ
cord-034340-3ksfpaf7	773	14	rarely	rarely	RB
cord-034340-3ksfpaf7	773	15	been	be	VBN
cord-034340-3ksfpaf7	773	16	reported	report	VBN
cord-034340-3ksfpaf7	773	17	(	(	-LRB-
cord-034340-3ksfpaf7	773	18	2	2	CD
cord-034340-3ksfpaf7	773	19	)	)	-RRB-
cord-034340-3ksfpaf7	773	20	.	.	.
cord-034340-3ksfpaf7	774	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	774	2	:	:	:
cord-034340-3ksfpaf7	775	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	775	2	present	present	VBP
cord-034340-3ksfpaf7	775	3	the	the	DT
cord-034340-3ksfpaf7	775	4	case	case	NN
cord-034340-3ksfpaf7	775	5	of	of	IN
cord-034340-3ksfpaf7	775	6	a	a	DT
cord-034340-3ksfpaf7	775	7	child	child	NN
cord-034340-3ksfpaf7	775	8	known	know	VBN
cord-034340-3ksfpaf7	775	9	to	to	TO
cord-034340-3ksfpaf7	775	10	have	have	VB
cord-034340-3ksfpaf7	775	11	sJIA	sjia	NN
cord-034340-3ksfpaf7	776	1	in	in	IN
cord-034340-3ksfpaf7	776	2	remission	remission	NN
cord-034340-3ksfpaf7	776	3	,	,	,
cord-034340-3ksfpaf7	776	4	who	who	WP
cord-034340-3ksfpaf7	776	5	presented	present	VBD
cord-034340-3ksfpaf7	776	6	a	a	DT
cord-034340-3ksfpaf7	776	7	Measles	Measles	NNP
cord-034340-3ksfpaf7	776	8	primary	primary	JJ
cord-034340-3ksfpaf7	776	9	infection	infection	NN
cord-034340-3ksfpaf7	776	10	and	and	CC
cord-034340-3ksfpaf7	776	11	a	a	DT
cord-034340-3ksfpaf7	776	12	secondary	secondary	JJ
cord-034340-3ksfpaf7	776	13	KD	KD	NNP
cord-034340-3ksfpaf7	776	14	complicated	complicate	VBN
cord-034340-3ksfpaf7	776	15	by	by	IN
cord-034340-3ksfpaf7	776	16	MAS	MAS	NNP
cord-034340-3ksfpaf7	776	17	.	.	.
cord-034340-3ksfpaf7	777	1	Methods	method	NNS
cord-034340-3ksfpaf7	777	2	:	:	:
cord-034340-3ksfpaf7	778	1	A	a	DT
cord-034340-3ksfpaf7	778	2	5	5	CD
cord-034340-3ksfpaf7	778	3	years	year	NNS
cord-034340-3ksfpaf7	778	4	old	old	JJ
cord-034340-3ksfpaf7	778	5	girl	girl	NN
cord-034340-3ksfpaf7	778	6	,	,	,
cord-034340-3ksfpaf7	778	7	not	not	RB
cord-034340-3ksfpaf7	778	8	fully	fully	RB
cord-034340-3ksfpaf7	778	9	vaccinated	vaccinate	VBN
cord-034340-3ksfpaf7	778	10	and	and	CC
cord-034340-3ksfpaf7	778	11	known	know	VBN
cord-034340-3ksfpaf7	778	12	to	to	TO
cord-034340-3ksfpaf7	778	13	have	have	VB
cord-034340-3ksfpaf7	778	14	sJIA	sjia	NN
cord-034340-3ksfpaf7	779	1	in	in	IN
cord-034340-3ksfpaf7	779	2	remission	remission	NN
cord-034340-3ksfpaf7	779	3	under	under	IN
cord-034340-3ksfpaf7	779	4	Methotrexate	Methotrexate	NNP
cord-034340-3ksfpaf7	779	5	,	,	,
cord-034340-3ksfpaf7	779	6	presented	present	VBN
cord-034340-3ksfpaf7	779	7	for	for	IN
cord-034340-3ksfpaf7	779	8	frequent	frequent	JJ
cord-034340-3ksfpaf7	779	9	high	high	JJ
cord-034340-3ksfpaf7	779	10	grade	grade	NN
cord-034340-3ksfpaf7	779	11	fever	fever	NN
cord-034340-3ksfpaf7	779	12	of	of	IN
cord-034340-3ksfpaf7	779	13	3	3	CD
cord-034340-3ksfpaf7	779	14	days	day	NNS
cord-034340-3ksfpaf7	779	15	duration	duration	NN
cord-034340-3ksfpaf7	779	16	associated	associate	VBN
cord-034340-3ksfpaf7	779	17	with	with	IN
cord-034340-3ksfpaf7	779	18	flat	flat	JJ
cord-034340-3ksfpaf7	779	19	flash	flash	NN
cord-034340-3ksfpaf7	779	20	red	red	JJ
cord-034340-3ksfpaf7	779	21	spots	spot	NNS
cord-034340-3ksfpaf7	779	22	on	on	IN
cord-034340-3ksfpaf7	779	23	the	the	DT
cord-034340-3ksfpaf7	779	24	face	face	NN
cord-034340-3ksfpaf7	779	25	and	and	CC
cord-034340-3ksfpaf7	779	26	trunk	trunk	NN
cord-034340-3ksfpaf7	779	27	as	as	RB
cord-034340-3ksfpaf7	779	28	well	well	RB
cord-034340-3ksfpaf7	779	29	as	as	IN
cord-034340-3ksfpaf7	779	30	the	the	DT
cord-034340-3ksfpaf7	779	31	palms	palm	NNS
cord-034340-3ksfpaf7	779	32	and	and	CC
cord-034340-3ksfpaf7	779	33	soles	sol	NNS
cord-034340-3ksfpaf7	779	34	.	.	.
cord-034340-3ksfpaf7	780	1	A	a	DT
cord-034340-3ksfpaf7	780	2	Koplik	Koplik	NNP
cord-034340-3ksfpaf7	780	3	's	's	POS
cord-034340-3ksfpaf7	780	4	spot	spot	NN
cord-034340-3ksfpaf7	780	5	was	be	VBD
cord-034340-3ksfpaf7	780	6	identified	identify	VBN
cord-034340-3ksfpaf7	780	7	.	.	.
cord-034340-3ksfpaf7	781	1	Conjunctivitis	Conjunctivitis	NNP
cord-034340-3ksfpaf7	781	2	and	and	CC
cord-034340-3ksfpaf7	781	3	coryza	coryza	NNP
cord-034340-3ksfpaf7	781	4	were	be	VBD
cord-034340-3ksfpaf7	781	5	also	also	RB
cord-034340-3ksfpaf7	781	6	present	present	JJ
cord-034340-3ksfpaf7	781	7	.	.	.
cord-034340-3ksfpaf7	782	1	Initial	initial	JJ
cord-034340-3ksfpaf7	782	2	viral	viral	JJ
cord-034340-3ksfpaf7	782	3	serology	serology	NN
cord-034340-3ksfpaf7	782	4	,	,	,
cord-034340-3ksfpaf7	782	5	including	include	VBG
cord-034340-3ksfpaf7	782	6	measles	measle	NNS
cord-034340-3ksfpaf7	782	7	,	,	,
cord-034340-3ksfpaf7	782	8	returned	return	VBD
cord-034340-3ksfpaf7	782	9	negative	negative	JJ
cord-034340-3ksfpaf7	782	10	.	.	.
cord-034340-3ksfpaf7	783	1	Fever	fever	NN
cord-034340-3ksfpaf7	783	2	persisted	persist	VBD
cord-034340-3ksfpaf7	783	3	and	and	CC
cord-034340-3ksfpaf7	783	4	on	on	IN
cord-034340-3ksfpaf7	783	5	day	day	NN
cord-034340-3ksfpaf7	783	6	7	7	CD
cord-034340-3ksfpaf7	783	7	,	,	,
cord-034340-3ksfpaf7	783	8	edema	edema	NN
cord-034340-3ksfpaf7	783	9	of	of	IN
cord-034340-3ksfpaf7	783	10	both	both	DT
cord-034340-3ksfpaf7	783	11	hands	hand	NNS
cord-034340-3ksfpaf7	783	12	and	and	CC
cord-034340-3ksfpaf7	783	13	feet	foot	NNS
cord-034340-3ksfpaf7	783	14	appeared	appear	VBD
cord-034340-3ksfpaf7	783	15	with	with	IN
cord-034340-3ksfpaf7	783	16	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	783	17	cervical	cervical	JJ
cord-034340-3ksfpaf7	783	18	adenopathy	adenopathy	NN
cord-034340-3ksfpaf7	783	19	,	,	,
cord-034340-3ksfpaf7	783	20	erythematous	erythematous	JJ
cord-034340-3ksfpaf7	783	21	tonsils	tonsil	NNS
cord-034340-3ksfpaf7	783	22	,	,	,
cord-034340-3ksfpaf7	783	23	gingivitis	gingivitis	NN
cord-034340-3ksfpaf7	783	24	,	,	,
cord-034340-3ksfpaf7	783	25	cracked	crack	VBN
cord-034340-3ksfpaf7	783	26	lips	lip	NNS
cord-034340-3ksfpaf7	783	27	and	and	CC
cord-034340-3ksfpaf7	783	28	hepatomegaly	hepatomegaly	NNP
cord-034340-3ksfpaf7	783	29	was	be	VBD
cord-034340-3ksfpaf7	783	30	noted	note	VBN
cord-034340-3ksfpaf7	783	31	.	.	.
cord-034340-3ksfpaf7	784	1	All	all	DT
cord-034340-3ksfpaf7	784	2	cultures	culture	NNS
cord-034340-3ksfpaf7	784	3	were	be	VBD
cord-034340-3ksfpaf7	784	4	negative	negative	JJ
cord-034340-3ksfpaf7	784	5	and	and	CC
cord-034340-3ksfpaf7	784	6	chest	chest	NN
cord-034340-3ksfpaf7	784	7	X	x	NN
cord-034340-3ksfpaf7	784	8	-	-	NN
cord-034340-3ksfpaf7	784	9	ray	ray	NN
cord-034340-3ksfpaf7	784	10	was	be	VBD
cord-034340-3ksfpaf7	784	11	normal	normal	JJ
cord-034340-3ksfpaf7	784	12	.	.	.
cord-034340-3ksfpaf7	785	1	Inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	785	2	markers	marker	NNS
cord-034340-3ksfpaf7	785	3	rose	rise	VBD
cord-034340-3ksfpaf7	785	4	up	up	RP
cord-034340-3ksfpaf7	785	5	.	.	.
cord-034340-3ksfpaf7	786	1	Viral	viral	JJ
cord-034340-3ksfpaf7	786	2	serology	serology	NN
cord-034340-3ksfpaf7	786	3	was	be	VBD
cord-034340-3ksfpaf7	786	4	repeated	repeat	VBN
cord-034340-3ksfpaf7	786	5	and	and	CC
cord-034340-3ksfpaf7	786	6	measles	measles	NNP
cord-034340-3ksfpaf7	786	7	IgM	IgM	NNP
cord-034340-3ksfpaf7	786	8	came	come	VBD
cord-034340-3ksfpaf7	786	9	back	back	RB
cord-034340-3ksfpaf7	786	10	positive	positive	JJ
cord-034340-3ksfpaf7	786	11	.	.	.
cord-034340-3ksfpaf7	787	1	Cardiac	cardiac	JJ
cord-034340-3ksfpaf7	787	2	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	787	3	ruled	rule	VBD
cord-034340-3ksfpaf7	787	4	out	out	RP
cord-034340-3ksfpaf7	787	5	coronary	coronary	JJ
cord-034340-3ksfpaf7	787	6	aneurism	aneurism	NN
cord-034340-3ksfpaf7	787	7	and	and	CC
cord-034340-3ksfpaf7	787	8	the	the	DT
cord-034340-3ksfpaf7	787	9	ophthalmic	ophthalmic	JJ
cord-034340-3ksfpaf7	787	10	exam	exam	NN
cord-034340-3ksfpaf7	787	11	showed	show	VBD
cord-034340-3ksfpaf7	787	12	no	no	DT
cord-034340-3ksfpaf7	787	13	uveitis	uveitis	NN
cord-034340-3ksfpaf7	787	14	.	.	.
cord-034340-3ksfpaf7	788	1	KD	KD	NNP
cord-034340-3ksfpaf7	788	2	criteria	criterion	NNS
cord-034340-3ksfpaf7	788	3	were	be	VBD
cord-034340-3ksfpaf7	788	4	met	meet	VBN
cord-034340-3ksfpaf7	788	5	and	and	CC
cord-034340-3ksfpaf7	788	6	2g	2g	NNS
cord-034340-3ksfpaf7	788	7	/	/	SYM
cord-034340-3ksfpaf7	788	8	kg	kg	NNS
cord-034340-3ksfpaf7	788	9	of	of	IN
cord-034340-3ksfpaf7	788	10	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	788	11	immunoglobulins	immunoglobulin	NNS
cord-034340-3ksfpaf7	788	12	(	(	-LRB-
cord-034340-3ksfpaf7	788	13	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	788	14	)	)	-RRB-
cord-034340-3ksfpaf7	788	15	were	be	VBD
cord-034340-3ksfpaf7	788	16	administered	administer	VBN
cord-034340-3ksfpaf7	788	17	.	.	.
cord-034340-3ksfpaf7	789	1	After	after	IN
cord-034340-3ksfpaf7	789	2	48	48	CD
cord-034340-3ksfpaf7	789	3	hours	hour	NNS
cord-034340-3ksfpaf7	789	4	of	of	IN
cord-034340-3ksfpaf7	789	5	clinical	clinical	JJ
cord-034340-3ksfpaf7	789	6	improvement	improvement	NN
cord-034340-3ksfpaf7	789	7	,	,	,
cord-034340-3ksfpaf7	789	8	fever	fever	NN
cord-034340-3ksfpaf7	789	9	reappeared	reappear	VBD
cord-034340-3ksfpaf7	789	10	and	and	CC
cord-034340-3ksfpaf7	789	11	the	the	DT
cord-034340-3ksfpaf7	789	12	patient	patient	NN
cord-034340-3ksfpaf7	789	13	returned	return	VBD
cord-034340-3ksfpaf7	789	14	to	to	TO
cord-034340-3ksfpaf7	789	15	be	be	VB
cord-034340-3ksfpaf7	789	16	ill	ill	RB
cord-034340-3ksfpaf7	789	17	looking	look	VBG
cord-034340-3ksfpaf7	789	18	although	although	IN
cord-034340-3ksfpaf7	789	19	the	the	DT
cord-034340-3ksfpaf7	789	20	rash	rash	NN
cord-034340-3ksfpaf7	789	21	regressed	regress	VBD
cord-034340-3ksfpaf7	789	22	.	.	.
cord-034340-3ksfpaf7	790	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	790	2	noted	note	VBD
cord-034340-3ksfpaf7	790	3	high	high	JJ
cord-034340-3ksfpaf7	790	4	ferritine(2016	ferritine(2016	NNP
cord-034340-3ksfpaf7	790	5	ng	ng	NNP
cord-034340-3ksfpaf7	790	6	/	/	SYM
cord-034340-3ksfpaf7	790	7	ml	ml	NNP
cord-034340-3ksfpaf7	790	8	)	)	-RRB-
cord-034340-3ksfpaf7	790	9	together	together	RB
cord-034340-3ksfpaf7	790	10	with	with	IN
cord-034340-3ksfpaf7	790	11	low	low	JJ
cord-034340-3ksfpaf7	790	12	C3	c3	NN
cord-034340-3ksfpaf7	790	13	,	,	,
cord-034340-3ksfpaf7	790	14	decrease	decrease	NN
cord-034340-3ksfpaf7	790	15	in	in	IN
cord-034340-3ksfpaf7	790	16	platelets(170	platelets(170	NNP
cord-034340-3ksfpaf7	790	17	x10	x10	NN
cord-034340-3ksfpaf7	790	18	3	3	CD
cord-034340-3ksfpaf7	790	19	/ml	/ml	.
cord-034340-3ksfpaf7	790	20	)	)	-RRB-
cord-034340-3ksfpaf7	790	21	and	and	CC
cord-034340-3ksfpaf7	790	22	elevation	elevation	NN
cord-034340-3ksfpaf7	790	23	of	of	IN
cord-034340-3ksfpaf7	790	24	hepatic	hepatic	JJ
cord-034340-3ksfpaf7	790	25	enzymes	enzyme	NNS
cord-034340-3ksfpaf7	790	26	,	,	,
cord-034340-3ksfpaf7	790	27	LDH	LDH	NNP
cord-034340-3ksfpaf7	790	28	and	and	CC
cord-034340-3ksfpaf7	790	29	CPK	CPK	NNP
cord-034340-3ksfpaf7	790	30	,	,	,
cord-034340-3ksfpaf7	790	31	without	without	IN
cord-034340-3ksfpaf7	790	32	increase	increase	NN
cord-034340-3ksfpaf7	790	33	in	in	IN
cord-034340-3ksfpaf7	790	34	the	the	DT
cord-034340-3ksfpaf7	790	35	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	790	36	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	790	37	.	.	.
cord-034340-3ksfpaf7	791	1	MAS	MAS	NNP
cord-034340-3ksfpaf7	791	2	was	be	VBD
cord-034340-3ksfpaf7	791	3	suspected	suspect	VBN
cord-034340-3ksfpaf7	791	4	and	and	CC
cord-034340-3ksfpaf7	791	5	a	a	DT
cord-034340-3ksfpaf7	791	6	bone	bone	NN
cord-034340-3ksfpaf7	791	7	marrow	marrow	NN
cord-034340-3ksfpaf7	791	8	aspirate	aspirate	NN
cord-034340-3ksfpaf7	791	9	showed	show	VBD
cord-034340-3ksfpaf7	791	10	the	the	DT
cord-034340-3ksfpaf7	791	11	presence	presence	NN
cord-034340-3ksfpaf7	791	12	of	of	IN
cord-034340-3ksfpaf7	791	13	mild	mild	JJ
cord-034340-3ksfpaf7	791	14	macrophage	macrophage	NN
cord-034340-3ksfpaf7	791	15	hemophagocytosis	hemophagocytosis	NN
cord-034340-3ksfpaf7	791	16	.	.	.
cord-034340-3ksfpaf7	792	1	Antibodies	antibody	NNS
cord-034340-3ksfpaf7	792	2	for	for	IN
cord-034340-3ksfpaf7	792	3	Lupus	Lupus	NNP
cord-034340-3ksfpaf7	792	4	and	and	CC
cord-034340-3ksfpaf7	792	5	auto	auto	NN
cord-034340-3ksfpaf7	792	6	-	-	HYPH
cord-034340-3ksfpaf7	792	7	immune	immune	JJ
cord-034340-3ksfpaf7	792	8	myositis	myositis	NN
cord-034340-3ksfpaf7	792	9	were	be	VBD
cord-034340-3ksfpaf7	792	10	all	all	DT
cord-034340-3ksfpaf7	792	11	negative	negative	JJ
cord-034340-3ksfpaf7	792	12	.	.	.
cord-034340-3ksfpaf7	793	1	Steroids	steroid	NNS
cord-034340-3ksfpaf7	793	2	were	be	VBD
cord-034340-3ksfpaf7	793	3	given	give	VBN
cord-034340-3ksfpaf7	793	4	,	,	,
cord-034340-3ksfpaf7	793	5	fever	fever	NN
cord-034340-3ksfpaf7	793	6	disappeared	disappear	VBD
cord-034340-3ksfpaf7	793	7	,	,	,
cord-034340-3ksfpaf7	793	8	and	and	CC
cord-034340-3ksfpaf7	793	9	spectacular	spectacular	JJ
cord-034340-3ksfpaf7	793	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	793	11	and	and	CC
cord-034340-3ksfpaf7	793	12	biological	biological	JJ
cord-034340-3ksfpaf7	793	13	improvements	improvement	NNS
cord-034340-3ksfpaf7	793	14	were	be	VBD
cord-034340-3ksfpaf7	793	15	objected	object	VBN
cord-034340-3ksfpaf7	793	16	.	.	.
cord-034340-3ksfpaf7	794	1	2	2	CD
cord-034340-3ksfpaf7	794	2	weeks	week	NNS
cord-034340-3ksfpaf7	794	3	later	later	RB
cord-034340-3ksfpaf7	794	4	,	,	,
cord-034340-3ksfpaf7	794	5	desquamation	desquamation	NN
cord-034340-3ksfpaf7	794	6	of	of	IN
cord-034340-3ksfpaf7	794	7	all	all	DT
cord-034340-3ksfpaf7	794	8	extremities	extremity	NNS
cord-034340-3ksfpaf7	794	9	was	be	VBD
cord-034340-3ksfpaf7	794	10	noted	note	VBN
cord-034340-3ksfpaf7	794	11	.	.	.
cord-034340-3ksfpaf7	795	1	SARS	SARS	NNP
cord-034340-3ksfpaf7	795	2	-	-	HYPH
cord-034340-3ksfpaf7	795	3	COV-2	COV-2	NNP
cord-034340-3ksfpaf7	795	4	was	be	VBD
cord-034340-3ksfpaf7	795	5	not	not	RB
cord-034340-3ksfpaf7	795	6	investigated	investigate	VBN
cord-034340-3ksfpaf7	795	7	because	because	IN
cord-034340-3ksfpaf7	795	8	historically	historically	RB
cord-034340-3ksfpaf7	795	9	this	this	DT
cord-034340-3ksfpaf7	795	10	case	case	NN
cord-034340-3ksfpaf7	795	11	presented	present	VBD
cord-034340-3ksfpaf7	795	12	1	1	CD
cord-034340-3ksfpaf7	795	13	year	year	NN
cord-034340-3ksfpaf7	795	14	earlier	early	RBR
cord-034340-3ksfpaf7	795	15	than	than	IN
cord-034340-3ksfpaf7	795	16	the	the	DT
cord-034340-3ksfpaf7	795	17	pandemic	pandemic	NN
cord-034340-3ksfpaf7	795	18	.	.	.
cord-034340-3ksfpaf7	796	1	Results	result	NNS
cord-034340-3ksfpaf7	796	2	:	:	:
cord-034340-3ksfpaf7	797	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	797	2	hereby	hereby	RB
cord-034340-3ksfpaf7	797	3	report	report	VBP
cord-034340-3ksfpaf7	797	4	,	,	,
cord-034340-3ksfpaf7	797	5	for	for	IN
cord-034340-3ksfpaf7	797	6	the	the	DT
cord-034340-3ksfpaf7	797	7	first	first	JJ
cord-034340-3ksfpaf7	797	8	time	time	NN
cord-034340-3ksfpaf7	797	9	,	,	,
cord-034340-3ksfpaf7	797	10	KD	KD	NNP
cord-034340-3ksfpaf7	797	11	and	and	CC
cord-034340-3ksfpaf7	797	12	MAS	MAS	NNP
cord-034340-3ksfpaf7	797	13	triggered	trigger	VBN
cord-034340-3ksfpaf7	797	14	by	by	IN
cord-034340-3ksfpaf7	797	15	Measles	Measles	NNP
cord-034340-3ksfpaf7	797	16	infection	infection	NN
cord-034340-3ksfpaf7	797	17	in	in	IN
cord-034340-3ksfpaf7	797	18	a	a	DT
cord-034340-3ksfpaf7	797	19	child	child	NN
cord-034340-3ksfpaf7	797	20	with	with	IN
cord-034340-3ksfpaf7	797	21	sJIA	sjia	NN
cord-034340-3ksfpaf7	797	22	in	in	IN
cord-034340-3ksfpaf7	797	23	remission	remission	NN
cord-034340-3ksfpaf7	797	24	.	.	.
cord-034340-3ksfpaf7	798	1	The	the	DT
cord-034340-3ksfpaf7	798	2	exact	exact	JJ
cord-034340-3ksfpaf7	798	3	mechanism	mechanism	NN
cord-034340-3ksfpaf7	798	4	involved	involve	VBN
cord-034340-3ksfpaf7	798	5	in	in	IN
cord-034340-3ksfpaf7	798	6	KD	KD	NNP
cord-034340-3ksfpaf7	798	7	-	-	HYPH
cord-034340-3ksfpaf7	798	8	induced	induce	VBN
cord-034340-3ksfpaf7	798	9	MAS	MAS	NNP
cord-034340-3ksfpaf7	798	10	and	and	CC
cord-034340-3ksfpaf7	798	11	Measles	Measles	NNP
cord-034340-3ksfpaf7	798	12	-	-	HYPH
cord-034340-3ksfpaf7	798	13	induced	induce	VBN
cord-034340-3ksfpaf7	798	14	MAS	MAS	NNP
cord-034340-3ksfpaf7	798	15	has	have	VBZ
cord-034340-3ksfpaf7	798	16	not	not	RB
cord-034340-3ksfpaf7	798	17	yet	yet	RB
cord-034340-3ksfpaf7	798	18	been	be	VBN
cord-034340-3ksfpaf7	798	19	defined	define	VBN
cord-034340-3ksfpaf7	798	20	but	but	CC
cord-034340-3ksfpaf7	798	21	a	a	DT
cord-034340-3ksfpaf7	798	22	defective	defective	JJ
cord-034340-3ksfpaf7	798	23	immune	immune	JJ
cord-034340-3ksfpaf7	798	24	response	response	NN
cord-034340-3ksfpaf7	798	25	is	be	VBZ
cord-034340-3ksfpaf7	798	26	suspected	suspect	VBN
cord-034340-3ksfpaf7	798	27	(	(	-LRB-
cord-034340-3ksfpaf7	798	28	3	3	CD
cord-034340-3ksfpaf7	798	29	)	)	-RRB-
cord-034340-3ksfpaf7	798	30	.	.	.
cord-034340-3ksfpaf7	799	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	799	2	:	:	:
cord-034340-3ksfpaf7	800	1	Significant	significant	JJ
cord-034340-3ksfpaf7	800	2	similarities	similarity	NNS
cord-034340-3ksfpaf7	800	3	and	and	CC
cord-034340-3ksfpaf7	800	4	overlap	overlap	VBP
cord-034340-3ksfpaf7	800	5	between	between	IN
cord-034340-3ksfpaf7	800	6	measles	measle	NNS
cord-034340-3ksfpaf7	800	7	,	,	,
cord-034340-3ksfpaf7	800	8	KD	KD	NNP
cord-034340-3ksfpaf7	800	9	,	,	,
cord-034340-3ksfpaf7	800	10	sJIA	sjia	NN
cord-034340-3ksfpaf7	800	11	and	and	CC
cord-034340-3ksfpaf7	800	12	MAS	MAS	NNP
cord-034340-3ksfpaf7	800	13	make	make	VBP
cord-034340-3ksfpaf7	800	14	an	an	DT
cord-034340-3ksfpaf7	800	15	early	early	JJ
cord-034340-3ksfpaf7	800	16	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	800	17	very	very	RB
cord-034340-3ksfpaf7	800	18	challenging	challenging	JJ
cord-034340-3ksfpaf7	800	19	(	(	-LRB-
cord-034340-3ksfpaf7	800	20	1)(3	1)(3	CD
cord-034340-3ksfpaf7	800	21	)	)	-RRB-
cord-034340-3ksfpaf7	800	22	.	.	.
cord-034340-3ksfpaf7	801	1	The	the	DT
cord-034340-3ksfpaf7	801	2	recent	recent	JJ
cord-034340-3ksfpaf7	801	3	COVID19	COVID19	NNP
cord-034340-3ksfpaf7	801	4	pandemic	pandemic	NN
cord-034340-3ksfpaf7	801	5	emphasizes	emphasize	VBZ
cord-034340-3ksfpaf7	801	6	how	how	WRB
cord-034340-3ksfpaf7	801	7	a	a	DT
cord-034340-3ksfpaf7	801	8	viral	viral	JJ
cord-034340-3ksfpaf7	801	9	illness	illness	NN
cord-034340-3ksfpaf7	801	10	can	can	MD
cord-034340-3ksfpaf7	801	11	be	be	VB
cord-034340-3ksfpaf7	801	12	responsible	responsible	JJ
cord-034340-3ksfpaf7	801	13	of	of	IN
cord-034340-3ksfpaf7	801	14	KD	KD	NNP
cord-034340-3ksfpaf7	801	15	and	and	CC
cord-034340-3ksfpaf7	801	16	sometimes	sometimes	RB
cord-034340-3ksfpaf7	801	17	degenerating	degenerate	VBG
cord-034340-3ksfpaf7	801	18	in	in	IN
cord-034340-3ksfpaf7	801	19	MAS	MAS	NNP
cord-034340-3ksfpaf7	801	20	.	.	.
cord-034340-3ksfpaf7	802	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	802	2	report	report	VBP
cord-034340-3ksfpaf7	802	3	this	this	DT
cord-034340-3ksfpaf7	802	4	clinical	clinical	JJ
cord-034340-3ksfpaf7	802	5	case	case	NN
cord-034340-3ksfpaf7	802	6	as	as	IN
cord-034340-3ksfpaf7	802	7	an	an	DT
cord-034340-3ksfpaf7	802	8	example	example	NN
cord-034340-3ksfpaf7	802	9	of	of	IN
cord-034340-3ksfpaf7	802	10	a	a	DT
cord-034340-3ksfpaf7	802	11	Systemic	Systemic	NNP
cord-034340-3ksfpaf7	802	12	Inflammatory	Inflammatory	NNP
cord-034340-3ksfpaf7	802	13	Syndrome	syndrome	NN
cord-034340-3ksfpaf7	802	14	(	(	-LRB-
cord-034340-3ksfpaf7	802	15	SIS	SIS	NNP
cord-034340-3ksfpaf7	802	16	)	)	-RRB-
cord-034340-3ksfpaf7	802	17	taking	take	VBG
cord-034340-3ksfpaf7	802	18	place	place	NN
cord-034340-3ksfpaf7	802	19	after	after	IN
cord-034340-3ksfpaf7	802	20	a	a	DT
cord-034340-3ksfpaf7	802	21	viral	viral	JJ
cord-034340-3ksfpaf7	802	22	infection	infection	NN
cord-034340-3ksfpaf7	802	23	to	to	IN
cord-034340-3ksfpaf7	802	24	Measles	Measles	NNP
cord-034340-3ksfpaf7	802	25	.	.	.
cord-034340-3ksfpaf7	803	1	In	in	IN
cord-034340-3ksfpaf7	803	2	the	the	DT
cord-034340-3ksfpaf7	803	3	era	era	NN
cord-034340-3ksfpaf7	803	4	of	of	IN
cord-034340-3ksfpaf7	803	5	COVID19	COVID19	NNP
cord-034340-3ksfpaf7	803	6	pandemic	pandemic	NN
cord-034340-3ksfpaf7	803	7	and	and	CC
cord-034340-3ksfpaf7	803	8	secondary	secondary	JJ
cord-034340-3ksfpaf7	803	9	SIS	SIS	NNP
cord-034340-3ksfpaf7	803	10	in	in	IN
cord-034340-3ksfpaf7	803	11	children	child	NNS
cord-034340-3ksfpaf7	803	12	,	,	,
cord-034340-3ksfpaf7	803	13	an	an	DT
cord-034340-3ksfpaf7	803	14	additional	additional	JJ
cord-034340-3ksfpaf7	803	15	challenge	challenge	NN
cord-034340-3ksfpaf7	803	16	is	be	VBZ
cord-034340-3ksfpaf7	803	17	present	present	JJ
cord-034340-3ksfpaf7	803	18	in	in	IN
cord-034340-3ksfpaf7	803	19	regions	region	NNS
cord-034340-3ksfpaf7	803	20	lacking	lack	VBG
cord-034340-3ksfpaf7	803	21	Measles	Measles	NNP
cord-034340-3ksfpaf7	803	22	vaccine	vaccine	NN
cord-034340-3ksfpaf7	803	23	coverage	coverage	NN
cord-034340-3ksfpaf7	803	24	.	.	.
cord-034340-3ksfpaf7	803	25	 	 	_SP
cord-034340-3ksfpaf7	804	1	None	none	NN
cord-034340-3ksfpaf7	804	2	declared	declare	VBD
cord-034340-3ksfpaf7	804	3	The	the	DT
cord-034340-3ksfpaf7	804	4	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	804	5	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	804	6	of	of	IN
cord-034340-3ksfpaf7	804	7	scurvy	scurvy	NN
cord-034340-3ksfpaf7	804	8	:	:	:
cord-034340-3ksfpaf7	804	9	a	a	DT
cord-034340-3ksfpaf7	804	10	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	804	11	challenge	challenge	NN
cord-034340-3ksfpaf7	804	12	for	for	IN
cord-034340-3ksfpaf7	804	13	the	the	DT
cord-034340-3ksfpaf7	804	14	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	804	15	P2	P2	NNP
cord-034340-3ksfpaf7	804	16	was	be	VBD
cord-034340-3ksfpaf7	804	17	a	a	DT
cord-034340-3ksfpaf7	804	18	5-year	5-year	CD
cord-034340-3ksfpaf7	804	19	-	-	HYPH
cord-034340-3ksfpaf7	804	20	old	old	JJ
cord-034340-3ksfpaf7	804	21	boy	boy	NN
cord-034340-3ksfpaf7	804	22	,	,	,
cord-034340-3ksfpaf7	804	23	with	with	IN
cord-034340-3ksfpaf7	804	24	autism	autism	NN
cord-034340-3ksfpaf7	804	25	spectrum	spectrum	NN
cord-034340-3ksfpaf7	804	26	disorder	disorder	NN
cord-034340-3ksfpaf7	804	27	,	,	,
cord-034340-3ksfpaf7	804	28	malnutrition	malnutrition	NN
cord-034340-3ksfpaf7	804	29	and	and	CC
cord-034340-3ksfpaf7	804	30	severe	severe	JJ
cord-034340-3ksfpaf7	804	31	food	food	NN
cord-034340-3ksfpaf7	804	32	selectivity	selectivity	NN
cord-034340-3ksfpaf7	804	33	,	,	,
cord-034340-3ksfpaf7	804	34	admitted	admit	VBN
cord-034340-3ksfpaf7	804	35	to	to	IN
cord-034340-3ksfpaf7	804	36	our	-PRON-	PRP$
cord-034340-3ksfpaf7	804	37	Unit	Unit	NNP
cord-034340-3ksfpaf7	804	38	for	for	IN
cord-034340-3ksfpaf7	804	39	refusal	refusal	NN
cord-034340-3ksfpaf7	804	40	to	to	TO
cord-034340-3ksfpaf7	804	41	bear	bear	VB
cord-034340-3ksfpaf7	804	42	weight	weight	NN
cord-034340-3ksfpaf7	804	43	and	and	CC
cord-034340-3ksfpaf7	804	44	bruises	bruise	NNS
cord-034340-3ksfpaf7	804	45	in	in	IN
cord-034340-3ksfpaf7	804	46	lower	low	JJR
cord-034340-3ksfpaf7	804	47	limbs	limb	NNS
cord-034340-3ksfpaf7	804	48	.	.	.
cord-034340-3ksfpaf7	805	1	The	the	DT
cord-034340-3ksfpaf7	805	2	auxological	auxological	JJ
cord-034340-3ksfpaf7	805	3	evaluation	evaluation	NN
cord-034340-3ksfpaf7	805	4	showed	show	VBD
cord-034340-3ksfpaf7	805	5	a	a	DT
cord-034340-3ksfpaf7	805	6	strongly	strongly	RB
cord-034340-3ksfpaf7	805	7	dystrophic	dystrophic	JJ
cord-034340-3ksfpaf7	805	8	aspect	aspect	NN
cord-034340-3ksfpaf7	805	9	.	.	.
cord-034340-3ksfpaf7	806	1	Coagulation	coagulation	NN
cord-034340-3ksfpaf7	806	2	profile	profile	NN
cord-034340-3ksfpaf7	806	3	and	and	CC
cord-034340-3ksfpaf7	806	4	main	main	JJ
cord-034340-3ksfpaf7	806	5	organ	organ	NN
cord-034340-3ksfpaf7	806	6	function	function	NN
cord-034340-3ksfpaf7	806	7	markers	marker	NNS
cord-034340-3ksfpaf7	806	8	were	be	VBD
cord-034340-3ksfpaf7	806	9	normal	normal	JJ
cord-034340-3ksfpaf7	806	10	.	.	.
cord-034340-3ksfpaf7	807	1	At	at	IN
cord-034340-3ksfpaf7	807	2	nutritional	nutritional	JJ
cord-034340-3ksfpaf7	807	3	biochemical	biochemical	JJ
cord-034340-3ksfpaf7	807	4	parameters	parameter	NNS
cord-034340-3ksfpaf7	807	5	evaluation	evaluation	NN
cord-034340-3ksfpaf7	807	6	,	,	,
cord-034340-3ksfpaf7	807	7	iron	iron	NN
cord-034340-3ksfpaf7	807	8	and	and	CC
cord-034340-3ksfpaf7	807	9	Vitamin	vitamin	NN
cord-034340-3ksfpaf7	807	10	C	c	NN
cord-034340-3ksfpaf7	807	11	deficiencies	deficiency	NNS
cord-034340-3ksfpaf7	807	12	were	be	VBD
cord-034340-3ksfpaf7	807	13	detected	detect	VBN
cord-034340-3ksfpaf7	808	1	(	(	-LRB-
cord-034340-3ksfpaf7	808	2	vitamin	vitamin	NN
cord-034340-3ksfpaf7	808	3	C	c	NN
cord-034340-3ksfpaf7	808	4	:	:	:
cord-034340-3ksfpaf7	809	1	2	2	CD
cord-034340-3ksfpaf7	809	2	μmol	μmol	NNP
cord-034340-3ksfpaf7	809	3	/	/	SYM
cord-034340-3ksfpaf7	809	4	l	l	NN
cord-034340-3ksfpaf7	809	5	)	)	-RRB-
cord-034340-3ksfpaf7	809	6	.	.	.
cord-034340-3ksfpaf7	810	1	Oral	oral	JJ
cord-034340-3ksfpaf7	810	2	vitamin	vitamin	NN
cord-034340-3ksfpaf7	810	3	C	c	NN
cord-034340-3ksfpaf7	810	4	therapy	therapy	NN
cord-034340-3ksfpaf7	810	5	was	be	VBD
cord-034340-3ksfpaf7	810	6	started	start	VBN
cord-034340-3ksfpaf7	810	7	,	,	,
cord-034340-3ksfpaf7	810	8	with	with	IN
cord-034340-3ksfpaf7	810	9	prompt	prompt	JJ
cord-034340-3ksfpaf7	810	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	810	11	response	response	NN
cord-034340-3ksfpaf7	810	12	.	.	.
cord-034340-3ksfpaf7	811	1	P3	P3	NNP
cord-034340-3ksfpaf7	811	2	was	be	VBD
cord-034340-3ksfpaf7	811	3	a	a	DT
cord-034340-3ksfpaf7	811	4	7-year	7-year	JJ
cord-034340-3ksfpaf7	811	5	-	-	HYPH
cord-034340-3ksfpaf7	811	6	old	old	JJ
cord-034340-3ksfpaf7	811	7	boy	boy	NN
cord-034340-3ksfpaf7	811	8	with	with	IN
cord-034340-3ksfpaf7	811	9	autism	autism	NN
cord-034340-3ksfpaf7	811	10	spectrum	spectrum	NN
cord-034340-3ksfpaf7	811	11	disorder	disorder	NN
cord-034340-3ksfpaf7	811	12	,	,	,
cord-034340-3ksfpaf7	811	13	admitted	admit	VBN
cord-034340-3ksfpaf7	811	14	to	to	IN
cord-034340-3ksfpaf7	811	15	our	-PRON-	PRP$
cord-034340-3ksfpaf7	811	16	Unit	Unit	NNP
cord-034340-3ksfpaf7	811	17	for	for	IN
cord-034340-3ksfpaf7	811	18	lameness	lameness	NN
cord-034340-3ksfpaf7	811	19	and	and	CC
cord-034340-3ksfpaf7	811	20	difficulty	difficulty	NN
cord-034340-3ksfpaf7	811	21	in	in	IN
cord-034340-3ksfpaf7	811	22	walking	walk	VBG
cord-034340-3ksfpaf7	811	23	for	for	IN
cord-034340-3ksfpaf7	811	24	a	a	DT
cord-034340-3ksfpaf7	811	25	month	month	NN
cord-034340-3ksfpaf7	811	26	.	.	.
cord-034340-3ksfpaf7	812	1	At	at	IN
cord-034340-3ksfpaf7	812	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	812	3	examination	examination	NN
cord-034340-3ksfpaf7	812	4	,	,	,
cord-034340-3ksfpaf7	812	5	a	a	DT
cord-034340-3ksfpaf7	812	6	mottled	mottled	JJ
cord-034340-3ksfpaf7	812	7	skin	skin	NN
cord-034340-3ksfpaf7	812	8	at	at	IN
cord-034340-3ksfpaf7	812	9	lower	low	JJR
cord-034340-3ksfpaf7	812	10	limbs	limb	NNS
cord-034340-3ksfpaf7	812	11	was	be	VBD
cord-034340-3ksfpaf7	812	12	noted	note	VBN
cord-034340-3ksfpaf7	812	13	.	.	.
cord-034340-3ksfpaf7	813	1	Joint	joint	JJ
cord-034340-3ksfpaf7	813	2	examination	examination	NN
cord-034340-3ksfpaf7	813	3	was	be	VBD
cord-034340-3ksfpaf7	813	4	normal	normal	JJ
cord-034340-3ksfpaf7	813	5	.	.	.
cord-034340-3ksfpaf7	814	1	Auxological	auxological	JJ
cord-034340-3ksfpaf7	814	2	parameters	parameter	NNS
cord-034340-3ksfpaf7	814	3	and	and	CC
cord-034340-3ksfpaf7	814	4	main	main	JJ
cord-034340-3ksfpaf7	814	5	blood	blood	NN
cord-034340-3ksfpaf7	814	6	tests	test	NNS
cord-034340-3ksfpaf7	814	7	were	be	VBD
cord-034340-3ksfpaf7	814	8	adequate	adequate	JJ
cord-034340-3ksfpaf7	814	9	for	for	IN
cord-034340-3ksfpaf7	814	10	age	age	NN
cord-034340-3ksfpaf7	814	11	.	.	.
cord-034340-3ksfpaf7	815	1	Given	give	VBN
cord-034340-3ksfpaf7	815	2	the	the	DT
cord-034340-3ksfpaf7	815	3	presence	presence	NN
cord-034340-3ksfpaf7	815	4	of	of	IN
cord-034340-3ksfpaf7	815	5	food	food	NN
cord-034340-3ksfpaf7	815	6	selectivity	selectivity	NN
cord-034340-3ksfpaf7	815	7	,	,	,
cord-034340-3ksfpaf7	815	8	he	-PRON-	PRP
cord-034340-3ksfpaf7	815	9	underwent	undergo	VBD
cord-034340-3ksfpaf7	815	10	serum	serum	JJ
cord-034340-3ksfpaf7	815	11	vitamin	vitamin	NN
cord-034340-3ksfpaf7	815	12	C	C	NNP
cord-034340-3ksfpaf7	815	13	dosage	dosage	NN
cord-034340-3ksfpaf7	815	14	(	(	-LRB-
cord-034340-3ksfpaf7	815	15	11	11	CD
cord-034340-3ksfpaf7	815	16	μmol	μmol	NNP
cord-034340-3ksfpaf7	815	17	/	/	SYM
cord-034340-3ksfpaf7	815	18	L	L	NNP
cord-034340-3ksfpaf7	815	19	)	)	-RRB-
cord-034340-3ksfpaf7	815	20	;	;	:
cord-034340-3ksfpaf7	815	21	hence	hence	RB
cord-034340-3ksfpaf7	815	22	he	-PRON-	PRP
cord-034340-3ksfpaf7	815	23	started	start	VBD
cord-034340-3ksfpaf7	815	24	oral	oral	JJ
cord-034340-3ksfpaf7	815	25	vitamin	vitamin	NN
cord-034340-3ksfpaf7	815	26	C	C	NNP
cord-034340-3ksfpaf7	815	27	therapy	therapy	NN
cord-034340-3ksfpaf7	815	28	,	,	,
cord-034340-3ksfpaf7	815	29	with	with	IN
cord-034340-3ksfpaf7	815	30	rapid	rapid	JJ
cord-034340-3ksfpaf7	815	31	clinical	clinical	JJ
cord-034340-3ksfpaf7	815	32	improvement	improvement	NN
cord-034340-3ksfpaf7	815	33	.	.	.
cord-034340-3ksfpaf7	816	1	P4	p4	NN
cord-034340-3ksfpaf7	816	2	was	be	VBD
cord-034340-3ksfpaf7	816	3	a	a	DT
cord-034340-3ksfpaf7	816	4	2	2	CD
cord-034340-3ksfpaf7	816	5	years	year	NNS
cord-034340-3ksfpaf7	816	6	old	old	JJ
cord-034340-3ksfpaf7	816	7	boy	boy	NN
cord-034340-3ksfpaf7	816	8	who	who	WP
cord-034340-3ksfpaf7	816	9	was	be	VBD
cord-034340-3ksfpaf7	816	10	referred	refer	VBN
cord-034340-3ksfpaf7	816	11	for	for	IN
cord-034340-3ksfpaf7	816	12	coxalgia	coxalgia	NNP
cord-034340-3ksfpaf7	816	13	and	and	CC
cord-034340-3ksfpaf7	816	14	fever	fever	NN
cord-034340-3ksfpaf7	816	15	.	.	.
cord-034340-3ksfpaf7	817	1	At	at	IN
cord-034340-3ksfpaf7	817	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	817	3	examination	examination	NN
cord-034340-3ksfpaf7	817	4	,	,	,
cord-034340-3ksfpaf7	817	5	pale	pale	JJ
cord-034340-3ksfpaf7	817	6	skin	skin	NN
cord-034340-3ksfpaf7	817	7	,	,	,
cord-034340-3ksfpaf7	817	8	gingival	gingival	NNP
cord-034340-3ksfpaf7	817	9	hyperemia	hyperemia	NN
cord-034340-3ksfpaf7	817	10	,	,	,
cord-034340-3ksfpaf7	817	11	and	and	CC
cord-034340-3ksfpaf7	817	12	pain	pain	NN
cord-034340-3ksfpaf7	817	13	in	in	IN
cord-034340-3ksfpaf7	817	14	mobilization	mobilization	NN
cord-034340-3ksfpaf7	817	15	of	of	IN
cord-034340-3ksfpaf7	817	16	the	the	DT
cord-034340-3ksfpaf7	817	17	left	left	JJ
cord-034340-3ksfpaf7	817	18	hip	hip	NN
cord-034340-3ksfpaf7	817	19	were	be	VBD
cord-034340-3ksfpaf7	817	20	present	present	JJ
cord-034340-3ksfpaf7	817	21	.	.	.
cord-034340-3ksfpaf7	818	1	Microcytic	microcytic	JJ
cord-034340-3ksfpaf7	818	2	anemia	anemia	NN
cord-034340-3ksfpaf7	818	3	was	be	VBD
cord-034340-3ksfpaf7	818	4	detected	detect	VBN
cord-034340-3ksfpaf7	818	5	,	,	,
cord-034340-3ksfpaf7	818	6	but	but	CC
cord-034340-3ksfpaf7	818	7	main	main	JJ
cord-034340-3ksfpaf7	818	8	organ	organ	NN
cord-034340-3ksfpaf7	818	9	and	and	CC
cord-034340-3ksfpaf7	818	10	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	818	11	markers	marker	NNS
cord-034340-3ksfpaf7	818	12	were	be	VBD
cord-034340-3ksfpaf7	818	13	normal	normal	JJ
cord-034340-3ksfpaf7	818	14	.	.	.
cord-034340-3ksfpaf7	819	1	No	no	DT
cord-034340-3ksfpaf7	819	2	evidence	evidence	NN
cord-034340-3ksfpaf7	819	3	of	of	IN
cord-034340-3ksfpaf7	819	4	infection	infection	NN
cord-034340-3ksfpaf7	819	5	was	be	VBD
cord-034340-3ksfpaf7	819	6	present	present	JJ
cord-034340-3ksfpaf7	819	7	.	.	.
cord-034340-3ksfpaf7	820	1	X	x	NN
cord-034340-3ksfpaf7	820	2	-	-	NN
cord-034340-3ksfpaf7	820	3	ray	ray	NN
cord-034340-3ksfpaf7	820	4	of	of	IN
cord-034340-3ksfpaf7	820	5	femur	femur	NN
cord-034340-3ksfpaf7	820	6	and	and	CC
cord-034340-3ksfpaf7	820	7	knee	knee	NN
cord-034340-3ksfpaf7	820	8	showed	show	VBD
cord-034340-3ksfpaf7	820	9	morpho	morpho	JJ
cord-034340-3ksfpaf7	820	10	-	-	HYPH
cord-034340-3ksfpaf7	820	11	structural	structural	JJ
cord-034340-3ksfpaf7	820	12	alteration	alteration	NN
cord-034340-3ksfpaf7	820	13	of	of	IN
cord-034340-3ksfpaf7	820	14	the	the	DT
cord-034340-3ksfpaf7	820	15	distal	distal	JJ
cord-034340-3ksfpaf7	820	16	metaphysis	metaphysis	NN
cord-034340-3ksfpaf7	820	17	bilaterally	bilaterally	RB
cord-034340-3ksfpaf7	820	18	.	.	.
cord-034340-3ksfpaf7	821	1	A	a	DT
cord-034340-3ksfpaf7	821	2	low	low	JJ
cord-034340-3ksfpaf7	821	3	intake	intake	NN
cord-034340-3ksfpaf7	821	4	of	of	IN
cord-034340-3ksfpaf7	821	5	fruit	fruit	NN
cord-034340-3ksfpaf7	821	6	and	and	CC
cord-034340-3ksfpaf7	821	7	vegetables	vegetable	NNS
cord-034340-3ksfpaf7	821	8	was	be	VBD
cord-034340-3ksfpaf7	821	9	reported	report	VBN
cord-034340-3ksfpaf7	821	10	;	;	:
cord-034340-3ksfpaf7	821	11	hence	hence	RB
cord-034340-3ksfpaf7	821	12	,	,	,
cord-034340-3ksfpaf7	821	13	dosage	dosage	NN
cord-034340-3ksfpaf7	821	14	of	of	IN
cord-034340-3ksfpaf7	821	15	vitamin	vitamin	NN
cord-034340-3ksfpaf7	821	16	C	C	NNP
cord-034340-3ksfpaf7	821	17	was	be	VBD
cord-034340-3ksfpaf7	821	18	performed	perform	VBN
cord-034340-3ksfpaf7	821	19	,	,	,
cord-034340-3ksfpaf7	821	20	resulting	result	VBG
cord-034340-3ksfpaf7	821	21	reduced	reduce	VBN
cord-034340-3ksfpaf7	821	22	(	(	-LRB-
cord-034340-3ksfpaf7	821	23	2.5	2.5	CD
cord-034340-3ksfpaf7	821	24	μmol	μmol	NNP
cord-034340-3ksfpaf7	821	25	/	/	SYM
cord-034340-3ksfpaf7	821	26	L	L	NNP
cord-034340-3ksfpaf7	821	27	)	)	-RRB-
cord-034340-3ksfpaf7	821	28	.	.	.
cord-034340-3ksfpaf7	822	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	822	2	started	start	VBD
cord-034340-3ksfpaf7	822	3	Vitamin	vitamin	NN
cord-034340-3ksfpaf7	822	4	C	c	NN
cord-034340-3ksfpaf7	822	5	oral	oral	JJ
cord-034340-3ksfpaf7	822	6	therapy	therapy	NN
cord-034340-3ksfpaf7	822	7	with	with	IN
cord-034340-3ksfpaf7	822	8	clinical	clinical	JJ
cord-034340-3ksfpaf7	822	9	response	response	NN
cord-034340-3ksfpaf7	822	10	.	.	.
cord-034340-3ksfpaf7	823	1	P5	p5	NN
cord-034340-3ksfpaf7	823	2	was	be	VBD
cord-034340-3ksfpaf7	823	3	a	a	DT
cord-034340-3ksfpaf7	823	4	13-year	13-year	JJ
cord-034340-3ksfpaf7	823	5	-	-	HYPH
cord-034340-3ksfpaf7	823	6	old	old	JJ
cord-034340-3ksfpaf7	823	7	girl	girl	NN
cord-034340-3ksfpaf7	823	8	with	with	IN
cord-034340-3ksfpaf7	823	9	behavioral	behavioral	JJ
cord-034340-3ksfpaf7	823	10	disorder	disorder	NN
cord-034340-3ksfpaf7	823	11	and	and	CC
cord-034340-3ksfpaf7	823	12	intellectual	intellectual	JJ
cord-034340-3ksfpaf7	823	13	disability	disability	NN
cord-034340-3ksfpaf7	823	14	,	,	,
cord-034340-3ksfpaf7	823	15	admitted	admit	VBN
cord-034340-3ksfpaf7	823	16	for	for	IN
cord-034340-3ksfpaf7	823	17	fever	fever	NN
cord-034340-3ksfpaf7	823	18	and	and	CC
cord-034340-3ksfpaf7	823	19	right	right	JJ
cord-034340-3ksfpaf7	823	20	knee	knee	NN
cord-034340-3ksfpaf7	823	21	swelling	swelling	NN
cord-034340-3ksfpaf7	823	22	which	which	WDT
cord-034340-3ksfpaf7	823	23	appeared	appear	VBD
cord-034340-3ksfpaf7	823	24	two	two	CD
cord-034340-3ksfpaf7	823	25	days	day	NNS
cord-034340-3ksfpaf7	823	26	after	after	IN
cord-034340-3ksfpaf7	823	27	a	a	DT
cord-034340-3ksfpaf7	823	28	right	right	JJ
cord-034340-3ksfpaf7	823	29	leg	leg	NN
cord-034340-3ksfpaf7	823	30	burning	burning	NN
cord-034340-3ksfpaf7	823	31	.	.	.
cord-034340-3ksfpaf7	824	1	C	C	NNP
cord-034340-3ksfpaf7	824	2	-	-	HYPH
cord-034340-3ksfpaf7	824	3	reactive	reactive	JJ
cord-034340-3ksfpaf7	824	4	protein	protein	NN
cord-034340-3ksfpaf7	824	5	and	and	CC
cord-034340-3ksfpaf7	824	6	ESR	ESR	NNP
cord-034340-3ksfpaf7	824	7	were	be	VBD
cord-034340-3ksfpaf7	824	8	elevated	elevate	VBN
cord-034340-3ksfpaf7	824	9	and	and	CC
cord-034340-3ksfpaf7	824	10	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	824	11	exam	exam	NN
cord-034340-3ksfpaf7	824	12	confirmed	confirm	VBD
cord-034340-3ksfpaf7	824	13	intra	intra	JJ
cord-034340-3ksfpaf7	824	14	-	-	JJ
cord-034340-3ksfpaf7	824	15	articular	articular	JJ
cord-034340-3ksfpaf7	824	16	knee	knee	NN
cord-034340-3ksfpaf7	824	17	effusion	effusion	NN
cord-034340-3ksfpaf7	824	18	.	.	.
cord-034340-3ksfpaf7	825	1	Suspecting	suspect	VBG
cord-034340-3ksfpaf7	825	2	a	a	DT
cord-034340-3ksfpaf7	825	3	septic	septic	JJ
cord-034340-3ksfpaf7	825	4	arthritis	arthritis	NN
cord-034340-3ksfpaf7	825	5	,	,	,
cord-034340-3ksfpaf7	825	6	antibiotic	antibiotic	JJ
cord-034340-3ksfpaf7	825	7	therapy	therapy	NN
cord-034340-3ksfpaf7	825	8	was	be	VBD
cord-034340-3ksfpaf7	825	9	started	start	VBN
cord-034340-3ksfpaf7	825	10	with	with	IN
cord-034340-3ksfpaf7	825	11	laboratory	laboratory	NN
cord-034340-3ksfpaf7	825	12	normalization	normalization	NN
cord-034340-3ksfpaf7	825	13	and	and	CC
cord-034340-3ksfpaf7	825	14	partial	partial	JJ
cord-034340-3ksfpaf7	825	15	clinical	clinical	JJ
cord-034340-3ksfpaf7	825	16	improvement	improvement	NN
cord-034340-3ksfpaf7	825	17	.	.	.
cord-034340-3ksfpaf7	826	1	Considering	consider	VBG
cord-034340-3ksfpaf7	826	2	the	the	DT
cord-034340-3ksfpaf7	826	3	persistence	persistence	NN
cord-034340-3ksfpaf7	826	4	of	of	IN
cord-034340-3ksfpaf7	826	5	knee	knee	NN
cord-034340-3ksfpaf7	826	6	swelling	swell	VBG
cord-034340-3ksfpaf7	826	7	after	after	IN
cord-034340-3ksfpaf7	826	8	nine	nine	CD
cord-034340-3ksfpaf7	826	9	days	day	NNS
cord-034340-3ksfpaf7	826	10	of	of	IN
cord-034340-3ksfpaf7	826	11	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	826	12	antibiotic	antibiotic	JJ
cord-034340-3ksfpaf7	826	13	therapy	therapy	NN
cord-034340-3ksfpaf7	826	14	,	,	,
cord-034340-3ksfpaf7	826	15	the	the	DT
cord-034340-3ksfpaf7	826	16	presence	presence	NN
cord-034340-3ksfpaf7	826	17	of	of	IN
cord-034340-3ksfpaf7	826	18	gingival	gingival	NNP
cord-034340-3ksfpaf7	826	19	hyperemia	hyperemia	NNP
cord-034340-3ksfpaf7	826	20	and	and	CC
cord-034340-3ksfpaf7	826	21	history	history	NN
cord-034340-3ksfpaf7	826	22	of	of	IN
cord-034340-3ksfpaf7	826	23	food	food	NN
cord-034340-3ksfpaf7	826	24	selectivity	selectivity	NN
cord-034340-3ksfpaf7	826	25	,	,	,
cord-034340-3ksfpaf7	826	26	vitamin	vitamin	NN
cord-034340-3ksfpaf7	826	27	C	c	NN
cord-034340-3ksfpaf7	826	28	dosage	dosage	NN
cord-034340-3ksfpaf7	826	29	was	be	VBD
cord-034340-3ksfpaf7	826	30	practiced	practice	VBN
cord-034340-3ksfpaf7	826	31	(	(	-LRB-
cord-034340-3ksfpaf7	826	32	12	12	CD
cord-034340-3ksfpaf7	826	33	μmol	μmol	NNP
cord-034340-3ksfpaf7	826	34	/	/	SYM
cord-034340-3ksfpaf7	826	35	l	l	NN
cord-034340-3ksfpaf7	826	36	)	)	-RRB-
cord-034340-3ksfpaf7	826	37	.	.	.
cord-034340-3ksfpaf7	827	1	Oral	oral	JJ
cord-034340-3ksfpaf7	827	2	vitamin	vitamin	NN
cord-034340-3ksfpaf7	827	3	C	c	NN
cord-034340-3ksfpaf7	827	4	was	be	VBD
cord-034340-3ksfpaf7	827	5	administered	administer	VBN
cord-034340-3ksfpaf7	827	6	with	with	IN
cord-034340-3ksfpaf7	827	7	complete	complete	JJ
cord-034340-3ksfpaf7	827	8	clinical	clinical	JJ
cord-034340-3ksfpaf7	827	9	resolution	resolution	NN
cord-034340-3ksfpaf7	827	10	.	.	.
cord-034340-3ksfpaf7	828	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	828	2	:	:	:
cord-034340-3ksfpaf7	829	1	Although	although	IN
cord-034340-3ksfpaf7	829	2	scurvy	scurvy	NN
cord-034340-3ksfpaf7	829	3	is	be	VBZ
cord-034340-3ksfpaf7	829	4	considered	consider	VBN
cord-034340-3ksfpaf7	829	5	a	a	DT
cord-034340-3ksfpaf7	829	6	disease	disease	NN
cord-034340-3ksfpaf7	829	7	of	of	IN
cord-034340-3ksfpaf7	829	8	the	the	DT
cord-034340-3ksfpaf7	829	9	past	past	NN
cord-034340-3ksfpaf7	829	10	,	,	,
cord-034340-3ksfpaf7	829	11	it	-PRON-	PRP
cord-034340-3ksfpaf7	829	12	still	still	RB
cord-034340-3ksfpaf7	829	13	occurs	occur	VBZ
cord-034340-3ksfpaf7	829	14	nowadays	nowadays	RB
cord-034340-3ksfpaf7	829	15	.	.	.
cord-034340-3ksfpaf7	830	1	Food	food	NN
cord-034340-3ksfpaf7	830	2	selectivity	selectivity	NN
cord-034340-3ksfpaf7	830	3	associated	associate	VBN
cord-034340-3ksfpaf7	830	4	to	to	IN
cord-034340-3ksfpaf7	830	5	autism	autism	NN
cord-034340-3ksfpaf7	830	6	is	be	VBZ
cord-034340-3ksfpaf7	830	7	a	a	DT
cord-034340-3ksfpaf7	830	8	major	major	JJ
cord-034340-3ksfpaf7	830	9	risk	risk	NN
cord-034340-3ksfpaf7	830	10	factor	factor	NN
cord-034340-3ksfpaf7	830	11	for	for	IN
cord-034340-3ksfpaf7	830	12	vitamin	vitamin	NN
cord-034340-3ksfpaf7	830	13	C	C	NNP
cord-034340-3ksfpaf7	830	14	deficiency	deficiency	NN
cord-034340-3ksfpaf7	830	15	in	in	IN
cord-034340-3ksfpaf7	830	16	childhood	childhood	NN
cord-034340-3ksfpaf7	830	17	.	.	.
cord-034340-3ksfpaf7	831	1	Rheumatologists	Rheumatologists	NNP
cord-034340-3ksfpaf7	831	2	should	should	MD
cord-034340-3ksfpaf7	831	3	take	take	VB
cord-034340-3ksfpaf7	831	4	into	into	IN
cord-034340-3ksfpaf7	831	5	account	account	NN
cord-034340-3ksfpaf7	831	6	the	the	DT
cord-034340-3ksfpaf7	831	7	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	831	8	of	of	IN
cord-034340-3ksfpaf7	831	9	scurvy	scurvy	NN
cord-034340-3ksfpaf7	831	10	in	in	IN
cord-034340-3ksfpaf7	831	11	the	the	DT
cord-034340-3ksfpaf7	831	12	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	831	13	approach	approach	NN
cord-034340-3ksfpaf7	831	14	of	of	IN
cord-034340-3ksfpaf7	831	15	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	831	16	disorders	disorder	NNS
cord-034340-3ksfpaf7	831	17	in	in	IN
cord-034340-3ksfpaf7	831	18	children	child	NNS
cord-034340-3ksfpaf7	831	19	,	,	,
cord-034340-3ksfpaf7	831	20	especially	especially	RB
cord-034340-3ksfpaf7	831	21	when	when	WRB
cord-034340-3ksfpaf7	831	22	development	development	NN
cord-034340-3ksfpaf7	831	23	disorders	disorder	NNS
cord-034340-3ksfpaf7	831	24	are	be	VBP
cord-034340-3ksfpaf7	831	25	present	present	JJ
cord-034340-3ksfpaf7	831	26	.	.	.
cord-034340-3ksfpaf7	832	1	15.4	15.4	CD
cord-034340-3ksfpaf7	832	2	%	%	NN
cord-034340-3ksfpaf7	832	3	)	)	-RRB-
cord-034340-3ksfpaf7	832	4	,	,	,
cord-034340-3ksfpaf7	832	5	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	832	6	dermatomyositis	dermatomyositis	NN
cord-034340-3ksfpaf7	832	7	(	(	-LRB-
cord-034340-3ksfpaf7	832	8	n=1	n=1	NNP
cord-034340-3ksfpaf7	832	9	)	)	-RRB-
cord-034340-3ksfpaf7	832	10	,	,	,
cord-034340-3ksfpaf7	832	11	sarcoidosis	sarcoidosis	FW
cord-034340-3ksfpaf7	832	12	(	(	-LRB-
cord-034340-3ksfpaf7	832	13	n=1	n=1	CD
cord-034340-3ksfpaf7	832	14	)	)	-RRB-
cord-034340-3ksfpaf7	832	15	,	,	,
cord-034340-3ksfpaf7	832	16	granulomatous	granulomatous	JJ
cord-034340-3ksfpaf7	832	17	polyangiitis	polyangiitis	NN
cord-034340-3ksfpaf7	832	18	(	(	-LRB-
cord-034340-3ksfpaf7	832	19	GPA	GPA	NNP
cord-034340-3ksfpaf7	832	20	)	)	-RRB-
cord-034340-3ksfpaf7	832	21	(	(	-LRB-
cord-034340-3ksfpaf7	832	22	n=1	n=1	FW
cord-034340-3ksfpaf7	832	23	)	)	-RRB-
cord-034340-3ksfpaf7	832	24	,	,	,
cord-034340-3ksfpaf7	832	25	Sting	sting	NN
cord-034340-3ksfpaf7	832	26	-	-	HYPH
cord-034340-3ksfpaf7	832	27	associated	associate	VBN
cord-034340-3ksfpaf7	832	28	vasculopathy	vasculopathy	NNP
cord-034340-3ksfpaf7	832	29	with	with	IN
cord-034340-3ksfpaf7	832	30	onset	onset	NN
cord-034340-3ksfpaf7	832	31	in	in	IN
cord-034340-3ksfpaf7	832	32	infancy	infancy	NN
cord-034340-3ksfpaf7	832	33	(	(	-LRB-
cord-034340-3ksfpaf7	832	34	SAVI	SAVI	NNP
cord-034340-3ksfpaf7	832	35	)	)	-RRB-
cord-034340-3ksfpaf7	832	36	(	(	-LRB-
cord-034340-3ksfpaf7	832	37	n=1	n=1	FW
cord-034340-3ksfpaf7	832	38	)	)	-RRB-
cord-034340-3ksfpaf7	832	39	,	,	,
cord-034340-3ksfpaf7	832	40	and	and	CC
cord-034340-3ksfpaf7	832	41	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	832	42	JIA	JIA	NNP
cord-034340-3ksfpaf7	832	43	(	(	-LRB-
cord-034340-3ksfpaf7	832	44	n=1	n=1	NNP
cord-034340-3ksfpaf7	832	45	)	)	-RRB-
cord-034340-3ksfpaf7	832	46	.	.	.
cord-034340-3ksfpaf7	833	1	Respiratory	respiratory	JJ
cord-034340-3ksfpaf7	833	2	symptoms	symptom	NNS
cord-034340-3ksfpaf7	833	3	were	be	VBD
cord-034340-3ksfpaf7	833	4	present	present	JJ
cord-034340-3ksfpaf7	833	5	in	in	IN
cord-034340-3ksfpaf7	833	6	6	6	CD
cord-034340-3ksfpaf7	833	7	(	(	-LRB-
cord-034340-3ksfpaf7	833	8	46.2	46.2	CD
cord-034340-3ksfpaf7	833	9	%	%	NN
cord-034340-3ksfpaf7	833	10	)	)	-RRB-
cord-034340-3ksfpaf7	833	11	patients	patient	NNS
cord-034340-3ksfpaf7	833	12	at	at	IN
cord-034340-3ksfpaf7	833	13	the	the	DT
cord-034340-3ksfpaf7	833	14	time	time	NN
cord-034340-3ksfpaf7	833	15	of	of	IN
cord-034340-3ksfpaf7	833	16	primary	primary	JJ
cord-034340-3ksfpaf7	833	17	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	833	18	.	.	.
cord-034340-3ksfpaf7	834	1	In	in	IN
cord-034340-3ksfpaf7	834	2	other	other	JJ
cord-034340-3ksfpaf7	834	3	patients	patient	NNS
cord-034340-3ksfpaf7	834	4	,	,	,
cord-034340-3ksfpaf7	834	5	the	the	DT
cord-034340-3ksfpaf7	834	6	time	time	NN
cord-034340-3ksfpaf7	834	7	period	period	NN
cord-034340-3ksfpaf7	834	8	between	between	IN
cord-034340-3ksfpaf7	834	9	the	the	DT
cord-034340-3ksfpaf7	834	10	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	834	11	of	of	IN
cord-034340-3ksfpaf7	834	12	the	the	DT
cord-034340-3ksfpaf7	834	13	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	834	14	disease	disease	NN
cord-034340-3ksfpaf7	834	15	and	and	CC
cord-034340-3ksfpaf7	834	16	the	the	DT
cord-034340-3ksfpaf7	834	17	onset	onset	NN
cord-034340-3ksfpaf7	834	18	of	of	IN
cord-034340-3ksfpaf7	834	19	the	the	DT
cord-034340-3ksfpaf7	834	20	respiratory	respiratory	JJ
cord-034340-3ksfpaf7	834	21	symptoms	symptom	NNS
cord-034340-3ksfpaf7	834	22	ranged	range	VBD
cord-034340-3ksfpaf7	834	23	from	from	IN
cord-034340-3ksfpaf7	834	24	1	1	CD
cord-034340-3ksfpaf7	834	25	to	to	TO
cord-034340-3ksfpaf7	834	26	12	12	CD
cord-034340-3ksfpaf7	834	27	years	year	NNS
cord-034340-3ksfpaf7	834	28	.	.	.
cord-034340-3ksfpaf7	835	1	Cough	cough	NN
cord-034340-3ksfpaf7	835	2	,	,	,
cord-034340-3ksfpaf7	835	3	the	the	DT
cord-034340-3ksfpaf7	835	4	most	most	RBS
cord-034340-3ksfpaf7	835	5	common	common	JJ
cord-034340-3ksfpaf7	835	6	symptom	symptom	NN
cord-034340-3ksfpaf7	835	7	,	,	,
cord-034340-3ksfpaf7	835	8	was	be	VBD
cord-034340-3ksfpaf7	835	9	present	present	JJ
cord-034340-3ksfpaf7	835	10	in	in	IN
cord-034340-3ksfpaf7	835	11	10	10	CD
cord-034340-3ksfpaf7	835	12	(	(	-LRB-
cord-034340-3ksfpaf7	835	13	76.9	76.9	CD
cord-034340-3ksfpaf7	835	14	%	%	NN
cord-034340-3ksfpaf7	835	15	)	)	-RRB-
cord-034340-3ksfpaf7	835	16	patients	patient	NNS
cord-034340-3ksfpaf7	835	17	.	.	.
cord-034340-3ksfpaf7	836	1	Six	six	CD
cord-034340-3ksfpaf7	836	2	patients	patient	NNS
cord-034340-3ksfpaf7	836	3	manifested	manifest	VBN
cord-034340-3ksfpaf7	836	4	with	with	IN
cord-034340-3ksfpaf7	836	5	cough	cough	NN
cord-034340-3ksfpaf7	836	6	and	and	CC
cord-034340-3ksfpaf7	836	7	sputum	sputum	NN
cord-034340-3ksfpaf7	836	8	.	.	.
cord-034340-3ksfpaf7	837	1	Six	six	CD
cord-034340-3ksfpaf7	837	2	(	(	-LRB-
cord-034340-3ksfpaf7	837	3	46.2	46.2	CD
cord-034340-3ksfpaf7	837	4	%	%	NN
cord-034340-3ksfpaf7	837	5	)	)	-RRB-
cord-034340-3ksfpaf7	838	1	patients	patient	NNS
cord-034340-3ksfpaf7	838	2	had	have	VBD
cord-034340-3ksfpaf7	838	3	shortness	shortness	NN
cord-034340-3ksfpaf7	838	4	of	of	IN
cord-034340-3ksfpaf7	838	5	breath	breath	NN
cord-034340-3ksfpaf7	838	6	and	and	CC
cord-034340-3ksfpaf7	838	7	one	one	CD
cord-034340-3ksfpaf7	838	8	patient	patient	NN
cord-034340-3ksfpaf7	838	9	had	have	VBD
cord-034340-3ksfpaf7	838	10	hemoptysis	hemoptysis	NN
cord-034340-3ksfpaf7	838	11	.	.	.
cord-034340-3ksfpaf7	839	1	On	on	IN
cord-034340-3ksfpaf7	839	2	the	the	DT
cord-034340-3ksfpaf7	839	3	physical	physical	JJ
cord-034340-3ksfpaf7	839	4	examination	examination	NN
cord-034340-3ksfpaf7	839	5	of	of	IN
cord-034340-3ksfpaf7	839	6	one	one	CD
cord-034340-3ksfpaf7	839	7	patient	patient	NN
cord-034340-3ksfpaf7	839	8	,	,	,
cord-034340-3ksfpaf7	839	9	rales	rale	NNS
cord-034340-3ksfpaf7	839	10	and	and	CC
cord-034340-3ksfpaf7	839	11	clubbing	clubbing	NN
cord-034340-3ksfpaf7	839	12	were	be	VBD
cord-034340-3ksfpaf7	839	13	detected	detect	VBN
cord-034340-3ksfpaf7	839	14	.	.	.
cord-034340-3ksfpaf7	840	1	High	high	JJ
cord-034340-3ksfpaf7	840	2	resonance	resonance	NN
cord-034340-3ksfpaf7	840	3	computerized	computerized	NN
cord-034340-3ksfpaf7	840	4	tomography	tomography	NN
cord-034340-3ksfpaf7	840	5	(	(	-LRB-
cord-034340-3ksfpaf7	840	6	HRCT	HRCT	NNP
cord-034340-3ksfpaf7	840	7	)	)	-RRB-
cord-034340-3ksfpaf7	840	8	was	be	VBD
cord-034340-3ksfpaf7	840	9	performed	perform	VBN
cord-034340-3ksfpaf7	840	10	in	in	IN
cord-034340-3ksfpaf7	840	11	all	all	DT
cord-034340-3ksfpaf7	840	12	patients	patient	NNS
cord-034340-3ksfpaf7	840	13	.	.	.
cord-034340-3ksfpaf7	841	1	HRCT	HRCT	NNP
cord-034340-3ksfpaf7	841	2	findings	finding	NNS
cord-034340-3ksfpaf7	841	3	were	be	VBD
cord-034340-3ksfpaf7	841	4	as	as	IN
cord-034340-3ksfpaf7	841	5	follows	follow	VBZ
cord-034340-3ksfpaf7	841	6	;	;	:
cord-034340-3ksfpaf7	841	7	lymphadenopathy	lymphadenopathy	JJ
cord-034340-3ksfpaf7	841	8	in	in	IN
cord-034340-3ksfpaf7	841	9	8	8	CD
cord-034340-3ksfpaf7	841	10	patients	patient	NNS
cord-034340-3ksfpaf7	841	11	(	(	-LRB-
cord-034340-3ksfpaf7	841	12	61.5	61.5	CD
cord-034340-3ksfpaf7	841	13	%	%	NN
cord-034340-3ksfpaf7	841	14	)	)	-RRB-
cord-034340-3ksfpaf7	841	15	,	,	,
cord-034340-3ksfpaf7	841	16	ground	ground	NN
cord-034340-3ksfpaf7	841	17	glass	glass	NN
cord-034340-3ksfpaf7	841	18	appearance	appearance	NN
cord-034340-3ksfpaf7	841	19	in	in	IN
cord-034340-3ksfpaf7	841	20	10	10	CD
cord-034340-3ksfpaf7	841	21	patients	patient	NNS
cord-034340-3ksfpaf7	841	22	(	(	-LRB-
cord-034340-3ksfpaf7	841	23	76.9	76.9	CD
cord-034340-3ksfpaf7	841	24	%	%	NN
cord-034340-3ksfpaf7	841	25	)	)	-RRB-
cord-034340-3ksfpaf7	841	26	,	,	,
cord-034340-3ksfpaf7	841	27	consolidation	consolidation	NN
cord-034340-3ksfpaf7	841	28	in	in	IN
cord-034340-3ksfpaf7	841	29	one	one	CD
cord-034340-3ksfpaf7	841	30	patient	patient	NN
cord-034340-3ksfpaf7	841	31	,	,	,
cord-034340-3ksfpaf7	841	32	pleural	pleural	JJ
cord-034340-3ksfpaf7	841	33	effusion	effusion	NN
cord-034340-3ksfpaf7	841	34	in	in	IN
cord-034340-3ksfpaf7	841	35	one	one	CD
cord-034340-3ksfpaf7	841	36	patient	patient	NN
cord-034340-3ksfpaf7	841	37	,	,	,
cord-034340-3ksfpaf7	841	38	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	841	39	nodule	nodule	NN
cord-034340-3ksfpaf7	841	40	in	in	IN
cord-034340-3ksfpaf7	841	41	4	4	CD
cord-034340-3ksfpaf7	841	42	patients	patient	NNS
cord-034340-3ksfpaf7	841	43	(	(	-LRB-
cord-034340-3ksfpaf7	841	44	30.8	30.8	CD
cord-034340-3ksfpaf7	841	45	%	%	NN
cord-034340-3ksfpaf7	841	46	)	)	-RRB-
cord-034340-3ksfpaf7	841	47	,	,	,
cord-034340-3ksfpaf7	841	48	fibrosis	fibrosis	NN
cord-034340-3ksfpaf7	841	49	in	in	IN
cord-034340-3ksfpaf7	841	50	one	one	CD
cord-034340-3ksfpaf7	841	51	patient	patient	NN
cord-034340-3ksfpaf7	841	52	,	,	,
cord-034340-3ksfpaf7	841	53	cystic	cystic	JJ
cord-034340-3ksfpaf7	841	54	lesions	lesion	NNS
cord-034340-3ksfpaf7	841	55	in	in	IN
cord-034340-3ksfpaf7	841	56	3	3	CD
cord-034340-3ksfpaf7	841	57	patients	patient	NNS
cord-034340-3ksfpaf7	841	58	(	(	-LRB-
cord-034340-3ksfpaf7	841	59	23.1	23.1	CD
cord-034340-3ksfpaf7	841	60	%	%	NN
cord-034340-3ksfpaf7	841	61	)	)	-RRB-
cord-034340-3ksfpaf7	841	62	,	,	,
cord-034340-3ksfpaf7	841	63	septal	septal	JJ
cord-034340-3ksfpaf7	841	64	thickening	thickening	NN
cord-034340-3ksfpaf7	841	65	in	in	IN
cord-034340-3ksfpaf7	841	66	5	5	CD
cord-034340-3ksfpaf7	841	67	patients	patient	NNS
cord-034340-3ksfpaf7	841	68	(	(	-LRB-
cord-034340-3ksfpaf7	841	69	38.5	38.5	CD
cord-034340-3ksfpaf7	841	70	%	%	NN
cord-034340-3ksfpaf7	841	71	)	)	-RRB-
cord-034340-3ksfpaf7	841	72	,	,	,
cord-034340-3ksfpaf7	841	73	bronchiectasis	bronchiectasis	NN
cord-034340-3ksfpaf7	841	74	in	in	IN
cord-034340-3ksfpaf7	841	75	one	one	CD
cord-034340-3ksfpaf7	841	76	patient	patient	NN
cord-034340-3ksfpaf7	841	77	,	,	,
cord-034340-3ksfpaf7	841	78	and	and	CC
cord-034340-3ksfpaf7	841	79	reverse	reverse	VB
cord-034340-3ksfpaf7	841	80	halo	halo	NN
cord-034340-3ksfpaf7	841	81	sign	sign	NN
cord-034340-3ksfpaf7	841	82	in	in	IN
cord-034340-3ksfpaf7	841	83	one	one	CD
cord-034340-3ksfpaf7	841	84	patient	patient	NN
cord-034340-3ksfpaf7	841	85	.	.	.
cord-034340-3ksfpaf7	842	1	In	in	IN
cord-034340-3ksfpaf7	842	2	echocardiographic	echocardiographic	JJ
cord-034340-3ksfpaf7	842	3	examination	examination	NN
cord-034340-3ksfpaf7	842	4	,	,	,
cord-034340-3ksfpaf7	842	5	only	only	RB
cord-034340-3ksfpaf7	842	6	one	one	CD
cord-034340-3ksfpaf7	842	7	patient	patient	NN
cord-034340-3ksfpaf7	842	8	had	have	VBD
cord-034340-3ksfpaf7	842	9	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	842	10	hypertension	hypertension	NN
cord-034340-3ksfpaf7	842	11	.	.	.
cord-034340-3ksfpaf7	843	1	Three	three	CD
cord-034340-3ksfpaf7	843	2	patients	patient	NNS
cord-034340-3ksfpaf7	843	3	underwent	undergo	VBD
cord-034340-3ksfpaf7	843	4	open	open	JJ
cord-034340-3ksfpaf7	843	5	lung	lung	NN
cord-034340-3ksfpaf7	843	6	biopsy	biopsy	NN
cord-034340-3ksfpaf7	843	7	,	,	,
cord-034340-3ksfpaf7	843	8	and	and	CC
cord-034340-3ksfpaf7	843	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	843	10	was	be	VBD
cord-034340-3ksfpaf7	843	11	made	make	VBN
cord-034340-3ksfpaf7	843	12	with	with	IN
cord-034340-3ksfpaf7	843	13	pathological	pathological	JJ
cord-034340-3ksfpaf7	843	14	examination	examination	NN
cord-034340-3ksfpaf7	843	15	of	of	IN
cord-034340-3ksfpaf7	843	16	the	the	DT
cord-034340-3ksfpaf7	843	17	lung	lung	NN
cord-034340-3ksfpaf7	843	18	tissue	tissue	NN
cord-034340-3ksfpaf7	843	19	.	.	.
cord-034340-3ksfpaf7	844	1	Of	of	IN
cord-034340-3ksfpaf7	844	2	these	these	DT
cord-034340-3ksfpaf7	844	3	three	three	CD
cord-034340-3ksfpaf7	844	4	patients	patient	NNS
cord-034340-3ksfpaf7	844	5	,	,	,
cord-034340-3ksfpaf7	844	6	two	two	CD
cord-034340-3ksfpaf7	844	7	(	(	-LRB-
cord-034340-3ksfpaf7	844	8	15.4	15.4	CD
cord-034340-3ksfpaf7	844	9	%	%	NN
cord-034340-3ksfpaf7	844	10	)	)	-RRB-
cord-034340-3ksfpaf7	844	11	had	have	VBD
cord-034340-3ksfpaf7	844	12	lymphocytic	lymphocytic	JJ
cord-034340-3ksfpaf7	844	13	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	844	14	pneumonia	pneumonia	NN
cord-034340-3ksfpaf7	844	15	(	(	-LRB-
cord-034340-3ksfpaf7	844	16	LIP	LIP	NNP
cord-034340-3ksfpaf7	844	17	)	)	-RRB-
cord-034340-3ksfpaf7	844	18	,	,	,
cord-034340-3ksfpaf7	844	19	and	and	CC
cord-034340-3ksfpaf7	844	20	one	one	CD
cord-034340-3ksfpaf7	844	21	patient	patient	NN
cord-034340-3ksfpaf7	844	22	had	have	VBD
cord-034340-3ksfpaf7	844	23	chronic	chronic	JJ
cord-034340-3ksfpaf7	844	24	inflammation	inflammation	NN
cord-034340-3ksfpaf7	844	25	and	and	CC
cord-034340-3ksfpaf7	844	26	focal	focal	JJ
cord-034340-3ksfpaf7	844	27	fibrosis	fibrosis	NN
cord-034340-3ksfpaf7	844	28	.	.	.
cord-034340-3ksfpaf7	845	1	Infectious	infectious	JJ
cord-034340-3ksfpaf7	845	2	lung	lung	NN
cord-034340-3ksfpaf7	845	3	disease	disease	NN
cord-034340-3ksfpaf7	845	4	was	be	VBD
cord-034340-3ksfpaf7	845	5	not	not	RB
cord-034340-3ksfpaf7	845	6	detected	detect	VBN
cord-034340-3ksfpaf7	845	7	in	in	IN
cord-034340-3ksfpaf7	845	8	any	any	DT
cord-034340-3ksfpaf7	845	9	patient	patient	NN
cord-034340-3ksfpaf7	845	10	.	.	.
cord-034340-3ksfpaf7	846	1	Ten	ten	CD
cord-034340-3ksfpaf7	846	2	patients	patient	NNS
cord-034340-3ksfpaf7	846	3	(	(	-LRB-
cord-034340-3ksfpaf7	846	4	76.9	76.9	CD
cord-034340-3ksfpaf7	846	5	%	%	NN
cord-034340-3ksfpaf7	846	6	)	)	-RRB-
cord-034340-3ksfpaf7	846	7	had	have	VBD
cord-034340-3ksfpaf7	846	8	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	846	9	lung	lung	NN
cord-034340-3ksfpaf7	846	10	disease	disease	NN
cord-034340-3ksfpaf7	846	11	associated	associate	VBN
cord-034340-3ksfpaf7	846	12	with	with	IN
cord-034340-3ksfpaf7	846	13	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	846	14	disease	disease	NN
cord-034340-3ksfpaf7	846	15	,	,	,
cord-034340-3ksfpaf7	846	16	one	one	CD
cord-034340-3ksfpaf7	846	17	patient	patient	NN
cord-034340-3ksfpaf7	846	18	had	have	VBD
cord-034340-3ksfpaf7	846	19	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	846	20	hemorrhage	hemorrhage	NN
cord-034340-3ksfpaf7	846	21	,	,	,
cord-034340-3ksfpaf7	846	22	one	one	CD
cord-034340-3ksfpaf7	846	23	patient	patient	NN
cord-034340-3ksfpaf7	846	24	had	have	VBD
cord-034340-3ksfpaf7	846	25	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	846	26	involvement	involvement	NN
cord-034340-3ksfpaf7	846	27	of	of	IN
cord-034340-3ksfpaf7	846	28	GPA	GPA	NNP
cord-034340-3ksfpaf7	846	29	,	,	,
cord-034340-3ksfpaf7	846	30	one	one	CD
cord-034340-3ksfpaf7	846	31	patient	patient	NN
cord-034340-3ksfpaf7	846	32	had	have	VBD
cord-034340-3ksfpaf7	846	33	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	846	34	involvement	involvement	NN
cord-034340-3ksfpaf7	846	35	of	of	IN
cord-034340-3ksfpaf7	846	36	sarcoidosis	sarcoidosis	NN
cord-034340-3ksfpaf7	846	37	.	.	.
cord-034340-3ksfpaf7	847	1	There	there	EX
cord-034340-3ksfpaf7	847	2	was	be	VBD
cord-034340-3ksfpaf7	847	3	no	no	DT
cord-034340-3ksfpaf7	847	4	statistically	statistically	RB
cord-034340-3ksfpaf7	847	5	significant	significant	JJ
cord-034340-3ksfpaf7	847	6	difference	difference	NN
cord-034340-3ksfpaf7	847	7	between	between	IN
cord-034340-3ksfpaf7	847	8	the	the	DT
cord-034340-3ksfpaf7	847	9	first	first	JJ
cord-034340-3ksfpaf7	847	10	and	and	CC
cord-034340-3ksfpaf7	847	11	last	last	JJ
cord-034340-3ksfpaf7	847	12	spirometry	spirometry	NN
cord-034340-3ksfpaf7	847	13	and	and	CC
cord-034340-3ksfpaf7	847	14	DLCO	DLCO	NNP
cord-034340-3ksfpaf7	847	15	values	value	NNS
cord-034340-3ksfpaf7	847	16	during	during	IN
cord-034340-3ksfpaf7	847	17	the	the	DT
cord-034340-3ksfpaf7	847	18	follow	follow	NN
cord-034340-3ksfpaf7	847	19	-	-	HYPH
cord-034340-3ksfpaf7	847	20	up	up	NN
cord-034340-3ksfpaf7	847	21	period	period	NN
cord-034340-3ksfpaf7	847	22	.	.	.
cord-034340-3ksfpaf7	848	1	Mortality	mortality	NN
cord-034340-3ksfpaf7	848	2	was	be	VBD
cord-034340-3ksfpaf7	848	3	7.5	7.5	CD
cord-034340-3ksfpaf7	848	4	%	%	NN
cord-034340-3ksfpaf7	848	5	(	(	-LRB-
cord-034340-3ksfpaf7	848	6	1/	1/	CD
cord-034340-3ksfpaf7	848	7	13	13	CD
cord-034340-3ksfpaf7	848	8	)	)	-RRB-
cord-034340-3ksfpaf7	848	9	in	in	IN
cord-034340-3ksfpaf7	848	10	this	this	DT
cord-034340-3ksfpaf7	848	11	cohort	cohort	NN
cord-034340-3ksfpaf7	848	12	.	.	.
cord-034340-3ksfpaf7	849	1	Active	active	JJ
cord-034340-3ksfpaf7	849	2	disease	disease	NN
cord-034340-3ksfpaf7	849	3	was	be	VBD
cord-034340-3ksfpaf7	849	4	significantly	significantly	RB
cord-034340-3ksfpaf7	849	5	associated	associate	VBN
cord-034340-3ksfpaf7	849	6	with	with	IN
cord-034340-3ksfpaf7	849	7	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	849	8	TC	TC	NNP
cord-034340-3ksfpaf7	849	9	,	,	,
cord-034340-3ksfpaf7	849	10	HDL	HDL	NNP
cord-034340-3ksfpaf7	849	11	,	,	,
cord-034340-3ksfpaf7	849	12	and	and	CC
cord-034340-3ksfpaf7	849	13	TG	TG	NNP
cord-034340-3ksfpaf7	849	14	levels	level	NNS
cord-034340-3ksfpaf7	849	15	(	(	-LRB-
cord-034340-3ksfpaf7	849	16	p=0.04	p=0.04	NNP
cord-034340-3ksfpaf7	849	17	*	*	NFP
cord-034340-3ksfpaf7	849	18	)	)	-RRB-
cord-034340-3ksfpaf7	849	19	,	,	,
cord-034340-3ksfpaf7	849	20	(	(	-LRB-
cord-034340-3ksfpaf7	849	21	p=0.03	p=0.03	NNP
cord-034340-3ksfpaf7	849	22	*	*	NFP
cord-034340-3ksfpaf7	849	23	)	)	-RRB-
cord-034340-3ksfpaf7	849	24	and	and	CC
cord-034340-3ksfpaf7	849	25	(	(	-LRB-
cord-034340-3ksfpaf7	849	26	p=0.04	p=0.04	NN
cord-034340-3ksfpaf7	849	27	*	*	NFP
cord-034340-3ksfpaf7	849	28	)	)	-RRB-
cord-034340-3ksfpaf7	849	29	respectively	respectively	RB
cord-034340-3ksfpaf7	849	30	.	.	.
cord-034340-3ksfpaf7	850	1	Multivariate	multivariate	JJ
cord-034340-3ksfpaf7	850	2	analysis	analysis	NN
cord-034340-3ksfpaf7	850	3	of	of	IN
cord-034340-3ksfpaf7	850	4	the	the	DT
cord-034340-3ksfpaf7	850	5	factors	factor	NNS
cord-034340-3ksfpaf7	850	6	affecting	affect	VBG
cord-034340-3ksfpaf7	850	7	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	850	8	cholesterol	cholesterol	NN
cord-034340-3ksfpaf7	850	9	level	level	NN
cord-034340-3ksfpaf7	850	10	revealed	reveal	VBD
cord-034340-3ksfpaf7	850	11	that	that	IN
cord-034340-3ksfpaf7	850	12	SLE	SLE	NNP
cord-034340-3ksfpaf7	850	13	is	be	VBZ
cord-034340-3ksfpaf7	850	14	a	a	DT
cord-034340-3ksfpaf7	850	15	significant	significant	JJ
cord-034340-3ksfpaf7	850	16	predictor	predictor	NN
cord-034340-3ksfpaf7	850	17	of	of	IN
cord-034340-3ksfpaf7	850	18	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	850	19	cholesterol	cholesterol	NN
cord-034340-3ksfpaf7	850	20	level	level	NN
cord-034340-3ksfpaf7	850	21	.	.	.
cord-034340-3ksfpaf7	851	1	Presence	presence	NN
cord-034340-3ksfpaf7	851	2	of	of	IN
cord-034340-3ksfpaf7	851	3	jSLE	jsle	JJ
cord-034340-3ksfpaf7	851	4	increase	increase	VB
cord-034340-3ksfpaf7	851	5	risk	risk	NN
cord-034340-3ksfpaf7	851	6	of	of	IN
cord-034340-3ksfpaf7	851	7	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	851	8	cholesterol	cholesterol	NN
cord-034340-3ksfpaf7	851	9	9	9	CD
cord-034340-3ksfpaf7	851	10	times	time	NNS
cord-034340-3ksfpaf7	851	11	more	more	JJR
cord-034340-3ksfpaf7	851	12	than	than	IN
cord-034340-3ksfpaf7	851	13	cases	case	NNS
cord-034340-3ksfpaf7	851	14	without	without	IN
cord-034340-3ksfpaf7	851	15	jSLE	jsle	NN
cord-034340-3ksfpaf7	851	16	.	.	.
cord-034340-3ksfpaf7	852	1	The	the	DT
cord-034340-3ksfpaf7	852	2	overall	overall	JJ
cord-034340-3ksfpaf7	852	3	percent	percent	NN
cord-034340-3ksfpaf7	852	4	predicted	predict	VBN
cord-034340-3ksfpaf7	852	5	was	be	VBD
cord-034340-3ksfpaf7	852	6	80	80	CD
cord-034340-3ksfpaf7	852	7	%	%	NN
cord-034340-3ksfpaf7	852	8	.	.	.
cord-034340-3ksfpaf7	853	1	Active	active	JJ
cord-034340-3ksfpaf7	853	2	disease	disease	NN
cord-034340-3ksfpaf7	853	3	is	be	VBZ
cord-034340-3ksfpaf7	853	4	a	a	DT
cord-034340-3ksfpaf7	853	5	significant	significant	JJ
cord-034340-3ksfpaf7	853	6	risk	risk	NN
cord-034340-3ksfpaf7	853	7	factor	factor	NN
cord-034340-3ksfpaf7	853	8	for	for	IN
cord-034340-3ksfpaf7	853	9	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	853	10	TG	TG	NNP
cord-034340-3ksfpaf7	853	11	with	with	IN
cord-034340-3ksfpaf7	853	12	increased	increase	VBN
cord-034340-3ksfpaf7	853	13	risk	risk	NN
cord-034340-3ksfpaf7	853	14	of	of	IN
cord-034340-3ksfpaf7	853	15	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	853	16	TG	TG	NNP
cord-034340-3ksfpaf7	853	17	by	by	IN
cord-034340-3ksfpaf7	853	18	3.2	3.2	CD
cord-034340-3ksfpaf7	853	19	among	among	IN
cord-034340-3ksfpaf7	853	20	cases	case	NNS
cord-034340-3ksfpaf7	853	21	with	with	IN
cord-034340-3ksfpaf7	853	22	active	active	JJ
cord-034340-3ksfpaf7	853	23	disease	disease	NN
cord-034340-3ksfpaf7	853	24	than	than	IN
cord-034340-3ksfpaf7	853	25	cases	case	NNS
cord-034340-3ksfpaf7	853	26	with	with	IN
cord-034340-3ksfpaf7	853	27	inactive	inactive	JJ
cord-034340-3ksfpaf7	853	28	disease	disease	NN
cord-034340-3ksfpaf7	853	29	.	.	.
cord-034340-3ksfpaf7	854	1	The	the	DT
cord-034340-3ksfpaf7	854	2	overall	overall	JJ
cord-034340-3ksfpaf7	854	3	percent	percent	NN
cord-034340-3ksfpaf7	854	4	predicted	predict	VBN
cord-034340-3ksfpaf7	854	5	was	be	VBD
cord-034340-3ksfpaf7	854	6	75.6	75.6	CD
cord-034340-3ksfpaf7	854	7	%	%	NN
cord-034340-3ksfpaf7	854	8	.	.	.
cord-034340-3ksfpaf7	855	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	855	2	:	:	:
cord-034340-3ksfpaf7	855	3	children	child	NNS
cord-034340-3ksfpaf7	855	4	with	with	IN
cord-034340-3ksfpaf7	855	5	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	855	6	diseases	disease	NNS
cord-034340-3ksfpaf7	855	7	showed	show	VBD
cord-034340-3ksfpaf7	855	8	significant	significant	JJ
cord-034340-3ksfpaf7	855	9	lipid	lipid	NN
cord-034340-3ksfpaf7	855	10	profile	profile	NN
cord-034340-3ksfpaf7	855	11	abnormalities	abnormality	NNS
cord-034340-3ksfpaf7	855	12	.	.	.
cord-034340-3ksfpaf7	856	1	Abnormal	abnormal	JJ
cord-034340-3ksfpaf7	856	2	TC	TC	NNP
cord-034340-3ksfpaf7	856	3	,	,	,
cord-034340-3ksfpaf7	856	4	HDL	HDL	NNP
cord-034340-3ksfpaf7	856	5	and	and	CC
cord-034340-3ksfpaf7	856	6	TG	TG	NNP
cord-034340-3ksfpaf7	856	7	are	be	VBP
cord-034340-3ksfpaf7	856	8	significantly	significantly	RB
cord-034340-3ksfpaf7	856	9	associated	associate	VBN
cord-034340-3ksfpaf7	856	10	with	with	IN
cord-034340-3ksfpaf7	856	11	active	active	JJ
cord-034340-3ksfpaf7	856	12	disease	disease	NN
cord-034340-3ksfpaf7	856	13	.	.	.
cord-034340-3ksfpaf7	857	1	Presence	presence	NN
cord-034340-3ksfpaf7	857	2	of	of	IN
cord-034340-3ksfpaf7	857	3	jSLE	jsle	JJ
cord-034340-3ksfpaf7	857	4	increase	increase	VB
cord-034340-3ksfpaf7	857	5	risk	risk	NN
cord-034340-3ksfpaf7	857	6	of	of	IN
cord-034340-3ksfpaf7	857	7	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	857	8	cholesterol	cholesterol	NN
cord-034340-3ksfpaf7	857	9	.	.	.
cord-034340-3ksfpaf7	858	1	Active	active	JJ
cord-034340-3ksfpaf7	858	2	disease	disease	NN
cord-034340-3ksfpaf7	858	3	is	be	VBZ
cord-034340-3ksfpaf7	858	4	a	a	DT
cord-034340-3ksfpaf7	858	5	significant	significant	JJ
cord-034340-3ksfpaf7	858	6	risk	risk	NN
cord-034340-3ksfpaf7	858	7	factor	factor	NN
cord-034340-3ksfpaf7	858	8	for	for	IN
cord-034340-3ksfpaf7	858	9	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	858	10	TG	TG	NNP
cord-034340-3ksfpaf7	858	11	.	.	.
cord-034340-3ksfpaf7	859	1	Therefore	therefore	RB
cord-034340-3ksfpaf7	859	2	,	,	,
cord-034340-3ksfpaf7	859	3	lipid	lipid	NN
cord-034340-3ksfpaf7	859	4	levels	level	NNS
cord-034340-3ksfpaf7	859	5	should	should	MD
cord-034340-3ksfpaf7	859	6	be	be	VB
cord-034340-3ksfpaf7	859	7	monitored	monitor	VBN
cord-034340-3ksfpaf7	859	8	regularly	regularly	RB
cord-034340-3ksfpaf7	859	9	and	and	CC
cord-034340-3ksfpaf7	859	10	managed	manage	VBN
cord-034340-3ksfpaf7	859	11	in	in	IN
cord-034340-3ksfpaf7	859	12	patients	patient	NNS
cord-034340-3ksfpaf7	859	13	with	with	IN
cord-034340-3ksfpaf7	859	14	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	859	15	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	859	16	diseases	disease	NNS
cord-034340-3ksfpaf7	859	17	to	to	TO
cord-034340-3ksfpaf7	859	18	minimize	minimize	VB
cord-034340-3ksfpaf7	859	19	the	the	DT
cord-034340-3ksfpaf7	859	20	longterm	longterm	JJ
cord-034340-3ksfpaf7	859	21	risk	risk	NN
cord-034340-3ksfpaf7	859	22	of	of	IN
cord-034340-3ksfpaf7	859	23	CVD	CVD	NNP
cord-034340-3ksfpaf7	859	24	.	.	.
cord-034340-3ksfpaf7	860	1	Methods	method	NNS
cord-034340-3ksfpaf7	860	2	:	:	:
cord-034340-3ksfpaf7	861	1	Non	non	JJ
cord-034340-3ksfpaf7	861	2	-	-	JJ
cord-034340-3ksfpaf7	861	3	experimental	experimental	JJ
cord-034340-3ksfpaf7	861	4	,	,	,
cord-034340-3ksfpaf7	861	5	cross	cross	JJ
cord-034340-3ksfpaf7	861	6	-	-	JJ
cord-034340-3ksfpaf7	861	7	sectional	sectional	JJ
cord-034340-3ksfpaf7	861	8	and	and	CC
cord-034340-3ksfpaf7	861	9	descriptive	descriptive	JJ
cord-034340-3ksfpaf7	861	10	study	study	NN
cord-034340-3ksfpaf7	861	11	.	.	.
cord-034340-3ksfpaf7	862	1	A	a	DT
cord-034340-3ksfpaf7	862	2	confidential	confidential	JJ
cord-034340-3ksfpaf7	862	3	survey	survey	NN
cord-034340-3ksfpaf7	862	4	was	be	VBD
cord-034340-3ksfpaf7	862	5	conducted	conduct	VBN
cord-034340-3ksfpaf7	862	6	online	online	RB
cord-034340-3ksfpaf7	862	7	,	,	,
cord-034340-3ksfpaf7	862	8	aimed	aim	VBN
cord-034340-3ksfpaf7	862	9	at	at	IN
cord-034340-3ksfpaf7	862	10	residents	resident	NNS
cord-034340-3ksfpaf7	862	11	and	and	CC
cord-034340-3ksfpaf7	862	12	attendings	attending	NNS
cord-034340-3ksfpaf7	862	13	who	who	WP
cord-034340-3ksfpaf7	862	14	deal	deal	VBP
cord-034340-3ksfpaf7	862	15	with	with	IN
cord-034340-3ksfpaf7	862	16	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	862	17	pain	pain	NN
cord-034340-3ksfpaf7	862	18	.	.	.
cord-034340-3ksfpaf7	863	1	Were	be	VBD
cord-034340-3ksfpaf7	863	2	addressed	address	VBN
cord-034340-3ksfpaf7	863	3	with	with	IN
cord-034340-3ksfpaf7	863	4	the	the	DT
cord-034340-3ksfpaf7	863	5	definitions	definition	NNS
cord-034340-3ksfpaf7	863	6	of	of	IN
cord-034340-3ksfpaf7	863	7	arthralgia	arthralgia	NNP
cord-034340-3ksfpaf7	863	8	,	,	,
cord-034340-3ksfpaf7	863	9	arthritis	arthritis	NN
cord-034340-3ksfpaf7	863	10	,	,	,
cord-034340-3ksfpaf7	863	11	myalgia	myalgia	NN
cord-034340-3ksfpaf7	863	12	,	,	,
cord-034340-3ksfpaf7	863	13	allodynia	allodynia	NNP
cord-034340-3ksfpaf7	863	14	and	and	CC
cord-034340-3ksfpaf7	863	15	hyperesthesia	hyperesthesia	NNP
cord-034340-3ksfpaf7	863	16	(	(	-LRB-
cord-034340-3ksfpaf7	863	17	between	between	IN
cord-034340-3ksfpaf7	863	18	five	five	CD
cord-034340-3ksfpaf7	863	19	to	to	TO
cord-034340-3ksfpaf7	863	20	seven	seven	CD
cord-034340-3ksfpaf7	863	21	options	option	NNS
cord-034340-3ksfpaf7	863	22	)	)	-RRB-
cord-034340-3ksfpaf7	863	23	with	with	IN
cord-034340-3ksfpaf7	863	24	only	only	RB
cord-034340-3ksfpaf7	863	25	one	one	CD
cord-034340-3ksfpaf7	863	26	correct	correct	JJ
cord-034340-3ksfpaf7	863	27	answer	answer	NN
cord-034340-3ksfpaf7	863	28	.	.	.
cord-034340-3ksfpaf7	864	1	Correct	correct	JJ
cord-034340-3ksfpaf7	864	2	definitions	definition	NNS
cord-034340-3ksfpaf7	864	3	:	:	:
cord-034340-3ksfpaf7	864	4	arthralgia	arthralgia	NNP
cord-034340-3ksfpaf7	864	5	(	(	-LRB-
cord-034340-3ksfpaf7	864	6	pain	pain	NN
cord-034340-3ksfpaf7	864	7	localized	localize	VBN
cord-034340-3ksfpaf7	864	8	to	to	IN
cord-034340-3ksfpaf7	864	9	the	the	DT
cord-034340-3ksfpaf7	864	10	joint	joint	JJ
cord-034340-3ksfpaf7	864	11	or	or	CC
cord-034340-3ksfpaf7	864	12	periarticular	periarticular	JJ
cord-034340-3ksfpaf7	864	13	structures	structure	NNS
cord-034340-3ksfpaf7	864	14	,	,	,
cord-034340-3ksfpaf7	864	15	as	as	IN
cord-034340-3ksfpaf7	864	16	a	a	DT
cord-034340-3ksfpaf7	864	17	only	only	JJ
cord-034340-3ksfpaf7	864	18	manifestation	manifestation	NN
cord-034340-3ksfpaf7	864	19	)	)	-RRB-
cord-034340-3ksfpaf7	864	20	;	;	:
cord-034340-3ksfpaf7	864	21	arthritis	arthritis	NN
cord-034340-3ksfpaf7	864	22	(	(	-LRB-
cord-034340-3ksfpaf7	864	23	Criterion	criterion	NN
cord-034340-3ksfpaf7	864	24	one	one	CD
cord-034340-3ksfpaf7	864	25	or	or	CC
cord-034340-3ksfpaf7	864	26	criterion	criterion	NN
cord-034340-3ksfpaf7	864	27	two	two	CD
cord-034340-3ksfpaf7	864	28	:	:	SYM
cord-034340-3ksfpaf7	864	29	1	1	CD
cord-034340-3ksfpaf7	864	30	-Joint	-joint	NN
cord-034340-3ksfpaf7	864	31	swelling	swell	VBG
cord-034340-3ksfpaf7	864	32	or	or	CC
cord-034340-3ksfpaf7	864	33	intra	intra	JJ
cord-034340-3ksfpaf7	864	34	-	-	JJ
cord-034340-3ksfpaf7	864	35	articular	articular	JJ
cord-034340-3ksfpaf7	864	36	effusion	effusion	NN
cord-034340-3ksfpaf7	864	37	/	/	SYM
cord-034340-3ksfpaf7	864	38	2	2	CD
cord-034340-3ksfpaf7	864	39	-Limitation	-limitation	NN
cord-034340-3ksfpaf7	864	40	of	of	IN
cord-034340-3ksfpaf7	864	41	joint	joint	JJ
cord-034340-3ksfpaf7	864	42	mobilization	mobilization	NN
cord-034340-3ksfpaf7	864	43	associated	associate	VBN
cord-034340-3ksfpaf7	864	44	with	with	IN
cord-034340-3ksfpaf7	864	45	at	at	RB
cord-034340-3ksfpaf7	864	46	least	least	RBS
cord-034340-3ksfpaf7	864	47	one	one	CD
cord-034340-3ksfpaf7	864	48	of	of	IN
cord-034340-3ksfpaf7	864	49	the	the	DT
cord-034340-3ksfpaf7	864	50	following	follow	VBG
cord-034340-3ksfpaf7	864	51	:	:	:
cord-034340-3ksfpaf7	864	52	a	a	LS
cord-034340-3ksfpaf7	864	53	)	)	-RRB-
cord-034340-3ksfpaf7	864	54	Pain	pain	NN
cord-034340-3ksfpaf7	864	55	b	b	NN
cord-034340-3ksfpaf7	864	56	)	)	-RRB-
cord-034340-3ksfpaf7	864	57	Tenderness	tenderness	NN
cord-034340-3ksfpaf7	864	58	c	c	NN
cord-034340-3ksfpaf7	864	59	)	)	-RRB-
cord-034340-3ksfpaf7	865	1	Swelling	swell	VBG
cord-034340-3ksfpaf7	865	2	d	d	CD
cord-034340-3ksfpaf7	865	3	)	)	-RRB-
cord-034340-3ksfpaf7	865	4	Heat	Heat	NNP
cord-034340-3ksfpaf7	865	5	)	)	-RRB-
cord-034340-3ksfpaf7	865	6	;	;	:
cord-034340-3ksfpaf7	865	7	myialgia	myialgia	NNP
cord-034340-3ksfpaf7	865	8	(	(	-LRB-
cord-034340-3ksfpaf7	865	9	pain	pain	NN
cord-034340-3ksfpaf7	865	10	with	with	IN
cord-034340-3ksfpaf7	865	11	muscular	muscular	JJ
cord-034340-3ksfpaf7	865	12	origin	origin	NN
cord-034340-3ksfpaf7	865	13	or	or	CC
cord-034340-3ksfpaf7	865	14	referred	refer	VBN
cord-034340-3ksfpaf7	865	15	to	to	IN
cord-034340-3ksfpaf7	865	16	muscle	muscle	NN
cord-034340-3ksfpaf7	865	17	,	,	,
cord-034340-3ksfpaf7	865	18	regardless	regardless	RB
cord-034340-3ksfpaf7	865	19	of	of	IN
cord-034340-3ksfpaf7	865	20	its	-PRON-	PRP$
cord-034340-3ksfpaf7	865	21	etiology	etiology	NN
cord-034340-3ksfpaf7	865	22	)	)	-RRB-
cord-034340-3ksfpaf7	865	23	;	;	:
cord-034340-3ksfpaf7	865	24	allodynia	allodynia	NN
cord-034340-3ksfpaf7	865	25	(	(	-LRB-
cord-034340-3ksfpaf7	865	26	pain	pain	NN
cord-034340-3ksfpaf7	865	27	resulting	result	VBG
cord-034340-3ksfpaf7	865	28	from	from	IN
cord-034340-3ksfpaf7	865	29	usually	usually	RB
cord-034340-3ksfpaf7	865	30	non	non	JJ
cord-034340-3ksfpaf7	865	31	-	-	JJ
cord-034340-3ksfpaf7	865	32	painful	painful	JJ
cord-034340-3ksfpaf7	865	33	stimulus	stimulus	NN
cord-034340-3ksfpaf7	865	34	)	)	-RRB-
cord-034340-3ksfpaf7	866	1	;	;	:
cord-034340-3ksfpaf7	866	2	hyperesthesia	hyperesthesia	NNP
cord-034340-3ksfpaf7	866	3	(	(	-LRB-
cord-034340-3ksfpaf7	866	4	coexistence	coexistence	NN
cord-034340-3ksfpaf7	866	5	of	of	IN
cord-034340-3ksfpaf7	866	6	allodynia	allodynia	NN
cord-034340-3ksfpaf7	866	7	plus	plus	CC
cord-034340-3ksfpaf7	866	8	hyperalgesia	hyperalgesia	NN
cord-034340-3ksfpaf7	867	1	-exaggerated	-exaggerated	JJ
cord-034340-3ksfpaf7	867	2	responses	response	NNS
cord-034340-3ksfpaf7	867	3	to	to	IN
cord-034340-3ksfpaf7	867	4	tactile	tactile	JJ
cord-034340-3ksfpaf7	867	5	and	and	CC
cord-034340-3ksfpaf7	867	6	thermal	thermal	JJ
cord-034340-3ksfpaf7	867	7	nociceptive	nociceptive	JJ
cord-034340-3ksfpaf7	867	8	and	and	CC
cord-034340-3ksfpaf7	867	9	nonnociceptive	nonnociceptive	NN
cord-034340-3ksfpaf7	867	10	stimuli	stimulus	NNS
cord-034340-3ksfpaf7	867	11	 	 	_SP
cord-034340-3ksfpaf7	868	1	The	the	DT
cord-034340-3ksfpaf7	868	2	association	association	NN
cord-034340-3ksfpaf7	868	3	of	of	IN
cord-034340-3ksfpaf7	868	4	pure	pure	JJ
cord-034340-3ksfpaf7	868	5	red	red	JJ
cord-034340-3ksfpaf7	868	6	cell	cell	NN
cord-034340-3ksfpaf7	868	7	aplasia	aplasia	NNP
cord-034340-3ksfpaf7	868	8	(	(	-LRB-
cord-034340-3ksfpaf7	868	9	PRCA	PRCA	NNP
cord-034340-3ksfpaf7	868	10	)	)	-RRB-
cord-034340-3ksfpaf7	868	11	with	with	IN
cord-034340-3ksfpaf7	868	12	thymoma	thymoma	NNP
cord-034340-3ksfpaf7	868	13	led	lead	VBD
cord-034340-3ksfpaf7	868	14	to	to	IN
cord-034340-3ksfpaf7	868	15	the	the	DT
cord-034340-3ksfpaf7	868	16	discovery	discovery	NN
cord-034340-3ksfpaf7	868	17	of	of	IN
cord-034340-3ksfpaf7	868	18	the	the	DT
cord-034340-3ksfpaf7	868	19	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	868	20	mechanisms	mechanism	NNS
cord-034340-3ksfpaf7	868	21	involved	involve	VBN
cord-034340-3ksfpaf7	868	22	in	in	IN
cord-034340-3ksfpaf7	868	23	the	the	DT
cord-034340-3ksfpaf7	868	24	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	868	25	of	of	IN
cord-034340-3ksfpaf7	868	26	this	this	DT
cord-034340-3ksfpaf7	868	27	rare	rare	JJ
cord-034340-3ksfpaf7	868	28	disease	disease	NN
cord-034340-3ksfpaf7	868	29	.	.	.
cord-034340-3ksfpaf7	869	1	Till	till	IN
cord-034340-3ksfpaf7	869	2	date	date	NN
cord-034340-3ksfpaf7	869	3	many	many	JJ
cord-034340-3ksfpaf7	869	4	adult	adult	NN
cord-034340-3ksfpaf7	869	5	case	case	NN
cord-034340-3ksfpaf7	869	6	reports	report	NNS
cord-034340-3ksfpaf7	869	7	have	have	VBP
cord-034340-3ksfpaf7	869	8	revealed	reveal	VBN
cord-034340-3ksfpaf7	869	9	a	a	DT
cord-034340-3ksfpaf7	869	10	strong	strong	JJ
cord-034340-3ksfpaf7	869	11	link	link	NN
cord-034340-3ksfpaf7	869	12	between	between	IN
cord-034340-3ksfpaf7	869	13	PRCA	PRCA	NNP
cord-034340-3ksfpaf7	869	14	and	and	CC
cord-034340-3ksfpaf7	869	15	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	869	16	diseases	disease	NNS
cord-034340-3ksfpaf7	869	17	,	,	,
cord-034340-3ksfpaf7	869	18	endocrine	endocrine	JJ
cord-034340-3ksfpaf7	869	19	disorders	disorder	NNS
cord-034340-3ksfpaf7	869	20	,	,	,
cord-034340-3ksfpaf7	869	21	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	869	22	diseases	disease	NNS
cord-034340-3ksfpaf7	869	23	,	,	,
cord-034340-3ksfpaf7	869	24	autoinflammation	autoinflammation	NN
cord-034340-3ksfpaf7	869	25	and	and	CC
cord-034340-3ksfpaf7	869	26	immune	immune	JJ
cord-034340-3ksfpaf7	869	27	dysregulation	dysregulation	NN
cord-034340-3ksfpaf7	869	28	.	.	.
cord-034340-3ksfpaf7	870	1	[	[	-LRB-
cord-034340-3ksfpaf7	870	2	1	1	CD
cord-034340-3ksfpaf7	870	3	]	]	-RRB-
cord-034340-3ksfpaf7	870	4	[	[	-LRB-
cord-034340-3ksfpaf7	870	5	2	2	CD
cord-034340-3ksfpaf7	870	6	]	]	-RRB-
cord-034340-3ksfpaf7	870	7	[	[	-LRB-
cord-034340-3ksfpaf7	870	8	3	3	CD
cord-034340-3ksfpaf7	870	9	]	]	-RRB-
cord-034340-3ksfpaf7	870	10	[	[	-LRB-
cord-034340-3ksfpaf7	870	11	4	4	CD
cord-034340-3ksfpaf7	870	12	]	]	-RRB-
cord-034340-3ksfpaf7	871	1	[	[	-LRB-
cord-034340-3ksfpaf7	871	2	5	5	LS
cord-034340-3ksfpaf7	871	3	]	]	-RRB-
cord-034340-3ksfpaf7	871	4	Objectives	Objectives	NNPS
cord-034340-3ksfpaf7	871	5	To	to	TO
cord-034340-3ksfpaf7	871	6	stimulate	stimulate	VB
cord-034340-3ksfpaf7	871	7	a	a	DT
cord-034340-3ksfpaf7	871	8	search	search	NN
cord-034340-3ksfpaf7	871	9	for	for	IN
cord-034340-3ksfpaf7	871	10	the	the	DT
cord-034340-3ksfpaf7	871	11	genetic	genetic	JJ
cord-034340-3ksfpaf7	871	12	and	and	CC
cord-034340-3ksfpaf7	871	13	immunological	immunological	JJ
cord-034340-3ksfpaf7	871	14	roots	root	NNS
cord-034340-3ksfpaf7	871	15	for	for	IN
cord-034340-3ksfpaf7	871	16	a	a	DT
cord-034340-3ksfpaf7	871	17	2.5	2.5	CD
cord-034340-3ksfpaf7	871	18	years	year	NNS
cord-034340-3ksfpaf7	871	19	old	old	JJ
cord-034340-3ksfpaf7	871	20	girl	girl	NN
cord-034340-3ksfpaf7	871	21	with	with	IN
cord-034340-3ksfpaf7	871	22	syndromic	syndromic	JJ
cord-034340-3ksfpaf7	871	23	face	face	NN
cord-034340-3ksfpaf7	871	24	,	,	,
cord-034340-3ksfpaf7	871	25	pure	pure	JJ
cord-034340-3ksfpaf7	871	26	red	red	JJ
cord-034340-3ksfpaf7	871	27	cell	cell	NN
cord-034340-3ksfpaf7	871	28	aplasia	aplasia	NNP
cord-034340-3ksfpaf7	871	29	,	,	,
cord-034340-3ksfpaf7	871	30	type	type	NN
cord-034340-3ksfpaf7	871	31	1	1	CD
cord-034340-3ksfpaf7	871	32	diabetes	diabetes	NN
cord-034340-3ksfpaf7	871	33	and	and	CC
cord-034340-3ksfpaf7	871	34	polyarthritis	polyarthritis	NNP
cord-034340-3ksfpaf7	871	35	.	.	.
cord-034340-3ksfpaf7	872	1	Methods	method	NNS
cord-034340-3ksfpaf7	873	1	This	this	DT
cord-034340-3ksfpaf7	873	2	is	be	VBZ
cord-034340-3ksfpaf7	873	3	a	a	DT
cord-034340-3ksfpaf7	873	4	story	story	NN
cord-034340-3ksfpaf7	873	5	of	of	IN
cord-034340-3ksfpaf7	873	6	a	a	DT
cord-034340-3ksfpaf7	873	7	2.5	2.5	CD
cord-034340-3ksfpaf7	873	8	years	year	NNS
cord-034340-3ksfpaf7	873	9	old	old	JJ
cord-034340-3ksfpaf7	873	10	girl	girl	NN
cord-034340-3ksfpaf7	873	11	with	with	IN
cord-034340-3ksfpaf7	873	12	pure	pure	JJ
cord-034340-3ksfpaf7	873	13	red	red	JJ
cord-034340-3ksfpaf7	873	14	cell	cell	NN
cord-034340-3ksfpaf7	873	15	aplasia	aplasia	NNP
cord-034340-3ksfpaf7	873	16	,	,	,
cord-034340-3ksfpaf7	873	17	type	type	NN
cord-034340-3ksfpaf7	873	18	1	1	CD
cord-034340-3ksfpaf7	873	19	diabetes	diabetes	NN
cord-034340-3ksfpaf7	873	20	and	and	CC
cord-034340-3ksfpaf7	873	21	polyarthritis	polyarthritis	NNP
cord-034340-3ksfpaf7	873	22	.	.	.
cord-034340-3ksfpaf7	874	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	874	2	was	be	VBD
cord-034340-3ksfpaf7	874	3	normal	normal	JJ
cord-034340-3ksfpaf7	874	4	till	till	IN
cord-034340-3ksfpaf7	874	5	7	7	CD
cord-034340-3ksfpaf7	874	6	months	month	NNS
cord-034340-3ksfpaf7	874	7	of	of	IN
cord-034340-3ksfpaf7	874	8	age	age	NN
cord-034340-3ksfpaf7	874	9	.	.	.
cord-034340-3ksfpaf7	875	1	At	at	IN
cord-034340-3ksfpaf7	875	2	the	the	DT
cord-034340-3ksfpaf7	875	3	age	age	NN
cord-034340-3ksfpaf7	875	4	of	of	IN
cord-034340-3ksfpaf7	875	5	8	8	CD
cord-034340-3ksfpaf7	875	6	months	month	NNS
cord-034340-3ksfpaf7	875	7	,	,	,
cord-034340-3ksfpaf7	875	8	she	-PRON-	PRP
cord-034340-3ksfpaf7	875	9	was	be	VBD
cord-034340-3ksfpaf7	875	10	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	875	11	with	with	IN
cord-034340-3ksfpaf7	875	12	type	type	NN
cord-034340-3ksfpaf7	875	13	1	1	CD
cord-034340-3ksfpaf7	875	14	diabetes	diabetes	NN
cord-034340-3ksfpaf7	875	15	.	.	.
cord-034340-3ksfpaf7	876	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	876	2	was	be	VBD
cord-034340-3ksfpaf7	876	3	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	876	4	by	by	IN
cord-034340-3ksfpaf7	876	5	her	-PRON-	PRP$
cord-034340-3ksfpaf7	876	6	paediatrician	paediatrician	NN
cord-034340-3ksfpaf7	876	7	in	in	IN
cord-034340-3ksfpaf7	876	8	view	view	NN
cord-034340-3ksfpaf7	876	9	of	of	IN
cord-034340-3ksfpaf7	876	10	generalized	generalized	JJ
cord-034340-3ksfpaf7	876	11	hypotonia	hypotonia	NNS
cord-034340-3ksfpaf7	876	12	,	,	,
cord-034340-3ksfpaf7	876	13	deformed	deformed	JJ
cord-034340-3ksfpaf7	876	14	pinna	pinna	NN
cord-034340-3ksfpaf7	876	15	,	,	,
cord-034340-3ksfpaf7	876	16	low	low	JJ
cord-034340-3ksfpaf7	876	17	set	set	NN
cord-034340-3ksfpaf7	876	18	ears	ear	NNS
cord-034340-3ksfpaf7	876	19	,	,	,
cord-034340-3ksfpaf7	876	20	midfacial	midfacial	NNP
cord-034340-3ksfpaf7	876	21	hypoplasia	hypoplasia	NN
cord-034340-3ksfpaf7	876	22	,	,	,
cord-034340-3ksfpaf7	876	23	blue	blue	JJ
cord-034340-3ksfpaf7	876	24	sclera	sclera	NN
cord-034340-3ksfpaf7	876	25	,	,	,
cord-034340-3ksfpaf7	876	26	umbilical	umbilical	JJ
cord-034340-3ksfpaf7	876	27	hernia	hernia	NN
cord-034340-3ksfpaf7	876	28	and	and	CC
cord-034340-3ksfpaf7	876	29	retracted	retract	VBD
cord-034340-3ksfpaf7	876	30	eyelids	eyelid	NNS
cord-034340-3ksfpaf7	876	31	.	.	.
cord-034340-3ksfpaf7	877	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	877	2	had	have	VBD
cord-034340-3ksfpaf7	877	3	multiple	multiple	JJ
cord-034340-3ksfpaf7	877	4	episodes	episode	NNS
cord-034340-3ksfpaf7	877	5	of	of	IN
cord-034340-3ksfpaf7	877	6	seizures	seizure	NNS
cord-034340-3ksfpaf7	877	7	during	during	IN
cord-034340-3ksfpaf7	877	8	next	next	JJ
cord-034340-3ksfpaf7	877	9	few	few	JJ
cord-034340-3ksfpaf7	877	10	months	month	NNS
cord-034340-3ksfpaf7	877	11	.	.	.
cord-034340-3ksfpaf7	878	1	To	to	IN
cord-034340-3ksfpaf7	878	2	me	-PRON-	PRP
cord-034340-3ksfpaf7	878	3	,	,	,
cord-034340-3ksfpaf7	878	4	she	-PRON-	PRP
cord-034340-3ksfpaf7	878	5	was	be	VBD
cord-034340-3ksfpaf7	878	6	presented	present	VBN
cord-034340-3ksfpaf7	878	7	with	with	IN
cord-034340-3ksfpaf7	878	8	one	one	CD
cord-034340-3ksfpaf7	878	9	year	year	NN
cord-034340-3ksfpaf7	878	10	history	history	NN
cord-034340-3ksfpaf7	878	11	of	of	IN
cord-034340-3ksfpaf7	878	12	polyarthritis	polyarthritis	NNP
cord-034340-3ksfpaf7	878	13	with	with	IN
cord-034340-3ksfpaf7	878	14	severe	severe	JJ
cord-034340-3ksfpaf7	878	15	pallor	pallor	NN
cord-034340-3ksfpaf7	878	16	requiring	require	VBG
cord-034340-3ksfpaf7	878	17	frequent	frequent	JJ
cord-034340-3ksfpaf7	878	18	blood	blood	NN
cord-034340-3ksfpaf7	878	19	transfusions	transfusion	NNS
cord-034340-3ksfpaf7	878	20	.	.	.
cord-034340-3ksfpaf7	879	1	Family	family	NN
cord-034340-3ksfpaf7	879	2	history	history	NN
cord-034340-3ksfpaf7	879	3	was	be	VBD
cord-034340-3ksfpaf7	879	4	inconclusive	inconclusive	JJ
cord-034340-3ksfpaf7	879	5	.	.	.
cord-034340-3ksfpaf7	880	1	Musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	880	2	examination	examination	NN
cord-034340-3ksfpaf7	880	3	showed	show	VBD
cord-034340-3ksfpaf7	880	4	polyarthritis	polyarthritis	NNP
cord-034340-3ksfpaf7	880	5	involving	involve	VBG
cord-034340-3ksfpaf7	880	6	right	right	JJ
cord-034340-3ksfpaf7	880	7	knee	knee	NN
cord-034340-3ksfpaf7	880	8	,	,	,
cord-034340-3ksfpaf7	880	9	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	880	10	ankles	ankle	NNS
cord-034340-3ksfpaf7	880	11	,	,	,
cord-034340-3ksfpaf7	880	12	fingers	finger	NNS
cord-034340-3ksfpaf7	880	13	and	and	CC
cord-034340-3ksfpaf7	880	14	toes	toe	NNS
cord-034340-3ksfpaf7	880	15	.	.	.
cord-034340-3ksfpaf7	881	1	Further	further	JJ
cord-034340-3ksfpaf7	881	2	examination	examination	NN
cord-034340-3ksfpaf7	881	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	881	4	haemolytic	haemolytic	JJ
cord-034340-3ksfpaf7	881	5	facies	facie	NNS
cord-034340-3ksfpaf7	881	6	and	and	CC
cord-034340-3ksfpaf7	881	7	hepatosplenomegaly	hepatosplenomegaly	NNS
cord-034340-3ksfpaf7	881	8	.	.	.
cord-034340-3ksfpaf7	882	1	I	-PRON-	PRP
cord-034340-3ksfpaf7	882	2	was	be	VBD
cord-034340-3ksfpaf7	882	3	not	not	RB
cord-034340-3ksfpaf7	882	4	able	able	JJ
cord-034340-3ksfpaf7	882	5	to	to	TO
cord-034340-3ksfpaf7	882	6	make	make	VB
cord-034340-3ksfpaf7	882	7	out	out	RP
cord-034340-3ksfpaf7	882	8	any	any	DT
cord-034340-3ksfpaf7	882	9	facial	facial	JJ
cord-034340-3ksfpaf7	882	10	dysmorphism	dysmorphism	NN
cord-034340-3ksfpaf7	882	11	mentioned	mention	VBN
cord-034340-3ksfpaf7	882	12	earlier	early	RBR
cord-034340-3ksfpaf7	882	13	by	by	IN
cord-034340-3ksfpaf7	882	14	her	-PRON-	PRP$
cord-034340-3ksfpaf7	882	15	paediatrician	paediatrician	NN
cord-034340-3ksfpaf7	882	16	.	.	.
cord-034340-3ksfpaf7	883	1	Results	result	NNS
cord-034340-3ksfpaf7	883	2	:	:	:
cord-034340-3ksfpaf7	884	1	Table	table	NN
cord-034340-3ksfpaf7	884	2	1	1	CD
cord-034340-3ksfpaf7	885	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	885	2	Early	early	JJ
cord-034340-3ksfpaf7	885	3	age	age	NN
cord-034340-3ksfpaf7	885	4	of	of	IN
cord-034340-3ksfpaf7	885	5	onset	onset	NN
cord-034340-3ksfpaf7	885	6	,	,	,
cord-034340-3ksfpaf7	885	7	pure	pure	JJ
cord-034340-3ksfpaf7	885	8	red	red	JJ
cord-034340-3ksfpaf7	885	9	cell	cell	NN
cord-034340-3ksfpaf7	885	10	aplasia	aplasia	NNP
cord-034340-3ksfpaf7	885	11	,	,	,
cord-034340-3ksfpaf7	885	12	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	885	13	and	and	CC
cord-034340-3ksfpaf7	885	14	endocrine	endocrine	JJ
cord-034340-3ksfpaf7	885	15	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	885	16	with	with	IN
cord-034340-3ksfpaf7	885	17	some	some	DT
cord-034340-3ksfpaf7	885	18	doubtful	doubtful	JJ
cord-034340-3ksfpaf7	885	19	facial	facial	JJ
cord-034340-3ksfpaf7	885	20	dysmorphism	dysmorphism	NN
cord-034340-3ksfpaf7	885	21	inspired	inspire	VBD
cord-034340-3ksfpaf7	885	22	me	-PRON-	PRP
cord-034340-3ksfpaf7	885	23	to	to	TO
cord-034340-3ksfpaf7	885	24	suspect	suspect	VB
cord-034340-3ksfpaf7	885	25	some	some	DT
cord-034340-3ksfpaf7	885	26	known	known	JJ
cord-034340-3ksfpaf7	885	27	or	or	CC
cord-034340-3ksfpaf7	885	28	unknown	unknown	JJ
cord-034340-3ksfpaf7	885	29	immune	immune	JJ
cord-034340-3ksfpaf7	885	30	dysregulation	dysregulation	NN
cord-034340-3ksfpaf7	885	31	syndrome	syndrome	NN
cord-034340-3ksfpaf7	885	32	in	in	IN
cord-034340-3ksfpaf7	885	33	this	this	DT
cord-034340-3ksfpaf7	885	34	child	child	NN
cord-034340-3ksfpaf7	885	35	.	.	.
cord-034340-3ksfpaf7	886	1	Genetic	genetic	JJ
cord-034340-3ksfpaf7	886	2	analysis	analysis	NN
cord-034340-3ksfpaf7	886	3	would	would	MD
cord-034340-3ksfpaf7	886	4	be	be	VB
cord-034340-3ksfpaf7	886	5	the	the	DT
cord-034340-3ksfpaf7	886	6	best	good	JJS
cord-034340-3ksfpaf7	886	7	possible	possible	JJ
cord-034340-3ksfpaf7	886	8	option	option	NN
cord-034340-3ksfpaf7	886	9	in	in	IN
cord-034340-3ksfpaf7	886	10	this	this	DT
cord-034340-3ksfpaf7	886	11	scenario	scenario	NN
cord-034340-3ksfpaf7	886	12	if	if	IN
cord-034340-3ksfpaf7	886	13	financial	financial	JJ
cord-034340-3ksfpaf7	886	14	condition	condition	NN
cord-034340-3ksfpaf7	886	15	permits	permit	VBZ
cord-034340-3ksfpaf7	886	16	.	.	.
cord-034340-3ksfpaf7	887	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	887	2	:	:	:
cord-034340-3ksfpaf7	887	3	Galactosialidosis	Galactosialidosis	NNP
cord-034340-3ksfpaf7	887	4	(	(	-LRB-
cord-034340-3ksfpaf7	887	5	GS	GS	NNP
cord-034340-3ksfpaf7	887	6	)	)	-RRB-
cord-034340-3ksfpaf7	887	7	is	be	VBZ
cord-034340-3ksfpaf7	887	8	a	a	DT
cord-034340-3ksfpaf7	887	9	rare	rare	JJ
cord-034340-3ksfpaf7	887	10	inherited	inherit	VBN
cord-034340-3ksfpaf7	887	11	lysosomal	lysosomal	JJ
cord-034340-3ksfpaf7	887	12	storage	storage	NN
cord-034340-3ksfpaf7	887	13	disorder	disorder	NN
cord-034340-3ksfpaf7	887	14	(	(	-LRB-
cord-034340-3ksfpaf7	887	15	LSD	LSD	NNP
cord-034340-3ksfpaf7	887	16	)	)	-RRB-
cord-034340-3ksfpaf7	887	17	which	which	WDT
cord-034340-3ksfpaf7	887	18	is	be	VBZ
cord-034340-3ksfpaf7	887	19	characterized	characterize	VBN
cord-034340-3ksfpaf7	887	20	by	by	IN
cord-034340-3ksfpaf7	887	21	a	a	DT
cord-034340-3ksfpaf7	887	22	defect	defect	NN
cord-034340-3ksfpaf7	887	23	in	in	IN
cord-034340-3ksfpaf7	887	24	the	the	DT
cord-034340-3ksfpaf7	887	25	lysosomal	lysosomal	JJ
cord-034340-3ksfpaf7	887	26	glycoprotein	glycoprotein	NN
cord-034340-3ksfpaf7	887	27	catabolism	catabolism	NN
cord-034340-3ksfpaf7	887	28	.	.	.
cord-034340-3ksfpaf7	888	1	Here	here	RB
cord-034340-3ksfpaf7	888	2	we	-PRON-	PRP
cord-034340-3ksfpaf7	888	3	report	report	VBP
cord-034340-3ksfpaf7	888	4	,	,	,
cord-034340-3ksfpaf7	888	5	for	for	IN
cord-034340-3ksfpaf7	888	6	the	the	DT
cord-034340-3ksfpaf7	888	7	first	first	JJ
cord-034340-3ksfpaf7	888	8	time	time	NN
cord-034340-3ksfpaf7	888	9	,	,	,
cord-034340-3ksfpaf7	888	10	a	a	DT
cord-034340-3ksfpaf7	888	11	case	case	NN
cord-034340-3ksfpaf7	888	12	of	of	IN
cord-034340-3ksfpaf7	888	13	a	a	DT
cord-034340-3ksfpaf7	888	14	child	child	NN
cord-034340-3ksfpaf7	888	15	affected	affect	VBN
cord-034340-3ksfpaf7	888	16	by	by	IN
cord-034340-3ksfpaf7	888	17	GS	GS	NNP
cord-034340-3ksfpaf7	888	18	who	who	WP
cord-034340-3ksfpaf7	888	19	presented	present	VBD
cord-034340-3ksfpaf7	888	20	with	with	IN
cord-034340-3ksfpaf7	888	21	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	888	22	episodes	episode	NNS
cord-034340-3ksfpaf7	888	23	of	of	IN
cord-034340-3ksfpaf7	888	24	extensive	extensive	JJ
cord-034340-3ksfpaf7	888	25	joint	joint	JJ
cord-034340-3ksfpaf7	888	26	inflammation	inflammation	NN
cord-034340-3ksfpaf7	888	27	in	in	IN
cord-034340-3ksfpaf7	888	28	both	both	DT
cord-034340-3ksfpaf7	888	29	knees	knee	NNS
cord-034340-3ksfpaf7	888	30	.	.	.
cord-034340-3ksfpaf7	889	1	Knowledge	knowledge	NN
cord-034340-3ksfpaf7	889	2	on	on	IN
cord-034340-3ksfpaf7	889	3	GS	GS	NNP
cord-034340-3ksfpaf7	889	4	related	relate	VBD
cord-034340-3ksfpaf7	889	5	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	889	6	joint	joint	JJ
cord-034340-3ksfpaf7	889	7	pathology	pathology	NN
cord-034340-3ksfpaf7	889	8	is	be	VBZ
cord-034340-3ksfpaf7	889	9	lacking	lack	VBG
cord-034340-3ksfpaf7	889	10	,	,	,
cord-034340-3ksfpaf7	889	11	which	which	WDT
cord-034340-3ksfpaf7	889	12	hampers	hamper	VBZ
cord-034340-3ksfpaf7	889	13	evaluation	evaluation	NN
cord-034340-3ksfpaf7	889	14	of	of	IN
cord-034340-3ksfpaf7	889	15	possible	possible	JJ
cord-034340-3ksfpaf7	889	16	mechanisms	mechanism	NNS
cord-034340-3ksfpaf7	889	17	that	that	WDT
cord-034340-3ksfpaf7	889	18	could	could	MD
cord-034340-3ksfpaf7	889	19	give	give	VB
cord-034340-3ksfpaf7	889	20	an	an	DT
cord-034340-3ksfpaf7	889	21	explanation	explanation	NN
cord-034340-3ksfpaf7	889	22	for	for	IN
cord-034340-3ksfpaf7	889	23	the	the	DT
cord-034340-3ksfpaf7	889	24	significant	significant	JJ
cord-034340-3ksfpaf7	889	25	arthritic	arthritic	JJ
cord-034340-3ksfpaf7	889	26	joint	joint	JJ
cord-034340-3ksfpaf7	889	27	abnormalities	abnormality	NNS
cord-034340-3ksfpaf7	889	28	as	as	IN
cord-034340-3ksfpaf7	889	29	observed	observe	VBN
cord-034340-3ksfpaf7	889	30	in	in	IN
cord-034340-3ksfpaf7	889	31	our	-PRON-	PRP$
cord-034340-3ksfpaf7	889	32	patient	patient	NN
cord-034340-3ksfpaf7	889	33	.	.	.
cord-034340-3ksfpaf7	890	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	890	2	:	:	:
cord-034340-3ksfpaf7	891	1	The	the	DT
cord-034340-3ksfpaf7	891	2	aim	aim	NN
cord-034340-3ksfpaf7	891	3	of	of	IN
cord-034340-3ksfpaf7	891	4	this	this	DT
cord-034340-3ksfpaf7	891	5	study	study	NN
cord-034340-3ksfpaf7	891	6	is	be	VBZ
cord-034340-3ksfpaf7	891	7	to	to	TO
cord-034340-3ksfpaf7	891	8	describe	describe	VB
cord-034340-3ksfpaf7	891	9	the	the	DT
cord-034340-3ksfpaf7	891	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	891	11	presentation	presentation	NN
cord-034340-3ksfpaf7	891	12	as	as	RB
cord-034340-3ksfpaf7	891	13	well	well	RB
cord-034340-3ksfpaf7	891	14	as	as	IN
cord-034340-3ksfpaf7	891	15	the	the	DT
cord-034340-3ksfpaf7	891	16	laboratory	laboratory	NN
cord-034340-3ksfpaf7	891	17	,	,	,
cord-034340-3ksfpaf7	891	18	radiologic	radiologic	JJ
cord-034340-3ksfpaf7	891	19	and	and	CC
cord-034340-3ksfpaf7	891	20	microscopic	microscopic	JJ
cord-034340-3ksfpaf7	891	21	features	feature	NNS
cord-034340-3ksfpaf7	891	22	of	of	IN
cord-034340-3ksfpaf7	891	23	this	this	DT
cord-034340-3ksfpaf7	891	24	extremely	extremely	RB
cord-034340-3ksfpaf7	891	25	rare	rare	JJ
cord-034340-3ksfpaf7	891	26	presentation	presentation	NN
cord-034340-3ksfpaf7	891	27	of	of	IN
cord-034340-3ksfpaf7	891	28	GS	GS	NNP
cord-034340-3ksfpaf7	891	29	.	.	.
cord-034340-3ksfpaf7	892	1	Furthermore	furthermore	RB
cord-034340-3ksfpaf7	892	2	,	,	,
cord-034340-3ksfpaf7	892	3	we	-PRON-	PRP
cord-034340-3ksfpaf7	892	4	conduct	conduct	VBP
cord-034340-3ksfpaf7	892	5	a	a	DT
cord-034340-3ksfpaf7	892	6	literature	literature	NN
cord-034340-3ksfpaf7	892	7	review	review	NN
cord-034340-3ksfpaf7	892	8	on	on	IN
cord-034340-3ksfpaf7	892	9	LSD	LSD	NNP
cord-034340-3ksfpaf7	892	10	's	's	POS
cord-034340-3ksfpaf7	892	11	complicated	complicate	VBN
cord-034340-3ksfpaf7	892	12	by	by	IN
cord-034340-3ksfpaf7	892	13	arthritis	arthritis	NN
cord-034340-3ksfpaf7	892	14	in	in	IN
cord-034340-3ksfpaf7	892	15	order	order	NN
cord-034340-3ksfpaf7	892	16	to	to	TO
cord-034340-3ksfpaf7	892	17	evaluate	evaluate	VB
cord-034340-3ksfpaf7	892	18	potential	potential	JJ
cord-034340-3ksfpaf7	892	19	mechanisms	mechanism	NNS
cord-034340-3ksfpaf7	892	20	that	that	WDT
cord-034340-3ksfpaf7	892	21	could	could	MD
cord-034340-3ksfpaf7	892	22	explain	explain	VB
cord-034340-3ksfpaf7	892	23	the	the	DT
cord-034340-3ksfpaf7	892	24	extensive	extensive	JJ
cord-034340-3ksfpaf7	892	25	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	892	26	joint	joint	JJ
cord-034340-3ksfpaf7	892	27	swelling	swelling	NN
cord-034340-3ksfpaf7	892	28	observed	observe	VBN
cord-034340-3ksfpaf7	892	29	in	in	IN
cord-034340-3ksfpaf7	892	30	our	-PRON-	PRP$
cord-034340-3ksfpaf7	892	31	patient	patient	NN
cord-034340-3ksfpaf7	892	32	.	.	.
cord-034340-3ksfpaf7	893	1	Methods	method	NNS
cord-034340-3ksfpaf7	893	2	:	:	:
cord-034340-3ksfpaf7	893	3	In	in	IN
cord-034340-3ksfpaf7	893	4	this	this	DT
cord-034340-3ksfpaf7	893	5	study	study	NN
cord-034340-3ksfpaf7	893	6	we	-PRON-	PRP
cord-034340-3ksfpaf7	893	7	present	present	VBP
cord-034340-3ksfpaf7	893	8	a	a	DT
cord-034340-3ksfpaf7	893	9	12-year	12-year	JJ
cord-034340-3ksfpaf7	893	10	-	-	HYPH
cord-034340-3ksfpaf7	893	11	old	old	JJ
cord-034340-3ksfpaf7	893	12	Turkish	turkish	JJ
cord-034340-3ksfpaf7	893	13	boy	boy	NN
cord-034340-3ksfpaf7	893	14	who	who	WP
cord-034340-3ksfpaf7	893	15	was	be	VBD
cord-034340-3ksfpaf7	893	16	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	893	17	with	with	IN
cord-034340-3ksfpaf7	893	18	GS	GS	NNP
cord-034340-3ksfpaf7	893	19	(	(	-LRB-
cord-034340-3ksfpaf7	893	20	late	late	JJ
cord-034340-3ksfpaf7	893	21	infantile	infantile	JJ
cord-034340-3ksfpaf7	893	22	form	form	NN
cord-034340-3ksfpaf7	893	23	)	)	-RRB-
cord-034340-3ksfpaf7	893	24	at	at	IN
cord-034340-3ksfpaf7	893	25	17	17	CD
cord-034340-3ksfpaf7	893	26	months	month	NNS
cord-034340-3ksfpaf7	893	27	of	of	IN
cord-034340-3ksfpaf7	893	28	age	age	NN
cord-034340-3ksfpaf7	893	29	.	.	.
cord-034340-3ksfpaf7	894	1	From	from	IN
cord-034340-3ksfpaf7	894	2	the	the	DT
cord-034340-3ksfpaf7	894	3	age	age	NN
cord-034340-3ksfpaf7	894	4	of	of	IN
cord-034340-3ksfpaf7	894	5	8	8	CD
cord-034340-3ksfpaf7	894	6	years	year	NNS
cord-034340-3ksfpaf7	894	7	,	,	,
cord-034340-3ksfpaf7	894	8	the	the	DT
cord-034340-3ksfpaf7	894	9	boy	boy	NN
cord-034340-3ksfpaf7	894	10	presented	present	VBN
cord-034340-3ksfpaf7	894	11	with	with	IN
cord-034340-3ksfpaf7	894	12	episodes	episode	NNS
cord-034340-3ksfpaf7	894	13	of	of	IN
cord-034340-3ksfpaf7	894	14	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	894	15	joint	joint	JJ
cord-034340-3ksfpaf7	894	16	pathology	pathology	NN
cord-034340-3ksfpaf7	894	17	of	of	IN
cord-034340-3ksfpaf7	894	18	the	the	DT
cord-034340-3ksfpaf7	894	19	knee	knee	NN
cord-034340-3ksfpaf7	894	20	.	.	.
cord-034340-3ksfpaf7	895	1	Informed	informed	JJ
cord-034340-3ksfpaf7	895	2	consent	consent	NN
cord-034340-3ksfpaf7	895	3	was	be	VBD
cord-034340-3ksfpaf7	895	4	obtained	obtain	VBN
cord-034340-3ksfpaf7	895	5	.	.	.
cord-034340-3ksfpaf7	896	1	Alongside	alongside	IN
cord-034340-3ksfpaf7	896	2	the	the	DT
cord-034340-3ksfpaf7	896	3	case	case	NN
cord-034340-3ksfpaf7	896	4	report	report	NN
cord-034340-3ksfpaf7	896	5	,	,	,
cord-034340-3ksfpaf7	896	6	a	a	DT
cord-034340-3ksfpaf7	896	7	literature	literature	NN
cord-034340-3ksfpaf7	896	8	review	review	NN
cord-034340-3ksfpaf7	896	9	using	use	VBG
cord-034340-3ksfpaf7	896	10	Medline	Medline	NNP
cord-034340-3ksfpaf7	896	11	was	be	VBD
cord-034340-3ksfpaf7	896	12	conducted	conduct	VBN
cord-034340-3ksfpaf7	896	13	.	.	.
cord-034340-3ksfpaf7	897	1	An	an	DT
cord-034340-3ksfpaf7	897	2	extensive	extensive	JJ
cord-034340-3ksfpaf7	897	3	list	list	NN
cord-034340-3ksfpaf7	897	4	of	of	IN
cord-034340-3ksfpaf7	897	5	known	know	VBN
cord-034340-3ksfpaf7	897	6	LSD	LSD	NNP
cord-034340-3ksfpaf7	897	7	's	's	POS
cord-034340-3ksfpaf7	897	8	was	be	VBD
cord-034340-3ksfpaf7	897	9	combined	combine	VBN
cord-034340-3ksfpaf7	897	10	with	with	IN
cord-034340-3ksfpaf7	897	11	the	the	DT
cord-034340-3ksfpaf7	897	12	terms	term	NNS
cord-034340-3ksfpaf7	897	13	:	:	:
cord-034340-3ksfpaf7	897	14	"	"	``
cord-034340-3ksfpaf7	897	15	arthritis	arthritis	NN
cord-034340-3ksfpaf7	897	16	"	"	''
cord-034340-3ksfpaf7	897	17	,	,	,
cord-034340-3ksfpaf7	897	18	"	"	''
cord-034340-3ksfpaf7	897	19	joint	joint	JJ
cord-034340-3ksfpaf7	897	20	inflammation	inflammation	NN
cord-034340-3ksfpaf7	897	21	"	"	''
cord-034340-3ksfpaf7	897	22	,	,	,
cord-034340-3ksfpaf7	897	23	"	"	``
cord-034340-3ksfpaf7	897	24	synovitis	synovitis	JJ
cord-034340-3ksfpaf7	897	25	"	"	''
cord-034340-3ksfpaf7	897	26	and	and	CC
cord-034340-3ksfpaf7	897	27	"	"	``
cord-034340-3ksfpaf7	897	28	synovial	synovial	JJ
cord-034340-3ksfpaf7	897	29	inflammation	inflammation	NN
cord-034340-3ksfpaf7	897	30	"	"	''
cord-034340-3ksfpaf7	897	31	.	.	.
cord-034340-3ksfpaf7	898	1	Cases	case	NNS
cord-034340-3ksfpaf7	898	2	in	in	IN
cord-034340-3ksfpaf7	898	3	which	which	WDT
cord-034340-3ksfpaf7	898	4	joint	joint	JJ
cord-034340-3ksfpaf7	898	5	inflammation	inflammation	NN
cord-034340-3ksfpaf7	898	6	was	be	VBD
cord-034340-3ksfpaf7	898	7	based	base	VBN
cord-034340-3ksfpaf7	898	8	on	on	IN
cord-034340-3ksfpaf7	898	9	a	a	DT
cord-034340-3ksfpaf7	898	10	probable	probable	JJ
cord-034340-3ksfpaf7	898	11	cause	cause	NN
cord-034340-3ksfpaf7	898	12	other	other	JJ
cord-034340-3ksfpaf7	898	13	than	than	IN
cord-034340-3ksfpaf7	898	14	the	the	DT
cord-034340-3ksfpaf7	898	15	underlying	underlie	VBG
cord-034340-3ksfpaf7	898	16	LSD	LSD	NNP
cord-034340-3ksfpaf7	898	17	were	be	VBD
cord-034340-3ksfpaf7	898	18	excluded	exclude	VBN
cord-034340-3ksfpaf7	898	19	.	.	.
cord-034340-3ksfpaf7	899	1	Results	result	NNS
cord-034340-3ksfpaf7	899	2	:	:	:
cord-034340-3ksfpaf7	900	1	In	in	IN
cord-034340-3ksfpaf7	900	2	the	the	DT
cord-034340-3ksfpaf7	900	3	present	present	JJ
cord-034340-3ksfpaf7	900	4	case	case	NN
cord-034340-3ksfpaf7	900	5	,	,	,
cord-034340-3ksfpaf7	900	6	owing	owe	VBG
cord-034340-3ksfpaf7	900	7	to	to	IN
cord-034340-3ksfpaf7	900	8	comprehensive	comprehensive	JJ
cord-034340-3ksfpaf7	900	9	examinations	examination	NNS
cord-034340-3ksfpaf7	900	10	(	(	-LRB-
cord-034340-3ksfpaf7	900	11	i.e.	i.e.	FW
cord-034340-3ksfpaf7	900	12	laboratory	laboratory	NN
cord-034340-3ksfpaf7	900	13	tests	test	NNS
cord-034340-3ksfpaf7	900	14	,	,	,
cord-034340-3ksfpaf7	900	15	imaging	imaging	NN
cord-034340-3ksfpaf7	900	16	and	and	CC
cord-034340-3ksfpaf7	900	17	microscopic	microscopic	JJ
cord-034340-3ksfpaf7	900	18	examination	examination	NN
cord-034340-3ksfpaf7	900	19	)	)	-RRB-
cord-034340-3ksfpaf7	900	20	multiple	multiple	JJ
cord-034340-3ksfpaf7	900	21	possible	possible	JJ
cord-034340-3ksfpaf7	900	22	causes	cause	NNS
cord-034340-3ksfpaf7	900	23	for	for	IN
cord-034340-3ksfpaf7	900	24	the	the	DT
cord-034340-3ksfpaf7	900	25	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	900	26	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	900	27	joint	joint	JJ
cord-034340-3ksfpaf7	900	28	pathology	pathology	NN
cord-034340-3ksfpaf7	900	29	could	could	MD
cord-034340-3ksfpaf7	900	30	be	be	VB
cord-034340-3ksfpaf7	900	31	rejected	reject	VBN
cord-034340-3ksfpaf7	900	32	(	(	-LRB-
cord-034340-3ksfpaf7	900	33	i.e.	i.e.	FW
cord-034340-3ksfpaf7	900	34	no	no	DT
cord-034340-3ksfpaf7	900	35	signs	sign	NNS
cord-034340-3ksfpaf7	900	36	of	of	IN
cord-034340-3ksfpaf7	900	37	infectious	infectious	JJ
cord-034340-3ksfpaf7	900	38	arthritis	arthritis	NN
cord-034340-3ksfpaf7	900	39	,	,	,
cord-034340-3ksfpaf7	900	40	reactive	reactive	JJ
cord-034340-3ksfpaf7	900	41	arthritis	arthritis	NN
cord-034340-3ksfpaf7	900	42	,	,	,
cord-034340-3ksfpaf7	900	43	osteoarthritis	osteoarthritis	NN
cord-034340-3ksfpaf7	900	44	,	,	,
cord-034340-3ksfpaf7	900	45	arthritis	arthritis	NN
cord-034340-3ksfpaf7	900	46	secondary	secondary	JJ
cord-034340-3ksfpaf7	900	47	to	to	IN
cord-034340-3ksfpaf7	900	48	a	a	DT
cord-034340-3ksfpaf7	900	49	malignancy	malignancy	NN
cord-034340-3ksfpaf7	900	50	or	or	CC
cord-034340-3ksfpaf7	900	51	crystal	crystal	NN
cord-034340-3ksfpaf7	900	52	induced	induce	VBN
cord-034340-3ksfpaf7	900	53	arthritis	arthritis	NN
cord-034340-3ksfpaf7	900	54	)	)	-RRB-
cord-034340-3ksfpaf7	900	55	.	.	.
cord-034340-3ksfpaf7	901	1	A	a	DT
cord-034340-3ksfpaf7	901	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	901	3	which	which	WDT
cord-034340-3ksfpaf7	901	4	could	could	MD
cord-034340-3ksfpaf7	901	5	explain	explain	VB
cord-034340-3ksfpaf7	901	6	the	the	DT
cord-034340-3ksfpaf7	901	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	901	8	picture	picture	NN
cord-034340-3ksfpaf7	901	9	is	be	VBZ
cord-034340-3ksfpaf7	901	10	the	the	DT
cord-034340-3ksfpaf7	901	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	901	12	subtype	subtype	NN
cord-034340-3ksfpaf7	901	13	:	:	:
cord-034340-3ksfpaf7	901	14	ANA	ANA	NNP
cord-034340-3ksfpaf7	901	15	negative	negative	JJ
cord-034340-3ksfpaf7	901	16	oligo	oligo	NN
cord-034340-3ksfpaf7	901	17	-	-	HYPH
cord-034340-3ksfpaf7	901	18	articular	articular	JJ
cord-034340-3ksfpaf7	901	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	901	20	.	.	.
cord-034340-3ksfpaf7	902	1	However	however	RB
cord-034340-3ksfpaf7	902	2	,	,	,
cord-034340-3ksfpaf7	902	3	microscopic	microscopic	JJ
cord-034340-3ksfpaf7	902	4	examination	examination	NN
cord-034340-3ksfpaf7	902	5	showed	show	VBD
cord-034340-3ksfpaf7	902	6	numerous	numerous	JJ
cord-034340-3ksfpaf7	902	7	foamy	foamy	NN
cord-034340-3ksfpaf7	902	8	macrophages	macrophage	NNS
cord-034340-3ksfpaf7	902	9	with	with	IN
cord-034340-3ksfpaf7	902	10	extensive	extensive	JJ
cord-034340-3ksfpaf7	902	11	vacuolization	vacuolization	NN
cord-034340-3ksfpaf7	902	12	in	in	IN
cord-034340-3ksfpaf7	902	13	the	the	DT
cord-034340-3ksfpaf7	902	14	synovial	synovial	JJ
cord-034340-3ksfpaf7	902	15	tissue	tissue	NN
cord-034340-3ksfpaf7	902	16	of	of	IN
cord-034340-3ksfpaf7	902	17	the	the	DT
cord-034340-3ksfpaf7	902	18	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	902	19	joint	joint	NN
cord-034340-3ksfpaf7	902	20	,	,	,
cord-034340-3ksfpaf7	902	21	which	which	WDT
cord-034340-3ksfpaf7	902	22	is	be	VBZ
cord-034340-3ksfpaf7	902	23	not	not	RB
cord-034340-3ksfpaf7	902	24	associated	associate	VBN
cord-034340-3ksfpaf7	902	25	with	with	IN
cord-034340-3ksfpaf7	902	26	JIA	JIA	NNP
cord-034340-3ksfpaf7	902	27	.	.	.
cord-034340-3ksfpaf7	903	1	Given	give	VBN
cord-034340-3ksfpaf7	903	2	the	the	DT
cord-034340-3ksfpaf7	903	3	evidence	evidence	NN
cord-034340-3ksfpaf7	903	4	of	of	IN
cord-034340-3ksfpaf7	903	5	storage	storage	NN
cord-034340-3ksfpaf7	903	6	products	product	NNS
cord-034340-3ksfpaf7	903	7	within	within	IN
cord-034340-3ksfpaf7	903	8	the	the	DT
cord-034340-3ksfpaf7	903	9	macrophages	macrophage	NNS
cord-034340-3ksfpaf7	903	10	of	of	IN
cord-034340-3ksfpaf7	903	11	the	the	DT
cord-034340-3ksfpaf7	903	12	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	903	13	synovial	synovial	JJ
cord-034340-3ksfpaf7	903	14	tissue	tissue	NN
cord-034340-3ksfpaf7	903	15	and	and	CC
cord-034340-3ksfpaf7	903	16	no	no	DT
cord-034340-3ksfpaf7	903	17	conclusive	conclusive	JJ
cord-034340-3ksfpaf7	903	18	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	903	19	,	,	,
cord-034340-3ksfpaf7	903	20	GS	GS	NNP
cord-034340-3ksfpaf7	903	21	itself	-PRON-	PRP
cord-034340-3ksfpaf7	903	22	should	should	MD
cord-034340-3ksfpaf7	903	23	be	be	VB
cord-034340-3ksfpaf7	903	24	considered	consider	VBN
cord-034340-3ksfpaf7	903	25	as	as	IN
cord-034340-3ksfpaf7	903	26	the	the	DT
cord-034340-3ksfpaf7	903	27	primary	primary	JJ
cord-034340-3ksfpaf7	903	28	cause	cause	NN
cord-034340-3ksfpaf7	903	29	for	for	IN
cord-034340-3ksfpaf7	903	30	the	the	DT
cord-034340-3ksfpaf7	903	31	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	903	32	arthritis	arthritis	NN
cord-034340-3ksfpaf7	903	33	.	.	.
cord-034340-3ksfpaf7	904	1	An	an	DT
cord-034340-3ksfpaf7	904	2	in	in	IN
cord-034340-3ksfpaf7	904	3	-	-	HYPH
cord-034340-3ksfpaf7	904	4	depth	depth	NN
cord-034340-3ksfpaf7	904	5	literature	literature	NN
cord-034340-3ksfpaf7	904	6	review	review	NN
cord-034340-3ksfpaf7	904	7	using	use	VBG
cord-034340-3ksfpaf7	904	8	Medline	Medline	NNP
cord-034340-3ksfpaf7	904	9	for	for	IN
cord-034340-3ksfpaf7	904	10	data	datum	NNS
cord-034340-3ksfpaf7	904	11	on	on	IN
cord-034340-3ksfpaf7	904	12	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	904	13	joint	joint	JJ
cord-034340-3ksfpaf7	904	14	pathology	pathology	NN
cord-034340-3ksfpaf7	904	15	in	in	IN
cord-034340-3ksfpaf7	904	16	LSD	LSD	NNP
cord-034340-3ksfpaf7	904	17	's	's	POS
cord-034340-3ksfpaf7	904	18	showed	show	VBD
cord-034340-3ksfpaf7	904	19	that	that	IN
cord-034340-3ksfpaf7	904	20	7	7	CD
cord-034340-3ksfpaf7	904	21	LSD	LSD	NNP
cord-034340-3ksfpaf7	904	22	subtypes	subtype	NNS
cord-034340-3ksfpaf7	904	23	(	(	-LRB-
cord-034340-3ksfpaf7	904	24	i.e.	i.e.	FW
cord-034340-3ksfpaf7	904	25	Fabry	Fabry	NNP
cord-034340-3ksfpaf7	904	26	disease	disease	NN
cord-034340-3ksfpaf7	904	27	,	,	,
cord-034340-3ksfpaf7	904	28	Farber	Farber	NNP
cord-034340-3ksfpaf7	904	29	lipogranulomatosis	lipogranulomatosis	NN
cord-034340-3ksfpaf7	904	30	,	,	,
cord-034340-3ksfpaf7	904	31	Gaucher	Gaucher	NNP
cord-034340-3ksfpaf7	904	32	disease	disease	NN
cord-034340-3ksfpaf7	904	33	type	type	NN
cord-034340-3ksfpaf7	904	34	1	1	CD
cord-034340-3ksfpaf7	904	35	,	,	,
cord-034340-3ksfpaf7	904	36	Mucopolysaccharidosis	Mucopolysaccharidosis	NNP
cord-034340-3ksfpaf7	904	37	IX	IX	NNP
cord-034340-3ksfpaf7	904	38	,	,	,
cord-034340-3ksfpaf7	904	39	a	a	NNP
cord-034340-3ksfpaf7	904	40	-	-	:
cord-034340-3ksfpaf7	904	41	Mannosidosis	Mannosidosis	NNP
cord-034340-3ksfpaf7	904	42	,	,	,
cord-034340-3ksfpaf7	904	43	Fucosidosis	Fucosidosis	NNP
cord-034340-3ksfpaf7	904	44	and	and	CC
cord-034340-3ksfpaf7	904	45	Cystinosis	Cystinosis	NNP
cord-034340-3ksfpaf7	904	46	)	)	-RRB-
cord-034340-3ksfpaf7	904	47	could	could	MD
cord-034340-3ksfpaf7	904	48	present	present	VB
cord-034340-3ksfpaf7	904	49	with	with	IN
cord-034340-3ksfpaf7	904	50	disease	disease	NN
cord-034340-3ksfpaf7	904	51	related	relate	VBN
cord-034340-3ksfpaf7	904	52	arthritis	arthritis	NN
cord-034340-3ksfpaf7	904	53	.	.	.
cord-034340-3ksfpaf7	905	1	Multiple	multiple	JJ
cord-034340-3ksfpaf7	905	2	potential	potential	JJ
cord-034340-3ksfpaf7	905	3	arthritic	arthritic	JJ
cord-034340-3ksfpaf7	905	4	mechanisms	mechanism	NNS
cord-034340-3ksfpaf7	905	5	secondary	secondary	JJ
cord-034340-3ksfpaf7	905	6	to	to	IN
cord-034340-3ksfpaf7	905	7	storage	storage	NN
cord-034340-3ksfpaf7	905	8	product	product	NN
cord-034340-3ksfpaf7	905	9	accumulation	accumulation	NN
cord-034340-3ksfpaf7	905	10	in	in	IN
cord-034340-3ksfpaf7	905	11	LSD	LSD	NNP
cord-034340-3ksfpaf7	905	12	's	's	POS
cord-034340-3ksfpaf7	905	13	have	have	VBP
cord-034340-3ksfpaf7	905	14	been	be	VBN
cord-034340-3ksfpaf7	905	15	described	describe	VBN
cord-034340-3ksfpaf7	905	16	,	,	,
cord-034340-3ksfpaf7	905	17	such	such	JJ
cord-034340-3ksfpaf7	905	18	as	as	IN
cord-034340-3ksfpaf7	905	19	:	:	:
cord-034340-3ksfpaf7	905	20	dysregulation	dysregulation	NN
cord-034340-3ksfpaf7	905	21	of	of	IN
cord-034340-3ksfpaf7	905	22	innate	innate	JJ
cord-034340-3ksfpaf7	905	23	immunity	immunity	NN
cord-034340-3ksfpaf7	905	24	and	and	CC
cord-034340-3ksfpaf7	905	25	increased	increase	VBN
cord-034340-3ksfpaf7	905	26	upregulation	upregulation	NN
cord-034340-3ksfpaf7	905	27	of	of	IN
cord-034340-3ksfpaf7	905	28	numerous	numerous	JJ
cord-034340-3ksfpaf7	905	29	pro	pro	JJ
cord-034340-3ksfpaf7	905	30	-	-	JJ
cord-034340-3ksfpaf7	905	31	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	905	32	proteins	protein	NNS
cord-034340-3ksfpaf7	905	33	.	.	.
cord-034340-3ksfpaf7	906	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	906	2	:	:	:
cord-034340-3ksfpaf7	907	1	Given	give	VBN
cord-034340-3ksfpaf7	907	2	the	the	DT
cord-034340-3ksfpaf7	907	3	evidence	evidence	NN
cord-034340-3ksfpaf7	907	4	of	of	IN
cord-034340-3ksfpaf7	907	5	storage	storage	NN
cord-034340-3ksfpaf7	907	6	products	product	NNS
cord-034340-3ksfpaf7	907	7	within	within	IN
cord-034340-3ksfpaf7	907	8	macrophages	macrophage	NNS
cord-034340-3ksfpaf7	907	9	of	of	IN
cord-034340-3ksfpaf7	907	10	the	the	DT
cord-034340-3ksfpaf7	907	11	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	907	12	synovial	synovial	JJ
cord-034340-3ksfpaf7	907	13	tissue	tissue	NN
cord-034340-3ksfpaf7	907	14	and	and	CC
cord-034340-3ksfpaf7	907	15	the	the	DT
cord-034340-3ksfpaf7	907	16	absence	absence	NN
cord-034340-3ksfpaf7	907	17	of	of	IN
cord-034340-3ksfpaf7	907	18	other	other	JJ
cord-034340-3ksfpaf7	907	19	etiological	etiological	JJ
cord-034340-3ksfpaf7	907	20	clues	clue	NNS
cord-034340-3ksfpaf7	907	21	,	,	,
cord-034340-3ksfpaf7	907	22	our	-PRON-	PRP$
cord-034340-3ksfpaf7	907	23	hypothesis	hypothesis	NN
cord-034340-3ksfpaf7	907	24	is	be	VBZ
cord-034340-3ksfpaf7	907	25	that	that	IN
cord-034340-3ksfpaf7	907	26	GS	GS	NNP
cord-034340-3ksfpaf7	907	27	itself	-PRON-	PRP
cord-034340-3ksfpaf7	907	28	is	be	VBZ
cord-034340-3ksfpaf7	907	29	the	the	DT
cord-034340-3ksfpaf7	907	30	primary	primary	JJ
cord-034340-3ksfpaf7	907	31	cause	cause	NN
cord-034340-3ksfpaf7	907	32	for	for	IN
cord-034340-3ksfpaf7	907	33	the	the	DT
cord-034340-3ksfpaf7	907	34	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	907	35	joint	joint	JJ
cord-034340-3ksfpaf7	907	36	pathology	pathology	NN
cord-034340-3ksfpaf7	907	37	in	in	IN
cord-034340-3ksfpaf7	907	38	our	-PRON-	PRP$
cord-034340-3ksfpaf7	907	39	patient	patient	NN
cord-034340-3ksfpaf7	907	40	.	.	.
cord-034340-3ksfpaf7	908	1	Although	although	IN
cord-034340-3ksfpaf7	908	2	,	,	,
cord-034340-3ksfpaf7	908	3	GS	GS	NNP
cord-034340-3ksfpaf7	908	4	can	can	MD
cord-034340-3ksfpaf7	908	5	not	not	RB
cord-034340-3ksfpaf7	908	6	be	be	VB
cord-034340-3ksfpaf7	908	7	linked	link	VBN
cord-034340-3ksfpaf7	908	8	directly	directly	RB
cord-034340-3ksfpaf7	908	9	to	to	IN
cord-034340-3ksfpaf7	908	10	joint	joint	JJ
cord-034340-3ksfpaf7	908	11	inflammation	inflammation	NN
cord-034340-3ksfpaf7	908	12	,	,	,
cord-034340-3ksfpaf7	908	13	lysosomal	lysosomal	JJ
cord-034340-3ksfpaf7	908	14	defects	defect	NNS
cord-034340-3ksfpaf7	908	15	have	have	VBP
cord-034340-3ksfpaf7	908	16	been	be	VBN
cord-034340-3ksfpaf7	908	17	associated	associate	VBN
cord-034340-3ksfpaf7	908	18	to	to	IN
cord-034340-3ksfpaf7	908	19	pro	pro	JJ
cord-034340-3ksfpaf7	908	20	-	-	JJ
cord-034340-3ksfpaf7	908	21	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	908	22	effects	effect	NNS
cord-034340-3ksfpaf7	908	23	that	that	WDT
cord-034340-3ksfpaf7	908	24	possibly	possibly	RB
cord-034340-3ksfpaf7	908	25	could	could	MD
cord-034340-3ksfpaf7	908	26	result	result	VB
cord-034340-3ksfpaf7	908	27	in	in	IN
cord-034340-3ksfpaf7	908	28	arthritic	arthritic	JJ
cord-034340-3ksfpaf7	908	29	disease	disease	NN
cord-034340-3ksfpaf7	908	30	.	.	.
cord-034340-3ksfpaf7	909	1	Future	future	JJ
cord-034340-3ksfpaf7	909	2	identification	identification	NN
cord-034340-3ksfpaf7	909	3	of	of	IN
cord-034340-3ksfpaf7	909	4	other	other	JJ
cord-034340-3ksfpaf7	909	5	patients	patient	NNS
cord-034340-3ksfpaf7	909	6	with	with	IN
cord-034340-3ksfpaf7	909	7	GS	GS	NNP
cord-034340-3ksfpaf7	909	8	is	be	VBZ
cord-034340-3ksfpaf7	909	9	required	require	VBN
cord-034340-3ksfpaf7	909	10	to	to	TO
cord-034340-3ksfpaf7	909	11	support	support	VB
cord-034340-3ksfpaf7	909	12	the	the	DT
cord-034340-3ksfpaf7	909	13	hypothesis	hypothesis	NN
cord-034340-3ksfpaf7	909	14	of	of	IN
cord-034340-3ksfpaf7	909	15	an	an	DT
cord-034340-3ksfpaf7	909	16	arthritic	arthritic	JJ
cord-034340-3ksfpaf7	909	17	clinical	clinical	JJ
cord-034340-3ksfpaf7	909	18	phenotype	phenotype	NN
cord-034340-3ksfpaf7	909	19	of	of	IN
cord-034340-3ksfpaf7	909	20	GS	GS	NNP
cord-034340-3ksfpaf7	909	21	and	and	CC
cord-034340-3ksfpaf7	909	22	to	to	TO
cord-034340-3ksfpaf7	909	23	assess	assess	VB
cord-034340-3ksfpaf7	909	24	underlying	underlying	JJ
cord-034340-3ksfpaf7	909	25	pathophysiology	pathophysiology	NN
cord-034340-3ksfpaf7	909	26	.	.	.
cord-034340-3ksfpaf7	910	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	910	2	:	:	:
cord-034340-3ksfpaf7	910	3	Joint	joint	JJ
cord-034340-3ksfpaf7	910	4	pain	pain	NN
cord-034340-3ksfpaf7	910	5	(	(	-LRB-
cord-034340-3ksfpaf7	910	6	JP	JP	NNP
cord-034340-3ksfpaf7	910	7	)	)	-RRB-
cord-034340-3ksfpaf7	910	8	is	be	VBZ
cord-034340-3ksfpaf7	910	9	a	a	DT
cord-034340-3ksfpaf7	910	10	relatively	relatively	RB
cord-034340-3ksfpaf7	910	11	common	common	JJ
cord-034340-3ksfpaf7	910	12	complaint	complaint	NN
cord-034340-3ksfpaf7	910	13	among	among	IN
cord-034340-3ksfpaf7	910	14	children	child	NNS
cord-034340-3ksfpaf7	910	15	and	and	CC
cord-034340-3ksfpaf7	910	16	adolescents	adolescent	NNS
cord-034340-3ksfpaf7	910	17	.	.	.
cord-034340-3ksfpaf7	911	1	A	a	DT
cord-034340-3ksfpaf7	911	2	painful	painful	JJ
cord-034340-3ksfpaf7	911	3	joint	joint	NN
cord-034340-3ksfpaf7	911	4	in	in	IN
cord-034340-3ksfpaf7	911	5	children	child	NNS
cord-034340-3ksfpaf7	911	6	for	for	IN
cord-034340-3ksfpaf7	911	7	many	many	JJ
cord-034340-3ksfpaf7	911	8	years	year	NNS
cord-034340-3ksfpaf7	911	9	continues	continue	VBZ
cord-034340-3ksfpaf7	911	10	to	to	TO
cord-034340-3ksfpaf7	911	11	maintain	maintain	VB
cord-034340-3ksfpaf7	911	12	the	the	DT
cord-034340-3ksfpaf7	911	13	status	status	NN
cord-034340-3ksfpaf7	911	14	of	of	IN
cord-034340-3ksfpaf7	911	15	the	the	DT
cord-034340-3ksfpaf7	911	16	most	most	RBS
cord-034340-3ksfpaf7	911	17	common	common	JJ
cord-034340-3ksfpaf7	911	18	symptom	symptom	NN
cord-034340-3ksfpaf7	911	19	of	of	IN
cord-034340-3ksfpaf7	911	20	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	911	21	arthritis	arthritis	NN
cord-034340-3ksfpaf7	911	22	.	.	.
cord-034340-3ksfpaf7	912	1	However	however	RB
cord-034340-3ksfpaf7	912	2	this	this	DT
cord-034340-3ksfpaf7	912	3	symptom	symptom	NN
cord-034340-3ksfpaf7	912	4	should	should	MD
cord-034340-3ksfpaf7	912	5	not	not	RB
cord-034340-3ksfpaf7	912	6	always	always	RB
cord-034340-3ksfpaf7	912	7	be	be	VB
cord-034340-3ksfpaf7	912	8	interpreted	interpret	VBN
cord-034340-3ksfpaf7	912	9	as	as	IN
cord-034340-3ksfpaf7	912	10	a	a	DT
cord-034340-3ksfpaf7	912	11	manifestation	manifestation	NN
cord-034340-3ksfpaf7	912	12	of	of	IN
cord-034340-3ksfpaf7	912	13	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	912	14	diseases	disease	NNS
cord-034340-3ksfpaf7	912	15	.	.	.
cord-034340-3ksfpaf7	913	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	913	2	:	:	:
cord-034340-3ksfpaf7	914	1	The	the	DT
cord-034340-3ksfpaf7	914	2	aim	aim	NN
cord-034340-3ksfpaf7	914	3	of	of	IN
cord-034340-3ksfpaf7	914	4	current	current	JJ
cord-034340-3ksfpaf7	914	5	review	review	NN
cord-034340-3ksfpaf7	914	6	is	be	VBZ
cord-034340-3ksfpaf7	914	7	to	to	TO
cord-034340-3ksfpaf7	914	8	debate	debate	NN
cord-034340-3ksfpaf7	914	9	of	of	IN
cord-034340-3ksfpaf7	914	10	the	the	DT
cord-034340-3ksfpaf7	914	11	structure	structure	NN
cord-034340-3ksfpaf7	914	12	in	in	IN
cord-034340-3ksfpaf7	914	13	children	child	NNS
cord-034340-3ksfpaf7	914	14	with	with	IN
cord-034340-3ksfpaf7	914	15	the	the	DT
cord-034340-3ksfpaf7	914	16	chief	chief	JJ
cord-034340-3ksfpaf7	914	17	complaint	complaint	NN
cord-034340-3ksfpaf7	914	18	of	of	IN
cord-034340-3ksfpaf7	914	19	JP	JP	NNP
cord-034340-3ksfpaf7	914	20	.	.	.
cord-034340-3ksfpaf7	915	1	Methods	method	NNS
cord-034340-3ksfpaf7	916	1	:	:	:
cord-034340-3ksfpaf7	916	2	We	-PRON-	PRP
cord-034340-3ksfpaf7	916	3	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	916	4	analysed	analyse	VBD
cord-034340-3ksfpaf7	916	5	our	-PRON-	PRP$
cord-034340-3ksfpaf7	916	6	series	series	NN
cord-034340-3ksfpaf7	916	7	of	of	IN
cord-034340-3ksfpaf7	916	8	600	600	CD
cord-034340-3ksfpaf7	916	9	children	child	NNS
cord-034340-3ksfpaf7	916	10	which	which	WDT
cord-034340-3ksfpaf7	916	11	attending	attend	VBG
cord-034340-3ksfpaf7	916	12	outpatient	outpatient	NN
cord-034340-3ksfpaf7	916	13	department	department	NN
cord-034340-3ksfpaf7	916	14	with	with	IN
cord-034340-3ksfpaf7	916	15	complaint	complaint	NN
cord-034340-3ksfpaf7	916	16	about	about	IN
cord-034340-3ksfpaf7	916	17	pain	pain	NN
cord-034340-3ksfpaf7	916	18	lasting	last	VBG
cord-034340-3ksfpaf7	916	19	longer	long	RBR
cord-034340-3ksfpaf7	916	20	than	than	IN
cord-034340-3ksfpaf7	916	21	two	two	CD
cord-034340-3ksfpaf7	916	22	months	month	NNS
cord-034340-3ksfpaf7	916	23	in	in	IN
cord-034340-3ksfpaf7	916	24	one	one	CD
cord-034340-3ksfpaf7	916	25	or	or	CC
cord-034340-3ksfpaf7	916	26	more	more	JJR
cord-034340-3ksfpaf7	916	27	joints	joint	NNS
cord-034340-3ksfpaf7	916	28	.	.	.
cord-034340-3ksfpaf7	917	1	The	the	DT
cord-034340-3ksfpaf7	917	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	917	3	,	,	,
cord-034340-3ksfpaf7	917	4	instrumental	instrumental	JJ
cord-034340-3ksfpaf7	917	5	and	and	CC
cord-034340-3ksfpaf7	917	6	laboratory	laboratory	NN
cord-034340-3ksfpaf7	917	7	pictures	picture	NNS
cord-034340-3ksfpaf7	917	8	were	be	VBD
cord-034340-3ksfpaf7	917	9	collected	collect	VBN
cord-034340-3ksfpaf7	917	10	.	.	.
cord-034340-3ksfpaf7	918	1	Special	special	JJ
cord-034340-3ksfpaf7	918	2	attention	attention	NN
cord-034340-3ksfpaf7	918	3	was	be	VBD
cord-034340-3ksfpaf7	918	4	paid	pay	VBN
cord-034340-3ksfpaf7	918	5	to	to	IN
cord-034340-3ksfpaf7	918	6	certain	certain	JJ
cord-034340-3ksfpaf7	918	7	aspect	aspect	NN
cord-034340-3ksfpaf7	918	8	of	of	IN
cord-034340-3ksfpaf7	918	9	medical	medical	JJ
cord-034340-3ksfpaf7	918	10	complaints	complaint	NNS
cord-034340-3ksfpaf7	918	11	,	,	,
cord-034340-3ksfpaf7	918	12	a	a	DT
cord-034340-3ksfpaf7	918	13	complete	complete	JJ
cord-034340-3ksfpaf7	918	14	and	and	CC
cord-034340-3ksfpaf7	918	15	accurate	accurate	JJ
cord-034340-3ksfpaf7	918	16	history	history	NN
cord-034340-3ksfpaf7	918	17	and	and	CC
cord-034340-3ksfpaf7	918	18	physical	physical	JJ
cord-034340-3ksfpaf7	918	19	examination	examination	NN
cord-034340-3ksfpaf7	918	20	.	.	.
cord-034340-3ksfpaf7	919	1	Different	different	JJ
cord-034340-3ksfpaf7	919	2	categories	category	NNS
cord-034340-3ksfpaf7	919	3	as	as	IN
cord-034340-3ksfpaf7	919	4	possible	possible	JJ
cord-034340-3ksfpaf7	919	5	etiologies	etiology	NNS
cord-034340-3ksfpaf7	919	6	of	of	IN
cord-034340-3ksfpaf7	919	7	JP	JP	NNP
cord-034340-3ksfpaf7	919	8	in	in	IN
cord-034340-3ksfpaf7	919	9	children	child	NNS
cord-034340-3ksfpaf7	919	10	were	be	VBD
cord-034340-3ksfpaf7	919	11	systematize	systematize	VB
cord-034340-3ksfpaf7	919	12	and	and	CC
cord-034340-3ksfpaf7	919	13	detailed	detail	VBN
cord-034340-3ksfpaf7	919	14	.	.	.
cord-034340-3ksfpaf7	920	1	Results	result	NNS
cord-034340-3ksfpaf7	920	2	:	:	:
cord-034340-3ksfpaf7	921	1	All	all	DT
cord-034340-3ksfpaf7	921	2	children	child	NNS
cord-034340-3ksfpaf7	921	3	were	be	VBD
cord-034340-3ksfpaf7	921	4	divided	divide	VBN
cord-034340-3ksfpaf7	921	5	into	into	IN
cord-034340-3ksfpaf7	921	6	several	several	JJ
cord-034340-3ksfpaf7	921	7	groups	group	NNS
cord-034340-3ksfpaf7	921	8	based	base	VBN
cord-034340-3ksfpaf7	921	9	on	on	IN
cord-034340-3ksfpaf7	921	10	their	-PRON-	PRP$
cord-034340-3ksfpaf7	921	11	anatomical	anatomical	JJ
cord-034340-3ksfpaf7	921	12	and	and	CC
cord-034340-3ksfpaf7	921	13	physiological	physiological	JJ
cord-034340-3ksfpaf7	921	14	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	921	15	of	of	IN
cord-034340-3ksfpaf7	921	16	osteoarticular	osteoarticular	NNP
cord-034340-3ksfpaf7	921	17	system	system	NN
cord-034340-3ksfpaf7	921	18	:	:	:
cord-034340-3ksfpaf7	921	19	the	the	DT
cord-034340-3ksfpaf7	921	20	first	first	JJ
cord-034340-3ksfpaf7	921	21	group	group	NN
cord-034340-3ksfpaf7	921	22	consisted	consist	VBD
cord-034340-3ksfpaf7	921	23	of	of	IN
cord-034340-3ksfpaf7	921	24	240	240	CD
cord-034340-3ksfpaf7	921	25	children	child	NNS
cord-034340-3ksfpaf7	921	26	under	under	IN
cord-034340-3ksfpaf7	921	27	6	6	CD
cord-034340-3ksfpaf7	921	28	-	-	SYM
cord-034340-3ksfpaf7	921	29	7	7	CD
cord-034340-3ksfpaf7	921	30	years	year	NNS
cord-034340-3ksfpaf7	921	31	old	old	JJ
cord-034340-3ksfpaf7	921	32	,	,	,
cord-034340-3ksfpaf7	922	1	the	the	DT
cord-034340-3ksfpaf7	922	2	second	second	JJ
cord-034340-3ksfpaf7	922	3	group	group	NN
cord-034340-3ksfpaf7	922	4	-220	-220	JJ
cord-034340-3ksfpaf7	922	5	children	child	NNS
cord-034340-3ksfpaf7	922	6	7	7	CD
cord-034340-3ksfpaf7	922	7	-	-	SYM
cord-034340-3ksfpaf7	922	8	12	12	CD
cord-034340-3ksfpaf7	922	9	years	year	NNS
cord-034340-3ksfpaf7	922	10	old	old	JJ
cord-034340-3ksfpaf7	922	11	,	,	,
cord-034340-3ksfpaf7	922	12	the	the	DT
cord-034340-3ksfpaf7	922	13	third	third	JJ
cord-034340-3ksfpaf7	922	14	group	group	NN
cord-034340-3ksfpaf7	922	15	-140	-140	VBD
cord-034340-3ksfpaf7	922	16	children	child	NNS
cord-034340-3ksfpaf7	922	17	over	over	IN
cord-034340-3ksfpaf7	922	18	12	12	CD
cord-034340-3ksfpaf7	922	19	years	year	NNS
cord-034340-3ksfpaf7	922	20	old	old	JJ
cord-034340-3ksfpaf7	922	21	.	.	.
cord-034340-3ksfpaf7	923	1	Research	research	NN
cord-034340-3ksfpaf7	923	2	suggests	suggest	VBZ
cord-034340-3ksfpaf7	923	3	that	that	IN
cord-034340-3ksfpaf7	923	4	more	more	JJR
cord-034340-3ksfpaf7	923	5	preschool	preschool	NN
cord-034340-3ksfpaf7	923	6	children	child	NNS
cord-034340-3ksfpaf7	923	7	were	be	VBD
cord-034340-3ksfpaf7	923	8	experience	experience	NN
cord-034340-3ksfpaf7	923	9	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	923	10	lower	low	JJR
cord-034340-3ksfpaf7	923	11	extremity	extremity	NN
cord-034340-3ksfpaf7	923	12	pain	pain	NN
cord-034340-3ksfpaf7	923	13	by	by	IN
cord-034340-3ksfpaf7	923	14	"	"	``
cord-034340-3ksfpaf7	923	15	post	post	JJ
cord-034340-3ksfpaf7	923	16	-	-	JJ
cord-034340-3ksfpaf7	923	17	walk	walk	JJ
cord-034340-3ksfpaf7	923	18	genesis	genesis	NN
cord-034340-3ksfpaf7	923	19	"	"	''
cord-034340-3ksfpaf7	923	20	due	due	IN
cord-034340-3ksfpaf7	923	21	to	to	IN
cord-034340-3ksfpaf7	923	22	natural	natural	JJ
cord-034340-3ksfpaf7	923	23	hypermobility	hypermobility	NN
cord-034340-3ksfpaf7	923	24	,	,	,
cord-034340-3ksfpaf7	923	25	immaturity	immaturity	NN
cord-034340-3ksfpaf7	923	26	of	of	IN
cord-034340-3ksfpaf7	923	27	sensory	sensory	JJ
cord-034340-3ksfpaf7	923	28	innervation	innervation	NN
cord-034340-3ksfpaf7	923	29	of	of	IN
cord-034340-3ksfpaf7	923	30	the	the	DT
cord-034340-3ksfpaf7	923	31	joints	joint	NNS
cord-034340-3ksfpaf7	923	32	and	and	CC
cord-034340-3ksfpaf7	923	33	imbalance	imbalance	NN
cord-034340-3ksfpaf7	923	34	of	of	IN
cord-034340-3ksfpaf7	923	35	the	the	DT
cord-034340-3ksfpaf7	923	36	leg	leg	NN
cord-034340-3ksfpaf7	923	37	muscles	muscle	NNS
cord-034340-3ksfpaf7	923	38	(	(	-LRB-
cord-034340-3ksfpaf7	923	39	e.g.	e.g.	RB
cord-034340-3ksfpaf7	923	40	growing	grow	VBG
cord-034340-3ksfpaf7	923	41	pains	pain	NNS
cord-034340-3ksfpaf7	923	42	)	)	-RRB-
cord-034340-3ksfpaf7	923	43	.	.	.
cord-034340-3ksfpaf7	924	1	The	the	DT
cord-034340-3ksfpaf7	924	2	second	second	JJ
cord-034340-3ksfpaf7	924	3	most	most	RBS
cord-034340-3ksfpaf7	924	4	common	common	JJ
cord-034340-3ksfpaf7	924	5	cause	cause	NN
cord-034340-3ksfpaf7	924	6	of	of	IN
cord-034340-3ksfpaf7	924	7	JP	JP	NNP
cord-034340-3ksfpaf7	924	8	was	be	VBD
cord-034340-3ksfpaf7	924	9	associated	associate	VBN
cord-034340-3ksfpaf7	924	10	with	with	IN
cord-034340-3ksfpaf7	924	11	intra	intra	JJ
cord-034340-3ksfpaf7	924	12	-or	-or	DT
cord-034340-3ksfpaf7	924	13	postinfectious	postinfectious	JJ
cord-034340-3ksfpaf7	924	14	factor	factor	NN
cord-034340-3ksfpaf7	924	15	(	(	-LRB-
cord-034340-3ksfpaf7	924	16	viral	viral	JJ
cord-034340-3ksfpaf7	924	17	,	,	,
cord-034340-3ksfpaf7	924	18	streptococcal	streptococcal	JJ
cord-034340-3ksfpaf7	924	19	and	and	CC
cord-034340-3ksfpaf7	924	20	chronic	chronic	JJ
cord-034340-3ksfpaf7	924	21	focal	focal	NN
cord-034340-3ksfpaf7	924	22	of	of	IN
cord-034340-3ksfpaf7	924	23	infection	infection	NN
cord-034340-3ksfpaf7	924	24	)	)	-RRB-
cord-034340-3ksfpaf7	924	25	.	.	.
cord-034340-3ksfpaf7	925	1	The	the	DT
cord-034340-3ksfpaf7	925	2	frequency	frequency	NN
cord-034340-3ksfpaf7	925	3	of	of	IN
cord-034340-3ksfpaf7	925	4	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	925	5	arthritis	arthritis	NN
cord-034340-3ksfpaf7	925	6	and	and	CC
cord-034340-3ksfpaf7	925	7	other	other	JJ
cord-034340-3ksfpaf7	925	8	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	925	9	diseases	disease	NNS
cord-034340-3ksfpaf7	925	10	in	in	IN
cord-034340-3ksfpaf7	925	11	children	child	NNS
cord-034340-3ksfpaf7	925	12	of	of	IN
cord-034340-3ksfpaf7	925	13	this	this	DT
cord-034340-3ksfpaf7	925	14	age	age	NN
cord-034340-3ksfpaf7	925	15	group	group	NN
cord-034340-3ksfpaf7	925	16	did	do	VBD
cord-034340-3ksfpaf7	925	17	not	not	RB
cord-034340-3ksfpaf7	925	18	exceed	exceed	VB
cord-034340-3ksfpaf7	925	19	10	10	CD
cord-034340-3ksfpaf7	925	20	%	%	NN
cord-034340-3ksfpaf7	925	21	.	.	.
cord-034340-3ksfpaf7	926	1	Special	special	JJ
cord-034340-3ksfpaf7	926	2	attention	attention	NN
cord-034340-3ksfpaf7	926	3	was	be	VBD
cord-034340-3ksfpaf7	926	4	paid	pay	VBN
cord-034340-3ksfpaf7	926	5	to	to	IN
cord-034340-3ksfpaf7	926	6	fever	fever	NN
cord-034340-3ksfpaf7	926	7	,	,	,
cord-034340-3ksfpaf7	926	8	chills	chill	NNS
cord-034340-3ksfpaf7	926	9	,	,	,
cord-034340-3ksfpaf7	926	10	malaise	malaise	NN
cord-034340-3ksfpaf7	926	11	,	,	,
cord-034340-3ksfpaf7	926	12	nightpain	nightpain	JJ
cord-034340-3ksfpaf7	926	13	and	and	CC
cord-034340-3ksfpaf7	926	14	constitutional	constitutional	JJ
cord-034340-3ksfpaf7	926	15	symptoms	symptom	NNS
cord-034340-3ksfpaf7	926	16	with	with	IN
cord-034340-3ksfpaf7	926	17	changes	change	NNS
cord-034340-3ksfpaf7	926	18	in	in	IN
cord-034340-3ksfpaf7	926	19	blood	blood	NN
cord-034340-3ksfpaf7	926	20	lab	lab	NN
cord-034340-3ksfpaf7	926	21	tests	test	NNS
cord-034340-3ksfpaf7	926	22	to	to	TO
cord-034340-3ksfpaf7	926	23	exclude	exclude	VB
cord-034340-3ksfpaf7	926	24	osteomyelitis	osteomyelitis	NN
cord-034340-3ksfpaf7	926	25	(	(	-LRB-
cord-034340-3ksfpaf7	926	26	inc	inc	NNP
cord-034340-3ksfpaf7	926	27	specific	specific	JJ
cord-034340-3ksfpaf7	926	28	cause	cause	NN
cord-034340-3ksfpaf7	926	29	)	)	-RRB-
cord-034340-3ksfpaf7	926	30	,	,	,
cord-034340-3ksfpaf7	926	31	malignancies	malignancy	NNS
cord-034340-3ksfpaf7	926	32	manifestation	manifestation	NN
cord-034340-3ksfpaf7	926	33	and	and	CC
cord-034340-3ksfpaf7	926	34	other	other	JJ
cord-034340-3ksfpaf7	926	35	bone	bone	NN
cord-034340-3ksfpaf7	926	36	tumors	tumor	NNS
cord-034340-3ksfpaf7	926	37	(	(	-LRB-
cord-034340-3ksfpaf7	926	38	less	less	JJR
cord-034340-3ksfpaf7	926	39	5	5	CD
cord-034340-3ksfpaf7	926	40	%	%	NN
cord-034340-3ksfpaf7	926	41	)	)	-RRB-
cord-034340-3ksfpaf7	926	42	.	.	.
cord-034340-3ksfpaf7	927	1	The	the	DT
cord-034340-3ksfpaf7	927	2	most	most	RBS
cord-034340-3ksfpaf7	927	3	common	common	JJ
cord-034340-3ksfpaf7	927	4	causes	cause	NNS
cord-034340-3ksfpaf7	927	5	of	of	IN
cord-034340-3ksfpaf7	927	6	joint	joint	JJ
cord-034340-3ksfpaf7	927	7	pain	pain	NN
cord-034340-3ksfpaf7	927	8	of	of	IN
cord-034340-3ksfpaf7	927	9	school	school	NN
cord-034340-3ksfpaf7	927	10	-	-	HYPH
cord-034340-3ksfpaf7	927	11	age	age	NN
cord-034340-3ksfpaf7	927	12	children	child	NNS
cord-034340-3ksfpaf7	927	13	were	be	VBD
cord-034340-3ksfpaf7	927	14	hypermobility	hypermobility	NN
cord-034340-3ksfpaf7	927	15	syndrome	syndrome	NN
cord-034340-3ksfpaf7	927	16	and	and	CC
cord-034340-3ksfpaf7	927	17	enthesopathy	enthesopathy	NNP
cord-034340-3ksfpaf7	927	18	(	(	-LRB-
cord-034340-3ksfpaf7	927	19	primary	primary	JJ
cord-034340-3ksfpaf7	927	20	,	,	,
cord-034340-3ksfpaf7	927	21	secondary	secondary	JJ
cord-034340-3ksfpaf7	927	22	)	)	-RRB-
cord-034340-3ksfpaf7	927	23	.	.	.
cord-034340-3ksfpaf7	928	1	Secondary	secondary	JJ
cord-034340-3ksfpaf7	928	2	enthesopathy	enthesopathy	NNP
cord-034340-3ksfpaf7	928	3	were	be	VBD
cord-034340-3ksfpaf7	928	4	result	result	NN
cord-034340-3ksfpaf7	928	5	of	of	IN
cord-034340-3ksfpaf7	928	6	changes	change	NNS
cord-034340-3ksfpaf7	928	7	in	in	IN
cord-034340-3ksfpaf7	928	8	nutrition	nutrition	NN
cord-034340-3ksfpaf7	928	9	,	,	,
cord-034340-3ksfpaf7	928	10	rapid	rapid	JJ
cord-034340-3ksfpaf7	928	11	growth	growth	NN
cord-034340-3ksfpaf7	928	12	and	and	CC
cord-034340-3ksfpaf7	928	13	excessive	excessive	JJ
cord-034340-3ksfpaf7	928	14	exercise	exercise	NN
cord-034340-3ksfpaf7	928	15	.	.	.
cord-034340-3ksfpaf7	929	1	Also	also	RB
cord-034340-3ksfpaf7	929	2	enthesopathy	enthesopathy	NNP
cord-034340-3ksfpaf7	929	3	were	be	VBD
cord-034340-3ksfpaf7	929	4	manifestation	manifestation	NN
cord-034340-3ksfpaf7	929	5	of	of	IN
cord-034340-3ksfpaf7	929	6	endocrine	endocrine	JJ
cord-034340-3ksfpaf7	929	7	,	,	,
cord-034340-3ksfpaf7	929	8	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	929	9	or	or	CC
cord-034340-3ksfpaf7	929	10	infectious	infectious	JJ
cord-034340-3ksfpaf7	929	11	diseases	disease	NNS
cord-034340-3ksfpaf7	929	12	.	.	.
cord-034340-3ksfpaf7	930	1	The	the	DT
cord-034340-3ksfpaf7	930	2	proportion	proportion	NN
cord-034340-3ksfpaf7	930	3	of	of	IN
cord-034340-3ksfpaf7	930	4	children	child	NNS
cord-034340-3ksfpaf7	930	5	with	with	IN
cord-034340-3ksfpaf7	930	6	the	the	DT
cord-034340-3ksfpaf7	930	7	onset	onset	NN
cord-034340-3ksfpaf7	930	8	of	of	IN
cord-034340-3ksfpaf7	930	9	chronic	chronic	JJ
cord-034340-3ksfpaf7	930	10	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	930	11	arthropathy	arthropathy	NNP
cord-034340-3ksfpaf7	930	12	also	also	RB
cord-034340-3ksfpaf7	930	13	did	do	VBD
cord-034340-3ksfpaf7	930	14	not	not	RB
cord-034340-3ksfpaf7	930	15	exceed	exceed	VB
cord-034340-3ksfpaf7	930	16	10	10	CD
cord-034340-3ksfpaf7	930	17	%	%	NN
cord-034340-3ksfpaf7	930	18	.	.	.
cord-034340-3ksfpaf7	931	1	Hypermobility	Hypermobility	NNP
cord-034340-3ksfpaf7	931	2	child	child	NN
cord-034340-3ksfpaf7	931	3	's	's	POS
cord-034340-3ksfpaf7	931	4	syndrome	syndrome	NN
cord-034340-3ksfpaf7	931	5	was	be	VBD
cord-034340-3ksfpaf7	931	6	characterized	characterize	VBN
cord-034340-3ksfpaf7	931	7	by	by	IN
cord-034340-3ksfpaf7	931	8	harmless	harmless	JJ
cord-034340-3ksfpaf7	931	9	pain	pain	NN
cord-034340-3ksfpaf7	931	10	(	(	-LRB-
cord-034340-3ksfpaf7	931	11	inc	inc	NNP
cord-034340-3ksfpaf7	931	12	low	low	JJ
cord-034340-3ksfpaf7	931	13	back	back	JJ
cord-034340-3ksfpaf7	931	14	pain	pain	NN
cord-034340-3ksfpaf7	931	15	)	)	-RRB-
cord-034340-3ksfpaf7	931	16	,	,	,
cord-034340-3ksfpaf7	931	17	linked	link	VBN
cord-034340-3ksfpaf7	931	18	to	to	IN
cord-034340-3ksfpaf7	931	19	physical	physical	JJ
cord-034340-3ksfpaf7	931	20	activity	activity	NN
cord-034340-3ksfpaf7	931	21	(	(	-LRB-
cord-034340-3ksfpaf7	931	22	less	less	JJR
cord-034340-3ksfpaf7	931	23	morning	morning	NN
cord-034340-3ksfpaf7	931	24	stiffness	stiffness	NN
cord-034340-3ksfpaf7	931	25	)	)	-RRB-
cord-034340-3ksfpaf7	931	26	.	.	.
cord-034340-3ksfpaf7	932	1	Over	over	IN
cord-034340-3ksfpaf7	932	2	the	the	DT
cord-034340-3ksfpaf7	932	3	past	past	JJ
cord-034340-3ksfpaf7	932	4	decade	decade	NN
cord-034340-3ksfpaf7	932	5	,	,	,
cord-034340-3ksfpaf7	932	6	we	-PRON-	PRP
cord-034340-3ksfpaf7	932	7	've	have	VB
cord-034340-3ksfpaf7	932	8	seen	see	VBN
cord-034340-3ksfpaf7	932	9	a	a	DT
cord-034340-3ksfpaf7	932	10	gradual	gradual	JJ
cord-034340-3ksfpaf7	932	11	increase	increase	NN
cord-034340-3ksfpaf7	932	12	in	in	IN
cord-034340-3ksfpaf7	932	13	the	the	DT
cord-034340-3ksfpaf7	932	14	number	number	NN
cord-034340-3ksfpaf7	932	15	of	of	IN
cord-034340-3ksfpaf7	932	16	children	child	NNS
cord-034340-3ksfpaf7	932	17	(	(	-LRB-
cord-034340-3ksfpaf7	932	18	95	95	CD
cord-034340-3ksfpaf7	932	19	%	%	NN
cord-034340-3ksfpaf7	932	20	were	be	VBD
cord-034340-3ksfpaf7	932	21	girls	girl	NNS
cord-034340-3ksfpaf7	932	22	)	)	-RRB-
cord-034340-3ksfpaf7	932	23	with	with	IN
cord-034340-3ksfpaf7	932	24	knee	knee	NN
cord-034340-3ksfpaf7	932	25	pain	pain	NN
cord-034340-3ksfpaf7	932	26	by	by	IN
cord-034340-3ksfpaf7	932	27	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	932	28	patellofemoral	patellofemoral	NNP
cord-034340-3ksfpaf7	932	29	and	and	CC
cord-034340-3ksfpaf7	932	30	mediopatellar	mediopatellar	NNP
cord-034340-3ksfpaf7	932	31	plica	plica	NNP
cord-034340-3ksfpaf7	932	32	syndromes	syndrome	NNS
cord-034340-3ksfpaf7	932	33	,	,	,
cord-034340-3ksfpaf7	932	34	patellar	patellar	JJ
cord-034340-3ksfpaf7	932	35	tendinitis	tendinitis	NN
cord-034340-3ksfpaf7	932	36	or	or	CC
cord-034340-3ksfpaf7	932	37	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	932	38	cause	cause	NN
cord-034340-3ksfpaf7	932	39	.	.	.
cord-034340-3ksfpaf7	933	1	In	in	IN
cord-034340-3ksfpaf7	933	2	most	most	JJS
cord-034340-3ksfpaf7	933	3	cases	case	NNS
cord-034340-3ksfpaf7	933	4	children	child	NNS
cord-034340-3ksfpaf7	933	5	was	be	VBD
cord-034340-3ksfpaf7	933	6	complicated	complicate	VBN
cord-034340-3ksfpaf7	933	7	by	by	IN
cord-034340-3ksfpaf7	933	8	syndrome	syndrome	NN
cord-034340-3ksfpaf7	933	9	of	of	IN
cord-034340-3ksfpaf7	933	10	increased	increase	VBN
cord-034340-3ksfpaf7	933	11	anxiety	anxiety	NN
cord-034340-3ksfpaf7	933	12	.	.	.
cord-034340-3ksfpaf7	934	1	The	the	DT
cord-034340-3ksfpaf7	934	2	share	share	NN
cord-034340-3ksfpaf7	934	3	of	of	IN
cord-034340-3ksfpaf7	934	4	true	true	JJ
cord-034340-3ksfpaf7	934	5	chronic	chronic	JJ
cord-034340-3ksfpaf7	934	6	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	934	7	arthropathies	arthropathy	NNS
cord-034340-3ksfpaf7	934	8	,	,	,
cord-034340-3ksfpaf7	934	9	including	include	VBG
cord-034340-3ksfpaf7	934	10	spondylitis	spondylitis	NN
cord-034340-3ksfpaf7	934	11	,	,	,
cord-034340-3ksfpaf7	934	12	in	in	IN
cord-034340-3ksfpaf7	934	13	children	child	NNS
cord-034340-3ksfpaf7	934	14	of	of	IN
cord-034340-3ksfpaf7	934	15	this	this	DT
cord-034340-3ksfpaf7	934	16	age	age	NN
cord-034340-3ksfpaf7	934	17	group	group	NN
cord-034340-3ksfpaf7	934	18	did	do	VBD
cord-034340-3ksfpaf7	934	19	not	not	RB
cord-034340-3ksfpaf7	934	20	exceed	exceed	VB
cord-034340-3ksfpaf7	934	21	10	10	CD
cord-034340-3ksfpaf7	934	22	%	%	NN
cord-034340-3ksfpaf7	934	23	.	.	.
cord-034340-3ksfpaf7	935	1	Fibromyalgia	fibromyalgia	NN
cord-034340-3ksfpaf7	935	2	were	be	VBD
cord-034340-3ksfpaf7	935	3	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	935	4	less	less	JJR
cord-034340-3ksfpaf7	935	5	5	5	CD
cord-034340-3ksfpaf7	935	6	%	%	NN
cord-034340-3ksfpaf7	935	7	.	.	.
cord-034340-3ksfpaf7	936	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	936	2	:	:	:
cord-034340-3ksfpaf7	937	1	A	a	DT
cord-034340-3ksfpaf7	937	2	significant	significant	JJ
cord-034340-3ksfpaf7	937	3	part	part	NN
cord-034340-3ksfpaf7	937	4	of	of	IN
cord-034340-3ksfpaf7	937	5	patients	patient	NNS
cord-034340-3ksfpaf7	937	6	in	in	IN
cord-034340-3ksfpaf7	937	7	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	937	8	's	's	POS
cord-034340-3ksfpaf7	937	9	practice	practice	NN
cord-034340-3ksfpaf7	937	10	is	be	VBZ
cord-034340-3ksfpaf7	937	11	children	child	NNS
cord-034340-3ksfpaf7	937	12	and	and	CC
cord-034340-3ksfpaf7	937	13	teenagers	teenager	NNS
cord-034340-3ksfpaf7	937	14	with	with	IN
cord-034340-3ksfpaf7	937	15	complaints	complaint	NNS
cord-034340-3ksfpaf7	937	16	of	of	IN
cord-034340-3ksfpaf7	937	17	pain	pain	NN
cord-034340-3ksfpaf7	937	18	.	.	.
cord-034340-3ksfpaf7	938	1	The	the	DT
cord-034340-3ksfpaf7	938	2	further	further	JJ
cord-034340-3ksfpaf7	938	3	volume	volume	NN
cord-034340-3ksfpaf7	938	4	of	of	IN
cord-034340-3ksfpaf7	938	5	examination	examination	NN
cord-034340-3ksfpaf7	938	6	and	and	CC
cord-034340-3ksfpaf7	938	7	the	the	DT
cord-034340-3ksfpaf7	938	8	choice	choice	NN
cord-034340-3ksfpaf7	938	9	of	of	IN
cord-034340-3ksfpaf7	938	10	treatment	treatment	NN
cord-034340-3ksfpaf7	938	11	course	course	NN
cord-034340-3ksfpaf7	938	12	depends	depend	VBZ
cord-034340-3ksfpaf7	938	13	on	on	IN
cord-034340-3ksfpaf7	938	14	the	the	DT
cord-034340-3ksfpaf7	938	15	capability	capability	NN
cord-034340-3ksfpaf7	938	16	of	of	IN
cord-034340-3ksfpaf7	938	17	the	the	DT
cord-034340-3ksfpaf7	938	18	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	938	19	to	to	TO
cord-034340-3ksfpaf7	938	20	define	define	VB
cord-034340-3ksfpaf7	938	21	the	the	DT
cord-034340-3ksfpaf7	938	22	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	938	23	and	and	CC
cord-034340-3ksfpaf7	938	24	non	non	JJ
cord-034340-3ksfpaf7	938	25	-	-	JJ
cord-034340-3ksfpaf7	938	26	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	938	27	genesis	genesis	NN
cord-034340-3ksfpaf7	938	28	of	of	IN
cord-034340-3ksfpaf7	938	29	pain	pain	NN
cord-034340-3ksfpaf7	938	30	.	.	.
cord-034340-3ksfpaf7	939	1	That	that	DT
cord-034340-3ksfpaf7	939	2	makes	make	VBZ
cord-034340-3ksfpaf7	939	3	the	the	DT
cord-034340-3ksfpaf7	939	4	problem	problem	NN
cord-034340-3ksfpaf7	939	5	of	of	IN
cord-034340-3ksfpaf7	939	6	differential	differential	JJ
cord-034340-3ksfpaf7	939	7	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	939	8	very	very	RB
cord-034340-3ksfpaf7	939	9	important	important	JJ
cord-034340-3ksfpaf7	939	10	.	.	.
cord-034340-3ksfpaf7	940	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	940	2	:	:	:
cord-034340-3ksfpaf7	940	3	To	to	TO
cord-034340-3ksfpaf7	940	4	conduct	conduct	VB
cord-034340-3ksfpaf7	940	5	a	a	DT
cord-034340-3ksfpaf7	940	6	comparative	comparative	JJ
cord-034340-3ksfpaf7	940	7	analysis	analysis	NN
cord-034340-3ksfpaf7	940	8	of	of	IN
cord-034340-3ksfpaf7	940	9	patients	patient	NNS
cord-034340-3ksfpaf7	940	10	with	with	IN
cord-034340-3ksfpaf7	940	11	a	a	DT
cord-034340-3ksfpaf7	940	12	principal	principal	JJ
cord-034340-3ksfpaf7	940	13	pain	pain	NN
cord-034340-3ksfpaf7	940	14	complaint	complaint	NN
cord-034340-3ksfpaf7	940	15	to	to	TO
cord-034340-3ksfpaf7	940	16	determine	determine	VB
cord-034340-3ksfpaf7	940	17	if	if	IN
cord-034340-3ksfpaf7	940	18	there	there	EX
cord-034340-3ksfpaf7	940	19	are	be	VBP
cord-034340-3ksfpaf7	940	20	significant	significant	JJ
cord-034340-3ksfpaf7	940	21	differences	difference	NNS
cord-034340-3ksfpaf7	940	22	in	in	IN
cord-034340-3ksfpaf7	940	23	the	the	DT
cord-034340-3ksfpaf7	940	24	groups	group	NNS
cord-034340-3ksfpaf7	940	25	with	with	IN
cord-034340-3ksfpaf7	940	26	the	the	DT
cord-034340-3ksfpaf7	940	27	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	940	28	and	and	CC
cord-034340-3ksfpaf7	940	29	noninflammatory	noninflammatory	JJ
cord-034340-3ksfpaf7	940	30	pain	pain	NN
cord-034340-3ksfpaf7	940	31	genesis	genesis	NN
cord-034340-3ksfpaf7	940	32	.	.	.
cord-034340-3ksfpaf7	941	1	Methods	method	NNS
cord-034340-3ksfpaf7	941	2	:	:	:
cord-034340-3ksfpaf7	942	1	The	the	DT
cord-034340-3ksfpaf7	942	2	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	942	3	study	study	NN
cord-034340-3ksfpaf7	942	4	included	include	VBD
cord-034340-3ksfpaf7	942	5	children	child	NNS
cord-034340-3ksfpaf7	942	6	who	who	WP
cord-034340-3ksfpaf7	942	7	consulted	consult	VBD
cord-034340-3ksfpaf7	942	8	a	a	DT
cord-034340-3ksfpaf7	942	9	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	942	10	in	in	IN
cord-034340-3ksfpaf7	942	11	the	the	DT
cord-034340-3ksfpaf7	942	12	outpatient	outpatient	NN
cord-034340-3ksfpaf7	942	13	clinic	clinic	NN
cord-034340-3ksfpaf7	942	14	in	in	IN
cord-034340-3ksfpaf7	942	15	the	the	DT
cord-034340-3ksfpaf7	942	16	period	period	NN
cord-034340-3ksfpaf7	942	17	2018	2018	CD
cord-034340-3ksfpaf7	942	18	-	-	SYM
cord-034340-3ksfpaf7	942	19	2020	2020	CD
cord-034340-3ksfpaf7	942	20	without	without	IN
cord-034340-3ksfpaf7	942	21	preliminary	preliminary	JJ
cord-034340-3ksfpaf7	942	22	selection	selection	NN
cord-034340-3ksfpaf7	942	23	(	(	-LRB-
cord-034340-3ksfpaf7	942	24	n	n	NN
cord-034340-3ksfpaf7	942	25	=	=	SYM
cord-034340-3ksfpaf7	942	26	176	176	CD
cord-034340-3ksfpaf7	942	27	)	)	-RRB-
cord-034340-3ksfpaf7	942	28	.	.	.
cord-034340-3ksfpaf7	943	1	Of	of	IN
cord-034340-3ksfpaf7	943	2	them	-PRON-	PRP
cord-034340-3ksfpaf7	943	3	there	there	EX
cord-034340-3ksfpaf7	943	4	were	be	VBD
cord-034340-3ksfpaf7	943	5	selected	select	VBN
cord-034340-3ksfpaf7	943	6	children	child	NNS
cord-034340-3ksfpaf7	943	7	with	with	IN
cord-034340-3ksfpaf7	943	8	principal	principal	JJ
cord-034340-3ksfpaf7	943	9	pain	pain	NN
cord-034340-3ksfpaf7	943	10	complaint	complaint	NN
cord-034340-3ksfpaf7	943	11	(	(	-LRB-
cord-034340-3ksfpaf7	943	12	n	n	NN
cord-034340-3ksfpaf7	943	13	=	=	SYM
cord-034340-3ksfpaf7	943	14	120	120	CD
cord-034340-3ksfpaf7	943	15	)	)	-RRB-
cord-034340-3ksfpaf7	943	16	.	.	.
cord-034340-3ksfpaf7	944	1	According	accord	VBG
cord-034340-3ksfpaf7	944	2	to	to	IN
cord-034340-3ksfpaf7	944	3	the	the	DT
cord-034340-3ksfpaf7	944	4	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	944	5	,	,	,
cord-034340-3ksfpaf7	944	6	the	the	DT
cord-034340-3ksfpaf7	944	7	children	child	NNS
cord-034340-3ksfpaf7	944	8	were	be	VBD
cord-034340-3ksfpaf7	944	9	divided	divide	VBN
cord-034340-3ksfpaf7	944	10	into	into	IN
cord-034340-3ksfpaf7	944	11	2	2	CD
cord-034340-3ksfpaf7	944	12	groups	group	NNS
cord-034340-3ksfpaf7	944	13	:	:	:
cord-034340-3ksfpaf7	944	14	those	those	DT
cord-034340-3ksfpaf7	944	15	who	who	WP
cord-034340-3ksfpaf7	944	16	have	have	VBP
cord-034340-3ksfpaf7	944	17	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	944	18	genesis	genesis	NN
cord-034340-3ksfpaf7	944	19	of	of	IN
cord-034340-3ksfpaf7	944	20	pain	pain	NN
cord-034340-3ksfpaf7	944	21	(	(	-LRB-
cord-034340-3ksfpaf7	944	22	A	A	NNP
cord-034340-3ksfpaf7	944	23	,	,	,
cord-034340-3ksfpaf7	944	24	n	n	NN
cord-034340-3ksfpaf7	944	25	=	=	SYM
cord-034340-3ksfpaf7	944	26	59	59	CD
cord-034340-3ksfpaf7	944	27	)	)	-RRB-
cord-034340-3ksfpaf7	944	28	and	and	CC
cord-034340-3ksfpaf7	944	29	those	those	DT
cord-034340-3ksfpaf7	944	30	with	with	IN
cord-034340-3ksfpaf7	944	31	noninflammatory	noninflammatory	JJ
cord-034340-3ksfpaf7	944	32	genesis	genesis	NN
cord-034340-3ksfpaf7	944	33	of	of	IN
cord-034340-3ksfpaf7	944	34	pain	pain	NN
cord-034340-3ksfpaf7	944	35	(	(	-LRB-
cord-034340-3ksfpaf7	944	36	B	b	NN
cord-034340-3ksfpaf7	944	37	,	,	,
cord-034340-3ksfpaf7	944	38	n	n	NN
cord-034340-3ksfpaf7	944	39	=	=	SYM
cord-034340-3ksfpaf7	944	40	61	61	CD
cord-034340-3ksfpaf7	944	41	)	)	-RRB-
cord-034340-3ksfpaf7	944	42	.	.	.
cord-034340-3ksfpaf7	945	1	The	the	DT
cord-034340-3ksfpaf7	945	2	group	group	NN
cord-034340-3ksfpaf7	945	3	A	a	NN
cord-034340-3ksfpaf7	945	4	included	include	VBD
cord-034340-3ksfpaf7	945	5	children	child	NNS
cord-034340-3ksfpaf7	945	6	with	with	IN
cord-034340-3ksfpaf7	945	7	such	such	JJ
cord-034340-3ksfpaf7	945	8	diagnoses	diagnosis	NNS
cord-034340-3ksfpaf7	945	9	as	as	IN
cord-034340-3ksfpaf7	945	10	:	:	:
cord-034340-3ksfpaf7	945	11	reactive	reactive	JJ
cord-034340-3ksfpaf7	945	12	,	,	,
cord-034340-3ksfpaf7	945	13	poststreptococcal	poststreptococcal	JJ
cord-034340-3ksfpaf7	945	14	and	and	CC
cord-034340-3ksfpaf7	945	15	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	945	16	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	945	17	arthritides	arthritide	NNS
cord-034340-3ksfpaf7	945	18	.	.	.
cord-034340-3ksfpaf7	946	1	The	the	DT
cord-034340-3ksfpaf7	946	2	group	group	NN
cord-034340-3ksfpaf7	946	3	B	b	NN
cord-034340-3ksfpaf7	946	4	included	include	VBD
cord-034340-3ksfpaf7	946	5	children	child	NNS
cord-034340-3ksfpaf7	946	6	with	with	IN
cord-034340-3ksfpaf7	946	7	arthralgia	arthralgia	NNP
cord-034340-3ksfpaf7	946	8	,	,	,
cord-034340-3ksfpaf7	946	9	chronic	chronic	JJ
cord-034340-3ksfpaf7	946	10	pain	pain	NN
cord-034340-3ksfpaf7	946	11	syndrome	syndrome	NN
cord-034340-3ksfpaf7	946	12	,	,	,
cord-034340-3ksfpaf7	946	13	orthopedic	orthopedic	NN
cord-034340-3ksfpaf7	946	14	pathology	pathology	NN
cord-034340-3ksfpaf7	946	15	,	,	,
cord-034340-3ksfpaf7	946	16	fibromyalgia	fibromyalgia	NN
cord-034340-3ksfpaf7	946	17	.	.	.
cord-034340-3ksfpaf7	947	1	Results	result	NNS
cord-034340-3ksfpaf7	947	2	:	:	:
cord-034340-3ksfpaf7	947	3	1	1	CD
cord-034340-3ksfpaf7	947	4	.	.	.
cord-034340-3ksfpaf7	948	1	Groups	group	NNS
cord-034340-3ksfpaf7	948	2	A	A	NNP
cord-034340-3ksfpaf7	948	3	and	and	CC
cord-034340-3ksfpaf7	948	4	B	b	NN
cord-034340-3ksfpaf7	948	5	differ	differ	VB
cord-034340-3ksfpaf7	948	6	in	in	IN
cord-034340-3ksfpaf7	948	7	the	the	DT
cord-034340-3ksfpaf7	948	8	average	average	JJ
cord-034340-3ksfpaf7	948	9	age	age	NN
cord-034340-3ksfpaf7	948	10	of	of	IN
cord-034340-3ksfpaf7	948	11	the	the	DT
cord-034340-3ksfpaf7	948	12	first	first	JJ
cord-034340-3ksfpaf7	948	13	complaints	complaint	NNS
cord-034340-3ksfpaf7	948	14	onset	onset	NN
cord-034340-3ksfpaf7	948	15	(	(	-LRB-
cord-034340-3ksfpaf7	948	16	t	t	NN
cord-034340-3ksfpaf7	948	17	-	-	HYPH
cord-034340-3ksfpaf7	948	18	criterion	criterion	NN
cord-034340-3ksfpaf7	948	19	for	for	IN
cord-034340-3ksfpaf7	948	20	equality	equality	NN
cord-034340-3ksfpaf7	948	21	of	of	IN
cord-034340-3ksfpaf7	948	22	means	mean	NNS
cord-034340-3ksfpaf7	948	23	)	)	-RRB-
cord-034340-3ksfpaf7	948	24	with	with	IN
cord-034340-3ksfpaf7	948	25	a	a	DT
cord-034340-3ksfpaf7	948	26	high	high	JJ
cord-034340-3ksfpaf7	948	27	degree	degree	NN
cord-034340-3ksfpaf7	948	28	of	of	IN
cord-034340-3ksfpaf7	948	29	statistical	statistical	JJ
cord-034340-3ksfpaf7	948	30	significance	significance	NN
cord-034340-3ksfpaf7	948	31	(	(	-LRB-
cord-034340-3ksfpaf7	948	32	Group	Group	NNP
cord-034340-3ksfpaf7	948	33	A	A	NNP
cord-034340-3ksfpaf7	948	34	=	=	SYM
cord-034340-3ksfpaf7	948	35	7,4	7,4	CD
cord-034340-3ksfpaf7	948	36	years	year	NNS
cord-034340-3ksfpaf7	948	37	;	;	:
cord-034340-3ksfpaf7	948	38	Group	Group	NNP
cord-034340-3ksfpaf7	948	39	B	B	NNP
cord-034340-3ksfpaf7	948	40	=	=	SYM
cord-034340-3ksfpaf7	948	41	9,3	9,3	CD
cord-034340-3ksfpaf7	948	42	years	year	NNS
cord-034340-3ksfpaf7	948	43	;	;	:
cord-034340-3ksfpaf7	948	44	p	p	NN
cord-034340-3ksfpaf7	948	45	=	=	SYM
cord-034340-3ksfpaf7	948	46	0.019	0.019	CD
cord-034340-3ksfpaf7	948	47	)	)	-RRB-
cord-034340-3ksfpaf7	948	48	.	.	.
cord-034340-3ksfpaf7	949	1	Which	which	WDT
cord-034340-3ksfpaf7	949	2	means	mean	VBZ
cord-034340-3ksfpaf7	949	3	that	that	IN
cord-034340-3ksfpaf7	949	4	in	in	IN
cord-034340-3ksfpaf7	949	5	Group	Group	NNP
cord-034340-3ksfpaf7	949	6	A	A	NNP
cord-034340-3ksfpaf7	949	7	more	more	RBR
cord-034340-3ksfpaf7	949	8	often	often	RB
cord-034340-3ksfpaf7	949	9	than	than	IN
cord-034340-3ksfpaf7	949	10	in	in	IN
cord-034340-3ksfpaf7	949	11	Group	Group	NNP
cord-034340-3ksfpaf7	949	12	B	B	NNP
cord-034340-3ksfpaf7	950	1	first	first	JJ
cord-034340-3ksfpaf7	950	2	complaints	complaint	NNS
cord-034340-3ksfpaf7	950	3	appear	appear	VBP
cord-034340-3ksfpaf7	950	4	in	in	IN
cord-034340-3ksfpaf7	950	5	the	the	DT
cord-034340-3ksfpaf7	950	6	age	age	NN
cord-034340-3ksfpaf7	950	7	between	between	IN
cord-034340-3ksfpaf7	950	8	1	1	CD
cord-034340-3ksfpaf7	950	9	to	to	IN
cord-034340-3ksfpaf7	950	10	10	10	CD
cord-034340-3ksfpaf7	950	11	while	while	NN
cord-034340-3ksfpaf7	950	12	in	in	IN
cord-034340-3ksfpaf7	950	13	Group	Group	NNP
cord-034340-3ksfpaf7	950	14	B	B	NNP
cord-034340-3ksfpaf7	950	15	more	more	RBR
cord-034340-3ksfpaf7	950	16	often	often	RB
cord-034340-3ksfpaf7	950	17	than	than	IN
cord-034340-3ksfpaf7	950	18	in	in	IN
cord-034340-3ksfpaf7	950	19	Group	Group	NNP
cord-034340-3ksfpaf7	950	20	A	A	NNP
cord-034340-3ksfpaf7	951	1	it	-PRON-	PRP
cord-034340-3ksfpaf7	951	2	happens	happen	VBZ
cord-034340-3ksfpaf7	951	3	in	in	IN
cord-034340-3ksfpaf7	951	4	the	the	DT
cord-034340-3ksfpaf7	951	5	age	age	NN
cord-034340-3ksfpaf7	951	6	between	between	IN
cord-034340-3ksfpaf7	951	7	11	11	CD
cord-034340-3ksfpaf7	951	8	to	to	IN
cord-034340-3ksfpaf7	951	9	16	16	CD
cord-034340-3ksfpaf7	951	10	.	.	.
cord-034340-3ksfpaf7	952	1	2	2	LS
cord-034340-3ksfpaf7	952	2	.	.	.
cord-034340-3ksfpaf7	953	1	There	there	EX
cord-034340-3ksfpaf7	953	2	was	be	VBD
cord-034340-3ksfpaf7	953	3	a	a	DT
cord-034340-3ksfpaf7	953	4	statistically	statistically	RB
cord-034340-3ksfpaf7	953	5	significant	significant	JJ
cord-034340-3ksfpaf7	953	6	difference	difference	NN
cord-034340-3ksfpaf7	953	7	in	in	IN
cord-034340-3ksfpaf7	953	8	the	the	DT
cord-034340-3ksfpaf7	953	9	means	mean	NNS
cord-034340-3ksfpaf7	953	10	between	between	IN
cord-034340-3ksfpaf7	953	11	Groups	group	NNS
cord-034340-3ksfpaf7	953	12	A	A	NNP
cord-034340-3ksfpaf7	953	13	and	and	CC
cord-034340-3ksfpaf7	953	14	B	b	NN
cord-034340-3ksfpaf7	953	15	in	in	IN
cord-034340-3ksfpaf7	953	16	time	time	NN
cord-034340-3ksfpaf7	953	17	between	between	IN
cord-034340-3ksfpaf7	953	18	the	the	DT
cord-034340-3ksfpaf7	953	19	onset	onset	NN
cord-034340-3ksfpaf7	953	20	of	of	IN
cord-034340-3ksfpaf7	953	21	first	first	JJ
cord-034340-3ksfpaf7	953	22	complaints	complaint	NNS
cord-034340-3ksfpaf7	953	23	and	and	CC
cord-034340-3ksfpaf7	953	24	the	the	DT
cord-034340-3ksfpaf7	953	25	first	first	JJ
cord-034340-3ksfpaf7	953	26	visit	visit	NN
cord-034340-3ksfpaf7	953	27	to	to	IN
cord-034340-3ksfpaf7	953	28	a	a	DT
cord-034340-3ksfpaf7	953	29	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	953	30	(	(	-LRB-
cord-034340-3ksfpaf7	953	31	p	p	NN
cord-034340-3ksfpaf7	953	32	=	=	SYM
cord-034340-3ksfpaf7	953	33	0.03	0.03	CD
cord-034340-3ksfpaf7	953	34	)	)	-RRB-
cord-034340-3ksfpaf7	954	1	Also	also	RB
cord-034340-3ksfpaf7	954	2	in	in	IN
cord-034340-3ksfpaf7	954	3	favor	favor	NN
cord-034340-3ksfpaf7	954	4	of	of	IN
cord-034340-3ksfpaf7	954	5	this	this	DT
cord-034340-3ksfpaf7	954	6	conclusion	conclusion	NN
cord-034340-3ksfpaf7	954	7	speaks	speak	VBZ
cord-034340-3ksfpaf7	954	8	the	the	DT
cord-034340-3ksfpaf7	954	9	fact	fact	NN
cord-034340-3ksfpaf7	954	10	that	that	IN
cord-034340-3ksfpaf7	954	11	in	in	IN
cord-034340-3ksfpaf7	954	12	Group	Group	NNP
cord-034340-3ksfpaf7	954	13	A	A	NNP
cord-034340-3ksfpaf7	954	14	the	the	DT
cord-034340-3ksfpaf7	954	15	number	number	NN
cord-034340-3ksfpaf7	954	16	of	of	IN
cord-034340-3ksfpaf7	954	17	visits	visit	NNS
cord-034340-3ksfpaf7	954	18	to	to	IN
cord-034340-3ksfpaf7	954	19	a	a	DT
cord-034340-3ksfpaf7	954	20	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	954	21	in	in	IN
cord-034340-3ksfpaf7	954	22	the	the	DT
cord-034340-3ksfpaf7	954	23	same	same	JJ
cord-034340-3ksfpaf7	954	24	year	year	NN
cord-034340-3ksfpaf7	954	25	when	when	WRB
cord-034340-3ksfpaf7	954	26	the	the	DT
cord-034340-3ksfpaf7	954	27	first	first	JJ
cord-034340-3ksfpaf7	954	28	complaints	complaint	NNS
cord-034340-3ksfpaf7	954	29	appear	appear	VBP
cord-034340-3ksfpaf7	954	30	is	be	VBZ
cord-034340-3ksfpaf7	954	31	almost	almost	RB
cord-034340-3ksfpaf7	954	32	2	2	CD
cord-034340-3ksfpaf7	954	33	times	time	NNS
cord-034340-3ksfpaf7	954	34	higher	high	JJR
cord-034340-3ksfpaf7	954	35	than	than	IN
cord-034340-3ksfpaf7	954	36	in	in	IN
cord-034340-3ksfpaf7	954	37	Group	Group	NNP
cord-034340-3ksfpaf7	954	38	B.	B.	NNP
cord-034340-3ksfpaf7	954	39	56	56	CD
cord-034340-3ksfpaf7	954	40	%	%	NN
cord-034340-3ksfpaf7	954	41	of	of	IN
cord-034340-3ksfpaf7	954	42	cases	case	NNS
cord-034340-3ksfpaf7	954	43	in	in	IN
cord-034340-3ksfpaf7	954	44	Group	Group	NNP
cord-034340-3ksfpaf7	954	45	A	A	NNP
cord-034340-3ksfpaf7	954	46	consulted	consult	VBD
cord-034340-3ksfpaf7	954	47	the	the	DT
cord-034340-3ksfpaf7	954	48	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	954	49	the	the	DT
cord-034340-3ksfpaf7	954	50	same	same	JJ
cord-034340-3ksfpaf7	954	51	year	year	NN
cord-034340-3ksfpaf7	954	52	when	when	WRB
cord-034340-3ksfpaf7	954	53	the	the	DT
cord-034340-3ksfpaf7	954	54	first	first	JJ
cord-034340-3ksfpaf7	954	55	complaints	complaint	NNS
cord-034340-3ksfpaf7	954	56	appeared	appear	VBD
cord-034340-3ksfpaf7	954	57	in	in	IN
cord-034340-3ksfpaf7	954	58	comparison	comparison	NN
cord-034340-3ksfpaf7	954	59	to	to	IN
cord-034340-3ksfpaf7	954	60	Group	Group	NNP
cord-034340-3ksfpaf7	954	61	B	B	NNP
cord-034340-3ksfpaf7	954	62	where	where	WRB
cord-034340-3ksfpaf7	954	63	only	only	RB
cord-034340-3ksfpaf7	954	64	31	31	CD
cord-034340-3ksfpaf7	954	65	%	%	NN
cord-034340-3ksfpaf7	954	66	of	of	IN
cord-034340-3ksfpaf7	954	67	patients	patient	NNS
cord-034340-3ksfpaf7	954	68	did	do	VBD
cord-034340-3ksfpaf7	954	69	the	the	DT
cord-034340-3ksfpaf7	954	70	same	same	JJ
cord-034340-3ksfpaf7	954	71	.	.	.
cord-034340-3ksfpaf7	955	1	Below	below	RB
cord-034340-3ksfpaf7	955	2	is	be	VBZ
cord-034340-3ksfpaf7	955	3	the	the	DT
cord-034340-3ksfpaf7	955	4	table	table	NN
cord-034340-3ksfpaf7	955	5	with	with	IN
cord-034340-3ksfpaf7	955	6	distribution	distribution	NN
cord-034340-3ksfpaf7	955	7	of	of	IN
cord-034340-3ksfpaf7	955	8	cases	case	NNS
cord-034340-3ksfpaf7	955	9	by	by	IN
cord-034340-3ksfpaf7	955	10	the	the	DT
cord-034340-3ksfpaf7	955	11	number	number	NN
cord-034340-3ksfpaf7	955	12	of	of	IN
cord-034340-3ksfpaf7	955	13	years	year	NNS
cord-034340-3ksfpaf7	955	14	between	between	IN
cord-034340-3ksfpaf7	955	15	the	the	DT
cord-034340-3ksfpaf7	955	16	first	first	JJ
cord-034340-3ksfpaf7	955	17	complaints	complaint	NNS
cord-034340-3ksfpaf7	955	18	onset	onset	NN
cord-034340-3ksfpaf7	955	19	and	and	CC
cord-034340-3ksfpaf7	955	20	the	the	DT
cord-034340-3ksfpaf7	955	21	first	first	JJ
cord-034340-3ksfpaf7	955	22	visit	visit	NN
cord-034340-3ksfpaf7	955	23	to	to	IN
cord-034340-3ksfpaf7	955	24	a	a	DT
cord-034340-3ksfpaf7	955	25	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	955	26	in	in	IN
cord-034340-3ksfpaf7	955	27	both	both	DT
cord-034340-3ksfpaf7	955	28	groups	group	NNS
cord-034340-3ksfpaf7	956	1	:	:	:
cord-034340-3ksfpaf7	956	2	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	956	3	:	:	:
cord-034340-3ksfpaf7	956	4	In	in	IN
cord-034340-3ksfpaf7	956	5	children	child	NNS
cord-034340-3ksfpaf7	956	6	with	with	IN
cord-034340-3ksfpaf7	956	7	arthritides	arthritide	NNS
cord-034340-3ksfpaf7	956	8	,	,	,
cord-034340-3ksfpaf7	956	9	the	the	DT
cord-034340-3ksfpaf7	956	10	first	first	JJ
cord-034340-3ksfpaf7	956	11	pain	pain	NN
cord-034340-3ksfpaf7	956	12	complaints	complaint	NNS
cord-034340-3ksfpaf7	956	13	appear	appear	VBP
cord-034340-3ksfpaf7	956	14	at	at	IN
cord-034340-3ksfpaf7	956	15	an	an	DT
cord-034340-3ksfpaf7	956	16	earlier	early	JJR
cord-034340-3ksfpaf7	956	17	age	age	NN
cord-034340-3ksfpaf7	956	18	(	(	-LRB-
cord-034340-3ksfpaf7	956	19	an	an	DT
cord-034340-3ksfpaf7	956	20	average	average	NN
cord-034340-3ksfpaf7	956	21	of	of	IN
cord-034340-3ksfpaf7	956	22	7.4	7.4	CD
cord-034340-3ksfpaf7	956	23	)	)	-RRB-
cord-034340-3ksfpaf7	956	24	,	,	,
cord-034340-3ksfpaf7	956	25	and	and	CC
cord-034340-3ksfpaf7	956	26	in	in	IN
cord-034340-3ksfpaf7	956	27	Group	Group	NNP
cord-034340-3ksfpaf7	956	28	B	B	NNP
cord-034340-3ksfpaf7	956	29	(	(	-LRB-
cord-034340-3ksfpaf7	956	30	an	an	DT
cord-034340-3ksfpaf7	956	31	average	average	NN
cord-034340-3ksfpaf7	956	32	of	of	IN
cord-034340-3ksfpaf7	956	33	9.3	9.3	CD
cord-034340-3ksfpaf7	956	34	)	)	-RRB-
cord-034340-3ksfpaf7	956	35	.	.	.
cord-034340-3ksfpaf7	957	1	Patients	patient	NNS
cord-034340-3ksfpaf7	957	2	with	with	IN
cord-034340-3ksfpaf7	957	3	arthritis	arthritis	NN
cord-034340-3ksfpaf7	957	4	more	more	RBR
cord-034340-3ksfpaf7	957	5	often	often	RB
cord-034340-3ksfpaf7	957	6	visit	visit	VBP
cord-034340-3ksfpaf7	957	7	a	a	DT
cord-034340-3ksfpaf7	957	8	rheumatologist	rheumatologist	NN
cord-034340-3ksfpaf7	957	9	earlier	early	RBR
cord-034340-3ksfpaf7	957	10	(	(	-LRB-
cord-034340-3ksfpaf7	957	11	within	within	IN
cord-034340-3ksfpaf7	957	12	1	1	CD
cord-034340-3ksfpaf7	957	13	year	year	NN
cord-034340-3ksfpaf7	957	14	after	after	IN
cord-034340-3ksfpaf7	957	15	the	the	DT
cord-034340-3ksfpaf7	957	16	first	first	JJ
cord-034340-3ksfpaf7	957	17	complaints	complaint	NNS
cord-034340-3ksfpaf7	957	18	)	)	-RRB-
cord-034340-3ksfpaf7	957	19	than	than	IN
cord-034340-3ksfpaf7	957	20	those	those	DT
cord-034340-3ksfpaf7	957	21	with	with	IN
cord-034340-3ksfpaf7	957	22	non	non	JJ
cord-034340-3ksfpaf7	957	23	-	-	JJ
cord-034340-3ksfpaf7	957	24	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	957	25	genesis	genesis	NN
cord-034340-3ksfpaf7	957	26	of	of	IN
cord-034340-3ksfpaf7	957	27	pain	pain	NN
cord-034340-3ksfpaf7	957	28	complaints	complaint	NNS
cord-034340-3ksfpaf7	957	29	.	.	.
cord-034340-3ksfpaf7	958	1	The	the	DT
cord-034340-3ksfpaf7	958	2	most	most	RBS
cord-034340-3ksfpaf7	958	3	common	common	JJ
cord-034340-3ksfpaf7	958	4	cause	cause	NN
cord-034340-3ksfpaf7	958	5	of	of	IN
cord-034340-3ksfpaf7	958	6	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	958	7	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	958	8	pain	pain	NN
cord-034340-3ksfpaf7	958	9	is	be	VBZ
cord-034340-3ksfpaf7	958	10	growing	grow	VBG
cord-034340-3ksfpaf7	958	11	pain	pain	NN
cord-034340-3ksfpaf7	958	12	(	(	-LRB-
cord-034340-3ksfpaf7	958	13	GP	GP	NNP
cord-034340-3ksfpaf7	958	14	)	)	-RRB-
cord-034340-3ksfpaf7	958	15	in	in	IN
cord-034340-3ksfpaf7	958	16	children	child	NNS
cord-034340-3ksfpaf7	958	17	.	.	.
cord-034340-3ksfpaf7	959	1	Differential	differential	JJ
cord-034340-3ksfpaf7	959	2	from	from	IN
cord-034340-3ksfpaf7	959	3	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	959	4	diseases	disease	NNS
cord-034340-3ksfpaf7	959	5	could	could	MD
cord-034340-3ksfpaf7	959	6	be	be	VB
cord-034340-3ksfpaf7	959	7	challenging	challenging	JJ
cord-034340-3ksfpaf7	959	8	in	in	IN
cord-034340-3ksfpaf7	959	9	some	some	DT
cord-034340-3ksfpaf7	959	10	cases	case	NNS
cord-034340-3ksfpaf7	959	11	since	since	IN
cord-034340-3ksfpaf7	959	12	there	there	EX
cord-034340-3ksfpaf7	959	13	are	be	VBP
cord-034340-3ksfpaf7	959	14	no	no	DT
cord-034340-3ksfpaf7	959	15	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	959	16	criteria	criterion	NNS
cord-034340-3ksfpaf7	959	17	for	for	IN
cord-034340-3ksfpaf7	959	18	GP	GP	NNP
cord-034340-3ksfpaf7	959	19	.	.	.
cord-034340-3ksfpaf7	960	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	960	2	:	:	:
cord-034340-3ksfpaf7	960	3	To	to	TO
cord-034340-3ksfpaf7	960	4	analyze	analyze	VB
cord-034340-3ksfpaf7	960	5	GP	gp	NN
cord-034340-3ksfpaf7	960	6	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	960	7	in	in	IN
cord-034340-3ksfpaf7	960	8	a	a	DT
cord-034340-3ksfpaf7	960	9	large	large	JJ
cord-034340-3ksfpaf7	960	10	cohort	cohort	NN
cord-034340-3ksfpaf7	960	11	of	of	IN
cord-034340-3ksfpaf7	960	12	patients	patient	NNS
cord-034340-3ksfpaf7	960	13	in	in	IN
cord-034340-3ksfpaf7	960	14	comparison	comparison	NN
cord-034340-3ksfpaf7	960	15	with	with	IN
cord-034340-3ksfpaf7	960	16	other	other	JJ
cord-034340-3ksfpaf7	960	17	non	non	JJ
cord-034340-3ksfpaf7	960	18	-	-	JJ
cord-034340-3ksfpaf7	960	19	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	960	20	and	and	CC
cord-034340-3ksfpaf7	960	21	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	960	22	diseases	disease	NNS
cord-034340-3ksfpaf7	960	23	causing	cause	VBG
cord-034340-3ksfpaf7	960	24	limb	limb	NN
cord-034340-3ksfpaf7	960	25	pain	pain	NN
cord-034340-3ksfpaf7	960	26	,	,	,
cord-034340-3ksfpaf7	960	27	and	and	CC
cord-034340-3ksfpaf7	960	28	to	to	TO
cord-034340-3ksfpaf7	960	29	simplify	simplify	VB
cord-034340-3ksfpaf7	960	30	the	the	DT
cord-034340-3ksfpaf7	960	31	GP	GP	NNP
cord-034340-3ksfpaf7	960	32	's	's	POS
cord-034340-3ksfpaf7	960	33	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	960	34	process	process	NN
cord-034340-3ksfpaf7	960	35	by	by	IN
cord-034340-3ksfpaf7	960	36	using	use	VBG
cord-034340-3ksfpaf7	960	37	machine	machine	NN
cord-034340-3ksfpaf7	960	38	learning	learning	NN
cord-034340-3ksfpaf7	960	39	(	(	-LRB-
cord-034340-3ksfpaf7	960	40	ML	ml	NN
cord-034340-3ksfpaf7	960	41	)	)	-RRB-
cord-034340-3ksfpaf7	960	42	techniques	technique	NNS
cord-034340-3ksfpaf7	960	43	.	.	.
cord-034340-3ksfpaf7	961	1	Methods	method	NNS
cord-034340-3ksfpaf7	961	2	:	:	:
cord-034340-3ksfpaf7	961	3	This	this	DT
cord-034340-3ksfpaf7	961	4	is	be	VBZ
cord-034340-3ksfpaf7	961	5	a	a	DT
cord-034340-3ksfpaf7	961	6	multicenter	multicenter	JJ
cord-034340-3ksfpaf7	961	7	cross	cross	JJ
cord-034340-3ksfpaf7	961	8	-	-	JJ
cord-034340-3ksfpaf7	961	9	sectional	sectional	JJ
cord-034340-3ksfpaf7	961	10	study	study	NN
cord-034340-3ksfpaf7	961	11	.	.	.
cord-034340-3ksfpaf7	962	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	962	2	:	:	:
cord-034340-3ksfpaf7	963	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	963	2	is	be	VBZ
cord-034340-3ksfpaf7	963	3	a	a	DT
cord-034340-3ksfpaf7	963	4	well	well	RB
cord-034340-3ksfpaf7	963	5	-	-	HYPH
cord-034340-3ksfpaf7	963	6	known	know	VBN
cord-034340-3ksfpaf7	963	7	fact	fact	NN
cord-034340-3ksfpaf7	963	8	that	that	IN
cord-034340-3ksfpaf7	963	9	the	the	DT
cord-034340-3ksfpaf7	963	10	period	period	NN
cord-034340-3ksfpaf7	963	11	of	of	IN
cord-034340-3ksfpaf7	963	12	intensive	intensive	JJ
cord-034340-3ksfpaf7	963	13	growth	growth	NN
cord-034340-3ksfpaf7	963	14	in	in	IN
cord-034340-3ksfpaf7	963	15	children	child	NNS
cord-034340-3ksfpaf7	963	16	is	be	VBZ
cord-034340-3ksfpaf7	963	17	associated	associate	VBN
cord-034340-3ksfpaf7	963	18	with	with	IN
cord-034340-3ksfpaf7	963	19	the	the	DT
cord-034340-3ksfpaf7	963	20	processes	process	NNS
cord-034340-3ksfpaf7	963	21	of	of	IN
cord-034340-3ksfpaf7	963	22	active	active	JJ
cord-034340-3ksfpaf7	963	23	bone	bone	NN
cord-034340-3ksfpaf7	963	24	mass	mass	NN
cord-034340-3ksfpaf7	963	25	accumulation	accumulation	NN
cord-034340-3ksfpaf7	963	26	and	and	CC
cord-034340-3ksfpaf7	963	27	coincides	coincide	VBZ
cord-034340-3ksfpaf7	963	28	with	with	IN
cord-034340-3ksfpaf7	963	29	them	-PRON-	PRP
cord-034340-3ksfpaf7	963	30	in	in	IN
cord-034340-3ksfpaf7	963	31	time	time	NN
cord-034340-3ksfpaf7	963	32	.	.	.
cord-034340-3ksfpaf7	964	1	One	one	CD
cord-034340-3ksfpaf7	964	2	of	of	IN
cord-034340-3ksfpaf7	964	3	the	the	DT
cord-034340-3ksfpaf7	964	4	most	most	RBS
cord-034340-3ksfpaf7	964	5	distinctive	distinctive	JJ
cord-034340-3ksfpaf7	964	6	indicators	indicator	NNS
cord-034340-3ksfpaf7	964	7	of	of	IN
cord-034340-3ksfpaf7	964	8	an	an	DT
cord-034340-3ksfpaf7	964	9	increase	increase	NN
cord-034340-3ksfpaf7	964	10	in	in	IN
cord-034340-3ksfpaf7	964	11	the	the	DT
cord-034340-3ksfpaf7	964	12	disease	disease	NN
cord-034340-3ksfpaf7	964	13	incidence	incidence	NN
cord-034340-3ksfpaf7	964	14	among	among	IN
cord-034340-3ksfpaf7	964	15	children	child	NNS
cord-034340-3ksfpaf7	964	16	for	for	IN
cord-034340-3ksfpaf7	964	17	the	the	DT
cord-034340-3ksfpaf7	964	18	recent	recent	JJ
cord-034340-3ksfpaf7	964	19	decade	decade	NN
cord-034340-3ksfpaf7	964	20	(	(	-LRB-
cord-034340-3ksfpaf7	964	21	+105,3	+105,3	JJ
cord-034340-3ksfpaf7	964	22	%	%	NN
cord-034340-3ksfpaf7	964	23	)	)	-RRB-
cord-034340-3ksfpaf7	964	24	can	can	MD
cord-034340-3ksfpaf7	964	25	be	be	VB
cord-034340-3ksfpaf7	964	26	found	find	VBN
cord-034340-3ksfpaf7	964	27	in	in	IN
cord-034340-3ksfpaf7	964	28	the	the	DT
cord-034340-3ksfpaf7	964	29	skeletal	skeletal	JJ
cord-034340-3ksfpaf7	964	30	disorders	disorder	NNS
cord-034340-3ksfpaf7	964	31	resulting	result	VBG
cord-034340-3ksfpaf7	964	32	from	from	IN
cord-034340-3ksfpaf7	964	33	disrupted	disrupt	VBN
cord-034340-3ksfpaf7	964	34	calcium	calcium	NN
cord-034340-3ksfpaf7	964	35	metabolism	metabolism	NN
cord-034340-3ksfpaf7	964	36	and	and	CC
cord-034340-3ksfpaf7	964	37	vitamin	vitamin	NN
cord-034340-3ksfpaf7	964	38	D	d	NN
cord-034340-3ksfpaf7	964	39	deficit	deficit	NN
cord-034340-3ksfpaf7	964	40	.	.	.
cord-034340-3ksfpaf7	965	1	The	the	DT
cord-034340-3ksfpaf7	965	2	latter	latter	JJ
cord-034340-3ksfpaf7	965	3	is	be	VBZ
cord-034340-3ksfpaf7	965	4	widespread	widespread	JJ
cord-034340-3ksfpaf7	965	5	in	in	IN
cord-034340-3ksfpaf7	965	6	Ukraine	Ukraine	NNP
cord-034340-3ksfpaf7	965	7	as	as	IN
cord-034340-3ksfpaf7	965	8	it	-PRON-	PRP
cord-034340-3ksfpaf7	965	9	is	be	VBZ
cord-034340-3ksfpaf7	965	10	observed	observe	VBN
cord-034340-3ksfpaf7	965	11	in	in	IN
cord-034340-3ksfpaf7	965	12	92	92	CD
cord-034340-3ksfpaf7	965	13	%	%	NN
cord-034340-3ksfpaf7	965	14	of	of	IN
cord-034340-3ksfpaf7	965	15	schoolers	schooler	NNS
cord-034340-3ksfpaf7	965	16	.	.	.
cord-034340-3ksfpaf7	966	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	966	2	:	:	:
cord-034340-3ksfpaf7	966	3	Establish	establish	VB
cord-034340-3ksfpaf7	966	4	the	the	DT
cord-034340-3ksfpaf7	966	5	specifics	specific	NNS
cord-034340-3ksfpaf7	966	6	of	of	IN
cord-034340-3ksfpaf7	966	7	the	the	DT
cord-034340-3ksfpaf7	966	8	structural	structural	JJ
cord-034340-3ksfpaf7	966	9	and	and	CC
cord-034340-3ksfpaf7	966	10	functional	functional	JJ
cord-034340-3ksfpaf7	966	11	status	status	NN
cord-034340-3ksfpaf7	966	12	of	of	IN
cord-034340-3ksfpaf7	966	13	the	the	DT
cord-034340-3ksfpaf7	966	14	bone	bone	NN
cord-034340-3ksfpaf7	966	15	tissue	tissue	NN
cord-034340-3ksfpaf7	966	16	in	in	IN
cord-034340-3ksfpaf7	966	17	children	child	NNS
cord-034340-3ksfpaf7	966	18	during	during	IN
cord-034340-3ksfpaf7	966	19	the	the	DT
cord-034340-3ksfpaf7	966	20	growth	growth	NN
cord-034340-3ksfpaf7	966	21	spurt	spurt	NN
cord-034340-3ksfpaf7	966	22	,	,	,
cord-034340-3ksfpaf7	966	23	taking	take	VBG
cord-034340-3ksfpaf7	966	24	account	account	NN
cord-034340-3ksfpaf7	966	25	of	of	IN
cord-034340-3ksfpaf7	966	26	the	the	DT
cord-034340-3ksfpaf7	966	27	degree	degree	NN
cord-034340-3ksfpaf7	966	28	of	of	IN
cord-034340-3ksfpaf7	966	29	vitamin	vitamin	NN
cord-034340-3ksfpaf7	966	30	D3	D3	NNP
cord-034340-3ksfpaf7	966	31	sufficiency	sufficiency	NN
cord-034340-3ksfpaf7	966	32	.	.	.
cord-034340-3ksfpaf7	967	1	Methods	method	NNS
cord-034340-3ksfpaf7	967	2	:	:	:
cord-034340-3ksfpaf7	967	3	The	the	DT
cord-034340-3ksfpaf7	967	4	examination	examination	NN
cord-034340-3ksfpaf7	967	5	covered	cover	VBD
cord-034340-3ksfpaf7	967	6	147	147	CD
cord-034340-3ksfpaf7	967	7	children	child	NNS
cord-034340-3ksfpaf7	967	8	aged	age	VBN
cord-034340-3ksfpaf7	967	9	9	9	CD
cord-034340-3ksfpaf7	967	10	-	-	SYM
cord-034340-3ksfpaf7	967	11	17	17	CD
cord-034340-3ksfpaf7	967	12	who	who	WP
cord-034340-3ksfpaf7	967	13	were	be	VBD
cord-034340-3ksfpaf7	967	14	divided	divide	VBN
cord-034340-3ksfpaf7	967	15	into	into	IN
cord-034340-3ksfpaf7	967	16	three	three	CD
cord-034340-3ksfpaf7	967	17	groups	group	NNS
cord-034340-3ksfpaf7	967	18	depending	depend	VBG
cord-034340-3ksfpaf7	967	19	on	on	IN
cord-034340-3ksfpaf7	967	20	the	the	DT
cord-034340-3ksfpaf7	967	21	presence	presence	NN
cord-034340-3ksfpaf7	967	22	of	of	IN
cord-034340-3ksfpaf7	967	23	the	the	DT
cord-034340-3ksfpaf7	967	24	growth	growth	NN
cord-034340-3ksfpaf7	967	25	spurt	spurt	NN
cord-034340-3ksfpaf7	967	26	(	(	-LRB-
cord-034340-3ksfpaf7	967	27	GS	GS	NNP
cord-034340-3ksfpaf7	967	28	)	)	-RRB-
cord-034340-3ksfpaf7	967	29	and	and	CC
cord-034340-3ksfpaf7	967	30	its	-PRON-	PRP$
cord-034340-3ksfpaf7	967	31	intensity	intensity	NN
cord-034340-3ksfpaf7	967	32	:	:	:
cord-034340-3ksfpaf7	967	33	group	group	NN
cord-034340-3ksfpaf7	967	34	1	1	CD
cord-034340-3ksfpaf7	967	35	-35	-35	NN
cord-034340-3ksfpaf7	967	36	children	child	NNS
cord-034340-3ksfpaf7	967	37	who	who	WP
cord-034340-3ksfpaf7	967	38	had	have	VBD
cord-034340-3ksfpaf7	967	39	become	become	VBN
cord-034340-3ksfpaf7	967	40	8	8	CD
cord-034340-3ksfpaf7	967	41	-	-	SYM
cord-034340-3ksfpaf7	967	42	12	12	CD
cord-034340-3ksfpaf7	967	43	cm	cm	NNS
cord-034340-3ksfpaf7	967	44	taller	tall	JJR
cord-034340-3ksfpaf7	967	45	for	for	IN
cord-034340-3ksfpaf7	967	46	the	the	DT
cord-034340-3ksfpaf7	967	47	year	year	NN
cord-034340-3ksfpaf7	967	48	in	in	IN
cord-034340-3ksfpaf7	967	49	question	question	NN
cord-034340-3ksfpaf7	967	50	;	;	:
cord-034340-3ksfpaf7	967	51	group	group	NN
cord-034340-3ksfpaf7	967	52	2	2	CD
cord-034340-3ksfpaf7	967	53	-32	-32	NN
cord-034340-3ksfpaf7	967	54	children	child	NNS
cord-034340-3ksfpaf7	967	55	who	who	WP
cord-034340-3ksfpaf7	967	56	had	have	VBD
cord-034340-3ksfpaf7	967	57	become	become	VBN
cord-034340-3ksfpaf7	967	58	taller	tall	JJR
cord-034340-3ksfpaf7	967	59	by	by	IN
cord-034340-3ksfpaf7	967	60	12	12	CD
cord-034340-3ksfpaf7	967	61	cm	cm	NNS
cord-034340-3ksfpaf7	967	62	or	or	CC
cord-034340-3ksfpaf7	967	63	more	more	JJR
cord-034340-3ksfpaf7	967	64	,	,	,
cord-034340-3ksfpaf7	967	65	group	group	NN
cord-034340-3ksfpaf7	967	66	3	3	CD
cord-034340-3ksfpaf7	967	67	-80	-80	NNP
cord-034340-3ksfpaf7	967	68	children	child	NNS
cord-034340-3ksfpaf7	967	69	who	who	WP
cord-034340-3ksfpaf7	967	70	had	have	VBD
cord-034340-3ksfpaf7	967	71	experienced	experience	VBN
cord-034340-3ksfpaf7	967	72	no	no	DT
cord-034340-3ksfpaf7	967	73	growth	growth	NN
cord-034340-3ksfpaf7	967	74	spurt	spurt	NN
cord-034340-3ksfpaf7	967	75	.	.	.
cord-034340-3ksfpaf7	968	1	Inclusion	inclusion	NN
cord-034340-3ksfpaf7	968	2	criteria	criterion	NNS
cord-034340-3ksfpaf7	968	3	were	be	VBD
cord-034340-3ksfpaf7	968	4	the	the	DT
cord-034340-3ksfpaf7	968	5	following	follow	VBG
cord-034340-3ksfpaf7	968	6	:	:	:
cord-034340-3ksfpaf7	968	7	no	no	DT
cord-034340-3ksfpaf7	968	8	chronic	chronic	JJ
cord-034340-3ksfpaf7	968	9	somatic	somatic	JJ
cord-034340-3ksfpaf7	968	10	or	or	CC
cord-034340-3ksfpaf7	968	11	endocrine	endocrine	JJ
cord-034340-3ksfpaf7	968	12	pathologies	pathology	NNS
cord-034340-3ksfpaf7	968	13	,	,	,
cord-034340-3ksfpaf7	968	14	no	no	DT
cord-034340-3ksfpaf7	968	15	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	968	16	disorders	disorder	NNS
cord-034340-3ksfpaf7	968	17	or	or	CC
cord-034340-3ksfpaf7	968	18	mineral	mineral	NN
cord-034340-3ksfpaf7	968	19	homeostasis	homeostasis	NN
cord-034340-3ksfpaf7	968	20	disruptions	disruption	NNS
cord-034340-3ksfpaf7	968	21	;	;	:
cord-034340-3ksfpaf7	968	22	physical	physical	JJ
cord-034340-3ksfpaf7	968	23	exertion	exertion	NN
cord-034340-3ksfpaf7	968	24	corresponding	correspond	VBG
cord-034340-3ksfpaf7	968	25	to	to	IN
cord-034340-3ksfpaf7	968	26	their	-PRON-	PRP$
cord-034340-3ksfpaf7	968	27	age	age	NN
cord-034340-3ksfpaf7	968	28	;	;	:
cord-034340-3ksfpaf7	968	29	the	the	DT
cord-034340-3ksfpaf7	968	30	children	child	NNS
cord-034340-3ksfpaf7	968	31	had	have	VBD
cord-034340-3ksfpaf7	968	32	not	not	RB
cord-034340-3ksfpaf7	968	33	been	be	VBN
cord-034340-3ksfpaf7	968	34	taking	take	VBG
cord-034340-3ksfpaf7	968	35	any	any	DT
cord-034340-3ksfpaf7	968	36	complexes	complex	NNS
cord-034340-3ksfpaf7	968	37	of	of	IN
cord-034340-3ksfpaf7	968	38	vitamins	vitamin	NNS
cord-034340-3ksfpaf7	968	39	and	and	CC
cord-034340-3ksfpaf7	968	40	minerals	mineral	NNS
cord-034340-3ksfpaf7	968	41	,	,	,
cord-034340-3ksfpaf7	968	42	including	include	VBG
cord-034340-3ksfpaf7	968	43	vitamin	vitamin	NN
cord-034340-3ksfpaf7	968	44	D	d	NN
cord-034340-3ksfpaf7	968	45	3	3	CD
cord-034340-3ksfpaf7	968	46	for	for	IN
cord-034340-3ksfpaf7	968	47	6	6	CD
cord-034340-3ksfpaf7	968	48	months	month	NNS
cord-034340-3ksfpaf7	968	49	before	before	IN
cord-034340-3ksfpaf7	968	50	the	the	DT
cord-034340-3ksfpaf7	968	51	examination	examination	NN
cord-034340-3ksfpaf7	968	52	.	.	.
cord-034340-3ksfpaf7	969	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	969	2	:	:	:
cord-034340-3ksfpaf7	969	3	Children	child	NNS
cord-034340-3ksfpaf7	969	4	aged	age	VBN
cord-034340-3ksfpaf7	969	5	9	9	CD
cord-034340-3ksfpaf7	969	6	-	-	SYM
cord-034340-3ksfpaf7	969	7	17	17	CD
cord-034340-3ksfpaf7	969	8	showed	show	VBD
cord-034340-3ksfpaf7	969	9	deficiency	deficiency	NN
cord-034340-3ksfpaf7	969	10	of	of	IN
cord-034340-3ksfpaf7	969	11	vitamin	vitamin	NN
cord-034340-3ksfpaf7	969	12	D	D	NNP
cord-034340-3ksfpaf7	969	13	3	3	CD
cord-034340-3ksfpaf7	969	14	reaching	reach	VBG
cord-034340-3ksfpaf7	969	15	100	100	CD
cord-034340-3ksfpaf7	969	16	%	%	NN
cord-034340-3ksfpaf7	969	17	which	which	WDT
cord-034340-3ksfpaf7	969	18	had	have	VBD
cord-034340-3ksfpaf7	969	19	no	no	DT
cord-034340-3ksfpaf7	969	20	correlation	correlation	NN
cord-034340-3ksfpaf7	969	21	with	with	IN
cord-034340-3ksfpaf7	969	22	the	the	DT
cord-034340-3ksfpaf7	969	23	presence	presence	NN
cord-034340-3ksfpaf7	969	24	or	or	CC
cord-034340-3ksfpaf7	969	25	intensity	intensity	NN
cord-034340-3ksfpaf7	969	26	of	of	IN
cord-034340-3ksfpaf7	969	27	the	the	DT
cord-034340-3ksfpaf7	969	28	growth	growth	NN
cord-034340-3ksfpaf7	969	29	spurt	spurt	NN
cord-034340-3ksfpaf7	969	30	.	.	.
cord-034340-3ksfpaf7	970	1	In	in	IN
cord-034340-3ksfpaf7	970	2	children	child	NNS
cord-034340-3ksfpaf7	970	3	who	who	WP
cord-034340-3ksfpaf7	970	4	experienced	experience	VBD
cord-034340-3ksfpaf7	970	5	growth	growth	NN
cord-034340-3ksfpaf7	970	6	spurt	spurt	NN
cord-034340-3ksfpaf7	970	7	,	,	,
cord-034340-3ksfpaf7	970	8	a	a	DT
cord-034340-3ksfpaf7	970	9	reduced	reduce	VBN
cord-034340-3ksfpaf7	970	10	BMD	bmd	NN
cord-034340-3ksfpaf7	970	11	proved	prove	VBD
cord-034340-3ksfpaf7	970	12	more	more	RBR
cord-034340-3ksfpaf7	970	13	frequent	frequent	JJ
cord-034340-3ksfpaf7	970	14	and	and	CC
cord-034340-3ksfpaf7	970	15	correlated	correlate	VBN
cord-034340-3ksfpaf7	970	16	with	with	IN
cord-034340-3ksfpaf7	970	17	the	the	DT
cord-034340-3ksfpaf7	970	18	spurt	spurt	JJ
cord-034340-3ksfpaf7	970	19	intensity	intensity	NN
cord-034340-3ksfpaf7	970	20	,	,	,
cord-034340-3ksfpaf7	970	21	however	however	RB
cord-034340-3ksfpaf7	970	22	,	,	,
cord-034340-3ksfpaf7	970	23	it	-PRON-	PRP
cord-034340-3ksfpaf7	970	24	did	do	VBD
cord-034340-3ksfpaf7	970	25	not	not	RB
cord-034340-3ksfpaf7	970	26	depend	depend	VB
cord-034340-3ksfpaf7	970	27	on	on	IN
cord-034340-3ksfpaf7	970	28	sufficiency	sufficiency	NN
cord-034340-3ksfpaf7	970	29	of	of	IN
cord-034340-3ksfpaf7	970	30	vitamin	vitamin	NN
cord-034340-3ksfpaf7	970	31	D	D	NNP
cord-034340-3ksfpaf7	970	32	3	3	CD
cord-034340-3ksfpaf7	970	33	.	.	.
cord-034340-3ksfpaf7	971	1	Therefore	therefore	RB
cord-034340-3ksfpaf7	971	2	,	,	,
cord-034340-3ksfpaf7	971	3	during	during	IN
cord-034340-3ksfpaf7	971	4	the	the	DT
cord-034340-3ksfpaf7	971	5	growth	growth	NN
cord-034340-3ksfpaf7	971	6	spurt	spurt	NN
cord-034340-3ksfpaf7	971	7	,	,	,
cord-034340-3ksfpaf7	971	8	disrupted	disrupt	VBD
cord-034340-3ksfpaf7	971	9	mineralization	mineralization	NN
cord-034340-3ksfpaf7	971	10	of	of	IN
cord-034340-3ksfpaf7	971	11	the	the	DT
cord-034340-3ksfpaf7	971	12	bone	bone	NN
cord-034340-3ksfpaf7	971	13	tissue	tissue	NN
cord-034340-3ksfpaf7	971	14	was	be	VBD
cord-034340-3ksfpaf7	971	15	influenced	influence	VBN
cord-034340-3ksfpaf7	971	16	not	not	RB
cord-034340-3ksfpaf7	971	17	only	only	RB
cord-034340-3ksfpaf7	971	18	by	by	IN
cord-034340-3ksfpaf7	971	19	the	the	DT
cord-034340-3ksfpaf7	971	20	vitamin	vitamin	NN
cord-034340-3ksfpaf7	971	21	D	d	NN
cord-034340-3ksfpaf7	971	22	deficit	deficit	NN
cord-034340-3ksfpaf7	971	23	but	but	CC
cord-034340-3ksfpaf7	971	24	also	also	RB
cord-034340-3ksfpaf7	971	25	by	by	IN
cord-034340-3ksfpaf7	971	26	the	the	DT
cord-034340-3ksfpaf7	971	27	correlation	correlation	NN
cord-034340-3ksfpaf7	971	28	between	between	IN
cord-034340-3ksfpaf7	971	29	the	the	DT
cord-034340-3ksfpaf7	971	30	bone	bone	NN
cord-034340-3ksfpaf7	971	31	tissue	tissue	NN
cord-034340-3ksfpaf7	971	32	mineralization	mineralization	NN
cord-034340-3ksfpaf7	971	33	rate	rate	NN
cord-034340-3ksfpaf7	971	34	and	and	CC
cord-034340-3ksfpaf7	971	35	intensity	intensity	NN
cord-034340-3ksfpaf7	971	36	of	of	IN
cord-034340-3ksfpaf7	971	37	growth	growth	NN
cord-034340-3ksfpaf7	971	38	in	in	IN
cord-034340-3ksfpaf7	971	39	the	the	DT
cord-034340-3ksfpaf7	971	40	children	child	NNS
cord-034340-3ksfpaf7	971	41	.	.	.
cord-034340-3ksfpaf7	972	1	Methods	method	NNS
cord-034340-3ksfpaf7	972	2	:	:	:
cord-034340-3ksfpaf7	973	1	A	a	DT
cord-034340-3ksfpaf7	973	2	self	self	NN
cord-034340-3ksfpaf7	973	3	-	-	HYPH
cord-034340-3ksfpaf7	973	4	reported	report	VBD
cord-034340-3ksfpaf7	973	5	25	25	CD
cord-034340-3ksfpaf7	973	6	question	question	NN
cord-034340-3ksfpaf7	973	7	online	online	JJ
cord-034340-3ksfpaf7	973	8	survey	survey	NN
cord-034340-3ksfpaf7	973	9	on	on	IN
cord-034340-3ksfpaf7	973	10	QOL	QOL	NNP
cord-034340-3ksfpaf7	973	11	of	of	IN
cord-034340-3ksfpaf7	973	12	patients	patient	NNS
cord-034340-3ksfpaf7	973	13	with	with	IN
cord-034340-3ksfpaf7	973	14	sJIA	sjia	NN
cord-034340-3ksfpaf7	973	15	and	and	CC
cord-034340-3ksfpaf7	973	16	AOSD	AOSD	NNP
cord-034340-3ksfpaf7	973	17	was	be	VBD
cord-034340-3ksfpaf7	973	18	developed	develop	VBN
cord-034340-3ksfpaf7	973	19	by	by	IN
cord-034340-3ksfpaf7	973	20	the	the	DT
cord-034340-3ksfpaf7	973	21	non	non	JJ
cord-034340-3ksfpaf7	973	22	-	-	JJ
cord-034340-3ksfpaf7	973	23	profit	profit	JJ
cord-034340-3ksfpaf7	973	24	organizations	organization	NNS
cord-034340-3ksfpaf7	973	25	,	,	,
cord-034340-3ksfpaf7	973	26	the	the	DT
cord-034340-3ksfpaf7	973	27	Autoinflammatory	Autoinflammatory	NNP
cord-034340-3ksfpaf7	973	28	Alliance	Alliance	NNP
cord-034340-3ksfpaf7	973	29	,	,	,
cord-034340-3ksfpaf7	973	30	KAISZ	KAISZ	NNP
cord-034340-3ksfpaf7	973	31	/	/	SYM
cord-034340-3ksfpaf7	973	32	VAISZ	VAISZ	NNP
cord-034340-3ksfpaf7	973	33	,	,	,
cord-034340-3ksfpaf7	973	34	ENCA	ENCA	NNP
cord-034340-3ksfpaf7	973	35	and	and	CC
cord-034340-3ksfpaf7	973	36	sJIA	sJIA	NNP
cord-034340-3ksfpaf7	973	37	Foundation	Foundation	NNP
cord-034340-3ksfpaf7	973	38	in	in	IN
cord-034340-3ksfpaf7	973	39	English	English	NNP
cord-034340-3ksfpaf7	973	40	and	and	CC
cord-034340-3ksfpaf7	973	41	translated	translate	VBN
cord-034340-3ksfpaf7	973	42	to	to	IN
cord-034340-3ksfpaf7	973	43	Dutch	Dutch	NNP
cord-034340-3ksfpaf7	973	44	.	.	.
cord-034340-3ksfpaf7	974	1	Respondents	respondent	NNS
cord-034340-3ksfpaf7	974	2	were	be	VBD
cord-034340-3ksfpaf7	974	3	recruited	recruit	VBN
cord-034340-3ksfpaf7	974	4	by	by	IN
cord-034340-3ksfpaf7	974	5	convenience	convenience	NN
cord-034340-3ksfpaf7	974	6	sampling	sampling	NN
cord-034340-3ksfpaf7	974	7	through	through	IN
cord-034340-3ksfpaf7	974	8	online	online	JJ
cord-034340-3ksfpaf7	974	9	social	social	JJ
cord-034340-3ksfpaf7	974	10	media	medium	NNS
cord-034340-3ksfpaf7	974	11	posts	post	NNS
cord-034340-3ksfpaf7	974	12	.	.	.
cord-034340-3ksfpaf7	975	1	Data	datum	NNS
cord-034340-3ksfpaf7	975	2	on	on	IN
cord-034340-3ksfpaf7	975	3	flares	flare	NNS
cord-034340-3ksfpaf7	975	4	,	,	,
cord-034340-3ksfpaf7	975	5	triggers	trigger	NNS
cord-034340-3ksfpaf7	975	6	,	,	,
cord-034340-3ksfpaf7	975	7	family	family	NN
cord-034340-3ksfpaf7	975	8	history	history	NN
cord-034340-3ksfpaf7	975	9	,	,	,
cord-034340-3ksfpaf7	975	10	and	and	CC
cord-034340-3ksfpaf7	975	11	correlation	correlation	NN
cord-034340-3ksfpaf7	975	12	of	of	IN
cord-034340-3ksfpaf7	975	13	symptoms	symptom	NNS
cord-034340-3ksfpaf7	975	14	with	with	IN
cord-034340-3ksfpaf7	975	15	labs	lab	NNS
cord-034340-3ksfpaf7	975	16	were	be	VBD
cord-034340-3ksfpaf7	975	17	collected	collect	VBN
cord-034340-3ksfpaf7	975	18	in	in	IN
cord-034340-3ksfpaf7	975	19	addition	addition	NN
cord-034340-3ksfpaf7	975	20	to	to	IN
cord-034340-3ksfpaf7	975	21	detailed	detailed	JJ
cord-034340-3ksfpaf7	975	22	information	information	NN
cord-034340-3ksfpaf7	975	23	on	on	IN
cord-034340-3ksfpaf7	975	24	QOL	QOL	NNP
cord-034340-3ksfpaf7	975	25	during	during	IN
cord-034340-3ksfpaf7	975	26	and	and	CC
cord-034340-3ksfpaf7	975	27	in	in	IN
cord-034340-3ksfpaf7	975	28	-	-	HYPH
cord-034340-3ksfpaf7	975	29	between	between	IN
cord-034340-3ksfpaf7	975	30	flares	flare	NNS
cord-034340-3ksfpaf7	975	31	.	.	.
cord-034340-3ksfpaf7	976	1	Results	result	NNS
cord-034340-3ksfpaf7	976	2	:	:	:
cord-034340-3ksfpaf7	977	1	Between	between	IN
cord-034340-3ksfpaf7	977	2	2017	2017	CD
cord-034340-3ksfpaf7	977	3	and	and	CC
cord-034340-3ksfpaf7	977	4	2019	2019	CD
cord-034340-3ksfpaf7	977	5	,	,	,
cord-034340-3ksfpaf7	977	6	there	there	EX
cord-034340-3ksfpaf7	977	7	were	be	VBD
cord-034340-3ksfpaf7	977	8	109	109	CD
cord-034340-3ksfpaf7	977	9	responses	response	NNS
cord-034340-3ksfpaf7	977	10	;	;	:
cord-034340-3ksfpaf7	977	11	54	54	CD
cord-034340-3ksfpaf7	977	12	were	be	VBD
cord-034340-3ksfpaf7	977	13	from	from	IN
cord-034340-3ksfpaf7	977	14	parents	parent	NNS
cord-034340-3ksfpaf7	977	15	of	of	IN
cord-034340-3ksfpaf7	977	16	children	child	NNS
cord-034340-3ksfpaf7	977	17	with	with	IN
cord-034340-3ksfpaf7	977	18	sJIA	sjia	NN
cord-034340-3ksfpaf7	977	19	,	,	,
cord-034340-3ksfpaf7	977	20	18	18	CD
cord-034340-3ksfpaf7	977	21	from	from	IN
cord-034340-3ksfpaf7	977	22	adults	adult	NNS
cord-034340-3ksfpaf7	977	23	with	with	IN
cord-034340-3ksfpaf7	977	24	sJIA	sjia	NN
cord-034340-3ksfpaf7	977	25	,	,	,
cord-034340-3ksfpaf7	977	26	and	and	CC
cord-034340-3ksfpaf7	977	27	37	37	CD
cord-034340-3ksfpaf7	977	28	from	from	IN
cord-034340-3ksfpaf7	977	29	adults	adult	NNS
cord-034340-3ksfpaf7	977	30	with	with	IN
cord-034340-3ksfpaf7	977	31	AOSD	AOSD	NNP
cord-034340-3ksfpaf7	977	32	.	.	.
cord-034340-3ksfpaf7	978	1	Interestingly	interestingly	RB
cord-034340-3ksfpaf7	978	2	,	,	,
cord-034340-3ksfpaf7	978	3	adults	adult	NNS
cord-034340-3ksfpaf7	978	4	(	(	-LRB-
cord-034340-3ksfpaf7	978	5	whether	whether	IN
cord-034340-3ksfpaf7	978	6	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	978	7	with	with	IN
cord-034340-3ksfpaf7	978	8	sJIA	sjia	NN
cord-034340-3ksfpaf7	978	9	or	or	CC
cord-034340-3ksfpaf7	978	10	AOSD	AOSD	NNP
cord-034340-3ksfpaf7	978	11	)	)	-RRB-
cord-034340-3ksfpaf7	978	12	were	be	VBD
cord-034340-3ksfpaf7	978	13	more	more	RBR
cord-034340-3ksfpaf7	978	14	likely	likely	JJ
cord-034340-3ksfpaf7	978	15	to	to	TO
cord-034340-3ksfpaf7	978	16	report	report	VB
cord-034340-3ksfpaf7	978	17	pain	pain	NN
cord-034340-3ksfpaf7	978	18	,	,	,
cord-034340-3ksfpaf7	978	19	fatigue	fatigue	NN
cord-034340-3ksfpaf7	978	20	,	,	,
cord-034340-3ksfpaf7	978	21	joint	joint	JJ
cord-034340-3ksfpaf7	978	22	swelling	swelling	NN
cord-034340-3ksfpaf7	978	23	or	or	CC
cord-034340-3ksfpaf7	978	24	arthritis	arthritis	NN
cord-034340-3ksfpaf7	978	25	,	,	,
cord-034340-3ksfpaf7	978	26	nausea	nausea	NN
cord-034340-3ksfpaf7	978	27	&	&	CC
cord-034340-3ksfpaf7	978	28	vomiting	vomiting	NN
cord-034340-3ksfpaf7	978	29	,	,	,
cord-034340-3ksfpaf7	978	30	and	and	CC
cord-034340-3ksfpaf7	978	31	diarrhea	diarrhea	NN
cord-034340-3ksfpaf7	978	32	during	during	IN
cord-034340-3ksfpaf7	978	33	flares	flare	NNS
cord-034340-3ksfpaf7	978	34	than	than	IN
cord-034340-3ksfpaf7	978	35	children	child	NNS
cord-034340-3ksfpaf7	978	36	.	.	.
cord-034340-3ksfpaf7	979	1	Adults	adult	NNS
cord-034340-3ksfpaf7	979	2	were	be	VBD
cord-034340-3ksfpaf7	979	3	also	also	RB
cord-034340-3ksfpaf7	979	4	more	more	RBR
cord-034340-3ksfpaf7	979	5	likely	likely	JJ
cord-034340-3ksfpaf7	979	6	to	to	TO
cord-034340-3ksfpaf7	979	7	describe	describe	VB
cord-034340-3ksfpaf7	979	8	flares	flare	NNS
cord-034340-3ksfpaf7	979	9	>	>	XX
cord-034340-3ksfpaf7	979	10	one	one	CD
cord-034340-3ksfpaf7	979	11	month	month	NN
cord-034340-3ksfpaf7	979	12	.	.	.
cord-034340-3ksfpaf7	980	1	80	80	CD
cord-034340-3ksfpaf7	980	2	%	%	NN
cord-034340-3ksfpaf7	980	3	of	of	IN
cord-034340-3ksfpaf7	980	4	patients	patient	NNS
cord-034340-3ksfpaf7	980	5	reported	report	VBN
cord-034340-3ksfpaf7	980	6	being	be	VBG
cord-034340-3ksfpaf7	980	7	"	"	``
cord-034340-3ksfpaf7	980	8	greatly	greatly	RB
cord-034340-3ksfpaf7	980	9	"	"	''
cord-034340-3ksfpaf7	980	10	or	or	CC
cord-034340-3ksfpaf7	980	11	"	"	``
cord-034340-3ksfpaf7	980	12	severely	severely	RB
cord-034340-3ksfpaf7	980	13	"	"	''
cord-034340-3ksfpaf7	980	14	limited	limited	JJ
cord-034340-3ksfpaf7	980	15	during	during	IN
cord-034340-3ksfpaf7	980	16	flares	flare	NNS
cord-034340-3ksfpaf7	980	17	.	.	.
cord-034340-3ksfpaf7	981	1	Between	between	IN
cord-034340-3ksfpaf7	981	2	flares	flare	NNS
cord-034340-3ksfpaf7	981	3	,	,	,
cord-034340-3ksfpaf7	981	4	20	20	CD
cord-034340-3ksfpaf7	981	5	%	%	NN
cord-034340-3ksfpaf7	981	6	reported	report	VBD
cord-034340-3ksfpaf7	981	7	being	be	VBG
cord-034340-3ksfpaf7	981	8	"	"	``
cord-034340-3ksfpaf7	981	9	greatly	greatly	RB
cord-034340-3ksfpaf7	981	10	"	"	''
cord-034340-3ksfpaf7	981	11	or	or	CC
cord-034340-3ksfpaf7	981	12	"	"	``
cord-034340-3ksfpaf7	981	13	severely	severely	RB
cord-034340-3ksfpaf7	981	14	"	"	''
cord-034340-3ksfpaf7	981	15	limited	limit	VBN
cord-034340-3ksfpaf7	981	16	while	while	IN
cord-034340-3ksfpaf7	981	17	59	59	CD
cord-034340-3ksfpaf7	981	18	%	%	NN
cord-034340-3ksfpaf7	981	19	were	be	VBD
cord-034340-3ksfpaf7	981	20	"	"	``
cord-034340-3ksfpaf7	981	21	somewhat	somewhat	RB
cord-034340-3ksfpaf7	981	22	"	"	''
cord-034340-3ksfpaf7	981	23	limited	limited	JJ
cord-034340-3ksfpaf7	981	24	.	.	.
cord-034340-3ksfpaf7	982	1	80	80	CD
cord-034340-3ksfpaf7	982	2	%	%	NN
cord-034340-3ksfpaf7	982	3	felt	feel	VBD
cord-034340-3ksfpaf7	982	4	their	-PRON-	PRP$
cord-034340-3ksfpaf7	982	5	condition	condition	NN
cord-034340-3ksfpaf7	982	6	affected	affect	VBD
cord-034340-3ksfpaf7	982	7	their	-PRON-	PRP$
cord-034340-3ksfpaf7	982	8	studies	study	NNS
cord-034340-3ksfpaf7	982	9	,	,	,
cord-034340-3ksfpaf7	982	10	job	job	NN
cord-034340-3ksfpaf7	982	11	,	,	,
cord-034340-3ksfpaf7	982	12	and	and	CC
cord-034340-3ksfpaf7	982	13	career	career	NN
cord-034340-3ksfpaf7	982	14	,	,	,
cord-034340-3ksfpaf7	982	15	including	include	VBG
cord-034340-3ksfpaf7	982	16	66	66	CD
cord-034340-3ksfpaf7	982	17	%	%	NN
cord-034340-3ksfpaf7	982	18	of	of	IN
cord-034340-3ksfpaf7	982	19	children	child	NNS
cord-034340-3ksfpaf7	982	20	with	with	IN
cord-034340-3ksfpaf7	982	21	sJIA	sjia	NN
cord-034340-3ksfpaf7	982	22	,	,	,
cord-034340-3ksfpaf7	982	23	100	100	CD
cord-034340-3ksfpaf7	982	24	%	%	NN
cord-034340-3ksfpaf7	982	25	of	of	IN
cord-034340-3ksfpaf7	982	26	adults	adult	NNS
cord-034340-3ksfpaf7	982	27	with	with	IN
cord-034340-3ksfpaf7	982	28	sJIA	sjia	NN
cord-034340-3ksfpaf7	982	29	,	,	,
cord-034340-3ksfpaf7	982	30	and	and	CC
cord-034340-3ksfpaf7	982	31	92	92	CD
cord-034340-3ksfpaf7	982	32	%	%	NN
cord-034340-3ksfpaf7	982	33	with	with	IN
cord-034340-3ksfpaf7	982	34	AOSD	AOSD	NNP
cord-034340-3ksfpaf7	982	35	.	.	.
cord-034340-3ksfpaf7	983	1	Respondents	respondent	NNS
cord-034340-3ksfpaf7	983	2	were	be	VBD
cord-034340-3ksfpaf7	983	3	asked	ask	VBN
cord-034340-3ksfpaf7	983	4	open	open	RB
cord-034340-3ksfpaf7	983	5	-	-	HYPH
cord-034340-3ksfpaf7	983	6	ended	ended	JJ
cord-034340-3ksfpaf7	983	7	questions	question	NNS
cord-034340-3ksfpaf7	983	8	regarding	regard	VBG
cord-034340-3ksfpaf7	983	9	their	-PRON-	PRP$
cord-034340-3ksfpaf7	983	10	experience	experience	NN
cord-034340-3ksfpaf7	983	11	with	with	IN
cord-034340-3ksfpaf7	983	12	disease	disease	NN
cord-034340-3ksfpaf7	983	13	flares	flare	NNS
cord-034340-3ksfpaf7	983	14	and	and	CC
cord-034340-3ksfpaf7	983	15	impact	impact	NN
cord-034340-3ksfpaf7	983	16	on	on	IN
cord-034340-3ksfpaf7	983	17	their	-PRON-	PRP$
cord-034340-3ksfpaf7	983	18	lives	life	NNS
cord-034340-3ksfpaf7	983	19	,	,	,
cord-034340-3ksfpaf7	983	20	and	and	CC
cord-034340-3ksfpaf7	983	21	specifically	specifically	RB
cord-034340-3ksfpaf7	983	22	how	how	WRB
cord-034340-3ksfpaf7	983	23	sJIA	sjia	JJ
cord-034340-3ksfpaf7	983	24	and	and	CC
cord-034340-3ksfpaf7	983	25	AOSD	aosd	JJ
cord-034340-3ksfpaf7	983	26	affected	affect	VBN
cord-034340-3ksfpaf7	983	27	work	work	NN
cord-034340-3ksfpaf7	983	28	,	,	,
cord-034340-3ksfpaf7	983	29	career	career	NN
cord-034340-3ksfpaf7	983	30	and	and	CC
cord-034340-3ksfpaf7	983	31	schooling	schooling	NN
cord-034340-3ksfpaf7	983	32	.	.	.
cord-034340-3ksfpaf7	984	1	Responses	response	NNS
cord-034340-3ksfpaf7	984	2	regarding	regard	VBG
cord-034340-3ksfpaf7	984	3	the	the	DT
cord-034340-3ksfpaf7	984	4	disease	disease	NN
cord-034340-3ksfpaf7	984	5	experience	experience	NN
cord-034340-3ksfpaf7	984	6	were	be	VBD
cord-034340-3ksfpaf7	984	7	classified	classify	VBN
cord-034340-3ksfpaf7	984	8	into	into	IN
cord-034340-3ksfpaf7	984	9	7	7	CD
cord-034340-3ksfpaf7	984	10	theme	theme	NN
cord-034340-3ksfpaf7	984	11	areas	area	NNS
cord-034340-3ksfpaf7	984	12	:	:	:
cord-034340-3ksfpaf7	984	13	1	1	LS
cord-034340-3ksfpaf7	984	14	)	)	-RRB-
cord-034340-3ksfpaf7	984	15	experience	experience	NN
cord-034340-3ksfpaf7	984	16	with	with	IN
cord-034340-3ksfpaf7	984	17	disease	disease	NN
cord-034340-3ksfpaf7	984	18	onset	onset	NN
cord-034340-3ksfpaf7	984	19	and	and	CC
cord-034340-3ksfpaf7	984	20	process	process	NN
cord-034340-3ksfpaf7	984	21	of	of	IN
cord-034340-3ksfpaf7	984	22	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	984	23	;	;	:
cord-034340-3ksfpaf7	984	24	2	2	LS
cord-034340-3ksfpaf7	984	25	)	)	-RRB-
cord-034340-3ksfpaf7	984	26	health	health	NN
cord-034340-3ksfpaf7	984	27	care	care	NN
cord-034340-3ksfpaf7	984	28	access	access	NN
cord-034340-3ksfpaf7	984	29	,	,	,
cord-034340-3ksfpaf7	984	30	quality	quality	NN
cord-034340-3ksfpaf7	984	31	,	,	,
cord-034340-3ksfpaf7	984	32	and	and	CC
cord-034340-3ksfpaf7	984	33	drug	drug	NN
cord-034340-3ksfpaf7	984	34	safety	safety	NN
cord-034340-3ksfpaf7	984	35	concerns	concern	NNS
cord-034340-3ksfpaf7	984	36	;	;	:
cord-034340-3ksfpaf7	984	37	3	3	LS
cord-034340-3ksfpaf7	984	38	)	)	-RRB-
cord-034340-3ksfpaf7	984	39	physical	physical	JJ
cord-034340-3ksfpaf7	984	40	impact	impact	NN
cord-034340-3ksfpaf7	984	41	of	of	IN
cord-034340-3ksfpaf7	984	42	the	the	DT
cord-034340-3ksfpaf7	984	43	disease	disease	NN
cord-034340-3ksfpaf7	984	44	including	include	VBG
cord-034340-3ksfpaf7	984	45	pain	pain	NN
cord-034340-3ksfpaf7	984	46	and	and	CC
cord-034340-3ksfpaf7	984	47	chronic	chronic	JJ
cord-034340-3ksfpaf7	984	48	fatigue	fatigue	NN
cord-034340-3ksfpaf7	984	49	;	;	:
cord-034340-3ksfpaf7	984	50	4	4	LS
cord-034340-3ksfpaf7	984	51	)	)	-RRB-
cord-034340-3ksfpaf7	984	52	social	social	JJ
cord-034340-3ksfpaf7	984	53	impact	impact	NN
cord-034340-3ksfpaf7	984	54	of	of	IN
cord-034340-3ksfpaf7	984	55	the	the	DT
cord-034340-3ksfpaf7	984	56	disease	disease	NN
cord-034340-3ksfpaf7	984	57	;	;	:
cord-034340-3ksfpaf7	984	58	5	5	LS
cord-034340-3ksfpaf7	984	59	)	)	-RRB-
cord-034340-3ksfpaf7	984	60	mental	mental	JJ
cord-034340-3ksfpaf7	984	61	health	health	NN
cord-034340-3ksfpaf7	984	62	and	and	CC
cord-034340-3ksfpaf7	984	63	emotional	emotional	JJ
cord-034340-3ksfpaf7	984	64	impact	impact	NN
cord-034340-3ksfpaf7	984	65	of	of	IN
cord-034340-3ksfpaf7	984	66	the	the	DT
cord-034340-3ksfpaf7	984	67	disease	disease	NN
cord-034340-3ksfpaf7	984	68	;	;	:
cord-034340-3ksfpaf7	984	69	6	6	CD
cord-034340-3ksfpaf7	984	70	)	)	-RRB-
cord-034340-3ksfpaf7	984	71	impact	impact	NN
cord-034340-3ksfpaf7	984	72	on	on	IN
cord-034340-3ksfpaf7	984	73	work	work	NN
cord-034340-3ksfpaf7	984	74	,	,	,
cord-034340-3ksfpaf7	984	75	career	career	NN
cord-034340-3ksfpaf7	984	76	,	,	,
cord-034340-3ksfpaf7	984	77	and	and	CC
cord-034340-3ksfpaf7	984	78	employment	employment	NN
cord-034340-3ksfpaf7	984	79	;	;	:
cord-034340-3ksfpaf7	984	80	and	and	CC
cord-034340-3ksfpaf7	984	81	7	7	CD
cord-034340-3ksfpaf7	984	82	)	)	-RRB-
cord-034340-3ksfpaf7	984	83	broad	broad	JJ
cord-034340-3ksfpaf7	984	84	impact	impact	NN
cord-034340-3ksfpaf7	984	85	on	on	IN
cord-034340-3ksfpaf7	984	86	life	life	NN
cord-034340-3ksfpaf7	984	87	and	and	CC
cord-034340-3ksfpaf7	984	88	lifestyle	lifestyle	NN
cord-034340-3ksfpaf7	984	89	.	.	.
cord-034340-3ksfpaf7	985	1	Responses	response	NNS
cord-034340-3ksfpaf7	985	2	regarding	regard	VBG
cord-034340-3ksfpaf7	985	3	effect	effect	NN
cord-034340-3ksfpaf7	985	4	on	on	IN
cord-034340-3ksfpaf7	985	5	work	work	NN
cord-034340-3ksfpaf7	985	6	,	,	,
cord-034340-3ksfpaf7	985	7	career	career	NN
cord-034340-3ksfpaf7	985	8	,	,	,
cord-034340-3ksfpaf7	985	9	and	and	CC
cord-034340-3ksfpaf7	985	10	schooling	schooling	NN
cord-034340-3ksfpaf7	985	11	were	be	VBD
cord-034340-3ksfpaf7	985	12	categorized	categorize	VBN
cord-034340-3ksfpaf7	985	13	into	into	IN
cord-034340-3ksfpaf7	985	14	3	3	CD
cord-034340-3ksfpaf7	985	15	theme	theme	NN
cord-034340-3ksfpaf7	985	16	areas	area	NNS
cord-034340-3ksfpaf7	985	17	:	:	:
cord-034340-3ksfpaf7	985	18	1	1	LS
cord-034340-3ksfpaf7	985	19	)	)	-RRB-
cord-034340-3ksfpaf7	985	20	physical	physical	JJ
cord-034340-3ksfpaf7	985	21	impact	impact	NN
cord-034340-3ksfpaf7	985	22	negatively	negatively	RB
cord-034340-3ksfpaf7	985	23	influencing	influence	VBG
cord-034340-3ksfpaf7	985	24	school	school	NN
cord-034340-3ksfpaf7	985	25	/	/	SYM
cord-034340-3ksfpaf7	985	26	work	work	NN
cord-034340-3ksfpaf7	985	27	productivity	productivity	NN
cord-034340-3ksfpaf7	985	28	;	;	:
cord-034340-3ksfpaf7	985	29	2	2	LS
cord-034340-3ksfpaf7	985	30	)	)	-RRB-
cord-034340-3ksfpaf7	985	31	lost	lose	VBN
cord-034340-3ksfpaf7	985	32	work	work	NN
cord-034340-3ksfpaf7	985	33	and	and	CC
cord-034340-3ksfpaf7	985	34	wages	wage	NNS
cord-034340-3ksfpaf7	985	35	,	,	,
cord-034340-3ksfpaf7	985	36	including	include	VBG
cord-034340-3ksfpaf7	985	37	unemployment	unemployment	NN
cord-034340-3ksfpaf7	985	38	and	and	CC
cord-034340-3ksfpaf7	985	39	needing	need	VBG
cord-034340-3ksfpaf7	985	40	disability	disability	NN
cord-034340-3ksfpaf7	985	41	benefits	benefit	NNS
cord-034340-3ksfpaf7	985	42	,	,	,
cord-034340-3ksfpaf7	985	43	and	and	CC
cord-034340-3ksfpaf7	985	44	parents	parent	NNS
cord-034340-3ksfpaf7	985	45	missing	miss	VBG
cord-034340-3ksfpaf7	985	46	work	work	NN
cord-034340-3ksfpaf7	985	47	to	to	TO
cord-034340-3ksfpaf7	985	48	care	care	VB
cord-034340-3ksfpaf7	985	49	for	for	IN
cord-034340-3ksfpaf7	985	50	the	the	DT
cord-034340-3ksfpaf7	985	51	child	child	NN
cord-034340-3ksfpaf7	985	52	;	;	:
cord-034340-3ksfpaf7	985	53	and	and	CC
cord-034340-3ksfpaf7	985	54	3	3	LS
cord-034340-3ksfpaf7	985	55	)	)	-RRB-
cord-034340-3ksfpaf7	985	56	the	the	DT
cord-034340-3ksfpaf7	985	57	socialemotional	socialemotional	JJ
cord-034340-3ksfpaf7	985	58	impact	impact	NN
cord-034340-3ksfpaf7	985	59	as	as	RB
cord-034340-3ksfpaf7	985	60	well	well	RB
cord-034340-3ksfpaf7	985	61	as	as	IN
cord-034340-3ksfpaf7	985	62	negative	negative	JJ
cord-034340-3ksfpaf7	985	63	effects	effect	NNS
cord-034340-3ksfpaf7	985	64	on	on	IN
cord-034340-3ksfpaf7	985	65	mental	mental	JJ
cord-034340-3ksfpaf7	985	66	health	health	NN
cord-034340-3ksfpaf7	985	67	.	.	.
cord-034340-3ksfpaf7	986	1	About	about	RB
cord-034340-3ksfpaf7	986	2	half	half	NN
cord-034340-3ksfpaf7	986	3	of	of	IN
cord-034340-3ksfpaf7	986	4	patients	patient	NNS
cord-034340-3ksfpaf7	986	5	regardless	regardless	RB
cord-034340-3ksfpaf7	986	6	of	of	IN
cord-034340-3ksfpaf7	986	7	age	age	NN
cord-034340-3ksfpaf7	986	8	reported	report	VBD
cord-034340-3ksfpaf7	986	9	the	the	DT
cord-034340-3ksfpaf7	986	10	name	name	NN
cord-034340-3ksfpaf7	986	11	sJIA	sjia	NN
cord-034340-3ksfpaf7	986	12	did	do	VBD
cord-034340-3ksfpaf7	986	13	not	not	RB
cord-034340-3ksfpaf7	986	14	represent	represent	VB
cord-034340-3ksfpaf7	986	15	well	well	RB
cord-034340-3ksfpaf7	986	16	the	the	DT
cord-034340-3ksfpaf7	986	17	disease	disease	NN
cord-034340-3ksfpaf7	986	18	,	,	,
cord-034340-3ksfpaf7	986	19	specifically	specifically	RB
cord-034340-3ksfpaf7	986	20	that	that	IN
cord-034340-3ksfpaf7	986	21	it	-PRON-	PRP
cord-034340-3ksfpaf7	986	22	did	do	VBD
cord-034340-3ksfpaf7	986	23	not	not	RB
cord-034340-3ksfpaf7	986	24	emphasize	emphasize	VB
cord-034340-3ksfpaf7	986	25	the	the	DT
cord-034340-3ksfpaf7	986	26	systemic	systemic	JJ
cord-034340-3ksfpaf7	986	27	symptoms	symptom	NNS
cord-034340-3ksfpaf7	986	28	,	,	,
cord-034340-3ksfpaf7	986	29	and	and	CC
cord-034340-3ksfpaf7	986	30	that	that	IN
cord-034340-3ksfpaf7	986	31	the	the	DT
cord-034340-3ksfpaf7	986	32	disease	disease	NN
cord-034340-3ksfpaf7	986	33	gets	get	VBZ
cord-034340-3ksfpaf7	986	34	confused	confuse	VBN
cord-034340-3ksfpaf7	986	35	with	with	IN
cord-034340-3ksfpaf7	986	36	other	other	JJ
cord-034340-3ksfpaf7	986	37	types	type	NNS
cord-034340-3ksfpaf7	986	38	of	of	IN
cord-034340-3ksfpaf7	986	39	arthritis	arthritis	NN
cord-034340-3ksfpaf7	986	40	.	.	.
cord-034340-3ksfpaf7	987	1	Adult	adult	NN
cord-034340-3ksfpaf7	987	2	patients	patient	NNS
cord-034340-3ksfpaf7	987	3	with	with	IN
cord-034340-3ksfpaf7	987	4	sJIA	sjia	NN
cord-034340-3ksfpaf7	987	5	did	do	VBD
cord-034340-3ksfpaf7	987	6	not	not	RB
cord-034340-3ksfpaf7	987	7	like	like	VB
cord-034340-3ksfpaf7	987	8	to	to	TO
cord-034340-3ksfpaf7	987	9	have	have	VB
cord-034340-3ksfpaf7	987	10	juvenile	juvenile	NN
cord-034340-3ksfpaf7	987	11	in	in	IN
cord-034340-3ksfpaf7	987	12	the	the	DT
cord-034340-3ksfpaf7	987	13	name	name	NN
cord-034340-3ksfpaf7	987	14	.	.	.
cord-034340-3ksfpaf7	988	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	988	2	:	:	:
cord-034340-3ksfpaf7	989	1	Children	child	NNS
cord-034340-3ksfpaf7	989	2	and	and	CC
cord-034340-3ksfpaf7	989	3	adults	adult	NNS
cord-034340-3ksfpaf7	989	4	with	with	IN
cord-034340-3ksfpaf7	989	5	sJIA	sjia	NN
cord-034340-3ksfpaf7	989	6	and	and	CC
cord-034340-3ksfpaf7	989	7	AOSD	aosd	JJ
cord-034340-3ksfpaf7	989	8	report	report	VBP
cord-034340-3ksfpaf7	989	9	high	high	JJ
cord-034340-3ksfpaf7	989	10	levels	level	NNS
cord-034340-3ksfpaf7	989	11	of	of	IN
cord-034340-3ksfpaf7	989	12	QOL	QOL	NNP
cord-034340-3ksfpaf7	989	13	limitation	limitation	NN
cord-034340-3ksfpaf7	989	14	and	and	CC
cord-034340-3ksfpaf7	989	15	effect	effect	NN
cord-034340-3ksfpaf7	989	16	on	on	IN
cord-034340-3ksfpaf7	989	17	school	school	NN
cord-034340-3ksfpaf7	989	18	,	,	,
cord-034340-3ksfpaf7	989	19	work	work	NN
cord-034340-3ksfpaf7	989	20	,	,	,
cord-034340-3ksfpaf7	989	21	and	and	CC
cord-034340-3ksfpaf7	989	22	career	career	NN
cord-034340-3ksfpaf7	989	23	,	,	,
cord-034340-3ksfpaf7	989	24	both	both	CC
cord-034340-3ksfpaf7	989	25	during	during	IN
cord-034340-3ksfpaf7	989	26	and	and	CC
cord-034340-3ksfpaf7	989	27	between	between	IN
cord-034340-3ksfpaf7	989	28	flares	flare	NNS
cord-034340-3ksfpaf7	989	29	.	.	.
cord-034340-3ksfpaf7	990	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	990	2	qualitative	qualitative	JJ
cord-034340-3ksfpaf7	990	3	data	data	NN
cord-034340-3ksfpaf7	990	4	emphasizes	emphasize	VBZ
cord-034340-3ksfpaf7	990	5	the	the	DT
cord-034340-3ksfpaf7	990	6	importance	importance	NN
cord-034340-3ksfpaf7	990	7	of	of	IN
cord-034340-3ksfpaf7	990	8	multidimensional	multidimensional	JJ
cord-034340-3ksfpaf7	990	9	evaluation	evaluation	NN
cord-034340-3ksfpaf7	990	10	of	of	IN
cord-034340-3ksfpaf7	990	11	disease	disease	NN
cord-034340-3ksfpaf7	990	12	with	with	IN
cord-034340-3ksfpaf7	990	13	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	990	14	input	input	NN
cord-034340-3ksfpaf7	990	15	from	from	IN
cord-034340-3ksfpaf7	990	16	the	the	DT
cord-034340-3ksfpaf7	990	17	patients	patient	NNS
cord-034340-3ksfpaf7	990	18	,	,	,
cord-034340-3ksfpaf7	990	19	which	which	WDT
cord-034340-3ksfpaf7	990	20	will	will	MD
cord-034340-3ksfpaf7	990	21	provide	provide	VB
cord-034340-3ksfpaf7	990	22	a	a	DT
cord-034340-3ksfpaf7	990	23	foundation	foundation	NN
cord-034340-3ksfpaf7	990	24	for	for	IN
cord-034340-3ksfpaf7	990	25	asking	ask	VBG
cord-034340-3ksfpaf7	990	26	more	more	RBR
cord-034340-3ksfpaf7	990	27	relevant	relevant	JJ
cord-034340-3ksfpaf7	990	28	research	research	NN
cord-034340-3ksfpaf7	990	29	questions	question	NNS
cord-034340-3ksfpaf7	990	30	to	to	TO
cord-034340-3ksfpaf7	990	31	foster	foster	VB
cord-034340-3ksfpaf7	990	32	better	well	JJR
cord-034340-3ksfpaf7	990	33	care	care	VB
cord-034340-3ksfpaf7	990	34	and	and	CC
cord-034340-3ksfpaf7	990	35	improve	improve	VB
cord-034340-3ksfpaf7	990	36	QOL	QOL	NNP
cord-034340-3ksfpaf7	990	37	.	.	.
cord-034340-3ksfpaf7	991	1	Results	result	NNS
cord-034340-3ksfpaf7	991	2	:	:	:
cord-034340-3ksfpaf7	992	1	In	in	IN
cord-034340-3ksfpaf7	992	2	total	total	JJ
cord-034340-3ksfpaf7	992	3	111	111	CD
cord-034340-3ksfpaf7	992	4	participants	participant	NNS
cord-034340-3ksfpaf7	992	5	were	be	VBD
cord-034340-3ksfpaf7	992	6	included	include	VBN
cord-034340-3ksfpaf7	992	7	in	in	IN
cord-034340-3ksfpaf7	992	8	the	the	DT
cord-034340-3ksfpaf7	992	9	study	study	NN
cord-034340-3ksfpaf7	992	10	:	:	:
cord-034340-3ksfpaf7	992	11	62	62	CD
cord-034340-3ksfpaf7	992	12	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	992	13	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	992	14	arthritis	arthritis	NN
cord-034340-3ksfpaf7	992	15	(	(	-LRB-
cord-034340-3ksfpaf7	992	16	JIA	JIA	NNP
cord-034340-3ksfpaf7	992	17	)	)	-RRB-
cord-034340-3ksfpaf7	992	18	patients	patient	NNS
cord-034340-3ksfpaf7	992	19	,	,	,
cord-034340-3ksfpaf7	992	20	and	and	CC
cord-034340-3ksfpaf7	992	21	49	49	CD
cord-034340-3ksfpaf7	992	22	their	-PRON-	PRP$
cord-034340-3ksfpaf7	992	23	parents	parent	NNS
cord-034340-3ksfpaf7	992	24	.	.	.
cord-034340-3ksfpaf7	993	1	The	the	DT
cord-034340-3ksfpaf7	993	2	mean	mean	JJ
cord-034340-3ksfpaf7	993	3	age	age	NN
cord-034340-3ksfpaf7	993	4	of	of	IN
cord-034340-3ksfpaf7	993	5	the	the	DT
cord-034340-3ksfpaf7	993	6	patients	patient	NNS
cord-034340-3ksfpaf7	993	7	was	be	VBD
cord-034340-3ksfpaf7	993	8	13.7	13.7	CD
cord-034340-3ksfpaf7	993	9	±	±	CD
cord-034340-3ksfpaf7	993	10	2.3	2.3	CD
cord-034340-3ksfpaf7	993	11	years	year	NNS
cord-034340-3ksfpaf7	993	12	.	.	.
cord-034340-3ksfpaf7	994	1	Significant	significant	JJ
cord-034340-3ksfpaf7	994	2	differences	difference	NNS
cord-034340-3ksfpaf7	994	3	were	be	VBD
cord-034340-3ksfpaf7	994	4	found	find	VBN
cord-034340-3ksfpaf7	994	5	between	between	IN
cord-034340-3ksfpaf7	994	6	patients	patient	NNS
cord-034340-3ksfpaf7	994	7	and	and	CC
cord-034340-3ksfpaf7	994	8	healthy	healthy	JJ
cord-034340-3ksfpaf7	994	9	children	child	NNS
cord-034340-3ksfpaf7	994	10	in	in	IN
cord-034340-3ksfpaf7	994	11	such	such	JJ
cord-034340-3ksfpaf7	994	12	HRQoL	HRQoL	NNP
cord-034340-3ksfpaf7	994	13	survey	survey	NN
cord-034340-3ksfpaf7	994	14	categories	category	NNS
cord-034340-3ksfpaf7	994	15	like	like	IN
cord-034340-3ksfpaf7	994	16	"	"	``
cord-034340-3ksfpaf7	994	17	Autonomy	Autonomy	NNP
cord-034340-3ksfpaf7	994	18	"	"	''
cord-034340-3ksfpaf7	994	19	and	and	CC
cord-034340-3ksfpaf7	994	20	"	"	``
cord-034340-3ksfpaf7	994	21	Financial	financial	JJ
cord-034340-3ksfpaf7	994	22	resources	resource	NNS
cord-034340-3ksfpaf7	994	23	"	"	''
cord-034340-3ksfpaf7	994	24	(	(	-LRB-
cord-034340-3ksfpaf7	994	25	p	p	NN
cord-034340-3ksfpaf7	994	26	<	<	XX
cord-034340-3ksfpaf7	994	27	0.05	0.05	CD
cord-034340-3ksfpaf7	994	28	)	)	-RRB-
cord-034340-3ksfpaf7	994	29	.	.	.
cord-034340-3ksfpaf7	995	1	Although	although	IN
cord-034340-3ksfpaf7	995	2	quality	quality	NN
cord-034340-3ksfpaf7	995	3	of	of	IN
cord-034340-3ksfpaf7	995	4	life	life	NN
cord-034340-3ksfpaf7	995	5	in	in	IN
cord-034340-3ksfpaf7	995	6	children	child	NNS
cord-034340-3ksfpaf7	995	7	's	's	POS
cord-034340-3ksfpaf7	995	8	with	with	IN
cord-034340-3ksfpaf7	995	9	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	995	10	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	995	11	arthritis	arthritis	NN
cord-034340-3ksfpaf7	995	12	was	be	VBD
cord-034340-3ksfpaf7	995	13	lower	low	JJR
cord-034340-3ksfpaf7	995	14	than	than	IN
cord-034340-3ksfpaf7	995	15	in	in	IN
cord-034340-3ksfpaf7	995	16	healthy	healthy	JJ
cord-034340-3ksfpaf7	995	17	children	child	NNS
cord-034340-3ksfpaf7	995	18	in	in	IN
cord-034340-3ksfpaf7	995	19	HRQoL	hrqol	DT
cord-034340-3ksfpaf7	995	20	survey	survey	NN
cord-034340-3ksfpaf7	995	21	category	category	NN
cord-034340-3ksfpaf7	995	22	"	"	``
cord-034340-3ksfpaf7	995	23	Self	self	NN
cord-034340-3ksfpaf7	995	24	perception	perception	NN
cord-034340-3ksfpaf7	995	25	"	"	''
cord-034340-3ksfpaf7	995	26	(	(	-LRB-
cord-034340-3ksfpaf7	995	27	p	p	NN
cord-034340-3ksfpaf7	995	28	<	<	XX
cord-034340-3ksfpaf7	995	29	0.05	0.05	CD
cord-034340-3ksfpaf7	995	30	)	)	-RRB-
cord-034340-3ksfpaf7	995	31	.	.	.
cord-034340-3ksfpaf7	996	1	After	after	IN
cord-034340-3ksfpaf7	996	2	analyzing	analyze	VBG
cord-034340-3ksfpaf7	996	3	data	datum	NNS
cord-034340-3ksfpaf7	996	4	no	no	DT
cord-034340-3ksfpaf7	996	5	significantly	significantly	RB
cord-034340-3ksfpaf7	996	6	differences	difference	NNS
cord-034340-3ksfpaf7	996	7	were	be	VBD
cord-034340-3ksfpaf7	996	8	found	find	VBN
cord-034340-3ksfpaf7	996	9	between	between	IN
cord-034340-3ksfpaf7	996	10	patients	patient	NNS
cord-034340-3ksfpaf7	996	11	and	and	CC
cord-034340-3ksfpaf7	996	12	parents	parent	NNS
cord-034340-3ksfpaf7	996	13	'	'	POS
cord-034340-3ksfpaf7	996	14	assessment	assessment	NN
cord-034340-3ksfpaf7	996	15	scores	score	NNS
cord-034340-3ksfpaf7	996	16	in	in	IN
cord-034340-3ksfpaf7	996	17	HRQoL	hrqol	DT
cord-034340-3ksfpaf7	996	18	survey	survey	NN
cord-034340-3ksfpaf7	996	19	categories	category	NNS
cord-034340-3ksfpaf7	996	20	(	(	-LRB-
cord-034340-3ksfpaf7	996	21	p	p	NN
cord-034340-3ksfpaf7	996	22	>	>	XX
cord-034340-3ksfpaf7	996	23	0.05	0.05	CD
cord-034340-3ksfpaf7	996	24	)	)	-RRB-
cord-034340-3ksfpaf7	996	25	.	.	.
cord-034340-3ksfpaf7	997	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	997	2	:	:	:
cord-034340-3ksfpaf7	998	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	998	2	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	998	3	arthritis	arthritis	NN
cord-034340-3ksfpaf7	998	4	has	have	VBZ
cord-034340-3ksfpaf7	998	5	a	a	DT
cord-034340-3ksfpaf7	998	6	moderate	moderate	JJ
cord-034340-3ksfpaf7	998	7	negative	negative	JJ
cord-034340-3ksfpaf7	998	8	influence	influence	NN
cord-034340-3ksfpaf7	998	9	on	on	IN
cord-034340-3ksfpaf7	998	10	HRQoL	HRQoL	NNP
cord-034340-3ksfpaf7	998	11	survey	survey	NN
cord-034340-3ksfpaf7	998	12	categories	category	NNS
cord-034340-3ksfpaf7	998	13	"	"	``
cord-034340-3ksfpaf7	998	14	Self	self	NN
cord-034340-3ksfpaf7	998	15	perception	perception	NN
cord-034340-3ksfpaf7	998	16	"	"	''
cord-034340-3ksfpaf7	998	17	,	,	,
cord-034340-3ksfpaf7	998	18	"	"	``
cord-034340-3ksfpaf7	998	19	Autonomy	Autonomy	NNP
cord-034340-3ksfpaf7	998	20	"	"	''
cord-034340-3ksfpaf7	998	21	and	and	CC
cord-034340-3ksfpaf7	998	22	"	"	``
cord-034340-3ksfpaf7	998	23	Financial	financial	JJ
cord-034340-3ksfpaf7	998	24	resources	resource	NNS
cord-034340-3ksfpaf7	998	25	"	"	''
cord-034340-3ksfpaf7	998	26	(	(	-LRB-
cord-034340-3ksfpaf7	998	27	p	p	NN
cord-034340-3ksfpaf7	998	28	<	<	XX
cord-034340-3ksfpaf7	998	29	0.05	0.05	CD
cord-034340-3ksfpaf7	998	30	)	)	-RRB-
cord-034340-3ksfpaf7	998	31	according	accord	VBG
cord-034340-3ksfpaf7	998	32	KIDSCREEN-52	KIDSCREEN-52	NNP
cord-034340-3ksfpaf7	998	33	queationnaire	queationnaire	NNP
cord-034340-3ksfpaf7	998	34	.	.	.
cord-034340-3ksfpaf7	999	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	999	2	:	:	:
cord-034340-3ksfpaf7	1000	1	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	1000	2	Dermatomyositis	Dermatomyositis	NNP
cord-034340-3ksfpaf7	1000	3	(	(	-LRB-
cord-034340-3ksfpaf7	1000	4	JDM	JDM	NNP
cord-034340-3ksfpaf7	1000	5	)	)	-RRB-
cord-034340-3ksfpaf7	1000	6	is	be	VBZ
cord-034340-3ksfpaf7	1000	7	often	often	RB
cord-034340-3ksfpaf7	1000	8	first	first	RB
cord-034340-3ksfpaf7	1000	9	identified	identify	VBN
cord-034340-3ksfpaf7	1000	10	by	by	IN
cord-034340-3ksfpaf7	1000	11	parents	parent	NNS
cord-034340-3ksfpaf7	1000	12	and	and	CC
cord-034340-3ksfpaf7	1000	13	carers	carer	NNS
cord-034340-3ksfpaf7	1000	14	as	as	IN
cord-034340-3ksfpaf7	1000	15	the	the	DT
cord-034340-3ksfpaf7	1000	16	red	red	JJ
cord-034340-3ksfpaf7	1000	17	facial	facial	JJ
cord-034340-3ksfpaf7	1000	18	rash	rash	NN
cord-034340-3ksfpaf7	1000	19	develops	develop	VBZ
cord-034340-3ksfpaf7	1000	20	.	.	.
cord-034340-3ksfpaf7	1001	1	The	the	DT
cord-034340-3ksfpaf7	1001	2	rash	rash	NN
cord-034340-3ksfpaf7	1001	3	can	can	MD
cord-034340-3ksfpaf7	1001	4	progress	progress	VB
cord-034340-3ksfpaf7	1001	5	and	and	CC
cord-034340-3ksfpaf7	1001	6	lead	lead	VB
cord-034340-3ksfpaf7	1001	7	to	to	IN
cord-034340-3ksfpaf7	1001	8	young	young	JJ
cord-034340-3ksfpaf7	1001	9	people	people	NNS
cord-034340-3ksfpaf7	1001	10	being	be	VBG
cord-034340-3ksfpaf7	1001	11	misdiagnosed	misdiagnose	VBN
cord-034340-3ksfpaf7	1001	12	with	with	IN
cord-034340-3ksfpaf7	1001	13	eczema	eczema	NN
cord-034340-3ksfpaf7	1001	14	,	,	,
cord-034340-3ksfpaf7	1001	15	scarlet	scarlet	JJ
cord-034340-3ksfpaf7	1001	16	fever	fever	NN
cord-034340-3ksfpaf7	1001	17	or	or	CC
cord-034340-3ksfpaf7	1001	18	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1001	19	.	.	.
cord-034340-3ksfpaf7	1002	1	However	however	RB
cord-034340-3ksfpaf7	1002	2	,	,	,
cord-034340-3ksfpaf7	1002	3	over	over	IN
cord-034340-3ksfpaf7	1002	4	time	time	NN
cord-034340-3ksfpaf7	1002	5	the	the	DT
cord-034340-3ksfpaf7	1002	6	obvious	obvious	JJ
cord-034340-3ksfpaf7	1002	7	signs	sign	NNS
cord-034340-3ksfpaf7	1002	8	of	of	IN
cord-034340-3ksfpaf7	1002	9	JDM	JDM	NNP
cord-034340-3ksfpaf7	1002	10	can	can	MD
cord-034340-3ksfpaf7	1002	11	become	become	VB
cord-034340-3ksfpaf7	1002	12	"	"	``
cord-034340-3ksfpaf7	1002	13	invisible	invisible	JJ
cord-034340-3ksfpaf7	1002	14	"	"	''
cord-034340-3ksfpaf7	1002	15	as	as	IN
cord-034340-3ksfpaf7	1002	16	treatment	treatment	NN
cord-034340-3ksfpaf7	1002	17	calms	calm	VBZ
cord-034340-3ksfpaf7	1002	18	the	the	DT
cord-034340-3ksfpaf7	1002	19	rashes	rash	NNS
cord-034340-3ksfpaf7	1002	20	and	and	CC
cord-034340-3ksfpaf7	1002	21	masks	mask	NNS
cord-034340-3ksfpaf7	1002	22	the	the	DT
cord-034340-3ksfpaf7	1002	23	outward	outward	JJ
cord-034340-3ksfpaf7	1002	24	signs	sign	NNS
cord-034340-3ksfpaf7	1002	25	of	of	IN
cord-034340-3ksfpaf7	1002	26	JDM	JDM	NNP
cord-034340-3ksfpaf7	1002	27	,	,	,
cord-034340-3ksfpaf7	1002	28	until	until	IN
cord-034340-3ksfpaf7	1002	29	a	a	DT
cord-034340-3ksfpaf7	1002	30	flare	flare	NN
cord-034340-3ksfpaf7	1002	31	occurs	occur	VBZ
cord-034340-3ksfpaf7	1002	32	,	,	,
cord-034340-3ksfpaf7	1002	33	when	when	WRB
cord-034340-3ksfpaf7	1002	34	the	the	DT
cord-034340-3ksfpaf7	1002	35	rashes	rash	NNS
cord-034340-3ksfpaf7	1002	36	can	can	MD
cord-034340-3ksfpaf7	1002	37	be	be	VB
cord-034340-3ksfpaf7	1002	38	a	a	DT
cord-034340-3ksfpaf7	1002	39	marker	marker	NN
cord-034340-3ksfpaf7	1002	40	for	for	IN
cord-034340-3ksfpaf7	1002	41	disease	disease	NN
cord-034340-3ksfpaf7	1002	42	activity	activity	NN
cord-034340-3ksfpaf7	1002	43	or	or	CC
cord-034340-3ksfpaf7	1002	44	progression	progression	NN
cord-034340-3ksfpaf7	1002	45	.	.	.
cord-034340-3ksfpaf7	1003	1	As	as	IN
cord-034340-3ksfpaf7	1003	2	part	part	NN
cord-034340-3ksfpaf7	1003	3	of	of	IN
cord-034340-3ksfpaf7	1003	4	a	a	DT
cord-034340-3ksfpaf7	1003	5	larger	large	JJR
cord-034340-3ksfpaf7	1003	6	study	study	NN
cord-034340-3ksfpaf7	1003	7	,	,	,
cord-034340-3ksfpaf7	1003	8	children	child	NNS
cord-034340-3ksfpaf7	1003	9	around	around	IN
cord-034340-3ksfpaf7	1003	10	the	the	DT
cord-034340-3ksfpaf7	1003	11	United	United	NNP
cord-034340-3ksfpaf7	1003	12	Kingdom	Kingdom	NNP
cord-034340-3ksfpaf7	1003	13	were	be	VBD
cord-034340-3ksfpaf7	1003	14	asked	ask	VBN
cord-034340-3ksfpaf7	1003	15	to	to	TO
cord-034340-3ksfpaf7	1003	16	discuss	discuss	VB
cord-034340-3ksfpaf7	1003	17	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1003	18	views	view	NNS
cord-034340-3ksfpaf7	1003	19	on	on	IN
cord-034340-3ksfpaf7	1003	20	whether	whether	IN
cord-034340-3ksfpaf7	1003	21	they	-PRON-	PRP
cord-034340-3ksfpaf7	1003	22	wanted	want	VBD
cord-034340-3ksfpaf7	1003	23	people	people	NNS
cord-034340-3ksfpaf7	1003	24	to	to	TO
cord-034340-3ksfpaf7	1003	25	be	be	VB
cord-034340-3ksfpaf7	1003	26	able	able	JJ
cord-034340-3ksfpaf7	1003	27	to	to	TO
cord-034340-3ksfpaf7	1003	28	see	see	VB
cord-034340-3ksfpaf7	1003	29	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1003	30	JDM	jdm	NN
cord-034340-3ksfpaf7	1003	31	.	.	.
cord-034340-3ksfpaf7	1004	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1004	2	:	:	:
cord-034340-3ksfpaf7	1004	3	To	to	TO
cord-034340-3ksfpaf7	1004	4	understand	understand	VB
cord-034340-3ksfpaf7	1004	5	the	the	DT
cord-034340-3ksfpaf7	1004	6	implications	implication	NNS
cord-034340-3ksfpaf7	1004	7	for	for	IN
cord-034340-3ksfpaf7	1004	8	children	child	NNS
cord-034340-3ksfpaf7	1004	9	and	and	CC
cord-034340-3ksfpaf7	1004	10	young	young	JJ
cord-034340-3ksfpaf7	1004	11	people	people	NNS
cord-034340-3ksfpaf7	1004	12	from	from	IN
cord-034340-3ksfpaf7	1004	13	having	have	VBG
cord-034340-3ksfpaf7	1004	14	a	a	DT
cord-034340-3ksfpaf7	1004	15	disease	disease	NN
cord-034340-3ksfpaf7	1004	16	that	that	WDT
cord-034340-3ksfpaf7	1004	17	has	have	VBZ
cord-034340-3ksfpaf7	1004	18	visible	visible	JJ
cord-034340-3ksfpaf7	1004	19	and	and	CC
cord-034340-3ksfpaf7	1004	20	invisible	invisible	JJ
cord-034340-3ksfpaf7	1004	21	phases	phase	NNS
cord-034340-3ksfpaf7	1004	22	and	and	CC
cord-034340-3ksfpaf7	1004	23	whether	whether	IN
cord-034340-3ksfpaf7	1004	24	they	-PRON-	PRP
cord-034340-3ksfpaf7	1004	25	want	want	VBP
cord-034340-3ksfpaf7	1004	26	others	other	NNS
cord-034340-3ksfpaf7	1004	27	to	to	TO
cord-034340-3ksfpaf7	1004	28	see	see	VB
cord-034340-3ksfpaf7	1004	29	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1004	30	JDM	jdm	NN
cord-034340-3ksfpaf7	1004	31	,	,	,
cord-034340-3ksfpaf7	1004	32	or	or	CC
cord-034340-3ksfpaf7	1004	33	not	not	RB
cord-034340-3ksfpaf7	1004	34	.	.	.
cord-034340-3ksfpaf7	1005	1	Methods	method	NNS
cord-034340-3ksfpaf7	1005	2	:	:	:
cord-034340-3ksfpaf7	1005	3	Children	child	NNS
cord-034340-3ksfpaf7	1005	4	and	and	CC
cord-034340-3ksfpaf7	1005	5	young	young	JJ
cord-034340-3ksfpaf7	1005	6	people	people	NNS
cord-034340-3ksfpaf7	1005	7	around	around	IN
cord-034340-3ksfpaf7	1005	8	the	the	DT
cord-034340-3ksfpaf7	1005	9	United	United	NNP
cord-034340-3ksfpaf7	1005	10	Kingdom	Kingdom	NNP
cord-034340-3ksfpaf7	1005	11	who	who	WP
cord-034340-3ksfpaf7	1005	12	were	be	VBD
cord-034340-3ksfpaf7	1005	13	already	already	RB
cord-034340-3ksfpaf7	1005	14	consented	consent	VBN
cord-034340-3ksfpaf7	1005	15	and	and	CC
cord-034340-3ksfpaf7	1005	16	enrolled	enrol	VBD
cord-034340-3ksfpaf7	1005	17	into	into	IN
cord-034340-3ksfpaf7	1005	18	the	the	DT
cord-034340-3ksfpaf7	1005	19	UK	UK	NNP
cord-034340-3ksfpaf7	1005	20	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	1005	21	Dermatomyositis	Dermatomyositis	NNP
cord-034340-3ksfpaf7	1005	22	Cohort	Cohort	NNP
cord-034340-3ksfpaf7	1005	23	and	and	CC
cord-034340-3ksfpaf7	1005	24	Biomarker	Biomarker	NNP
cord-034340-3ksfpaf7	1005	25	Study	Study	NNP
cord-034340-3ksfpaf7	1005	26	were	be	VBD
cord-034340-3ksfpaf7	1005	27	asked	ask	VBN
cord-034340-3ksfpaf7	1005	28	to	to	TO
cord-034340-3ksfpaf7	1005	29	complete	complete	VB
cord-034340-3ksfpaf7	1005	30	a	a	DT
cord-034340-3ksfpaf7	1005	31	bespoke	bespoke	JJ
cord-034340-3ksfpaf7	1005	32	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1005	33	.	.	.
cord-034340-3ksfpaf7	1006	1	There	there	EX
cord-034340-3ksfpaf7	1006	2	was	be	VBD
cord-034340-3ksfpaf7	1006	3	a	a	DT
cord-034340-3ksfpaf7	1006	4	mix	mix	NN
cord-034340-3ksfpaf7	1006	5	of	of	IN
cord-034340-3ksfpaf7	1006	6	open	open	JJ
cord-034340-3ksfpaf7	1006	7	and	and	CC
cord-034340-3ksfpaf7	1006	8	closed	closed	JJ
cord-034340-3ksfpaf7	1006	9	questions	question	NNS
cord-034340-3ksfpaf7	1006	10	,	,	,
cord-034340-3ksfpaf7	1006	11	and	and	CC
cord-034340-3ksfpaf7	1006	12	it	-PRON-	PRP
cord-034340-3ksfpaf7	1006	13	was	be	VBD
cord-034340-3ksfpaf7	1006	14	administered	administer	VBN
cord-034340-3ksfpaf7	1006	15	in	in	IN
cord-034340-3ksfpaf7	1006	16	paper	paper	NN
cord-034340-3ksfpaf7	1006	17	format	format	NN
cord-034340-3ksfpaf7	1006	18	to	to	IN
cord-034340-3ksfpaf7	1006	19	all	all	DT
cord-034340-3ksfpaf7	1006	20	children	child	NNS
cord-034340-3ksfpaf7	1006	21	and	and	CC
cord-034340-3ksfpaf7	1006	22	young	young	JJ
cord-034340-3ksfpaf7	1006	23	people	people	NNS
cord-034340-3ksfpaf7	1006	24	between	between	IN
cord-034340-3ksfpaf7	1006	25	the	the	DT
cord-034340-3ksfpaf7	1006	26	ages	age	NNS
cord-034340-3ksfpaf7	1006	27	of	of	IN
cord-034340-3ksfpaf7	1006	28	8	8	CD
cord-034340-3ksfpaf7	1006	29	and	and	CC
cord-034340-3ksfpaf7	1006	30	19	19	CD
cord-034340-3ksfpaf7	1006	31	years	year	NNS
cord-034340-3ksfpaf7	1006	32	of	of	IN
cord-034340-3ksfpaf7	1006	33	age	age	NN
cord-034340-3ksfpaf7	1006	34	for	for	IN
cord-034340-3ksfpaf7	1006	35	self	self	NN
cord-034340-3ksfpaf7	1006	36	-	-	HYPH
cord-034340-3ksfpaf7	1006	37	completion	completion	NN
cord-034340-3ksfpaf7	1006	38	,	,	,
cord-034340-3ksfpaf7	1006	39	either	either	CC
cord-034340-3ksfpaf7	1006	40	on	on	IN
cord-034340-3ksfpaf7	1006	41	the	the	DT
cord-034340-3ksfpaf7	1006	42	paper	paper	NN
cord-034340-3ksfpaf7	1006	43	forms	form	NNS
cord-034340-3ksfpaf7	1006	44	,	,	,
cord-034340-3ksfpaf7	1006	45	or	or	CC
cord-034340-3ksfpaf7	1006	46	via	via	IN
cord-034340-3ksfpaf7	1006	47	a	a	DT
cord-034340-3ksfpaf7	1006	48	secure	secure	JJ
cord-034340-3ksfpaf7	1006	49	web	web	NN
cord-034340-3ksfpaf7	1006	50	-	-	HYPH
cord-034340-3ksfpaf7	1006	51	based	base	VBN
cord-034340-3ksfpaf7	1006	52	software	software	NN
cord-034340-3ksfpaf7	1006	53	system	system	NN
cord-034340-3ksfpaf7	1006	54	.	.	.
cord-034340-3ksfpaf7	1007	1	The	the	DT
cord-034340-3ksfpaf7	1007	2	questionnaires	questionnaire	NNS
cord-034340-3ksfpaf7	1007	3	were	be	VBD
cord-034340-3ksfpaf7	1007	4	administered	administer	VBN
cord-034340-3ksfpaf7	1007	5	at	at	IN
cord-034340-3ksfpaf7	1007	6	the	the	DT
cord-034340-3ksfpaf7	1007	7	end	end	NN
cord-034340-3ksfpaf7	1007	8	of	of	IN
cord-034340-3ksfpaf7	1007	9	2018	2018	CD
cord-034340-3ksfpaf7	1007	10	.	.	.
cord-034340-3ksfpaf7	1008	1	Numeric	numeric	JJ
cord-034340-3ksfpaf7	1008	2	data	datum	NNS
cord-034340-3ksfpaf7	1008	3	were	be	VBD
cord-034340-3ksfpaf7	1008	4	described	describe	VBN
cord-034340-3ksfpaf7	1008	5	and	and	CC
cord-034340-3ksfpaf7	1008	6	qualitative	qualitative	JJ
cord-034340-3ksfpaf7	1008	7	data	datum	NNS
cord-034340-3ksfpaf7	1008	8	were	be	VBD
cord-034340-3ksfpaf7	1008	9	analysed	analyse	VBN
cord-034340-3ksfpaf7	1008	10	using	use	VBG
cord-034340-3ksfpaf7	1008	11	standard	standard	JJ
cord-034340-3ksfpaf7	1008	12	content	content	NN
cord-034340-3ksfpaf7	1008	13	analysis	analysis	NN
cord-034340-3ksfpaf7	1008	14	.	.	.
cord-034340-3ksfpaf7	1009	1	Results	result	NNS
cord-034340-3ksfpaf7	1009	2	:	:	:
cord-034340-3ksfpaf7	1009	3	246	246	CD
cord-034340-3ksfpaf7	1009	4	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1009	5	packs	pack	NNS
cord-034340-3ksfpaf7	1009	6	were	be	VBD
cord-034340-3ksfpaf7	1009	7	sent	send	VBN
cord-034340-3ksfpaf7	1009	8	out	out	RP
cord-034340-3ksfpaf7	1009	9	,	,	,
cord-034340-3ksfpaf7	1009	10	with	with	IN
cord-034340-3ksfpaf7	1009	11	127	127	CD
cord-034340-3ksfpaf7	1009	12	(	(	-LRB-
cord-034340-3ksfpaf7	1009	13	52	52	CD
cord-034340-3ksfpaf7	1009	14	%	%	NN
cord-034340-3ksfpaf7	1009	15	)	)	-RRB-
cord-034340-3ksfpaf7	1009	16	being	be	VBG
cord-034340-3ksfpaf7	1009	17	returned	return	VBN
cord-034340-3ksfpaf7	1009	18	.	.	.
cord-034340-3ksfpaf7	1010	1	Of	of	IN
cord-034340-3ksfpaf7	1010	2	these	these	DT
cord-034340-3ksfpaf7	1010	3	4	4	CD
cord-034340-3ksfpaf7	1010	4	could	could	MD
cord-034340-3ksfpaf7	1010	5	not	not	RB
cord-034340-3ksfpaf7	1010	6	be	be	VB
cord-034340-3ksfpaf7	1010	7	used	use	VBN
cord-034340-3ksfpaf7	1010	8	due	due	IN
cord-034340-3ksfpaf7	1010	9	to	to	IN
cord-034340-3ksfpaf7	1010	10	practical	practical	JJ
cord-034340-3ksfpaf7	1010	11	reasons	reason	NNS
cord-034340-3ksfpaf7	1010	12	,	,	,
cord-034340-3ksfpaf7	1010	13	such	such	JJ
cord-034340-3ksfpaf7	1010	14	as	as	IN
cord-034340-3ksfpaf7	1010	15	only	only	JJ
cord-034340-3ksfpaf7	1010	16	demographic	demographic	JJ
cord-034340-3ksfpaf7	1010	17	data	datum	NNS
cord-034340-3ksfpaf7	1010	18	being	be	VBG
cord-034340-3ksfpaf7	1010	19	completed	complete	VBN
cord-034340-3ksfpaf7	1010	20	,	,	,
cord-034340-3ksfpaf7	1010	21	which	which	WDT
cord-034340-3ksfpaf7	1010	22	left	leave	VBD
cord-034340-3ksfpaf7	1010	23	a	a	DT
cord-034340-3ksfpaf7	1010	24	sample	sample	NN
cord-034340-3ksfpaf7	1010	25	of	of	IN
cord-034340-3ksfpaf7	1010	26	123	123	CD
cord-034340-3ksfpaf7	1010	27	.	.	.
cord-034340-3ksfpaf7	1010	28	98	98	CD
cord-034340-3ksfpaf7	1010	29	(	(	-LRB-
cord-034340-3ksfpaf7	1010	30	80	80	CD
cord-034340-3ksfpaf7	1010	31	%	%	NN
cord-034340-3ksfpaf7	1010	32	)	)	-RRB-
cord-034340-3ksfpaf7	1010	33	of	of	IN
cord-034340-3ksfpaf7	1010	34	the	the	DT
cord-034340-3ksfpaf7	1010	35	122	122	CD
cord-034340-3ksfpaf7	1010	36	who	who	WP
cord-034340-3ksfpaf7	1010	37	responded	respond	VBD
cord-034340-3ksfpaf7	1011	1	said	say	VBD
cord-034340-3ksfpaf7	1011	2	other	other	JJ
cord-034340-3ksfpaf7	1011	3	people	people	NNS
cord-034340-3ksfpaf7	1011	4	could	could	MD
cord-034340-3ksfpaf7	1011	5	not	not	RB
cord-034340-3ksfpaf7	1011	6	see	see	VB
cord-034340-3ksfpaf7	1011	7	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1011	8	JDM	jdm	NN
cord-034340-3ksfpaf7	1011	9	,	,	,
cord-034340-3ksfpaf7	1011	10	with	with	IN
cord-034340-3ksfpaf7	1011	11	only	only	RB
cord-034340-3ksfpaf7	1011	12	11	11	CD
cord-034340-3ksfpaf7	1011	13	(	(	-LRB-
cord-034340-3ksfpaf7	1011	14	9	9	CD
cord-034340-3ksfpaf7	1011	15	%	%	NN
cord-034340-3ksfpaf7	1011	16	)	)	-RRB-
cord-034340-3ksfpaf7	1011	17	saying	say	VBG
cord-034340-3ksfpaf7	1011	18	it	-PRON-	PRP
cord-034340-3ksfpaf7	1011	19	was	be	VBD
cord-034340-3ksfpaf7	1011	20	visible	visible	JJ
cord-034340-3ksfpaf7	1011	21	and	and	CC
cord-034340-3ksfpaf7	1011	22	13	13	CD
cord-034340-3ksfpaf7	1011	23	(	(	-LRB-
cord-034340-3ksfpaf7	1011	24	11	11	CD
cord-034340-3ksfpaf7	1011	25	%	%	NN
cord-034340-3ksfpaf7	1011	26	)	)	-RRB-
cord-034340-3ksfpaf7	1011	27	saying	say	VBG
cord-034340-3ksfpaf7	1011	28	they	-PRON-	PRP
cord-034340-3ksfpaf7	1011	29	did	do	VBD
cord-034340-3ksfpaf7	1011	30	not	not	RB
cord-034340-3ksfpaf7	1011	31	know	know	VB
cord-034340-3ksfpaf7	1011	32	if	if	IN
cord-034340-3ksfpaf7	1011	33	others	other	NNS
cord-034340-3ksfpaf7	1011	34	can	can	MD
cord-034340-3ksfpaf7	1011	35	see	see	VB
cord-034340-3ksfpaf7	1011	36	it	-PRON-	PRP
cord-034340-3ksfpaf7	1011	37	.	.	.
cord-034340-3ksfpaf7	1012	1	1	1	CD
cord-034340-3ksfpaf7	1012	2	did	do	VBD
cord-034340-3ksfpaf7	1012	3	not	not	RB
cord-034340-3ksfpaf7	1012	4	respond	respond	VB
cord-034340-3ksfpaf7	1012	5	to	to	IN
cord-034340-3ksfpaf7	1012	6	the	the	DT
cord-034340-3ksfpaf7	1012	7	question	question	NN
cord-034340-3ksfpaf7	1012	8	as	as	IN
cord-034340-3ksfpaf7	1012	9	said	say	VBD
cord-034340-3ksfpaf7	1012	10	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1012	11	JDM	JDM	NNP
cord-034340-3ksfpaf7	1012	12	has	have	VBZ
cord-034340-3ksfpaf7	1012	13	gone	go	VBN
cord-034340-3ksfpaf7	1012	14	away	away	RB
cord-034340-3ksfpaf7	1012	15	.	.	.
cord-034340-3ksfpaf7	1013	1	They	-PRON-	PRP
cord-034340-3ksfpaf7	1013	2	were	be	VBD
cord-034340-3ksfpaf7	1013	3	then	then	RB
cord-034340-3ksfpaf7	1013	4	asked	ask	VBN
cord-034340-3ksfpaf7	1013	5	whether	whether	IN
cord-034340-3ksfpaf7	1013	6	it	-PRON-	PRP
cord-034340-3ksfpaf7	1013	7	was	be	VBD
cord-034340-3ksfpaf7	1013	8	a	a	DT
cord-034340-3ksfpaf7	1013	9	good	good	JJ
cord-034340-3ksfpaf7	1013	10	or	or	CC
cord-034340-3ksfpaf7	1013	11	bad	bad	JJ
cord-034340-3ksfpaf7	1013	12	thing	thing	NN
cord-034340-3ksfpaf7	1013	13	for	for	IN
cord-034340-3ksfpaf7	1013	14	others	other	NNS
cord-034340-3ksfpaf7	1013	15	to	to	TO
cord-034340-3ksfpaf7	1013	16	be	be	VB
cord-034340-3ksfpaf7	1013	17	able	able	JJ
cord-034340-3ksfpaf7	1013	18	to	to	TO
cord-034340-3ksfpaf7	1013	19	see	see	VB
cord-034340-3ksfpaf7	1013	20	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1013	21	JDM	jdm	NN
cord-034340-3ksfpaf7	1013	22	or	or	CC
cord-034340-3ksfpaf7	1013	23	for	for	IN
cord-034340-3ksfpaf7	1013	24	others	other	NNS
cord-034340-3ksfpaf7	1013	25	not	not	RB
cord-034340-3ksfpaf7	1013	26	to	to	TO
cord-034340-3ksfpaf7	1013	27	be	be	VB
cord-034340-3ksfpaf7	1013	28	able	able	JJ
cord-034340-3ksfpaf7	1013	29	to	to	TO
cord-034340-3ksfpaf7	1013	30	see	see	VB
cord-034340-3ksfpaf7	1013	31	it	-PRON-	PRP
cord-034340-3ksfpaf7	1013	32	.	.	.
cord-034340-3ksfpaf7	1014	1	41	41	CD
cord-034340-3ksfpaf7	1014	2	young	young	JJ
cord-034340-3ksfpaf7	1014	3	people	people	NNS
cord-034340-3ksfpaf7	1014	4	left	leave	VBD
cord-034340-3ksfpaf7	1014	5	comments	comment	NNS
cord-034340-3ksfpaf7	1014	6	as	as	IN
cord-034340-3ksfpaf7	1014	7	to	to	IN
cord-034340-3ksfpaf7	1014	8	why	why	WRB
cord-034340-3ksfpaf7	1014	9	it	-PRON-	PRP
cord-034340-3ksfpaf7	1014	10	was	be	VBD
cord-034340-3ksfpaf7	1014	11	a	a	DT
cord-034340-3ksfpaf7	1014	12	good	good	JJ
cord-034340-3ksfpaf7	1014	13	thing	thing	NN
cord-034340-3ksfpaf7	1014	14	,	,	,
cord-034340-3ksfpaf7	1014	15	36	36	CD
cord-034340-3ksfpaf7	1014	16	left	leave	VBN
cord-034340-3ksfpaf7	1014	17	comments	comment	NNS
cord-034340-3ksfpaf7	1014	18	as	as	IN
cord-034340-3ksfpaf7	1014	19	to	to	IN
cord-034340-3ksfpaf7	1014	20	why	why	WRB
cord-034340-3ksfpaf7	1014	21	it	-PRON-	PRP
cord-034340-3ksfpaf7	1014	22	was	be	VBD
cord-034340-3ksfpaf7	1014	23	a	a	DT
cord-034340-3ksfpaf7	1014	24	bad	bad	JJ
cord-034340-3ksfpaf7	1014	25	thing	thing	NN
cord-034340-3ksfpaf7	1014	26	and	and	CC
cord-034340-3ksfpaf7	1014	27	14	14	CD
cord-034340-3ksfpaf7	1014	28	left	left	JJ
cord-034340-3ksfpaf7	1014	29	comments	comment	NNS
cord-034340-3ksfpaf7	1014	30	to	to	IN
cord-034340-3ksfpaf7	1014	31	why	why	WRB
cord-034340-3ksfpaf7	1014	32	they	-PRON-	PRP
cord-034340-3ksfpaf7	1014	33	said	say	VBD
cord-034340-3ksfpaf7	1014	34	do	do	VB
cord-034340-3ksfpaf7	1014	35	n't	not	RB
cord-034340-3ksfpaf7	1014	36	know	know	VB
cord-034340-3ksfpaf7	1014	37	,	,	,
cord-034340-3ksfpaf7	1014	38	table	table	NN
cord-034340-3ksfpaf7	1014	39	1	1	CD
cord-034340-3ksfpaf7	1014	40	presents	present	VBZ
cord-034340-3ksfpaf7	1014	41	the	the	DT
cord-034340-3ksfpaf7	1014	42	top	top	JJ
cord-034340-3ksfpaf7	1014	43	ranking	rank	VBG
cord-034340-3ksfpaf7	1014	44	response	response	NN
cord-034340-3ksfpaf7	1014	45	for	for	IN
cord-034340-3ksfpaf7	1014	46	the	the	DT
cord-034340-3ksfpaf7	1014	47	three	three	CD
cord-034340-3ksfpaf7	1014	48	multichoice	multichoice	NN
cord-034340-3ksfpaf7	1014	49	answers	answer	NNS
cord-034340-3ksfpaf7	1014	50	.	.	.
cord-034340-3ksfpaf7	1015	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1015	2	:	:	:
cord-034340-3ksfpaf7	1016	1	This	this	DT
cord-034340-3ksfpaf7	1016	2	study	study	NN
cord-034340-3ksfpaf7	1016	3	has	have	VBZ
cord-034340-3ksfpaf7	1016	4	highlighted	highlight	VBN
cord-034340-3ksfpaf7	1016	5	the	the	DT
cord-034340-3ksfpaf7	1016	6	disparity	disparity	NN
cord-034340-3ksfpaf7	1016	7	between	between	IN
cord-034340-3ksfpaf7	1016	8	young	young	JJ
cord-034340-3ksfpaf7	1016	9	people	people	NNS
cord-034340-3ksfpaf7	1016	10	wanting	want	VBG
cord-034340-3ksfpaf7	1016	11	others	other	NNS
cord-034340-3ksfpaf7	1016	12	to	to	TO
cord-034340-3ksfpaf7	1016	13	see	see	VB
cord-034340-3ksfpaf7	1016	14	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1016	15	JDM	jdm	NN
cord-034340-3ksfpaf7	1016	16	so	so	IN
cord-034340-3ksfpaf7	1016	17	that	that	IN
cord-034340-3ksfpaf7	1016	18	they	-PRON-	PRP
cord-034340-3ksfpaf7	1016	19	gain	gain	VBP
cord-034340-3ksfpaf7	1016	20	more	more	JJR
cord-034340-3ksfpaf7	1016	21	understanding	understanding	NN
cord-034340-3ksfpaf7	1016	22	and	and	CC
cord-034340-3ksfpaf7	1016	23	empathy	empathy	NN
cord-034340-3ksfpaf7	1016	24	from	from	IN
cord-034340-3ksfpaf7	1016	25	those	those	DT
cord-034340-3ksfpaf7	1016	26	around	around	IN
cord-034340-3ksfpaf7	1016	27	them	-PRON-	PRP
cord-034340-3ksfpaf7	1016	28	,	,	,
cord-034340-3ksfpaf7	1016	29	but	but	CC
cord-034340-3ksfpaf7	1016	30	equally	equally	RB
cord-034340-3ksfpaf7	1016	31	,	,	,
cord-034340-3ksfpaf7	1016	32	wanting	want	VBG
cord-034340-3ksfpaf7	1016	33	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1016	34	JDM	jdm	NN
cord-034340-3ksfpaf7	1016	35	to	to	TO
cord-034340-3ksfpaf7	1016	36	be	be	VB
cord-034340-3ksfpaf7	1016	37	invisible	invisible	JJ
cord-034340-3ksfpaf7	1016	38	,	,	,
cord-034340-3ksfpaf7	1016	39	so	so	IN
cord-034340-3ksfpaf7	1016	40	that	that	IN
cord-034340-3ksfpaf7	1016	41	they	-PRON-	PRP
cord-034340-3ksfpaf7	1016	42	feel	feel	VBP
cord-034340-3ksfpaf7	1016	43	the	the	DT
cord-034340-3ksfpaf7	1016	44	same	same	JJ
cord-034340-3ksfpaf7	1016	45	as	as	IN
cord-034340-3ksfpaf7	1016	46	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1016	47	peers	peer	NNS
cord-034340-3ksfpaf7	1016	48	.	.	.
cord-034340-3ksfpaf7	1017	1	Whilst	whilst	IN
cord-034340-3ksfpaf7	1017	2	many	many	JJ
cord-034340-3ksfpaf7	1017	3	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1017	4	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1017	5	conditions	condition	NNS
cord-034340-3ksfpaf7	1017	6	are	be	VBP
cord-034340-3ksfpaf7	1017	7	in	in	IN
cord-034340-3ksfpaf7	1017	8	fact	fact	NN
cord-034340-3ksfpaf7	1017	9	invisible	invisible	JJ
cord-034340-3ksfpaf7	1017	10	,	,	,
cord-034340-3ksfpaf7	1017	11	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1017	12	data	datum	NNS
cord-034340-3ksfpaf7	1017	13	illustrate	illustrate	VBP
cord-034340-3ksfpaf7	1017	14	that	that	IN
cord-034340-3ksfpaf7	1017	15	JDM	JDM	NNP
cord-034340-3ksfpaf7	1017	16	often	often	RB
cord-034340-3ksfpaf7	1017	17	gives	give	VBZ
cord-034340-3ksfpaf7	1017	18	children	child	NNS
cord-034340-3ksfpaf7	1017	19	and	and	CC
cord-034340-3ksfpaf7	1017	20	young	young	JJ
cord-034340-3ksfpaf7	1017	21	people	people	NNS
cord-034340-3ksfpaf7	1017	22	a	a	DT
cord-034340-3ksfpaf7	1017	23	taste	taste	NN
cord-034340-3ksfpaf7	1017	24	of	of	IN
cord-034340-3ksfpaf7	1017	25	both	both	CC
cord-034340-3ksfpaf7	1017	26	visible	visible	JJ
cord-034340-3ksfpaf7	1017	27	and	and	CC
cord-034340-3ksfpaf7	1017	28	invisible	invisible	JJ
cord-034340-3ksfpaf7	1017	29	phases	phase	NNS
cord-034340-3ksfpaf7	1017	30	of	of	IN
cord-034340-3ksfpaf7	1017	31	disease	disease	NN
cord-034340-3ksfpaf7	1017	32	activity	activity	NN
cord-034340-3ksfpaf7	1017	33	.	.	.
cord-034340-3ksfpaf7	1018	1	As	as	IN
cord-034340-3ksfpaf7	1018	2	one	one	CD
cord-034340-3ksfpaf7	1018	3	young	young	JJ
cord-034340-3ksfpaf7	1018	4	person	person	NN
cord-034340-3ksfpaf7	1018	5	said	say	VBD
cord-034340-3ksfpaf7	1018	6	"	"	``
cord-034340-3ksfpaf7	1018	7	It	-PRON-	PRP
cord-034340-3ksfpaf7	1018	8	's	be	VBZ
cord-034340-3ksfpaf7	1018	9	not	not	RB
cord-034340-3ksfpaf7	1018	10	good	good	JJ
cord-034340-3ksfpaf7	1018	11	,	,	,
cord-034340-3ksfpaf7	1018	12	nor	nor	CC
cord-034340-3ksfpaf7	1018	13	badit	badit	NNP
cord-034340-3ksfpaf7	1018	14	's	's	POS
cord-034340-3ksfpaf7	1018	15	good	good	JJ
cord-034340-3ksfpaf7	1018	16	that	that	IN
cord-034340-3ksfpaf7	1018	17	it	-PRON-	PRP
cord-034340-3ksfpaf7	1018	18	's	be	VBZ
cord-034340-3ksfpaf7	1018	19	invisible	invisible	JJ
cord-034340-3ksfpaf7	1018	20	sometimes	sometimes	RB
cord-034340-3ksfpaf7	1019	1	so	so	CC
cord-034340-3ksfpaf7	1019	2	I	-PRON-	PRP
cord-034340-3ksfpaf7	1019	3	can	can	MD
cord-034340-3ksfpaf7	1019	4	blend	blend	VB
cord-034340-3ksfpaf7	1019	5	in	in	RP
cord-034340-3ksfpaf7	1019	6	without	without	IN
cord-034340-3ksfpaf7	1019	7	the	the	DT
cord-034340-3ksfpaf7	1019	8	disabled	disabled	JJ
cord-034340-3ksfpaf7	1019	9	stereotype	stereotype	NN
cord-034340-3ksfpaf7	1019	10	.	.	.
cord-034340-3ksfpaf7	1020	1	However	however	RB
cord-034340-3ksfpaf7	1020	2	,	,	,
cord-034340-3ksfpaf7	1020	3	sometimes	sometimes	RB
cord-034340-3ksfpaf7	1020	4	it	-PRON-	PRP
cord-034340-3ksfpaf7	1020	5	needs	need	VBZ
cord-034340-3ksfpaf7	1020	6	to	to	TO
cord-034340-3ksfpaf7	1020	7	be	be	VB
cord-034340-3ksfpaf7	1020	8	seen	see	VBN
cord-034340-3ksfpaf7	1020	9	so	so	IN
cord-034340-3ksfpaf7	1020	10	I	-PRON-	PRP
cord-034340-3ksfpaf7	1020	11	can	can	MD
cord-034340-3ksfpaf7	1020	12	be	be	VB
cord-034340-3ksfpaf7	1020	13	understood	understand	VBN
cord-034340-3ksfpaf7	1020	14	and	and	CC
cord-034340-3ksfpaf7	1020	15	not	not	RB
cord-034340-3ksfpaf7	1020	16	challenged	challenge	VBN
cord-034340-3ksfpaf7	1020	17	"	"	''
cord-034340-3ksfpaf7	1020	18	.	.	.
cord-034340-3ksfpaf7	1021	1	Disclosure	disclosure	NN
cord-034340-3ksfpaf7	1021	2	of	of	IN
cord-034340-3ksfpaf7	1021	3	Interest	Interest	NNP
cord-034340-3ksfpaf7	1022	1	:	:	:
cord-034340-3ksfpaf7	1022	2	None	none	NN
cord-034340-3ksfpaf7	1022	3	declared	declare	VBD
cord-034340-3ksfpaf7	1022	4	Multidimensional	Multidimensional	NNP
cord-034340-3ksfpaf7	1022	5	Assessment	Assessment	NNP
cord-034340-3ksfpaf7	1022	6	Report	Report	NNP
cord-034340-3ksfpaf7	1022	7	(	(	-LRB-
cord-034340-3ksfpaf7	1022	8	J	J	NNP
cord-034340-3ksfpaf7	1022	9	-	-	HYPH
cord-034340-3ksfpaf7	1022	10	FiMAR	FiMAR	NNP
cord-034340-3ksfpaf7	1022	11	)	)	-RRB-
cord-034340-3ksfpaf7	1023	1	which	which	WDT
cord-034340-3ksfpaf7	1023	2	includes	include	VBZ
cord-034340-3ksfpaf7	1023	3	comprehensive	comprehensive	JJ
cord-034340-3ksfpaf7	1023	4	patient	patient	JJ
cord-034340-3ksfpaf7	1023	5	self	self	NN
cord-034340-3ksfpaf7	1023	6	-	-	HYPH
cord-034340-3ksfpaf7	1023	7	report	report	NN
cord-034340-3ksfpaf7	1023	8	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1023	9	and	and	CC
cord-034340-3ksfpaf7	1023	10	numerical	numerical	JJ
cord-034340-3ksfpaf7	1023	11	rating	rating	NN
cord-034340-3ksfpaf7	1023	12	scales	scale	NNS
cord-034340-3ksfpaf7	1023	13	to	to	TO
cord-034340-3ksfpaf7	1023	14	measure	measure	VB
cord-034340-3ksfpaf7	1023	15	pain	pain	NN
cord-034340-3ksfpaf7	1023	16	,	,	,
cord-034340-3ksfpaf7	1023	17	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1023	18	,	,	,
cord-034340-3ksfpaf7	1023	19	headache	headache	NN
cord-034340-3ksfpaf7	1023	20	,	,	,
cord-034340-3ksfpaf7	1023	21	sleep	sleep	NN
cord-034340-3ksfpaf7	1023	22	quality	quality	NN
cord-034340-3ksfpaf7	1023	23	,	,	,
cord-034340-3ksfpaf7	1023	24	physical	physical	JJ
cord-034340-3ksfpaf7	1023	25	function	function	NN
cord-034340-3ksfpaf7	1023	26	,	,	,
cord-034340-3ksfpaf7	1023	27	psychological	psychological	JJ
cord-034340-3ksfpaf7	1023	28	state	state	NN
cord-034340-3ksfpaf7	1023	29	,	,	,
cord-034340-3ksfpaf7	1023	30	health	health	NN
cord-034340-3ksfpaf7	1023	31	-	-	HYPH
cord-034340-3ksfpaf7	1023	32	related	relate	VBN
cord-034340-3ksfpaf7	1023	33	quality	quality	NN
cord-034340-3ksfpaf7	1023	34	of	of	IN
cord-034340-3ksfpaf7	1023	35	life	life	NN
cord-034340-3ksfpaf7	1023	36	,	,	,
cord-034340-3ksfpaf7	1023	37	satisfaction	satisfaction	NN
cord-034340-3ksfpaf7	1023	38	with	with	IN
cord-034340-3ksfpaf7	1023	39	illness	illness	NN
cord-034340-3ksfpaf7	1023	40	course	course	NN
cord-034340-3ksfpaf7	1023	41	.	.	.
cord-034340-3ksfpaf7	1024	1	The	the	DT
cord-034340-3ksfpaf7	1024	2	J	J	NNP
cord-034340-3ksfpaf7	1024	3	-	-	HYPH
cord-034340-3ksfpaf7	1024	4	FiMAR	FiMAR	NNP
cord-034340-3ksfpaf7	1024	5	has	have	VBZ
cord-034340-3ksfpaf7	1024	6	been	be	VBN
cord-034340-3ksfpaf7	1024	7	devised	devise	VBN
cord-034340-3ksfpaf7	1024	8	according	accord	VBG
cord-034340-3ksfpaf7	1024	9	to	to	IN
cord-034340-3ksfpaf7	1024	10	the	the	DT
cord-034340-3ksfpaf7	1024	11	Outcome	outcome	NN
cord-034340-3ksfpaf7	1024	12	measure	measure	NN
cord-034340-3ksfpaf7	1024	13	in	in	IN
cord-034340-3ksfpaf7	1024	14	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1024	15	(	(	-LRB-
cord-034340-3ksfpaf7	1024	16	OMERACT	OMERACT	NNP
cord-034340-3ksfpaf7	1024	17	)	)	-RRB-
cord-034340-3ksfpaf7	1024	18	guidelines	guideline	NNS
cord-034340-3ksfpaf7	1024	19	.	.	.
cord-034340-3ksfpaf7	1025	1	Discriminant	discriminant	JJ
cord-034340-3ksfpaf7	1025	2	ability	ability	NN
cord-034340-3ksfpaf7	1025	3	of	of	IN
cord-034340-3ksfpaf7	1025	4	the	the	DT
cord-034340-3ksfpaf7	1025	5	multidimensional	multidimensional	JJ
cord-034340-3ksfpaf7	1025	6	tool	tool	NN
cord-034340-3ksfpaf7	1025	7	was	be	VBD
cord-034340-3ksfpaf7	1025	8	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	1025	9	by	by	IN
cord-034340-3ksfpaf7	1025	10	testing	test	VBG
cord-034340-3ksfpaf7	1025	11	it	-PRON-	PRP
cord-034340-3ksfpaf7	1025	12	in	in	IN
cord-034340-3ksfpaf7	1025	13	a	a	DT
cord-034340-3ksfpaf7	1025	14	control	control	NN
cord-034340-3ksfpaf7	1025	15	group	group	NN
cord-034340-3ksfpaf7	1025	16	including	include	VBG
cord-034340-3ksfpaf7	1025	17	healthy	healthy	JJ
cord-034340-3ksfpaf7	1025	18	controls	control	NNS
cord-034340-3ksfpaf7	1025	19	and	and	CC
cord-034340-3ksfpaf7	1025	20	patients	patient	NNS
cord-034340-3ksfpaf7	1025	21	affected	affect	VBN
cord-034340-3ksfpaf7	1025	22	by	by	IN
cord-034340-3ksfpaf7	1025	23	active	active	JJ
cord-034340-3ksfpaf7	1025	24	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1025	25	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1025	26	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1025	27	(	(	-LRB-
cord-034340-3ksfpaf7	1025	28	JIA	JIA	NNP
cord-034340-3ksfpaf7	1025	29	)	)	-RRB-
cord-034340-3ksfpaf7	1025	30	.	.	.
cord-034340-3ksfpaf7	1026	1	The	the	DT
cord-034340-3ksfpaf7	1026	2	psychosocial	psychosocial	JJ
cord-034340-3ksfpaf7	1026	3	consequences	consequence	NNS
cord-034340-3ksfpaf7	1026	4	of	of	IN
cord-034340-3ksfpaf7	1026	5	chronic	chronic	JJ
cord-034340-3ksfpaf7	1026	6	pain	pain	NN
cord-034340-3ksfpaf7	1026	7	were	be	VBD
cord-034340-3ksfpaf7	1026	8	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	1026	9	by	by	IN
cord-034340-3ksfpaf7	1026	10	using	use	VBG
cord-034340-3ksfpaf7	1026	11	the	the	DT
cord-034340-3ksfpaf7	1026	12	Children	Children	NNP
cord-034340-3ksfpaf7	1026	13	Depression	Depression	NNP
cord-034340-3ksfpaf7	1026	14	Index	Index	NNP
cord-034340-3ksfpaf7	1026	15	(	(	-LRB-
cord-034340-3ksfpaf7	1026	16	CDI	CDI	NNP
cord-034340-3ksfpaf7	1026	17	)	)	-RRB-
cord-034340-3ksfpaf7	1026	18	and	and	CC
cord-034340-3ksfpaf7	1026	19	the	the	DT
cord-034340-3ksfpaf7	1026	20	Multidimensional	Multidimensional	NNP
cord-034340-3ksfpaf7	1026	21	Anxiety	Anxiety	NNP
cord-034340-3ksfpaf7	1026	22	Scale	Scale	NNP
cord-034340-3ksfpaf7	1026	23	for	for	IN
cord-034340-3ksfpaf7	1026	24	Children	child	NNS
cord-034340-3ksfpaf7	1026	25	(	(	-LRB-
cord-034340-3ksfpaf7	1026	26	MASC	MASC	NNP
cord-034340-3ksfpaf7	1026	27	)	)	-RRB-
cord-034340-3ksfpaf7	1026	28	.	.	.
cord-034340-3ksfpaf7	1027	1	The	the	DT
cord-034340-3ksfpaf7	1027	2	objective	objective	JJ
cord-034340-3ksfpaf7	1027	3	sleep	sleep	NN
cord-034340-3ksfpaf7	1027	4	quality	quality	NN
cord-034340-3ksfpaf7	1027	5	was	be	VBD
cord-034340-3ksfpaf7	1027	6	measured	measure	VBN
cord-034340-3ksfpaf7	1027	7	by	by	IN
cord-034340-3ksfpaf7	1027	8	overnight	overnight	JJ
cord-034340-3ksfpaf7	1027	9	polysomnography	polysomnography	NN
cord-034340-3ksfpaf7	1027	10	.	.	.
cord-034340-3ksfpaf7	1028	1	Results	result	NNS
cord-034340-3ksfpaf7	1028	2	:	:	:
cord-034340-3ksfpaf7	1029	1	Table	table	NN
cord-034340-3ksfpaf7	1029	2	1	1	CD
cord-034340-3ksfpaf7	1029	3	shows	show	VBZ
cord-034340-3ksfpaf7	1029	4	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1029	5	and	and	CC
cord-034340-3ksfpaf7	1029	6	the	the	DT
cord-034340-3ksfpaf7	1029	7	most	most	RBS
cord-034340-3ksfpaf7	1029	8	represented	represent	VBN
cord-034340-3ksfpaf7	1029	9	somatic	somatic	JJ
cord-034340-3ksfpaf7	1029	10	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1029	11	in	in	IN
cord-034340-3ksfpaf7	1029	12	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1029	13	cohort	cohort	NN
cord-034340-3ksfpaf7	1029	14	of	of	IN
cord-034340-3ksfpaf7	1029	15	JFS	JFS	NNP
cord-034340-3ksfpaf7	1029	16	patients	patient	NNS
cord-034340-3ksfpaf7	1029	17	at	at	IN
cord-034340-3ksfpaf7	1029	18	the	the	DT
cord-034340-3ksfpaf7	1029	19	study	study	NN
cord-034340-3ksfpaf7	1029	20	enter	enter	NN
cord-034340-3ksfpaf7	1029	21	.	.	.
cord-034340-3ksfpaf7	1030	1	Polysomnography	Polysomnography	NNP
cord-034340-3ksfpaf7	1030	2	was	be	VBD
cord-034340-3ksfpaf7	1030	3	performed	perform	VBN
cord-034340-3ksfpaf7	1030	4	in	in	IN
cord-034340-3ksfpaf7	1030	5	21	21	CD
cord-034340-3ksfpaf7	1030	6	patients	patient	NNS
cord-034340-3ksfpaf7	1030	7	with	with	IN
cord-034340-3ksfpaf7	1030	8	sleep	sleep	NN
cord-034340-3ksfpaf7	1030	9	disturbance	disturbance	NN
cord-034340-3ksfpaf7	1030	10	;	;	:
cord-034340-3ksfpaf7	1030	11	8/21	8/21	CD
cord-034340-3ksfpaf7	1030	12	(	(	-LRB-
cord-034340-3ksfpaf7	1030	13	38.1	38.1	CD
cord-034340-3ksfpaf7	1030	14	%	%	NN
cord-034340-3ksfpaf7	1030	15	)	)	-RRB-
cord-034340-3ksfpaf7	1030	16	showed	show	VBD
cord-034340-3ksfpaf7	1030	17	an	an	DT
cord-034340-3ksfpaf7	1030	18	electroencephalographic	electroencephalographic	JJ
cord-034340-3ksfpaf7	1030	19	pattern	pattern	NN
cord-034340-3ksfpaf7	1030	20	of	of	IN
cord-034340-3ksfpaf7	1030	21	alpha	alpha	NN
cord-034340-3ksfpaf7	1030	22	wave	wave	NN
cord-034340-3ksfpaf7	1030	23	intrusion	intrusion	NN
cord-034340-3ksfpaf7	1030	24	in	in	IN
cord-034340-3ksfpaf7	1030	25	slow	slow	JJ
cord-034340-3ksfpaf7	1030	26	wave	wave	NN
cord-034340-3ksfpaf7	1030	27	sleep	sleep	NN
cord-034340-3ksfpaf7	1030	28	(	(	-LRB-
cord-034340-3ksfpaf7	1030	29	SWS	SWS	NNP
cord-034340-3ksfpaf7	1030	30	)	)	-RRB-
cord-034340-3ksfpaf7	1030	31	.	.	.
cord-034340-3ksfpaf7	1031	1	The	the	DT
cord-034340-3ksfpaf7	1031	2	presence	presence	NN
cord-034340-3ksfpaf7	1031	3	of	of	IN
cord-034340-3ksfpaf7	1031	4	objective	objective	JJ
cord-034340-3ksfpaf7	1031	5	sleep	sleep	NN
cord-034340-3ksfpaf7	1031	6	disorders	disorder	NNS
cord-034340-3ksfpaf7	1031	7	was	be	VBD
cord-034340-3ksfpaf7	1031	8	significantly	significantly	RB
cord-034340-3ksfpaf7	1031	9	correlated	correlate	VBN
cord-034340-3ksfpaf7	1031	10	to	to	IN
cord-034340-3ksfpaf7	1031	11	CDI	CDI	NNP
cord-034340-3ksfpaf7	1031	12	score	score	NN
cord-034340-3ksfpaf7	1031	13	rs	rs	XX
cord-034340-3ksfpaf7	1031	14	-0,775	-0,775	NNP
cord-034340-3ksfpaf7	1032	1	(	(	-LRB-
cord-034340-3ksfpaf7	1032	2	p≤0,0001	p≤0,0001	CD
cord-034340-3ksfpaf7	1032	3	)	)	-RRB-
cord-034340-3ksfpaf7	1032	4	and	and	CC
cord-034340-3ksfpaf7	1032	5	MASC	MASC	NNP
cord-034340-3ksfpaf7	1032	6	0,61	0,61	CD
cord-034340-3ksfpaf7	1032	7	(	(	-LRB-
cord-034340-3ksfpaf7	1032	8	p=0,005	p=0,005	NNP
cord-034340-3ksfpaf7	1032	9	)	)	-RRB-
cord-034340-3ksfpaf7	1032	10	.	.	.
cord-034340-3ksfpaf7	1033	1	From	from	IN
cord-034340-3ksfpaf7	1033	2	November	November	NNP
cord-034340-3ksfpaf7	1033	3	2016	2016	CD
cord-034340-3ksfpaf7	1033	4	to	to	IN
cord-034340-3ksfpaf7	1033	5	April	April	NNP
cord-034340-3ksfpaf7	1033	6	2020	2020	CD
cord-034340-3ksfpaf7	1034	1	J	J	NNP
cord-034340-3ksfpaf7	1034	2	-	-	HYPH
cord-034340-3ksfpaf7	1034	3	FiMAR	FiMAR	NNP
cord-034340-3ksfpaf7	1034	4	was	be	VBD
cord-034340-3ksfpaf7	1034	5	completed	complete	VBN
cord-034340-3ksfpaf7	1034	6	by	by	IN
cord-034340-3ksfpaf7	1034	7	43	43	CD
cord-034340-3ksfpaf7	1034	8	JFS	JFS	NNP
cord-034340-3ksfpaf7	1034	9	patients	patient	NNS
cord-034340-3ksfpaf7	1034	10	(	(	-LRB-
cord-034340-3ksfpaf7	1034	11	F	F	NNP
cord-034340-3ksfpaf7	1034	12	35	35	CD
cord-034340-3ksfpaf7	1034	13	(	(	-LRB-
cord-034340-3ksfpaf7	1034	14	81.4	81.4	CD
cord-034340-3ksfpaf7	1034	15	%	%	NN
cord-034340-3ksfpaf7	1034	16	)	)	-RRB-
cord-034340-3ksfpaf7	1034	17	,	,	,
cord-034340-3ksfpaf7	1034	18	median	median	JJ
cord-034340-3ksfpaf7	1034	19	age	age	NN
cord-034340-3ksfpaf7	1034	20	14.7	14.7	CD
cord-034340-3ksfpaf7	1034	21	years	year	NNS
cord-034340-3ksfpaf7	1034	22	[	[	-LRB-
cord-034340-3ksfpaf7	1034	23	7.1	7.1	CD
cord-034340-3ksfpaf7	1034	24	-	-	HYPH
cord-034340-3ksfpaf7	1034	25	17.6	17.6	CD
cord-034340-3ksfpaf7	1034	26	]	]	-RRB-
cord-034340-3ksfpaf7	1034	27	,	,	,
cord-034340-3ksfpaf7	1034	28	median	median	JJ
cord-034340-3ksfpaf7	1034	29	disease	disease	NN
cord-034340-3ksfpaf7	1034	30	duration	duration	NN
cord-034340-3ksfpaf7	1034	31	1.9	1.9	CD
cord-034340-3ksfpaf7	1034	32	years	year	NNS
cord-034340-3ksfpaf7	1034	33	[	[	-LRB-
cord-034340-3ksfpaf7	1034	34	0.1	0.1	CD
cord-034340-3ksfpaf7	1034	35	-	-	HYPH
cord-034340-3ksfpaf7	1034	36	7.8	7.8	CD
cord-034340-3ksfpaf7	1034	37	]	]	-RRB-
cord-034340-3ksfpaf7	1034	38	)	)	-RRB-
cord-034340-3ksfpaf7	1034	39	in	in	IN
cord-034340-3ksfpaf7	1034	40	125	125	CD
cord-034340-3ksfpaf7	1034	41	visits	visit	NNS
cord-034340-3ksfpaf7	1034	42	.	.	.
cord-034340-3ksfpaf7	1035	1	All	all	DT
cord-034340-3ksfpaf7	1035	2	patients	patient	NNS
cord-034340-3ksfpaf7	1035	3	filled	fill	VBD
cord-034340-3ksfpaf7	1035	4	out	out	RP
cord-034340-3ksfpaf7	1035	5	the	the	DT
cord-034340-3ksfpaf7	1035	6	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1035	7	in	in	IN
cord-034340-3ksfpaf7	1035	8	a	a	DT
cord-034340-3ksfpaf7	1035	9	short	short	JJ
cord-034340-3ksfpaf7	1035	10	time	time	NN
cord-034340-3ksfpaf7	1035	11	(	(	-LRB-
cord-034340-3ksfpaf7	1035	12	<	<	NNP
cord-034340-3ksfpaf7	1035	13	15	15	CD
cord-034340-3ksfpaf7	1035	14	minutes	minute	NNS
cord-034340-3ksfpaf7	1035	15	)	)	-RRB-
cord-034340-3ksfpaf7	1035	16	and	and	CC
cord-034340-3ksfpaf7	1035	17	considered	consider	VBD
cord-034340-3ksfpaf7	1035	18	it	-PRON-	PRP
cord-034340-3ksfpaf7	1035	19	simple	simple	JJ
cord-034340-3ksfpaf7	1035	20	and	and	CC
cord-034340-3ksfpaf7	1035	21	easy	easy	JJ
cord-034340-3ksfpaf7	1035	22	to	to	TO
cord-034340-3ksfpaf7	1035	23	understand	understand	VB
cord-034340-3ksfpaf7	1035	24	.	.	.
cord-034340-3ksfpaf7	1036	1	JFS	JFS	NNP
cord-034340-3ksfpaf7	1036	2	patients	patient	NNS
cord-034340-3ksfpaf7	1036	3	showed	show	VBD
cord-034340-3ksfpaf7	1036	4	significantly	significantly	RB
cord-034340-3ksfpaf7	1036	5	higher	high	JJR
cord-034340-3ksfpaf7	1036	6	score	score	NN
cord-034340-3ksfpaf7	1036	7	for	for	IN
cord-034340-3ksfpaf7	1036	8	pain	pain	NN
cord-034340-3ksfpaf7	1036	9	,	,	,
cord-034340-3ksfpaf7	1036	10	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1036	11	,	,	,
cord-034340-3ksfpaf7	1036	12	poor	poor	JJ
cord-034340-3ksfpaf7	1036	13	physical	physical	JJ
cord-034340-3ksfpaf7	1036	14	function	function	NN
cord-034340-3ksfpaf7	1036	15	and	and	CC
cord-034340-3ksfpaf7	1036	16	measure	measure	NN
cord-034340-3ksfpaf7	1036	17	of	of	IN
cord-034340-3ksfpaf7	1036	18	psychological	psychological	JJ
cord-034340-3ksfpaf7	1036	19	distress	distress	NN
cord-034340-3ksfpaf7	1036	20	than	than	IN
cord-034340-3ksfpaf7	1036	21	healthy	healthy	JJ
cord-034340-3ksfpaf7	1036	22	controls	control	NNS
cord-034340-3ksfpaf7	1036	23	and	and	CC
cord-034340-3ksfpaf7	1036	24	JIA	JIA	NNP
cord-034340-3ksfpaf7	1036	25	patients	patient	NNS
cord-034340-3ksfpaf7	1036	26	(	(	-LRB-
cord-034340-3ksfpaf7	1036	27	p<0.05	p<0.05	CD
cord-034340-3ksfpaf7	1036	28	for	for	IN
cord-034340-3ksfpaf7	1036	29	each	each	DT
cord-034340-3ksfpaf7	1036	30	item	item	NN
cord-034340-3ksfpaf7	1036	31	)	)	-RRB-
cord-034340-3ksfpaf7	1036	32	.	.	.
cord-034340-3ksfpaf7	1037	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1037	2	:	:	:
cord-034340-3ksfpaf7	1037	3	JFS	JFS	NNP
cord-034340-3ksfpaf7	1037	4	patients	patient	NNS
cord-034340-3ksfpaf7	1037	5	presented	present	VBD
cord-034340-3ksfpaf7	1037	6	significantly	significantly	RB
cord-034340-3ksfpaf7	1037	7	higher	high	JJR
cord-034340-3ksfpaf7	1037	8	pain	pain	NN
cord-034340-3ksfpaf7	1037	9	experience	experience	NN
cord-034340-3ksfpaf7	1037	10	,	,	,
cord-034340-3ksfpaf7	1037	11	functional	functional	JJ
cord-034340-3ksfpaf7	1037	12	disability	disability	NN
cord-034340-3ksfpaf7	1037	13	,	,	,
cord-034340-3ksfpaf7	1037	14	and	and	CC
cord-034340-3ksfpaf7	1037	15	impaired	impaired	JJ
cord-034340-3ksfpaf7	1037	16	quality	quality	NN
cord-034340-3ksfpaf7	1037	17	of	of	IN
cord-034340-3ksfpaf7	1037	18	life	life	NN
cord-034340-3ksfpaf7	1037	19	than	than	IN
cord-034340-3ksfpaf7	1037	20	patients	patient	NNS
cord-034340-3ksfpaf7	1037	21	with	with	IN
cord-034340-3ksfpaf7	1037	22	active	active	JJ
cord-034340-3ksfpaf7	1037	23	JIA	JIA	NNP
cord-034340-3ksfpaf7	1037	24	.	.	.
cord-034340-3ksfpaf7	1038	1	A	a	DT
cord-034340-3ksfpaf7	1038	2	relevant	relevant	JJ
cord-034340-3ksfpaf7	1038	3	percentage	percentage	NN
cord-034340-3ksfpaf7	1038	4	of	of	IN
cord-034340-3ksfpaf7	1038	5	JFS	JFS	NNP
cord-034340-3ksfpaf7	1038	6	patients	patient	NNS
cord-034340-3ksfpaf7	1038	7	experience	experience	VBP
cord-034340-3ksfpaf7	1038	8	sleep	sleep	NN
cord-034340-3ksfpaf7	1038	9	disturbances	disturbance	NNS
cord-034340-3ksfpaf7	1038	10	,	,	,
cord-034340-3ksfpaf7	1038	11	which	which	WDT
cord-034340-3ksfpaf7	1038	12	were	be	VBD
cord-034340-3ksfpaf7	1038	13	correlated	correlate	VBN
cord-034340-3ksfpaf7	1038	14	with	with	IN
cord-034340-3ksfpaf7	1038	15	mood	mood	NN
cord-034340-3ksfpaf7	1038	16	and	and	CC
cord-034340-3ksfpaf7	1038	17	anxiety	anxiety	NN
cord-034340-3ksfpaf7	1038	18	disorders	disorder	NNS
cord-034340-3ksfpaf7	1038	19	.	.	.
cord-034340-3ksfpaf7	1039	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1039	2	multidimensional	multidimensional	JJ
cord-034340-3ksfpaf7	1039	3	tool	tool	NN
cord-034340-3ksfpaf7	1039	4	was	be	VBD
cord-034340-3ksfpaf7	1039	5	feasible	feasible	JJ
cord-034340-3ksfpaf7	1039	6	and	and	CC
cord-034340-3ksfpaf7	1039	7	able	able	JJ
cord-034340-3ksfpaf7	1039	8	to	to	TO
cord-034340-3ksfpaf7	1039	9	quantify	quantify	VB
cord-034340-3ksfpaf7	1039	10	global	global	JJ
cord-034340-3ksfpaf7	1039	11	JFS	JFS	NNP
cord-034340-3ksfpaf7	1039	12	severity	severity	NN
cord-034340-3ksfpaf7	1039	13	.	.	.
cord-034340-3ksfpaf7	1040	1	This	this	DT
cord-034340-3ksfpaf7	1040	2	multidimensional	multidimensional	JJ
cord-034340-3ksfpaf7	1040	3	tool	tool	NN
cord-034340-3ksfpaf7	1040	4	,	,	,
cord-034340-3ksfpaf7	1040	5	by	by	IN
cord-034340-3ksfpaf7	1040	6	measuring	measure	VBG
cord-034340-3ksfpaf7	1040	7	the	the	DT
cord-034340-3ksfpaf7	1040	8	main	main	JJ
cord-034340-3ksfpaf7	1040	9	domains	domain	NNS
cord-034340-3ksfpaf7	1040	10	affected	affect	VBN
cord-034340-3ksfpaf7	1040	11	by	by	IN
cord-034340-3ksfpaf7	1040	12	the	the	DT
cord-034340-3ksfpaf7	1040	13	disease	disease	NN
cord-034340-3ksfpaf7	1040	14	,	,	,
cord-034340-3ksfpaf7	1040	15	could	could	MD
cord-034340-3ksfpaf7	1040	16	be	be	VB
cord-034340-3ksfpaf7	1040	17	promising	promise	VBG
cord-034340-3ksfpaf7	1040	18	to	to	TO
cord-034340-3ksfpaf7	1040	19	individualize	individualize	VB
cord-034340-3ksfpaf7	1040	20	treatment	treatment	NN
cord-034340-3ksfpaf7	1040	21	strategy	strategy	NN
cord-034340-3ksfpaf7	1040	22	and	and	CC
cord-034340-3ksfpaf7	1040	23	to	to	TO
cord-034340-3ksfpaf7	1040	24	test	test	VB
cord-034340-3ksfpaf7	1040	25	its	-PRON-	PRP$
cord-034340-3ksfpaf7	1040	26	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1040	27	.	.	.
cord-034340-3ksfpaf7	1041	1	Disclosure	disclosure	NN
cord-034340-3ksfpaf7	1041	2	of	of	IN
cord-034340-3ksfpaf7	1041	3	Interest	Interest	NNP
cord-034340-3ksfpaf7	1042	1	:	:	:
cord-034340-3ksfpaf7	1042	2	None	none	NN
cord-034340-3ksfpaf7	1042	3	declared	declare	VBD
cord-034340-3ksfpaf7	1042	4	Introduction	introduction	NN
cord-034340-3ksfpaf7	1042	5	:	:	:
cord-034340-3ksfpaf7	1042	6	Fatigue	fatigue	NN
cord-034340-3ksfpaf7	1042	7	is	be	VBZ
cord-034340-3ksfpaf7	1042	8	a	a	DT
cord-034340-3ksfpaf7	1042	9	subjective	subjective	JJ
cord-034340-3ksfpaf7	1042	10	state	state	NN
cord-034340-3ksfpaf7	1042	11	of	of	IN
cord-034340-3ksfpaf7	1042	12	overwhelming	overwhelming	NN
cord-034340-3ksfpaf7	1042	13	,	,	,
cord-034340-3ksfpaf7	1042	14	sustained	sustained	JJ
cord-034340-3ksfpaf7	1042	15	exhaustion	exhaustion	NN
cord-034340-3ksfpaf7	1042	16	and	and	CC
cord-034340-3ksfpaf7	1042	17	decreased	decrease	VBD
cord-034340-3ksfpaf7	1042	18	physical	physical	JJ
cord-034340-3ksfpaf7	1042	19	and	and	CC
cord-034340-3ksfpaf7	1042	20	mental	mental	JJ
cord-034340-3ksfpaf7	1042	21	capacity	capacity	NN
cord-034340-3ksfpaf7	1042	22	,	,	,
cord-034340-3ksfpaf7	1042	23	which	which	WDT
cord-034340-3ksfpaf7	1042	24	is	be	VBZ
cord-034340-3ksfpaf7	1042	25	not	not	RB
cord-034340-3ksfpaf7	1042	26	relieved	relieve	VBN
cord-034340-3ksfpaf7	1042	27	by	by	IN
cord-034340-3ksfpaf7	1042	28	rest	rest	NN
cord-034340-3ksfpaf7	1042	29	.	.	.
cord-034340-3ksfpaf7	1043	1	Fatigue	fatigue	NN
cord-034340-3ksfpaf7	1043	2	is	be	VBZ
cord-034340-3ksfpaf7	1043	3	the	the	DT
cord-034340-3ksfpaf7	1043	4	most	most	RBS
cord-034340-3ksfpaf7	1043	5	common	common	JJ
cord-034340-3ksfpaf7	1043	6	complaint	complaint	NN
cord-034340-3ksfpaf7	1043	7	in	in	IN
cord-034340-3ksfpaf7	1043	8	children	child	NNS
cord-034340-3ksfpaf7	1043	9	and	and	CC
cord-034340-3ksfpaf7	1043	10	teens	teen	NNS
cord-034340-3ksfpaf7	1043	11	with	with	IN
cord-034340-3ksfpaf7	1043	12	an	an	DT
cord-034340-3ksfpaf7	1043	13	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1043	14	disease	disease	NN
cord-034340-3ksfpaf7	1043	15	,	,	,
cord-034340-3ksfpaf7	1043	16	besides	besides	IN
cord-034340-3ksfpaf7	1043	17	the	the	DT
cord-034340-3ksfpaf7	1043	18	disease	disease	NN
cord-034340-3ksfpaf7	1043	19	related	relate	VBN
cord-034340-3ksfpaf7	1043	20	flares	flare	NNS
cord-034340-3ksfpaf7	1043	21	.	.	.
cord-034340-3ksfpaf7	1044	1	The	the	DT
cord-034340-3ksfpaf7	1044	2	purpose	purpose	NN
cord-034340-3ksfpaf7	1044	3	for	for	IN
cord-034340-3ksfpaf7	1044	4	this	this	DT
cord-034340-3ksfpaf7	1044	5	study	study	NN
cord-034340-3ksfpaf7	1044	6	was	be	VBD
cord-034340-3ksfpaf7	1044	7	to	to	TO
cord-034340-3ksfpaf7	1044	8	show	show	VB
cord-034340-3ksfpaf7	1044	9	that	that	IN
cord-034340-3ksfpaf7	1044	10	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1044	11	is	be	VBZ
cord-034340-3ksfpaf7	1044	12	a	a	DT
cord-034340-3ksfpaf7	1044	13	serious	serious	JJ
cord-034340-3ksfpaf7	1044	14	issue	issue	NN
cord-034340-3ksfpaf7	1044	15	for	for	IN
cord-034340-3ksfpaf7	1044	16	children	child	NNS
cord-034340-3ksfpaf7	1044	17	and	and	CC
cord-034340-3ksfpaf7	1044	18	young	young	JJ
cord-034340-3ksfpaf7	1044	19	people	people	NNS
cord-034340-3ksfpaf7	1044	20	with	with	IN
cord-034340-3ksfpaf7	1044	21	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1044	22	diseases	disease	NNS
cord-034340-3ksfpaf7	1044	23	.	.	.
cord-034340-3ksfpaf7	1045	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1045	2	hypothesized	hypothesize	VBD
cord-034340-3ksfpaf7	1045	3	that	that	DT
cord-034340-3ksfpaf7	1045	4	age	age	NN
cord-034340-3ksfpaf7	1045	5	,	,	,
cord-034340-3ksfpaf7	1045	6	gender	gender	NN
cord-034340-3ksfpaf7	1045	7	and/	and/	CD
cord-034340-3ksfpaf7	1045	8	or	or	CC
cord-034340-3ksfpaf7	1045	9	the	the	DT
cord-034340-3ksfpaf7	1045	10	type	type	NN
cord-034340-3ksfpaf7	1045	11	of	of	IN
cord-034340-3ksfpaf7	1045	12	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1045	13	disease	disease	NN
cord-034340-3ksfpaf7	1045	14	could	could	MD
cord-034340-3ksfpaf7	1045	15	have	have	VB
cord-034340-3ksfpaf7	1045	16	differing	differ	VBG
cord-034340-3ksfpaf7	1045	17	effects	effect	NNS
cord-034340-3ksfpaf7	1045	18	on	on	IN
cord-034340-3ksfpaf7	1045	19	the	the	DT
cord-034340-3ksfpaf7	1045	20	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1045	21	experience	experience	NN
cord-034340-3ksfpaf7	1045	22	.	.	.
cord-034340-3ksfpaf7	1046	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1046	2	:	:	:
cord-034340-3ksfpaf7	1046	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1046	4	aimed	aim	VBD
cord-034340-3ksfpaf7	1046	5	to	to	TO
cord-034340-3ksfpaf7	1046	6	investigate	investigate	VB
cord-034340-3ksfpaf7	1046	7	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1046	8	in	in	IN
cord-034340-3ksfpaf7	1046	9	children	child	NNS
cord-034340-3ksfpaf7	1046	10	and	and	CC
cord-034340-3ksfpaf7	1046	11	young	young	JJ
cord-034340-3ksfpaf7	1046	12	people	people	NNS
cord-034340-3ksfpaf7	1046	13	(	(	-LRB-
cord-034340-3ksfpaf7	1046	14	CYP	CYP	NNP
cord-034340-3ksfpaf7	1046	15	)	)	-RRB-
cord-034340-3ksfpaf7	1046	16	with	with	IN
cord-034340-3ksfpaf7	1046	17	autoinflammatory	autoinflammatory	NNP
cord-034340-3ksfpaf7	1046	18	disease	disease	NN
cord-034340-3ksfpaf7	1046	19	,	,	,
cord-034340-3ksfpaf7	1046	20	including	include	VBG
cord-034340-3ksfpaf7	1046	21	how	how	WRB
cord-034340-3ksfpaf7	1046	22	this	this	DT
cord-034340-3ksfpaf7	1046	23	affected	affect	VBD
cord-034340-3ksfpaf7	1046	24	them	-PRON-	PRP
cord-034340-3ksfpaf7	1046	25	on	on	IN
cord-034340-3ksfpaf7	1046	26	a	a	DT
cord-034340-3ksfpaf7	1046	27	daily	daily	JJ
cord-034340-3ksfpaf7	1046	28	basis	basis	NN
cord-034340-3ksfpaf7	1046	29	.	.	.
cord-034340-3ksfpaf7	1047	1	Methods	method	NNS
cord-034340-3ksfpaf7	1047	2	:	:	:
cord-034340-3ksfpaf7	1047	3	CYP	CYP	NNP
cord-034340-3ksfpaf7	1047	4	with	with	IN
cord-034340-3ksfpaf7	1047	5	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1047	6	diseases	disease	NNS
cord-034340-3ksfpaf7	1047	7	were	be	VBD
cord-034340-3ksfpaf7	1047	8	invited	invite	VBN
cord-034340-3ksfpaf7	1047	9	to	to	TO
cord-034340-3ksfpaf7	1047	10	complete	complete	VB
cord-034340-3ksfpaf7	1047	11	an	an	DT
cord-034340-3ksfpaf7	1047	12	online	online	JJ
cord-034340-3ksfpaf7	1047	13	survey	survey	NN
cord-034340-3ksfpaf7	1047	14	,	,	,
cord-034340-3ksfpaf7	1047	15	providing	provide	VBG
cord-034340-3ksfpaf7	1047	16	details	detail	NNS
cord-034340-3ksfpaf7	1047	17	about	about	IN
cord-034340-3ksfpaf7	1047	18	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1047	19	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1047	20	and	and	CC
cord-034340-3ksfpaf7	1047	21	how	how	WRB
cord-034340-3ksfpaf7	1047	22	it	-PRON-	PRP
cord-034340-3ksfpaf7	1047	23	affected	affect	VBD
cord-034340-3ksfpaf7	1047	24	them	-PRON-	PRP
cord-034340-3ksfpaf7	1047	25	.	.	.
cord-034340-3ksfpaf7	1048	1	The	the	DT
cord-034340-3ksfpaf7	1048	2	survey	survey	NN
cord-034340-3ksfpaf7	1048	3	was	be	VBD
cord-034340-3ksfpaf7	1048	4	developed	develop	VBN
cord-034340-3ksfpaf7	1048	5	by	by	IN
cord-034340-3ksfpaf7	1048	6	the	the	DT
cord-034340-3ksfpaf7	1048	7	non	non	JJ
cord-034340-3ksfpaf7	1048	8	-	-	JJ
cord-034340-3ksfpaf7	1048	9	profit	profit	JJ
cord-034340-3ksfpaf7	1048	10	organizations	organization	NNS
cord-034340-3ksfpaf7	1048	11	Autoinflammatory	Autoinflammatory	NNP
cord-034340-3ksfpaf7	1048	12	Alliance	Alliance	NNP
cord-034340-3ksfpaf7	1048	13	and	and	CC
cord-034340-3ksfpaf7	1048	14	KAISZ	KAISZ	NNP
cord-034340-3ksfpaf7	1048	15	/	/	SYM
cord-034340-3ksfpaf7	1048	16	VAISZ	VAISZ	NNP
cord-034340-3ksfpaf7	1048	17	,	,	,
cord-034340-3ksfpaf7	1048	18	in	in	IN
cord-034340-3ksfpaf7	1048	19	English	English	NNP
cord-034340-3ksfpaf7	1048	20	.	.	.
cord-034340-3ksfpaf7	1049	1	Respondents	respondent	NNS
cord-034340-3ksfpaf7	1049	2	were	be	VBD
cord-034340-3ksfpaf7	1049	3	recruited	recruit	VBN
cord-034340-3ksfpaf7	1049	4	by	by	IN
cord-034340-3ksfpaf7	1049	5	convenience	convenience	NN
cord-034340-3ksfpaf7	1049	6	sampling	sampling	NN
cord-034340-3ksfpaf7	1049	7	through	through	IN
cord-034340-3ksfpaf7	1049	8	online	online	JJ
cord-034340-3ksfpaf7	1049	9	social	social	JJ
cord-034340-3ksfpaf7	1049	10	media	medium	NNS
cord-034340-3ksfpaf7	1049	11	posts	post	NNS
cord-034340-3ksfpaf7	1049	12	.	.	.
cord-034340-3ksfpaf7	1050	1	Data	datum	NNS
cord-034340-3ksfpaf7	1050	2	on	on	IN
cord-034340-3ksfpaf7	1050	3	age	age	NN
cord-034340-3ksfpaf7	1050	4	,	,	,
cord-034340-3ksfpaf7	1050	5	gender	gender	NN
cord-034340-3ksfpaf7	1050	6	and	and	CC
cord-034340-3ksfpaf7	1050	7	disease	disease	NN
cord-034340-3ksfpaf7	1050	8	were	be	VBD
cord-034340-3ksfpaf7	1050	9	collected	collect	VBN
cord-034340-3ksfpaf7	1050	10	in	in	IN
cord-034340-3ksfpaf7	1050	11	addition	addition	NN
cord-034340-3ksfpaf7	1050	12	to	to	IN
cord-034340-3ksfpaf7	1050	13	information	information	NN
cord-034340-3ksfpaf7	1050	14	on	on	IN
cord-034340-3ksfpaf7	1050	15	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1050	16	experience	experience	NN
cord-034340-3ksfpaf7	1050	17	of	of	IN
cord-034340-3ksfpaf7	1050	18	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1050	19	on	on	IN
cord-034340-3ksfpaf7	1050	20	school	school	NN
cord-034340-3ksfpaf7	1050	21	and	and	CC
cord-034340-3ksfpaf7	1050	22	social	social	JJ
cord-034340-3ksfpaf7	1050	23	interaction	interaction	NN
cord-034340-3ksfpaf7	1050	24	.	.	.
cord-034340-3ksfpaf7	1051	1	A	a	DT
cord-034340-3ksfpaf7	1051	2	total	total	NN
cord-034340-3ksfpaf7	1051	3	of	of	IN
cord-034340-3ksfpaf7	1051	4	114	114	CD
cord-034340-3ksfpaf7	1051	5	CYP	CYP	NNP
cord-034340-3ksfpaf7	1051	6	(	(	-LRB-
cord-034340-3ksfpaf7	1051	7	age	age	NN
cord-034340-3ksfpaf7	1051	8	range	range	VBP
cord-034340-3ksfpaf7	1051	9	7	7	CD
cord-034340-3ksfpaf7	1051	10	-	-	SYM
cord-034340-3ksfpaf7	1051	11	18	18	CD
cord-034340-3ksfpaf7	1051	12	years	year	NNS
cord-034340-3ksfpaf7	1051	13	)	)	-RRB-
cord-034340-3ksfpaf7	1051	14	with	with	IN
cord-034340-3ksfpaf7	1051	15	an	an	DT
cord-034340-3ksfpaf7	1051	16	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1051	17	disease	disease	NN
cord-034340-3ksfpaf7	1051	18	responded	respond	VBD
cord-034340-3ksfpaf7	1051	19	to	to	IN
cord-034340-3ksfpaf7	1051	20	the	the	DT
cord-034340-3ksfpaf7	1051	21	survey	survey	NN
cord-034340-3ksfpaf7	1051	22	(	(	-LRB-
cord-034340-3ksfpaf7	1051	23	52	52	CD
cord-034340-3ksfpaf7	1051	24	%	%	NN
cord-034340-3ksfpaf7	1051	25	female	female	NN
cord-034340-3ksfpaf7	1051	26	)	)	-RRB-
cord-034340-3ksfpaf7	1051	27	.	.	.
cord-034340-3ksfpaf7	1052	1	Results	result	NNS
cord-034340-3ksfpaf7	1052	2	:	:	:
cord-034340-3ksfpaf7	1053	1	The	the	DT
cord-034340-3ksfpaf7	1053	2	majority	majority	NN
cord-034340-3ksfpaf7	1053	3	of	of	IN
cord-034340-3ksfpaf7	1053	4	respondents	respondent	NNS
cord-034340-3ksfpaf7	1053	5	(	(	-LRB-
cord-034340-3ksfpaf7	1053	6	81	81	CD
cord-034340-3ksfpaf7	1053	7	%	%	NN
cord-034340-3ksfpaf7	1053	8	)	)	-RRB-
cord-034340-3ksfpaf7	1053	9	reported	report	VBD
cord-034340-3ksfpaf7	1053	10	experiencing	experience	VBG
cord-034340-3ksfpaf7	1053	11	both	both	DT
cord-034340-3ksfpaf7	1053	12	mental	mental	JJ
cord-034340-3ksfpaf7	1053	13	and	and	CC
cord-034340-3ksfpaf7	1053	14	physical	physical	JJ
cord-034340-3ksfpaf7	1053	15	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1053	16	.	.	.
cord-034340-3ksfpaf7	1054	1	Respondents	respondent	NNS
cord-034340-3ksfpaf7	1054	2	were	be	VBD
cord-034340-3ksfpaf7	1054	3	asked	ask	VBN
cord-034340-3ksfpaf7	1054	4	how	how	WRB
cord-034340-3ksfpaf7	1054	5	much	much	JJ
cord-034340-3ksfpaf7	1054	6	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1054	7	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1054	8	affected	affect	VBD
cord-034340-3ksfpaf7	1054	9	them	-PRON-	PRP
cord-034340-3ksfpaf7	1054	10	,	,	,
cord-034340-3ksfpaf7	1054	11	on	on	IN
cord-034340-3ksfpaf7	1054	12	a	a	DT
cord-034340-3ksfpaf7	1054	13	scale	scale	NN
cord-034340-3ksfpaf7	1054	14	of	of	IN
cord-034340-3ksfpaf7	1054	15	0	0	CD
cord-034340-3ksfpaf7	1054	16	to	to	IN
cord-034340-3ksfpaf7	1054	17	10	10	CD
cord-034340-3ksfpaf7	1054	18	;	;	:
cord-034340-3ksfpaf7	1054	19	overall	overall	RB
cord-034340-3ksfpaf7	1054	20	,	,	,
cord-034340-3ksfpaf7	1054	21	the	the	DT
cord-034340-3ksfpaf7	1054	22	mean	mean	JJ
cord-034340-3ksfpaf7	1054	23	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1054	24	score	score	NN
cord-034340-3ksfpaf7	1054	25	was	be	VBD
cord-034340-3ksfpaf7	1054	26	6.6	6.6	CD
cord-034340-3ksfpaf7	1054	27	.	.	.
cord-034340-3ksfpaf7	1055	1	However	however	RB
cord-034340-3ksfpaf7	1055	2	,	,	,
cord-034340-3ksfpaf7	1055	3	young	young	JJ
cord-034340-3ksfpaf7	1055	4	people	people	NNS
cord-034340-3ksfpaf7	1055	5	aged	age	VBN
cord-034340-3ksfpaf7	1055	6	15	15	CD
cord-034340-3ksfpaf7	1055	7	or	or	CC
cord-034340-3ksfpaf7	1055	8	over	over	RB
cord-034340-3ksfpaf7	1055	9	reported	report	VBN
cord-034340-3ksfpaf7	1055	10	a	a	DT
cord-034340-3ksfpaf7	1055	11	significantly	significantly	RB
cord-034340-3ksfpaf7	1055	12	higher	high	JJR
cord-034340-3ksfpaf7	1055	13	impact	impact	NN
cord-034340-3ksfpaf7	1055	14	than	than	IN
cord-034340-3ksfpaf7	1055	15	those	those	DT
cord-034340-3ksfpaf7	1055	16	aged	age	VBN
cord-034340-3ksfpaf7	1055	17	11	11	CD
cord-034340-3ksfpaf7	1055	18	-	-	SYM
cord-034340-3ksfpaf7	1055	19	14	14	CD
cord-034340-3ksfpaf7	1055	20	years	year	NNS
cord-034340-3ksfpaf7	1055	21	(	(	-LRB-
cord-034340-3ksfpaf7	1055	22	mean	mean	VB
cord-034340-3ksfpaf7	1055	23	7.5	7.5	CD
cord-034340-3ksfpaf7	1055	24	,	,	,
cord-034340-3ksfpaf7	1055	25	p=0.012	p=0.012	NNP
cord-034340-3ksfpaf7	1055	26	)	)	-RRB-
cord-034340-3ksfpaf7	1055	27	.	.	.
cord-034340-3ksfpaf7	1056	1	Different	different	JJ
cord-034340-3ksfpaf7	1056	2	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1056	3	diseases	disease	NNS
cord-034340-3ksfpaf7	1056	4	were	be	VBD
cord-034340-3ksfpaf7	1056	5	surveyed	survey	VBN
cord-034340-3ksfpaf7	1056	6	:	:	:
cord-034340-3ksfpaf7	1056	7	CRMO	CRMO	NNP
cord-034340-3ksfpaf7	1056	8	25	25	CD
cord-034340-3ksfpaf7	1056	9	%	%	NN
cord-034340-3ksfpaf7	1056	10	,	,	,
cord-034340-3ksfpaf7	1056	11	CAPS	cap	NNS
cord-034340-3ksfpaf7	1056	12	20	20	CD
cord-034340-3ksfpaf7	1056	13	%	%	NN
cord-034340-3ksfpaf7	1056	14	,	,	,
cord-034340-3ksfpaf7	1056	15	PFAPA	PFAPA	NNP
cord-034340-3ksfpaf7	1056	16	12	12	CD
cord-034340-3ksfpaf7	1056	17	%	%	NN
cord-034340-3ksfpaf7	1056	18	also	also	RB
cord-034340-3ksfpaf7	1056	19	Unclassified	Unclassified	NNP
cord-034340-3ksfpaf7	1056	20	SAID	say	VBD
cord-034340-3ksfpaf7	1056	21	(	(	-LRB-
cord-034340-3ksfpaf7	1056	22	uSAID	usaid	LS
cord-034340-3ksfpaf7	1056	23	)	)	-RRB-
cord-034340-3ksfpaf7	1056	24	with	with	IN
cord-034340-3ksfpaf7	1056	25	23	23	CD
cord-034340-3ksfpaf7	1056	26	%	%	NN
cord-034340-3ksfpaf7	1056	27	.	.	.
cord-034340-3ksfpaf7	1057	1	In	in	IN
cord-034340-3ksfpaf7	1057	2	the	the	DT
cord-034340-3ksfpaf7	1057	3	open	open	JJ
cord-034340-3ksfpaf7	1057	4	-	-	HYPH
cord-034340-3ksfpaf7	1057	5	response	response	NN
cord-034340-3ksfpaf7	1057	6	portion	portion	NN
cord-034340-3ksfpaf7	1057	7	of	of	IN
cord-034340-3ksfpaf7	1057	8	the	the	DT
cord-034340-3ksfpaf7	1057	9	survey	survey	NN
cord-034340-3ksfpaf7	1057	10	,	,	,
cord-034340-3ksfpaf7	1057	11	81	81	CD
cord-034340-3ksfpaf7	1057	12	%	%	NN
cord-034340-3ksfpaf7	1057	13	of	of	IN
cord-034340-3ksfpaf7	1057	14	respondents	respondent	NNS
cord-034340-3ksfpaf7	1057	15	reported	report	VBN
cord-034340-3ksfpaf7	1057	16	that	that	IN
cord-034340-3ksfpaf7	1057	17	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1057	18	was	be	VBD
cord-034340-3ksfpaf7	1057	19	physical	physical	JJ
cord-034340-3ksfpaf7	1057	20	,	,	,
cord-034340-3ksfpaf7	1057	21	as	as	RB
cord-034340-3ksfpaf7	1057	22	well	well	RB
cord-034340-3ksfpaf7	1057	23	as	as	IN
cord-034340-3ksfpaf7	1057	24	mental	mental	JJ
cord-034340-3ksfpaf7	1057	25	,	,	,
cord-034340-3ksfpaf7	1057	26	in	in	IN
cord-034340-3ksfpaf7	1057	27	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1057	28	experience	experience	NN
cord-034340-3ksfpaf7	1057	29	.	.	.
cord-034340-3ksfpaf7	1058	1	Most	Most	JJS
cord-034340-3ksfpaf7	1058	2	(	(	-LRB-
cord-034340-3ksfpaf7	1058	3	89	89	CD
cord-034340-3ksfpaf7	1058	4	%	%	NN
cord-034340-3ksfpaf7	1058	5	)	)	-RRB-
cord-034340-3ksfpaf7	1058	6	reported	report	VBD
cord-034340-3ksfpaf7	1058	7	that	that	IN
cord-034340-3ksfpaf7	1058	8	someone	someone	NN
cord-034340-3ksfpaf7	1058	9	had	have	VBD
cord-034340-3ksfpaf7	1058	10	doubted	doubt	VBN
cord-034340-3ksfpaf7	1058	11	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1058	12	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1058	13	in	in	IN
cord-034340-3ksfpaf7	1058	14	the	the	DT
cord-034340-3ksfpaf7	1058	15	past	past	NN
cord-034340-3ksfpaf7	1058	16	;	;	:
cord-034340-3ksfpaf7	1058	17	29	29	CD
cord-034340-3ksfpaf7	1058	18	%	%	NN
cord-034340-3ksfpaf7	1058	19	had	have	VBD
cord-034340-3ksfpaf7	1058	20	found	find	VBN
cord-034340-3ksfpaf7	1058	21	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1058	22	teachers	teacher	NNS
cord-034340-3ksfpaf7	1058	23	had	have	VBD
cord-034340-3ksfpaf7	1058	24	doubted	doubt	VBN
cord-034340-3ksfpaf7	1058	25	them	-PRON-	PRP
cord-034340-3ksfpaf7	1058	26	,	,	,
cord-034340-3ksfpaf7	1058	27	26	26	CD
cord-034340-3ksfpaf7	1058	28	%	%	NN
cord-034340-3ksfpaf7	1058	29	had	have	VBD
cord-034340-3ksfpaf7	1058	30	friends	friend	NNS
cord-034340-3ksfpaf7	1058	31	who	who	WP
cord-034340-3ksfpaf7	1058	32	doubted	doubt	VBD
cord-034340-3ksfpaf7	1058	33	them	-PRON-	PRP
cord-034340-3ksfpaf7	1058	34	,	,	,
cord-034340-3ksfpaf7	1058	35	and	and	CC
cord-034340-3ksfpaf7	1058	36	24	24	CD
cord-034340-3ksfpaf7	1058	37	%	%	NN
cord-034340-3ksfpaf7	1058	38	reported	report	VBD
cord-034340-3ksfpaf7	1058	39	that	that	IN
cord-034340-3ksfpaf7	1058	40	they	-PRON-	PRP
cord-034340-3ksfpaf7	1058	41	felt	feel	VBD
cord-034340-3ksfpaf7	1058	42	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1058	43	doctors	doctor	NNS
cord-034340-3ksfpaf7	1058	44	had	have	VBD
cord-034340-3ksfpaf7	1058	45	doubted	doubt	VBN
cord-034340-3ksfpaf7	1058	46	them	-PRON-	PRP
cord-034340-3ksfpaf7	1058	47	.	.	.
cord-034340-3ksfpaf7	1059	1	Children	child	NNS
cord-034340-3ksfpaf7	1059	2	and	and	CC
cord-034340-3ksfpaf7	1059	3	young	young	JJ
cord-034340-3ksfpaf7	1059	4	people	people	NNS
cord-034340-3ksfpaf7	1059	5	also	also	RB
cord-034340-3ksfpaf7	1059	6	felt	feel	VBD
cord-034340-3ksfpaf7	1059	7	a	a	DT
cord-034340-3ksfpaf7	1059	8	number	number	NN
cord-034340-3ksfpaf7	1059	9	of	of	IN
cord-034340-3ksfpaf7	1059	10	activities	activity	NNS
cord-034340-3ksfpaf7	1059	11	made	make	VBD
cord-034340-3ksfpaf7	1059	12	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1059	13	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1059	14	worse	bad	JJR
cord-034340-3ksfpaf7	1059	15	(	(	-LRB-
cord-034340-3ksfpaf7	1059	16	table	table	NN
cord-034340-3ksfpaf7	1059	17	1	1	CD
cord-034340-3ksfpaf7	1059	18	)	)	-RRB-
cord-034340-3ksfpaf7	1059	19	.	.	.
cord-034340-3ksfpaf7	1060	1	"	"	''
cord-034340-3ksfpaf7	1061	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1061	2	:	:	:
cord-034340-3ksfpaf7	1061	3	CYP	CYP	NNP
cord-034340-3ksfpaf7	1061	4	with	with	IN
cord-034340-3ksfpaf7	1061	5	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1061	6	diseases	disease	NNS
cord-034340-3ksfpaf7	1061	7	experience	experience	VBP
cord-034340-3ksfpaf7	1061	8	physical	physical	JJ
cord-034340-3ksfpaf7	1061	9	and	and	CC
cord-034340-3ksfpaf7	1061	10	mental	mental	JJ
cord-034340-3ksfpaf7	1061	11	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1061	12	.	.	.
cord-034340-3ksfpaf7	1062	1	Health	health	NN
cord-034340-3ksfpaf7	1062	2	professionals	professional	NNS
cord-034340-3ksfpaf7	1062	3	and	and	CC
cord-034340-3ksfpaf7	1062	4	teachers	teacher	NNS
cord-034340-3ksfpaf7	1062	5	should	should	MD
cord-034340-3ksfpaf7	1062	6	listen	listen	VB
cord-034340-3ksfpaf7	1062	7	to	to	IN
cord-034340-3ksfpaf7	1062	8	patients	patient	NNS
cord-034340-3ksfpaf7	1062	9	reporting	report	VBG
cord-034340-3ksfpaf7	1062	10	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1062	11	,	,	,
cord-034340-3ksfpaf7	1062	12	validate	validate	VBP
cord-034340-3ksfpaf7	1062	13	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1062	14	experience	experience	NN
cord-034340-3ksfpaf7	1062	15	,	,	,
cord-034340-3ksfpaf7	1062	16	and	and	CC
cord-034340-3ksfpaf7	1062	17	help	help	VB
cord-034340-3ksfpaf7	1062	18	find	find	VB
cord-034340-3ksfpaf7	1062	19	ways	way	NNS
cord-034340-3ksfpaf7	1062	20	to	to	TO
cord-034340-3ksfpaf7	1062	21	support	support	VB
cord-034340-3ksfpaf7	1062	22	them	-PRON-	PRP
cord-034340-3ksfpaf7	1062	23	.	.	.
cord-034340-3ksfpaf7	1063	1	Identifying	identify	VBG
cord-034340-3ksfpaf7	1063	2	resources	resource	NNS
cord-034340-3ksfpaf7	1063	3	to	to	TO
cord-034340-3ksfpaf7	1063	4	help	help	VB
cord-034340-3ksfpaf7	1063	5	the	the	DT
cord-034340-3ksfpaf7	1063	6	patients	patient	NNS
cord-034340-3ksfpaf7	1063	7	with	with	IN
cord-034340-3ksfpaf7	1063	8	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1063	9	,	,	,
cord-034340-3ksfpaf7	1063	10	and	and	CC
cord-034340-3ksfpaf7	1063	11	referrals	referral	NNS
cord-034340-3ksfpaf7	1063	12	to	to	IN
cord-034340-3ksfpaf7	1063	13	therapy	therapy	NN
cord-034340-3ksfpaf7	1063	14	and	and	CC
cord-034340-3ksfpaf7	1063	15	mental	mental	JJ
cord-034340-3ksfpaf7	1063	16	health	health	NN
cord-034340-3ksfpaf7	1063	17	resources	resource	NNS
cord-034340-3ksfpaf7	1063	18	as	as	IN
cord-034340-3ksfpaf7	1063	19	needed	need	VBN
cord-034340-3ksfpaf7	1063	20	may	may	MD
cord-034340-3ksfpaf7	1063	21	help	help	VB
cord-034340-3ksfpaf7	1063	22	the	the	DT
cord-034340-3ksfpaf7	1063	23	patients	patient	NNS
cord-034340-3ksfpaf7	1063	24	to	to	TO
cord-034340-3ksfpaf7	1063	25	better	well	RBR
cord-034340-3ksfpaf7	1063	26	cope	cope	VB
cord-034340-3ksfpaf7	1063	27	and	and	CC
cord-034340-3ksfpaf7	1063	28	manage	manage	VB
cord-034340-3ksfpaf7	1063	29	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1063	30	chronic	chronic	JJ
cord-034340-3ksfpaf7	1063	31	disease	disease	NN
cord-034340-3ksfpaf7	1063	32	.	.	.
cord-034340-3ksfpaf7	1064	1	Further	further	JJ
cord-034340-3ksfpaf7	1064	2	studies	study	NNS
cord-034340-3ksfpaf7	1064	3	will	will	MD
cord-034340-3ksfpaf7	1064	4	include	include	VB
cord-034340-3ksfpaf7	1064	5	patient	patient	JJ
cord-034340-3ksfpaf7	1064	6	engagement	engagement	NN
cord-034340-3ksfpaf7	1064	7	in	in	IN
cord-034340-3ksfpaf7	1064	8	designing	design	VBG
cord-034340-3ksfpaf7	1064	9	questionnaires	questionnaire	NNS
cord-034340-3ksfpaf7	1064	10	about	about	IN
cord-034340-3ksfpaf7	1064	11	all	all	DT
cord-034340-3ksfpaf7	1064	12	aspects	aspect	NNS
cord-034340-3ksfpaf7	1064	13	of	of	IN
cord-034340-3ksfpaf7	1064	14	life	life	NN
cord-034340-3ksfpaf7	1064	15	and	and	CC
cord-034340-3ksfpaf7	1064	16	autoinflammatory	autoinflammatory	NNP
cord-034340-3ksfpaf7	1064	17	disease	disease	NN
cord-034340-3ksfpaf7	1064	18	will	will	MD
cord-034340-3ksfpaf7	1064	19	help	help	VB
cord-034340-3ksfpaf7	1064	20	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1064	21	understanding	understanding	NN
cord-034340-3ksfpaf7	1064	22	of	of	IN
cord-034340-3ksfpaf7	1064	23	these	these	DT
cord-034340-3ksfpaf7	1064	24	complex	complex	JJ
cord-034340-3ksfpaf7	1064	25	conditions	condition	NNS
cord-034340-3ksfpaf7	1064	26	and	and	CC
cord-034340-3ksfpaf7	1064	27	how	how	WRB
cord-034340-3ksfpaf7	1064	28	they	-PRON-	PRP
cord-034340-3ksfpaf7	1064	29	affect	affect	VBP
cord-034340-3ksfpaf7	1064	30	patients	patient	NNS
cord-034340-3ksfpaf7	1064	31	.	.	.
cord-034340-3ksfpaf7	1065	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1065	2	:	:	:
cord-034340-3ksfpaf7	1066	1	Scleromyositis	Scleromyositis	NNP
cord-034340-3ksfpaf7	1066	2	is	be	VBZ
cord-034340-3ksfpaf7	1066	3	the	the	DT
cord-034340-3ksfpaf7	1066	4	most	most	RBS
cord-034340-3ksfpaf7	1066	5	common	common	JJ
cord-034340-3ksfpaf7	1066	6	overlap	overlap	NN
cord-034340-3ksfpaf7	1066	7	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1066	8	but	but	CC
cord-034340-3ksfpaf7	1066	9	is	be	VBZ
cord-034340-3ksfpaf7	1066	10	rarely	rarely	RB
cord-034340-3ksfpaf7	1066	11	observed	observe	VBN
cord-034340-3ksfpaf7	1066	12	in	in	IN
cord-034340-3ksfpaf7	1066	13	childhood	childhood	NN
cord-034340-3ksfpaf7	1066	14	.	.	.
cord-034340-3ksfpaf7	1067	1	This	this	DT
cord-034340-3ksfpaf7	1067	2	disorder	disorder	NN
cord-034340-3ksfpaf7	1067	3	involves	involve	VBZ
cord-034340-3ksfpaf7	1067	4	two	two	CD
cord-034340-3ksfpaf7	1067	5	different	different	JJ
cord-034340-3ksfpaf7	1067	6	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1067	7	diseases	disease	NNS
cord-034340-3ksfpaf7	1067	8	:	:	:
cord-034340-3ksfpaf7	1067	9	systemic	systemic	JJ
cord-034340-3ksfpaf7	1067	10	scleroderma	scleroderma	NNS
cord-034340-3ksfpaf7	1067	11	(	(	-LRB-
cord-034340-3ksfpaf7	1067	12	SSc	SSc	NNS
cord-034340-3ksfpaf7	1067	13	)	)	-RRB-
cord-034340-3ksfpaf7	1067	14	and	and	CC
cord-034340-3ksfpaf7	1067	15	polymyositis	polymyositis	NNP
cord-034340-3ksfpaf7	1067	16	(	(	-LRB-
cord-034340-3ksfpaf7	1067	17	PM	PM	NNP
cord-034340-3ksfpaf7	1067	18	)	)	-RRB-
cord-034340-3ksfpaf7	1067	19	.	.	.
cord-034340-3ksfpaf7	1068	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1068	2	:	:	:
cord-034340-3ksfpaf7	1068	3	To	to	TO
cord-034340-3ksfpaf7	1068	4	describe	describe	VB
cord-034340-3ksfpaf7	1068	5	the	the	DT
cord-034340-3ksfpaf7	1068	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	1068	7	course	course	NN
cord-034340-3ksfpaf7	1068	8	of	of	IN
cord-034340-3ksfpaf7	1068	9	a	a	DT
cord-034340-3ksfpaf7	1068	10	SSc	SSc	NNS
cord-034340-3ksfpaf7	1068	11	/	/	SYM
cord-034340-3ksfpaf7	1068	12	PM	pm	NN
cord-034340-3ksfpaf7	1068	13	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1068	14	in	in	IN
cord-034340-3ksfpaf7	1068	15	a	a	DT
cord-034340-3ksfpaf7	1068	16	young	young	JJ
cord-034340-3ksfpaf7	1068	17	girl	girl	NN
cord-034340-3ksfpaf7	1068	18	.	.	.
cord-034340-3ksfpaf7	1069	1	Methods	method	NNS
cord-034340-3ksfpaf7	1069	2	:	:	:
cord-034340-3ksfpaf7	1070	1	Case	case	NN
cord-034340-3ksfpaf7	1070	2	report	report	NN
cord-034340-3ksfpaf7	1070	3	Results	result	NNS
cord-034340-3ksfpaf7	1070	4	:	:	:
cord-034340-3ksfpaf7	1070	5	An	an	DT
cord-034340-3ksfpaf7	1070	6	11-year	11-year	JJ
cord-034340-3ksfpaf7	1070	7	-	-	HYPH
cord-034340-3ksfpaf7	1070	8	old	old	JJ
cord-034340-3ksfpaf7	1070	9	female	female	NN
cord-034340-3ksfpaf7	1070	10	was	be	VBD
cord-034340-3ksfpaf7	1070	11	admitted	admit	VBN
cord-034340-3ksfpaf7	1070	12	to	to	IN
cord-034340-3ksfpaf7	1070	13	the	the	DT
cord-034340-3ksfpaf7	1070	14	Neurological	Neurological	NNP
cord-034340-3ksfpaf7	1070	15	Unit	Unit	NNP
cord-034340-3ksfpaf7	1070	16	of	of	IN
cord-034340-3ksfpaf7	1070	17	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1070	18	hospital	hospital	NN
cord-034340-3ksfpaf7	1070	19	for	for	IN
cord-034340-3ksfpaf7	1070	20	creatine	creatine	NN
cord-034340-3ksfpaf7	1070	21	phosphokinase	phosphokinase	NN
cord-034340-3ksfpaf7	1070	22	(	(	-LRB-
cord-034340-3ksfpaf7	1070	23	CPK	CPK	NNP
cord-034340-3ksfpaf7	1070	24	)	)	-RRB-
cord-034340-3ksfpaf7	1070	25	increase	increase	NN
cord-034340-3ksfpaf7	1070	26	and	and	CC
cord-034340-3ksfpaf7	1070	27	hypertransaminasemia	hypertransaminasemia	NN
cord-034340-3ksfpaf7	1070	28	associated	associate	VBN
cord-034340-3ksfpaf7	1070	29	to	to	IN
cord-034340-3ksfpaf7	1070	30	sporadic	sporadic	JJ
cord-034340-3ksfpaf7	1070	31	episodes	episode	NNS
cord-034340-3ksfpaf7	1070	32	of	of	IN
cord-034340-3ksfpaf7	1070	33	right	right	JJ
cord-034340-3ksfpaf7	1070	34	calf	calf	NN
cord-034340-3ksfpaf7	1070	35	pain	pain	NN
cord-034340-3ksfpaf7	1070	36	.	.	.
cord-034340-3ksfpaf7	1071	1	Familiarity	familiarity	NN
cord-034340-3ksfpaf7	1071	2	for	for	IN
cord-034340-3ksfpaf7	1071	3	muscular	muscular	JJ
cord-034340-3ksfpaf7	1071	4	dystrophy	dystrophy	NN
cord-034340-3ksfpaf7	1071	5	was	be	VBD
cord-034340-3ksfpaf7	1071	6	reported	report	VBN
cord-034340-3ksfpaf7	1071	7	in	in	IN
cord-034340-3ksfpaf7	1071	8	the	the	DT
cord-034340-3ksfpaf7	1071	9	maternal	maternal	JJ
cord-034340-3ksfpaf7	1071	10	branch	branch	NN
cord-034340-3ksfpaf7	1071	11	.	.	.
cord-034340-3ksfpaf7	1072	1	Muscle	muscle	NN
cord-034340-3ksfpaf7	1072	2	tone	tone	NN
cord-034340-3ksfpaf7	1072	3	and	and	CC
cord-034340-3ksfpaf7	1072	4	trophism	trophism	NN
cord-034340-3ksfpaf7	1072	5	were	be	VBD
cord-034340-3ksfpaf7	1072	6	preserved	preserve	VBN
cord-034340-3ksfpaf7	1072	7	at	at	IN
cord-034340-3ksfpaf7	1072	8	initial	initial	JJ
cord-034340-3ksfpaf7	1072	9	neurological	neurological	JJ
cord-034340-3ksfpaf7	1072	10	evaluation	evaluation	NN
cord-034340-3ksfpaf7	1072	11	.	.	.
cord-034340-3ksfpaf7	1073	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	1073	2	investigation	investigation	NN
cord-034340-3ksfpaf7	1073	3	confirmed	confirm	VBD
cord-034340-3ksfpaf7	1073	4	increased	increase	VBN
cord-034340-3ksfpaf7	1073	5	muscle	muscle	NN
cord-034340-3ksfpaf7	1073	6	enzyme	enzyme	NN
cord-034340-3ksfpaf7	1073	7	levels	level	NNS
cord-034340-3ksfpaf7	1073	8	,	,	,
cord-034340-3ksfpaf7	1073	9	including	include	VBG
cord-034340-3ksfpaf7	1073	10	CPK	CPK	NNP
cord-034340-3ksfpaf7	1073	11	(	(	-LRB-
cord-034340-3ksfpaf7	1073	12	x70	x70	NN
cord-034340-3ksfpaf7	1073	13	)	)	-RRB-
cord-034340-3ksfpaf7	1074	1	(	(	-LRB-
cord-034340-3ksfpaf7	1074	2	CK	CK	NNP
cord-034340-3ksfpaf7	1074	3	-	-	HYPH
cord-034340-3ksfpaf7	1074	4	MM	MM	NNP
cord-034340-3ksfpaf7	1074	5	94.5	94.5	CD
cord-034340-3ksfpaf7	1074	6	%	%	NN
cord-034340-3ksfpaf7	1074	7	,	,	,
cord-034340-3ksfpaf7	1074	8	CK	CK	NNP
cord-034340-3ksfpaf7	1074	9	-	-	HYPH
cord-034340-3ksfpaf7	1074	10	MB	MB	NNP
cord-034340-3ksfpaf7	1074	11	5.5	5.5	CD
cord-034340-3ksfpaf7	1074	12	%	%	NN
cord-034340-3ksfpaf7	1074	13	)	)	-RRB-
cord-034340-3ksfpaf7	1074	14	,	,	,
cord-034340-3ksfpaf7	1074	15	aldolase	aldolase	NN
cord-034340-3ksfpaf7	1074	16	(	(	-LRB-
cord-034340-3ksfpaf7	1074	17	x7	x7	NNP
cord-034340-3ksfpaf7	1074	18	)	)	-RRB-
cord-034340-3ksfpaf7	1074	19	,	,	,
cord-034340-3ksfpaf7	1074	20	cardiac	cardiac	NN
cord-034340-3ksfpaf7	1074	21	troponin	troponin	NN
cord-034340-3ksfpaf7	1074	22	(	(	-LRB-
cord-034340-3ksfpaf7	1074	23	x10	x10	CD
cord-034340-3ksfpaf7	1074	24	)	)	-RRB-
cord-034340-3ksfpaf7	1074	25	and	and	CC
cord-034340-3ksfpaf7	1074	26	myoglobin	myoglobin	NN
cord-034340-3ksfpaf7	1074	27	(	(	-LRB-
cord-034340-3ksfpaf7	1074	28	x10	x10	CD
cord-034340-3ksfpaf7	1074	29	)	)	-RRB-
cord-034340-3ksfpaf7	1074	30	.	.	.
cord-034340-3ksfpaf7	1075	1	Suspecting	suspect	VBG
cord-034340-3ksfpaf7	1075	2	a	a	DT
cord-034340-3ksfpaf7	1075	3	primary	primary	JJ
cord-034340-3ksfpaf7	1075	4	muscle	muscle	NN
cord-034340-3ksfpaf7	1075	5	disease	disease	NN
cord-034340-3ksfpaf7	1075	6	,	,	,
cord-034340-3ksfpaf7	1075	7	she	-PRON-	PRP
cord-034340-3ksfpaf7	1075	8	underwent	undergo	VBD
cord-034340-3ksfpaf7	1075	9	a	a	DT
cord-034340-3ksfpaf7	1075	10	total	total	JJ
cord-034340-3ksfpaf7	1075	11	body	body	NN
cord-034340-3ksfpaf7	1075	12	STIR	stir	NN
cord-034340-3ksfpaf7	1075	13	-	-	HYPH
cord-034340-3ksfpaf7	1075	14	MRI	MRI	NNP
cord-034340-3ksfpaf7	1075	15	which	which	WDT
cord-034340-3ksfpaf7	1075	16	showed	show	VBD
cord-034340-3ksfpaf7	1075	17	a	a	DT
cord-034340-3ksfpaf7	1075	18	diffuse	diffuse	JJ
cord-034340-3ksfpaf7	1075	19	edema	edema	NN
cord-034340-3ksfpaf7	1075	20	of	of	IN
cord-034340-3ksfpaf7	1075	21	gluteus	gluteu	NNS
cord-034340-3ksfpaf7	1075	22	medius	medius	NN
cord-034340-3ksfpaf7	1075	23	bilaterally	bilaterally	RB
cord-034340-3ksfpaf7	1075	24	and	and	CC
cord-034340-3ksfpaf7	1075	25	a	a	DT
cord-034340-3ksfpaf7	1075	26	muscle	muscle	NN
cord-034340-3ksfpaf7	1075	27	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1075	28	revealing	reveal	VBG
cord-034340-3ksfpaf7	1075	29	a	a	DT
cord-034340-3ksfpaf7	1075	30	marked	marked	JJ
cord-034340-3ksfpaf7	1075	31	muscle	muscle	NN
cord-034340-3ksfpaf7	1075	32	damage	damage	NN
cord-034340-3ksfpaf7	1075	33	with	with	IN
cord-034340-3ksfpaf7	1075	34	dystrophic	dystrophic	JJ
cord-034340-3ksfpaf7	1075	35	aspects	aspect	NNS
cord-034340-3ksfpaf7	1075	36	and	and	CC
cord-034340-3ksfpaf7	1075	37	normality	normality	NN
cord-034340-3ksfpaf7	1075	38	of	of	IN
cord-034340-3ksfpaf7	1075	39	the	the	DT
cord-034340-3ksfpaf7	1075	40	tested	test	VBN
cord-034340-3ksfpaf7	1075	41	proteins	protein	NNS
cord-034340-3ksfpaf7	1075	42	.	.	.
cord-034340-3ksfpaf7	1076	1	A	a	DT
cord-034340-3ksfpaf7	1076	2	genetic	genetic	JJ
cord-034340-3ksfpaf7	1076	3	extended	extend	VBN
cord-034340-3ksfpaf7	1076	4	panel	panel	NN
cord-034340-3ksfpaf7	1076	5	for	for	IN
cord-034340-3ksfpaf7	1076	6	congenital	congenital	JJ
cord-034340-3ksfpaf7	1076	7	myopathies	myopathy	NNS
cord-034340-3ksfpaf7	1076	8	resulted	result	VBD
cord-034340-3ksfpaf7	1076	9	negative	negative	JJ
cord-034340-3ksfpaf7	1076	10	.	.	.
cord-034340-3ksfpaf7	1077	1	After	after	IN
cord-034340-3ksfpaf7	1077	2	4	4	CD
cord-034340-3ksfpaf7	1077	3	months	month	NNS
cord-034340-3ksfpaf7	1077	4	,	,	,
cord-034340-3ksfpaf7	1077	5	a	a	DT
cord-034340-3ksfpaf7	1077	6	new	new	JJ
cord-034340-3ksfpaf7	1077	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	1077	8	examination	examination	NN
cord-034340-3ksfpaf7	1077	9	showed	show	VBD
cord-034340-3ksfpaf7	1077	10	the	the	DT
cord-034340-3ksfpaf7	1077	11	occurrence	occurrence	NN
cord-034340-3ksfpaf7	1077	12	of	of	IN
cord-034340-3ksfpaf7	1077	13	general	general	JJ
cord-034340-3ksfpaf7	1077	14	skin	skin	NN
cord-034340-3ksfpaf7	1077	15	induration	induration	NN
cord-034340-3ksfpaf7	1077	16	,	,	,
cord-034340-3ksfpaf7	1077	17	sclerodactyly	sclerodactyly	NNP
cord-034340-3ksfpaf7	1077	18	and	and	CC
cord-034340-3ksfpaf7	1077	19	tightening	tightening	NN
cord-034340-3ksfpaf7	1077	20	of	of	IN
cord-034340-3ksfpaf7	1077	21	the	the	DT
cord-034340-3ksfpaf7	1077	22	face	face	NN
cord-034340-3ksfpaf7	1077	23	skin	skin	NN
cord-034340-3ksfpaf7	1077	24	.	.	.
cord-034340-3ksfpaf7	1078	1	Appearance	appearance	NN
cord-034340-3ksfpaf7	1078	2	of	of	IN
cord-034340-3ksfpaf7	1078	3	dysphagia	dysphagia	NN
cord-034340-3ksfpaf7	1078	4	was	be	VBD
cord-034340-3ksfpaf7	1078	5	also	also	RB
cord-034340-3ksfpaf7	1078	6	reported	report	VBN
cord-034340-3ksfpaf7	1078	7	,	,	,
cord-034340-3ksfpaf7	1078	8	and	and	CC
cord-034340-3ksfpaf7	1078	9	muscle	muscle	NN
cord-034340-3ksfpaf7	1078	10	enzyme	enzyme	NN
cord-034340-3ksfpaf7	1078	11	increase	increase	NN
cord-034340-3ksfpaf7	1078	12	persisted	persist	VBD
cord-034340-3ksfpaf7	1078	13	.	.	.
cord-034340-3ksfpaf7	1079	1	In	in	IN
cord-034340-3ksfpaf7	1079	2	suspicion	suspicion	NN
cord-034340-3ksfpaf7	1079	3	of	of	IN
cord-034340-3ksfpaf7	1079	4	an	an	DT
cord-034340-3ksfpaf7	1079	5	SSc	SSc	NNS
cord-034340-3ksfpaf7	1079	6	/	/	SYM
cord-034340-3ksfpaf7	1079	7	PM	PM	NNP
cord-034340-3ksfpaf7	1079	8	overlap	overlap	VBP
cord-034340-3ksfpaf7	1079	9	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1079	10	,	,	,
cord-034340-3ksfpaf7	1079	11	she	-PRON-	PRP
cord-034340-3ksfpaf7	1079	12	was	be	VBD
cord-034340-3ksfpaf7	1079	13	referred	refer	VBN
cord-034340-3ksfpaf7	1079	14	to	to	IN
cord-034340-3ksfpaf7	1079	15	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1079	16	Unit	Unit	NNP
cord-034340-3ksfpaf7	1079	17	.	.	.
cord-034340-3ksfpaf7	1080	1	Nailfold	Nailfold	NNP
cord-034340-3ksfpaf7	1080	2	capillaroscopy	capillaroscopy	NN
cord-034340-3ksfpaf7	1080	3	showed	show	VBD
cord-034340-3ksfpaf7	1080	4	capillary	capillary	JJ
cord-034340-3ksfpaf7	1080	5	dilatation	dilatation	NN
cord-034340-3ksfpaf7	1080	6	and	and	CC
cord-034340-3ksfpaf7	1080	7	branching	branching	NN
cord-034340-3ksfpaf7	1080	8	,	,	,
cord-034340-3ksfpaf7	1080	9	megacapillaries	megacapillarie	NNS
cord-034340-3ksfpaf7	1080	10	and	and	CC
cord-034340-3ksfpaf7	1080	11	diffuse	diffuse	VB
cord-034340-3ksfpaf7	1080	12	microhemorrhages	microhemorrhage	NNS
cord-034340-3ksfpaf7	1080	13	.	.	.
cord-034340-3ksfpaf7	1081	1	Reduction	reduction	NN
cord-034340-3ksfpaf7	1081	2	of	of	IN
cord-034340-3ksfpaf7	1081	3	esophageal	esophageal	JJ
cord-034340-3ksfpaf7	1081	4	contractions	contraction	NNS
cord-034340-3ksfpaf7	1081	5	amplitude	amplitude	VBP
cord-034340-3ksfpaf7	1081	6	and	and	CC
cord-034340-3ksfpaf7	1081	7	hypotensive	hypotensive	JJ
cord-034340-3ksfpaf7	1081	8	lower	low	JJR
cord-034340-3ksfpaf7	1081	9	esophageal	esophageal	JJ
cord-034340-3ksfpaf7	1081	10	sphincter	sphincter	NN
cord-034340-3ksfpaf7	1081	11	pressure	pressure	NN
cord-034340-3ksfpaf7	1081	12	were	be	VBD
cord-034340-3ksfpaf7	1081	13	observed	observe	VBN
cord-034340-3ksfpaf7	1081	14	at	at	IN
cord-034340-3ksfpaf7	1081	15	esophageal	esophageal	NN
cord-034340-3ksfpaf7	1081	16	manometry	manometry	NNP
cord-034340-3ksfpaf7	1081	17	test	test	NN
cord-034340-3ksfpaf7	1081	18	.	.	.
cord-034340-3ksfpaf7	1082	1	High	high	JJ
cord-034340-3ksfpaf7	1082	2	-	-	HYPH
cord-034340-3ksfpaf7	1082	3	resolution	resolution	NN
cord-034340-3ksfpaf7	1082	4	CT	CT	NNP
cord-034340-3ksfpaf7	1082	5	of	of	IN
cord-034340-3ksfpaf7	1082	6	lungs	lung	NNS
cord-034340-3ksfpaf7	1082	7	and	and	CC
cord-034340-3ksfpaf7	1082	8	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	1082	9	function	function	NN
cord-034340-3ksfpaf7	1082	10	testing	testing	NN
cord-034340-3ksfpaf7	1082	11	were	be	VBD
cord-034340-3ksfpaf7	1082	12	normal	normal	JJ
cord-034340-3ksfpaf7	1082	13	.	.	.
cord-034340-3ksfpaf7	1083	1	Skin	skin	NN
cord-034340-3ksfpaf7	1083	2	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1083	3	showed	show	VBD
cord-034340-3ksfpaf7	1083	4	sclerodermiform	sclerodermiform	JJ
cord-034340-3ksfpaf7	1083	5	findings	finding	NNS
cord-034340-3ksfpaf7	1083	6	.	.	.
cord-034340-3ksfpaf7	1084	1	Immunological	immunological	JJ
cord-034340-3ksfpaf7	1084	2	studies	study	NNS
cord-034340-3ksfpaf7	1084	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1084	4	a	a	DT
cord-034340-3ksfpaf7	1084	5	positivity	positivity	NN
cord-034340-3ksfpaf7	1084	6	of	of	IN
cord-034340-3ksfpaf7	1084	7	antinuclear	antinuclear	JJ
cord-034340-3ksfpaf7	1084	8	antibody	antibody	NN
cord-034340-3ksfpaf7	1084	9	(	(	-LRB-
cord-034340-3ksfpaf7	1084	10	1:320	1:320	CD
cord-034340-3ksfpaf7	1084	11	)	)	-RRB-
cord-034340-3ksfpaf7	1084	12	and	and	CC
cord-034340-3ksfpaf7	1084	13	anti	anti	NNS
cord-034340-3ksfpaf7	1084	14	-	-	NNP
cord-034340-3ksfpaf7	1084	15	Ku	Ku	NNP
cord-034340-3ksfpaf7	1084	16	.	.	.
cord-034340-3ksfpaf7	1085	1	Anti	anti	JJ
cord-034340-3ksfpaf7	1085	2	-	-	JJ
cord-034340-3ksfpaf7	1085	3	PM	PM	NNP
cord-034340-3ksfpaf7	1085	4	-	-	HYPH
cord-034340-3ksfpaf7	1085	5	Scl	Scl	NNP
cord-034340-3ksfpaf7	1085	6	resulted	result	VBD
cord-034340-3ksfpaf7	1085	7	negative	negative	JJ
cord-034340-3ksfpaf7	1085	8	.	.	.
cord-034340-3ksfpaf7	1086	1	An	an	DT
cord-034340-3ksfpaf7	1086	2	oral	oral	JJ
cord-034340-3ksfpaf7	1086	3	corticosteroid	corticosteroid	NN
cord-034340-3ksfpaf7	1086	4	therapy	therapy	NN
cord-034340-3ksfpaf7	1086	5	(	(	-LRB-
cord-034340-3ksfpaf7	1086	6	prednisone	prednisone	NNP
cord-034340-3ksfpaf7	1086	7	,	,	,
cord-034340-3ksfpaf7	1086	8	1.5	1.5	CD
cord-034340-3ksfpaf7	1086	9	mg	mg	NNP
cord-034340-3ksfpaf7	1086	10	/	/	SYM
cord-034340-3ksfpaf7	1086	11	kg	kg	NNP
cord-034340-3ksfpaf7	1086	12	/	/	SYM
cord-034340-3ksfpaf7	1086	13	day	day	NN
cord-034340-3ksfpaf7	1086	14	)	)	-RRB-
cord-034340-3ksfpaf7	1086	15	was	be	VBD
cord-034340-3ksfpaf7	1086	16	started	start	VBN
cord-034340-3ksfpaf7	1086	17	in	in	IN
cord-034340-3ksfpaf7	1086	18	association	association	NN
cord-034340-3ksfpaf7	1086	19	with	with	IN
cord-034340-3ksfpaf7	1086	20	subcutaneous	subcutaneous	JJ
cord-034340-3ksfpaf7	1086	21	Methotrexate	Methotrexate	NNP
cord-034340-3ksfpaf7	1086	22	(	(	-LRB-
cord-034340-3ksfpaf7	1086	23	15	15	CD
cord-034340-3ksfpaf7	1086	24	mg	mg	NNP
cord-034340-3ksfpaf7	1086	25	/	/	SYM
cord-034340-3ksfpaf7	1086	26	m	m	NN
cord-034340-3ksfpaf7	1086	27	2	2	CD
cord-034340-3ksfpaf7	1086	28	/week	/week	,
cord-034340-3ksfpaf7	1086	29	)	)	-RRB-
cord-034340-3ksfpaf7	1086	30	and	and	CC
cord-034340-3ksfpaf7	1086	31	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1086	32	immunoglobulins	immunoglobulin	NNS
cord-034340-3ksfpaf7	1086	33	(	(	-LRB-
cord-034340-3ksfpaf7	1086	34	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1086	35	)	)	-RRB-
cord-034340-3ksfpaf7	1087	1	(	(	-LRB-
cord-034340-3ksfpaf7	1087	2	2gr	2gr	NNP
cord-034340-3ksfpaf7	1087	3	/	/	SYM
cord-034340-3ksfpaf7	1087	4	kg	kg	NN
cord-034340-3ksfpaf7	1087	5	every	every	DT
cord-034340-3ksfpaf7	1087	6	two	two	CD
cord-034340-3ksfpaf7	1087	7	weeks	week	NNS
cord-034340-3ksfpaf7	1087	8	)	)	-RRB-
cord-034340-3ksfpaf7	1087	9	.	.	.
cord-034340-3ksfpaf7	1088	1	Improvement	improvement	NN
cord-034340-3ksfpaf7	1088	2	of	of	IN
cord-034340-3ksfpaf7	1088	3	skin	skin	NN
cord-034340-3ksfpaf7	1088	4	manifestation	manifestation	NN
cord-034340-3ksfpaf7	1088	5	,	,	,
cord-034340-3ksfpaf7	1088	6	joint	joint	JJ
cord-034340-3ksfpaf7	1088	7	mobility	mobility	NN
cord-034340-3ksfpaf7	1088	8	,	,	,
cord-034340-3ksfpaf7	1088	9	as	as	RB
cord-034340-3ksfpaf7	1088	10	well	well	RB
cord-034340-3ksfpaf7	1088	11	as	as	IN
cord-034340-3ksfpaf7	1088	12	normalization	normalization	NN
cord-034340-3ksfpaf7	1088	13	of	of	IN
cord-034340-3ksfpaf7	1088	14	serum	serum	NN
cord-034340-3ksfpaf7	1088	15	CPK	CPK	NNP
cord-034340-3ksfpaf7	1088	16	levels	level	NNS
cord-034340-3ksfpaf7	1088	17	were	be	VBD
cord-034340-3ksfpaf7	1088	18	observed	observe	VBN
cord-034340-3ksfpaf7	1088	19	.	.	.
cord-034340-3ksfpaf7	1089	1	Over	over	IN
cord-034340-3ksfpaf7	1089	2	3	3	CD
cord-034340-3ksfpaf7	1089	3	months	month	NNS
cord-034340-3ksfpaf7	1089	4	,	,	,
cord-034340-3ksfpaf7	1089	5	prednisone	prednisone	NN
cord-034340-3ksfpaf7	1089	6	and	and	CC
cord-034340-3ksfpaf7	1089	7	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1089	8	were	be	VBD
cord-034340-3ksfpaf7	1089	9	slowly	slowly	RB
cord-034340-3ksfpaf7	1089	10	discontinued	discontinue	VBN
cord-034340-3ksfpaf7	1089	11	up	up	IN
cord-034340-3ksfpaf7	1089	12	to	to	IN
cord-034340-3ksfpaf7	1089	13	the	the	DT
cord-034340-3ksfpaf7	1089	14	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	1089	15	dosage	dosage	NN
cord-034340-3ksfpaf7	1089	16	of	of	IN
cord-034340-3ksfpaf7	1089	17	0.9	0.9	CD
cord-034340-3ksfpaf7	1089	18	/	/	SYM
cord-034340-3ksfpaf7	1089	19	mg	mg	NN
cord-034340-3ksfpaf7	1089	20	/	/	SYM
cord-034340-3ksfpaf7	1089	21	day	day	NN
cord-034340-3ksfpaf7	1089	22	and	and	CC
cord-034340-3ksfpaf7	1089	23	2	2	CD
cord-034340-3ksfpaf7	1089	24	gr	gr	NNP
cord-034340-3ksfpaf7	1089	25	/	/	SYM
cord-034340-3ksfpaf7	1089	26	kg	kg	NNP
cord-034340-3ksfpaf7	1089	27	every	every	DT
cord-034340-3ksfpaf7	1089	28	4	4	CD
cord-034340-3ksfpaf7	1089	29	weeks	week	NNS
cord-034340-3ksfpaf7	1089	30	,	,	,
cord-034340-3ksfpaf7	1089	31	respectively	respectively	RB
cord-034340-3ksfpaf7	1089	32	.	.	.
cord-034340-3ksfpaf7	1090	1	MTX	MTX	NNP
cord-034340-3ksfpaf7	1090	2	is	be	VBZ
cord-034340-3ksfpaf7	1090	3	still	still	RB
cord-034340-3ksfpaf7	1090	4	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	1090	5	at	at	IN
cord-034340-3ksfpaf7	1090	6	the	the	DT
cord-034340-3ksfpaf7	1090	7	same	same	JJ
cord-034340-3ksfpaf7	1090	8	dosage	dosage	NN
cord-034340-3ksfpaf7	1090	9	.	.	.
cord-034340-3ksfpaf7	1091	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1091	2	:	:	:
cord-034340-3ksfpaf7	1092	1	The	the	DT
cord-034340-3ksfpaf7	1092	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1092	3	of	of	IN
cord-034340-3ksfpaf7	1092	4	overlap	overlap	VB
cord-034340-3ksfpaf7	1092	5	connective	connective	JJ
cord-034340-3ksfpaf7	1092	6	tissue	tissue	NN
cord-034340-3ksfpaf7	1092	7	disease	disease	NN
cord-034340-3ksfpaf7	1092	8	syndromes	syndrome	NNS
cord-034340-3ksfpaf7	1092	9	may	may	MD
cord-034340-3ksfpaf7	1092	10	be	be	VB
cord-034340-3ksfpaf7	1092	11	challenging	challenging	JJ
cord-034340-3ksfpaf7	1092	12	in	in	IN
cord-034340-3ksfpaf7	1092	13	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1092	14	age	age	NN
cord-034340-3ksfpaf7	1092	15	.	.	.
cord-034340-3ksfpaf7	1093	1	Different	different	JJ
cord-034340-3ksfpaf7	1093	2	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1093	3	may	may	MD
cord-034340-3ksfpaf7	1093	4	be	be	VB
cord-034340-3ksfpaf7	1093	5	prevalent	prevalent	JJ
cord-034340-3ksfpaf7	1093	6	at	at	IN
cord-034340-3ksfpaf7	1093	7	different	different	JJ
cord-034340-3ksfpaf7	1093	8	stages	stage	NNS
cord-034340-3ksfpaf7	1093	9	throughout	throughout	IN
cord-034340-3ksfpaf7	1093	10	the	the	DT
cord-034340-3ksfpaf7	1093	11	course	course	NN
cord-034340-3ksfpaf7	1093	12	of	of	IN
cord-034340-3ksfpaf7	1093	13	the	the	DT
cord-034340-3ksfpaf7	1093	14	disease	disease	NN
cord-034340-3ksfpaf7	1093	15	.	.	.
cord-034340-3ksfpaf7	1094	1	In	in	IN
cord-034340-3ksfpaf7	1094	2	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1094	3	patient	patient	NN
cord-034340-3ksfpaf7	1094	4	,	,	,
cord-034340-3ksfpaf7	1094	5	a	a	DT
cord-034340-3ksfpaf7	1094	6	localized	localize	VBN
cord-034340-3ksfpaf7	1094	7	myositis	myositis	NN
cord-034340-3ksfpaf7	1094	8	preceded	precede	VBD
cord-034340-3ksfpaf7	1094	9	the	the	DT
cord-034340-3ksfpaf7	1094	10	SS	SS	NNP
cord-034340-3ksfpaf7	1094	11	onset	onset	NN
cord-034340-3ksfpaf7	1094	12	by	by	IN
cord-034340-3ksfpaf7	1094	13	about	about	RB
cord-034340-3ksfpaf7	1094	14	four	four	CD
cord-034340-3ksfpaf7	1094	15	months	month	NNS
cord-034340-3ksfpaf7	1094	16	.	.	.
cord-034340-3ksfpaf7	1095	1	Even	even	RB
cord-034340-3ksfpaf7	1095	2	though	though	IN
cord-034340-3ksfpaf7	1095	3	the	the	DT
cord-034340-3ksfpaf7	1095	4	use	use	NN
cord-034340-3ksfpaf7	1095	5	of	of	IN
cord-034340-3ksfpaf7	1095	6	high	high	JJ
cord-034340-3ksfpaf7	1095	7	dose	dose	NN
cord-034340-3ksfpaf7	1095	8	of	of	IN
cord-034340-3ksfpaf7	1095	9	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	1095	10	is	be	VBZ
cord-034340-3ksfpaf7	1095	11	associated	associate	VBN
cord-034340-3ksfpaf7	1095	12	to	to	IN
cord-034340-3ksfpaf7	1095	13	a	a	DT
cord-034340-3ksfpaf7	1095	14	higher	high	JJR
cord-034340-3ksfpaf7	1095	15	incidence	incidence	NN
cord-034340-3ksfpaf7	1095	16	of	of	IN
cord-034340-3ksfpaf7	1095	17	renal	renal	JJ
cord-034340-3ksfpaf7	1095	18	crisis	crisis	NN
cord-034340-3ksfpaf7	1095	19	in	in	IN
cord-034340-3ksfpaf7	1095	20	patients	patient	NNS
cord-034340-3ksfpaf7	1095	21	with	with	IN
cord-034340-3ksfpaf7	1095	22	cSS	cSS	NNP
cord-034340-3ksfpaf7	1095	23	,	,	,
cord-034340-3ksfpaf7	1095	24	a	a	DT
cord-034340-3ksfpaf7	1095	25	combined	combine	VBN
cord-034340-3ksfpaf7	1095	26	therapy	therapy	NN
cord-034340-3ksfpaf7	1095	27	with	with	IN
cord-034340-3ksfpaf7	1095	28	high	high	JJ
cord-034340-3ksfpaf7	1095	29	doses	dose	NNS
cord-034340-3ksfpaf7	1095	30	of	of	IN
cord-034340-3ksfpaf7	1095	31	oral	oral	JJ
cord-034340-3ksfpaf7	1095	32	steroids	steroid	NNS
cord-034340-3ksfpaf7	1095	33	,	,	,
cord-034340-3ksfpaf7	1095	34	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1095	35	and	and	CC
cord-034340-3ksfpaf7	1095	36	MTX	MTX	NNP
cord-034340-3ksfpaf7	1095	37	was	be	VBD
cord-034340-3ksfpaf7	1095	38	safe	safe	JJ
cord-034340-3ksfpaf7	1095	39	and	and	CC
cord-034340-3ksfpaf7	1095	40	effective	effective	JJ
cord-034340-3ksfpaf7	1095	41	in	in	IN
cord-034340-3ksfpaf7	1095	42	skin	skin	NN
cord-034340-3ksfpaf7	1095	43	,	,	,
cord-034340-3ksfpaf7	1095	44	muscle	muscle	NN
cord-034340-3ksfpaf7	1095	45	and	and	CC
cord-034340-3ksfpaf7	1095	46	joint	joint	NN
cord-034340-3ksfpaf7	1096	1	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1096	2	in	in	IN
cord-034340-3ksfpaf7	1096	3	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1096	4	patient	patient	NN
cord-034340-3ksfpaf7	1096	5	.	.	.
cord-034340-3ksfpaf7	1097	1	Results	result	NNS
cord-034340-3ksfpaf7	1097	2	:	:	:
cord-034340-3ksfpaf7	1098	1	A	a	DT
cord-034340-3ksfpaf7	1098	2	total	total	NN
cord-034340-3ksfpaf7	1098	3	of	of	IN
cord-034340-3ksfpaf7	1098	4	336	336	CD
cord-034340-3ksfpaf7	1098	5	images	image	NNS
cord-034340-3ksfpaf7	1098	6	were	be	VBD
cord-034340-3ksfpaf7	1098	7	obtained	obtain	VBN
cord-034340-3ksfpaf7	1098	8	from	from	IN
cord-034340-3ksfpaf7	1098	9	118	118	CD
cord-034340-3ksfpaf7	1098	10	healthy	healthy	JJ
cord-034340-3ksfpaf7	1098	11	children	child	NNS
cord-034340-3ksfpaf7	1098	12	included	include	VBN
cord-034340-3ksfpaf7	1098	13	in	in	IN
cord-034340-3ksfpaf7	1098	14	the	the	DT
cord-034340-3ksfpaf7	1098	15	study	study	NN
cord-034340-3ksfpaf7	1098	16	and	and	CC
cord-034340-3ksfpaf7	1098	17	708	708	CD
cord-034340-3ksfpaf7	1098	18	capillary	capillary	JJ
cord-034340-3ksfpaf7	1098	19	measurements	measurement	NNS
cord-034340-3ksfpaf7	1098	20	were	be	VBD
cord-034340-3ksfpaf7	1098	21	made	make	VBN
cord-034340-3ksfpaf7	1098	22	.	.	.
cord-034340-3ksfpaf7	1099	1	Capillary	capillary	JJ
cord-034340-3ksfpaf7	1099	2	density	density	NN
cord-034340-3ksfpaf7	1099	3	was	be	VBD
cord-034340-3ksfpaf7	1099	4	significantly	significantly	RB
cord-034340-3ksfpaf7	1099	5	higher	high	JJR
cord-034340-3ksfpaf7	1099	6	in	in	IN
cord-034340-3ksfpaf7	1099	7	Group	Group	NNP
cord-034340-3ksfpaf7	1099	8	4	4	CD
cord-034340-3ksfpaf7	1099	9	than	than	IN
cord-034340-3ksfpaf7	1099	10	in	in	IN
cord-034340-3ksfpaf7	1099	11	Groups	group	NNS
cord-034340-3ksfpaf7	1099	12	1	1	CD
cord-034340-3ksfpaf7	1099	13	and	and	CC
cord-034340-3ksfpaf7	1099	14	2	2	CD
cord-034340-3ksfpaf7	1099	15	.	.	.
cord-034340-3ksfpaf7	1100	1	Arterial	arterial	JJ
cord-034340-3ksfpaf7	1100	2	width	width	NN
cord-034340-3ksfpaf7	1100	3	was	be	VBD
cord-034340-3ksfpaf7	1100	4	significantly	significantly	RB
cord-034340-3ksfpaf7	1100	5	lower	low	JJR
cord-034340-3ksfpaf7	1100	6	in	in	IN
cord-034340-3ksfpaf7	1100	7	Group	Group	NNP
cord-034340-3ksfpaf7	1100	8	1	1	CD
cord-034340-3ksfpaf7	1100	9	as	as	IN
cord-034340-3ksfpaf7	1100	10	compared	compare	VBN
cord-034340-3ksfpaf7	1100	11	to	to	IN
cord-034340-3ksfpaf7	1100	12	Group	Group	NNP
cord-034340-3ksfpaf7	1100	13	3	3	CD
cord-034340-3ksfpaf7	1100	14	and	and	CC
cord-034340-3ksfpaf7	1100	15	4	4	CD
cord-034340-3ksfpaf7	1100	16	,	,	,
cord-034340-3ksfpaf7	1100	17	and	and	CC
cord-034340-3ksfpaf7	1100	18	in	in	IN
cord-034340-3ksfpaf7	1100	19	Group	Group	NNP
cord-034340-3ksfpaf7	1100	20	2	2	CD
cord-034340-3ksfpaf7	1100	21	as	as	IN
cord-034340-3ksfpaf7	1100	22	compared	compare	VBN
cord-034340-3ksfpaf7	1100	23	to	to	IN
cord-034340-3ksfpaf7	1100	24	Group	Group	NNP
cord-034340-3ksfpaf7	1100	25	4	4	CD
cord-034340-3ksfpaf7	1100	26	.	.	.
cord-034340-3ksfpaf7	1101	1	Apical	Apical	NNP
cord-034340-3ksfpaf7	1101	2	loop	loop	NN
cord-034340-3ksfpaf7	1101	3	width	width	NN
cord-034340-3ksfpaf7	1101	4	and	and	CC
cord-034340-3ksfpaf7	1101	5	capillary	capillary	JJ
cord-034340-3ksfpaf7	1101	6	distance	distance	NN
cord-034340-3ksfpaf7	1101	7	were	be	VBD
cord-034340-3ksfpaf7	1101	8	significantly	significantly	RB
cord-034340-3ksfpaf7	1101	9	lower	low	JJR
cord-034340-3ksfpaf7	1101	10	in	in	IN
cord-034340-3ksfpaf7	1101	11	Group	Group	NNP
cord-034340-3ksfpaf7	1101	12	1	1	CD
cord-034340-3ksfpaf7	1101	13	compared	compare	VBN
cord-034340-3ksfpaf7	1101	14	to	to	IN
cord-034340-3ksfpaf7	1101	15	Group	Group	NNP
cord-034340-3ksfpaf7	1101	16	2	2	CD
cord-034340-3ksfpaf7	1101	17	and	and	CC
cord-034340-3ksfpaf7	1101	18	3	3	CD
cord-034340-3ksfpaf7	1101	19	and	and	CC
cord-034340-3ksfpaf7	1101	20	4	4	CD
cord-034340-3ksfpaf7	1101	21	.	.	.
cord-034340-3ksfpaf7	1102	1	There	there	EX
cord-034340-3ksfpaf7	1102	2	was	be	VBD
cord-034340-3ksfpaf7	1102	3	no	no	DT
cord-034340-3ksfpaf7	1102	4	significant	significant	JJ
cord-034340-3ksfpaf7	1102	5	difference	difference	NN
cord-034340-3ksfpaf7	1102	6	between	between	IN
cord-034340-3ksfpaf7	1102	7	the	the	DT
cord-034340-3ksfpaf7	1102	8	age	age	NN
cord-034340-3ksfpaf7	1102	9	groups	group	NNS
cord-034340-3ksfpaf7	1102	10	in	in	IN
cord-034340-3ksfpaf7	1102	11	terms	term	NNS
cord-034340-3ksfpaf7	1102	12	of	of	IN
cord-034340-3ksfpaf7	1102	13	capillary	capillary	JJ
cord-034340-3ksfpaf7	1102	14	length	length	NN
cord-034340-3ksfpaf7	1102	15	and	and	CC
cord-034340-3ksfpaf7	1102	16	venous	venous	JJ
cord-034340-3ksfpaf7	1102	17	width	width	NN
cord-034340-3ksfpaf7	1102	18	.	.	.
cord-034340-3ksfpaf7	1103	1	There	there	EX
cord-034340-3ksfpaf7	1103	2	was	be	VBD
cord-034340-3ksfpaf7	1103	3	no	no	DT
cord-034340-3ksfpaf7	1103	4	difference	difference	NN
cord-034340-3ksfpaf7	1103	5	between	between	IN
cord-034340-3ksfpaf7	1103	6	the	the	DT
cord-034340-3ksfpaf7	1103	7	groups	group	NNS
cord-034340-3ksfpaf7	1103	8	in	in	IN
cord-034340-3ksfpaf7	1103	9	terms	term	NNS
cord-034340-3ksfpaf7	1103	10	of	of	IN
cord-034340-3ksfpaf7	1103	11	capillary	capillary	JJ
cord-034340-3ksfpaf7	1103	12	morphology	morphology	NN
cord-034340-3ksfpaf7	1103	13	.	.	.
cord-034340-3ksfpaf7	1104	1	In	in	IN
cord-034340-3ksfpaf7	1104	2	total	total	JJ
cord-034340-3ksfpaf7	1104	3	336	336	CD
cord-034340-3ksfpaf7	1104	4	image	image	NN
cord-034340-3ksfpaf7	1104	5	evaluations	evaluation	NNS
cord-034340-3ksfpaf7	1104	6	,	,	,
cord-034340-3ksfpaf7	1104	7	capillary	capillary	JJ
cord-034340-3ksfpaf7	1104	8	tortuosity	tortuosity	NN
cord-034340-3ksfpaf7	1104	9	was	be	VBD
cord-034340-3ksfpaf7	1104	10	<	<	XX
cord-034340-3ksfpaf7	1104	11	50	50	CD
cord-034340-3ksfpaf7	1104	12	%	%	NN
cord-034340-3ksfpaf7	1104	13	in	in	IN
cord-034340-3ksfpaf7	1104	14	67.8	67.8	CD
cord-034340-3ksfpaf7	1104	15	%	%	NN
cord-034340-3ksfpaf7	1104	16	,	,	,
cord-034340-3ksfpaf7	1104	17	and	and	CC
cord-034340-3ksfpaf7	1104	18	>	>	XX
cord-034340-3ksfpaf7	1104	19	50	50	CD
cord-034340-3ksfpaf7	1104	20	%	%	NN
cord-034340-3ksfpaf7	1104	21	in	in	IN
cord-034340-3ksfpaf7	1104	22	4.2	4.2	CD
cord-034340-3ksfpaf7	1104	23	%	%	NN
cord-034340-3ksfpaf7	1104	24	,	,	,
cord-034340-3ksfpaf7	1104	25	and	and	CC
cord-034340-3ksfpaf7	1104	26	capillary	capillary	JJ
cord-034340-3ksfpaf7	1104	27	crossing	crossing	NN
cord-034340-3ksfpaf7	1104	28	were	be	VBD
cord-034340-3ksfpaf7	1104	29	<	<	XX
cord-034340-3ksfpaf7	1104	30	50	50	CD
cord-034340-3ksfpaf7	1104	31	%	%	NN
cord-034340-3ksfpaf7	1104	32	in	in	IN
cord-034340-3ksfpaf7	1104	33	52.5	52.5	CD
cord-034340-3ksfpaf7	1104	34	%	%	NN
cord-034340-3ksfpaf7	1105	1	and	and	CC
cord-034340-3ksfpaf7	1105	2	>	>	XX
cord-034340-3ksfpaf7	1105	3	50	50	CD
cord-034340-3ksfpaf7	1105	4	%	%	NN
cord-034340-3ksfpaf7	1105	5	in	in	IN
cord-034340-3ksfpaf7	1105	6	3.4	3.4	CD
cord-034340-3ksfpaf7	1105	7	%	%	NN
cord-034340-3ksfpaf7	1105	8	.	.	.
cord-034340-3ksfpaf7	1106	1	While	while	IN
cord-034340-3ksfpaf7	1106	2	the	the	DT
cord-034340-3ksfpaf7	1106	3	enlarged	enlarged	JJ
cord-034340-3ksfpaf7	1106	4	capillary	capillary	NN
cord-034340-3ksfpaf7	1106	5	was	be	VBD
cord-034340-3ksfpaf7	1106	6	4.7	4.7	CD
cord-034340-3ksfpaf7	1106	7	%	%	NN
cord-034340-3ksfpaf7	1106	8	and	and	CC
cord-034340-3ksfpaf7	1106	9	the	the	DT
cord-034340-3ksfpaf7	1106	10	avascular	avascular	JJ
cord-034340-3ksfpaf7	1106	11	area	area	NN
cord-034340-3ksfpaf7	1106	12	was	be	VBD
cord-034340-3ksfpaf7	1106	13	4.2	4.2	CD
cord-034340-3ksfpaf7	1106	14	%	%	NN
cord-034340-3ksfpaf7	1106	15	,	,	,
cord-034340-3ksfpaf7	1106	16	capillary	capillary	JJ
cord-034340-3ksfpaf7	1106	17	branching	branch	VBG
cord-034340-3ksfpaf7	1106	18	,	,	,
cord-034340-3ksfpaf7	1106	19	capillary	capillary	JJ
cord-034340-3ksfpaf7	1106	20	meandering	meandering	NN
cord-034340-3ksfpaf7	1106	21	,	,	,
cord-034340-3ksfpaf7	1106	22	microhemorrhage	microhemorrhage	NN
cord-034340-3ksfpaf7	1106	23	,	,	,
cord-034340-3ksfpaf7	1106	24	and	and	CC
cord-034340-3ksfpaf7	1106	25	giant	giant	JJ
cord-034340-3ksfpaf7	1106	26	capillary	capillary	NN
cord-034340-3ksfpaf7	1106	27	were	be	VBD
cord-034340-3ksfpaf7	1106	28	not	not	RB
cord-034340-3ksfpaf7	1106	29	detected	detect	VBN
cord-034340-3ksfpaf7	1106	30	in	in	IN
cord-034340-3ksfpaf7	1106	31	any	any	DT
cord-034340-3ksfpaf7	1106	32	case	case	NN
cord-034340-3ksfpaf7	1106	33	.	.	.
cord-034340-3ksfpaf7	1107	1	There	there	EX
cord-034340-3ksfpaf7	1107	2	was	be	VBD
cord-034340-3ksfpaf7	1107	3	a	a	DT
cord-034340-3ksfpaf7	1107	4	good	good	JJ
cord-034340-3ksfpaf7	1107	5	level	level	NN
cord-034340-3ksfpaf7	1107	6	of	of	IN
cord-034340-3ksfpaf7	1107	7	agreement	agreement	NN
cord-034340-3ksfpaf7	1107	8	between	between	IN
cord-034340-3ksfpaf7	1107	9	the	the	DT
cord-034340-3ksfpaf7	1107	10	researchers	researcher	NNS
cord-034340-3ksfpaf7	1107	11	,	,	,
cord-034340-3ksfpaf7	1107	12	as	as	IN
cord-034340-3ksfpaf7	1107	13	20	20	CD
cord-034340-3ksfpaf7	1107	14	cases	case	NNS
cord-034340-3ksfpaf7	1107	15	with	with	IN
cord-034340-3ksfpaf7	1107	16	120	120	CD
cord-034340-3ksfpaf7	1107	17	capillaries	capillary	NNS
cord-034340-3ksfpaf7	1107	18	were	be	VBD
cord-034340-3ksfpaf7	1107	19	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	1107	20	with	with	IN
cord-034340-3ksfpaf7	1107	21	a	a	DT
cord-034340-3ksfpaf7	1107	22	good	good	JJ
cord-034340-3ksfpaf7	1107	23	level	level	NN
cord-034340-3ksfpaf7	1107	24	of	of	IN
cord-034340-3ksfpaf7	1107	25	agreement	agreement	NN
cord-034340-3ksfpaf7	1107	26	(	(	-LRB-
cord-034340-3ksfpaf7	1107	27	Table	table	NN
cord-034340-3ksfpaf7	1107	28	1	1	CD
cord-034340-3ksfpaf7	1107	29	)	)	-RRB-
cord-034340-3ksfpaf7	1107	30	.	.	.
cord-034340-3ksfpaf7	1108	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1108	2	:	:	:
cord-034340-3ksfpaf7	1109	1	This	this	DT
cord-034340-3ksfpaf7	1109	2	is	be	VBZ
cord-034340-3ksfpaf7	1109	3	the	the	DT
cord-034340-3ksfpaf7	1109	4	first	first	JJ
cord-034340-3ksfpaf7	1109	5	study	study	NN
cord-034340-3ksfpaf7	1109	6	to	to	TO
cord-034340-3ksfpaf7	1109	7	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1109	8	capillary	capillary	JJ
cord-034340-3ksfpaf7	1109	9	morphology	morphology	NN
cord-034340-3ksfpaf7	1109	10	in	in	IN
cord-034340-3ksfpaf7	1109	11	healthy	healthy	JJ
cord-034340-3ksfpaf7	1109	12	Turkish	turkish	JJ
cord-034340-3ksfpaf7	1109	13	children	child	NNS
cord-034340-3ksfpaf7	1109	14	.	.	.
cord-034340-3ksfpaf7	1110	1	This	this	DT
cord-034340-3ksfpaf7	1110	2	study	study	NN
cord-034340-3ksfpaf7	1110	3	also	also	RB
cord-034340-3ksfpaf7	1110	4	adds	add	VBZ
cord-034340-3ksfpaf7	1110	5	that	that	IN
cord-034340-3ksfpaf7	1110	6	some	some	DT
cord-034340-3ksfpaf7	1110	7	special	special	JJ
cord-034340-3ksfpaf7	1110	8	forms	form	NNS
cord-034340-3ksfpaf7	1110	9	such	such	JJ
cord-034340-3ksfpaf7	1110	10	as	as	IN
cord-034340-3ksfpaf7	1110	11	enlarged	enlarged	JJ
cord-034340-3ksfpaf7	1110	12	capillary	capillary	NN
cord-034340-3ksfpaf7	1110	13	and	and	CC
cord-034340-3ksfpaf7	1110	14	avascular	avascular	JJ
cord-034340-3ksfpaf7	1110	15	area	area	NN
cord-034340-3ksfpaf7	1110	16	,	,	,
cord-034340-3ksfpaf7	1110	17	which	which	WDT
cord-034340-3ksfpaf7	1110	18	is	be	VBZ
cord-034340-3ksfpaf7	1110	19	always	always	RB
cord-034340-3ksfpaf7	1110	20	named	name	VBN
cord-034340-3ksfpaf7	1110	21	as	as	RB
cord-034340-3ksfpaf7	1110	22	pathological	pathological	JJ
cord-034340-3ksfpaf7	1110	23	in	in	IN
cord-034340-3ksfpaf7	1110	24	adult	adult	NN
cord-034340-3ksfpaf7	1110	25	age	age	NN
cord-034340-3ksfpaf7	1110	26	,	,	,
cord-034340-3ksfpaf7	1110	27	can	can	MD
cord-034340-3ksfpaf7	1110	28	be	be	VB
cord-034340-3ksfpaf7	1110	29	seen	see	VBN
cord-034340-3ksfpaf7	1110	30	in	in	IN
cord-034340-3ksfpaf7	1110	31	healthy	healthy	JJ
cord-034340-3ksfpaf7	1110	32	children	child	NNS
cord-034340-3ksfpaf7	1110	33	.	.	.
cord-034340-3ksfpaf7	1111	1	These	these	DT
cord-034340-3ksfpaf7	1111	2	data	datum	NNS
cord-034340-3ksfpaf7	1111	3	will	will	MD
cord-034340-3ksfpaf7	1111	4	be	be	VB
cord-034340-3ksfpaf7	1111	5	guiding	guide	VBG
cord-034340-3ksfpaf7	1111	6	in	in	IN
cord-034340-3ksfpaf7	1111	7	capillaroscopic	capillaroscopic	NNP
cord-034340-3ksfpaf7	1111	8	studies	study	NNS
cord-034340-3ksfpaf7	1111	9	in	in	IN
cord-034340-3ksfpaf7	1111	10	various	various	JJ
cord-034340-3ksfpaf7	1111	11	patient	patient	NN
cord-034340-3ksfpaf7	1111	12	groups	group	NNS
cord-034340-3ksfpaf7	1111	13	,	,	,
cord-034340-3ksfpaf7	1111	14	particularly	particularly	RB
cord-034340-3ksfpaf7	1111	15	in	in	IN
cord-034340-3ksfpaf7	1111	16	children	child	NNS
cord-034340-3ksfpaf7	1111	17	with	with	IN
cord-034340-3ksfpaf7	1111	18	collagen	collagen	NN
cord-034340-3ksfpaf7	1111	19	vascular	vascular	JJ
cord-034340-3ksfpaf7	1111	20	diseases	disease	NNS
cord-034340-3ksfpaf7	1111	21	.	.	.
cord-034340-3ksfpaf7	1112	1	Methods	method	NNS
cord-034340-3ksfpaf7	1112	2	:	:	:
cord-034340-3ksfpaf7	1112	3	308	308	CD
cord-034340-3ksfpaf7	1112	4	patients	patient	NNS
cord-034340-3ksfpaf7	1112	5	with	with	IN
cord-034340-3ksfpaf7	1112	6	JIA	JIA	NNP
cord-034340-3ksfpaf7	1112	7	were	be	VBD
cord-034340-3ksfpaf7	1112	8	tested	test	VBN
cord-034340-3ksfpaf7	1112	9	for	for	IN
cord-034340-3ksfpaf7	1112	10	HLA	HLA	NNP
cord-034340-3ksfpaf7	1112	11	-	-	HYPH
cord-034340-3ksfpaf7	1112	12	B27	B27	NNP
cord-034340-3ksfpaf7	1112	13	.	.	.
cord-034340-3ksfpaf7	1113	1	They	-PRON-	PRP
cord-034340-3ksfpaf7	1113	2	were	be	VBD
cord-034340-3ksfpaf7	1113	3	divided	divide	VBN
cord-034340-3ksfpaf7	1113	4	into	into	IN
cord-034340-3ksfpaf7	1113	5	2	2	CD
cord-034340-3ksfpaf7	1113	6	groups	group	NNS
cord-034340-3ksfpaf7	1113	7	:	:	:
cord-034340-3ksfpaf7	1113	8	1	1	LS
cord-034340-3ksfpaf7	1113	9	)	)	-RRB-
cord-034340-3ksfpaf7	1113	10	HLA	HLA	NNP
cord-034340-3ksfpaf7	1113	11	-	-	HYPH
cord-034340-3ksfpaf7	1113	12	B27	B27	NNP
cord-034340-3ksfpaf7	1113	13	positive	positive	JJ
cord-034340-3ksfpaf7	1113	14	and	and	CC
cord-034340-3ksfpaf7	1113	15	2	2	LS
cord-034340-3ksfpaf7	1113	16	)	)	-RRB-
cord-034340-3ksfpaf7	1113	17	HLA	HLA	NNP
cord-034340-3ksfpaf7	1113	18	-	-	HYPH
cord-034340-3ksfpaf7	1113	19	B27	B27	NNP
cord-034340-3ksfpaf7	1113	20	negative	negative	JJ
cord-034340-3ksfpaf7	1113	21	.	.	.
cord-034340-3ksfpaf7	1114	1	Results	result	NNS
cord-034340-3ksfpaf7	1114	2	:	:	:
cord-034340-3ksfpaf7	1115	1	100	100	CD
cord-034340-3ksfpaf7	1115	2	patients	patient	NNS
cord-034340-3ksfpaf7	1115	3	(	(	-LRB-
cord-034340-3ksfpaf7	1115	4	32,5	32,5	CD
cord-034340-3ksfpaf7	1115	5	%	%	NN
cord-034340-3ksfpaf7	1115	6	)	)	-RRB-
cord-034340-3ksfpaf7	1115	7	were	be	VBD
cord-034340-3ksfpaf7	1115	8	HLA	HLA	NNP
cord-034340-3ksfpaf7	1115	9	-	-	HYPH
cord-034340-3ksfpaf7	1115	10	B27	B27	NNP
cord-034340-3ksfpaf7	1115	11	positive	positive	JJ
cord-034340-3ksfpaf7	1115	12	and	and	CC
cord-034340-3ksfpaf7	1115	13	all	all	DT
cord-034340-3ksfpaf7	1115	14	of	of	IN
cord-034340-3ksfpaf7	1115	15	them	-PRON-	PRP
cord-034340-3ksfpaf7	1115	16	are	be	VBP
cord-034340-3ksfpaf7	1115	17	fulfilled	fulfil	VBN
cord-034340-3ksfpaf7	1115	18	the	the	DT
cord-034340-3ksfpaf7	1115	19	EULAR	EULAR	NNP
cord-034340-3ksfpaf7	1115	20	criteria	criterion	NNS
cord-034340-3ksfpaf7	1115	21	of	of	IN
cord-034340-3ksfpaf7	1115	22	entesitis	entesitis	NNP
cord-034340-3ksfpaf7	1115	23	-	-	HYPH
cord-034340-3ksfpaf7	1115	24	related	relate	VBN
cord-034340-3ksfpaf7	1115	25	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1115	26	(	(	-LRB-
cord-034340-3ksfpaf7	1115	27	ERA	ERA	NNP
cord-034340-3ksfpaf7	1115	28	)	)	-RRB-
cord-034340-3ksfpaf7	1115	29	.	.	.
cord-034340-3ksfpaf7	1116	1	The	the	DT
cord-034340-3ksfpaf7	1116	2	group	group	NN
cord-034340-3ksfpaf7	1116	3	2	2	CD
cord-034340-3ksfpaf7	1116	4	consists	consist	VBZ
cord-034340-3ksfpaf7	1116	5	of	of	IN
cord-034340-3ksfpaf7	1116	6	208	208	CD
cord-034340-3ksfpaf7	1116	7	patients	patient	NNS
cord-034340-3ksfpaf7	1116	8	(	(	-LRB-
cord-034340-3ksfpaf7	1116	9	67.5	67.5	CD
cord-034340-3ksfpaf7	1116	10	%	%	NN
cord-034340-3ksfpaf7	1116	11	)	)	-RRB-
cord-034340-3ksfpaf7	1116	12	.	.	.
cord-034340-3ksfpaf7	1117	1	There	there	EX
cord-034340-3ksfpaf7	1117	2	's	be	VBZ
cord-034340-3ksfpaf7	1117	3	no	no	DT
cord-034340-3ksfpaf7	1117	4	statistical	statistical	JJ
cord-034340-3ksfpaf7	1117	5	difference	difference	NN
cord-034340-3ksfpaf7	1117	6	between	between	IN
cord-034340-3ksfpaf7	1117	7	both	both	DT
cord-034340-3ksfpaf7	1117	8	groups	group	NNS
cord-034340-3ksfpaf7	1117	9	in	in	IN
cord-034340-3ksfpaf7	1117	10	active	active	JJ
cord-034340-3ksfpaf7	1117	11	joint	joint	JJ
cord-034340-3ksfpaf7	1117	12	count	count	NN
cord-034340-3ksfpaf7	1117	13	,	,	,
cord-034340-3ksfpaf7	1117	14	ANA	ANA	NNP
cord-034340-3ksfpaf7	1117	15	-	-	HYPH
cord-034340-3ksfpaf7	1117	16	positivity	positivity	NN
cord-034340-3ksfpaf7	1117	17	and	and	CC
cord-034340-3ksfpaf7	1117	18	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1117	19	frequency	frequency	NN
cord-034340-3ksfpaf7	1117	20	,	,	,
cord-034340-3ksfpaf7	1117	21	the	the	DT
cord-034340-3ksfpaf7	1117	22	rate	rate	NN
cord-034340-3ksfpaf7	1117	23	of	of	IN
cord-034340-3ksfpaf7	1117	24	use	use	NN
cord-034340-3ksfpaf7	1117	25	methotrexate	methotrexate	NN
cord-034340-3ksfpaf7	1117	26	and	and	CC
cord-034340-3ksfpaf7	1117	27	time	time	NN
cord-034340-3ksfpaf7	1117	28	before	before	IN
cord-034340-3ksfpaf7	1117	29	biologics	biologic	NNS
cord-034340-3ksfpaf7	1117	30	.	.	.
cord-034340-3ksfpaf7	1118	1	No	no	DT
cord-034340-3ksfpaf7	1118	2	difference	difference	NN
cord-034340-3ksfpaf7	1118	3	in	in	IN
cord-034340-3ksfpaf7	1118	4	axial	axial	JJ
cord-034340-3ksfpaf7	1118	5	cervical	cervical	JJ
cord-034340-3ksfpaf7	1118	6	spine	spine	NN
cord-034340-3ksfpaf7	1118	7	12	12	CD
cord-034340-3ksfpaf7	1118	8	(	(	-LRB-
cord-034340-3ksfpaf7	1118	9	12.0	12.0	CD
cord-034340-3ksfpaf7	1118	10	%	%	NN
cord-034340-3ksfpaf7	1118	11	)	)	-RRB-
cord-034340-3ksfpaf7	1118	12	vs	vs	IN
cord-034340-3ksfpaf7	1118	13	21	21	CD
cord-034340-3ksfpaf7	1118	14	(	(	-LRB-
cord-034340-3ksfpaf7	1118	15	10.1	10.1	CD
cord-034340-3ksfpaf7	1118	16	%	%	NN
cord-034340-3ksfpaf7	1118	17	)	)	-RRB-
cord-034340-3ksfpaf7	1118	18	(	(	-LRB-
cord-034340-3ksfpaf7	1118	19	p=0.613	p=0.613	NNP
cord-034340-3ksfpaf7	1118	20	)	)	-RRB-
cord-034340-3ksfpaf7	1118	21	and	and	CC
cord-034340-3ksfpaf7	1118	22	sacroiliac	sacroiliac	NN
cord-034340-3ksfpaf7	1118	23	joints	joint	NNS
cord-034340-3ksfpaf7	1118	24	18	18	CD
cord-034340-3ksfpaf7	1118	25	(	(	-LRB-
cord-034340-3ksfpaf7	1118	26	18.0	18.0	CD
cord-034340-3ksfpaf7	1118	27	%	%	NN
cord-034340-3ksfpaf7	1118	28	)	)	-RRB-
cord-034340-3ksfpaf7	1118	29	vs	vs	IN
cord-034340-3ksfpaf7	1118	30	23/207	23/207	CD
cord-034340-3ksfpaf7	1118	31	(	(	-LRB-
cord-034340-3ksfpaf7	1118	32	11.1	11.1	CD
cord-034340-3ksfpaf7	1118	33	%	%	NN
cord-034340-3ksfpaf7	1118	34	)	)	-RRB-
cord-034340-3ksfpaf7	1118	35	(	(	-LRB-
cord-034340-3ksfpaf7	1118	36	p=0.097	p=0.097	NNP
cord-034340-3ksfpaf7	1118	37	)	)	-RRB-
cord-034340-3ksfpaf7	1119	1	involvement	involvement	NN
cord-034340-3ksfpaf7	1119	2	was	be	VBD
cord-034340-3ksfpaf7	1119	3	observed	observe	VBN
cord-034340-3ksfpaf7	1119	4	.	.	.
cord-034340-3ksfpaf7	1120	1	HLA	HLA	NNP
cord-034340-3ksfpaf7	1120	2	B27(+	B27(+	NNP
cord-034340-3ksfpaf7	1120	3	)	)	-RRB-
cord-034340-3ksfpaf7	1121	1	patients	patient	NNS
cord-034340-3ksfpaf7	1121	2	often	often	RB
cord-034340-3ksfpaf7	1121	3	received	receive	VBD
cord-034340-3ksfpaf7	1121	4	pulse	pulse	NN
cord-034340-3ksfpaf7	1121	5	therapy	therapy	NN
cord-034340-3ksfpaf7	1121	6	with	with	IN
cord-034340-3ksfpaf7	1121	7	methylprednisolone	methylprednisolone	NN
cord-034340-3ksfpaf7	1121	8	due	due	JJ
cord-034340-3ksfpaf7	1121	9	to	to	IN
cord-034340-3ksfpaf7	1121	10	increased	increase	VBN
cord-034340-3ksfpaf7	1121	11	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1121	12	activity	activity	NN
cord-034340-3ksfpaf7	1121	13	and	and	CC
cord-034340-3ksfpaf7	1121	14	severe	severe	JJ
cord-034340-3ksfpaf7	1121	15	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1121	16	(	(	-LRB-
cord-034340-3ksfpaf7	1121	17	22	22	CD
cord-034340-3ksfpaf7	1121	18	%	%	NN
cord-034340-3ksfpaf7	1121	19	vs	vs	IN
cord-034340-3ksfpaf7	1121	20	11.1	11.1	CD
cord-034340-3ksfpaf7	1121	21	%	%	NN
cord-034340-3ksfpaf7	1121	22	,	,	,
cord-034340-3ksfpaf7	1121	23	p=0.011	p=0.011	NNP
cord-034340-3ksfpaf7	1121	24	)	)	-RRB-
cord-034340-3ksfpaf7	1121	25	.	.	.
cord-034340-3ksfpaf7	1122	1	Other	other	JJ
cord-034340-3ksfpaf7	1122	2	parameters	parameter	NNS
cord-034340-3ksfpaf7	1122	3	are	be	VBP
cord-034340-3ksfpaf7	1122	4	listed	list	VBN
cord-034340-3ksfpaf7	1122	5	in	in	IN
cord-034340-3ksfpaf7	1122	6	Table1	Table1	NNP
cord-034340-3ksfpaf7	1122	7	.	.	.
cord-034340-3ksfpaf7	1123	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1123	2	:	:	:
cord-034340-3ksfpaf7	1123	3	patients	patient	NNS
cord-034340-3ksfpaf7	1123	4	with	with	IN
cord-034340-3ksfpaf7	1123	5	HLA	HLA	NNP
cord-034340-3ksfpaf7	1123	6	-	-	HYPH
cord-034340-3ksfpaf7	1123	7	B27	B27	NNP
cord-034340-3ksfpaf7	1123	8	positivity	positivity	NN
cord-034340-3ksfpaf7	1123	9	were	be	VBD
cord-034340-3ksfpaf7	1123	10	characterized	characterize	VBN
cord-034340-3ksfpaf7	1123	11	by	by	IN
cord-034340-3ksfpaf7	1123	12	male	male	JJ
cord-034340-3ksfpaf7	1123	13	predominance	predominance	NN
cord-034340-3ksfpaf7	1123	14	,	,	,
cord-034340-3ksfpaf7	1123	15	more	more	RBR
cord-034340-3ksfpaf7	1123	16	often	often	RB
cord-034340-3ksfpaf7	1123	17	hip	hip	JJ
cord-034340-3ksfpaf7	1123	18	involvement	involvement	NN
cord-034340-3ksfpaf7	1123	19	,	,	,
cord-034340-3ksfpaf7	1123	20	higher	high	JJR
cord-034340-3ksfpaf7	1123	21	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1123	22	activity	activity	NN
cord-034340-3ksfpaf7	1123	23	and	and	CC
cord-034340-3ksfpaf7	1123	24	the	the	DT
cord-034340-3ksfpaf7	1123	25	need	need	NN
cord-034340-3ksfpaf7	1123	26	for	for	IN
cord-034340-3ksfpaf7	1123	27	more	more	RBR
cord-034340-3ksfpaf7	1123	28	frequent	frequent	JJ
cord-034340-3ksfpaf7	1123	29	use	use	NN
cord-034340-3ksfpaf7	1123	30	biologics	biologic	NNS
cord-034340-3ksfpaf7	1123	31	.	.	.
cord-034340-3ksfpaf7	1124	1	The	the	DT
cord-034340-3ksfpaf7	1124	2	rate	rate	NN
cord-034340-3ksfpaf7	1124	3	of	of	IN
cord-034340-3ksfpaf7	1124	4	axial	axial	JJ
cord-034340-3ksfpaf7	1124	5	involvement	involvement	NN
cord-034340-3ksfpaf7	1124	6	was	be	VBD
cord-034340-3ksfpaf7	1124	7	n't	not	RB
cord-034340-3ksfpaf7	1124	8	different	different	JJ
cord-034340-3ksfpaf7	1124	9	in	in	IN
cord-034340-3ksfpaf7	1124	10	HLA	HLA	NNP
cord-034340-3ksfpaf7	1124	11	-	-	HYPH
cord-034340-3ksfpaf7	1124	12	B27	B27	NNP
cord-034340-3ksfpaf7	1124	13	positive	positive	JJ
cord-034340-3ksfpaf7	1124	14	and	and	CC
cord-034340-3ksfpaf7	1124	15	negative	negative	JJ
cord-034340-3ksfpaf7	1124	16	patients	patient	NNS
cord-034340-3ksfpaf7	1124	17	,	,	,
cord-034340-3ksfpaf7	1124	18	that	that	WDT
cord-034340-3ksfpaf7	1124	19	needs	need	VBZ
cord-034340-3ksfpaf7	1124	20	further	further	JJ
cord-034340-3ksfpaf7	1124	21	study	study	NN
cord-034340-3ksfpaf7	1124	22	and	and	CC
cord-034340-3ksfpaf7	1124	23	creating	create	VBG
cord-034340-3ksfpaf7	1124	24	more	more	RBR
cord-034340-3ksfpaf7	1124	25	accurate	accurate	JJ
cord-034340-3ksfpaf7	1124	26	classification	classification	NN
cord-034340-3ksfpaf7	1124	27	criteria	criterion	NNS
cord-034340-3ksfpaf7	1124	28	for	for	IN
cord-034340-3ksfpaf7	1124	29	JSA	JSA	NNP
cord-034340-3ksfpaf7	1124	30	.	.	.
cord-034340-3ksfpaf7	1125	1	Disclosure	disclosure	NN
cord-034340-3ksfpaf7	1125	2	of	of	IN
cord-034340-3ksfpaf7	1125	3	Interest	Interest	NNP
cord-034340-3ksfpaf7	1126	1	:	:	:
cord-034340-3ksfpaf7	1126	2	None	none	NN
cord-034340-3ksfpaf7	1126	3	declared	declare	VBD
cord-034340-3ksfpaf7	1126	4	Introduction	introduction	NN
cord-034340-3ksfpaf7	1126	5	:	:	:
cord-034340-3ksfpaf7	1126	6	Although	although	IN
cord-034340-3ksfpaf7	1126	7	gut	gut	NN
cord-034340-3ksfpaf7	1126	8	is	be	VBZ
cord-034340-3ksfpaf7	1126	9	increasingly	increasingly	RB
cord-034340-3ksfpaf7	1126	10	recognized	recognize	VBN
cord-034340-3ksfpaf7	1126	11	as	as	IN
cord-034340-3ksfpaf7	1126	12	origin	origin	NN
cord-034340-3ksfpaf7	1126	13	and/or	and/or	CC
cord-034340-3ksfpaf7	1126	14	target	target	NN
cord-034340-3ksfpaf7	1126	15	of	of	IN
cord-034340-3ksfpaf7	1126	16	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1126	17	in	in	IN
cord-034340-3ksfpaf7	1126	18	adult	adult	NN
cord-034340-3ksfpaf7	1126	19	onset	onset	NN
cord-034340-3ksfpaf7	1126	20	spondyloarthritis	spondyloarthritis	NN
cord-034340-3ksfpaf7	1126	21	(	(	-LRB-
cord-034340-3ksfpaf7	1126	22	SpA	spa	NN
cord-034340-3ksfpaf7	1126	23	)	)	-RRB-
cord-034340-3ksfpaf7	1126	24	,	,	,
cord-034340-3ksfpaf7	1126	25	the	the	DT
cord-034340-3ksfpaf7	1126	26	incidence	incidence	NN
cord-034340-3ksfpaf7	1126	27	of	of	IN
cord-034340-3ksfpaf7	1126	28	gut	gut	NN
cord-034340-3ksfpaf7	1126	29	involvement	involvement	NN
cord-034340-3ksfpaf7	1126	30	in	in	IN
cord-034340-3ksfpaf7	1126	31	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1126	32	SpA	spa	NN
cord-034340-3ksfpaf7	1126	33	(	(	-LRB-
cord-034340-3ksfpaf7	1127	1	jSpA	jspa	JJ
cord-034340-3ksfpaf7	1127	2	)	)	-RRB-
cord-034340-3ksfpaf7	1127	3	patients	patient	NNS
cord-034340-3ksfpaf7	1127	4	is	be	VBZ
cord-034340-3ksfpaf7	1127	5	still	still	RB
cord-034340-3ksfpaf7	1127	6	largely	largely	RB
cord-034340-3ksfpaf7	1127	7	unknown	unknown	JJ
cord-034340-3ksfpaf7	1127	8	,	,	,
cord-034340-3ksfpaf7	1127	9	mostly	mostly	RB
cord-034340-3ksfpaf7	1127	10	due	due	IN
cord-034340-3ksfpaf7	1127	11	to	to	IN
cord-034340-3ksfpaf7	1127	12	the	the	DT
cord-034340-3ksfpaf7	1127	13	lack	lack	NN
cord-034340-3ksfpaf7	1127	14	of	of	IN
cord-034340-3ksfpaf7	1127	15	reliable	reliable	JJ
cord-034340-3ksfpaf7	1127	16	non	non	JJ
cord-034340-3ksfpaf7	1127	17	-	-	JJ
cord-034340-3ksfpaf7	1127	18	invasive	invasive	JJ
cord-034340-3ksfpaf7	1127	19	tests	test	NNS
cord-034340-3ksfpaf7	1127	20	.	.	.
cord-034340-3ksfpaf7	1128	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1128	2	:	:	:
cord-034340-3ksfpaf7	1128	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1128	4	performed	perform	VBD
cord-034340-3ksfpaf7	1128	5	a	a	DT
cord-034340-3ksfpaf7	1128	6	cross	cross	JJ
cord-034340-3ksfpaf7	1128	7	-	-	JJ
cord-034340-3ksfpaf7	1128	8	sectional	sectional	JJ
cord-034340-3ksfpaf7	1128	9	study	study	NN
cord-034340-3ksfpaf7	1128	10	of	of	IN
cord-034340-3ksfpaf7	1128	11	fecal	fecal	JJ
cord-034340-3ksfpaf7	1128	12	calprotectin	calprotectin	NNP
cord-034340-3ksfpaf7	1128	13	(	(	-LRB-
cord-034340-3ksfpaf7	1128	14	fCAL	fCAL	NNP
cord-034340-3ksfpaf7	1128	15	)	)	-RRB-
cord-034340-3ksfpaf7	1128	16	,	,	,
cord-034340-3ksfpaf7	1128	17	a	a	DT
cord-034340-3ksfpaf7	1128	18	surrogate	surrogate	JJ
cord-034340-3ksfpaf7	1128	19	marker	marker	NN
cord-034340-3ksfpaf7	1128	20	of	of	IN
cord-034340-3ksfpaf7	1128	21	gut	gut	NN
cord-034340-3ksfpaf7	1128	22	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1128	23	,	,	,
cord-034340-3ksfpaf7	1128	24	in	in	IN
cord-034340-3ksfpaf7	1128	25	patients	patient	NNS
cord-034340-3ksfpaf7	1128	26	with	with	IN
cord-034340-3ksfpaf7	1128	27	jSpA	jSpA	NNP
cord-034340-3ksfpaf7	1128	28	,	,	,
cord-034340-3ksfpaf7	1128	29	other	other	JJ
cord-034340-3ksfpaf7	1128	30	forms	form	NNS
cord-034340-3ksfpaf7	1128	31	of	of	IN
cord-034340-3ksfpaf7	1128	32	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1128	33	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1128	34	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1128	35	(	(	-LRB-
cord-034340-3ksfpaf7	1128	36	JIA	JIA	NNP
cord-034340-3ksfpaf7	1128	37	)	)	-RRB-
cord-034340-3ksfpaf7	1128	38	and	and	CC
cord-034340-3ksfpaf7	1128	39	noninflammatory	noninflammatory	JJ
cord-034340-3ksfpaf7	1128	40	(	(	-LRB-
cord-034340-3ksfpaf7	1128	41	NI	NI	NNP
cord-034340-3ksfpaf7	1128	42	)	)	-RRB-
cord-034340-3ksfpaf7	1128	43	conditions	condition	NNS
cord-034340-3ksfpaf7	1128	44	.	.	.
cord-034340-3ksfpaf7	1129	1	Methods	method	NNS
cord-034340-3ksfpaf7	1129	2	:	:	:
cord-034340-3ksfpaf7	1130	1	fCAL	fCAL	NNP
cord-034340-3ksfpaf7	1130	2	was	be	VBD
cord-034340-3ksfpaf7	1130	3	measured	measure	VBN
cord-034340-3ksfpaf7	1130	4	by	by	IN
cord-034340-3ksfpaf7	1130	5	commercially	commercially	RB
cord-034340-3ksfpaf7	1130	6	available	available	JJ
cord-034340-3ksfpaf7	1130	7	assay	assay	NN
cord-034340-3ksfpaf7	1130	8	in	in	IN
cord-034340-3ksfpaf7	1130	9	stool	stool	NN
cord-034340-3ksfpaf7	1130	10	samples	sample	NNS
cord-034340-3ksfpaf7	1130	11	of	of	IN
cord-034340-3ksfpaf7	1130	12	enthesitis	enthesitis	NNP
cord-034340-3ksfpaf7	1130	13	related	relate	VBN
cord-034340-3ksfpaf7	1130	14	(	(	-LRB-
cord-034340-3ksfpaf7	1130	15	ErA	era	NN
cord-034340-3ksfpaf7	1130	16	)	)	-RRB-
cord-034340-3ksfpaf7	1130	17	,	,	,
cord-034340-3ksfpaf7	1130	18	psoriatic	psoriatic	JJ
cord-034340-3ksfpaf7	1130	19	(	(	-LRB-
cord-034340-3ksfpaf7	1130	20	PsA	PsA	NNP
cord-034340-3ksfpaf7	1130	21	)	)	-RRB-
cord-034340-3ksfpaf7	1130	22	and	and	CC
cord-034340-3ksfpaf7	1130	23	patients	patient	NNS
cord-034340-3ksfpaf7	1130	24	with	with	IN
cord-034340-3ksfpaf7	1130	25	other	other	JJ
cord-034340-3ksfpaf7	1130	26	JIA	JIA	NNP
cord-034340-3ksfpaf7	1130	27	subtypes	subtype	NNS
cord-034340-3ksfpaf7	1130	28	(	(	-LRB-
cord-034340-3ksfpaf7	1130	29	oligo	oligo	NNP
cord-034340-3ksfpaf7	1130	30	-	-	HYPH
cord-034340-3ksfpaf7	1130	31	and	and	CC
cord-034340-3ksfpaf7	1130	32	poly	poly	JJ
cord-034340-3ksfpaf7	1130	33	-	-	HYPH
cord-034340-3ksfpaf7	1130	34	articular	articular	JJ
cord-034340-3ksfpaf7	1130	35	)	)	-RRB-
cord-034340-3ksfpaf7	1130	36	who	who	WP
cord-034340-3ksfpaf7	1130	37	fulfilled	fulfil	VBD
cord-034340-3ksfpaf7	1130	38	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	1130	39	criteria	criterion	NNS
cord-034340-3ksfpaf7	1130	40	,	,	,
cord-034340-3ksfpaf7	1130	41	as	as	RB
cord-034340-3ksfpaf7	1130	42	well	well	RB
cord-034340-3ksfpaf7	1130	43	as	as	IN
cord-034340-3ksfpaf7	1130	44	in	in	IN
cord-034340-3ksfpaf7	1130	45	children	child	NNS
cord-034340-3ksfpaf7	1130	46	with	with	IN
cord-034340-3ksfpaf7	1130	47	NI	NI	NNP
cord-034340-3ksfpaf7	1130	48	causes	cause	NNS
cord-034340-3ksfpaf7	1130	49	of	of	IN
cord-034340-3ksfpaf7	1130	50	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	1130	51	pain	pain	NN
cord-034340-3ksfpaf7	1130	52	(	(	-LRB-
cord-034340-3ksfpaf7	1130	53	NI	NI	NNP
cord-034340-3ksfpaf7	1130	54	-	-	HYPH
cord-034340-3ksfpaf7	1130	55	MSD	MSD	NNP
cord-034340-3ksfpaf7	1130	56	)	)	-RRB-
cord-034340-3ksfpaf7	1130	57	,	,	,
cord-034340-3ksfpaf7	1130	58	regardless	regardless	RB
cord-034340-3ksfpaf7	1130	59	of	of	IN
cord-034340-3ksfpaf7	1130	60	the	the	DT
cord-034340-3ksfpaf7	1130	61	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1130	62	(	(	-LRB-
cord-034340-3ksfpaf7	1130	63	GI	GI	NNP
cord-034340-3ksfpaf7	1130	64	)	)	-RRB-
cord-034340-3ksfpaf7	1130	65	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1130	66	(	(	-LRB-
cord-034340-3ksfpaf7	1130	67	Table	table	NN
cord-034340-3ksfpaf7	1130	68	1	1	CD
cord-034340-3ksfpaf7	1130	69	)	)	-RRB-
cord-034340-3ksfpaf7	1130	70	.	.	.
cord-034340-3ksfpaf7	1131	1	fCAL	fCAL	NNP
cord-034340-3ksfpaf7	1131	2	was	be	VBD
cord-034340-3ksfpaf7	1131	3	compared	compare	VBN
cord-034340-3ksfpaf7	1131	4	among	among	IN
cord-034340-3ksfpaf7	1131	5	different	different	JJ
cord-034340-3ksfpaf7	1131	6	groups	group	NNS
cord-034340-3ksfpaf7	1131	7	of	of	IN
cord-034340-3ksfpaf7	1131	8	patients	patient	NNS
cord-034340-3ksfpaf7	1131	9	and	and	CC
cord-034340-3ksfpaf7	1131	10	correlated	correlate	VBN
cord-034340-3ksfpaf7	1131	11	with	with	IN
cord-034340-3ksfpaf7	1131	12	demographic	demographic	JJ
cord-034340-3ksfpaf7	1131	13	data	datum	NNS
cord-034340-3ksfpaf7	1131	14	,	,	,
cord-034340-3ksfpaf7	1131	15	clinical	clinical	JJ
cord-034340-3ksfpaf7	1131	16	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1131	17	,	,	,
cord-034340-3ksfpaf7	1131	18	treatment	treatment	NN
cord-034340-3ksfpaf7	1131	19	modalities	modality	NNS
cord-034340-3ksfpaf7	1131	20	and	and	CC
cord-034340-3ksfpaf7	1131	21	disease	disease	NN
cord-034340-3ksfpaf7	1131	22	activity	activity	NN
cord-034340-3ksfpaf7	1131	23	measured	measure	VBN
cord-034340-3ksfpaf7	1131	24	by	by	IN
cord-034340-3ksfpaf7	1131	25	jSpADA	jSpADA	NNP
cord-034340-3ksfpaf7	1131	26	.	.	.
cord-034340-3ksfpaf7	1132	1	The	the	DT
cord-034340-3ksfpaf7	1132	2	values	value	NNS
cord-034340-3ksfpaf7	1132	3	were	be	VBD
cord-034340-3ksfpaf7	1132	4	also	also	RB
cord-034340-3ksfpaf7	1132	5	dichotomized	dichotomize	VBN
cord-034340-3ksfpaf7	1132	6	to	to	IN
cord-034340-3ksfpaf7	1132	7	<	<	XX
cord-034340-3ksfpaf7	1132	8	50	50	CD
cord-034340-3ksfpaf7	1132	9	mg	mg	NNP
cord-034340-3ksfpaf7	1132	10	/	/	SYM
cord-034340-3ksfpaf7	1132	11	kg	kg	NNS
cord-034340-3ksfpaf7	1132	12	,	,	,
cord-034340-3ksfpaf7	1132	13	50	50	CD
cord-034340-3ksfpaf7	1132	14	-	-	SYM
cord-034340-3ksfpaf7	1132	15	200	200	CD
cord-034340-3ksfpaf7	1132	16	mg	mg	NNP
cord-034340-3ksfpaf7	1132	17	/	/	SYM
cord-034340-3ksfpaf7	1132	18	kg	kg	NNP
cord-034340-3ksfpaf7	1132	19	,	,	,
cord-034340-3ksfpaf7	1132	20	and	and	CC
cord-034340-3ksfpaf7	1132	21	>	>	XX
cord-034340-3ksfpaf7	1132	22	200	200	CD
cord-034340-3ksfpaf7	1132	23	mg	mg	NNP
cord-034340-3ksfpaf7	1132	24	/	/	SYM
cord-034340-3ksfpaf7	1132	25	kg	kg	NNP
cord-034340-3ksfpaf7	1132	26	,	,	,
cord-034340-3ksfpaf7	1132	27	which	which	WDT
cord-034340-3ksfpaf7	1132	28	was	be	VBD
cord-034340-3ksfpaf7	1132	29	regarded	regard	VBN
cord-034340-3ksfpaf7	1132	30	as	as	RB
cord-034340-3ksfpaf7	1132	31	normal	normal	JJ
cord-034340-3ksfpaf7	1132	32	,	,	,
cord-034340-3ksfpaf7	1132	33	slightly	slightly	RB
cord-034340-3ksfpaf7	1132	34	increased	increase	VBN
cord-034340-3ksfpaf7	1132	35	and	and	CC
cord-034340-3ksfpaf7	1132	36	increased	increase	VBD
cord-034340-3ksfpaf7	1132	37	,	,	,
cord-034340-3ksfpaf7	1132	38	respectively	respectively	RB
cord-034340-3ksfpaf7	1132	39	.	.	.
cord-034340-3ksfpaf7	1133	1	Ileocolonoscopy	Ileocolonoscopy	NNP
cord-034340-3ksfpaf7	1133	2	was	be	VBD
cord-034340-3ksfpaf7	1133	3	performed	perform	VBN
cord-034340-3ksfpaf7	1133	4	in	in	IN
cord-034340-3ksfpaf7	1133	5	one	one	CD
cord-034340-3ksfpaf7	1133	6	patient	patient	NN
cord-034340-3ksfpaf7	1133	7	.	.	.
cord-034340-3ksfpaf7	1133	8	 	 	_SP
cord-034340-3ksfpaf7	1134	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1134	2	study	study	NN
cord-034340-3ksfpaf7	1134	3	has	have	VBZ
cord-034340-3ksfpaf7	1134	4	shown	show	VBN
cord-034340-3ksfpaf7	1134	5	that	that	IN
cord-034340-3ksfpaf7	1134	6	fCAL	fcal	NN
cord-034340-3ksfpaf7	1134	7	levels	level	NNS
cord-034340-3ksfpaf7	1134	8	are	be	VBP
cord-034340-3ksfpaf7	1134	9	significantly	significantly	RB
cord-034340-3ksfpaf7	1134	10	higher	high	JJR
cord-034340-3ksfpaf7	1134	11	in	in	IN
cord-034340-3ksfpaf7	1134	12	ErA	era	NN
cord-034340-3ksfpaf7	1134	13	patients	patient	NNS
cord-034340-3ksfpaf7	1134	14	compared	compare	VBN
cord-034340-3ksfpaf7	1134	15	to	to	IN
cord-034340-3ksfpaf7	1134	16	other	other	JJ
cord-034340-3ksfpaf7	1134	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	1134	18	(	(	-LRB-
cord-034340-3ksfpaf7	1134	19	p=0.03	p=0.03	NN
cord-034340-3ksfpaf7	1134	20	)	)	-RRB-
cord-034340-3ksfpaf7	1135	1	and/or	and/or	CC
cord-034340-3ksfpaf7	1135	2	NI	NI	NNP
cord-034340-3ksfpaf7	1135	3	-	-	HYPH
cord-034340-3ksfpaf7	1135	4	MSD	MSD	NNP
cord-034340-3ksfpaf7	1135	5	(	(	-LRB-
cord-034340-3ksfpaf7	1135	6	p=0.03	p=0.03	NN
cord-034340-3ksfpaf7	1135	7	)	)	-RRB-
cord-034340-3ksfpaf7	1135	8	patients	patient	NNS
cord-034340-3ksfpaf7	1135	9	.	.	.
cord-034340-3ksfpaf7	1136	1	Moreover	moreover	RB
cord-034340-3ksfpaf7	1136	2	,	,	,
cord-034340-3ksfpaf7	1136	3	almost	almost	RB
cord-034340-3ksfpaf7	1136	4	a	a	DT
cord-034340-3ksfpaf7	1136	5	third	third	NN
cord-034340-3ksfpaf7	1136	6	of	of	IN
cord-034340-3ksfpaf7	1136	7	patients	patient	NNS
cord-034340-3ksfpaf7	1136	8	with	with	IN
cord-034340-3ksfpaf7	1136	9	ErA	era	NN
cord-034340-3ksfpaf7	1136	10	had	have	VBD
cord-034340-3ksfpaf7	1136	11	levels	level	NNS
cord-034340-3ksfpaf7	1136	12	of	of	IN
cord-034340-3ksfpaf7	1137	1	fCAL	fcal	NN
cord-034340-3ksfpaf7	1137	2	above	above	IN
cord-034340-3ksfpaf7	1137	3	the	the	DT
cord-034340-3ksfpaf7	1137	4	range	range	NN
cord-034340-3ksfpaf7	1137	5	regarded	regard	VBN
cord-034340-3ksfpaf7	1137	6	as	as	IN
cord-034340-3ksfpaf7	1137	7	normal	normal	JJ
cord-034340-3ksfpaf7	1137	8	,	,	,
cord-034340-3ksfpaf7	1137	9	which	which	WDT
cord-034340-3ksfpaf7	1137	10	adds	add	VBZ
cord-034340-3ksfpaf7	1137	11	to	to	IN
cord-034340-3ksfpaf7	1137	12	the	the	DT
cord-034340-3ksfpaf7	1137	13	number	number	NN
cord-034340-3ksfpaf7	1137	14	of	of	IN
cord-034340-3ksfpaf7	1137	15	evidences	evidence	NNS
cord-034340-3ksfpaf7	1137	16	for	for	IN
cord-034340-3ksfpaf7	1137	17	a	a	DT
cord-034340-3ksfpaf7	1137	18	gut	gut	NN
cord-034340-3ksfpaf7	1137	19	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1137	20	in	in	IN
cord-034340-3ksfpaf7	1137	21	this	this	DT
cord-034340-3ksfpaf7	1137	22	particular	particular	JJ
cord-034340-3ksfpaf7	1137	23	type	type	NN
cord-034340-3ksfpaf7	1137	24	of	of	IN
cord-034340-3ksfpaf7	1137	25	JIA	JIA	NNP
cord-034340-3ksfpaf7	1137	26	.	.	.
cord-034340-3ksfpaf7	1138	1	Besides	besides	RB
cord-034340-3ksfpaf7	1138	2	,	,	,
cord-034340-3ksfpaf7	1138	3	the	the	DT
cord-034340-3ksfpaf7	1138	4	fCAL	fcal	NN
cord-034340-3ksfpaf7	1138	5	levels	level	NNS
cord-034340-3ksfpaf7	1138	6	were	be	VBD
cord-034340-3ksfpaf7	1138	7	higher	high	JJR
cord-034340-3ksfpaf7	1138	8	in	in	IN
cord-034340-3ksfpaf7	1138	9	those	those	DT
cord-034340-3ksfpaf7	1138	10	with	with	IN
cord-034340-3ksfpaf7	1138	11	axial	axial	JJ
cord-034340-3ksfpaf7	1138	12	involvement	involvement	NN
cord-034340-3ksfpaf7	1138	13	,	,	,
cord-034340-3ksfpaf7	1138	14	which	which	WDT
cord-034340-3ksfpaf7	1138	15	further	further	RB
cord-034340-3ksfpaf7	1138	16	suppots	suppot	VBZ
cord-034340-3ksfpaf7	1138	17	the	the	DT
cord-034340-3ksfpaf7	1138	18	association	association	NNP
cord-034340-3ksfpaf7	1138	19	of	of	IN
cord-034340-3ksfpaf7	1138	20	gut	gut	NNP
cord-034340-3ksfpaf7	1138	21	and	and	CC
cord-034340-3ksfpaf7	1138	22	axial	axial	JJ
cord-034340-3ksfpaf7	1138	23	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1138	24	in	in	IN
cord-034340-3ksfpaf7	1138	25	children	child	NNS
cord-034340-3ksfpaf7	1138	26	with	with	IN
cord-034340-3ksfpaf7	1138	27	ErA.	ErA.	NNP
cord-034340-3ksfpaf7	1139	1	Although	although	IN
cord-034340-3ksfpaf7	1139	2	endoscopy	endoscopy	NN
cord-034340-3ksfpaf7	1139	3	remains	remain	VBZ
cord-034340-3ksfpaf7	1139	4	a	a	DT
cord-034340-3ksfpaf7	1139	5	gold	gold	NN
cord-034340-3ksfpaf7	1139	6	standard	standard	NN
cord-034340-3ksfpaf7	1139	7	for	for	IN
cord-034340-3ksfpaf7	1139	8	the	the	DT
cord-034340-3ksfpaf7	1139	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1139	10	of	of	IN
cord-034340-3ksfpaf7	1139	11	gut	gut	NN
cord-034340-3ksfpaf7	1139	12	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1139	13	,	,	,
cord-034340-3ksfpaf7	1139	14	fCAL	fcal	NN
cord-034340-3ksfpaf7	1139	15	can	can	MD
cord-034340-3ksfpaf7	1139	16	help	help	VB
cord-034340-3ksfpaf7	1139	17	to	to	TO
cord-034340-3ksfpaf7	1139	18	select	select	VB
cord-034340-3ksfpaf7	1139	19	children	child	NNS
cord-034340-3ksfpaf7	1139	20	with	with	IN
cord-034340-3ksfpaf7	1139	21	ErA	era	NN
cord-034340-3ksfpaf7	1139	22	who	who	WP
cord-034340-3ksfpaf7	1139	23	might	may	MD
cord-034340-3ksfpaf7	1139	24	benefit	benefit	VB
cord-034340-3ksfpaf7	1139	25	from	from	IN
cord-034340-3ksfpaf7	1139	26	this	this	DT
cord-034340-3ksfpaf7	1139	27	invasive	invasive	JJ
cord-034340-3ksfpaf7	1139	28	procedure	procedure	NN
cord-034340-3ksfpaf7	1139	29	,	,	,
cord-034340-3ksfpaf7	1139	30	regardless	regardless	RB
cord-034340-3ksfpaf7	1139	31	of	of	IN
cord-034340-3ksfpaf7	1139	32	the	the	DT
cord-034340-3ksfpaf7	1139	33	GI	GI	NNP
cord-034340-3ksfpaf7	1139	34	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1139	35	,	,	,
cord-034340-3ksfpaf7	1139	36	as	as	IN
cord-034340-3ksfpaf7	1139	37	shown	show	VBN
cord-034340-3ksfpaf7	1139	38	in	in	IN
cord-034340-3ksfpaf7	1139	39	one	one	CD
cord-034340-3ksfpaf7	1139	40	patient	patient	NN
cord-034340-3ksfpaf7	1139	41	with	with	IN
cord-034340-3ksfpaf7	1139	42	the	the	DT
cord-034340-3ksfpaf7	1139	43	highest	high	JJS
cord-034340-3ksfpaf7	1139	44	fCAL	fcal	JJ
cord-034340-3ksfpaf7	1139	45	concentration	concentration	NN
cord-034340-3ksfpaf7	1139	46	in	in	IN
cord-034340-3ksfpaf7	1139	47	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1139	48	study	study	NN
cord-034340-3ksfpaf7	1139	49	.	.	.
cord-034340-3ksfpaf7	1140	1	Moreover	moreover	RB
cord-034340-3ksfpaf7	1140	2	,	,	,
cord-034340-3ksfpaf7	1140	3	fCAL	fcal	NN
cord-034340-3ksfpaf7	1140	4	levels	level	NNS
cord-034340-3ksfpaf7	1140	5	seems	seem	VBZ
cord-034340-3ksfpaf7	1140	6	not	not	RB
cord-034340-3ksfpaf7	1140	7	to	to	TO
cord-034340-3ksfpaf7	1140	8	be	be	VB
cord-034340-3ksfpaf7	1140	9	influenced	influence	VBN
cord-034340-3ksfpaf7	1140	10	by	by	IN
cord-034340-3ksfpaf7	1140	11	disease	disease	NN
cord-034340-3ksfpaf7	1140	12	characteristic	characteristic	NN
cord-034340-3ksfpaf7	1140	13	and/or	and/or	CC
cord-034340-3ksfpaf7	1140	14	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	1140	15	therapy	therapy	NN
cord-034340-3ksfpaf7	1140	16	intake	intake	NN
cord-034340-3ksfpaf7	1140	17	.	.	.
cord-034340-3ksfpaf7	1141	1	Therefore	therefore	RB
cord-034340-3ksfpaf7	1141	2	,	,	,
cord-034340-3ksfpaf7	1141	3	fCAL	fcal	NN
cord-034340-3ksfpaf7	1141	4	should	should	MD
cord-034340-3ksfpaf7	1141	5	be	be	VB
cord-034340-3ksfpaf7	1141	6	a	a	DT
cord-034340-3ksfpaf7	1141	7	part	part	NN
cord-034340-3ksfpaf7	1141	8	of	of	IN
cord-034340-3ksfpaf7	1141	9	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	1141	10	workup	workup	NN
cord-034340-3ksfpaf7	1141	11	in	in	IN
cord-034340-3ksfpaf7	1141	12	children	child	NNS
cord-034340-3ksfpaf7	1141	13	with	with	IN
cord-034340-3ksfpaf7	1141	14	any	any	DT
cord-034340-3ksfpaf7	1141	15	type	type	NN
cord-034340-3ksfpaf7	1141	16	of	of	IN
cord-034340-3ksfpaf7	1141	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	1141	18	,	,	,
cord-034340-3ksfpaf7	1141	19	but	but	CC
cord-034340-3ksfpaf7	1141	20	most	most	RBS
cord-034340-3ksfpaf7	1141	21	importantly	importantly	RB
cord-034340-3ksfpaf7	1141	22	in	in	IN
cord-034340-3ksfpaf7	1141	23	those	those	DT
cord-034340-3ksfpaf7	1141	24	with	with	IN
cord-034340-3ksfpaf7	1141	25	ErA.	ErA.	NNP
cord-034340-3ksfpaf7	1141	26	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1141	27	potential	potential	JJ
cord-034340-3ksfpaf7	1141	28	predictor	predictor	NN
cord-034340-3ksfpaf7	1141	29	variables	variable	NNS
cord-034340-3ksfpaf7	1141	30	of	of	IN
cord-034340-3ksfpaf7	1141	31	Magnetic	Magnetic	NNP
cord-034340-3ksfpaf7	1141	32	Resonance	Resonance	NNP
cord-034340-3ksfpaf7	1141	33	Imaging	Imaging	NNP
cord-034340-3ksfpaf7	1141	34	(	(	-LRB-
cord-034340-3ksfpaf7	1141	35	MRI	MRI	NNP
cord-034340-3ksfpaf7	1141	36	)	)	-RRB-
cord-034340-3ksfpaf7	1141	37	SIJ	SIJ	NNP
cord-034340-3ksfpaf7	1141	38	remission	remission	NN
cord-034340-3ksfpaf7	1141	39	Methods	method	NNS
cord-034340-3ksfpaf7	1141	40	:	:	:
cord-034340-3ksfpaf7	1142	1	Retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1142	2	review	review	NN
cord-034340-3ksfpaf7	1142	3	of	of	IN
cord-034340-3ksfpaf7	1142	4	prospectively	prospectively	RB
cord-034340-3ksfpaf7	1142	5	collected	collect	VBN
cord-034340-3ksfpaf7	1142	6	data	datum	NNS
cord-034340-3ksfpaf7	1142	7	.	.	.
cord-034340-3ksfpaf7	1143	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1143	2	included	include	VBD
cord-034340-3ksfpaf7	1143	3	patients	patient	NNS
cord-034340-3ksfpaf7	1143	4	with	with	IN
cord-034340-3ksfpaf7	1143	5	ERA	ERA	NNP
cord-034340-3ksfpaf7	1143	6	(	(	-LRB-
cord-034340-3ksfpaf7	1143	7	according	accord	VBG
cord-034340-3ksfpaf7	1143	8	to	to	IN
cord-034340-3ksfpaf7	1143	9	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	1143	10	criteria	criterion	NNS
cord-034340-3ksfpaf7	1143	11	)	)	-RRB-
cord-034340-3ksfpaf7	1143	12	continuously	continuously	RB
cord-034340-3ksfpaf7	1143	13	treated	treat	VBN
cord-034340-3ksfpaf7	1143	14	with	with	IN
cord-034340-3ksfpaf7	1143	15	anti	anti	JJ
cord-034340-3ksfpaf7	1143	16	-	-	JJ
cord-034340-3ksfpaf7	1143	17	TNF	tnf	JJ
cord-034340-3ksfpaf7	1143	18	agents	agent	NNS
cord-034340-3ksfpaf7	1143	19	for	for	IN
cord-034340-3ksfpaf7	1143	20	≥	≥	CD
cord-034340-3ksfpaf7	1143	21	12	12	CD
cord-034340-3ksfpaf7	1143	22	months	month	NNS
cord-034340-3ksfpaf7	1143	23	who	who	WP
cord-034340-3ksfpaf7	1143	24	had	have	VBD
cord-034340-3ksfpaf7	1143	25	at	at	RB
cord-034340-3ksfpaf7	1143	26	least	least	RBS
cord-034340-3ksfpaf7	1143	27	two	two	CD
cord-034340-3ksfpaf7	1143	28	MRIs	mri	NNS
cord-034340-3ksfpaf7	1143	29	of	of	IN
cord-034340-3ksfpaf7	1143	30	the	the	DT
cord-034340-3ksfpaf7	1143	31	sacroiliac	sacroiliac	NN
cord-034340-3ksfpaf7	1143	32	joints	joint	NNS
cord-034340-3ksfpaf7	1143	33	performed	perform	VBN
cord-034340-3ksfpaf7	1143	34	before	before	IN
cord-034340-3ksfpaf7	1143	35	starting	start	VBG
cord-034340-3ksfpaf7	1143	36	anti	anti	JJ
cord-034340-3ksfpaf7	1143	37	-	-	JJ
cord-034340-3ksfpaf7	1143	38	TNF	TNF	NNP
cord-034340-3ksfpaf7	1143	39	therapy	therapy	NN
cord-034340-3ksfpaf7	1143	40	(	(	-LRB-
cord-034340-3ksfpaf7	1143	41	baseline	baseline	NN
cord-034340-3ksfpaf7	1143	42	)	)	-RRB-
cord-034340-3ksfpaf7	1143	43	and	and	CC
cord-034340-3ksfpaf7	1143	44	during	during	IN
cord-034340-3ksfpaf7	1143	45	the	the	DT
cord-034340-3ksfpaf7	1143	46	follow	follow	NN
cord-034340-3ksfpaf7	1143	47	up	up	RP
cord-034340-3ksfpaf7	1143	48	(	(	-LRB-
cord-034340-3ksfpaf7	1143	49	>	>	NFP
cord-034340-3ksfpaf7	1143	50	12	12	CD
cord-034340-3ksfpaf7	1143	51	months	month	NNS
cord-034340-3ksfpaf7	1143	52	after	after	IN
cord-034340-3ksfpaf7	1143	53	anti	anti	JJ
cord-034340-3ksfpaf7	1143	54	-	-	JJ
cord-034340-3ksfpaf7	1143	55	TNF	TNF	NNP
cord-034340-3ksfpaf7	1143	56	treatment	treatment	NN
cord-034340-3ksfpaf7	1143	57	)	)	-RRB-
cord-034340-3ksfpaf7	1143	58	.	.	.
cord-034340-3ksfpaf7	1144	1	SI	SI	NNP
cord-034340-3ksfpaf7	1144	2	joints	joint	NNS
cord-034340-3ksfpaf7	1144	3	were	be	VBD
cord-034340-3ksfpaf7	1144	4	examined	examine	VBN
cord-034340-3ksfpaf7	1144	5	using	use	VBG
cord-034340-3ksfpaf7	1144	6	T1-weighted	t1-weighte	VBN
cord-034340-3ksfpaf7	1144	7	images	image	NNS
cord-034340-3ksfpaf7	1144	8	,	,	,
cord-034340-3ksfpaf7	1144	9	T2	T2	NNP
cord-034340-3ksfpaf7	1144	10	fastsuppressed	fastsuppressed	JJ
cord-034340-3ksfpaf7	1144	11	and	and	CC
cord-034340-3ksfpaf7	1144	12	short	short	JJ
cord-034340-3ksfpaf7	1144	13	-	-	HYPH
cord-034340-3ksfpaf7	1144	14	tau	tau	NN
cord-034340-3ksfpaf7	1144	15	inversión	inversión	NN
cord-034340-3ksfpaf7	1144	16	recovery	recovery	NN
cord-034340-3ksfpaf7	1144	17	.	.	.
cord-034340-3ksfpaf7	1145	1	The	the	DT
cord-034340-3ksfpaf7	1145	2	SPARCC	SPARCC	NNP
cord-034340-3ksfpaf7	1145	3	-	-	HYPH
cord-034340-3ksfpaf7	1145	4	SIS	SIS	NNP
cord-034340-3ksfpaf7	1145	5	was	be	VBD
cord-034340-3ksfpaf7	1145	6	scored	score	VBN
cord-034340-3ksfpaf7	1145	7	by	by	IN
cord-034340-3ksfpaf7	1145	8	two	two	CD
cord-034340-3ksfpaf7	1145	9	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1145	10	radiologists	radiologist	NNS
cord-034340-3ksfpaf7	1145	11	.	.	.
cord-034340-3ksfpaf7	1146	1	SPARCC	SPARCC	NNP
cord-034340-3ksfpaf7	1146	2	-	-	HYPH
cord-034340-3ksfpaf7	1146	3	SIS	SIS	NNP
cord-034340-3ksfpaf7	1146	4	assessed	assess	VBD
cord-034340-3ksfpaf7	1146	5	the	the	DT
cord-034340-3ksfpaf7	1146	6	presence	presence	NN
cord-034340-3ksfpaf7	1146	7	,	,	,
cord-034340-3ksfpaf7	1146	8	depth	depth	NN
cord-034340-3ksfpaf7	1146	9	and	and	CC
cord-034340-3ksfpaf7	1146	10	intensity	intensity	NN
cord-034340-3ksfpaf7	1146	11	of	of	IN
cord-034340-3ksfpaf7	1146	12	bone	bone	NN
cord-034340-3ksfpaf7	1146	13	marrow	marrow	NN
cord-034340-3ksfpaf7	1146	14	edema	edema	NN
cord-034340-3ksfpaf7	1146	15	(	(	-LRB-
cord-034340-3ksfpaf7	1146	16	BME	BME	NNP
cord-034340-3ksfpaf7	1146	17	)	)	-RRB-
cord-034340-3ksfpaf7	1146	18	on	on	IN
cord-034340-3ksfpaf7	1146	19	consecutive	consecutive	JJ
cord-034340-3ksfpaf7	1146	20	six	six	CD
cord-034340-3ksfpaf7	1146	21	slices	slice	NNS
cord-034340-3ksfpaf7	1146	22	in	in	IN
cord-034340-3ksfpaf7	1146	23	the	the	DT
cord-034340-3ksfpaf7	1146	24	iliac	iliac	NNP
cord-034340-3ksfpaf7	1146	25	and	and	CC
cord-034340-3ksfpaf7	1146	26	sacrum	sacrum	NNP
cord-034340-3ksfpaf7	1146	27	bones	bone	NNS
cord-034340-3ksfpaf7	1146	28	.	.	.
cord-034340-3ksfpaf7	1147	1	Scoring	scoring	NN
cord-034340-3ksfpaf7	1147	2	is	be	VBZ
cord-034340-3ksfpaf7	1147	3	composed	compose	VBN
cord-034340-3ksfpaf7	1147	4	by	by	IN
cord-034340-3ksfpaf7	1147	5	:	:	:
cord-034340-3ksfpaf7	1147	6	BME	BME	NNP
cord-034340-3ksfpaf7	1147	7	(	(	-LRB-
cord-034340-3ksfpaf7	1147	8	0	0	CD
cord-034340-3ksfpaf7	1147	9	-	-	SYM
cord-034340-3ksfpaf7	1147	10	48	48	CD
cord-034340-3ksfpaf7	1147	11	)	)	-RRB-
cord-034340-3ksfpaf7	1147	12	,	,	,
cord-034340-3ksfpaf7	1147	13	BM	BM	NNP
cord-034340-3ksfpaf7	1147	14	intensity	intensity	NN
cord-034340-3ksfpaf7	1147	15	(	(	-LRB-
cord-034340-3ksfpaf7	1147	16	0	0	CD
cord-034340-3ksfpaf7	1147	17	-	-	SYM
cord-034340-3ksfpaf7	1147	18	12	12	CD
cord-034340-3ksfpaf7	1147	19	)	)	-RRB-
cord-034340-3ksfpaf7	1147	20	,	,	,
cord-034340-3ksfpaf7	1147	21	BM	BM	NNP
cord-034340-3ksfpaf7	1147	22	depth	depth	NN
cord-034340-3ksfpaf7	1147	23	(	(	-LRB-
cord-034340-3ksfpaf7	1147	24	0	0	CD
cord-034340-3ksfpaf7	1147	25	-	-	SYM
cord-034340-3ksfpaf7	1147	26	12	12	CD
cord-034340-3ksfpaf7	1147	27	Introduction	introduction	NN
cord-034340-3ksfpaf7	1147	28	:	:	:
cord-034340-3ksfpaf7	1147	29	Several	several	JJ
cord-034340-3ksfpaf7	1147	30	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1147	31	patients	patient	NNS
cord-034340-3ksfpaf7	1147	32	manifest	manifest	VBP
cord-034340-3ksfpaf7	1147	33	conditions	condition	NNS
cord-034340-3ksfpaf7	1147	34	commonly	commonly	RB
cord-034340-3ksfpaf7	1147	35	misdiagnosed	misdiagnose	VBN
cord-034340-3ksfpaf7	1147	36	as	as	IN
cord-034340-3ksfpaf7	1147	37	spider	spider	NN
cord-034340-3ksfpaf7	1147	38	bites	bite	NNS
cord-034340-3ksfpaf7	1147	39	,	,	,
cord-034340-3ksfpaf7	1147	40	which	which	WDT
cord-034340-3ksfpaf7	1147	41	however	however	RB
cord-034340-3ksfpaf7	1147	42	,	,	,
cord-034340-3ksfpaf7	1147	43	can	can	MD
cord-034340-3ksfpaf7	1147	44	include	include	VB
cord-034340-3ksfpaf7	1147	45	other	other	JJ
cord-034340-3ksfpaf7	1147	46	arthropods	arthropod	NNS
cord-034340-3ksfpaf7	1147	47	bites	bite	NNS
cord-034340-3ksfpaf7	1147	48	;	;	:
cord-034340-3ksfpaf7	1147	49	bacterial	bacterial	JJ
cord-034340-3ksfpaf7	1147	50	,	,	,
cord-034340-3ksfpaf7	1147	51	viral	viral	JJ
cord-034340-3ksfpaf7	1147	52	,	,	,
cord-034340-3ksfpaf7	1147	53	and	and	CC
cord-034340-3ksfpaf7	1147	54	mycotic	mycotic	JJ
cord-034340-3ksfpaf7	1147	55	infections	infection	NNS
cord-034340-3ksfpaf7	1147	56	;	;	:
cord-034340-3ksfpaf7	1147	57	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1147	58	;	;	:
cord-034340-3ksfpaf7	1147	59	dermatological	dermatological	JJ
cord-034340-3ksfpaf7	1147	60	diseases	disease	NNS
cord-034340-3ksfpaf7	1147	61	;	;	:
cord-034340-3ksfpaf7	1147	62	miscellaneous	miscellaneous	JJ
cord-034340-3ksfpaf7	1147	63	conditions	condition	NNS
cord-034340-3ksfpaf7	1147	64	as	as	IN
cord-034340-3ksfpaf7	1147	65	drug	drug	NN
cord-034340-3ksfpaf7	1147	66	reactions	reaction	NNS
cord-034340-3ksfpaf7	1147	67	,	,	,
cord-034340-3ksfpaf7	1147	68	chemical	chemical	NN
cord-034340-3ksfpaf7	1147	69	injuries	injury	NNS
cord-034340-3ksfpaf7	1147	70	.	.	.
cord-034340-3ksfpaf7	1148	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1148	2	:	:	:
cord-034340-3ksfpaf7	1149	1	In	in	IN
cord-034340-3ksfpaf7	1149	2	Italy	Italy	NNP
cord-034340-3ksfpaf7	1149	3	,	,	,
cord-034340-3ksfpaf7	1149	4	spiders	spider	NNS
cord-034340-3ksfpaf7	1149	5	which	which	WDT
cord-034340-3ksfpaf7	1149	6	are	be	VBP
cord-034340-3ksfpaf7	1149	7	likely	likely	JJ
cord-034340-3ksfpaf7	1149	8	to	to	TO
cord-034340-3ksfpaf7	1149	9	be	be	VB
cord-034340-3ksfpaf7	1149	10	associated	associate	VBN
cord-034340-3ksfpaf7	1149	11	with	with	IN
cord-034340-3ksfpaf7	1149	12	severe	severe	JJ
cord-034340-3ksfpaf7	1149	13	toxin	toxin	NN
cord-034340-3ksfpaf7	1149	14	mediated	mediate	VBN
cord-034340-3ksfpaf7	1149	15	tissue	tissue	NN
cord-034340-3ksfpaf7	1149	16	damage	damage	NN
cord-034340-3ksfpaf7	1149	17	are	be	VBP
cord-034340-3ksfpaf7	1149	18	uncommon	uncommon	JJ
cord-034340-3ksfpaf7	1149	19	,	,	,
cord-034340-3ksfpaf7	1149	20	especially	especially	RB
cord-034340-3ksfpaf7	1149	21	in	in	IN
cord-034340-3ksfpaf7	1149	22	urban	urban	JJ
cord-034340-3ksfpaf7	1149	23	zones	zone	NNS
cord-034340-3ksfpaf7	1149	24	.	.	.
cord-034340-3ksfpaf7	1150	1	However	however	RB
cord-034340-3ksfpaf7	1150	2	,	,	,
cord-034340-3ksfpaf7	1150	3	a	a	DT
cord-034340-3ksfpaf7	1150	4	minor	minor	JJ
cord-034340-3ksfpaf7	1150	5	trauma	trauma	NN
cord-034340-3ksfpaf7	1150	6	may	may	MD
cord-034340-3ksfpaf7	1150	7	be	be	VB
cord-034340-3ksfpaf7	1150	8	a	a	DT
cord-034340-3ksfpaf7	1150	9	precipitating	precipitate	VBG
cord-034340-3ksfpaf7	1150	10	factor	factor	NN
cord-034340-3ksfpaf7	1150	11	for	for	IN
cord-034340-3ksfpaf7	1150	12	pyoderma	pyoderma	NN
cord-034340-3ksfpaf7	1150	13	gangrenosum	gangrenosum	NNP
cord-034340-3ksfpaf7	1150	14	particularly	particularly	RB
cord-034340-3ksfpaf7	1150	15	over	over	IN
cord-034340-3ksfpaf7	1150	16	the	the	DT
cord-034340-3ksfpaf7	1150	17	legs	leg	NNS
cord-034340-3ksfpaf7	1150	18	,	,	,
cord-034340-3ksfpaf7	1150	19	in	in	IN
cord-034340-3ksfpaf7	1150	20	association	association	NN
cord-034340-3ksfpaf7	1150	21	with	with	IN
cord-034340-3ksfpaf7	1150	22	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1150	23	bowel	bowel	NN
cord-034340-3ksfpaf7	1150	24	disease	disease	NN
cord-034340-3ksfpaf7	1150	25	,	,	,
cord-034340-3ksfpaf7	1150	26	haematologic	haematologic	JJ
cord-034340-3ksfpaf7	1150	27	diseases	disease	NNS
cord-034340-3ksfpaf7	1150	28	and	and	CC
cord-034340-3ksfpaf7	1150	29	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	1150	30	Idiopathic	Idiopathic	NNP
cord-034340-3ksfpaf7	1150	31	Arthritis	Arthritis	NNP
cord-034340-3ksfpaf7	1150	32	(	(	-LRB-
cord-034340-3ksfpaf7	1150	33	JIA	JIA	NNP
cord-034340-3ksfpaf7	1150	34	)	)	-RRB-
cord-034340-3ksfpaf7	1150	35	.	.	.
cord-034340-3ksfpaf7	1151	1	Methods	method	NNS
cord-034340-3ksfpaf7	1151	2	:	:	:
cord-034340-3ksfpaf7	1151	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1151	4	describe	describe	VBP
cord-034340-3ksfpaf7	1151	5	a	a	DT
cord-034340-3ksfpaf7	1151	6	11-years	11-years	CD
cord-034340-3ksfpaf7	1151	7	old	old	JJ
cord-034340-3ksfpaf7	1151	8	boy	boy	NN
cord-034340-3ksfpaf7	1151	9	with	with	IN
cord-034340-3ksfpaf7	1151	10	pyoderma	pyoderma	NNP
cord-034340-3ksfpaf7	1151	11	gangrenosum	gangrenosum	NNP
cord-034340-3ksfpaf7	1151	12	complicated	complicated	JJ
cord-034340-3ksfpaf7	1151	13	spider	spider	NN
cord-034340-3ksfpaf7	1151	14	bite	bite	NN
cord-034340-3ksfpaf7	1151	15	in	in	IN
cord-034340-3ksfpaf7	1151	16	association	association	NN
cord-034340-3ksfpaf7	1151	17	with	with	IN
cord-034340-3ksfpaf7	1151	18	systemic	systemic	JJ
cord-034340-3ksfpaf7	1151	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	1151	20	(	(	-LRB-
cord-034340-3ksfpaf7	1151	21	sJIA	sjia	NN
cord-034340-3ksfpaf7	1151	22	)	)	-RRB-
cord-034340-3ksfpaf7	1151	23	.	.	.
cord-034340-3ksfpaf7	1152	1	The	the	DT
cord-034340-3ksfpaf7	1152	2	patient	patient	NN
cord-034340-3ksfpaf7	1152	3	was	be	VBD
cord-034340-3ksfpaf7	1152	4	in	in	IN
cord-034340-3ksfpaf7	1152	5	clinical	clinical	JJ
cord-034340-3ksfpaf7	1152	6	remission	remission	NN
cord-034340-3ksfpaf7	1152	7	after	after	IN
cord-034340-3ksfpaf7	1152	8	the	the	DT
cord-034340-3ksfpaf7	1152	9	start	start	NN
cord-034340-3ksfpaf7	1152	10	of	of	IN
cord-034340-3ksfpaf7	1152	11	the	the	DT
cord-034340-3ksfpaf7	1152	12	sJIA	sjia	NN
cord-034340-3ksfpaf7	1152	13	,	,	,
cord-034340-3ksfpaf7	1152	14	occurred	occur	VBD
cord-034340-3ksfpaf7	1152	15	two	two	CD
cord-034340-3ksfpaf7	1152	16	months	month	NNS
cord-034340-3ksfpaf7	1152	17	before	before	RB
cord-034340-3ksfpaf7	1152	18	,	,	,
cord-034340-3ksfpaf7	1152	19	still	still	RB
cord-034340-3ksfpaf7	1152	20	treated	treat	VBN
cord-034340-3ksfpaf7	1152	21	with	with	IN
cord-034340-3ksfpaf7	1152	22	tapering	taper	VBG
cord-034340-3ksfpaf7	1152	23	doses	dose	NNS
cord-034340-3ksfpaf7	1152	24	of	of	IN
cord-034340-3ksfpaf7	1152	25	steroids	steroid	NNS
cord-034340-3ksfpaf7	1152	26	and	and	CC
cord-034340-3ksfpaf7	1152	27	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1152	28	,	,	,
cord-034340-3ksfpaf7	1152	29	with	with	IN
cord-034340-3ksfpaf7	1152	30	the	the	DT
cord-034340-3ksfpaf7	1152	31	normalization	normalization	NN
cord-034340-3ksfpaf7	1152	32	of	of	IN
cord-034340-3ksfpaf7	1152	33	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1152	34	parameters	parameter	NNS
cord-034340-3ksfpaf7	1152	35	(	(	-LRB-
cord-034340-3ksfpaf7	1152	36	CRP	CRP	NNP
cord-034340-3ksfpaf7	1152	37	,	,	,
cord-034340-3ksfpaf7	1152	38	ESR	ESR	NNP
cord-034340-3ksfpaf7	1152	39	,	,	,
cord-034340-3ksfpaf7	1152	40	SAA	SAA	NNP
cord-034340-3ksfpaf7	1152	41	,	,	,
cord-034340-3ksfpaf7	1152	42	ferritin	ferritin	NN
cord-034340-3ksfpaf7	1152	43	)	)	-RRB-
cord-034340-3ksfpaf7	1152	44	and	and	CC
cord-034340-3ksfpaf7	1152	45	clinical	clinical	JJ
cord-034340-3ksfpaf7	1152	46	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1152	47	.	.	.
cord-034340-3ksfpaf7	1153	1	Only	only	RB
cord-034340-3ksfpaf7	1153	2	a	a	DT
cord-034340-3ksfpaf7	1153	3	mild	mild	JJ
cord-034340-3ksfpaf7	1153	4	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1153	5	of	of	IN
cord-034340-3ksfpaf7	1153	6	the	the	DT
cord-034340-3ksfpaf7	1153	7	knee	knee	NN
cord-034340-3ksfpaf7	1153	8	persisted	persist	VBD
cord-034340-3ksfpaf7	1153	9	and	and	CC
cord-034340-3ksfpaf7	1153	10	for	for	IN
cord-034340-3ksfpaf7	1153	11	this	this	DT
cord-034340-3ksfpaf7	1153	12	reason	reason	NN
cord-034340-3ksfpaf7	1153	13	he	-PRON-	PRP
cord-034340-3ksfpaf7	1153	14	was	be	VBD
cord-034340-3ksfpaf7	1153	15	still	still	RB
cord-034340-3ksfpaf7	1153	16	treated	treat	VBN
cord-034340-3ksfpaf7	1153	17	with	with	IN
cord-034340-3ksfpaf7	1153	18	steroids	steroid	NNS
cord-034340-3ksfpaf7	1153	19	.	.	.
cord-034340-3ksfpaf7	1154	1	Furthermore	furthermore	RB
cord-034340-3ksfpaf7	1154	2	,	,	,
cord-034340-3ksfpaf7	1154	3	he	-PRON-	PRP
cord-034340-3ksfpaf7	1154	4	developed	develop	VBD
cord-034340-3ksfpaf7	1154	5	hyperglycemia	hyperglycemia	NN
cord-034340-3ksfpaf7	1154	6	,	,	,
cord-034340-3ksfpaf7	1154	7	requiring	require	VBG
cord-034340-3ksfpaf7	1154	8	insulin	insulin	NN
cord-034340-3ksfpaf7	1154	9	treatment	treatment	NN
cord-034340-3ksfpaf7	1154	10	.	.	.
cord-034340-3ksfpaf7	1155	1	The	the	DT
cord-034340-3ksfpaf7	1155	2	first	first	JJ
cord-034340-3ksfpaf7	1155	3	dermatological	dermatological	JJ
cord-034340-3ksfpaf7	1155	4	manifestation	manifestation	NN
cord-034340-3ksfpaf7	1155	5	which	which	WDT
cord-034340-3ksfpaf7	1155	6	he	-PRON-	PRP
cord-034340-3ksfpaf7	1155	7	referred	refer	VBD
cord-034340-3ksfpaf7	1155	8	was	be	VBD
cord-034340-3ksfpaf7	1155	9	a	a	DT
cord-034340-3ksfpaf7	1155	10	red	red	JJ
cord-034340-3ksfpaf7	1155	11	dot	dot	NN
cord-034340-3ksfpaf7	1155	12	of	of	IN
cord-034340-3ksfpaf7	1155	13	the	the	DT
cord-034340-3ksfpaf7	1155	14	leg	leg	NN
cord-034340-3ksfpaf7	1155	15	skin	skin	NN
cord-034340-3ksfpaf7	1155	16	.	.	.
cord-034340-3ksfpaf7	1156	1	In	in	IN
cord-034340-3ksfpaf7	1156	2	a	a	DT
cord-034340-3ksfpaf7	1156	3	few	few	JJ
cord-034340-3ksfpaf7	1156	4	days	day	NNS
cord-034340-3ksfpaf7	1156	5	,	,	,
cord-034340-3ksfpaf7	1156	6	the	the	DT
cord-034340-3ksfpaf7	1156	7	erythema	erythema	NN
cord-034340-3ksfpaf7	1156	8	enlarged	enlarged	JJ
cord-034340-3ksfpaf7	1156	9	,	,	,
cord-034340-3ksfpaf7	1156	10	involving	involve	VBG
cord-034340-3ksfpaf7	1156	11	an	an	DT
cord-034340-3ksfpaf7	1156	12	area	area	NN
cord-034340-3ksfpaf7	1156	13	of	of	IN
cord-034340-3ksfpaf7	1156	14	7	7	CD
cord-034340-3ksfpaf7	1156	15	x	x	SYM
cord-034340-3ksfpaf7	1156	16	7	7	CD
cord-034340-3ksfpaf7	1156	17	cm	cm	NNS
cord-034340-3ksfpaf7	1156	18	,	,	,
cord-034340-3ksfpaf7	1156	19	with	with	IN
cord-034340-3ksfpaf7	1156	20	oedema	oedema	NN
cord-034340-3ksfpaf7	1156	21	,	,	,
cord-034340-3ksfpaf7	1156	22	pain	pain	NN
cord-034340-3ksfpaf7	1156	23	,	,	,
cord-034340-3ksfpaf7	1156	24	and	and	CC
cord-034340-3ksfpaf7	1156	25	blisters	blister	NNS
cord-034340-3ksfpaf7	1156	26	,	,	,
cord-034340-3ksfpaf7	1156	27	evolving	evolve	VBG
cord-034340-3ksfpaf7	1156	28	in	in	IN
cord-034340-3ksfpaf7	1156	29	a	a	DT
cord-034340-3ksfpaf7	1156	30	necrotic	necrotic	JJ
cord-034340-3ksfpaf7	1156	31	lesion	lesion	NN
cord-034340-3ksfpaf7	1156	32	,	,	,
cord-034340-3ksfpaf7	1156	33	with	with	IN
cord-034340-3ksfpaf7	1156	34	purulent	purulent	JJ
cord-034340-3ksfpaf7	1156	35	exudate	exudate	NN
cord-034340-3ksfpaf7	1156	36	,	,	,
cord-034340-3ksfpaf7	1156	37	surrounded	surround	VBN
cord-034340-3ksfpaf7	1156	38	by	by	IN
cord-034340-3ksfpaf7	1156	39	a	a	DT
cord-034340-3ksfpaf7	1156	40	haemorrhagic	haemorrhagic	JJ
cord-034340-3ksfpaf7	1156	41	zone	zone	NN
cord-034340-3ksfpaf7	1156	42	.	.	.
cord-034340-3ksfpaf7	1157	1	Results	result	NNS
cord-034340-3ksfpaf7	1157	2	:	:	:
cord-034340-3ksfpaf7	1158	1	Haematological	Haematological	NNP
cord-034340-3ksfpaf7	1158	2	controls	control	NNS
cord-034340-3ksfpaf7	1158	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1158	4	neutrophilic	neutrophilic	NNP
cord-034340-3ksfpaf7	1158	5	leucocytosis	leucocytosis	NNP
cord-034340-3ksfpaf7	1158	6	,	,	,
cord-034340-3ksfpaf7	1158	7	increased	increase	VBD
cord-034340-3ksfpaf7	1158	8	CRP	CRP	NNP
cord-034340-3ksfpaf7	1158	9	and	and	CC
cord-034340-3ksfpaf7	1158	10	procalcitonin	procalcitonin	NNS
cord-034340-3ksfpaf7	1158	11	.	.	.
cord-034340-3ksfpaf7	1159	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1159	2	started	start	VBD
cord-034340-3ksfpaf7	1159	3	treatment	treatment	NN
cord-034340-3ksfpaf7	1159	4	with	with	IN
cord-034340-3ksfpaf7	1159	5	intra	intra	NNP
cord-034340-3ksfpaf7	1159	6	venous	venous	JJ
cord-034340-3ksfpaf7	1159	7	administration	administration	NNP
cord-034340-3ksfpaf7	1159	8	of	of	IN
cord-034340-3ksfpaf7	1159	9	teicoplanin	teicoplanin	NNP
cord-034340-3ksfpaf7	1159	10	plus	plus	CC
cord-034340-3ksfpaf7	1159	11	ceftriaxone	ceftriaxone	NN
cord-034340-3ksfpaf7	1159	12	,	,	,
cord-034340-3ksfpaf7	1159	13	with	with	IN
cord-034340-3ksfpaf7	1159	14	no	no	DT
cord-034340-3ksfpaf7	1159	15	resolution	resolution	NN
cord-034340-3ksfpaf7	1159	16	of	of	IN
cord-034340-3ksfpaf7	1159	17	the	the	DT
cord-034340-3ksfpaf7	1159	18	clinical	clinical	JJ
cord-034340-3ksfpaf7	1159	19	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1159	20	and	and	CC
cord-034340-3ksfpaf7	1159	21	the	the	DT
cord-034340-3ksfpaf7	1159	22	reduction	reduction	NN
cord-034340-3ksfpaf7	1159	23	of	of	IN
cord-034340-3ksfpaf7	1159	24	leukocytosis	leukocytosis	NNP
cord-034340-3ksfpaf7	1159	25	,	,	,
cord-034340-3ksfpaf7	1159	26	CRP	CRP	NNP
cord-034340-3ksfpaf7	1159	27	,	,	,
cord-034340-3ksfpaf7	1159	28	procalcitonin	procalcitonin	NNS
cord-034340-3ksfpaf7	1159	29	.	.	.
cord-034340-3ksfpaf7	1160	1	A	a	DT
cord-034340-3ksfpaf7	1160	2	culture	culture	NN
cord-034340-3ksfpaf7	1160	3	swab	swab	NN
cord-034340-3ksfpaf7	1160	4	was	be	VBD
cord-034340-3ksfpaf7	1160	5	performed	perform	VBN
cord-034340-3ksfpaf7	1160	6	and	and	CC
cord-034340-3ksfpaf7	1160	7	was	be	VBD
cord-034340-3ksfpaf7	1160	8	positive	positive	JJ
cord-034340-3ksfpaf7	1160	9	for	for	IN
cord-034340-3ksfpaf7	1160	10	Pseudomonas	Pseudomonas	NNP
cord-034340-3ksfpaf7	1160	11	Aeruginosa	Aeruginosa	NNP
cord-034340-3ksfpaf7	1160	12	,	,	,
cord-034340-3ksfpaf7	1160	13	confirmed	confirm	VBN
cord-034340-3ksfpaf7	1160	14	by	by	IN
cord-034340-3ksfpaf7	1160	15	PCR	PCR	NNP
cord-034340-3ksfpaf7	1160	16	on	on	IN
cord-034340-3ksfpaf7	1160	17	the	the	DT
cord-034340-3ksfpaf7	1160	18	culture	culture	NN
cord-034340-3ksfpaf7	1160	19	.	.	.
cord-034340-3ksfpaf7	1161	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1161	2	started	start	VBD
cord-034340-3ksfpaf7	1161	3	ciprofloxacin	ciprofloxacin	NN
cord-034340-3ksfpaf7	1161	4	and	and	CC
cord-034340-3ksfpaf7	1161	5	surgical	surgical	JJ
cord-034340-3ksfpaf7	1161	6	curettage	curettage	NN
cord-034340-3ksfpaf7	1161	7	of	of	IN
cord-034340-3ksfpaf7	1161	8	the	the	DT
cord-034340-3ksfpaf7	1161	9	lesion	lesion	NN
cord-034340-3ksfpaf7	1161	10	,	,	,
cord-034340-3ksfpaf7	1161	11	with	with	IN
cord-034340-3ksfpaf7	1161	12	the	the	DT
cord-034340-3ksfpaf7	1161	13	resolution	resolution	NN
cord-034340-3ksfpaf7	1161	14	of	of	IN
cord-034340-3ksfpaf7	1161	15	the	the	DT
cord-034340-3ksfpaf7	1161	16	lesion	lesion	NN
cord-034340-3ksfpaf7	1161	17	and	and	CC
cord-034340-3ksfpaf7	1161	18	the	the	DT
cord-034340-3ksfpaf7	1161	19	normalization	normalization	NN
cord-034340-3ksfpaf7	1161	20	of	of	IN
cord-034340-3ksfpaf7	1161	21	biochemical	biochemical	JJ
cord-034340-3ksfpaf7	1161	22	parameters	parameter	NNS
cord-034340-3ksfpaf7	1161	23	.	.	.
cord-034340-3ksfpaf7	1162	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1162	2	:	:	:
cord-034340-3ksfpaf7	1163	1	The	the	DT
cord-034340-3ksfpaf7	1163	2	aspect	aspect	NN
cord-034340-3ksfpaf7	1163	3	of	of	IN
cord-034340-3ksfpaf7	1163	4	the	the	DT
cord-034340-3ksfpaf7	1163	5	lesion	lesion	NN
cord-034340-3ksfpaf7	1163	6	and	and	CC
cord-034340-3ksfpaf7	1163	7	its	-PRON-	PRP$
cord-034340-3ksfpaf7	1163	8	evolution	evolution	NN
cord-034340-3ksfpaf7	1163	9	were	be	VBD
cord-034340-3ksfpaf7	1163	10	evocative	evocative	JJ
cord-034340-3ksfpaf7	1163	11	of	of	IN
cord-034340-3ksfpaf7	1163	12	a	a	DT
cord-034340-3ksfpaf7	1163	13	spider	spider	NN
cord-034340-3ksfpaf7	1163	14	bite	bite	NN
cord-034340-3ksfpaf7	1163	15	suggested	suggest	VBN
cord-034340-3ksfpaf7	1163	16	by	by	IN
cord-034340-3ksfpaf7	1163	17	anamnestic	anamnestic	JJ
cord-034340-3ksfpaf7	1163	18	records	record	NNS
cord-034340-3ksfpaf7	1163	19	,	,	,
cord-034340-3ksfpaf7	1163	20	complicated	complicate	VBN
cord-034340-3ksfpaf7	1163	21	by	by	IN
cord-034340-3ksfpaf7	1163	22	a	a	DT
cord-034340-3ksfpaf7	1163	23	pyoderma	pyoderma	NN
cord-034340-3ksfpaf7	1163	24	gangrenosum	gangrenosum	NN
cord-034340-3ksfpaf7	1163	25	secondary	secondary	JJ
cord-034340-3ksfpaf7	1163	26	to	to	IN
cord-034340-3ksfpaf7	1163	27	Pseudomonas	Pseudomonas	NNP
cord-034340-3ksfpaf7	1163	28	Aeruginosa	Aeruginosa	NNP
cord-034340-3ksfpaf7	1163	29	.	.	.
cord-034340-3ksfpaf7	1164	1	The	the	DT
cord-034340-3ksfpaf7	1164	2	underlying	underlie	VBG
cord-034340-3ksfpaf7	1164	3	disease	disease	NN
cord-034340-3ksfpaf7	1164	4	,	,	,
cord-034340-3ksfpaf7	1164	5	the	the	DT
cord-034340-3ksfpaf7	1164	6	immune	immune	JJ
cord-034340-3ksfpaf7	1164	7	suppressive	suppressive	JJ
cord-034340-3ksfpaf7	1164	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1164	9	,	,	,
cord-034340-3ksfpaf7	1164	10	with	with	IN
cord-034340-3ksfpaf7	1164	11	steroids	steroid	NNS
cord-034340-3ksfpaf7	1164	12	and	and	CC
cord-034340-3ksfpaf7	1164	13	biological	biological	JJ
cord-034340-3ksfpaf7	1164	14	drugs	drug	NNS
cord-034340-3ksfpaf7	1164	15	,	,	,
cord-034340-3ksfpaf7	1164	16	the	the	DT
cord-034340-3ksfpaf7	1164	17	hyperglycaemic	hyperglycaemic	JJ
cord-034340-3ksfpaf7	1164	18	pattern	pattern	NN
cord-034340-3ksfpaf7	1164	19	of	of	IN
cord-034340-3ksfpaf7	1164	20	the	the	DT
cord-034340-3ksfpaf7	1164	21	patient	patient	NN
cord-034340-3ksfpaf7	1164	22	allowed	allow	VBD
cord-034340-3ksfpaf7	1164	23	the	the	DT
cord-034340-3ksfpaf7	1164	24	severe	severe	JJ
cord-034340-3ksfpaf7	1164	25	evolution	evolution	NN
cord-034340-3ksfpaf7	1164	26	of	of	IN
cord-034340-3ksfpaf7	1164	27	the	the	DT
cord-034340-3ksfpaf7	1164	28	spider	spider	NN
cord-034340-3ksfpaf7	1164	29	bite	bite	NN
cord-034340-3ksfpaf7	1164	30	.	.	.
cord-034340-3ksfpaf7	1165	1	Children	child	NNS
cord-034340-3ksfpaf7	1165	2	in	in	IN
cord-034340-3ksfpaf7	1165	3	treatment	treatment	NN
cord-034340-3ksfpaf7	1165	4	with	with	IN
cord-034340-3ksfpaf7	1165	5	immune	immune	JJ
cord-034340-3ksfpaf7	1165	6	suppressive	suppressive	JJ
cord-034340-3ksfpaf7	1165	7	and/or	and/or	CC
cord-034340-3ksfpaf7	1165	8	biologic	biologic	JJ
cord-034340-3ksfpaf7	1165	9	drugs	drug	NNS
cord-034340-3ksfpaf7	1165	10	are	be	VBP
cord-034340-3ksfpaf7	1165	11	at	at	IN
cord-034340-3ksfpaf7	1165	12	high	high	JJ
cord-034340-3ksfpaf7	1165	13	risk	risk	NN
cord-034340-3ksfpaf7	1165	14	of	of	IN
cord-034340-3ksfpaf7	1165	15	infections	infection	NNS
cord-034340-3ksfpaf7	1165	16	.	.	.
cord-034340-3ksfpaf7	1166	1	Skin	skin	NN
cord-034340-3ksfpaf7	1166	2	lesions	lesion	NNS
cord-034340-3ksfpaf7	1166	3	,	,	,
cord-034340-3ksfpaf7	1166	4	as	as	IN
cord-034340-3ksfpaf7	1166	5	arthropods	arthropod	NNS
cord-034340-3ksfpaf7	1166	6	bites	bite	NNS
cord-034340-3ksfpaf7	1166	7	,	,	,
cord-034340-3ksfpaf7	1166	8	can	can	MD
cord-034340-3ksfpaf7	1166	9	be	be	VB
cord-034340-3ksfpaf7	1166	10	a	a	DT
cord-034340-3ksfpaf7	1166	11	facility	facility	NN
cord-034340-3ksfpaf7	1166	12	for	for	IN
cord-034340-3ksfpaf7	1166	13	superinfection	superinfection	NN
cord-034340-3ksfpaf7	1166	14	,	,	,
cord-034340-3ksfpaf7	1166	15	with	with	IN
cord-034340-3ksfpaf7	1166	16	possible	possible	JJ
cord-034340-3ksfpaf7	1166	17	haematological	haematological	JJ
cord-034340-3ksfpaf7	1166	18	and	and	CC
cord-034340-3ksfpaf7	1166	19	systemic	systemic	JJ
cord-034340-3ksfpaf7	1166	20	diffusion	diffusion	NN
cord-034340-3ksfpaf7	1166	21	.	.	.
cord-034340-3ksfpaf7	1167	1	The	the	DT
cord-034340-3ksfpaf7	1167	2	strict	strict	JJ
cord-034340-3ksfpaf7	1167	3	application	application	NN
cord-034340-3ksfpaf7	1167	4	of	of	IN
cord-034340-3ksfpaf7	1167	5	the	the	DT
cord-034340-3ksfpaf7	1167	6	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	1167	7	1	1	CD
cord-034340-3ksfpaf7	1167	8	requirement	requirement	NN
cord-034340-3ksfpaf7	1167	9	for	for	IN
cord-034340-3ksfpaf7	1167	10	the	the	DT
cord-034340-3ksfpaf7	1167	11	presence	presence	NN
cord-034340-3ksfpaf7	1167	12	of	of	IN
cord-034340-3ksfpaf7	1167	13	documented	document	VBN
cord-034340-3ksfpaf7	1167	14	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1167	15	for	for	IN
cord-034340-3ksfpaf7	1167	16	the	the	DT
cord-034340-3ksfpaf7	1167	17	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1167	18	of	of	IN
cord-034340-3ksfpaf7	1167	19	sJIA	sjia	NN
cord-034340-3ksfpaf7	1167	20	,	,	,
cord-034340-3ksfpaf7	1167	21	early	early	RB
cord-034340-3ksfpaf7	1167	22	in	in	IN
cord-034340-3ksfpaf7	1167	23	the	the	DT
cord-034340-3ksfpaf7	1167	24	disease	disease	NN
cord-034340-3ksfpaf7	1167	25	course	course	NN
cord-034340-3ksfpaf7	1167	26	,	,	,
cord-034340-3ksfpaf7	1167	27	may	may	MD
cord-034340-3ksfpaf7	1167	28	result	result	VB
cord-034340-3ksfpaf7	1167	29	in	in	IN
cord-034340-3ksfpaf7	1167	30	unnecessary	unnecessary	JJ
cord-034340-3ksfpaf7	1167	31	delays	delay	NNS
cord-034340-3ksfpaf7	1167	32	in	in	IN
cord-034340-3ksfpaf7	1167	33	initiating	initiate	VBG
cord-034340-3ksfpaf7	1167	34	appropriate	appropriate	JJ
cord-034340-3ksfpaf7	1167	35	treatment	treatment	NN
cord-034340-3ksfpaf7	1167	36	.	.	.
cord-034340-3ksfpaf7	1168	1	In	in	IN
cord-034340-3ksfpaf7	1168	2	preliminary	preliminary	JJ
cord-034340-3ksfpaf7	1168	3	PRINTO	PRINTO	NNP
cord-034340-3ksfpaf7	1168	4	2	2	CD
cord-034340-3ksfpaf7	1168	5	classification	classification	NN
cord-034340-3ksfpaf7	1168	6	criteria	criterion	NNS
cord-034340-3ksfpaf7	1168	7	for	for	IN
cord-034340-3ksfpaf7	1168	8	sJIA	sjia	NN
cord-034340-3ksfpaf7	1168	9	,	,	,
cord-034340-3ksfpaf7	1168	10	this	this	DT
cord-034340-3ksfpaf7	1168	11	mandatory	mandatory	JJ
cord-034340-3ksfpaf7	1168	12	requirement	requirement	NN
cord-034340-3ksfpaf7	1168	13	of	of	IN
cord-034340-3ksfpaf7	1168	14	documented	document	VBN
cord-034340-3ksfpaf7	1168	15	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1168	16	has	have	VBZ
cord-034340-3ksfpaf7	1168	17	been	be	VBN
cord-034340-3ksfpaf7	1168	18	modified	modify	VBN
cord-034340-3ksfpaf7	1168	19	.	.	.
cord-034340-3ksfpaf7	1169	1	To	to	TO
cord-034340-3ksfpaf7	1169	2	measure	measure	VB
cord-034340-3ksfpaf7	1169	3	performance	performance	NN
cord-034340-3ksfpaf7	1169	4	of	of	IN
cord-034340-3ksfpaf7	1169	5	preliminary	preliminary	JJ
cord-034340-3ksfpaf7	1169	6	PRINTO	PRINTO	NNP
cord-034340-3ksfpaf7	1169	7	classification	classification	NN
cord-034340-3ksfpaf7	1169	8	criteria	criterion	NNS
cord-034340-3ksfpaf7	1169	9	for	for	IN
cord-034340-3ksfpaf7	1169	10	sJIA	sjia	NN
cord-034340-3ksfpaf7	1169	11	in	in	IN
cord-034340-3ksfpaf7	1169	12	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1169	13	Indian	indian	JJ
cord-034340-3ksfpaf7	1169	14	cohort	cohort	NN
cord-034340-3ksfpaf7	1169	15	.	.	.
cord-034340-3ksfpaf7	1170	1	Methods	method	NNS
cord-034340-3ksfpaf7	1171	1	I	-PRON-	PRP
cord-034340-3ksfpaf7	1171	2	gathered	gather	VBD
cord-034340-3ksfpaf7	1171	3	a	a	DT
cord-034340-3ksfpaf7	1171	4	data	data	NN
cord-034340-3ksfpaf7	1171	5	of	of	IN
cord-034340-3ksfpaf7	1171	6	seven	seven	CD
cord-034340-3ksfpaf7	1171	7	sJIA	sjia	JJ
cord-034340-3ksfpaf7	1171	8	patients	patient	NNS
cord-034340-3ksfpaf7	1171	9	who	who	WP
cord-034340-3ksfpaf7	1171	10	attended	attend	VBD
cord-034340-3ksfpaf7	1171	11	dev	dev	JJ
cord-034340-3ksfpaf7	1171	12	children	child	NNS
cord-034340-3ksfpaf7	1171	13	's	's	POS
cord-034340-3ksfpaf7	1171	14	hospital	hospital	NN
cord-034340-3ksfpaf7	1171	15	between	between	IN
cord-034340-3ksfpaf7	1171	16	Jan	Jan	NNP
cord-034340-3ksfpaf7	1171	17	2019	2019	CD
cord-034340-3ksfpaf7	1171	18	and	and	CC
cord-034340-3ksfpaf7	1171	19	Jan	Jan	NNP
cord-034340-3ksfpaf7	1171	20	2020	2020	CD
cord-034340-3ksfpaf7	1171	21	.	.	.
cord-034340-3ksfpaf7	1172	1	My	-PRON-	PRP$
cord-034340-3ksfpaf7	1172	2	data	datum	NNS
cord-034340-3ksfpaf7	1172	3	included	include	VBD
cord-034340-3ksfpaf7	1172	4	demographics	demographic	NNS
cord-034340-3ksfpaf7	1172	5	,	,	,
cord-034340-3ksfpaf7	1172	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	1172	7	presentation	presentation	NN
cord-034340-3ksfpaf7	1172	8	,	,	,
cord-034340-3ksfpaf7	1172	9	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1172	10	parameters	parameter	NNS
cord-034340-3ksfpaf7	1172	11	and	and	CC
cord-034340-3ksfpaf7	1172	12	outcome	outcome	NN
cord-034340-3ksfpaf7	1172	13	of	of	IN
cord-034340-3ksfpaf7	1172	14	these	these	DT
cord-034340-3ksfpaf7	1172	15	patients	patient	NNS
cord-034340-3ksfpaf7	1172	16	.	.	.
cord-034340-3ksfpaf7	1173	1	All	all	PDT
cord-034340-3ksfpaf7	1173	2	these	these	DT
cord-034340-3ksfpaf7	1173	3	patients	patient	NNS
cord-034340-3ksfpaf7	1173	4	were	be	VBD
cord-034340-3ksfpaf7	1173	5	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1173	6	at	at	IN
cord-034340-3ksfpaf7	1173	7	an	an	DT
cord-034340-3ksfpaf7	1173	8	early	early	JJ
cord-034340-3ksfpaf7	1173	9	stage	stage	NN
cord-034340-3ksfpaf7	1173	10	by	by	IN
cord-034340-3ksfpaf7	1173	11	clinical	clinical	JJ
cord-034340-3ksfpaf7	1173	12	judgement	judgement	NN
cord-034340-3ksfpaf7	1173	13	irrespective	irrespective	RB
cord-034340-3ksfpaf7	1173	14	of	of	IN
cord-034340-3ksfpaf7	1173	15	fulfilment	fulfilment	NN
cord-034340-3ksfpaf7	1173	16	of	of	IN
cord-034340-3ksfpaf7	1173	17	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	1173	18	criteria	criterion	NNS
cord-034340-3ksfpaf7	1173	19	.	.	.
cord-034340-3ksfpaf7	1174	1	I	-PRON-	PRP
cord-034340-3ksfpaf7	1174	2	applied	apply	VBD
cord-034340-3ksfpaf7	1174	3	preliminary	preliminary	JJ
cord-034340-3ksfpaf7	1174	4	PRINTO	PRINTO	NNP
cord-034340-3ksfpaf7	1174	5	classification	classification	NN
cord-034340-3ksfpaf7	1174	6	criteria	criterion	NNS
cord-034340-3ksfpaf7	1174	7	for	for	IN
cord-034340-3ksfpaf7	1174	8	all	all	DT
cord-034340-3ksfpaf7	1174	9	.	.	.
cord-034340-3ksfpaf7	1175	1	Average	average	JJ
cord-034340-3ksfpaf7	1175	2	age	age	NN
cord-034340-3ksfpaf7	1175	3	of	of	IN
cord-034340-3ksfpaf7	1175	4	selected	select	VBN
cord-034340-3ksfpaf7	1175	5	children	child	NNS
cord-034340-3ksfpaf7	1175	6	(	(	-LRB-
cord-034340-3ksfpaf7	1175	7	4	4	CD
cord-034340-3ksfpaf7	1175	8	girls	girl	NNS
cord-034340-3ksfpaf7	1175	9	and	and	CC
cord-034340-3ksfpaf7	1175	10	3	3	CD
cord-034340-3ksfpaf7	1175	11	boys	boy	NNS
cord-034340-3ksfpaf7	1175	12	)	)	-RRB-
cord-034340-3ksfpaf7	1175	13	was	be	VBD
cord-034340-3ksfpaf7	1175	14	5.1	5.1	CD
cord-034340-3ksfpaf7	1175	15	years	year	NNS
cord-034340-3ksfpaf7	1175	16	.	.	.
cord-034340-3ksfpaf7	1176	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1177	1	A	a	DT
cord-034340-3ksfpaf7	1177	2	preliminary	preliminary	JJ
cord-034340-3ksfpaf7	1177	3	PRINTO	PRINTO	NNP
cord-034340-3ksfpaf7	1177	4	classification	classification	NN
cord-034340-3ksfpaf7	1177	5	criteria	criterion	NNS
cord-034340-3ksfpaf7	1177	6	for	for	IN
cord-034340-3ksfpaf7	1177	7	sJIA	sjia	NN
cord-034340-3ksfpaf7	1177	8	has	have	VBZ
cord-034340-3ksfpaf7	1177	9	been	be	VBN
cord-034340-3ksfpaf7	1177	10	validated	validate	VBN
cord-034340-3ksfpaf7	1177	11	in	in	IN
cord-034340-3ksfpaf7	1177	12	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1177	13	cohort	cohort	NN
cord-034340-3ksfpaf7	1177	14	.	.	.
cord-034340-3ksfpaf7	1178	1	There	there	EX
cord-034340-3ksfpaf7	1178	2	are	be	VBP
cord-034340-3ksfpaf7	1178	3	many	many	JJ
cord-034340-3ksfpaf7	1178	4	raised	raise	VBN
cord-034340-3ksfpaf7	1178	5	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1178	6	markers	marker	NNS
cord-034340-3ksfpaf7	1178	7	in	in	IN
cord-034340-3ksfpaf7	1178	8	most	most	JJS
cord-034340-3ksfpaf7	1178	9	of	of	IN
cord-034340-3ksfpaf7	1178	10	these	these	DT
cord-034340-3ksfpaf7	1178	11	patients	patient	NNS
cord-034340-3ksfpaf7	1178	12	other	other	JJ
cord-034340-3ksfpaf7	1178	13	than	than	IN
cord-034340-3ksfpaf7	1178	14	WBC	WBC	NNP
cord-034340-3ksfpaf7	1178	15	count	count	NN
cord-034340-3ksfpaf7	1178	16	.	.	.
cord-034340-3ksfpaf7	1179	1	These	these	DT
cord-034340-3ksfpaf7	1179	2	markers	marker	NNS
cord-034340-3ksfpaf7	1179	3	should	should	MD
cord-034340-3ksfpaf7	1179	4	be	be	VB
cord-034340-3ksfpaf7	1179	5	considered	consider	VBN
cord-034340-3ksfpaf7	1179	6	to	to	TO
cord-034340-3ksfpaf7	1179	7	be	be	VB
cord-034340-3ksfpaf7	1179	8	added	add	VBN
cord-034340-3ksfpaf7	1179	9	in	in	IN
cord-034340-3ksfpaf7	1179	10	supportive	supportive	JJ
cord-034340-3ksfpaf7	1179	11	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1179	12	criteria	criterion	NNS
cord-034340-3ksfpaf7	1179	13	to	to	TO
cord-034340-3ksfpaf7	1179	14	be	be	VB
cord-034340-3ksfpaf7	1179	15	more	more	RBR
cord-034340-3ksfpaf7	1179	16	specific	specific	JJ
cord-034340-3ksfpaf7	1179	17	towards	towards	IN
cord-034340-3ksfpaf7	1179	18	the	the	DT
cord-034340-3ksfpaf7	1179	19	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1179	20	.	.	.
cord-034340-3ksfpaf7	1180	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1180	2	is	be	VBZ
cord-034340-3ksfpaf7	1180	3	important	important	JJ
cord-034340-3ksfpaf7	1180	4	to	to	TO
cord-034340-3ksfpaf7	1180	5	add	add	VB
cord-034340-3ksfpaf7	1180	6	PID	PID	NNP
cord-034340-3ksfpaf7	1180	7	in	in	IN
cord-034340-3ksfpaf7	1180	8	exclusion	exclusion	NN
cord-034340-3ksfpaf7	1180	9	list	list	NN
cord-034340-3ksfpaf7	1180	10	especially	especially	RB
cord-034340-3ksfpaf7	1180	11	in	in	IN
cord-034340-3ksfpaf7	1180	12	a	a	DT
cord-034340-3ksfpaf7	1180	13	case	case	NN
cord-034340-3ksfpaf7	1180	14	of	of	IN
cord-034340-3ksfpaf7	1180	15	sJIA	sjia	NN
cord-034340-3ksfpaf7	1180	16	with	with	IN
cord-034340-3ksfpaf7	1180	17	MAS	MAS	NNP
cord-034340-3ksfpaf7	1180	18	at	at	IN
cord-034340-3ksfpaf7	1180	19	onset	onset	NN
cord-034340-3ksfpaf7	1180	20	.	.	.
cord-034340-3ksfpaf7	1181	1	3	3	CD
cord-034340-3ksfpaf7	1181	2	Trial	trial	NN
cord-034340-3ksfpaf7	1181	3	registration	registration	NN
cord-034340-3ksfpaf7	1181	4	identifying	identify	VBG
cord-034340-3ksfpaf7	1181	5	number	number	NN
cord-034340-3ksfpaf7	1181	6	Leningrad	Leningrad	NNP
cord-034340-3ksfpaf7	1181	7	's	's	POS
cord-034340-3ksfpaf7	1181	8	Regional	Regional	NNP
cord-034340-3ksfpaf7	1181	9	Children	Children	NNPS
cord-034340-3ksfpaf7	1181	10	'	'	POS
cord-034340-3ksfpaf7	1181	11	Two	two	CD
cord-034340-3ksfpaf7	1181	12	patient	patient	NN
cord-034340-3ksfpaf7	1181	13	stopped	stop	VBD
cord-034340-3ksfpaf7	1181	14	treatment	treatment	NN
cord-034340-3ksfpaf7	1181	15	within	within	IN
cord-034340-3ksfpaf7	1181	16	6	6	CD
cord-034340-3ksfpaf7	1181	17	months	month	NNS
cord-034340-3ksfpaf7	1181	18	from	from	IN
cord-034340-3ksfpaf7	1181	19	therapy	therapy	NN
cord-034340-3ksfpaf7	1181	20	start	start	NN
cord-034340-3ksfpaf7	1181	21	:	:	:
cord-034340-3ksfpaf7	1181	22	due	due	IN
cord-034340-3ksfpaf7	1181	23	to	to	IN
cord-034340-3ksfpaf7	1181	24	primary	primary	JJ
cord-034340-3ksfpaf7	1181	25	inefficiency	inefficiency	NN
cord-034340-3ksfpaf7	1181	26	(	(	-LRB-
cord-034340-3ksfpaf7	1181	27	1	1	CD
cord-034340-3ksfpaf7	1181	28	)	)	-RRB-
cord-034340-3ksfpaf7	1181	29	and	and	CC
cord-034340-3ksfpaf7	1181	30	allergic	allergic	JJ
cord-034340-3ksfpaf7	1181	31	reaction	reaction	NN
cord-034340-3ksfpaf7	1181	32	(	(	-LRB-
cord-034340-3ksfpaf7	1181	33	1	1	CD
cord-034340-3ksfpaf7	1181	34	)	)	-RRB-
cord-034340-3ksfpaf7	1181	35	.	.	.
cord-034340-3ksfpaf7	1182	1	Five	five	CD
cord-034340-3ksfpaf7	1182	2	(	(	-LRB-
cord-034340-3ksfpaf7	1182	3	5/11	5/11	CD
cord-034340-3ksfpaf7	1182	4	)	)	-RRB-
cord-034340-3ksfpaf7	1182	5	patients	patient	NNS
cord-034340-3ksfpaf7	1182	6	were	be	VBD
cord-034340-3ksfpaf7	1182	7	-	-	HYPH
cord-034340-3ksfpaf7	1182	8	co	co	NN
cord-034340-3ksfpaf7	1182	9	-	-	VBN
cord-034340-3ksfpaf7	1182	10	administered	administer	VBN
cord-034340-3ksfpaf7	1182	11	with	with	IN
cord-034340-3ksfpaf7	1182	12	cDMARDs	cDMARDs	,
cord-034340-3ksfpaf7	1182	13	,	,	,
cord-034340-3ksfpaf7	1182	14	other	other	JJ
cord-034340-3ksfpaf7	1182	15	5with	5with	CD
cord-034340-3ksfpaf7	1182	16	oral	oral	JJ
cord-034340-3ksfpaf7	1182	17	GC	GC	NNP
cord-034340-3ksfpaf7	1182	18	,	,	,
cord-034340-3ksfpaf7	1182	19	and	and	CC
cord-034340-3ksfpaf7	1182	20	6	6	CD
cord-034340-3ksfpaf7	1182	21	subjects	subject	NNS
cord-034340-3ksfpaf7	1182	22	had	have	VBD
cord-034340-3ksfpaf7	1182	23	been	be	VBN
cord-034340-3ksfpaf7	1182	24	previously	previously	RB
cord-034340-3ksfpaf7	1182	25	exposed	expose	VBN
cord-034340-3ksfpaf7	1182	26	to	to	IN
cord-034340-3ksfpaf7	1182	27	other	other	JJ
cord-034340-3ksfpaf7	1182	28	biologic	biologic	JJ
cord-034340-3ksfpaf7	1182	29	drugs	drug	NNS
cord-034340-3ksfpaf7	1182	30	.	.	.
cord-034340-3ksfpaf7	1183	1	Whole	whole	JJ
cord-034340-3ksfpaf7	1183	2	5	5	CD
cord-034340-3ksfpaf7	1183	3	patients	patient	NNS
cord-034340-3ksfpaf7	1183	4	stopped	stop	VBD
cord-034340-3ksfpaf7	1183	5	therapy	therapy	NN
cord-034340-3ksfpaf7	1183	6	due	due	IN
cord-034340-3ksfpaf7	1183	7	to	to	IN
cord-034340-3ksfpaf7	1183	8	secondary	secondary	JJ
cord-034340-3ksfpaf7	1183	9	inefficiency	inefficiency	NN
cord-034340-3ksfpaf7	1183	10	:	:	:
cord-034340-3ksfpaf7	1183	11	2	2	CD
cord-034340-3ksfpaf7	1183	12	patients	patient	NNS
cord-034340-3ksfpaf7	1183	13	were	be	VBD
cord-034340-3ksfpaf7	1183	14	switched	switch	VBN
cord-034340-3ksfpaf7	1183	15	on	on	IN
cord-034340-3ksfpaf7	1183	16	TOC	TOC	NNP
cord-034340-3ksfpaf7	1183	17	,	,	,
cord-034340-3ksfpaf7	1183	18	other	other	JJ
cord-034340-3ksfpaf7	1183	19	children	child	NNS
cord-034340-3ksfpaf7	1183	20	were	be	VBD
cord-034340-3ksfpaf7	1183	21	switched	switch	VBN
cord-034340-3ksfpaf7	1183	22	on	on	IN
cord-034340-3ksfpaf7	1183	23	ETA	ETA	NNP
cord-034340-3ksfpaf7	1183	24	(	(	-LRB-
cord-034340-3ksfpaf7	1183	25	1	1	CD
cord-034340-3ksfpaf7	1183	26	)	)	-RRB-
cord-034340-3ksfpaf7	1183	27	Introduction	introduction	NN
cord-034340-3ksfpaf7	1183	28	:	:	:
cord-034340-3ksfpaf7	1183	29	Systemic	systemic	JJ
cord-034340-3ksfpaf7	1183	30	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1183	31	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1183	32	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1183	33	(	(	-LRB-
cord-034340-3ksfpaf7	1183	34	sJIA	sjia	NN
cord-034340-3ksfpaf7	1183	35	)	)	-RRB-
cord-034340-3ksfpaf7	1183	36	is	be	VBZ
cord-034340-3ksfpaf7	1183	37	a	a	DT
cord-034340-3ksfpaf7	1183	38	rare	rare	JJ
cord-034340-3ksfpaf7	1183	39	,	,	,
cord-034340-3ksfpaf7	1183	40	complex	complex	JJ
cord-034340-3ksfpaf7	1183	41	auto	auto	NN
cord-034340-3ksfpaf7	1183	42	-	-	HYPH
cord-034340-3ksfpaf7	1183	43	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1183	44	disease	disease	NN
cord-034340-3ksfpaf7	1183	45	with	with	IN
cord-034340-3ksfpaf7	1183	46	significant	significant	JJ
cord-034340-3ksfpaf7	1183	47	morbidity	morbidity	NN
cord-034340-3ksfpaf7	1183	48	including	include	VBG
cord-034340-3ksfpaf7	1183	49	fever	fever	NN
cord-034340-3ksfpaf7	1183	50	,	,	,
cord-034340-3ksfpaf7	1183	51	rash	rash	JJ
cord-034340-3ksfpaf7	1183	52	,	,	,
cord-034340-3ksfpaf7	1183	53	serositis	serositis	NN
cord-034340-3ksfpaf7	1183	54	and	and	CC
cord-034340-3ksfpaf7	1183	55	articular	articular	JJ
cord-034340-3ksfpaf7	1183	56	problems	problem	NNS
cord-034340-3ksfpaf7	1183	57	.	.	.
cord-034340-3ksfpaf7	1184	1	With	with	IN
cord-034340-3ksfpaf7	1184	2	the	the	DT
cord-034340-3ksfpaf7	1184	3	availability	availability	NN
cord-034340-3ksfpaf7	1184	4	of	of	IN
cord-034340-3ksfpaf7	1184	5	interleukin-1	interleukin-1	NN
cord-034340-3ksfpaf7	1184	6	(	(	-LRB-
cord-034340-3ksfpaf7	1184	7	IL-1	IL-1	NNP
cord-034340-3ksfpaf7	1184	8	)	)	-RRB-
cord-034340-3ksfpaf7	1184	9	and	and	CC
cord-034340-3ksfpaf7	1184	10	IL-6	IL-6	NNP
cord-034340-3ksfpaf7	1184	11	inhibitor	inhibitor	NN
cord-034340-3ksfpaf7	1184	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1184	13	,	,	,
cord-034340-3ksfpaf7	1184	14	morbidity	morbidity	NN
cord-034340-3ksfpaf7	1184	15	has	have	VBZ
cord-034340-3ksfpaf7	1184	16	significantly	significantly	RB
cord-034340-3ksfpaf7	1184	17	reduced	reduce	VBN
cord-034340-3ksfpaf7	1184	18	and	and	CC
cord-034340-3ksfpaf7	1184	19	the	the	DT
cord-034340-3ksfpaf7	1184	20	outcome	outcome	NN
cord-034340-3ksfpaf7	1184	21	for	for	IN
cord-034340-3ksfpaf7	1184	22	sJIA	sjia	JJ
cord-034340-3ksfpaf7	1184	23	patients	patient	NNS
cord-034340-3ksfpaf7	1184	24	has	have	VBZ
cord-034340-3ksfpaf7	1184	25	improved	improve	VBN
cord-034340-3ksfpaf7	1184	26	.	.	.
cord-034340-3ksfpaf7	1185	1	However	however	RB
cord-034340-3ksfpaf7	1185	2	,	,	,
cord-034340-3ksfpaf7	1185	3	differences	difference	NNS
cord-034340-3ksfpaf7	1185	4	in	in	IN
cord-034340-3ksfpaf7	1185	5	access	access	NN
cord-034340-3ksfpaf7	1185	6	to	to	IN
cord-034340-3ksfpaf7	1185	7	care	care	NN
cord-034340-3ksfpaf7	1185	8	and	and	CC
cord-034340-3ksfpaf7	1185	9	differences	difference	NNS
cord-034340-3ksfpaf7	1185	10	in	in	IN
cord-034340-3ksfpaf7	1185	11	treatment	treatment	NN
cord-034340-3ksfpaf7	1185	12	strategies	strategy	NNS
cord-034340-3ksfpaf7	1185	13	between	between	IN
cord-034340-3ksfpaf7	1185	14	countries	country	NNS
cord-034340-3ksfpaf7	1185	15	in	in	IN
cord-034340-3ksfpaf7	1185	16	and	and	CC
cord-034340-3ksfpaf7	1185	17	outside	outside	RB
cord-034340-3ksfpaf7	1185	18	of	of	IN
cord-034340-3ksfpaf7	1185	19	Europe	Europe	NNP
cord-034340-3ksfpaf7	1185	20	remain	remain	VBP
cord-034340-3ksfpaf7	1185	21	a	a	DT
cord-034340-3ksfpaf7	1185	22	concern	concern	NN
cord-034340-3ksfpaf7	1185	23	.	.	.
cord-034340-3ksfpaf7	1186	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1186	2	:	:	:
cord-034340-3ksfpaf7	1186	3	The	the	DT
cord-034340-3ksfpaf7	1186	4	Single	Single	NNP
cord-034340-3ksfpaf7	1186	5	Hub	Hub	NNP
cord-034340-3ksfpaf7	1186	6	and	and	CC
cord-034340-3ksfpaf7	1186	7	Access	Access	NNP
cord-034340-3ksfpaf7	1186	8	point	point	NN
cord-034340-3ksfpaf7	1186	9	for	for	IN
cord-034340-3ksfpaf7	1186	10	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1186	11	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1186	12	in	in	IN
cord-034340-3ksfpaf7	1186	13	Europe	Europe	NNP
cord-034340-3ksfpaf7	1186	14	(	(	-LRB-
cord-034340-3ksfpaf7	1186	15	SHARE	SHARE	NNP
cord-034340-3ksfpaf7	1186	16	)	)	-RRB-
cord-034340-3ksfpaf7	1186	17	consortium	consortium	NN
cord-034340-3ksfpaf7	1186	18	aimed	aim	VBN
cord-034340-3ksfpaf7	1186	19	to	to	TO
cord-034340-3ksfpaf7	1186	20	develop	develop	VB
cord-034340-3ksfpaf7	1186	21	best	good	JJS
cord-034340-3ksfpaf7	1186	22	practices	practice	NNS
cord-034340-3ksfpaf7	1186	23	for	for	IN
cord-034340-3ksfpaf7	1186	24	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1186	25	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1186	26	diseases	disease	NNS
cord-034340-3ksfpaf7	1186	27	in	in	IN
cord-034340-3ksfpaf7	1186	28	order	order	NN
cord-034340-3ksfpaf7	1186	29	to	to	TO
cord-034340-3ksfpaf7	1186	30	decrease	decrease	VB
cord-034340-3ksfpaf7	1186	31	differences	difference	NNS
cord-034340-3ksfpaf7	1186	32	in	in	IN
cord-034340-3ksfpaf7	1186	33	care	care	NN
cord-034340-3ksfpaf7	1186	34	between	between	IN
cord-034340-3ksfpaf7	1186	35	European	european	JJ
cord-034340-3ksfpaf7	1186	36	countries	country	NNS
cord-034340-3ksfpaf7	1186	37	.	.	.
cord-034340-3ksfpaf7	1187	1	Here	here	RB
cord-034340-3ksfpaf7	1187	2	,	,	,
cord-034340-3ksfpaf7	1187	3	we	-PRON-	PRP
cord-034340-3ksfpaf7	1187	4	present	present	VBP
cord-034340-3ksfpaf7	1187	5	the	the	DT
cord-034340-3ksfpaf7	1187	6	final	final	JJ
cord-034340-3ksfpaf7	1187	7	results	result	NNS
cord-034340-3ksfpaf7	1187	8	of	of	IN
cord-034340-3ksfpaf7	1187	9	the	the	DT
cord-034340-3ksfpaf7	1187	10	literature	literature	NN
cord-034340-3ksfpaf7	1187	11	review	review	NN
cord-034340-3ksfpaf7	1187	12	and	and	CC
cord-034340-3ksfpaf7	1187	13	a	a	DT
cord-034340-3ksfpaf7	1187	14	series	series	NN
cord-034340-3ksfpaf7	1187	15	of	of	IN
cord-034340-3ksfpaf7	1187	16	consensus	consensus	NN
cord-034340-3ksfpaf7	1187	17	meetings	meeting	NNS
cord-034340-3ksfpaf7	1187	18	on	on	IN
cord-034340-3ksfpaf7	1187	19	defining	define	VBG
cord-034340-3ksfpaf7	1187	20	overarching	overarching	JJ
cord-034340-3ksfpaf7	1187	21	,	,	,
cord-034340-3ksfpaf7	1187	22	diagnostic	diagnostic	JJ
cord-034340-3ksfpaf7	1187	23	and	and	CC
cord-034340-3ksfpaf7	1187	24	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	1187	25	recommendations	recommendation	NNS
cord-034340-3ksfpaf7	1187	26	for	for	IN
cord-034340-3ksfpaf7	1187	27	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1187	28	and	and	CC
cord-034340-3ksfpaf7	1187	29	treatment	treatment	NN
cord-034340-3ksfpaf7	1187	30	of	of	IN
cord-034340-3ksfpaf7	1187	31	sJIA	sjia	NN
cord-034340-3ksfpaf7	1187	32	.	.	.
cord-034340-3ksfpaf7	1188	1	Methods	method	NNS
cord-034340-3ksfpaf7	1188	2	:	:	:
cord-034340-3ksfpaf7	1188	3	The	the	DT
cord-034340-3ksfpaf7	1188	4	SHARE	share	NN
cord-034340-3ksfpaf7	1188	5	methodology	methodology	NN
cord-034340-3ksfpaf7	1188	6	has	have	VBZ
cord-034340-3ksfpaf7	1188	7	been	be	VBN
cord-034340-3ksfpaf7	1188	8	previously	previously	RB
cord-034340-3ksfpaf7	1188	9	published	publish	VBN
cord-034340-3ksfpaf7	1188	10	,	,	,
cord-034340-3ksfpaf7	1188	11	including	include	VBG
cord-034340-3ksfpaf7	1188	12	the	the	DT
cord-034340-3ksfpaf7	1188	13	use	use	NN
cord-034340-3ksfpaf7	1188	14	of	of	IN
cord-034340-3ksfpaf7	1188	15	the	the	DT
cord-034340-3ksfpaf7	1188	16	EULAR	EULAR	NNP
cord-034340-3ksfpaf7	1188	17	standardized	standardize	VBN
cord-034340-3ksfpaf7	1188	18	operating	operating	NN
cord-034340-3ksfpaf7	1188	19	procedure	procedure	NN
cord-034340-3ksfpaf7	1188	20	for	for	IN
cord-034340-3ksfpaf7	1188	21	developing	develop	VBG
cord-034340-3ksfpaf7	1188	22	best	good	JJS
cord-034340-3ksfpaf7	1188	23	practice	practice	NN
cord-034340-3ksfpaf7	1188	24	recommendations	recommendation	NNS
cord-034340-3ksfpaf7	1188	25	.	.	.
cord-034340-3ksfpaf7	1189	1	As	as	IN
cord-034340-3ksfpaf7	1189	2	per	per	IN
cord-034340-3ksfpaf7	1189	3	these	these	DT
cord-034340-3ksfpaf7	1189	4	guidelines	guideline	NNS
cord-034340-3ksfpaf7	1189	5	,	,	,
cord-034340-3ksfpaf7	1189	6	a	a	DT
cord-034340-3ksfpaf7	1189	7	methodologist	methodologist	NN
cord-034340-3ksfpaf7	1189	8	provided	provide	VBN
cord-034340-3ksfpaf7	1189	9	supervision	supervision	NN
cord-034340-3ksfpaf7	1189	10	during	during	IN
cord-034340-3ksfpaf7	1189	11	the	the	DT
cord-034340-3ksfpaf7	1189	12	process	process	NN
cord-034340-3ksfpaf7	1189	13	and	and	CC
cord-034340-3ksfpaf7	1189	14	consensus	consensus	NN
cord-034340-3ksfpaf7	1189	15	meetings	meeting	NNS
cord-034340-3ksfpaf7	1189	16	.	.	.
cord-034340-3ksfpaf7	1190	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1190	2	:	:	:
cord-034340-3ksfpaf7	1190	3	HScore	HScore	NNP
cord-034340-3ksfpaf7	1190	4	seems	seem	VBZ
cord-034340-3ksfpaf7	1190	5	to	to	TO
cord-034340-3ksfpaf7	1190	6	perform	perform	VB
cord-034340-3ksfpaf7	1190	7	slightly	slightly	RB
cord-034340-3ksfpaf7	1190	8	better	well	JJR
cord-034340-3ksfpaf7	1190	9	than	than	IN
cord-034340-3ksfpaf7	1190	10	MS	MS	NNP
cord-034340-3ksfpaf7	1190	11	-	-	HYPH
cord-034340-3ksfpaf7	1190	12	score	score	NN
cord-034340-3ksfpaf7	1190	13	for	for	IN
cord-034340-3ksfpaf7	1190	14	the	the	DT
cord-034340-3ksfpaf7	1190	15	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1190	16	of	of	IN
cord-034340-3ksfpaf7	1190	17	MAS	MAS	NNP
cord-034340-3ksfpaf7	1190	18	in	in	IN
cord-034340-3ksfpaf7	1190	19	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1190	20	cohort	cohort	NN
cord-034340-3ksfpaf7	1190	21	.	.	.
cord-034340-3ksfpaf7	1190	22	 	 	_SP
cord-034340-3ksfpaf7	1191	1	Early	early	JJ
cord-034340-3ksfpaf7	1191	2	inhibition	inhibition	NN
cord-034340-3ksfpaf7	1191	3	of	of	IN
cord-034340-3ksfpaf7	1191	4	IL-1	IL-1	NNP
cord-034340-3ksfpaf7	1191	5	is	be	VBZ
cord-034340-3ksfpaf7	1191	6	discussed	discuss	VBN
cord-034340-3ksfpaf7	1191	7	to	to	TO
cord-034340-3ksfpaf7	1191	8	play	play	VB
cord-034340-3ksfpaf7	1191	9	an	an	DT
cord-034340-3ksfpaf7	1191	10	important	important	JJ
cord-034340-3ksfpaf7	1191	11	role	role	NN
cord-034340-3ksfpaf7	1191	12	in	in	IN
cord-034340-3ksfpaf7	1191	13	the	the	DT
cord-034340-3ksfpaf7	1191	14	disease	disease	NN
cord-034340-3ksfpaf7	1191	15	course	course	NN
cord-034340-3ksfpaf7	1191	16	of	of	IN
cord-034340-3ksfpaf7	1191	17	sJIA	sjia	NN
cord-034340-3ksfpaf7	1191	18	1	1	CD
cord-034340-3ksfpaf7	1191	19	.	.	.
cord-034340-3ksfpaf7	1192	1	Assuming	assume	VBG
cord-034340-3ksfpaf7	1192	2	that	that	DT
cord-034340-3ksfpaf7	1192	3	pretreatment	pretreatment	NN
cord-034340-3ksfpaf7	1192	4	with	with	IN
cord-034340-3ksfpaf7	1192	5	other	other	JJ
cord-034340-3ksfpaf7	1192	6	DMARDs	dmard	NNS
cord-034340-3ksfpaf7	1192	7	leads	lead	VBZ
cord-034340-3ksfpaf7	1192	8	to	to	IN
cord-034340-3ksfpaf7	1192	9	a	a	DT
cord-034340-3ksfpaf7	1192	10	later	later	JJ
cord-034340-3ksfpaf7	1192	11	start	start	NN
cord-034340-3ksfpaf7	1192	12	of	of	IN
cord-034340-3ksfpaf7	1192	13	therapy	therapy	NN
cord-034340-3ksfpaf7	1192	14	with	with	IN
cord-034340-3ksfpaf7	1192	15	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1192	16	,	,	,
cord-034340-3ksfpaf7	1192	17	this	this	DT
cord-034340-3ksfpaf7	1192	18	analysis	analysis	NN
cord-034340-3ksfpaf7	1192	19	evaluates	evaluate	VBZ
cord-034340-3ksfpaf7	1192	20	the	the	DT
cord-034340-3ksfpaf7	1192	21	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1192	22	of	of	IN
cord-034340-3ksfpaf7	1192	23	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1192	24	as	as	IN
cord-034340-3ksfpaf7	1192	25	first	first	JJ
cord-034340-3ksfpaf7	1192	26	-	-	HYPH
cord-034340-3ksfpaf7	1192	27	line	line	NN
cord-034340-3ksfpaf7	1192	28	vs.	vs.	IN
cord-034340-3ksfpaf7	1192	29	second	second	JJ
cord-034340-3ksfpaf7	1192	30	-	-	HYPH
cord-034340-3ksfpaf7	1192	31	line	line	NN
cord-034340-3ksfpaf7	1192	32	DMARD	DMARD	NNP
cord-034340-3ksfpaf7	1192	33	.	.	.
cord-034340-3ksfpaf7	1193	1	To	to	TO
cord-034340-3ksfpaf7	1193	2	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1193	3	the	the	DT
cord-034340-3ksfpaf7	1193	4	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1193	5	of	of	IN
cord-034340-3ksfpaf7	1193	6	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1193	7	as	as	IN
cord-034340-3ksfpaf7	1193	8	first	first	RB
cord-034340-3ksfpaf7	1193	9	used	use	VBN
cord-034340-3ksfpaf7	1193	10	biological	biological	JJ
cord-034340-3ksfpaf7	1193	11	DMARD	DMARD	NNP
cord-034340-3ksfpaf7	1193	12	in	in	IN
cord-034340-3ksfpaf7	1193	13	sJIA	sjia	NN
cord-034340-3ksfpaf7	1193	14	compared	compare	VBN
cord-034340-3ksfpaf7	1193	15	to	to	IN
cord-034340-3ksfpaf7	1193	16	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1193	17	in	in	IN
cord-034340-3ksfpaf7	1193	18	sJIA	sjia	NN
cord-034340-3ksfpaf7	1193	19	-	-	HYPH
cord-034340-3ksfpaf7	1193	20	patients	patient	NNS
cord-034340-3ksfpaf7	1193	21	pretreated	pretreate	VBN
cord-034340-3ksfpaf7	1193	22	with	with	IN
cord-034340-3ksfpaf7	1193	23	other	other	JJ
cord-034340-3ksfpaf7	1193	24	DMARDs	dmard	NNS
cord-034340-3ksfpaf7	1193	25	.	.	.
cord-034340-3ksfpaf7	1194	1	Methods	method	NNS
cord-034340-3ksfpaf7	1194	2	SJIA	sjia	NN
cord-034340-3ksfpaf7	1194	3	-	-	HYPH
cord-034340-3ksfpaf7	1194	4	patients	patient	NNS
cord-034340-3ksfpaf7	1194	5	documented	document	VBN
cord-034340-3ksfpaf7	1194	6	in	in	IN
cord-034340-3ksfpaf7	1194	7	the	the	DT
cord-034340-3ksfpaf7	1194	8	German	german	JJ
cord-034340-3ksfpaf7	1194	9	Biologic	Biologic	NNP
cord-034340-3ksfpaf7	1194	10	Registry	Registry	NNP
cord-034340-3ksfpaf7	1194	11	for	for	IN
cord-034340-3ksfpaf7	1194	12	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	1194	13	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1194	14	(	(	-LRB-
cord-034340-3ksfpaf7	1194	15	BiKeR	BiKeR	NNP
cord-034340-3ksfpaf7	1194	16	)	)	-RRB-
cord-034340-3ksfpaf7	1194	17	,	,	,
cord-034340-3ksfpaf7	1194	18	who	who	WP
cord-034340-3ksfpaf7	1194	19	were	be	VBD
cord-034340-3ksfpaf7	1194	20	exposed	expose	VBN
cord-034340-3ksfpaf7	1194	21	to	to	IN
cord-034340-3ksfpaf7	1194	22	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1194	23	,	,	,
cord-034340-3ksfpaf7	1194	24	were	be	VBD
cord-034340-3ksfpaf7	1194	25	identified	identify	VBN
cord-034340-3ksfpaf7	1194	26	.	.	.
cord-034340-3ksfpaf7	1195	1	For	for	IN
cord-034340-3ksfpaf7	1195	2	the	the	DT
cord-034340-3ksfpaf7	1195	3	first	first	JJ
cord-034340-3ksfpaf7	1195	4	-	-	HYPH
cord-034340-3ksfpaf7	1195	5	line	line	NN
cord-034340-3ksfpaf7	1195	6	(	(	-LRB-
cord-034340-3ksfpaf7	1195	7	FL	FL	NNP
cord-034340-3ksfpaf7	1195	8	)	)	-RRB-
cord-034340-3ksfpaf7	1195	9	group	group	NN
cord-034340-3ksfpaf7	1195	10	DMARD	DMARD	NNP
cord-034340-3ksfpaf7	1195	11	naïve	naïve	JJ
cord-034340-3ksfpaf7	1195	12	patients	patient	NNS
cord-034340-3ksfpaf7	1195	13	were	be	VBD
cord-034340-3ksfpaf7	1195	14	selected	select	VBN
cord-034340-3ksfpaf7	1195	15	,	,	,
cord-034340-3ksfpaf7	1195	16	prior	prior	JJ
cord-034340-3ksfpaf7	1195	17	treatment	treatment	NN
cord-034340-3ksfpaf7	1195	18	with	with	IN
cord-034340-3ksfpaf7	1195	19	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	1195	20	and/or	and/or	CC
cord-034340-3ksfpaf7	1195	21	NSAIDs	NSAIDs	NNPS
cord-034340-3ksfpaf7	1195	22	was	be	VBD
cord-034340-3ksfpaf7	1195	23	allowed	allow	VBN
cord-034340-3ksfpaf7	1195	24	.	.	.
cord-034340-3ksfpaf7	1196	1	Patients	patient	NNS
cord-034340-3ksfpaf7	1196	2	receiving	receive	VBG
cord-034340-3ksfpaf7	1196	3	any	any	DT
cord-034340-3ksfpaf7	1196	4	DMARD	DMARD	NNP
cord-034340-3ksfpaf7	1196	5	prior	prior	RB
cord-034340-3ksfpaf7	1196	6	to	to	IN
cord-034340-3ksfpaf7	1196	7	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1196	8	entered	enter	VBD
cord-034340-3ksfpaf7	1196	9	the	the	DT
cord-034340-3ksfpaf7	1196	10	second	second	JJ
cord-034340-3ksfpaf7	1196	11	-	-	HYPH
cord-034340-3ksfpaf7	1196	12	line	line	NN
cord-034340-3ksfpaf7	1196	13	(	(	-LRB-
cord-034340-3ksfpaf7	1196	14	SL	SL	NNP
cord-034340-3ksfpaf7	1196	15	)	)	-RRB-
cord-034340-3ksfpaf7	1196	16	group	group	NN
cord-034340-3ksfpaf7	1196	17	.	.	.
cord-034340-3ksfpaf7	1197	1	Both	both	DT
cord-034340-3ksfpaf7	1197	2	groups	group	NNS
cord-034340-3ksfpaf7	1197	3	were	be	VBD
cord-034340-3ksfpaf7	1197	4	compared	compare	VBN
cord-034340-3ksfpaf7	1197	5	in	in	IN
cord-034340-3ksfpaf7	1197	6	a	a	DT
cord-034340-3ksfpaf7	1197	7	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1197	8	intention	intention	NN
cord-034340-3ksfpaf7	1197	9	-	-	HYPH
cord-034340-3ksfpaf7	1197	10	to	to	IN
cord-034340-3ksfpaf7	1197	11	-	-	HYPH
cord-034340-3ksfpaf7	1197	12	treat	treat	NN
cord-034340-3ksfpaf7	1197	13	-	-	HYPH
cord-034340-3ksfpaf7	1197	14	analysis	analysis	NN
cord-034340-3ksfpaf7	1197	15	.	.	.
cord-034340-3ksfpaf7	1198	1	Effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1198	2	 	 	_SP
cord-034340-3ksfpaf7	1198	3	Canakinumab	Canakinumab	NNP
cord-034340-3ksfpaf7	1198	4	treatment	treatment	NN
cord-034340-3ksfpaf7	1198	5	showed	show	VBD
cord-034340-3ksfpaf7	1198	6	good	good	JJ
cord-034340-3ksfpaf7	1198	7	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1198	8	in	in	IN
cord-034340-3ksfpaf7	1198	9	sJIA	sjia	NN
cord-034340-3ksfpaf7	1198	10	both	both	CC
cord-034340-3ksfpaf7	1198	11	as	as	IN
cord-034340-3ksfpaf7	1198	12	first	first	JJ
cord-034340-3ksfpaf7	1198	13	-	-	HYPH
cord-034340-3ksfpaf7	1198	14	and	and	CC
cord-034340-3ksfpaf7	1198	15	second	second	JJ
cord-034340-3ksfpaf7	1198	16	-	-	HYPH
cord-034340-3ksfpaf7	1198	17	line	line	NN
cord-034340-3ksfpaf7	1198	18	DMARD	DMARD	NNP
cord-034340-3ksfpaf7	1198	19	.	.	.
cord-034340-3ksfpaf7	1199	1	After	after	IN
cord-034340-3ksfpaf7	1199	2	6	6	CD
cord-034340-3ksfpaf7	1199	3	months	month	NNS
cord-034340-3ksfpaf7	1199	4	the	the	DT
cord-034340-3ksfpaf7	1199	5	use	use	NN
cord-034340-3ksfpaf7	1199	6	of	of	IN
cord-034340-3ksfpaf7	1199	7	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1199	8	as	as	IN
cord-034340-3ksfpaf7	1199	9	first	first	JJ
cord-034340-3ksfpaf7	1199	10	-	-	HYPH
cord-034340-3ksfpaf7	1199	11	line	line	NN
cord-034340-3ksfpaf7	1199	12	DMARD	DMARD	NNP
cord-034340-3ksfpaf7	1199	13	is	be	VBZ
cord-034340-3ksfpaf7	1199	14	associated	associate	VBN
cord-034340-3ksfpaf7	1199	15	with	with	IN
cord-034340-3ksfpaf7	1199	16	higher	high	JJR
cord-034340-3ksfpaf7	1199	17	response	response	NN
cord-034340-3ksfpaf7	1199	18	rates	rate	NNS
cord-034340-3ksfpaf7	1199	19	compared	compare	VBN
cord-034340-3ksfpaf7	1199	20	to	to	IN
cord-034340-3ksfpaf7	1199	21	second	second	JJ
cord-034340-3ksfpaf7	1199	22	-	-	HYPH
cord-034340-3ksfpaf7	1199	23	line	line	NN
cord-034340-3ksfpaf7	1199	24	use	use	NN
cord-034340-3ksfpaf7	1199	25	.	.	.
cord-034340-3ksfpaf7	1200	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1200	2	data	data	NN
cord-034340-3ksfpaf7	1200	3	support	support	VBP
cord-034340-3ksfpaf7	1200	4	the	the	DT
cord-034340-3ksfpaf7	1200	5	hypothesis	hypothesis	NN
cord-034340-3ksfpaf7	1200	6	that	that	IN
cord-034340-3ksfpaf7	1200	7	early	early	JJ
cord-034340-3ksfpaf7	1200	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1200	9	with	with	IN
cord-034340-3ksfpaf7	1200	10	canakinumab	canakinumab	NNP
cord-034340-3ksfpaf7	1200	11	is	be	VBZ
cord-034340-3ksfpaf7	1200	12	associated	associate	VBN
cord-034340-3ksfpaf7	1200	13	with	with	IN
cord-034340-3ksfpaf7	1200	14	good	good	JJ
cord-034340-3ksfpaf7	1200	15	therapeutical	therapeutical	JJ
cord-034340-3ksfpaf7	1200	16	response	response	NN
cord-034340-3ksfpaf7	1200	17	and	and	CC
cord-034340-3ksfpaf7	1200	18	a	a	DT
cord-034340-3ksfpaf7	1200	19	positive	positive	JJ
cord-034340-3ksfpaf7	1200	20	effect	effect	NN
cord-034340-3ksfpaf7	1200	21	on	on	IN
cord-034340-3ksfpaf7	1200	22	the	the	DT
cord-034340-3ksfpaf7	1200	23	disease	disease	NN
cord-034340-3ksfpaf7	1200	24	course	course	NN
cord-034340-3ksfpaf7	1200	25	of	of	IN
cord-034340-3ksfpaf7	1200	26	sJIA	sjia	NN
cord-034340-3ksfpaf7	1200	27	.	.	.
cord-034340-3ksfpaf7	1201	1	Results	result	NNS
cord-034340-3ksfpaf7	1201	2	:	:	:
cord-034340-3ksfpaf7	1202	1	A	a	DT
cord-034340-3ksfpaf7	1202	2	total	total	NN
cord-034340-3ksfpaf7	1202	3	of	of	IN
cord-034340-3ksfpaf7	1202	4	11	11	CD
cord-034340-3ksfpaf7	1202	5	children	child	NNS
cord-034340-3ksfpaf7	1202	6	(	(	-LRB-
cord-034340-3ksfpaf7	1202	7	9	9	CD
cord-034340-3ksfpaf7	1202	8	girls	girl	NNS
cord-034340-3ksfpaf7	1202	9	)	)	-RRB-
cord-034340-3ksfpaf7	1202	10	with	with	IN
cord-034340-3ksfpaf7	1202	11	SLE	SLE	NNP
cord-034340-3ksfpaf7	1202	12	were	be	VBD
cord-034340-3ksfpaf7	1202	13	identified	identify	VBN
cord-034340-3ksfpaf7	1202	14	.	.	.
cord-034340-3ksfpaf7	1203	1	Median	median	JJ
cord-034340-3ksfpaf7	1203	2	age	age	NN
cord-034340-3ksfpaf7	1203	3	of	of	IN
cord-034340-3ksfpaf7	1203	4	symptom	symptom	NN
cord-034340-3ksfpaf7	1203	5	onset	onset	NN
cord-034340-3ksfpaf7	1203	6	and	and	CC
cord-034340-3ksfpaf7	1203	7	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1203	8	was	be	VBD
cord-034340-3ksfpaf7	1203	9	14	14	CD
cord-034340-3ksfpaf7	1203	10	years(range	years(range	SYM
cord-034340-3ksfpaf7	1203	11	8	8	CD
cord-034340-3ksfpaf7	1203	12	-	-	SYM
cord-034340-3ksfpaf7	1203	13	17	17	CD
cord-034340-3ksfpaf7	1203	14	years	year	NNS
cord-034340-3ksfpaf7	1203	15	)	)	-RRB-
cord-034340-3ksfpaf7	1203	16	and	and	CC
cord-034340-3ksfpaf7	1203	17	11	11	CD
cord-034340-3ksfpaf7	1203	18	years	year	NNS
cord-034340-3ksfpaf7	1203	19	respectively	respectively	RB
cord-034340-3ksfpaf7	1203	20	.	.	.
cord-034340-3ksfpaf7	1204	1	The	the	DT
cord-034340-3ksfpaf7	1204	2	presenting	present	VBG
cord-034340-3ksfpaf7	1204	3	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1204	4	were	be	VBD
cord-034340-3ksfpaf7	1204	5	fever(5	fever(5	JJ
cord-034340-3ksfpaf7	1204	6	)	)	-RRB-
cord-034340-3ksfpaf7	1204	7	,	,	,
cord-034340-3ksfpaf7	1204	8	oral	oral	JJ
cord-034340-3ksfpaf7	1204	9	ulcers(3	ulcers(3	CD
cord-034340-3ksfpaf7	1204	10	)	)	-RRB-
cord-034340-3ksfpaf7	1204	11	,	,	,
cord-034340-3ksfpaf7	1204	12	alopecia(3	alopecia(3	NNP
cord-034340-3ksfpaf7	1204	13	)	)	-RRB-
cord-034340-3ksfpaf7	1204	14	,	,	,
cord-034340-3ksfpaf7	1204	15	malar	malar	NNP
cord-034340-3ksfpaf7	1204	16	rash(4	rash(4	NNP
cord-034340-3ksfpaf7	1204	17	)	)	-RRB-
cord-034340-3ksfpaf7	1204	18	,	,	,
cord-034340-3ksfpaf7	1204	19	photosensitivity(5	photosensitivity(5	NNP
cord-034340-3ksfpaf7	1204	20	)	)	-RRB-
cord-034340-3ksfpaf7	1204	21	,	,	,
cord-034340-3ksfpaf7	1204	22	renal	renal	JJ
cord-034340-3ksfpaf7	1204	23	involvement	involvement	NN
cord-034340-3ksfpaf7	1204	24	(	(	-LRB-
cord-034340-3ksfpaf7	1204	25	5	5	CD
cord-034340-3ksfpaf7	1204	26	)	)	-RRB-
cord-034340-3ksfpaf7	1204	27	,	,	,
cord-034340-3ksfpaf7	1204	28	seizures(1	seizures(1	IN
cord-034340-3ksfpaf7	1204	29	)	)	-RRB-
cord-034340-3ksfpaf7	1204	30	and	and	CC
cord-034340-3ksfpaf7	1204	31	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1204	32	complaints	complaint	NNS
cord-034340-3ksfpaf7	1204	33	(	(	-LRB-
cord-034340-3ksfpaf7	1204	34	1	1	CD
cord-034340-3ksfpaf7	1204	35	)	)	-RRB-
cord-034340-3ksfpaf7	1205	1	apart	apart	RB
cord-034340-3ksfpaf7	1205	2	from	from	IN
cord-034340-3ksfpaf7	1205	3	some	some	DT
cord-034340-3ksfpaf7	1205	4	unusual	unusual	JJ
cord-034340-3ksfpaf7	1205	5	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1205	6	of	of	IN
cord-034340-3ksfpaf7	1205	7	isolated	isolate	VBN
cord-034340-3ksfpaf7	1205	8	peripheral	peripheral	JJ
cord-034340-3ksfpaf7	1205	9	arthritis(1	arthritis(1	NN
cord-034340-3ksfpaf7	1205	10	)	)	-RRB-
cord-034340-3ksfpaf7	1205	11	,	,	,
cord-034340-3ksfpaf7	1205	12	isolated	isolate	VBN
cord-034340-3ksfpaf7	1205	13	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	1205	14	pleural	pleural	NN
cord-034340-3ksfpaf7	1205	15	effusion(1	effusion(1	NN
cord-034340-3ksfpaf7	1205	16	)	)	-RRB-
cord-034340-3ksfpaf7	1205	17	,	,	,
cord-034340-3ksfpaf7	1205	18	macrophage	macrophage	NN
cord-034340-3ksfpaf7	1205	19	activation	activation	NN
cord-034340-3ksfpaf7	1205	20	syndrome(2	syndrome(2	NNP
cord-034340-3ksfpaf7	1205	21	)	)	-RRB-
cord-034340-3ksfpaf7	1205	22	.	.	.
cord-034340-3ksfpaf7	1206	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	1206	2	investigations	investigation	NNS
cord-034340-3ksfpaf7	1206	3	:	:	:
cord-034340-3ksfpaf7	1206	4	Hemogram	Hemogram	NNP
cord-034340-3ksfpaf7	1206	5	revealed	reveal	VBD
cord-034340-3ksfpaf7	1206	6	anemia	anemia	NN
cord-034340-3ksfpaf7	1206	7	in	in	IN
cord-034340-3ksfpaf7	1206	8	8	8	CD
cord-034340-3ksfpaf7	1206	9	children	child	NNS
cord-034340-3ksfpaf7	1206	10	and	and	CC
cord-034340-3ksfpaf7	1206	11	thrombocytopenia	thrombocytopenia	NN
cord-034340-3ksfpaf7	1206	12	in	in	IN
cord-034340-3ksfpaf7	1206	13	5	5	CD
cord-034340-3ksfpaf7	1206	14	.	.	.
cord-034340-3ksfpaf7	1207	1	Urine	urine	NN
cord-034340-3ksfpaf7	1207	2	examination	examination	NN
cord-034340-3ksfpaf7	1207	3	showed	show	VBD
cord-034340-3ksfpaf7	1207	4	nephrotic	nephrotic	JJ
cord-034340-3ksfpaf7	1207	5	range	range	NN
cord-034340-3ksfpaf7	1207	6	proteinuria	proteinuria	NN
cord-034340-3ksfpaf7	1207	7	in	in	IN
cord-034340-3ksfpaf7	1207	8	1	1	CD
cord-034340-3ksfpaf7	1207	9	child	child	NN
cord-034340-3ksfpaf7	1207	10	and	and	CC
cord-034340-3ksfpaf7	1207	11	subnephrotic	subnephrotic	JJ
cord-034340-3ksfpaf7	1207	12	proteinuria	proteinuria	NN
cord-034340-3ksfpaf7	1207	13	in	in	IN
cord-034340-3ksfpaf7	1207	14	2	2	CD
cord-034340-3ksfpaf7	1207	15	.	.	.
cord-034340-3ksfpaf7	1208	1	Microscopic	microscopic	JJ
cord-034340-3ksfpaf7	1208	2	hematuria	hematuria	NN
cord-034340-3ksfpaf7	1208	3	was	be	VBD
cord-034340-3ksfpaf7	1208	4	noted	note	VBN
cord-034340-3ksfpaf7	1208	5	in	in	IN
cord-034340-3ksfpaf7	1208	6	2	2	CD
cord-034340-3ksfpaf7	1208	7	pateints	pateint	NNS
cord-034340-3ksfpaf7	1208	8	.	.	.
cord-034340-3ksfpaf7	1209	1	Renal	renal	JJ
cord-034340-3ksfpaf7	1209	2	function	function	NN
cord-034340-3ksfpaf7	1209	3	tests	test	NNS
cord-034340-3ksfpaf7	1209	4	were	be	VBD
cord-034340-3ksfpaf7	1209	5	deranged	deranged	JJ
cord-034340-3ksfpaf7	1209	6	in	in	IN
cord-034340-3ksfpaf7	1209	7	2	2	CD
cord-034340-3ksfpaf7	1209	8	cases	case	NNS
cord-034340-3ksfpaf7	1209	9	.	.	.
cord-034340-3ksfpaf7	1210	1	ANA	ANA	NNP
cord-034340-3ksfpaf7	1210	2	,	,	,
cord-034340-3ksfpaf7	1210	3	Anti	anti	JJ
cord-034340-3ksfpaf7	1210	4	dsDNA	dsdna	JJ
cord-034340-3ksfpaf7	1210	5	positivity	positivity	NN
cord-034340-3ksfpaf7	1210	6	and	and	CC
cord-034340-3ksfpaf7	1210	7	hypocomplimentemia	hypocomplimentemia	NNP
cord-034340-3ksfpaf7	1210	8	were	be	VBD
cord-034340-3ksfpaf7	1210	9	present	present	JJ
cord-034340-3ksfpaf7	1210	10	in	in	IN
cord-034340-3ksfpaf7	1210	11	all	all	DT
cord-034340-3ksfpaf7	1210	12	.	.	.
cord-034340-3ksfpaf7	1211	1	Renal	renal	JJ
cord-034340-3ksfpaf7	1211	2	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1211	3	was	be	VBD
cord-034340-3ksfpaf7	1211	4	done	do	VBN
cord-034340-3ksfpaf7	1211	5	in	in	IN
cord-034340-3ksfpaf7	1211	6	4	4	CD
cord-034340-3ksfpaf7	1211	7	patients	patient	NNS
cord-034340-3ksfpaf7	1211	8	,	,	,
cord-034340-3ksfpaf7	1211	9	2	2	CD
cord-034340-3ksfpaf7	1211	10	had	have	VBD
cord-034340-3ksfpaf7	1211	11	class	class	NN
cord-034340-3ksfpaf7	1211	12	IV	iv	NN
cord-034340-3ksfpaf7	1211	13	,	,	,
cord-034340-3ksfpaf7	1211	14	one	one	CD
cord-034340-3ksfpaf7	1211	15	class	class	NN
cord-034340-3ksfpaf7	1211	16	III	iii	NN
cord-034340-3ksfpaf7	1211	17	and	and	CC
cord-034340-3ksfpaf7	1211	18	one	one	CD
cord-034340-3ksfpaf7	1212	1	had	have	VBD
cord-034340-3ksfpaf7	1212	2	class	class	NN
cord-034340-3ksfpaf7	1212	3	V	v	NN
cord-034340-3ksfpaf7	1212	4	lupus	lupus	NN
cord-034340-3ksfpaf7	1212	5	nephritis	nephritis	NN
cord-034340-3ksfpaf7	1212	6	.	.	.
cord-034340-3ksfpaf7	1213	1	All	all	DT
cord-034340-3ksfpaf7	1213	2	patients	patient	NNS
cord-034340-3ksfpaf7	1213	3	were	be	VBD
cord-034340-3ksfpaf7	1213	4	initiated	initiate	VBN
cord-034340-3ksfpaf7	1213	5	on	on	IN
cord-034340-3ksfpaf7	1213	6	hydroxychloroquine	hydroxychloroquine	NN
cord-034340-3ksfpaf7	1213	7	and	and	CC
cord-034340-3ksfpaf7	1213	8	photoprotection	photoprotection	NN
cord-034340-3ksfpaf7	1213	9	.	.	.
cord-034340-3ksfpaf7	1214	1	Children	child	NNS
cord-034340-3ksfpaf7	1214	2	with	with	IN
cord-034340-3ksfpaf7	1214	3	renal	renal	JJ
cord-034340-3ksfpaf7	1214	4	involvement	involvement	NN
cord-034340-3ksfpaf7	1214	5	were	be	VBD
cord-034340-3ksfpaf7	1214	6	given	give	VBN
cord-034340-3ksfpaf7	1214	7	pulse	pulse	NN
cord-034340-3ksfpaf7	1214	8	methylprednisolone	methylprednisolone	NN
cord-034340-3ksfpaf7	1214	9	followed	follow	VBN
cord-034340-3ksfpaf7	1214	10	by	by	IN
cord-034340-3ksfpaf7	1214	11	tapering	taper	VBG
cord-034340-3ksfpaf7	1214	12	doses	dose	NNS
cord-034340-3ksfpaf7	1214	13	of	of	IN
cord-034340-3ksfpaf7	1214	14	oral	oral	JJ
cord-034340-3ksfpaf7	1214	15	prednisolone	prednisolone	NN
cord-034340-3ksfpaf7	1214	16	and	and	CC
cord-034340-3ksfpaf7	1214	17	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1214	18	,	,	,
cord-034340-3ksfpaf7	1214	19	monthly	monthly	JJ
cord-034340-3ksfpaf7	1214	20	cyclophosphamide	cyclophosphamide	RB
cord-034340-3ksfpaf7	1214	21	.	.	.
cord-034340-3ksfpaf7	1215	1	Azathioprine	Azathioprine	NNP
cord-034340-3ksfpaf7	1215	2	was	be	VBD
cord-034340-3ksfpaf7	1215	3	used	use	VBN
cord-034340-3ksfpaf7	1215	4	as	as	IN
cord-034340-3ksfpaf7	1215	5	maintenance	maintenance	NN
cord-034340-3ksfpaf7	1215	6	therapy	therapy	NN
cord-034340-3ksfpaf7	1215	7	in	in	IN
cord-034340-3ksfpaf7	1215	8	all	all	DT
cord-034340-3ksfpaf7	1215	9	.	.	.
cord-034340-3ksfpaf7	1216	1	Subcutaneous	subcutaneous	JJ
cord-034340-3ksfpaf7	1216	2	weekly	weekly	JJ
cord-034340-3ksfpaf7	1216	3	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	1216	4	was	be	VBD
cord-034340-3ksfpaf7	1216	5	used	use	VBN
cord-034340-3ksfpaf7	1216	6	in	in	IN
cord-034340-3ksfpaf7	1216	7	2	2	CD
cord-034340-3ksfpaf7	1216	8	patients	patient	NNS
cord-034340-3ksfpaf7	1216	9	.	.	.
cord-034340-3ksfpaf7	1217	1	One	one	CD
cord-034340-3ksfpaf7	1217	2	child	child	NN
cord-034340-3ksfpaf7	1217	3	(	(	-LRB-
cord-034340-3ksfpaf7	1217	4	MAS	MAS	NNP
cord-034340-3ksfpaf7	1217	5	)	)	-RRB-
cord-034340-3ksfpaf7	1217	6	died	die	VBD
cord-034340-3ksfpaf7	1217	7	during	during	IN
cord-034340-3ksfpaf7	1217	8	disease	disease	NN
cord-034340-3ksfpaf7	1217	9	course	course	NN
cord-034340-3ksfpaf7	1217	10	.	.	.
cord-034340-3ksfpaf7	1218	1	Disease	Disease	NNP
cord-034340-3ksfpaf7	1218	2	continues	continue	VBZ
cord-034340-3ksfpaf7	1218	3	to	to	TO
cord-034340-3ksfpaf7	1218	4	be	be	VB
cord-034340-3ksfpaf7	1218	5	in	in	IN
cord-034340-3ksfpaf7	1218	6	remission	remission	NN
cord-034340-3ksfpaf7	1218	7	in	in	IN
cord-034340-3ksfpaf7	1218	8	rest	rest	NN
cord-034340-3ksfpaf7	1218	9	.	.	.
cord-034340-3ksfpaf7	1219	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1219	2	:	:	:
cord-034340-3ksfpaf7	1219	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1219	4	found	find	VBD
cord-034340-3ksfpaf7	1219	5	a	a	DT
cord-034340-3ksfpaf7	1219	6	significant	significant	JJ
cord-034340-3ksfpaf7	1219	7	female	female	JJ
cord-034340-3ksfpaf7	1219	8	preponderance	preponderance	NN
cord-034340-3ksfpaf7	1219	9	in	in	IN
cord-034340-3ksfpaf7	1219	10	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1219	11	study	study	NN
cord-034340-3ksfpaf7	1219	12	group	group	NN
cord-034340-3ksfpaf7	1219	13	.	.	.
cord-034340-3ksfpaf7	1220	1	Renal	renal	JJ
cord-034340-3ksfpaf7	1220	2	involvement	involvement	NN
cord-034340-3ksfpaf7	1220	3	was	be	VBD
cord-034340-3ksfpaf7	1220	4	the	the	DT
cord-034340-3ksfpaf7	1220	5	commonest	common	JJS
cord-034340-3ksfpaf7	1220	6	presentation	presentation	NN
cord-034340-3ksfpaf7	1220	7	.	.	.
cord-034340-3ksfpaf7	1221	1	Some	some	DT
cord-034340-3ksfpaf7	1221	2	unusual	unusual	JJ
cord-034340-3ksfpaf7	1221	3	presentations	presentation	NNS
cord-034340-3ksfpaf7	1221	4	were	be	VBD
cord-034340-3ksfpaf7	1221	5	also	also	RB
cord-034340-3ksfpaf7	1221	6	seen	see	VBN
cord-034340-3ksfpaf7	1221	7	.	.	.
cord-034340-3ksfpaf7	1222	1	Early	early	JJ
cord-034340-3ksfpaf7	1222	2	recognition	recognition	NN
cord-034340-3ksfpaf7	1222	3	of	of	IN
cord-034340-3ksfpaf7	1222	4	SLE	SLE	NNP
cord-034340-3ksfpaf7	1222	5	is	be	VBZ
cord-034340-3ksfpaf7	1222	6	critical	critical	JJ
cord-034340-3ksfpaf7	1222	7	for	for	IN
cord-034340-3ksfpaf7	1222	8	timely	timely	JJ
cord-034340-3ksfpaf7	1222	9	initiation	initiation	NN
cord-034340-3ksfpaf7	1222	10	of	of	IN
cord-034340-3ksfpaf7	1222	11	appropriate	appropriate	JJ
cord-034340-3ksfpaf7	1222	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1222	13	.	.	.
cord-034340-3ksfpaf7	1223	1	This	this	DT
cord-034340-3ksfpaf7	1223	2	is	be	VBZ
cord-034340-3ksfpaf7	1223	3	the	the	DT
cord-034340-3ksfpaf7	1223	4	first	first	JJ
cord-034340-3ksfpaf7	1223	5	report	report	NN
cord-034340-3ksfpaf7	1223	6	of	of	IN
cord-034340-3ksfpaf7	1223	7	a	a	DT
cord-034340-3ksfpaf7	1223	8	cohort	cohort	NN
cord-034340-3ksfpaf7	1223	9	of	of	IN
cord-034340-3ksfpaf7	1223	10	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	1223	11	SLE	SLE	NNP
cord-034340-3ksfpaf7	1223	12	from	from	IN
cord-034340-3ksfpaf7	1223	13	this	this	DT
cord-034340-3ksfpaf7	1223	14	part	part	NN
cord-034340-3ksfpaf7	1223	15	of	of	IN
cord-034340-3ksfpaf7	1223	16	India	India	NNP
cord-034340-3ksfpaf7	1223	17	.	.	.
cord-034340-3ksfpaf7	1224	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1224	2	:	:	:
cord-034340-3ksfpaf7	1225	1	Autoantibodies	Autoantibodies	NNP
cord-034340-3ksfpaf7	1225	2	in	in	IN
cord-034340-3ksfpaf7	1225	3	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1225	4	may	may	MD
cord-034340-3ksfpaf7	1225	5	be	be	VB
cord-034340-3ksfpaf7	1225	6	IgG	IgG	NNP
cord-034340-3ksfpaf7	1225	7	/	/	,
cord-034340-3ksfpaf7	1225	8	IgM/	igm/	RB
cord-034340-3ksfpaf7	1226	1	IgA.	IgA.	NNP
cord-034340-3ksfpaf7	1227	1	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1227	2	can	can	MD
cord-034340-3ksfpaf7	1227	3	be	be	VB
cord-034340-3ksfpaf7	1227	4	divided	divide	VBN
cord-034340-3ksfpaf7	1227	5	into	into	IN
cord-034340-3ksfpaf7	1227	6	primary	primary	JJ
cord-034340-3ksfpaf7	1227	7	or	or	CC
cord-034340-3ksfpaf7	1227	8	secondary	secondary	JJ
cord-034340-3ksfpaf7	1227	9	(	(	-LRB-
cord-034340-3ksfpaf7	1227	10	e.g.	e.g.	RB
cord-034340-3ksfpaf7	1227	11	SLE	SLE	NNP
cord-034340-3ksfpaf7	1227	12	,	,	,
cord-034340-3ksfpaf7	1227	13	lymphoproliferative	lymphoproliferative	JJ
cord-034340-3ksfpaf7	1227	14	diseases	disease	NNS
cord-034340-3ksfpaf7	1227	15	,	,	,
cord-034340-3ksfpaf7	1227	16	infections	infection	NNS
cord-034340-3ksfpaf7	1227	17	,	,	,
cord-034340-3ksfpaf7	1227	18	medications	medication	NNS
cord-034340-3ksfpaf7	1227	19	)	)	-RRB-
cord-034340-3ksfpaf7	1227	20	.	.	.
cord-034340-3ksfpaf7	1228	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1228	2	is	be	VBZ
cord-034340-3ksfpaf7	1228	3	also	also	RB
cord-034340-3ksfpaf7	1228	4	classified	classify	VBN
cord-034340-3ksfpaf7	1228	5	based	base	VBN
cord-034340-3ksfpaf7	1228	6	on	on	IN
cord-034340-3ksfpaf7	1228	7	the	the	DT
cord-034340-3ksfpaf7	1228	8	temperature	temperature	NN
cord-034340-3ksfpaf7	1228	9	at	at	IN
cord-034340-3ksfpaf7	1228	10	which	which	WDT
cord-034340-3ksfpaf7	1228	11	the	the	DT
cord-034340-3ksfpaf7	1228	12	antibody	antibody	NN
cord-034340-3ksfpaf7	1228	13	reacts	react	VBZ
cord-034340-3ksfpaf7	1228	14	to	to	IN
cord-034340-3ksfpaf7	1228	15	erythrocytes	erythrocyte	NNS
cord-034340-3ksfpaf7	1228	16	,	,	,
cord-034340-3ksfpaf7	1228	17	and	and	CC
cord-034340-3ksfpaf7	1228	18	can	can	MD
cord-034340-3ksfpaf7	1228	19	be	be	VB
cord-034340-3ksfpaf7	1228	20	warm	warm	JJ
cord-034340-3ksfpaf7	1228	21	(	(	-LRB-
cord-034340-3ksfpaf7	1228	22	IgG	IgG	NNP
cord-034340-3ksfpaf7	1228	23	or	or	CC
cord-034340-3ksfpaf7	1228	24	IgA	IgA	NNP
cord-034340-3ksfpaf7	1228	25	)	)	-RRB-
cord-034340-3ksfpaf7	1228	26	or	or	CC
cord-034340-3ksfpaf7	1228	27	cold	cold	JJ
cord-034340-3ksfpaf7	1228	28	(	(	-LRB-
cord-034340-3ksfpaf7	1228	29	IgM	IgM	NNP
cord-034340-3ksfpaf7	1228	30	or	or	CC
cord-034340-3ksfpaf7	1228	31	C3	C3	NNP
cord-034340-3ksfpaf7	1228	32	)	)	-RRB-
cord-034340-3ksfpaf7	1228	33	.	.	.
cord-034340-3ksfpaf7	1229	1	In	in	IN
cord-034340-3ksfpaf7	1229	2	warm	warm	JJ
cord-034340-3ksfpaf7	1229	3	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1229	4	,	,	,
cord-034340-3ksfpaf7	1229	5	the	the	DT
cord-034340-3ksfpaf7	1229	6	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1229	7	react	react	VBP
cord-034340-3ksfpaf7	1229	8	at	at	IN
cord-034340-3ksfpaf7	1229	9	temperatures	temperature	NNS
cord-034340-3ksfpaf7	1229	10	≥37ºC	≥37ºC	NNP
cord-034340-3ksfpaf7	1229	11	,	,	,
cord-034340-3ksfpaf7	1229	12	not	not	RB
cord-034340-3ksfpaf7	1229	13	activating	activate	VBG
cord-034340-3ksfpaf7	1229	14	the	the	DT
cord-034340-3ksfpaf7	1229	15	complement	complement	NN
cord-034340-3ksfpaf7	1229	16	system	system	NN
cord-034340-3ksfpaf7	1229	17	and	and	CC
cord-034340-3ksfpaf7	1229	18	not	not	RB
cord-034340-3ksfpaf7	1229	19	undergoing	undergo	VBG
cord-034340-3ksfpaf7	1229	20	agglutination	agglutination	NN
cord-034340-3ksfpaf7	1229	21	in	in	IN
cord-034340-3ksfpaf7	1229	22	vitro	vitro	FW
cord-034340-3ksfpaf7	1229	23	.	.	.
cord-034340-3ksfpaf7	1230	1	In	in	IN
cord-034340-3ksfpaf7	1230	2	cold	cold	JJ
cord-034340-3ksfpaf7	1230	3	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1230	4	,	,	,
cord-034340-3ksfpaf7	1230	5	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1230	6	react	react	VBP
cord-034340-3ksfpaf7	1230	7	at	at	IN
cord-034340-3ksfpaf7	1230	8	temperatures	temperature	NNS
cord-034340-3ksfpaf7	1230	9	below	below	IN
cord-034340-3ksfpaf7	1230	10	37ºC	37ºc	CD
cord-034340-3ksfpaf7	1230	11	,	,	,
cord-034340-3ksfpaf7	1230	12	activating	activate	VBG
cord-034340-3ksfpaf7	1230	13	the	the	DT
cord-034340-3ksfpaf7	1230	14	complement	complement	NN
cord-034340-3ksfpaf7	1230	15	system	system	NN
cord-034340-3ksfpaf7	1230	16	with	with	IN
cord-034340-3ksfpaf7	1230	17	in	in	FW
cord-034340-3ksfpaf7	1230	18	vitro	vitro	FW
cord-034340-3ksfpaf7	1230	19	agglutination	agglutination	NN
cord-034340-3ksfpaf7	1230	20	.	.	.
cord-034340-3ksfpaf7	1231	1	Mixed	mixed	JJ
cord-034340-3ksfpaf7	1231	2	AIHA	AIHA	NNP
cord-034340-3ksfpaf7	1231	3	(	(	-LRB-
cord-034340-3ksfpaf7	1231	4	warm	warm	JJ
cord-034340-3ksfpaf7	1231	5	and	and	CC
cord-034340-3ksfpaf7	1231	6	cold	cold	JJ
cord-034340-3ksfpaf7	1231	7	)	)	-RRB-
cord-034340-3ksfpaf7	1231	8	is	be	VBZ
cord-034340-3ksfpaf7	1231	9	rare	rare	JJ
cord-034340-3ksfpaf7	1231	10	and	and	CC
cord-034340-3ksfpaf7	1231	11	occurs	occur	VBZ
cord-034340-3ksfpaf7	1231	12	in	in	IN
cord-034340-3ksfpaf7	1231	13	<	<	NNP
cord-034340-3ksfpaf7	1231	14	10	10	CD
cord-034340-3ksfpaf7	1231	15	%	%	NN
cord-034340-3ksfpaf7	1231	16	of	of	IN
cord-034340-3ksfpaf7	1231	17	AIHA	AIHA	NNP
cord-034340-3ksfpaf7	1231	18	cases	case	NNS
cord-034340-3ksfpaf7	1231	19	and	and	CC
cord-034340-3ksfpaf7	1231	20	can	can	MD
cord-034340-3ksfpaf7	1231	21	occur	occur	VB
cord-034340-3ksfpaf7	1231	22	at	at	IN
cord-034340-3ksfpaf7	1231	23	any	any	DT
cord-034340-3ksfpaf7	1231	24	age	age	NN
cord-034340-3ksfpaf7	1231	25	,	,	,
cord-034340-3ksfpaf7	1231	26	but	but	CC
cord-034340-3ksfpaf7	1231	27	is	be	VBZ
cord-034340-3ksfpaf7	1231	28	extremely	extremely	RB
cord-034340-3ksfpaf7	1231	29	rare	rare	JJ
cord-034340-3ksfpaf7	1231	30	in	in	IN
cord-034340-3ksfpaf7	1231	31	children	child	NNS
cord-034340-3ksfpaf7	1231	32	.	.	.
cord-034340-3ksfpaf7	1232	1	The	the	DT
cord-034340-3ksfpaf7	1232	2	prevalence	prevalence	NN
cord-034340-3ksfpaf7	1232	3	of	of	IN
cord-034340-3ksfpaf7	1232	4	the	the	DT
cord-034340-3ksfpaf7	1232	5	mixed	mixed	JJ
cord-034340-3ksfpaf7	1232	6	form	form	NN
cord-034340-3ksfpaf7	1232	7	is	be	VBZ
cord-034340-3ksfpaf7	1232	8	less	less	JJR
cord-034340-3ksfpaf7	1232	9	than	than	IN
cord-034340-3ksfpaf7	1232	10	1/1,000,000	1/1,000,000	CD
cord-034340-3ksfpaf7	1232	11	patients	patient	NNS
cord-034340-3ksfpaf7	1232	12	with	with	IN
cord-034340-3ksfpaf7	1232	13	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1232	14	.	.	.
cord-034340-3ksfpaf7	1233	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1233	2	:	:	:
cord-034340-3ksfpaf7	1233	3	To	to	TO
cord-034340-3ksfpaf7	1233	4	report	report	VB
cord-034340-3ksfpaf7	1233	5	a	a	DT
cord-034340-3ksfpaf7	1233	6	rare	rare	JJ
cord-034340-3ksfpaf7	1233	7	case	case	NN
cord-034340-3ksfpaf7	1233	8	of	of	IN
cord-034340-3ksfpaf7	1233	9	mixed	mixed	JJ
cord-034340-3ksfpaf7	1233	10	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1233	11	and	and	CC
cord-034340-3ksfpaf7	1233	12	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1233	13	intracranial	intracranial	JJ
cord-034340-3ksfpaf7	1233	14	hypertension(IIH	hypertension(iih	ADD
cord-034340-3ksfpaf7	1233	15	)	)	-RRB-
cord-034340-3ksfpaf7	1233	16	in	in	IN
cord-034340-3ksfpaf7	1233	17	a	a	DT
cord-034340-3ksfpaf7	1233	18	15-years	15-years	CD
cord-034340-3ksfpaf7	1233	19	old	old	JJ
cord-034340-3ksfpaf7	1233	20	female	female	JJ
cord-034340-3ksfpaf7	1233	21	patient	patient	NN
cord-034340-3ksfpaf7	1233	22	with	with	IN
cord-034340-3ksfpaf7	1233	23	a	a	DT
cord-034340-3ksfpaf7	1233	24	previous	previous	JJ
cord-034340-3ksfpaf7	1233	25	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1233	26	of	of	IN
cord-034340-3ksfpaf7	1233	27	SLE	SLE	NNP
cord-034340-3ksfpaf7	1233	28	and	and	CC
cord-034340-3ksfpaf7	1233	29	APS	APS	NNP
cord-034340-3ksfpaf7	1233	30	.	.	.
cord-034340-3ksfpaf7	1234	1	Methods	method	NNS
cord-034340-3ksfpaf7	1234	2	:	:	:
cord-034340-3ksfpaf7	1235	1	Case	case	NN
cord-034340-3ksfpaf7	1235	2	report	report	NN
cord-034340-3ksfpaf7	1235	3	and	and	CC
cord-034340-3ksfpaf7	1235	4	literature	literature	NN
cord-034340-3ksfpaf7	1235	5	review	review	NN
cord-034340-3ksfpaf7	1235	6	.	.	.
cord-034340-3ksfpaf7	1236	1	Results	result	NNS
cord-034340-3ksfpaf7	1236	2	:	:	:
cord-034340-3ksfpaf7	1237	1	A	a	DT
cord-034340-3ksfpaf7	1237	2	15-years	15-years	CD
cord-034340-3ksfpaf7	1237	3	old	old	JJ
cord-034340-3ksfpaf7	1237	4	female	female	JJ
cord-034340-3ksfpaf7	1237	5	adolescent	adolescent	NN
cord-034340-3ksfpaf7	1237	6	previously	previously	RB
cord-034340-3ksfpaf7	1237	7	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1237	8	with	with	IN
cord-034340-3ksfpaf7	1237	9	SLE	SLE	NNP
cord-034340-3ksfpaf7	1237	10	/	/	SYM
cord-034340-3ksfpaf7	1237	11	APS	APS	NNP
cord-034340-3ksfpaf7	1237	12	since	since	IN
cord-034340-3ksfpaf7	1237	13	2017	2017	CD
cord-034340-3ksfpaf7	1237	14	was	be	VBD
cord-034340-3ksfpaf7	1237	15	in	in	IN
cord-034340-3ksfpaf7	1237	16	remission	remission	NN
cord-034340-3ksfpaf7	1237	17	on	on	IN
cord-034340-3ksfpaf7	1237	18	hydroxychloroquine(400mg);azathioprine(150mg);aspirin(100mg);vitaminD3(1.000IU);calcium(1	hydroxychloroquine(400mg);azathioprine(150mg);aspirin(100mg);vitaminD3(1.000IU);calcium(1	NNP
cord-034340-3ksfpaf7	1237	19	g	g	NNP
cord-034340-3ksfpaf7	1237	20	)	)	-RRB-
cord-034340-3ksfpaf7	1237	21	,	,	,
cord-034340-3ksfpaf7	1237	22	and	and	CC
cord-034340-3ksfpaf7	1237	23	sunscreen	sunscreen	NN
cord-034340-3ksfpaf7	1237	24	.	.	.
cord-034340-3ksfpaf7	1238	1	In	in	IN
cord-034340-3ksfpaf7	1238	2	April	April	NNP
cord-034340-3ksfpaf7	1238	3	2020	2020	CD
cord-034340-3ksfpaf7	1238	4	,	,	,
cord-034340-3ksfpaf7	1238	5	she	-PRON-	PRP
cord-034340-3ksfpaf7	1238	6	had	have	VBD
cord-034340-3ksfpaf7	1238	7	a	a	DT
cord-034340-3ksfpaf7	1238	8	relapse	relapse	NN
cord-034340-3ksfpaf7	1238	9	presenting	present	VBG
cord-034340-3ksfpaf7	1238	10	with	with	IN
cord-034340-3ksfpaf7	1238	11	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1238	12	,	,	,
cord-034340-3ksfpaf7	1238	13	myositis	myositis	NN
cord-034340-3ksfpaf7	1238	14	,	,	,
cord-034340-3ksfpaf7	1238	15	headache	headache	NN
cord-034340-3ksfpaf7	1238	16	,	,	,
cord-034340-3ksfpaf7	1238	17	hypocomplementemia	hypocomplementemia	NNP
cord-034340-3ksfpaf7	1238	18	,	,	,
cord-034340-3ksfpaf7	1238	19	and	and	CC
cord-034340-3ksfpaf7	1238	20	severe	severe	JJ
cord-034340-3ksfpaf7	1238	21	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1238	22	hemolytic	hemolytic	JJ
cord-034340-3ksfpaf7	1238	23	anemia	anemia	NN
cord-034340-3ksfpaf7	1238	24	(	(	-LRB-
cord-034340-3ksfpaf7	1238	25	Hb	Hb	NNP
cord-034340-3ksfpaf7	1238	26	of	of	IN
cord-034340-3ksfpaf7	1238	27	4g	4g	CD
cord-034340-3ksfpaf7	1238	28	/	/	SYM
cord-034340-3ksfpaf7	1238	29	dL	dl	NN
cord-034340-3ksfpaf7	1238	30	)	)	-RRB-
cord-034340-3ksfpaf7	1239	1	(	(	-LRB-
cord-034340-3ksfpaf7	1239	2	SLEDAI-2K=18	SLEDAI-2K=18	NNP
cord-034340-3ksfpaf7	1239	3	points	point	NNS
cord-034340-3ksfpaf7	1239	4	)	)	-RRB-
cord-034340-3ksfpaf7	1239	5	.	.	.
cord-034340-3ksfpaf7	1240	1	Mixed	mixed	JJ
cord-034340-3ksfpaf7	1240	2	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1240	3	was	be	VBD
cord-034340-3ksfpaf7	1240	4	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1240	5	base	base	NN
cord-034340-3ksfpaf7	1240	6	on	on	IN
cord-034340-3ksfpaf7	1240	7	a	a	DT
cord-034340-3ksfpaf7	1240	8	Direct	Direct	NNP
cord-034340-3ksfpaf7	1240	9	/	/	SYM
cord-034340-3ksfpaf7	1240	10	Indirect	Indirect	NNP
cord-034340-3ksfpaf7	1240	11	Coombs	Coombs	NNP
cord-034340-3ksfpaf7	1240	12	test	test	NN
cord-034340-3ksfpaf7	1240	13	4/4+;DirectAntiglobulinTesting	4/4+;directantiglobulintesting	CD
cord-034340-3ksfpaf7	1240	14	showing	show	VBG
cord-034340-3ksfpaf7	1240	15	anti	anti	JJ
cord-034340-3ksfpaf7	1240	16	-	-	JJ
cord-034340-3ksfpaf7	1240	17	IgA(weak),anti	iga(weak),anti	JJ
cord-034340-3ksfpaf7	1240	18	-	-	HYPH
cord-034340-3ksfpaf7	1240	19	IgM(3+/4+),anti	IgM(3+/4+),anti	NNP
cord-034340-3ksfpaf7	1240	20	-	-	HYPH
cord-034340-3ksfpaf7	1240	21	IgG(3+/4+),anti	IgG(3+/4+),anti	NNP
cord-034340-3ksfpaf7	1240	22	-	-	HYPH
cord-034340-3ksfpaf7	1240	23	C3c(weak),anti	C3c(weak),anti	NNP
cord-034340-3ksfpaf7	1240	24	-	-	HYPH
cord-034340-3ksfpaf7	1240	25	C3d	C3d	NNP
cord-034340-3ksfpaf7	1240	26	(	(	-LRB-
cord-034340-3ksfpaf7	1240	27	3+/4+);IgG1/3subclasses	3+/4+);igg1/3subclasse	NNS
cord-034340-3ksfpaf7	1240	28	with	with	IN
cord-034340-3ksfpaf7	1240	29	a	a	DT
cord-034340-3ksfpaf7	1240	30	reaction	reaction	NN
cord-034340-3ksfpaf7	1240	31	of	of	IN
cord-034340-3ksfpaf7	1240	32	1:100(2+/4+);an	1:100(2+/4+);an	CD
cord-034340-3ksfpaf7	1240	33	eleven	eleven	CD
cord-034340-3ksfpaf7	1240	34	cell	cell	NN
cord-034340-3ksfpaf7	1240	35	antibody	antibody	NN
cord-034340-3ksfpaf7	1240	36	panel	panel	NN
cord-034340-3ksfpaf7	1240	37	positive	positive	JJ
cord-034340-3ksfpaf7	1240	38	revealing	reveal	VBG
cord-034340-3ksfpaf7	1240	39	a	a	DT
cord-034340-3ksfpaf7	1240	40	cold	cold	JJ
cord-034340-3ksfpaf7	1240	41	and	and	CC
cord-034340-3ksfpaf7	1240	42	warm	warm	JJ
cord-034340-3ksfpaf7	1240	43	antibody	antibody	NN
cord-034340-3ksfpaf7	1240	44	,	,	,
cord-034340-3ksfpaf7	1240	45	and	and	CC
cord-034340-3ksfpaf7	1240	46	adsorption	adsorption	NN
cord-034340-3ksfpaf7	1240	47	technique	technique	NN
cord-034340-3ksfpaf7	1240	48	revealing	reveal	VBG
cord-034340-3ksfpaf7	1240	49	a	a	DT
cord-034340-3ksfpaf7	1240	50	cold	cold	JJ
cord-034340-3ksfpaf7	1240	51	and	and	CC
cord-034340-3ksfpaf7	1240	52	warm	warm	JJ
cord-034340-3ksfpaf7	1240	53	autoantibody	autoantibody	NN
cord-034340-3ksfpaf7	1240	54	.	.	.
cord-034340-3ksfpaf7	1241	1	Chest	Chest	NNP
cord-034340-3ksfpaf7	1241	2	CT	CT	NNP
cord-034340-3ksfpaf7	1241	3	showed	show	VBD
cord-034340-3ksfpaf7	1241	4	bibasilar	bibasilar	JJ
cord-034340-3ksfpaf7	1241	5	subsegmental	subsegmental	NNP
cord-034340-3ksfpaf7	1241	6	atelectasis	atelectasis	NN
cord-034340-3ksfpaf7	1241	7	,	,	,
cord-034340-3ksfpaf7	1242	1	head	head	NNP
cord-034340-3ksfpaf7	1242	2	CT	CT	NNP
cord-034340-3ksfpaf7	1242	3	/	/	SYM
cord-034340-3ksfpaf7	1242	4	MRI	MRI	NNP
cord-034340-3ksfpaf7	1242	5	was	be	VBD
cord-034340-3ksfpaf7	1242	6	normal	normal	JJ
cord-034340-3ksfpaf7	1242	7	and	and	CC
cord-034340-3ksfpaf7	1242	8	LP	LP	NNP
cord-034340-3ksfpaf7	1242	9	showed	show	VBD
cord-034340-3ksfpaf7	1242	10	a	a	DT
cord-034340-3ksfpaf7	1242	11	high	high	JJ
cord-034340-3ksfpaf7	1242	12	opening	opening	NN
cord-034340-3ksfpaf7	1242	13	pressure	pressure	NN
cord-034340-3ksfpaf7	1242	14	of	of	IN
cord-034340-3ksfpaf7	1242	15	45cmH2O	45cmh2o	CD
cord-034340-3ksfpaf7	1242	16	with	with	IN
cord-034340-3ksfpaf7	1242	17	a	a	DT
cord-034340-3ksfpaf7	1242	18	normal	normal	JJ
cord-034340-3ksfpaf7	1242	19	cell	cell	NN
cord-034340-3ksfpaf7	1242	20	count	count	NN
cord-034340-3ksfpaf7	1242	21	.	.	.
cord-034340-3ksfpaf7	1243	1	After	after	IN
cord-034340-3ksfpaf7	1243	2	the	the	DT
cord-034340-3ksfpaf7	1243	3	procedure	procedure	NN
cord-034340-3ksfpaf7	1243	4	,	,	,
cord-034340-3ksfpaf7	1243	5	the	the	DT
cord-034340-3ksfpaf7	1243	6	patient	patient	NN
cord-034340-3ksfpaf7	1243	7	reported	report	VBD
cord-034340-3ksfpaf7	1243	8	improvement	improvement	NN
cord-034340-3ksfpaf7	1243	9	in	in	IN
cord-034340-3ksfpaf7	1243	10	the	the	DT
cord-034340-3ksfpaf7	1243	11	pain	pain	NN
cord-034340-3ksfpaf7	1243	12	and	and	CC
cord-034340-3ksfpaf7	1243	13	was	be	VBD
cord-034340-3ksfpaf7	1243	14	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1243	15	with	with	IN
cord-034340-3ksfpaf7	1243	16	IIH	IIH	NNP
cord-034340-3ksfpaf7	1243	17	.	.	.
cord-034340-3ksfpaf7	1244	1	The	the	DT
cord-034340-3ksfpaf7	1244	2	patient	patient	NN
cord-034340-3ksfpaf7	1244	3	was	be	VBD
cord-034340-3ksfpaf7	1244	4	screened	screen	VBN
cord-034340-3ksfpaf7	1244	5	for	for	IN
cord-034340-3ksfpaf7	1244	6	secondary	secondary	JJ
cord-034340-3ksfpaf7	1244	7	causes	cause	NNS
cord-034340-3ksfpaf7	1244	8	for	for	IN
cord-034340-3ksfpaf7	1244	9	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1244	10	(	(	-LRB-
cord-034340-3ksfpaf7	1244	11	table	table	NN
cord-034340-3ksfpaf7	1244	12	1	1	CD
cord-034340-3ksfpaf7	1244	13	)	)	-RRB-
cord-034340-3ksfpaf7	1244	14	due	due	IN
cord-034340-3ksfpaf7	1244	15	to	to	IN
cord-034340-3ksfpaf7	1244	16	the	the	DT
cord-034340-3ksfpaf7	1244	17	unusual	unusual	JJ
cord-034340-3ksfpaf7	1244	18	mixed	mixed	JJ
cord-034340-3ksfpaf7	1244	19	type	type	NN
cord-034340-3ksfpaf7	1244	20	pattern	pattern	NN
cord-034340-3ksfpaf7	1244	21	and	and	CC
cord-034340-3ksfpaf7	1244	22	serology	serology	NN
cord-034340-3ksfpaf7	1244	23	was	be	VBD
cord-034340-3ksfpaf7	1244	24	positive	positive	JJ
cord-034340-3ksfpaf7	1244	25	for	for	IN
cord-034340-3ksfpaf7	1244	26	Chlamydia	Chlamydia	NNP
cord-034340-3ksfpaf7	1244	27	trachomatis	trachomatis	NN
cord-034340-3ksfpaf7	1244	28	(	(	-LRB-
cord-034340-3ksfpaf7	1244	29	IgM	IgM	NNP
cord-034340-3ksfpaf7	1244	30	)	)	-RRB-
cord-034340-3ksfpaf7	1244	31	and	and	CC
cord-034340-3ksfpaf7	1244	32	Mycoplasma	Mycoplasma	NNP
cord-034340-3ksfpaf7	1244	33	pneumoniae	pneumoniae	NNS
cord-034340-3ksfpaf7	1244	34	(	(	-LRB-
cord-034340-3ksfpaf7	1244	35	indeterminate	indeterminate	JJ
cord-034340-3ksfpaf7	1244	36	-	-	HYPH
cord-034340-3ksfpaf7	1244	37	IgM	igm	JJ
cord-034340-3ksfpaf7	1244	38	/	/	SYM
cord-034340-3ksfpaf7	1244	39	positive	positive	JJ
cord-034340-3ksfpaf7	1244	40	-	-	HYPH
cord-034340-3ksfpaf7	1244	41	IgG	igg	NN
cord-034340-3ksfpaf7	1244	42	)	)	-RRB-
cord-034340-3ksfpaf7	1244	43	suggesting	suggest	VBG
cord-034340-3ksfpaf7	1244	44	a	a	DT
cord-034340-3ksfpaf7	1244	45	recent	recent	JJ
cord-034340-3ksfpaf7	1244	46	infectious	infectious	JJ
cord-034340-3ksfpaf7	1244	47	trigger	trigger	NN
cord-034340-3ksfpaf7	1244	48	causing	cause	VBG
cord-034340-3ksfpaf7	1244	49	reactivation	reactivation	NN
cord-034340-3ksfpaf7	1244	50	of	of	IN
cord-034340-3ksfpaf7	1244	51	the	the	DT
cord-034340-3ksfpaf7	1244	52	underlying	underlie	VBG
cord-034340-3ksfpaf7	1244	53	disease	disease	NN
cord-034340-3ksfpaf7	1244	54	with	with	IN
cord-034340-3ksfpaf7	1244	55	a	a	DT
cord-034340-3ksfpaf7	1244	56	probable	probable	JJ
cord-034340-3ksfpaf7	1244	57	cross	cross	NN
cord-034340-3ksfpaf7	1244	58	-	-	NN
cord-034340-3ksfpaf7	1244	59	reactivity	reactivity	NN
cord-034340-3ksfpaf7	1244	60	.	.	.
cord-034340-3ksfpaf7	1245	1	The	the	DT
cord-034340-3ksfpaf7	1245	2	patient	patient	NN
cord-034340-3ksfpaf7	1245	3	treated	treat	VBN
cord-034340-3ksfpaf7	1245	4	with	with	IN
cord-034340-3ksfpaf7	1245	5	10-days	10-days	CD
cord-034340-3ksfpaf7	1245	6	of	of	IN
cord-034340-3ksfpaf7	1245	7	clarithromycin	clarithromycin	NNS
cord-034340-3ksfpaf7	1245	8	.	.	.
cord-034340-3ksfpaf7	1246	1	Before	before	IN
cord-034340-3ksfpaf7	1246	2	the	the	DT
cord-034340-3ksfpaf7	1246	3	infectious	infectious	JJ
cord-034340-3ksfpaf7	1246	4	screening	screening	NN
cord-034340-3ksfpaf7	1246	5	came	come	VBD
cord-034340-3ksfpaf7	1246	6	back	back	RB
cord-034340-3ksfpaf7	1246	7	negative	negative	JJ
cord-034340-3ksfpaf7	1246	8	,	,	,
cord-034340-3ksfpaf7	1246	9	AHAI	AHAI	NNP
cord-034340-3ksfpaf7	1246	10	was	be	VBD
cord-034340-3ksfpaf7	1246	11	treated	treat	VBN
cord-034340-3ksfpaf7	1246	12	with	with	IN
cord-034340-3ksfpaf7	1246	13	a	a	DT
cord-034340-3ksfpaf7	1246	14	single	single	JJ
cord-034340-3ksfpaf7	1246	15	dose	dose	NN
cord-034340-3ksfpaf7	1246	16	of	of	IN
cord-034340-3ksfpaf7	1246	17	IVIG(1g	IVIG(1g	NNS
cord-034340-3ksfpaf7	1246	18	/	/	SYM
cord-034340-3ksfpaf7	1246	19	kg	kg	NNP
cord-034340-3ksfpaf7	1246	20	)	)	-RRB-
cord-034340-3ksfpaf7	1246	21	and	and	CC
cord-034340-3ksfpaf7	1246	22	then	then	RB
cord-034340-3ksfpaf7	1246	23	,	,	,
cord-034340-3ksfpaf7	1246	24	with	with	IN
cord-034340-3ksfpaf7	1246	25	3-days	3-days	CD
cord-034340-3ksfpaf7	1246	26	of	of	IN
cord-034340-3ksfpaf7	1246	27	methylprednisolone(1g	methylprednisolone(1g	NNP
cord-034340-3ksfpaf7	1246	28	/	/	SYM
cord-034340-3ksfpaf7	1246	29	day	day	NN
cord-034340-3ksfpaf7	1246	30	)	)	-RRB-
cord-034340-3ksfpaf7	1246	31	.	.	.
cord-034340-3ksfpaf7	1247	1	Azathioprine	Azathioprine	NNP
cord-034340-3ksfpaf7	1247	2	was	be	VBD
cord-034340-3ksfpaf7	1247	3	replaced	replace	VBN
cord-034340-3ksfpaf7	1247	4	by	by	IN
cord-034340-3ksfpaf7	1247	5	mycophenolate	mycophenolate	NNP
cord-034340-3ksfpaf7	1247	6	mofetil	mofetil	NNP
cord-034340-3ksfpaf7	1247	7	.	.	.
cord-034340-3ksfpaf7	1248	1	Due	due	IN
cord-034340-3ksfpaf7	1248	2	to	to	IN
cord-034340-3ksfpaf7	1248	3	headache	headache	NN
cord-034340-3ksfpaf7	1248	4	recurrence	recurrence	NN
cord-034340-3ksfpaf7	1248	5	,	,	,
cord-034340-3ksfpaf7	1248	6	acetazolamide(500mg	acetazolamide(500mg	JJ
cord-034340-3ksfpaf7	1248	7	/	/	SYM
cord-034340-3ksfpaf7	1248	8	day	day	NN
cord-034340-3ksfpaf7	1248	9	)	)	-RRB-
cord-034340-3ksfpaf7	1248	10	was	be	VBD
cord-034340-3ksfpaf7	1248	11	started	start	VBN
cord-034340-3ksfpaf7	1248	12	,	,	,
cord-034340-3ksfpaf7	1248	13	and	and	CC
cord-034340-3ksfpaf7	1248	14	the	the	DT
cord-034340-3ksfpaf7	1248	15	patient	patient	NN
cord-034340-3ksfpaf7	1248	16	referred	refer	VBD
cord-034340-3ksfpaf7	1248	17	no	no	DT
cord-034340-3ksfpaf7	1248	18	pain	pain	NN
cord-034340-3ksfpaf7	1248	19	.	.	.
cord-034340-3ksfpaf7	1249	1	The	the	DT
cord-034340-3ksfpaf7	1249	2	patient	patient	NN
cord-034340-3ksfpaf7	1249	3	was	be	VBD
cord-034340-3ksfpaf7	1249	4	discharged	discharge	VBN
cord-034340-3ksfpaf7	1249	5	with	with	IN
cord-034340-3ksfpaf7	1249	6	a	a	DT
cord-034340-3ksfpaf7	1249	7	resolution	resolution	NN
cord-034340-3ksfpaf7	1249	8	of	of	IN
cord-034340-3ksfpaf7	1249	9	the	the	DT
cord-034340-3ksfpaf7	1249	10	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1249	11	.	.	.
cord-034340-3ksfpaf7	1250	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1250	2	:	:	:
cord-034340-3ksfpaf7	1250	3	To	to	IN
cord-034340-3ksfpaf7	1250	4	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1250	5	knowledge	knowledge	NN
cord-034340-3ksfpaf7	1250	6	,	,	,
cord-034340-3ksfpaf7	1250	7	the	the	DT
cord-034340-3ksfpaf7	1250	8	association	association	NN
cord-034340-3ksfpaf7	1250	9	of	of	IN
cord-034340-3ksfpaf7	1250	10	GBS	GBS	NNP
cord-034340-3ksfpaf7	1250	11	and	and	CC
cord-034340-3ksfpaf7	1250	12	BBE	BBE	NNP
cord-034340-3ksfpaf7	1250	13	has	have	VBZ
cord-034340-3ksfpaf7	1250	14	been	be	VBN
cord-034340-3ksfpaf7	1250	15	described	describe	VBN
cord-034340-3ksfpaf7	1250	16	in	in	IN
cord-034340-3ksfpaf7	1250	17	adults	adult	NNS
cord-034340-3ksfpaf7	1250	18	only	only	RB
cord-034340-3ksfpaf7	1250	19	.	.	.
cord-034340-3ksfpaf7	1251	1	Methods	method	NNS
cord-034340-3ksfpaf7	1251	2	:	:	:
cord-034340-3ksfpaf7	1251	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1251	4	here	here	RB
cord-034340-3ksfpaf7	1251	5	describe	describe	VBP
cord-034340-3ksfpaf7	1251	6	a	a	DT
cord-034340-3ksfpaf7	1251	7	child	child	NN
cord-034340-3ksfpaf7	1251	8	presenting	present	VBG
cord-034340-3ksfpaf7	1251	9	at	at	IN
cord-034340-3ksfpaf7	1251	10	SLE	SLE	NNP
cord-034340-3ksfpaf7	1251	11	disease	disease	NN
cord-034340-3ksfpaf7	1251	12	-	-	HYPH
cord-034340-3ksfpaf7	1251	13	onset	onset	NN
cord-034340-3ksfpaf7	1251	14	with	with	IN
cord-034340-3ksfpaf7	1251	15	an	an	DT
cord-034340-3ksfpaf7	1251	16	overlap	overlap	NN
cord-034340-3ksfpaf7	1251	17	of	of	IN
cord-034340-3ksfpaf7	1251	18	peripheral	peripheral	JJ
cord-034340-3ksfpaf7	1251	19	(	(	-LRB-
cord-034340-3ksfpaf7	1251	20	GBS	GBS	NNP
cord-034340-3ksfpaf7	1251	21	)	)	-RRB-
cord-034340-3ksfpaf7	1251	22	and	and	CC
cord-034340-3ksfpaf7	1251	23	central	central	JJ
cord-034340-3ksfpaf7	1251	24	(	(	-LRB-
cord-034340-3ksfpaf7	1251	25	BBE	bbe	VB
cord-034340-3ksfpaf7	1251	26	)	)	-RRB-
cord-034340-3ksfpaf7	1251	27	nervous	nervous	JJ
cord-034340-3ksfpaf7	1251	28	system	system	NN
cord-034340-3ksfpaf7	1251	29	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1251	30	,	,	,
cord-034340-3ksfpaf7	1251	31	highlighting	highlight	VBG
cord-034340-3ksfpaf7	1251	32	the	the	DT
cord-034340-3ksfpaf7	1251	33	possible	possible	JJ
cord-034340-3ksfpaf7	1251	34	association	association	NN
cord-034340-3ksfpaf7	1251	35	between	between	IN
cord-034340-3ksfpaf7	1251	36	these	these	DT
cord-034340-3ksfpaf7	1251	37	two	two	CD
cord-034340-3ksfpaf7	1251	38	entities	entity	NNS
cord-034340-3ksfpaf7	1251	39	in	in	IN
cord-034340-3ksfpaf7	1251	40	children	child	NNS
cord-034340-3ksfpaf7	1251	41	.	.	.
cord-034340-3ksfpaf7	1252	1	Results	result	NNS
cord-034340-3ksfpaf7	1252	2	:	:	:
cord-034340-3ksfpaf7	1253	1	An	an	DT
cord-034340-3ksfpaf7	1253	2	11-year	11-year	JJ
cord-034340-3ksfpaf7	1253	3	-	-	HYPH
cord-034340-3ksfpaf7	1253	4	old	old	JJ
cord-034340-3ksfpaf7	1253	5	healthy	healthy	JJ
cord-034340-3ksfpaf7	1253	6	girl	girl	NN
cord-034340-3ksfpaf7	1253	7	presented	present	VBN
cord-034340-3ksfpaf7	1253	8	with	with	IN
cord-034340-3ksfpaf7	1253	9	acute	acute	JJ
cord-034340-3ksfpaf7	1253	10	ataxia	ataxia	NN
cord-034340-3ksfpaf7	1253	11	,	,	,
cord-034340-3ksfpaf7	1253	12	ophtalmoparesis	ophtalmoparesis	NN
cord-034340-3ksfpaf7	1253	13	and	and	CC
cord-034340-3ksfpaf7	1253	14	altered	altered	JJ
cord-034340-3ksfpaf7	1253	15	level	level	NN
cord-034340-3ksfpaf7	1253	16	of	of	IN
cord-034340-3ksfpaf7	1253	17	consciousness	consciousness	NN
cord-034340-3ksfpaf7	1253	18	,	,	,
cord-034340-3ksfpaf7	1253	19	rapidly	rapidly	RB
cord-034340-3ksfpaf7	1253	20	followed	follow	VBN
cord-034340-3ksfpaf7	1253	21	by	by	IN
cord-034340-3ksfpaf7	1253	22	areflexia	areflexia	NNP
cord-034340-3ksfpaf7	1253	23	,	,	,
cord-034340-3ksfpaf7	1253	24	facial	facial	JJ
cord-034340-3ksfpaf7	1253	25	paresis	paresis	NN
cord-034340-3ksfpaf7	1253	26	,	,	,
cord-034340-3ksfpaf7	1253	27	swallowing	swallow	VBG
cord-034340-3ksfpaf7	1253	28	difficulties	difficulty	NNS
cord-034340-3ksfpaf7	1253	29	,	,	,
cord-034340-3ksfpaf7	1253	30	sensory	sensory	JJ
cord-034340-3ksfpaf7	1253	31	deficits	deficit	NNS
cord-034340-3ksfpaf7	1253	32	,	,	,
cord-034340-3ksfpaf7	1253	33	paresis	paresis	NN
cord-034340-3ksfpaf7	1253	34	in	in	IN
cord-034340-3ksfpaf7	1253	35	all	all	DT
cord-034340-3ksfpaf7	1253	36	four	four	CD
cord-034340-3ksfpaf7	1253	37	limbs	limb	NNS
cord-034340-3ksfpaf7	1253	38	and	and	CC
cord-034340-3ksfpaf7	1253	39	respiratory	respiratory	JJ
cord-034340-3ksfpaf7	1253	40	insufficiency	insufficiency	NN
cord-034340-3ksfpaf7	1253	41	.	.	.
cord-034340-3ksfpaf7	1254	1	These	these	DT
cord-034340-3ksfpaf7	1254	2	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1254	3	were	be	VBD
cord-034340-3ksfpaf7	1254	4	accompanied	accompany	VBN
cord-034340-3ksfpaf7	1254	5	by	by	IN
cord-034340-3ksfpaf7	1254	6	pleuro	pleuro	NNP
cord-034340-3ksfpaf7	1254	7	-	-	HYPH
cord-034340-3ksfpaf7	1254	8	pericardial	pericardial	JJ
cord-034340-3ksfpaf7	1254	9	serositis	serositis	NN
cord-034340-3ksfpaf7	1254	10	,	,	,
cord-034340-3ksfpaf7	1254	11	proteinuria	proteinuria	NN
cord-034340-3ksfpaf7	1254	12	and	and	CC
cord-034340-3ksfpaf7	1254	13	hypertension	hypertension	NN
cord-034340-3ksfpaf7	1254	14	.	.	.
cord-034340-3ksfpaf7	1255	1	Immunological	immunological	JJ
cord-034340-3ksfpaf7	1255	2	investigations	investigation	NNS
cord-034340-3ksfpaf7	1255	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1255	4	the	the	DT
cord-034340-3ksfpaf7	1255	5	presence	presence	NN
cord-034340-3ksfpaf7	1255	6	of	of	IN
cord-034340-3ksfpaf7	1255	7	positive	positive	JJ
cord-034340-3ksfpaf7	1255	8	ANA	ANA	NNP
cord-034340-3ksfpaf7	1255	9	and	and	CC
cord-034340-3ksfpaf7	1255	10	ds	ds	NNP
cord-034340-3ksfpaf7	1255	11	-	-	HYPH
cord-034340-3ksfpaf7	1255	12	DNA	DNA	NNP
cord-034340-3ksfpaf7	1255	13	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1255	14	.	.	.
cord-034340-3ksfpaf7	1256	1	The	the	DT
cord-034340-3ksfpaf7	1256	2	renal	renal	JJ
cord-034340-3ksfpaf7	1256	3	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1256	4	showed	show	VBD
cord-034340-3ksfpaf7	1256	5	a	a	DT
cord-034340-3ksfpaf7	1256	6	stage	stage	NN
cord-034340-3ksfpaf7	1256	7	III	iii	CD
cord-034340-3ksfpaf7	1256	8	lupus	lupus	NN
cord-034340-3ksfpaf7	1256	9	nephritis	nephritis	NN
cord-034340-3ksfpaf7	1256	10	.	.	.
cord-034340-3ksfpaf7	1257	1	Hence	hence	RB
cord-034340-3ksfpaf7	1257	2	,	,	,
cord-034340-3ksfpaf7	1257	3	the	the	DT
cord-034340-3ksfpaf7	1257	4	clinical	clinical	JJ
cord-034340-3ksfpaf7	1257	5	,	,	,
cord-034340-3ksfpaf7	1257	6	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1257	7	findings	finding	NNS
cord-034340-3ksfpaf7	1257	8	and	and	CC
cord-034340-3ksfpaf7	1257	9	biopsy	biopsy	NNP
cord-034340-3ksfpaf7	1257	10	report	report	NN
cord-034340-3ksfpaf7	1257	11	led	lead	VBD
cord-034340-3ksfpaf7	1257	12	to	to	IN
cord-034340-3ksfpaf7	1257	13	the	the	DT
cord-034340-3ksfpaf7	1257	14	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1257	15	of	of	IN
cord-034340-3ksfpaf7	1257	16	pSLE	psle	NN
cord-034340-3ksfpaf7	1257	17	.	.	.
cord-034340-3ksfpaf7	1258	1	Brain	brain	NN
cord-034340-3ksfpaf7	1258	2	and	and	CC
cord-034340-3ksfpaf7	1258	3	spine	spine	NN
cord-034340-3ksfpaf7	1258	4	MRI	MRI	NNP
cord-034340-3ksfpaf7	1258	5	did	do	VBD
cord-034340-3ksfpaf7	1258	6	not	not	RB
cord-034340-3ksfpaf7	1258	7	show	show	VB
cord-034340-3ksfpaf7	1258	8	any	any	DT
cord-034340-3ksfpaf7	1258	9	abnormalities	abnormality	NNS
cord-034340-3ksfpaf7	1258	10	;	;	:
cord-034340-3ksfpaf7	1258	11	diffuse	diffuse	VB
cord-034340-3ksfpaf7	1258	12	slowing	slow	VBG
cord-034340-3ksfpaf7	1258	13	compatible	compatible	JJ
cord-034340-3ksfpaf7	1258	14	with	with	IN
cord-034340-3ksfpaf7	1258	15	nonspecific	nonspecific	JJ
cord-034340-3ksfpaf7	1258	16	encephalopathy	encephalopathy	NN
cord-034340-3ksfpaf7	1258	17	was	be	VBD
cord-034340-3ksfpaf7	1258	18	seen	see	VBN
cord-034340-3ksfpaf7	1258	19	on	on	IN
cord-034340-3ksfpaf7	1258	20	EEG	EEG	NNP
cord-034340-3ksfpaf7	1258	21	.	.	.
cord-034340-3ksfpaf7	1259	1	Nerve	nerve	NN
cord-034340-3ksfpaf7	1259	2	conduction	conduction	NN
cord-034340-3ksfpaf7	1259	3	studies	study	NNS
cord-034340-3ksfpaf7	1259	4	(	(	-LRB-
cord-034340-3ksfpaf7	1259	5	NCS	NCS	NNP
cord-034340-3ksfpaf7	1259	6	)	)	-RRB-
cord-034340-3ksfpaf7	1259	7	confirmed	confirm	VBD
cord-034340-3ksfpaf7	1259	8	the	the	DT
cord-034340-3ksfpaf7	1259	9	clinical	clinical	JJ
cord-034340-3ksfpaf7	1259	10	suspicion	suspicion	NN
cord-034340-3ksfpaf7	1259	11	of	of	IN
cord-034340-3ksfpaf7	1259	12	acute	acute	JJ
cord-034340-3ksfpaf7	1259	13	polyradiculoneuropathy	polyradiculoneuropathy	JJ
cord-034340-3ksfpaf7	1259	14	with	with	IN
cord-034340-3ksfpaf7	1259	15	proximal	proximal	JJ
cord-034340-3ksfpaf7	1259	16	interruption	interruption	NN
cord-034340-3ksfpaf7	1259	17	of	of	IN
cord-034340-3ksfpaf7	1259	18	motor	motor	NN
cord-034340-3ksfpaf7	1259	19	nerve	nerve	NN
cord-034340-3ksfpaf7	1259	20	conduction	conduction	NN
cord-034340-3ksfpaf7	1259	21	,	,	,
cord-034340-3ksfpaf7	1259	22	compatible	compatible	JJ
cord-034340-3ksfpaf7	1259	23	with	with	IN
cord-034340-3ksfpaf7	1259	24	Guillain	Guillain	NNP
cord-034340-3ksfpaf7	1259	25	-	-	HYPH
cord-034340-3ksfpaf7	1259	26	Barré	Barré	NNP
cord-034340-3ksfpaf7	1259	27	-	-	HYPH
cord-034340-3ksfpaf7	1259	28	like	like	JJ
cord-034340-3ksfpaf7	1259	29	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1259	30	.	.	.
cord-034340-3ksfpaf7	1260	1	CSF	CSF	NNP
cord-034340-3ksfpaf7	1260	2	analysis	analysis	NN
cord-034340-3ksfpaf7	1260	3	(	(	-LRB-
cord-034340-3ksfpaf7	1260	4	performed	perform	VBN
cord-034340-3ksfpaf7	1260	5	twice	twice	RB
cord-034340-3ksfpaf7	1260	6	)	)	-RRB-
cord-034340-3ksfpaf7	1260	7	remained	remain	VBD
cord-034340-3ksfpaf7	1260	8	normal	normal	JJ
cord-034340-3ksfpaf7	1260	9	.	.	.
cord-034340-3ksfpaf7	1261	1	The	the	DT
cord-034340-3ksfpaf7	1261	2	patient	patient	NN
cord-034340-3ksfpaf7	1261	3	was	be	VBD
cord-034340-3ksfpaf7	1261	4	treated	treat	VBN
cord-034340-3ksfpaf7	1261	5	with	with	IN
cord-034340-3ksfpaf7	1261	6	glucocorticoids	glucocorticoid	NNS
cord-034340-3ksfpaf7	1261	7	,	,	,
cord-034340-3ksfpaf7	1261	8	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1261	9	immunoglobulins	immunoglobulin	NNS
cord-034340-3ksfpaf7	1261	10	,	,	,
cord-034340-3ksfpaf7	1261	11	cyclophosphamide	cyclophosphamide	RB
cord-034340-3ksfpaf7	1261	12	as	as	RB
cord-034340-3ksfpaf7	1261	13	well	well	RB
cord-034340-3ksfpaf7	1261	14	as	as	IN
cord-034340-3ksfpaf7	1261	15	plasmapheresis	plasmapheresis	NN
cord-034340-3ksfpaf7	1261	16	.	.	.
cord-034340-3ksfpaf7	1262	1	The	the	DT
cord-034340-3ksfpaf7	1262	2	neurological	neurological	JJ
cord-034340-3ksfpaf7	1262	3	and	and	CC
cord-034340-3ksfpaf7	1262	4	physical	physical	JJ
cord-034340-3ksfpaf7	1262	5	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1262	6	improved	improve	VBN
cord-034340-3ksfpaf7	1262	7	gradually	gradually	RB
cord-034340-3ksfpaf7	1262	8	with	with	IN
cord-034340-3ksfpaf7	1262	9	complete	complete	JJ
cord-034340-3ksfpaf7	1262	10	neurological	neurological	JJ
cord-034340-3ksfpaf7	1262	11	recovery	recovery	NN
cord-034340-3ksfpaf7	1262	12	four	four	CD
cord-034340-3ksfpaf7	1262	13	months	month	NNS
cord-034340-3ksfpaf7	1262	14	after	after	IN
cord-034340-3ksfpaf7	1262	15	onset	onset	NN
cord-034340-3ksfpaf7	1262	16	.	.	.
cord-034340-3ksfpaf7	1263	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1263	2	:	:	:
cord-034340-3ksfpaf7	1263	3	Overlapping	overlapping	JJ
cord-034340-3ksfpaf7	1263	4	forms	form	NNS
cord-034340-3ksfpaf7	1263	5	of	of	IN
cord-034340-3ksfpaf7	1263	6	BBE	BBE	NNP
cord-034340-3ksfpaf7	1263	7	/	/	SYM
cord-034340-3ksfpaf7	1263	8	GBS	GBS	NNP
cord-034340-3ksfpaf7	1263	9	have	have	VBP
cord-034340-3ksfpaf7	1263	10	never	never	RB
cord-034340-3ksfpaf7	1263	11	been	be	VBN
cord-034340-3ksfpaf7	1263	12	described	describe	VBN
cord-034340-3ksfpaf7	1263	13	in	in	IN
cord-034340-3ksfpaf7	1263	14	association	association	NN
cord-034340-3ksfpaf7	1263	15	to	to	IN
cord-034340-3ksfpaf7	1263	16	SLE	SLE	NNP
cord-034340-3ksfpaf7	1263	17	in	in	IN
cord-034340-3ksfpaf7	1263	18	children	child	NNS
cord-034340-3ksfpaf7	1263	19	.	.	.
cord-034340-3ksfpaf7	1264	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1264	2	patient	patient	NN
cord-034340-3ksfpaf7	1264	3	's	's	POS
cord-034340-3ksfpaf7	1264	4	presentation	presentation	NN
cord-034340-3ksfpaf7	1264	5	and	and	CC
cord-034340-3ksfpaf7	1264	6	evolution	evolution	NN
cord-034340-3ksfpaf7	1264	7	fulfilled	fulfil	VBD
cord-034340-3ksfpaf7	1264	8	the	the	DT
cord-034340-3ksfpaf7	1264	9	criteria	criterion	NNS
cord-034340-3ksfpaf7	1264	10	for	for	IN
cord-034340-3ksfpaf7	1264	11	such	such	PDT
cord-034340-3ksfpaf7	1264	12	an	an	DT
cord-034340-3ksfpaf7	1264	13	overlap	overlap	NN
cord-034340-3ksfpaf7	1264	14	,	,	,
cord-034340-3ksfpaf7	1264	15	occurring	occur	VBG
cord-034340-3ksfpaf7	1264	16	at	at	IN
cord-034340-3ksfpaf7	1264	17	pSLE	psle	CD
cord-034340-3ksfpaf7	1264	18	onset	onset	NN
cord-034340-3ksfpaf7	1264	19	.	.	.
cord-034340-3ksfpaf7	1265	1	Although	although	IN
cord-034340-3ksfpaf7	1265	2	SLE	SLE	NNP
cord-034340-3ksfpaf7	1265	3	and	and	CC
cord-034340-3ksfpaf7	1265	4	BBE	BBE	NNP
cord-034340-3ksfpaf7	1265	5	/	/	SYM
cord-034340-3ksfpaf7	1265	6	GBS	GBS	NNP
cord-034340-3ksfpaf7	1265	7	are	be	VBP
cord-034340-3ksfpaf7	1265	8	rare	rare	JJ
cord-034340-3ksfpaf7	1265	9	entities	entity	NNS
cord-034340-3ksfpaf7	1265	10	,	,	,
cord-034340-3ksfpaf7	1265	11	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1265	12	case	case	NN
cord-034340-3ksfpaf7	1265	13	suggests	suggest	VBZ
cord-034340-3ksfpaf7	1265	14	that	that	IN
cord-034340-3ksfpaf7	1265	15	there	there	EX
cord-034340-3ksfpaf7	1265	16	may	may	MD
cord-034340-3ksfpaf7	1265	17	be	be	VB
cord-034340-3ksfpaf7	1265	18	a	a	DT
cord-034340-3ksfpaf7	1265	19	common	common	JJ
cord-034340-3ksfpaf7	1265	20	underlying	underlying	JJ
cord-034340-3ksfpaf7	1265	21	immune	immune	JJ
cord-034340-3ksfpaf7	1265	22	background	background	NN
cord-034340-3ksfpaf7	1265	23	.	.	.
cord-034340-3ksfpaf7	1266	1	This	this	DT
cord-034340-3ksfpaf7	1266	2	association	association	NN
cord-034340-3ksfpaf7	1266	3	should	should	MD
cord-034340-3ksfpaf7	1266	4	be	be	VB
cord-034340-3ksfpaf7	1266	5	recognized	recognize	VBN
cord-034340-3ksfpaf7	1266	6	early	early	RB
cord-034340-3ksfpaf7	1266	7	for	for	IN
cord-034340-3ksfpaf7	1266	8	rapid	rapid	JJ
cord-034340-3ksfpaf7	1266	9	and	and	CC
cord-034340-3ksfpaf7	1266	10	appropriate	appropriate	JJ
cord-034340-3ksfpaf7	1266	11	treatment	treatment	NN
cord-034340-3ksfpaf7	1266	12	initiation	initiation	NN
cord-034340-3ksfpaf7	1266	13	.	.	.
cord-034340-3ksfpaf7	1267	1	Infantile	infantile	JJ
cord-034340-3ksfpaf7	1267	2	antiphospholipid	antiphospholipid	NNP
cord-034340-3ksfpaf7	1267	3	antibody	antibody	NN
cord-034340-3ksfpaf7	1267	4	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1267	5	:	:	:
cord-034340-3ksfpaf7	1267	6	acquired	acquire	VBN
cord-034340-3ksfpaf7	1267	7	and	and	CC
cord-034340-3ksfpaf7	1267	8	de	de	NNP
cord-034340-3ksfpaf7	1267	9	novo	novo	NNP
cord-034340-3ksfpaf7	1267	10	APL	APL	NNP
cord-034340-3ksfpaf7	1267	11	appearance	appearance	NN
cord-034340-3ksfpaf7	1267	12	in	in	IN
cord-034340-3ksfpaf7	1267	13	four	four	CD
cord-034340-3ksfpaf7	1267	14	infants	infant	NNS
cord-034340-3ksfpaf7	1267	15	T.	T.	NNP
cord-034340-3ksfpaf7	1267	16	Giani	Giani	NNP
cord-034340-3ksfpaf7	1267	17	1	1	CD
cord-034340-3ksfpaf7	1267	18	,	,	,
cord-034340-3ksfpaf7	1267	19	G.	G.	NNP
cord-034340-3ksfpaf7	1267	20	Ferrara	Ferrara	NNP
cord-034340-3ksfpaf7	1267	21	2	2	CD
cord-034340-3ksfpaf7	1267	22	,	,	,
cord-034340-3ksfpaf7	1267	23	A.	A.	NNP
cord-034340-3ksfpaf7	1267	24	Mauro	Mauro	NNP
cord-034340-3ksfpaf7	1267	25	3	3	CD
cord-034340-3ksfpaf7	1267	26	,	,	,
cord-034340-3ksfpaf7	1267	27	R.	R.	NNP
cord-034340-3ksfpaf7	1267	28	Cimaz	Cimaz	NNP
cord-034340-3ksfpaf7	1268	1	4	4	CD
cord-034340-3ksfpaf7	1268	2	Introduction	introduction	NN
cord-034340-3ksfpaf7	1268	3	:	:	:
cord-034340-3ksfpaf7	1269	1	Antiphospholipid	Antiphospholipid	NNP
cord-034340-3ksfpaf7	1269	2	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1269	3	(	(	-LRB-
cord-034340-3ksfpaf7	1269	4	APS	APS	NNP
cord-034340-3ksfpaf7	1269	5	)	)	-RRB-
cord-034340-3ksfpaf7	1269	6	is	be	VBZ
cord-034340-3ksfpaf7	1269	7	a	a	DT
cord-034340-3ksfpaf7	1269	8	rare	rare	JJ
cord-034340-3ksfpaf7	1269	9	condition	condition	NN
cord-034340-3ksfpaf7	1269	10	in	in	IN
cord-034340-3ksfpaf7	1269	11	the	the	DT
cord-034340-3ksfpaf7	1269	12	neonatal	neonatal	JJ
cord-034340-3ksfpaf7	1269	13	age	age	NN
cord-034340-3ksfpaf7	1269	14	.	.	.
cord-034340-3ksfpaf7	1270	1	In	in	IN
cord-034340-3ksfpaf7	1270	2	most	most	JJS
cord-034340-3ksfpaf7	1270	3	cases	case	NNS
cord-034340-3ksfpaf7	1270	4	it	-PRON-	PRP
cord-034340-3ksfpaf7	1270	5	is	be	VBZ
cord-034340-3ksfpaf7	1270	6	considered	consider	VBN
cord-034340-3ksfpaf7	1270	7	a	a	DT
cord-034340-3ksfpaf7	1270	8	passively	passively	RB
cord-034340-3ksfpaf7	1270	9	acquired	acquire	VBN
cord-034340-3ksfpaf7	1270	10	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1270	11	disease	disease	NN
cord-034340-3ksfpaf7	1270	12	,	,	,
cord-034340-3ksfpaf7	1270	13	due	due	IN
cord-034340-3ksfpaf7	1270	14	to	to	IN
cord-034340-3ksfpaf7	1270	15	a	a	DT
cord-034340-3ksfpaf7	1270	16	transplacental	transplacental	JJ
cord-034340-3ksfpaf7	1270	17	passage	passage	NN
cord-034340-3ksfpaf7	1270	18	of	of	IN
cord-034340-3ksfpaf7	1270	19	maternal	maternal	JJ
cord-034340-3ksfpaf7	1270	20	antiphospholipid	antiphospholipid	NNP
cord-034340-3ksfpaf7	1270	21	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1270	22	(	(	-LRB-
cord-034340-3ksfpaf7	1270	23	aPL	aPL	NNP
cord-034340-3ksfpaf7	1270	24	)	)	-RRB-
cord-034340-3ksfpaf7	1270	25	.	.	.
cord-034340-3ksfpaf7	1271	1	Exceedingly	exceedingly	RB
cord-034340-3ksfpaf7	1271	2	unusual	unusual	JJ
cord-034340-3ksfpaf7	1271	3	is	be	VBZ
cord-034340-3ksfpaf7	1271	4	the	the	DT
cord-034340-3ksfpaf7	1271	5	de	de	FW
cord-034340-3ksfpaf7	1271	6	novo	novo	NNP
cord-034340-3ksfpaf7	1271	7	production	production	NN
cord-034340-3ksfpaf7	1271	8	of	of	IN
cord-034340-3ksfpaf7	1271	9	aPL	apl	CD
cord-034340-3ksfpaf7	1271	10	in	in	IN
cord-034340-3ksfpaf7	1271	11	newborns	newborn	NNS
cord-034340-3ksfpaf7	1271	12	and	and	CC
cord-034340-3ksfpaf7	1271	13	infants	infant	NNS
cord-034340-3ksfpaf7	1271	14	.	.	.
cord-034340-3ksfpaf7	1272	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1272	2	:	:	:
cord-034340-3ksfpaf7	1272	3	To	to	TO
cord-034340-3ksfpaf7	1272	4	describe	describe	VB
cord-034340-3ksfpaf7	1272	5	four	four	CD
cord-034340-3ksfpaf7	1272	6	infants	infant	NNS
cord-034340-3ksfpaf7	1272	7	who	who	WP
cord-034340-3ksfpaf7	1272	8	developed	develop	VBD
cord-034340-3ksfpaf7	1272	9	an	an	DT
cord-034340-3ksfpaf7	1272	10	early	early	JJ
cord-034340-3ksfpaf7	1272	11	brain	brain	NN
cord-034340-3ksfpaf7	1272	12	stroke	stroke	NN
cord-034340-3ksfpaf7	1272	13	with	with	IN
cord-034340-3ksfpaf7	1272	14	increased	increased	JJ
cord-034340-3ksfpaf7	1272	15	and	and	CC
cord-034340-3ksfpaf7	1272	16	persistent	persistent	JJ
cord-034340-3ksfpaf7	1272	17	levels	level	NNS
cord-034340-3ksfpaf7	1272	18	of	of	IN
cord-034340-3ksfpaf7	1272	19	aPL	aPL	NNP
cord-034340-3ksfpaf7	1272	20	,	,	,
cord-034340-3ksfpaf7	1272	21	even	even	RB
cord-034340-3ksfpaf7	1272	22	after	after	IN
cord-034340-3ksfpaf7	1272	23	six	six	CD
cord-034340-3ksfpaf7	1272	24	months	month	NNS
cord-034340-3ksfpaf7	1272	25	of	of	IN
cord-034340-3ksfpaf7	1272	26	life	life	NN
cord-034340-3ksfpaf7	1272	27	.	.	.
cord-034340-3ksfpaf7	1273	1	Methods	method	NNS
cord-034340-3ksfpaf7	1273	2	:	:	:
cord-034340-3ksfpaf7	1273	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1273	4	reviewed	review	VBD
cord-034340-3ksfpaf7	1273	5	the	the	DT
cord-034340-3ksfpaf7	1273	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	1273	7	charts	chart	NNS
cord-034340-3ksfpaf7	1273	8	of	of	IN
cord-034340-3ksfpaf7	1273	9	four	four	CD
cord-034340-3ksfpaf7	1273	10	such	such	JJ
cord-034340-3ksfpaf7	1273	11	infants	infant	NNS
cord-034340-3ksfpaf7	1273	12	,	,	,
cord-034340-3ksfpaf7	1273	13	followed	follow	VBD
cord-034340-3ksfpaf7	1273	14	from	from	IN
cord-034340-3ksfpaf7	1273	15	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1273	16	up	up	IN
cord-034340-3ksfpaf7	1273	17	to	to	TO
cord-034340-3ksfpaf7	1273	18	two	two	CD
cord-034340-3ksfpaf7	1273	19	years	year	NNS
cord-034340-3ksfpaf7	1273	20	after	after	IN
cord-034340-3ksfpaf7	1273	21	the	the	DT
cord-034340-3ksfpaf7	1273	22	disappearance	disappearance	NN
cord-034340-3ksfpaf7	1273	23	of	of	IN
cord-034340-3ksfpaf7	1273	24	aPL	aPL	NNP
cord-034340-3ksfpaf7	1273	25	.	.	.
cord-034340-3ksfpaf7	1274	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1274	2	:	:	:
cord-034340-3ksfpaf7	1274	3	Common	common	JJ
cord-034340-3ksfpaf7	1274	4	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1274	5	of	of	IN
cord-034340-3ksfpaf7	1274	6	these	these	DT
cord-034340-3ksfpaf7	1274	7	four	four	CD
cord-034340-3ksfpaf7	1274	8	children	child	NNS
cord-034340-3ksfpaf7	1274	9	are	be	VBP
cord-034340-3ksfpaf7	1274	10	the	the	DT
cord-034340-3ksfpaf7	1274	11	development	development	NN
cord-034340-3ksfpaf7	1274	12	of	of	IN
cord-034340-3ksfpaf7	1274	13	brain	brain	NN
cord-034340-3ksfpaf7	1274	14	stroke	stroke	NN
cord-034340-3ksfpaf7	1274	15	and	and	CC
cord-034340-3ksfpaf7	1274	16	the	the	DT
cord-034340-3ksfpaf7	1274	17	increased	increased	JJ
cord-034340-3ksfpaf7	1274	18	and	and	CC
cord-034340-3ksfpaf7	1274	19	persistent	persistent	JJ
cord-034340-3ksfpaf7	1274	20	aPL	apl	CD
cord-034340-3ksfpaf7	1274	21	levels	level	NNS
cord-034340-3ksfpaf7	1274	22	even	even	RB
cord-034340-3ksfpaf7	1274	23	after	after	IN
cord-034340-3ksfpaf7	1274	24	six	six	CD
cord-034340-3ksfpaf7	1274	25	months	month	NNS
cord-034340-3ksfpaf7	1274	26	of	of	IN
cord-034340-3ksfpaf7	1274	27	life	life	NN
cord-034340-3ksfpaf7	1274	28	.	.	.
cord-034340-3ksfpaf7	1275	1	This	this	DT
cord-034340-3ksfpaf7	1275	2	opens	open	VBZ
cord-034340-3ksfpaf7	1275	3	the	the	DT
cord-034340-3ksfpaf7	1275	4	window	window	NN
cord-034340-3ksfpaf7	1275	5	on	on	IN
cord-034340-3ksfpaf7	1275	6	a	a	DT
cord-034340-3ksfpaf7	1275	7	gray	gray	JJ
cord-034340-3ksfpaf7	1275	8	zone	zone	NN
cord-034340-3ksfpaf7	1275	9	related	relate	VBN
cord-034340-3ksfpaf7	1275	10	to	to	IN
cord-034340-3ksfpaf7	1275	11	the	the	DT
cord-034340-3ksfpaf7	1275	12	origin	origin	NN
cord-034340-3ksfpaf7	1275	13	of	of	IN
cord-034340-3ksfpaf7	1275	14	these	these	DT
cord-034340-3ksfpaf7	1275	15	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1275	16	(	(	-LRB-
cord-034340-3ksfpaf7	1275	17	maternal	maternal	JJ
cord-034340-3ksfpaf7	1275	18	or	or	CC
cord-034340-3ksfpaf7	1275	19	neonatal	neonatal	JJ
cord-034340-3ksfpaf7	1275	20	)	)	-RRB-
cord-034340-3ksfpaf7	1275	21	and	and	CC
cord-034340-3ksfpaf7	1275	22	on	on	IN
cord-034340-3ksfpaf7	1275	23	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1275	24	role	role	NN
cord-034340-3ksfpaf7	1275	25	in	in	IN
cord-034340-3ksfpaf7	1275	26	the	the	DT
cord-034340-3ksfpaf7	1275	27	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	1275	28	of	of	IN
cord-034340-3ksfpaf7	1275	29	the	the	DT
cord-034340-3ksfpaf7	1275	30	infantile	infantile	JJ
cord-034340-3ksfpaf7	1275	31	brain	brain	NN
cord-034340-3ksfpaf7	1275	32	stroke	stroke	NN
cord-034340-3ksfpaf7	1275	33	.	.	.
cord-034340-3ksfpaf7	1276	1	patients	patient	NNS
cord-034340-3ksfpaf7	1276	2	had	have	VBD
cord-034340-3ksfpaf7	1276	3	over	over	IN
cord-034340-3ksfpaf7	1276	4	20	20	CD
cord-034340-3ksfpaf7	1276	5	%	%	NN
cord-034340-3ksfpaf7	1276	6	of	of	IN
cord-034340-3ksfpaf7	1276	7	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1276	8	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1276	9	completed	complete	VBN
cord-034340-3ksfpaf7	1276	10	but	but	CC
cord-034340-3ksfpaf7	1276	11	only	only	RB
cord-034340-3ksfpaf7	1276	12	2	2	CD
cord-034340-3ksfpaf7	1276	13	had	have	VBD
cord-034340-3ksfpaf7	1276	14	over	over	IN
cord-034340-3ksfpaf7	1276	15	80	80	CD
cord-034340-3ksfpaf7	1276	16	%	%	NN
cord-034340-3ksfpaf7	1276	17	.	.	.
cord-034340-3ksfpaf7	1277	1	Aspects	aspect	NNS
cord-034340-3ksfpaf7	1277	2	of	of	IN
cord-034340-3ksfpaf7	1277	3	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1277	4	that	that	WDT
cord-034340-3ksfpaf7	1277	5	were	be	VBD
cord-034340-3ksfpaf7	1277	6	more	more	JJR
cord-034340-3ksfpaf7	1277	7	time	time	NN
cord-034340-3ksfpaf7	1277	8	intensive	intensive	JJ
cord-034340-3ksfpaf7	1277	9	or	or	CC
cord-034340-3ksfpaf7	1277	10	were	be	VBD
cord-034340-3ksfpaf7	1277	11	required	require	VBN
cord-034340-3ksfpaf7	1277	12	less	less	RBR
cord-034340-3ksfpaf7	1277	13	regularly	regularly	RB
cord-034340-3ksfpaf7	1277	14	were	be	VBD
cord-034340-3ksfpaf7	1277	15	most	most	RBS
cord-034340-3ksfpaf7	1277	16	frequently	frequently	RB
cord-034340-3ksfpaf7	1277	17	overlooked	overlook	VBN
cord-034340-3ksfpaf7	1277	18	.	.	.
cord-034340-3ksfpaf7	1278	1	There	there	EX
cord-034340-3ksfpaf7	1278	2	was	be	VBD
cord-034340-3ksfpaf7	1278	3	a	a	DT
cord-034340-3ksfpaf7	1278	4	statistically	statistically	RB
cord-034340-3ksfpaf7	1278	5	significant	significant	JJ
cord-034340-3ksfpaf7	1278	6	increase	increase	NN
cord-034340-3ksfpaf7	1278	7	in	in	IN
cord-034340-3ksfpaf7	1278	8	the	the	DT
cord-034340-3ksfpaf7	1278	9	percentage	percentage	NN
cord-034340-3ksfpaf7	1278	10	of	of	IN
cord-034340-3ksfpaf7	1278	11	completed	complete	VBN
cord-034340-3ksfpaf7	1278	12	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1278	13	in	in	IN
cord-034340-3ksfpaf7	1278	14	those	those	DT
cord-034340-3ksfpaf7	1278	15	patients	patient	NNS
cord-034340-3ksfpaf7	1278	16	for	for	IN
cord-034340-3ksfpaf7	1278	17	whom	whom	WP
cord-034340-3ksfpaf7	1278	18	the	the	DT
cord-034340-3ksfpaf7	1278	19	Lupus	Lupus	NNP
cord-034340-3ksfpaf7	1278	20	Checklist	Checklist	NNP
cord-034340-3ksfpaf7	1278	21	was	be	VBD
cord-034340-3ksfpaf7	1278	22	used	use	VBN
cord-034340-3ksfpaf7	1278	23	compared	compare	VBN
cord-034340-3ksfpaf7	1278	24	to	to	IN
cord-034340-3ksfpaf7	1278	25	patients	patient	NNS
cord-034340-3ksfpaf7	1278	26	where	where	WRB
cord-034340-3ksfpaf7	1278	27	a	a	DT
cord-034340-3ksfpaf7	1278	28	checklist	checklist	NN
cord-034340-3ksfpaf7	1278	29	was	be	VBD
cord-034340-3ksfpaf7	1278	30	not	not	RB
cord-034340-3ksfpaf7	1278	31	used	use	VBN
cord-034340-3ksfpaf7	1278	32	(	(	-LRB-
cord-034340-3ksfpaf7	1278	33	p=0.00	p=0.00	NNP
cord-034340-3ksfpaf7	1278	34	)	)	-RRB-
cord-034340-3ksfpaf7	1278	35	.	.	.
cord-034340-3ksfpaf7	1279	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1279	2	:	:	:
cord-034340-3ksfpaf7	1279	3	There	there	EX
cord-034340-3ksfpaf7	1279	4	is	be	VBZ
cord-034340-3ksfpaf7	1279	5	significant	significant	JJ
cord-034340-3ksfpaf7	1279	6	room	room	NN
cord-034340-3ksfpaf7	1279	7	for	for	IN
cord-034340-3ksfpaf7	1279	8	improvement	improvement	NN
cord-034340-3ksfpaf7	1279	9	in	in	IN
cord-034340-3ksfpaf7	1279	10	the	the	DT
cord-034340-3ksfpaf7	1279	11	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1279	12	of	of	IN
cord-034340-3ksfpaf7	1279	13	these	these	DT
cord-034340-3ksfpaf7	1279	14	patients	patient	NNS
cord-034340-3ksfpaf7	1279	15	with	with	IN
cord-034340-3ksfpaf7	1279	16	JSLE	JSLE	NNP
cord-034340-3ksfpaf7	1279	17	in	in	IN
cord-034340-3ksfpaf7	1279	18	the	the	DT
cord-034340-3ksfpaf7	1279	19	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1279	20	clinic	clinic	NN
cord-034340-3ksfpaf7	1279	21	.	.	.
cord-034340-3ksfpaf7	1280	1	This	this	DT
cord-034340-3ksfpaf7	1280	2	audit	audit	NN
cord-034340-3ksfpaf7	1280	3	illustrates	illustrate	VBZ
cord-034340-3ksfpaf7	1280	4	that	that	IN
cord-034340-3ksfpaf7	1280	5	more	more	RBR
cord-034340-3ksfpaf7	1280	6	diligent	diligent	JJ
cord-034340-3ksfpaf7	1280	7	use	use	NN
cord-034340-3ksfpaf7	1280	8	of	of	IN
cord-034340-3ksfpaf7	1280	9	the	the	DT
cord-034340-3ksfpaf7	1280	10	Lupus	Lupus	NNP
cord-034340-3ksfpaf7	1280	11	Checklist	Checklist	NNP
cord-034340-3ksfpaf7	1280	12	and	and	CC
cord-034340-3ksfpaf7	1280	13	an	an	DT
cord-034340-3ksfpaf7	1280	14	overall	overall	JJ
cord-034340-3ksfpaf7	1280	15	improvement	improvement	NN
cord-034340-3ksfpaf7	1280	16	in	in	IN
cord-034340-3ksfpaf7	1280	17	sustained	sustained	JJ
cord-034340-3ksfpaf7	1280	18	use	use	NN
cord-034340-3ksfpaf7	1280	19	of	of	IN
cord-034340-3ksfpaf7	1280	20	the	the	DT
cord-034340-3ksfpaf7	1280	21	checklist	checklist	NN
cord-034340-3ksfpaf7	1280	22	will	will	MD
cord-034340-3ksfpaf7	1280	23	help	help	VB
cord-034340-3ksfpaf7	1280	24	to	to	TO
cord-034340-3ksfpaf7	1280	25	improve	improve	VB
cord-034340-3ksfpaf7	1280	26	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1280	27	of	of	IN
cord-034340-3ksfpaf7	1280	28	these	these	DT
cord-034340-3ksfpaf7	1280	29	patients	patient	NNS
cord-034340-3ksfpaf7	1280	30	.	.	.
cord-034340-3ksfpaf7	1281	1	Evidence	evidence	NN
cord-034340-3ksfpaf7	1281	2	suggests	suggest	VBZ
cord-034340-3ksfpaf7	1281	3	that	that	IN
cord-034340-3ksfpaf7	1281	4	checklists	checklist	NNS
cord-034340-3ksfpaf7	1281	5	are	be	VBP
cord-034340-3ksfpaf7	1281	6	underutilised	underutilise	VBN
cord-034340-3ksfpaf7	1281	7	in	in	IN
cord-034340-3ksfpaf7	1281	8	medicine	medicine	NN
cord-034340-3ksfpaf7	1281	9	and	and	CC
cord-034340-3ksfpaf7	1281	10	wider	wide	JJR
cord-034340-3ksfpaf7	1281	11	implementation	implementation	NN
cord-034340-3ksfpaf7	1281	12	of	of	IN
cord-034340-3ksfpaf7	1281	13	this	this	DT
cord-034340-3ksfpaf7	1281	14	simple	simple	JJ
cord-034340-3ksfpaf7	1281	15	tool	tool	NN
cord-034340-3ksfpaf7	1281	16	could	could	MD
cord-034340-3ksfpaf7	1281	17	improve	improve	VB
cord-034340-3ksfpaf7	1281	18	patient	patient	JJ
cord-034340-3ksfpaf7	1281	19	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1281	20	.	.	.
cord-034340-3ksfpaf7	1282	1	3	3	CD
cord-034340-3ksfpaf7	1282	2	,	,	,
cord-034340-3ksfpaf7	1282	3	4	4	CD
cord-034340-3ksfpaf7	1282	4	,	,	,
cord-034340-3ksfpaf7	1282	5	5	5	CD
cord-034340-3ksfpaf7	1282	6	Interventions	intervention	NNS
cord-034340-3ksfpaf7	1282	7	such	such	JJ
cord-034340-3ksfpaf7	1282	8	as	as	IN
cord-034340-3ksfpaf7	1282	9	in	in	IN
cord-034340-3ksfpaf7	1282	10	person	person	NN
cord-034340-3ksfpaf7	1282	11	or	or	CC
cord-034340-3ksfpaf7	1282	12	electronic	electronic	JJ
cord-034340-3ksfpaf7	1282	13	reminders	reminder	NNS
cord-034340-3ksfpaf7	1282	14	,	,	,
cord-034340-3ksfpaf7	1282	15	or	or	CC
cord-034340-3ksfpaf7	1282	16	audits	audits	NN
cord-034340-3ksfpaf7	1282	17	with	with	IN
cord-034340-3ksfpaf7	1282	18	feedback	feedback	NN
cord-034340-3ksfpaf7	1282	19	to	to	IN
cord-034340-3ksfpaf7	1282	20	physicians	physician	NNS
cord-034340-3ksfpaf7	1282	21	could	could	MD
cord-034340-3ksfpaf7	1282	22	improve	improve	VB
cord-034340-3ksfpaf7	1282	23	usage	usage	NN
cord-034340-3ksfpaf7	1282	24	over	over	IN
cord-034340-3ksfpaf7	1282	25	time	time	NN
cord-034340-3ksfpaf7	1282	26	.	.	.
cord-034340-3ksfpaf7	1283	1	The	the	DT
cord-034340-3ksfpaf7	1283	2	application	application	NN
cord-034340-3ksfpaf7	1283	3	of	of	IN
cord-034340-3ksfpaf7	1283	4	the	the	DT
cord-034340-3ksfpaf7	1283	5	Lupus	Lupus	NNP
cord-034340-3ksfpaf7	1283	6	Checklist	Checklist	NNP
cord-034340-3ksfpaf7	1283	7	or	or	CC
cord-034340-3ksfpaf7	1283	8	a	a	DT
cord-034340-3ksfpaf7	1283	9	similar	similar	JJ
cord-034340-3ksfpaf7	1283	10	document	document	NN
cord-034340-3ksfpaf7	1283	11	in	in	IN
cord-034340-3ksfpaf7	1283	12	other	other	JJ
cord-034340-3ksfpaf7	1283	13	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1283	14	clinics	clinic	NNS
cord-034340-3ksfpaf7	1283	15	is	be	VBZ
cord-034340-3ksfpaf7	1283	16	important	important	JJ
cord-034340-3ksfpaf7	1283	17	for	for	IN
cord-034340-3ksfpaf7	1283	18	comprehensive	comprehensive	JJ
cord-034340-3ksfpaf7	1283	19	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1283	20	of	of	IN
cord-034340-3ksfpaf7	1283	21	a	a	DT
cord-034340-3ksfpaf7	1283	22	condition	condition	NN
cord-034340-3ksfpaf7	1283	23	as	as	RB
cord-034340-3ksfpaf7	1283	24	complex	complex	JJ
cord-034340-3ksfpaf7	1283	25	as	as	IN
cord-034340-3ksfpaf7	1283	26	JSLE	JSLE	NNP
cord-034340-3ksfpaf7	1283	27	and	and	CC
cord-034340-3ksfpaf7	1283	28	has	have	VBZ
cord-034340-3ksfpaf7	1283	29	the	the	DT
cord-034340-3ksfpaf7	1283	30	potential	potential	NN
cord-034340-3ksfpaf7	1283	31	to	to	TO
cord-034340-3ksfpaf7	1283	32	prevent	prevent	VB
cord-034340-3ksfpaf7	1283	33	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	1283	34	damage	damage	NN
cord-034340-3ksfpaf7	1283	35	and	and	CC
cord-034340-3ksfpaf7	1283	36	medication	medication	NN
cord-034340-3ksfpaf7	1283	37	toxicity	toxicity	NN
cord-034340-3ksfpaf7	1283	38	in	in	IN
cord-034340-3ksfpaf7	1283	39	this	this	DT
cord-034340-3ksfpaf7	1283	40	high	high	JJ
cord-034340-3ksfpaf7	1283	41	-	-	HYPH
cord-034340-3ksfpaf7	1283	42	risk	risk	NN
cord-034340-3ksfpaf7	1283	43	population	population	NN
cord-034340-3ksfpaf7	1283	44	.	.	.
cord-034340-3ksfpaf7	1284	1	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1284	2	onset	onset	NN
cord-034340-3ksfpaf7	1284	3	and	and	CC
cord-034340-3ksfpaf7	1284	4	this	this	DT
cord-034340-3ksfpaf7	1284	5	cluster	cluster	NN
cord-034340-3ksfpaf7	1284	6	have	have	VBP
cord-034340-3ksfpaf7	1284	7	may	may	MD
cord-034340-3ksfpaf7	1284	8	more	more	RBR
cord-034340-3ksfpaf7	1284	9	severe	severe	JJ
cord-034340-3ksfpaf7	1284	10	kidney	kidney	NN
cord-034340-3ksfpaf7	1284	11	,	,	,
cord-034340-3ksfpaf7	1284	12	neuropsychiatric	neuropsychiatric	JJ
cord-034340-3ksfpaf7	1284	13	or	or	CC
cord-034340-3ksfpaf7	1284	14	hematological	hematological	JJ
cord-034340-3ksfpaf7	1284	15	involvement	involvement	NN
cord-034340-3ksfpaf7	1284	16	.	.	.
cord-034340-3ksfpaf7	1285	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1285	2	:	:	:
cord-034340-3ksfpaf7	1286	1	The	the	DT
cord-034340-3ksfpaf7	1286	2	aim	aim	NN
cord-034340-3ksfpaf7	1286	3	of	of	IN
cord-034340-3ksfpaf7	1286	4	this	this	DT
cord-034340-3ksfpaf7	1286	5	study	study	NN
cord-034340-3ksfpaf7	1286	6	was	be	VBD
cord-034340-3ksfpaf7	1286	7	to	to	TO
cord-034340-3ksfpaf7	1286	8	assess	assess	VB
cord-034340-3ksfpaf7	1286	9	the	the	DT
cord-034340-3ksfpaf7	1286	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	1286	11	and	and	CC
cord-034340-3ksfpaf7	1286	12	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1286	13	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1286	14	,	,	,
cord-034340-3ksfpaf7	1286	15	disease	disease	NN
cord-034340-3ksfpaf7	1286	16	activity	activity	NN
cord-034340-3ksfpaf7	1286	17	,	,	,
cord-034340-3ksfpaf7	1286	18	and	and	CC
cord-034340-3ksfpaf7	1286	19	treatment	treatment	NN
cord-034340-3ksfpaf7	1286	20	response	response	NN
cord-034340-3ksfpaf7	1286	21	of	of	IN
cord-034340-3ksfpaf7	1286	22	patients	patient	NNS
cord-034340-3ksfpaf7	1286	23	with	with	IN
cord-034340-3ksfpaf7	1286	24	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1286	25	SLE	SLE	NNP
cord-034340-3ksfpaf7	1286	26	(	(	-LRB-
cord-034340-3ksfpaf7	1286	27	jSLE	jSLE	NNP
cord-034340-3ksfpaf7	1286	28	)	)	-RRB-
cord-034340-3ksfpaf7	1286	29	.	.	.
cord-034340-3ksfpaf7	1287	1	Methods	method	NNS
cord-034340-3ksfpaf7	1287	2	:	:	:
cord-034340-3ksfpaf7	1287	3	This	this	DT
cord-034340-3ksfpaf7	1287	4	is	be	VBZ
cord-034340-3ksfpaf7	1287	5	a	a	DT
cord-034340-3ksfpaf7	1287	6	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1287	7	study	study	NN
cord-034340-3ksfpaf7	1287	8	involving	involve	VBG
cord-034340-3ksfpaf7	1287	9	patients	patient	NNS
cord-034340-3ksfpaf7	1287	10	between	between	IN
cord-034340-3ksfpaf7	1287	11	1	1	CD
cord-034340-3ksfpaf7	1287	12	July	July	NNP
cord-034340-3ksfpaf7	1287	13	2016	2016	CD
cord-034340-3ksfpaf7	1287	14	and	and	CC
cord-034340-3ksfpaf7	1287	15	1	1	CD
cord-034340-3ksfpaf7	1287	16	January	January	NNP
cord-034340-3ksfpaf7	1287	17	2020	2020	CD
cord-034340-3ksfpaf7	1287	18	.	.	.
cord-034340-3ksfpaf7	1288	1	The	the	DT
cord-034340-3ksfpaf7	1288	2	data	datum	NNS
cord-034340-3ksfpaf7	1288	3	of	of	IN
cord-034340-3ksfpaf7	1288	4	patients	patient	NNS
cord-034340-3ksfpaf7	1288	5	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1288	6	with	with	IN
cord-034340-3ksfpaf7	1288	7	jSLE	jsle	NN
cord-034340-3ksfpaf7	1288	8	and	and	CC
cord-034340-3ksfpaf7	1288	9	followed	follow	VBD
cord-034340-3ksfpaf7	1288	10	up	up	RP
cord-034340-3ksfpaf7	1288	11	for	for	IN
cord-034340-3ksfpaf7	1288	12	a	a	DT
cord-034340-3ksfpaf7	1288	13	minimum	minimum	NN
cord-034340-3ksfpaf7	1288	14	of	of	IN
cord-034340-3ksfpaf7	1288	15	6	6	CD
cord-034340-3ksfpaf7	1288	16	months	month	NNS
cord-034340-3ksfpaf7	1288	17	,	,	,
cord-034340-3ksfpaf7	1288	18	were	be	VBD
cord-034340-3ksfpaf7	1288	19	collected	collect	VBN
cord-034340-3ksfpaf7	1288	20	.	.	.
cord-034340-3ksfpaf7	1289	1	The	the	DT
cord-034340-3ksfpaf7	1289	2	SLEDAI-2	SLEDAI-2	NNP
cord-034340-3ksfpaf7	1289	3	K	K	NNP
cord-034340-3ksfpaf7	1289	4	scores	score	NNS
cord-034340-3ksfpaf7	1289	5	at	at	IN
cord-034340-3ksfpaf7	1289	6	initiation	initiation	NN
cord-034340-3ksfpaf7	1289	7	and	and	CC
cord-034340-3ksfpaf7	1289	8	at	at	IN
cord-034340-3ksfpaf7	1289	9	the	the	DT
cord-034340-3ksfpaf7	1289	10	follow	follow	NN
cord-034340-3ksfpaf7	1289	11	-	-	HYPH
cord-034340-3ksfpaf7	1289	12	up	up	NN
cord-034340-3ksfpaf7	1289	13	(	(	-LRB-
cord-034340-3ksfpaf7	1289	14	1st	1st	NN
cord-034340-3ksfpaf7	1289	15	,	,	,
cord-034340-3ksfpaf7	1289	16	3rd	3rd	JJ
cord-034340-3ksfpaf7	1289	17	,	,	,
cord-034340-3ksfpaf7	1289	18	6th	6th	NN
cord-034340-3ksfpaf7	1289	19	,	,	,
cord-034340-3ksfpaf7	1289	20	and	and	CC
cord-034340-3ksfpaf7	1289	21	12th	12th	JJ
cord-034340-3ksfpaf7	1289	22	months	month	NNS
cord-034340-3ksfpaf7	1289	23	of	of	IN
cord-034340-3ksfpaf7	1289	24	treatment	treatment	NN
cord-034340-3ksfpaf7	1289	25	)	)	-RRB-
cord-034340-3ksfpaf7	1289	26	were	be	VBD
cord-034340-3ksfpaf7	1289	27	examined	examine	VBN
cord-034340-3ksfpaf7	1289	28	.	.	.
cord-034340-3ksfpaf7	1290	1	The	the	DT
cord-034340-3ksfpaf7	1290	2	SLEDAI-2	SLEDAI-2	NNP
cord-034340-3ksfpaf7	1290	3	K	K	NNP
cord-034340-3ksfpaf7	1290	4	score	score	NN
cord-034340-3ksfpaf7	1290	5	was	be	VBD
cord-034340-3ksfpaf7	1290	6	considered	consider	VBN
cord-034340-3ksfpaf7	1290	7	to	to	TO
cord-034340-3ksfpaf7	1290	8	be	be	VB
cord-034340-3ksfpaf7	1290	9	≤4	≤4	NNP
cord-034340-3ksfpaf7	1290	10	,	,	,
cord-034340-3ksfpaf7	1290	11	for	for	IN
cord-034340-3ksfpaf7	1290	12	disease	disease	NN
cord-034340-3ksfpaf7	1290	13	remission	remission	NN
cord-034340-3ksfpaf7	1290	14	status	status	NN
cord-034340-3ksfpaf7	1290	15	.	.	.
cord-034340-3ksfpaf7	1291	1	Results	result	NNS
cord-034340-3ksfpaf7	1291	2	:	:	:
cord-034340-3ksfpaf7	1292	1	A	a	DT
cord-034340-3ksfpaf7	1292	2	total	total	NN
cord-034340-3ksfpaf7	1292	3	of	of	IN
cord-034340-3ksfpaf7	1292	4	49	49	CD
cord-034340-3ksfpaf7	1292	5	children	child	NNS
cord-034340-3ksfpaf7	1292	6	were	be	VBD
cord-034340-3ksfpaf7	1292	7	included	include	VBN
cord-034340-3ksfpaf7	1292	8	in	in	IN
cord-034340-3ksfpaf7	1292	9	to	to	IN
cord-034340-3ksfpaf7	1292	10	the	the	DT
cord-034340-3ksfpaf7	1292	11	study	study	NN
cord-034340-3ksfpaf7	1292	12	.	.	.
cord-034340-3ksfpaf7	1293	1	The	the	DT
cord-034340-3ksfpaf7	1293	2	female	female	JJ
cord-034340-3ksfpaf7	1293	3	/	/	SYM
cord-034340-3ksfpaf7	1293	4	male	male	JJ
cord-034340-3ksfpaf7	1293	5	ratio	ratio	NN
cord-034340-3ksfpaf7	1293	6	was	be	VBD
cord-034340-3ksfpaf7	1293	7	4.4/1	4.4/1	CD
cord-034340-3ksfpaf7	1293	8	and	and	CC
cord-034340-3ksfpaf7	1293	9	the	the	DT
cord-034340-3ksfpaf7	1293	10	median	median	JJ
cord-034340-3ksfpaf7	1293	11	age	age	NN
cord-034340-3ksfpaf7	1293	12	of	of	IN
cord-034340-3ksfpaf7	1293	13	the	the	DT
cord-034340-3ksfpaf7	1293	14	patients	patient	NNS
cord-034340-3ksfpaf7	1293	15	at	at	IN
cord-034340-3ksfpaf7	1293	16	the	the	DT
cord-034340-3ksfpaf7	1293	17	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1293	18	was	be	VBD
cord-034340-3ksfpaf7	1293	19	13	13	CD
cord-034340-3ksfpaf7	1293	20	(	(	-LRB-
cord-034340-3ksfpaf7	1293	21	IQR	iqr	NN
cord-034340-3ksfpaf7	1293	22	:	:	:
cord-034340-3ksfpaf7	1293	23	11.1	11.1	CD
cord-034340-3ksfpaf7	1293	24	-	-	HYPH
cord-034340-3ksfpaf7	1293	25	15.2	15.2	CD
cord-034340-3ksfpaf7	1293	26	)	)	-RRB-
cord-034340-3ksfpaf7	1293	27	years	year	NNS
cord-034340-3ksfpaf7	1293	28	.	.	.
cord-034340-3ksfpaf7	1294	1	The	the	DT
cord-034340-3ksfpaf7	1294	2	median	median	JJ
cord-034340-3ksfpaf7	1294	3	follow	follow	NN
cord-034340-3ksfpaf7	1294	4	-	-	HYPH
cord-034340-3ksfpaf7	1294	5	up	up	NN
cord-034340-3ksfpaf7	1294	6	of	of	IN
cord-034340-3ksfpaf7	1294	7	patients	patient	NNS
cord-034340-3ksfpaf7	1294	8	was	be	VBD
cord-034340-3ksfpaf7	1294	9	19	19	CD
cord-034340-3ksfpaf7	1294	10	(	(	-LRB-
cord-034340-3ksfpaf7	1294	11	IQR	IQR	NNP
cord-034340-3ksfpaf7	1294	12	:	:	:
cord-034340-3ksfpaf7	1294	13	12	12	CD
cord-034340-3ksfpaf7	1294	14	-	-	SYM
cord-034340-3ksfpaf7	1294	15	25	25	CD
cord-034340-3ksfpaf7	1294	16	)	)	-RRB-
cord-034340-3ksfpaf7	1294	17	month	month	NN
cord-034340-3ksfpaf7	1294	18	.	.	.
cord-034340-3ksfpaf7	1295	1	Four	four	CD
cord-034340-3ksfpaf7	1295	2	of	of	IN
cord-034340-3ksfpaf7	1295	3	the	the	DT
cord-034340-3ksfpaf7	1295	4	patients	patient	NNS
cord-034340-3ksfpaf7	1295	5	were	be	VBD
cord-034340-3ksfpaf7	1295	6	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1295	7	with	with	IN
cord-034340-3ksfpaf7	1295	8	monogenic	monogenic	NNP
cord-034340-3ksfpaf7	1295	9	SLE	SLE	NNP
cord-034340-3ksfpaf7	1295	10	.	.	.
cord-034340-3ksfpaf7	1296	1	Two	two	CD
cord-034340-3ksfpaf7	1296	2	siblings	sibling	NNS
cord-034340-3ksfpaf7	1296	3	were	be	VBD
cord-034340-3ksfpaf7	1296	4	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1296	5	with	with	IN
cord-034340-3ksfpaf7	1296	6	c3	c3	NN
cord-034340-3ksfpaf7	1296	7	deficiency	deficiency	NN
cord-034340-3ksfpaf7	1296	8	and	and	CC
cord-034340-3ksfpaf7	1296	9	two	two	CD
cord-034340-3ksfpaf7	1296	10	were	be	VBD
cord-034340-3ksfpaf7	1296	11	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1296	12	with	with	IN
cord-034340-3ksfpaf7	1296	13	familial	familial	JJ
cord-034340-3ksfpaf7	1296	14	chilblain	chilblain	JJ
cord-034340-3ksfpaf7	1296	15	lupus	lupus	NN
cord-034340-3ksfpaf7	1296	16	.	.	.
cord-034340-3ksfpaf7	1297	1	The	the	DT
cord-034340-3ksfpaf7	1297	2	most	most	RBS
cord-034340-3ksfpaf7	1297	3	common	common	JJ
cord-034340-3ksfpaf7	1297	4	clinical	clinical	JJ
cord-034340-3ksfpaf7	1297	5	findings	finding	NNS
cord-034340-3ksfpaf7	1297	6	were	be	VBD
cord-034340-3ksfpaf7	1297	7	found	find	VBN
cord-034340-3ksfpaf7	1297	8	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	1297	9	complaints	complaint	NNS
cord-034340-3ksfpaf7	1297	10	(	(	-LRB-
cord-034340-3ksfpaf7	1297	11	69.4	69.4	CD
cord-034340-3ksfpaf7	1297	12	%	%	NN
cord-034340-3ksfpaf7	1297	13	)	)	-RRB-
cord-034340-3ksfpaf7	1297	14	,	,	,
cord-034340-3ksfpaf7	1297	15	malar	malar	NNP
cord-034340-3ksfpaf7	1297	16	rash	rash	NNP
cord-034340-3ksfpaf7	1297	17	(	(	-LRB-
cord-034340-3ksfpaf7	1297	18	51	51	CD
cord-034340-3ksfpaf7	1297	19	%	%	NN
cord-034340-3ksfpaf7	1297	20	)	)	-RRB-
cord-034340-3ksfpaf7	1297	21	,	,	,
cord-034340-3ksfpaf7	1297	22	oral	oral	JJ
cord-034340-3ksfpaf7	1297	23	ulcers	ulcer	NNS
cord-034340-3ksfpaf7	1297	24	(	(	-LRB-
cord-034340-3ksfpaf7	1297	25	38.8	38.8	CD
cord-034340-3ksfpaf7	1297	26	%	%	NN
cord-034340-3ksfpaf7	1297	27	)	)	-RRB-
cord-034340-3ksfpaf7	1297	28	,	,	,
cord-034340-3ksfpaf7	1297	29	and	and	CC
cord-034340-3ksfpaf7	1297	30	fever	fever	NN
cord-034340-3ksfpaf7	1297	31	(	(	-LRB-
cord-034340-3ksfpaf7	1297	32	30.6	30.6	CD
cord-034340-3ksfpaf7	1297	33	%	%	NN
cord-034340-3ksfpaf7	1297	34	)	)	-RRB-
cord-034340-3ksfpaf7	1297	35	,	,	,
cord-034340-3ksfpaf7	1297	36	respectively	respectively	RB
cord-034340-3ksfpaf7	1297	37	in	in	IN
cord-034340-3ksfpaf7	1297	38	over	over	IN
cord-034340-3ksfpaf7	1297	39	all	all	PDT
cord-034340-3ksfpaf7	1297	40	the	the	DT
cord-034340-3ksfpaf7	1297	41	group	group	NN
cord-034340-3ksfpaf7	1297	42	.	.	.
cord-034340-3ksfpaf7	1298	1	The	the	DT
cord-034340-3ksfpaf7	1298	2	frequency	frequency	NN
cord-034340-3ksfpaf7	1298	3	of	of	IN
cord-034340-3ksfpaf7	1298	4	involvement	involvement	NN
cord-034340-3ksfpaf7	1298	5	of	of	IN
cord-034340-3ksfpaf7	1298	6	the	the	DT
cord-034340-3ksfpaf7	1298	7	system	system	NN
cord-034340-3ksfpaf7	1298	8	and	and	CC
cord-034340-3ksfpaf7	1298	9	organs	organ	NNS
cord-034340-3ksfpaf7	1298	10	was	be	VBD
cord-034340-3ksfpaf7	1298	11	as	as	IN
cord-034340-3ksfpaf7	1298	12	follows	follow	VBZ
cord-034340-3ksfpaf7	1298	13	;	;	:
cord-034340-3ksfpaf7	1298	14	mucocutaneous	mucocutaneous	NNP
cord-034340-3ksfpaf7	1298	15	77.6	77.6	CD
cord-034340-3ksfpaf7	1298	16	%	%	NN
cord-034340-3ksfpaf7	1298	17	,	,	,
cord-034340-3ksfpaf7	1298	18	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	1298	19	69.4	69.4	CD
cord-034340-3ksfpaf7	1298	20	%	%	NN
cord-034340-3ksfpaf7	1298	21	,	,	,
cord-034340-3ksfpaf7	1298	22	renal	renal	JJ
cord-034340-3ksfpaf7	1298	23	44.9	44.9	CD
cord-034340-3ksfpaf7	1298	24	%	%	NN
cord-034340-3ksfpaf7	1298	25	,	,	,
cord-034340-3ksfpaf7	1298	26	hematological	hematological	JJ
cord-034340-3ksfpaf7	1298	27	34.7	34.7	CD
cord-034340-3ksfpaf7	1298	28	%	%	NN
cord-034340-3ksfpaf7	1298	29	,	,	,
cord-034340-3ksfpaf7	1298	30	serous	serous	JJ
cord-034340-3ksfpaf7	1298	31	membranes	membrane	NNS
cord-034340-3ksfpaf7	1298	32	16.3	16.3	CD
cord-034340-3ksfpaf7	1298	33	%	%	NN
cord-034340-3ksfpaf7	1298	34	,	,	,
cord-034340-3ksfpaf7	1298	35	neuropsychiatric	neuropsychiatric	JJ
cord-034340-3ksfpaf7	1298	36	12.2	12.2	CD
cord-034340-3ksfpaf7	1298	37	%	%	NN
cord-034340-3ksfpaf7	1298	38	,	,	,
cord-034340-3ksfpaf7	1298	39	respectively	respectively	RB
cord-034340-3ksfpaf7	1298	40	.	.	.
cord-034340-3ksfpaf7	1299	1	All	all	DT
cord-034340-3ksfpaf7	1299	2	patients	patient	NNS
cord-034340-3ksfpaf7	1299	3	had	have	VBD
cord-034340-3ksfpaf7	1299	4	anti	anti	JJ
cord-034340-3ksfpaf7	1299	5	-	-	JJ
cord-034340-3ksfpaf7	1299	6	nuclear	nuclear	JJ
cord-034340-3ksfpaf7	1299	7	antibody	antibody	NN
cord-034340-3ksfpaf7	1299	8	positivity	positivity	NN
cord-034340-3ksfpaf7	1299	9	,	,	,
cord-034340-3ksfpaf7	1299	10	while	while	IN
cord-034340-3ksfpaf7	1299	11	46.9	46.9	CD
cord-034340-3ksfpaf7	1299	12	%	%	NN
cord-034340-3ksfpaf7	1299	13	had	have	VBD
cord-034340-3ksfpaf7	1299	14	anti	anti	JJ
cord-034340-3ksfpaf7	1299	15	-	-	JJ
cord-034340-3ksfpaf7	1299	16	ds	ds	NNP
cord-034340-3ksfpaf7	1299	17	DNA	DNA	NNP
cord-034340-3ksfpaf7	1299	18	,	,	,
cord-034340-3ksfpaf7	1299	19	14.3	14.3	CD
cord-034340-3ksfpaf7	1299	20	%	%	NN
cord-034340-3ksfpaf7	1299	21	had	have	VBD
cord-034340-3ksfpaf7	1299	22	anti	anti	JJ
cord-034340-3ksfpaf7	1299	23	-	-	JJ
cord-034340-3ksfpaf7	1299	24	Sm	sm	JJ
cord-034340-3ksfpaf7	1299	25	and	and	CC
cord-034340-3ksfpaf7	1299	26	8.2	8.2	CD
cord-034340-3ksfpaf7	1299	27	%	%	NN
cord-034340-3ksfpaf7	1299	28	had	have	VBD
cord-034340-3ksfpaf7	1299	29	antiphospholipid	antiphospholipid	NNP
cord-034340-3ksfpaf7	1299	30	antibody	antibody	NN
cord-034340-3ksfpaf7	1299	31	positivity	positivity	NN
cord-034340-3ksfpaf7	1299	32	.	.	.
cord-034340-3ksfpaf7	1300	1	While	while	IN
cord-034340-3ksfpaf7	1300	2	all	all	DT
cord-034340-3ksfpaf7	1300	3	patients	patient	NNS
cord-034340-3ksfpaf7	1300	4	received	receive	VBD
cord-034340-3ksfpaf7	1300	5	hydroxychloroquine	hydroxychloroquine	NN
cord-034340-3ksfpaf7	1300	6	treatment	treatment	NN
cord-034340-3ksfpaf7	1300	7	,	,	,
cord-034340-3ksfpaf7	1300	8	22.4	22.4	CD
cord-034340-3ksfpaf7	1300	9	%	%	NN
cord-034340-3ksfpaf7	1300	10	of	of	IN
cord-034340-3ksfpaf7	1300	11	the	the	DT
cord-034340-3ksfpaf7	1300	12	patients	patient	NNS
cord-034340-3ksfpaf7	1300	13	were	be	VBD
cord-034340-3ksfpaf7	1300	14	received	receive	VBN
cord-034340-3ksfpaf7	1300	15	were	be	VBD
cord-034340-3ksfpaf7	1300	16	mycophenolate	mycophenolate	NNP
cord-034340-3ksfpaf7	1300	17	mofetil	mofetil	NNP
cord-034340-3ksfpaf7	1300	18	,	,	,
cord-034340-3ksfpaf7	1300	19	22.4	22.4	CD
cord-034340-3ksfpaf7	1300	20	%	%	NN
cord-034340-3ksfpaf7	1300	21	were	be	VBD
cord-034340-3ksfpaf7	1300	22	azathioprine	azathioprine	JJ
cord-034340-3ksfpaf7	1300	23	,	,	,
cord-034340-3ksfpaf7	1300	24	14.3	14.3	CD
cord-034340-3ksfpaf7	1300	25	%	%	NN
cord-034340-3ksfpaf7	1300	26	cyclophosphamide	cyclophosphamide	RB
cord-034340-3ksfpaf7	1300	27	,	,	,
cord-034340-3ksfpaf7	1300	28	12.2	12.2	CD
cord-034340-3ksfpaf7	1300	29	%	%	NN
cord-034340-3ksfpaf7	1300	30	methotrexate	methotrexate	NN
cord-034340-3ksfpaf7	1300	31	and	and	CC
cord-034340-3ksfpaf7	1300	32	10.2	10.2	CD
cord-034340-3ksfpaf7	1300	33	%	%	NN
cord-034340-3ksfpaf7	1300	34	were	be	VBD
cord-034340-3ksfpaf7	1300	35	rituximab	rituximab	VBN
cord-034340-3ksfpaf7	1300	36	.	.	.
cord-034340-3ksfpaf7	1301	1	The	the	DT
cord-034340-3ksfpaf7	1301	2	median	median	JJ
cord-034340-3ksfpaf7	1301	3	SLEDAI-2	SLEDAI-2	NNP
cord-034340-3ksfpaf7	1301	4	K	K	NNP
cord-034340-3ksfpaf7	1301	5	score	score	NN
cord-034340-3ksfpaf7	1301	6	was	be	VBD
cord-034340-3ksfpaf7	1301	7	14	14	CD
cord-034340-3ksfpaf7	1302	1	(	(	-LRB-
cord-034340-3ksfpaf7	1302	2	IQR	IQR	NNP
cord-034340-3ksfpaf7	1302	3	:	:	:
cord-034340-3ksfpaf7	1302	4	10	10	CD
cord-034340-3ksfpaf7	1302	5	-	-	SYM
cord-034340-3ksfpaf7	1302	6	18.5	18.5	CD
cord-034340-3ksfpaf7	1302	7	)	)	-RRB-
cord-034340-3ksfpaf7	1302	8	at	at	IN
cord-034340-3ksfpaf7	1302	9	admission	admission	NN
cord-034340-3ksfpaf7	1302	10	,	,	,
cord-034340-3ksfpaf7	1302	11	besides	besides	IN
cord-034340-3ksfpaf7	1302	12	it	-PRON-	PRP
cord-034340-3ksfpaf7	1302	13	was	be	VBD
cord-034340-3ksfpaf7	1302	14	found	find	VBN
cord-034340-3ksfpaf7	1302	15	to	to	IN
cord-034340-3ksfpaf7	1302	16	6	6	CD
cord-034340-3ksfpaf7	1302	17	(	(	-LRB-
cord-034340-3ksfpaf7	1302	18	IQR	iqr	NN
cord-034340-3ksfpaf7	1302	19	:	:	:
cord-034340-3ksfpaf7	1302	20	4	4	CD
cord-034340-3ksfpaf7	1302	21	-	-	SYM
cord-034340-3ksfpaf7	1302	22	12	12	CD
cord-034340-3ksfpaf7	1302	23	)	)	-RRB-
cord-034340-3ksfpaf7	1302	24	,	,	,
cord-034340-3ksfpaf7	1302	25	4	4	CD
cord-034340-3ksfpaf7	1302	26	(	(	-LRB-
cord-034340-3ksfpaf7	1302	27	IQR	iqr	NN
cord-034340-3ksfpaf7	1302	28	:	:	:
cord-034340-3ksfpaf7	1302	29	2	2	CD
cord-034340-3ksfpaf7	1302	30	-	-	SYM
cord-034340-3ksfpaf7	1302	31	6	6	CD
cord-034340-3ksfpaf7	1302	32	)	)	-RRB-
cord-034340-3ksfpaf7	1302	33	,	,	,
cord-034340-3ksfpaf7	1302	34	2	2	CD
cord-034340-3ksfpaf7	1302	35	(	(	-LRB-
cord-034340-3ksfpaf7	1302	36	IQR	iqr	NN
cord-034340-3ksfpaf7	1302	37	:	:	:
cord-034340-3ksfpaf7	1302	38	0	0	CD
cord-034340-3ksfpaf7	1302	39	-	-	SYM
cord-034340-3ksfpaf7	1302	40	6	6	CD
cord-034340-3ksfpaf7	1302	41	)	)	-RRB-
cord-034340-3ksfpaf7	1302	42	in	in	IN
cord-034340-3ksfpaf7	1302	43	the	the	DT
cord-034340-3ksfpaf7	1302	44	1st	1st	NN
cord-034340-3ksfpaf7	1302	45	,	,	,
cord-034340-3ksfpaf7	1302	46	6th	6th	JJ
cord-034340-3ksfpaf7	1302	47	and	and	CC
cord-034340-3ksfpaf7	1302	48	12th	12th	JJ
cord-034340-3ksfpaf7	1302	49	months	month	NNS
cord-034340-3ksfpaf7	1302	50	of	of	IN
cord-034340-3ksfpaf7	1302	51	treatment	treatment	NN
cord-034340-3ksfpaf7	1302	52	,	,	,
cord-034340-3ksfpaf7	1302	53	respectively	respectively	RB
cord-034340-3ksfpaf7	1302	54	.	.	.
cord-034340-3ksfpaf7	1303	1	While	while	IN
cord-034340-3ksfpaf7	1303	2	98	98	CD
cord-034340-3ksfpaf7	1303	3	%	%	NN
cord-034340-3ksfpaf7	1303	4	of	of	IN
cord-034340-3ksfpaf7	1303	5	the	the	DT
cord-034340-3ksfpaf7	1303	6	patients	patient	NNS
cord-034340-3ksfpaf7	1303	7	had	have	VBD
cord-034340-3ksfpaf7	1303	8	active	active	JJ
cord-034340-3ksfpaf7	1303	9	disease	disease	NN
cord-034340-3ksfpaf7	1303	10	at	at	IN
cord-034340-3ksfpaf7	1303	11	admission	admission	NN
cord-034340-3ksfpaf7	1303	12	,	,	,
cord-034340-3ksfpaf7	1303	13	67.3	67.3	CD
cord-034340-3ksfpaf7	1303	14	%	%	NN
cord-034340-3ksfpaf7	1303	15	at	at	IN
cord-034340-3ksfpaf7	1303	16	1	1	CD
cord-034340-3ksfpaf7	1303	17	months	month	NNS
cord-034340-3ksfpaf7	1303	18	,	,	,
cord-034340-3ksfpaf7	1304	1	32.7	32.7	CD
cord-034340-3ksfpaf7	1304	2	%	%	NN
cord-034340-3ksfpaf7	1304	3	at	at	IN
cord-034340-3ksfpaf7	1304	4	6	6	CD
cord-034340-3ksfpaf7	1304	5	months	month	NNS
cord-034340-3ksfpaf7	1304	6	and	and	CC
cord-034340-3ksfpaf7	1304	7	22.4	22.4	CD
cord-034340-3ksfpaf7	1304	8	%	%	NN
cord-034340-3ksfpaf7	1304	9	at	at	IN
cord-034340-3ksfpaf7	1304	10	12	12	CD
cord-034340-3ksfpaf7	1304	11	months	month	NNS
cord-034340-3ksfpaf7	1304	12	still	still	RB
cord-034340-3ksfpaf7	1304	13	had	have	VBD
cord-034340-3ksfpaf7	1304	14	active	active	JJ
cord-034340-3ksfpaf7	1304	15	disease	disease	NN
cord-034340-3ksfpaf7	1304	16	(	(	-LRB-
cord-034340-3ksfpaf7	1304	17	SLEDAI-2	SLEDAI-2	NNP
cord-034340-3ksfpaf7	1304	18	K	K	NNP
cord-034340-3ksfpaf7	1304	19	>	>	XX
cord-034340-3ksfpaf7	1304	20	4	4	CD
cord-034340-3ksfpaf7	1304	21	)	)	-RRB-
cord-034340-3ksfpaf7	1304	22	.	.	.
cord-034340-3ksfpaf7	1305	1	Patients	patient	NNS
cord-034340-3ksfpaf7	1305	2	with	with	IN
cord-034340-3ksfpaf7	1305	3	initially	initially	RB
cord-034340-3ksfpaf7	1305	4	high	high	JJ
cord-034340-3ksfpaf7	1305	5	SLEDAI-2	SLEDAI-2	NNP
cord-034340-3ksfpaf7	1305	6	K	K	NNP
cord-034340-3ksfpaf7	1305	7	scores	score	NNS
cord-034340-3ksfpaf7	1305	8	had	have	VBD
cord-034340-3ksfpaf7	1305	9	significantly	significantly	RB
cord-034340-3ksfpaf7	1305	10	lower	low	JJR
cord-034340-3ksfpaf7	1305	11	remission	remission	NN
cord-034340-3ksfpaf7	1305	12	rates	rate	NNS
cord-034340-3ksfpaf7	1305	13	in	in	IN
cord-034340-3ksfpaf7	1305	14	the	the	DT
cord-034340-3ksfpaf7	1305	15	first	first	JJ
cord-034340-3ksfpaf7	1305	16	month	month	NN
cord-034340-3ksfpaf7	1305	17	(	(	-LRB-
cord-034340-3ksfpaf7	1305	18	p=0.003	p=0.003	NNP
cord-034340-3ksfpaf7	1305	19	)	)	-RRB-
cord-034340-3ksfpaf7	1305	20	.	.	.
cord-034340-3ksfpaf7	1306	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1306	2	was	be	VBD
cord-034340-3ksfpaf7	1306	3	observed	observe	VBN
cord-034340-3ksfpaf7	1306	4	that	that	IN
cord-034340-3ksfpaf7	1306	5	patients	patient	NNS
cord-034340-3ksfpaf7	1306	6	with	with	IN
cord-034340-3ksfpaf7	1306	7	high	high	JJ
cord-034340-3ksfpaf7	1306	8	SLEDAI-2	SLEDAI-2	NNP
cord-034340-3ksfpaf7	1306	9	K	K	NNP
cord-034340-3ksfpaf7	1306	10	scores	score	NNS
cord-034340-3ksfpaf7	1306	11	in	in	IN
cord-034340-3ksfpaf7	1306	12	admission	admission	NN
cord-034340-3ksfpaf7	1306	13	were	be	VBD
cord-034340-3ksfpaf7	1306	14	more	more	RBR
cord-034340-3ksfpaf7	1306	15	resistant	resistant	JJ
cord-034340-3ksfpaf7	1306	16	to	to	IN
cord-034340-3ksfpaf7	1306	17	conventional	conventional	JJ
cord-034340-3ksfpaf7	1306	18	immunosuppressive	immunosuppressive	JJ
cord-034340-3ksfpaf7	1306	19	treatments	treatment	NNS
cord-034340-3ksfpaf7	1306	20	and	and	CC
cord-034340-3ksfpaf7	1306	21	the	the	DT
cord-034340-3ksfpaf7	1306	22	use	use	NN
cord-034340-3ksfpaf7	1306	23	of	of	IN
cord-034340-3ksfpaf7	1306	24	rituximab	rituximab	NN
cord-034340-3ksfpaf7	1306	25	was	be	VBD
cord-034340-3ksfpaf7	1306	26	more	more	RBR
cord-034340-3ksfpaf7	1306	27	frequent	frequent	JJ
cord-034340-3ksfpaf7	1306	28	in	in	IN
cord-034340-3ksfpaf7	1306	29	these	these	DT
cord-034340-3ksfpaf7	1306	30	patients	patient	NNS
cord-034340-3ksfpaf7	1306	31	.	.	.
cord-034340-3ksfpaf7	1307	1	At	at	RB
cord-034340-3ksfpaf7	1307	2	least	least	RBS
cord-034340-3ksfpaf7	1307	3	one	one	CD
cord-034340-3ksfpaf7	1307	4	major	major	JJ
cord-034340-3ksfpaf7	1307	5	organ	organ	NN
cord-034340-3ksfpaf7	1307	6	(	(	-LRB-
cord-034340-3ksfpaf7	1307	7	renal	renal	JJ
cord-034340-3ksfpaf7	1307	8	,	,	,
cord-034340-3ksfpaf7	1307	9	hematological	hematological	JJ
cord-034340-3ksfpaf7	1307	10	,	,	,
cord-034340-3ksfpaf7	1307	11	neurological	neurological	JJ
cord-034340-3ksfpaf7	1307	12	)	)	-RRB-
cord-034340-3ksfpaf7	1307	13	were	be	VBD
cord-034340-3ksfpaf7	1307	14	affected	affect	VBN
cord-034340-3ksfpaf7	1307	15	in	in	IN
cord-034340-3ksfpaf7	1307	16	57	57	CD
cord-034340-3ksfpaf7	1307	17	%	%	NN
cord-034340-3ksfpaf7	1307	18	of	of	IN
cord-034340-3ksfpaf7	1307	19	patients	patient	NNS
cord-034340-3ksfpaf7	1307	20	.	.	.
cord-034340-3ksfpaf7	1308	1	The	the	DT
cord-034340-3ksfpaf7	1308	2	remission	remission	NN
cord-034340-3ksfpaf7	1308	3	rate	rate	NN
cord-034340-3ksfpaf7	1308	4	of	of	IN
cord-034340-3ksfpaf7	1308	5	these	these	DT
cord-034340-3ksfpaf7	1308	6	patients	patient	NNS
cord-034340-3ksfpaf7	1308	7	at	at	IN
cord-034340-3ksfpaf7	1308	8	6	6	CD
cord-034340-3ksfpaf7	1308	9	months	month	NNS
cord-034340-3ksfpaf7	1308	10	was	be	VBD
cord-034340-3ksfpaf7	1308	11	found	find	VBN
cord-034340-3ksfpaf7	1308	12	significantly	significantly	RB
cord-034340-3ksfpaf7	1308	13	decreased	decrease	VBD
cord-034340-3ksfpaf7	1308	14	compared	compare	VBN
cord-034340-3ksfpaf7	1308	15	to	to	IN
cord-034340-3ksfpaf7	1308	16	the	the	DT
cord-034340-3ksfpaf7	1308	17	others	other	NNS
cord-034340-3ksfpaf7	1308	18	(	(	-LRB-
cord-034340-3ksfpaf7	1308	19	p	p	NN
cord-034340-3ksfpaf7	1308	20	<	<	XX
cord-034340-3ksfpaf7	1308	21	0.005	0.005	CD
cord-034340-3ksfpaf7	1308	22	)	)	-RRB-
cord-034340-3ksfpaf7	1308	23	.	.	.
cord-034340-3ksfpaf7	1309	1	Renal	renal	JJ
cord-034340-3ksfpaf7	1309	2	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1309	3	was	be	VBD
cord-034340-3ksfpaf7	1309	4	performed	perform	VBN
cord-034340-3ksfpaf7	1309	5	in	in	IN
cord-034340-3ksfpaf7	1309	6	21	21	CD
cord-034340-3ksfpaf7	1309	7	patients	patient	NNS
cord-034340-3ksfpaf7	1309	8	(	(	-LRB-
cord-034340-3ksfpaf7	1309	9	42.9	42.9	CD
cord-034340-3ksfpaf7	1309	10	%	%	NN
cord-034340-3ksfpaf7	1309	11	)	)	-RRB-
cord-034340-3ksfpaf7	1309	12	.	.	.
cord-034340-3ksfpaf7	1310	1	12	12	CD
cord-034340-3ksfpaf7	1310	2	of	of	IN
cord-034340-3ksfpaf7	1310	3	them	-PRON-	PRP
cord-034340-3ksfpaf7	1310	4	had	have	VBD
cord-034340-3ksfpaf7	1310	5	type	type	NN
cord-034340-3ksfpaf7	1310	6	4	4	CD
cord-034340-3ksfpaf7	1310	7	lupus	lupus	NN
cord-034340-3ksfpaf7	1310	8	nephritis	nephritis	NN
cord-034340-3ksfpaf7	1310	9	(	(	-LRB-
cord-034340-3ksfpaf7	1310	10	LN	ln	NN
cord-034340-3ksfpaf7	1310	11	)	)	-RRB-
cord-034340-3ksfpaf7	1311	1	,	,	,
cord-034340-3ksfpaf7	1311	2	5	5	CD
cord-034340-3ksfpaf7	1311	3	had	have	VBD
cord-034340-3ksfpaf7	1311	4	type	type	NN
cord-034340-3ksfpaf7	1311	5	2	2	CD
cord-034340-3ksfpaf7	1311	6	,	,	,
cord-034340-3ksfpaf7	1311	7	2	2	CD
cord-034340-3ksfpaf7	1311	8	had	have	VBD
cord-034340-3ksfpaf7	1311	9	type	type	NN
cord-034340-3ksfpaf7	1311	10	3	3	CD
cord-034340-3ksfpaf7	1311	11	,	,	,
cord-034340-3ksfpaf7	1311	12	and	and	CC
cord-034340-3ksfpaf7	1311	13	1	1	CD
cord-034340-3ksfpaf7	1311	14	had	have	VBD
cord-034340-3ksfpaf7	1311	15	type	type	NN
cord-034340-3ksfpaf7	1311	16	5	5	CD
cord-034340-3ksfpaf7	1311	17	.	.	.
cord-034340-3ksfpaf7	1312	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1312	2	was	be	VBD
cord-034340-3ksfpaf7	1312	3	observed	observe	VBN
cord-034340-3ksfpaf7	1312	4	that	that	IN
cord-034340-3ksfpaf7	1312	5	patients	patient	NNS
cord-034340-3ksfpaf7	1312	6	with	with	IN
cord-034340-3ksfpaf7	1312	7	renal	renal	JJ
cord-034340-3ksfpaf7	1312	8	involvement	involvement	NN
cord-034340-3ksfpaf7	1312	9	were	be	VBD
cord-034340-3ksfpaf7	1312	10	the	the	DT
cord-034340-3ksfpaf7	1312	11	group	group	NN
cord-034340-3ksfpaf7	1312	12	that	that	WDT
cord-034340-3ksfpaf7	1312	13	reached	reach	VBD
cord-034340-3ksfpaf7	1312	14	remission	remission	NN
cord-034340-3ksfpaf7	1312	15	latest	late	JJS
cord-034340-3ksfpaf7	1312	16	.	.	.
cord-034340-3ksfpaf7	1313	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1313	2	:	:	:
cord-034340-3ksfpaf7	1314	1	The	the	DT
cord-034340-3ksfpaf7	1314	2	presence	presence	NN
cord-034340-3ksfpaf7	1314	3	of	of	IN
cord-034340-3ksfpaf7	1314	4	high	high	JJ
cord-034340-3ksfpaf7	1314	5	initial	initial	JJ
cord-034340-3ksfpaf7	1314	6	SLEDAI-2	SLEDAI-2	NNP
cord-034340-3ksfpaf7	1314	7	K	K	NNP
cord-034340-3ksfpaf7	1314	8	scores	score	NNS
cord-034340-3ksfpaf7	1314	9	and	and	CC
cord-034340-3ksfpaf7	1314	10	the	the	DT
cord-034340-3ksfpaf7	1314	11	major	major	JJ
cord-034340-3ksfpaf7	1314	12	organ	organ	NN
cord-034340-3ksfpaf7	1314	13	involvement	involvement	NN
cord-034340-3ksfpaf7	1314	14	have	have	VBP
cord-034340-3ksfpaf7	1314	15	poor	poor	JJ
cord-034340-3ksfpaf7	1314	16	predictive	predictive	JJ
cord-034340-3ksfpaf7	1314	17	value	value	NN
cord-034340-3ksfpaf7	1314	18	to	to	TO
cord-034340-3ksfpaf7	1314	19	achieve	achieve	VB
cord-034340-3ksfpaf7	1314	20	inactive	inactive	JJ
cord-034340-3ksfpaf7	1314	21	disease	disease	NN
cord-034340-3ksfpaf7	1314	22	.	.	.
cord-034340-3ksfpaf7	1315	1	A	a	DT
cord-034340-3ksfpaf7	1315	2	two	two	CD
cord-034340-3ksfpaf7	1315	3	year	year	NN
cord-034340-3ksfpaf7	1315	4	old	old	JJ
cord-034340-3ksfpaf7	1315	5	girl	girl	NN
cord-034340-3ksfpaf7	1315	6	of	of	IN
cord-034340-3ksfpaf7	1315	7	consanguineous	consanguineous	JJ
cord-034340-3ksfpaf7	1315	8	parents	parent	NNS
cord-034340-3ksfpaf7	1315	9	presented	present	VBN
cord-034340-3ksfpaf7	1315	10	to	to	IN
cord-034340-3ksfpaf7	1315	11	hospital	hospital	NN
cord-034340-3ksfpaf7	1315	12	at	at	IN
cord-034340-3ksfpaf7	1315	13	13	13	CD
cord-034340-3ksfpaf7	1315	14	months	month	NNS
cord-034340-3ksfpaf7	1315	15	of	of	IN
cord-034340-3ksfpaf7	1315	16	age	age	NN
cord-034340-3ksfpaf7	1315	17	with	with	IN
cord-034340-3ksfpaf7	1315	18	fever	fever	NN
cord-034340-3ksfpaf7	1315	19	and	and	CC
cord-034340-3ksfpaf7	1315	20	erythematous	erythematous	JJ
cord-034340-3ksfpaf7	1315	21	macular	macular	JJ
cord-034340-3ksfpaf7	1315	22	rash	rash	NN
cord-034340-3ksfpaf7	1315	23	on	on	IN
cord-034340-3ksfpaf7	1315	24	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1315	25	cheeks	cheek	NNS
cord-034340-3ksfpaf7	1315	26	which	which	WDT
cord-034340-3ksfpaf7	1315	27	spread	spread	VBD
cord-034340-3ksfpaf7	1315	28	to	to	IN
cord-034340-3ksfpaf7	1315	29	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1315	30	nose	nose	NN
cord-034340-3ksfpaf7	1315	31	,	,	,
cord-034340-3ksfpaf7	1315	32	chin	chin	NNP
cord-034340-3ksfpaf7	1315	33	,	,	,
cord-034340-3ksfpaf7	1315	34	and	and	CC
cord-034340-3ksfpaf7	1315	35	ears	ear	NNS
cord-034340-3ksfpaf7	1315	36	.	.	.
cord-034340-3ksfpaf7	1316	1	The	the	DT
cord-034340-3ksfpaf7	1316	2	rash	rash	NN
cord-034340-3ksfpaf7	1316	3	started	start	VBD
cord-034340-3ksfpaf7	1316	4	a	a	DT
cord-034340-3ksfpaf7	1316	5	month	month	NN
cord-034340-3ksfpaf7	1316	6	prior	prior	RB
cord-034340-3ksfpaf7	1316	7	,	,	,
cord-034340-3ksfpaf7	1316	8	and	and	CC
cord-034340-3ksfpaf7	1316	9	progressed	progress	VBD
cord-034340-3ksfpaf7	1316	10	over	over	IN
cord-034340-3ksfpaf7	1316	11	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1316	12	entire	entire	JJ
cord-034340-3ksfpaf7	1316	13	body	body	NN
cord-034340-3ksfpaf7	1316	14	.	.	.
cord-034340-3ksfpaf7	1317	1	A	a	DT
cord-034340-3ksfpaf7	1317	2	skin	skin	NN
cord-034340-3ksfpaf7	1317	3	swab	swab	NN
cord-034340-3ksfpaf7	1317	4	grew	grow	VBD
cord-034340-3ksfpaf7	1317	5	staphylococcus	staphylococcus	NN
cord-034340-3ksfpaf7	1317	6	aureus	aureus	NN
cord-034340-3ksfpaf7	1317	7	but	but	CC
cord-034340-3ksfpaf7	1317	8	the	the	DT
cord-034340-3ksfpaf7	1317	9	rash	rash	NN
cord-034340-3ksfpaf7	1317	10	did	do	VBD
cord-034340-3ksfpaf7	1317	11	n't	not	RB
cord-034340-3ksfpaf7	1317	12	respond	respond	VB
cord-034340-3ksfpaf7	1317	13	to	to	IN
cord-034340-3ksfpaf7	1317	14	topical	topical	JJ
cord-034340-3ksfpaf7	1317	15	antibiotics	antibiotic	NNS
cord-034340-3ksfpaf7	1317	16	.	.	.
cord-034340-3ksfpaf7	1318	1	Review	Review	NNP
cord-034340-3ksfpaf7	1318	2	of	of	IN
cord-034340-3ksfpaf7	1318	3	systems	system	NNS
cord-034340-3ksfpaf7	1318	4	was	be	VBD
cord-034340-3ksfpaf7	1318	5	unremarkable	unremarkable	JJ
cord-034340-3ksfpaf7	1318	6	except	except	IN
cord-034340-3ksfpaf7	1318	7	for	for	IN
cord-034340-3ksfpaf7	1318	8	longstanding	longstanding	JJ
cord-034340-3ksfpaf7	1318	9	oral	oral	JJ
cord-034340-3ksfpaf7	1318	10	thrush	thrush	NN
cord-034340-3ksfpaf7	1318	11	and	and	CC
cord-034340-3ksfpaf7	1318	12	diaper	diaper	NN
cord-034340-3ksfpaf7	1318	13	rash	rash	NN
cord-034340-3ksfpaf7	1318	14	.	.	.
cord-034340-3ksfpaf7	1319	1	Birth	birth	NN
cord-034340-3ksfpaf7	1319	2	and	and	CC
cord-034340-3ksfpaf7	1319	3	family	family	NN
cord-034340-3ksfpaf7	1319	4	history	history	NN
cord-034340-3ksfpaf7	1319	5	were	be	VBD
cord-034340-3ksfpaf7	1319	6	unremarkable	unremarkable	JJ
cord-034340-3ksfpaf7	1319	7	.	.	.
cord-034340-3ksfpaf7	1320	1	On	on	IN
cord-034340-3ksfpaf7	1320	2	exam	exam	NN
cord-034340-3ksfpaf7	1320	3	she	-PRON-	PRP
cord-034340-3ksfpaf7	1320	4	had	have	VBD
cord-034340-3ksfpaf7	1320	5	a	a	DT
cord-034340-3ksfpaf7	1320	6	diffuse	diffuse	JJ
cord-034340-3ksfpaf7	1320	7	,	,	,
cord-034340-3ksfpaf7	1320	8	erythematous	erythematous	JJ
cord-034340-3ksfpaf7	1320	9	,	,	,
cord-034340-3ksfpaf7	1320	10	morbilliform	morbilliform	NNP
cord-034340-3ksfpaf7	1320	11	eruption	eruption	NN
cord-034340-3ksfpaf7	1320	12	over	over	IN
cord-034340-3ksfpaf7	1320	13	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1320	14	face	face	NN
cord-034340-3ksfpaf7	1320	15	and	and	CC
cord-034340-3ksfpaf7	1320	16	body	body	NN
cord-034340-3ksfpaf7	1320	17	.	.	.
cord-034340-3ksfpaf7	1321	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1321	2	had	have	VBD
cord-034340-3ksfpaf7	1321	3	facial	facial	JJ
cord-034340-3ksfpaf7	1321	4	swelling	swelling	NN
cord-034340-3ksfpaf7	1321	5	,	,	,
cord-034340-3ksfpaf7	1321	6	orbital	orbital	JJ
cord-034340-3ksfpaf7	1321	7	edema	edema	NN
cord-034340-3ksfpaf7	1321	8	and	and	CC
cord-034340-3ksfpaf7	1321	9	vasculitic	vasculitic	JJ
cord-034340-3ksfpaf7	1321	10	oral	oral	JJ
cord-034340-3ksfpaf7	1321	11	ulcers	ulcer	NNS
cord-034340-3ksfpaf7	1321	12	.	.	.
cord-034340-3ksfpaf7	1322	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1322	2	had	have	VBD
cord-034340-3ksfpaf7	1322	3	leukopenia	leukopenia	NN
cord-034340-3ksfpaf7	1322	4	mainly	mainly	RB
cord-034340-3ksfpaf7	1322	5	neutropenia	neutropenia	NN
cord-034340-3ksfpaf7	1322	6	,	,	,
cord-034340-3ksfpaf7	1323	1	low	low	JJ
cord-034340-3ksfpaf7	1323	2	hemoglobin	hemoglobin	NN
cord-034340-3ksfpaf7	1323	3	,	,	,
cord-034340-3ksfpaf7	1323	4	with	with	IN
cord-034340-3ksfpaf7	1323	5	normal	normal	JJ
cord-034340-3ksfpaf7	1323	6	platelets	platelet	NNS
cord-034340-3ksfpaf7	1323	7	.	.	.
cord-034340-3ksfpaf7	1324	1	Her	-PRON-	PRP$
cord-034340-3ksfpaf7	1324	2	liver	liver	NN
cord-034340-3ksfpaf7	1324	3	enzymes	enzyme	NNS
cord-034340-3ksfpaf7	1324	4	and	and	CC
cord-034340-3ksfpaf7	1324	5	erythrocyte	erythrocyte	NN
cord-034340-3ksfpaf7	1324	6	sedimentation	sedimentation	NN
cord-034340-3ksfpaf7	1324	7	rate	rate	NN
cord-034340-3ksfpaf7	1324	8	(	(	-LRB-
cord-034340-3ksfpaf7	1324	9	ESR	ESR	NNP
cord-034340-3ksfpaf7	1324	10	)	)	-RRB-
cord-034340-3ksfpaf7	1324	11	were	be	VBD
cord-034340-3ksfpaf7	1324	12	high	high	JJ
cord-034340-3ksfpaf7	1324	13	while	while	IN
cord-034340-3ksfpaf7	1324	14	C	c	NN
cord-034340-3ksfpaf7	1324	15	-	-	HYPH
cord-034340-3ksfpaf7	1324	16	reactive	reactive	JJ
cord-034340-3ksfpaf7	1324	17	protein	protein	NN
cord-034340-3ksfpaf7	1324	18	,	,	,
cord-034340-3ksfpaf7	1324	19	immunoglobulins	immunoglobulin	NNS
cord-034340-3ksfpaf7	1324	20	,	,	,
cord-034340-3ksfpaf7	1324	21	C3	C3	NNP
cord-034340-3ksfpaf7	1324	22	and	and	CC
cord-034340-3ksfpaf7	1324	23	C4	C4	NNP
cord-034340-3ksfpaf7	1324	24	were	be	VBD
cord-034340-3ksfpaf7	1324	25	normal	normal	JJ
cord-034340-3ksfpaf7	1324	26	.	.	.
cord-034340-3ksfpaf7	1325	1	Cultures	culture	NNS
cord-034340-3ksfpaf7	1325	2	were	be	VBD
cord-034340-3ksfpaf7	1325	3	negative	negative	JJ
cord-034340-3ksfpaf7	1325	4	,	,	,
cord-034340-3ksfpaf7	1325	5	however	however	RB
cord-034340-3ksfpaf7	1325	6	she	-PRON-	PRP
cord-034340-3ksfpaf7	1325	7	was	be	VBD
cord-034340-3ksfpaf7	1325	8	positive	positive	JJ
cord-034340-3ksfpaf7	1325	9	for	for	IN
cord-034340-3ksfpaf7	1325	10	adenovirus	adenovirus	NN
cord-034340-3ksfpaf7	1325	11	,	,	,
cord-034340-3ksfpaf7	1325	12	mycoplasma	mycoplasma	NN
cord-034340-3ksfpaf7	1325	13	and	and	CC
cord-034340-3ksfpaf7	1325	14	EBV	EBV	NNP
cord-034340-3ksfpaf7	1325	15	(	(	-LRB-
cord-034340-3ksfpaf7	1325	16	EBV	EBV	NNP
cord-034340-3ksfpaf7	1325	17	load	load	NN
cord-034340-3ksfpaf7	1325	18	was	be	VBD
cord-034340-3ksfpaf7	1325	19	6000	6000	CD
cord-034340-3ksfpaf7	1325	20	IU	IU	NNP
cord-034340-3ksfpaf7	1325	21	/	/	SYM
cord-034340-3ksfpaf7	1325	22	ml	ml	NN
cord-034340-3ksfpaf7	1325	23	)	)	-RRB-
cord-034340-3ksfpaf7	1325	24	.	.	.
cord-034340-3ksfpaf7	1326	1	Autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1326	2	hepatitis	hepatitis	NN
cord-034340-3ksfpaf7	1326	3	work	work	NN
cord-034340-3ksfpaf7	1326	4	up	up	RP
cord-034340-3ksfpaf7	1326	5	was	be	VBD
cord-034340-3ksfpaf7	1326	6	negative	negative	JJ
cord-034340-3ksfpaf7	1326	7	.	.	.
cord-034340-3ksfpaf7	1327	1	The	the	DT
cord-034340-3ksfpaf7	1327	2	direct	direct	JJ
cord-034340-3ksfpaf7	1327	3	coombs	coombs	NNP
cord-034340-3ksfpaf7	1327	4	test	test	NN
cord-034340-3ksfpaf7	1327	5	,	,	,
cord-034340-3ksfpaf7	1327	6	antinuclear	antinuclear	JJ
cord-034340-3ksfpaf7	1327	7	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1327	8	(	(	-LRB-
cord-034340-3ksfpaf7	1327	9	1:640	1:640	CD
cord-034340-3ksfpaf7	1327	10	)	)	-RRB-
cord-034340-3ksfpaf7	1327	11	,	,	,
cord-034340-3ksfpaf7	1327	12	Ro	Ro	NNP
cord-034340-3ksfpaf7	1327	13	,	,	,
cord-034340-3ksfpaf7	1327	14	RNP	RNP	NNP
cord-034340-3ksfpaf7	1327	15	and	and	CC
cord-034340-3ksfpaf7	1327	16	SmD	SmD	NNP
cord-034340-3ksfpaf7	1327	17	were	be	VBD
cord-034340-3ksfpaf7	1327	18	positive	positive	JJ
cord-034340-3ksfpaf7	1327	19	.	.	.
cord-034340-3ksfpaf7	1328	1	CH50	CH50	NNP
cord-034340-3ksfpaf7	1328	2	came	come	VBD
cord-034340-3ksfpaf7	1328	3	low	low	RB
cord-034340-3ksfpaf7	1328	4	as	as	RB
cord-034340-3ksfpaf7	1328	5	well	well	RB
cord-034340-3ksfpaf7	1328	6	as	as	IN
cord-034340-3ksfpaf7	1328	7	C1q	C1q	NNP
cord-034340-3ksfpaf7	1328	8	level	level	NN
cord-034340-3ksfpaf7	1328	9	of	of	IN
cord-034340-3ksfpaf7	1328	10	4	4	CD
cord-034340-3ksfpaf7	1328	11	mg	mg	NNP
cord-034340-3ksfpaf7	1328	12	/	/	SYM
cord-034340-3ksfpaf7	1328	13	dL	dl	NN
cord-034340-3ksfpaf7	1328	14	(	(	-LRB-
cord-034340-3ksfpaf7	1328	15	normal	normal	JJ
cord-034340-3ksfpaf7	1328	16	range	range	NN
cord-034340-3ksfpaf7	1328	17	12	12	CD
cord-034340-3ksfpaf7	1328	18	-	-	SYM
cord-034340-3ksfpaf7	1328	19	22	22	CD
cord-034340-3ksfpaf7	1328	20	mg	mg	NNP
cord-034340-3ksfpaf7	1328	21	/	/	SYM
cord-034340-3ksfpaf7	1328	22	dL	dl	NN
cord-034340-3ksfpaf7	1328	23	)	)	-RRB-
cord-034340-3ksfpaf7	1328	24	.	.	.
cord-034340-3ksfpaf7	1329	1	Lymphocyte	lymphocyte	NN
cord-034340-3ksfpaf7	1329	2	subsets	subset	NNS
cord-034340-3ksfpaf7	1329	3	showed	show	VBD
cord-034340-3ksfpaf7	1329	4	reduced	reduce	VBN
cord-034340-3ksfpaf7	1329	5	CD4	CD4	NNP
cord-034340-3ksfpaf7	1329	6	and	and	CC
cord-034340-3ksfpaf7	1329	7	NK	NK	NNP
cord-034340-3ksfpaf7	1329	8	cells	cell	NNS
cord-034340-3ksfpaf7	1329	9	.	.	.
cord-034340-3ksfpaf7	1330	1	Bone	bone	NN
cord-034340-3ksfpaf7	1330	2	marrow	marrow	NN
cord-034340-3ksfpaf7	1330	3	aspiration	aspiration	NN
cord-034340-3ksfpaf7	1330	4	showed	show	VBD
cord-034340-3ksfpaf7	1330	5	active	active	JJ
cord-034340-3ksfpaf7	1330	6	marrow	marrow	NN
cord-034340-3ksfpaf7	1330	7	.	.	.
cord-034340-3ksfpaf7	1331	1	Skin	skin	NN
cord-034340-3ksfpaf7	1331	2	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1331	3	showed	show	VBD
cord-034340-3ksfpaf7	1331	4	chronic	chronic	JJ
cord-034340-3ksfpaf7	1331	5	non	non	JJ
cord-034340-3ksfpaf7	1331	6	-	-	JJ
cord-034340-3ksfpaf7	1331	7	specific	specific	JJ
cord-034340-3ksfpaf7	1331	8	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1331	9	(	(	-LRB-
cord-034340-3ksfpaf7	1331	10	immunofluorescence	immunofluorescence	NN
cord-034340-3ksfpaf7	1331	11	and	and	CC
cord-034340-3ksfpaf7	1331	12	electron	electron	NN
cord-034340-3ksfpaf7	1331	13	microscopy	microscopy	NNS
cord-034340-3ksfpaf7	1331	14	were	be	VBD
cord-034340-3ksfpaf7	1331	15	not	not	RB
cord-034340-3ksfpaf7	1331	16	available	available	JJ
cord-034340-3ksfpaf7	1331	17	)	)	-RRB-
cord-034340-3ksfpaf7	1331	18	.	.	.
cord-034340-3ksfpaf7	1332	1	Echocardiogram	Echocardiogram	NNP
cord-034340-3ksfpaf7	1332	2	showed	show	VBD
cord-034340-3ksfpaf7	1332	3	dilatation	dilatation	NN
cord-034340-3ksfpaf7	1332	4	of	of	IN
cord-034340-3ksfpaf7	1332	5	the	the	DT
cord-034340-3ksfpaf7	1332	6	left	left	JJ
cord-034340-3ksfpaf7	1332	7	coronaries	coronary	NNS
cord-034340-3ksfpaf7	1332	8	.	.	.
cord-034340-3ksfpaf7	1333	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1333	2	was	be	VBD
cord-034340-3ksfpaf7	1333	3	treated	treat	VBN
cord-034340-3ksfpaf7	1333	4	with	with	IN
cord-034340-3ksfpaf7	1333	5	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1333	6	immunoglobulin	immunoglobulin	NN
cord-034340-3ksfpaf7	1333	7	(	(	-LRB-
cord-034340-3ksfpaf7	1333	8	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1333	9	)	)	-RRB-
cord-034340-3ksfpaf7	1333	10	for	for	IN
cord-034340-3ksfpaf7	1333	11	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1333	12	disease	disease	NN
cord-034340-3ksfpaf7	1333	13	with	with	IN
cord-034340-3ksfpaf7	1333	14	no	no	DT
cord-034340-3ksfpaf7	1333	15	improvement	improvement	NN
cord-034340-3ksfpaf7	1333	16	.	.	.
cord-034340-3ksfpaf7	1334	1	Therefore	therefore	RB
cord-034340-3ksfpaf7	1334	2	pulse	pulse	NN
cord-034340-3ksfpaf7	1334	3	steroid	steroid	NN
cord-034340-3ksfpaf7	1334	4	30mg	30mg	NN
cord-034340-3ksfpaf7	1334	5	/	/	SYM
cord-034340-3ksfpaf7	1334	6	kg	kg	NNS
cord-034340-3ksfpaf7	1334	7	followed	follow	VBD
cord-034340-3ksfpaf7	1334	8	by	by	IN
cord-034340-3ksfpaf7	1334	9	2	2	CD
cord-034340-3ksfpaf7	1334	10	mg	mg	NNP
cord-034340-3ksfpaf7	1334	11	/	/	SYM
cord-034340-3ksfpaf7	1334	12	kg	kg	NNP
cord-034340-3ksfpaf7	1334	13	was	be	VBD
cord-034340-3ksfpaf7	1334	14	initiated	initiate	VBN
cord-034340-3ksfpaf7	1334	15	.	.	.
cord-034340-3ksfpaf7	1335	1	Her	-PRON-	PRP$
cord-034340-3ksfpaf7	1335	2	rash	rash	JJ
cord-034340-3ksfpaf7	1335	3	,	,	,
cord-034340-3ksfpaf7	1335	4	facial	facial	JJ
cord-034340-3ksfpaf7	1335	5	swelling	swelling	NN
cord-034340-3ksfpaf7	1335	6	and	and	CC
cord-034340-3ksfpaf7	1335	7	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	1335	8	blood	blood	NN
cord-034340-3ksfpaf7	1335	9	counts	count	NNS
cord-034340-3ksfpaf7	1335	10	improved	improve	VBN
cord-034340-3ksfpaf7	1335	11	dramatically	dramatically	RB
cord-034340-3ksfpaf7	1335	12	.	.	.
cord-034340-3ksfpaf7	1336	1	Whole	whole	JJ
cord-034340-3ksfpaf7	1336	2	Exome	Exome	NNP
cord-034340-3ksfpaf7	1336	3	sequence	sequence	NN
cord-034340-3ksfpaf7	1336	4	showed	show	VBD
cord-034340-3ksfpaf7	1336	5	homozygous	homozygous	JJ
cord-034340-3ksfpaf7	1336	6	variant	variant	NN
cord-034340-3ksfpaf7	1336	7	c.469G	c.469G	NNP
cord-034340-3ksfpaf7	1336	8	>	>	XX
cord-034340-3ksfpaf7	1336	9	T	t	NN
cord-034340-3ksfpaf7	1336	10	p.	p.	NN
cord-034340-3ksfpaf7	1337	1	G157C	G157C	NNP
cord-034340-3ksfpaf7	1337	2	at	at	IN
cord-034340-3ksfpaf7	1337	3	the	the	DT
cord-034340-3ksfpaf7	1337	4	C1qA	C1qA	NNP
cord-034340-3ksfpaf7	1337	5	gene	gene	NN
cord-034340-3ksfpaf7	1337	6	.	.	.
cord-034340-3ksfpaf7	1338	1	While	while	IN
cord-034340-3ksfpaf7	1338	2	tapering	taper	VBG
cord-034340-3ksfpaf7	1338	3	steroids	steroid	NNS
cord-034340-3ksfpaf7	1338	4	she	-PRON-	PRP
cord-034340-3ksfpaf7	1338	5	flared	flare	VBD
cord-034340-3ksfpaf7	1338	6	so	so	RB
cord-034340-3ksfpaf7	1338	7	subcutaneous	subcutaneous	JJ
cord-034340-3ksfpaf7	1338	8	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	1338	9	was	be	VBD
cord-034340-3ksfpaf7	1338	10	started	start	VBN
cord-034340-3ksfpaf7	1338	11	.	.	.
cord-034340-3ksfpaf7	1339	1	Unfortunately	unfortunately	RB
cord-034340-3ksfpaf7	1339	2	,	,	,
cord-034340-3ksfpaf7	1339	3	she	-PRON-	PRP
cord-034340-3ksfpaf7	1339	4	continued	continue	VBD
cord-034340-3ksfpaf7	1339	5	to	to	TO
cord-034340-3ksfpaf7	1339	6	have	have	VB
cord-034340-3ksfpaf7	1339	7	rash	rash	JJ
cord-034340-3ksfpaf7	1339	8	,	,	,
cord-034340-3ksfpaf7	1339	9	leukopenia	leukopenia	NN
cord-034340-3ksfpaf7	1339	10	and	and	CC
cord-034340-3ksfpaf7	1339	11	high	high	JJ
cord-034340-3ksfpaf7	1339	12	liver	liver	NN
cord-034340-3ksfpaf7	1339	13	enzymes	enzyme	NNS
cord-034340-3ksfpaf7	1339	14	,	,	,
cord-034340-3ksfpaf7	1339	15	so	so	IN
cord-034340-3ksfpaf7	1339	16	treatment	treatment	NN
cord-034340-3ksfpaf7	1339	17	was	be	VBD
cord-034340-3ksfpaf7	1339	18	switched	switch	VBN
cord-034340-3ksfpaf7	1339	19	to	to	IN
cord-034340-3ksfpaf7	1339	20	mycophenolate	mycophenolate	NNP
cord-034340-3ksfpaf7	1339	21	mofetil	mofetil	NNP
cord-034340-3ksfpaf7	1339	22	and	and	CC
cord-034340-3ksfpaf7	1339	23	hydroxychloroquine	hydroxychloroquine	NNP
cord-034340-3ksfpaf7	1339	24	.	.	.
cord-034340-3ksfpaf7	1340	1	However	however	RB
cord-034340-3ksfpaf7	1340	2	she	-PRON-	PRP
cord-034340-3ksfpaf7	1340	3	did	do	VBD
cord-034340-3ksfpaf7	1340	4	not	not	RB
cord-034340-3ksfpaf7	1340	5	improve	improve	VB
cord-034340-3ksfpaf7	1340	6	and	and	CC
cord-034340-3ksfpaf7	1340	7	started	start	VBD
cord-034340-3ksfpaf7	1340	8	to	to	TO
cord-034340-3ksfpaf7	1340	9	have	have	VB
cord-034340-3ksfpaf7	1340	10	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	1340	11	bacterial	bacterial	JJ
cord-034340-3ksfpaf7	1340	12	and	and	CC
cord-034340-3ksfpaf7	1340	13	viral	viral	JJ
cord-034340-3ksfpaf7	1340	14	infections	infection	NNS
cord-034340-3ksfpaf7	1340	15	that	that	WDT
cord-034340-3ksfpaf7	1340	16	included	include	VBD
cord-034340-3ksfpaf7	1340	17	cellulitis	cellulitis	NN
cord-034340-3ksfpaf7	1340	18	,	,	,
cord-034340-3ksfpaf7	1340	19	gastroenteritis	gastroenteritis	NN
cord-034340-3ksfpaf7	1340	20	and	and	CC
cord-034340-3ksfpaf7	1340	21	upper	upper	JJ
cord-034340-3ksfpaf7	1340	22	respiratory	respiratory	JJ
cord-034340-3ksfpaf7	1340	23	tract	tract	NN
cord-034340-3ksfpaf7	1340	24	infection	infection	NN
cord-034340-3ksfpaf7	1340	25	.	.	.
cord-034340-3ksfpaf7	1341	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1341	2	started	start	VBD
cord-034340-3ksfpaf7	1341	3	her	-PRON-	PRP
cord-034340-3ksfpaf7	1341	4	on	on	IN
cord-034340-3ksfpaf7	1341	5	regular	regular	JJ
cord-034340-3ksfpaf7	1341	6	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1341	7	,	,	,
cord-034340-3ksfpaf7	1341	8	which	which	WDT
cord-034340-3ksfpaf7	1341	9	helped	help	VBD
cord-034340-3ksfpaf7	1341	10	with	with	IN
cord-034340-3ksfpaf7	1341	11	infections	infection	NNS
cord-034340-3ksfpaf7	1341	12	and	and	CC
cord-034340-3ksfpaf7	1341	13	allowed	allow	VBN
cord-034340-3ksfpaf7	1341	14	for	for	IN
cord-034340-3ksfpaf7	1341	15	weaning	weaning	NN
cord-034340-3ksfpaf7	1341	16	of	of	IN
cord-034340-3ksfpaf7	1341	17	steroids	steroid	NNS
cord-034340-3ksfpaf7	1341	18	.	.	.
cord-034340-3ksfpaf7	1342	1	However	however	RB
cord-034340-3ksfpaf7	1342	2	she	-PRON-	PRP
cord-034340-3ksfpaf7	1342	3	developed	develop	VBD
cord-034340-3ksfpaf7	1342	4	alopecia	alopecia	NN
cord-034340-3ksfpaf7	1342	5	and	and	CC
cord-034340-3ksfpaf7	1342	6	lower	low	JJR
cord-034340-3ksfpaf7	1342	7	limb	limb	NN
cord-034340-3ksfpaf7	1342	8	spasticity	spasticity	NN
cord-034340-3ksfpaf7	1342	9	with	with	IN
cord-034340-3ksfpaf7	1342	10	delayed	delay	VBN
cord-034340-3ksfpaf7	1342	11	walking	walking	NN
cord-034340-3ksfpaf7	1342	12	.	.	.
cord-034340-3ksfpaf7	1343	1	MRI	MRI	NNP
cord-034340-3ksfpaf7	1343	2	brain	brain	NN
cord-034340-3ksfpaf7	1343	3	and	and	CC
cord-034340-3ksfpaf7	1343	4	spine	spine	NN
cord-034340-3ksfpaf7	1343	5	was	be	VBD
cord-034340-3ksfpaf7	1343	6	normal	normal	JJ
cord-034340-3ksfpaf7	1343	7	.	.	.
cord-034340-3ksfpaf7	1344	1	Upon	upon	IN
cord-034340-3ksfpaf7	1344	2	reanalysis	reanalysis	NN
cord-034340-3ksfpaf7	1344	3	of	of	IN
cord-034340-3ksfpaf7	1344	4	the	the	DT
cord-034340-3ksfpaf7	1344	5	WES	WES	NNP
cord-034340-3ksfpaf7	1344	6	,	,	,
cord-034340-3ksfpaf7	1344	7	two	two	CD
cord-034340-3ksfpaf7	1344	8	other	other	JJ
cord-034340-3ksfpaf7	1344	9	homozygous	homozygous	JJ
cord-034340-3ksfpaf7	1344	10	mutations	mutation	NNS
cord-034340-3ksfpaf7	1344	11	at	at	IN
cord-034340-3ksfpaf7	1344	12	KIF1C	kif1c	CD
cord-034340-3ksfpaf7	1344	13	and	and	CC
cord-034340-3ksfpaf7	1344	14	APG7	APG7	NNP
cord-034340-3ksfpaf7	1344	15	were	be	VBD
cord-034340-3ksfpaf7	1344	16	identified	identify	VBN
cord-034340-3ksfpaf7	1344	17	and	and	CC
cord-034340-3ksfpaf7	1344	18	associated	associate	VBN
cord-034340-3ksfpaf7	1344	19	with	with	IN
cord-034340-3ksfpaf7	1344	20	spastic	spastic	JJ
cord-034340-3ksfpaf7	1344	21	paraplegia	paraplegia	NN
cord-034340-3ksfpaf7	1344	22	,	,	,
cord-034340-3ksfpaf7	1344	23	but	but	CC
cord-034340-3ksfpaf7	1344	24	reported	report	VBD
cord-034340-3ksfpaf7	1344	25	as	as	IN
cord-034340-3ksfpaf7	1344	26	variants	variant	NNS
cord-034340-3ksfpaf7	1344	27	of	of	IN
cord-034340-3ksfpaf7	1344	28	unknown	unknown	JJ
cord-034340-3ksfpaf7	1344	29	significant	significant	JJ
cord-034340-3ksfpaf7	1344	30	.	.	.
cord-034340-3ksfpaf7	1345	1	Fresh	fresh	JJ
cord-034340-3ksfpaf7	1345	2	frozen	frozen	JJ
cord-034340-3ksfpaf7	1345	3	plasma	plasma	NN
cord-034340-3ksfpaf7	1345	4	(	(	-LRB-
cord-034340-3ksfpaf7	1345	5	FFP	FFP	NNP
cord-034340-3ksfpaf7	1345	6	)	)	-RRB-
cord-034340-3ksfpaf7	1345	7	transfusions	transfusion	NNS
cord-034340-3ksfpaf7	1345	8	were	be	VBD
cord-034340-3ksfpaf7	1345	9	started	start	VBN
cord-034340-3ksfpaf7	1345	10	,	,	,
cord-034340-3ksfpaf7	1345	11	initially	initially	RB
cord-034340-3ksfpaf7	1345	12	weekly	weekly	RB
cord-034340-3ksfpaf7	1345	13	,	,	,
cord-034340-3ksfpaf7	1345	14	then	then	RB
cord-034340-3ksfpaf7	1345	15	every	every	DT
cord-034340-3ksfpaf7	1345	16	two	two	CD
cord-034340-3ksfpaf7	1345	17	weeks	week	NNS
cord-034340-3ksfpaf7	1345	18	and	and	CC
cord-034340-3ksfpaf7	1345	19	subsequently	subsequently	RB
cord-034340-3ksfpaf7	1345	20	every	every	DT
cord-034340-3ksfpaf7	1345	21	four	four	CD
cord-034340-3ksfpaf7	1345	22	weeks	week	NNS
cord-034340-3ksfpaf7	1345	23	.	.	.
cord-034340-3ksfpaf7	1346	1	The	the	DT
cord-034340-3ksfpaf7	1346	2	rash	rash	NN
cord-034340-3ksfpaf7	1346	3	disappeared	disappear	VBD
cord-034340-3ksfpaf7	1346	4	,	,	,
cord-034340-3ksfpaf7	1346	5	leukopenia	leukopenia	NN
cord-034340-3ksfpaf7	1346	6	and	and	CC
cord-034340-3ksfpaf7	1346	7	ESR	ESR	NNP
cord-034340-3ksfpaf7	1346	8	improved	improve	VBD
cord-034340-3ksfpaf7	1346	9	and	and	CC
cord-034340-3ksfpaf7	1346	10	we	-PRON-	PRP
cord-034340-3ksfpaf7	1346	11	were	be	VBD
cord-034340-3ksfpaf7	1346	12	able	able	JJ
cord-034340-3ksfpaf7	1346	13	to	to	TO
cord-034340-3ksfpaf7	1346	14	discontinue	discontinue	VB
cord-034340-3ksfpaf7	1346	15	steroids	steroid	NNS
cord-034340-3ksfpaf7	1347	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1347	2	:	:	:
cord-034340-3ksfpaf7	1347	3	Early	early	JJ
cord-034340-3ksfpaf7	1347	4	-	-	HYPH
cord-034340-3ksfpaf7	1347	5	onset	onset	NN
cord-034340-3ksfpaf7	1347	6	SLE	sle	NN
cord-034340-3ksfpaf7	1347	7	with	with	IN
cord-034340-3ksfpaf7	1347	8	a	a	DT
cord-034340-3ksfpaf7	1347	9	severe	severe	JJ
cord-034340-3ksfpaf7	1347	10	course	course	NN
cord-034340-3ksfpaf7	1347	11	of	of	IN
cord-034340-3ksfpaf7	1347	12	disease	disease	NN
cord-034340-3ksfpaf7	1347	13	raises	raise	VBZ
cord-034340-3ksfpaf7	1347	14	the	the	DT
cord-034340-3ksfpaf7	1347	15	possibility	possibility	NN
cord-034340-3ksfpaf7	1347	16	of	of	IN
cord-034340-3ksfpaf7	1347	17	a	a	DT
cord-034340-3ksfpaf7	1347	18	genetic	genetic	JJ
cord-034340-3ksfpaf7	1347	19	etiology	etiology	NN
cord-034340-3ksfpaf7	1347	20	.	.	.
cord-034340-3ksfpaf7	1348	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1348	2	are	be	VBP
cord-034340-3ksfpaf7	1348	3	reporting	report	VBG
cord-034340-3ksfpaf7	1348	4	,	,	,
cord-034340-3ksfpaf7	1348	5	for	for	IN
cord-034340-3ksfpaf7	1348	6	the	the	DT
cord-034340-3ksfpaf7	1348	7	first	first	JJ
cord-034340-3ksfpaf7	1348	8	time	time	NN
cord-034340-3ksfpaf7	1348	9	,	,	,
cord-034340-3ksfpaf7	1348	10	a	a	DT
cord-034340-3ksfpaf7	1348	11	rare	rare	JJ
cord-034340-3ksfpaf7	1348	12	missense	missense	NN
cord-034340-3ksfpaf7	1348	13	mutation	mutation	NN
cord-034340-3ksfpaf7	1348	14	G	g	NN
cord-034340-3ksfpaf7	1349	1	>	>	XX
cord-034340-3ksfpaf7	1350	1	T	T	NNP
cord-034340-3ksfpaf7	1350	2	in	in	IN
cord-034340-3ksfpaf7	1350	3	exon	exon	NN
cord-034340-3ksfpaf7	1350	4	3	3	CD
cord-034340-3ksfpaf7	1350	5	of	of	IN
cord-034340-3ksfpaf7	1350	6	the	the	DT
cord-034340-3ksfpaf7	1350	7	C1qA	C1qA	NNP
cord-034340-3ksfpaf7	1350	8	gene	gene	NN
cord-034340-3ksfpaf7	1350	9	that	that	WDT
cord-034340-3ksfpaf7	1350	10	resulted	result	VBD
cord-034340-3ksfpaf7	1350	11	in	in	IN
cord-034340-3ksfpaf7	1350	12	an	an	DT
cord-034340-3ksfpaf7	1350	13	amino	amino	NN
cord-034340-3ksfpaf7	1350	14	acid	acid	NN
cord-034340-3ksfpaf7	1350	15	substitution	substitution	NN
cord-034340-3ksfpaf7	1350	16	that	that	WDT
cord-034340-3ksfpaf7	1350	17	is	be	VBZ
cord-034340-3ksfpaf7	1350	18	pathogenic	pathogenic	JJ
cord-034340-3ksfpaf7	1350	19	.	.	.
cord-034340-3ksfpaf7	1351	1	Interestingly	interestingly	RB
cord-034340-3ksfpaf7	1351	2	,	,	,
cord-034340-3ksfpaf7	1351	3	she	-PRON-	PRP
cord-034340-3ksfpaf7	1351	4	had	have	VBD
cord-034340-3ksfpaf7	1351	5	other	other	JJ
cord-034340-3ksfpaf7	1351	6	mutations	mutation	NNS
cord-034340-3ksfpaf7	1351	7	associated	associate	VBN
cord-034340-3ksfpaf7	1351	8	with	with	IN
cord-034340-3ksfpaf7	1351	9	neurological	neurological	JJ
cord-034340-3ksfpaf7	1351	10	manifestation	manifestation	NN
cord-034340-3ksfpaf7	1351	11	that	that	WDT
cord-034340-3ksfpaf7	1351	12	never	never	RB
cord-034340-3ksfpaf7	1351	13	reported	report	VBD
cord-034340-3ksfpaf7	1351	14	together	together	RB
cord-034340-3ksfpaf7	1351	15	before	before	RB
cord-034340-3ksfpaf7	1351	16	and	and	CC
cord-034340-3ksfpaf7	1351	17	altered	alter	VBD
cord-034340-3ksfpaf7	1351	18	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1351	19	phenotype	phenotype	NN
cord-034340-3ksfpaf7	1351	20	.	.	.
cord-034340-3ksfpaf7	1352	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1352	2	has	have	VBZ
cord-034340-3ksfpaf7	1352	3	responded	respond	VBN
cord-034340-3ksfpaf7	1352	4	well	well	RB
cord-034340-3ksfpaf7	1352	5	to	to	IN
cord-034340-3ksfpaf7	1352	6	FFP	FFP	NNP
cord-034340-3ksfpaf7	1352	7	as	as	IN
cord-034340-3ksfpaf7	1352	8	has	have	VBZ
cord-034340-3ksfpaf7	1352	9	been	be	VBN
cord-034340-3ksfpaf7	1352	10	reported	report	VBN
cord-034340-3ksfpaf7	1352	11	in	in	IN
cord-034340-3ksfpaf7	1352	12	a	a	DT
cord-034340-3ksfpaf7	1352	13	few	few	JJ
cord-034340-3ksfpaf7	1352	14	case	case	NN
cord-034340-3ksfpaf7	1352	15	reports	report	NNS
cord-034340-3ksfpaf7	1352	16	Results	result	NNS
cord-034340-3ksfpaf7	1352	17	:	:	:
cord-034340-3ksfpaf7	1352	18	A	a	DT
cord-034340-3ksfpaf7	1352	19	total	total	NN
cord-034340-3ksfpaf7	1352	20	of	of	IN
cord-034340-3ksfpaf7	1352	21	148	148	CD
cord-034340-3ksfpaf7	1352	22	pSLE	psle	NN
cord-034340-3ksfpaf7	1352	23	under	under	IN
cord-034340-3ksfpaf7	1352	24	the	the	DT
cord-034340-3ksfpaf7	1352	25	age	age	NN
cord-034340-3ksfpaf7	1352	26	of	of	IN
cord-034340-3ksfpaf7	1352	27	13	13	CD
cord-034340-3ksfpaf7	1352	28	years	year	NNS
cord-034340-3ksfpaf7	1352	29	were	be	VBD
cord-034340-3ksfpaf7	1352	30	included	include	VBN
cord-034340-3ksfpaf7	1352	31	,	,	,
cord-034340-3ksfpaf7	1352	32	30	30	CD
cord-034340-3ksfpaf7	1352	33	%	%	NN
cord-034340-3ksfpaf7	1352	34	(	(	-LRB-
cord-034340-3ksfpaf7	1352	35	n	n	NN
cord-034340-3ksfpaf7	1352	36	=	=	SYM
cord-034340-3ksfpaf7	1352	37	44	44	CD
cord-034340-3ksfpaf7	1352	38	)	)	-RRB-
cord-034340-3ksfpaf7	1352	39	were	be	VBD
cord-034340-3ksfpaf7	1352	40	males	male	NNS
cord-034340-3ksfpaf7	1352	41	.	.	.
cord-034340-3ksfpaf7	1353	1	The	the	DT
cord-034340-3ksfpaf7	1353	2	overall	overall	JJ
cord-034340-3ksfpaf7	1353	3	mean	mean	JJ
cord-034340-3ksfpaf7	1353	4	age	age	NN
cord-034340-3ksfpaf7	1353	5	at	at	IN
cord-034340-3ksfpaf7	1353	6	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1353	7	was	be	VBD
cord-034340-3ksfpaf7	1354	1	7.6	7.6	CD
cord-034340-3ksfpaf7	1354	2	±	±	CD
cord-034340-3ksfpaf7	1354	3	3.5	3.5	CD
cord-034340-3ksfpaf7	1354	4	years	year	NNS
cord-034340-3ksfpaf7	1354	5	and	and	CC
cord-034340-3ksfpaf7	1354	6	median	median	JJ
cord-034340-3ksfpaf7	1354	7	disease	disease	NN
cord-034340-3ksfpaf7	1354	8	duration	duration	NN
cord-034340-3ksfpaf7	1354	9	was	be	VBD
cord-034340-3ksfpaf7	1354	10	9.5	9.5	CD
cord-034340-3ksfpaf7	1354	11	(	(	-LRB-
cord-034340-3ksfpaf7	1354	12	5	5	CD
cord-034340-3ksfpaf7	1354	13	-	-	SYM
cord-034340-3ksfpaf7	1354	14	13	13	CD
cord-034340-3ksfpaf7	1354	15	)	)	-RRB-
cord-034340-3ksfpaf7	1354	16	years	year	NNS
cord-034340-3ksfpaf7	1354	17	.	.	.
cord-034340-3ksfpaf7	1355	1	HUV	HUV	NNP
cord-034340-3ksfpaf7	1355	2	was	be	VBD
cord-034340-3ksfpaf7	1355	3	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1355	4	in	in	IN
cord-034340-3ksfpaf7	1355	5	34.5	34.5	CD
cord-034340-3ksfpaf7	1355	6	%	%	NN
cord-034340-3ksfpaf7	1355	7	(	(	-LRB-
cord-034340-3ksfpaf7	1355	8	n	n	NN
cord-034340-3ksfpaf7	1355	9	=	=	SYM
cord-034340-3ksfpaf7	1355	10	51	51	CD
cord-034340-3ksfpaf7	1355	11	)	)	-RRB-
cord-034340-3ksfpaf7	1355	12	of	of	IN
cord-034340-3ksfpaf7	1355	13	pSLE	pSLE	NNP
cord-034340-3ksfpaf7	1355	14	cohort	cohort	NN
cord-034340-3ksfpaf7	1355	15	.	.	.
cord-034340-3ksfpaf7	1356	1	pSLE	pSLE	NNP
cord-034340-3ksfpaf7	1356	2	with	with	IN
cord-034340-3ksfpaf7	1356	3	UV	UV	NNP
cord-034340-3ksfpaf7	1356	4	were	be	VBD
cord-034340-3ksfpaf7	1356	5	more	more	RBR
cord-034340-3ksfpaf7	1356	6	likely	likely	JJ
cord-034340-3ksfpaf7	1356	7	to	to	TO
cord-034340-3ksfpaf7	1356	8	be	be	VB
cord-034340-3ksfpaf7	1356	9	males	male	NNS
cord-034340-3ksfpaf7	1356	10	(	(	-LRB-
cord-034340-3ksfpaf7	1356	11	57	57	CD
cord-034340-3ksfpaf7	1356	12	%	%	NN
cord-034340-3ksfpaf7	1356	13	vs	vs	IN
cord-034340-3ksfpaf7	1356	14	15	15	CD
cord-034340-3ksfpaf7	1356	15	%	%	NN
cord-034340-3ksfpaf7	1356	16	;	;	:
cord-034340-3ksfpaf7	1356	17	P	p	NN
cord-034340-3ksfpaf7	1356	18	<	<	XX
cord-034340-3ksfpaf7	1356	19	0.001	0.001	CD
cord-034340-3ksfpaf7	1356	20	)	)	-RRB-
cord-034340-3ksfpaf7	1356	21	,	,	,
cord-034340-3ksfpaf7	1356	22	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1356	23	at	at	IN
cord-034340-3ksfpaf7	1356	24	a	a	DT
cord-034340-3ksfpaf7	1356	25	younger	young	JJR
cord-034340-3ksfpaf7	1356	26	age	age	NN
cord-034340-3ksfpaf7	1356	27	(	(	-LRB-
cord-034340-3ksfpaf7	1356	28	5.9	5.9	CD
cord-034340-3ksfpaf7	1356	29	vs	vs	IN
cord-034340-3ksfpaf7	1356	30	8.5	8.5	CD
cord-034340-3ksfpaf7	1356	31	years	year	NNS
cord-034340-3ksfpaf7	1356	32	;	;	:
cord-034340-3ksfpaf7	1356	33	P	p	NN
cord-034340-3ksfpaf7	1356	34	<	<	XX
cord-034340-3ksfpaf7	1356	35	0.001	0.001	CD
cord-034340-3ksfpaf7	1356	36	)	)	-RRB-
cord-034340-3ksfpaf7	1356	37	,	,	,
cord-034340-3ksfpaf7	1356	38	have	have	VBP
cord-034340-3ksfpaf7	1356	39	a	a	DT
cord-034340-3ksfpaf7	1356	40	family	family	NN
cord-034340-3ksfpaf7	1356	41	history	history	NN
cord-034340-3ksfpaf7	1356	42	of	of	IN
cord-034340-3ksfpaf7	1356	43	SLE	SLE	NNP
cord-034340-3ksfpaf7	1356	44	(	(	-LRB-
cord-034340-3ksfpaf7	1356	45	53	53	CD
cord-034340-3ksfpaf7	1356	46	%	%	NN
cord-034340-3ksfpaf7	1356	47	vs	vs	IN
cord-034340-3ksfpaf7	1356	48	36	36	CD
cord-034340-3ksfpaf7	1356	49	%	%	NN
cord-034340-3ksfpaf7	1356	50	;	;	:
cord-034340-3ksfpaf7	1356	51	P	p	NN
cord-034340-3ksfpaf7	1356	52	=	=	SYM
cord-034340-3ksfpaf7	1356	53	0.044	0.044	CD
cord-034340-3ksfpaf7	1356	54	)	)	-RRB-
cord-034340-3ksfpaf7	1356	55	and	and	CC
cord-034340-3ksfpaf7	1356	56	have	have	VBP
cord-034340-3ksfpaf7	1356	57	conjunctivitis	conjunctivitis	NN
cord-034340-3ksfpaf7	1356	58	more	more	RBR
cord-034340-3ksfpaf7	1356	59	frequently	frequently	RB
cord-034340-3ksfpaf7	1356	60	(	(	-LRB-
cord-034340-3ksfpaf7	1356	61	32	32	CD
cord-034340-3ksfpaf7	1356	62	%	%	NN
cord-034340-3ksfpaf7	1356	63	vs	vs	IN
cord-034340-3ksfpaf7	1356	64	5.3	5.3	CD
cord-034340-3ksfpaf7	1356	65	%	%	NN
cord-034340-3ksfpaf7	1356	66	;	;	:
cord-034340-3ksfpaf7	1356	67	P	p	NN
cord-034340-3ksfpaf7	1356	68	<	<	XX
cord-034340-3ksfpaf7	1356	69	0.001	0.001	CD
cord-034340-3ksfpaf7	1356	70	)	)	-RRB-
cord-034340-3ksfpaf7	1356	71	than	than	IN
cord-034340-3ksfpaf7	1356	72	pSLE	psle	RB
cord-034340-3ksfpaf7	1356	73	without	without	IN
cord-034340-3ksfpaf7	1356	74	UV	uv	NN
cord-034340-3ksfpaf7	1356	75	.	.	.
cord-034340-3ksfpaf7	1357	1	pSLE	pSLE	NNP
cord-034340-3ksfpaf7	1357	2	with	with	IN
cord-034340-3ksfpaf7	1357	3	UV	uv	NN
cord-034340-3ksfpaf7	1357	4	were	be	VBD
cord-034340-3ksfpaf7	1357	5	also	also	RB
cord-034340-3ksfpaf7	1357	6	less	less	RBR
cord-034340-3ksfpaf7	1357	7	likely	likely	JJ
cord-034340-3ksfpaf7	1357	8	to	to	TO
cord-034340-3ksfpaf7	1357	9	have	have	VB
cord-034340-3ksfpaf7	1357	10	CNS	CNS	NNP
cord-034340-3ksfpaf7	1357	11	involvement	involvement	NN
cord-034340-3ksfpaf7	1357	12	(	(	-LRB-
cord-034340-3ksfpaf7	1357	13	7.6	7.6	CD
cord-034340-3ksfpaf7	1357	14	%	%	NN
cord-034340-3ksfpaf7	1357	15	vs	vs	IN
cord-034340-3ksfpaf7	1357	16	20	20	CD
cord-034340-3ksfpaf7	1357	17	%	%	NN
cord-034340-3ksfpaf7	1357	18	;	;	:
cord-034340-3ksfpaf7	1357	19	P	p	NN
cord-034340-3ksfpaf7	1357	20	=	=	SYM
cord-034340-3ksfpaf7	1357	21	0.045	0.045	CD
cord-034340-3ksfpaf7	1357	22	)	)	-RRB-
cord-034340-3ksfpaf7	1357	23	and	and	CC
cord-034340-3ksfpaf7	1357	24	hematological	hematological	JJ
cord-034340-3ksfpaf7	1357	25	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1357	26	such	such	JJ
cord-034340-3ksfpaf7	1357	27	as	as	IN
cord-034340-3ksfpaf7	1357	28	leukopenia	leukopenia	NN
cord-034340-3ksfpaf7	1357	29	(	(	-LRB-
cord-034340-3ksfpaf7	1357	30	9.4	9.4	CD
cord-034340-3ksfpaf7	1357	31	%	%	NN
cord-034340-3ksfpaf7	1357	32	vs	vs	IN
cord-034340-3ksfpaf7	1357	33	24	24	CD
cord-034340-3ksfpaf7	1357	34	%	%	NN
cord-034340-3ksfpaf7	1357	35	;	;	:
cord-034340-3ksfpaf7	1357	36	P	p	NN
cord-034340-3ksfpaf7	1357	37	=	=	SYM
cord-034340-3ksfpaf7	1357	38	0.028	0.028	CD
cord-034340-3ksfpaf7	1357	39	)	)	-RRB-
cord-034340-3ksfpaf7	1357	40	and	and	CC
cord-034340-3ksfpaf7	1357	41	thrombocytopenia	thrombocytopenia	NN
cord-034340-3ksfpaf7	1357	42	(	(	-LRB-
cord-034340-3ksfpaf7	1357	43	5.7	5.7	CD
cord-034340-3ksfpaf7	1357	44	%	%	NN
cord-034340-3ksfpaf7	1357	45	vs	vs	IN
cord-034340-3ksfpaf7	1357	46	18	18	CD
cord-034340-3ksfpaf7	1357	47	%	%	NN
cord-034340-3ksfpaf7	1357	48	;	;	:
cord-034340-3ksfpaf7	1357	49	P	p	NN
cord-034340-3ksfpaf7	1357	50	=	=	SYM
cord-034340-3ksfpaf7	1357	51	0.045	0.045	CD
cord-034340-3ksfpaf7	1357	52	)	)	-RRB-
cord-034340-3ksfpaf7	1357	53	.	.	.
cord-034340-3ksfpaf7	1358	1	In	in	IN
cord-034340-3ksfpaf7	1358	2	addition	addition	NN
cord-034340-3ksfpaf7	1358	3	,	,	,
cord-034340-3ksfpaf7	1358	4	pSLE	psle	RB
cord-034340-3ksfpaf7	1358	5	with	with	IN
cord-034340-3ksfpaf7	1358	6	UV	uv	NN
cord-034340-3ksfpaf7	1358	7	were	be	VBD
cord-034340-3ksfpaf7	1358	8	more	more	RBR
cord-034340-3ksfpaf7	1358	9	likely	likely	JJ
cord-034340-3ksfpaf7	1358	10	to	to	TO
cord-034340-3ksfpaf7	1358	11	be	be	VB
cord-034340-3ksfpaf7	1358	12	associated	associate	VBN
cord-034340-3ksfpaf7	1358	13	with	with	IN
cord-034340-3ksfpaf7	1358	14	low	low	JJ
cord-034340-3ksfpaf7	1358	15	C3	c3	NN
cord-034340-3ksfpaf7	1358	16	complement	complement	NN
cord-034340-3ksfpaf7	1358	17	count	count	NN
cord-034340-3ksfpaf7	1358	18	(	(	-LRB-
cord-034340-3ksfpaf7	1358	19	94	94	CD
cord-034340-3ksfpaf7	1358	20	%	%	NN
cord-034340-3ksfpaf7	1358	21	vs	vs	IN
cord-034340-3ksfpaf7	1358	22	66	66	CD
cord-034340-3ksfpaf7	1358	23	%	%	NN
cord-034340-3ksfpaf7	1358	24	;	;	:
cord-034340-3ksfpaf7	1358	25	P	p	NN
cord-034340-3ksfpaf7	1358	26	<	<	XX
cord-034340-3ksfpaf7	1358	27	0.001	0.001	CD
cord-034340-3ksfpaf7	1358	28	)	)	-RRB-
cord-034340-3ksfpaf7	1358	29	and	and	CC
cord-034340-3ksfpaf7	1358	30	positive	positive	JJ
cord-034340-3ksfpaf7	1358	31	cytoplasmic	cytoplasmic	JJ
cord-034340-3ksfpaf7	1358	32	ANCA	ANCA	NNP
cord-034340-3ksfpaf7	1358	33	(	(	-LRB-
cord-034340-3ksfpaf7	1358	34	11	11	CD
cord-034340-3ksfpaf7	1358	35	%	%	NN
cord-034340-3ksfpaf7	1358	36	vs	vs	IN
cord-034340-3ksfpaf7	1358	37	0	0	CD
cord-034340-3ksfpaf7	1358	38	%	%	NN
cord-034340-3ksfpaf7	1358	39	;	;	:
cord-034340-3ksfpaf7	1358	40	P	p	NN
cord-034340-3ksfpaf7	1358	41	=	=	SYM
cord-034340-3ksfpaf7	1358	42	0.022).However	0.022).however	NN
cord-034340-3ksfpaf7	1358	43	,	,	,
cord-034340-3ksfpaf7	1358	44	the	the	DT
cord-034340-3ksfpaf7	1358	45	pSLE	psle	NN
cord-034340-3ksfpaf7	1358	46	with	with	IN
cord-034340-3ksfpaf7	1358	47	UV	uv	NN
cord-034340-3ksfpaf7	1358	48	cohort	cohort	NN
cord-034340-3ksfpaf7	1358	49	were	be	VBD
cord-034340-3ksfpaf7	1358	50	less	less	RBR
cord-034340-3ksfpaf7	1358	51	likely	likely	JJ
cord-034340-3ksfpaf7	1358	52	to	to	TO
cord-034340-3ksfpaf7	1358	53	be	be	VB
cord-034340-3ksfpaf7	1358	54	associated	associate	VBN
cord-034340-3ksfpaf7	1358	55	with	with	IN
cord-034340-3ksfpaf7	1358	56	ANA	ANA	NNP
cord-034340-3ksfpaf7	1358	57	(	(	-LRB-
cord-034340-3ksfpaf7	1358	58	65	65	CD
cord-034340-3ksfpaf7	1358	59	%	%	NN
cord-034340-3ksfpaf7	1358	60	vs	vs	IN
cord-034340-3ksfpaf7	1358	61	83	83	CD
cord-034340-3ksfpaf7	1358	62	%	%	NN
cord-034340-3ksfpaf7	1358	63	;	;	:
cord-034340-3ksfpaf7	1358	64	P	p	NN
cord-034340-3ksfpaf7	1358	65	=	=	SYM
cord-034340-3ksfpaf7	1358	66	0.016	0.016	CD
cord-034340-3ksfpaf7	1358	67	)	)	-RRB-
cord-034340-3ksfpaf7	1358	68	,	,	,
cord-034340-3ksfpaf7	1358	69	DsDNA	DsDNA	NNP
cord-034340-3ksfpaf7	1359	1	(	(	-LRB-
cord-034340-3ksfpaf7	1359	2	56	56	CD
cord-034340-3ksfpaf7	1359	3	%	%	NN
cord-034340-3ksfpaf7	1359	4	vs	vs	IN
cord-034340-3ksfpaf7	1359	5	72	72	CD
cord-034340-3ksfpaf7	1359	6	%	%	NN
cord-034340-3ksfpaf7	1359	7	;	;	:
cord-034340-3ksfpaf7	1359	8	P	p	NN
cord-034340-3ksfpaf7	1359	9	=	=	SYM
cord-034340-3ksfpaf7	1359	10	0.042	0.042	CD
cord-034340-3ksfpaf7	1359	11	)	)	-RRB-
cord-034340-3ksfpaf7	1359	12	and	and	CC
cord-034340-3ksfpaf7	1359	13	perinuclear	perinuclear	NNP
cord-034340-3ksfpaf7	1359	14	anti	anti	JJ
cord-034340-3ksfpaf7	1359	15	-	-	JJ
cord-034340-3ksfpaf7	1359	16	neutrophil	neutrophil	JJ
cord-034340-3ksfpaf7	1359	17	cytoplasmic	cytoplasmic	JJ
cord-034340-3ksfpaf7	1359	18	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1359	19	(	(	-LRB-
cord-034340-3ksfpaf7	1359	20	33	33	CD
cord-034340-3ksfpaf7	1359	21	%	%	NN
cord-034340-3ksfpaf7	1359	22	vs	vs	IN
cord-034340-3ksfpaf7	1359	23	55	55	CD
cord-034340-3ksfpaf7	1359	24	%	%	NN
cord-034340-3ksfpaf7	1359	25	;	;	:
cord-034340-3ksfpaf7	1359	26	P	p	NN
cord-034340-3ksfpaf7	1359	27	=	=	SYM
cord-034340-3ksfpaf7	1359	28	0.047	0.047	CD
cord-034340-3ksfpaf7	1359	29	)	)	-RRB-
cord-034340-3ksfpaf7	1359	30	.	.	.
cord-034340-3ksfpaf7	1360	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1360	2	:	:	:
cord-034340-3ksfpaf7	1360	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1360	4	report	report	VBP
cord-034340-3ksfpaf7	1360	5	a	a	DT
cord-034340-3ksfpaf7	1360	6	high	high	JJ
cord-034340-3ksfpaf7	1360	7	occurrence	occurrence	NN
cord-034340-3ksfpaf7	1360	8	of	of	IN
cord-034340-3ksfpaf7	1360	9	HUV	HUV	NNP
cord-034340-3ksfpaf7	1360	10	in	in	IN
cord-034340-3ksfpaf7	1360	11	pSLE	psle	JJ
cord-034340-3ksfpaf7	1360	12	cohort	cohort	NN
cord-034340-3ksfpaf7	1360	13	(	(	-LRB-
cord-034340-3ksfpaf7	1360	14	34.5	34.5	CD
cord-034340-3ksfpaf7	1360	15	%	%	NN
cord-034340-3ksfpaf7	1360	16	)	)	-RRB-
cord-034340-3ksfpaf7	1360	17	associated	associate	VBN
cord-034340-3ksfpaf7	1360	18	with	with	IN
cord-034340-3ksfpaf7	1360	19	unique	unique	JJ
cord-034340-3ksfpaf7	1360	20	demographic	demographic	JJ
cord-034340-3ksfpaf7	1360	21	,	,	,
cord-034340-3ksfpaf7	1360	22	clinical	clinical	JJ
cord-034340-3ksfpaf7	1360	23	features	feature	NNS
cord-034340-3ksfpaf7	1360	24	and	and	CC
cord-034340-3ksfpaf7	1360	25	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1360	26	features	feature	NNS
cord-034340-3ksfpaf7	1360	27	.	.	.
cord-034340-3ksfpaf7	1361	1	The	the	DT
cord-034340-3ksfpaf7	1361	2	debate	debate	NN
cord-034340-3ksfpaf7	1361	3	regarding	regard	VBG
cord-034340-3ksfpaf7	1361	4	whether	whether	IN
cord-034340-3ksfpaf7	1361	5	HUV	HUV	NNP
cord-034340-3ksfpaf7	1361	6	is	be	VBZ
cord-034340-3ksfpaf7	1361	7	a	a	DT
cord-034340-3ksfpaf7	1361	8	rare	rare	JJ
cord-034340-3ksfpaf7	1361	9	subset	subset	JJ
cord-034340-3ksfpaf7	1361	10	or	or	CC
cord-034340-3ksfpaf7	1361	11	unusual	unusual	JJ
cord-034340-3ksfpaf7	1361	12	type	type	NN
cord-034340-3ksfpaf7	1361	13	of	of	IN
cord-034340-3ksfpaf7	1361	14	SLE	SLE	NNP
cord-034340-3ksfpaf7	1361	15	,	,	,
cord-034340-3ksfpaf7	1361	16	or	or	CC
cord-034340-3ksfpaf7	1361	17	is	be	VBZ
cord-034340-3ksfpaf7	1361	18	a	a	DT
cord-034340-3ksfpaf7	1361	19	separate	separate	JJ
cord-034340-3ksfpaf7	1361	20	entity	entity	NN
cord-034340-3ksfpaf7	1361	21	altogether	altogether	RB
cord-034340-3ksfpaf7	1361	22	,	,	,
cord-034340-3ksfpaf7	1361	23	continues	continue	VBZ
cord-034340-3ksfpaf7	1361	24	.	.	.
cord-034340-3ksfpaf7	1362	1	However	however	RB
cord-034340-3ksfpaf7	1362	2	,	,	,
cord-034340-3ksfpaf7	1362	3	the	the	DT
cord-034340-3ksfpaf7	1362	4	overlap	overlap	NN
cord-034340-3ksfpaf7	1362	5	in	in	IN
cord-034340-3ksfpaf7	1362	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	1362	7	,	,	,
cord-034340-3ksfpaf7	1362	8	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1362	9	and	and	CC
cord-034340-3ksfpaf7	1362	10	genetic	genetic	JJ
cord-034340-3ksfpaf7	1362	11	mutation	mutation	NN
cord-034340-3ksfpaf7	1362	12	supports	support	VBZ
cord-034340-3ksfpaf7	1362	13	the	the	DT
cord-034340-3ksfpaf7	1362	14	notion	notion	NN
cord-034340-3ksfpaf7	1362	15	that	that	IN
cord-034340-3ksfpaf7	1362	16	HUV	HUV	NNP
cord-034340-3ksfpaf7	1362	17	and	and	CC
cord-034340-3ksfpaf7	1362	18	SLE	SLE	NNP
cord-034340-3ksfpaf7	1362	19	fall	fall	VBP
cord-034340-3ksfpaf7	1362	20	into	into	IN
cord-034340-3ksfpaf7	1362	21	the	the	DT
cord-034340-3ksfpaf7	1362	22	same	same	JJ
cord-034340-3ksfpaf7	1362	23	spectrum	spectrum	NN
cord-034340-3ksfpaf7	1362	24	of	of	IN
cord-034340-3ksfpaf7	1362	25	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1362	26	disease	disease	NN
cord-034340-3ksfpaf7	1362	27	with	with	IN
cord-034340-3ksfpaf7	1362	28	similar	similar	JJ
cord-034340-3ksfpaf7	1362	29	disease	disease	NN
cord-034340-3ksfpaf7	1362	30	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	1362	31	.	.	.
cord-034340-3ksfpaf7	1363	1	However	however	RB
cord-034340-3ksfpaf7	1363	2	,	,	,
cord-034340-3ksfpaf7	1363	3	further	further	JJ
cord-034340-3ksfpaf7	1363	4	studies	study	NNS
cord-034340-3ksfpaf7	1363	5	are	be	VBP
cord-034340-3ksfpaf7	1363	6	needed	need	VBN
cord-034340-3ksfpaf7	1363	7	to	to	TO
cord-034340-3ksfpaf7	1363	8	reach	reach	VB
cord-034340-3ksfpaf7	1363	9	clear	clear	JJ
cord-034340-3ksfpaf7	1363	10	conclusions	conclusion	NNS
cord-034340-3ksfpaf7	1363	11	regarding	regard	VBG
cord-034340-3ksfpaf7	1363	12	the	the	DT
cord-034340-3ksfpaf7	1363	13	relationship	relationship	NN
cord-034340-3ksfpaf7	1363	14	between	between	IN
cord-034340-3ksfpaf7	1363	15	HUV	HUV	NNP
cord-034340-3ksfpaf7	1363	16	and	and	CC
cord-034340-3ksfpaf7	1363	17	SLE	SLE	NNP
cord-034340-3ksfpaf7	1363	18	.	.	.
cord-034340-3ksfpaf7	1364	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1364	2	:	:	:
cord-034340-3ksfpaf7	1365	1	The	the	DT
cord-034340-3ksfpaf7	1365	2	last	last	JJ
cord-034340-3ksfpaf7	1365	3	decade	decade	NN
cord-034340-3ksfpaf7	1365	4	has	have	VBZ
cord-034340-3ksfpaf7	1365	5	brought	bring	VBN
cord-034340-3ksfpaf7	1365	6	a	a	DT
cord-034340-3ksfpaf7	1365	7	lot	lot	NN
cord-034340-3ksfpaf7	1365	8	to	to	IN
cord-034340-3ksfpaf7	1365	9	the	the	DT
cord-034340-3ksfpaf7	1365	10	approaches	approach	NNS
cord-034340-3ksfpaf7	1365	11	to	to	IN
cord-034340-3ksfpaf7	1365	12	the	the	DT
cord-034340-3ksfpaf7	1365	13	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1365	14	and	and	CC
cord-034340-3ksfpaf7	1365	15	treatment	treatment	NN
cord-034340-3ksfpaf7	1365	16	of	of	IN
cord-034340-3ksfpaf7	1365	17	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1365	18	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1365	19	.	.	.
cord-034340-3ksfpaf7	1366	1	In	in	IN
cord-034340-3ksfpaf7	1366	2	Russia	Russia	NNP
cord-034340-3ksfpaf7	1366	3	,	,	,
cord-034340-3ksfpaf7	1366	4	the	the	DT
cord-034340-3ksfpaf7	1366	5	actualization	actualization	NN
cord-034340-3ksfpaf7	1366	6	of	of	IN
cord-034340-3ksfpaf7	1366	7	the	the	DT
cord-034340-3ksfpaf7	1366	8	problem	problem	NN
cord-034340-3ksfpaf7	1366	9	of	of	IN
cord-034340-3ksfpaf7	1366	10	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1366	11	and	and	CC
cord-034340-3ksfpaf7	1366	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1366	13	of	of	IN
cord-034340-3ksfpaf7	1366	14	JIA	JIA	NNP
cord-034340-3ksfpaf7	1366	15	required	require	VBD
cord-034340-3ksfpaf7	1366	16	the	the	DT
cord-034340-3ksfpaf7	1366	17	development	development	NN
cord-034340-3ksfpaf7	1366	18	of	of	IN
cord-034340-3ksfpaf7	1366	19	federal	federal	JJ
cord-034340-3ksfpaf7	1366	20	standards	standard	NNS
cord-034340-3ksfpaf7	1366	21	,	,	,
cord-034340-3ksfpaf7	1366	22	which	which	WDT
cord-034340-3ksfpaf7	1366	23	provide	provide	VBP
cord-034340-3ksfpaf7	1366	24	the	the	DT
cord-034340-3ksfpaf7	1366	25	most	most	RBS
cord-034340-3ksfpaf7	1366	26	detailed	detailed	JJ
cord-034340-3ksfpaf7	1366	27	algorithms	algorithm	NNS
cord-034340-3ksfpaf7	1366	28	for	for	IN
cord-034340-3ksfpaf7	1366	29	medical	medical	JJ
cord-034340-3ksfpaf7	1366	30	care	care	NN
cord-034340-3ksfpaf7	1366	31	,	,	,
cord-034340-3ksfpaf7	1366	32	both	both	CC
cord-034340-3ksfpaf7	1366	33	at	at	IN
cord-034340-3ksfpaf7	1366	34	the	the	DT
cord-034340-3ksfpaf7	1366	35	stage	stage	NN
cord-034340-3ksfpaf7	1366	36	of	of	IN
cord-034340-3ksfpaf7	1366	37	inpatient	inpatient	JJ
cord-034340-3ksfpaf7	1366	38	and	and	CC
cord-034340-3ksfpaf7	1366	39	outpatient	outpatient	NN
cord-034340-3ksfpaf7	1366	40	care	care	NN
cord-034340-3ksfpaf7	1366	41	.	.	.
cord-034340-3ksfpaf7	1367	1	In	in	IN
cord-034340-3ksfpaf7	1367	2	the	the	DT
cord-034340-3ksfpaf7	1367	3	regions	region	NNS
cord-034340-3ksfpaf7	1367	4	of	of	IN
cord-034340-3ksfpaf7	1367	5	the	the	DT
cord-034340-3ksfpaf7	1367	6	Russian	Russian	NNP
cord-034340-3ksfpaf7	1367	7	Federation	Federation	NNP
cord-034340-3ksfpaf7	1367	8	,	,	,
cord-034340-3ksfpaf7	1367	9	the	the	DT
cord-034340-3ksfpaf7	1367	10	effective	effective	JJ
cord-034340-3ksfpaf7	1367	11	use	use	NN
cord-034340-3ksfpaf7	1367	12	of	of	IN
cord-034340-3ksfpaf7	1367	13	these	these	DT
cord-034340-3ksfpaf7	1367	14	documents	document	NNS
cord-034340-3ksfpaf7	1367	15	required	require	VBD
cord-034340-3ksfpaf7	1367	16	a	a	DT
cord-034340-3ksfpaf7	1367	17	whole	whole	JJ
cord-034340-3ksfpaf7	1367	18	range	range	NN
cord-034340-3ksfpaf7	1367	19	of	of	IN
cord-034340-3ksfpaf7	1367	20	additional	additional	JJ
cord-034340-3ksfpaf7	1367	21	educated	educate	VBN
cord-034340-3ksfpaf7	1367	22	activities	activity	NNS
cord-034340-3ksfpaf7	1367	23	,	,	,
cord-034340-3ksfpaf7	1367	24	both	both	CC
cord-034340-3ksfpaf7	1367	25	with	with	IN
cord-034340-3ksfpaf7	1367	26	students	student	NNS
cord-034340-3ksfpaf7	1367	27	of	of	IN
cord-034340-3ksfpaf7	1367	28	medical	medical	JJ
cord-034340-3ksfpaf7	1367	29	universities	university	NNS
cord-034340-3ksfpaf7	1367	30	,	,	,
cord-034340-3ksfpaf7	1367	31	as	as	RB
cord-034340-3ksfpaf7	1367	32	well	well	RB
cord-034340-3ksfpaf7	1367	33	as	as	IN
cord-034340-3ksfpaf7	1367	34	with	with	IN
cord-034340-3ksfpaf7	1367	35	the	the	DT
cord-034340-3ksfpaf7	1367	36	medical	medical	JJ
cord-034340-3ksfpaf7	1367	37	and	and	CC
cord-034340-3ksfpaf7	1367	38	nursing	nursing	NN
cord-034340-3ksfpaf7	1367	39	community	community	NN
cord-034340-3ksfpaf7	1367	40	,	,	,
cord-034340-3ksfpaf7	1367	41	in	in	IN
cord-034340-3ksfpaf7	1367	42	addition	addition	NN
cord-034340-3ksfpaf7	1367	43	,	,	,
cord-034340-3ksfpaf7	1367	44	a	a	DT
cord-034340-3ksfpaf7	1367	45	set	set	NN
cord-034340-3ksfpaf7	1367	46	of	of	IN
cord-034340-3ksfpaf7	1367	47	work	work	NN
cord-034340-3ksfpaf7	1367	48	was	be	VBD
cord-034340-3ksfpaf7	1367	49	carried	carry	VBN
cord-034340-3ksfpaf7	1367	50	out	out	RP
cord-034340-3ksfpaf7	1367	51	to	to	TO
cord-034340-3ksfpaf7	1367	52	create	create	VB
cord-034340-3ksfpaf7	1367	53	a	a	DT
cord-034340-3ksfpaf7	1367	54	regional	regional	JJ
cord-034340-3ksfpaf7	1367	55	regulatory	regulatory	JJ
cord-034340-3ksfpaf7	1367	56	framework	framework	NN
cord-034340-3ksfpaf7	1367	57	.	.	.
cord-034340-3ksfpaf7	1368	1	In	in	IN
cord-034340-3ksfpaf7	1368	2	the	the	DT
cord-034340-3ksfpaf7	1368	3	total	total	JJ
cord-034340-3ksfpaf7	1368	4	biological	biological	JJ
cord-034340-3ksfpaf7	1368	5	therapy	therapy	NN
cord-034340-3ksfpaf7	1368	6	pool	pool	NN
cord-034340-3ksfpaf7	1368	7	,	,	,
cord-034340-3ksfpaf7	1368	8	67	67	CD
cord-034340-3ksfpaf7	1368	9	%	%	NN
cord-034340-3ksfpaf7	1368	10	of	of	IN
cord-034340-3ksfpaf7	1368	11	patients	patient	NNS
cord-034340-3ksfpaf7	1368	12	receive	receive	VBP
cord-034340-3ksfpaf7	1368	13	TNF	TNF	NNP
cord-034340-3ksfpaf7	1368	14	-	-	HYPH
cord-034340-3ksfpaf7	1368	15	alpha	alpha	NN
cord-034340-3ksfpaf7	1368	16	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1368	17	,	,	,
cord-034340-3ksfpaf7	1368	18	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1368	19	to	to	IN
cord-034340-3ksfpaf7	1368	20	IL-6	IL-6	NNP
cord-034340-3ksfpaf7	1368	21	receive	receive	VB
cord-034340-3ksfpaf7	1368	22	27	27	CD
cord-034340-3ksfpaf7	1368	23	%	%	NN
cord-034340-3ksfpaf7	1368	24	of	of	IN
cord-034340-3ksfpaf7	1368	25	patients	patient	NNS
cord-034340-3ksfpaf7	1368	26	,	,	,
cord-034340-3ksfpaf7	1368	27	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1368	28	to	to	IN
cord-034340-3ksfpaf7	1368	29	IL-1	IL-1	NNP
cord-034340-3ksfpaf7	1368	30	-6,25	-6,25	:
cord-034340-3ksfpaf7	1368	31	%	%	NN
cord-034340-3ksfpaf7	1368	32	.	.	.
cord-034340-3ksfpaf7	1369	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1369	2	is	be	VBZ
cord-034340-3ksfpaf7	1369	3	worth	worth	JJ
cord-034340-3ksfpaf7	1369	4	noting	note	VBG
cord-034340-3ksfpaf7	1369	5	that	that	IN
cord-034340-3ksfpaf7	1369	6	when	when	WRB
cord-034340-3ksfpaf7	1369	7	using	use	VBG
cord-034340-3ksfpaf7	1369	8	biological	biological	JJ
cord-034340-3ksfpaf7	1369	9	agents	agent	NNS
cord-034340-3ksfpaf7	1369	10	in	in	IN
cord-034340-3ksfpaf7	1369	11	60	60	CD
cord-034340-3ksfpaf7	1369	12	%	%	NN
cord-034340-3ksfpaf7	1369	13	of	of	IN
cord-034340-3ksfpaf7	1369	14	cases	case	NNS
cord-034340-3ksfpaf7	1369	15	,	,	,
cord-034340-3ksfpaf7	1369	16	the	the	DT
cord-034340-3ksfpaf7	1369	17	criterion	criterion	NN
cord-034340-3ksfpaf7	1369	18	of	of	IN
cord-034340-3ksfpaf7	1369	19	an	an	DT
cord-034340-3ksfpaf7	1369	20	inactive	inactive	JJ
cord-034340-3ksfpaf7	1369	21	disease	disease	NN
cord-034340-3ksfpaf7	1369	22	was	be	VBD
cord-034340-3ksfpaf7	1369	23	achieved	achieve	VBN
cord-034340-3ksfpaf7	1369	24	by	by	IN
cord-034340-3ksfpaf7	1369	25	4	4	CD
cord-034340-3ksfpaf7	1369	26	-	-	SYM
cord-034340-3ksfpaf7	1369	27	5	5	CD
cord-034340-3ksfpaf7	1369	28	months	month	NNS
cord-034340-3ksfpaf7	1369	29	,	,	,
cord-034340-3ksfpaf7	1369	30	which	which	WDT
cord-034340-3ksfpaf7	1369	31	was	be	VBD
cord-034340-3ksfpaf7	1369	32	characterized	characterize	VBN
cord-034340-3ksfpaf7	1369	33	by	by	IN
cord-034340-3ksfpaf7	1369	34	the	the	DT
cord-034340-3ksfpaf7	1369	35	absence	absence	NN
cord-034340-3ksfpaf7	1369	36	of	of	IN
cord-034340-3ksfpaf7	1369	37	acute	acute	JJ
cord-034340-3ksfpaf7	1369	38	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1369	39	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1369	40	,	,	,
cord-034340-3ksfpaf7	1369	41	normalization	normalization	NN
cord-034340-3ksfpaf7	1369	42	of	of	IN
cord-034340-3ksfpaf7	1369	43	ESR	ESR	NNP
cord-034340-3ksfpaf7	1369	44	and	and	CC
cord-034340-3ksfpaf7	1369	45	CRP	CRP	NNP
cord-034340-3ksfpaf7	1369	46	.	.	.
cord-034340-3ksfpaf7	1370	1	Monitoring	monitoring	NN
cord-034340-3ksfpaf7	1370	2	of	of	IN
cord-034340-3ksfpaf7	1370	3	patients	patient	NNS
cord-034340-3ksfpaf7	1370	4	with	with	IN
cord-034340-3ksfpaf7	1370	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	1370	6	receiving	receive	VBG
cord-034340-3ksfpaf7	1370	7	biological	biological	JJ
cord-034340-3ksfpaf7	1370	8	agents	agent	NNS
cord-034340-3ksfpaf7	1370	9	required	require	VBD
cord-034340-3ksfpaf7	1370	10	the	the	DT
cord-034340-3ksfpaf7	1370	11	conduct	conduct	NN
cord-034340-3ksfpaf7	1370	12	of	of	IN
cord-034340-3ksfpaf7	1370	13	a	a	DT
cord-034340-3ksfpaf7	1370	14	number	number	NN
cord-034340-3ksfpaf7	1370	15	of	of	IN
cord-034340-3ksfpaf7	1370	16	educational	educational	JJ
cord-034340-3ksfpaf7	1370	17	activities	activity	NNS
cord-034340-3ksfpaf7	1370	18	for	for	IN
cord-034340-3ksfpaf7	1370	19	medical	medical	JJ
cord-034340-3ksfpaf7	1370	20	personnel	personnel	NNS
cord-034340-3ksfpaf7	1370	21	,	,	,
cord-034340-3ksfpaf7	1370	22	the	the	DT
cord-034340-3ksfpaf7	1370	23	creation	creation	NN
cord-034340-3ksfpaf7	1370	24	of	of	IN
cord-034340-3ksfpaf7	1370	25	an	an	DT
cord-034340-3ksfpaf7	1370	26	additional	additional	JJ
cord-034340-3ksfpaf7	1370	27	methodological	methodological	JJ
cord-034340-3ksfpaf7	1370	28	base	base	NN
cord-034340-3ksfpaf7	1370	29	.	.	.
cord-034340-3ksfpaf7	1371	1	For	for	IN
cord-034340-3ksfpaf7	1371	2	further	further	JJ
cord-034340-3ksfpaf7	1371	3	training	training	NN
cord-034340-3ksfpaf7	1371	4	of	of	IN
cord-034340-3ksfpaf7	1371	5	young	young	JJ
cord-034340-3ksfpaf7	1371	6	specialists	specialist	NNS
cord-034340-3ksfpaf7	1371	7	at	at	IN
cord-034340-3ksfpaf7	1371	8	the	the	DT
cord-034340-3ksfpaf7	1371	9	regional	regional	JJ
cord-034340-3ksfpaf7	1371	10	medical	medical	NNP
cord-034340-3ksfpaf7	1371	11	university	university	NNP
cord-034340-3ksfpaf7	1371	12	,	,	,
cord-034340-3ksfpaf7	1371	13	a	a	DT
cord-034340-3ksfpaf7	1371	14	program	program	NN
cord-034340-3ksfpaf7	1371	15	of	of	IN
cord-034340-3ksfpaf7	1371	16	an	an	DT
cord-034340-3ksfpaf7	1371	17	additional	additional	JJ
cord-034340-3ksfpaf7	1371	18	educational	educational	JJ
cord-034340-3ksfpaf7	1371	19	course	course	NN
cord-034340-3ksfpaf7	1371	20	in	in	IN
cord-034340-3ksfpaf7	1371	21	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1371	22	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1371	23	was	be	VBD
cord-034340-3ksfpaf7	1371	24	developed	develop	VBN
cord-034340-3ksfpaf7	1371	25	and	and	CC
cord-034340-3ksfpaf7	1371	26	introduced	introduce	VBN
cord-034340-3ksfpaf7	1371	27	.	.	.
cord-034340-3ksfpaf7	1372	1	A	a	DT
cord-034340-3ksfpaf7	1372	2	regional	regional	JJ
cord-034340-3ksfpaf7	1372	3	patient	patient	NN
cord-034340-3ksfpaf7	1372	4	organization	organization	NN
cord-034340-3ksfpaf7	1372	5	was	be	VBD
cord-034340-3ksfpaf7	1372	6	established	establish	VBN
cord-034340-3ksfpaf7	1372	7	and	and	CC
cord-034340-3ksfpaf7	1372	8	also	also	RB
cord-034340-3ksfpaf7	1372	9	required	require	VBD
cord-034340-3ksfpaf7	1372	10	a	a	DT
cord-034340-3ksfpaf7	1372	11	set	set	NN
cord-034340-3ksfpaf7	1372	12	of	of	IN
cord-034340-3ksfpaf7	1372	13	information	information	NN
cord-034340-3ksfpaf7	1372	14	activities	activity	NNS
cord-034340-3ksfpaf7	1372	15	by	by	IN
cord-034340-3ksfpaf7	1372	16	the	the	DT
cord-034340-3ksfpaf7	1372	17	medical	medical	JJ
cord-034340-3ksfpaf7	1372	18	community	community	NN
cord-034340-3ksfpaf7	1372	19	.	.	.
cord-034340-3ksfpaf7	1373	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1373	2	:	:	:
cord-034340-3ksfpaf7	1374	1	In	in	IN
cord-034340-3ksfpaf7	1374	2	the	the	DT
cord-034340-3ksfpaf7	1374	3	Saratov	Saratov	NNP
cord-034340-3ksfpaf7	1374	4	region	region	NN
cord-034340-3ksfpaf7	1374	5	of	of	IN
cord-034340-3ksfpaf7	1374	6	the	the	DT
cord-034340-3ksfpaf7	1374	7	Russian	Russian	NNP
cord-034340-3ksfpaf7	1374	8	Federation	Federation	NNP
cord-034340-3ksfpaf7	1374	9	,	,	,
cord-034340-3ksfpaf7	1374	10	about	about	RB
cord-034340-3ksfpaf7	1374	11	20	20	CD
cord-034340-3ksfpaf7	1374	12	%	%	NN
cord-034340-3ksfpaf7	1374	13	of	of	IN
cord-034340-3ksfpaf7	1374	14	patients	patient	NNS
cord-034340-3ksfpaf7	1374	15	with	with	IN
cord-034340-3ksfpaf7	1374	16	JIA	JIA	NNP
cord-034340-3ksfpaf7	1374	17	receive	receive	VBP
cord-034340-3ksfpaf7	1374	18	biological	biological	JJ
cord-034340-3ksfpaf7	1374	19	therapy	therapy	NN
cord-034340-3ksfpaf7	1374	20	,	,	,
cord-034340-3ksfpaf7	1374	21	which	which	WDT
cord-034340-3ksfpaf7	1374	22	corresponds	correspond	VBZ
cord-034340-3ksfpaf7	1374	23	to	to	IN
cord-034340-3ksfpaf7	1374	24	the	the	DT
cord-034340-3ksfpaf7	1374	25	average	average	JJ
cord-034340-3ksfpaf7	1374	26	indicators	indicator	NNS
cord-034340-3ksfpaf7	1374	27	according	accord	VBG
cord-034340-3ksfpaf7	1374	28	to	to	IN
cord-034340-3ksfpaf7	1374	29	the	the	DT
cord-034340-3ksfpaf7	1374	30	literature	literature	NN
cord-034340-3ksfpaf7	1374	31	.	.	.
cord-034340-3ksfpaf7	1375	1	In	in	IN
cord-034340-3ksfpaf7	1375	2	the	the	DT
cord-034340-3ksfpaf7	1375	3	structure	structure	NN
cord-034340-3ksfpaf7	1375	4	of	of	IN
cord-034340-3ksfpaf7	1375	5	the	the	DT
cord-034340-3ksfpaf7	1375	6	biological	biological	JJ
cord-034340-3ksfpaf7	1375	7	drugs	drug	NNS
cord-034340-3ksfpaf7	1375	8	used	use	VBN
cord-034340-3ksfpaf7	1375	9	,	,	,
cord-034340-3ksfpaf7	1375	10	the	the	DT
cord-034340-3ksfpaf7	1375	11	group	group	NN
cord-034340-3ksfpaf7	1375	12	of	of	IN
cord-034340-3ksfpaf7	1375	13	TNF	TNF	NNP
cord-034340-3ksfpaf7	1375	14	-	-	HYPH
cord-034340-3ksfpaf7	1375	15	alpha	alpha	NN
cord-034340-3ksfpaf7	1375	16	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1375	17	is	be	VBZ
cord-034340-3ksfpaf7	1375	18	preserved	preserve	VBN
cord-034340-3ksfpaf7	1375	19	-67	-67	CD
cord-034340-3ksfpaf7	1375	20	%	%	NN
cord-034340-3ksfpaf7	1375	21	.	.	.
cord-034340-3ksfpaf7	1376	1	The	the	DT
cord-034340-3ksfpaf7	1376	2	introduction	introduction	NN
cord-034340-3ksfpaf7	1376	3	of	of	IN
cord-034340-3ksfpaf7	1376	4	modern	modern	JJ
cord-034340-3ksfpaf7	1376	5	methods	method	NNS
cord-034340-3ksfpaf7	1376	6	of	of	IN
cord-034340-3ksfpaf7	1376	7	treatment	treatment	NN
cord-034340-3ksfpaf7	1376	8	using	use	VBG
cord-034340-3ksfpaf7	1376	9	biological	biological	JJ
cord-034340-3ksfpaf7	1376	10	agents	agent	NNS
cord-034340-3ksfpaf7	1376	11	in	in	IN
cord-034340-3ksfpaf7	1376	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	1376	13	has	have	VBZ
cord-034340-3ksfpaf7	1376	14	significantly	significantly	RB
cord-034340-3ksfpaf7	1376	15	increased	increase	VBN
cord-034340-3ksfpaf7	1376	16	the	the	DT
cord-034340-3ksfpaf7	1376	17	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1376	18	of	of	IN
cord-034340-3ksfpaf7	1376	19	treatment	treatment	NN
cord-034340-3ksfpaf7	1376	20	,	,	,
cord-034340-3ksfpaf7	1376	21	but	but	CC
cord-034340-3ksfpaf7	1376	22	it	-PRON-	PRP
cord-034340-3ksfpaf7	1376	23	required	require	VBD
cord-034340-3ksfpaf7	1376	24	the	the	DT
cord-034340-3ksfpaf7	1376	25	organization	organization	NN
cord-034340-3ksfpaf7	1376	26	of	of	IN
cord-034340-3ksfpaf7	1376	27	additional	additional	JJ
cord-034340-3ksfpaf7	1376	28	information	information	NN
cord-034340-3ksfpaf7	1376	29	support	support	NN
cord-034340-3ksfpaf7	1376	30	for	for	IN
cord-034340-3ksfpaf7	1376	31	medical	medical	JJ
cord-034340-3ksfpaf7	1376	32	personnel	personnel	NNS
cord-034340-3ksfpaf7	1376	33	.	.	.
cord-034340-3ksfpaf7	1377	1	Disclosure	disclosure	NN
cord-034340-3ksfpaf7	1377	2	of	of	IN
cord-034340-3ksfpaf7	1377	3	Interest	Interest	NNP
cord-034340-3ksfpaf7	1378	1	:	:	:
cord-034340-3ksfpaf7	1378	2	None	none	NN
cord-034340-3ksfpaf7	1378	3	declared	declare	VBD
cord-034340-3ksfpaf7	1378	4	Introduction	introduction	NN
cord-034340-3ksfpaf7	1378	5	:	:	:
cord-034340-3ksfpaf7	1379	1	Immunogenicity	immunogenicity	NN
cord-034340-3ksfpaf7	1379	2	and	and	CC
cord-034340-3ksfpaf7	1379	3	development	development	NN
cord-034340-3ksfpaf7	1379	4	of	of	IN
cord-034340-3ksfpaf7	1379	5	anti	anti	JJ
cord-034340-3ksfpaf7	1379	6	-	-	JJ
cord-034340-3ksfpaf7	1379	7	drug	drug	JJ
cord-034340-3ksfpaf7	1379	8	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1379	9	have	have	VBP
cord-034340-3ksfpaf7	1379	10	been	be	VBN
cord-034340-3ksfpaf7	1379	11	associated	associate	VBN
cord-034340-3ksfpaf7	1379	12	with	with	IN
cord-034340-3ksfpaf7	1379	13	treatment	treatment	NN
cord-034340-3ksfpaf7	1379	14	failure	failure	NN
cord-034340-3ksfpaf7	1379	15	and	and	CC
cord-034340-3ksfpaf7	1379	16	adverse	adverse	JJ
cord-034340-3ksfpaf7	1379	17	events	event	NNS
cord-034340-3ksfpaf7	1379	18	during	during	IN
cord-034340-3ksfpaf7	1379	19	biologic	biologic	JJ
cord-034340-3ksfpaf7	1379	20	treatment	treatment	NN
cord-034340-3ksfpaf7	1379	21	.	.	.
cord-034340-3ksfpaf7	1380	1	Anti	anti	JJ
cord-034340-3ksfpaf7	1380	2	-	-	JJ
cord-034340-3ksfpaf7	1380	3	drug	drug	JJ
cord-034340-3ksfpaf7	1380	4	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1380	5	(	(	-LRB-
cord-034340-3ksfpaf7	1380	6	ADAs	ADAs	NNP
cord-034340-3ksfpaf7	1380	7	)	)	-RRB-
cord-034340-3ksfpaf7	1380	8	have	have	VBP
cord-034340-3ksfpaf7	1380	9	been	be	VBN
cord-034340-3ksfpaf7	1380	10	reported	report	VBN
cord-034340-3ksfpaf7	1380	11	in	in	IN
cord-034340-3ksfpaf7	1380	12	21	21	CD
cord-034340-3ksfpaf7	1380	13	%	%	NN
cord-034340-3ksfpaf7	1380	14	of	of	IN
cord-034340-3ksfpaf7	1380	15	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	1380	16	Idiopathic	Idiopathic	NNP
cord-034340-3ksfpaf7	1380	17	Arthritis	Arthritis	NNP
cord-034340-3ksfpaf7	1380	18	patients	patient	NNS
cord-034340-3ksfpaf7	1380	19	treated	treat	VBN
cord-034340-3ksfpaf7	1380	20	with	with	IN
cord-034340-3ksfpaf7	1380	21	Adalimumab	Adalimumab	NNP
cord-034340-3ksfpaf7	1380	22	.	.	.
cord-034340-3ksfpaf7	1381	1	However	however	RB
cord-034340-3ksfpaf7	1381	2	,	,	,
cord-034340-3ksfpaf7	1381	3	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1381	4	role	role	NN
cord-034340-3ksfpaf7	1381	5	in	in	IN
cord-034340-3ksfpaf7	1381	6	reducing	reduce	VBG
cord-034340-3ksfpaf7	1381	7	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1381	8	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1381	9	is	be	VBZ
cord-034340-3ksfpaf7	1381	10	still	still	RB
cord-034340-3ksfpaf7	1381	11	debated	debate	VBN
cord-034340-3ksfpaf7	1381	12	due	due	IN
cord-034340-3ksfpaf7	1381	13	to	to	IN
cord-034340-3ksfpaf7	1381	14	conflicting	conflicting	JJ
cord-034340-3ksfpaf7	1381	15	results	result	NNS
cord-034340-3ksfpaf7	1381	16	.	.	.
cord-034340-3ksfpaf7	1382	1	No	no	DT
cord-034340-3ksfpaf7	1382	2	study	study	NN
cord-034340-3ksfpaf7	1382	3	has	have	VBZ
cord-034340-3ksfpaf7	1382	4	been	be	VBN
cord-034340-3ksfpaf7	1382	5	directed	direct	VBN
cord-034340-3ksfpaf7	1382	6	toward	toward	IN
cord-034340-3ksfpaf7	1382	7	identification	identification	NN
cord-034340-3ksfpaf7	1382	8	of	of	IN
cord-034340-3ksfpaf7	1382	9	neutralizing	neutralize	VBG
cord-034340-3ksfpaf7	1382	10	ADAs	ada	NNS
cord-034340-3ksfpaf7	1382	11	in	in	IN
cord-034340-3ksfpaf7	1382	12	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1382	13	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1382	14	disorders	disorder	NNS
cord-034340-3ksfpaf7	1382	15	.	.	.
cord-034340-3ksfpaf7	1383	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1383	2	:	:	:
cord-034340-3ksfpaf7	1383	3	Aim	aim	VB
cord-034340-3ksfpaf7	1383	4	of	of	IN
cord-034340-3ksfpaf7	1383	5	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1383	6	study	study	NN
cord-034340-3ksfpaf7	1383	7	was	be	VBD
cord-034340-3ksfpaf7	1383	8	to	to	TO
cord-034340-3ksfpaf7	1383	9	detect	detect	VB
cord-034340-3ksfpaf7	1383	10	ADAs	ada	NNS
cord-034340-3ksfpaf7	1383	11	,	,	,
cord-034340-3ksfpaf7	1383	12	along	along	IN
cord-034340-3ksfpaf7	1383	13	with	with	IN
cord-034340-3ksfpaf7	1383	14	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1383	15	clinical	clinical	JJ
cord-034340-3ksfpaf7	1383	16	relevance	relevance	NN
cord-034340-3ksfpaf7	1383	17	,	,	,
cord-034340-3ksfpaf7	1383	18	using	use	VBG
cord-034340-3ksfpaf7	1383	19	a	a	DT
cord-034340-3ksfpaf7	1383	20	new	new	JJ
cord-034340-3ksfpaf7	1383	21	theranostic	theranostic	JJ
cord-034340-3ksfpaf7	1383	22	peptide	peptide	NN
cord-034340-3ksfpaf7	1383	23	-	-	HYPH
cord-034340-3ksfpaf7	1383	24	base	base	NN
cord-034340-3ksfpaf7	1383	25	assay	assay	NN
cord-034340-3ksfpaf7	1383	26	in	in	IN
cord-034340-3ksfpaf7	1383	27	a	a	DT
cord-034340-3ksfpaf7	1383	28	cohort	cohort	NN
cord-034340-3ksfpaf7	1383	29	of	of	IN
cord-034340-3ksfpaf7	1383	30	children	child	NNS
cord-034340-3ksfpaf7	1383	31	with	with	IN
cord-034340-3ksfpaf7	1383	32	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1383	33	chronic	chronic	JJ
cord-034340-3ksfpaf7	1383	34	diseases	disease	NNS
cord-034340-3ksfpaf7	1383	35	on	on	IN
cord-034340-3ksfpaf7	1383	36	Adalimumab	Adalimumab	NNP
cord-034340-3ksfpaf7	1383	37	treatment	treatment	NN
cord-034340-3ksfpaf7	1383	38	.	.	.
cord-034340-3ksfpaf7	1384	1	Methods	method	NNS
cord-034340-3ksfpaf7	1384	2	:	:	:
cord-034340-3ksfpaf7	1384	3	Six	six	CD
cord-034340-3ksfpaf7	1384	4	candidate	candidate	NN
cord-034340-3ksfpaf7	1384	5	Adalimumab	Adalimumab	NNS
cord-034340-3ksfpaf7	1384	6	derived	derive	VBD
cord-034340-3ksfpaf7	1384	7	peptide	peptide	NN
cord-034340-3ksfpaf7	1384	8	antigens	antigen	NNS
cord-034340-3ksfpaf7	1384	9	(	(	-LRB-
cord-034340-3ksfpaf7	1384	10	HC	HC	NNP
cord-034340-3ksfpaf7	1384	11	-	-	HYPH
cord-034340-3ksfpaf7	1384	12	CDR1	CDR1	NNP
cord-034340-3ksfpaf7	1384	13	,	,	,
cord-034340-3ksfpaf7	1384	14	HC	HC	NNP
cord-034340-3ksfpaf7	1384	15	CDR2	CDR2	NNP
cord-034340-3ksfpaf7	1384	16	,	,	,
cord-034340-3ksfpaf7	1384	17	HC	HC	NNP
cord-034340-3ksfpaf7	1384	18	CDR3	CDR3	NNP
cord-034340-3ksfpaf7	1384	19	,	,	,
cord-034340-3ksfpaf7	1384	20	LC	LC	NNP
cord-034340-3ksfpaf7	1384	21	CDR1	CDR1	NNP
cord-034340-3ksfpaf7	1384	22	,	,	,
cord-034340-3ksfpaf7	1384	23	LC	LC	NNP
cord-034340-3ksfpaf7	1384	24	CDR	CDR	NNP
cord-034340-3ksfpaf7	1384	25	2	2	CD
cord-034340-3ksfpaf7	1384	26	,	,	,
cord-034340-3ksfpaf7	1384	27	LC	LC	NNP
cord-034340-3ksfpaf7	1384	28	CDR3	CDR3	NNP
cord-034340-3ksfpaf7	1384	29	)	)	-RRB-
cord-034340-3ksfpaf7	1384	30	have	have	VBP
cord-034340-3ksfpaf7	1384	31	been	be	VBN
cord-034340-3ksfpaf7	1384	32	developed	develop	VBN
cord-034340-3ksfpaf7	1384	33	and	and	CC
cord-034340-3ksfpaf7	1384	34	optimized	optimize	VBN
cord-034340-3ksfpaf7	1384	35	to	to	TO
cord-034340-3ksfpaf7	1384	36	be	be	VB
cord-034340-3ksfpaf7	1384	37	tested	test	VBN
cord-034340-3ksfpaf7	1384	38	.	.	.
cord-034340-3ksfpaf7	1385	1	Their	-PRON-	PRP$
cord-034340-3ksfpaf7	1385	2	performance	performance	NN
cord-034340-3ksfpaf7	1385	3	has	have	VBZ
cord-034340-3ksfpaf7	1385	4	been	be	VBN
cord-034340-3ksfpaf7	1385	5	compared	compare	VBN
cord-034340-3ksfpaf7	1385	6	with	with	IN
cord-034340-3ksfpaf7	1385	7	commercial	commercial	JJ
cord-034340-3ksfpaf7	1385	8	ELISA	ELISA	NNP
cord-034340-3ksfpaf7	1385	9	kit	kit	NN
cord-034340-3ksfpaf7	1385	10	and	and	CC
cord-034340-3ksfpaf7	1385	11	a	a	DT
cord-034340-3ksfpaf7	1385	12	SPR	SPR	NNP
cord-034340-3ksfpaf7	1385	13	-	-	HYPH
cord-034340-3ksfpaf7	1385	14	based	base	VBN
cord-034340-3ksfpaf7	1385	15	optical	optical	JJ
cord-034340-3ksfpaf7	1385	16	assay	assay	NN
cord-034340-3ksfpaf7	1385	17	(	(	-LRB-
cord-034340-3ksfpaf7	1385	18	Biacore	Biacore	NNP
cord-034340-3ksfpaf7	1385	19	®	®	NNP
cord-034340-3ksfpaf7	1385	20	)	)	-RRB-
cord-034340-3ksfpaf7	1385	21	.	.	.
cord-034340-3ksfpaf7	1386	1	Assays	assay	NNS
cord-034340-3ksfpaf7	1386	2	have	have	VBP
cord-034340-3ksfpaf7	1386	3	been	be	VBN
cord-034340-3ksfpaf7	1386	4	performed	perform	VBN
cord-034340-3ksfpaf7	1386	5	in	in	IN
cord-034340-3ksfpaf7	1386	6	sera	sera	NNP
cord-034340-3ksfpaf7	1386	7	of	of	IN
cord-034340-3ksfpaf7	1386	8	a	a	DT
cord-034340-3ksfpaf7	1386	9	cohort	cohort	NN
cord-034340-3ksfpaf7	1386	10	of	of	IN
cord-034340-3ksfpaf7	1386	11	children	child	NNS
cord-034340-3ksfpaf7	1386	12	receiving	receive	VBG
cord-034340-3ksfpaf7	1386	13	Adalimumab	Adalimumab	NNP
cord-034340-3ksfpaf7	1386	14	due	due	IN
cord-034340-3ksfpaf7	1386	15	to	to	IN
cord-034340-3ksfpaf7	1386	16	an	an	DT
cord-034340-3ksfpaf7	1386	17	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1386	18	chronic	chronic	JJ
cord-034340-3ksfpaf7	1386	19	disease	disease	NN
cord-034340-3ksfpaf7	1386	20	.	.	.
cord-034340-3ksfpaf7	1387	1	Mean	mean	JJ
cord-034340-3ksfpaf7	1387	2	age	age	NN
cord-034340-3ksfpaf7	1387	3	,	,	,
cord-034340-3ksfpaf7	1387	4	disease	disease	NN
cord-034340-3ksfpaf7	1387	5	duration	duration	NN
cord-034340-3ksfpaf7	1387	6	,	,	,
cord-034340-3ksfpaf7	1387	7	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	1387	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1387	9	with	with	IN
cord-034340-3ksfpaf7	1387	10	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	1387	11	(	(	-LRB-
cord-034340-3ksfpaf7	1387	12	MTX	MTX	NNP
cord-034340-3ksfpaf7	1387	13	)	)	-RRB-
cord-034340-3ksfpaf7	1387	14	,	,	,
cord-034340-3ksfpaf7	1387	15	ANA	ANA	NNP
cord-034340-3ksfpaf7	1387	16	positivity	positivity	NN
cord-034340-3ksfpaf7	1387	17	,	,	,
cord-034340-3ksfpaf7	1387	18	disease	disease	NN
cord-034340-3ksfpaf7	1387	19	activity	activity	NN
cord-034340-3ksfpaf7	1387	20	parameters	parameter	NNS
cord-034340-3ksfpaf7	1387	21	and	and	CC
cord-034340-3ksfpaf7	1387	22	scores	score	NNS
cord-034340-3ksfpaf7	1387	23	at	at	IN
cord-034340-3ksfpaf7	1387	24	the	the	DT
cord-034340-3ksfpaf7	1387	25	time	time	NN
cord-034340-3ksfpaf7	1387	26	of	of	IN
cord-034340-3ksfpaf7	1387	27	ADA	ADA	NNP
cord-034340-3ksfpaf7	1387	28	determination	determination	NN
cord-034340-3ksfpaf7	1387	29	have	have	VBP
cord-034340-3ksfpaf7	1387	30	been	be	VBN
cord-034340-3ksfpaf7	1387	31	recorded	record	VBN
cord-034340-3ksfpaf7	1387	32	.	.	.
cord-034340-3ksfpaf7	1388	1	Chisquare	Chisquare	NNP
cord-034340-3ksfpaf7	1388	2	,	,	,
cord-034340-3ksfpaf7	1388	3	and	and	CC
cord-034340-3ksfpaf7	1388	4	Fisher	Fisher	NNP
cord-034340-3ksfpaf7	1388	5	exact	exact	JJ
cord-034340-3ksfpaf7	1388	6	test	test	NN
cord-034340-3ksfpaf7	1388	7	were	be	VBD
cord-034340-3ksfpaf7	1388	8	used	use	VBN
cord-034340-3ksfpaf7	1388	9	to	to	TO
cord-034340-3ksfpaf7	1388	10	compare	compare	VB
cord-034340-3ksfpaf7	1388	11	data	datum	NNS
cord-034340-3ksfpaf7	1388	12	.	.	.
cord-034340-3ksfpaf7	1389	1	Pearson	Pearson	NNP
cord-034340-3ksfpaf7	1389	2	's	's	POS
cord-034340-3ksfpaf7	1389	3	and	and	CC
cord-034340-3ksfpaf7	1389	4	Spearman	Spearman	NNP
cord-034340-3ksfpaf7	1389	5	's	's	POS
cord-034340-3ksfpaf7	1389	6	correlation	correlation	NN
cord-034340-3ksfpaf7	1389	7	tests	test	NNS
cord-034340-3ksfpaf7	1389	8	were	be	VBD
cord-034340-3ksfpaf7	1389	9	used	use	VBN
cord-034340-3ksfpaf7	1389	10	to	to	TO
cord-034340-3ksfpaf7	1389	11	determine	determine	VB
cord-034340-3ksfpaf7	1389	12	correlation	correlation	NN
cord-034340-3ksfpaf7	1389	13	coefficients	coefficient	NNS
cord-034340-3ksfpaf7	1389	14	for	for	IN
cord-034340-3ksfpaf7	1389	15	entered	enter	VBN
cord-034340-3ksfpaf7	1389	16	variables	variable	NNS
cord-034340-3ksfpaf7	1389	17	.	.	.
cord-034340-3ksfpaf7	1390	1	Results	result	NNS
cord-034340-3ksfpaf7	1390	2	:	:	:
cord-034340-3ksfpaf7	1390	3	Eighteen	eighteen	CD
cord-034340-3ksfpaf7	1390	4	(	(	-LRB-
cord-034340-3ksfpaf7	1390	5	14	14	CD
cord-034340-3ksfpaf7	1390	6	F	F	NNP
cord-034340-3ksfpaf7	1390	7	,	,	,
cord-034340-3ksfpaf7	1390	8	median	median	JJ
cord-034340-3ksfpaf7	1390	9	age	age	NN
cord-034340-3ksfpaf7	1390	10	12.6	12.6	CD
cord-034340-3ksfpaf7	1390	11	,	,	,
cord-034340-3ksfpaf7	1390	12	range	range	VBP
cord-034340-3ksfpaf7	1390	13	3.8	3.8	CD
cord-034340-3ksfpaf7	1390	14	-	-	SYM
cord-034340-3ksfpaf7	1390	15	16	16	CD
cord-034340-3ksfpaf7	1390	16	,	,	,
cord-034340-3ksfpaf7	1390	17	yrs	yr	NNS
cord-034340-3ksfpaf7	1390	18	)	)	-RRB-
cord-034340-3ksfpaf7	1390	19	patients	patient	NNS
cord-034340-3ksfpaf7	1390	20	were	be	VBD
cord-034340-3ksfpaf7	1390	21	enrolled	enrol	VBN
cord-034340-3ksfpaf7	1390	22	:	:	:
cord-034340-3ksfpaf7	1390	23	16	16	CD
cord-034340-3ksfpaf7	1390	24	affected	affect	VBN
cord-034340-3ksfpaf7	1390	25	by	by	IN
cord-034340-3ksfpaf7	1390	26	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	1390	27	Idiopathic	Idiopathic	NNP
cord-034340-3ksfpaf7	1390	28	Arthritis	Arthritis	NNP
cord-034340-3ksfpaf7	1390	29	,	,	,
cord-034340-3ksfpaf7	1390	30	7	7	CD
cord-034340-3ksfpaf7	1390	31	of	of	IN
cord-034340-3ksfpaf7	1390	32	whom	whom	WP
cord-034340-3ksfpaf7	1390	33	complicated	complicate	VBN
cord-034340-3ksfpaf7	1390	34	by	by	IN
cord-034340-3ksfpaf7	1390	35	JIA	JIA	NNP
cord-034340-3ksfpaf7	1390	36	-associated	-associate	VBD
cord-034340-3ksfpaf7	1390	37	chronic	chronic	JJ
cord-034340-3ksfpaf7	1390	38	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1390	39	,	,	,
cord-034340-3ksfpaf7	1390	40	and	and	CC
cord-034340-3ksfpaf7	1390	41	2	2	CD
cord-034340-3ksfpaf7	1390	42	patients	patient	NNS
cord-034340-3ksfpaf7	1390	43	affected	affect	VBN
cord-034340-3ksfpaf7	1390	44	by	by	IN
cord-034340-3ksfpaf7	1390	45	chronic	chronic	JJ
cord-034340-3ksfpaf7	1390	46	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1390	47	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1390	48	.	.	.
cord-034340-3ksfpaf7	1391	1	Peptide	peptide	NN
cord-034340-3ksfpaf7	1391	2	assay	assay	NN
cord-034340-3ksfpaf7	1391	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1391	4	ADAs	ADAs	NNP
cord-034340-3ksfpaf7	1391	5	in	in	IN
cord-034340-3ksfpaf7	1391	6	8	8	CD
cord-034340-3ksfpaf7	1391	7	children	child	NNS
cord-034340-3ksfpaf7	1391	8	,	,	,
cord-034340-3ksfpaf7	1391	9	Biacore	Biacore	NNP
cord-034340-3ksfpaf7	1391	10	in	in	IN
cord-034340-3ksfpaf7	1391	11	6	6	CD
cord-034340-3ksfpaf7	1391	12	,	,	,
cord-034340-3ksfpaf7	1391	13	commercial	commercial	JJ
cord-034340-3ksfpaf7	1391	14	Elisa	Elisa	NNP
cord-034340-3ksfpaf7	1391	15	in	in	IN
cord-034340-3ksfpaf7	1391	16	5	5	CD
cord-034340-3ksfpaf7	1391	17	.	.	.
cord-034340-3ksfpaf7	1392	1	Of	of	IN
cord-034340-3ksfpaf7	1392	2	note	note	NN
cord-034340-3ksfpaf7	1392	3	,	,	,
cord-034340-3ksfpaf7	1392	4	we	-PRON-	PRP
cord-034340-3ksfpaf7	1392	5	found	find	VBD
cord-034340-3ksfpaf7	1392	6	total	total	JJ
cord-034340-3ksfpaf7	1392	7	concordance	concordance	NN
cord-034340-3ksfpaf7	1392	8	among	among	IN
cord-034340-3ksfpaf7	1392	9	the	the	DT
cord-034340-3ksfpaf7	1392	10	3	3	CD
cord-034340-3ksfpaf7	1392	11	tests	test	NNS
cord-034340-3ksfpaf7	1392	12	just	just	RB
cord-034340-3ksfpaf7	1392	13	in	in	IN
cord-034340-3ksfpaf7	1392	14	2	2	CD
cord-034340-3ksfpaf7	1392	15	patients	patient	NNS
cord-034340-3ksfpaf7	1392	16	.	.	.
cord-034340-3ksfpaf7	1393	1	No	no	DT
cord-034340-3ksfpaf7	1393	2	significant	significant	JJ
cord-034340-3ksfpaf7	1393	3	correlation	correlation	NN
cord-034340-3ksfpaf7	1393	4	has	have	VBZ
cord-034340-3ksfpaf7	1393	5	been	be	VBN
cord-034340-3ksfpaf7	1393	6	proven	prove	VBN
cord-034340-3ksfpaf7	1393	7	among	among	IN
cord-034340-3ksfpaf7	1393	8	the	the	DT
cord-034340-3ksfpaf7	1393	9	3	3	CD
cord-034340-3ksfpaf7	1393	10	ADA	ADA	NNP
cord-034340-3ksfpaf7	1393	11	determinations	determination	NNS
cord-034340-3ksfpaf7	1393	12	.	.	.
cord-034340-3ksfpaf7	1394	1	Biacore	Biacore	NNP
cord-034340-3ksfpaf7	1394	2	and	and	CC
cord-034340-3ksfpaf7	1394	3	ELISA	ELISA	NNP
cord-034340-3ksfpaf7	1394	4	determination	determination	NN
cord-034340-3ksfpaf7	1394	5	showed	show	VBD
cord-034340-3ksfpaf7	1394	6	significant	significant	JJ
cord-034340-3ksfpaf7	1394	7	concordance	concordance	NN
cord-034340-3ksfpaf7	1394	8	(	(	-LRB-
cord-034340-3ksfpaf7	1394	9	r	r	NNP
cord-034340-3ksfpaf7	1394	10	s	s	NN
cord-034340-3ksfpaf7	1394	11	:	:	:
cord-034340-3ksfpaf7	1394	12	0.72	0.72	CD
cord-034340-3ksfpaf7	1394	13	,	,	,
cord-034340-3ksfpaf7	1394	14	p<0.006	p<0.006	CD
cord-034340-3ksfpaf7	1394	15	)	)	-RRB-
cord-034340-3ksfpaf7	1394	16	.	.	.
cord-034340-3ksfpaf7	1395	1	The	the	DT
cord-034340-3ksfpaf7	1395	2	presence	presence	NN
cord-034340-3ksfpaf7	1395	3	of	of	IN
cord-034340-3ksfpaf7	1395	4	HC	HC	NNP
cord-034340-3ksfpaf7	1395	5	CDR3	CDR3	NNP
cord-034340-3ksfpaf7	1395	6	and	and	CC
cord-034340-3ksfpaf7	1395	7	LC	LC	NNP
cord-034340-3ksfpaf7	1395	8	CDR	CDR	NNP
cord-034340-3ksfpaf7	1395	9	3	3	CD
cord-034340-3ksfpaf7	1395	10	resulted	result	VBD
cord-034340-3ksfpaf7	1395	11	significantly	significantly	RB
cord-034340-3ksfpaf7	1395	12	correlated	correlate	VBN
cord-034340-3ksfpaf7	1395	13	with	with	IN
cord-034340-3ksfpaf7	1395	14	disease	disease	NN
cord-034340-3ksfpaf7	1395	15	activity	activity	NN
cord-034340-3ksfpaf7	1395	16	(	(	-LRB-
cord-034340-3ksfpaf7	1395	17	r	r	NNP
cord-034340-3ksfpaf7	1395	18	s	s	NN
cord-034340-3ksfpaf7	1395	19	:	:	:
cord-034340-3ksfpaf7	1395	20	0.57	0.57	CD
cord-034340-3ksfpaf7	1395	21	,	,	,
cord-034340-3ksfpaf7	1395	22	p<0.05	p<0.05	CD
cord-034340-3ksfpaf7	1395	23	)	)	-RRB-
cord-034340-3ksfpaf7	1395	24	,	,	,
cord-034340-3ksfpaf7	1395	25	and	and	CC
cord-034340-3ksfpaf7	1395	26	,	,	,
cord-034340-3ksfpaf7	1395	27	inversely	inversely	RB
cord-034340-3ksfpaf7	1395	28	,	,	,
cord-034340-3ksfpaf7	1395	29	with	with	IN
cord-034340-3ksfpaf7	1395	30	disease	disease	NN
cord-034340-3ksfpaf7	1395	31	remission	remission	NN
cord-034340-3ksfpaf7	1395	32	on	on	IN
cord-034340-3ksfpaf7	1395	33	treatment	treatment	NN
cord-034340-3ksfpaf7	1395	34	(	(	-LRB-
cord-034340-3ksfpaf7	1395	35	r	r	NN
cord-034340-3ksfpaf7	1395	36	s	s	NN
cord-034340-3ksfpaf7	1396	1	=	=	SYM
cord-034340-3ksfpaf7	1396	2	-0.523	-0.523	NNP
cord-034340-3ksfpaf7	1396	3	,	,	,
cord-034340-3ksfpaf7	1396	4	p<0.05	p<0.05	CD
cord-034340-3ksfpaf7	1396	5	)	)	-RRB-
cord-034340-3ksfpaf7	1396	6	.	.	.
cord-034340-3ksfpaf7	1397	1	No	no	DT
cord-034340-3ksfpaf7	1397	2	patient	patient	NN
cord-034340-3ksfpaf7	1397	3	experienced	experience	VBD
cord-034340-3ksfpaf7	1397	4	severe	severe	JJ
cord-034340-3ksfpaf7	1397	5	adverse	adverse	JJ
cord-034340-3ksfpaf7	1397	6	events	event	NNS
cord-034340-3ksfpaf7	1397	7	and	and	CC
cord-034340-3ksfpaf7	1397	8	no	no	DT
cord-034340-3ksfpaf7	1397	9	correlation	correlation	NN
cord-034340-3ksfpaf7	1397	10	with	with	IN
cord-034340-3ksfpaf7	1397	11	ADAs	ADAs	NNP
cord-034340-3ksfpaf7	1397	12	has	have	VBZ
cord-034340-3ksfpaf7	1397	13	been	be	VBN
cord-034340-3ksfpaf7	1397	14	revealed	reveal	VBN
cord-034340-3ksfpaf7	1397	15	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1397	16	:	:	:
cord-034340-3ksfpaf7	1398	1	In	in	IN
cord-034340-3ksfpaf7	1398	2	chronic	chronic	JJ
cord-034340-3ksfpaf7	1398	3	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1398	4	disorders	disorder	NNS
cord-034340-3ksfpaf7	1398	5	,	,	,
cord-034340-3ksfpaf7	1398	6	novel	novel	JJ
cord-034340-3ksfpaf7	1398	7	reliable	reliable	JJ
cord-034340-3ksfpaf7	1398	8	methods	method	NNS
cord-034340-3ksfpaf7	1398	9	are	be	VBP
cord-034340-3ksfpaf7	1398	10	urgently	urgently	RB
cord-034340-3ksfpaf7	1398	11	required	require	VBN
cord-034340-3ksfpaf7	1398	12	to	to	TO
cord-034340-3ksfpaf7	1398	13	guide	guide	VB
cord-034340-3ksfpaf7	1398	14	clinical	clinical	JJ
cord-034340-3ksfpaf7	1398	15	decision	decision	NN
cord-034340-3ksfpaf7	1398	16	and	and	CC
cord-034340-3ksfpaf7	1398	17	support	support	NN
cord-034340-3ksfpaf7	1398	18	decisions	decision	NNS
cord-034340-3ksfpaf7	1398	19	about	about	IN
cord-034340-3ksfpaf7	1398	20	switching	switch	VBG
cord-034340-3ksfpaf7	1398	21	within	within	IN
cord-034340-3ksfpaf7	1398	22	or	or	CC
cord-034340-3ksfpaf7	1398	23	between	between	IN
cord-034340-3ksfpaf7	1398	24	drugs	drug	NNS
cord-034340-3ksfpaf7	1398	25	in	in	IN
cord-034340-3ksfpaf7	1398	26	refractory	refractory	JJ
cord-034340-3ksfpaf7	1398	27	children	child	NNS
cord-034340-3ksfpaf7	1398	28	.	.	.
cord-034340-3ksfpaf7	1399	1	The	the	DT
cord-034340-3ksfpaf7	1399	2	3	3	CD
cord-034340-3ksfpaf7	1399	3	different	different	JJ
cord-034340-3ksfpaf7	1399	4	methods	method	NNS
cord-034340-3ksfpaf7	1399	5	,	,	,
cord-034340-3ksfpaf7	1399	6	since	since	IN
cord-034340-3ksfpaf7	1399	7	based	base	VBN
cord-034340-3ksfpaf7	1399	8	on	on	IN
cord-034340-3ksfpaf7	1399	9	different	different	JJ
cord-034340-3ksfpaf7	1399	10	antigenic	antigenic	JJ
cord-034340-3ksfpaf7	1399	11	probes	probe	NNS
cord-034340-3ksfpaf7	1399	12	,	,	,
cord-034340-3ksfpaf7	1399	13	detect	detect	VB
cord-034340-3ksfpaf7	1399	14	different	different	JJ
cord-034340-3ksfpaf7	1399	15	antibody	antibody	NN
cord-034340-3ksfpaf7	1399	16	populations	population	NNS
cord-034340-3ksfpaf7	1399	17	.	.	.
cord-034340-3ksfpaf7	1400	1	The	the	DT
cord-034340-3ksfpaf7	1400	2	present	present	JJ
cord-034340-3ksfpaf7	1400	3	peptide	peptide	NN
cord-034340-3ksfpaf7	1400	4	-	-	HYPH
cord-034340-3ksfpaf7	1400	5	based	base	VBN
cord-034340-3ksfpaf7	1400	6	assays	assay	NNS
cord-034340-3ksfpaf7	1400	7	might	may	MD
cord-034340-3ksfpaf7	1400	8	contribute	contribute	VB
cord-034340-3ksfpaf7	1400	9	to	to	TO
cord-034340-3ksfpaf7	1400	10	identify	identify	VB
cord-034340-3ksfpaf7	1400	11	neutralizing	neutralize	VBG
cord-034340-3ksfpaf7	1400	12	ADAs	ada	NNS
cord-034340-3ksfpaf7	1400	13	in	in	IN
cord-034340-3ksfpaf7	1400	14	patients	patient	NNS
cord-034340-3ksfpaf7	1400	15	treated	treat	VBN
cord-034340-3ksfpaf7	1400	16	with	with	IN
cord-034340-3ksfpaf7	1400	17	Adalimumab	Adalimumab	NNP
cord-034340-3ksfpaf7	1400	18	.	.	.
cord-034340-3ksfpaf7	1401	1	Further	further	JJ
cord-034340-3ksfpaf7	1401	2	validation	validation	NN
cord-034340-3ksfpaf7	1401	3	in	in	IN
cord-034340-3ksfpaf7	1401	4	larger	large	JJR
cord-034340-3ksfpaf7	1401	5	cohort	cohort	NN
cord-034340-3ksfpaf7	1401	6	is	be	VBZ
cord-034340-3ksfpaf7	1401	7	required	require	VBN
cord-034340-3ksfpaf7	1401	8	.	.	.
cord-034340-3ksfpaf7	1402	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1402	2	:	:	:
cord-034340-3ksfpaf7	1403	1	Non	non	JJ
cord-034340-3ksfpaf7	1403	2	-	-	JJ
cord-034340-3ksfpaf7	1403	3	bacterial	bacterial	JJ
cord-034340-3ksfpaf7	1403	4	multifocal	multifocal	JJ
cord-034340-3ksfpaf7	1403	5	osteomyelitis	osteomyelitis	NN
cord-034340-3ksfpaf7	1403	6	(	(	-LRB-
cord-034340-3ksfpaf7	1403	7	NBO	NBO	NNP
cord-034340-3ksfpaf7	1403	8	)	)	-RRB-
cord-034340-3ksfpaf7	1403	9	is	be	VBZ
cord-034340-3ksfpaf7	1403	10	a	a	DT
cord-034340-3ksfpaf7	1403	11	rare	rare	JJ
cord-034340-3ksfpaf7	1403	12	polygenic	polygenic	JJ
cord-034340-3ksfpaf7	1403	13	autoinflammatory	autoinflammatory	NNP
cord-034340-3ksfpaf7	1403	14	disease	disease	NN
cord-034340-3ksfpaf7	1403	15	,	,	,
cord-034340-3ksfpaf7	1403	16	which	which	WDT
cord-034340-3ksfpaf7	1403	17	is	be	VBZ
cord-034340-3ksfpaf7	1403	18	difficult	difficult	JJ
cord-034340-3ksfpaf7	1403	19	to	to	TO
cord-034340-3ksfpaf7	1403	20	diagnose	diagnose	VB
cord-034340-3ksfpaf7	1403	21	and	and	CC
cord-034340-3ksfpaf7	1403	22	treat	treat	VB
cord-034340-3ksfpaf7	1403	23	.	.	.
cord-034340-3ksfpaf7	1404	1	Because	because	IN
cord-034340-3ksfpaf7	1404	2	of	of	IN
cord-034340-3ksfpaf7	1404	3	combination	combination	NN
cord-034340-3ksfpaf7	1404	4	of	of	IN
cord-034340-3ksfpaf7	1404	5	bone	bone	NN
cord-034340-3ksfpaf7	1404	6	lesions	lesion	NNS
cord-034340-3ksfpaf7	1404	7	with	with	IN
cord-034340-3ksfpaf7	1404	8	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1404	9	and/	and/	NNP
cord-034340-3ksfpaf7	1404	10	or	or	CC
cord-034340-3ksfpaf7	1404	11	axial	axial	JJ
cord-034340-3ksfpaf7	1404	12	skeleton	skeleton	NN
cord-034340-3ksfpaf7	1404	13	damage	damage	NN
cord-034340-3ksfpaf7	1404	14	in	in	IN
cord-034340-3ksfpaf7	1404	15	most	most	JJS
cord-034340-3ksfpaf7	1404	16	cases	case	NNS
cord-034340-3ksfpaf7	1404	17	the	the	DT
cord-034340-3ksfpaf7	1404	18	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1404	19	of	of	IN
cord-034340-3ksfpaf7	1404	20	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1404	21	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1404	22	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1404	23	(	(	-LRB-
cord-034340-3ksfpaf7	1404	24	JIA	JIA	NNP
cord-034340-3ksfpaf7	1404	25	)	)	-RRB-
cord-034340-3ksfpaf7	1404	26	or	or	CC
cord-034340-3ksfpaf7	1404	27	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1404	28	ankylosing	ankylosing	NN
cord-034340-3ksfpaf7	1404	29	spondylitis	spondylitis	NN
cord-034340-3ksfpaf7	1404	30	(	(	-LRB-
cord-034340-3ksfpaf7	1404	31	JAS	JAS	NNP
cord-034340-3ksfpaf7	1404	32	)	)	-RRB-
cord-034340-3ksfpaf7	1404	33	may	may	MD
cord-034340-3ksfpaf7	1404	34	be	be	VB
cord-034340-3ksfpaf7	1404	35	establish	establish	VB
cord-034340-3ksfpaf7	1404	36	as	as	IN
cord-034340-3ksfpaf7	1404	37	a	a	DT
cord-034340-3ksfpaf7	1404	38	concurrent	concurrent	JJ
cord-034340-3ksfpaf7	1404	39	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1404	40	,	,	,
cord-034340-3ksfpaf7	1404	41	so	so	CC
cord-034340-3ksfpaf7	1404	42	this	this	DT
cord-034340-3ksfpaf7	1404	43	allows	allow	VBZ
cord-034340-3ksfpaf7	1404	44	to	to	IN
cord-034340-3ksfpaf7	1404	45	legal	legal	JJ
cord-034340-3ksfpaf7	1404	46	use	use	NN
cord-034340-3ksfpaf7	1404	47	of	of	IN
cord-034340-3ksfpaf7	1404	48	Biologics	Biologics	NNP
cord-034340-3ksfpaf7	1404	49	(	(	-LRB-
cord-034340-3ksfpaf7	1404	50	BA	BA	NNP
cord-034340-3ksfpaf7	1404	51	)	)	-RRB-
cord-034340-3ksfpaf7	1404	52	for	for	IN
cord-034340-3ksfpaf7	1404	53	the	the	DT
cord-034340-3ksfpaf7	1404	54	treatment	treatment	NN
cord-034340-3ksfpaf7	1404	55	.	.	.
cord-034340-3ksfpaf7	1405	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1405	2	:	:	:
cord-034340-3ksfpaf7	1405	3	To	to	TO
cord-034340-3ksfpaf7	1405	4	analyze	analyze	VB
cord-034340-3ksfpaf7	1405	5	the	the	DT
cord-034340-3ksfpaf7	1405	6	single	single	JJ
cord-034340-3ksfpaf7	1405	7	center	center	NN
cord-034340-3ksfpaf7	1405	8	experience	experience	NN
cord-034340-3ksfpaf7	1405	9	of	of	IN
cord-034340-3ksfpaf7	1405	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	1405	11	and	and	CC
cord-034340-3ksfpaf7	1405	12	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1405	13	features	feature	NNS
cord-034340-3ksfpaf7	1405	14	of	of	IN
cord-034340-3ksfpaf7	1405	15	multifocal	multifocal	JJ
cord-034340-3ksfpaf7	1405	16	NBO	NBO	NNP
cord-034340-3ksfpaf7	1405	17	in	in	IN
cord-034340-3ksfpaf7	1405	18	patients	patient	NNS
cord-034340-3ksfpaf7	1405	19	(	(	-LRB-
cord-034340-3ksfpaf7	1405	20	pts	pts	NN
cord-034340-3ksfpaf7	1405	21	)	)	-RRB-
cord-034340-3ksfpaf7	1405	22	who	who	WP
cord-034340-3ksfpaf7	1405	23	were	be	VBD
cord-034340-3ksfpaf7	1405	24	treated	treat	VBN
cord-034340-3ksfpaf7	1405	25	by	by	IN
cord-034340-3ksfpaf7	1405	26	BA	BA	NNP
cord-034340-3ksfpaf7	1405	27	for	for	IN
cord-034340-3ksfpaf7	1405	28	the	the	DT
cord-034340-3ksfpaf7	1405	29	last	last	JJ
cord-034340-3ksfpaf7	1405	30	8	8	CD
cord-034340-3ksfpaf7	1405	31	years	year	NNS
cord-034340-3ksfpaf7	1405	32	.	.	.
cord-034340-3ksfpaf7	1406	1	Methods	method	NNS
cord-034340-3ksfpaf7	1406	2	:	:	:
cord-034340-3ksfpaf7	1407	1	The	the	DT
cord-034340-3ksfpaf7	1407	2	study	study	NN
cord-034340-3ksfpaf7	1407	3	involved	involve	VBD
cord-034340-3ksfpaf7	1407	4	a	a	DT
cord-034340-3ksfpaf7	1407	5	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1407	6	cohort	cohort	NN
cord-034340-3ksfpaf7	1407	7	of	of	IN
cord-034340-3ksfpaf7	1407	8	multifocal	multifocal	JJ
cord-034340-3ksfpaf7	1407	9	NBO	NBO	NNP
cord-034340-3ksfpaf7	1407	10	pts	pts	XX
cord-034340-3ksfpaf7	1407	11	treated	treat	VBN
cord-034340-3ksfpaf7	1407	12	by	by	IN
cord-034340-3ksfpaf7	1407	13	different	different	JJ
cord-034340-3ksfpaf7	1407	14	BA	BA	NNP
cord-034340-3ksfpaf7	1407	15	in	in	IN
cord-034340-3ksfpaf7	1407	16	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1407	17	clinic	clinic	NN
cord-034340-3ksfpaf7	1407	18	from	from	IN
cord-034340-3ksfpaf7	1407	19	2013	2013	CD
cord-034340-3ksfpaf7	1407	20	to	to	IN
cord-034340-3ksfpaf7	1407	21	2020	2020	CD
cord-034340-3ksfpaf7	1407	22	.	.	.
cord-034340-3ksfpaf7	1408	1	All	all	DT
cord-034340-3ksfpaf7	1408	2	of	of	IN
cord-034340-3ksfpaf7	1408	3	them	-PRON-	PRP
cord-034340-3ksfpaf7	1408	4	underwent	undergo	VBD
cord-034340-3ksfpaf7	1408	5	standard	standard	JJ
cord-034340-3ksfpaf7	1408	6	rheumatological	rheumatological	JJ
cord-034340-3ksfpaf7	1408	7	examination	examination	NN
cord-034340-3ksfpaf7	1408	8	.	.	.
cord-034340-3ksfpaf7	1409	1	In	in	IN
cord-034340-3ksfpaf7	1409	2	order	order	NN
cord-034340-3ksfpaf7	1409	3	to	to	TO
cord-034340-3ksfpaf7	1409	4	examine	examine	VB
cord-034340-3ksfpaf7	1409	5	all	all	DT
cord-034340-3ksfpaf7	1409	6	localizations	localization	NNS
cord-034340-3ksfpaf7	1409	7	of	of	IN
cord-034340-3ksfpaf7	1409	8	the	the	DT
cord-034340-3ksfpaf7	1409	9	bone	bone	NN
cord-034340-3ksfpaf7	1409	10	damage	damage	NN
cord-034340-3ksfpaf7	1409	11	,	,	,
cord-034340-3ksfpaf7	1409	12	a	a	DT
cord-034340-3ksfpaf7	1409	13	scintigraphy	scintigraphy	NN
cord-034340-3ksfpaf7	1409	14	and/	and/	NN
cord-034340-3ksfpaf7	1409	15	or	or	CC
cord-034340-3ksfpaf7	1409	16	"	"	``
cord-034340-3ksfpaf7	1409	17	whole	whole	JJ
cord-034340-3ksfpaf7	1409	18	body	body	NN
cord-034340-3ksfpaf7	1409	19	"	"	''
cord-034340-3ksfpaf7	1409	20	MRI	MRI	NNP
cord-034340-3ksfpaf7	1409	21	scan	scan	NN
cord-034340-3ksfpaf7	1409	22	was	be	VBD
cord-034340-3ksfpaf7	1409	23	performed	perform	VBN
cord-034340-3ksfpaf7	1409	24	.	.	.
cord-034340-3ksfpaf7	1410	1	Results	result	NNS
cord-034340-3ksfpaf7	1410	2	:	:	:
cord-034340-3ksfpaf7	1411	1	Among	among	IN
cord-034340-3ksfpaf7	1411	2	the	the	DT
cord-034340-3ksfpaf7	1411	3	whole	whole	JJ
cord-034340-3ksfpaf7	1411	4	group	group	NN
cord-034340-3ksfpaf7	1411	5	of	of	IN
cord-034340-3ksfpaf7	1411	6	pts	pts	NN
cord-034340-3ksfpaf7	1411	7	with	with	IN
cord-034340-3ksfpaf7	1411	8	NBO	NBO	NNP
cord-034340-3ksfpaf7	1411	9	(	(	-LRB-
cord-034340-3ksfpaf7	1411	10	n=40	n=40	JJ
cord-034340-3ksfpaf7	1411	11	)	)	-RRB-
cord-034340-3ksfpaf7	1411	12	we	-PRON-	PRP
cord-034340-3ksfpaf7	1411	13	identified	identify	VBD
cord-034340-3ksfpaf7	1411	14	13	13	CD
cord-034340-3ksfpaf7	1411	15	pts	pt	NNS
cord-034340-3ksfpaf7	1411	16	treated	treat	VBN
cord-034340-3ksfpaf7	1411	17	by	by	IN
cord-034340-3ksfpaf7	1411	18	BA	BA	NNP
cord-034340-3ksfpaf7	1411	19	(	(	-LRB-
cord-034340-3ksfpaf7	1411	20	TNF	TNF	NNP
cord-034340-3ksfpaf7	1411	21	-	-	HYPH
cord-034340-3ksfpaf7	1411	22	inhibitors	inhibitors	NNP
cord-034340-3ksfpaf7	1411	23	only	only	RB
cord-034340-3ksfpaf7	1411	24	)	)	-RRB-
cord-034340-3ksfpaf7	1411	25	.	.	.
cord-034340-3ksfpaf7	1412	1	The	the	DT
cord-034340-3ksfpaf7	1412	2	majority	majority	NN
cord-034340-3ksfpaf7	1412	3	were	be	VBD
cord-034340-3ksfpaf7	1412	4	girls	girl	NNS
cord-034340-3ksfpaf7	1412	5	(	(	-LRB-
cord-034340-3ksfpaf7	1412	6	n=9	n=9	NN
cord-034340-3ksfpaf7	1412	7	,	,	,
cord-034340-3ksfpaf7	1412	8	69	69	CD
cord-034340-3ksfpaf7	1412	9	%	%	NN
cord-034340-3ksfpaf7	1412	10	)	)	-RRB-
cord-034340-3ksfpaf7	1412	11	.	.	.
cord-034340-3ksfpaf7	1413	1	Age	age	NN
cord-034340-3ksfpaf7	1413	2	at	at	IN
cord-034340-3ksfpaf7	1413	3	disease	disease	NN
cord-034340-3ksfpaf7	1413	4	onset	onset	NN
cord-034340-3ksfpaf7	1413	5	was	be	VBD
cord-034340-3ksfpaf7	1413	6	10.2	10.2	CD
cord-034340-3ksfpaf7	1413	7	years	year	NNS
cord-034340-3ksfpaf7	1413	8	in	in	IN
cord-034340-3ksfpaf7	1413	9	average	average	JJ
cord-034340-3ksfpaf7	1413	10	(	(	-LRB-
cord-034340-3ksfpaf7	1413	11	Me	Me	NNP
cord-034340-3ksfpaf7	1413	12	10.2	10.2	CD
cord-034340-3ksfpaf7	1413	13	range	range	VBP
cord-034340-3ksfpaf7	1413	14	1.3	1.3	CD
cord-034340-3ksfpaf7	1413	15	-	-	HYPH
cord-034340-3ksfpaf7	1413	16	16.5	16.5	CD
cord-034340-3ksfpaf7	1413	17	)	)	-RRB-
cord-034340-3ksfpaf7	1413	18	.	.	.
cord-034340-3ksfpaf7	1414	1	For	for	IN
cord-034340-3ksfpaf7	1414	2	legal	legal	JJ
cord-034340-3ksfpaf7	1414	3	reason	reason	NN
cord-034340-3ksfpaf7	1414	4	of	of	IN
cord-034340-3ksfpaf7	1414	5	BA	BA	NNP
cord-034340-3ksfpaf7	1414	6	administration	administration	NN
cord-034340-3ksfpaf7	1414	7	,	,	,
cord-034340-3ksfpaf7	1414	8	we	-PRON-	PRP
cord-034340-3ksfpaf7	1414	9	classified	classify	VBD
cord-034340-3ksfpaf7	1414	10	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1414	11	patients	patient	NNS
cord-034340-3ksfpaf7	1414	12	according	accord	VBG
cord-034340-3ksfpaf7	1414	13	to	to	IN
cord-034340-3ksfpaf7	1414	14	rheumatological	rheumatological	JJ
cord-034340-3ksfpaf7	1414	15	features	feature	NNS
cord-034340-3ksfpaf7	1414	16	as	as	IN
cord-034340-3ksfpaf7	1414	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	1414	18	or	or	CC
cord-034340-3ksfpaf7	1414	19	JAS	JAS	NNP
cord-034340-3ksfpaf7	1414	20	.	.	.
cord-034340-3ksfpaf7	1415	1	7	7	CD
cord-034340-3ksfpaf7	1415	2	pts	pt	NNS
cord-034340-3ksfpaf7	1415	3	had	have	VBD
cord-034340-3ksfpaf7	1415	4	JIA	JIA	NNP
cord-034340-3ksfpaf7	1415	5	(	(	-LRB-
cord-034340-3ksfpaf7	1415	6	5	5	CD
cord-034340-3ksfpaf7	1415	7	girls	girl	NNS
cord-034340-3ksfpaf7	1415	8	)	)	-RRB-
cord-034340-3ksfpaf7	1415	9	,	,	,
cord-034340-3ksfpaf7	1415	10	6	6	CD
cord-034340-3ksfpaf7	1415	11	pts	pt	NNS
cord-034340-3ksfpaf7	1415	12	had	have	VBD
cord-034340-3ksfpaf7	1415	13	JAS	JAS	NNP
cord-034340-3ksfpaf7	1415	14	(	(	-LRB-
cord-034340-3ksfpaf7	1415	15	4	4	CD
cord-034340-3ksfpaf7	1415	16	girls	girl	NNS
cord-034340-3ksfpaf7	1415	17	)	)	-RRB-
cord-034340-3ksfpaf7	1415	18	.	.	.
cord-034340-3ksfpaf7	1416	1	Among	among	IN
cord-034340-3ksfpaf7	1416	2	13	13	CD
cord-034340-3ksfpaf7	1416	3	pts	pt	NNS
cord-034340-3ksfpaf7	1416	4	9	9	CD
cord-034340-3ksfpaf7	1416	5	had	have	VBD
cord-034340-3ksfpaf7	1416	6	oligoarthritis	oligoarthritis	JJ
cord-034340-3ksfpaf7	1416	7	(	(	-LRB-
cord-034340-3ksfpaf7	1416	8	69	69	CD
cord-034340-3ksfpaf7	1416	9	%	%	NN
cord-034340-3ksfpaf7	1416	10	)	)	-RRB-
cord-034340-3ksfpaf7	1416	11	,	,	,
cord-034340-3ksfpaf7	1416	12	4	4	CD
cord-034340-3ksfpaf7	1416	13	had	have	VBD
cord-034340-3ksfpaf7	1416	14	polyarthritis	polyarthritis	NN
cord-034340-3ksfpaf7	1416	15	of	of	IN
cord-034340-3ksfpaf7	1416	16	low	low	JJ
cord-034340-3ksfpaf7	1416	17	limbs	limb	NNS
cord-034340-3ksfpaf7	1416	18	(	(	-LRB-
cord-034340-3ksfpaf7	1416	19	hip	hip	NN
cord-034340-3ksfpaf7	1416	20	,	,	,
cord-034340-3ksfpaf7	1416	21	knee	knee	NN
cord-034340-3ksfpaf7	1416	22	,	,	,
cord-034340-3ksfpaf7	1416	23	ankle	ankle	NN
cord-034340-3ksfpaf7	1416	24	)	)	-RRB-
cord-034340-3ksfpaf7	1416	25	.	.	.
cord-034340-3ksfpaf7	1417	1	Axial	axial	JJ
cord-034340-3ksfpaf7	1417	2	involvement	involvement	NN
cord-034340-3ksfpaf7	1417	3	was	be	VBD
cord-034340-3ksfpaf7	1417	4	represented	represent	VBN
cord-034340-3ksfpaf7	1417	5	by	by	IN
cord-034340-3ksfpaf7	1417	6	active	active	JJ
cord-034340-3ksfpaf7	1417	7	erosive	erosive	JJ
cord-034340-3ksfpaf7	1417	8	sacroiliitis	sacroiliitis	NN
cord-034340-3ksfpaf7	1417	9	with	with	IN
cord-034340-3ksfpaf7	1417	10	deep	deep	JJ
cord-034340-3ksfpaf7	1417	11	bone	bone	NN
cord-034340-3ksfpaf7	1417	12	marrow	marrow	NN
cord-034340-3ksfpaf7	1417	13	edema	edema	NN
cord-034340-3ksfpaf7	1417	14	on	on	IN
cord-034340-3ksfpaf7	1417	15	MRI	MRI	NNP
cord-034340-3ksfpaf7	1417	16	scan	scan	NN
cord-034340-3ksfpaf7	1417	17	in	in	IN
cord-034340-3ksfpaf7	1417	18	9	9	CD
cord-034340-3ksfpaf7	1417	19	pts	pt	NNS
cord-034340-3ksfpaf7	1417	20	(	(	-LRB-
cord-034340-3ksfpaf7	1417	21	69	69	CD
cord-034340-3ksfpaf7	1417	22	%	%	NN
cord-034340-3ksfpaf7	1417	23	)	)	-RRB-
cord-034340-3ksfpaf7	1417	24	,	,	,
cord-034340-3ksfpaf7	1417	25	active	active	JJ
cord-034340-3ksfpaf7	1417	26	spondylitis	spondylitis	NN
cord-034340-3ksfpaf7	1417	27	of	of	IN
cord-034340-3ksfpaf7	1417	28	several	several	JJ
cord-034340-3ksfpaf7	1417	29	bodies	body	NNS
cord-034340-3ksfpaf7	1417	30	in	in	IN
cord-034340-3ksfpaf7	1417	31	thoracic	thoracic	JJ
cord-034340-3ksfpaf7	1417	32	spinein	spinein	JJ
cord-034340-3ksfpaf7	1417	33	2	2	CD
cord-034340-3ksfpaf7	1417	34	;	;	,
cord-034340-3ksfpaf7	1417	35	erosive	erosive	JJ
cord-034340-3ksfpaf7	1417	36	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1417	37	with	with	IN
cord-034340-3ksfpaf7	1417	38	partial	partial	JJ
cord-034340-3ksfpaf7	1417	39	ankyloses	ankylose	NNS
cord-034340-3ksfpaf7	1417	40	of	of	IN
cord-034340-3ksfpaf7	1417	41	facet	facet	NN
cord-034340-3ksfpaf7	1417	42	joints	joint	NNS
cord-034340-3ksfpaf7	1417	43	of	of	IN
cord-034340-3ksfpaf7	1417	44	neck	neck	NN
cord-034340-3ksfpaf7	1417	45	in	in	IN
cord-034340-3ksfpaf7	1417	46	3	3	CD
cord-034340-3ksfpaf7	1417	47	pts	pts	NN
cord-034340-3ksfpaf7	1417	48	,	,	,
cord-034340-3ksfpaf7	1417	49	multiple	multiple	JJ
cord-034340-3ksfpaf7	1417	50	syndesmophytes	syndesmophyte	NNS
cord-034340-3ksfpaf7	1417	51	in	in	IN
cord-034340-3ksfpaf7	1417	52	1	1	CD
cord-034340-3ksfpaf7	1417	53	girl	girl	NN
cord-034340-3ksfpaf7	1417	54	.	.	.
cord-034340-3ksfpaf7	1418	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1418	2	found	find	VBD
cord-034340-3ksfpaf7	1418	3	that	that	IN
cord-034340-3ksfpaf7	1418	4	definite	definite	JJ
cord-034340-3ksfpaf7	1418	5	axial	axial	JJ
cord-034340-3ksfpaf7	1418	6	lesions	lesion	NNS
cord-034340-3ksfpaf7	1418	7	in	in	IN
cord-034340-3ksfpaf7	1418	8	NBO	NBO	NNP
cord-034340-3ksfpaf7	1418	9	developed	develop	VBD
cord-034340-3ksfpaf7	1418	10	in	in	IN
cord-034340-3ksfpaf7	1418	11	very	very	RB
cord-034340-3ksfpaf7	1418	12	young	young	JJ
cord-034340-3ksfpaf7	1418	13	children	child	NNS
cord-034340-3ksfpaf7	1418	14	(	(	-LRB-
cord-034340-3ksfpaf7	1418	15	in	in	IN
cord-034340-3ksfpaf7	1418	16	2	2	CD
cord-034340-3ksfpaf7	1418	17	y.old	y.old	RB
cord-034340-3ksfpaf7	1418	18	at	at	IN
cord-034340-3ksfpaf7	1418	19	minimum	minimum	NN
cord-034340-3ksfpaf7	1418	20	)	)	-RRB-
cord-034340-3ksfpaf7	1418	21	,	,	,
cord-034340-3ksfpaf7	1418	22	much	much	RB
cord-034340-3ksfpaf7	1418	23	earlier	early	RBR
cord-034340-3ksfpaf7	1418	24	than	than	IN
cord-034340-3ksfpaf7	1418	25	in	in	IN
cord-034340-3ksfpaf7	1418	26	"	"	``
cord-034340-3ksfpaf7	1418	27	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1418	28	"	"	''
cord-034340-3ksfpaf7	1418	29	JAS	JAS	NNP
cord-034340-3ksfpaf7	1418	30	.	.	.
cord-034340-3ksfpaf7	1419	1	HLA	HLA	NNP
cord-034340-3ksfpaf7	1419	2	B27	B27	NNP
cord-034340-3ksfpaf7	1419	3	was	be	VBD
cord-034340-3ksfpaf7	1419	4	presented	present	VBN
cord-034340-3ksfpaf7	1419	5	in	in	IN
cord-034340-3ksfpaf7	1419	6	5	5	CD
cord-034340-3ksfpaf7	1419	7	pts	pt	NNS
cord-034340-3ksfpaf7	1419	8	(	(	-LRB-
cord-034340-3ksfpaf7	1419	9	39	39	CD
cord-034340-3ksfpaf7	1419	10	%	%	NN
cord-034340-3ksfpaf7	1419	11	)	)	-RRB-
cord-034340-3ksfpaf7	1419	12	,	,	,
cord-034340-3ksfpaf7	1419	13	5	5	CD
cord-034340-3ksfpaf7	1419	14	pts	pt	NNS
cord-034340-3ksfpaf7	1419	15	had	have	VBD
cord-034340-3ksfpaf7	1419	16	ANA	ANA	NNP
cord-034340-3ksfpaf7	1419	17	in	in	IN
cord-034340-3ksfpaf7	1419	18	high	high	JJ
cord-034340-3ksfpaf7	1419	19	titer	titer	NN
cord-034340-3ksfpaf7	1419	20	(	(	-LRB-
cord-034340-3ksfpaf7	1419	21	all	all	DT
cord-034340-3ksfpaf7	1419	22	of	of	IN
cord-034340-3ksfpaf7	1419	23	those	those	DT
cord-034340-3ksfpaf7	1419	24	HLA	HLA	NNP
cord-034340-3ksfpaf7	1419	25	B27-negative	B27-negative	NNP
cord-034340-3ksfpaf7	1419	26	)	)	-RRB-
cord-034340-3ksfpaf7	1419	27	.	.	.
cord-034340-3ksfpaf7	1420	1	The	the	DT
cord-034340-3ksfpaf7	1420	2	pts	pts	NN
cord-034340-3ksfpaf7	1420	3	had	have	VBD
cord-034340-3ksfpaf7	1420	4	bone	bone	NN
cord-034340-3ksfpaf7	1420	5	lesions	lesion	NNS
cord-034340-3ksfpaf7	1420	6	in	in	IN
cord-034340-3ksfpaf7	1420	7	different	different	JJ
cord-034340-3ksfpaf7	1420	8	parts	part	NNS
cord-034340-3ksfpaf7	1420	9	of	of	IN
cord-034340-3ksfpaf7	1420	10	skeleton	skeleton	NN
cord-034340-3ksfpaf7	1420	11	:	:	:
cord-034340-3ksfpaf7	1420	12	vertebral	vertebral	JJ
cord-034340-3ksfpaf7	1420	13	bodies	body	NNS
cord-034340-3ksfpaf7	1420	14	-5	-5	NNP
cord-034340-3ksfpaf7	1420	15	pts	pts	NNP
cord-034340-3ksfpaf7	1420	16	,	,	,
cord-034340-3ksfpaf7	1420	17	clavicle	clavicle	NN
cord-034340-3ksfpaf7	1420	18	-1	-1	NN
cord-034340-3ksfpaf7	1420	19	,	,	,
cord-034340-3ksfpaf7	1421	1	sternum	sternum	NNP
cord-034340-3ksfpaf7	1421	2	,	,	,
cord-034340-3ksfpaf7	1421	3	ribs	rib	NNS
cord-034340-3ksfpaf7	1421	4	-1	-1	JJ
cord-034340-3ksfpaf7	1421	5	,	,	,
cord-034340-3ksfpaf7	1421	6	extremities	extremity	NNS
cord-034340-3ksfpaf7	1421	7	bones	bone	NNS
cord-034340-3ksfpaf7	1421	8	,	,	,
cord-034340-3ksfpaf7	1421	9	metaphysic	metaphysic	NN
cord-034340-3ksfpaf7	1421	10	mostly	mostly	RB
cord-034340-3ksfpaf7	1421	11	(	(	-LRB-
cord-034340-3ksfpaf7	1421	12	tibial	tibial	NN
cord-034340-3ksfpaf7	1421	13	,	,	,
cord-034340-3ksfpaf7	1421	14	fibular	fibular	JJ
cord-034340-3ksfpaf7	1421	15	-7	-7	IN
cord-034340-3ksfpaf7	1421	16	pts	pt	NNS
cord-034340-3ksfpaf7	1421	17	)	)	-RRB-
cord-034340-3ksfpaf7	1421	18	,	,	,
cord-034340-3ksfpaf7	1421	19	sacroiliac	sacroiliac	NN
cord-034340-3ksfpaf7	1421	20	region	region	NN
cord-034340-3ksfpaf7	1421	21	-4	-4	:
cord-034340-3ksfpaf7	1421	22	pts	pts	NNP
cord-034340-3ksfpaf7	1421	23	.	.	.
cord-034340-3ksfpaf7	1422	1	Extraskeletal	extraskeletal	JJ
cord-034340-3ksfpaf7	1422	2	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1422	3	were	be	VBD
cord-034340-3ksfpaf7	1422	4	observed	observe	VBN
cord-034340-3ksfpaf7	1422	5	in	in	IN
cord-034340-3ksfpaf7	1422	6	3	3	CD
cord-034340-3ksfpaf7	1422	7	pts	pts	NN
cord-034340-3ksfpaf7	1422	8	,	,	,
cord-034340-3ksfpaf7	1422	9	one	one	CD
cord-034340-3ksfpaf7	1422	10	in	in	IN
cord-034340-3ksfpaf7	1422	11	each	each	DT
cord-034340-3ksfpaf7	1422	12	condition	condition	NN
cord-034340-3ksfpaf7	1422	13	-uveitis	-uveitis	NN
cord-034340-3ksfpaf7	1422	14	,	,	,
cord-034340-3ksfpaf7	1422	15	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1422	16	pustulosus	pustulosus	NNP
cord-034340-3ksfpaf7	1422	17	,	,	,
cord-034340-3ksfpaf7	1422	18	acnae	acnae	NNP
cord-034340-3ksfpaf7	1422	19	conglobate	conglobate	NNP
cord-034340-3ksfpaf7	1422	20	.	.	.
cord-034340-3ksfpaf7	1423	1	In	in	IN
cord-034340-3ksfpaf7	1423	2	a	a	DT
cord-034340-3ksfpaf7	1423	3	girl	girl	NN
cord-034340-3ksfpaf7	1423	4	with	with	IN
cord-034340-3ksfpaf7	1423	5	very	very	RB
cord-034340-3ksfpaf7	1423	6	severe	severe	JJ
cord-034340-3ksfpaf7	1423	7	course	course	NN
cord-034340-3ksfpaf7	1423	8	of	of	IN
cord-034340-3ksfpaf7	1423	9	disease	disease	NN
cord-034340-3ksfpaf7	1423	10	,	,	,
cord-034340-3ksfpaf7	1423	11	not	not	RB
cord-034340-3ksfpaf7	1423	12	responded	respond	VBN
cord-034340-3ksfpaf7	1423	13	to	to	IN
cord-034340-3ksfpaf7	1423	14	any	any	DT
cord-034340-3ksfpaf7	1423	15	therapy	therapy	NN
cord-034340-3ksfpaf7	1423	16	NBO	NBO	NNP
cord-034340-3ksfpaf7	1423	17	was	be	VBD
cord-034340-3ksfpaf7	1423	18	combined	combine	VBN
cord-034340-3ksfpaf7	1423	19	with	with	IN
cord-034340-3ksfpaf7	1423	20	familial	familial	JJ
cord-034340-3ksfpaf7	1423	21	Mediterranean	mediterranean	JJ
cord-034340-3ksfpaf7	1423	22	fever	fever	NN
cord-034340-3ksfpaf7	1423	23	.	.	.
cord-034340-3ksfpaf7	1424	1	High	high	JJ
cord-034340-3ksfpaf7	1424	2	level	level	NN
cord-034340-3ksfpaf7	1424	3	of	of	IN
cord-034340-3ksfpaf7	1424	4	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1424	5	activity	activity	NN
cord-034340-3ksfpaf7	1424	6	were	be	VBD
cord-034340-3ksfpaf7	1424	7	detected	detect	VBN
cord-034340-3ksfpaf7	1424	8	before	before	IN
cord-034340-3ksfpaf7	1424	9	biologics	biologic	NNS
cord-034340-3ksfpaf7	1424	10	in	in	IN
cord-034340-3ksfpaf7	1424	11	10	10	CD
cord-034340-3ksfpaf7	1424	12	pts	pt	NNS
cord-034340-3ksfpaf7	1424	13	(	(	-LRB-
cord-034340-3ksfpaf7	1424	14	77	77	CD
cord-034340-3ksfpaf7	1424	15	%	%	NN
cord-034340-3ksfpaf7	1424	16	)	)	-RRB-
cord-034340-3ksfpaf7	1424	17	:	:	:
cord-034340-3ksfpaf7	1424	18	ESR	ESR	NNP
cord-034340-3ksfpaf7	1424	19	acceleration	acceleration	NN
cord-034340-3ksfpaf7	1424	20	up	up	IN
cord-034340-3ksfpaf7	1424	21	to	to	TO
cord-034340-3ksfpaf7	1424	22	60	60	CD
cord-034340-3ksfpaf7	1424	23	mm	mm	NNP
cord-034340-3ksfpaf7	1424	24	/	/	SYM
cord-034340-3ksfpaf7	1424	25	h	h	NN
cord-034340-3ksfpaf7	1424	26	,	,	,
cord-034340-3ksfpaf7	1424	27	increase	increase	NN
cord-034340-3ksfpaf7	1424	28	of	of	IN
cord-034340-3ksfpaf7	1424	29	CRP	crp	NN
cord-034340-3ksfpaf7	1424	30	up	up	RB
cord-034340-3ksfpaf7	1425	1	to	to	IN
cord-034340-3ksfpaf7	1425	2	80	80	CD
cord-034340-3ksfpaf7	1425	3	mg	mg	NNP
cord-034340-3ksfpaf7	1425	4	/	/	SYM
cord-034340-3ksfpaf7	1425	5	l	l	NN
cord-034340-3ksfpaf7	1425	6	.	.	.
cord-034340-3ksfpaf7	1426	1	Treatment	treatment	NN
cord-034340-3ksfpaf7	1426	2	included	include	VBD
cord-034340-3ksfpaf7	1426	3	NSAIDS	NSAIDS	NNP
cord-034340-3ksfpaf7	1426	4	(	(	-LRB-
cord-034340-3ksfpaf7	1426	5	all	all	DT
cord-034340-3ksfpaf7	1426	6	)	)	-RRB-
cord-034340-3ksfpaf7	1426	7	,	,	,
cord-034340-3ksfpaf7	1426	8	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	1426	9	(	(	-LRB-
cord-034340-3ksfpaf7	1426	10	7	7	CD
cord-034340-3ksfpaf7	1426	11	pts	pts	NNP
cord-034340-3ksfpaf7	1426	12	)	)	-RRB-
cord-034340-3ksfpaf7	1426	13	,	,	,
cord-034340-3ksfpaf7	1426	14	sulfasalazine	sulfasalazine	NNP
cord-034340-3ksfpaf7	1426	15	(	(	-LRB-
cord-034340-3ksfpaf7	1426	16	6	6	CD
cord-034340-3ksfpaf7	1426	17	pts	pt	NNS
cord-034340-3ksfpaf7	1426	18	,	,	,
cord-034340-3ksfpaf7	1426	19	but	but	CC
cord-034340-3ksfpaf7	1426	20	it	-PRON-	PRP
cord-034340-3ksfpaf7	1426	21	was	be	VBD
cord-034340-3ksfpaf7	1426	22	withdrawn	withdraw	VBN
cord-034340-3ksfpaf7	1426	23	in	in	IN
cord-034340-3ksfpaf7	1426	24	all	all	DT
cord-034340-3ksfpaf7	1426	25	pts	pt	NNS
cord-034340-3ksfpaf7	1426	26	)	)	-RRB-
cord-034340-3ksfpaf7	1426	27	,	,	,
cord-034340-3ksfpaf7	1426	28	bisphosphonates	bisphosphonates	NNP
cord-034340-3ksfpaf7	1426	29	(	(	-LRB-
cord-034340-3ksfpaf7	1426	30	1	1	CD
cord-034340-3ksfpaf7	1426	31	pt	pt	NN
cord-034340-3ksfpaf7	1426	32	)	)	-RRB-
cord-034340-3ksfpaf7	1426	33	,	,	,
cord-034340-3ksfpaf7	1426	34	prednisolone	prednisolone	NN
cord-034340-3ksfpaf7	1426	35	(	(	-LRB-
cord-034340-3ksfpaf7	1426	36	3	3	CD
cord-034340-3ksfpaf7	1426	37	pts	pts	CD
cord-034340-3ksfpaf7	1426	38	)	)	-RRB-
cord-034340-3ksfpaf7	1426	39	.	.	.
cord-034340-3ksfpaf7	1427	1	Because	because	IN
cord-034340-3ksfpaf7	1427	2	of	of	IN
cord-034340-3ksfpaf7	1427	3	high	high	JJ
cord-034340-3ksfpaf7	1427	4	activity	activity	NN
cord-034340-3ksfpaf7	1427	5	of	of	IN
cord-034340-3ksfpaf7	1427	6	NBO	NBO	NNP
cord-034340-3ksfpaf7	1427	7	with	with	IN
cord-034340-3ksfpaf7	1427	8	appearance	appearance	NN
cord-034340-3ksfpaf7	1427	9	of	of	IN
cord-034340-3ksfpaf7	1427	10	new	new	JJ
cord-034340-3ksfpaf7	1427	11	bone	bone	NN
cord-034340-3ksfpaf7	1427	12	lesions	lesion	NNS
cord-034340-3ksfpaf7	1427	13	and	and	CC
cord-034340-3ksfpaf7	1427	14	persistent	persistent	JJ
cord-034340-3ksfpaf7	1427	15	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1427	16	TNF	TNF	NNP
cord-034340-3ksfpaf7	1427	17	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1427	18	were	be	VBD
cord-034340-3ksfpaf7	1427	19	administrated	administrate	VBN
cord-034340-3ksfpaf7	1427	20	:	:	:
cord-034340-3ksfpaf7	1428	1	etanercept	etanercept	NNP
cord-034340-3ksfpaf7	1428	2	in	in	IN
cord-034340-3ksfpaf7	1428	3	10	10	CD
cord-034340-3ksfpaf7	1428	4	pts	pt	NNS
cord-034340-3ksfpaf7	1428	5	,	,	,
cord-034340-3ksfpaf7	1428	6	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1428	7	-4	-4	NNP
cord-034340-3ksfpaf7	1428	8	(	(	-LRB-
cord-034340-3ksfpaf7	1428	9	2	2	CD
cord-034340-3ksfpaf7	1428	10	as	as	IN
cord-034340-3ksfpaf7	1428	11	first	first	JJ
cord-034340-3ksfpaf7	1428	12	line	line	NN
cord-034340-3ksfpaf7	1428	13	,	,	,
cord-034340-3ksfpaf7	1428	14	2second	2second	CD
cord-034340-3ksfpaf7	1428	15	line	line	NN
cord-034340-3ksfpaf7	1428	16	)	)	-RRB-
cord-034340-3ksfpaf7	1428	17	,	,	,
cord-034340-3ksfpaf7	1428	18	golimumab	golimumab	NNP
cord-034340-3ksfpaf7	1428	19	-1	-1	NNP
cord-034340-3ksfpaf7	1428	20	.	.	.
cord-034340-3ksfpaf7	1429	1	At	at	IN
cord-034340-3ksfpaf7	1429	2	the	the	DT
cord-034340-3ksfpaf7	1429	3	start	start	NN
cord-034340-3ksfpaf7	1429	4	of	of	IN
cord-034340-3ksfpaf7	1429	5	BA	BA	NNP
cord-034340-3ksfpaf7	1429	6	the	the	DT
cord-034340-3ksfpaf7	1429	7	average	average	JJ
cord-034340-3ksfpaf7	1429	8	age	age	NN
cord-034340-3ksfpaf7	1429	9	was	be	VBD
cord-034340-3ksfpaf7	1429	10	13.7	13.7	CD
cord-034340-3ksfpaf7	1429	11	years	year	NNS
cord-034340-3ksfpaf7	1429	12	(	(	-LRB-
cord-034340-3ksfpaf7	1429	13	range	range	VBP
cord-034340-3ksfpaf7	1429	14	7.2	7.2	CD
cord-034340-3ksfpaf7	1429	15	-	-	HYPH
cord-034340-3ksfpaf7	1429	16	17.9	17.9	CD
cord-034340-3ksfpaf7	1429	17	)	)	-RRB-
cord-034340-3ksfpaf7	1429	18	;	;	:
cord-034340-3ksfpaf7	1429	19	mean	mean	VB
cord-034340-3ksfpaf7	1429	20	disease	disease	NN
cord-034340-3ksfpaf7	1429	21	duration	duration	NN
cord-034340-3ksfpaf7	1429	22	was	be	VBD
cord-034340-3ksfpaf7	1429	23	3,4	3,4	CD
cord-034340-3ksfpaf7	1429	24	years	year	NNS
cord-034340-3ksfpaf7	1430	1	(	(	-LRB-
cord-034340-3ksfpaf7	1430	2	range	range	VBP
cord-034340-3ksfpaf7	1430	3	0.3	0.3	CD
cord-034340-3ksfpaf7	1430	4	-	-	HYPH
cord-034340-3ksfpaf7	1430	5	8.1	8.1	CD
cord-034340-3ksfpaf7	1430	6	)	)	-RRB-
cord-034340-3ksfpaf7	1430	7	.	.	.
cord-034340-3ksfpaf7	1431	1	There	there	EX
cord-034340-3ksfpaf7	1431	2	were	be	VBD
cord-034340-3ksfpaf7	1431	3	2	2	CD
cord-034340-3ksfpaf7	1431	4	cases	case	NNS
cord-034340-3ksfpaf7	1431	5	of	of	IN
cord-034340-3ksfpaf7	1431	6	withdrawals	withdrawal	NNS
cord-034340-3ksfpaf7	1431	7	.	.	.
cord-034340-3ksfpaf7	1432	1	Due	due	IN
cord-034340-3ksfpaf7	1432	2	to	to	IN
cord-034340-3ksfpaf7	1432	3	inefficacy	inefficacy	NN
cord-034340-3ksfpaf7	1432	4	etanercept	etanercept	NNP
cord-034340-3ksfpaf7	1432	5	was	be	VBD
cord-034340-3ksfpaf7	1432	6	switched	switch	VBN
cord-034340-3ksfpaf7	1432	7	to	to	IN
cord-034340-3ksfpaf7	1432	8	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1432	9	.	.	.
cord-034340-3ksfpaf7	1433	1	Disease	disease	NN
cord-034340-3ksfpaf7	1433	2	activity	activity	NN
cord-034340-3ksfpaf7	1433	3	decreasing	decreasing	NN
cord-034340-3ksfpaf7	1433	4	was	be	VBD
cord-034340-3ksfpaf7	1433	5	reached	reach	VBN
cord-034340-3ksfpaf7	1433	6	in	in	IN
cord-034340-3ksfpaf7	1433	7	the	the	DT
cord-034340-3ksfpaf7	1433	8	most	most	JJS
cord-034340-3ksfpaf7	1433	9	of	of	IN
cord-034340-3ksfpaf7	1433	10	the	the	DT
cord-034340-3ksfpaf7	1433	11	patients	patient	NNS
cord-034340-3ksfpaf7	1433	12	(	(	-LRB-
cord-034340-3ksfpaf7	1433	13	12	12	CD
cord-034340-3ksfpaf7	1433	14	from	from	IN
cord-034340-3ksfpaf7	1433	15	13	13	CD
cord-034340-3ksfpaf7	1433	16	)	)	-RRB-
cord-034340-3ksfpaf7	1433	17	.	.	.
cord-034340-3ksfpaf7	1434	1	Among	among	IN
cord-034340-3ksfpaf7	1434	2	them	-PRON-	PRP
cord-034340-3ksfpaf7	1434	3	2	2	CD
cord-034340-3ksfpaf7	1434	4	pts	pt	NNS
cord-034340-3ksfpaf7	1434	5	developed	develop	VBD
cord-034340-3ksfpaf7	1434	6	the	the	DT
cord-034340-3ksfpaf7	1434	7	whole	whole	JJ
cord-034340-3ksfpaf7	1434	8	remission	remission	NN
cord-034340-3ksfpaf7	1434	9	with	with	IN
cord-034340-3ksfpaf7	1434	10	resolving	resolve	VBG
cord-034340-3ksfpaf7	1434	11	of	of	IN
cord-034340-3ksfpaf7	1434	12	active	active	JJ
cord-034340-3ksfpaf7	1434	13	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1434	14	and	and	CC
cord-034340-3ksfpaf7	1434	15	bone	bone	NN
cord-034340-3ksfpaf7	1434	16	marrow	marrow	NN
cord-034340-3ksfpaf7	1434	17	edema	edema	NN
cord-034340-3ksfpaf7	1434	18	spots	spot	NNS
cord-034340-3ksfpaf7	1434	19	.	.	.
cord-034340-3ksfpaf7	1435	1	Skin	skin	NN
cord-034340-3ksfpaf7	1435	2	lesions	lesion	NNS
cord-034340-3ksfpaf7	1435	3	(	(	-LRB-
cord-034340-3ksfpaf7	1435	4	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1435	5	pustulosis	pustulosis	NN
cord-034340-3ksfpaf7	1435	6	and	and	CC
cord-034340-3ksfpaf7	1435	7	acnae	acnae	NNP
cord-034340-3ksfpaf7	1435	8	conglobate	conglobate	NNP
cord-034340-3ksfpaf7	1435	9	)	)	-RRB-
cord-034340-3ksfpaf7	1435	10	were	be	VBD
cord-034340-3ksfpaf7	1435	11	significantly	significantly	RB
cord-034340-3ksfpaf7	1435	12	improved	improve	VBN
cord-034340-3ksfpaf7	1435	13	.	.	.
cord-034340-3ksfpaf7	1436	1	There	there	EX
cord-034340-3ksfpaf7	1436	2	were	be	VBD
cord-034340-3ksfpaf7	1436	3	no	no	DT
cord-034340-3ksfpaf7	1436	4	adverse	adverse	JJ
cord-034340-3ksfpaf7	1436	5	events	event	NNS
cord-034340-3ksfpaf7	1436	6	during	during	IN
cord-034340-3ksfpaf7	1436	7	the	the	DT
cord-034340-3ksfpaf7	1436	8	TNF	TNF	NNP
cord-034340-3ksfpaf7	1436	9	therapy	therapy	NN
cord-034340-3ksfpaf7	1436	10	.	.	.
cord-034340-3ksfpaf7	1437	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1437	2	:	:	:
cord-034340-3ksfpaf7	1438	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1438	2	experience	experience	NN
cord-034340-3ksfpaf7	1438	3	of	of	IN
cord-034340-3ksfpaf7	1438	4	the	the	DT
cord-034340-3ksfpaf7	1438	5	therapy	therapy	NN
cord-034340-3ksfpaf7	1438	6	with	with	IN
cord-034340-3ksfpaf7	1438	7	TNF	TNF	NNP
cord-034340-3ksfpaf7	1438	8	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1438	9	in	in	IN
cord-034340-3ksfpaf7	1438	10	patients	patient	NNS
cord-034340-3ksfpaf7	1438	11	with	with	IN
cord-034340-3ksfpaf7	1438	12	high	high	JJ
cord-034340-3ksfpaf7	1438	13	NBO	NBO	NNP
cord-034340-3ksfpaf7	1438	14	activity	activity	NN
cord-034340-3ksfpaf7	1438	15	has	have	VBZ
cord-034340-3ksfpaf7	1438	16	shown	show	VBN
cord-034340-3ksfpaf7	1438	17	that	that	IN
cord-034340-3ksfpaf7	1438	18	this	this	DT
cord-034340-3ksfpaf7	1438	19	is	be	VBZ
cord-034340-3ksfpaf7	1438	20	a	a	DT
cord-034340-3ksfpaf7	1438	21	good	good	JJ
cord-034340-3ksfpaf7	1438	22	and	and	CC
cord-034340-3ksfpaf7	1438	23	safe	safe	JJ
cord-034340-3ksfpaf7	1438	24	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	1438	25	option	option	NN
cord-034340-3ksfpaf7	1438	26	that	that	WDT
cord-034340-3ksfpaf7	1438	27	is	be	VBZ
cord-034340-3ksfpaf7	1438	28	expected	expect	VBN
cord-034340-3ksfpaf7	1438	29	to	to	TO
cord-034340-3ksfpaf7	1438	30	prevent	prevent	VB
cord-034340-3ksfpaf7	1438	31	progression	progression	NN
cord-034340-3ksfpaf7	1438	32	and	and	CC
cord-034340-3ksfpaf7	1438	33	bone	bone	NN
cord-034340-3ksfpaf7	1438	34	destruction	destruction	NN
cord-034340-3ksfpaf7	1438	35	.	.	.
cord-034340-3ksfpaf7	1438	36	.	.	.
cord-034340-3ksfpaf7	1439	1	AE	AE	NNP
cord-034340-3ksfpaf7	1439	2	were	be	VBD
cord-034340-3ksfpaf7	1439	3	reported	report	VBN
cord-034340-3ksfpaf7	1439	4	for	for	IN
cord-034340-3ksfpaf7	1439	5	71.7	71.7	CD
cord-034340-3ksfpaf7	1439	6	%	%	NN
cord-034340-3ksfpaf7	1439	7	of	of	IN
cord-034340-3ksfpaf7	1439	8	patients	patient	NNS
cord-034340-3ksfpaf7	1439	9	,	,	,
cord-034340-3ksfpaf7	1439	10	most	most	JJS
cord-034340-3ksfpaf7	1439	11	within	within	IN
cord-034340-3ksfpaf7	1439	12	24	24	CD
cord-034340-3ksfpaf7	1439	13	to	to	TO
cord-034340-3ksfpaf7	1439	14	48	48	CD
cord-034340-3ksfpaf7	1439	15	hours	hour	NNS
cord-034340-3ksfpaf7	1439	16	after	after	IN
cord-034340-3ksfpaf7	1439	17	the	the	DT
cord-034340-3ksfpaf7	1439	18	first	first	JJ
cord-034340-3ksfpaf7	1439	19	or	or	CC
cord-034340-3ksfpaf7	1439	20	second	second	JJ
cord-034340-3ksfpaf7	1439	21	injection	injection	NN
cord-034340-3ksfpaf7	1439	22	:	:	:
cord-034340-3ksfpaf7	1439	23	flu	flu	NN
cord-034340-3ksfpaf7	1439	24	-	-	HYPH
cord-034340-3ksfpaf7	1439	25	like	like	JJ
cord-034340-3ksfpaf7	1439	26	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1439	27	(	(	-LRB-
cord-034340-3ksfpaf7	1439	28	57.5	57.5	CD
cord-034340-3ksfpaf7	1439	29	%	%	NN
cord-034340-3ksfpaf7	1439	30	)	)	-RRB-
cord-034340-3ksfpaf7	1439	31	,	,	,
cord-034340-3ksfpaf7	1439	32	hypocalcaemia	hypocalcaemia	NNP
cord-034340-3ksfpaf7	1439	33	(	(	-LRB-
cord-034340-3ksfpaf7	1439	34	37.5	37.5	CD
cord-034340-3ksfpaf7	1439	35	%	%	NN
cord-034340-3ksfpaf7	1439	36	)	)	-RRB-
cord-034340-3ksfpaf7	1439	37	and	and	CC
cord-034340-3ksfpaf7	1439	38	hypophosphatemia	hypophosphatemia	NNP
cord-034340-3ksfpaf7	1439	39	(	(	-LRB-
cord-034340-3ksfpaf7	1439	40	20	20	CD
cord-034340-3ksfpaf7	1439	41	%	%	NN
cord-034340-3ksfpaf7	1439	42	)	)	-RRB-
cord-034340-3ksfpaf7	1439	43	.	.	.
cord-034340-3ksfpaf7	1440	1	Underweight	underweight	JJ
cord-034340-3ksfpaf7	1440	2	patients	patient	NNS
cord-034340-3ksfpaf7	1440	3	(	(	-LRB-
cord-034340-3ksfpaf7	1440	4	body	body	NN
cord-034340-3ksfpaf7	1440	5	mass	mass	NN
cord-034340-3ksfpaf7	1440	6	index	index	NN
cord-034340-3ksfpaf7	1440	7	<	<	XX
cord-034340-3ksfpaf7	1440	8	18.5	18.5	CD
cord-034340-3ksfpaf7	1440	9	kg	kg	NNS
cord-034340-3ksfpaf7	1440	10	/	/	SYM
cord-034340-3ksfpaf7	1440	11	m²	m²	NNP
cord-034340-3ksfpaf7	1440	12	)	)	-RRB-
cord-034340-3ksfpaf7	1440	13	accounted	account	VBD
cord-034340-3ksfpaf7	1440	14	for	for	IN
cord-034340-3ksfpaf7	1440	15	50	50	CD
cord-034340-3ksfpaf7	1440	16	%	%	NN
cord-034340-3ksfpaf7	1440	17	of	of	IN
cord-034340-3ksfpaf7	1440	18	hypocalcaemia	hypocalcaemia	NN
cord-034340-3ksfpaf7	1440	19	.	.	.
cord-034340-3ksfpaf7	1441	1	The	the	DT
cord-034340-3ksfpaf7	1441	2	frequency	frequency	NN
cord-034340-3ksfpaf7	1441	3	of	of	IN
cord-034340-3ksfpaf7	1441	4	all	all	PDT
cord-034340-3ksfpaf7	1441	5	the	the	DT
cord-034340-3ksfpaf7	1441	6	AE	AE	NNP
cord-034340-3ksfpaf7	1441	7	not	not	RB
cord-034340-3ksfpaf7	1441	8	significantly	significantly	RB
cord-034340-3ksfpaf7	1441	9	decreased	decrease	VBD
cord-034340-3ksfpaf7	1441	10	with	with	IN
cord-034340-3ksfpaf7	1441	11	the	the	DT
cord-034340-3ksfpaf7	1441	12	reduction	reduction	NN
cord-034340-3ksfpaf7	1441	13	of	of	IN
cord-034340-3ksfpaf7	1441	14	the	the	DT
cord-034340-3ksfpaf7	1441	15	first	first	JJ
cord-034340-3ksfpaf7	1441	16	dose	dose	NN
cord-034340-3ksfpaf7	1441	17	.	.	.
cord-034340-3ksfpaf7	1442	1	Only	only	RB
cord-034340-3ksfpaf7	1442	2	one	one	CD
cord-034340-3ksfpaf7	1442	3	serious	serious	JJ
cord-034340-3ksfpaf7	1442	4	hyponatremia	hyponatremia	NN
cord-034340-3ksfpaf7	1442	5	occurred	occur	VBD
cord-034340-3ksfpaf7	1442	6	corresponding	correspond	VBG
cord-034340-3ksfpaf7	1442	7	to	to	IN
cord-034340-3ksfpaf7	1442	8	a	a	DT
cord-034340-3ksfpaf7	1442	9	patient	patient	NN
cord-034340-3ksfpaf7	1442	10	with	with	IN
cord-034340-3ksfpaf7	1442	11	renal	renal	JJ
cord-034340-3ksfpaf7	1442	12	failure	failure	NN
cord-034340-3ksfpaf7	1442	13	before	before	IN
cord-034340-3ksfpaf7	1442	14	treatment	treatment	NN
cord-034340-3ksfpaf7	1442	15	.	.	.
cord-034340-3ksfpaf7	1443	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1443	2	:	:	:
cord-034340-3ksfpaf7	1444	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1444	2	results	result	NNS
cord-034340-3ksfpaf7	1444	3	were	be	VBD
cord-034340-3ksfpaf7	1444	4	similar	similar	JJ
cord-034340-3ksfpaf7	1444	5	to	to	IN
cord-034340-3ksfpaf7	1444	6	those	those	DT
cord-034340-3ksfpaf7	1444	7	previously	previously	RB
cord-034340-3ksfpaf7	1444	8	published	publish	VBN
cord-034340-3ksfpaf7	1444	9	:	:	:
cord-034340-3ksfpaf7	1444	10	bisphosphonates	bisphosphonates	NNP
cord-034340-3ksfpaf7	1444	11	are	be	VBP
cord-034340-3ksfpaf7	1444	12	safe	safe	JJ
cord-034340-3ksfpaf7	1444	13	for	for	IN
cord-034340-3ksfpaf7	1444	14	osteoporosis	osteoporosis	NN
cord-034340-3ksfpaf7	1444	15	in	in	IN
cord-034340-3ksfpaf7	1444	16	children	child	NNS
cord-034340-3ksfpaf7	1444	17	.	.	.
cord-034340-3ksfpaf7	1445	1	In	in	IN
cord-034340-3ksfpaf7	1445	2	the	the	DT
cord-034340-3ksfpaf7	1445	3	literature	literature	NN
cord-034340-3ksfpaf7	1445	4	,	,	,
cord-034340-3ksfpaf7	1445	5	SAE	SAE	NNP
cord-034340-3ksfpaf7	1445	6	are	be	VBP
cord-034340-3ksfpaf7	1445	7	very	very	RB
cord-034340-3ksfpaf7	1445	8	rare	rare	JJ
cord-034340-3ksfpaf7	1445	9	in	in	IN
cord-034340-3ksfpaf7	1445	10	children	child	NNS
cord-034340-3ksfpaf7	1445	11	,	,	,
cord-034340-3ksfpaf7	1445	12	being	be	VBG
cord-034340-3ksfpaf7	1445	13	limited	limit	VBN
cord-034340-3ksfpaf7	1445	14	to	to	IN
cord-034340-3ksfpaf7	1445	15	anecdotal	anecdotal	JJ
cord-034340-3ksfpaf7	1445	16	osteopetrosis	osteopetrosis	NN
cord-034340-3ksfpaf7	1445	17	in	in	IN
cord-034340-3ksfpaf7	1445	18	cases	case	NNS
cord-034340-3ksfpaf7	1445	19	of	of	IN
cord-034340-3ksfpaf7	1445	20	higher	high	JJR
cord-034340-3ksfpaf7	1445	21	doses	dose	NNS
cord-034340-3ksfpaf7	1445	22	and	and	CC
cord-034340-3ksfpaf7	1445	23	long	long	JJ
cord-034340-3ksfpaf7	1445	24	-	-	HYPH
cord-034340-3ksfpaf7	1445	25	term	term	NN
cord-034340-3ksfpaf7	1445	26	treatment	treatment	NN
cord-034340-3ksfpaf7	1445	27	,	,	,
cord-034340-3ksfpaf7	1445	28	and	and	CC
cord-034340-3ksfpaf7	1445	29	delayed	delay	VBN
cord-034340-3ksfpaf7	1445	30	bone	bone	NN
cord-034340-3ksfpaf7	1445	31	healing	healing	NN
cord-034340-3ksfpaf7	1445	32	.	.	.
cord-034340-3ksfpaf7	1446	1	Anecdotal	anecdotal	JJ
cord-034340-3ksfpaf7	1446	2	osteonecrosis	osteonecrosis	NN
cord-034340-3ksfpaf7	1446	3	of	of	IN
cord-034340-3ksfpaf7	1446	4	the	the	DT
cord-034340-3ksfpaf7	1446	5	jaw	jaw	NN
cord-034340-3ksfpaf7	1446	6	in	in	IN
cord-034340-3ksfpaf7	1446	7	adults	adult	NNS
cord-034340-3ksfpaf7	1446	8	has	have	VBZ
cord-034340-3ksfpaf7	1446	9	never	never	RB
cord-034340-3ksfpaf7	1446	10	been	be	VBN
cord-034340-3ksfpaf7	1446	11	described	describe	VBN
cord-034340-3ksfpaf7	1446	12	in	in	IN
cord-034340-3ksfpaf7	1446	13	children	child	NNS
cord-034340-3ksfpaf7	1446	14	.	.	.
cord-034340-3ksfpaf7	1447	1	The	the	DT
cord-034340-3ksfpaf7	1447	2	use	use	NN
cord-034340-3ksfpaf7	1447	3	of	of	IN
cord-034340-3ksfpaf7	1447	4	bisphosphonates	bisphosphonate	NNS
cord-034340-3ksfpaf7	1447	5	beforehand	beforehand	RB
cord-034340-3ksfpaf7	1447	6	requires	require	VBZ
cord-034340-3ksfpaf7	1447	7	dietary	dietary	JJ
cord-034340-3ksfpaf7	1447	8	measures	measure	NNS
cord-034340-3ksfpaf7	1447	9	(	(	-LRB-
cord-034340-3ksfpaf7	1447	10	vitamin	vitamin	NN
cord-034340-3ksfpaf7	1447	11	D	d	NN
cord-034340-3ksfpaf7	1447	12	and	and	CC
cord-034340-3ksfpaf7	1447	13	calcium	calcium	NN
cord-034340-3ksfpaf7	1447	14	supplementation	supplementation	NN
cord-034340-3ksfpaf7	1447	15	)	)	-RRB-
cord-034340-3ksfpaf7	1447	16	.	.	.
cord-034340-3ksfpaf7	1448	1	Furthers	further	VBZ
cord-034340-3ksfpaf7	1448	2	systematic	systematic	JJ
cord-034340-3ksfpaf7	1448	3	collection	collection	NN
cord-034340-3ksfpaf7	1448	4	on	on	IN
cord-034340-3ksfpaf7	1448	5	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1448	6	and	and	CC
cord-034340-3ksfpaf7	1448	7	safety	safety	NN
cord-034340-3ksfpaf7	1448	8	parameters	parameter	NNS
cord-034340-3ksfpaf7	1448	9	for	for	IN
cord-034340-3ksfpaf7	1448	10	each	each	DT
cord-034340-3ksfpaf7	1448	11	Bisphosphonates	Bisphosphonates	NNP
cord-034340-3ksfpaf7	1448	12	drug	drug	NN
cord-034340-3ksfpaf7	1448	13	should	should	MD
cord-034340-3ksfpaf7	1448	14	confirm	confirm	VB
cord-034340-3ksfpaf7	1448	15	these	these	DT
cord-034340-3ksfpaf7	1448	16	data	datum	NNS
cord-034340-3ksfpaf7	1448	17	.	.	.
cord-034340-3ksfpaf7	1449	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1449	2	:	:	:
cord-034340-3ksfpaf7	1450	1	The	the	DT
cord-034340-3ksfpaf7	1450	2	use	use	NN
cord-034340-3ksfpaf7	1450	3	of	of	IN
cord-034340-3ksfpaf7	1450	4	biosimilars	biosimilar	NNS
cord-034340-3ksfpaf7	1450	5	in	in	IN
cord-034340-3ksfpaf7	1450	6	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1450	7	has	have	VBZ
cord-034340-3ksfpaf7	1450	8	increased	increase	VBN
cord-034340-3ksfpaf7	1450	9	significantly	significantly	RB
cord-034340-3ksfpaf7	1450	10	over	over	IN
cord-034340-3ksfpaf7	1450	11	the	the	DT
cord-034340-3ksfpaf7	1450	12	last	last	JJ
cord-034340-3ksfpaf7	1450	13	5	5	CD
cord-034340-3ksfpaf7	1450	14	years	year	NNS
cord-034340-3ksfpaf7	1450	15	and	and	CC
cord-034340-3ksfpaf7	1450	16	has	have	VBZ
cord-034340-3ksfpaf7	1450	17	resulted	result	VBN
cord-034340-3ksfpaf7	1450	18	in	in	IN
cord-034340-3ksfpaf7	1450	19	considerable	considerable	JJ
cord-034340-3ksfpaf7	1450	20	cost	cost	NN
cord-034340-3ksfpaf7	1450	21	savings	saving	NNS
cord-034340-3ksfpaf7	1450	22	.	.	.
cord-034340-3ksfpaf7	1451	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1451	2	:	:	:
cord-034340-3ksfpaf7	1451	3	To	to	TO
cord-034340-3ksfpaf7	1451	4	assess	assess	VB
cord-034340-3ksfpaf7	1451	5	the	the	DT
cord-034340-3ksfpaf7	1451	6	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1451	7	and	and	CC
cord-034340-3ksfpaf7	1451	8	tolerability	tolerability	NN
cord-034340-3ksfpaf7	1451	9	of	of	IN
cord-034340-3ksfpaf7	1451	10	the	the	DT
cord-034340-3ksfpaf7	1451	11	Adalimumab	Adalimumab	NNP
cord-034340-3ksfpaf7	1451	12	biosimilar	biosimilar	NN
cord-034340-3ksfpaf7	1451	13	ABP	ABP	NNP
cord-034340-3ksfpaf7	1451	14	501	501	CD
cord-034340-3ksfpaf7	1451	15	in	in	IN
cord-034340-3ksfpaf7	1451	16	patients	patient	NNS
cord-034340-3ksfpaf7	1451	17	with	with	IN
cord-034340-3ksfpaf7	1451	18	JIA	JIA	NNP
cord-034340-3ksfpaf7	1451	19	.	.	.
cord-034340-3ksfpaf7	1452	1	Methods	method	NNS
cord-034340-3ksfpaf7	1452	2	:	:	:
cord-034340-3ksfpaf7	1453	1	A	a	DT
cord-034340-3ksfpaf7	1453	2	database	database	NN
cord-034340-3ksfpaf7	1453	3	of	of	IN
cord-034340-3ksfpaf7	1453	4	patients	patient	NNS
cord-034340-3ksfpaf7	1453	5	prescribed	prescribe	VBN
cord-034340-3ksfpaf7	1453	6	Adalimumab	Adalimumab	NNS
cord-034340-3ksfpaf7	1453	7	in	in	IN
cord-034340-3ksfpaf7	1453	8	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1453	9	service	service	NN
cord-034340-3ksfpaf7	1453	10	has	have	VBZ
cord-034340-3ksfpaf7	1453	11	been	be	VBN
cord-034340-3ksfpaf7	1453	12	screened	screen	VBN
cord-034340-3ksfpaf7	1453	13	to	to	TO
cord-034340-3ksfpaf7	1453	14	identify	identify	VB
cord-034340-3ksfpaf7	1453	15	patients	patient	NNS
cord-034340-3ksfpaf7	1453	16	with	with	IN
cord-034340-3ksfpaf7	1453	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	1453	18	,	,	,
cord-034340-3ksfpaf7	1453	19	who	who	WP
cord-034340-3ksfpaf7	1453	20	switched	switch	VBD
cord-034340-3ksfpaf7	1453	21	from	from	IN
cord-034340-3ksfpaf7	1453	22	the	the	DT
cord-034340-3ksfpaf7	1453	23	originator	originator	NN
cord-034340-3ksfpaf7	1453	24	to	to	IN
cord-034340-3ksfpaf7	1453	25	the	the	DT
cord-034340-3ksfpaf7	1453	26	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1453	27	.	.	.
cord-034340-3ksfpaf7	1454	1	Only	only	RB
cord-034340-3ksfpaf7	1454	2	patients	patient	NNS
cord-034340-3ksfpaf7	1454	3	who	who	WP
cord-034340-3ksfpaf7	1454	4	had	have	VBD
cord-034340-3ksfpaf7	1454	5	a	a	DT
cord-034340-3ksfpaf7	1454	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	1454	7	review	review	NN
cord-034340-3ksfpaf7	1454	8	since	since	IN
cord-034340-3ksfpaf7	1454	9	they	-PRON-	PRP
cord-034340-3ksfpaf7	1454	10	had	have	VBD
cord-034340-3ksfpaf7	1454	11	started	start	VBN
cord-034340-3ksfpaf7	1454	12	the	the	DT
cord-034340-3ksfpaf7	1454	13	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1454	14	were	be	VBD
cord-034340-3ksfpaf7	1454	15	included	include	VBN
cord-034340-3ksfpaf7	1454	16	.	.	.
cord-034340-3ksfpaf7	1455	1	A	a	DT
cord-034340-3ksfpaf7	1455	2	paired	pair	VBN
cord-034340-3ksfpaf7	1455	3	-	-	HYPH
cord-034340-3ksfpaf7	1455	4	samples	sample	NNS
cord-034340-3ksfpaf7	1455	5	t	t	NN
cord-034340-3ksfpaf7	1455	6	-	-	HYPH
cord-034340-3ksfpaf7	1455	7	test	test	NN
cord-034340-3ksfpaf7	1455	8	was	be	VBD
cord-034340-3ksfpaf7	1455	9	conducted	conduct	VBN
cord-034340-3ksfpaf7	1455	10	to	to	TO
cord-034340-3ksfpaf7	1455	11	compare	compare	VB
cord-034340-3ksfpaf7	1455	12	the	the	DT
cord-034340-3ksfpaf7	1455	13	number	number	NN
cord-034340-3ksfpaf7	1455	14	of	of	IN
cord-034340-3ksfpaf7	1455	15	active	active	JJ
cord-034340-3ksfpaf7	1455	16	joints	joint	NNS
cord-034340-3ksfpaf7	1455	17	at	at	IN
cord-034340-3ksfpaf7	1455	18	the	the	DT
cord-034340-3ksfpaf7	1455	19	clinic	clinic	NN
cord-034340-3ksfpaf7	1455	20	appointment	appointment	NN
cord-034340-3ksfpaf7	1455	21	before	before	IN
cord-034340-3ksfpaf7	1455	22	and	and	CC
cord-034340-3ksfpaf7	1455	23	after	after	IN
cord-034340-3ksfpaf7	1455	24	the	the	DT
cord-034340-3ksfpaf7	1455	25	initiation	initiation	NN
cord-034340-3ksfpaf7	1455	26	of	of	IN
cord-034340-3ksfpaf7	1455	27	the	the	DT
cord-034340-3ksfpaf7	1455	28	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1455	29	treatment	treatment	NN
cord-034340-3ksfpaf7	1455	30	.	.	.
cord-034340-3ksfpaf7	1456	1	The	the	DT
cord-034340-3ksfpaf7	1456	2	frequency	frequency	NN
cord-034340-3ksfpaf7	1456	3	and	and	CC
cord-034340-3ksfpaf7	1456	4	type	type	NN
cord-034340-3ksfpaf7	1456	5	of	of	IN
cord-034340-3ksfpaf7	1456	6	side	side	NN
cord-034340-3ksfpaf7	1456	7	effects	effect	NNS
cord-034340-3ksfpaf7	1456	8	,	,	,
cord-034340-3ksfpaf7	1456	9	the	the	DT
cord-034340-3ksfpaf7	1456	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	1456	11	response	response	NN
cord-034340-3ksfpaf7	1456	12	and	and	CC
cord-034340-3ksfpaf7	1456	13	the	the	DT
cord-034340-3ksfpaf7	1456	14	number	number	NN
cord-034340-3ksfpaf7	1456	15	of	of	IN
cord-034340-3ksfpaf7	1456	16	patients	patient	NNS
cord-034340-3ksfpaf7	1456	17	who	who	WP
cord-034340-3ksfpaf7	1456	18	switched	switch	VBD
cord-034340-3ksfpaf7	1456	19	back	back	RB
cord-034340-3ksfpaf7	1456	20	to	to	IN
cord-034340-3ksfpaf7	1456	21	the	the	DT
cord-034340-3ksfpaf7	1456	22	originator	originator	NN
cord-034340-3ksfpaf7	1456	23	have	have	VBP
cord-034340-3ksfpaf7	1456	24	been	be	VBN
cord-034340-3ksfpaf7	1456	25	collected	collect	VBN
cord-034340-3ksfpaf7	1456	26	.	.	.
cord-034340-3ksfpaf7	1457	1	Results	result	NNS
cord-034340-3ksfpaf7	1457	2	:	:	:
cord-034340-3ksfpaf7	1458	1	Sixty	sixty	CD
cord-034340-3ksfpaf7	1458	2	-	-	HYPH
cord-034340-3ksfpaf7	1458	3	one	one	CD
cord-034340-3ksfpaf7	1458	4	patients	patient	NNS
cord-034340-3ksfpaf7	1458	5	who	who	WP
cord-034340-3ksfpaf7	1458	6	switched	switch	VBD
cord-034340-3ksfpaf7	1458	7	to	to	IN
cord-034340-3ksfpaf7	1458	8	the	the	DT
cord-034340-3ksfpaf7	1458	9	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1458	10	ABP	ABP	NNP
cord-034340-3ksfpaf7	1458	11	501	501	CD
cord-034340-3ksfpaf7	1458	12	between	between	IN
cord-034340-3ksfpaf7	1458	13	February	February	NNP
cord-034340-3ksfpaf7	1458	14	2019	2019	CD
cord-034340-3ksfpaf7	1458	15	and	and	CC
cord-034340-3ksfpaf7	1458	16	February	February	NNP
cord-034340-3ksfpaf7	1458	17	2020	2020	CD
cord-034340-3ksfpaf7	1458	18	were	be	VBD
cord-034340-3ksfpaf7	1458	19	included	include	VBN
cord-034340-3ksfpaf7	1458	20	.	.	.
cord-034340-3ksfpaf7	1459	1	They	-PRON-	PRP
cord-034340-3ksfpaf7	1459	2	were	be	VBD
cord-034340-3ksfpaf7	1459	3	comprised	comprise	VBN
cord-034340-3ksfpaf7	1459	4	of	of	IN
cord-034340-3ksfpaf7	1459	5	30	30	CD
cord-034340-3ksfpaf7	1459	6	enthesitis	enthesitis	NN
cord-034340-3ksfpaf7	1459	7	-	-	HYPH
cord-034340-3ksfpaf7	1459	8	related	relate	VBN
cord-034340-3ksfpaf7	1459	9	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1459	10	(	(	-LRB-
cord-034340-3ksfpaf7	1459	11	ERA	ERA	NNP
cord-034340-3ksfpaf7	1459	12	)	)	-RRB-
cord-034340-3ksfpaf7	1459	13	,	,	,
cord-034340-3ksfpaf7	1459	14	13	13	CD
cord-034340-3ksfpaf7	1459	15	polyarthritis	polyarthritis	NN
cord-034340-3ksfpaf7	1459	16	,	,	,
cord-034340-3ksfpaf7	1459	17	9	9	CD
cord-034340-3ksfpaf7	1459	18	oligoarthritis	oligoarthritis	NN
cord-034340-3ksfpaf7	1459	19	,	,	,
cord-034340-3ksfpaf7	1459	20	6	6	CD
cord-034340-3ksfpaf7	1459	21	psoriatic	psoriatic	NN
cord-034340-3ksfpaf7	1459	22	and	and	CC
cord-034340-3ksfpaf7	1459	23	3	3	CD
cord-034340-3ksfpaf7	1459	24	systemic	systemic	JJ
cord-034340-3ksfpaf7	1459	25	JIA	JIA	NNP
cord-034340-3ksfpaf7	1459	26	patients	patient	NNS
cord-034340-3ksfpaf7	1459	27	.	.	.
cord-034340-3ksfpaf7	1460	1	Their	-PRON-	PRP$
cord-034340-3ksfpaf7	1460	2	baseline	baseline	JJ
cord-034340-3ksfpaf7	1460	3	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1460	4	and	and	CC
cord-034340-3ksfpaf7	1460	5	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1460	6	are	be	VBP
cord-034340-3ksfpaf7	1460	7	summarised	summarise	VBN
cord-034340-3ksfpaf7	1460	8	in	in	IN
cord-034340-3ksfpaf7	1460	9	Table	Table	NNP
cord-034340-3ksfpaf7	1460	10	.	.	.
cord-034340-3ksfpaf7	1461	1	The	the	DT
cord-034340-3ksfpaf7	1461	2	mean	mean	JJ
cord-034340-3ksfpaf7	1461	3	duration	duration	NN
cord-034340-3ksfpaf7	1461	4	of	of	IN
cord-034340-3ksfpaf7	1461	5	follow	follow	NN
cord-034340-3ksfpaf7	1461	6	-	-	HYPH
cord-034340-3ksfpaf7	1461	7	up	up	NN
cord-034340-3ksfpaf7	1461	8	after	after	IN
cord-034340-3ksfpaf7	1461	9	the	the	DT
cord-034340-3ksfpaf7	1461	10	switch	switch	NN
cord-034340-3ksfpaf7	1461	11	to	to	IN
cord-034340-3ksfpaf7	1461	12	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1461	13	was	be	VBD
cord-034340-3ksfpaf7	1461	14	10	10	CD
cord-034340-3ksfpaf7	1461	15	months	month	NNS
cord-034340-3ksfpaf7	1462	1	(	(	-LRB-
cord-034340-3ksfpaf7	1462	2	range	range	NNP
cord-034340-3ksfpaf7	1462	3	2	2	CD
cord-034340-3ksfpaf7	1462	4	-	-	SYM
cord-034340-3ksfpaf7	1462	5	23	23	CD
cord-034340-3ksfpaf7	1462	6	)	)	-RRB-
cord-034340-3ksfpaf7	1462	7	.	.	.
cord-034340-3ksfpaf7	1463	1	Eleven	eleven	CD
cord-034340-3ksfpaf7	1463	2	patients	patient	NNS
cord-034340-3ksfpaf7	1463	3	(	(	-LRB-
cord-034340-3ksfpaf7	1463	4	18	18	CD
cord-034340-3ksfpaf7	1463	5	%	%	NN
cord-034340-3ksfpaf7	1463	6	)	)	-RRB-
cord-034340-3ksfpaf7	1463	7	reported	report	VBN
cord-034340-3ksfpaf7	1463	8	side	side	NN
cord-034340-3ksfpaf7	1463	9	effects	effect	NNS
cord-034340-3ksfpaf7	1463	10	;	;	:
cord-034340-3ksfpaf7	1463	11	the	the	DT
cord-034340-3ksfpaf7	1463	12	most	most	RBS
cord-034340-3ksfpaf7	1463	13	common	common	JJ
cord-034340-3ksfpaf7	1463	14	side	side	NN
cord-034340-3ksfpaf7	1463	15	effect	effect	NN
cord-034340-3ksfpaf7	1463	16	(	(	-LRB-
cord-034340-3ksfpaf7	1463	17	n=7	n=7	NNS
cord-034340-3ksfpaf7	1463	18	,	,	,
cord-034340-3ksfpaf7	1463	19	63.6	63.6	CD
cord-034340-3ksfpaf7	1463	20	%	%	NN
cord-034340-3ksfpaf7	1463	21	)	)	-RRB-
cord-034340-3ksfpaf7	1463	22	was	be	VBD
cord-034340-3ksfpaf7	1463	23	injection	injection	NN
cord-034340-3ksfpaf7	1463	24	site	site	NN
cord-034340-3ksfpaf7	1463	25	reactions	reaction	NNS
cord-034340-3ksfpaf7	1463	26	and	and	CC
cord-034340-3ksfpaf7	1463	27	the	the	DT
cord-034340-3ksfpaf7	1463	28	remaining	remain	VBG
cord-034340-3ksfpaf7	1463	29	4	4	CD
cord-034340-3ksfpaf7	1463	30	consisted	consisted	NNS
cord-034340-3ksfpaf7	1463	31	of	of	IN
cord-034340-3ksfpaf7	1463	32	anaphylaxis	anaphylaxis	NN
cord-034340-3ksfpaf7	1463	33	,	,	,
cord-034340-3ksfpaf7	1463	34	druginduced	druginduced	JJ
cord-034340-3ksfpaf7	1463	35	lupus	lupus	NN
cord-034340-3ksfpaf7	1463	36	,	,	,
cord-034340-3ksfpaf7	1463	37	dizziness	dizziness	NN
cord-034340-3ksfpaf7	1463	38	and	and	CC
cord-034340-3ksfpaf7	1463	39	bone	bone	NN
cord-034340-3ksfpaf7	1463	40	pain	pain	NN
cord-034340-3ksfpaf7	1463	41	,	,	,
cord-034340-3ksfpaf7	1463	42	respectively	respectively	RB
cord-034340-3ksfpaf7	1463	43	.	.	.
cord-034340-3ksfpaf7	1464	1	Seven	seven	CD
cord-034340-3ksfpaf7	1464	2	patients	patient	NNS
cord-034340-3ksfpaf7	1464	3	(	(	-LRB-
cord-034340-3ksfpaf7	1464	4	11.5	11.5	CD
cord-034340-3ksfpaf7	1464	5	%	%	NN
cord-034340-3ksfpaf7	1464	6	)	)	-RRB-
cord-034340-3ksfpaf7	1464	7	reverted	revert	VBD
cord-034340-3ksfpaf7	1464	8	to	to	IN
cord-034340-3ksfpaf7	1464	9	the	the	DT
cord-034340-3ksfpaf7	1464	10	Adalimumab	Adalimumab	NNP
cord-034340-3ksfpaf7	1464	11	originator	originator	NN
cord-034340-3ksfpaf7	1464	12	,	,	,
cord-034340-3ksfpaf7	1464	13	4	4	CD
cord-034340-3ksfpaf7	1464	14	as	as	IN
cord-034340-3ksfpaf7	1464	15	a	a	DT
cord-034340-3ksfpaf7	1464	16	result	result	NN
cord-034340-3ksfpaf7	1464	17	of	of	IN
cord-034340-3ksfpaf7	1464	18	side	side	NN
cord-034340-3ksfpaf7	1464	19	effects	effect	NNS
cord-034340-3ksfpaf7	1464	20	,	,	,
cord-034340-3ksfpaf7	1464	21	3	3	CD
cord-034340-3ksfpaf7	1464	22	because	because	IN
cord-034340-3ksfpaf7	1464	23	of	of	IN
cord-034340-3ksfpaf7	1464	24	ineffectiveness	ineffectiveness	NN
cord-034340-3ksfpaf7	1464	25	and	and	CC
cord-034340-3ksfpaf7	1464	26	one	one	CD
cord-034340-3ksfpaf7	1464	27	patient	patient	NN
cord-034340-3ksfpaf7	1464	28	for	for	IN
cord-034340-3ksfpaf7	1464	29	both	both	DT
cord-034340-3ksfpaf7	1464	30	reasons	reason	NNS
cord-034340-3ksfpaf7	1464	31	.	.	.
cord-034340-3ksfpaf7	1465	1	In	in	IN
cord-034340-3ksfpaf7	1465	2	addition	addition	NN
cord-034340-3ksfpaf7	1465	3	,	,	,
cord-034340-3ksfpaf7	1465	4	3	3	CD
cord-034340-3ksfpaf7	1465	5	patients	patient	NNS
cord-034340-3ksfpaf7	1465	6	were	be	VBD
cord-034340-3ksfpaf7	1465	7	changed	change	VBN
cord-034340-3ksfpaf7	1465	8	to	to	IN
cord-034340-3ksfpaf7	1465	9	a	a	DT
cord-034340-3ksfpaf7	1465	10	different	different	JJ
cord-034340-3ksfpaf7	1465	11	biologic	biologic	NN
cord-034340-3ksfpaf7	1465	12	,	,	,
cord-034340-3ksfpaf7	1465	13	one	one	CD
cord-034340-3ksfpaf7	1465	14	patient	patient	NN
cord-034340-3ksfpaf7	1465	15	due	due	IN
cord-034340-3ksfpaf7	1465	16	to	to	IN
cord-034340-3ksfpaf7	1465	17	allergy	allergy	NN
cord-034340-3ksfpaf7	1465	18	to	to	IN
cord-034340-3ksfpaf7	1465	19	both	both	CC
cord-034340-3ksfpaf7	1465	20	the	the	DT
cord-034340-3ksfpaf7	1465	21	originator	originator	NN
cord-034340-3ksfpaf7	1465	22	and	and	CC
cord-034340-3ksfpaf7	1465	23	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1465	24	and	and	CC
cord-034340-3ksfpaf7	1465	25	the	the	DT
cord-034340-3ksfpaf7	1465	26	other	other	JJ
cord-034340-3ksfpaf7	1465	27	two	two	CD
cord-034340-3ksfpaf7	1465	28	patients	patient	NNS
cord-034340-3ksfpaf7	1465	29	had	have	VBD
cord-034340-3ksfpaf7	1465	30	active	active	JJ
cord-034340-3ksfpaf7	1465	31	disease	disease	NN
cord-034340-3ksfpaf7	1465	32	on	on	IN
cord-034340-3ksfpaf7	1465	33	the	the	DT
cord-034340-3ksfpaf7	1465	34	originator	originator	NN
cord-034340-3ksfpaf7	1465	35	and	and	CC
cord-034340-3ksfpaf7	1465	36	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1465	37	Adalimumab	Adalimumab	NNP
cord-034340-3ksfpaf7	1465	38	.	.	.
cord-034340-3ksfpaf7	1466	1	Two	two	CD
cord-034340-3ksfpaf7	1466	2	patients	patient	NNS
cord-034340-3ksfpaf7	1466	3	stopped	stop	VBD
cord-034340-3ksfpaf7	1466	4	the	the	DT
cord-034340-3ksfpaf7	1466	5	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1466	6	and	and	CC
cord-034340-3ksfpaf7	1466	7	remained	remain	VBD
cord-034340-3ksfpaf7	1466	8	off	off	RP
cord-034340-3ksfpaf7	1466	9	any	any	DT
cord-034340-3ksfpaf7	1466	10	biologic	biologic	JJ
cord-034340-3ksfpaf7	1466	11	,	,	,
cord-034340-3ksfpaf7	1466	12	in	in	IN
cord-034340-3ksfpaf7	1466	13	the	the	DT
cord-034340-3ksfpaf7	1466	14	first	first	JJ
cord-034340-3ksfpaf7	1466	15	case	case	NN
cord-034340-3ksfpaf7	1466	16	this	this	DT
cord-034340-3ksfpaf7	1466	17	was	be	VBD
cord-034340-3ksfpaf7	1466	18	due	due	JJ
cord-034340-3ksfpaf7	1466	19	to	to	IN
cord-034340-3ksfpaf7	1466	20	a	a	DT
cord-034340-3ksfpaf7	1466	21	side	side	NN
cord-034340-3ksfpaf7	1466	22	effect	effect	NN
cord-034340-3ksfpaf7	1466	23	and	and	CC
cord-034340-3ksfpaf7	1466	24	in	in	IN
cord-034340-3ksfpaf7	1466	25	the	the	DT
cord-034340-3ksfpaf7	1466	26	second	second	JJ
cord-034340-3ksfpaf7	1466	27	case	case	NN
cord-034340-3ksfpaf7	1466	28	it	-PRON-	PRP
cord-034340-3ksfpaf7	1466	29	was	be	VBD
cord-034340-3ksfpaf7	1466	30	patient	patient	JJ
cord-034340-3ksfpaf7	1466	31	's	's	POS
cord-034340-3ksfpaf7	1466	32	choice	choice	NN
cord-034340-3ksfpaf7	1466	33	.	.	.
cord-034340-3ksfpaf7	1467	1	On	on	IN
cord-034340-3ksfpaf7	1467	2	the	the	DT
cord-034340-3ksfpaf7	1467	3	whole	whole	NN
cord-034340-3ksfpaf7	1467	4	,	,	,
cord-034340-3ksfpaf7	1467	5	78.7	78.7	CD
cord-034340-3ksfpaf7	1467	6	%	%	NN
cord-034340-3ksfpaf7	1467	7	of	of	IN
cord-034340-3ksfpaf7	1467	8	patients	patient	NNS
cord-034340-3ksfpaf7	1467	9	had	have	VBD
cord-034340-3ksfpaf7	1467	10	remained	remain	VBN
cord-034340-3ksfpaf7	1467	11	on	on	IN
cord-034340-3ksfpaf7	1467	12	ABP	ABP	NNP
cord-034340-3ksfpaf7	1467	13	501	501	CD
cord-034340-3ksfpaf7	1467	14	at	at	IN
cord-034340-3ksfpaf7	1467	15	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1467	16	last	last	JJ
cord-034340-3ksfpaf7	1467	17	visit	visit	NN
cord-034340-3ksfpaf7	1467	18	.	.	.
cord-034340-3ksfpaf7	1468	1	There	there	EX
cord-034340-3ksfpaf7	1468	2	was	be	VBD
cord-034340-3ksfpaf7	1468	3	no	no	DT
cord-034340-3ksfpaf7	1468	4	significant	significant	JJ
cord-034340-3ksfpaf7	1468	5	difference	difference	NN
cord-034340-3ksfpaf7	1468	6	in	in	IN
cord-034340-3ksfpaf7	1468	7	the	the	DT
cord-034340-3ksfpaf7	1468	8	active	active	JJ
cord-034340-3ksfpaf7	1468	9	joint	joint	JJ
cord-034340-3ksfpaf7	1468	10	count	count	NN
cord-034340-3ksfpaf7	1468	11	before	before	IN
cord-034340-3ksfpaf7	1468	12	the	the	DT
cord-034340-3ksfpaf7	1468	13	biosimilar	biosimilar	NNP
cord-034340-3ksfpaf7	1468	14	was	be	VBD
cord-034340-3ksfpaf7	1468	15	started	start	VBN
cord-034340-3ksfpaf7	1468	16	(	(	-LRB-
cord-034340-3ksfpaf7	1468	17	mean	mean	VB
cord-034340-3ksfpaf7	1468	18	0.55+/-1.11	0.55+/-1.11	CD
cord-034340-3ksfpaf7	1468	19	)	)	-RRB-
cord-034340-3ksfpaf7	1468	20	and	and	CC
cord-034340-3ksfpaf7	1468	21	after	after	IN
cord-034340-3ksfpaf7	1468	22	the	the	DT
cord-034340-3ksfpaf7	1468	23	switch	switch	NN
cord-034340-3ksfpaf7	1468	24	(	(	-LRB-
cord-034340-3ksfpaf7	1468	25	mean	mean	VB
cord-034340-3ksfpaf7	1468	26	0.6+/-1.59	0.6+/-1.59	CD
cord-034340-3ksfpaf7	1468	27	)	)	-RRB-
cord-034340-3ksfpaf7	1468	28	,	,	,
cord-034340-3ksfpaf7	1468	29	(	(	-LRB-
cord-034340-3ksfpaf7	1468	30	p=	p=	NNP
cord-034340-3ksfpaf7	1468	31	0.855	0.855	CD
cord-034340-3ksfpaf7	1468	32	)	)	-RRB-
cord-034340-3ksfpaf7	1468	33	.	.	.
cord-034340-3ksfpaf7	1469	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1469	2	:	:	:
cord-034340-3ksfpaf7	1470	1	Golimumab	Golimumab	NNP
cord-034340-3ksfpaf7	1470	2	(	(	-LRB-
cord-034340-3ksfpaf7	1470	3	GOL	GOL	NNP
cord-034340-3ksfpaf7	1470	4	)	)	-RRB-
cord-034340-3ksfpaf7	1470	5	is	be	VBZ
cord-034340-3ksfpaf7	1470	6	approved	approve	VBN
cord-034340-3ksfpaf7	1470	7	for	for	IN
cord-034340-3ksfpaf7	1470	8	polyarticular	polyarticular	JJ
cord-034340-3ksfpaf7	1470	9	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1470	10	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1470	11	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1470	12	(	(	-LRB-
cord-034340-3ksfpaf7	1470	13	pJIA	pjia	JJ
cord-034340-3ksfpaf7	1470	14	)	)	-RRB-
cord-034340-3ksfpaf7	1470	15	in	in	IN
cord-034340-3ksfpaf7	1470	16	patients	patient	NNS
cord-034340-3ksfpaf7	1470	17	of	of	IN
cord-034340-3ksfpaf7	1470	18	≥2years	≥2year	NNS
cord-034340-3ksfpaf7	1470	19	but	but	CC
cord-034340-3ksfpaf7	1470	20	long	long	JJ
cord-034340-3ksfpaf7	1470	21	-	-	HYPH
cord-034340-3ksfpaf7	1470	22	term	term	NN
cord-034340-3ksfpaf7	1470	23	safety	safety	NN
cord-034340-3ksfpaf7	1470	24	data	datum	NNS
cord-034340-3ksfpaf7	1470	25	are	be	VBP
cord-034340-3ksfpaf7	1470	26	limited	limited	JJ
cord-034340-3ksfpaf7	1470	27	.	.	.
cord-034340-3ksfpaf7	1471	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1471	2	:	:	:
cord-034340-3ksfpaf7	1471	3	Prospective	prospective	JJ
cord-034340-3ksfpaf7	1471	4	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1471	5	of	of	IN
cord-034340-3ksfpaf7	1471	6	long	long	JJ
cord-034340-3ksfpaf7	1471	7	-	-	HYPH
cord-034340-3ksfpaf7	1471	8	term	term	NN
cord-034340-3ksfpaf7	1471	9	safety	safety	NN
cord-034340-3ksfpaf7	1471	10	and	and	CC
cord-034340-3ksfpaf7	1471	11	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1471	12	of	of	IN
cord-034340-3ksfpaf7	1471	13	GOL	GOL	NNP
cord-034340-3ksfpaf7	1471	14	in	in	IN
cord-034340-3ksfpaf7	1471	15	routine	routine	JJ
cord-034340-3ksfpaf7	1471	16	care	care	NN
cord-034340-3ksfpaf7	1471	17	using	use	VBG
cord-034340-3ksfpaf7	1471	18	the	the	DT
cord-034340-3ksfpaf7	1471	19	BIKER	biker	NN
cord-034340-3ksfpaf7	1471	20	-	-	HYPH
cord-034340-3ksfpaf7	1471	21	registry	registry	NN
cord-034340-3ksfpaf7	1471	22	.	.	.
cord-034340-3ksfpaf7	1472	1	Methods	method	NNS
cord-034340-3ksfpaf7	1472	2	:	:	:
cord-034340-3ksfpaf7	1473	1	Baseline	baseline	JJ
cord-034340-3ksfpaf7	1473	2	demographics	demographic	NNS
cord-034340-3ksfpaf7	1473	3	,	,	,
cord-034340-3ksfpaf7	1473	4	clinical	clinical	JJ
cord-034340-3ksfpaf7	1473	5	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1473	6	,	,	,
cord-034340-3ksfpaf7	1473	7	disease	disease	NN
cord-034340-3ksfpaf7	1473	8	activity	activity	NN
cord-034340-3ksfpaf7	1473	9	and	and	CC
cord-034340-3ksfpaf7	1473	10	safety	safety	NN
cord-034340-3ksfpaf7	1473	11	parameters	parameter	NNS
cord-034340-3ksfpaf7	1473	12	were	be	VBD
cord-034340-3ksfpaf7	1473	13	compared	compare	VBN
cord-034340-3ksfpaf7	1473	14	to	to	IN
cord-034340-3ksfpaf7	1473	15	a	a	DT
cord-034340-3ksfpaf7	1473	16	contemporary	contemporary	JJ
cord-034340-3ksfpaf7	1473	17	1:2	1:2	CD
cord-034340-3ksfpaf7	1473	18	matched	match	VBN
cord-034340-3ksfpaf7	1473	19	control	control	NN
cord-034340-3ksfpaf7	1473	20	cohort	cohort	NN
cord-034340-3ksfpaf7	1473	21	using	use	VBG
cord-034340-3ksfpaf7	1473	22	alternative	alternative	JJ
cord-034340-3ksfpaf7	1473	23	TNF	TNF	NNP
cord-034340-3ksfpaf7	1473	24	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1473	25	or	or	CC
cord-034340-3ksfpaf7	1473	26	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	1473	27	without	without	IN
cord-034340-3ksfpaf7	1473	28	exposure	exposure	NN
cord-034340-3ksfpaf7	1473	29	to	to	IN
cord-034340-3ksfpaf7	1473	30	a	a	DT
cord-034340-3ksfpaf7	1473	31	biologic	biologic	NN
cord-034340-3ksfpaf7	1473	32	.	.	.
cord-034340-3ksfpaf7	1474	1	Efficacy	efficacy	NN
cord-034340-3ksfpaf7	1474	2	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1474	3	were	be	VBD
cord-034340-3ksfpaf7	1474	4	JADAS10	JADAS10	NNP
cord-034340-3ksfpaf7	1474	5	,	,	,
cord-034340-3ksfpaf7	1474	6	joint	joint	JJ
cord-034340-3ksfpaf7	1474	7	counts	count	NNS
cord-034340-3ksfpaf7	1474	8	and	and	CC
cord-034340-3ksfpaf7	1474	9	functional	functional	JJ
cord-034340-3ksfpaf7	1474	10	status	status	NN
cord-034340-3ksfpaf7	1474	11	.	.	.
cord-034340-3ksfpaf7	1475	1	Safety	safety	NN
cord-034340-3ksfpaf7	1475	2	assessments	assessment	NNS
cord-034340-3ksfpaf7	1475	3	were	be	VBD
cord-034340-3ksfpaf7	1475	4	based	base	VBN
cord-034340-3ksfpaf7	1475	5	on	on	IN
cord-034340-3ksfpaf7	1475	6	adverse	adverse	JJ
cord-034340-3ksfpaf7	1475	7	events	event	NNS
cord-034340-3ksfpaf7	1475	8	(	(	-LRB-
cord-034340-3ksfpaf7	1475	9	AE	AE	NNP
cord-034340-3ksfpaf7	1475	10	)	)	-RRB-
cord-034340-3ksfpaf7	1475	11	reports	report	NNS
cord-034340-3ksfpaf7	1475	12	.	.	.
cord-034340-3ksfpaf7	1476	1	Results	result	NNS
cord-034340-3ksfpaf7	1476	2	:	:	:
cord-034340-3ksfpaf7	1477	1	In	in	IN
cord-034340-3ksfpaf7	1477	2	this	this	DT
cord-034340-3ksfpaf7	1477	3	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	1477	4	study	study	NN
cord-034340-3ksfpaf7	1477	5	,	,	,
cord-034340-3ksfpaf7	1477	6	65	65	CD
cord-034340-3ksfpaf7	1477	7	pts	pts	NN
cord-034340-3ksfpaf7	1477	8	initiating	initiate	VBG
cord-034340-3ksfpaf7	1477	9	GOL	GOL	NNP
cord-034340-3ksfpaf7	1477	10	were	be	VBD
cord-034340-3ksfpaf7	1477	11	matched	match	VBN
cord-034340-3ksfpaf7	1477	12	to	to	IN
cord-034340-3ksfpaf7	1477	13	130	130	CD
cord-034340-3ksfpaf7	1477	14	with	with	IN
cord-034340-3ksfpaf7	1477	15	alternative	alternative	JJ
cord-034340-3ksfpaf7	1477	16	TNFi	TNFi	NNS
cord-034340-3ksfpaf7	1477	17	and	and	CC
cord-034340-3ksfpaf7	1477	18	65	65	CD
cord-034340-3ksfpaf7	1477	19	biologic	biologic	JJ
cord-034340-3ksfpaf7	1477	20	-	-	HYPH
cord-034340-3ksfpaf7	1477	21	naïve	naïve	JJ
cord-034340-3ksfpaf7	1477	22	pts	pt	NNS
cord-034340-3ksfpaf7	1477	23	.	.	.
cord-034340-3ksfpaf7	1478	1	Pts	Pts	NNP
cord-034340-3ksfpaf7	1478	2	starting	start	VBG
cord-034340-3ksfpaf7	1478	3	GOL	GOL	NNP
cord-034340-3ksfpaf7	1478	4	had	have	VBD
cord-034340-3ksfpaf7	1478	5	a	a	DT
cord-034340-3ksfpaf7	1478	6	longer	long	JJR
cord-034340-3ksfpaf7	1478	7	disease	disease	NN
cord-034340-3ksfpaf7	1478	8	duration	duration	NN
cord-034340-3ksfpaf7	1478	9	(	(	-LRB-
cord-034340-3ksfpaf7	1478	10	p<0.0001	p<0.0001	NNP
cord-034340-3ksfpaf7	1478	11	)	)	-RRB-
cord-034340-3ksfpaf7	1478	12	and	and	CC
cord-034340-3ksfpaf7	1478	13	use	use	NN
cord-034340-3ksfpaf7	1478	14	of	of	IN
cord-034340-3ksfpaf7	1478	15	GOL	GOL	NNP
cord-034340-3ksfpaf7	1478	16	was	be	VBD
cord-034340-3ksfpaf7	1478	17	significantly	significantly	RB
cord-034340-3ksfpaf7	1478	18	more	more	RBR
cord-034340-3ksfpaf7	1478	19	often	often	RB
cord-034340-3ksfpaf7	1478	20	second	second	JJ
cord-034340-3ksfpaf7	1478	21	line	line	NN
cord-034340-3ksfpaf7	1478	22	(	(	-LRB-
cord-034340-3ksfpaf7	1478	23	84.6	84.6	CD
cord-034340-3ksfpaf7	1478	24	%	%	NN
cord-034340-3ksfpaf7	1478	25	vs	vs	IN
cord-034340-3ksfpaf7	1478	26	22.3	22.3	CD
cord-034340-3ksfpaf7	1478	27	%	%	NN
cord-034340-3ksfpaf7	1478	28	,	,	,
cord-034340-3ksfpaf7	1478	29	p	p	NN
cord-034340-3ksfpaf7	1478	30	<	<	XX
cord-034340-3ksfpaf7	1478	31	0.0001	0.0001	CD
cord-034340-3ksfpaf7	1478	32	)	)	-RRB-
cord-034340-3ksfpaf7	1478	33	and	and	CC
cord-034340-3ksfpaf7	1478	34	thus	thus	RB
cord-034340-3ksfpaf7	1478	35	disease	disease	NN
cord-034340-3ksfpaf7	1478	36	activity	activity	NN
cord-034340-3ksfpaf7	1478	37	was	be	VBD
cord-034340-3ksfpaf7	1478	38	lower	low	JJR
cord-034340-3ksfpaf7	1478	39	at	at	IN
cord-034340-3ksfpaf7	1478	40	baseline	baseline	NN
cord-034340-3ksfpaf7	1478	41	.	.	.
cord-034340-3ksfpaf7	1479	1	Pts	Pts	NNP
cord-034340-3ksfpaf7	1479	2	in	in	IN
cord-034340-3ksfpaf7	1479	3	the	the	DT
cord-034340-3ksfpaf7	1479	4	GOL	GOL	NNP
cord-034340-3ksfpaf7	1479	5	cohort	cohort	NN
cord-034340-3ksfpaf7	1479	6	used	use	VBD
cord-034340-3ksfpaf7	1479	7	less	less	JJR
cord-034340-3ksfpaf7	1479	8	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	1479	9	,	,	,
cord-034340-3ksfpaf7	1479	10	otherwise	otherwise	RB
cord-034340-3ksfpaf7	1479	11	patients	patient	NNS
cord-034340-3ksfpaf7	1479	12	were	be	VBD
cord-034340-3ksfpaf7	1479	13	comparable	comparable	JJ
cord-034340-3ksfpaf7	1479	14	with	with	IN
cord-034340-3ksfpaf7	1479	15	pts	pt	NNS
cord-034340-3ksfpaf7	1479	16	treated	treat	VBN
cord-034340-3ksfpaf7	1479	17	with	with	IN
cord-034340-3ksfpaf7	1479	18	other	other	JJ
cord-034340-3ksfpaf7	1479	19	TNFi	TNFi	NNS
cord-034340-3ksfpaf7	1479	20	(	(	-LRB-
cord-034340-3ksfpaf7	1479	21	Table	table	NN
cord-034340-3ksfpaf7	1479	22	1	1	CD
cord-034340-3ksfpaf7	1479	23	)	)	-RRB-
cord-034340-3ksfpaf7	1479	24	.	.	.
cord-034340-3ksfpaf7	1480	1	In	in	IN
cord-034340-3ksfpaf7	1480	2	GOL	GOL	NNP
cord-034340-3ksfpaf7	1480	3	treated	treat	VBD
cord-034340-3ksfpaf7	1480	4	ps	ps	NN
cord-034340-3ksfpaf7	1481	1	a	a	DT
cord-034340-3ksfpaf7	1481	2	marked	marked	JJ
cord-034340-3ksfpaf7	1481	3	clinical	clinical	JJ
cord-034340-3ksfpaf7	1481	4	response	response	NN
cord-034340-3ksfpaf7	1481	5	was	be	VBD
cord-034340-3ksfpaf7	1481	6	noted	note	VBN
cord-034340-3ksfpaf7	1481	7	at	at	IN
cord-034340-3ksfpaf7	1481	8	6	6	CD
cord-034340-3ksfpaf7	1481	9	months	month	NNS
cord-034340-3ksfpaf7	1481	10	and	and	CC
cord-034340-3ksfpaf7	1481	11	beyond	beyond	IN
cord-034340-3ksfpaf7	1481	12	,	,	,
cord-034340-3ksfpaf7	1481	13	indicating	indicate	VBG
cord-034340-3ksfpaf7	1481	14	the	the	DT
cord-034340-3ksfpaf7	1481	15	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1481	16	of	of	IN
cord-034340-3ksfpaf7	1481	17	GOL	GOL	NNP
cord-034340-3ksfpaf7	1481	18	in	in	IN
cord-034340-3ksfpaf7	1481	19	the	the	DT
cord-034340-3ksfpaf7	1481	20	treatment	treatment	NN
cord-034340-3ksfpaf7	1481	21	of	of	IN
cord-034340-3ksfpaf7	1481	22	pJIA	pjia	NN
cord-034340-3ksfpaf7	1481	23	.	.	.
cord-034340-3ksfpaf7	1482	1	A	a	DT
cord-034340-3ksfpaf7	1482	2	significant	significant	JJ
cord-034340-3ksfpaf7	1482	3	decrease	decrease	NN
cord-034340-3ksfpaf7	1482	4	of	of	IN
cord-034340-3ksfpaf7	1482	5	the	the	DT
cord-034340-3ksfpaf7	1482	6	mean	mean	JJ
cord-034340-3ksfpaf7	1482	7	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	1482	8	10	10	CD
cord-034340-3ksfpaf7	1482	9	11.3	11.3	CD
cord-034340-3ksfpaf7	1482	10	to	to	IN
cord-034340-3ksfpaf7	1482	11	5.3	5.3	CD
cord-034340-3ksfpaf7	1482	12	(	(	-LRB-
cord-034340-3ksfpaf7	1482	13	p=	p=	NNP
cord-034340-3ksfpaf7	1482	14	0.0008	0.0008	CD
cord-034340-3ksfpaf7	1482	15	)	)	-RRB-
cord-034340-3ksfpaf7	1482	16	after	after	IN
cord-034340-3ksfpaf7	1482	17	6	6	CD
cord-034340-3ksfpaf7	1482	18	months	month	NNS
cord-034340-3ksfpaf7	1482	19	of	of	IN
cord-034340-3ksfpaf7	1482	20	treatment	treatment	NN
cord-034340-3ksfpaf7	1482	21	was	be	VBD
cord-034340-3ksfpaf7	1482	22	observed	observe	VBN
cord-034340-3ksfpaf7	1482	23	,	,	,
cord-034340-3ksfpaf7	1482	24	as	as	RB
cord-034340-3ksfpaf7	1482	25	well	well	RB
cord-034340-3ksfpaf7	1482	26	as	as	IN
cord-034340-3ksfpaf7	1482	27	JIA	JIA	NNP
cord-034340-3ksfpaf7	1482	28	ACR	ACR	NNP
cord-034340-3ksfpaf7	1482	29	30/50/70/90	30/50/70/90	CD
cord-034340-3ksfpaf7	1482	30	response	response	NN
cord-034340-3ksfpaf7	1482	31	rates	rate	NNS
cord-034340-3ksfpaf7	1482	32	of	of	IN
cord-034340-3ksfpaf7	1482	33	61/59/42/29	61/59/42/29	CD
cord-034340-3ksfpaf7	1482	34	%	%	NN
cord-034340-3ksfpaf7	1482	35	.	.	.
cord-034340-3ksfpaf7	1483	1	JADAS	jadas	NN
cord-034340-3ksfpaf7	1483	2	remission	remission	NN
cord-034340-3ksfpaf7	1483	3	and	and	CC
cord-034340-3ksfpaf7	1483	4	minimal	minimal	JJ
cord-034340-3ksfpaf7	1483	5	disease	disease	NN
cord-034340-3ksfpaf7	1483	6	activity	activity	NN
cord-034340-3ksfpaf7	1483	7	was	be	VBD
cord-034340-3ksfpaf7	1483	8	observed	observe	VBN
cord-034340-3ksfpaf7	1483	9	in	in	IN
cord-034340-3ksfpaf7	1483	10	27	27	CD
cord-034340-3ksfpaf7	1483	11	%	%	NN
cord-034340-3ksfpaf7	1483	12	and	and	CC
cord-034340-3ksfpaf7	1483	13	53.7	53.7	CD
cord-034340-3ksfpaf7	1483	14	%	%	NN
cord-034340-3ksfpaf7	1483	15	after	after	IN
cord-034340-3ksfpaf7	1483	16	6	6	CD
cord-034340-3ksfpaf7	1483	17	months	month	NNS
cord-034340-3ksfpaf7	1483	18	and	and	CC
cord-034340-3ksfpaf7	1483	19	in	in	IN
cord-034340-3ksfpaf7	1483	20	39	39	CD
cord-034340-3ksfpaf7	1483	21	%	%	NN
cord-034340-3ksfpaf7	1483	22	and	and	CC
cord-034340-3ksfpaf7	1483	23	54	54	CD
cord-034340-3ksfpaf7	1483	24	%	%	NN
cord-034340-3ksfpaf7	1483	25	after	after	IN
cord-034340-3ksfpaf7	1483	26	12	12	CD
cord-034340-3ksfpaf7	1483	27	months	month	NNS
cord-034340-3ksfpaf7	1483	28	of	of	IN
cord-034340-3ksfpaf7	1483	29	treatment	treatment	NN
cord-034340-3ksfpaf7	1483	30	.	.	.
cord-034340-3ksfpaf7	1484	1	Rates	rate	NNS
cord-034340-3ksfpaf7	1484	2	of	of	IN
cord-034340-3ksfpaf7	1484	3	AE	AE	NNP
cord-034340-3ksfpaf7	1484	4	,	,	,
cord-034340-3ksfpaf7	1484	5	SAE	SAE	NNP
cord-034340-3ksfpaf7	1484	6	and	and	CC
cord-034340-3ksfpaf7	1484	7	infectious	infectious	JJ
cord-034340-3ksfpaf7	1484	8	AE	AE	NNP
cord-034340-3ksfpaf7	1484	9	were	be	VBD
cord-034340-3ksfpaf7	1484	10	comparable	comparable	JJ
cord-034340-3ksfpaf7	1484	11	in	in	IN
cord-034340-3ksfpaf7	1484	12	the	the	DT
cord-034340-3ksfpaf7	1484	13	GOL	GOL	NNP
cord-034340-3ksfpaf7	1484	14	cohort	cohort	NN
cord-034340-3ksfpaf7	1484	15	(	(	-LRB-
cord-034340-3ksfpaf7	1484	16	87.5/100PY	87.5/100py	CD
cord-034340-3ksfpaf7	1484	17	,	,	,
cord-034340-3ksfpaf7	1484	18	3.4/100PY	3.4/100py	CD
cord-034340-3ksfpaf7	1484	19	and	and	CC
cord-034340-3ksfpaf7	1484	20	11.1/100PY	11.1/100py	CD
cord-034340-3ksfpaf7	1484	21	)	)	-RRB-
cord-034340-3ksfpaf7	1484	22	,	,	,
cord-034340-3ksfpaf7	1484	23	the	the	DT
cord-034340-3ksfpaf7	1484	24	alternative	alternative	JJ
cord-034340-3ksfpaf7	1484	25	TNFi	TNFi	NNP
cord-034340-3ksfpaf7	1484	26	cohort	cohort	NN
cord-034340-3ksfpaf7	1484	27	(	(	-LRB-
cord-034340-3ksfpaf7	1484	28	92.3/100PY	92.3/100py	CD
cord-034340-3ksfpaf7	1484	29	,	,	,
cord-034340-3ksfpaf7	1484	30	2.9/100PY	2.9/100py	CD
cord-034340-3ksfpaf7	1484	31	and	and	CC
cord-034340-3ksfpaf7	1484	32	9.7/100PY	9.7/100py	CD
cord-034340-3ksfpaf7	1484	33	)	)	-RRB-
cord-034340-3ksfpaf7	1484	34	and	and	CC
cord-034340-3ksfpaf7	1484	35	the	the	DT
cord-034340-3ksfpaf7	1484	36	MTX	MTX	NNP
cord-034340-3ksfpaf7	1484	37	only	only	RB
cord-034340-3ksfpaf7	1484	38	cohort	cohort	NN
cord-034340-3ksfpaf7	1484	39	(	(	-LRB-
cord-034340-3ksfpaf7	1484	40	121.2/100PY	121.2/100py	CD
cord-034340-3ksfpaf7	1484	41	,	,	,
cord-034340-3ksfpaf7	1484	42	2.1/100PY	2.1/100py	CD
cord-034340-3ksfpaf7	1484	43	and	and	CC
cord-034340-3ksfpaf7	1484	44	18.5/100PY	18.5/100py	CD
cord-034340-3ksfpaf7	1484	45	)	)	-RRB-
cord-034340-3ksfpaf7	1484	46	.	.	.
cord-034340-3ksfpaf7	1485	1	SAE	SAE	NNP
cord-034340-3ksfpaf7	1485	2	reported	report	VBD
cord-034340-3ksfpaf7	1485	3	in	in	IN
cord-034340-3ksfpaf7	1485	4	the	the	DT
cord-034340-3ksfpaf7	1485	5	GOL	GOL	NNP
cord-034340-3ksfpaf7	1485	6	cohort	cohort	NN
cord-034340-3ksfpaf7	1485	7	were	be	VBD
cord-034340-3ksfpaf7	1485	8	flares	flare	NNS
cord-034340-3ksfpaf7	1485	9	of	of	IN
cord-034340-3ksfpaf7	1485	10	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1485	11	and	and	CC
cord-034340-3ksfpaf7	1485	12	of	of	IN
cord-034340-3ksfpaf7	1485	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	1485	14	(	(	-LRB-
cord-034340-3ksfpaf7	1485	15	each	each	DT
cord-034340-3ksfpaf7	1485	16	1	1	CD
cord-034340-3ksfpaf7	1485	17	)	)	-RRB-
cord-034340-3ksfpaf7	1485	18	and	and	CC
cord-034340-3ksfpaf7	1485	19	fibromyalgia	fibromyalgia	NNP
cord-034340-3ksfpaf7	1485	20	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1485	21	(	(	-LRB-
cord-034340-3ksfpaf7	1485	22	1	1	CD
cord-034340-3ksfpaf7	1485	23	)	)	-RRB-
cord-034340-3ksfpaf7	1485	24	.	.	.
cord-034340-3ksfpaf7	1486	1	SAE	SAE	NNP
cord-034340-3ksfpaf7	1486	2	reported	report	VBD
cord-034340-3ksfpaf7	1486	3	in	in	IN
cord-034340-3ksfpaf7	1486	4	the	the	DT
cord-034340-3ksfpaf7	1486	5	alternative	alternative	JJ
cord-034340-3ksfpaf7	1486	6	TNF	TNF	NNP
cord-034340-3ksfpaf7	1486	7	cohort	cohort	NN
cord-034340-3ksfpaf7	1486	8	was	be	VBD
cord-034340-3ksfpaf7	1486	9	two	two	CD
cord-034340-3ksfpaf7	1486	10	serious	serious	JJ
cord-034340-3ksfpaf7	1486	11	infections	infection	NNS
cord-034340-3ksfpaf7	1486	12	(	(	-LRB-
cord-034340-3ksfpaf7	1486	13	both	both	DT
cord-034340-3ksfpaf7	1486	14	influenza	influenza	NN
cord-034340-3ksfpaf7	1486	15	)	)	-RRB-
cord-034340-3ksfpaf7	1486	16	,	,	,
cord-034340-3ksfpaf7	1486	17	one	one	CD
cord-034340-3ksfpaf7	1486	18	knee	knee	NN
cord-034340-3ksfpaf7	1486	19	ligament	ligament	NN
cord-034340-3ksfpaf7	1486	20	injury	injury	NN
cord-034340-3ksfpaf7	1486	21	,	,	,
cord-034340-3ksfpaf7	1486	22	one	one	CD
cord-034340-3ksfpaf7	1486	23	flare	flare	NN
cord-034340-3ksfpaf7	1486	24	of	of	IN
cord-034340-3ksfpaf7	1486	25	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1486	26	and	and	CC
cord-034340-3ksfpaf7	1486	27	one	one	CD
cord-034340-3ksfpaf7	1486	28	hyperventilation	hyperventilation	NN
cord-034340-3ksfpaf7	1486	29	.	.	.
cord-034340-3ksfpaf7	1487	1	No	no	DT
cord-034340-3ksfpaf7	1487	2	case	case	NN
cord-034340-3ksfpaf7	1487	3	of	of	IN
cord-034340-3ksfpaf7	1487	4	pregnancy	pregnancy	NN
cord-034340-3ksfpaf7	1487	5	,	,	,
cord-034340-3ksfpaf7	1487	6	malignancy	malignancy	NN
cord-034340-3ksfpaf7	1487	7	or	or	CC
cord-034340-3ksfpaf7	1487	8	death	death	NN
cord-034340-3ksfpaf7	1487	9	was	be	VBD
cord-034340-3ksfpaf7	1487	10	reported	report	VBN
cord-034340-3ksfpaf7	1487	11	.	.	.
cord-034340-3ksfpaf7	1488	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1488	2	:	:	:
cord-034340-3ksfpaf7	1489	1	Golimumab	Golimumab	NNP
cord-034340-3ksfpaf7	1489	2	seems	seem	VBZ
cord-034340-3ksfpaf7	1489	3	an	an	DT
cord-034340-3ksfpaf7	1489	4	effective	effective	JJ
cord-034340-3ksfpaf7	1489	5	in	in	IN
cord-034340-3ksfpaf7	1489	6	treatment	treatment	NN
cord-034340-3ksfpaf7	1489	7	of	of	IN
cord-034340-3ksfpaf7	1489	8	pJIA	pjia	NN
cord-034340-3ksfpaf7	1489	9	.	.	.
cord-034340-3ksfpaf7	1490	1	Tolerability	tolerability	NN
cord-034340-3ksfpaf7	1490	2	was	be	VBD
cord-034340-3ksfpaf7	1490	3	acceptable	acceptable	JJ
cord-034340-3ksfpaf7	1490	4	and	and	CC
cord-034340-3ksfpaf7	1490	5	comparable	comparable	JJ
cord-034340-3ksfpaf7	1490	6	to	to	IN
cord-034340-3ksfpaf7	1490	7	alternative	alternative	JJ
cord-034340-3ksfpaf7	1490	8	TNFi	TNFi	NNS
cord-034340-3ksfpaf7	1490	9	or	or	CC
cord-034340-3ksfpaf7	1490	10	MTX	MTX	NNP
cord-034340-3ksfpaf7	1490	11	.	.	.
cord-034340-3ksfpaf7	1491	1	Recruitment	recruitment	NN
cord-034340-3ksfpaf7	1491	2	to	to	IN
cord-034340-3ksfpaf7	1491	3	the	the	DT
cord-034340-3ksfpaf7	1491	4	project	project	NN
cord-034340-3ksfpaf7	1491	5	is	be	VBZ
cord-034340-3ksfpaf7	1491	6	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	1491	7	.	.	.
cord-034340-3ksfpaf7	1492	1	Disclosure	disclosure	NN
cord-034340-3ksfpaf7	1492	2	of	of	IN
cord-034340-3ksfpaf7	1492	3	Interest	Interest	NNP
cord-034340-3ksfpaf7	1493	1	None	none	NN
cord-034340-3ksfpaf7	1493	2	declared	declare	VBD
cord-034340-3ksfpaf7	1493	3	Introduction	introduction	NN
cord-034340-3ksfpaf7	1493	4	:	:	:
cord-034340-3ksfpaf7	1493	5	Methotrexate	Methotrexate	NNP
cord-034340-3ksfpaf7	1493	6	(	(	-LRB-
cord-034340-3ksfpaf7	1493	7	MTX	MTX	NNP
cord-034340-3ksfpaf7	1493	8	)	)	-RRB-
cord-034340-3ksfpaf7	1493	9	is	be	VBZ
cord-034340-3ksfpaf7	1493	10	one	one	CD
cord-034340-3ksfpaf7	1493	11	of	of	IN
cord-034340-3ksfpaf7	1493	12	the	the	DT
cord-034340-3ksfpaf7	1493	13	most	most	RBS
cord-034340-3ksfpaf7	1493	14	commonly	commonly	RB
cord-034340-3ksfpaf7	1493	15	used	use	VBN
cord-034340-3ksfpaf7	1493	16	disease	disease	NN
cord-034340-3ksfpaf7	1493	17	-	-	HYPH
cord-034340-3ksfpaf7	1493	18	modifying	modify	VBG
cord-034340-3ksfpaf7	1493	19	anti	anti	JJ
cord-034340-3ksfpaf7	1493	20	-	-	JJ
cord-034340-3ksfpaf7	1493	21	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1493	22	drug	drug	NN
cord-034340-3ksfpaf7	1493	23	in	in	IN
cord-034340-3ksfpaf7	1493	24	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1493	25	practice	practice	NN
cord-034340-3ksfpaf7	1493	26	.	.	.
cord-034340-3ksfpaf7	1494	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1494	2	has	have	VBZ
cord-034340-3ksfpaf7	1494	3	some	some	DT
cord-034340-3ksfpaf7	1494	4	side	side	JJ
cord-034340-3ksfpaf7	1494	5	effects	effect	NNS
cord-034340-3ksfpaf7	1494	6	that	that	WDT
cord-034340-3ksfpaf7	1494	7	can	can	MD
cord-034340-3ksfpaf7	1494	8	impair	impair	VB
cord-034340-3ksfpaf7	1494	9	quality	quality	NN
cord-034340-3ksfpaf7	1494	10	of	of	IN
cord-034340-3ksfpaf7	1494	11	life	life	NN
cord-034340-3ksfpaf7	1494	12	.	.	.
cord-034340-3ksfpaf7	1495	1	The	the	DT
cord-034340-3ksfpaf7	1495	2	most	most	RBS
cord-034340-3ksfpaf7	1495	3	common	common	JJ
cord-034340-3ksfpaf7	1495	4	of	of	IN
cord-034340-3ksfpaf7	1495	5	them	-PRON-	PRP
cord-034340-3ksfpaf7	1495	6	is	be	VBZ
cord-034340-3ksfpaf7	1495	7	associated	associate	VBN
cord-034340-3ksfpaf7	1495	8	with	with	IN
cord-034340-3ksfpaf7	1495	9	the	the	DT
cord-034340-3ksfpaf7	1495	10	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1495	11	tract	tract	NN
cord-034340-3ksfpaf7	1495	12	.	.	.
cord-034340-3ksfpaf7	1496	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1496	2	:	:	:
cord-034340-3ksfpaf7	1497	1	The	the	DT
cord-034340-3ksfpaf7	1497	2	aim	aim	NN
cord-034340-3ksfpaf7	1497	3	of	of	IN
cord-034340-3ksfpaf7	1497	4	the	the	DT
cord-034340-3ksfpaf7	1497	5	study	study	NN
cord-034340-3ksfpaf7	1497	6	is	be	VBZ
cord-034340-3ksfpaf7	1497	7	to	to	TO
cord-034340-3ksfpaf7	1497	8	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1497	9	and	and	CC
cord-034340-3ksfpaf7	1497	10	compare	compare	VB
cord-034340-3ksfpaf7	1497	11	the	the	DT
cord-034340-3ksfpaf7	1497	12	frequency	frequency	NN
cord-034340-3ksfpaf7	1497	13	of	of	IN
cord-034340-3ksfpaf7	1497	14	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	1497	15	intolerance	intolerance	NN
cord-034340-3ksfpaf7	1497	16	in	in	IN
cord-034340-3ksfpaf7	1497	17	adult	adult	NN
cord-034340-3ksfpaf7	1497	18	and	and	CC
cord-034340-3ksfpaf7	1497	19	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1497	20	patients	patient	NNS
cord-034340-3ksfpaf7	1497	21	.	.	.
cord-034340-3ksfpaf7	1498	1	Methods	method	NNS
cord-034340-3ksfpaf7	1498	2	:	:	:
cord-034340-3ksfpaf7	1498	3	Patients	patient	NNS
cord-034340-3ksfpaf7	1498	4	with	with	IN
cord-034340-3ksfpaf7	1498	5	rheumatologic	rheumatologic	JJ
cord-034340-3ksfpaf7	1498	6	diseases	disease	NNS
cord-034340-3ksfpaf7	1498	7	followed	follow	VBN
cord-034340-3ksfpaf7	1498	8	in	in	IN
cord-034340-3ksfpaf7	1498	9	Hacettepe	Hacettepe	NNP
cord-034340-3ksfpaf7	1498	10	University	University	NNP
cord-034340-3ksfpaf7	1498	11	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	1498	12	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1498	13	and	and	CC
cord-034340-3ksfpaf7	1498	14	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1498	15	departments	department	NNS
cord-034340-3ksfpaf7	1498	16	who	who	WP
cord-034340-3ksfpaf7	1498	17	used	use	VBD
cord-034340-3ksfpaf7	1498	18	oral	oral	JJ
cord-034340-3ksfpaf7	1498	19	or	or	CC
cord-034340-3ksfpaf7	1498	20	parenteral	parenteral	JJ
cord-034340-3ksfpaf7	1498	21	methotrexate	methotrexate	NNP
cord-034340-3ksfpaf7	1498	22	for	for	IN
cord-034340-3ksfpaf7	1498	23	at	at	RB
cord-034340-3ksfpaf7	1498	24	least	least	JJS
cord-034340-3ksfpaf7	1498	25	3	3	CD
cord-034340-3ksfpaf7	1498	26	months	month	NNS
cord-034340-3ksfpaf7	1498	27	were	be	VBD
cord-034340-3ksfpaf7	1498	28	included	include	VBN
cord-034340-3ksfpaf7	1498	29	in	in	IN
cord-034340-3ksfpaf7	1498	30	the	the	DT
cord-034340-3ksfpaf7	1498	31	study	study	NN
cord-034340-3ksfpaf7	1498	32	.	.	.
cord-034340-3ksfpaf7	1499	1	Methotrexate	methotrexate	JJ
cord-034340-3ksfpaf7	1499	2	intolerance	intolerance	NN
cord-034340-3ksfpaf7	1499	3	was	be	VBD
cord-034340-3ksfpaf7	1499	4	assessed	assess	VBN
cord-034340-3ksfpaf7	1499	5	using	use	VBG
cord-034340-3ksfpaf7	1499	6	'	'	``
cord-034340-3ksfpaf7	1499	7	Methotrexate	Methotrexate	NNP
cord-034340-3ksfpaf7	1499	8	Intolerance	intolerance	NN
cord-034340-3ksfpaf7	1499	9	Severity	severity	NN
cord-034340-3ksfpaf7	1499	10	Score	score	NN
cord-034340-3ksfpaf7	1499	11	(	(	-LRB-
cord-034340-3ksfpaf7	1499	12	MISS	MISS	NNP
cord-034340-3ksfpaf7	1499	13	)	)	-RRB-
cord-034340-3ksfpaf7	1499	14	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1499	15	.	.	.
cord-034340-3ksfpaf7	1500	1	The	the	DT
cord-034340-3ksfpaf7	1500	2	MISS	MISS	NNP
cord-034340-3ksfpaf7	1500	3	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1500	4	consisted	consist	VBD
cord-034340-3ksfpaf7	1500	5	of	of	IN
cord-034340-3ksfpaf7	1500	6	5	5	CD
cord-034340-3ksfpaf7	1500	7	parts	part	NNS
cord-034340-3ksfpaf7	1500	8	:	:	:
cord-034340-3ksfpaf7	1500	9	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1500	10	pain	pain	NN
cord-034340-3ksfpaf7	1500	11	,	,	,
cord-034340-3ksfpaf7	1500	12	nausea	nausea	NN
cord-034340-3ksfpaf7	1500	13	,	,	,
cord-034340-3ksfpaf7	1500	14	vomiting	vomiting	NN
cord-034340-3ksfpaf7	1500	15	,	,	,
cord-034340-3ksfpaf7	1500	16	fatigue	fatigue	NN
cord-034340-3ksfpaf7	1500	17	and	and	CC
cord-034340-3ksfpaf7	1500	18	behavioral	behavioral	JJ
cord-034340-3ksfpaf7	1500	19	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1500	20	.	.	.
cord-034340-3ksfpaf7	1501	1	The	the	DT
cord-034340-3ksfpaf7	1501	2	patients	patient	NNS
cord-034340-3ksfpaf7	1501	3	scored	score	VBD
cord-034340-3ksfpaf7	1501	4	the	the	DT
cord-034340-3ksfpaf7	1501	5	severity	severity	NN
cord-034340-3ksfpaf7	1501	6	of	of	IN
cord-034340-3ksfpaf7	1501	7	each	each	DT
cord-034340-3ksfpaf7	1501	8	symptom	symptom	NN
cord-034340-3ksfpaf7	1501	9	separately	separately	RB
cord-034340-3ksfpaf7	1501	10	;	;	:
cord-034340-3ksfpaf7	1501	11	0	0	NFP
cord-034340-3ksfpaf7	1502	1	:	:	:
cord-034340-3ksfpaf7	1502	2	no	no	DT
cord-034340-3ksfpaf7	1502	3	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1502	4	,	,	,
cord-034340-3ksfpaf7	1502	5	1	1	CD
cord-034340-3ksfpaf7	1502	6	:	:	:
cord-034340-3ksfpaf7	1502	7	mild	mild	JJ
cord-034340-3ksfpaf7	1502	8	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1502	9	,	,	,
cord-034340-3ksfpaf7	1502	10	2	2	CD
cord-034340-3ksfpaf7	1502	11	:	:	:
cord-034340-3ksfpaf7	1502	12	moderate	moderate	JJ
cord-034340-3ksfpaf7	1502	13	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1502	14	,	,	,
cord-034340-3ksfpaf7	1502	15	3	3	CD
cord-034340-3ksfpaf7	1502	16	:	:	:
cord-034340-3ksfpaf7	1502	17	severe	severe	JJ
cord-034340-3ksfpaf7	1502	18	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1502	19	.	.	.
cord-034340-3ksfpaf7	1503	1	A	a	DT
cord-034340-3ksfpaf7	1503	2	total	total	JJ
cord-034340-3ksfpaf7	1503	3	score	score	NN
cord-034340-3ksfpaf7	1503	4	of	of	IN
cord-034340-3ksfpaf7	1503	5	6	6	CD
cord-034340-3ksfpaf7	1503	6	or	or	CC
cord-034340-3ksfpaf7	1503	7	more	more	JJR
cord-034340-3ksfpaf7	1503	8	was	be	VBD
cord-034340-3ksfpaf7	1503	9	defined	define	VBN
cord-034340-3ksfpaf7	1503	10	as	as	IN
cord-034340-3ksfpaf7	1503	11	MTX	MTX	NNP
cord-034340-3ksfpaf7	1503	12	intolerance	intolerance	NN
cord-034340-3ksfpaf7	1503	13	.	.	.
cord-034340-3ksfpaf7	1504	1	Visual	visual	JJ
cord-034340-3ksfpaf7	1504	2	analogue	analogue	NN
cord-034340-3ksfpaf7	1504	3	scale	scale	NN
cord-034340-3ksfpaf7	1504	4	(	(	-LRB-
cord-034340-3ksfpaf7	1504	5	VAS	vas	NN
cord-034340-3ksfpaf7	1504	6	)	)	-RRB-
cord-034340-3ksfpaf7	1504	7	ranging	range	VBG
cord-034340-3ksfpaf7	1504	8	from	from	IN
cord-034340-3ksfpaf7	1504	9	0	0	CD
cord-034340-3ksfpaf7	1504	10	cm	cm	NN
cord-034340-3ksfpaf7	1504	11	to	to	IN
cord-034340-3ksfpaf7	1504	12	10	10	CD
cord-034340-3ksfpaf7	1504	13	cm	cm	NNS
cord-034340-3ksfpaf7	1504	14	was	be	VBD
cord-034340-3ksfpaf7	1504	15	performed	perform	VBN
cord-034340-3ksfpaf7	1504	16	to	to	IN
cord-034340-3ksfpaf7	1504	17	each	each	DT
cord-034340-3ksfpaf7	1504	18	patient	patient	NN
cord-034340-3ksfpaf7	1504	19	concurrently	concurrently	RB
cord-034340-3ksfpaf7	1504	20	with	with	IN
cord-034340-3ksfpaf7	1504	21	the	the	DT
cord-034340-3ksfpaf7	1504	22	MISS	MISS	NNP
cord-034340-3ksfpaf7	1504	23	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1504	24	.	.	.
cord-034340-3ksfpaf7	1505	1	In	in	IN
cord-034340-3ksfpaf7	1505	2	the	the	DT
cord-034340-3ksfpaf7	1505	3	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1505	4	patient	patient	NN
cord-034340-3ksfpaf7	1505	5	group	group	NN
cord-034340-3ksfpaf7	1505	6	,	,	,
cord-034340-3ksfpaf7	1505	7	MISS	MISS	NNP
cord-034340-3ksfpaf7	1505	8	questionnaire	questionnaire	NN
cord-034340-3ksfpaf7	1505	9	and	and	CC
cord-034340-3ksfpaf7	1505	10	VAS	VAS	NNP
cord-034340-3ksfpaf7	1505	11	assessment	assessment	NN
cord-034340-3ksfpaf7	1505	12	were	be	VBD
cord-034340-3ksfpaf7	1505	13	applied	apply	VBN
cord-034340-3ksfpaf7	1505	14	to	to	IN
cord-034340-3ksfpaf7	1505	15	both	both	DT
cord-034340-3ksfpaf7	1505	16	patients	patient	NNS
cord-034340-3ksfpaf7	1505	17	and	and	CC
cord-034340-3ksfpaf7	1505	18	families	family	NNS
cord-034340-3ksfpaf7	1505	19	.	.	.
cord-034340-3ksfpaf7	1506	1	Results	result	NNS
cord-034340-3ksfpaf7	1506	2	:	:	:
cord-034340-3ksfpaf7	1507	1	A	a	DT
cord-034340-3ksfpaf7	1507	2	total	total	NN
cord-034340-3ksfpaf7	1507	3	of	of	IN
cord-034340-3ksfpaf7	1507	4	100	100	CD
cord-034340-3ksfpaf7	1507	5	patients	patient	NNS
cord-034340-3ksfpaf7	1507	6	,	,	,
cord-034340-3ksfpaf7	1507	7	50	50	CD
cord-034340-3ksfpaf7	1507	8	of	of	IN
cord-034340-3ksfpaf7	1507	9	whom	whom	WP
cord-034340-3ksfpaf7	1507	10	were	be	VBD
cord-034340-3ksfpaf7	1507	11	children	child	NNS
cord-034340-3ksfpaf7	1507	12	,	,	,
cord-034340-3ksfpaf7	1507	13	enrolled	enrol	VBN
cord-034340-3ksfpaf7	1507	14	in	in	IN
cord-034340-3ksfpaf7	1507	15	the	the	DT
cord-034340-3ksfpaf7	1507	16	study	study	NN
cord-034340-3ksfpaf7	1507	17	.	.	.
cord-034340-3ksfpaf7	1508	1	The	the	DT
cord-034340-3ksfpaf7	1508	2	mean	mean	JJ
cord-034340-3ksfpaf7	1508	3	age	age	NN
cord-034340-3ksfpaf7	1508	4	for	for	IN
cord-034340-3ksfpaf7	1508	5	children	child	NNS
cord-034340-3ksfpaf7	1508	6	and	and	CC
cord-034340-3ksfpaf7	1508	7	adults	adult	NNS
cord-034340-3ksfpaf7	1508	8	were	be	VBD
cord-034340-3ksfpaf7	1508	9	11.78	11.78	CD
cord-034340-3ksfpaf7	1508	10	(	(	-LRB-
cord-034340-3ksfpaf7	1508	11	±	±	NNP
cord-034340-3ksfpaf7	1508	12	3.4	3.4	CD
cord-034340-3ksfpaf7	1508	13	)	)	-RRB-
cord-034340-3ksfpaf7	1508	14	and	and	CC
cord-034340-3ksfpaf7	1508	15	52.9	52.9	CD
cord-034340-3ksfpaf7	1508	16	(	(	-LRB-
cord-034340-3ksfpaf7	1508	17	±	±	CD
cord-034340-3ksfpaf7	1508	18	11.8	11.8	CD
cord-034340-3ksfpaf7	1508	19	)	)	-RRB-
cord-034340-3ksfpaf7	1508	20	respectively	respectively	RB
cord-034340-3ksfpaf7	1508	21	.	.	.
cord-034340-3ksfpaf7	1509	1	The	the	DT
cord-034340-3ksfpaf7	1509	2	most	most	RBS
cord-034340-3ksfpaf7	1509	3	frequent	frequent	JJ
cord-034340-3ksfpaf7	1509	4	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1509	5	of	of	IN
cord-034340-3ksfpaf7	1509	6	patients	patient	NNS
cord-034340-3ksfpaf7	1509	7	was	be	VBD
cord-034340-3ksfpaf7	1509	8	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1509	9	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1509	10	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1509	11	(	(	-LRB-
cord-034340-3ksfpaf7	1509	12	78.0	78.0	CD
cord-034340-3ksfpaf7	1509	13	%	%	NN
cord-034340-3ksfpaf7	1509	14	)	)	-RRB-
cord-034340-3ksfpaf7	1509	15	in	in	IN
cord-034340-3ksfpaf7	1509	16	children	child	NNS
cord-034340-3ksfpaf7	1509	17	and	and	CC
cord-034340-3ksfpaf7	1509	18	rheumatoid	rheumatoid	NN
cord-034340-3ksfpaf7	1509	19	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1509	20	in	in	IN
cord-034340-3ksfpaf7	1509	21	adults	adult	NNS
cord-034340-3ksfpaf7	1509	22	(	(	-LRB-
cord-034340-3ksfpaf7	1509	23	68.0	68.0	CD
cord-034340-3ksfpaf7	1509	24	%	%	NN
cord-034340-3ksfpaf7	1509	25	)	)	-RRB-
cord-034340-3ksfpaf7	1509	26	.	.	.
cord-034340-3ksfpaf7	1510	1	The	the	DT
cord-034340-3ksfpaf7	1510	2	mean	mean	JJ
cord-034340-3ksfpaf7	1510	3	MTX	MTX	NNP
cord-034340-3ksfpaf7	1510	4	dose	dose	NN
cord-034340-3ksfpaf7	1510	5	in	in	IN
cord-034340-3ksfpaf7	1510	6	adults	adult	NNS
cord-034340-3ksfpaf7	1510	7	and	and	CC
cord-034340-3ksfpaf7	1510	8	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1510	9	group	group	NN
cord-034340-3ksfpaf7	1510	10	was	be	VBD
cord-034340-3ksfpaf7	1510	11	12.5	12.5	CD
cord-034340-3ksfpaf7	1510	12	(	(	-LRB-
cord-034340-3ksfpaf7	1510	13	±3	±3	NNP
cord-034340-3ksfpaf7	1510	14	)	)	-RRB-
cord-034340-3ksfpaf7	1511	1	mg	mg	NNP
cord-034340-3ksfpaf7	1512	1	vs	vs	IN
cord-034340-3ksfpaf7	1512	2	14.5	14.5	CD
cord-034340-3ksfpaf7	1512	3	(	(	-LRB-
cord-034340-3ksfpaf7	1512	4	±	±	NNP
cord-034340-3ksfpaf7	1512	5	3.6	3.6	CD
cord-034340-3ksfpaf7	1512	6	)	)	-RRB-
cord-034340-3ksfpaf7	1512	7	mg	mg	NN
cord-034340-3ksfpaf7	1513	1	(	(	-LRB-
cord-034340-3ksfpaf7	1513	2	p	p	NN
cord-034340-3ksfpaf7	1513	3	:	:	:
cord-034340-3ksfpaf7	1513	4	0.004	0.004	CD
cord-034340-3ksfpaf7	1513	5	)	)	-RRB-
cord-034340-3ksfpaf7	1513	6	.	.	.
cord-034340-3ksfpaf7	1514	1	The	the	DT
cord-034340-3ksfpaf7	1514	2	prevalence	prevalence	NN
cord-034340-3ksfpaf7	1514	3	of	of	IN
cord-034340-3ksfpaf7	1514	4	MTX	MTX	NNP
cord-034340-3ksfpaf7	1514	5	intolerance	intolerance	NN
cord-034340-3ksfpaf7	1514	6	in	in	IN
cord-034340-3ksfpaf7	1514	7	children	child	NNS
cord-034340-3ksfpaf7	1514	8	and	and	CC
cord-034340-3ksfpaf7	1514	9	adults	adult	NNS
cord-034340-3ksfpaf7	1514	10	were	be	VBD
cord-034340-3ksfpaf7	1514	11	66.0	66.0	CD
cord-034340-3ksfpaf7	1514	12	%	%	NN
cord-034340-3ksfpaf7	1514	13	(	(	-LRB-
cord-034340-3ksfpaf7	1514	14	n:33	n:33	UH
cord-034340-3ksfpaf7	1514	15	)	)	-RRB-
cord-034340-3ksfpaf7	1514	16	and	and	CC
cord-034340-3ksfpaf7	1514	17	14.0	14.0	CD
cord-034340-3ksfpaf7	1514	18	%	%	NN
cord-034340-3ksfpaf7	1514	19	(	(	-LRB-
cord-034340-3ksfpaf7	1514	20	n:7	n:7	NNP
cord-034340-3ksfpaf7	1514	21	)	)	-RRB-
cord-034340-3ksfpaf7	1514	22	respectively	respectively	RB
cord-034340-3ksfpaf7	1514	23	.	.	.
cord-034340-3ksfpaf7	1515	1	The	the	DT
cord-034340-3ksfpaf7	1515	2	mean	mean	JJ
cord-034340-3ksfpaf7	1515	3	MISS	MISS	NNP
cord-034340-3ksfpaf7	1515	4	score	score	NN
cord-034340-3ksfpaf7	1515	5	in	in	IN
cord-034340-3ksfpaf7	1515	6	the	the	DT
cord-034340-3ksfpaf7	1515	7	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1515	8	group	group	NN
cord-034340-3ksfpaf7	1515	9	was	be	VBD
cord-034340-3ksfpaf7	1515	10	higher	high	JJR
cord-034340-3ksfpaf7	1515	11	compared	compare	VBN
cord-034340-3ksfpaf7	1515	12	with	with	IN
cord-034340-3ksfpaf7	1515	13	the	the	DT
cord-034340-3ksfpaf7	1515	14	adults	adult	NNS
cord-034340-3ksfpaf7	1515	15	(	(	-LRB-
cord-034340-3ksfpaf7	1515	16	12.4±9.4	12.4±9.4	CD
cord-034340-3ksfpaf7	1515	17	vs	vs	IN
cord-034340-3ksfpaf7	1515	18	1.84±4.5	1.84±4.5	CD
cord-034340-3ksfpaf7	1515	19	,	,	,
cord-034340-3ksfpaf7	1515	20	p<0.001	p<0.001	CD
cord-034340-3ksfpaf7	1515	21	)	)	-RRB-
cord-034340-3ksfpaf7	1515	22	.	.	.
cord-034340-3ksfpaf7	1516	1	Similarly	similarly	RB
cord-034340-3ksfpaf7	1516	2	,	,	,
cord-034340-3ksfpaf7	1516	3	the	the	DT
cord-034340-3ksfpaf7	1516	4	mean	mean	JJ
cord-034340-3ksfpaf7	1516	5	VAS	VAS	NNP
cord-034340-3ksfpaf7	1516	6	scores	score	NNS
cord-034340-3ksfpaf7	1516	7	were	be	VBD
cord-034340-3ksfpaf7	1516	8	higher	high	JJR
cord-034340-3ksfpaf7	1516	9	in	in	IN
cord-034340-3ksfpaf7	1516	10	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1516	11	group	group	NN
cord-034340-3ksfpaf7	1516	12	(	(	-LRB-
cord-034340-3ksfpaf7	1516	13	1.2±2.4	1.2±2.4	CD
cord-034340-3ksfpaf7	1516	14	vs	vs	IN
cord-034340-3ksfpaf7	1516	15	4.2±3.2	4.2±3.2	CD
cord-034340-3ksfpaf7	1516	16	(	(	-LRB-
cord-034340-3ksfpaf7	1516	17	p<0.001	p<0.001	CD
cord-034340-3ksfpaf7	1516	18	)	)	-RRB-
cord-034340-3ksfpaf7	1516	19	)	)	-RRB-
cord-034340-3ksfpaf7	1516	20	.	.	.
cord-034340-3ksfpaf7	1517	1	There	there	EX
cord-034340-3ksfpaf7	1517	2	was	be	VBD
cord-034340-3ksfpaf7	1517	3	a	a	DT
cord-034340-3ksfpaf7	1517	4	strong	strong	JJ
cord-034340-3ksfpaf7	1517	5	correlation	correlation	NN
cord-034340-3ksfpaf7	1517	6	between	between	IN
cord-034340-3ksfpaf7	1517	7	MISS	MISS	NNP
cord-034340-3ksfpaf7	1517	8	and	and	CC
cord-034340-3ksfpaf7	1517	9	VAS	VAS	NNP
cord-034340-3ksfpaf7	1517	10	scores	score	NNS
cord-034340-3ksfpaf7	1517	11	between	between	IN
cord-034340-3ksfpaf7	1517	12	family	family	NN
cord-034340-3ksfpaf7	1517	13	and	and	CC
cord-034340-3ksfpaf7	1517	14	child	child	NN
cord-034340-3ksfpaf7	1517	15	evaluations	evaluation	NNS
cord-034340-3ksfpaf7	1517	16	(	(	-LRB-
cord-034340-3ksfpaf7	1517	17	p	p	NN
cord-034340-3ksfpaf7	1517	18	<	<	XX
cord-034340-3ksfpaf7	1517	19	0.01	0.01	CD
cord-034340-3ksfpaf7	1517	20	,	,	,
cord-034340-3ksfpaf7	1518	1	r	r	LS
cord-034340-3ksfpaf7	1518	2	=	=	SYM
cord-034340-3ksfpaf7	1518	3	0.95	0.95	CD
cord-034340-3ksfpaf7	1518	4	/	/	SYM
cord-034340-3ksfpaf7	1518	5	p	p	NN
cord-034340-3ksfpaf7	1518	6	<	<	NNP
cord-034340-3ksfpaf7	1518	7	0.01	0.01	CD
cord-034340-3ksfpaf7	1518	8	,	,	,
cord-034340-3ksfpaf7	1518	9	r	r	NN
cord-034340-3ksfpaf7	1518	10	=	=	SYM
cord-034340-3ksfpaf7	1518	11	0.94	0.94	CD
cord-034340-3ksfpaf7	1518	12	)	)	-RRB-
cord-034340-3ksfpaf7	1518	13	.	.	.
cord-034340-3ksfpaf7	1519	1	Abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1519	2	pain	pain	NN
cord-034340-3ksfpaf7	1519	3	,	,	,
cord-034340-3ksfpaf7	1519	4	nausea	nausea	NN
cord-034340-3ksfpaf7	1519	5	,	,	,
cord-034340-3ksfpaf7	1519	6	vomiting	vomiting	NN
cord-034340-3ksfpaf7	1519	7	and	and	CC
cord-034340-3ksfpaf7	1519	8	behavioral	behavioral	JJ
cord-034340-3ksfpaf7	1519	9	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1519	10	were	be	VBD
cord-034340-3ksfpaf7	1519	11	observed	observe	VBN
cord-034340-3ksfpaf7	1519	12	more	more	RBR
cord-034340-3ksfpaf7	1519	13	frequently	frequently	RB
cord-034340-3ksfpaf7	1519	14	in	in	IN
cord-034340-3ksfpaf7	1519	15	children	child	NNS
cord-034340-3ksfpaf7	1519	16	compared	compare	VBN
cord-034340-3ksfpaf7	1519	17	to	to	IN
cord-034340-3ksfpaf7	1519	18	adults	adult	NNS
cord-034340-3ksfpaf7	1519	19	.	.	.
cord-034340-3ksfpaf7	1520	1	Results	result	NNS
cord-034340-3ksfpaf7	1520	2	:	:	:
cord-034340-3ksfpaf7	1521	1	3(4	3(4	CD
cord-034340-3ksfpaf7	1521	2	%	%	NN
cord-034340-3ksfpaf7	1521	3	)	)	-RRB-
cord-034340-3ksfpaf7	1521	4	out	out	IN
cord-034340-3ksfpaf7	1521	5	of	of	IN
cord-034340-3ksfpaf7	1521	6	73	73	CD
cord-034340-3ksfpaf7	1521	7	patients	patient	NNS
cord-034340-3ksfpaf7	1521	8	were	be	VBD
cord-034340-3ksfpaf7	1521	9	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1521	10	with	with	IN
cord-034340-3ksfpaf7	1521	11	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1521	12	denovo	denovo	NNP
cord-034340-3ksfpaf7	1521	13	.	.	.
cord-034340-3ksfpaf7	1522	1	One	one	CD
cord-034340-3ksfpaf7	1522	2	patient	patient	NN
cord-034340-3ksfpaf7	1522	3	was	be	VBD
cord-034340-3ksfpaf7	1522	4	treated	treat	VBN
cord-034340-3ksfpaf7	1522	5	with	with	IN
cord-034340-3ksfpaf7	1522	6	ADA	ADA	NNP
cord-034340-3ksfpaf7	1522	7	(	(	-LRB-
cord-034340-3ksfpaf7	1522	8	a	a	DT
cord-034340-3ksfpaf7	1522	9	girl	girl	NN
cord-034340-3ksfpaf7	1522	10	with	with	IN
cord-034340-3ksfpaf7	1522	11	undifferentiated	undifferentiated	JJ
cord-034340-3ksfpaf7	1522	12	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1522	13	who	who	WP
cord-034340-3ksfpaf7	1522	14	had	have	VBD
cord-034340-3ksfpaf7	1522	15	positive	positive	JJ
cord-034340-3ksfpaf7	1522	16	HLA	HLA	NNP
cord-034340-3ksfpaf7	1522	17	-	-	HYPH
cord-034340-3ksfpaf7	1522	18	B	B	NNP
cord-034340-3ksfpaf7	1522	19	27	27	CD
cord-034340-3ksfpaf7	1522	20	,	,	,
cord-034340-3ksfpaf7	1522	21	ANF	ANF	NNP
cord-034340-3ksfpaf7	1522	22	and	and	CC
cord-034340-3ksfpaf7	1522	23	family	family	NN
cord-034340-3ksfpaf7	1522	24	history	history	NN
cord-034340-3ksfpaf7	1522	25	of	of	IN
cord-034340-3ksfpaf7	1522	26	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1523	1	-her	-her	:
cord-034340-3ksfpaf7	1523	2	grandmother	grandmother	NN
cord-034340-3ksfpaf7	1523	3	had	have	VBD
cord-034340-3ksfpaf7	1523	4	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1523	5	)	)	-RRB-
cord-034340-3ksfpaf7	1523	6	,	,	,
cord-034340-3ksfpaf7	1523	7	2	2	CD
cord-034340-3ksfpaf7	1523	8	patients	patient	NNS
cord-034340-3ksfpaf7	1523	9	were	be	VBD
cord-034340-3ksfpaf7	1523	10	treated	treat	VBN
cord-034340-3ksfpaf7	1523	11	with	with	IN
cord-034340-3ksfpaf7	1523	12	ETA	ETA	NNP
cord-034340-3ksfpaf7	1523	13	(	(	-LRB-
cord-034340-3ksfpaf7	1523	14	both	both	DT
cord-034340-3ksfpaf7	1523	15	female	female	JJ
cord-034340-3ksfpaf7	1523	16	,	,	,
cord-034340-3ksfpaf7	1523	17	one	one	CD
cord-034340-3ksfpaf7	1523	18	patient	patient	NN
cord-034340-3ksfpaf7	1523	19	had	have	VBD
cord-034340-3ksfpaf7	1523	20	undifferentiated	undifferentiated	JJ
cord-034340-3ksfpaf7	1523	21	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1523	22	,	,	,
cord-034340-3ksfpaf7	1523	23	the	the	DT
cord-034340-3ksfpaf7	1523	24	other	other	JJ
cord-034340-3ksfpaf7	1523	25	had	have	VBD
cord-034340-3ksfpaf7	1523	26	enthesitis	enthesitis	NN
cord-034340-3ksfpaf7	1523	27	-	-	HYPH
cord-034340-3ksfpaf7	1523	28	related	relate	VBN
cord-034340-3ksfpaf7	1523	29	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1523	30	;	;	:
cord-034340-3ksfpaf7	1523	31	both	both	DT
cord-034340-3ksfpaf7	1523	32	patients	patient	NNS
cord-034340-3ksfpaf7	1523	33	had	have	VBD
cord-034340-3ksfpaf7	1523	34	positive	positive	JJ
cord-034340-3ksfpaf7	1523	35	HLA	HLA	NNP
cord-034340-3ksfpaf7	1523	36	-B	-B	NNP
cord-034340-3ksfpaf7	1523	37	27	27	CD
cord-034340-3ksfpaf7	1523	38	and	and	CC
cord-034340-3ksfpaf7	1523	39	ANF	ANF	NNP
cord-034340-3ksfpaf7	1523	40	negative	negative	JJ
cord-034340-3ksfpaf7	1523	41	)	)	-RRB-
cord-034340-3ksfpaf7	1523	42	.	.	.
cord-034340-3ksfpaf7	1524	1	2	2	CD
cord-034340-3ksfpaf7	1524	2	patients	patient	NNS
cord-034340-3ksfpaf7	1524	3	achieved	achieve	VBD
cord-034340-3ksfpaf7	1524	4	significant	significant	JJ
cord-034340-3ksfpaf7	1524	5	improvement	improvement	NN
cord-034340-3ksfpaf7	1524	6	after	after	IN
cord-034340-3ksfpaf7	1524	7	changing	change	VBG
cord-034340-3ksfpaf7	1524	8	TNFalpha	tnfalpha	NN
cord-034340-3ksfpaf7	1524	9	inhibitor	inhibitor	NN
cord-034340-3ksfpaf7	1524	10	(	(	-LRB-
cord-034340-3ksfpaf7	1524	11	1-ADA	1-ada	CD
cord-034340-3ksfpaf7	1524	12	,	,	,
cord-034340-3ksfpaf7	1524	13	1-ETA	1-eta	CD
cord-034340-3ksfpaf7	1524	14	)	)	-RRB-
cord-034340-3ksfpaf7	1524	15	,	,	,
cord-034340-3ksfpaf7	1524	16	1	1	CD
cord-034340-3ksfpaf7	1524	17	patient	patient	NN
cord-034340-3ksfpaf7	1524	18	(	(	-LRB-
cord-034340-3ksfpaf7	1524	19	was	be	VBD
cord-034340-3ksfpaf7	1524	20	treated	treat	VBN
cord-034340-3ksfpaf7	1524	21	with	with	IN
cord-034340-3ksfpaf7	1524	22	ETA	ETA	NNP
cord-034340-3ksfpaf7	1524	23	)	)	-RRB-
cord-034340-3ksfpaf7	1524	24	had	have	VBD
cord-034340-3ksfpaf7	1524	25	significant	significant	JJ
cord-034340-3ksfpaf7	1524	26	improvement	improvement	NN
cord-034340-3ksfpaf7	1524	27	after	after	IN
cord-034340-3ksfpaf7	1524	28	discontinuation	discontinuation	NN
cord-034340-3ksfpaf7	1524	29	of	of	IN
cord-034340-3ksfpaf7	1524	30	biological	biological	JJ
cord-034340-3ksfpaf7	1524	31	therapy	therapy	NN
cord-034340-3ksfpaf7	1524	32	.	.	.
cord-034340-3ksfpaf7	1525	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1525	2	:	:	:
cord-034340-3ksfpaf7	1526	1	This	this	DT
cord-034340-3ksfpaf7	1526	2	single	single	JJ
cord-034340-3ksfpaf7	1526	3	-	-	HYPH
cord-034340-3ksfpaf7	1526	4	center	center	NN
cord-034340-3ksfpaf7	1526	5	observational	observational	JJ
cord-034340-3ksfpaf7	1526	6	study	study	NN
cord-034340-3ksfpaf7	1526	7	demonstrates	demonstrate	VBZ
cord-034340-3ksfpaf7	1526	8	the	the	DT
cord-034340-3ksfpaf7	1526	9	possibility	possibility	NN
cord-034340-3ksfpaf7	1526	10	of	of	IN
cord-034340-3ksfpaf7	1526	11	developing	develop	VBG
cord-034340-3ksfpaf7	1526	12	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1526	13	de	de	NNP
cord-034340-3ksfpaf7	1526	14	-	-	NNP
cord-034340-3ksfpaf7	1526	15	novo	novo	NN
cord-034340-3ksfpaf7	1526	16	in	in	IN
cord-034340-3ksfpaf7	1526	17	patients	patient	NNS
cord-034340-3ksfpaf7	1526	18	with	with	IN
cord-034340-3ksfpaf7	1526	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	1526	20	receiving	receive	VBG
cord-034340-3ksfpaf7	1526	21	TNF	TNF	NNP
cord-034340-3ksfpaf7	1526	22	-	-	HYPH
cord-034340-3ksfpaf7	1526	23	alpha	alpha	NN
cord-034340-3ksfpaf7	1526	24	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1526	25	.	.	.
cord-034340-3ksfpaf7	1527	1	Although	although	IN
cord-034340-3ksfpaf7	1527	2	more	more	RBR
cord-034340-3ksfpaf7	1527	3	extensive	extensive	JJ
cord-034340-3ksfpaf7	1527	4	research	research	NN
cord-034340-3ksfpaf7	1527	5	is	be	VBZ
cord-034340-3ksfpaf7	1527	6	needed	need	VBN
cord-034340-3ksfpaf7	1527	7	,	,	,
cord-034340-3ksfpaf7	1527	8	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1527	9	data	datum	NNS
cord-034340-3ksfpaf7	1527	10	suggest	suggest	VBP
cord-034340-3ksfpaf7	1527	11	that	that	IN
cord-034340-3ksfpaf7	1527	12	discontinuing	discontinue	VBG
cord-034340-3ksfpaf7	1527	13	the	the	DT
cord-034340-3ksfpaf7	1527	14	TNF	TNF	NNP
cord-034340-3ksfpaf7	1527	15	-	-	HYPH
cord-034340-3ksfpaf7	1527	16	alpha	alpha	NN
cord-034340-3ksfpaf7	1527	17	inhibitor	inhibitor	NN
cord-034340-3ksfpaf7	1527	18	or	or	CC
cord-034340-3ksfpaf7	1527	19	switching	switch	VBG
cord-034340-3ksfpaf7	1527	20	to	to	IN
cord-034340-3ksfpaf7	1527	21	another	another	DT
cord-034340-3ksfpaf7	1527	22	TNFalpha	TNFalpha	NNP
cord-034340-3ksfpaf7	1527	23	inhibitor	inhibitor	NN
cord-034340-3ksfpaf7	1527	24	in	in	IN
cord-034340-3ksfpaf7	1527	25	patients	patient	NNS
cord-034340-3ksfpaf7	1527	26	with	with	IN
cord-034340-3ksfpaf7	1527	27	psoriasis	psoriasis	NN
cord-034340-3ksfpaf7	1527	28	de	de	NNP
cord-034340-3ksfpaf7	1527	29	-	-	HYPH
cord-034340-3ksfpaf7	1527	30	novo	novo	NNP
cord-034340-3ksfpaf7	1527	31	should	should	MD
cord-034340-3ksfpaf7	1527	32	be	be	VB
cord-034340-3ksfpaf7	1527	33	considered	consider	VBN
cord-034340-3ksfpaf7	1527	34	as	as	IN
cord-034340-3ksfpaf7	1527	35	a	a	DT
cord-034340-3ksfpaf7	1527	36	treatment	treatment	NN
cord-034340-3ksfpaf7	1527	37	strategy	strategy	NN
cord-034340-3ksfpaf7	1527	38	in	in	IN
cord-034340-3ksfpaf7	1527	39	such	such	JJ
cord-034340-3ksfpaf7	1527	40	cases	case	NNS
cord-034340-3ksfpaf7	1527	41	.	.	.
cord-034340-3ksfpaf7	1528	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1528	2	:	:	:
cord-034340-3ksfpaf7	1528	3	Long	long	JJ
cord-034340-3ksfpaf7	1528	4	-	-	HYPH
cord-034340-3ksfpaf7	1528	5	term	term	NN
cord-034340-3ksfpaf7	1528	6	surveillance	surveillance	NN
cord-034340-3ksfpaf7	1528	7	of	of	IN
cord-034340-3ksfpaf7	1528	8	patients	patient	NNS
cord-034340-3ksfpaf7	1528	9	newly	newly	RB
cord-034340-3ksfpaf7	1528	10	initiating	initiate	VBG
cord-034340-3ksfpaf7	1528	11	TOC	TOC	NNP
cord-034340-3ksfpaf7	1528	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1528	13	for	for	IN
cord-034340-3ksfpaf7	1528	14	at	at	RB
cord-034340-3ksfpaf7	1528	15	least	least	JJS
cord-034340-3ksfpaf7	1528	16	5	5	CD
cord-034340-3ksfpaf7	1528	17	years	year	NNS
cord-034340-3ksfpaf7	1528	18	compared	compare	VBN
cord-034340-3ksfpaf7	1528	19	to	to	IN
cord-034340-3ksfpaf7	1528	20	a	a	DT
cord-034340-3ksfpaf7	1528	21	cohort	cohort	NN
cord-034340-3ksfpaf7	1528	22	of	of	IN
cord-034340-3ksfpaf7	1528	23	patients	patient	NNS
cord-034340-3ksfpaf7	1528	24	newly	newly	RB
cord-034340-3ksfpaf7	1528	25	initiating	initiate	VBG
cord-034340-3ksfpaf7	1528	26	a	a	DT
cord-034340-3ksfpaf7	1528	27	comparator	comparator	NN
cord-034340-3ksfpaf7	1528	28	biologic	biologic	JJ
cord-034340-3ksfpaf7	1528	29	using	use	VBG
cord-034340-3ksfpaf7	1528	30	the	the	DT
cord-034340-3ksfpaf7	1528	31	BIKER	biker	NN
cord-034340-3ksfpaf7	1528	32	-	-	HYPH
cord-034340-3ksfpaf7	1528	33	registry	registry	NN
cord-034340-3ksfpaf7	1528	34	.	.	.
cord-034340-3ksfpaf7	1529	1	Methods	method	NNS
cord-034340-3ksfpaf7	1529	2	:	:	:
cord-034340-3ksfpaf7	1529	3	Baseline	baseline	JJ
cord-034340-3ksfpaf7	1529	4	demographics	demographic	NNS
cord-034340-3ksfpaf7	1529	5	,	,	,
cord-034340-3ksfpaf7	1529	6	clinical	clinical	JJ
cord-034340-3ksfpaf7	1529	7	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1529	8	and	and	CC
cord-034340-3ksfpaf7	1529	9	disease	disease	NN
cord-034340-3ksfpaf7	1529	10	activity	activity	NN
cord-034340-3ksfpaf7	1529	11	,	,	,
cord-034340-3ksfpaf7	1529	12	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1529	13	and	and	CC
cord-034340-3ksfpaf7	1529	14	safety	safety	NN
cord-034340-3ksfpaf7	1529	15	parameters	parameter	NNS
cord-034340-3ksfpaf7	1529	16	were	be	VBD
cord-034340-3ksfpaf7	1529	17	compared	compare	VBN
cord-034340-3ksfpaf7	1529	18	.	.	.
cord-034340-3ksfpaf7	1530	1	Efficacy	efficacy	NN
cord-034340-3ksfpaf7	1530	2	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1530	3	were	be	VBD
cord-034340-3ksfpaf7	1530	4	JADAS10	JADAS10	NNP
cord-034340-3ksfpaf7	1530	5	,	,	,
cord-034340-3ksfpaf7	1530	6	joint	joint	JJ
cord-034340-3ksfpaf7	1530	7	counts	count	NNS
cord-034340-3ksfpaf7	1530	8	and	and	CC
cord-034340-3ksfpaf7	1530	9	functional	functional	JJ
cord-034340-3ksfpaf7	1530	10	status	status	NN
cord-034340-3ksfpaf7	1530	11	Safety	safety	NN
cord-034340-3ksfpaf7	1530	12	was	be	VBD
cord-034340-3ksfpaf7	1530	13	assessed	assess	VBN
cord-034340-3ksfpaf7	1530	14	by	by	IN
cord-034340-3ksfpaf7	1530	15	adverse	adverse	JJ
cord-034340-3ksfpaf7	1530	16	events	event	NNS
cord-034340-3ksfpaf7	1530	17	(	(	-LRB-
cord-034340-3ksfpaf7	1530	18	AE	AE	NNP
cord-034340-3ksfpaf7	1530	19	)	)	-RRB-
cord-034340-3ksfpaf7	1530	20	reports	report	NNS
cord-034340-3ksfpaf7	1530	21	.	.	.
cord-034340-3ksfpaf7	1531	1	Results	result	NNS
cord-034340-3ksfpaf7	1531	2	:	:	:
cord-034340-3ksfpaf7	1531	3	161	161	CD
cord-034340-3ksfpaf7	1531	4	patients	patient	NNS
cord-034340-3ksfpaf7	1531	5	with	with	IN
cord-034340-3ksfpaf7	1531	6	161	161	CD
cord-034340-3ksfpaf7	1531	7	matched	match	VBN
cord-034340-3ksfpaf7	1531	8	controls	control	NNS
cord-034340-3ksfpaf7	1531	9	have	have	VBP
cord-034340-3ksfpaf7	1531	10	been	be	VBN
cord-034340-3ksfpaf7	1531	11	recruited	recruit	VBN
cord-034340-3ksfpaf7	1531	12	.	.	.
cord-034340-3ksfpaf7	1532	1	Patients	patient	NNS
cord-034340-3ksfpaf7	1532	2	starting	start	VBG
cord-034340-3ksfpaf7	1532	3	on	on	IN
cord-034340-3ksfpaf7	1532	4	TOC	TOC	NNP
cord-034340-3ksfpaf7	1532	5	were	be	VBD
cord-034340-3ksfpaf7	1532	6	older	old	JJR
cord-034340-3ksfpaf7	1532	7	at	at	IN
cord-034340-3ksfpaf7	1532	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1532	9	start	start	NN
cord-034340-3ksfpaf7	1532	10	(	(	-LRB-
cord-034340-3ksfpaf7	1532	11	12.1	12.1	CD
cord-034340-3ksfpaf7	1532	12	vs.	vs.	FW
cord-034340-3ksfpaf7	1532	13	10.1	10.1	CD
cord-034340-3ksfpaf7	1532	14	years	year	NNS
cord-034340-3ksfpaf7	1532	15	(	(	-LRB-
cord-034340-3ksfpaf7	1532	16	y	y	NN
cord-034340-3ksfpaf7	1532	17	)	)	-RRB-
cord-034340-3ksfpaf7	1532	18	;	;	:
cord-034340-3ksfpaf7	1532	19	p<0.0001	p<0.0001	NNP
cord-034340-3ksfpaf7	1532	20	)	)	-RRB-
cord-034340-3ksfpaf7	1532	21	and	and	CC
cord-034340-3ksfpaf7	1532	22	had	have	VBD
cord-034340-3ksfpaf7	1532	23	a	a	DT
cord-034340-3ksfpaf7	1532	24	longer	long	JJR
cord-034340-3ksfpaf7	1532	25	disease	disease	NN
cord-034340-3ksfpaf7	1532	26	duration	duration	NN
cord-034340-3ksfpaf7	1532	27	(	(	-LRB-
cord-034340-3ksfpaf7	1532	28	p	p	NN
cord-034340-3ksfpaf7	1532	29	<	<	XX
cord-034340-3ksfpaf7	1532	30	0.0001	0.0001	CD
cord-034340-3ksfpaf7	1532	31	)	)	-RRB-
cord-034340-3ksfpaf7	1532	32	.	.	.
cord-034340-3ksfpaf7	1533	1	TOC	TOC	NNP
cord-034340-3ksfpaf7	1533	2	was	be	VBD
cord-034340-3ksfpaf7	1533	3	significantly	significantly	RB
cord-034340-3ksfpaf7	1533	4	more	more	RBR
cord-034340-3ksfpaf7	1533	5	often	often	RB
cord-034340-3ksfpaf7	1533	6	a	a	DT
cord-034340-3ksfpaf7	1533	7	second	second	JJ
cord-034340-3ksfpaf7	1533	8	line	line	NN
cord-034340-3ksfpaf7	1533	9	biologic	biologic	JJ
cord-034340-3ksfpaf7	1533	10	(	(	-LRB-
cord-034340-3ksfpaf7	1533	11	p	p	NN
cord-034340-3ksfpaf7	1533	12	<	<	XX
cord-034340-3ksfpaf7	1533	13	0.0001	0.0001	CD
cord-034340-3ksfpaf7	1533	14	)	)	-RRB-
cord-034340-3ksfpaf7	1533	15	.	.	.
cord-034340-3ksfpaf7	1534	1	Baseline	baseline	JJ
cord-034340-3ksfpaf7	1534	2	JADAS10	JADAS10	NNP
cord-034340-3ksfpaf7	1535	1	(	(	-LRB-
cord-034340-3ksfpaf7	1535	2	17+/-10	17+/-10	CD
cord-034340-3ksfpaf7	1535	3	vs	vs	IN
cord-034340-3ksfpaf7	1535	4	15+/-6	15+/-6	CD
cord-034340-3ksfpaf7	1535	5	)	)	-RRB-
cord-034340-3ksfpaf7	1535	6	,	,	,
cord-034340-3ksfpaf7	1535	7	CHAQ	CHAQ	NNP
cord-034340-3ksfpaf7	1535	8	-	-	HYPH
cord-034340-3ksfpaf7	1535	9	DI	DI	NNP
cord-034340-3ksfpaf7	1535	10	(	(	-LRB-
cord-034340-3ksfpaf7	1535	11	0.63+/-0.63	0.63+/-0.63	NNP
cord-034340-3ksfpaf7	1535	12	vs	vs	IN
cord-034340-3ksfpaf7	1535	13	0.65+/-0,64	0.65+/-0,64	CD
cord-034340-3ksfpaf7	1535	14	)	)	-RRB-
cord-034340-3ksfpaf7	1535	15	,	,	,
cord-034340-3ksfpaf7	1535	16	ESR	ESR	NNP
cord-034340-3ksfpaf7	1535	17	18+/-15	18+/-15	CD
cord-034340-3ksfpaf7	1535	18	mm	mm	NNP
cord-034340-3ksfpaf7	1535	19	/	/	SYM
cord-034340-3ksfpaf7	1535	20	h	h	NN
cord-034340-3ksfpaf7	1535	21	vs.	vs.	FW
cord-034340-3ksfpaf7	1535	22	21+/-21	21+/-21	CD
cord-034340-3ksfpaf7	1535	23	mm	mm	NNP
cord-034340-3ksfpaf7	1535	24	/	/	SYM
cord-034340-3ksfpaf7	1535	25	h	h	NN
cord-034340-3ksfpaf7	1535	26	and	and	CC
cord-034340-3ksfpaf7	1535	27	active	active	JJ
cord-034340-3ksfpaf7	1535	28	joint	joint	JJ
cord-034340-3ksfpaf7	1535	29	counts	count	NNS
cord-034340-3ksfpaf7	1535	30	(	(	-LRB-
cord-034340-3ksfpaf7	1535	31	7+/-7	7+/-7	NNP
cord-034340-3ksfpaf7	1535	32	vs.	vs.	FW
cord-034340-3ksfpaf7	1535	33	6+/-5	6+/-5	NN
cord-034340-3ksfpaf7	1535	34	)	)	-RRB-
cord-034340-3ksfpaf7	1535	35	were	be	VBD
cord-034340-3ksfpaf7	1535	36	comparable	comparable	JJ
cord-034340-3ksfpaf7	1535	37	.	.	.
cord-034340-3ksfpaf7	1536	1	Upon	upon	IN
cord-034340-3ksfpaf7	1536	2	TOC	TOC	NNP
cord-034340-3ksfpaf7	1536	3	a	a	DT
cord-034340-3ksfpaf7	1536	4	substantial	substantial	JJ
cord-034340-3ksfpaf7	1536	5	response	response	NN
cord-034340-3ksfpaf7	1536	6	with	with	IN
cord-034340-3ksfpaf7	1536	7	a	a	DT
cord-034340-3ksfpaf7	1536	8	significant	significant	JJ
cord-034340-3ksfpaf7	1536	9	reduction	reduction	NN
cord-034340-3ksfpaf7	1536	10	in	in	IN
cord-034340-3ksfpaf7	1536	11	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	1536	12	10	10	CD
cord-034340-3ksfpaf7	1536	13	from	from	IN
cord-034340-3ksfpaf7	1536	14	16.8	16.8	CD
cord-034340-3ksfpaf7	1536	15	to	to	IN
cord-034340-3ksfpaf7	1536	16	3.4	3.4	CD
cord-034340-3ksfpaf7	1536	17	(	(	-LRB-
cord-034340-3ksfpaf7	1536	18	p<0.0001	p<0.0001	NNP
cord-034340-3ksfpaf7	1536	19	)	)	-RRB-
cord-034340-3ksfpaf7	1536	20	after	after	IN
cord-034340-3ksfpaf7	1536	21	12	12	CD
cord-034340-3ksfpaf7	1536	22	months	month	NNS
cord-034340-3ksfpaf7	1536	23	of	of	IN
cord-034340-3ksfpaf7	1536	24	treatment	treatment	NN
cord-034340-3ksfpaf7	1536	25	was	be	VBD
cord-034340-3ksfpaf7	1536	26	observed	observe	VBN
cord-034340-3ksfpaf7	1536	27	.	.	.
cord-034340-3ksfpaf7	1537	1	There	there	EX
cord-034340-3ksfpaf7	1537	2	were	be	VBD
cord-034340-3ksfpaf7	1537	3	no	no	DT
cord-034340-3ksfpaf7	1537	4	significant	significant	JJ
cord-034340-3ksfpaf7	1537	5	differences	difference	NNS
cord-034340-3ksfpaf7	1537	6	between	between	IN
cord-034340-3ksfpaf7	1537	7	patients	patient	NNS
cord-034340-3ksfpaf7	1537	8	from	from	IN
cord-034340-3ksfpaf7	1537	9	the	the	DT
cord-034340-3ksfpaf7	1537	10	TOC	TOC	NNP
cord-034340-3ksfpaf7	1537	11	cohort	cohort	NN
cord-034340-3ksfpaf7	1537	12	and	and	CC
cord-034340-3ksfpaf7	1537	13	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1537	14	matched	match	VBN
cord-034340-3ksfpaf7	1537	15	controls	control	NNS
cord-034340-3ksfpaf7	1537	16	in	in	IN
cord-034340-3ksfpaf7	1537	17	the	the	DT
cord-034340-3ksfpaf7	1537	18	JIA	JIA	NNP
cord-034340-3ksfpaf7	1537	19	ACR	ACR	NNP
cord-034340-3ksfpaf7	1537	20	30/50/70/90	30/50/70/90	CD
cord-034340-3ksfpaf7	1537	21	criteria	criterion	NNS
cord-034340-3ksfpaf7	1537	22	,	,	,
cord-034340-3ksfpaf7	1537	23	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	1537	24	10	10	CD
cord-034340-3ksfpaf7	1537	25	,	,	,
cord-034340-3ksfpaf7	1537	26	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	1537	27	remission	remission	NN
cord-034340-3ksfpaf7	1537	28	and	and	CC
cord-034340-3ksfpaf7	1537	29	minimal	minimal	JJ
cord-034340-3ksfpaf7	1537	30	disease	disease	NN
cord-034340-3ksfpaf7	1537	31	activity	activity	NN
cord-034340-3ksfpaf7	1537	32	was	be	VBD
cord-034340-3ksfpaf7	1537	33	reached	reach	VBN
cord-034340-3ksfpaf7	1537	34	by	by	IN
cord-034340-3ksfpaf7	1537	35	comparable	comparable	JJ
cord-034340-3ksfpaf7	1537	36	numbers	number	NNS
cord-034340-3ksfpaf7	1537	37	(	(	-LRB-
cord-034340-3ksfpaf7	1537	38	TOC	TOC	NNP
cord-034340-3ksfpaf7	1537	39	37	37	CD
cord-034340-3ksfpaf7	1537	40	%	%	NN
cord-034340-3ksfpaf7	1537	41	and	and	CC
cord-034340-3ksfpaf7	1537	42	58	58	CD
cord-034340-3ksfpaf7	1537	43	%	%	NN
cord-034340-3ksfpaf7	1537	44	;	;	,
cord-034340-3ksfpaf7	1537	45	control	control	NNP
cord-034340-3ksfpaf7	1537	46	cohort	cohort	NN
cord-034340-3ksfpaf7	1537	47	37	37	CD
cord-034340-3ksfpaf7	1537	48	%	%	NN
cord-034340-3ksfpaf7	1537	49	and	and	CC
cord-034340-3ksfpaf7	1537	50	60	60	CD
cord-034340-3ksfpaf7	1537	51	%	%	NN
cord-034340-3ksfpaf7	1537	52	)	)	-RRB-
cord-034340-3ksfpaf7	1537	53	.	.	.
cord-034340-3ksfpaf7	1538	1	The	the	DT
cord-034340-3ksfpaf7	1538	2	total	total	JJ
cord-034340-3ksfpaf7	1538	3	number	number	NN
cord-034340-3ksfpaf7	1538	4	of	of	IN
cord-034340-3ksfpaf7	1538	5	AE	AE	NNP
cord-034340-3ksfpaf7	1538	6	was	be	VBD
cord-034340-3ksfpaf7	1538	7	comparable	comparable	JJ
cord-034340-3ksfpaf7	1539	1	(	(	-LRB-
cord-034340-3ksfpaf7	1539	2	TOC	TOC	NNP
cord-034340-3ksfpaf7	1539	3	cohort	cohort	NN
cord-034340-3ksfpaf7	1539	4	n=201	n=201	CD
cord-034340-3ksfpaf7	1539	5	AE	AE	NNP
cord-034340-3ksfpaf7	1539	6	;	;	,
cord-034340-3ksfpaf7	1539	7	(	(	-LRB-
cord-034340-3ksfpaf7	1539	8	77/	77/	CD
cord-034340-3ksfpaf7	1539	9	100PY	100PY	NNP
cord-034340-3ksfpaf7	1539	10	)	)	-RRB-
cord-034340-3ksfpaf7	1539	11	;	;	:
cord-034340-3ksfpaf7	1539	12	control	control	VB
cord-034340-3ksfpaf7	1539	13	cohort	cohort	NN
cord-034340-3ksfpaf7	1539	14	n=207	n=207	NNP
cord-034340-3ksfpaf7	1539	15	;	;	:
cord-034340-3ksfpaf7	1539	16	(	(	-LRB-
cord-034340-3ksfpaf7	1539	17	65/100PY	65/100py	CD
cord-034340-3ksfpaf7	1539	18	;	;	:
cord-034340-3ksfpaf7	1539	19	RR	RR	NNP
cord-034340-3ksfpaf7	1539	20	1.2	1.2	CD
cord-034340-3ksfpaf7	1539	21	;	;	:
cord-034340-3ksfpaf7	1539	22	95%CI	95%ci	CD
cord-034340-3ksfpaf7	1539	23	0.99	0.99	CD
cord-034340-3ksfpaf7	1539	24	-	-	SYM
cord-034340-3ksfpaf7	1539	25	1.4	1.4	CD
cord-034340-3ksfpaf7	1539	26	)	)	-RRB-
cord-034340-3ksfpaf7	1539	27	.	.	.
cord-034340-3ksfpaf7	1540	1	More	more	RBR
cord-034340-3ksfpaf7	1540	2	serious	serious	JJ
cord-034340-3ksfpaf7	1540	3	AE	AE	NNP
cord-034340-3ksfpaf7	1540	4	(	(	-LRB-
cord-034340-3ksfpaf7	1540	5	SAE	SAE	NNP
cord-034340-3ksfpaf7	1540	6	)	)	-RRB-
cord-034340-3ksfpaf7	1540	7	were	be	VBD
cord-034340-3ksfpaf7	1540	8	reported	report	VBN
cord-034340-3ksfpaf7	1540	9	with	with	IN
cord-034340-3ksfpaf7	1540	10	TOC	TOC	NNP
cord-034340-3ksfpaf7	1540	11	.	.	.
cord-034340-3ksfpaf7	1541	1	Serious	serious	JJ
cord-034340-3ksfpaf7	1541	2	infections	infection	NNS
cord-034340-3ksfpaf7	1541	3	were	be	VBD
cord-034340-3ksfpaf7	1541	4	documented	document	VBN
cord-034340-3ksfpaf7	1541	5	at	at	IN
cord-034340-3ksfpaf7	1541	6	lower	low	JJR
cord-034340-3ksfpaf7	1541	7	frequency	frequency	NN
cord-034340-3ksfpaf7	1541	8	with	with	IN
cord-034340-3ksfpaf7	1541	9	TOC	TOC	NNP
cord-034340-3ksfpaf7	1541	10	.	.	.
cord-034340-3ksfpaf7	1542	1	Uveitis	Uveitis	NNP
cord-034340-3ksfpaf7	1542	2	events	event	NNS
cord-034340-3ksfpaf7	1542	3	were	be	VBD
cord-034340-3ksfpaf7	1542	4	documented	document	VBN
cord-034340-3ksfpaf7	1542	5	at	at	IN
cord-034340-3ksfpaf7	1542	6	significantly	significantly	RB
cord-034340-3ksfpaf7	1542	7	higher	high	JJR
cord-034340-3ksfpaf7	1542	8	frequency	frequency	NN
cord-034340-3ksfpaf7	1542	9	with	with	IN
cord-034340-3ksfpaf7	1542	10	TNF	TNF	NNP
cord-034340-3ksfpaf7	1542	11	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1542	12	most	most	RBS
cord-034340-3ksfpaf7	1542	13	likely	likely	JJ
cord-034340-3ksfpaf7	1542	14	due	due	IN
cord-034340-3ksfpaf7	1542	15	to	to	IN
cord-034340-3ksfpaf7	1542	16	a	a	DT
cord-034340-3ksfpaf7	1542	17	selection	selection	NN
cord-034340-3ksfpaf7	1542	18	bias	bias	NN
cord-034340-3ksfpaf7	1542	19	(	(	-LRB-
cord-034340-3ksfpaf7	1542	20	Table	table	NN
cord-034340-3ksfpaf7	1542	21	1	1	CD
cord-034340-3ksfpaf7	1542	22	)	)	-RRB-
cord-034340-3ksfpaf7	1542	23	.	.	.
cord-034340-3ksfpaf7	1543	1	SAE	SAE	NNP
cord-034340-3ksfpaf7	1543	2	with	with	IN
cord-034340-3ksfpaf7	1543	3	TOC	TOC	NNP
cord-034340-3ksfpaf7	1543	4	were	be	VBD
cord-034340-3ksfpaf7	1543	5	depression	depression	NN
cord-034340-3ksfpaf7	1543	6	(	(	-LRB-
cord-034340-3ksfpaf7	1543	7	n=3	n=3	NN
cord-034340-3ksfpaf7	1543	8	)	)	-RRB-
cord-034340-3ksfpaf7	1543	9	in	in	IN
cord-034340-3ksfpaf7	1543	10	2	2	CD
cord-034340-3ksfpaf7	1543	11	with	with	IN
cord-034340-3ksfpaf7	1543	12	suicidal	suicidal	JJ
cord-034340-3ksfpaf7	1543	13	intent	intent	NN
cord-034340-3ksfpaf7	1543	14	,	,	,
cord-034340-3ksfpaf7	1543	15	exacerbation	exacerbation	NN
cord-034340-3ksfpaf7	1543	16	of	of	IN
cord-034340-3ksfpaf7	1543	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	1543	18	(	(	-LRB-
cord-034340-3ksfpaf7	1543	19	n=2	n=2	NNP
cord-034340-3ksfpaf7	1543	20	)	)	-RRB-
cord-034340-3ksfpaf7	1543	21	,	,	,
cord-034340-3ksfpaf7	1543	22	septic	septic	JJ
cord-034340-3ksfpaf7	1543	23	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1543	24	,	,	,
cord-034340-3ksfpaf7	1543	25	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1543	26	infection	infection	NN
cord-034340-3ksfpaf7	1543	27	,	,	,
cord-034340-3ksfpaf7	1543	28	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1543	29	pain	pain	NN
cord-034340-3ksfpaf7	1543	30	,	,	,
cord-034340-3ksfpaf7	1543	31	colitis	colitis	NN
cord-034340-3ksfpaf7	1543	32	,	,	,
cord-034340-3ksfpaf7	1543	33	paronychia	paronychia	NNP
cord-034340-3ksfpaf7	1543	34	and	and	CC
cord-034340-3ksfpaf7	1543	35	fracture	fracture	NN
cord-034340-3ksfpaf7	1543	36	.	.	.
cord-034340-3ksfpaf7	1544	1	SAE	SAE	NNP
cord-034340-3ksfpaf7	1544	2	in	in	IN
cord-034340-3ksfpaf7	1544	3	the	the	DT
cord-034340-3ksfpaf7	1544	4	control	control	NN
cord-034340-3ksfpaf7	1544	5	cohort	cohort	NN
cord-034340-3ksfpaf7	1544	6	were	be	VBD
cord-034340-3ksfpaf7	1544	7	depression	depression	NN
cord-034340-3ksfpaf7	1544	8	,	,	,
cord-034340-3ksfpaf7	1544	9	osteomyelitis	osteomyelitis	NN
cord-034340-3ksfpaf7	1544	10	,	,	,
cord-034340-3ksfpaf7	1544	11	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1544	12	infection	infection	NN
cord-034340-3ksfpaf7	1544	13	and	and	CC
cord-034340-3ksfpaf7	1544	14	disease	disease	NN
cord-034340-3ksfpaf7	1544	15	flare	flare	NN
cord-034340-3ksfpaf7	1544	16	.	.	.
cord-034340-3ksfpaf7	1545	1	No	no	DT
cord-034340-3ksfpaf7	1545	2	significant	significant	JJ
cord-034340-3ksfpaf7	1545	3	differences	difference	NNS
cord-034340-3ksfpaf7	1545	4	regarding	regard	VBG
cord-034340-3ksfpaf7	1545	5	cytopenias	cytopenia	NNS
cord-034340-3ksfpaf7	1545	6	and	and	CC
cord-034340-3ksfpaf7	1545	7	elevated	elevated	JJ
cord-034340-3ksfpaf7	1545	8	transaminases	transaminase	NNS
cord-034340-3ksfpaf7	1545	9	were	be	VBD
cord-034340-3ksfpaf7	1545	10	observed	observe	VBN
cord-034340-3ksfpaf7	1545	11	.	.	.
cord-034340-3ksfpaf7	1546	1	No	no	DT
cord-034340-3ksfpaf7	1546	2	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1546	3	perforation	perforation	NN
cord-034340-3ksfpaf7	1546	4	,	,	,
cord-034340-3ksfpaf7	1546	5	no	no	DT
cord-034340-3ksfpaf7	1546	6	vascular	vascular	JJ
cord-034340-3ksfpaf7	1546	7	events	event	NNS
cord-034340-3ksfpaf7	1546	8	and	and	CC
cord-034340-3ksfpaf7	1546	9	no	no	DT
cord-034340-3ksfpaf7	1546	10	deaths	death	NNS
cord-034340-3ksfpaf7	1546	11	occurred	occur	VBD
cord-034340-3ksfpaf7	1546	12	.	.	.
cord-034340-3ksfpaf7	1547	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1547	2	:	:	:
cord-034340-3ksfpaf7	1548	1	TOC	TOC	NNP
cord-034340-3ksfpaf7	1548	2	was	be	VBD
cord-034340-3ksfpaf7	1548	3	effective	effective	JJ
cord-034340-3ksfpaf7	1548	4	and	and	CC
cord-034340-3ksfpaf7	1548	5	comparable	comparable	JJ
cord-034340-3ksfpaf7	1548	6	to	to	IN
cord-034340-3ksfpaf7	1548	7	treatment	treatment	NN
cord-034340-3ksfpaf7	1548	8	with	with	IN
cord-034340-3ksfpaf7	1548	9	alternative	alternative	JJ
cord-034340-3ksfpaf7	1548	10	biologics	biologic	NNS
cord-034340-3ksfpaf7	1548	11	.	.	.
cord-034340-3ksfpaf7	1549	1	Tolerability	tolerability	NN
cord-034340-3ksfpaf7	1549	2	was	be	VBD
cord-034340-3ksfpaf7	1549	3	acceptable	acceptable	JJ
cord-034340-3ksfpaf7	1549	4	.	.	.
cord-034340-3ksfpaf7	1550	1	As	as	IN
cord-034340-3ksfpaf7	1550	2	TOC	TOC	NNP
cord-034340-3ksfpaf7	1550	3	was	be	VBD
cord-034340-3ksfpaf7	1550	4	given	give	VBN
cord-034340-3ksfpaf7	1550	5	as	as	IN
cord-034340-3ksfpaf7	1550	6	a	a	DT
cord-034340-3ksfpaf7	1550	7	second	second	JJ
cord-034340-3ksfpaf7	1550	8	-	-	HYPH
cord-034340-3ksfpaf7	1550	9	line	line	NN
cord-034340-3ksfpaf7	1550	10	biologic	biologic	JJ
cord-034340-3ksfpaf7	1550	11	in	in	IN
cord-034340-3ksfpaf7	1550	12	the	the	DT
cord-034340-3ksfpaf7	1550	13	vast	vast	JJ
cord-034340-3ksfpaf7	1550	14	majority	majority	NN
cord-034340-3ksfpaf7	1550	15	of	of	IN
cord-034340-3ksfpaf7	1550	16	patients	patient	NNS
cord-034340-3ksfpaf7	1550	17	comparisons	comparison	NNS
cord-034340-3ksfpaf7	1550	18	between	between	IN
cord-034340-3ksfpaf7	1550	19	the	the	DT
cord-034340-3ksfpaf7	1550	20	2	2	CD
cord-034340-3ksfpaf7	1550	21	cohorts	cohort	NNS
cord-034340-3ksfpaf7	1550	22	have	have	VBP
cord-034340-3ksfpaf7	1550	23	to	to	TO
cord-034340-3ksfpaf7	1550	24	be	be	VB
cord-034340-3ksfpaf7	1550	25	interpreted	interpret	VBN
cord-034340-3ksfpaf7	1550	26	carefully	carefully	RB
cord-034340-3ksfpaf7	1550	27	.	.	.
cord-034340-3ksfpaf7	1551	1	Observation	observation	NN
cord-034340-3ksfpaf7	1551	2	is	be	VBZ
cord-034340-3ksfpaf7	1551	3	ongoing	ongoing	JJ
cord-034340-3ksfpaf7	1551	4	.	.	.
cord-034340-3ksfpaf7	1552	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1552	2	:	:	:
cord-034340-3ksfpaf7	1553	1	In	in	IN
cord-034340-3ksfpaf7	1553	2	this	this	DT
cord-034340-3ksfpaf7	1553	3	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1553	4	cohort	cohort	NN
cord-034340-3ksfpaf7	1553	5	study	study	NN
cord-034340-3ksfpaf7	1553	6	in	in	IN
cord-034340-3ksfpaf7	1553	7	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1553	8	patients	patient	NNS
cord-034340-3ksfpaf7	1553	9	on	on	IN
cord-034340-3ksfpaf7	1553	10	RTX	rtx	NN
cord-034340-3ksfpaf7	1553	11	-	-	HYPH
cord-034340-3ksfpaf7	1553	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1553	13	,	,	,
cord-034340-3ksfpaf7	1553	14	we	-PRON-	PRP
cord-034340-3ksfpaf7	1553	15	found	find	VBD
cord-034340-3ksfpaf7	1553	16	undetectable	undetectable	JJ
cord-034340-3ksfpaf7	1553	17	low	low	JJ
cord-034340-3ksfpaf7	1553	18	drug	drug	NN
cord-034340-3ksfpaf7	1553	19	levels	level	NNS
cord-034340-3ksfpaf7	1553	20	in	in	IN
cord-034340-3ksfpaf7	1553	21	ADApositive	adapositive	JJ
cord-034340-3ksfpaf7	1553	22	patients	patient	NNS
cord-034340-3ksfpaf7	1553	23	,	,	,
cord-034340-3ksfpaf7	1553	24	indicative	indicative	JJ
cord-034340-3ksfpaf7	1553	25	for	for	IN
cord-034340-3ksfpaf7	1553	26	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1553	27	neutralizing	neutralize	VBG
cord-034340-3ksfpaf7	1553	28	capacity	capacity	NN
cord-034340-3ksfpaf7	1553	29	.	.	.
cord-034340-3ksfpaf7	1554	1	Consequently	consequently	RB
cord-034340-3ksfpaf7	1554	2	,	,	,
cord-034340-3ksfpaf7	1554	3	the	the	DT
cord-034340-3ksfpaf7	1554	4	lack	lack	NN
cord-034340-3ksfpaf7	1554	5	of	of	IN
cord-034340-3ksfpaf7	1554	6	B	b	NN
cord-034340-3ksfpaf7	1554	7	-	-	HYPH
cord-034340-3ksfpaf7	1554	8	cel	cel	NN
cord-034340-3ksfpaf7	1554	9	depletion	depletion	NN
cord-034340-3ksfpaf7	1554	10	leads	lead	VBZ
cord-034340-3ksfpaf7	1554	11	to	to	IN
cord-034340-3ksfpaf7	1554	12	reduced	reduce	VBN
cord-034340-3ksfpaf7	1554	13	treatment	treatment	NN
cord-034340-3ksfpaf7	1554	14	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1554	15	.	.	.
cord-034340-3ksfpaf7	1555	1	Patients	patient	NNS
cord-034340-3ksfpaf7	1555	2	with	with	IN
cord-034340-3ksfpaf7	1555	3	SLE	SLE	NNP
cord-034340-3ksfpaf7	1555	4	seem	seem	VBP
cord-034340-3ksfpaf7	1555	5	more	more	RBR
cord-034340-3ksfpaf7	1555	6	susceptible	susceptible	JJ
cord-034340-3ksfpaf7	1555	7	to	to	TO
cord-034340-3ksfpaf7	1555	8	develop	develop	VB
cord-034340-3ksfpaf7	1555	9	ADA	ADA	NNP
cord-034340-3ksfpaf7	1555	10	.	.	.
cord-034340-3ksfpaf7	1556	1	If	if	IN
cord-034340-3ksfpaf7	1556	2	ADA	ADA	NNP
cord-034340-3ksfpaf7	1556	3	are	be	VBP
cord-034340-3ksfpaf7	1556	4	detected	detect	VBN
cord-034340-3ksfpaf7	1556	5	,	,	,
cord-034340-3ksfpaf7	1556	6	continuation	continuation	NN
cord-034340-3ksfpaf7	1556	7	of	of	IN
cord-034340-3ksfpaf7	1556	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1556	9	seems	seem	VBZ
cord-034340-3ksfpaf7	1556	10	non	non	JJ
cord-034340-3ksfpaf7	1556	11	-	-	JJ
cord-034340-3ksfpaf7	1556	12	effective	effective	JJ
cord-034340-3ksfpaf7	1556	13	and	and	CC
cord-034340-3ksfpaf7	1556	14	changing	change	VBG
cord-034340-3ksfpaf7	1556	15	medication	medication	NN
cord-034340-3ksfpaf7	1556	16	is	be	VBZ
cord-034340-3ksfpaf7	1556	17	advised	advise	VBN
cord-034340-3ksfpaf7	1556	18	.	.	.
cord-034340-3ksfpaf7	1557	1	Certainly	certainly	RB
cord-034340-3ksfpaf7	1557	2	when	when	WRB
cord-034340-3ksfpaf7	1557	3	considering	consider	VBG
cord-034340-3ksfpaf7	1557	4	that	that	IN
cord-034340-3ksfpaf7	1557	5	,	,	,
cord-034340-3ksfpaf7	1557	6	in	in	IN
cord-034340-3ksfpaf7	1557	7	this	this	DT
cord-034340-3ksfpaf7	1557	8	study	study	NN
cord-034340-3ksfpaf7	1557	9	,	,	,
cord-034340-3ksfpaf7	1557	10	anaphylactic	anaphylactic	JJ
cord-034340-3ksfpaf7	1557	11	reactions	reaction	NNS
cord-034340-3ksfpaf7	1557	12	only	only	RB
cord-034340-3ksfpaf7	1557	13	occurred	occur	VBD
cord-034340-3ksfpaf7	1557	14	in	in	IN
cord-034340-3ksfpaf7	1557	15	ADA	ADA	NNP
cord-034340-3ksfpaf7	1557	16	-	-	HYPH
cord-034340-3ksfpaf7	1557	17	positive	positive	JJ
cord-034340-3ksfpaf7	1557	18	patients	patient	NNS
cord-034340-3ksfpaf7	1557	19	.	.	.
cord-034340-3ksfpaf7	1558	1	None	none	NN
cord-034340-3ksfpaf7	1558	2	declared	declare	VBD
cord-034340-3ksfpaf7	1558	3	Objectives	objective	NNS
cord-034340-3ksfpaf7	1558	4	:	:	:
cord-034340-3ksfpaf7	1558	5	The	the	DT
cord-034340-3ksfpaf7	1558	6	aim	aim	NN
cord-034340-3ksfpaf7	1558	7	of	of	IN
cord-034340-3ksfpaf7	1558	8	this	this	DT
cord-034340-3ksfpaf7	1558	9	study	study	NN
cord-034340-3ksfpaf7	1558	10	was	be	VBD
cord-034340-3ksfpaf7	1558	11	to	to	TO
cord-034340-3ksfpaf7	1558	12	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1558	13	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	1558	14	the	the	DT
cord-034340-3ksfpaf7	1558	15	long	long	JJ
cord-034340-3ksfpaf7	1558	16	-	-	HYPH
cord-034340-3ksfpaf7	1558	17	term	term	NN
cord-034340-3ksfpaf7	1558	18	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1558	19	and	and	CC
cord-034340-3ksfpaf7	1558	20	safety	safety	NN
cord-034340-3ksfpaf7	1558	21	of	of	IN
cord-034340-3ksfpaf7	1558	22	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1558	23	in	in	IN
cord-034340-3ksfpaf7	1558	24	patients	patient	NNS
cord-034340-3ksfpaf7	1558	25	with	with	IN
cord-034340-3ksfpaf7	1558	26	JIAassociated	JIAassociated	NNP
cord-034340-3ksfpaf7	1558	27	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1558	28	.	.	.
cord-034340-3ksfpaf7	1559	1	Methods	method	NNS
cord-034340-3ksfpaf7	1560	1	:	:	:
cord-034340-3ksfpaf7	1560	2	We	-PRON-	PRP
cord-034340-3ksfpaf7	1560	3	have	have	VBP
cord-034340-3ksfpaf7	1560	4	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	1560	5	analysed	analyse	VBN
cord-034340-3ksfpaf7	1560	6	nineteen	nineteen	CD
cord-034340-3ksfpaf7	1560	7	JIA	JIA	NNP
cord-034340-3ksfpaf7	1560	8	patiens	patien	NNS
cord-034340-3ksfpaf7	1560	9	data	datum	NNS
cord-034340-3ksfpaf7	1560	10	with	with	IN
cord-034340-3ksfpaf7	1560	11	associated	associated	JJ
cord-034340-3ksfpaf7	1560	12	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1560	13	from	from	IN
cord-034340-3ksfpaf7	1560	14	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1560	15	centre	centre	NN
cord-034340-3ksfpaf7	1560	16	registry	registry	NN
cord-034340-3ksfpaf7	1560	17	between	between	IN
cord-034340-3ksfpaf7	1560	18	2010	2010	CD
cord-034340-3ksfpaf7	1560	19	and	and	CC
cord-034340-3ksfpaf7	1560	20	2020	2020	CD
cord-034340-3ksfpaf7	1560	21	,	,	,
cord-034340-3ksfpaf7	1560	22	treated	treat	VBN
cord-034340-3ksfpaf7	1560	23	with	with	IN
cord-034340-3ksfpaf7	1560	24	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1560	25	after	after	IN
cord-034340-3ksfpaf7	1560	26	failure	failure	NN
cord-034340-3ksfpaf7	1560	27	of	of	IN
cord-034340-3ksfpaf7	1560	28	treatment	treatment	NN
cord-034340-3ksfpaf7	1560	29	with	with	IN
cord-034340-3ksfpaf7	1560	30	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	1560	31	and	and	CC
cord-034340-3ksfpaf7	1560	32	metotrexate	metotrexate	NN
cord-034340-3ksfpaf7	1560	33	.	.	.
cord-034340-3ksfpaf7	1561	1	Demografic	demografic	JJ
cord-034340-3ksfpaf7	1561	2	data	datum	NNS
cord-034340-3ksfpaf7	1561	3	and	and	CC
cord-034340-3ksfpaf7	1561	4	blood	blood	NN
cord-034340-3ksfpaf7	1561	5	samples	sample	NNS
cord-034340-3ksfpaf7	1561	6	were	be	VBD
cord-034340-3ksfpaf7	1561	7	collected	collect	VBN
cord-034340-3ksfpaf7	1561	8	at	at	IN
cord-034340-3ksfpaf7	1561	9	different	different	JJ
cord-034340-3ksfpaf7	1561	10	time	time	NN
cord-034340-3ksfpaf7	1561	11	points	point	NNS
cord-034340-3ksfpaf7	1561	12	while	while	IN
cord-034340-3ksfpaf7	1561	13	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1561	14	activity	activity	NN
cord-034340-3ksfpaf7	1561	15	was	be	VBD
cord-034340-3ksfpaf7	1561	16	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	1561	17	by	by	IN
cord-034340-3ksfpaf7	1561	18	slit	slit	JJ
cord-034340-3ksfpaf7	1561	19	-	-	HYPH
cord-034340-3ksfpaf7	1561	20	lamp	lamp	NN
cord-034340-3ksfpaf7	1561	21	biomicroscopy	biomicroscopy	NN
cord-034340-3ksfpaf7	1561	22	.	.	.
cord-034340-3ksfpaf7	1562	1	Adverse	adverse	JJ
cord-034340-3ksfpaf7	1562	2	events	event	NNS
cord-034340-3ksfpaf7	1562	3	were	be	VBD
cord-034340-3ksfpaf7	1562	4	recorded	record	VBN
cord-034340-3ksfpaf7	1562	5	.	.	.
cord-034340-3ksfpaf7	1563	1	Results	result	NNS
cord-034340-3ksfpaf7	1563	2	:	:	:
cord-034340-3ksfpaf7	1564	1	Registry	registry	NN
cord-034340-3ksfpaf7	1564	2	records	record	NNS
cord-034340-3ksfpaf7	1564	3	provided	provide	VBD
cord-034340-3ksfpaf7	1564	4	10	10	CD
cord-034340-3ksfpaf7	1564	5	years	year	NNS
cord-034340-3ksfpaf7	1564	6	follow	follow	VB
cord-034340-3ksfpaf7	1564	7	up	up	IN
cord-034340-3ksfpaf7	1564	8	of	of	IN
cord-034340-3ksfpaf7	1564	9	19	19	CD
cord-034340-3ksfpaf7	1564	10	JIA	JIA	NNP
cord-034340-3ksfpaf7	1564	11	patients	patient	VBZ
cord-034340-3ksfpaf7	1564	12	data	datum	NNS
cord-034340-3ksfpaf7	1564	13	with	with	IN
cord-034340-3ksfpaf7	1564	14	associated	associated	JJ
cord-034340-3ksfpaf7	1564	15	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1564	16	.	.	.
cord-034340-3ksfpaf7	1565	1	Eleven	eleven	CD
cord-034340-3ksfpaf7	1565	2	patients	patient	NNS
cord-034340-3ksfpaf7	1565	3	were	be	VBD
cord-034340-3ksfpaf7	1565	4	females	female	NNS
cord-034340-3ksfpaf7	1565	5	(	(	-LRB-
cord-034340-3ksfpaf7	1565	6	57.90	57.90	CD
cord-034340-3ksfpaf7	1565	7	%	%	NN
cord-034340-3ksfpaf7	1565	8	)	)	-RRB-
cord-034340-3ksfpaf7	1565	9	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1565	10	as	as	IN
cord-034340-3ksfpaf7	1565	11	oligo	oligo	NNP
cord-034340-3ksfpaf7	1565	12	/	/	SYM
cord-034340-3ksfpaf7	1565	13	extended	extend	VBD
cord-034340-3ksfpaf7	1565	14	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	1565	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	1565	16	while	while	IN
cord-034340-3ksfpaf7	1565	17	eight	eight	CD
cord-034340-3ksfpaf7	1565	18	(	(	-LRB-
cord-034340-3ksfpaf7	1565	19	42.10	42.10	CD
cord-034340-3ksfpaf7	1565	20	%	%	NN
cord-034340-3ksfpaf7	1565	21	)	)	-RRB-
cord-034340-3ksfpaf7	1565	22	were	be	VBD
cord-034340-3ksfpaf7	1565	23	males	male	NNS
cord-034340-3ksfpaf7	1565	24	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1565	25	as	as	IN
cord-034340-3ksfpaf7	1565	26	enthesitis	enthesitis	NNP
cord-034340-3ksfpaf7	1565	27	related	relate	VBN
cord-034340-3ksfpaf7	1565	28	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1565	29	(	(	-LRB-
cord-034340-3ksfpaf7	1565	30	ERA	ERA	NNP
cord-034340-3ksfpaf7	1565	31	)	)	-RRB-
cord-034340-3ksfpaf7	1565	32	.	.	.
cord-034340-3ksfpaf7	1566	1	Before	before	IN
cord-034340-3ksfpaf7	1566	2	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1566	3	was	be	VBD
cord-034340-3ksfpaf7	1566	4	prescribed	prescribe	VBN
cord-034340-3ksfpaf7	1566	5	,	,	,
cord-034340-3ksfpaf7	1566	6	all	all	DT
cord-034340-3ksfpaf7	1566	7	patients	patient	NNS
cord-034340-3ksfpaf7	1566	8	were	be	VBD
cord-034340-3ksfpaf7	1566	9	previously	previously	RB
cord-034340-3ksfpaf7	1566	10	treated	treat	VBN
cord-034340-3ksfpaf7	1566	11	with	with	IN
cord-034340-3ksfpaf7	1566	12	metotrexate	metotrexate	NN
cord-034340-3ksfpaf7	1566	13	during	during	IN
cord-034340-3ksfpaf7	1566	14	3.5	3.5	CD
cord-034340-3ksfpaf7	1566	15	years	year	NNS
cord-034340-3ksfpaf7	1566	16	in	in	IN
cord-034340-3ksfpaf7	1566	17	avarage	avarage	JJ
cord-034340-3ksfpaf7	1566	18	dose	dose	NN
cord-034340-3ksfpaf7	1566	19	of	of	IN
cord-034340-3ksfpaf7	1566	20	10	10	CD
cord-034340-3ksfpaf7	1566	21	mg/	mg/	NN
cord-034340-3ksfpaf7	1566	22	m	m	NNP
cord-034340-3ksfpaf7	1566	23	2	2	CD
cord-034340-3ksfpaf7	1566	24	weekly	weekly	NN
cord-034340-3ksfpaf7	1566	25	.	.	.
cord-034340-3ksfpaf7	1567	1	The	the	DT
cord-034340-3ksfpaf7	1567	2	mean	mean	JJ
cord-034340-3ksfpaf7	1567	3	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1567	4	duration	duration	NN
cord-034340-3ksfpaf7	1567	5	,	,	,
cord-034340-3ksfpaf7	1567	6	before	before	IN
cord-034340-3ksfpaf7	1567	7	adalimumab	adalimumab	NNP
cord-034340-3ksfpaf7	1567	8	administration	administration	NN
cord-034340-3ksfpaf7	1567	9	was	be	VBD
cord-034340-3ksfpaf7	1567	10	9	9	CD
cord-034340-3ksfpaf7	1567	11	months	month	NNS
cord-034340-3ksfpaf7	1567	12	.	.	.
cord-034340-3ksfpaf7	1568	1	Ten	ten	CD
cord-034340-3ksfpaf7	1568	2	years	year	NNS
cord-034340-3ksfpaf7	1568	3	long	long	RB
cord-034340-3ksfpaf7	1568	4	follow	follow	VBP
cord-034340-3ksfpaf7	1568	5	up	up	RP
cord-034340-3ksfpaf7	1568	6	period	period	NN
cord-034340-3ksfpaf7	1569	1	have	have	VBP
cord-034340-3ksfpaf7	1569	2	showed	show	VBN
cord-034340-3ksfpaf7	1569	3	that	that	IN
cord-034340-3ksfpaf7	1569	4	there	there	EX
cord-034340-3ksfpaf7	1569	5	were	be	VBD
cord-034340-3ksfpaf7	1569	6	no	no	DT
cord-034340-3ksfpaf7	1569	7	new	new	JJ
cord-034340-3ksfpaf7	1569	8	relapsis	relapsis	NN
cord-034340-3ksfpaf7	1569	9	of	of	IN
cord-034340-3ksfpaf7	1569	10	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1569	11	while	while	IN
cord-034340-3ksfpaf7	1569	12	patients	patient	NNS
cord-034340-3ksfpaf7	1569	13	were	be	VBD
cord-034340-3ksfpaf7	1569	14	receiving	receive	VBG
cord-034340-3ksfpaf7	1569	15	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1569	16	and	and	CC
cord-034340-3ksfpaf7	1569	17	metotrexate	metotrexate	NN
cord-034340-3ksfpaf7	1569	18	.	.	.
cord-034340-3ksfpaf7	1570	1	All	all	DT
cord-034340-3ksfpaf7	1570	2	of	of	IN
cord-034340-3ksfpaf7	1570	3	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1570	4	patients	patient	NNS
cord-034340-3ksfpaf7	1570	5	were	be	VBD
cord-034340-3ksfpaf7	1570	6	able	able	JJ
cord-034340-3ksfpaf7	1570	7	to	to	TO
cord-034340-3ksfpaf7	1570	8	gradually	gradually	RB
cord-034340-3ksfpaf7	1570	9	tapper	tapper	VB
cord-034340-3ksfpaf7	1570	10	and	and	CC
cord-034340-3ksfpaf7	1570	11	stop	stop	VB
cord-034340-3ksfpaf7	1570	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1570	13	with	with	IN
cord-034340-3ksfpaf7	1570	14	topical	topical	JJ
cord-034340-3ksfpaf7	1570	15	steroids	steroid	NNS
cord-034340-3ksfpaf7	1570	16	two	two	CD
cord-034340-3ksfpaf7	1570	17	months	month	NNS
cord-034340-3ksfpaf7	1570	18	after	after	IN
cord-034340-3ksfpaf7	1570	19	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1570	20	commencing	commence	VBG
cord-034340-3ksfpaf7	1570	21	.	.	.
cord-034340-3ksfpaf7	1571	1	Seven	seven	CD
cord-034340-3ksfpaf7	1571	2	patients	patient	NNS
cord-034340-3ksfpaf7	1571	3	were	be	VBD
cord-034340-3ksfpaf7	1571	4	able	able	JJ
cord-034340-3ksfpaf7	1571	5	to	to	TO
cord-034340-3ksfpaf7	1571	6	stop	stop	VB
cord-034340-3ksfpaf7	1571	7	biological	biological	JJ
cord-034340-3ksfpaf7	1571	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1571	9	after	after	IN
cord-034340-3ksfpaf7	1571	10	4.3	4.3	CD
cord-034340-3ksfpaf7	1571	11	years	year	NNS
cord-034340-3ksfpaf7	1571	12	of	of	IN
cord-034340-3ksfpaf7	1571	13	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1571	14	usage	usage	NN
cord-034340-3ksfpaf7	1571	15	.	.	.
cord-034340-3ksfpaf7	1572	1	Uveitis	Uveitis	NNP
cord-034340-3ksfpaf7	1572	2	relapsed	relapse	VBD
cord-034340-3ksfpaf7	1572	3	three	three	CD
cord-034340-3ksfpaf7	1572	4	monts	mont	NNS
cord-034340-3ksfpaf7	1572	5	after	after	IN
cord-034340-3ksfpaf7	1572	6	the	the	DT
cord-034340-3ksfpaf7	1572	7	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1572	8	discontinuation	discontinuation	VBP
cord-034340-3ksfpaf7	1572	9	only	only	RB
cord-034340-3ksfpaf7	1572	10	in	in	IN
cord-034340-3ksfpaf7	1572	11	one	one	CD
cord-034340-3ksfpaf7	1572	12	patient	patient	NN
cord-034340-3ksfpaf7	1572	13	.	.	.
cord-034340-3ksfpaf7	1573	1	Two	two	CD
cord-034340-3ksfpaf7	1573	2	patient	patient	NN
cord-034340-3ksfpaf7	1573	3	were	be	VBD
cord-034340-3ksfpaf7	1573	4	lost	lose	VBN
cord-034340-3ksfpaf7	1573	5	to	to	TO
cord-034340-3ksfpaf7	1573	6	follow	follow	VB
cord-034340-3ksfpaf7	1573	7	up	up	RP
cord-034340-3ksfpaf7	1573	8	during	during	IN
cord-034340-3ksfpaf7	1573	9	the	the	DT
cord-034340-3ksfpaf7	1573	10	transitional	transitional	JJ
cord-034340-3ksfpaf7	1573	11	period	period	NN
cord-034340-3ksfpaf7	1573	12	.	.	.
cord-034340-3ksfpaf7	1574	1	No	no	DT
cord-034340-3ksfpaf7	1574	2	serious	serious	JJ
cord-034340-3ksfpaf7	1574	3	adverse	adverse	JJ
cord-034340-3ksfpaf7	1574	4	events	event	NNS
cord-034340-3ksfpaf7	1574	5	were	be	VBD
cord-034340-3ksfpaf7	1574	6	recorded	record	VBN
cord-034340-3ksfpaf7	1574	7	.	.	.
cord-034340-3ksfpaf7	1575	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1575	2	:	:	:
cord-034340-3ksfpaf7	1575	3	During	during	IN
cord-034340-3ksfpaf7	1575	4	the	the	DT
cord-034340-3ksfpaf7	1575	5	long	long	JJ
cord-034340-3ksfpaf7	1575	6	term	term	NN
cord-034340-3ksfpaf7	1575	7	follow	follow	VB
cord-034340-3ksfpaf7	1575	8	up	up	RP
cord-034340-3ksfpaf7	1575	9	period	period	NN
cord-034340-3ksfpaf7	1576	1	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	1576	2	have	have	VBP
cord-034340-3ksfpaf7	1576	3	shown	show	VBN
cord-034340-3ksfpaf7	1576	4	good	good	JJ
cord-034340-3ksfpaf7	1576	5	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1576	6	and	and	CC
cord-034340-3ksfpaf7	1576	7	safety	safety	NN
cord-034340-3ksfpaf7	1576	8	profile	profile	NN
cord-034340-3ksfpaf7	1576	9	in	in	IN
cord-034340-3ksfpaf7	1576	10	JIA	JIA	NNP
cord-034340-3ksfpaf7	1576	11	patients	patient	NNS
cord-034340-3ksfpaf7	1576	12	with	with	IN
cord-034340-3ksfpaf7	1576	13	active	active	JJ
cord-034340-3ksfpaf7	1576	14	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1576	15	ocular	ocular	JJ
cord-034340-3ksfpaf7	1576	16	disease	disease	NN
cord-034340-3ksfpaf7	1576	17	.	.	.
cord-034340-3ksfpaf7	1577	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1577	2	:	:	:
cord-034340-3ksfpaf7	1578	1	Post	post	JJ
cord-034340-3ksfpaf7	1578	2	-	-	JJ
cord-034340-3ksfpaf7	1578	3	streptococcal	streptococcal	JJ
cord-034340-3ksfpaf7	1578	4	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1578	5	is	be	VBZ
cord-034340-3ksfpaf7	1578	6	a	a	DT
cord-034340-3ksfpaf7	1578	7	systemic	systemic	JJ
cord-034340-3ksfpaf7	1578	8	immunemediated	immunemediated	JJ
cord-034340-3ksfpaf7	1578	9	complication	complication	NN
cord-034340-3ksfpaf7	1578	10	of	of	IN
cord-034340-3ksfpaf7	1578	11	beta	beta	JJ
cord-034340-3ksfpaf7	1578	12	-	-	HYPH
cord-034340-3ksfpaf7	1578	13	haemolytic	haemolytic	JJ
cord-034340-3ksfpaf7	1578	14	streptococci	streptococcus	NNS
cord-034340-3ksfpaf7	1578	15	infection	infection	NN
cord-034340-3ksfpaf7	1578	16	,	,	,
cord-034340-3ksfpaf7	1578	17	mostly	mostly	RB
cord-034340-3ksfpaf7	1578	18	seen	see	VBN
cord-034340-3ksfpaf7	1578	19	as	as	IN
cord-034340-3ksfpaf7	1578	20	post	post	JJ
cord-034340-3ksfpaf7	1578	21	-	-	JJ
cord-034340-3ksfpaf7	1578	22	streptococcal	streptococcal	JJ
cord-034340-3ksfpaf7	1578	23	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1578	24	,	,	,
cord-034340-3ksfpaf7	1578	25	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1578	26	fever	fever	NN
cord-034340-3ksfpaf7	1578	27	or	or	CC
cord-034340-3ksfpaf7	1578	28	glomerulonephritis	glomerulonephritis	NN
cord-034340-3ksfpaf7	1578	29	.	.	.
cord-034340-3ksfpaf7	1579	1	Uveitis	Uveitis	NNP
cord-034340-3ksfpaf7	1579	2	is	be	VBZ
cord-034340-3ksfpaf7	1579	3	an	an	DT
cord-034340-3ksfpaf7	1579	4	uncommon	uncommon	JJ
cord-034340-3ksfpaf7	1579	5	manifestation	manifestation	NN
cord-034340-3ksfpaf7	1579	6	of	of	IN
cord-034340-3ksfpaf7	1579	7	this	this	DT
cord-034340-3ksfpaf7	1579	8	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1579	9	.	.	.
cord-034340-3ksfpaf7	1580	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1580	2	:	:	:
cord-034340-3ksfpaf7	1581	1	Case	case	NN
cord-034340-3ksfpaf7	1581	2	report	report	NN
cord-034340-3ksfpaf7	1581	3	Methods	method	NNS
cord-034340-3ksfpaf7	1581	4	:	:	:
cord-034340-3ksfpaf7	1582	1	Case	case	NN
cord-034340-3ksfpaf7	1582	2	report	report	NN
cord-034340-3ksfpaf7	1582	3	Results	result	NNS
cord-034340-3ksfpaf7	1583	1	:	:	:
cord-034340-3ksfpaf7	1583	2	A	a	DT
cord-034340-3ksfpaf7	1583	3	previously	previously	RB
cord-034340-3ksfpaf7	1583	4	healthy	healthy	JJ
cord-034340-3ksfpaf7	1583	5	7-year	7-year	JJ
cord-034340-3ksfpaf7	1583	6	-	-	HYPH
cord-034340-3ksfpaf7	1583	7	old	old	JJ
cord-034340-3ksfpaf7	1583	8	female	female	NN
cord-034340-3ksfpaf7	1583	9	was	be	VBD
cord-034340-3ksfpaf7	1583	10	admitted	admit	VBN
cord-034340-3ksfpaf7	1583	11	at	at	IN
cord-034340-3ksfpaf7	1583	12	the	the	DT
cord-034340-3ksfpaf7	1583	13	emergency	emergency	NN
cord-034340-3ksfpaf7	1583	14	department	department	NN
cord-034340-3ksfpaf7	1583	15	with	with	IN
cord-034340-3ksfpaf7	1583	16	prolonged	prolong	VBN
cord-034340-3ksfpaf7	1583	17	fever	fever	NN
cord-034340-3ksfpaf7	1583	18	,	,	,
cord-034340-3ksfpaf7	1583	19	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1583	20	and	and	CC
cord-034340-3ksfpaf7	1583	21	red	red	JJ
cord-034340-3ksfpaf7	1583	22	eye	eye	NN
cord-034340-3ksfpaf7	1583	23	.	.	.
cord-034340-3ksfpaf7	1584	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1584	2	had	have	VBD
cord-034340-3ksfpaf7	1584	3	a	a	DT
cord-034340-3ksfpaf7	1584	4	4-month	4-month	JJ
cord-034340-3ksfpaf7	1584	5	history	history	NN
cord-034340-3ksfpaf7	1584	6	of	of	IN
cord-034340-3ksfpaf7	1584	7	febrile	febrile	JJ
cord-034340-3ksfpaf7	1584	8	episodes	episode	NNS
cord-034340-3ksfpaf7	1584	9	every	every	DT
cord-034340-3ksfpaf7	1584	10	two	two	CD
cord-034340-3ksfpaf7	1584	11	weeks	week	NNS
cord-034340-3ksfpaf7	1584	12	,	,	,
cord-034340-3ksfpaf7	1584	13	with	with	IN
cord-034340-3ksfpaf7	1584	14	axillary	axillary	JJ
cord-034340-3ksfpaf7	1584	15	temperature	temperature	NN
cord-034340-3ksfpaf7	1584	16	ranging	range	VBG
cord-034340-3ksfpaf7	1584	17	from	from	IN
cord-034340-3ksfpaf7	1584	18	37,8	37,8	CD
cord-034340-3ksfpaf7	1584	19	to	to	IN
cord-034340-3ksfpaf7	1584	20	39ºC.	39ºc.	CD
cord-034340-3ksfpaf7	1584	21	Migratory	migratory	JJ
cord-034340-3ksfpaf7	1584	22	arthralgia	arthralgia	NN
cord-034340-3ksfpaf7	1584	23	affecting	affect	VBG
cord-034340-3ksfpaf7	1584	24	both	both	CC
cord-034340-3ksfpaf7	1584	25	knees	knee	NNS
cord-034340-3ksfpaf7	1584	26	and	and	CC
cord-034340-3ksfpaf7	1584	27	tibiotarsal	tibiotarsal	NN
cord-034340-3ksfpaf7	1584	28	joints	joint	NNS
cord-034340-3ksfpaf7	1584	29	showed	show	VBD
cord-034340-3ksfpaf7	1584	30	up	up	RP
cord-034340-3ksfpaf7	1584	31	two	two	CD
cord-034340-3ksfpaf7	1584	32	months	month	NNS
cord-034340-3ksfpaf7	1584	33	after	after	IN
cord-034340-3ksfpaf7	1584	34	the	the	DT
cord-034340-3ksfpaf7	1584	35	fever	fever	NN
cord-034340-3ksfpaf7	1584	36	onset	onset	NN
cord-034340-3ksfpaf7	1584	37	and	and	CC
cord-034340-3ksfpaf7	1584	38	worsened	worsen	VBD
cord-034340-3ksfpaf7	1584	39	in	in	IN
cord-034340-3ksfpaf7	1584	40	the	the	DT
cord-034340-3ksfpaf7	1584	41	previous	previous	JJ
cord-034340-3ksfpaf7	1584	42	week	week	NN
cord-034340-3ksfpaf7	1584	43	,	,	,
cord-034340-3ksfpaf7	1584	44	with	with	IN
cord-034340-3ksfpaf7	1584	45	refusal	refusal	NN
cord-034340-3ksfpaf7	1584	46	to	to	TO
cord-034340-3ksfpaf7	1584	47	walk	walk	VB
cord-034340-3ksfpaf7	1584	48	.	.	.
cord-034340-3ksfpaf7	1585	1	Non	non	JJ
cord-034340-3ksfpaf7	1585	2	-	-	JJ
cord-034340-3ksfpaf7	1585	3	painful	painful	JJ
cord-034340-3ksfpaf7	1585	4	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	1585	5	red	red	JJ
cord-034340-3ksfpaf7	1585	6	eye	eye	NN
cord-034340-3ksfpaf7	1585	7	for	for	IN
cord-034340-3ksfpaf7	1585	8	several	several	JJ
cord-034340-3ksfpaf7	1585	9	weeks	week	NNS
cord-034340-3ksfpaf7	1585	10	was	be	VBD
cord-034340-3ksfpaf7	1585	11	mentioned	mention	VBN
cord-034340-3ksfpaf7	1585	12	.	.	.
cord-034340-3ksfpaf7	1586	1	Other	other	JJ
cord-034340-3ksfpaf7	1586	2	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1586	3	were	be	VBD
cord-034340-3ksfpaf7	1586	4	absent	absent	JJ
cord-034340-3ksfpaf7	1586	5	.	.	.
cord-034340-3ksfpaf7	1587	1	Recent	recent	JJ
cord-034340-3ksfpaf7	1587	2	infections	infection	NNS
cord-034340-3ksfpaf7	1587	3	were	be	VBD
cord-034340-3ksfpaf7	1587	4	denied	deny	VBN
cord-034340-3ksfpaf7	1587	5	and	and	CC
cord-034340-3ksfpaf7	1587	6	family	family	NN
cord-034340-3ksfpaf7	1587	7	history	history	NN
cord-034340-3ksfpaf7	1587	8	was	be	VBD
cord-034340-3ksfpaf7	1587	9	irrelevant	irrelevant	JJ
cord-034340-3ksfpaf7	1587	10	.	.	.
cord-034340-3ksfpaf7	1588	1	Physical	physical	JJ
cord-034340-3ksfpaf7	1588	2	examination	examination	NN
cord-034340-3ksfpaf7	1588	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1588	4	lower	low	JJR
cord-034340-3ksfpaf7	1588	5	limb	limb	NN
cord-034340-3ksfpaf7	1588	6	muscular	muscular	JJ
cord-034340-3ksfpaf7	1588	7	atrophy	atrophy	NN
cord-034340-3ksfpaf7	1588	8	,	,	,
cord-034340-3ksfpaf7	1588	9	knees	knee	NNS
cord-034340-3ksfpaf7	1588	10	pain	pain	NN
cord-034340-3ksfpaf7	1588	11	and	and	CC
cord-034340-3ksfpaf7	1588	12	impaired	impaired	JJ
cord-034340-3ksfpaf7	1588	13	function	function	NN
cord-034340-3ksfpaf7	1588	14	and	and	CC
cord-034340-3ksfpaf7	1588	15	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	1588	16	tibiotarsal	tibiotarsal	NN
cord-034340-3ksfpaf7	1588	17	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1588	18	with	with	IN
cord-034340-3ksfpaf7	1588	19	inability	inability	NN
cord-034340-3ksfpaf7	1588	20	to	to	TO
cord-034340-3ksfpaf7	1588	21	walk	walk	VB
cord-034340-3ksfpaf7	1588	22	.	.	.
cord-034340-3ksfpaf7	1589	1	Ophthalmological	ophthalmological	JJ
cord-034340-3ksfpaf7	1589	2	observation	observation	NN
cord-034340-3ksfpaf7	1589	3	showed	show	VBD
cord-034340-3ksfpaf7	1589	4	a	a	DT
cord-034340-3ksfpaf7	1589	5	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	1589	6	non	non	JJ
cord-034340-3ksfpaf7	1589	7	-	-	JJ
cord-034340-3ksfpaf7	1589	8	granulomatous	granulomatous	JJ
cord-034340-3ksfpaf7	1589	9	anterior	anterior	JJ
cord-034340-3ksfpaf7	1589	10	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1589	11	.	.	.
cord-034340-3ksfpaf7	1590	1	Sequential	sequential	JJ
cord-034340-3ksfpaf7	1590	2	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1590	3	work	work	NN
cord-034340-3ksfpaf7	1590	4	up	up	RP
cord-034340-3ksfpaf7	1590	5	revealed	reveal	VBD
cord-034340-3ksfpaf7	1590	6	a	a	DT
cord-034340-3ksfpaf7	1590	7	maximum	maximum	JJ
cord-034340-3ksfpaf7	1590	8	eritrocitary	eritrocitary	JJ
cord-034340-3ksfpaf7	1590	9	sedimentation	sedimentation	NN
cord-034340-3ksfpaf7	1590	10	rate	rate	NN
cord-034340-3ksfpaf7	1590	11	of	of	IN
cord-034340-3ksfpaf7	1590	12	135	135	CD
cord-034340-3ksfpaf7	1590	13	mm	mm	NNP
cord-034340-3ksfpaf7	1590	14	/	/	SYM
cord-034340-3ksfpaf7	1590	15	h	h	NNP
cord-034340-3ksfpaf7	1590	16	,	,	,
cord-034340-3ksfpaf7	1590	17	maximum	maximum	JJ
cord-034340-3ksfpaf7	1590	18	c	c	NN
cord-034340-3ksfpaf7	1590	19	-	-	HYPH
cord-034340-3ksfpaf7	1590	20	reactive	reactive	JJ
cord-034340-3ksfpaf7	1590	21	protein	protein	NN
cord-034340-3ksfpaf7	1590	22	of	of	IN
cord-034340-3ksfpaf7	1590	23	5,3	5,3	CD
cord-034340-3ksfpaf7	1590	24	mg	mg	NNP
cord-034340-3ksfpaf7	1590	25	/	/	SYM
cord-034340-3ksfpaf7	1590	26	dL	dl	NN
cord-034340-3ksfpaf7	1590	27	,	,	,
cord-034340-3ksfpaf7	1590	28	microcytic	microcytic	JJ
cord-034340-3ksfpaf7	1590	29	hypochromic	hypochromic	JJ
cord-034340-3ksfpaf7	1590	30	anemia	anemia	NN
cord-034340-3ksfpaf7	1590	31	,	,	,
cord-034340-3ksfpaf7	1590	32	positive	positive	JJ
cord-034340-3ksfpaf7	1590	33	antistreptolysin	antistreptolysin	NNP
cord-034340-3ksfpaf7	1590	34	O	O	NNP
cord-034340-3ksfpaf7	1590	35	titer	titer	NN
cord-034340-3ksfpaf7	1590	36	(	(	-LRB-
cord-034340-3ksfpaf7	1590	37	ASOT	ASOT	NNP
cord-034340-3ksfpaf7	1590	38	)	)	-RRB-
cord-034340-3ksfpaf7	1590	39	(	(	-LRB-
cord-034340-3ksfpaf7	1590	40	initial	initial	JJ
cord-034340-3ksfpaf7	1590	41	result	result	NN
cord-034340-3ksfpaf7	1590	42	of	of	IN
cord-034340-3ksfpaf7	1590	43	1250	1250	CD
cord-034340-3ksfpaf7	1590	44	that	that	WDT
cord-034340-3ksfpaf7	1590	45	increased	increase	VBD
cord-034340-3ksfpaf7	1590	46	to	to	IN
cord-034340-3ksfpaf7	1590	47	2500	2500	CD
cord-034340-3ksfpaf7	1590	48	in	in	IN
cord-034340-3ksfpaf7	1590	49	4	4	CD
cord-034340-3ksfpaf7	1590	50	weeks	week	NNS
cord-034340-3ksfpaf7	1590	51	and	and	CC
cord-034340-3ksfpaf7	1590	52	later	later	RB
cord-034340-3ksfpaf7	1590	53	decreased	decrease	VBD
cord-034340-3ksfpaf7	1590	54	to	to	IN
cord-034340-3ksfpaf7	1590	55	500	500	CD
cord-034340-3ksfpaf7	1590	56	)	)	-RRB-
cord-034340-3ksfpaf7	1590	57	and	and	CC
cord-034340-3ksfpaf7	1590	58	negative	negative	JJ
cord-034340-3ksfpaf7	1590	59	anti	anti	JJ
cord-034340-3ksfpaf7	1590	60	-	-	JJ
cord-034340-3ksfpaf7	1590	61	nuclear	nuclear	JJ
cord-034340-3ksfpaf7	1590	62	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1590	63	.	.	.
cord-034340-3ksfpaf7	1591	1	Cardiac	cardiac	JJ
cord-034340-3ksfpaf7	1591	2	involvement	involvement	NN
cord-034340-3ksfpaf7	1591	3	was	be	VBD
cord-034340-3ksfpaf7	1591	4	excluded	exclude	VBN
cord-034340-3ksfpaf7	1591	5	.	.	.
cord-034340-3ksfpaf7	1592	1	The	the	DT
cord-034340-3ksfpaf7	1592	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1592	3	of	of	IN
cord-034340-3ksfpaf7	1592	4	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1592	5	fever	fever	NN
cord-034340-3ksfpaf7	1592	6	with	with	IN
cord-034340-3ksfpaf7	1592	7	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	1592	8	poststreptococcal	poststreptococcal	JJ
cord-034340-3ksfpaf7	1592	9	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1592	10	was	be	VBD
cord-034340-3ksfpaf7	1592	11	assumed	assume	VBN
cord-034340-3ksfpaf7	1592	12	and	and	CC
cord-034340-3ksfpaf7	1592	13	the	the	DT
cord-034340-3ksfpaf7	1592	14	patient	patient	NN
cord-034340-3ksfpaf7	1592	15	was	be	VBD
cord-034340-3ksfpaf7	1592	16	treated	treat	VBN
cord-034340-3ksfpaf7	1592	17	with	with	IN
cord-034340-3ksfpaf7	1592	18	oral	oral	JJ
cord-034340-3ksfpaf7	1592	19	and	and	CC
cord-034340-3ksfpaf7	1592	20	topical	topical	JJ
cord-034340-3ksfpaf7	1592	21	ophthalmic	ophthalmic	JJ
cord-034340-3ksfpaf7	1592	22	corticosteroids	corticosteroid	NNS
cord-034340-3ksfpaf7	1592	23	with	with	IN
cord-034340-3ksfpaf7	1592	24	prompt	prompt	JJ
cord-034340-3ksfpaf7	1592	25	clinical	clinical	JJ
cord-034340-3ksfpaf7	1592	26	resolution	resolution	NN
cord-034340-3ksfpaf7	1592	27	of	of	IN
cord-034340-3ksfpaf7	1592	28	fever	fever	NN
cord-034340-3ksfpaf7	1592	29	,	,	,
cord-034340-3ksfpaf7	1592	30	acute	acute	JJ
cord-034340-3ksfpaf7	1592	31	polyarthritis	polyarthritis	NN
cord-034340-3ksfpaf7	1592	32	and	and	CC
cord-034340-3ksfpaf7	1592	33	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1592	34	.	.	.
cord-034340-3ksfpaf7	1593	1	No	no	DT
cord-034340-3ksfpaf7	1593	2	relapse	relapse	NN
cord-034340-3ksfpaf7	1593	3	occurred	occur	VBD
cord-034340-3ksfpaf7	1593	4	in	in	IN
cord-034340-3ksfpaf7	1593	5	a	a	DT
cord-034340-3ksfpaf7	1593	6	5-year	5-year	CD
cord-034340-3ksfpaf7	1593	7	follow	follow	NN
cord-034340-3ksfpaf7	1593	8	-	-	HYPH
cord-034340-3ksfpaf7	1593	9	up	up	NN
cord-034340-3ksfpaf7	1593	10	.	.	.
cord-034340-3ksfpaf7	1594	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1594	2	:	:	:
cord-034340-3ksfpaf7	1595	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1595	2	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1595	3	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1595	4	(	(	-LRB-
cord-034340-3ksfpaf7	1595	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	1595	6	)	)	-RRB-
cord-034340-3ksfpaf7	1595	7	is	be	VBZ
cord-034340-3ksfpaf7	1595	8	the	the	DT
cord-034340-3ksfpaf7	1595	9	most	most	RBS
cord-034340-3ksfpaf7	1595	10	common	common	JJ
cord-034340-3ksfpaf7	1595	11	cause	cause	NN
cord-034340-3ksfpaf7	1595	12	of	of	IN
cord-034340-3ksfpaf7	1595	13	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1595	14	in	in	IN
cord-034340-3ksfpaf7	1595	15	childhood	childhood	NN
cord-034340-3ksfpaf7	1595	16	.	.	.
cord-034340-3ksfpaf7	1596	1	Although	although	IN
cord-034340-3ksfpaf7	1596	2	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1596	3	patient	patient	JJ
cord-034340-3ksfpaf7	1596	4	clinical	clinical	JJ
cord-034340-3ksfpaf7	1596	5	course	course	NN
cord-034340-3ksfpaf7	1596	6	could	could	MD
cord-034340-3ksfpaf7	1596	7	initially	initially	RB
cord-034340-3ksfpaf7	1596	8	raise	raise	VB
cord-034340-3ksfpaf7	1596	9	the	the	DT
cord-034340-3ksfpaf7	1596	10	possibility	possibility	NN
cord-034340-3ksfpaf7	1596	11	of	of	IN
cord-034340-3ksfpaf7	1596	12	systemic	systemic	JJ
cord-034340-3ksfpaf7	1596	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	1596	14	(	(	-LRB-
cord-034340-3ksfpaf7	1596	15	sJIA	sJIA	NNP
cord-034340-3ksfpaf7	1596	16	)	)	-RRB-
cord-034340-3ksfpaf7	1596	17	,	,	,
cord-034340-3ksfpaf7	1596	18	the	the	DT
cord-034340-3ksfpaf7	1596	19	criteria	criterion	NNS
cord-034340-3ksfpaf7	1596	20	that	that	WDT
cord-034340-3ksfpaf7	1596	21	define	define	VBP
cord-034340-3ksfpaf7	1596	22	this	this	DT
cord-034340-3ksfpaf7	1596	23	entity	entity	NN
cord-034340-3ksfpaf7	1596	24	were	be	VBD
cord-034340-3ksfpaf7	1596	25	n't	not	RB
cord-034340-3ksfpaf7	1596	26	all	all	DT
cord-034340-3ksfpaf7	1596	27	present	present	JJ
cord-034340-3ksfpaf7	1596	28	and	and	CC
cord-034340-3ksfpaf7	1596	29	clinical	clinical	JJ
cord-034340-3ksfpaf7	1596	30	and	and	CC
cord-034340-3ksfpaf7	1596	31	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1596	32	findings	finding	NNS
cord-034340-3ksfpaf7	1596	33	were	be	VBD
cord-034340-3ksfpaf7	1596	34	more	more	RBR
cord-034340-3ksfpaf7	1596	35	supportive	supportive	JJ
cord-034340-3ksfpaf7	1596	36	of	of	IN
cord-034340-3ksfpaf7	1596	37	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1596	38	fever	fever	NN
cord-034340-3ksfpaf7	1596	39	.	.	.
cord-034340-3ksfpaf7	1597	1	Besides	besides	RB
cord-034340-3ksfpaf7	1597	2	,	,	,
cord-034340-3ksfpaf7	1597	3	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1597	4	occurs	occur	VBZ
cord-034340-3ksfpaf7	1597	5	exceptionally	exceptionally	RB
cord-034340-3ksfpaf7	1597	6	in	in	IN
cord-034340-3ksfpaf7	1597	7	sJIA	sjia	NN
cord-034340-3ksfpaf7	1597	8	,	,	,
cord-034340-3ksfpaf7	1597	9	which	which	WDT
cord-034340-3ksfpaf7	1597	10	turned	turn	VBD
cord-034340-3ksfpaf7	1597	11	this	this	DT
cord-034340-3ksfpaf7	1597	12	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1597	13	even	even	RB
cord-034340-3ksfpaf7	1597	14	less	less	RBR
cord-034340-3ksfpaf7	1597	15	reasonable	reasonable	JJ
cord-034340-3ksfpaf7	1597	16	.	.	.
cord-034340-3ksfpaf7	1598	1	In	in	IN
cord-034340-3ksfpaf7	1598	2	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1598	3	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1598	4	Unit	Unit	NNP
cord-034340-3ksfpaf7	1598	5	,	,	,
cord-034340-3ksfpaf7	1598	6	among	among	IN
cord-034340-3ksfpaf7	1598	7	563	563	CD
cord-034340-3ksfpaf7	1598	8	patients	patient	NNS
cord-034340-3ksfpaf7	1598	9	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1598	10	with	with	IN
cord-034340-3ksfpaf7	1598	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	1598	12	in	in	IN
cord-034340-3ksfpaf7	1598	13	32	32	CD
cord-034340-3ksfpaf7	1598	14	years	year	NNS
cord-034340-3ksfpaf7	1598	15	,	,	,
cord-034340-3ksfpaf7	1598	16	89	89	CD
cord-034340-3ksfpaf7	1598	17	had	have	VBD
cord-034340-3ksfpaf7	1598	18	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1598	19	.	.	.
cord-034340-3ksfpaf7	1599	1	However	however	RB
cord-034340-3ksfpaf7	1599	2	,	,	,
cord-034340-3ksfpaf7	1599	3	in	in	IN
cord-034340-3ksfpaf7	1599	4	the	the	DT
cord-034340-3ksfpaf7	1599	5	group	group	NN
cord-034340-3ksfpaf7	1599	6	of	of	IN
cord-034340-3ksfpaf7	1599	7	51	51	CD
cord-034340-3ksfpaf7	1599	8	patients	patient	NNS
cord-034340-3ksfpaf7	1599	9	with	with	IN
cord-034340-3ksfpaf7	1599	10	sJIA	sjia	NN
cord-034340-3ksfpaf7	1600	1	only	only	RB
cord-034340-3ksfpaf7	1600	2	one	one	CD
cord-034340-3ksfpaf7	1600	3	had	have	VBD
cord-034340-3ksfpaf7	1600	4	ocular	ocular	JJ
cord-034340-3ksfpaf7	1600	5	involvement	involvement	NN
cord-034340-3ksfpaf7	1600	6	,	,	,
cord-034340-3ksfpaf7	1600	7	a	a	DT
cord-034340-3ksfpaf7	1600	8	boy	boy	NN
cord-034340-3ksfpaf7	1600	9	with	with	IN
cord-034340-3ksfpaf7	1600	10	isolated	isolate	VBN
cord-034340-3ksfpaf7	1600	11	vitritis	vitritis	NNP
cord-034340-3ksfpaf7	1600	12	.	.	.
cord-034340-3ksfpaf7	1601	1	Post	post	JJ
cord-034340-3ksfpaf7	1601	2	-	-	JJ
cord-034340-3ksfpaf7	1601	3	streptococcal	streptococcal	JJ
cord-034340-3ksfpaf7	1601	4	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1601	5	(	(	-LRB-
cord-034340-3ksfpaf7	1601	6	PSU	PSU	NNP
cord-034340-3ksfpaf7	1601	7	)	)	-RRB-
cord-034340-3ksfpaf7	1601	8	typically	typically	RB
cord-034340-3ksfpaf7	1601	9	presents	present	VBZ
cord-034340-3ksfpaf7	1601	10	as	as	IN
cord-034340-3ksfpaf7	1601	11	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	1601	12	,	,	,
cord-034340-3ksfpaf7	1601	13	non	non	JJ
cord-034340-3ksfpaf7	1601	14	-	-	JJ
cord-034340-3ksfpaf7	1601	15	granulomatous	granulomatous	JJ
cord-034340-3ksfpaf7	1601	16	anterior	anterior	JJ
cord-034340-3ksfpaf7	1601	17	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1601	18	,	,	,
cord-034340-3ksfpaf7	1601	19	as	as	IN
cord-034340-3ksfpaf7	1601	20	described	describe	VBN
cord-034340-3ksfpaf7	1601	21	in	in	IN
cord-034340-3ksfpaf7	1601	22	this	this	DT
cord-034340-3ksfpaf7	1601	23	case	case	NN
cord-034340-3ksfpaf7	1601	24	.	.	.
cord-034340-3ksfpaf7	1602	1	As	as	IN
cord-034340-3ksfpaf7	1602	2	streptococcal	streptococcal	JJ
cord-034340-3ksfpaf7	1602	3	infection	infection	NN
cord-034340-3ksfpaf7	1602	4	is	be	VBZ
cord-034340-3ksfpaf7	1602	5	very	very	RB
cord-034340-3ksfpaf7	1602	6	common	common	JJ
cord-034340-3ksfpaf7	1602	7	among	among	IN
cord-034340-3ksfpaf7	1602	8	children	child	NNS
cord-034340-3ksfpaf7	1602	9	and	and	CC
cord-034340-3ksfpaf7	1602	10	many	many	JJ
cord-034340-3ksfpaf7	1602	11	patients	patient	NNS
cord-034340-3ksfpaf7	1602	12	may	may	MD
cord-034340-3ksfpaf7	1602	13	experience	experience	VB
cord-034340-3ksfpaf7	1602	14	subclinical	subclinical	JJ
cord-034340-3ksfpaf7	1602	15	infection	infection	NN
cord-034340-3ksfpaf7	1602	16	.	.	.
cord-034340-3ksfpaf7	1603	1	PSU	PSU	NNP
cord-034340-3ksfpaf7	1603	2	should	should	MD
cord-034340-3ksfpaf7	1603	3	be	be	VB
cord-034340-3ksfpaf7	1603	4	considered	consider	VBN
cord-034340-3ksfpaf7	1603	5	in	in	IN
cord-034340-3ksfpaf7	1603	6	all	all	DT
cord-034340-3ksfpaf7	1603	7	patients	patient	NNS
cord-034340-3ksfpaf7	1603	8	with	with	IN
cord-034340-3ksfpaf7	1603	9	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1603	10	along	along	IN
cord-034340-3ksfpaf7	1603	11	with	with	IN
cord-034340-3ksfpaf7	1603	12	positive	positive	JJ
cord-034340-3ksfpaf7	1603	13	ASOT	ASOT	NNP
cord-034340-3ksfpaf7	1603	14	and	and	CC
cord-034340-3ksfpaf7	1603	15	negative	negative	JJ
cord-034340-3ksfpaf7	1603	16	routine	routine	JJ
cord-034340-3ksfpaf7	1603	17	investigations	investigation	NNS
cord-034340-3ksfpaf7	1603	18	for	for	IN
cord-034340-3ksfpaf7	1603	19	other	other	JJ
cord-034340-3ksfpaf7	1603	20	causes	cause	NNS
cord-034340-3ksfpaf7	1603	21	.	.	.
cord-034340-3ksfpaf7	1604	1	Although	although	IN
cord-034340-3ksfpaf7	1604	2	PSU	PSU	NNP
cord-034340-3ksfpaf7	1604	3	has	have	VBZ
cord-034340-3ksfpaf7	1604	4	been	be	VBN
cord-034340-3ksfpaf7	1604	5	described	describe	VBN
cord-034340-3ksfpaf7	1604	6	in	in	IN
cord-034340-3ksfpaf7	1604	7	literature	literature	NN
cord-034340-3ksfpaf7	1604	8	,	,	,
cord-034340-3ksfpaf7	1604	9	to	to	IN
cord-034340-3ksfpaf7	1604	10	the	the	DT
cord-034340-3ksfpaf7	1604	11	best	good	JJS
cord-034340-3ksfpaf7	1604	12	of	of	IN
cord-034340-3ksfpaf7	1604	13	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1604	14	knowledge	knowledge	NN
cord-034340-3ksfpaf7	1604	15	,	,	,
cord-034340-3ksfpaf7	1604	16	this	this	DT
cord-034340-3ksfpaf7	1604	17	is	be	VBZ
cord-034340-3ksfpaf7	1604	18	the	the	DT
cord-034340-3ksfpaf7	1604	19	first	first	JJ
cord-034340-3ksfpaf7	1604	20	reported	report	VBN
cord-034340-3ksfpaf7	1604	21	case	case	NN
cord-034340-3ksfpaf7	1604	22	of	of	IN
cord-034340-3ksfpaf7	1604	23	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	1604	24	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1604	25	fever	fever	NN
cord-034340-3ksfpaf7	1604	26	and	and	CC
cord-034340-3ksfpaf7	1604	27	PSU	psu	NN
cord-034340-3ksfpaf7	1604	28	.	.	.
cord-034340-3ksfpaf7	1604	29	.	.	.
cord-034340-3ksfpaf7	1605	1	ADA	ADA	NNP
cord-034340-3ksfpaf7	1605	2	was	be	VBD
cord-034340-3ksfpaf7	1605	3	first	first	RB
cord-034340-3ksfpaf7	1605	4	tapered	tapered	JJ
cord-034340-3ksfpaf7	1605	5	to	to	IN
cord-034340-3ksfpaf7	1605	6	every	every	DT
cord-034340-3ksfpaf7	1605	7	3	3	CD
cord-034340-3ksfpaf7	1605	8	weeks	week	NNS
cord-034340-3ksfpaf7	1605	9	by	by	IN
cord-034340-3ksfpaf7	1605	10	76	76	CD
cord-034340-3ksfpaf7	1605	11	%	%	NN
cord-034340-3ksfpaf7	1605	12	of	of	IN
cord-034340-3ksfpaf7	1605	13	the	the	DT
cord-034340-3ksfpaf7	1605	14	responders	responder	NNS
cord-034340-3ksfpaf7	1605	15	and	and	CC
cord-034340-3ksfpaf7	1605	16	then	then	RB
cord-034340-3ksfpaf7	1605	17	to	to	IN
cord-034340-3ksfpaf7	1605	18	every	every	DT
cord-034340-3ksfpaf7	1605	19	4	4	CD
cord-034340-3ksfpaf7	1605	20	weeks	week	NNS
cord-034340-3ksfpaf7	1605	21	by	by	IN
cord-034340-3ksfpaf7	1605	22	49	49	CD
cord-034340-3ksfpaf7	1605	23	%	%	NN
cord-034340-3ksfpaf7	1605	24	before	before	IN
cord-034340-3ksfpaf7	1605	25	discontinuing	discontinue	VBG
cord-034340-3ksfpaf7	1605	26	.	.	.
cord-034340-3ksfpaf7	1606	1	Fewer	few	JJR
cord-034340-3ksfpaf7	1606	2	respondents	respondent	NNS
cord-034340-3ksfpaf7	1606	3	used	use	VBD
cord-034340-3ksfpaf7	1606	4	or	or	CC
cord-034340-3ksfpaf7	1606	5	tapered	taper	VBN
cord-034340-3ksfpaf7	1606	6	IFX	IFX	NNP
cord-034340-3ksfpaf7	1606	7	,	,	,
cord-034340-3ksfpaf7	1606	8	TOC	TOC	NNP
cord-034340-3ksfpaf7	1606	9	or	or	CC
cord-034340-3ksfpaf7	1606	10	ABA	ABA	NNP
cord-034340-3ksfpaf7	1606	11	.	.	.
cord-034340-3ksfpaf7	1607	1	Around	around	IN
cord-034340-3ksfpaf7	1607	2	65	65	CD
cord-034340-3ksfpaf7	1607	3	%	%	NN
cord-034340-3ksfpaf7	1607	4	tapered	taper	VBD
cord-034340-3ksfpaf7	1607	5	the	the	DT
cord-034340-3ksfpaf7	1607	6	interval	interval	NN
cord-034340-3ksfpaf7	1607	7	and	and	CC
cord-034340-3ksfpaf7	1607	8	20	20	CD
cord-034340-3ksfpaf7	1607	9	%	%	NN
cord-034340-3ksfpaf7	1607	10	tapered	taper	VBD
cord-034340-3ksfpaf7	1607	11	the	the	DT
cord-034340-3ksfpaf7	1607	12	dose	dose	NN
cord-034340-3ksfpaf7	1607	13	and	and	CC
cord-034340-3ksfpaf7	1607	14	interval	interval	NN
cord-034340-3ksfpaf7	1607	15	for	for	IN
cord-034340-3ksfpaf7	1607	16	ABA	ABA	NNP
cord-034340-3ksfpaf7	1607	17	,	,	,
cord-034340-3ksfpaf7	1607	18	26	26	CD
cord-034340-3ksfpaf7	1607	19	%	%	NN
cord-034340-3ksfpaf7	1607	20	for	for	IN
cord-034340-3ksfpaf7	1607	21	TOC	TOC	NNP
cord-034340-3ksfpaf7	1607	22	and	and	CC
cord-034340-3ksfpaf7	1607	23	37	37	CD
cord-034340-3ksfpaf7	1607	24	%	%	NN
cord-034340-3ksfpaf7	1608	1	IFX	IFX	NNP
cord-034340-3ksfpaf7	1608	2	There	there	EX
cord-034340-3ksfpaf7	1608	3	were	be	VBD
cord-034340-3ksfpaf7	1608	4	differences	difference	NNS
cord-034340-3ksfpaf7	1608	5	in	in	IN
cord-034340-3ksfpaf7	1608	6	the	the	DT
cord-034340-3ksfpaf7	1608	7	duration	duration	NN
cord-034340-3ksfpaf7	1608	8	of	of	IN
cord-034340-3ksfpaf7	1608	9	tapering	taper	VBG
cord-034340-3ksfpaf7	1608	10	prior	prior	RB
cord-034340-3ksfpaf7	1608	11	to	to	IN
cord-034340-3ksfpaf7	1608	12	discontinuation	discontinuation	NN
cord-034340-3ksfpaf7	1608	13	of	of	IN
cord-034340-3ksfpaf7	1608	14	specific	specific	JJ
cord-034340-3ksfpaf7	1608	15	medications	medication	NNS
cord-034340-3ksfpaf7	1608	16	.	.	.
cord-034340-3ksfpaf7	1609	1	For	for	IN
cord-034340-3ksfpaf7	1609	2	ADA	ADA	NNP
cord-034340-3ksfpaf7	1609	3	it	-PRON-	PRP
cord-034340-3ksfpaf7	1609	4	was	be	VBD
cord-034340-3ksfpaf7	1609	5	6	6	CD
cord-034340-3ksfpaf7	1609	6	months	month	NNS
cord-034340-3ksfpaf7	1609	7	in	in	IN
cord-034340-3ksfpaf7	1609	8	62	62	CD
cord-034340-3ksfpaf7	1609	9	%	%	NN
cord-034340-3ksfpaf7	1609	10	,	,	,
cord-034340-3ksfpaf7	1609	11	12	12	CD
cord-034340-3ksfpaf7	1609	12	months	month	NNS
cord-034340-3ksfpaf7	1609	13	in	in	IN
cord-034340-3ksfpaf7	1609	14	36	36	CD
cord-034340-3ksfpaf7	1609	15	%	%	NN
cord-034340-3ksfpaf7	1609	16	,	,	,
cord-034340-3ksfpaf7	1609	17	and	and	CC
cord-034340-3ksfpaf7	1609	18	24	24	CD
cord-034340-3ksfpaf7	1609	19	months	month	NNS
cord-034340-3ksfpaf7	1609	20	in	in	IN
cord-034340-3ksfpaf7	1609	21	10	10	CD
cord-034340-3ksfpaf7	1609	22	%	%	NN
cord-034340-3ksfpaf7	1609	23	.	.	.
cord-034340-3ksfpaf7	1610	1	For	for	IN
cord-034340-3ksfpaf7	1610	2	IFX	IFX	NNP
cord-034340-3ksfpaf7	1610	3	it	-PRON-	PRP
cord-034340-3ksfpaf7	1610	4	was	be	VBD
cord-034340-3ksfpaf7	1610	5	6	6	CD
cord-034340-3ksfpaf7	1610	6	months	month	NNS
cord-034340-3ksfpaf7	1610	7	in	in	IN
cord-034340-3ksfpaf7	1610	8	27	27	CD
cord-034340-3ksfpaf7	1610	9	%	%	NN
cord-034340-3ksfpaf7	1610	10	,	,	,
cord-034340-3ksfpaf7	1610	11	12	12	CD
cord-034340-3ksfpaf7	1610	12	months	month	NNS
cord-034340-3ksfpaf7	1610	13	in	in	IN
cord-034340-3ksfpaf7	1610	14	45	45	CD
cord-034340-3ksfpaf7	1610	15	%	%	NN
cord-034340-3ksfpaf7	1610	16	,	,	,
cord-034340-3ksfpaf7	1610	17	and	and	CC
cord-034340-3ksfpaf7	1610	18	24	24	CD
cord-034340-3ksfpaf7	1610	19	months	month	NNS
cord-034340-3ksfpaf7	1610	20	in	in	IN
cord-034340-3ksfpaf7	1610	21	33	33	CD
cord-034340-3ksfpaf7	1610	22	%	%	NN
cord-034340-3ksfpaf7	1610	23	.	.	.
cord-034340-3ksfpaf7	1611	1	For	for	IN
cord-034340-3ksfpaf7	1611	2	TOC	TOC	NNP
cord-034340-3ksfpaf7	1611	3	it	-PRON-	PRP
cord-034340-3ksfpaf7	1611	4	was	be	VBD
cord-034340-3ksfpaf7	1611	5	40	40	CD
cord-034340-3ksfpaf7	1611	6	%	%	NN
cord-034340-3ksfpaf7	1611	7	after	after	IN
cord-034340-3ksfpaf7	1611	8	4	4	CD
cord-034340-3ksfpaf7	1611	9	weeks	week	NNS
cord-034340-3ksfpaf7	1611	10	,	,	,
cord-034340-3ksfpaf7	1611	11	87	87	CD
cord-034340-3ksfpaf7	1611	12	%	%	NN
cord-034340-3ksfpaf7	1611	13	after	after	IN
cord-034340-3ksfpaf7	1611	14	6	6	CD
cord-034340-3ksfpaf7	1611	15	weeks	week	NNS
cord-034340-3ksfpaf7	1611	16	and	and	CC
cord-034340-3ksfpaf7	1611	17	53	53	CD
cord-034340-3ksfpaf7	1611	18	%	%	NN
cord-034340-3ksfpaf7	1611	19	after	after	IN
cord-034340-3ksfpaf7	1611	20	24	24	CD
cord-034340-3ksfpaf7	1611	21	weeks	week	NNS
cord-034340-3ksfpaf7	1611	22	.	.	.
cord-034340-3ksfpaf7	1612	1	For	for	IN
cord-034340-3ksfpaf7	1612	2	ABA	ABA	NNP
cord-034340-3ksfpaf7	1612	3	i.v	i.v	NNP
cord-034340-3ksfpaf7	1612	4	.	.	.
cord-034340-3ksfpaf7	1613	1	it	-PRON-	PRP
cord-034340-3ksfpaf7	1613	2	was	be	VBD
cord-034340-3ksfpaf7	1613	3	30	30	CD
cord-034340-3ksfpaf7	1613	4	%	%	NN
cord-034340-3ksfpaf7	1613	5	after	after	IN
cord-034340-3ksfpaf7	1613	6	8	8	CD
cord-034340-3ksfpaf7	1613	7	weeks	week	NNS
cord-034340-3ksfpaf7	1613	8	,	,	,
cord-034340-3ksfpaf7	1613	9	and	and	CC
cord-034340-3ksfpaf7	1613	10	90	90	CD
cord-034340-3ksfpaf7	1613	11	%	%	NN
cord-034340-3ksfpaf7	1613	12	after	after	IN
cord-034340-3ksfpaf7	1613	13	12	12	CD
cord-034340-3ksfpaf7	1613	14	weeks	week	NNS
cord-034340-3ksfpaf7	1613	15	.	.	.
cord-034340-3ksfpaf7	1614	1	If	if	IN
cord-034340-3ksfpaf7	1614	2	combination	combination	NN
cord-034340-3ksfpaf7	1614	3	therapy	therapy	NN
cord-034340-3ksfpaf7	1614	4	was	be	VBD
cord-034340-3ksfpaf7	1614	5	used	use	VBN
cord-034340-3ksfpaf7	1614	6	,	,	,
cord-034340-3ksfpaf7	1614	7	36	36	CD
cord-034340-3ksfpaf7	1614	8	%	%	NN
cord-034340-3ksfpaf7	1614	9	tapered	taper	VBD
cord-034340-3ksfpaf7	1614	10	the	the	DT
cord-034340-3ksfpaf7	1614	11	bDMARD	bDMARD	NNP
cord-034340-3ksfpaf7	1615	1	first	first	RB
cord-034340-3ksfpaf7	1615	2	,	,	,
cord-034340-3ksfpaf7	1615	3	62	62	CD
cord-034340-3ksfpaf7	1615	4	%	%	NN
cord-034340-3ksfpaf7	1615	5	csDMARD	csDMARD	NNP
cord-034340-3ksfpaf7	1615	6	first	first	RB
cord-034340-3ksfpaf7	1615	7	,	,	,
cord-034340-3ksfpaf7	1615	8	and	and	CC
cord-034340-3ksfpaf7	1615	9	12	12	CD
cord-034340-3ksfpaf7	1615	10	%	%	NN
cord-034340-3ksfpaf7	1615	11	both	both	CC
cord-034340-3ksfpaf7	1615	12	simultaneously	simultaneously	RB
cord-034340-3ksfpaf7	1615	13	.	.	.
cord-034340-3ksfpaf7	1616	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1616	2	:	:	:
cord-034340-3ksfpaf7	1617	1	This	this	DT
cord-034340-3ksfpaf7	1617	2	is	be	VBZ
cord-034340-3ksfpaf7	1617	3	the	the	DT
cord-034340-3ksfpaf7	1617	4	first	first	JJ
cord-034340-3ksfpaf7	1617	5	survey	survey	NN
cord-034340-3ksfpaf7	1617	6	to	to	TO
cord-034340-3ksfpaf7	1617	7	describe	describe	VB
cord-034340-3ksfpaf7	1617	8	"	"	``
cord-034340-3ksfpaf7	1617	9	real	real	JJ
cord-034340-3ksfpaf7	1617	10	world	world	NN
cord-034340-3ksfpaf7	1617	11	"	"	''
cord-034340-3ksfpaf7	1617	12	medication	medication	NN
cord-034340-3ksfpaf7	1617	13	tapering	tapering	NN
cord-034340-3ksfpaf7	1617	14	and	and	CC
cord-034340-3ksfpaf7	1617	15	discontinuation	discontinuation	NN
cord-034340-3ksfpaf7	1617	16	practices	practice	NNS
cord-034340-3ksfpaf7	1617	17	of	of	IN
cord-034340-3ksfpaf7	1617	18	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1617	19	rheumatologists	rheumatologist	NNS
cord-034340-3ksfpaf7	1617	20	and	and	CC
cord-034340-3ksfpaf7	1617	21	ophthalmologists	ophthalmologist	NNS
cord-034340-3ksfpaf7	1617	22	globally	globally	RB
cord-034340-3ksfpaf7	1617	23	.	.	.
cord-034340-3ksfpaf7	1618	1	Most	Most	JJS
cord-034340-3ksfpaf7	1618	2	physicians	physician	NNS
cord-034340-3ksfpaf7	1618	3	start	start	VBP
cord-034340-3ksfpaf7	1618	4	to	to	IN
cord-034340-3ksfpaf7	1618	5	taper	taper	NN
cord-034340-3ksfpaf7	1618	6	medication	medication	NN
cord-034340-3ksfpaf7	1618	7	after	after	IN
cord-034340-3ksfpaf7	1618	8	24	24	CD
cord-034340-3ksfpaf7	1618	9	months	month	NNS
cord-034340-3ksfpaf7	1618	10	of	of	IN
cord-034340-3ksfpaf7	1618	11	remission	remission	NN
cord-034340-3ksfpaf7	1618	12	on	on	IN
cord-034340-3ksfpaf7	1618	13	medication	medication	NN
cord-034340-3ksfpaf7	1618	14	and	and	CC
cord-034340-3ksfpaf7	1618	15	discontinue	discontinue	VB
cord-034340-3ksfpaf7	1618	16	after	after	IN
cord-034340-3ksfpaf7	1618	17	the	the	DT
cord-034340-3ksfpaf7	1618	18	6	6	CD
cord-034340-3ksfpaf7	1618	19	to	to	TO
cord-034340-3ksfpaf7	1618	20	12	12	CD
cord-034340-3ksfpaf7	1618	21	months	month	NNS
cord-034340-3ksfpaf7	1618	22	of	of	IN
cord-034340-3ksfpaf7	1618	23	tapering	taper	VBG
cord-034340-3ksfpaf7	1618	24	.	.	.
cord-034340-3ksfpaf7	1619	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1619	2	would	would	MD
cord-034340-3ksfpaf7	1619	3	like	like	VB
cord-034340-3ksfpaf7	1619	4	to	to	TO
cord-034340-3ksfpaf7	1619	5	thank	thank	VB
cord-034340-3ksfpaf7	1619	6	all	all	PDT
cord-034340-3ksfpaf7	1619	7	the	the	DT
cord-034340-3ksfpaf7	1619	8	participating	participate	VBG
cord-034340-3ksfpaf7	1619	9	colleagues	colleague	NNS
cord-034340-3ksfpaf7	1619	10	,	,	,
cord-034340-3ksfpaf7	1619	11	who	who	WP
cord-034340-3ksfpaf7	1619	12	took	take	VBD
cord-034340-3ksfpaf7	1619	13	time	time	NN
cord-034340-3ksfpaf7	1619	14	to	to	TO
cord-034340-3ksfpaf7	1619	15	fill	fill	VB
cord-034340-3ksfpaf7	1619	16	out	out	RP
cord-034340-3ksfpaf7	1619	17	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1619	18	surve	surve	JJ
cord-034340-3ksfpaf7	1619	19	Introduction	introduction	NN
cord-034340-3ksfpaf7	1619	20	:	:	:
cord-034340-3ksfpaf7	1619	21	JIA	JIA	NNP
cord-034340-3ksfpaf7	1619	22	-	-	HYPH
cord-034340-3ksfpaf7	1619	23	associated	associate	VBN
cord-034340-3ksfpaf7	1619	24	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1620	1	(	(	-LRB-
cord-034340-3ksfpaf7	1620	2	JIA	JIA	NNP
cord-034340-3ksfpaf7	1620	3	-	-	HYPH
cord-034340-3ksfpaf7	1620	4	U	U	NNP
cord-034340-3ksfpaf7	1620	5	)	)	-RRB-
cord-034340-3ksfpaf7	1620	6	occurs	occur	VBZ
cord-034340-3ksfpaf7	1620	7	in	in	IN
cord-034340-3ksfpaf7	1620	8	10	10	CD
cord-034340-3ksfpaf7	1620	9	-	-	SYM
cord-034340-3ksfpaf7	1620	10	20	20	CD
cord-034340-3ksfpaf7	1620	11	%	%	NN
cord-034340-3ksfpaf7	1620	12	of	of	IN
cord-034340-3ksfpaf7	1620	13	children	child	NNS
cord-034340-3ksfpaf7	1620	14	with	with	IN
cord-034340-3ksfpaf7	1620	15	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	1620	16	Idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1620	17	Arthritis	arthritis	NN
cord-034340-3ksfpaf7	1620	18	(	(	-LRB-
cord-034340-3ksfpaf7	1620	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	1620	20	)	)	-RRB-
cord-034340-3ksfpaf7	1620	21	and	and	CC
cord-034340-3ksfpaf7	1620	22	typically	typically	RB
cord-034340-3ksfpaf7	1620	23	asymptomatic	asymptomatic	JJ
cord-034340-3ksfpaf7	1620	24	,	,	,
cord-034340-3ksfpaf7	1620	25	and	and	CC
cord-034340-3ksfpaf7	1620	26	sight	sight	NN
cord-034340-3ksfpaf7	1620	27	-	-	HYPH
cord-034340-3ksfpaf7	1620	28	threatening	threaten	VBG
cord-034340-3ksfpaf7	1620	29	complications	complication	NNS
cord-034340-3ksfpaf7	1620	30	occur	occur	VBP
cord-034340-3ksfpaf7	1620	31	in	in	IN
cord-034340-3ksfpaf7	1620	32	50	50	CD
cord-034340-3ksfpaf7	1620	33	%	%	NN
cord-034340-3ksfpaf7	1620	34	of	of	IN
cord-034340-3ksfpaf7	1620	35	children	child	NNS
cord-034340-3ksfpaf7	1620	36	,	,	,
cord-034340-3ksfpaf7	1620	37	(	(	-LRB-
cord-034340-3ksfpaf7	1620	38	i.e.	i.e.	FW
cord-034340-3ksfpaf7	1620	39	cataracts	cataract	NNS
cord-034340-3ksfpaf7	1620	40	,	,	,
cord-034340-3ksfpaf7	1620	41	vision	vision	NN
cord-034340-3ksfpaf7	1620	42	loss	loss	NN
cord-034340-3ksfpaf7	1620	43	)	)	-RRB-
cord-034340-3ksfpaf7	1620	44	.	.	.
cord-034340-3ksfpaf7	1621	1	Frequent	frequent	JJ
cord-034340-3ksfpaf7	1621	2	ophthalmic	ophthalmic	JJ
cord-034340-3ksfpaf7	1621	3	examinations	examination	NNS
cord-034340-3ksfpaf7	1621	4	are	be	VBP
cord-034340-3ksfpaf7	1621	5	important	important	JJ
cord-034340-3ksfpaf7	1621	6	for	for	IN
cord-034340-3ksfpaf7	1621	7	early	early	JJ
cord-034340-3ksfpaf7	1621	8	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1621	9	and	and	CC
cord-034340-3ksfpaf7	1621	10	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1621	11	of	of	IN
cord-034340-3ksfpaf7	1621	12	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1621	13	activity	activity	NN
cord-034340-3ksfpaf7	1621	14	.	.	.
cord-034340-3ksfpaf7	1622	1	Even	even	RB
cord-034340-3ksfpaf7	1622	2	after	after	IN
cord-034340-3ksfpaf7	1622	3	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1622	4	is	be	VBZ
cord-034340-3ksfpaf7	1622	5	controlled	control	VBN
cord-034340-3ksfpaf7	1622	6	,	,	,
cord-034340-3ksfpaf7	1622	7	risk	risk	NN
cord-034340-3ksfpaf7	1622	8	of	of	IN
cord-034340-3ksfpaf7	1622	9	disease	disease	NN
cord-034340-3ksfpaf7	1622	10	exacerbation	exacerbation	NN
cord-034340-3ksfpaf7	1622	11	still	still	RB
cord-034340-3ksfpaf7	1622	12	exists	exist	VBZ
cord-034340-3ksfpaf7	1622	13	.	.	.
cord-034340-3ksfpaf7	1623	1	Therefore	therefore	RB
cord-034340-3ksfpaf7	1623	2	,	,	,
cord-034340-3ksfpaf7	1623	3	frequent	frequent	JJ
cord-034340-3ksfpaf7	1623	4	ophthalmic	ophthalmic	JJ
cord-034340-3ksfpaf7	1623	5	screening	screening	NN
cord-034340-3ksfpaf7	1623	6	and	and	CC
cord-034340-3ksfpaf7	1623	7	monitoring	monitoring	NN
cord-034340-3ksfpaf7	1623	8	is	be	VBZ
cord-034340-3ksfpaf7	1623	9	important	important	JJ
cord-034340-3ksfpaf7	1623	10	for	for	IN
cord-034340-3ksfpaf7	1623	11	detection	detection	NN
cord-034340-3ksfpaf7	1623	12	and	and	CC
cord-034340-3ksfpaf7	1623	13	management	management	NN
cord-034340-3ksfpaf7	1623	14	of	of	IN
cord-034340-3ksfpaf7	1623	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	1623	16	-	-	HYPH
cord-034340-3ksfpaf7	1623	17	associated	associate	VBN
cord-034340-3ksfpaf7	1623	18	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1624	1	(	(	-LRB-
cord-034340-3ksfpaf7	1624	2	JIA	JIA	NNP
cord-034340-3ksfpaf7	1624	3	-	-	HYPH
cord-034340-3ksfpaf7	1624	4	U	U	NNP
cord-034340-3ksfpaf7	1624	5	)	)	-RRB-
cord-034340-3ksfpaf7	1624	6	.	.	.
cord-034340-3ksfpaf7	1625	1	S100	S100	NNP
cord-034340-3ksfpaf7	1625	2	proteins	protein	NNS
cord-034340-3ksfpaf7	1625	3	,	,	,
cord-034340-3ksfpaf7	1625	4	cytokines	cytokine	NNS
cord-034340-3ksfpaf7	1625	5	,	,	,
cord-034340-3ksfpaf7	1625	6	and	and	CC
cord-034340-3ksfpaf7	1625	7	chemokines	chemokine	NNS
cord-034340-3ksfpaf7	1625	8	detected	detect	VBN
cord-034340-3ksfpaf7	1625	9	in	in	IN
cord-034340-3ksfpaf7	1625	10	aqueous	aqueous	JJ
cord-034340-3ksfpaf7	1625	11	humor	humor	NN
cord-034340-3ksfpaf7	1625	12	of	of	IN
cord-034340-3ksfpaf7	1625	13	patients	patient	NNS
cord-034340-3ksfpaf7	1625	14	with	with	IN
cord-034340-3ksfpaf7	1625	15	uveitis	uveiti	NNS
cord-034340-3ksfpaf7	1625	16	are	be	VBP
cord-034340-3ksfpaf7	1625	17	also	also	RB
cord-034340-3ksfpaf7	1625	18	detected	detect	VBN
cord-034340-3ksfpaf7	1625	19	in	in	IN
cord-034340-3ksfpaf7	1625	20	tears	tear	NNS
cord-034340-3ksfpaf7	1625	21	.	.	.
cord-034340-3ksfpaf7	1626	1	Biomarker	Biomarker	NNP
cord-034340-3ksfpaf7	1626	2	discovery	discovery	NN
cord-034340-3ksfpaf7	1626	3	using	use	VBG
cord-034340-3ksfpaf7	1626	4	tears	tear	NNS
cord-034340-3ksfpaf7	1626	5	is	be	VBZ
cord-034340-3ksfpaf7	1626	6	promising	promising	JJ
cord-034340-3ksfpaf7	1626	7	since	since	IN
cord-034340-3ksfpaf7	1626	8	collection	collection	NN
cord-034340-3ksfpaf7	1626	9	is	be	VBZ
cord-034340-3ksfpaf7	1626	10	noninvasive	noninvasive	JJ
cord-034340-3ksfpaf7	1626	11	,	,	,
cord-034340-3ksfpaf7	1626	12	feasible	feasible	JJ
cord-034340-3ksfpaf7	1626	13	,	,	,
cord-034340-3ksfpaf7	1626	14	well	well	RB
cord-034340-3ksfpaf7	1626	15	-	-	HYPH
cord-034340-3ksfpaf7	1626	16	tolerated	tolerate	VBN
cord-034340-3ksfpaf7	1626	17	,	,	,
cord-034340-3ksfpaf7	1626	18	and	and	CC
cord-034340-3ksfpaf7	1626	19	close	close	RB
cord-034340-3ksfpaf7	1626	20	to	to	IN
cord-034340-3ksfpaf7	1626	21	the	the	DT
cord-034340-3ksfpaf7	1626	22	target	target	NN
cord-034340-3ksfpaf7	1626	23	organ	organ	NN
cord-034340-3ksfpaf7	1626	24	.	.	.
cord-034340-3ksfpaf7	1627	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1627	2	:	:	:
cord-034340-3ksfpaf7	1627	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1627	4	aim	aim	VBP
cord-034340-3ksfpaf7	1627	5	to	to	TO
cord-034340-3ksfpaf7	1627	6	determine	determine	VB
cord-034340-3ksfpaf7	1627	7	if	if	IN
cord-034340-3ksfpaf7	1627	8	S100	S100	NNP
cord-034340-3ksfpaf7	1627	9	proteins	protein	NNS
cord-034340-3ksfpaf7	1627	10	,	,	,
cord-034340-3ksfpaf7	1627	11	cytokines	cytokine	NNS
cord-034340-3ksfpaf7	1627	12	,	,	,
cord-034340-3ksfpaf7	1627	13	and	and	CC
cord-034340-3ksfpaf7	1627	14	chemokines	chemokine	NNS
cord-034340-3ksfpaf7	1627	15	levels	level	NNS
cord-034340-3ksfpaf7	1627	16	differ	differ	VBP
cord-034340-3ksfpaf7	1627	17	in	in	IN
cord-034340-3ksfpaf7	1627	18	tears	tear	NNS
cord-034340-3ksfpaf7	1627	19	of	of	IN
cord-034340-3ksfpaf7	1627	20	children	child	NNS
cord-034340-3ksfpaf7	1627	21	with	with	IN
cord-034340-3ksfpaf7	1627	22	JIA	JIA	NNP
cord-034340-3ksfpaf7	1627	23	and	and	CC
cord-034340-3ksfpaf7	1627	24	JIA	JIA	NNP
cord-034340-3ksfpaf7	1627	25	-	-	HYPH
cord-034340-3ksfpaf7	1627	26	U	U	NNP
cord-034340-3ksfpaf7	1627	27	and	and	CC
cord-034340-3ksfpaf7	1627	28	in	in	IN
cord-034340-3ksfpaf7	1627	29	children	child	NNS
cord-034340-3ksfpaf7	1627	30	with	with	IN
cord-034340-3ksfpaf7	1627	31	JIA	JIA	NNP
cord-034340-3ksfpaf7	1627	32	-	-	HYPH
cord-034340-3ksfpaf7	1627	33	U	U	NNP
cord-034340-3ksfpaf7	1627	34	by	by	IN
cord-034340-3ksfpaf7	1627	35	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1627	36	activity	activity	NN
cord-034340-3ksfpaf7	1627	37	.	.	.
cord-034340-3ksfpaf7	1628	1	Methods	method	NNS
cord-034340-3ksfpaf7	1628	2	:	:	:
cord-034340-3ksfpaf7	1628	3	Tears	tear	NNS
cord-034340-3ksfpaf7	1628	4	were	be	VBD
cord-034340-3ksfpaf7	1628	5	collected	collect	VBN
cord-034340-3ksfpaf7	1628	6	using	use	VBG
cord-034340-3ksfpaf7	1628	7	Schirmer	Schirmer	NNP
cord-034340-3ksfpaf7	1628	8	strips	strip	NNS
cord-034340-3ksfpaf7	1628	9	from	from	IN
cord-034340-3ksfpaf7	1628	10	children	child	NNS
cord-034340-3ksfpaf7	1628	11	≥5	≥5	NNS
cord-034340-3ksfpaf7	1628	12	years	year	NNS
cord-034340-3ksfpaf7	1628	13	old	old	JJ
cord-034340-3ksfpaf7	1628	14	with	with	IN
cord-034340-3ksfpaf7	1628	15	oligo	oligo	NN
cord-034340-3ksfpaf7	1628	16	-	-	HYPH
cord-034340-3ksfpaf7	1628	17	or	or	CC
cord-034340-3ksfpaf7	1628	18	polyarticular	polyarticular	JJ
cord-034340-3ksfpaf7	1628	19	RF	rf	NN
cord-034340-3ksfpaf7	1629	1	negative	negative	JJ
cord-034340-3ksfpaf7	1629	2	JIA	JIA	NNP
cord-034340-3ksfpaf7	1629	3	with	with	IN
cord-034340-3ksfpaf7	1629	4	(	(	-LRB-
cord-034340-3ksfpaf7	1629	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	1629	6	-	-	HYPH
cord-034340-3ksfpaf7	1629	7	U	U	NNP
cord-034340-3ksfpaf7	1629	8	)	)	-RRB-
cord-034340-3ksfpaf7	1629	9	and	and	CC
cord-034340-3ksfpaf7	1629	10	without	without	IN
cord-034340-3ksfpaf7	1629	11	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1629	12	(	(	-LRB-
cord-034340-3ksfpaf7	1629	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	1629	14	-	-	HYPH
cord-034340-3ksfpaf7	1629	15	no	no	NNP
cord-034340-3ksfpaf7	1629	16	-	-	HYPH
cord-034340-3ksfpaf7	1629	17	U	U	NNP
cord-034340-3ksfpaf7	1629	18	)	)	-RRB-
cord-034340-3ksfpaf7	1629	19	,	,	,
cord-034340-3ksfpaf7	1629	20	and	and	CC
cord-034340-3ksfpaf7	1629	21	in	in	IN
cord-034340-3ksfpaf7	1629	22	children	child	NNS
cord-034340-3ksfpaf7	1629	23	with	with	IN
cord-034340-3ksfpaf7	1629	24	JIA	JIA	NNP
cord-034340-3ksfpaf7	1629	25	-	-	HYPH
cord-034340-3ksfpaf7	1629	26	U	U	NNP
cord-034340-3ksfpaf7	1630	1	at	at	IN
cord-034340-3ksfpaf7	1630	2	time	time	NN
cord-034340-3ksfpaf7	1630	3	of	of	IN
cord-034340-3ksfpaf7	1630	4	active	active	JJ
cord-034340-3ksfpaf7	1630	5	and	and	CC
cord-034340-3ksfpaf7	1630	6	inactive	inactive	JJ
cord-034340-3ksfpaf7	1630	7	eye	eye	NN
cord-034340-3ksfpaf7	1630	8	disease	disease	NN
cord-034340-3ksfpaf7	1630	9	.	.	.
cord-034340-3ksfpaf7	1631	1	Activity	activity	NN
cord-034340-3ksfpaf7	1631	2	was	be	VBD
cord-034340-3ksfpaf7	1631	3	defined	define	VBN
cord-034340-3ksfpaf7	1631	4	by	by	IN
cord-034340-3ksfpaf7	1631	5	Standardization	Standardization	NNP
cord-034340-3ksfpaf7	1631	6	of	of	IN
cord-034340-3ksfpaf7	1631	7	Uveitis	Uveitis	NNP
cord-034340-3ksfpaf7	1631	8	Nomenclature	Nomenclature	NNP
cord-034340-3ksfpaf7	1631	9	(	(	-LRB-
cord-034340-3ksfpaf7	1631	10	SUN	SUN	NNP
cord-034340-3ksfpaf7	1631	11	)	)	-RRB-
cord-034340-3ksfpaf7	1631	12	criteria	criterion	NNS
cord-034340-3ksfpaf7	1631	13	.	.	.
cord-034340-3ksfpaf7	1632	1	Active	active	JJ
cord-034340-3ksfpaf7	1632	2	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1632	3	was	be	VBD
cord-034340-3ksfpaf7	1632	4	anterior	anterior	JJ
cord-034340-3ksfpaf7	1632	5	chamber	chamber	NN
cord-034340-3ksfpaf7	1632	6	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1632	7	grade	grade	NN
cord-034340-3ksfpaf7	1632	8	≥0.5	≥0.5	NNP
cord-034340-3ksfpaf7	1632	9	+	+	CC
cord-034340-3ksfpaf7	1632	10	cells	cell	NNS
cord-034340-3ksfpaf7	1632	11	.	.	.
cord-034340-3ksfpaf7	1633	1	S100A8	S100A8	NNP
cord-034340-3ksfpaf7	1633	2	,	,	,
cord-034340-3ksfpaf7	1633	3	A9	A9	NNP
cord-034340-3ksfpaf7	1633	4	,	,	,
cord-034340-3ksfpaf7	1633	5	and	and	CC
cord-034340-3ksfpaf7	1633	6	A12	A12	NNP
cord-034340-3ksfpaf7	1633	7	were	be	VBD
cord-034340-3ksfpaf7	1633	8	measured	measure	VBN
cord-034340-3ksfpaf7	1633	9	by	by	IN
cord-034340-3ksfpaf7	1633	10	ELISA	ELISA	NNP
cord-034340-3ksfpaf7	1633	11	,	,	,
cord-034340-3ksfpaf7	1633	12	and	and	CC
cord-034340-3ksfpaf7	1633	13	IL-18	IL-18	NNP
cord-034340-3ksfpaf7	1633	14	,	,	,
cord-034340-3ksfpaf7	1633	15	IL-8	IL-8	NNP
cord-034340-3ksfpaf7	1633	16	,	,	,
cord-034340-3ksfpaf7	1633	17	IP-10	IP-10	NNP
cord-034340-3ksfpaf7	1633	18	,	,	,
cord-034340-3ksfpaf7	1633	19	MCP-1	MCP-1	NNP
cord-034340-3ksfpaf7	1633	20	,	,	,
cord-034340-3ksfpaf7	1633	21	RANT	rant	NN
cord-034340-3ksfpaf7	1633	22	ES	es	NN
cord-034340-3ksfpaf7	1633	23	,	,	,
cord-034340-3ksfpaf7	1633	24	and	and	CC
cord-034340-3ksfpaf7	1633	25	sICAM-1	sICAM-1	NNP
cord-034340-3ksfpaf7	1633	26	by	by	IN
cord-034340-3ksfpaf7	1633	27	Luminex	Luminex	NNP
cord-034340-3ksfpaf7	1633	28	assays	assay	NNS
cord-034340-3ksfpaf7	1633	29	.	.	.
cord-034340-3ksfpaf7	1634	1	Biomarker	Biomarker	NNP
cord-034340-3ksfpaf7	1634	2	levels	level	NNS
cord-034340-3ksfpaf7	1634	3	were	be	VBD
cord-034340-3ksfpaf7	1634	4	compared	compare	VBN
cord-034340-3ksfpaf7	1634	5	in	in	IN
cord-034340-3ksfpaf7	1634	6	children	child	NNS
cord-034340-3ksfpaf7	1634	7	with	with	IN
cord-034340-3ksfpaf7	1634	8	1	1	CD
cord-034340-3ksfpaf7	1634	9	)	)	-RRB-
cord-034340-3ksfpaf7	1635	1	JIA	JIA	NNP
cord-034340-3ksfpaf7	1635	2	-	-	HYPH
cord-034340-3ksfpaf7	1635	3	no	no	NNP
cord-034340-3ksfpaf7	1635	4	-	-	HYPH
cord-034340-3ksfpaf7	1635	5	U	u	NN
cord-034340-3ksfpaf7	1635	6	(	(	-LRB-
cord-034340-3ksfpaf7	1635	7	n=8	n=8	NN
cord-034340-3ksfpaf7	1635	8	)	)	-RRB-
cord-034340-3ksfpaf7	1635	9	to	to	IN
cord-034340-3ksfpaf7	1635	10	active	active	JJ
cord-034340-3ksfpaf7	1635	11	JIA	JIA	NNP
cord-034340-3ksfpaf7	1635	12	-	-	HYPH
cord-034340-3ksfpaf7	1635	13	U	U	NNP
cord-034340-3ksfpaf7	1635	14	(	(	-LRB-
cord-034340-3ksfpaf7	1635	15	n=8	n=8	NN
cord-034340-3ksfpaf7	1635	16	)	)	-RRB-
cord-034340-3ksfpaf7	1635	17	,	,	,
cord-034340-3ksfpaf7	1635	18	and	and	CC
cord-034340-3ksfpaf7	1635	19	2	2	LS
cord-034340-3ksfpaf7	1635	20	)	)	-RRB-
cord-034340-3ksfpaf7	1635	21	JIA	JIA	NNP
cord-034340-3ksfpaf7	1635	22	-	-	HYPH
cord-034340-3ksfpaf7	1635	23	U	U	NNP
cord-034340-3ksfpaf7	1635	24	(	(	-LRB-
cord-034340-3ksfpaf7	1635	25	n=8	n=8	NN
cord-034340-3ksfpaf7	1635	26	)	)	-RRB-
cord-034340-3ksfpaf7	1635	27	at	at	IN
cord-034340-3ksfpaf7	1635	28	time	time	NN
cord-034340-3ksfpaf7	1635	29	of	of	IN
cord-034340-3ksfpaf7	1635	30	active	active	JJ
cord-034340-3ksfpaf7	1635	31	and	and	CC
cord-034340-3ksfpaf7	1635	32	inactive	inactive	JJ
cord-034340-3ksfpaf7	1635	33	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1635	34	.	.	.
cord-034340-3ksfpaf7	1636	1	Results	result	NNS
cord-034340-3ksfpaf7	1636	2	:	:	:
cord-034340-3ksfpaf7	1637	1	Children	child	NNS
cord-034340-3ksfpaf7	1637	2	with	with	IN
cord-034340-3ksfpaf7	1637	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	1637	4	-	-	HYPH
cord-034340-3ksfpaf7	1637	5	no	no	NNP
cord-034340-3ksfpaf7	1637	6	-	-	HYPH
cord-034340-3ksfpaf7	1637	7	U	U	NNP
cord-034340-3ksfpaf7	1637	8	and	and	CC
cord-034340-3ksfpaf7	1637	9	JIA	JIA	NNP
cord-034340-3ksfpaf7	1637	10	-	-	HYPH
cord-034340-3ksfpaf7	1637	11	U	U	NNP
cord-034340-3ksfpaf7	1637	12	were	be	VBD
cord-034340-3ksfpaf7	1637	13	matched	match	VBN
cord-034340-3ksfpaf7	1637	14	by	by	IN
cord-034340-3ksfpaf7	1637	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	1637	16	subtype	subtype	NN
cord-034340-3ksfpaf7	1637	17	and	and	CC
cord-034340-3ksfpaf7	1637	18	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1637	19	activity	activity	NN
cord-034340-3ksfpaf7	1637	20	.	.	.
cord-034340-3ksfpaf7	1638	1	They	-PRON-	PRP
cord-034340-3ksfpaf7	1638	2	had	have	VBD
cord-034340-3ksfpaf7	1638	3	primarily	primarily	RB
cord-034340-3ksfpaf7	1638	4	oligoarticular	oligoarticular	JJ
cord-034340-3ksfpaf7	1638	5	JIA	JIA	NNP
cord-034340-3ksfpaf7	1638	6	(	(	-LRB-
cord-034340-3ksfpaf7	1638	7	63	63	CD
cord-034340-3ksfpaf7	1638	8	%	%	NN
cord-034340-3ksfpaf7	1638	9	)	)	-RRB-
cord-034340-3ksfpaf7	1638	10	,	,	,
cord-034340-3ksfpaf7	1638	11	active	active	JJ
cord-034340-3ksfpaf7	1638	12	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1638	13	(	(	-LRB-
cord-034340-3ksfpaf7	1638	14	25	25	CD
cord-034340-3ksfpaf7	1638	15	%	%	NN
cord-034340-3ksfpaf7	1638	16	)	)	-RRB-
cord-034340-3ksfpaf7	1638	17	,	,	,
cord-034340-3ksfpaf7	1638	18	and	and	CC
cord-034340-3ksfpaf7	1638	19	were	be	VBD
cord-034340-3ksfpaf7	1638	20	on	on	IN
cord-034340-3ksfpaf7	1638	21	systemic	systemic	JJ
cord-034340-3ksfpaf7	1638	22	medication	medication	NN
cord-034340-3ksfpaf7	1638	23	(	(	-LRB-
cord-034340-3ksfpaf7	1638	24	75	75	CD
cord-034340-3ksfpaf7	1638	25	%	%	NN
cord-034340-3ksfpaf7	1638	26	)	)	-RRB-
cord-034340-3ksfpaf7	1638	27	.	.	.
cord-034340-3ksfpaf7	1639	1	At	at	IN
cord-034340-3ksfpaf7	1639	2	time	time	NN
cord-034340-3ksfpaf7	1639	3	of	of	IN
cord-034340-3ksfpaf7	1639	4	active	active	JJ
cord-034340-3ksfpaf7	1639	5	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1639	6	,	,	,
cord-034340-3ksfpaf7	1639	7	75	75	CD
cord-034340-3ksfpaf7	1639	8	%	%	NN
cord-034340-3ksfpaf7	1639	9	had	have	VBD
cord-034340-3ksfpaf7	1639	10	grade	grade	NN
cord-034340-3ksfpaf7	1639	11	0.5	0.5	CD
cord-034340-3ksfpaf7	1639	12	+	+	CD
cord-034340-3ksfpaf7	1639	13	,	,	,
cord-034340-3ksfpaf7	1639	14	and	and	CC
cord-034340-3ksfpaf7	1639	15	25	25	CD
cord-034340-3ksfpaf7	1639	16	%	%	NN
cord-034340-3ksfpaf7	1639	17	had	have	VBD
cord-034340-3ksfpaf7	1639	18	1	1	CD
cord-034340-3ksfpaf7	1639	19	+	+	SYM
cord-034340-3ksfpaf7	1639	20	and	and	CC
cord-034340-3ksfpaf7	1639	21	mean	mean	VB
cord-034340-3ksfpaf7	1639	22	interval	interval	NN
cord-034340-3ksfpaf7	1639	23	between	between	IN
cord-034340-3ksfpaf7	1639	24	time	time	NN
cord-034340-3ksfpaf7	1639	25	of	of	IN
cord-034340-3ksfpaf7	1639	26	active	active	JJ
cord-034340-3ksfpaf7	1639	27	and	and	CC
cord-034340-3ksfpaf7	1639	28	inactive	inactive	JJ
cord-034340-3ksfpaf7	1639	29	disease	disease	NN
cord-034340-3ksfpaf7	1639	30	was	be	VBD
cord-034340-3ksfpaf7	1639	31	11	11	CD
cord-034340-3ksfpaf7	1639	32	months	month	NNS
cord-034340-3ksfpaf7	1639	33	.	.	.
cord-034340-3ksfpaf7	1640	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1640	2	found	find	VBD
cord-034340-3ksfpaf7	1640	3	that	that	IN
cord-034340-3ksfpaf7	1640	4	levels	level	NNS
cord-034340-3ksfpaf7	1640	5	of	of	IN
cord-034340-3ksfpaf7	1640	6	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	1640	7	in	in	IN
cord-034340-3ksfpaf7	1640	8	tears	tear	NNS
cord-034340-3ksfpaf7	1640	9	of	of	IN
cord-034340-3ksfpaf7	1640	10	children	child	NNS
cord-034340-3ksfpaf7	1640	11	with	with	IN
cord-034340-3ksfpaf7	1640	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	1640	13	-	-	HYPH
cord-034340-3ksfpaf7	1640	14	no	no	NNP
cord-034340-3ksfpaf7	1640	15	-	-	HYPH
cord-034340-3ksfpaf7	1640	16	U	u	NN
cord-034340-3ksfpaf7	1640	17	compared	compare	VBN
cord-034340-3ksfpaf7	1640	18	to	to	IN
cord-034340-3ksfpaf7	1640	19	active	active	JJ
cord-034340-3ksfpaf7	1640	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	1640	21	-	-	HYPH
cord-034340-3ksfpaf7	1640	22	U	U	NNP
cord-034340-3ksfpaf7	1640	23	were	be	VBD
cord-034340-3ksfpaf7	1640	24	similar	similar	JJ
cord-034340-3ksfpaf7	1640	25	.	.	.
cord-034340-3ksfpaf7	1641	1	Although	although	IN
cord-034340-3ksfpaf7	1641	2	not	not	RB
cord-034340-3ksfpaf7	1641	3	statistically	statistically	RB
cord-034340-3ksfpaf7	1641	4	significant	significant	JJ
cord-034340-3ksfpaf7	1641	5	,	,	,
cord-034340-3ksfpaf7	1641	6	levels	level	NNS
cord-034340-3ksfpaf7	1641	7	of	of	IN
cord-034340-3ksfpaf7	1641	8	S100A12	s100a12	NN
cord-034340-3ksfpaf7	1641	9	(	(	-LRB-
cord-034340-3ksfpaf7	1641	10	mean	mean	VB
cord-034340-3ksfpaf7	1641	11	difference	difference	NN
cord-034340-3ksfpaf7	1641	12	12,190	12,190	CD
cord-034340-3ksfpaf7	1641	13	pg	pg	NNP
cord-034340-3ksfpaf7	1641	14	/	/	SYM
cord-034340-3ksfpaf7	1641	15	ML	ML	NNP
cord-034340-3ksfpaf7	1641	16	[	[	-LRB-
cord-034340-3ksfpaf7	1641	17	95	95	CD
cord-034340-3ksfpaf7	1641	18	%	%	NN
cord-034340-3ksfpaf7	1642	1	CI	CI	NNP
cord-034340-3ksfpaf7	1642	2	-4847	-4847	:
cord-034340-3ksfpaf7	1642	3	to	to	IN
cord-034340-3ksfpaf7	1642	4	29,227	29,227	CD
cord-034340-3ksfpaf7	1642	5	]	]	-RRB-
cord-034340-3ksfpaf7	1642	6	,	,	,
cord-034340-3ksfpaf7	1642	7	P=	P=	NNP
cord-034340-3ksfpaf7	1642	8	0.14	0.14	CD
cord-034340-3ksfpaf7	1642	9	)	)	-RRB-
cord-034340-3ksfpaf7	1642	10	and	and	CC
cord-034340-3ksfpaf7	1642	11	sICAM-1	sICAM-1	NNP
cord-034340-3ksfpaf7	1642	12	(	(	-LRB-
cord-034340-3ksfpaf7	1642	13	5329	5329	CD
cord-034340-3ksfpaf7	1642	14	pg	pg	NNP
cord-034340-3ksfpaf7	1642	15	/	/	SYM
cord-034340-3ksfpaf7	1642	16	ML	ML	NNP
cord-034340-3ksfpaf7	1642	17	[	[	-LRB-
cord-034340-3ksfpaf7	1642	18	95	95	CD
cord-034340-3ksfpaf7	1642	19	%	%	NN
cord-034340-3ksfpaf7	1643	1	CI	CI	NNP
cord-034340-3ksfpaf7	1643	2	-5372	-5372	,
cord-034340-3ksfpaf7	1643	3	to	to	IN
cord-034340-3ksfpaf7	1643	4	16,031	16,031	CD
cord-034340-3ksfpaf7	1643	5	]	]	-RRB-
cord-034340-3ksfpaf7	1643	6	,	,	,
cord-034340-3ksfpaf7	1643	7	P=0.28	P=0.28	NNP
cord-034340-3ksfpaf7	1643	8	)	)	-RRB-
cord-034340-3ksfpaf7	1643	9	were	be	VBD
cord-034340-3ksfpaf7	1643	10	higher	high	JJR
cord-034340-3ksfpaf7	1643	11	when	when	WRB
cord-034340-3ksfpaf7	1643	12	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1643	13	was	be	VBD
cord-034340-3ksfpaf7	1643	14	active	active	JJ
cord-034340-3ksfpaf7	1643	15	compared	compare	VBN
cord-034340-3ksfpaf7	1643	16	to	to	IN
cord-034340-3ksfpaf7	1643	17	inactive	inactive	JJ
cord-034340-3ksfpaf7	1643	18	.	.	.
cord-034340-3ksfpaf7	1644	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1644	2	:	:	:
cord-034340-3ksfpaf7	1645	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1645	2	results	result	NNS
cord-034340-3ksfpaf7	1645	3	suggest	suggest	VBP
cord-034340-3ksfpaf7	1645	4	that	that	IN
cord-034340-3ksfpaf7	1645	5	S100A12	s100a12	NN
cord-034340-3ksfpaf7	1645	6	and	and	CC
cord-034340-3ksfpaf7	1645	7	sICAM-1	sICAM-1	NNP
cord-034340-3ksfpaf7	1645	8	are	be	VBP
cord-034340-3ksfpaf7	1645	9	potential	potential	JJ
cord-034340-3ksfpaf7	1645	10	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	1645	11	of	of	IN
cord-034340-3ksfpaf7	1645	12	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1645	13	activity	activity	NN
cord-034340-3ksfpaf7	1645	14	in	in	IN
cord-034340-3ksfpaf7	1645	15	JIA	JIA	NNP
cord-034340-3ksfpaf7	1645	16	-	-	HYPH
cord-034340-3ksfpaf7	1645	17	U	U	NNP
cord-034340-3ksfpaf7	1645	18	,	,	,
cord-034340-3ksfpaf7	1645	19	but	but	CC
cord-034340-3ksfpaf7	1645	20	not	not	RB
cord-034340-3ksfpaf7	1645	21	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1645	22	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1645	23	.	.	.
cord-034340-3ksfpaf7	1646	1	Thus	thus	RB
cord-034340-3ksfpaf7	1646	2	,	,	,
cord-034340-3ksfpaf7	1646	3	neutrophils	neutrophil	NNS
cord-034340-3ksfpaf7	1646	4	may	may	MD
cord-034340-3ksfpaf7	1646	5	play	play	VB
cord-034340-3ksfpaf7	1646	6	a	a	DT
cord-034340-3ksfpaf7	1646	7	role	role	NN
cord-034340-3ksfpaf7	1646	8	in	in	IN
cord-034340-3ksfpaf7	1646	9	the	the	DT
cord-034340-3ksfpaf7	1646	10	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	1646	11	of	of	IN
cord-034340-3ksfpaf7	1646	12	anterior	anterior	NNP
cord-034340-3ksfpaf7	1646	13	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1646	14	which	which	WDT
cord-034340-3ksfpaf7	1646	15	has	have	VBZ
cord-034340-3ksfpaf7	1646	16	been	be	VBN
cord-034340-3ksfpaf7	1646	17	reported	report	VBN
cord-034340-3ksfpaf7	1646	18	in	in	IN
cord-034340-3ksfpaf7	1646	19	an	an	DT
cord-034340-3ksfpaf7	1646	20	animal	animal	NN
cord-034340-3ksfpaf7	1646	21	model	model	NN
cord-034340-3ksfpaf7	1646	22	of	of	IN
cord-034340-3ksfpaf7	1646	23	acute	acute	JJ
cord-034340-3ksfpaf7	1646	24	anterior	anterior	JJ
cord-034340-3ksfpaf7	1646	25	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1646	26	.	.	.
cord-034340-3ksfpaf7	1647	1	Identifying	identify	VBG
cord-034340-3ksfpaf7	1647	2	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	1647	3	using	use	VBG
cord-034340-3ksfpaf7	1647	4	tears	tear	NNS
cord-034340-3ksfpaf7	1647	5	provides	provide	VBZ
cord-034340-3ksfpaf7	1647	6	a	a	DT
cord-034340-3ksfpaf7	1647	7	noninvasive	noninvasive	JJ
cord-034340-3ksfpaf7	1647	8	and	and	CC
cord-034340-3ksfpaf7	1647	9	objective	objective	JJ
cord-034340-3ksfpaf7	1647	10	method	method	NN
cord-034340-3ksfpaf7	1647	11	of	of	IN
cord-034340-3ksfpaf7	1647	12	monitoring	monitor	VBG
cord-034340-3ksfpaf7	1647	13	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1647	14	.	.	.
cord-034340-3ksfpaf7	1648	1	Limitations	limitation	NNS
cord-034340-3ksfpaf7	1648	2	are	be	VBP
cord-034340-3ksfpaf7	1648	3	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1648	4	heterogeneous	heterogeneous	JJ
cord-034340-3ksfpaf7	1648	5	cohort	cohort	NN
cord-034340-3ksfpaf7	1648	6	that	that	WDT
cord-034340-3ksfpaf7	1648	7	varied	vary	VBN
cord-034340-3ksfpaf7	1648	8	by	by	IN
cord-034340-3ksfpaf7	1648	9	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1648	10	severity	severity	NN
cord-034340-3ksfpaf7	1648	11	and	and	CC
cord-034340-3ksfpaf7	1648	12	immunosuppression	immunosuppression	NN
cord-034340-3ksfpaf7	1648	13	,	,	,
cord-034340-3ksfpaf7	1648	14	and	and	CC
cord-034340-3ksfpaf7	1648	15	minimally	minimally	RB
cord-034340-3ksfpaf7	1648	16	active	active	JJ
cord-034340-3ksfpaf7	1648	17	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1648	18	.	.	.
cord-034340-3ksfpaf7	1649	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1649	2	were	be	VBD
cord-034340-3ksfpaf7	1649	3	underpowered	underpowere	VBN
cord-034340-3ksfpaf7	1649	4	to	to	TO
cord-034340-3ksfpaf7	1649	5	detect	detect	VB
cord-034340-3ksfpaf7	1649	6	statistically	statistically	RB
cord-034340-3ksfpaf7	1649	7	significant	significant	JJ
cord-034340-3ksfpaf7	1649	8	differences	difference	NNS
cord-034340-3ksfpaf7	1649	9	and	and	CC
cord-034340-3ksfpaf7	1649	10	continue	continue	VB
cord-034340-3ksfpaf7	1649	11	to	to	TO
cord-034340-3ksfpaf7	1649	12	collect	collect	VB
cord-034340-3ksfpaf7	1649	13	tears	tear	NNS
cord-034340-3ksfpaf7	1649	14	prospectively	prospectively	RB
cord-034340-3ksfpaf7	1649	15	in	in	IN
cord-034340-3ksfpaf7	1649	16	children	child	NNS
cord-034340-3ksfpaf7	1649	17	with	with	IN
cord-034340-3ksfpaf7	1649	18	JIA	JIA	NNP
cord-034340-3ksfpaf7	1649	19	-	-	HYPH
cord-034340-3ksfpaf7	1649	20	U	U	NNP
cord-034340-3ksfpaf7	1649	21	with	with	IN
cord-034340-3ksfpaf7	1649	22	goal	goal	NN
cord-034340-3ksfpaf7	1649	23	of	of	IN
cord-034340-3ksfpaf7	1649	24	n=28	n=28	NN
cord-034340-3ksfpaf7	1649	25	.	.	.
cord-034340-3ksfpaf7	1650	1	Despite	despite	IN
cord-034340-3ksfpaf7	1650	2	low	low	JJ
cord-034340-3ksfpaf7	1650	3	uveitis	uveitis	NN
cord-034340-3ksfpaf7	1650	4	activity	activity	NN
cord-034340-3ksfpaf7	1650	5	,	,	,
cord-034340-3ksfpaf7	1650	6	we	-PRON-	PRP
cord-034340-3ksfpaf7	1650	7	were	be	VBD
cord-034340-3ksfpaf7	1650	8	still	still	RB
cord-034340-3ksfpaf7	1650	9	able	able	JJ
cord-034340-3ksfpaf7	1650	10	to	to	TO
cord-034340-3ksfpaf7	1650	11	detect	detect	VB
cord-034340-3ksfpaf7	1650	12	differences	difference	NNS
cord-034340-3ksfpaf7	1650	13	.	.	.
cord-034340-3ksfpaf7	1651	1	Further	further	JJ
cord-034340-3ksfpaf7	1651	2	studies	study	NNS
cord-034340-3ksfpaf7	1651	3	in	in	IN
cord-034340-3ksfpaf7	1651	4	larger	large	JJR
cord-034340-3ksfpaf7	1651	5	and	and	CC
cord-034340-3ksfpaf7	1651	6	diverse	diverse	JJ
cord-034340-3ksfpaf7	1651	7	cohorts	cohort	NNS
cord-034340-3ksfpaf7	1651	8	are	be	VBP
cord-034340-3ksfpaf7	1651	9	necessary	necessary	JJ
cord-034340-3ksfpaf7	1651	10	to	to	TO
cord-034340-3ksfpaf7	1651	11	assess	assess	VB
cord-034340-3ksfpaf7	1651	12	the	the	DT
cord-034340-3ksfpaf7	1651	13	role	role	NN
cord-034340-3ksfpaf7	1651	14	of	of	IN
cord-034340-3ksfpaf7	1651	15	S100A12	s100a12	NN
cord-034340-3ksfpaf7	1651	16	and	and	CC
cord-034340-3ksfpaf7	1651	17	sICAM-1	sICAM-1	NNP
cord-034340-3ksfpaf7	1651	18	in	in	IN
cord-034340-3ksfpaf7	1651	19	JIA	JIA	NNP
cord-034340-3ksfpaf7	1651	20	-	-	HYPH
cord-034340-3ksfpaf7	1651	21	U.	U.	NNP
cord-034340-3ksfpaf7	1651	22	Objectives	Objectives	NNP
cord-034340-3ksfpaf7	1651	23	:	:	:
cord-034340-3ksfpaf7	1652	1	To	to	TO
cord-034340-3ksfpaf7	1652	2	report	report	VB
cord-034340-3ksfpaf7	1652	3	an	an	DT
cord-034340-3ksfpaf7	1652	4	extremely	extremely	RB
cord-034340-3ksfpaf7	1652	5	rare	rare	JJ
cord-034340-3ksfpaf7	1652	6	presentation	presentation	NN
cord-034340-3ksfpaf7	1652	7	of	of	IN
cord-034340-3ksfpaf7	1652	8	GPA	GPA	NNP
cord-034340-3ksfpaf7	1652	9	in	in	IN
cord-034340-3ksfpaf7	1652	10	a	a	DT
cord-034340-3ksfpaf7	1652	11	12	12	CD
cord-034340-3ksfpaf7	1652	12	year	year	NN
cord-034340-3ksfpaf7	1652	13	old	old	JJ
cord-034340-3ksfpaf7	1652	14	with	with	IN
cord-034340-3ksfpaf7	1652	15	acute	acute	JJ
cord-034340-3ksfpaf7	1652	16	digital	digital	JJ
cord-034340-3ksfpaf7	1652	17	ischemia	ischemia	NN
cord-034340-3ksfpaf7	1652	18	.	.	.
cord-034340-3ksfpaf7	1653	1	A	a	DT
cord-034340-3ksfpaf7	1653	2	12	12	CD
cord-034340-3ksfpaf7	1653	3	year	year	NN
cord-034340-3ksfpaf7	1653	4	old	old	JJ
cord-034340-3ksfpaf7	1653	5	boy	boy	NN
cord-034340-3ksfpaf7	1653	6	,	,	,
cord-034340-3ksfpaf7	1653	7	with	with	IN
cord-034340-3ksfpaf7	1653	8	a	a	DT
cord-034340-3ksfpaf7	1653	9	background	background	NN
cord-034340-3ksfpaf7	1653	10	of	of	IN
cord-034340-3ksfpaf7	1653	11	poorly	poorly	RB
cord-034340-3ksfpaf7	1653	12	controlled	control	VBN
cord-034340-3ksfpaf7	1653	13	type	type	NN
cord-034340-3ksfpaf7	1653	14	1	1	CD
cord-034340-3ksfpaf7	1653	15	diabetes	diabetes	NN
cord-034340-3ksfpaf7	1653	16	and	and	CC
cord-034340-3ksfpaf7	1653	17	hypothyroidism	hypothyroidism	NN
cord-034340-3ksfpaf7	1653	18	,	,	,
cord-034340-3ksfpaf7	1653	19	initially	initially	RB
cord-034340-3ksfpaf7	1653	20	presented	present	VBD
cord-034340-3ksfpaf7	1653	21	to	to	IN
cord-034340-3ksfpaf7	1653	22	hospital	hospital	NN
cord-034340-3ksfpaf7	1653	23	unwell	unwell	JJ
cord-034340-3ksfpaf7	1653	24	with	with	IN
cord-034340-3ksfpaf7	1653	25	diabetic	diabetic	JJ
cord-034340-3ksfpaf7	1653	26	ketoacidosis	ketoacidosis	NN
cord-034340-3ksfpaf7	1653	27	.	.	.
cord-034340-3ksfpaf7	1654	1	Treatment	treatment	NN
cord-034340-3ksfpaf7	1654	2	was	be	VBD
cord-034340-3ksfpaf7	1654	3	initiated	initiate	VBN
cord-034340-3ksfpaf7	1654	4	promptly	promptly	RB
cord-034340-3ksfpaf7	1654	5	with	with	IN
cord-034340-3ksfpaf7	1654	6	good	good	JJ
cord-034340-3ksfpaf7	1654	7	response	response	NN
cord-034340-3ksfpaf7	1654	8	.	.	.
cord-034340-3ksfpaf7	1655	1	Furthermore	furthermore	RB
cord-034340-3ksfpaf7	1655	2	,	,	,
cord-034340-3ksfpaf7	1655	3	he	-PRON-	PRP
cord-034340-3ksfpaf7	1655	4	was	be	VBD
cord-034340-3ksfpaf7	1655	5	found	find	VBN
cord-034340-3ksfpaf7	1655	6	to	to	TO
cord-034340-3ksfpaf7	1655	7	have	have	VB
cord-034340-3ksfpaf7	1655	8	weight	weight	NN
cord-034340-3ksfpaf7	1655	9	loss	loss	NN
cord-034340-3ksfpaf7	1655	10	,	,	,
cord-034340-3ksfpaf7	1655	11	productive	productive	JJ
cord-034340-3ksfpaf7	1655	12	cough	cough	NN
cord-034340-3ksfpaf7	1655	13	and	and	CC
cord-034340-3ksfpaf7	1655	14	hearing	hear	VBG
cord-034340-3ksfpaf7	1655	15	loss	loss	NN
cord-034340-3ksfpaf7	1655	16	over	over	IN
cord-034340-3ksfpaf7	1655	17	the	the	DT
cord-034340-3ksfpaf7	1655	18	past	past	JJ
cord-034340-3ksfpaf7	1655	19	3	3	CD
cord-034340-3ksfpaf7	1655	20	months	month	NNS
cord-034340-3ksfpaf7	1655	21	.	.	.
cord-034340-3ksfpaf7	1656	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1656	2	was	be	VBD
cord-034340-3ksfpaf7	1656	3	haemodynamically	haemodynamically	RB
cord-034340-3ksfpaf7	1656	4	stable	stable	JJ
cord-034340-3ksfpaf7	1656	5	,	,	,
cord-034340-3ksfpaf7	1656	6	but	but	CC
cord-034340-3ksfpaf7	1656	7	very	very	RB
cord-034340-3ksfpaf7	1656	8	pale	pale	JJ
cord-034340-3ksfpaf7	1656	9	and	and	CC
cord-034340-3ksfpaf7	1656	10	cachectic	cachectic	JJ
cord-034340-3ksfpaf7	1656	11	.	.	.
cord-034340-3ksfpaf7	1657	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1657	2	had	have	VBD
cord-034340-3ksfpaf7	1657	3	reduced	reduce	VBN
cord-034340-3ksfpaf7	1657	4	air	air	NN
cord-034340-3ksfpaf7	1657	5	entry	entry	NN
cord-034340-3ksfpaf7	1657	6	and	and	CC
cord-034340-3ksfpaf7	1657	7	crackles	crackle	NNS
cord-034340-3ksfpaf7	1657	8	on	on	IN
cord-034340-3ksfpaf7	1657	9	the	the	DT
cord-034340-3ksfpaf7	1657	10	right	right	NN
cord-034340-3ksfpaf7	1657	11	.	.	.
cord-034340-3ksfpaf7	1658	1	There	there	EX
cord-034340-3ksfpaf7	1658	2	was	be	VBD
cord-034340-3ksfpaf7	1658	3	hypertonia	hypertonia	NNP
cord-034340-3ksfpaf7	1658	4	and	and	CC
cord-034340-3ksfpaf7	1658	5	clonus	clonu	VBN
cord-034340-3ksfpaf7	1658	6	in	in	IN
cord-034340-3ksfpaf7	1658	7	his	-PRON-	PRP$
cord-034340-3ksfpaf7	1658	8	lower	low	JJR
cord-034340-3ksfpaf7	1658	9	limbs	limb	NNS
cord-034340-3ksfpaf7	1658	10	.	.	.
cord-034340-3ksfpaf7	1659	1	Blood	blood	NN
cord-034340-3ksfpaf7	1659	2	tests	test	NNS
cord-034340-3ksfpaf7	1659	3	showed	show	VBD
cord-034340-3ksfpaf7	1659	4	microcytic	microcytic	JJ
cord-034340-3ksfpaf7	1659	5	hypochromic	hypochromic	JJ
cord-034340-3ksfpaf7	1659	6	anaemia	anaemia	NN
cord-034340-3ksfpaf7	1659	7	(	(	-LRB-
cord-034340-3ksfpaf7	1659	8	Hb	Hb	NNP
cord-034340-3ksfpaf7	1659	9	82g	82g	NNPS
cord-034340-3ksfpaf7	1659	10	/	/	SYM
cord-034340-3ksfpaf7	1659	11	L	L	NNP
cord-034340-3ksfpaf7	1659	12	)	)	-RRB-
cord-034340-3ksfpaf7	1659	13	,	,	,
cord-034340-3ksfpaf7	1659	14	normal	normal	JJ
cord-034340-3ksfpaf7	1659	15	white	white	JJ
cord-034340-3ksfpaf7	1659	16	cell	cell	NN
cord-034340-3ksfpaf7	1659	17	count	count	NN
cord-034340-3ksfpaf7	1659	18	,	,	,
cord-034340-3ksfpaf7	1659	19	thrombocytosis	thrombocytosis	NNP
cord-034340-3ksfpaf7	1659	20	and	and	CC
cord-034340-3ksfpaf7	1659	21	raised	raise	VBD
cord-034340-3ksfpaf7	1659	22	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1659	23	markers	marker	NNS
cord-034340-3ksfpaf7	1659	24	(	(	-LRB-
cord-034340-3ksfpaf7	1659	25	CRP	CRP	NNP
cord-034340-3ksfpaf7	1659	26	138mg	138mg	NNP
cord-034340-3ksfpaf7	1659	27	/	/	SYM
cord-034340-3ksfpaf7	1659	28	L	L	NNP
cord-034340-3ksfpaf7	1659	29	and	and	CC
cord-034340-3ksfpaf7	1659	30	ESR	ESR	NNP
cord-034340-3ksfpaf7	1659	31	68	68	CD
cord-034340-3ksfpaf7	1659	32	mm	mm	NNP
cord-034340-3ksfpaf7	1659	33	/	/	SYM
cord-034340-3ksfpaf7	1659	34	hr	hr	NN
cord-034340-3ksfpaf7	1659	35	)	)	-RRB-
cord-034340-3ksfpaf7	1659	36	.	.	.
cord-034340-3ksfpaf7	1660	1	His	-PRON-	PRP$
cord-034340-3ksfpaf7	1660	2	chest	chest	NN
cord-034340-3ksfpaf7	1660	3	x	x	NN
cord-034340-3ksfpaf7	1660	4	-	-	NN
cord-034340-3ksfpaf7	1660	5	ray	ray	NN
cord-034340-3ksfpaf7	1660	6	showed	show	VBD
cord-034340-3ksfpaf7	1660	7	enlargement	enlargement	NN
cord-034340-3ksfpaf7	1660	8	of	of	IN
cord-034340-3ksfpaf7	1660	9	the	the	DT
cord-034340-3ksfpaf7	1660	10	right	right	JJ
cord-034340-3ksfpaf7	1660	11	hilum	hilum	NN
cord-034340-3ksfpaf7	1660	12	with	with	IN
cord-034340-3ksfpaf7	1660	13	consolidation/	consolidation/	CD
cord-034340-3ksfpaf7	1660	14	atelectasis	atelectasis	NN
cord-034340-3ksfpaf7	1660	15	extending	extend	VBG
cord-034340-3ksfpaf7	1660	16	into	into	IN
cord-034340-3ksfpaf7	1660	17	the	the	DT
cord-034340-3ksfpaf7	1660	18	middle	middle	NN
cord-034340-3ksfpaf7	1660	19	and	and	CC
cord-034340-3ksfpaf7	1660	20	lower	lower	VB
cord-034340-3ksfpaf7	1660	21	lobes	lobe	NNS
cord-034340-3ksfpaf7	1660	22	.	.	.
cord-034340-3ksfpaf7	1661	1	MRI	MRI	NNP
cord-034340-3ksfpaf7	1661	2	scans	scan	NNS
cord-034340-3ksfpaf7	1661	3	of	of	IN
cord-034340-3ksfpaf7	1661	4	head	head	NN
cord-034340-3ksfpaf7	1661	5	and	and	CC
cord-034340-3ksfpaf7	1661	6	spine	spine	NN
cord-034340-3ksfpaf7	1661	7	were	be	VBD
cord-034340-3ksfpaf7	1661	8	normal	normal	JJ
cord-034340-3ksfpaf7	1661	9	apart	apart	RB
cord-034340-3ksfpaf7	1661	10	from	from	IN
cord-034340-3ksfpaf7	1661	11	fluid	fluid	JJ
cord-034340-3ksfpaf7	1661	12	opacification	opacification	NN
cord-034340-3ksfpaf7	1661	13	in	in	IN
cord-034340-3ksfpaf7	1661	14	the	the	DT
cord-034340-3ksfpaf7	1661	15	paranasal	paranasal	NN
cord-034340-3ksfpaf7	1661	16	sinuses	sinus	NNS
cord-034340-3ksfpaf7	1661	17	.	.	.
cord-034340-3ksfpaf7	1662	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1662	2	was	be	VBD
cord-034340-3ksfpaf7	1662	3	screened	screen	VBN
cord-034340-3ksfpaf7	1662	4	for	for	IN
cord-034340-3ksfpaf7	1662	5	infections	infection	NNS
cord-034340-3ksfpaf7	1662	6	including	include	VBG
cord-034340-3ksfpaf7	1662	7	Tuberculosis	tuberculosis	NN
cord-034340-3ksfpaf7	1662	8	and	and	CC
cord-034340-3ksfpaf7	1662	9	started	start	VBD
cord-034340-3ksfpaf7	1662	10	on	on	IN
cord-034340-3ksfpaf7	1662	11	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1662	12	antibiotics	antibiotic	NNS
cord-034340-3ksfpaf7	1662	13	.	.	.
cord-034340-3ksfpaf7	1663	1	On	on	IN
cord-034340-3ksfpaf7	1663	2	day	day	NN
cord-034340-3ksfpaf7	1663	3	13	13	CD
cord-034340-3ksfpaf7	1663	4	,	,	,
cord-034340-3ksfpaf7	1663	5	he	-PRON-	PRP
cord-034340-3ksfpaf7	1663	6	developed	develop	VBD
cord-034340-3ksfpaf7	1663	7	painful	painful	JJ
cord-034340-3ksfpaf7	1663	8	bluish	bluish	JJ
cord-034340-3ksfpaf7	1663	9	discolouration	discolouration	NN
cord-034340-3ksfpaf7	1663	10	of	of	IN
cord-034340-3ksfpaf7	1663	11	his	-PRON-	PRP$
cord-034340-3ksfpaf7	1663	12	left	left	JJ
cord-034340-3ksfpaf7	1663	13	hand	hand	NN
cord-034340-3ksfpaf7	1663	14	,	,	,
cord-034340-3ksfpaf7	1663	15	particularly	particularly	RB
cord-034340-3ksfpaf7	1663	16	his	-PRON-	PRP$
cord-034340-3ksfpaf7	1663	17	thumb	thumb	NN
cord-034340-3ksfpaf7	1663	18	,	,	,
cord-034340-3ksfpaf7	1663	19	index	index	NN
cord-034340-3ksfpaf7	1663	20	and	and	CC
cord-034340-3ksfpaf7	1663	21	middle	middle	JJ
cord-034340-3ksfpaf7	1663	22	fingers	finger	NNS
cord-034340-3ksfpaf7	1663	23	.	.	.
cord-034340-3ksfpaf7	1664	1	His	-PRON-	PRP$
cord-034340-3ksfpaf7	1664	2	left	left	JJ
cord-034340-3ksfpaf7	1664	3	radial	radial	JJ
cord-034340-3ksfpaf7	1664	4	and	and	CC
cord-034340-3ksfpaf7	1664	5	brachial	brachial	JJ
cord-034340-3ksfpaf7	1664	6	pulses	pulse	NNS
cord-034340-3ksfpaf7	1664	7	were	be	VBD
cord-034340-3ksfpaf7	1664	8	n't	not	RB
cord-034340-3ksfpaf7	1664	9	palpable	palpable	JJ
cord-034340-3ksfpaf7	1664	10	.	.	.
cord-034340-3ksfpaf7	1665	1	A	a	DT
cord-034340-3ksfpaf7	1665	2	heparin	heparin	JJ
cord-034340-3ksfpaf7	1665	3	infusion	infusion	NN
cord-034340-3ksfpaf7	1665	4	was	be	VBD
cord-034340-3ksfpaf7	1665	5	started	start	VBN
cord-034340-3ksfpaf7	1665	6	.	.	.
cord-034340-3ksfpaf7	1666	1	A	a	DT
cord-034340-3ksfpaf7	1666	2	Doppler	Doppler	NNP
cord-034340-3ksfpaf7	1666	3	scan	scan	NN
cord-034340-3ksfpaf7	1666	4	showed	show	VBD
cord-034340-3ksfpaf7	1666	5	occlusion	occlusion	NN
cord-034340-3ksfpaf7	1666	6	of	of	IN
cord-034340-3ksfpaf7	1666	7	radial	radial	JJ
cord-034340-3ksfpaf7	1666	8	and	and	CC
cord-034340-3ksfpaf7	1666	9	ulnar	ulnar	JJ
cord-034340-3ksfpaf7	1666	10	arteries	artery	NNS
cord-034340-3ksfpaf7	1666	11	proximal	proximal	JJ
cord-034340-3ksfpaf7	1666	12	to	to	IN
cord-034340-3ksfpaf7	1666	13	the	the	DT
cord-034340-3ksfpaf7	1666	14	wrist	wrist	NN
cord-034340-3ksfpaf7	1666	15	with	with	IN
cord-034340-3ksfpaf7	1666	16	no	no	DT
cord-034340-3ksfpaf7	1666	17	clear	clear	JJ
cord-034340-3ksfpaf7	1666	18	thrombus	thrombus	NN
cord-034340-3ksfpaf7	1666	19	.	.	.
cord-034340-3ksfpaf7	1667	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1667	2	had	have	VBD
cord-034340-3ksfpaf7	1667	3	a	a	DT
cord-034340-3ksfpaf7	1667	4	CT	CT	NNP
cord-034340-3ksfpaf7	1667	5	thoracic	thoracic	JJ
cord-034340-3ksfpaf7	1667	6	aorta	aorta	NN
cord-034340-3ksfpaf7	1667	7	with	with	IN
cord-034340-3ksfpaf7	1667	8	contrast	contrast	NN
cord-034340-3ksfpaf7	1667	9	which	which	WDT
cord-034340-3ksfpaf7	1667	10	showed	show	VBD
cord-034340-3ksfpaf7	1667	11	proximal	proximal	JJ
cord-034340-3ksfpaf7	1667	12	left	left	JJ
cord-034340-3ksfpaf7	1667	13	radial	radial	JJ
cord-034340-3ksfpaf7	1667	14	artery	artery	NN
cord-034340-3ksfpaf7	1667	15	occlusion	occlusion	NN
cord-034340-3ksfpaf7	1667	16	and	and	CC
cord-034340-3ksfpaf7	1667	17	distal	distal	JJ
cord-034340-3ksfpaf7	1667	18	ulnar	ulnar	JJ
cord-034340-3ksfpaf7	1667	19	artery	artery	NN
cord-034340-3ksfpaf7	1667	20	occlusion	occlusion	NN
cord-034340-3ksfpaf7	1667	21	with	with	IN
cord-034340-3ksfpaf7	1667	22	no	no	DT
cord-034340-3ksfpaf7	1667	23	evidence	evidence	NN
cord-034340-3ksfpaf7	1667	24	of	of	IN
cord-034340-3ksfpaf7	1667	25	proximal	proximal	JJ
cord-034340-3ksfpaf7	1667	26	embolic	embolic	JJ
cord-034340-3ksfpaf7	1667	27	source	source	NN
cord-034340-3ksfpaf7	1667	28	or	or	CC
cord-034340-3ksfpaf7	1667	29	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1667	30	.	.	.
cord-034340-3ksfpaf7	1668	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1668	2	showed	show	VBD
cord-034340-3ksfpaf7	1668	3	multiple	multiple	JJ
cord-034340-3ksfpaf7	1668	4	perihilar	perihilar	JJ
cord-034340-3ksfpaf7	1668	5	masses	masse	NNS
cord-034340-3ksfpaf7	1668	6	(	(	-LRB-
cord-034340-3ksfpaf7	1668	7	lymph	lymph	NN
cord-034340-3ksfpaf7	1668	8	nodes	node	NNS
cord-034340-3ksfpaf7	1668	9	)	)	-RRB-
cord-034340-3ksfpaf7	1668	10	in	in	IN
cord-034340-3ksfpaf7	1668	11	the	the	DT
cord-034340-3ksfpaf7	1668	12	right	right	JJ
cord-034340-3ksfpaf7	1668	13	lung	lung	NN
cord-034340-3ksfpaf7	1668	14	and	and	CC
cord-034340-3ksfpaf7	1668	15	peripheral	peripheral	JJ
cord-034340-3ksfpaf7	1668	16	parenchymal	parenchymal	NN
cord-034340-3ksfpaf7	1668	17	masses	masse	NNS
cord-034340-3ksfpaf7	1668	18	in	in	IN
cord-034340-3ksfpaf7	1668	19	both	both	DT
cord-034340-3ksfpaf7	1668	20	lungs	lung	NNS
cord-034340-3ksfpaf7	1668	21	,	,	,
cord-034340-3ksfpaf7	1668	22	suggestive	suggestive	JJ
cord-034340-3ksfpaf7	1668	23	of	of	IN
cord-034340-3ksfpaf7	1668	24	atypical	atypical	JJ
cord-034340-3ksfpaf7	1668	25	infection	infection	NN
cord-034340-3ksfpaf7	1668	26	or	or	CC
cord-034340-3ksfpaf7	1668	27	connective	connective	JJ
cord-034340-3ksfpaf7	1668	28	tissue	tissue	NN
cord-034340-3ksfpaf7	1668	29	disease	disease	NN
cord-034340-3ksfpaf7	1668	30	.	.	.
cord-034340-3ksfpaf7	1669	1	Blood	blood	NN
cord-034340-3ksfpaf7	1669	2	tests	test	NNS
cord-034340-3ksfpaf7	1669	3	still	still	RB
cord-034340-3ksfpaf7	1669	4	showed	show	VBD
cord-034340-3ksfpaf7	1669	5	raised	raise	VBN
cord-034340-3ksfpaf7	1669	6	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1669	7	markers(CRP	markers(CRP	NNP
cord-034340-3ksfpaf7	1669	8	107mg	107mg	NNP
cord-034340-3ksfpaf7	1669	9	/	/	SYM
cord-034340-3ksfpaf7	1669	10	L	L	NNP
cord-034340-3ksfpaf7	1669	11	,	,	,
cord-034340-3ksfpaf7	1669	12	ESR	ESR	NNP
cord-034340-3ksfpaf7	1669	13	86	86	CD
cord-034340-3ksfpaf7	1669	14	mm	mm	NNP
cord-034340-3ksfpaf7	1669	15	/	/	SYM
cord-034340-3ksfpaf7	1669	16	hr	hr	NN
cord-034340-3ksfpaf7	1669	17	and	and	CC
cord-034340-3ksfpaf7	1669	18	platelets	platelet	VBZ
cord-034340-3ksfpaf7	1669	19	658	658	CD
cord-034340-3ksfpaf7	1669	20	10	10	CD
cord-034340-3ksfpaf7	1669	21	9	9	CD
cord-034340-3ksfpaf7	1669	22	/L	/l	CD
cord-034340-3ksfpaf7	1669	23	)	)	-RRB-
cord-034340-3ksfpaf7	1669	24	.	.	.
cord-034340-3ksfpaf7	1670	1	An	an	DT
cord-034340-3ksfpaf7	1670	2	autoantibody	autoantibody	NN
cord-034340-3ksfpaf7	1670	3	screen	screen	NN
cord-034340-3ksfpaf7	1670	4	showed	show	VBD
cord-034340-3ksfpaf7	1670	5	positive	positive	JJ
cord-034340-3ksfpaf7	1670	6	ANCA	ANCA	NNP
cord-034340-3ksfpaf7	1670	7	with	with	IN
cord-034340-3ksfpaf7	1670	8	strongly	strongly	RB
cord-034340-3ksfpaf7	1670	9	positive	positive	JJ
cord-034340-3ksfpaf7	1670	10	anti	anti	AFX
cord-034340-3ksfpaf7	1670	11	PR3(>100	PR3(>100	NNP
cord-034340-3ksfpaf7	1670	12	U	U	NNP
cord-034340-3ksfpaf7	1670	13	/	/	SYM
cord-034340-3ksfpaf7	1670	14	mL	mL	NNP
cord-034340-3ksfpaf7	1670	15	)	)	-RRB-
cord-034340-3ksfpaf7	1670	16	;	;	:
cord-034340-3ksfpaf7	1670	17	other	other	JJ
cord-034340-3ksfpaf7	1670	18	autoantibodies	autoantibody	NNS
cord-034340-3ksfpaf7	1670	19	,	,	,
cord-034340-3ksfpaf7	1670	20	including	include	VBG
cord-034340-3ksfpaf7	1670	21	ANA	ANA	NNP
cord-034340-3ksfpaf7	1670	22	,	,	,
cord-034340-3ksfpaf7	1670	23	ds	ds	NNP
cord-034340-3ksfpaf7	1670	24	DNA	DNA	NNP
cord-034340-3ksfpaf7	1670	25	and	and	CC
cord-034340-3ksfpaf7	1670	26	anti	anti	JJ
cord-034340-3ksfpaf7	1670	27	-	-	JJ
cord-034340-3ksfpaf7	1670	28	phospholipid	phospholipid	JJ
cord-034340-3ksfpaf7	1670	29	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1670	30	,	,	,
cord-034340-3ksfpaf7	1670	31	were	be	VBD
cord-034340-3ksfpaf7	1670	32	negative	negative	JJ
cord-034340-3ksfpaf7	1670	33	.	.	.
cord-034340-3ksfpaf7	1671	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1671	2	developed	develop	VBD
cord-034340-3ksfpaf7	1671	3	further	further	JJ
cord-034340-3ksfpaf7	1671	4	ischaemia	ischaemia	NN
cord-034340-3ksfpaf7	1671	5	with	with	IN
cord-034340-3ksfpaf7	1671	6	bluish	bluish	JJ
cord-034340-3ksfpaf7	1671	7	,	,	,
cord-034340-3ksfpaf7	1671	8	painful	painful	JJ
cord-034340-3ksfpaf7	1671	9	discoloration	discoloration	NN
cord-034340-3ksfpaf7	1671	10	of	of	IN
cord-034340-3ksfpaf7	1671	11	his	-PRON-	PRP$
cord-034340-3ksfpaf7	1671	12	right	right	JJ
cord-034340-3ksfpaf7	1671	13	foot	foot	NN
cord-034340-3ksfpaf7	1671	14	,	,	,
cord-034340-3ksfpaf7	1671	15	especially	especially	RB
cord-034340-3ksfpaf7	1671	16	right	right	RB
cord-034340-3ksfpaf7	1671	17	great	great	JJ
cord-034340-3ksfpaf7	1671	18	toe	toe	NN
cord-034340-3ksfpaf7	1671	19	,	,	,
cord-034340-3ksfpaf7	1671	20	with	with	IN
cord-034340-3ksfpaf7	1671	21	a	a	DT
cord-034340-3ksfpaf7	1671	22	weakly	weakly	RB
cord-034340-3ksfpaf7	1671	23	palpable	palpable	JJ
cord-034340-3ksfpaf7	1671	24	dorsalis	dorsalis	NN
cord-034340-3ksfpaf7	1671	25	pedis	pedis	NN
cord-034340-3ksfpaf7	1671	26	pulse	pulse	NN
cord-034340-3ksfpaf7	1671	27	.	.	.
cord-034340-3ksfpaf7	1672	1	Doppler	Doppler	NNP
cord-034340-3ksfpaf7	1672	2	scan	scan	NN
cord-034340-3ksfpaf7	1672	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1672	4	occlusion	occlusion	NN
cord-034340-3ksfpaf7	1672	5	/	/	SYM
cord-034340-3ksfpaf7	1672	6	narrowing	narrowing	NN
cord-034340-3ksfpaf7	1672	7	of	of	IN
cord-034340-3ksfpaf7	1672	8	the	the	DT
cord-034340-3ksfpaf7	1672	9	posterior	posterior	JJ
cord-034340-3ksfpaf7	1672	10	tibial	tibial	JJ
cord-034340-3ksfpaf7	1672	11	artery	artery	NN
cord-034340-3ksfpaf7	1672	12	6	6	CD
cord-034340-3ksfpaf7	1672	13	cm	cm	NNS
cord-034340-3ksfpaf7	1672	14	proximal	proximal	JJ
cord-034340-3ksfpaf7	1672	15	to	to	IN
cord-034340-3ksfpaf7	1672	16	the	the	DT
cord-034340-3ksfpaf7	1672	17	ankle	ankle	NN
cord-034340-3ksfpaf7	1672	18	.	.	.
cord-034340-3ksfpaf7	1673	1	Following	follow	VBG
cord-034340-3ksfpaf7	1673	2	vascular	vascular	JJ
cord-034340-3ksfpaf7	1673	3	team	team	NN
cord-034340-3ksfpaf7	1673	4	advice	advice	NN
cord-034340-3ksfpaf7	1673	5	,	,	,
cord-034340-3ksfpaf7	1673	6	he	-PRON-	PRP
cord-034340-3ksfpaf7	1673	7	was	be	VBD
cord-034340-3ksfpaf7	1673	8	started	start	VBN
cord-034340-3ksfpaf7	1673	9	on	on	IN
cord-034340-3ksfpaf7	1673	10	ilioprost	ilioprost	JJ
cord-034340-3ksfpaf7	1673	11	infusion	infusion	NN
cord-034340-3ksfpaf7	1673	12	to	to	TO
cord-034340-3ksfpaf7	1673	13	aid	aid	VB
cord-034340-3ksfpaf7	1673	14	reperfusion	reperfusion	NN
cord-034340-3ksfpaf7	1673	15	of	of	IN
cord-034340-3ksfpaf7	1673	16	the	the	DT
cord-034340-3ksfpaf7	1673	17	extremities	extremity	NNS
cord-034340-3ksfpaf7	1673	18	involved	involve	VBN
cord-034340-3ksfpaf7	1673	19	,	,	,
cord-034340-3ksfpaf7	1673	20	with	with	IN
cord-034340-3ksfpaf7	1673	21	good	good	JJ
cord-034340-3ksfpaf7	1673	22	results	result	NNS
cord-034340-3ksfpaf7	1673	23	.	.	.
cord-034340-3ksfpaf7	1674	1	Based	base	VBN
cord-034340-3ksfpaf7	1674	2	on	on	IN
cord-034340-3ksfpaf7	1674	3	clinical	clinical	JJ
cord-034340-3ksfpaf7	1674	4	and	and	CC
cord-034340-3ksfpaf7	1674	5	lab	lab	NN
cord-034340-3ksfpaf7	1674	6	features	feature	NNS
cord-034340-3ksfpaf7	1674	7	of	of	IN
cord-034340-3ksfpaf7	1674	8	systemic	systemic	JJ
cord-034340-3ksfpaf7	1674	9	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1674	10	,	,	,
cord-034340-3ksfpaf7	1674	11	evidence	evidence	NN
cord-034340-3ksfpaf7	1674	12	of	of	IN
cord-034340-3ksfpaf7	1674	13	upper	upper	JJ
cord-034340-3ksfpaf7	1674	14	airway	airway	NNP
cord-034340-3ksfpaf7	1674	15	involvement(bilateral	involvement(bilateral	JJ
cord-034340-3ksfpaf7	1674	16	conductive	conductive	JJ
cord-034340-3ksfpaf7	1674	17	hearing	hear	VBG
cord-034340-3ksfpaf7	1674	18	loss	loss	NN
cord-034340-3ksfpaf7	1674	19	and	and	CC
cord-034340-3ksfpaf7	1674	20	sinusitis	sinusitis	NN
cord-034340-3ksfpaf7	1674	21	on	on	IN
cord-034340-3ksfpaf7	1674	22	MRI	MRI	NNP
cord-034340-3ksfpaf7	1674	23	scan	scan	NN
cord-034340-3ksfpaf7	1674	24	)	)	-RRB-
cord-034340-3ksfpaf7	1674	25	,	,	,
cord-034340-3ksfpaf7	1674	26	parenchymal	parenchymal	NN
cord-034340-3ksfpaf7	1674	27	lesions	lesion	NNS
cord-034340-3ksfpaf7	1674	28	on	on	IN
cord-034340-3ksfpaf7	1674	29	CT	CT	NNP
cord-034340-3ksfpaf7	1674	30	chest	chest	NN
cord-034340-3ksfpaf7	1674	31	and	and	CC
cord-034340-3ksfpaf7	1674	32	strong	strong	JJ
cord-034340-3ksfpaf7	1674	33	PR3	pr3	JJ
cord-034340-3ksfpaf7	1674	34	positivity	positivity	NN
cord-034340-3ksfpaf7	1674	35	,	,	,
cord-034340-3ksfpaf7	1674	36	a	a	DT
cord-034340-3ksfpaf7	1674	37	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1674	38	of	of	IN
cord-034340-3ksfpaf7	1674	39	GPA	GPA	NNP
cord-034340-3ksfpaf7	1674	40	was	be	VBD
cord-034340-3ksfpaf7	1674	41	made	make	VBN
cord-034340-3ksfpaf7	1674	42	.	.	.
cord-034340-3ksfpaf7	1675	1	Results	result	NNS
cord-034340-3ksfpaf7	1675	2	:	:	:
cord-034340-3ksfpaf7	1676	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1676	2	patient	patient	NN
cord-034340-3ksfpaf7	1676	3	responded	respond	VBD
cord-034340-3ksfpaf7	1676	4	well	well	RB
cord-034340-3ksfpaf7	1676	5	to	to	IN
cord-034340-3ksfpaf7	1676	6	therapy	therapy	NN
cord-034340-3ksfpaf7	1676	7	including	include	VBG
cord-034340-3ksfpaf7	1676	8	multiple	multiple	JJ
cord-034340-3ksfpaf7	1676	9	pulses	pulse	NNS
cord-034340-3ksfpaf7	1676	10	of	of	IN
cord-034340-3ksfpaf7	1676	11	high	high	JJ
cord-034340-3ksfpaf7	1676	12	dose	dose	NN
cord-034340-3ksfpaf7	1676	13	methylprednisolone	methylprednisolone	NN
cord-034340-3ksfpaf7	1676	14	and	and	CC
cord-034340-3ksfpaf7	1676	15	cyclophosphamide	cyclophosphamide	NN
cord-034340-3ksfpaf7	1676	16	,	,	,
cord-034340-3ksfpaf7	1676	17	with	with	IN
cord-034340-3ksfpaf7	1676	18	improvement	improvement	NN
cord-034340-3ksfpaf7	1676	19	of	of	IN
cord-034340-3ksfpaf7	1676	20	all	all	DT
cord-034340-3ksfpaf7	1676	21	organs	organ	NNS
cord-034340-3ksfpaf7	1676	22	involved	involve	VBN
cord-034340-3ksfpaf7	1676	23	and	and	CC
cord-034340-3ksfpaf7	1676	24	no	no	DT
cord-034340-3ksfpaf7	1676	25	further	further	JJ
cord-034340-3ksfpaf7	1676	26	digital	digital	JJ
cord-034340-3ksfpaf7	1676	27	ischemia	ischemia	NN
cord-034340-3ksfpaf7	1676	28	.	.	.
cord-034340-3ksfpaf7	1677	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1677	2	:	:	:
cord-034340-3ksfpaf7	1678	1	Although	although	IN
cord-034340-3ksfpaf7	1678	2	GPA	GPA	NNP
cord-034340-3ksfpaf7	1678	3	is	be	VBZ
cord-034340-3ksfpaf7	1678	4	very	very	RB
cord-034340-3ksfpaf7	1678	5	rare	rare	JJ
cord-034340-3ksfpaf7	1678	6	in	in	IN
cord-034340-3ksfpaf7	1678	7	children	child	NNS
cord-034340-3ksfpaf7	1678	8	,	,	,
cord-034340-3ksfpaf7	1678	9	it	-PRON-	PRP
cord-034340-3ksfpaf7	1678	10	is	be	VBZ
cord-034340-3ksfpaf7	1678	11	associated	associate	VBN
cord-034340-3ksfpaf7	1678	12	with	with	IN
cord-034340-3ksfpaf7	1678	13	high	high	JJ
cord-034340-3ksfpaf7	1678	14	morbidity	morbidity	NN
cord-034340-3ksfpaf7	1678	15	and	and	CC
cord-034340-3ksfpaf7	1678	16	mortality	mortality	NN
cord-034340-3ksfpaf7	1678	17	.	.	.
cord-034340-3ksfpaf7	1679	1	Many	many	JJ
cord-034340-3ksfpaf7	1679	2	studies	study	NNS
cord-034340-3ksfpaf7	1679	3	show	show	VBP
cord-034340-3ksfpaf7	1679	4	that	that	IN
cord-034340-3ksfpaf7	1679	5	the	the	DT
cord-034340-3ksfpaf7	1679	6	spectrum	spectrum	NN
cord-034340-3ksfpaf7	1679	7	of	of	IN
cord-034340-3ksfpaf7	1679	8	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1679	9	GPA	GPA	NNP
cord-034340-3ksfpaf7	1679	10	is	be	VBZ
cord-034340-3ksfpaf7	1679	11	not	not	RB
cord-034340-3ksfpaf7	1679	12	vastly	vastly	RB
cord-034340-3ksfpaf7	1679	13	different	different	JJ
cord-034340-3ksfpaf7	1679	14	from	from	IN
cord-034340-3ksfpaf7	1679	15	adults	adult	NNS
cord-034340-3ksfpaf7	1679	16	,	,	,
cord-034340-3ksfpaf7	1679	17	except	except	IN
cord-034340-3ksfpaf7	1679	18	for	for	IN
cord-034340-3ksfpaf7	1679	19	higher	high	JJR
cord-034340-3ksfpaf7	1679	20	gender	gender	NN
cord-034340-3ksfpaf7	1679	21	bias	bias	NN
cord-034340-3ksfpaf7	1679	22	towards	towards	IN
cord-034340-3ksfpaf7	1679	23	female	female	JJ
cord-034340-3ksfpaf7	1679	24	,	,	,
cord-034340-3ksfpaf7	1679	25	more	more	RBR
cord-034340-3ksfpaf7	1679	26	constitutional	constitutional	JJ
cord-034340-3ksfpaf7	1679	27	and	and	CC
cord-034340-3ksfpaf7	1679	28	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	1679	29	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1679	30	and	and	CC
cord-034340-3ksfpaf7	1679	31	higher	high	JJR
cord-034340-3ksfpaf7	1679	32	risk	risk	NN
cord-034340-3ksfpaf7	1679	33	of	of	IN
cord-034340-3ksfpaf7	1679	34	subglottic	subglottic	JJ
cord-034340-3ksfpaf7	1679	35	stenosis	stenosis	NN
cord-034340-3ksfpaf7	1679	36	.	.	.
cord-034340-3ksfpaf7	1680	1	Although	although	IN
cord-034340-3ksfpaf7	1680	2	there	there	EX
cord-034340-3ksfpaf7	1680	3	are	be	VBP
cord-034340-3ksfpaf7	1680	4	a	a	DT
cord-034340-3ksfpaf7	1680	5	handful	handful	NN
cord-034340-3ksfpaf7	1680	6	of	of	IN
cord-034340-3ksfpaf7	1680	7	case	case	NN
cord-034340-3ksfpaf7	1680	8	reports	report	NNS
cord-034340-3ksfpaf7	1680	9	of	of	IN
cord-034340-3ksfpaf7	1680	10	digital	digital	JJ
cord-034340-3ksfpaf7	1680	11	ischaemia	ischaemia	NN
cord-034340-3ksfpaf7	1680	12	in	in	IN
cord-034340-3ksfpaf7	1680	13	adults	adult	NNS
cord-034340-3ksfpaf7	1680	14	with	with	IN
cord-034340-3ksfpaf7	1680	15	GPA	GPA	NNP
cord-034340-3ksfpaf7	1680	16	,	,	,
cord-034340-3ksfpaf7	1680	17	to	to	IN
cord-034340-3ksfpaf7	1680	18	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1680	19	knowledge	knowledge	NN
cord-034340-3ksfpaf7	1680	20	this	this	DT
cord-034340-3ksfpaf7	1680	21	is	be	VBZ
cord-034340-3ksfpaf7	1680	22	the	the	DT
cord-034340-3ksfpaf7	1680	23	first	first	JJ
cord-034340-3ksfpaf7	1680	24	case	case	NN
cord-034340-3ksfpaf7	1680	25	report	report	NN
cord-034340-3ksfpaf7	1680	26	of	of	IN
cord-034340-3ksfpaf7	1680	27	acute	acute	JJ
cord-034340-3ksfpaf7	1680	28	digital	digital	JJ
cord-034340-3ksfpaf7	1680	29	ischaemia	ischaemia	NN
cord-034340-3ksfpaf7	1680	30	in	in	IN
cord-034340-3ksfpaf7	1680	31	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1680	32	GPA	GPA	NNP
cord-034340-3ksfpaf7	1680	33	.	.	.
cord-034340-3ksfpaf7	1681	1	Early	early	JJ
cord-034340-3ksfpaf7	1681	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1681	3	and	and	CC
cord-034340-3ksfpaf7	1681	4	prompt	prompt	JJ
cord-034340-3ksfpaf7	1681	5	treatment	treatment	NN
cord-034340-3ksfpaf7	1681	6	with	with	IN
cord-034340-3ksfpaf7	1681	7	a	a	DT
cord-034340-3ksfpaf7	1681	8	multidisciplinary	multidisciplinary	JJ
cord-034340-3ksfpaf7	1681	9	team	team	NN
cord-034340-3ksfpaf7	1681	10	approach	approach	NN
cord-034340-3ksfpaf7	1681	11	is	be	VBZ
cord-034340-3ksfpaf7	1681	12	paramount	paramount	NN
cord-034340-3ksfpaf7	1681	13	for	for	IN
cord-034340-3ksfpaf7	1681	14	good	good	JJ
cord-034340-3ksfpaf7	1681	15	outcome	outcome	NN
cord-034340-3ksfpaf7	1681	16	.	.	.
cord-034340-3ksfpaf7	1682	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1682	2	:	:	:
cord-034340-3ksfpaf7	1683	1	Adenosine	Adenosine	NNP
cord-034340-3ksfpaf7	1683	2	deaminase-2	deaminase-2	NNP
cord-034340-3ksfpaf7	1683	3	deficiency	deficiency	NN
cord-034340-3ksfpaf7	1683	4	(	(	-LRB-
cord-034340-3ksfpaf7	1683	5	DADA2	DADA2	NNP
cord-034340-3ksfpaf7	1683	6	)	)	-RRB-
cord-034340-3ksfpaf7	1683	7	is	be	VBZ
cord-034340-3ksfpaf7	1683	8	a	a	DT
cord-034340-3ksfpaf7	1683	9	monogenic	monogenic	NNP
cord-034340-3ksfpaf7	1683	10	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1683	11	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1683	12	whose	whose	WP$
cord-034340-3ksfpaf7	1683	13	presentation	presentation	NN
cord-034340-3ksfpaf7	1683	14	ranges	range	VBZ
cord-034340-3ksfpaf7	1683	15	from	from	IN
cord-034340-3ksfpaf7	1683	16	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	1683	17	fevers	fever	NNS
cord-034340-3ksfpaf7	1683	18	and	and	CC
cord-034340-3ksfpaf7	1683	19	livedo	livedo	VB
cord-034340-3ksfpaf7	1683	20	reticularis	reticularis	JJ
cord-034340-3ksfpaf7	1683	21	to	to	IN
cord-034340-3ksfpaf7	1683	22	systemic	systemic	JJ
cord-034340-3ksfpaf7	1683	23	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1683	24	,	,	,
cord-034340-3ksfpaf7	1683	25	hematologic	hematologic	JJ
cord-034340-3ksfpaf7	1683	26	and	and	CC
cord-034340-3ksfpaf7	1683	27	immunologic	immunologic	JJ
cord-034340-3ksfpaf7	1683	28	abnormalities	abnormality	NNS
cord-034340-3ksfpaf7	1683	29	,	,	,
cord-034340-3ksfpaf7	1683	30	and	and	CC
cord-034340-3ksfpaf7	1683	31	early	early	JJ
cord-034340-3ksfpaf7	1683	32	-	-	HYPH
cord-034340-3ksfpaf7	1683	33	onset	onset	NN
cord-034340-3ksfpaf7	1683	34	stroke	stroke	NN
cord-034340-3ksfpaf7	1683	35	.	.	.
cord-034340-3ksfpaf7	1684	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1684	2	is	be	VBZ
cord-034340-3ksfpaf7	1684	3	characterized	characterize	VBN
cord-034340-3ksfpaf7	1684	4	by	by	IN
cord-034340-3ksfpaf7	1684	5	biallelic	biallelic	NN
cord-034340-3ksfpaf7	1684	6	loss	loss	NN
cord-034340-3ksfpaf7	1684	7	-	-	HYPH
cord-034340-3ksfpaf7	1684	8	of	of	IN
cord-034340-3ksfpaf7	1684	9	-	-	HYPH
cord-034340-3ksfpaf7	1684	10	function	function	NN
cord-034340-3ksfpaf7	1684	11	mutations	mutation	NNS
cord-034340-3ksfpaf7	1684	12	in	in	IN
cord-034340-3ksfpaf7	1684	13	the	the	DT
cord-034340-3ksfpaf7	1684	14	encoding	encoding	NN
cord-034340-3ksfpaf7	1684	15	gene	gene	NN
cord-034340-3ksfpaf7	1684	16	of	of	IN
cord-034340-3ksfpaf7	1684	17	ADA2	ADA2	NNP
cord-034340-3ksfpaf7	1684	18	protein	protein	NN
cord-034340-3ksfpaf7	1684	19	and	and	CC
cord-034340-3ksfpaf7	1684	20	low	low	JJ
cord-034340-3ksfpaf7	1684	21	levels	level	NNS
cord-034340-3ksfpaf7	1684	22	of	of	IN
cord-034340-3ksfpaf7	1684	23	ADA2	ADA2	NNP
cord-034340-3ksfpaf7	1684	24	enzymatic	enzymatic	JJ
cord-034340-3ksfpaf7	1684	25	activity	activity	NN
cord-034340-3ksfpaf7	1684	26	in	in	IN
cord-034340-3ksfpaf7	1684	27	the	the	DT
cord-034340-3ksfpaf7	1684	28	peripheral	peripheral	JJ
cord-034340-3ksfpaf7	1684	29	blood	blood	NN
cord-034340-3ksfpaf7	1684	30	.	.	.
cord-034340-3ksfpaf7	1685	1	The	the	DT
cord-034340-3ksfpaf7	1685	2	genotype	genotype	NN
cord-034340-3ksfpaf7	1685	3	and	and	CC
cord-034340-3ksfpaf7	1685	4	phenotype	phenotype	NN
cord-034340-3ksfpaf7	1685	5	features	feature	NNS
cord-034340-3ksfpaf7	1685	6	of	of	IN
cord-034340-3ksfpaf7	1685	7	DADA2	DADA2	NNP
cord-034340-3ksfpaf7	1685	8	has	have	VBZ
cord-034340-3ksfpaf7	1685	9	a	a	DT
cord-034340-3ksfpaf7	1685	10	wide	wide	JJ
cord-034340-3ksfpaf7	1685	11	spectrum	spectrum	NN
cord-034340-3ksfpaf7	1685	12	.	.	.
cord-034340-3ksfpaf7	1686	1	Treatment	treatment	NN
cord-034340-3ksfpaf7	1686	2	with	with	IN
cord-034340-3ksfpaf7	1686	3	anti	anti	JJ
cord-034340-3ksfpaf7	1686	4	-	-	JJ
cord-034340-3ksfpaf7	1686	5	TNF	TNF	NNP
cord-034340-3ksfpaf7	1686	6	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1686	7	is	be	VBZ
cord-034340-3ksfpaf7	1686	8	effective	effective	JJ
cord-034340-3ksfpaf7	1686	9	in	in	IN
cord-034340-3ksfpaf7	1686	10	controlling	control	VBG
cord-034340-3ksfpaf7	1686	11	vascular	vascular	JJ
cord-034340-3ksfpaf7	1686	12	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1686	13	and	and	CC
cord-034340-3ksfpaf7	1686	14	reducing	reduce	VBG
cord-034340-3ksfpaf7	1686	15	strokes	stroke	NNS
cord-034340-3ksfpaf7	1686	16	.	.	.
cord-034340-3ksfpaf7	1687	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1687	2	:	:	:
cord-034340-3ksfpaf7	1687	3	To	to	TO
cord-034340-3ksfpaf7	1687	4	describe	describe	VB
cord-034340-3ksfpaf7	1687	5	two	two	CD
cord-034340-3ksfpaf7	1687	6	sisters	sister	NNS
cord-034340-3ksfpaf7	1687	7	with	with	IN
cord-034340-3ksfpaf7	1687	8	different	different	JJ
cord-034340-3ksfpaf7	1687	9	presentations	presentation	NNS
cord-034340-3ksfpaf7	1687	10	of	of	IN
cord-034340-3ksfpaf7	1687	11	DADA2	DADA2	NNS
cord-034340-3ksfpaf7	1687	12	and	and	CC
cord-034340-3ksfpaf7	1687	13	a	a	DT
cord-034340-3ksfpaf7	1687	14	deletion	deletion	NN
cord-034340-3ksfpaf7	1687	15	mutation	mutation	NN
cord-034340-3ksfpaf7	1687	16	on	on	IN
cord-034340-3ksfpaf7	1687	17	exon	exon	NNP
cord-034340-3ksfpaf7	1687	18	7	7	CD
cord-034340-3ksfpaf7	1687	19	of	of	IN
cord-034340-3ksfpaf7	1687	20	the	the	DT
cord-034340-3ksfpaf7	1687	21	ADA2	ADA2	NNP
cord-034340-3ksfpaf7	1687	22	gene	gene	NN
cord-034340-3ksfpaf7	1687	23	.	.	.
cord-034340-3ksfpaf7	1688	1	Methods	method	NNS
cord-034340-3ksfpaf7	1688	2	:	:	:
cord-034340-3ksfpaf7	1688	3	Medical	medical	JJ
cord-034340-3ksfpaf7	1688	4	data	datum	NNS
cord-034340-3ksfpaf7	1688	5	was	be	VBD
cord-034340-3ksfpaf7	1688	6	used	use	VBN
cord-034340-3ksfpaf7	1688	7	to	to	TO
cord-034340-3ksfpaf7	1688	8	describe	describe	VB
cord-034340-3ksfpaf7	1688	9	the	the	DT
cord-034340-3ksfpaf7	1688	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	1688	11	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1688	12	of	of	IN
cord-034340-3ksfpaf7	1688	13	two	two	CD
cord-034340-3ksfpaf7	1688	14	siblings	sibling	NNS
cord-034340-3ksfpaf7	1688	15	.	.	.
cord-034340-3ksfpaf7	1689	1	Parental	parental	JJ
cord-034340-3ksfpaf7	1689	2	informed	informed	JJ
cord-034340-3ksfpaf7	1689	3	consent	consent	NN
cord-034340-3ksfpaf7	1689	4	was	be	VBD
cord-034340-3ksfpaf7	1689	5	obtained	obtain	VBN
cord-034340-3ksfpaf7	1689	6	.	.	.
cord-034340-3ksfpaf7	1690	1	Results	result	NNS
cord-034340-3ksfpaf7	1690	2	:	:	:
cord-034340-3ksfpaf7	1690	3	Patient	patient	NN
cord-034340-3ksfpaf7	1690	4	1	1	CD
cord-034340-3ksfpaf7	1690	5	:	:	:
cord-034340-3ksfpaf7	1691	1	A	a	DT
cord-034340-3ksfpaf7	1691	2	10-year	10-year	CD
cord-034340-3ksfpaf7	1691	3	-	-	HYPH
cord-034340-3ksfpaf7	1691	4	old	old	JJ
cord-034340-3ksfpaf7	1691	5	female	female	NN
cord-034340-3ksfpaf7	1691	6	had	have	VBD
cord-034340-3ksfpaf7	1691	7	presented	present	VBN
cord-034340-3ksfpaf7	1691	8	with	with	IN
cord-034340-3ksfpaf7	1691	9	fever	fever	NN
cord-034340-3ksfpaf7	1691	10	,	,	,
cord-034340-3ksfpaf7	1691	11	rash	rash	JJ
cord-034340-3ksfpaf7	1691	12	,	,	,
cord-034340-3ksfpaf7	1691	13	arthralgia	arthralgia	NNP
cord-034340-3ksfpaf7	1691	14	,	,	,
cord-034340-3ksfpaf7	1691	15	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-034340-3ksfpaf7	1691	16	,	,	,
cord-034340-3ksfpaf7	1691	17	and	and	CC
cord-034340-3ksfpaf7	1691	18	coombs	coombs	NNP
cord-034340-3ksfpaf7	1691	19	positive	positive	JJ
cord-034340-3ksfpaf7	1691	20	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1691	21	hemolytic	hemolytic	JJ
cord-034340-3ksfpaf7	1691	22	anemia	anemia	NN
cord-034340-3ksfpaf7	1691	23	(	(	-LRB-
cord-034340-3ksfpaf7	1691	24	AIHA	AIHA	NNP
cord-034340-3ksfpaf7	1691	25	)	)	-RRB-
cord-034340-3ksfpaf7	1691	26	at	at	IN
cord-034340-3ksfpaf7	1691	27	the	the	DT
cord-034340-3ksfpaf7	1691	28	age	age	NN
cord-034340-3ksfpaf7	1691	29	of	of	IN
cord-034340-3ksfpaf7	1691	30	7	7	CD
cord-034340-3ksfpaf7	1691	31	years	year	NNS
cord-034340-3ksfpaf7	1691	32	.	.	.
cord-034340-3ksfpaf7	1692	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1692	2	had	have	VBD
cord-034340-3ksfpaf7	1692	3	been	be	VBN
cord-034340-3ksfpaf7	1692	4	followed	follow	VBN
cord-034340-3ksfpaf7	1692	5	with	with	IN
cord-034340-3ksfpaf7	1692	6	a	a	DT
cord-034340-3ksfpaf7	1692	7	suspected	suspect	VBN
cord-034340-3ksfpaf7	1692	8	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1692	9	of	of	IN
cord-034340-3ksfpaf7	1692	10	systemic	systemic	JJ
cord-034340-3ksfpaf7	1692	11	lupus	lupus	NN
cord-034340-3ksfpaf7	1692	12	erythematosus	erythematosus	NN
cord-034340-3ksfpaf7	1692	13	(	(	-LRB-
cord-034340-3ksfpaf7	1692	14	SLE	SLE	NNP
cord-034340-3ksfpaf7	1692	15	)	)	-RRB-
cord-034340-3ksfpaf7	1692	16	and	and	CC
cord-034340-3ksfpaf7	1692	17	steroids	steroid	NNS
cord-034340-3ksfpaf7	1692	18	,	,	,
cord-034340-3ksfpaf7	1692	19	azathioprine	azathioprine	RB
cord-034340-3ksfpaf7	1692	20	,	,	,
cord-034340-3ksfpaf7	1692	21	mycophenolate	mycophenolate	NNP
cord-034340-3ksfpaf7	1692	22	mofetil	mofetil	NNP
cord-034340-3ksfpaf7	1692	23	had	have	VBD
cord-034340-3ksfpaf7	1692	24	been	be	VBN
cord-034340-3ksfpaf7	1692	25	used	use	VBN
cord-034340-3ksfpaf7	1692	26	.	.	.
cord-034340-3ksfpaf7	1693	1	Her	-PRON-	PRP$
cord-034340-3ksfpaf7	1693	2	ANA	ANA	NNP
cord-034340-3ksfpaf7	1693	3	and	and	CC
cord-034340-3ksfpaf7	1693	4	complement	complement	NN
cord-034340-3ksfpaf7	1693	5	levels	level	NNS
cord-034340-3ksfpaf7	1693	6	were	be	VBD
cord-034340-3ksfpaf7	1693	7	normal	normal	JJ
cord-034340-3ksfpaf7	1693	8	.	.	.
cord-034340-3ksfpaf7	1694	1	Because	because	IN
cord-034340-3ksfpaf7	1694	2	of	of	IN
cord-034340-3ksfpaf7	1694	3	unmet	unmet	JJ
cord-034340-3ksfpaf7	1694	4	classification	classification	NN
cord-034340-3ksfpaf7	1694	5	criteria	criterion	NNS
cord-034340-3ksfpaf7	1694	6	of	of	IN
cord-034340-3ksfpaf7	1694	7	SLE	SLE	NNP
cord-034340-3ksfpaf7	1694	8	,	,	,
cord-034340-3ksfpaf7	1694	9	genetic	genetic	JJ
cord-034340-3ksfpaf7	1694	10	testing	testing	NN
cord-034340-3ksfpaf7	1694	11	had	have	VBD
cord-034340-3ksfpaf7	1694	12	been	be	VBN
cord-034340-3ksfpaf7	1694	13	done	do	VBN
cord-034340-3ksfpaf7	1694	14	,	,	,
cord-034340-3ksfpaf7	1694	15	and	and	CC
cord-034340-3ksfpaf7	1694	16	no	no	DT
cord-034340-3ksfpaf7	1694	17	mutation	mutation	NN
cord-034340-3ksfpaf7	1694	18	found	find	VBN
cord-034340-3ksfpaf7	1694	19	in	in	IN
cord-034340-3ksfpaf7	1694	20	the	the	DT
cord-034340-3ksfpaf7	1694	21	ADA2	ADA2	NNP
cord-034340-3ksfpaf7	1694	22	gene	gene	NN
cord-034340-3ksfpaf7	1694	23	.	.	.
cord-034340-3ksfpaf7	1695	1	Cranial	cranial	JJ
cord-034340-3ksfpaf7	1695	2	MR	MR	NNP
cord-034340-3ksfpaf7	1695	3	and	and	CC
cord-034340-3ksfpaf7	1695	4	MR	MR	NNP
cord-034340-3ksfpaf7	1695	5	angiography	angiography	NNP
cord-034340-3ksfpaf7	1695	6	was	be	VBD
cord-034340-3ksfpaf7	1695	7	normal	normal	JJ
cord-034340-3ksfpaf7	1695	8	.	.	.
cord-034340-3ksfpaf7	1696	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1696	2	was	be	VBD
cord-034340-3ksfpaf7	1696	3	referred	refer	VBN
cord-034340-3ksfpaf7	1696	4	to	to	IN
cord-034340-3ksfpaf7	1696	5	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1696	6	clinic	clinic	NN
cord-034340-3ksfpaf7	1696	7	after	after	IN
cord-034340-3ksfpaf7	1696	8	2.5	2.5	CD
cord-034340-3ksfpaf7	1696	9	years	year	NNS
cord-034340-3ksfpaf7	1696	10	of	of	IN
cord-034340-3ksfpaf7	1696	11	the	the	DT
cord-034340-3ksfpaf7	1696	12	first	first	JJ
cord-034340-3ksfpaf7	1696	13	manifestation	manifestation	NN
cord-034340-3ksfpaf7	1696	14	.	.	.
cord-034340-3ksfpaf7	1697	1	Physical	physical	JJ
cord-034340-3ksfpaf7	1697	2	examination	examination	NN
cord-034340-3ksfpaf7	1697	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1697	4	Raynaud	Raynaud	NNP
cord-034340-3ksfpaf7	1697	5	phenomenon	phenomenon	NN
cord-034340-3ksfpaf7	1697	6	on	on	IN
cord-034340-3ksfpaf7	1697	7	both	both	DT
cord-034340-3ksfpaf7	1697	8	hands	hand	NNS
cord-034340-3ksfpaf7	1697	9	and	and	CC
cord-034340-3ksfpaf7	1697	10	feet	foot	NNS
cord-034340-3ksfpaf7	1697	11	,	,	,
cord-034340-3ksfpaf7	1697	12	livedo	livedo	NNP
cord-034340-3ksfpaf7	1697	13	reticularis	reticularis	NNPS
cord-034340-3ksfpaf7	1697	14	,	,	,
cord-034340-3ksfpaf7	1697	15	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1697	16	,	,	,
cord-034340-3ksfpaf7	1697	17	and	and	CC
cord-034340-3ksfpaf7	1697	18	splenomegaly	splenomegaly	NN
cord-034340-3ksfpaf7	1697	19	.	.	.
cord-034340-3ksfpaf7	1698	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	1698	2	tests	test	NNS
cord-034340-3ksfpaf7	1698	3	indicated	indicate	VBD
cord-034340-3ksfpaf7	1698	4	an	an	DT
cord-034340-3ksfpaf7	1698	5	increase	increase	NN
cord-034340-3ksfpaf7	1698	6	in	in	IN
cord-034340-3ksfpaf7	1698	7	acute	acute	JJ
cord-034340-3ksfpaf7	1698	8	phase	phase	NN
cord-034340-3ksfpaf7	1698	9	reactants	reactant	NNS
cord-034340-3ksfpaf7	1698	10	,	,	,
cord-034340-3ksfpaf7	1698	11	CD19	CD19	NNP
cord-034340-3ksfpaf7	1698	12	,	,	,
cord-034340-3ksfpaf7	1698	13	CD20	CD20	NNP
cord-034340-3ksfpaf7	1698	14	,	,	,
cord-034340-3ksfpaf7	1698	15	and	and	CC
cord-034340-3ksfpaf7	1698	16	switched	switch	VBD
cord-034340-3ksfpaf7	1698	17	memory	memory	NN
cord-034340-3ksfpaf7	1698	18	B	b	NN
cord-034340-3ksfpaf7	1698	19	cell	cell	NN
cord-034340-3ksfpaf7	1698	20	lymphopenia	lymphopenia	NNP
cord-034340-3ksfpaf7	1698	21	,	,	,
cord-034340-3ksfpaf7	1698	22	and	and	CC
cord-034340-3ksfpaf7	1698	23	hypogammaglobulinemia	hypogammaglobulinemia	NNP
cord-034340-3ksfpaf7	1698	24	.	.	.
cord-034340-3ksfpaf7	1699	1	Because	because	IN
cord-034340-3ksfpaf7	1699	2	of	of	IN
cord-034340-3ksfpaf7	1699	3	prolonged	prolonged	JJ
cord-034340-3ksfpaf7	1699	4	fevers	fever	NNS
cord-034340-3ksfpaf7	1699	5	,	,	,
cord-034340-3ksfpaf7	1699	6	a	a	DT
cord-034340-3ksfpaf7	1699	7	thorax	thorax	NN
cord-034340-3ksfpaf7	1699	8	CT	CT	NNP
cord-034340-3ksfpaf7	1699	9	was	be	VBD
cord-034340-3ksfpaf7	1699	10	obtained	obtain	VBN
cord-034340-3ksfpaf7	1699	11	and	and	CC
cord-034340-3ksfpaf7	1699	12	aneurisms	aneurism	NNS
cord-034340-3ksfpaf7	1699	13	of	of	IN
cord-034340-3ksfpaf7	1699	14	the	the	DT
cord-034340-3ksfpaf7	1699	15	renal	renal	JJ
cord-034340-3ksfpaf7	1699	16	artery	artery	NN
cord-034340-3ksfpaf7	1699	17	were	be	VBD
cord-034340-3ksfpaf7	1699	18	seen	see	VBN
cord-034340-3ksfpaf7	1699	19	.	.	.
cord-034340-3ksfpaf7	1700	1	Abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1700	2	CT	CT	NNP
cord-034340-3ksfpaf7	1700	3	angiography	angiography	NN
cord-034340-3ksfpaf7	1700	4	indicated	indicate	VBD
cord-034340-3ksfpaf7	1700	5	multiple	multiple	JJ
cord-034340-3ksfpaf7	1700	6	aneurysms	aneurysm	NNS
cord-034340-3ksfpaf7	1700	7	of	of	IN
cord-034340-3ksfpaf7	1700	8	both	both	DT
cord-034340-3ksfpaf7	1700	9	renal	renal	JJ
cord-034340-3ksfpaf7	1700	10	,	,	,
cord-034340-3ksfpaf7	1700	11	intercostal	intercostal	JJ
cord-034340-3ksfpaf7	1700	12	,	,	,
cord-034340-3ksfpaf7	1700	13	and	and	CC
cord-034340-3ksfpaf7	1700	14	hepatic	hepatic	JJ
cord-034340-3ksfpaf7	1700	15	arteries	artery	NNS
cord-034340-3ksfpaf7	1700	16	.	.	.
cord-034340-3ksfpaf7	1701	1	Repeated	repeat	VBN
cord-034340-3ksfpaf7	1701	2	genetic	genetic	JJ
cord-034340-3ksfpaf7	1701	3	analysis	analysis	NN
cord-034340-3ksfpaf7	1701	4	of	of	IN
cord-034340-3ksfpaf7	1701	5	the	the	DT
cord-034340-3ksfpaf7	1701	6	ADA2	ADA2	NNP
cord-034340-3ksfpaf7	1701	7	gene	gene	NN
cord-034340-3ksfpaf7	1701	8	showed	show	VBD
cord-034340-3ksfpaf7	1701	9	a	a	DT
cord-034340-3ksfpaf7	1701	10	homozygous	homozygous	JJ
cord-034340-3ksfpaf7	1701	11	deletion	deletion	NN
cord-034340-3ksfpaf7	1701	12	mutation	mutation	NN
cord-034340-3ksfpaf7	1701	13	on	on	IN
cord-034340-3ksfpaf7	1701	14	exon	exon	NNP
cord-034340-3ksfpaf7	1701	15	7	7	CD
cord-034340-3ksfpaf7	1701	16	.	.	.
cord-034340-3ksfpaf7	1702	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1702	2	has	have	VBZ
cord-034340-3ksfpaf7	1702	3	been	be	VBN
cord-034340-3ksfpaf7	1702	4	followed	follow	VBN
cord-034340-3ksfpaf7	1702	5	on	on	IN
cord-034340-3ksfpaf7	1702	6	anti	anti	JJ
cord-034340-3ksfpaf7	1702	7	-	-	JJ
cord-034340-3ksfpaf7	1702	8	TNF	TNF	NNP
cord-034340-3ksfpaf7	1702	9	and	and	CC
cord-034340-3ksfpaf7	1702	10	IV	IV	NNP
cord-034340-3ksfpaf7	1702	11	immunoglobulin	immunoglobulin	NN
cord-034340-3ksfpaf7	1702	12	without	without	IN
cord-034340-3ksfpaf7	1702	13	severe	severe	JJ
cord-034340-3ksfpaf7	1702	14	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1702	15	for	for	IN
cord-034340-3ksfpaf7	1702	16	a	a	DT
cord-034340-3ksfpaf7	1702	17	year	year	NN
cord-034340-3ksfpaf7	1702	18	.	.	.
cord-034340-3ksfpaf7	1703	1	Patient	patient	NN
cord-034340-3ksfpaf7	1703	2	2	2	CD
cord-034340-3ksfpaf7	1703	3	:	:	:
cord-034340-3ksfpaf7	1704	1	The	the	DT
cord-034340-3ksfpaf7	1704	2	older	old	JJR
cord-034340-3ksfpaf7	1704	3	sister	sister	NN
cord-034340-3ksfpaf7	1704	4	had	have	VBD
cord-034340-3ksfpaf7	1704	5	been	be	VBN
cord-034340-3ksfpaf7	1704	6	followed	follow	VBN
cord-034340-3ksfpaf7	1704	7	with	with	IN
cord-034340-3ksfpaf7	1704	8	a	a	DT
cord-034340-3ksfpaf7	1704	9	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1704	10	of	of	IN
cord-034340-3ksfpaf7	1704	11	familial	familial	JJ
cord-034340-3ksfpaf7	1704	12	Mediterranean	mediterranean	JJ
cord-034340-3ksfpaf7	1704	13	fever	fever	NN
cord-034340-3ksfpaf7	1704	14	with	with	IN
cord-034340-3ksfpaf7	1704	15	E148Q	e148q	JJ
cord-034340-3ksfpaf7	1704	16	heterozygous	heterozygous	JJ
cord-034340-3ksfpaf7	1704	17	mutation	mutation	NN
cord-034340-3ksfpaf7	1704	18	because	because	IN
cord-034340-3ksfpaf7	1704	19	of	of	IN
cord-034340-3ksfpaf7	1704	20	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	1704	21	fever	fever	NN
cord-034340-3ksfpaf7	1704	22	,	,	,
cord-034340-3ksfpaf7	1704	23	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1704	24	pain	pain	NN
cord-034340-3ksfpaf7	1704	25	,	,	,
cord-034340-3ksfpaf7	1704	26	erysipelas	erysipela	NNS
cord-034340-3ksfpaf7	1704	27	-	-	HYPH
cord-034340-3ksfpaf7	1704	28	like	like	JJ
cord-034340-3ksfpaf7	1704	29	erythema	erythema	NN
cord-034340-3ksfpaf7	1704	30	,	,	,
cord-034340-3ksfpaf7	1704	31	elevated	elevated	JJ
cord-034340-3ksfpaf7	1704	32	acute	acute	JJ
cord-034340-3ksfpaf7	1704	33	phase	phase	NN
cord-034340-3ksfpaf7	1704	34	reactants	reactant	NNS
cord-034340-3ksfpaf7	1704	35	,	,	,
cord-034340-3ksfpaf7	1704	36	and	and	CC
cord-034340-3ksfpaf7	1704	37	splenomegaly	splenomegaly	NN
cord-034340-3ksfpaf7	1704	38	.	.	.
cord-034340-3ksfpaf7	1705	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1705	2	did	do	VBD
cord-034340-3ksfpaf7	1705	3	not	not	RB
cord-034340-3ksfpaf7	1705	4	have	have	VB
cord-034340-3ksfpaf7	1705	5	any	any	DT
cord-034340-3ksfpaf7	1705	6	other	other	JJ
cord-034340-3ksfpaf7	1705	7	cutaneous	cutaneous	JJ
cord-034340-3ksfpaf7	1705	8	or	or	CC
cord-034340-3ksfpaf7	1705	9	systemic	systemic	JJ
cord-034340-3ksfpaf7	1705	10	findings	finding	NNS
cord-034340-3ksfpaf7	1705	11	.	.	.
cord-034340-3ksfpaf7	1706	1	Because	because	IN
cord-034340-3ksfpaf7	1706	2	of	of	IN
cord-034340-3ksfpaf7	1706	3	parental	parental	JJ
cord-034340-3ksfpaf7	1706	4	consanguinity	consanguinity	NN
cord-034340-3ksfpaf7	1706	5	,	,	,
cord-034340-3ksfpaf7	1706	6	the	the	DT
cord-034340-3ksfpaf7	1706	7	ADA2	ADA2	NNP
cord-034340-3ksfpaf7	1706	8	gene	gene	NN
cord-034340-3ksfpaf7	1706	9	was	be	VBD
cord-034340-3ksfpaf7	1706	10	analyzed	analyze	VBN
cord-034340-3ksfpaf7	1706	11	and	and	CC
cord-034340-3ksfpaf7	1706	12	a	a	DT
cord-034340-3ksfpaf7	1706	13	homozygous	homozygous	JJ
cord-034340-3ksfpaf7	1706	14	deletion	deletion	NN
cord-034340-3ksfpaf7	1706	15	mutation	mutation	NN
cord-034340-3ksfpaf7	1706	16	on	on	IN
cord-034340-3ksfpaf7	1706	17	exon	exon	NNP
cord-034340-3ksfpaf7	1706	18	7	7	CD
cord-034340-3ksfpaf7	1706	19	was	be	VBD
cord-034340-3ksfpaf7	1706	20	found	find	VBN
cord-034340-3ksfpaf7	1706	21	.	.	.
cord-034340-3ksfpaf7	1707	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1707	2	has	have	VBZ
cord-034340-3ksfpaf7	1707	3	been	be	VBN
cord-034340-3ksfpaf7	1707	4	followed	follow	VBN
cord-034340-3ksfpaf7	1707	5	without	without	IN
cord-034340-3ksfpaf7	1707	6	any	any	DT
cord-034340-3ksfpaf7	1707	7	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1707	8	after	after	IN
cord-034340-3ksfpaf7	1707	9	anti	anti	JJ
cord-034340-3ksfpaf7	1707	10	-	-	JJ
cord-034340-3ksfpaf7	1707	11	TNF	TNF	NNP
cord-034340-3ksfpaf7	1707	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1707	13	.	.	.
cord-034340-3ksfpaf7	1708	1	Throat	throat	NN
cord-034340-3ksfpaf7	1708	2	swab	swab	NN
cord-034340-3ksfpaf7	1708	3	was	be	VBD
cord-034340-3ksfpaf7	1708	4	negative	negative	JJ
cord-034340-3ksfpaf7	1708	5	.	.	.
cord-034340-3ksfpaf7	1709	1	Abdomen	Abdomen	NNP
cord-034340-3ksfpaf7	1709	2	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	1709	3	showed	show	VBD
cord-034340-3ksfpaf7	1709	4	bowel	bowel	JJ
cord-034340-3ksfpaf7	1709	5	wall	wall	NN
cord-034340-3ksfpaf7	1709	6	thickening	thickening	NN
cord-034340-3ksfpaf7	1709	7	,	,	,
cord-034340-3ksfpaf7	1709	8	testis	testis	NN
cord-034340-3ksfpaf7	1709	9	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	1709	10	was	be	VBD
cord-034340-3ksfpaf7	1709	11	normal	normal	JJ
cord-034340-3ksfpaf7	1709	12	.	.	.
cord-034340-3ksfpaf7	1710	1	HSP	HSP	NNP
cord-034340-3ksfpaf7	1710	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1710	3	was	be	VBD
cord-034340-3ksfpaf7	1710	4	confirmed	confirm	VBN
cord-034340-3ksfpaf7	1710	5	.	.	.
cord-034340-3ksfpaf7	1711	1	Methylprednisolone	Methylprednisolone	NNP
cord-034340-3ksfpaf7	1711	2	iv	iv	NNP
cord-034340-3ksfpaf7	1711	3	was	be	VBD
cord-034340-3ksfpaf7	1711	4	administered	administer	VBN
cord-034340-3ksfpaf7	1711	5	for	for	IN
cord-034340-3ksfpaf7	1711	6	three	three	CD
cord-034340-3ksfpaf7	1711	7	days	day	NNS
cord-034340-3ksfpaf7	1711	8	,	,	,
cord-034340-3ksfpaf7	1711	9	then	then	RB
cord-034340-3ksfpaf7	1711	10	oral	oral	JJ
cord-034340-3ksfpaf7	1711	11	prednisone	prednisone	NNP
cord-034340-3ksfpaf7	1711	12	was	be	VBD
cord-034340-3ksfpaf7	1711	13	started	start	VBN
cord-034340-3ksfpaf7	1711	14	.	.	.
cord-034340-3ksfpaf7	1712	1	Purpuric	purpuric	JJ
cord-034340-3ksfpaf7	1712	2	lesions	lesion	NNS
cord-034340-3ksfpaf7	1712	3	,	,	,
cord-034340-3ksfpaf7	1712	4	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1712	5	pain	pain	NN
cord-034340-3ksfpaf7	1712	6	persisted	persist	VBD
cord-034340-3ksfpaf7	1712	7	,	,	,
cord-034340-3ksfpaf7	1712	8	so	so	RB
cord-034340-3ksfpaf7	1712	9	we	-PRON-	PRP
cord-034340-3ksfpaf7	1712	10	decided	decide	VBD
cord-034340-3ksfpaf7	1712	11	to	to	TO
cord-034340-3ksfpaf7	1712	12	add	add	VB
cord-034340-3ksfpaf7	1712	13	MMF	MMF	NNP
cord-034340-3ksfpaf7	1712	14	(	(	-LRB-
cord-034340-3ksfpaf7	1712	15	600mg/	600mg/	CD
cord-034340-3ksfpaf7	1712	16	m	m	CD
cord-034340-3ksfpaf7	1712	17	2	2	CD
cord-034340-3ksfpaf7	1712	18	/day	/day	.
cord-034340-3ksfpaf7	1712	19	)	)	-RRB-
cord-034340-3ksfpaf7	1712	20	and	and	CC
cord-034340-3ksfpaf7	1712	21	prednisone	prednisone	NNP
cord-034340-3ksfpaf7	1712	22	was	be	VBD
cord-034340-3ksfpaf7	1712	23	tapered	taper	VBN
cord-034340-3ksfpaf7	1712	24	in	in	IN
cord-034340-3ksfpaf7	1712	25	a	a	DT
cord-034340-3ksfpaf7	1712	26	month	month	NN
cord-034340-3ksfpaf7	1712	27	.	.	.
cord-034340-3ksfpaf7	1713	1	Results	result	NNS
cord-034340-3ksfpaf7	1713	2	:	:	:
cord-034340-3ksfpaf7	1714	1	Thanks	thank	NNS
cord-034340-3ksfpaf7	1714	2	to	to	IN
cord-034340-3ksfpaf7	1714	3	MMF	mmf	NN
cord-034340-3ksfpaf7	1714	4	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1714	5	lesions	lesion	NNS
cord-034340-3ksfpaf7	1714	6	and	and	CC
cord-034340-3ksfpaf7	1714	7	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1714	8	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1714	9	disappeared	disappear	VBD
cord-034340-3ksfpaf7	1714	10	in	in	IN
cord-034340-3ksfpaf7	1714	11	few	few	JJ
cord-034340-3ksfpaf7	1714	12	days	day	NNS
cord-034340-3ksfpaf7	1714	13	.	.	.
cord-034340-3ksfpaf7	1715	1	MMF	MMF	NNP
cord-034340-3ksfpaf7	1715	2	was	be	VBD
cord-034340-3ksfpaf7	1715	3	continued	continue	VBN
cord-034340-3ksfpaf7	1715	4	for	for	IN
cord-034340-3ksfpaf7	1715	5	a	a	DT
cord-034340-3ksfpaf7	1715	6	month	month	NN
cord-034340-3ksfpaf7	1715	7	,	,	,
cord-034340-3ksfpaf7	1715	8	tapered	taper	VBN
cord-034340-3ksfpaf7	1715	9	in	in	IN
cord-034340-3ksfpaf7	1715	10	6	6	CD
cord-034340-3ksfpaf7	1715	11	months	month	NNS
cord-034340-3ksfpaf7	1715	12	.	.	.
cord-034340-3ksfpaf7	1716	1	There	there	EX
cord-034340-3ksfpaf7	1716	2	was	be	VBD
cord-034340-3ksfpaf7	1716	3	no	no	DT
cord-034340-3ksfpaf7	1716	4	evidence	evidence	NN
cord-034340-3ksfpaf7	1716	5	of	of	IN
cord-034340-3ksfpaf7	1716	6	relapse	relapse	NN
cord-034340-3ksfpaf7	1716	7	in	in	IN
cord-034340-3ksfpaf7	1716	8	a	a	DT
cord-034340-3ksfpaf7	1716	9	6	6	CD
cord-034340-3ksfpaf7	1716	10	months	month	NNS
cord-034340-3ksfpaf7	1716	11	follow	follow	VBP
cord-034340-3ksfpaf7	1716	12	up	up	RP
cord-034340-3ksfpaf7	1716	13	.	.	.
cord-034340-3ksfpaf7	1717	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1717	2	:	:	:
cord-034340-3ksfpaf7	1717	3	These	these	DT
cord-034340-3ksfpaf7	1717	4	cases	case	NNS
cord-034340-3ksfpaf7	1717	5	suggest	suggest	VBP
cord-034340-3ksfpaf7	1717	6	that	that	IN
cord-034340-3ksfpaf7	1717	7	MMF	MMF	NNP
cord-034340-3ksfpaf7	1717	8	may	may	MD
cord-034340-3ksfpaf7	1717	9	be	be	VB
cord-034340-3ksfpaf7	1717	10	useful	useful	JJ
cord-034340-3ksfpaf7	1717	11	to	to	TO
cord-034340-3ksfpaf7	1717	12	induce	induce	VB
cord-034340-3ksfpaf7	1717	13	and	and	CC
cord-034340-3ksfpaf7	1717	14	maintain	maintain	VB
cord-034340-3ksfpaf7	1717	15	remission	remission	NN
cord-034340-3ksfpaf7	1717	16	of	of	IN
cord-034340-3ksfpaf7	1717	17	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	1717	18	HSP	HSP	NNP
cord-034340-3ksfpaf7	1717	19	with	with	IN
cord-034340-3ksfpaf7	1717	20	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1717	21	involvement	involvement	NN
cord-034340-3ksfpaf7	1717	22	.	.	.
cord-034340-3ksfpaf7	1718	1	Multicenter	multicenter	JJ
cord-034340-3ksfpaf7	1718	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	1718	3	trials	trial	NNS
cord-034340-3ksfpaf7	1718	4	with	with	IN
cord-034340-3ksfpaf7	1718	5	long	long	JJ
cord-034340-3ksfpaf7	1718	6	-	-	HYPH
cord-034340-3ksfpaf7	1718	7	term	term	NN
cord-034340-3ksfpaf7	1718	8	follow	follow	VB
cord-034340-3ksfpaf7	1718	9	up	up	RP
cord-034340-3ksfpaf7	1718	10	to	to	TO
cord-034340-3ksfpaf7	1718	11	confirm	confirm	VB
cord-034340-3ksfpaf7	1718	12	the	the	DT
cord-034340-3ksfpaf7	1718	13	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1718	14	of	of	IN
cord-034340-3ksfpaf7	1718	15	MMF	mmf	NN
cord-034340-3ksfpaf7	1718	16	in	in	IN
cord-034340-3ksfpaf7	1718	17	the	the	DT
cord-034340-3ksfpaf7	1718	18	treatment	treatment	NN
cord-034340-3ksfpaf7	1718	19	of	of	IN
cord-034340-3ksfpaf7	1718	20	HSP	HSP	NNP
cord-034340-3ksfpaf7	1718	21	with	with	IN
cord-034340-3ksfpaf7	1718	22	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	1718	23	involvement	involvement	NN
cord-034340-3ksfpaf7	1718	24	are	be	VBP
cord-034340-3ksfpaf7	1718	25	needed	need	VBN
cord-034340-3ksfpaf7	1718	26	.	.	.
cord-034340-3ksfpaf7	1719	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1719	2	:	:	:
cord-034340-3ksfpaf7	1720	1	Henoch	Henoch	NNP
cord-034340-3ksfpaf7	1720	2	-	-	HYPH
cord-034340-3ksfpaf7	1720	3	Schönlein	Schönlein	NNP
cord-034340-3ksfpaf7	1720	4	purpura	purpura	NN
cord-034340-3ksfpaf7	1720	5	(	(	-LRB-
cord-034340-3ksfpaf7	1720	6	HSP	HSP	NNP
cord-034340-3ksfpaf7	1720	7	)	)	-RRB-
cord-034340-3ksfpaf7	1720	8	,	,	,
cord-034340-3ksfpaf7	1720	9	the	the	DT
cord-034340-3ksfpaf7	1720	10	most	most	RBS
cord-034340-3ksfpaf7	1720	11	common	common	JJ
cord-034340-3ksfpaf7	1720	12	childhood	childhood	NN
cord-034340-3ksfpaf7	1720	13	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1720	14	.	.	.
cord-034340-3ksfpaf7	1721	1	Cholecystitis	Cholecystitis	NNP
cord-034340-3ksfpaf7	1721	2	is	be	VBZ
cord-034340-3ksfpaf7	1721	3	extremely	extremely	RB
cord-034340-3ksfpaf7	1721	4	rare	rare	JJ
cord-034340-3ksfpaf7	1721	5	in	in	IN
cord-034340-3ksfpaf7	1721	6	patients	patient	NNS
cord-034340-3ksfpaf7	1721	7	with	with	IN
cord-034340-3ksfpaf7	1721	8	HSP	HSP	NNP
cord-034340-3ksfpaf7	1721	9	.	.	.
cord-034340-3ksfpaf7	1722	1	This	this	DT
cord-034340-3ksfpaf7	1722	2	is	be	VBZ
cord-034340-3ksfpaf7	1722	3	the	the	DT
cord-034340-3ksfpaf7	1722	4	first	first	JJ
cord-034340-3ksfpaf7	1722	5	case	case	NN
cord-034340-3ksfpaf7	1722	6	of	of	IN
cord-034340-3ksfpaf7	1722	7	a	a	DT
cord-034340-3ksfpaf7	1722	8	Libyan	libyan	JJ
cord-034340-3ksfpaf7	1722	9	child	child	NN
cord-034340-3ksfpaf7	1722	10	presenting	present	VBG
cord-034340-3ksfpaf7	1722	11	with	with	IN
cord-034340-3ksfpaf7	1722	12	HSP	HSP	NNP
cord-034340-3ksfpaf7	1722	13	complicated	complicate	VBN
cord-034340-3ksfpaf7	1722	14	by	by	IN
cord-034340-3ksfpaf7	1722	15	calculus	calculus	NN
cord-034340-3ksfpaf7	1722	16	cholecystitis	cholecystitis	NN
cord-034340-3ksfpaf7	1722	17	HSP	HSP	NNP
cord-034340-3ksfpaf7	1722	18	nephritis	nephritis	NN
cord-034340-3ksfpaf7	1722	19	.	.	.
cord-034340-3ksfpaf7	1723	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1723	2	:	:	:
cord-034340-3ksfpaf7	1723	3	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1723	4	aim	aim	NN
cord-034340-3ksfpaf7	1723	5	is	be	VBZ
cord-034340-3ksfpaf7	1723	6	to	to	TO
cord-034340-3ksfpaf7	1723	7	present	present	VB
cord-034340-3ksfpaf7	1723	8	an	an	DT
cord-034340-3ksfpaf7	1723	9	unusual	unusual	JJ
cord-034340-3ksfpaf7	1723	10	case	case	NN
cord-034340-3ksfpaf7	1723	11	of	of	IN
cord-034340-3ksfpaf7	1723	12	gall	gall	NN
cord-034340-3ksfpaf7	1723	13	bladder	bladder	NN
cord-034340-3ksfpaf7	1723	14	involvement	involvement	NN
cord-034340-3ksfpaf7	1723	15	in	in	IN
cord-034340-3ksfpaf7	1723	16	an	an	DT
cord-034340-3ksfpaf7	1723	17	8-year	8-year	JJ
cord-034340-3ksfpaf7	1723	18	-	-	HYPH
cord-034340-3ksfpaf7	1723	19	old	old	JJ
cord-034340-3ksfpaf7	1723	20	Libyan	libyan	JJ
cord-034340-3ksfpaf7	1723	21	female	female	NN
cord-034340-3ksfpaf7	1723	22	affected	affect	VBN
cord-034340-3ksfpaf7	1723	23	by	by	IN
cord-034340-3ksfpaf7	1723	24	HSP	HSP	NNP
cord-034340-3ksfpaf7	1723	25	.	.	.
cord-034340-3ksfpaf7	1724	1	Methods	method	NNS
cord-034340-3ksfpaf7	1724	2	:	:	:
cord-034340-3ksfpaf7	1724	3	a	a	DT
cord-034340-3ksfpaf7	1724	4	case	case	NN
cord-034340-3ksfpaf7	1724	5	reports	report	VBZ
cord-034340-3ksfpaf7	1724	6	study	study	NN
cord-034340-3ksfpaf7	1724	7	Results	result	NNS
cord-034340-3ksfpaf7	1724	8	:	:	:
cord-034340-3ksfpaf7	1724	9	:	:	:
cord-034340-3ksfpaf7	1724	10	we	-PRON-	PRP
cord-034340-3ksfpaf7	1724	11	report	report	VBP
cord-034340-3ksfpaf7	1724	12	an	an	DT
cord-034340-3ksfpaf7	1724	13	unusual	unusual	JJ
cord-034340-3ksfpaf7	1724	14	case	case	NN
cord-034340-3ksfpaf7	1724	15	of	of	IN
cord-034340-3ksfpaf7	1724	16	gall	gall	NN
cord-034340-3ksfpaf7	1724	17	bladder	bladder	NN
cord-034340-3ksfpaf7	1724	18	involvement	involvement	NN
cord-034340-3ksfpaf7	1724	19	in	in	IN
cord-034340-3ksfpaf7	1724	20	an	an	DT
cord-034340-3ksfpaf7	1724	21	8-year	8-year	JJ
cord-034340-3ksfpaf7	1724	22	-	-	HYPH
cord-034340-3ksfpaf7	1724	23	old	old	JJ
cord-034340-3ksfpaf7	1724	24	Libyan	libyan	JJ
cord-034340-3ksfpaf7	1724	25	female	female	NN
cord-034340-3ksfpaf7	1724	26	with	with	IN
cord-034340-3ksfpaf7	1724	27	HSP	HSP	NNP
cord-034340-3ksfpaf7	1724	28	.	.	.
cord-034340-3ksfpaf7	1725	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1725	2	was	be	VBD
cord-034340-3ksfpaf7	1725	3	referred	refer	VBN
cord-034340-3ksfpaf7	1725	4	to	to	IN
cord-034340-3ksfpaf7	1725	5	a	a	DT
cord-034340-3ksfpaf7	1725	6	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1725	7	clinic	clinic	NN
cord-034340-3ksfpaf7	1725	8	due	due	IN
cord-034340-3ksfpaf7	1725	9	to	to	IN
cord-034340-3ksfpaf7	1725	10	HSP	HSP	NNP
cord-034340-3ksfpaf7	1725	11	with	with	IN
cord-034340-3ksfpaf7	1725	12	chronic	chronic	JJ
cord-034340-3ksfpaf7	1725	13	calculus	calculus	NN
cord-034340-3ksfpaf7	1725	14	cholecystitis	cholecystitis	NN
cord-034340-3ksfpaf7	1725	15	and	and	CC
cord-034340-3ksfpaf7	1725	16	distended	distend	VBD
cord-034340-3ksfpaf7	1725	17	small	small	JJ
cord-034340-3ksfpaf7	1725	18	bowel	bowel	NN
cord-034340-3ksfpaf7	1725	19	with	with	IN
cord-034340-3ksfpaf7	1725	20	fluid	fluid	JJ
cord-034340-3ksfpaf7	1725	21	-	-	HYPH
cord-034340-3ksfpaf7	1725	22	like	like	JJ
cord-034340-3ksfpaf7	1725	23	fecal	fecal	JJ
cord-034340-3ksfpaf7	1725	24	material	material	NN
cord-034340-3ksfpaf7	1725	25	with	with	IN
cord-034340-3ksfpaf7	1725	26	no	no	DT
cord-034340-3ksfpaf7	1725	27	evidence	evidence	NN
cord-034340-3ksfpaf7	1725	28	of	of	IN
cord-034340-3ksfpaf7	1725	29	intussusception	intussusception	NN
cord-034340-3ksfpaf7	1725	30	on	on	IN
cord-034340-3ksfpaf7	1725	31	an	an	DT
cord-034340-3ksfpaf7	1725	32	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1725	33	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	1725	34	.	.	.
cord-034340-3ksfpaf7	1726	1	The	the	DT
cord-034340-3ksfpaf7	1726	2	patient	patient	NN
cord-034340-3ksfpaf7	1726	3	had	have	VBD
cord-034340-3ksfpaf7	1726	4	a	a	DT
cord-034340-3ksfpaf7	1726	5	one	one	CD
cord-034340-3ksfpaf7	1726	6	-	-	HYPH
cord-034340-3ksfpaf7	1726	7	month	month	NN
cord-034340-3ksfpaf7	1726	8	history	history	NN
cord-034340-3ksfpaf7	1726	9	of	of	IN
cord-034340-3ksfpaf7	1726	10	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1726	11	pain	pain	NN
cord-034340-3ksfpaf7	1726	12	,	,	,
cord-034340-3ksfpaf7	1726	13	purpuric	purpuric	JJ
cord-034340-3ksfpaf7	1726	14	lesion	lesion	NN
cord-034340-3ksfpaf7	1726	15	on	on	IN
cord-034340-3ksfpaf7	1726	16	lower	low	JJR
cord-034340-3ksfpaf7	1726	17	limbs	limb	NNS
cord-034340-3ksfpaf7	1726	18	and	and	CC
cord-034340-3ksfpaf7	1726	19	swelling	swell	VBG
cord-034340-3ksfpaf7	1726	20	in	in	IN
cord-034340-3ksfpaf7	1726	21	both	both	DT
cord-034340-3ksfpaf7	1726	22	feet	foot	NNS
cord-034340-3ksfpaf7	1726	23	.	.	.
cord-034340-3ksfpaf7	1727	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1727	2	was	be	VBD
cord-034340-3ksfpaf7	1727	3	admitted	admit	VBN
cord-034340-3ksfpaf7	1727	4	3	3	CD
cord-034340-3ksfpaf7	1727	5	times	time	NNS
cord-034340-3ksfpaf7	1727	6	to	to	IN
cord-034340-3ksfpaf7	1727	7	another	another	DT
cord-034340-3ksfpaf7	1727	8	hospital	hospital	NN
cord-034340-3ksfpaf7	1727	9	before	before	IN
cord-034340-3ksfpaf7	1727	10	being	be	VBG
cord-034340-3ksfpaf7	1727	11	referred	refer	VBN
cord-034340-3ksfpaf7	1727	12	to	to	IN
cord-034340-3ksfpaf7	1727	13	the	the	DT
cord-034340-3ksfpaf7	1727	14	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1727	15	clinic	clinic	NN
cord-034340-3ksfpaf7	1727	16	.	.	.
cord-034340-3ksfpaf7	1728	1	An	an	DT
cord-034340-3ksfpaf7	1728	2	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1728	3	sonography	sonography	NN
cord-034340-3ksfpaf7	1728	4	revealed	reveal	VBD
cord-034340-3ksfpaf7	1728	5	a	a	DT
cord-034340-3ksfpaf7	1728	6	distended	distended	JJ
cord-034340-3ksfpaf7	1728	7	small	small	JJ
cord-034340-3ksfpaf7	1728	8	bowel	bowel	NN
cord-034340-3ksfpaf7	1728	9	with	with	IN
cord-034340-3ksfpaf7	1728	10	fluid	fluid	JJ
cord-034340-3ksfpaf7	1728	11	-	-	HYPH
cord-034340-3ksfpaf7	1728	12	like	like	JJ
cord-034340-3ksfpaf7	1728	13	fecal	fecal	JJ
cord-034340-3ksfpaf7	1728	14	material	material	NN
cord-034340-3ksfpaf7	1728	15	with	with	IN
cord-034340-3ksfpaf7	1728	16	no	no	DT
cord-034340-3ksfpaf7	1728	17	evidence	evidence	NN
cord-034340-3ksfpaf7	1728	18	of	of	IN
cord-034340-3ksfpaf7	1728	19	intussusception	intussusception	NN
cord-034340-3ksfpaf7	1728	20	and	and	CC
cord-034340-3ksfpaf7	1728	21	chronic	chronic	JJ
cord-034340-3ksfpaf7	1728	22	calculus	calculus	NN
cord-034340-3ksfpaf7	1728	23	cholecystitis	cholecystitis	NN
cord-034340-3ksfpaf7	1728	24	;	;	:
cord-034340-3ksfpaf7	1728	25	they	-PRON-	PRP
cord-034340-3ksfpaf7	1728	26	treated	treat	VBD
cord-034340-3ksfpaf7	1728	27	her	-PRON-	PRP
cord-034340-3ksfpaf7	1728	28	with	with	IN
cord-034340-3ksfpaf7	1728	29	Urosdoxycholic	urosdoxycholic	JJ
cord-034340-3ksfpaf7	1728	30	acid	acid	NN
cord-034340-3ksfpaf7	1728	31	tab	tab	NN
cord-034340-3ksfpaf7	1728	32	at	at	IN
cord-034340-3ksfpaf7	1728	33	250	250	CD
cord-034340-3ksfpaf7	1728	34	mg	mg	NN
cord-034340-3ksfpaf7	1728	35	per	per	IN
cord-034340-3ksfpaf7	1728	36	day	day	NN
cord-034340-3ksfpaf7	1728	37	and	and	CC
cord-034340-3ksfpaf7	1728	38	ibuprofen	ibuprofen	NN
cord-034340-3ksfpaf7	1728	39	syrup	syrup	NN
cord-034340-3ksfpaf7	1728	40	.	.	.
cord-034340-3ksfpaf7	1729	1	Then	then	RB
cord-034340-3ksfpaf7	1729	2	referred	refer	VBD
cord-034340-3ksfpaf7	1729	3	to	to	IN
cord-034340-3ksfpaf7	1729	4	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1729	5	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1729	6	clinic	clinic	NN
cord-034340-3ksfpaf7	1729	7	.	.	.
cord-034340-3ksfpaf7	1730	1	After	after	IN
cord-034340-3ksfpaf7	1730	2	40	40	CD
cord-034340-3ksfpaf7	1730	3	days	day	NNS
cord-034340-3ksfpaf7	1730	4	,	,	,
cord-034340-3ksfpaf7	1730	5	she	-PRON-	PRP
cord-034340-3ksfpaf7	1730	6	showed	show	VBD
cord-034340-3ksfpaf7	1730	7	a	a	DT
cord-034340-3ksfpaf7	1730	8	purpuric	purpuric	JJ
cord-034340-3ksfpaf7	1730	9	rash	rash	NN
cord-034340-3ksfpaf7	1730	10	over	over	IN
cord-034340-3ksfpaf7	1730	11	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1730	12	lower	low	JJR
cord-034340-3ksfpaf7	1730	13	extremities	extremity	NNS
cord-034340-3ksfpaf7	1730	14	,	,	,
cord-034340-3ksfpaf7	1730	15	mainly	mainly	RB
cord-034340-3ksfpaf7	1730	16	over	over	IN
cord-034340-3ksfpaf7	1730	17	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1730	18	thighs	thigh	NNS
cord-034340-3ksfpaf7	1730	19	and	and	CC
cord-034340-3ksfpaf7	1730	20	buttocks	buttock	NNS
cord-034340-3ksfpaf7	1730	21	,	,	,
cord-034340-3ksfpaf7	1730	22	microscopic	microscopic	JJ
cord-034340-3ksfpaf7	1730	23	hematuria	hematuria	NN
cord-034340-3ksfpaf7	1730	24	,	,	,
cord-034340-3ksfpaf7	1730	25	no	no	DT
cord-034340-3ksfpaf7	1730	26	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1730	27	,	,	,
cord-034340-3ksfpaf7	1730	28	no	no	DT
cord-034340-3ksfpaf7	1730	29	fever	fever	NN
cord-034340-3ksfpaf7	1730	30	,	,	,
cord-034340-3ksfpaf7	1730	31	no	no	DT
cord-034340-3ksfpaf7	1730	32	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	1730	33	pain	pain	NN
cord-034340-3ksfpaf7	1730	34	;	;	:
cord-034340-3ksfpaf7	1730	35	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1730	36	blood	blood	NN
cord-034340-3ksfpaf7	1730	37	pressure	pressure	NN
cord-034340-3ksfpaf7	1730	38	was	be	VBD
cord-034340-3ksfpaf7	1730	39	normal	normal	JJ
cord-034340-3ksfpaf7	1730	40	at90\55mmHg	at90\55mmhg	RB
cord-034340-3ksfpaf7	1730	41	,	,	,
cord-034340-3ksfpaf7	1730	42	and	and	CC
cord-034340-3ksfpaf7	1730	43	she	-PRON-	PRP
cord-034340-3ksfpaf7	1730	44	had	have	VBD
cord-034340-3ksfpaf7	1730	45	normal	normal	JJ
cord-034340-3ksfpaf7	1730	46	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1730	47	tests	test	NNS
cord-034340-3ksfpaf7	1730	48	(	(	-LRB-
cord-034340-3ksfpaf7	1730	49	CBC	CBC	NNP
cord-034340-3ksfpaf7	1730	50	,	,	,
cord-034340-3ksfpaf7	1730	51	WBC	WBC	NNP
cord-034340-3ksfpaf7	1730	52	7.7	7.7	CD
cord-034340-3ksfpaf7	1730	53	,	,	,
cord-034340-3ksfpaf7	1730	54	HGB	HGB	NNP
cord-034340-3ksfpaf7	1730	55	10.8	10.8	CD
cord-034340-3ksfpaf7	1730	56	,	,	,
cord-034340-3ksfpaf7	1730	57	Platelets	platelet	NNS
cord-034340-3ksfpaf7	1730	58	356	356	CD
cord-034340-3ksfpaf7	1730	59	ESR	ESR	NNP
cord-034340-3ksfpaf7	1730	60	20ml\hour	20ml\hour	CD
cord-034340-3ksfpaf7	1731	1	,	,	,
cord-034340-3ksfpaf7	1731	2	CRP	CRP	NNP
cord-034340-3ksfpaf7	1731	3	1mg\dl	1mg\dl	NNP
cord-034340-3ksfpaf7	1731	4	was	be	VBD
cord-034340-3ksfpaf7	1731	5	negative	negative	JJ
cord-034340-3ksfpaf7	1731	6	,	,	,
cord-034340-3ksfpaf7	1731	7	C3	C3	NNP
cord-034340-3ksfpaf7	1731	8	was	be	VBD
cord-034340-3ksfpaf7	1731	9	150mg\dl	150mg\dl	CD
cord-034340-3ksfpaf7	1731	10	within	within	IN
cord-034340-3ksfpaf7	1731	11	normal	normal	JJ
cord-034340-3ksfpaf7	1731	12	range	range	NN
cord-034340-3ksfpaf7	1732	1	90	90	CD
cord-034340-3ksfpaf7	1732	2	-	-	SYM
cord-034340-3ksfpaf7	1732	3	180mg\dl	180mg\dl	CD
cord-034340-3ksfpaf7	1732	4	,	,	,
cord-034340-3ksfpaf7	1732	5	C4	C4	NNP
cord-034340-3ksfpaf7	1732	6	was	be	VBD
cord-034340-3ksfpaf7	1732	7	35.4	35.4	CD
cord-034340-3ksfpaf7	1732	8	mg\dl	mg\dl	NN
cord-034340-3ksfpaf7	1732	9	within	within	IN
cord-034340-3ksfpaf7	1732	10	normal	normal	JJ
cord-034340-3ksfpaf7	1732	11	range	range	NN
cord-034340-3ksfpaf7	1732	12	10	10	CD
cord-034340-3ksfpaf7	1732	13	-	-	SYM
cord-034340-3ksfpaf7	1732	14	40	40	CD
cord-034340-3ksfpaf7	1732	15	,	,	,
cord-034340-3ksfpaf7	1732	16	ANCA	ANCA	NNP
cord-034340-3ksfpaf7	1732	17	,	,	,
cord-034340-3ksfpaf7	1732	18	ANA	ANA	NNP
cord-034340-3ksfpaf7	1732	19	,	,	,
cord-034340-3ksfpaf7	1732	20	as	as	RB
cord-034340-3ksfpaf7	1732	21	well	well	RB
cord-034340-3ksfpaf7	1732	22	AntidsDNA	AntidsDNA	.
cord-034340-3ksfpaf7	1733	1	Ab	Ab	NNP
cord-034340-3ksfpaf7	1733	2	yielded	yield	VBD
cord-034340-3ksfpaf7	1733	3	negative	negative	JJ
cord-034340-3ksfpaf7	1733	4	,	,	,
cord-034340-3ksfpaf7	1733	5	Antistreptolysin	Antistreptolysin	NNP
cord-034340-3ksfpaf7	1733	6	-	-	HYPH
cord-034340-3ksfpaf7	1733	7	O	O	NNP
cord-034340-3ksfpaf7	1733	8	(	(	-LRB-
cord-034340-3ksfpaf7	1733	9	ASO	ASO	NNP
cord-034340-3ksfpaf7	1733	10	)	)	-RRB-
cord-034340-3ksfpaf7	1733	11	titer	titer	NN
cord-034340-3ksfpaf7	1733	12	was	be	VBD
cord-034340-3ksfpaf7	1733	13	250	250	CD
cord-034340-3ksfpaf7	1733	14	Todd	Todd	NNP
cord-034340-3ksfpaf7	1733	15	,	,	,
cord-034340-3ksfpaf7	1733	16	LFT	LFT	NNP
cord-034340-3ksfpaf7	1733	17	included	include	VBD
cord-034340-3ksfpaf7	1733	18	total	total	JJ
cord-034340-3ksfpaf7	1733	19	bilirubin	bilirubin	NN
cord-034340-3ksfpaf7	1733	20	,	,	,
cord-034340-3ksfpaf7	1733	21	direct	direct	JJ
cord-034340-3ksfpaf7	1733	22	,	,	,
cord-034340-3ksfpaf7	1733	23	indirect	indirect	JJ
cord-034340-3ksfpaf7	1733	24	GPT	gpt	NN
cord-034340-3ksfpaf7	1733	25	,	,	,
cord-034340-3ksfpaf7	1733	26	GOT	GOT	NNP
cord-034340-3ksfpaf7	1733	27	,	,	,
cord-034340-3ksfpaf7	1733	28	U	U	NNP
cord-034340-3ksfpaf7	1733	29	,	,	,
cord-034340-3ksfpaf7	1733	30	creatinine	creatinine	NN
cord-034340-3ksfpaf7	1733	31	)	)	-RRB-
cord-034340-3ksfpaf7	1733	32	except	except	IN
cord-034340-3ksfpaf7	1733	33	urine	urine	NN
cord-034340-3ksfpaf7	1733	34	routine	routine	NN
cord-034340-3ksfpaf7	1733	35	showed	show	VBD
cord-034340-3ksfpaf7	1733	36	mild	mild	JJ
cord-034340-3ksfpaf7	1733	37	microscopic	microscopic	JJ
cord-034340-3ksfpaf7	1733	38	hematuria	hematuria	NN
cord-034340-3ksfpaf7	1733	39	RBC	RBC	NNP
cord-034340-3ksfpaf7	1733	40	100	100	CD
cord-034340-3ksfpaf7	1733	41	HPF	HPF	NNP
cord-034340-3ksfpaf7	1733	42	,	,	,
cord-034340-3ksfpaf7	1733	43	protein	protein	NN
cord-034340-3ksfpaf7	1733	44	was	be	VBD
cord-034340-3ksfpaf7	1733	45	Nil	nil	NN
cord-034340-3ksfpaf7	1733	46	)	)	-RRB-
cord-034340-3ksfpaf7	1733	47	urine	urine	NN
cord-034340-3ksfpaf7	1733	48	for	for	IN
cord-034340-3ksfpaf7	1733	49	pro	pro	JJ
cord-034340-3ksfpaf7	1733	50	-	-	JJ
cord-034340-3ksfpaf7	1733	51	tein	tein	JJ
cord-034340-3ksfpaf7	1733	52	Disclosure	Disclosure	NNP
cord-034340-3ksfpaf7	1733	53	of	of	IN
cord-034340-3ksfpaf7	1733	54	Interest	Interest	NNP
cord-034340-3ksfpaf7	1734	1	None	none	NN
cord-034340-3ksfpaf7	1734	2	declared	declare	VBD
cord-034340-3ksfpaf7	1734	3	P161	P161	NNP
cord-034340-3ksfpaf7	1734	4	Correlation	correlation	NN
cord-034340-3ksfpaf7	1734	5	of	of	IN
cord-034340-3ksfpaf7	1734	6	serum	serum	NN
cord-034340-3ksfpaf7	1734	7	neopterin	neopterin	JJ
cord-034340-3ksfpaf7	1734	8	levels	level	NNS
cord-034340-3ksfpaf7	1734	9	with	with	IN
cord-034340-3ksfpaf7	1734	10	disease	disease	NN
cord-034340-3ksfpaf7	1734	11	activity	activity	NN
cord-034340-3ksfpaf7	1734	12	and	and	CC
cord-034340-3ksfpaf7	1734	13	Moneta	Moneta	NNP
cord-034340-3ksfpaf7	1734	14	1	1	CD
cord-034340-3ksfpaf7	1734	15	1	1	CD
cord-034340-3ksfpaf7	1734	16	Division	Division	NNP
cord-034340-3ksfpaf7	1734	17	of	of	IN
cord-034340-3ksfpaf7	1734	18	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1734	19	,	,	,
cord-034340-3ksfpaf7	1734	20	IRCCS	IRCCS	NNP
cord-034340-3ksfpaf7	1734	21	,	,	,
cord-034340-3ksfpaf7	1734	22	Ospedale	Ospedale	NNP
cord-034340-3ksfpaf7	1734	23	Pediatrico	Pediatrico	NNP
cord-034340-3ksfpaf7	1734	24	Bambino	Bambino	NNP
cord-034340-3ksfpaf7	1734	25	Gesù	Gesù	NNP
cord-034340-3ksfpaf7	1734	26	,	,	,
cord-034340-3ksfpaf7	1734	27	Roma	Roma	NNP
cord-034340-3ksfpaf7	1734	28	;	;	:
cord-034340-3ksfpaf7	1734	29	2	2	CD
cord-034340-3ksfpaf7	1734	30	University	University	NNP
cord-034340-3ksfpaf7	1734	31	of	of	IN
cord-034340-3ksfpaf7	1734	32	Genova	Genova	NNP
cord-034340-3ksfpaf7	1734	33	A	a	DT
cord-034340-3ksfpaf7	1734	34	multinational	multinational	JJ
cord-034340-3ksfpaf7	1734	35	study	study	NN
cord-034340-3ksfpaf7	1734	36	of	of	IN
cord-034340-3ksfpaf7	1734	37	thrombotic	thrombotic	JJ
cord-034340-3ksfpaf7	1734	38	microangiopathy	microangiopathy	NNP
cord-034340-3ksfpaf7	1734	39	in	in	IN
cord-034340-3ksfpaf7	1734	40	macrophage	macrophage	NN
cord-034340-3ksfpaf7	1734	41	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1734	42	Clinical	clinical	JJ
cord-034340-3ksfpaf7	1734	43	impact	impact	NN
cord-034340-3ksfpaf7	1734	44	of	of	IN
cord-034340-3ksfpaf7	1734	45	a	a	DT
cord-034340-3ksfpaf7	1734	46	targeted	target	VBN
cord-034340-3ksfpaf7	1734	47	next	next	JJ
cord-034340-3ksfpaf7	1734	48	-	-	HYPH
cord-034340-3ksfpaf7	1734	49	generation	generation	NN
cord-034340-3ksfpaf7	1734	50	sequencing	sequencing	NN
cord-034340-3ksfpaf7	1734	51	gene	gene	NN
cord-034340-3ksfpaf7	1734	52	panel	panel	NN
cord-034340-3ksfpaf7	1734	53	for	for	IN
cord-034340-3ksfpaf7	1734	54	autoinflammation	autoinflammation	NN
cord-034340-3ksfpaf7	1734	55	and	and	CC
cord-034340-3ksfpaf7	1734	56	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1734	57	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	1734	58	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	1734	59	to	to	TO
cord-034340-3ksfpaf7	1734	60	facilitate	facilitate	VB
cord-034340-3ksfpaf7	1734	61	differential	differential	JJ
cord-034340-3ksfpaf7	1734	62	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1734	63	between	between	IN
cord-034340-3ksfpaf7	1734	64	measles	measle	NNS
cord-034340-3ksfpaf7	1734	65	and	and	CC
cord-034340-3ksfpaf7	1734	66	kawasaki	kawasaki	NNP
cord-034340-3ksfpaf7	1734	67	disease	disease	NN
cord-034340-3ksfpaf7	1734	68	in	in	IN
cord-034340-3ksfpaf7	1734	69	a	a	DT
cord-034340-3ksfpaf7	1734	70	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1734	71	emergency	emergency	NN
cord-034340-3ksfpaf7	1734	72	room	room	NN
cord-034340-3ksfpaf7	1734	73	:	:	:
cord-034340-3ksfpaf7	1735	1	A	a	DT
cord-034340-3ksfpaf7	1735	2	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1735	3	study	study	NN
cord-034340-3ksfpaf7	1735	4	A	a	DT
cord-034340-3ksfpaf7	1735	5	rare	rare	JJ
cord-034340-3ksfpaf7	1735	6	case	case	NN
cord-034340-3ksfpaf7	1735	7	of	of	IN
cord-034340-3ksfpaf7	1735	8	measles	measles	NN
cord-034340-3ksfpaf7	1735	9	-	-	HYPH
cord-034340-3ksfpaf7	1735	10	associated	associate	VBN
cord-034340-3ksfpaf7	1735	11	hemophagocytic	hemophagocytic	JJ
cord-034340-3ksfpaf7	1735	12	lymphohistiocytosis	lymphohistiocytosis	NN
cord-034340-3ksfpaf7	1735	13	in	in	IN
cord-034340-3ksfpaf7	1735	14	an	an	DT
cord-034340-3ksfpaf7	1735	15	infant	infant	NN
cord-034340-3ksfpaf7	1735	16	.	.	.
cord-034340-3ksfpaf7	1736	1	Cureus	Cureus	NNP
cord-034340-3ksfpaf7	1736	2	Children	Children	NNP
cord-034340-3ksfpaf7	1736	3	's	's	POS
cord-034340-3ksfpaf7	1736	4	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	1736	5	and	and	CC
cord-034340-3ksfpaf7	1736	6	diffuse	diffuse	JJ
cord-034340-3ksfpaf7	1736	7	lung	lung	NN
cord-034340-3ksfpaf7	1736	8	disease	disease	NN
cord-034340-3ksfpaf7	1736	9	Respiratory	Respiratory	NNP
cord-034340-3ksfpaf7	1736	10	Complications	complication	NNS
cord-034340-3ksfpaf7	1736	11	of	of	IN
cord-034340-3ksfpaf7	1736	12	the	the	DT
cord-034340-3ksfpaf7	1736	13	rheumatological	rheumatological	JJ
cord-034340-3ksfpaf7	1736	14	diseases	disease	NNS
cord-034340-3ksfpaf7	1736	15	in	in	IN
cord-034340-3ksfpaf7	1736	16	childhood	childhood	NN
cord-034340-3ksfpaf7	1736	17	on	on	IN
cord-034340-3ksfpaf7	1736	18	behalf	behalf	NN
cord-034340-3ksfpaf7	1736	19	of	of	IN
cord-034340-3ksfpaf7	1736	20	Dr	Dr	NNP
cord-034340-3ksfpaf7	1736	21	Nishant	Nishant	NNP
cord-034340-3ksfpaf7	1736	22	Dharsandiya	Dharsandiya	NNP
cord-034340-3ksfpaf7	1736	23	and	and	CC
cord-034340-3ksfpaf7	1736	24	Dr	Dr	NNP
cord-034340-3ksfpaf7	1736	25	J.P.	J.P.	NNP
cord-034340-3ksfpaf7	1736	26	Keshrani	Keshrani	NNP
cord-034340-3ksfpaf7	1736	27	Paediatric	Paediatric	NNP
cord-034340-3ksfpaf7	1736	28	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1736	29	&	&	CC
cord-034340-3ksfpaf7	1736	30	Immunology	Immunology	NNP
cord-034340-3ksfpaf7	1736	31	,	,	,
cord-034340-3ksfpaf7	1736	32	Dev	Dev	NNP
cord-034340-3ksfpaf7	1736	33	Children	Children	NNP
cord-034340-3ksfpaf7	1736	34	's	's	POS
cord-034340-3ksfpaf7	1736	35	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	1736	36	Arthritis	arthritis	NN
cord-034340-3ksfpaf7	1736	37	Care	care	NN
cord-034340-3ksfpaf7	1736	38	Res	Res	NNP
cord-034340-3ksfpaf7	1736	39	(	(	-LRB-
cord-034340-3ksfpaf7	1736	40	Hoboken	Hoboken	NNP
cord-034340-3ksfpaf7	1736	41	)	)	-RRB-
cord-034340-3ksfpaf7	1736	42	Disclosure	Disclosure	NNP
cord-034340-3ksfpaf7	1736	43	of	of	IN
cord-034340-3ksfpaf7	1736	44	Interest	Interest	NNP
cord-034340-3ksfpaf7	1736	45	:	:	:
cord-034340-3ksfpaf7	1737	1	None	none	NN
cord-034340-3ksfpaf7	1737	2	declared	declare	VBD
cord-034340-3ksfpaf7	1737	3	Development	Development	NNP
cord-034340-3ksfpaf7	1737	4	and	and	CC
cord-034340-3ksfpaf7	1737	5	initial	initial	JJ
cord-034340-3ksfpaf7	1737	6	validation	validation	NN
cord-034340-3ksfpaf7	1737	7	of	of	IN
cord-034340-3ksfpaf7	1737	8	the	the	DT
cord-034340-3ksfpaf7	1737	9	MS	MS	NNP
cord-034340-3ksfpaf7	1737	10	score	score	NN
cord-034340-3ksfpaf7	1737	11	for	for	IN
cord-034340-3ksfpaf7	1737	12	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1737	13	of	of	IN
cord-034340-3ksfpaf7	1737	14	macrophage	macrophage	NN
cord-034340-3ksfpaf7	1737	15	activation	activation	NN
cord-034340-3ksfpaf7	1737	16	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1737	17	in	in	IN
cord-034340-3ksfpaf7	1737	18	systemic	systemic	JJ
cord-034340-3ksfpaf7	1737	19	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1737	20	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1737	21	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1737	22	Development	Development	NNP
cord-034340-3ksfpaf7	1737	23	and	and	CC
cord-034340-3ksfpaf7	1737	24	validation	validation	NN
cord-034340-3ksfpaf7	1737	25	of	of	IN
cord-034340-3ksfpaf7	1737	26	the	the	DT
cord-034340-3ksfpaf7	1737	27	HScore	HScore	NNP
cord-034340-3ksfpaf7	1737	28	,	,	,
cord-034340-3ksfpaf7	1737	29	a	a	DT
cord-034340-3ksfpaf7	1737	30	score	score	NN
cord-034340-3ksfpaf7	1737	31	for	for	IN
cord-034340-3ksfpaf7	1737	32	the	the	DT
cord-034340-3ksfpaf7	1737	33	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1737	34	of	of	IN
cord-034340-3ksfpaf7	1737	35	reactive	reactive	JJ
cord-034340-3ksfpaf7	1737	36	hemophagocytic	hemophagocytic	JJ
cord-034340-3ksfpaf7	1737	37	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1737	38	double	double	RB
cord-034340-3ksfpaf7	1737	39	-	-	HYPH
cord-034340-3ksfpaf7	1737	40	blind	blind	JJ
cord-034340-3ksfpaf7	1737	41	,	,	,
cord-034340-3ksfpaf7	1737	42	placebo	placebo	NN
cord-034340-3ksfpaf7	1737	43	-	-	HYPH
cord-034340-3ksfpaf7	1737	44	controlled	control	VBN
cord-034340-3ksfpaf7	1737	45	study	study	NN
cord-034340-3ksfpaf7	1737	46	of	of	IN
cord-034340-3ksfpaf7	1737	47	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	1737	48	in	in	IN
cord-034340-3ksfpaf7	1737	49	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1737	50	and	and	CC
cord-034340-3ksfpaf7	1737	51	adult	adult	NN
cord-034340-3ksfpaf7	1737	52	patients	patient	NNS
cord-034340-3ksfpaf7	1737	53	with	with	IN
cord-034340-3ksfpaf7	1737	54	Still	Still	NNP
cord-034340-3ksfpaf7	1737	55	's	's	POS
cord-034340-3ksfpaf7	1737	56	disease	disease	NN
cord-034340-3ksfpaf7	1737	57	L.	L.	NNP
cord-034340-3ksfpaf7	1737	58	Schanberg	Schanberg	NNP
cord-034340-3ksfpaf7	1737	59	1	1	CD
cord-034340-3ksfpaf7	1737	60	,	,	,
cord-034340-3ksfpaf7	1737	61	P.	P.	NNP
cord-034340-3ksfpaf7	1737	62	Nigrovic	Nigrovic	NNP
cord-034340-3ksfpaf7	1737	63	2	2	CD
cord-034340-3ksfpaf7	1737	64	Duke	Duke	NNP
cord-034340-3ksfpaf7	1737	65	Children	Children	NNPS
cord-034340-3ksfpaf7	1737	66	's	's	POS
cord-034340-3ksfpaf7	1737	67	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	1737	68	&	&	CC
cord-034340-3ksfpaf7	1737	69	Health	Health	NNP
cord-034340-3ksfpaf7	1737	70	Center	Center	NNP
cord-034340-3ksfpaf7	1737	71	,	,	,
cord-034340-3ksfpaf7	1737	72	Durham	Durham	NNP
cord-034340-3ksfpaf7	1737	73	;	;	:
cord-034340-3ksfpaf7	1737	74	2	2	CD
cord-034340-3ksfpaf7	1737	75	Boston	Boston	NNP
cord-034340-3ksfpaf7	1737	76	Children	Children	NNPS
cord-034340-3ksfpaf7	1737	77	's	's	POS
cord-034340-3ksfpaf7	1737	78	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	1737	79	,	,	,
cord-034340-3ksfpaf7	1737	80	Boston	Boston	NNP
cord-034340-3ksfpaf7	1737	81	;	;	:
cord-034340-3ksfpaf7	1737	82	3	3	CD
cord-034340-3ksfpaf7	1737	83	Children	Children	NNPS
cord-034340-3ksfpaf7	1737	84	's	's	POS
cord-034340-3ksfpaf7	1737	85	Mercy	Mercy	NNP
cord-034340-3ksfpaf7	1737	86	Kansas	Kansas	NNP
cord-034340-3ksfpaf7	1737	87	City	City	NNP
cord-034340-3ksfpaf7	1737	88	,	,	,
cord-034340-3ksfpaf7	1737	89	Kansas	Kansas	NNP
cord-034340-3ksfpaf7	1737	90	City	City	NNP
cord-034340-3ksfpaf7	1737	91	;	;	:
cord-034340-3ksfpaf7	1737	92	4	4	CD
cord-034340-3ksfpaf7	1737	93	University	University	NNP
cord-034340-3ksfpaf7	1737	94	of	of	IN
cord-034340-3ksfpaf7	1737	95	Alabama	Alabama	NNP
cord-034340-3ksfpaf7	1737	96	at	at	IN
cord-034340-3ksfpaf7	1737	97	Birmingham	Birmingham	NNP
cord-034340-3ksfpaf7	1737	98	,	,	,
cord-034340-3ksfpaf7	1737	99	Birmingham	Birmingham	NNP
cord-034340-3ksfpaf7	1737	100	;	;	:
cord-034340-3ksfpaf7	1737	101	5	5	CD
cord-034340-3ksfpaf7	1737	102	Nationwide	Nationwide	NNP
cord-034340-3ksfpaf7	1737	103	Children	Children	NNPS
cord-034340-3ksfpaf7	1737	104	's	's	POS
cord-034340-3ksfpaf7	1737	105	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	1737	106	,	,	,
cord-034340-3ksfpaf7	1737	107	Columbus	Columbus	NNP
cord-034340-3ksfpaf7	1737	108	;	;	:
cord-034340-3ksfpaf7	1737	109	6	6	CD
cord-034340-3ksfpaf7	1737	110	University	University	NNP
cord-034340-3ksfpaf7	1737	111	of	of	IN
cord-034340-3ksfpaf7	1737	112	Iowa	Iowa	NNP
cord-034340-3ksfpaf7	1737	113	Hospitals	Hospitals	NNPS
cord-034340-3ksfpaf7	1737	114	and	and	CC
cord-034340-3ksfpaf7	1737	115	Clinics	Clinics	NNPS
cord-034340-3ksfpaf7	1737	116	Children	Children	NNPS
cord-034340-3ksfpaf7	1737	117	and	and	CC
cord-034340-3ksfpaf7	1737	118	adolescents	adolescent	NNS
cord-034340-3ksfpaf7	1737	119	with	with	IN
cord-034340-3ksfpaf7	1737	120	SLE	SLE	NNP
cord-034340-3ksfpaf7	1737	121	:	:	:
cord-034340-3ksfpaf7	1737	122	not	not	RB
cord-034340-3ksfpaf7	1737	123	just	just	RB
cord-034340-3ksfpaf7	1737	124	little	little	JJ
cord-034340-3ksfpaf7	1737	125	adults	adult	NNS
cord-034340-3ksfpaf7	1738	1	Severe	severe	JJ
cord-034340-3ksfpaf7	1738	2	disease	disease	NN
cord-034340-3ksfpaf7	1738	3	presentation	presentation	NN
cord-034340-3ksfpaf7	1738	4	and	and	CC
cord-034340-3ksfpaf7	1738	5	poor	poor	JJ
cord-034340-3ksfpaf7	1738	6	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1738	7	among	among	IN
cord-034340-3ksfpaf7	1738	8	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1738	9	systemic	systemic	JJ
cord-034340-3ksfpaf7	1738	10	lupus	lupus	NN
cord-034340-3ksfpaf7	1738	11	erythematosus	erythematosus	NN
cord-034340-3ksfpaf7	1738	12	patients	patient	NNS
cord-034340-3ksfpaf7	1738	13	in	in	IN
cord-034340-3ksfpaf7	1738	14	South	South	NNP
cord-034340-3ksfpaf7	1738	15	Africa	Africa	NNP
cord-034340-3ksfpaf7	1739	1	The	the	DT
cord-034340-3ksfpaf7	1739	2	Checklist	Checklist	NNP
cord-034340-3ksfpaf7	1739	3	Manifesto	Manifesto	NNP
cord-034340-3ksfpaf7	1739	4	:	:	:
cord-034340-3ksfpaf7	1739	5	How	how	WRB
cord-034340-3ksfpaf7	1739	6	to	to	TO
cord-034340-3ksfpaf7	1739	7	Get	get	VB
cord-034340-3ksfpaf7	1739	8	Things	thing	NNS
cord-034340-3ksfpaf7	1740	1	Right	Right	NNP
cord-034340-3ksfpaf7	1740	2	Clinical	clinical	JJ
cord-034340-3ksfpaf7	1740	3	review	review	NN
cord-034340-3ksfpaf7	1740	4	:	:	:
cord-034340-3ksfpaf7	1741	1	Checklists	checklist	NNS
cord-034340-3ksfpaf7	1741	2	-translating	-translate	VBG
cord-034340-3ksfpaf7	1741	3	evidence	evidence	NN
cord-034340-3ksfpaf7	1741	4	into	into	IN
cord-034340-3ksfpaf7	1741	5	practice	practice	NN
cord-034340-3ksfpaf7	1742	1	The	the	DT
cord-034340-3ksfpaf7	1742	2	WHO	WHO	NNP
cord-034340-3ksfpaf7	1742	3	surgical	surgical	JJ
cord-034340-3ksfpaf7	1742	4	safety	safety	NN
cord-034340-3ksfpaf7	1742	5	checklist	checklist	NN
cord-034340-3ksfpaf7	1742	6	:	:	:
cord-034340-3ksfpaf7	1742	7	a	a	DT
cord-034340-3ksfpaf7	1742	8	review	review	NN
cord-034340-3ksfpaf7	1742	9	Pehlivanoğlu	Pehlivanoğlu	NNP
cord-034340-3ksfpaf7	1743	1	3	3	LS
cord-034340-3ksfpaf7	1743	2	P283	P283	NNP
cord-034340-3ksfpaf7	1743	3	Gastrointestinal	Gastrointestinal	NNP
cord-034340-3ksfpaf7	1743	4	Henoch	Henoch	NNP
cord-034340-3ksfpaf7	1743	5	-	-	HYPH
cord-034340-3ksfpaf7	1743	6	Schönlein	Schönlein	NNP
cord-034340-3ksfpaf7	1743	7	purpura	purpura	NN
cord-034340-3ksfpaf7	1743	8	treated	treat	VBN
cord-034340-3ksfpaf7	1743	9	with	with	IN
cord-034340-3ksfpaf7	1743	10	mycophenolate	mycophenolate	NNP
cord-034340-3ksfpaf7	1743	11	mofetil	mofetil	NNP
cord-034340-3ksfpaf7	1743	12	:	:	:
cord-034340-3ksfpaf7	1743	13	description	description	NN
cord-034340-3ksfpaf7	1743	14	of	of	IN
cord-034340-3ksfpaf7	1743	15	two	two	CD
cord-034340-3ksfpaf7	1743	16	case	case	NN
cord-034340-3ksfpaf7	1743	17	reports	report	VBZ
cord-034340-3ksfpaf7	1743	18	Venous	venous	JJ
cord-034340-3ksfpaf7	1743	19	vessel	vessel	NN
cord-034340-3ksfpaf7	1743	20	wall	wall	NN
cord-034340-3ksfpaf7	1743	21	thickness	thickness	NN
cord-034340-3ksfpaf7	1743	22	in	in	IN
cord-034340-3ksfpaf7	1743	23	lower	low	JJR
cord-034340-3ksfpaf7	1743	24	extremity	extremity	NN
cord-034340-3ksfpaf7	1743	25	is	be	VBZ
cord-034340-3ksfpaf7	1743	26	increased	increase	VBN
cord-034340-3ksfpaf7	1743	27	in	in	IN
cord-034340-3ksfpaf7	1743	28	male	male	JJ
cord-034340-3ksfpaf7	1743	29	patients	patient	NNS
cord-034340-3ksfpaf7	1743	30	with	with	IN
cord-034340-3ksfpaf7	1743	31	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	1743	32	's	's	POS
cord-034340-3ksfpaf7	1743	33	disease	disease	NN
cord-034340-3ksfpaf7	1743	34	Increased	increase	VBN
cord-034340-3ksfpaf7	1743	35	vein	vein	NN
cord-034340-3ksfpaf7	1743	36	wall	wall	NN
cord-034340-3ksfpaf7	1743	37	thickness	thickness	NN
cord-034340-3ksfpaf7	1743	38	in	in	IN
cord-034340-3ksfpaf7	1744	1	Behçet	Behçet	NNP
cord-034340-3ksfpaf7	1744	2	disease	disease	NN
cord-034340-3ksfpaf7	1744	3	Polyarteritis	Polyarteritis	NNP
cord-034340-3ksfpaf7	1745	1	nodosa	nodosa	RB
cord-034340-3ksfpaf7	1745	2	:	:	:
cord-034340-3ksfpaf7	1746	1	A	a	DT
cord-034340-3ksfpaf7	1746	2	contemporary	contemporary	JJ
cord-034340-3ksfpaf7	1746	3	overview	overview	NN
cord-034340-3ksfpaf7	1746	4	EULAR	EULAR	NNP
cord-034340-3ksfpaf7	1746	5	/	/	SYM
cord-034340-3ksfpaf7	1746	6	PRINTO	PRINTO	NNP
cord-034340-3ksfpaf7	1746	7	/	/	SYM
cord-034340-3ksfpaf7	1746	8	PRES	PRES	NNP
cord-034340-3ksfpaf7	1746	9	criteria	criterion	NNS
cord-034340-3ksfpaf7	1746	10	for	for	IN
cord-034340-3ksfpaf7	1746	11	Henoch	Henoch	NNP
cord-034340-3ksfpaf7	1746	12	-Schönlein	-Schönlein	NNP
cord-034340-3ksfpaf7	1746	13	purpura	purpura	NN
cord-034340-3ksfpaf7	1746	14	,	,	,
cord-034340-3ksfpaf7	1746	15	childhood	childhood	NN
cord-034340-3ksfpaf7	1746	16	polyarteritis	polyarteritis	NNP
cord-034340-3ksfpaf7	1746	17	nodosa	nodosa	NNP
cord-034340-3ksfpaf7	1746	18	,	,	,
cord-034340-3ksfpaf7	1746	19	childhood	childhood	NN
cord-034340-3ksfpaf7	1746	20	Wegener	Wegener	NNP
cord-034340-3ksfpaf7	1746	21	granulomatosis	granulomatosis	NN
cord-034340-3ksfpaf7	1746	22	and	and	CC
cord-034340-3ksfpaf7	1747	1	childhood	childhood	NN
cord-034340-3ksfpaf7	1747	2	Takayasu	Takayasu	NNP
cord-034340-3ksfpaf7	1747	3	arteritis	arteritis	NN
cord-034340-3ksfpaf7	1747	4	:	:	:
cord-034340-3ksfpaf7	1748	1	Ankara	Ankara	NNP
cord-034340-3ksfpaf7	1748	2	Six	six	CD
cord-034340-3ksfpaf7	1748	3	patients	patient	NNS
cord-034340-3ksfpaf7	1748	4	were	be	VBD
cord-034340-3ksfpaf7	1748	5	treated	treat	VBN
cord-034340-3ksfpaf7	1748	6	with	with	IN
cord-034340-3ksfpaf7	1748	7	canakinumab	canakinumab	NNS
cord-034340-3ksfpaf7	1748	8	and	and	CC
cord-034340-3ksfpaf7	1748	9	2	2	CD
cord-034340-3ksfpaf7	1748	10	patients	patient	NNS
cord-034340-3ksfpaf7	1748	11	with	with	IN
cord-034340-3ksfpaf7	1748	12	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	1748	13	.	.	.
cord-034340-3ksfpaf7	1749	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1749	2	:	:	:
cord-034340-3ksfpaf7	1750	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1750	2	is	be	VBZ
cord-034340-3ksfpaf7	1750	3	known	know	VBN
cord-034340-3ksfpaf7	1750	4	that	that	IN
cord-034340-3ksfpaf7	1750	5	excessive	excessive	JJ
cord-034340-3ksfpaf7	1750	6	production	production	NN
cord-034340-3ksfpaf7	1750	7	of	of	IN
cord-034340-3ksfpaf7	1750	8	IL-1β	il-1β	NN
cord-034340-3ksfpaf7	1750	9	can	can	MD
cord-034340-3ksfpaf7	1750	10	cause	cause	VB
cord-034340-3ksfpaf7	1750	11	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1750	12	bone	bone	NN
cord-034340-3ksfpaf7	1750	13	loss	loss	NN
cord-034340-3ksfpaf7	1750	14	and	and	CC
cord-034340-3ksfpaf7	1750	15	abnormality	abnormality	NN
cord-034340-3ksfpaf7	1750	16	.	.	.
cord-034340-3ksfpaf7	1751	1	Vitamin	vitamin	NN
cord-034340-3ksfpaf7	1751	2	D	d	NN
cord-034340-3ksfpaf7	1751	3	deficiency	deficiency	NN
cord-034340-3ksfpaf7	1751	4	and	and	CC
cord-034340-3ksfpaf7	1751	5	osteopenia/	osteopenia/	CD
cord-034340-3ksfpaf7	1751	6	osteoporosis	osteoporosis	NN
cord-034340-3ksfpaf7	1751	7	may	may	MD
cord-034340-3ksfpaf7	1751	8	cause	cause	VB
cord-034340-3ksfpaf7	1751	9	additional	additional	JJ
cord-034340-3ksfpaf7	1751	10	musculoskeletal	musculoskeletal	JJ
cord-034340-3ksfpaf7	1751	11	problems	problem	NNS
cord-034340-3ksfpaf7	1751	12	besides	besides	IN
cord-034340-3ksfpaf7	1751	13	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1751	14	and	and	CC
cord-034340-3ksfpaf7	1751	15	joint	joint	JJ
cord-034340-3ksfpaf7	1751	16	destruction	destruction	NN
cord-034340-3ksfpaf7	1751	17	in	in	IN
cord-034340-3ksfpaf7	1751	18	CAPS	cap	NNS
cord-034340-3ksfpaf7	1751	19	.	.	.
cord-034340-3ksfpaf7	1752	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1752	2	think	think	VBP
cord-034340-3ksfpaf7	1752	3	that	that	IN
cord-034340-3ksfpaf7	1752	4	Ca	Ca	NNP
cord-034340-3ksfpaf7	1752	5	metabolism	metabolism	NN
cord-034340-3ksfpaf7	1752	6	and	and	CC
cord-034340-3ksfpaf7	1752	7	bone	bone	NN
cord-034340-3ksfpaf7	1752	8	mineral	mineral	NN
cord-034340-3ksfpaf7	1752	9	density	density	NN
cord-034340-3ksfpaf7	1752	10	measurements	measurement	NNS
cord-034340-3ksfpaf7	1752	11	should	should	MD
cord-034340-3ksfpaf7	1752	12	be	be	VB
cord-034340-3ksfpaf7	1752	13	a	a	DT
cord-034340-3ksfpaf7	1752	14	part	part	NN
cord-034340-3ksfpaf7	1752	15	of	of	IN
cord-034340-3ksfpaf7	1752	16	routine	routine	JJ
cord-034340-3ksfpaf7	1752	17	controls	control	NNS
cord-034340-3ksfpaf7	1752	18	in	in	IN
cord-034340-3ksfpaf7	1752	19	patients	patient	NNS
cord-034340-3ksfpaf7	1752	20	with	with	IN
cord-034340-3ksfpaf7	1752	21	CAPS	cap	NNS
cord-034340-3ksfpaf7	1752	22	.	.	.
cord-034340-3ksfpaf7	1753	1	Disclosure	disclosure	NN
cord-034340-3ksfpaf7	1753	2	of	of	IN
cord-034340-3ksfpaf7	1753	3	Interest	Interest	NNP
cord-034340-3ksfpaf7	1754	1	None	none	NN
cord-034340-3ksfpaf7	1754	2	declared	declare	VBD
cord-034340-3ksfpaf7	1754	3	AB007	AB007	NNP
cord-034340-3ksfpaf7	1754	4	Clinical	clinical	JJ
cord-034340-3ksfpaf7	1754	5	and	and	CC
cord-034340-3ksfpaf7	1754	6	genetic	genetic	JJ
cord-034340-3ksfpaf7	1754	7	features	feature	NNS
cord-034340-3ksfpaf7	1754	8	of	of	IN
cord-034340-3ksfpaf7	1754	9	patients	patient	NNS
cord-034340-3ksfpaf7	1754	10	with	with	IN
cord-034340-3ksfpaf7	1754	11	periodic	periodic	JJ
cord-034340-3ksfpaf7	1754	12	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1754	13	associated	associate	VBN
cord-034340-3ksfpaf7	1754	14	with	with	IN
cord-034340-3ksfpaf7	1754	15	mutation	mutation	NN
cord-034340-3ksfpaf7	1754	16	of	of	IN
cord-034340-3ksfpaf7	1754	17	the	the	DT
cord-034340-3ksfpaf7	1754	18	tumor	tumor	NN
cord-034340-3ksfpaf7	1754	19	necrosis	necrosis	NN
cord-034340-3ksfpaf7	1754	20	factor	factor	NN
cord-034340-3ksfpaf7	1754	21	receptor	receptor	NN
cord-034340-3ksfpaf7	1754	22	gene	gene	NN
cord-034340-3ksfpaf7	1754	23	and	and	CC
cord-034340-3ksfpaf7	1754	24	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1754	25	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1754	26	having	have	VBG
cord-034340-3ksfpaf7	1754	27	mutations	mutation	NNS
cord-034340-3ksfpaf7	1754	28	in	in	IN
cord-034340-3ksfpaf7	1754	29	TNFRSF1A	tnfrsf1a	NN
cord-034340-3ksfpaf7	1754	30	gene	gene	NN
cord-034340-3ksfpaf7	1754	31	M	M	NNP
cord-034340-3ksfpaf7	1754	32	Active	Active	NNP
cord-034340-3ksfpaf7	1754	33	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1754	34	in	in	IN
cord-034340-3ksfpaf7	1754	35	8/9	8/9	CD
cord-034340-3ksfpaf7	1754	36	,	,	,
cord-034340-3ksfpaf7	1754	37	it	-PRON-	PRP
cord-034340-3ksfpaf7	1754	38	was	be	VBD
cord-034340-3ksfpaf7	1754	39	poly	poly	JJ
cord-034340-3ksfpaf7	1754	40	in	in	IN
cord-034340-3ksfpaf7	1754	41	2	2	CD
cord-034340-3ksfpaf7	1754	42	,	,	,
cord-034340-3ksfpaf7	1754	43	oligo	oligo	NN
cord-034340-3ksfpaf7	1754	44	in	in	IN
cord-034340-3ksfpaf7	1754	45	6	6	CD
cord-034340-3ksfpaf7	1754	46	.	.	.
cord-034340-3ksfpaf7	1755	1	When	when	WRB
cord-034340-3ksfpaf7	1755	2	assessing	assess	VBG
cord-034340-3ksfpaf7	1755	3	the	the	DT
cord-034340-3ksfpaf7	1755	4	clinical	clinical	JJ
cord-034340-3ksfpaf7	1755	5	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1755	6	and	and	CC
cord-034340-3ksfpaf7	1755	7	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1755	8	activity	activity	NN
cord-034340-3ksfpaf7	1755	9	of	of	IN
cord-034340-3ksfpaf7	1755	10	patients	patient	NNS
cord-034340-3ksfpaf7	1755	11	with	with	IN
cord-034340-3ksfpaf7	1755	12	JIA	JIA	NNP
cord-034340-3ksfpaf7	1755	13	,	,	,
cord-034340-3ksfpaf7	1755	14	it	-PRON-	PRP
cord-034340-3ksfpaf7	1755	15	was	be	VBD
cord-034340-3ksfpaf7	1755	16	revealed	reveal	VBN
cord-034340-3ksfpaf7	1755	17	that	that	IN
cord-034340-3ksfpaf7	1755	18	in	in	IN
cord-034340-3ksfpaf7	1755	19	the	the	DT
cord-034340-3ksfpaf7	1755	20	onset	onset	NN
cord-034340-3ksfpaf7	1755	21	of	of	IN
cord-034340-3ksfpaf7	1755	22	the	the	DT
cord-034340-3ksfpaf7	1755	23	disease	disease	NN
cord-034340-3ksfpaf7	1755	24	,	,	,
cord-034340-3ksfpaf7	1755	25	systemic	systemic	JJ
cord-034340-3ksfpaf7	1755	26	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1755	27	were	be	VBD
cord-034340-3ksfpaf7	1755	28	observed	observe	VBN
cord-034340-3ksfpaf7	1755	29	in	in	IN
cord-034340-3ksfpaf7	1755	30	8/12	8/12	CD
cord-034340-3ksfpaf7	1755	31	:	:	:
cord-034340-3ksfpaf7	1755	32	fever	fever	NN
cord-034340-3ksfpaf7	1755	33	in	in	IN
cord-034340-3ksfpaf7	1755	34	8/12	8/12	CD
cord-034340-3ksfpaf7	1755	35	,	,	,
cord-034340-3ksfpaf7	1755	36	rash	rash	JJ
cord-034340-3ksfpaf7	1755	37	in	in	IN
cord-034340-3ksfpaf7	1755	38	4/12	4/12	CD
cord-034340-3ksfpaf7	1755	39	,	,	,
cord-034340-3ksfpaf7	1755	40	hepatosplenomegaly	hepatosplenomegaly	NNP
cord-034340-3ksfpaf7	1755	41	in	in	IN
cord-034340-3ksfpaf7	1755	42	5/	5/	CD
cord-034340-3ksfpaf7	1755	43	12	12	CD
cord-034340-3ksfpaf7	1755	44	,	,	,
cord-034340-3ksfpaf7	1755	45	pneumonitis	pneumonitis	NN
cord-034340-3ksfpaf7	1755	46	in	in	IN
cord-034340-3ksfpaf7	1755	47	2/12	2/12	CD
cord-034340-3ksfpaf7	1755	48	,	,	,
cord-034340-3ksfpaf7	1755	49	carditis	carditis	NNP
cord-034340-3ksfpaf7	1755	50	in	in	IN
cord-034340-3ksfpaf7	1755	51	1/12	1/12	CD
cord-034340-3ksfpaf7	1755	52	and	and	CC
cord-034340-3ksfpaf7	1755	53	lymphadenopathy	lymphadenopathy	JJ
cord-034340-3ksfpaf7	1755	54	in	in	IN
cord-034340-3ksfpaf7	1755	55	5/12	5/12	CD
cord-034340-3ksfpaf7	1755	56	.	.	.
cord-034340-3ksfpaf7	1756	1	High	high	JJ
cord-034340-3ksfpaf7	1756	2	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1756	3	activity	activity	NN
cord-034340-3ksfpaf7	1756	4	was	be	VBD
cord-034340-3ksfpaf7	1756	5	recorded	record	VBN
cord-034340-3ksfpaf7	1756	6	in	in	IN
cord-034340-3ksfpaf7	1756	7	11/12	11/12	CD
cord-034340-3ksfpaf7	1756	8	.	.	.
cord-034340-3ksfpaf7	1757	1	Active	active	JJ
cord-034340-3ksfpaf7	1757	2	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1757	3	in	in	IN
cord-034340-3ksfpaf7	1757	4	10/12	10/12	CD
cord-034340-3ksfpaf7	1758	1	,	,	,
cord-034340-3ksfpaf7	1758	2	it	-PRON-	PRP
cord-034340-3ksfpaf7	1758	3	was	be	VBD
cord-034340-3ksfpaf7	1758	4	polys	poly	NNS
cord-034340-3ksfpaf7	1758	5	in	in	IN
cord-034340-3ksfpaf7	1758	6	4	4	CD
cord-034340-3ksfpaf7	1758	7	,	,	,
cord-034340-3ksfpaf7	1758	8	oligo	oligo	NN
cord-034340-3ksfpaf7	1758	9	in	in	IN
cord-034340-3ksfpaf7	1758	10	6	6	CD
cord-034340-3ksfpaf7	1758	11	.	.	.
cord-034340-3ksfpaf7	1759	1	In	in	IN
cord-034340-3ksfpaf7	1759	2	all	all	DT
cord-034340-3ksfpaf7	1759	3	100	100	CD
cord-034340-3ksfpaf7	1759	4	%	%	NN
cord-034340-3ksfpaf7	1759	5	of	of	IN
cord-034340-3ksfpaf7	1759	6	patients	patient	NNS
cord-034340-3ksfpaf7	1759	7	,	,	,
cord-034340-3ksfpaf7	1759	8	the	the	DT
cord-034340-3ksfpaf7	1759	9	nucleotide	nucleotide	JJ
cord-034340-3ksfpaf7	1759	10	variants	variant	NNS
cord-034340-3ksfpaf7	1759	11	of	of	IN
cord-034340-3ksfpaf7	1759	12	the	the	DT
cord-034340-3ksfpaf7	1759	13	TNFRSF1A	tnfrsf1a	NN
cord-034340-3ksfpaf7	1759	14	gene	gene	NN
cord-034340-3ksfpaf7	1759	15	were	be	VBD
cord-034340-3ksfpaf7	1759	16	identified	identify	VBN
cord-034340-3ksfpaf7	1759	17	in	in	IN
cord-034340-3ksfpaf7	1759	18	the	the	DT
cord-034340-3ksfpaf7	1759	19	study	study	NN
cord-034340-3ksfpaf7	1759	20	.	.	.
cord-034340-3ksfpaf7	1760	1	9/21	9/21	CD
cord-034340-3ksfpaf7	1760	2	of	of	IN
cord-034340-3ksfpaf7	1760	3	patients	patient	NNS
cord-034340-3ksfpaf7	1760	4	were	be	VBD
cord-034340-3ksfpaf7	1760	5	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1760	6	with	with	IN
cord-034340-3ksfpaf7	1760	7	TRAPS	trap	NNS
cord-034340-3ksfpaf7	1760	8	.	.	.
cord-034340-3ksfpaf7	1761	1	The	the	DT
cord-034340-3ksfpaf7	1761	2	most	most	RBS
cord-034340-3ksfpaf7	1761	3	frequent	frequent	JJ
cord-034340-3ksfpaf7	1761	4	heterozygous	heterozygous	JJ
cord-034340-3ksfpaf7	1761	5	variant	variant	NN
cord-034340-3ksfpaf7	1761	6	of	of	IN
cord-034340-3ksfpaf7	1761	7	TNFRSF1A	tnfrsf1a	NN
cord-034340-3ksfpaf7	1761	8	gene	gene	NN
cord-034340-3ksfpaf7	1761	9	with	with	IN
cord-034340-3ksfpaf7	1761	10	nucleotide	nucleotide	JJ
cord-034340-3ksfpaf7	1761	11	substitution	substitution	NN
cord-034340-3ksfpaf7	1761	12	of	of	IN
cord-034340-3ksfpaf7	1761	13	c.362	c.362	NNP
cord-034340-3ksfpaf7	1761	14	G	g	NN
cord-034340-3ksfpaf7	1762	1	>	>	XX
cord-034340-3ksfpaf7	1763	1	A	a	DT
cord-034340-3ksfpaf7	1763	2	was	be	VBD
cord-034340-3ksfpaf7	1763	3	found	find	VBN
cord-034340-3ksfpaf7	1763	4	in	in	IN
cord-034340-3ksfpaf7	1763	5	7/9	7/9	CD
cord-034340-3ksfpaf7	1763	6	of	of	IN
cord-034340-3ksfpaf7	1763	7	patients	patient	NNS
cord-034340-3ksfpaf7	1763	8	,	,	,
cord-034340-3ksfpaf7	1763	9	in	in	IN
cord-034340-3ksfpaf7	1763	10	1/9	1/9	CD
cord-034340-3ksfpaf7	1763	11	of	of	IN
cord-034340-3ksfpaf7	1763	12	patients	patient	NNS
cord-034340-3ksfpaf7	1763	13	it	-PRON-	PRP
cord-034340-3ksfpaf7	1763	14	was	be	VBD
cord-034340-3ksfpaf7	1763	15	found	find	VBN
cord-034340-3ksfpaf7	1763	16	homozygous	homozygous	JJ
cord-034340-3ksfpaf7	1763	17	variant	variant	NN
cord-034340-3ksfpaf7	1763	18	with	with	IN
cord-034340-3ksfpaf7	1763	19	nucleotide	nucleotide	JJ
cord-034340-3ksfpaf7	1763	20	substitution	substitution	NN
cord-034340-3ksfpaf7	1763	21	of	of	IN
cord-034340-3ksfpaf7	1763	22	c.362	c.362	NNP
cord-034340-3ksfpaf7	1763	23	G	g	NN
cord-034340-3ksfpaf7	1764	1	>	>	XX
cord-034340-3ksfpaf7	1765	1	A	a	LS
cord-034340-3ksfpaf7	1765	2	,	,	,
cord-034340-3ksfpaf7	1765	3	in	in	IN
cord-034340-3ksfpaf7	1765	4	1/9	1/9	CD
cord-034340-3ksfpaf7	1765	5	of	of	IN
cord-034340-3ksfpaf7	1765	6	children	child	NNS
cord-034340-3ksfpaf7	1765	7	it	-PRON-	PRP
cord-034340-3ksfpaf7	1765	8	was	be	VBD
cord-034340-3ksfpaf7	1765	9	found	find	VBN
cord-034340-3ksfpaf7	1765	10	heterozygous	heterozygous	JJ
cord-034340-3ksfpaf7	1765	11	variant	variant	NN
cord-034340-3ksfpaf7	1765	12	with	with	IN
cord-034340-3ksfpaf7	1765	13	deletion	deletion	NN
cord-034340-3ksfpaf7	1765	14	of	of	IN
cord-034340-3ksfpaf7	1765	15	c.337_339del	c.337_339del	NN
cord-034340-3ksfpaf7	1765	16	.	.	.
cord-034340-3ksfpaf7	1766	1	All	all	DT
cord-034340-3ksfpaf7	1766	2	of	of	IN
cord-034340-3ksfpaf7	1766	3	these	these	DT
cord-034340-3ksfpaf7	1766	4	variants	variant	NNS
cord-034340-3ksfpaf7	1766	5	are	be	VBP
cord-034340-3ksfpaf7	1766	6	pathogenic	pathogenic	JJ
cord-034340-3ksfpaf7	1766	7	.	.	.
cord-034340-3ksfpaf7	1767	1	12/21	12/21	CD
cord-034340-3ksfpaf7	1767	2	of	of	IN
cord-034340-3ksfpaf7	1767	3	patients	patient	NNS
cord-034340-3ksfpaf7	1767	4	were	be	VBD
cord-034340-3ksfpaf7	1767	5	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1767	6	with	with	IN
cord-034340-3ksfpaf7	1767	7	JA	JA	NNP
cord-034340-3ksfpaf7	1767	8	:	:	:
cord-034340-3ksfpaf7	1768	1	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1768	2	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1768	3	with	with	IN
cord-034340-3ksfpaf7	1768	4	a	a	DT
cord-034340-3ksfpaf7	1768	5	systemic	systemic	JJ
cord-034340-3ksfpaf7	1768	6	onset	onset	NN
cord-034340-3ksfpaf7	1768	7	was	be	VBD
cord-034340-3ksfpaf7	1768	8	in	in	IN
cord-034340-3ksfpaf7	1768	9	7/12	7/12	CD
cord-034340-3ksfpaf7	1768	10	,	,	,
cord-034340-3ksfpaf7	1768	11	paucarticular	paucarticular	JJ
cord-034340-3ksfpaf7	1768	12	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1768	13	was	be	VBD
cord-034340-3ksfpaf7	1768	14	in	in	IN
cord-034340-3ksfpaf7	1768	15	2/12	2/12	CD
cord-034340-3ksfpaf7	1768	16	,	,	,
cord-034340-3ksfpaf7	1769	1	in	in	IN
cord-034340-3ksfpaf7	1769	2	1/12	1/12	CD
cord-034340-3ksfpaf7	1769	3	it	-PRON-	PRP
cord-034340-3ksfpaf7	1769	4	was	be	VBD
cord-034340-3ksfpaf7	1769	5	poly	poly	NNP
cord-034340-3ksfpaf7	1769	6	RF	RF	NNP
cord-034340-3ksfpaf7	1769	7	-	-	:
cord-034340-3ksfpaf7	1769	8	and	and	CC
cord-034340-3ksfpaf7	1769	9	in	in	IN
cord-034340-3ksfpaf7	1769	10	1/12	1/12	CD
cord-034340-3ksfpaf7	1769	11	it	-PRON-	PRP
cord-034340-3ksfpaf7	1769	12	was	be	VBD
cord-034340-3ksfpaf7	1769	13	psoriatic	psoriatic	JJ
cord-034340-3ksfpaf7	1769	14	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1769	15	.	.	.
cord-034340-3ksfpaf7	1770	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1770	2	is	be	VBZ
cord-034340-3ksfpaf7	1770	3	worth	worth	JJ
cord-034340-3ksfpaf7	1770	4	noting	note	VBG
cord-034340-3ksfpaf7	1770	5	to	to	TO
cord-034340-3ksfpaf7	1770	6	note	note	VB
cord-034340-3ksfpaf7	1770	7	that	that	IN
cord-034340-3ksfpaf7	1770	8	in	in	IN
cord-034340-3ksfpaf7	1770	9	6/12	6/12	CD
cord-034340-3ksfpaf7	1770	10	a	a	DT
cord-034340-3ksfpaf7	1770	11	heterozygous	heterozygous	JJ
cord-034340-3ksfpaf7	1770	12	version	version	NN
cord-034340-3ksfpaf7	1770	13	of	of	IN
cord-034340-3ksfpaf7	1770	14	the	the	DT
cord-034340-3ksfpaf7	1770	15	TNFRSF1A	TNFRSF1A	NNP
cord-034340-3ksfpaf7	1770	16	gene	gene	NN
cord-034340-3ksfpaf7	1770	17	was	be	VBD
cord-034340-3ksfpaf7	1770	18	detected	detect	VBN
cord-034340-3ksfpaf7	1770	19	with	with	IN
cord-034340-3ksfpaf7	1770	20	a	a	DT
cord-034340-3ksfpaf7	1770	21	nucleotide	nucleotide	JJ
cord-034340-3ksfpaf7	1770	22	substitution	substitution	NN
cord-034340-3ksfpaf7	1770	23	c.362	c.362	NN
cord-034340-3ksfpaf7	1770	24	G	g	NN
cord-034340-3ksfpaf7	1771	1	>	>	XX
cord-034340-3ksfpaf7	1772	1	A	a	DT
cord-034340-3ksfpaf7	1772	2	,	,	,
cord-034340-3ksfpaf7	1772	3	however	however	RB
cord-034340-3ksfpaf7	1772	4	,	,	,
cord-034340-3ksfpaf7	1772	5	considering	consider	VBG
cord-034340-3ksfpaf7	1772	6	the	the	DT
cord-034340-3ksfpaf7	1772	7	absence	absence	NN
cord-034340-3ksfpaf7	1772	8	of	of	IN
cord-034340-3ksfpaf7	1772	9	clinical	clinical	JJ
cord-034340-3ksfpaf7	1772	10	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1772	11	of	of	IN
cord-034340-3ksfpaf7	1772	12	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1772	13	disease	disease	NN
cord-034340-3ksfpaf7	1772	14	and	and	CC
cord-034340-3ksfpaf7	1772	15	active	active	JJ
cord-034340-3ksfpaf7	1772	16	articular	articular	JJ
cord-034340-3ksfpaf7	1772	17	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1772	18	in	in	IN
cord-034340-3ksfpaf7	1772	19	these	these	DT
cord-034340-3ksfpaf7	1772	20	patients	patient	NNS
cord-034340-3ksfpaf7	1772	21	,	,	,
cord-034340-3ksfpaf7	1772	22	children	child	NNS
cord-034340-3ksfpaf7	1772	23	were	be	VBD
cord-034340-3ksfpaf7	1772	24	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1772	25	with	with	IN
cord-034340-3ksfpaf7	1772	26	JA	JA	NNP
cord-034340-3ksfpaf7	1772	27	.	.	.
cord-034340-3ksfpaf7	1773	1	In	in	IN
cord-034340-3ksfpaf7	1773	2	addition	addition	NN
cord-034340-3ksfpaf7	1773	3	Dvoryakovskaya	Dvoryakovskaya	NNP
cord-034340-3ksfpaf7	1774	1	:	:	:
cord-034340-3ksfpaf7	1774	2	None	none	NN
cord-034340-3ksfpaf7	1774	3	declared	declare	VBD
cord-034340-3ksfpaf7	1774	4	,	,	,
cord-034340-3ksfpaf7	1774	5	A.	A.	NNP
cord-034340-3ksfpaf7	1774	6	Mamutova	Mamutova	NNP
cord-034340-3ksfpaf7	1774	7	Speaker	Speaker	NNP
cord-034340-3ksfpaf7	1774	8	Bureau	Bureau	NNP
cord-034340-3ksfpaf7	1774	9	of	of	IN
cord-034340-3ksfpaf7	1774	10	:	:	:
cord-034340-3ksfpaf7	1774	11	Novartis	Novartis	NNP
cord-034340-3ksfpaf7	1774	12	,	,	,
cord-034340-3ksfpaf7	1774	13	K.	K.	NNP
cord-034340-3ksfpaf7	1774	14	Isayeva	Isayeva	NNP
cord-034340-3ksfpaf7	1774	15	:	:	:
cord-034340-3ksfpaf7	1774	16	None	none	NN
cord-034340-3ksfpaf7	1774	17	declared	declare	VBD
cord-034340-3ksfpaf7	1774	18	,	,	,
cord-034340-3ksfpaf7	1774	19	R.	R.	NNP
cord-034340-3ksfpaf7	1774	20	Denisova	Denisova	NNP
cord-034340-3ksfpaf7	1774	21	Speaker	Speaker	NNP
cord-034340-3ksfpaf7	1774	22	Bureau	Bureau	NNP
cord-034340-3ksfpaf7	1774	23	of	of	IN
cord-034340-3ksfpaf7	1774	24	:	:	:
cord-034340-3ksfpaf7	1774	25	Novartis	Novartis	NNP
cord-034340-3ksfpaf7	1774	26	COVID-19	COVID-19	NNP
cord-034340-3ksfpaf7	1774	27	and	and	CC
cord-034340-3ksfpaf7	1774	28	relapsing	relapse	VBG
cord-034340-3ksfpaf7	1774	29	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1774	30	disease	disease	NN
cord-034340-3ksfpaf7	1774	31	:	:	:
cord-034340-3ksfpaf7	1774	32	a	a	DT
cord-034340-3ksfpaf7	1774	33	case	case	NN
cord-034340-3ksfpaf7	1774	34	report	report	NN
cord-034340-3ksfpaf7	1774	35	during	during	IN
cord-034340-3ksfpaf7	1774	36	the	the	DT
cord-034340-3ksfpaf7	1774	37	pandemia	pandemia	NN
cord-034340-3ksfpaf7	1774	38	M.	M.	NNP
cord-034340-3ksfpaf7	1774	39	C.	C.	NNP
cord-034340-3ksfpaf7	1774	40	Maggio	Maggio	NNP
cord-034340-3ksfpaf7	1774	41	AB009	AB009	NNP
cord-034340-3ksfpaf7	1774	42	Introduction	introduction	NN
cord-034340-3ksfpaf7	1774	43	:	:	:
cord-034340-3ksfpaf7	1774	44	The	the	DT
cord-034340-3ksfpaf7	1774	45	pandemia	pandemia	NN
cord-034340-3ksfpaf7	1774	46	of	of	IN
cord-034340-3ksfpaf7	1774	47	COVID-19	COVID-19	NNP
cord-034340-3ksfpaf7	1774	48	remains	remain	VBZ
cord-034340-3ksfpaf7	1774	49	a	a	DT
cord-034340-3ksfpaf7	1774	50	global	global	JJ
cord-034340-3ksfpaf7	1774	51	health	health	NN
cord-034340-3ksfpaf7	1774	52	alarm	alarm	NN
cord-034340-3ksfpaf7	1774	53	with	with	IN
cord-034340-3ksfpaf7	1774	54	high	high	JJ
cord-034340-3ksfpaf7	1774	55	incidence	incidence	NN
cord-034340-3ksfpaf7	1774	56	of	of	IN
cord-034340-3ksfpaf7	1774	57	lethality	lethality	NN
cord-034340-3ksfpaf7	1774	58	,	,	,
cord-034340-3ksfpaf7	1774	59	especially	especially	RB
cord-034340-3ksfpaf7	1774	60	in	in	IN
cord-034340-3ksfpaf7	1774	61	older	old	JJR
cord-034340-3ksfpaf7	1774	62	age	age	NN
cord-034340-3ksfpaf7	1774	63	groups	group	NNS
cord-034340-3ksfpaf7	1774	64	who	who	WP
cord-034340-3ksfpaf7	1774	65	suffer	suffer	VBP
cord-034340-3ksfpaf7	1774	66	from	from	IN
cord-034340-3ksfpaf7	1774	67	underlying	underlie	VBG
cord-034340-3ksfpaf7	1774	68	medical	medical	JJ
cord-034340-3ksfpaf7	1774	69	conditions	condition	NNS
cord-034340-3ksfpaf7	1774	70	.	.	.
cord-034340-3ksfpaf7	1775	1	However	however	RB
cord-034340-3ksfpaf7	1775	2	,	,	,
cord-034340-3ksfpaf7	1775	3	children	child	NNS
cord-034340-3ksfpaf7	1775	4	are	be	VBP
cord-034340-3ksfpaf7	1775	5	less	less	RBR
cord-034340-3ksfpaf7	1775	6	likely	likely	JJ
cord-034340-3ksfpaf7	1775	7	to	to	TO
cord-034340-3ksfpaf7	1775	8	manifest	manifest	VB
cord-034340-3ksfpaf7	1775	9	severe	severe	JJ
cord-034340-3ksfpaf7	1775	10	conditions	condition	NNS
cord-034340-3ksfpaf7	1775	11	.	.	.
cord-034340-3ksfpaf7	1776	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1776	2	:	:	:
cord-034340-3ksfpaf7	1776	3	COVID-19	COVID-19	NNP
cord-034340-3ksfpaf7	1776	4	was	be	VBD
cord-034340-3ksfpaf7	1776	5	correlated	correlate	VBN
cord-034340-3ksfpaf7	1776	6	to	to	IN
cord-034340-3ksfpaf7	1776	7	a	a	DT
cord-034340-3ksfpaf7	1776	8	higher	high	JJR
cord-034340-3ksfpaf7	1776	9	incidence	incidence	NN
cord-034340-3ksfpaf7	1776	10	and	and	CC
cord-034340-3ksfpaf7	1776	11	a	a	DT
cord-034340-3ksfpaf7	1776	12	suspected	suspect	VBN
cord-034340-3ksfpaf7	1776	13	increased	increase	VBN
cord-034340-3ksfpaf7	1776	14	risk	risk	NN
cord-034340-3ksfpaf7	1776	15	of	of	IN
cord-034340-3ksfpaf7	1776	16	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1776	17	Disease	Disease	NNP
cord-034340-3ksfpaf7	1776	18	(	(	-LRB-
cord-034340-3ksfpaf7	1776	19	KD	KD	NNP
cord-034340-3ksfpaf7	1776	20	)	)	-RRB-
cord-034340-3ksfpaf7	1776	21	in	in	IN
cord-034340-3ksfpaf7	1776	22	children	child	NNS
cord-034340-3ksfpaf7	1776	23	Anamnestic	anamnestic	JJ
cord-034340-3ksfpaf7	1776	24	records	record	NNS
cord-034340-3ksfpaf7	1776	25	revealed	reveal	VBD
cord-034340-3ksfpaf7	1776	26	a	a	DT
cord-034340-3ksfpaf7	1776	27	previous	previous	JJ
cord-034340-3ksfpaf7	1776	28	KD	KD	NNP
cord-034340-3ksfpaf7	1776	29	,	,	,
cord-034340-3ksfpaf7	1776	30	without	without	IN
cord-034340-3ksfpaf7	1776	31	coronary	coronary	JJ
cord-034340-3ksfpaf7	1776	32	artery	artery	NN
cord-034340-3ksfpaf7	1776	33	lesions	lesion	NNS
cord-034340-3ksfpaf7	1776	34	(	(	-LRB-
cord-034340-3ksfpaf7	1776	35	CAL	CAL	NNP
cord-034340-3ksfpaf7	1776	36	)	)	-RRB-
cord-034340-3ksfpaf7	1776	37	,	,	,
cord-034340-3ksfpaf7	1776	38	1	1	CD
cord-034340-3ksfpaf7	1776	39	year	year	NN
cord-034340-3ksfpaf7	1776	40	before	before	RB
cord-034340-3ksfpaf7	1776	41	.	.	.
cord-034340-3ksfpaf7	1777	1	Results	result	NNS
cord-034340-3ksfpaf7	1777	2	:	:	:
cord-034340-3ksfpaf7	1778	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1778	2	was	be	VBD
cord-034340-3ksfpaf7	1778	3	treated	treat	VBN
cord-034340-3ksfpaf7	1778	4	with	with	IN
cord-034340-3ksfpaf7	1778	5	antibiotics	antibiotic	NNS
cord-034340-3ksfpaf7	1778	6	,	,	,
cord-034340-3ksfpaf7	1778	7	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1778	8	infusion	infusion	NN
cord-034340-3ksfpaf7	1778	9	of	of	IN
cord-034340-3ksfpaf7	1778	10	Immunoglobulins	Immunoglobulins	NNP
cord-034340-3ksfpaf7	1778	11	(	(	-LRB-
cord-034340-3ksfpaf7	1778	12	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1778	13	)	)	-RRB-
cord-034340-3ksfpaf7	1778	14	(	(	-LRB-
cord-034340-3ksfpaf7	1778	15	2	2	CD
cord-034340-3ksfpaf7	1778	16	gr	gr	NNP
cord-034340-3ksfpaf7	1778	17	/	/	SYM
cord-034340-3ksfpaf7	1778	18	Kg	Kg	NNP
cord-034340-3ksfpaf7	1778	19	)	)	-RRB-
cord-034340-3ksfpaf7	1778	20	,	,	,
cord-034340-3ksfpaf7	1778	21	acetylsalicylic	acetylsalicylic	JJ
cord-034340-3ksfpaf7	1778	22	acid	acid	NN
cord-034340-3ksfpaf7	1778	23	(	(	-LRB-
cord-034340-3ksfpaf7	1778	24	ASA	ASA	NNP
cord-034340-3ksfpaf7	1778	25	)	)	-RRB-
cord-034340-3ksfpaf7	1779	1	(	(	-LRB-
cord-034340-3ksfpaf7	1779	2	50	50	CD
cord-034340-3ksfpaf7	1779	3	mg	mg	NNP
cord-034340-3ksfpaf7	1779	4	/	/	SYM
cord-034340-3ksfpaf7	1779	5	Kg	Kg	NNP
cord-034340-3ksfpaf7	1779	6	in	in	IN
cord-034340-3ksfpaf7	1779	7	4	4	CD
cord-034340-3ksfpaf7	1779	8	doses	dose	NNS
cord-034340-3ksfpaf7	1779	9	/	/	SYM
cord-034340-3ksfpaf7	1779	10	day	day	NN
cord-034340-3ksfpaf7	1779	11	)	)	-RRB-
cord-034340-3ksfpaf7	1779	12	and	and	CC
cord-034340-3ksfpaf7	1779	13	reached	reach	VBD
cord-034340-3ksfpaf7	1779	14	defervescence	defervescence	NN
cord-034340-3ksfpaf7	1779	15	into	into	IN
cord-034340-3ksfpaf7	1779	16	2	2	CD
cord-034340-3ksfpaf7	1779	17	days	day	NNS
cord-034340-3ksfpaf7	1779	18	.	.	.
cord-034340-3ksfpaf7	1780	1	Echocardiography	echocardiography	NN
cord-034340-3ksfpaf7	1780	2	excluded	exclude	VBD
cord-034340-3ksfpaf7	1780	3	CAL	CAL	NNP
cord-034340-3ksfpaf7	1780	4	.	.	.
cord-034340-3ksfpaf7	1781	1	The	the	DT
cord-034340-3ksfpaf7	1781	2	nasopharyngeal	nasopharyngeal	JJ
cord-034340-3ksfpaf7	1781	3	swab	swab	NN
cord-034340-3ksfpaf7	1781	4	for	for	IN
cord-034340-3ksfpaf7	1781	5	SARS	SARS	NNP
cord-034340-3ksfpaf7	1781	6	-	-	HYPH
cord-034340-3ksfpaf7	1781	7	COV-2	COV-2	NNP
cord-034340-3ksfpaf7	1781	8	was	be	VBD
cord-034340-3ksfpaf7	1781	9	doubt	doubt	NN
cord-034340-3ksfpaf7	1781	10	.	.	.
cord-034340-3ksfpaf7	1782	1	The	the	DT
cord-034340-3ksfpaf7	1782	2	second	second	JJ
cord-034340-3ksfpaf7	1782	3	throat	throat	NN
cord-034340-3ksfpaf7	1782	4	swab	swab	NN
cord-034340-3ksfpaf7	1782	5	done	do	VBN
cord-034340-3ksfpaf7	1782	6	the	the	DT
cord-034340-3ksfpaf7	1782	7	day	day	NN
cord-034340-3ksfpaf7	1782	8	after	after	IN
cord-034340-3ksfpaf7	1782	9	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1782	10	infusion	infusion	NN
cord-034340-3ksfpaf7	1782	11	,	,	,
cord-034340-3ksfpaf7	1782	12	was	be	VBD
cord-034340-3ksfpaf7	1782	13	negative	negative	JJ
cord-034340-3ksfpaf7	1782	14	;	;	:
cord-034340-3ksfpaf7	1782	15	however	however	RB
cord-034340-3ksfpaf7	1782	16	,	,	,
cord-034340-3ksfpaf7	1782	17	the	the	DT
cord-034340-3ksfpaf7	1782	18	third	third	JJ
cord-034340-3ksfpaf7	1782	19	nasopharyngeal	nasopharyngeal	JJ
cord-034340-3ksfpaf7	1782	20	swab	swab	NN
cord-034340-3ksfpaf7	1782	21	for	for	IN
cord-034340-3ksfpaf7	1782	22	SARS	SARS	NNP
cord-034340-3ksfpaf7	1782	23	-	-	HYPH
cord-034340-3ksfpaf7	1782	24	COV-2	COV-2	NNP
cord-034340-3ksfpaf7	1782	25	,	,	,
cord-034340-3ksfpaf7	1782	26	done	do	VBN
cord-034340-3ksfpaf7	1782	27	4	4	CD
cord-034340-3ksfpaf7	1782	28	days	day	NNS
cord-034340-3ksfpaf7	1782	29	after	after	IN
cord-034340-3ksfpaf7	1782	30	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1782	31	infusion	infusion	NN
cord-034340-3ksfpaf7	1782	32	,	,	,
cord-034340-3ksfpaf7	1782	33	was	be	VBD
cord-034340-3ksfpaf7	1782	34	positive	positive	JJ
cord-034340-3ksfpaf7	1782	35	.	.	.
cord-034340-3ksfpaf7	1783	1	Chest	chest	NN
cord-034340-3ksfpaf7	1783	2	x	x	NN
cord-034340-3ksfpaf7	1783	3	-	-	NN
cord-034340-3ksfpaf7	1783	4	ray	ray	NNP
cord-034340-3ksfpaf7	1783	5	showed	show	VBD
cord-034340-3ksfpaf7	1783	6	a	a	DT
cord-034340-3ksfpaf7	1783	7	significant	significant	JJ
cord-034340-3ksfpaf7	1783	8	lung	lung	NN
cord-034340-3ksfpaf7	1783	9	interstitial	interstitial	JJ
cord-034340-3ksfpaf7	1783	10	thickening	thickening	NN
cord-034340-3ksfpaf7	1783	11	.	.	.
cord-034340-3ksfpaf7	1784	1	IL-6	IL-6	NNP
cord-034340-3ksfpaf7	1784	2	levels	level	NNS
cord-034340-3ksfpaf7	1784	3	were	be	VBD
cord-034340-3ksfpaf7	1784	4	<	<	XX
cord-034340-3ksfpaf7	1785	1	6.25	6.25	CD
cord-034340-3ksfpaf7	1785	2	pg	pg	NNP
cord-034340-3ksfpaf7	1785	3	/	/	SYM
cord-034340-3ksfpaf7	1785	4	ml	ml	NN
cord-034340-3ksfpaf7	1786	1	(	(	-LRB-
cord-034340-3ksfpaf7	1786	2	n.v	n.v	NNP
cord-034340-3ksfpaf7	1786	3	.	.	.
cord-034340-3ksfpaf7	1787	1	<	<	NNP
cord-034340-3ksfpaf7	1787	2	6.25	6.25	CD
cord-034340-3ksfpaf7	1787	3	pg	pg	NNP
cord-034340-3ksfpaf7	1787	4	/	/	SYM
cord-034340-3ksfpaf7	1787	5	ml	ml	NNP
cord-034340-3ksfpaf7	1787	6	)	)	-RRB-
cord-034340-3ksfpaf7	1787	7	.	.	.
cord-034340-3ksfpaf7	1788	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1788	2	continued	continue	VBD
cord-034340-3ksfpaf7	1788	3	treatment	treatment	NN
cord-034340-3ksfpaf7	1788	4	with	with	IN
cord-034340-3ksfpaf7	1788	5	antibiotics	antibiotic	NNS
cord-034340-3ksfpaf7	1788	6	,	,	,
cord-034340-3ksfpaf7	1788	7	ASA	ASA	NNP
cord-034340-3ksfpaf7	1788	8	(	(	-LRB-
cord-034340-3ksfpaf7	1788	9	5	5	CD
cord-034340-3ksfpaf7	1788	10	mg	mg	NNP
cord-034340-3ksfpaf7	1788	11	/	/	SYM
cord-034340-3ksfpaf7	1788	12	Kg	Kg	NNP
cord-034340-3ksfpaf7	1788	13	/	/	SYM
cord-034340-3ksfpaf7	1788	14	day	day	NN
cord-034340-3ksfpaf7	1788	15	)	)	-RRB-
cord-034340-3ksfpaf7	1788	16	,	,	,
cord-034340-3ksfpaf7	1788	17	with	with	IN
cord-034340-3ksfpaf7	1788	18	the	the	DT
cord-034340-3ksfpaf7	1788	19	progressive	progressive	JJ
cord-034340-3ksfpaf7	1788	20	resolution	resolution	NN
cord-034340-3ksfpaf7	1788	21	of	of	IN
cord-034340-3ksfpaf7	1788	22	the	the	DT
cord-034340-3ksfpaf7	1788	23	clinical	clinical	JJ
cord-034340-3ksfpaf7	1788	24	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1788	25	and	and	CC
cord-034340-3ksfpaf7	1788	26	of	of	IN
cord-034340-3ksfpaf7	1788	27	the	the	DT
cord-034340-3ksfpaf7	1788	28	normalization	normalization	NN
cord-034340-3ksfpaf7	1788	29	of	of	IN
cord-034340-3ksfpaf7	1788	30	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1788	31	findings	finding	NNS
cord-034340-3ksfpaf7	1788	32	.	.	.
cord-034340-3ksfpaf7	1789	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1789	2	:	:	:
cord-034340-3ksfpaf7	1790	1	The	the	DT
cord-034340-3ksfpaf7	1790	2	peculiar	peculiar	JJ
cord-034340-3ksfpaf7	1790	3	outcome	outcome	NN
cord-034340-3ksfpaf7	1790	4	of	of	IN
cord-034340-3ksfpaf7	1790	5	the	the	DT
cord-034340-3ksfpaf7	1790	6	patient	patient	NN
cord-034340-3ksfpaf7	1790	7	is	be	VBZ
cord-034340-3ksfpaf7	1790	8	the	the	DT
cord-034340-3ksfpaf7	1790	9	correlation	correlation	NN
cord-034340-3ksfpaf7	1790	10	of	of	IN
cord-034340-3ksfpaf7	1790	11	COVID-19	COVID-19	NNP
cord-034340-3ksfpaf7	1790	12	with	with	IN
cord-034340-3ksfpaf7	1790	13	KD	KD	NNP
cord-034340-3ksfpaf7	1790	14	,	,	,
cord-034340-3ksfpaf7	1790	15	recently	recently	RB
cord-034340-3ksfpaf7	1790	16	reported	report	VBD
cord-034340-3ksfpaf7	1790	17	as	as	IN
cord-034340-3ksfpaf7	1790	18	associated	associate	VBN
cord-034340-3ksfpaf7	1790	19	.	.	.
cord-034340-3ksfpaf7	1791	1	KD	KD	NNP
cord-034340-3ksfpaf7	1791	2	is	be	VBZ
cord-034340-3ksfpaf7	1791	3	considered	consider	VBN
cord-034340-3ksfpaf7	1791	4	as	as	IN
cord-034340-3ksfpaf7	1791	5	a	a	DT
cord-034340-3ksfpaf7	1791	6	multifactorial	multifactorial	JJ
cord-034340-3ksfpaf7	1791	7	autoinflammatory	autoinflammatory	JJ
cord-034340-3ksfpaf7	1791	8	disease	disease	NN
cord-034340-3ksfpaf7	1791	9	,	,	,
cord-034340-3ksfpaf7	1791	10	induced	induce	VBN
cord-034340-3ksfpaf7	1791	11	by	by	IN
cord-034340-3ksfpaf7	1791	12	a	a	DT
cord-034340-3ksfpaf7	1791	13	cytokine	cytokine	NN
cord-034340-3ksfpaf7	1791	14	hypersecretion	hypersecretion	NN
cord-034340-3ksfpaf7	1791	15	with	with	IN
cord-034340-3ksfpaf7	1791	16	a	a	DT
cord-034340-3ksfpaf7	1791	17	systemic	systemic	JJ
cord-034340-3ksfpaf7	1791	18	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1791	19	.	.	.
cord-034340-3ksfpaf7	1792	1	COVID-19	COVID-19	NNP
cord-034340-3ksfpaf7	1792	2	is	be	VBZ
cord-034340-3ksfpaf7	1792	3	considered	consider	VBN
cord-034340-3ksfpaf7	1792	4	a	a	DT
cord-034340-3ksfpaf7	1792	5	cytokine	cytokine	NN
cord-034340-3ksfpaf7	1792	6	storm	storm	NN
cord-034340-3ksfpaf7	1792	7	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1792	8	,	,	,
cord-034340-3ksfpaf7	1792	9	with	with	IN
cord-034340-3ksfpaf7	1792	10	a	a	DT
cord-034340-3ksfpaf7	1792	11	severe	severe	JJ
cord-034340-3ksfpaf7	1792	12	systemic	systemic	JJ
cord-034340-3ksfpaf7	1792	13	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1792	14	.	.	.
cord-034340-3ksfpaf7	1793	1	SARS	SARS	NNP
cord-034340-3ksfpaf7	1793	2	-	-	HYPH
cord-034340-3ksfpaf7	1793	3	COV-2	COV-2	NNP
cord-034340-3ksfpaf7	1793	4	infection	infection	NN
cord-034340-3ksfpaf7	1793	5	could	could	MD
cord-034340-3ksfpaf7	1793	6	be	be	VB
cord-034340-3ksfpaf7	1793	7	the	the	DT
cord-034340-3ksfpaf7	1793	8	trigger	trigger	NN
cord-034340-3ksfpaf7	1793	9	that	that	WDT
cord-034340-3ksfpaf7	1793	10	could	could	MD
cord-034340-3ksfpaf7	1793	11	lead	lead	VB
cord-034340-3ksfpaf7	1793	12	to	to	IN
cord-034340-3ksfpaf7	1793	13	hyperinflammation	hyperinflammation	NN
cord-034340-3ksfpaf7	1793	14	of	of	IN
cord-034340-3ksfpaf7	1793	15	KD	KD	NNP
cord-034340-3ksfpaf7	1793	16	.	.	.
cord-034340-3ksfpaf7	1794	1	The	the	DT
cord-034340-3ksfpaf7	1794	2	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1794	3	infusion	infusion	NN
cord-034340-3ksfpaf7	1794	4	could	could	MD
cord-034340-3ksfpaf7	1794	5	explain	explain	VB
cord-034340-3ksfpaf7	1794	6	the	the	DT
cord-034340-3ksfpaf7	1794	7	transient	transient	JJ
cord-034340-3ksfpaf7	1794	8	negative	negative	JJ
cord-034340-3ksfpaf7	1794	9	swab	swab	NN
cord-034340-3ksfpaf7	1794	10	for	for	IN
cord-034340-3ksfpaf7	1794	11	SARS	SARS	NNP
cord-034340-3ksfpaf7	1794	12	-	-	HYPH
cord-034340-3ksfpaf7	1794	13	COV-2	COV-2	NNP
cord-034340-3ksfpaf7	1794	14	,	,	,
cord-034340-3ksfpaf7	1794	15	with	with	IN
cord-034340-3ksfpaf7	1794	16	the	the	DT
cord-034340-3ksfpaf7	1794	17	successive	successive	JJ
cord-034340-3ksfpaf7	1794	18	positive	positive	JJ
cord-034340-3ksfpaf7	1794	19	relieve	relieve	NN
cord-034340-3ksfpaf7	1794	20	lasting	last	VBG
cord-034340-3ksfpaf7	1794	21	7	7	CD
cord-034340-3ksfpaf7	1794	22	days	day	NNS
cord-034340-3ksfpaf7	1794	23	,	,	,
cord-034340-3ksfpaf7	1794	24	and	and	CC
cord-034340-3ksfpaf7	1794	25	the	the	DT
cord-034340-3ksfpaf7	1794	26	normal	normal	JJ
cord-034340-3ksfpaf7	1794	27	levels	level	NNS
cord-034340-3ksfpaf7	1794	28	of	of	IN
cord-034340-3ksfpaf7	1794	29	IL-6	IL-6	NNP
cord-034340-3ksfpaf7	1794	30	,	,	,
cord-034340-3ksfpaf7	1794	31	detected	detect	VBN
cord-034340-3ksfpaf7	1794	32	after	after	IN
cord-034340-3ksfpaf7	1794	33	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1794	34	infusion	infusion	NN
cord-034340-3ksfpaf7	1794	35	.	.	.
cord-034340-3ksfpaf7	1795	1	Relapsing	relapse	VBG
cord-034340-3ksfpaf7	1795	2	KD	KD	NNP
cord-034340-3ksfpaf7	1795	3	is	be	VBZ
cord-034340-3ksfpaf7	1795	4	rare	rare	JJ
cord-034340-3ksfpaf7	1795	5	(	(	-LRB-
cord-034340-3ksfpaf7	1795	6	1.7	1.7	CD
cord-034340-3ksfpaf7	1795	7	-	-	SYM
cord-034340-3ksfpaf7	1795	8	3.5	3.5	CD
cord-034340-3ksfpaf7	1795	9	%	%	NN
cord-034340-3ksfpaf7	1795	10	)	)	-RRB-
cord-034340-3ksfpaf7	1795	11	;	;	:
cord-034340-3ksfpaf7	1795	12	in	in	IN
cord-034340-3ksfpaf7	1795	13	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1795	14	patient	patient	NN
cord-034340-3ksfpaf7	1795	15	this	this	DT
cord-034340-3ksfpaf7	1795	16	event	event	NN
cord-034340-3ksfpaf7	1795	17	could	could	MD
cord-034340-3ksfpaf7	1795	18	be	be	VB
cord-034340-3ksfpaf7	1795	19	triggered	trigger	VBN
cord-034340-3ksfpaf7	1795	20	by	by	IN
cord-034340-3ksfpaf7	1795	21	the	the	DT
cord-034340-3ksfpaf7	1795	22	documented	document	VBN
cord-034340-3ksfpaf7	1795	23	SARS	SARS	NNP
cord-034340-3ksfpaf7	1795	24	-	-	HYPH
cord-034340-3ksfpaf7	1795	25	COV-2	COV-2	NNP
cord-034340-3ksfpaf7	1795	26	infection	infection	NN
cord-034340-3ksfpaf7	1795	27	.	.	.
cord-034340-3ksfpaf7	1796	1	Disclosure	disclosure	NN
cord-034340-3ksfpaf7	1796	2	of	of	IN
cord-034340-3ksfpaf7	1796	3	Interest	Interest	NNP
cord-034340-3ksfpaf7	1797	1	None	none	NN
cord-034340-3ksfpaf7	1797	2	declared	declare	VBD
cord-034340-3ksfpaf7	1797	3	Disclosure	Disclosure	NNP
cord-034340-3ksfpaf7	1797	4	of	of	IN
cord-034340-3ksfpaf7	1797	5	Interest	Interest	NNP
cord-034340-3ksfpaf7	1798	1	None	none	NN
cord-034340-3ksfpaf7	1798	2	declared	declare	VBD
cord-034340-3ksfpaf7	1798	3	AB012	AB012	NNP
cord-034340-3ksfpaf7	1798	4	Spectrum	Spectrum	NNP
cord-034340-3ksfpaf7	1798	5	of	of	IN
cord-034340-3ksfpaf7	1798	6	systemic	systemic	JJ
cord-034340-3ksfpaf7	1798	7	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1798	8	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1798	9	in	in	IN
cord-034340-3ksfpaf7	1798	10	children	child	NNS
cord-034340-3ksfpaf7	1798	11	during	during	IN
cord-034340-3ksfpaf7	1798	12	COVID	COVID	NNP
cord-034340-3ksfpaf7	1798	13	19	19	CD
cord-034340-3ksfpaf7	1798	14	pandemic	pandemic	NN
cord-034340-3ksfpaf7	1798	15	in	in	IN
cord-034340-3ksfpaf7	1798	16	India	India	NNP
cord-034340-3ksfpaf7	1798	17	D.	D.	NNP
cord-034340-3ksfpaf7	1798	18	B.	B.	NNP
cord-034340-3ksfpaf7	1798	19	Pandya	Pandya	NNP
cord-034340-3ksfpaf7	1798	20	,	,	,
cord-034340-3ksfpaf7	1798	21	on	on	IN
cord-034340-3ksfpaf7	1798	22	behalf	behalf	NN
cord-034340-3ksfpaf7	1798	23	of	of	IN
cord-034340-3ksfpaf7	1798	24	Dr	Dr	NNP
cord-034340-3ksfpaf7	1798	25	Haresh	Haresh	NNP
cord-034340-3ksfpaf7	1798	26	Dobariya	Dobariya	NNP
cord-034340-3ksfpaf7	1798	27	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	1798	28	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1798	29	&	&	CC
cord-034340-3ksfpaf7	1798	30	Immunology	Immunology	NNP
cord-034340-3ksfpaf7	1798	31	,	,	,
cord-034340-3ksfpaf7	1798	32	Dev	Dev	NNP
cord-034340-3ksfpaf7	1798	33	Children	Children	NNP
cord-034340-3ksfpaf7	1798	34	's	's	POS
cord-034340-3ksfpaf7	1798	35	Hospital	Hospital	NNP
cord-034340-3ksfpaf7	1799	1	AB025	AB025	NNP
cord-034340-3ksfpaf7	1799	2	Rituximab	Rituximab	NNP
cord-034340-3ksfpaf7	1799	3	for	for	IN
cord-034340-3ksfpaf7	1799	4	treatment	treatment	NN
cord-034340-3ksfpaf7	1799	5	of	of	IN
cord-034340-3ksfpaf7	1799	6	resistant	resistant	JJ
cord-034340-3ksfpaf7	1799	7	Paediatric	Paediatric	NNP
cord-034340-3ksfpaf7	1799	8	MCTD	MCTD	NNP
cord-034340-3ksfpaf7	1799	9	V.	V.	NNP
cord-034340-3ksfpaf7	1799	10	Paisal	Paisal	NNP
cord-034340-3ksfpaf7	1799	11	,	,	,
cord-034340-3ksfpaf7	1799	12	S.	S.	NNP
cord-034340-3ksfpaf7	1799	13	Compeyrot	Compeyrot	NNP
cord-034340-3ksfpaf7	1799	14	-	-	HYPH
cord-034340-3ksfpaf7	1799	15	Lacassagne	Lacassagne	NNP
cord-034340-3ksfpaf7	1799	16	Paediatric	Paediatric	NNP
cord-034340-3ksfpaf7	1799	17	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1800	1	The	the	DT
cord-034340-3ksfpaf7	1800	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1800	3	and	and	CC
cord-034340-3ksfpaf7	1800	4	classification	classification	NN
cord-034340-3ksfpaf7	1800	5	of	of	IN
cord-034340-3ksfpaf7	1800	6	of	of	IN
cord-034340-3ksfpaf7	1800	7	mixed	mixed	JJ
cord-034340-3ksfpaf7	1800	8	connective	connective	JJ
cord-034340-3ksfpaf7	1800	9	tissue	tissue	NN
cord-034340-3ksfpaf7	1800	10	disease	disease	NN
cord-034340-3ksfpaf7	1800	11	Mixed	mix	VBN
cord-034340-3ksfpaf7	1800	12	connective	connective	JJ
cord-034340-3ksfpaf7	1800	13	tissue	tissue	NN
cord-034340-3ksfpaf7	1800	14	disease	disease	NN
cord-034340-3ksfpaf7	1800	15	in	in	IN
cord-034340-3ksfpaf7	1800	16	children	child	NNS
cord-034340-3ksfpaf7	1800	17	-case	-case	NNP
cord-034340-3ksfpaf7	1800	18	series	series	NNP
cord-034340-3ksfpaf7	1801	1	The	the	DT
cord-034340-3ksfpaf7	1801	2	value	value	NN
cord-034340-3ksfpaf7	1801	3	of	of	IN
cord-034340-3ksfpaf7	1801	4	Rituximab	Rituximab	NNP
cord-034340-3ksfpaf7	1801	5	treatment	treatment	NN
cord-034340-3ksfpaf7	1801	6	in	in	IN
cord-034340-3ksfpaf7	1801	7	primary	primary	JJ
cord-034340-3ksfpaf7	1801	8	Sjögren	Sjögren	NNP
cord-034340-3ksfpaf7	1801	9	's	's	POS
cord-034340-3ksfpaf7	1801	10	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1801	11	Juvenile	Juvenile	NNP
cord-034340-3ksfpaf7	1801	12	Idiopathic	Idiopathic	NNP
cord-034340-3ksfpaf7	1801	13	Arthritis	Arthritis	NNP
cord-034340-3ksfpaf7	1801	14	a	a	DT
cord-034340-3ksfpaf7	1801	15	multifaceted	multifaceted	JJ
cord-034340-3ksfpaf7	1801	16	approach	approach	NN
cord-034340-3ksfpaf7	1801	17	is	be	VBZ
cord-034340-3ksfpaf7	1801	18	essential	essential	JJ
cord-034340-3ksfpaf7	1801	19	for	for	IN
cord-034340-3ksfpaf7	1801	20	robust	robust	JJ
cord-034340-3ksfpaf7	1801	21	rehabilitation	rehabilitation	NN
cord-034340-3ksfpaf7	1801	22	M	M	NNP
cord-034340-3ksfpaf7	1801	23	Methods	Methods	NNPS
cord-034340-3ksfpaf7	1801	24	:	:	:
cord-034340-3ksfpaf7	1802	1	In	in	IN
cord-034340-3ksfpaf7	1802	2	a	a	DT
cord-034340-3ksfpaf7	1802	3	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1802	4	study	study	NN
cord-034340-3ksfpaf7	1802	5	92	92	CD
cord-034340-3ksfpaf7	1802	6	children	child	NNS
cord-034340-3ksfpaf7	1802	7	(	(	-LRB-
cord-034340-3ksfpaf7	1802	8	89	89	CD
cord-034340-3ksfpaf7	1802	9	%	%	NN
cord-034340-3ksfpaf7	1802	10	girls	girl	NNS
cord-034340-3ksfpaf7	1802	11	)	)	-RRB-
cord-034340-3ksfpaf7	1802	12	aged	aged	JJ
cord-034340-3ksfpaf7	1802	13	median	median	NN
cord-034340-3ksfpaf7	1802	14	(	(	-LRB-
cord-034340-3ksfpaf7	1802	15	IQR	IQR	NNP
cord-034340-3ksfpaf7	1802	16	)	)	-RRB-
cord-034340-3ksfpaf7	1802	17	4,2	4,2	CD
cord-034340-3ksfpaf7	1802	18	(	(	-LRB-
cord-034340-3ksfpaf7	1802	19	1,6	1,6	CD
cord-034340-3ksfpaf7	1802	20	-7,6	-7,6	NNP
cord-034340-3ksfpaf7	1802	21	)	)	-RRB-
cord-034340-3ksfpaf7	1802	22	years	year	NNS
cord-034340-3ksfpaf7	1802	23	with	with	IN
cord-034340-3ksfpaf7	1802	24	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	1802	25	onset	onset	NN
cord-034340-3ksfpaf7	1802	26	JIA	JIA	NNP
cord-034340-3ksfpaf7	1802	27	without	without	IN
cord-034340-3ksfpaf7	1802	28	extra	extra	JJ
cord-034340-3ksfpaf7	1802	29	-	-	JJ
cord-034340-3ksfpaf7	1802	30	articular	articular	JJ
cord-034340-3ksfpaf7	1802	31	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	1802	32	(	(	-LRB-
cord-034340-3ksfpaf7	1802	33	oligo	oligo	NNP
cord-034340-3ksfpaf7	1802	34	-	-	HYPH
cord-034340-3ksfpaf7	1802	35	JA	JA	NNP
cord-034340-3ksfpaf7	1802	36	)	)	-RRB-
cord-034340-3ksfpaf7	1802	37	who	who	WP
cord-034340-3ksfpaf7	1802	38	did	do	VBD
cord-034340-3ksfpaf7	1802	39	not	not	RB
cord-034340-3ksfpaf7	1802	40	received	receive	VBN
cord-034340-3ksfpaf7	1802	41	DMARDs	dmard	NNS
cord-034340-3ksfpaf7	1802	42	were	be	VBD
cord-034340-3ksfpaf7	1802	43	monitored	monitor	VBN
cord-034340-3ksfpaf7	1802	44	.	.	.
cord-034340-3ksfpaf7	1803	1	All	all	DT
cord-034340-3ksfpaf7	1803	2	children	child	NNS
cord-034340-3ksfpaf7	1803	3	were	be	VBD
cord-034340-3ksfpaf7	1803	4	met	meet	VBN
cord-034340-3ksfpaf7	1803	5	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	1803	6	criteria	criterion	NNS
cord-034340-3ksfpaf7	1803	7	.	.	.
cord-034340-3ksfpaf7	1804	1	Ttriamcinolone	Ttriamcinolone	NNP
cord-034340-3ksfpaf7	1804	2	acetonide	acetonide	NN
cord-034340-3ksfpaf7	1804	3	(	(	-LRB-
cord-034340-3ksfpaf7	1804	4	TA	TA	NNP
cord-034340-3ksfpaf7	1804	5	)	)	-RRB-
cord-034340-3ksfpaf7	1804	6	was	be	VBD
cord-034340-3ksfpaf7	1804	7	administered	administer	VBN
cord-034340-3ksfpaf7	1804	8	intra	intra	JJ
cord-034340-3ksfpaf7	1804	9	-	-	JJ
cord-034340-3ksfpaf7	1804	10	articular	articular	JJ
cord-034340-3ksfpaf7	1804	11	at	at	IN
cord-034340-3ksfpaf7	1804	12	a	a	DT
cord-034340-3ksfpaf7	1804	13	dose	dose	NN
cord-034340-3ksfpaf7	1804	14	of	of	IN
cord-034340-3ksfpaf7	1804	15	20	20	CD
cord-034340-3ksfpaf7	1804	16	-	-	SYM
cord-034340-3ksfpaf7	1804	17	40	40	CD
cord-034340-3ksfpaf7	1804	18	mg	mg	NN
cord-034340-3ksfpaf7	1804	19	with	with	IN
cord-034340-3ksfpaf7	1804	20	an	an	DT
cord-034340-3ksfpaf7	1804	21	injection	injection	NN
cord-034340-3ksfpaf7	1804	22	interval	interval	NN
cord-034340-3ksfpaf7	1804	23	of	of	IN
cord-034340-3ksfpaf7	1804	24	3	3	CD
cord-034340-3ksfpaf7	1804	25	-	-	SYM
cord-034340-3ksfpaf7	1804	26	6	6	CD
cord-034340-3ksfpaf7	1804	27	-	-	SYM
cord-034340-3ksfpaf7	1804	28	12	12	CD
cord-034340-3ksfpaf7	1804	29	months	month	NNS
cord-034340-3ksfpaf7	1804	30	which	which	WDT
cord-034340-3ksfpaf7	1804	31	was	be	VBD
cord-034340-3ksfpaf7	1804	32	depended	depend	VBN
cord-034340-3ksfpaf7	1804	33	on	on	IN
cord-034340-3ksfpaf7	1804	34	the	the	DT
cord-034340-3ksfpaf7	1804	35	activity	activity	NN
cord-034340-3ksfpaf7	1804	36	of	of	IN
cord-034340-3ksfpaf7	1804	37	the	the	DT
cord-034340-3ksfpaf7	1804	38	disease	disease	NN
cord-034340-3ksfpaf7	1804	39	.	.	.
cord-034340-3ksfpaf7	1805	1	The	the	DT
cord-034340-3ksfpaf7	1805	2	maximum	maximum	JJ
cord-034340-3ksfpaf7	1805	3	allowable	allowable	JJ
cord-034340-3ksfpaf7	1805	4	number	number	NN
cord-034340-3ksfpaf7	1805	5	of	of	IN
cord-034340-3ksfpaf7	1805	6	consecutive	consecutive	JJ
cord-034340-3ksfpaf7	1805	7	isolated	isolate	VBN
cord-034340-3ksfpaf7	1805	8	intra	intra	JJ
cord-034340-3ksfpaf7	1805	9	-	-	JJ
cord-034340-3ksfpaf7	1805	10	articular	articular	JJ
cord-034340-3ksfpaf7	1805	11	injections	injection	NNS
cord-034340-3ksfpaf7	1805	12	(	(	-LRB-
cord-034340-3ksfpaf7	1805	13	is	be	VBZ
cord-034340-3ksfpaf7	1805	14	-	-	:
cord-034340-3ksfpaf7	1805	15	IAI	IAI	NNP
cord-034340-3ksfpaf7	1805	16	)	)	-RRB-
cord-034340-3ksfpaf7	1805	17	was	be	VBD
cord-034340-3ksfpaf7	1805	18	3	3	CD
cord-034340-3ksfpaf7	1805	19	-	-	SYM
cord-034340-3ksfpaf7	1805	20	4	4	CD
cord-034340-3ksfpaf7	1805	21	.	.	.
cord-034340-3ksfpaf7	1806	1	A	a	DT
cord-034340-3ksfpaf7	1806	2	total	total	NN
cord-034340-3ksfpaf7	1806	3	of	of	IN
cord-034340-3ksfpaf7	1806	4	218	218	CD
cord-034340-3ksfpaf7	1806	5	active	active	JJ
cord-034340-3ksfpaf7	1806	6	joints	joint	NNS
cord-034340-3ksfpaf7	1806	7	were	be	VBD
cord-034340-3ksfpaf7	1806	8	injected	inject	VBN
cord-034340-3ksfpaf7	1806	9	with	with	IN
cord-034340-3ksfpaf7	1806	10	TA	TA	NNP
cord-034340-3ksfpaf7	1806	11	:	:	:
cord-034340-3ksfpaf7	1806	12	knees	knee	NNS
cord-034340-3ksfpaf7	1806	13	-156	-156	VBZ
cord-034340-3ksfpaf7	1806	14	injections	injection	NNS
cord-034340-3ksfpaf7	1806	15	,	,	,
cord-034340-3ksfpaf7	1806	16	ankles	ankle	NNS
cord-034340-3ksfpaf7	1806	17	-62	-62	NN
cord-034340-3ksfpaf7	1806	18	injections	injection	NNS
cord-034340-3ksfpaf7	1806	19	.	.	.
cord-034340-3ksfpaf7	1807	1	All	all	DT
cord-034340-3ksfpaf7	1807	2	children	child	NNS
cord-034340-3ksfpaf7	1807	3	were	be	VBD
cord-034340-3ksfpaf7	1807	4	divided	divide	VBN
cord-034340-3ksfpaf7	1807	5	into	into	IN
cord-034340-3ksfpaf7	1807	6	two	two	CD
cord-034340-3ksfpaf7	1807	7	groups	group	NNS
cord-034340-3ksfpaf7	1807	8	:	:	:
cord-034340-3ksfpaf7	1807	9	active	active	JJ
cord-034340-3ksfpaf7	1807	10	/	/	SYM
cord-034340-3ksfpaf7	1807	11	inactive	inactive	JJ
cord-034340-3ksfpaf7	1807	12	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1807	13	based	base	VBN
cord-034340-3ksfpaf7	1807	14	on	on	IN
cord-034340-3ksfpaf7	1807	15	the	the	DT
cord-034340-3ksfpaf7	1807	16	effectiveness	effectiveness	NN
cord-034340-3ksfpaf7	1807	17	of	of	IN
cord-034340-3ksfpaf7	1807	18	local	local	JJ
cord-034340-3ksfpaf7	1807	19	corticosteroid	corticosteroid	NN
cord-034340-3ksfpaf7	1807	20	treatment	treatment	NN
cord-034340-3ksfpaf7	1807	21	.	.	.
cord-034340-3ksfpaf7	1808	1	The	the	DT
cord-034340-3ksfpaf7	1808	2	average	average	JJ
cord-034340-3ksfpaf7	1808	3	follow	follow	NN
cord-034340-3ksfpaf7	1808	4	-	-	HYPH
cord-034340-3ksfpaf7	1808	5	up	up	NN
cord-034340-3ksfpaf7	1808	6	was	be	VBD
cord-034340-3ksfpaf7	1808	7	48	48	CD
cord-034340-3ksfpaf7	1808	8	and	and	CC
cord-034340-3ksfpaf7	1808	9	physicians	physician	NNS
cord-034340-3ksfpaf7	1808	10	'	'	POS
cord-034340-3ksfpaf7	1808	11	assessment	assessment	NN
cord-034340-3ksfpaf7	1808	12	of	of	IN
cord-034340-3ksfpaf7	1808	13	JIA	JIA	NNP
cord-034340-3ksfpaf7	1808	14	disease	disease	NN
cord-034340-3ksfpaf7	1808	15	activity	activity	NN
cord-034340-3ksfpaf7	1808	16	Efficacy	Efficacy	NNP
cord-034340-3ksfpaf7	1808	17	is	be	VBZ
cord-034340-3ksfpaf7	1808	18	-	-	:
cord-034340-3ksfpaf7	1808	19	IAI	IAI	NNP
cord-034340-3ksfpaf7	1808	20	of	of	IN
cord-034340-3ksfpaf7	1808	21	TA	TA	NNP
cord-034340-3ksfpaf7	1808	22	was	be	VBD
cord-034340-3ksfpaf7	1808	23	no	no	DT
cord-034340-3ksfpaf7	1808	24	associated	associate	VBN
cord-034340-3ksfpaf7	1808	25	significantly	significantly	RB
cord-034340-3ksfpaf7	1808	26	with	with	IN
cord-034340-3ksfpaf7	1808	27	number	number	NN
cord-034340-3ksfpaf7	1808	28	of	of	IN
cord-034340-3ksfpaf7	1808	29	active	active	JJ
cord-034340-3ksfpaf7	1808	30	joint	joint	NN
cord-034340-3ksfpaf7	1808	31	of	of	IN
cord-034340-3ksfpaf7	1808	32	onset	onset	NN
cord-034340-3ksfpaf7	1808	33	oligo	oligo	NNP
cord-034340-3ksfpaf7	1808	34	-	-	HYPH
cord-034340-3ksfpaf7	1808	35	JA	JA	NNP
cord-034340-3ksfpaf7	1808	36	,	,	,
cord-034340-3ksfpaf7	1808	37	cJADAS10	cJADAS10	NNS
cord-034340-3ksfpaf7	1808	38	,	,	,
cord-034340-3ksfpaf7	1808	39	serum	serum	NN
cord-034340-3ksfpaf7	1808	40	level	level	NN
cord-034340-3ksfpaf7	1808	41	of	of	IN
cord-034340-3ksfpaf7	1808	42	CRP	CRP	NNP
cord-034340-3ksfpaf7	1808	43	mg	mg	NNP
cord-034340-3ksfpaf7	1808	44	/	/	SYM
cord-034340-3ksfpaf7	1808	45	ml	ml	XX
cord-034340-3ksfpaf7	1808	46	,	,	,
cord-034340-3ksfpaf7	1808	47	ESR	ESR	NNP
cord-034340-3ksfpaf7	1808	48	mm	mm	NNP
cord-034340-3ksfpaf7	1808	49	/	/	SYM
cord-034340-3ksfpaf7	1808	50	h	h	NNP
cord-034340-3ksfpaf7	1808	51	,	,	,
cord-034340-3ksfpaf7	1808	52	IL6	IL6	NNP
cord-034340-3ksfpaf7	1808	53	pg	pg	NNP
cord-034340-3ksfpaf7	1808	54	/	/	SYM
cord-034340-3ksfpaf7	1808	55	ml	ml	NNP
cord-034340-3ksfpaf7	1808	56	and	and	CC
cord-034340-3ksfpaf7	1808	57	TNF	TNF	NNP
cord-034340-3ksfpaf7	1808	58	-	-	HYPH
cord-034340-3ksfpaf7	1808	59	α	α	NNP
cord-034340-3ksfpaf7	1808	60	pg	pg	NNP
cord-034340-3ksfpaf7	1808	61	/	/	SYM
cord-034340-3ksfpaf7	1808	62	ml	ml	NN
cord-034340-3ksfpaf7	1808	63	,	,	,
cord-034340-3ksfpaf7	1808	64	titer	titer	NN
cord-034340-3ksfpaf7	1808	65	of	of	IN
cord-034340-3ksfpaf7	1808	66	ANF	ANF	NNP
cord-034340-3ksfpaf7	1808	67	.	.	.
cord-034340-3ksfpaf7	1809	1	The	the	DT
cord-034340-3ksfpaf7	1809	2	mean	mean	JJ
cord-034340-3ksfpaf7	1809	3	inflamed	inflamed	JJ
cord-034340-3ksfpaf7	1809	4	synovial	synovial	JJ
cord-034340-3ksfpaf7	1809	5	fluid	fluid	NN
cord-034340-3ksfpaf7	1809	6	of	of	IN
cord-034340-3ksfpaf7	1809	7	IL6	il6	NN
cord-034340-3ksfpaf7	1809	8	levels	level	NNS
cord-034340-3ksfpaf7	1809	9	2208	2208	CD
cord-034340-3ksfpaf7	1809	10	Abstracts	abstract	NNS
cord-034340-3ksfpaf7	1809	11	from	from	IN
cord-034340-3ksfpaf7	1809	12	conferences	conference	NNS
cord-034340-3ksfpaf7	1809	13	and	and	CC
cord-034340-3ksfpaf7	1809	14	relevant	relevant	JJ
cord-034340-3ksfpaf7	1809	15	studies	study	NNS
cord-034340-3ksfpaf7	1809	16	were	be	VBD
cord-034340-3ksfpaf7	1809	17	added	add	VBN
cord-034340-3ksfpaf7	1809	18	.	.	.
cord-034340-3ksfpaf7	1810	1	RCTs	RCTs	NNP
cord-034340-3ksfpaf7	1810	2	were	be	VBD
cord-034340-3ksfpaf7	1810	3	included	include	VBN
cord-034340-3ksfpaf7	1810	4	if	if	IN
cord-034340-3ksfpaf7	1810	5	(	(	-LRB-
cord-034340-3ksfpaf7	1810	6	i	i	NN
cord-034340-3ksfpaf7	1810	7	)	)	-RRB-
cord-034340-3ksfpaf7	1810	8	patients	patient	NNS
cord-034340-3ksfpaf7	1810	9	were	be	VBD
cord-034340-3ksfpaf7	1810	10	aged	age	VBN
cord-034340-3ksfpaf7	1810	11	≤	≤	NNS
cord-034340-3ksfpaf7	1810	12	20	20	CD
cord-034340-3ksfpaf7	1810	13	years	year	NNS
cord-034340-3ksfpaf7	1810	14	,	,	,
cord-034340-3ksfpaf7	1810	15	(	(	-LRB-
cord-034340-3ksfpaf7	1810	16	ii	ii	NN
cord-034340-3ksfpaf7	1810	17	)	)	-RRB-
cord-034340-3ksfpaf7	1810	18	patients	patient	NNS
cord-034340-3ksfpaf7	1810	19	had	have	VBD
cord-034340-3ksfpaf7	1810	20	a	a	DT
cord-034340-3ksfpaf7	1810	21	previous	previous	JJ
cord-034340-3ksfpaf7	1810	22	defined	define	VBN
cord-034340-3ksfpaf7	1810	23	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1810	24	rheumatic	rheumatic	JJ
cord-034340-3ksfpaf7	1810	25	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1810	26	and	and	CC
cord-034340-3ksfpaf7	1810	27	(	(	-LRB-
cord-034340-3ksfpaf7	1810	28	iii	iii	NN
cord-034340-3ksfpaf7	1810	29	)	)	-RRB-
cord-034340-3ksfpaf7	1811	1	RCT	RCT	NNP
cord-034340-3ksfpaf7	1811	2	met	meet	VBD
cord-034340-3ksfpaf7	1811	3	predefined	predefined	JJ
cord-034340-3ksfpaf7	1811	4	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1811	5	.	.	.
cord-034340-3ksfpaf7	1812	1	Studies	study	NNS
cord-034340-3ksfpaf7	1812	2	were	be	VBD
cord-034340-3ksfpaf7	1812	3	excluded	exclude	VBN
cord-034340-3ksfpaf7	1812	4	in	in	IN
cord-034340-3ksfpaf7	1812	5	case	case	NN
cord-034340-3ksfpaf7	1812	6	of	of	IN
cord-034340-3ksfpaf7	1812	7	(	(	-LRB-
cord-034340-3ksfpaf7	1812	8	i	i	NN
cord-034340-3ksfpaf7	1812	9	)	)	-RRB-
cord-034340-3ksfpaf7	1812	10	observational	observational	JJ
cord-034340-3ksfpaf7	1812	11	or	or	CC
cord-034340-3ksfpaf7	1812	12	single	single	JJ
cord-034340-3ksfpaf7	1812	13	arm	arm	NN
cord-034340-3ksfpaf7	1812	14	study	study	NN
cord-034340-3ksfpaf7	1812	15	or	or	CC
cord-034340-3ksfpaf7	1812	16	(	(	-LRB-
cord-034340-3ksfpaf7	1812	17	ii	ii	NN
cord-034340-3ksfpaf7	1812	18	)	)	-RRB-
cord-034340-3ksfpaf7	1812	19	sample	sample	NN
cord-034340-3ksfpaf7	1812	20	size	size	NN
cord-034340-3ksfpaf7	1812	21	≤	≤	NNP
cord-034340-3ksfpaf7	1812	22	5	5	CD
cord-034340-3ksfpaf7	1812	23	patients	patient	NNS
cord-034340-3ksfpaf7	1812	24	.	.	.
cord-034340-3ksfpaf7	1813	1	Study	study	NN
cord-034340-3ksfpaf7	1813	2	design	design	NN
cord-034340-3ksfpaf7	1813	3	,	,	,
cord-034340-3ksfpaf7	1813	4	location	location	NN
cord-034340-3ksfpaf7	1813	5	,	,	,
cord-034340-3ksfpaf7	1813	6	duration	duration	NN
cord-034340-3ksfpaf7	1813	7	,	,	,
cord-034340-3ksfpaf7	1813	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1813	9	,	,	,
cord-034340-3ksfpaf7	1813	10	population	population	NN
cord-034340-3ksfpaf7	1813	11	,	,	,
cord-034340-3ksfpaf7	1813	12	sample	sample	NN
cord-034340-3ksfpaf7	1813	13	size	size	NN
cord-034340-3ksfpaf7	1813	14	,	,	,
cord-034340-3ksfpaf7	1813	15	age	age	NN
cord-034340-3ksfpaf7	1813	16	criteria	criterion	NNS
cord-034340-3ksfpaf7	1813	17	,	,	,
cord-034340-3ksfpaf7	1813	18	gender	gender	NN
cord-034340-3ksfpaf7	1813	19	,	,	,
cord-034340-3ksfpaf7	1813	20	concomitant	concomitant	JJ
cord-034340-3ksfpaf7	1813	21	treatments	treatment	NNS
cord-034340-3ksfpaf7	1813	22	and	and	CC
cord-034340-3ksfpaf7	1813	23	primary	primary	JJ
cord-034340-3ksfpaf7	1813	24	outcome	outcome	NN
cord-034340-3ksfpaf7	1813	25	was	be	VBD
cord-034340-3ksfpaf7	1813	26	extracted	extract	VBN
cord-034340-3ksfpaf7	1813	27	.	.	.
cord-034340-3ksfpaf7	1814	1	Results	result	NNS
cord-034340-3ksfpaf7	1814	2	:	:	:
cord-034340-3ksfpaf7	1815	1	Out	out	IN
cord-034340-3ksfpaf7	1815	2	of	of	IN
cord-034340-3ksfpaf7	1815	3	550	550	CD
cord-034340-3ksfpaf7	1815	4	screened	screen	VBN
cord-034340-3ksfpaf7	1815	5	references	reference	NNS
cord-034340-3ksfpaf7	1815	6	,	,	,
cord-034340-3ksfpaf7	1815	7	62	62	CD
cord-034340-3ksfpaf7	1815	8	references	reference	NNS
cord-034340-3ksfpaf7	1815	9	reporting	report	VBG
cord-034340-3ksfpaf7	1815	10	35	35	CD
cord-034340-3ksfpaf7	1815	11	unique	unique	JJ
cord-034340-3ksfpaf7	1815	12	RCTs	rct	NNS
cord-034340-3ksfpaf7	1815	13	in	in	IN
cord-034340-3ksfpaf7	1815	14	PiRD	PiRD	NNP
cord-034340-3ksfpaf7	1815	15	.	.	.
cord-034340-3ksfpaf7	1816	1	All	all	DT
cord-034340-3ksfpaf7	1816	2	35	35	CD
cord-034340-3ksfpaf7	1816	3	RCTs	rct	NNS
cord-034340-3ksfpaf7	1816	4	reported	report	VBD
cord-034340-3ksfpaf7	1816	5	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1816	6	while	while	IN
cord-034340-3ksfpaf7	1816	7	34/35	34/35	CD
cord-034340-3ksfpaf7	1816	8	RCTs	RCTs	NNP
cord-034340-3ksfpaf7	1816	9	provided	provide	VBD
cord-034340-3ksfpaf7	1816	10	safety	safety	NN
cord-034340-3ksfpaf7	1816	11	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1816	12	and	and	CC
cord-034340-3ksfpaf7	1816	13	15/35	15/35	CD
cord-034340-3ksfpaf7	1816	14	RCTs	rct	NNS
cord-034340-3ksfpaf7	1816	15	provided	provide	VBD
cord-034340-3ksfpaf7	1816	16	PK	PK	NNP
cord-034340-3ksfpaf7	1816	17	data	datum	NNS
cord-034340-3ksfpaf7	1816	18	.	.	.
cord-034340-3ksfpaf7	1817	1	Ten	ten	CD
cord-034340-3ksfpaf7	1817	2	of	of	IN
cord-034340-3ksfpaf7	1817	3	17	17	CD
cord-034340-3ksfpaf7	1817	4	reviewed	review	VBN
cord-034340-3ksfpaf7	1817	5	bDMARDs	bdmards	NN
cord-034340-3ksfpaf7	1817	6	are	be	VBP
cord-034340-3ksfpaf7	1817	7	approved	approve	VBN
cord-034340-3ksfpaf7	1817	8	for	for	IN
cord-034340-3ksfpaf7	1817	9	PiRDs	pird	NNS
cord-034340-3ksfpaf7	1817	10	by	by	IN
cord-034340-3ksfpaf7	1817	11	the	the	DT
cord-034340-3ksfpaf7	1817	12	Food	Food	NNP
cord-034340-3ksfpaf7	1817	13	and	and	CC
cord-034340-3ksfpaf7	1817	14	Drug	Drug	NNP
cord-034340-3ksfpaf7	1817	15	Administration	Administration	NNP
cord-034340-3ksfpaf7	1817	16	(	(	-LRB-
cord-034340-3ksfpaf7	1817	17	FDA	FDA	NNP
cord-034340-3ksfpaf7	1817	18	)	)	-RRB-
cord-034340-3ksfpaf7	1817	19	.	.	.
cord-034340-3ksfpaf7	1818	1	Of	of	IN
cord-034340-3ksfpaf7	1818	2	these	these	DT
cord-034340-3ksfpaf7	1818	3	,	,	,
cord-034340-3ksfpaf7	1818	4	seven	seven	CD
cord-034340-3ksfpaf7	1818	5	had	have	VBD
cord-034340-3ksfpaf7	1818	6	≤	≤	NNP
cord-034340-3ksfpaf7	1818	7	2	2	CD
cord-034340-3ksfpaf7	1818	8	RCTs	rct	NNS
cord-034340-3ksfpaf7	1818	9	.	.	.
cord-034340-3ksfpaf7	1819	1	The	the	DT
cord-034340-3ksfpaf7	1819	2	most	most	RBS
cord-034340-3ksfpaf7	1819	3	common	common	JJ
cord-034340-3ksfpaf7	1819	4	intervention	intervention	NN
cord-034340-3ksfpaf7	1819	5	was	be	VBD
cord-034340-3ksfpaf7	1819	6	TNF	TNF	NNP
cord-034340-3ksfpaf7	1819	7	inhibitors	inhibitor	NNS
cord-034340-3ksfpaf7	1819	8	(	(	-LRB-
cord-034340-3ksfpaf7	1819	9	63	63	CD
cord-034340-3ksfpaf7	1819	10	%	%	NN
cord-034340-3ksfpaf7	1819	11	)	)	-RRB-
cord-034340-3ksfpaf7	1820	1	Treatment	treatment	NN
cord-034340-3ksfpaf7	1820	2	with	with	IN
cord-034340-3ksfpaf7	1820	3	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1820	4	immunoglobulin	immunoglobulin	NN
cord-034340-3ksfpaf7	1820	5	(	(	-LRB-
cord-034340-3ksfpaf7	1820	6	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1820	7	)	)	-RRB-
cord-034340-3ksfpaf7	1820	8	significantly	significantly	RB
cord-034340-3ksfpaf7	1820	9	reduces	reduce	VBZ
cord-034340-3ksfpaf7	1820	10	the	the	DT
cord-034340-3ksfpaf7	1820	11	risk	risk	NN
cord-034340-3ksfpaf7	1820	12	of	of	IN
cord-034340-3ksfpaf7	1820	13	CAAs	CAAs	NNP
cord-034340-3ksfpaf7	1820	14	.	.	.
cord-034340-3ksfpaf7	1821	1	However	however	RB
cord-034340-3ksfpaf7	1821	2	,	,	,
cord-034340-3ksfpaf7	1821	3	up	up	IN
cord-034340-3ksfpaf7	1821	4	to	to	TO
cord-034340-3ksfpaf7	1821	5	20	20	CD
cord-034340-3ksfpaf7	1821	6	%	%	NN
cord-034340-3ksfpaf7	1821	7	of	of	IN
cord-034340-3ksfpaf7	1821	8	cases	case	NNS
cord-034340-3ksfpaf7	1821	9	are	be	VBP
cord-034340-3ksfpaf7	1821	10	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1821	11	resistant	resistant	JJ
cord-034340-3ksfpaf7	1821	12	with	with	IN
cord-034340-3ksfpaf7	1821	13	a	a	DT
cord-034340-3ksfpaf7	1821	14	higher	high	JJR
cord-034340-3ksfpaf7	1821	15	risk	risk	NN
cord-034340-3ksfpaf7	1821	16	of	of	IN
cord-034340-3ksfpaf7	1821	17	cardiovascular	cardiovascular	JJ
cord-034340-3ksfpaf7	1821	18	complications	complication	NNS
cord-034340-3ksfpaf7	1821	19	.	.	.
cord-034340-3ksfpaf7	1822	1	Currently	currently	RB
cord-034340-3ksfpaf7	1822	2	several	several	JJ
cord-034340-3ksfpaf7	1822	3	second	second	JJ
cord-034340-3ksfpaf7	1822	4	-	-	HYPH
cord-034340-3ksfpaf7	1822	5	line	line	NN
cord-034340-3ksfpaf7	1822	6	treatments	treatment	NNS
cord-034340-3ksfpaf7	1822	7	are	be	VBP
cord-034340-3ksfpaf7	1822	8	available	available	JJ
cord-034340-3ksfpaf7	1822	9	for	for	IN
cord-034340-3ksfpaf7	1822	10	refractory	refractory	JJ
cord-034340-3ksfpaf7	1822	11	KD	KD	NNP
cord-034340-3ksfpaf7	1822	12	.	.	.
cord-034340-3ksfpaf7	1823	1	Nonetheless	nonetheless	RB
cord-034340-3ksfpaf7	1823	2	,	,	,
cord-034340-3ksfpaf7	1823	3	the	the	DT
cord-034340-3ksfpaf7	1823	4	existing	exist	VBG
cord-034340-3ksfpaf7	1823	5	literature	literature	NN
cord-034340-3ksfpaf7	1823	6	is	be	VBZ
cord-034340-3ksfpaf7	1823	7	still	still	RB
cord-034340-3ksfpaf7	1823	8	unable	unable	JJ
cord-034340-3ksfpaf7	1823	9	to	to	TO
cord-034340-3ksfpaf7	1823	10	identify	identify	VB
cord-034340-3ksfpaf7	1823	11	which	which	WDT
cord-034340-3ksfpaf7	1823	12	treatment	treatment	NN
cord-034340-3ksfpaf7	1823	13	is	be	VBZ
cord-034340-3ksfpaf7	1823	14	the	the	DT
cord-034340-3ksfpaf7	1823	15	most	most	RBS
cord-034340-3ksfpaf7	1823	16	effective	effective	JJ
cord-034340-3ksfpaf7	1823	17	.	.	.
cord-034340-3ksfpaf7	1824	1	Recent	recent	JJ
cord-034340-3ksfpaf7	1824	2	studies	study	NNS
cord-034340-3ksfpaf7	1824	3	suggest	suggest	VBP
cord-034340-3ksfpaf7	1824	4	that	that	IN
cord-034340-3ksfpaf7	1824	5	a	a	DT
cord-034340-3ksfpaf7	1824	6	IL-1	IL-1	NNP
cord-034340-3ksfpaf7	1824	7	receptor	receptor	NN
cord-034340-3ksfpaf7	1824	8	antagonist	antagonist	NN
cord-034340-3ksfpaf7	1824	9	(	(	-LRB-
cord-034340-3ksfpaf7	1824	10	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	1824	11	)	)	-RRB-
cord-034340-3ksfpaf7	1824	12	may	may	MD
cord-034340-3ksfpaf7	1824	13	be	be	VB
cord-034340-3ksfpaf7	1824	14	an	an	DT
cord-034340-3ksfpaf7	1824	15	effective	effective	JJ
cord-034340-3ksfpaf7	1824	16	therapy	therapy	NN
cord-034340-3ksfpaf7	1824	17	in	in	IN
cord-034340-3ksfpaf7	1824	18	refractory	refractory	JJ
cord-034340-3ksfpaf7	1824	19	KD	KD	NNP
cord-034340-3ksfpaf7	1824	20	.	.	.
cord-034340-3ksfpaf7	1825	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1825	2	:	:	:
cord-034340-3ksfpaf7	1825	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1825	4	report	report	VBP
cord-034340-3ksfpaf7	1825	5	the	the	DT
cord-034340-3ksfpaf7	1825	6	case	case	NN
cord-034340-3ksfpaf7	1825	7	of	of	IN
cord-034340-3ksfpaf7	1825	8	a	a	DT
cord-034340-3ksfpaf7	1825	9	3	3	CD
cord-034340-3ksfpaf7	1825	10	year	year	NN
cord-034340-3ksfpaf7	1825	11	-	-	HYPH
cord-034340-3ksfpaf7	1825	12	old	old	JJ
cord-034340-3ksfpaf7	1825	13	boy	boy	NN
cord-034340-3ksfpaf7	1825	14	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1825	15	with	with	IN
cord-034340-3ksfpaf7	1825	16	KD	KD	NNP
cord-034340-3ksfpaf7	1825	17	refractory	refractory	JJ
cord-034340-3ksfpaf7	1825	18	to	to	IN
cord-034340-3ksfpaf7	1825	19	conventional	conventional	JJ
cord-034340-3ksfpaf7	1825	20	treatment	treatment	NN
cord-034340-3ksfpaf7	1825	21	,	,	,
cord-034340-3ksfpaf7	1825	22	who	who	WP
cord-034340-3ksfpaf7	1825	23	developed	develop	VBD
cord-034340-3ksfpaf7	1825	24	giant	giant	JJ
cord-034340-3ksfpaf7	1825	25	CAAs	CAAs	NNP
cord-034340-3ksfpaf7	1825	26	successfully	successfully	RB
cord-034340-3ksfpaf7	1825	27	treated	treat	VBN
cord-034340-3ksfpaf7	1825	28	with	with	IN
cord-034340-3ksfpaf7	1825	29	subcutaneous	subcutaneous	JJ
cord-034340-3ksfpaf7	1825	30	(	(	-LRB-
cord-034340-3ksfpaf7	1825	31	sc	sc	NNP
cord-034340-3ksfpaf7	1825	32	)	)	-RRB-
cord-034340-3ksfpaf7	1825	33	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	1825	34	.	.	.
cord-034340-3ksfpaf7	1826	1	Methods	method	NNS
cord-034340-3ksfpaf7	1826	2	:	:	:
cord-034340-3ksfpaf7	1827	1	Case	case	NN
cord-034340-3ksfpaf7	1827	2	report	report	NN
cord-034340-3ksfpaf7	1827	3	.	.	.
cord-034340-3ksfpaf7	1828	1	Results	result	NNS
cord-034340-3ksfpaf7	1828	2	:	:	:
cord-034340-3ksfpaf7	1829	1	A	a	DT
cord-034340-3ksfpaf7	1829	2	3	3	CD
cord-034340-3ksfpaf7	1829	3	year	year	NN
cord-034340-3ksfpaf7	1829	4	-	-	HYPH
cord-034340-3ksfpaf7	1829	5	old	old	JJ
cord-034340-3ksfpaf7	1829	6	boy	boy	NN
cord-034340-3ksfpaf7	1829	7	was	be	VBD
cord-034340-3ksfpaf7	1829	8	referred	refer	VBN
cord-034340-3ksfpaf7	1829	9	to	to	IN
cord-034340-3ksfpaf7	1829	10	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1829	11	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	1829	12	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1829	13	Unit	Unit	NNP
cord-034340-3ksfpaf7	1829	14	18	18	CD
cord-034340-3ksfpaf7	1829	15	days	day	NNS
cord-034340-3ksfpaf7	1829	16	after	after	IN
cord-034340-3ksfpaf7	1829	17	the	the	DT
cord-034340-3ksfpaf7	1829	18	onset	onset	NN
cord-034340-3ksfpaf7	1829	19	of	of	IN
cord-034340-3ksfpaf7	1829	20	a	a	DT
cord-034340-3ksfpaf7	1829	21	Typical	typical	JJ
cord-034340-3ksfpaf7	1829	22	refractory	refractory	JJ
cord-034340-3ksfpaf7	1829	23	KD	kd	NN
cord-034340-3ksfpaf7	1829	24	.	.	.
cord-034340-3ksfpaf7	1830	1	He	-PRON-	PRP
cord-034340-3ksfpaf7	1830	2	had	have	VBD
cord-034340-3ksfpaf7	1830	3	been	be	VBN
cord-034340-3ksfpaf7	1830	4	previously	previously	RB
cord-034340-3ksfpaf7	1830	5	treated	treat	VBN
cord-034340-3ksfpaf7	1830	6	at	at	IN
cord-034340-3ksfpaf7	1830	7	a	a	DT
cord-034340-3ksfpaf7	1830	8	local	local	JJ
cord-034340-3ksfpaf7	1830	9	hospital	hospital	NN
cord-034340-3ksfpaf7	1830	10	with	with	IN
cord-034340-3ksfpaf7	1830	11	two	two	CD
cord-034340-3ksfpaf7	1830	12	doses	dose	NNS
cord-034340-3ksfpaf7	1830	13	of	of	IN
cord-034340-3ksfpaf7	1830	14	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1830	15	(	(	-LRB-
cord-034340-3ksfpaf7	1830	16	2	2	CD
cord-034340-3ksfpaf7	1830	17	g	g	NN
cord-034340-3ksfpaf7	1830	18	/	/	SYM
cord-034340-3ksfpaf7	1830	19	kg	kg	NNP
cord-034340-3ksfpaf7	1830	20	)	)	-RRB-
cord-034340-3ksfpaf7	1830	21	,	,	,
cord-034340-3ksfpaf7	1830	22	infused	infuse	VBN
cord-034340-3ksfpaf7	1830	23	respectively	respectively	RB
cord-034340-3ksfpaf7	1830	24	8	8	CD
cord-034340-3ksfpaf7	1830	25	and	and	CC
cord-034340-3ksfpaf7	1830	26	11	11	CD
cord-034340-3ksfpaf7	1830	27	days	day	NNS
cord-034340-3ksfpaf7	1830	28	after	after	IN
cord-034340-3ksfpaf7	1830	29	the	the	DT
cord-034340-3ksfpaf7	1830	30	onset	onset	NN
cord-034340-3ksfpaf7	1830	31	of	of	IN
cord-034340-3ksfpaf7	1830	32	the	the	DT
cord-034340-3ksfpaf7	1830	33	fever	fever	NN
cord-034340-3ksfpaf7	1830	34	.	.	.
cord-034340-3ksfpaf7	1831	1	Afterwards	afterwards	RB
cord-034340-3ksfpaf7	1831	2	,	,	,
cord-034340-3ksfpaf7	1831	3	given	give	VBN
cord-034340-3ksfpaf7	1831	4	the	the	DT
cord-034340-3ksfpaf7	1831	5	persisting	persist	VBG
cord-034340-3ksfpaf7	1831	6	fever	fever	NN
cord-034340-3ksfpaf7	1831	7	,	,	,
cord-034340-3ksfpaf7	1831	8	doses	dose	NNS
cord-034340-3ksfpaf7	1831	9	of	of	IN
cord-034340-3ksfpaf7	1831	10	pulse	pulse	NN
cord-034340-3ksfpaf7	1831	11	intravenous	intravenous	JJ
cord-034340-3ksfpaf7	1831	12	(	(	-LRB-
cord-034340-3ksfpaf7	1831	13	IV	IV	NNP
cord-034340-3ksfpaf7	1831	14	)	)	-RRB-
cord-034340-3ksfpaf7	1831	15	methylprednisolone	methylprednisolone	NNP
cord-034340-3ksfpaf7	1831	16	(	(	-LRB-
cord-034340-3ksfpaf7	1831	17	MPDN	MPDN	NNP
cord-034340-3ksfpaf7	1831	18	30	30	CD
cord-034340-3ksfpaf7	1831	19	mg	mg	NNP
cord-034340-3ksfpaf7	1831	20	/	/	SYM
cord-034340-3ksfpaf7	1831	21	kg	kg	NNP
cord-034340-3ksfpaf7	1831	22	/	/	SYM
cord-034340-3ksfpaf7	1831	23	day	day	NN
cord-034340-3ksfpaf7	1831	24	)	)	-RRB-
cord-034340-3ksfpaf7	1831	25	have	have	VBP
cord-034340-3ksfpaf7	1831	26	been	be	VBN
cord-034340-3ksfpaf7	1831	27	used	use	VBN
cord-034340-3ksfpaf7	1831	28	for	for	IN
cord-034340-3ksfpaf7	1831	29	3	3	CD
cord-034340-3ksfpaf7	1831	30	days	day	NNS
cord-034340-3ksfpaf7	1831	31	followed	follow	VBN
cord-034340-3ksfpaf7	1831	32	by	by	IN
cord-034340-3ksfpaf7	1831	33	oral	oral	JJ
cord-034340-3ksfpaf7	1831	34	prednisone	prednisone	NNP
cord-034340-3ksfpaf7	1831	35	(	(	-LRB-
cord-034340-3ksfpaf7	1831	36	2	2	CD
cord-034340-3ksfpaf7	1831	37	mg	mg	NNP
cord-034340-3ksfpaf7	1831	38	/	/	SYM
cord-034340-3ksfpaf7	1831	39	kg	kg	NNP
cord-034340-3ksfpaf7	1831	40	/	/	SYM
cord-034340-3ksfpaf7	1831	41	day	day	NN
cord-034340-3ksfpaf7	1831	42	)	)	-RRB-
cord-034340-3ksfpaf7	1831	43	.	.	.
cord-034340-3ksfpaf7	1832	1	Treatment	treatment	NN
cord-034340-3ksfpaf7	1832	2	with	with	IN
cord-034340-3ksfpaf7	1832	3	Acetylsalicylic	Acetylsalicylic	NNP
cord-034340-3ksfpaf7	1832	4	Acid	acid	NN
cord-034340-3ksfpaf7	1832	5	(	(	-LRB-
cord-034340-3ksfpaf7	1832	6	60	60	CD
cord-034340-3ksfpaf7	1832	7	mg	mg	NNP
cord-034340-3ksfpaf7	1832	8	/	/	SYM
cord-034340-3ksfpaf7	1832	9	Kg	Kg	NNP
cord-034340-3ksfpaf7	1832	10	/	/	SYM
cord-034340-3ksfpaf7	1832	11	day	day	NN
cord-034340-3ksfpaf7	1832	12	q8h	q8h	NNP
cord-034340-3ksfpaf7	1832	13	)	)	-RRB-
cord-034340-3ksfpaf7	1832	14	was	be	VBD
cord-034340-3ksfpaf7	1832	15	also	also	RB
cord-034340-3ksfpaf7	1832	16	started	start	VBN
cord-034340-3ksfpaf7	1832	17	.	.	.
cord-034340-3ksfpaf7	1833	1	Following	follow	VBG
cord-034340-3ksfpaf7	1833	2	a	a	DT
cord-034340-3ksfpaf7	1833	3	transient	transient	JJ
cord-034340-3ksfpaf7	1833	4	defervescence	defervescence	NN
cord-034340-3ksfpaf7	1833	5	the	the	DT
cord-034340-3ksfpaf7	1833	6	day	day	NN
cord-034340-3ksfpaf7	1833	7	after	after	IN
cord-034340-3ksfpaf7	1833	8	the	the	DT
cord-034340-3ksfpaf7	1833	9	first	first	JJ
cord-034340-3ksfpaf7	1833	10	IV	IV	NNP
cord-034340-3ksfpaf7	1833	11	pulse	pulse	NN
cord-034340-3ksfpaf7	1833	12	MPDN	MPDN	NNP
cord-034340-3ksfpaf7	1833	13	,	,	,
cord-034340-3ksfpaf7	1833	14	fever	fever	NN
cord-034340-3ksfpaf7	1833	15	relapsed	relapse	VBN
cord-034340-3ksfpaf7	1833	16	and	and	CC
cord-034340-3ksfpaf7	1833	17	the	the	DT
cord-034340-3ksfpaf7	1833	18	echocardiography	echocardiography	NN
cord-034340-3ksfpaf7	1833	19	showed	show	VBD
cord-034340-3ksfpaf7	1833	20	CAAs	caas	NN
cord-034340-3ksfpaf7	1833	21	of	of	IN
cord-034340-3ksfpaf7	1833	22	Left	Left	NNP
cord-034340-3ksfpaf7	1833	23	Main	Main	NNP
cord-034340-3ksfpaf7	1833	24	Coronary	Coronary	NNP
cord-034340-3ksfpaf7	1833	25	Artery	artery	NN
cord-034340-3ksfpaf7	1833	26	(	(	-LRB-
cord-034340-3ksfpaf7	1833	27	LMCA	LMCA	NNP
cord-034340-3ksfpaf7	1833	28	)	)	-RRB-
cord-034340-3ksfpaf7	1833	29	,	,	,
cord-034340-3ksfpaf7	1833	30	Left	leave	VBN
cord-034340-3ksfpaf7	1833	31	Anterior	Anterior	NNP
cord-034340-3ksfpaf7	1833	32	Descending	descend	VBG
cord-034340-3ksfpaf7	1833	33	(	(	-LRB-
cord-034340-3ksfpaf7	1833	34	LAD	LAD	NNP
cord-034340-3ksfpaf7	1833	35	)	)	-RRB-
cord-034340-3ksfpaf7	1833	36	and	and	CC
cord-034340-3ksfpaf7	1833	37	Right	Right	NNP
cord-034340-3ksfpaf7	1833	38	Coronary	Coronary	NNP
cord-034340-3ksfpaf7	1833	39	Artery	artery	NN
cord-034340-3ksfpaf7	1833	40	(	(	-LRB-
cord-034340-3ksfpaf7	1834	1	RCA	RCA	NNP
cord-034340-3ksfpaf7	1834	2	)	)	-RRB-
cord-034340-3ksfpaf7	1834	3	Rationale	rationale	NN
cord-034340-3ksfpaf7	1834	4	and	and	CC
cord-034340-3ksfpaf7	1834	5	study	study	NN
cord-034340-3ksfpaf7	1834	6	design	design	NN
cord-034340-3ksfpaf7	1834	7	for	for	IN
cord-034340-3ksfpaf7	1834	8	a	a	DT
cord-034340-3ksfpaf7	1834	9	phase	phase	NN
cord-034340-3ksfpaf7	1834	10	I	-PRON-	PRP
cord-034340-3ksfpaf7	1834	11	/	/	SYM
cord-034340-3ksfpaf7	1834	12	IIa	IIa	NNP
cord-034340-3ksfpaf7	1834	13	trial	trial	NN
cord-034340-3ksfpaf7	1834	14	of	of	IN
cord-034340-3ksfpaf7	1834	15	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	1834	16	in	in	IN
cord-034340-3ksfpaf7	1834	17	children	child	NNS
cord-034340-3ksfpaf7	1834	18	with	with	IN
cord-034340-3ksfpaf7	1834	19	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1834	20	disease	disease	NN
cord-034340-3ksfpaf7	1834	21	and	and	CC
cord-034340-3ksfpaf7	1834	22	early	early	JJ
cord-034340-3ksfpaf7	1834	23	coronary	coronary	JJ
cord-034340-3ksfpaf7	1834	24	artery	artery	NN
cord-034340-3ksfpaf7	1834	25	abnormalities	abnormality	NNS
cord-034340-3ksfpaf7	1835	1	(	(	-LRB-
cord-034340-3ksfpaf7	1835	2	The	the	DT
cord-034340-3ksfpaf7	1835	3	ANAKID	ANAKID	NNP
cord-034340-3ksfpaf7	1835	4	Trial	trial	NN
cord-034340-3ksfpaf7	1835	5	)	)	-RRB-
cord-034340-3ksfpaf7	1836	1	The	the	DT
cord-034340-3ksfpaf7	1836	2	use	use	NN
cord-034340-3ksfpaf7	1836	3	of	of	IN
cord-034340-3ksfpaf7	1836	4	interleukin	interleukin	NN
cord-034340-3ksfpaf7	1836	5	1	1	CD
cord-034340-3ksfpaf7	1836	6	receptor	receptor	NN
cord-034340-3ksfpaf7	1836	7	antagonist	antagonist	NN
cord-034340-3ksfpaf7	1836	8	(	(	-LRB-
cord-034340-3ksfpaf7	1836	9	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	1836	10	)	)	-RRB-
cord-034340-3ksfpaf7	1836	11	in	in	IN
cord-034340-3ksfpaf7	1836	12	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1836	13	disease	disease	NN
cord-034340-3ksfpaf7	1836	14	:	:	:
cord-034340-3ksfpaf7	1836	15	A	a	DT
cord-034340-3ksfpaf7	1836	16	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1836	17	cases	case	NNS
cord-034340-3ksfpaf7	1836	18	series	series	NN
cord-034340-3ksfpaf7	1836	19	There	there	EX
cord-034340-3ksfpaf7	1836	20	are	be	VBP
cord-034340-3ksfpaf7	1836	21	few	few	JJ
cord-034340-3ksfpaf7	1836	22	reports	report	NNS
cord-034340-3ksfpaf7	1836	23	of	of	IN
cord-034340-3ksfpaf7	1836	24	acute	acute	JJ
cord-034340-3ksfpaf7	1836	25	kidney	kidney	NN
cord-034340-3ksfpaf7	1836	26	injury	injury	NN
cord-034340-3ksfpaf7	1836	27	(	(	-LRB-
cord-034340-3ksfpaf7	1836	28	AKI	AKI	NNP
cord-034340-3ksfpaf7	1836	29	)	)	-RRB-
cord-034340-3ksfpaf7	1836	30	in	in	IN
cord-034340-3ksfpaf7	1836	31	KD	KD	NNP
cord-034340-3ksfpaf7	1836	32	,	,	,
cord-034340-3ksfpaf7	1836	33	defined	define	VBN
cord-034340-3ksfpaf7	1836	34	as	as	IN
cord-034340-3ksfpaf7	1836	35	serum	serum	NN
cord-034340-3ksfpaf7	1836	36	creatinine	creatinine	NN
cord-034340-3ksfpaf7	1836	37	level	level	NN
cord-034340-3ksfpaf7	1836	38	elevation	elevation	NN
cord-034340-3ksfpaf7	1836	39	to	to	IN
cord-034340-3ksfpaf7	1836	40	more	more	JJR
cord-034340-3ksfpaf7	1836	41	than	than	IN
cord-034340-3ksfpaf7	1836	42	1.5	1.5	CD
cord-034340-3ksfpaf7	1836	43	times	time	NNS
cord-034340-3ksfpaf7	1836	44	of	of	IN
cord-034340-3ksfpaf7	1836	45	baseline	baseline	JJ
cord-034340-3ksfpaf7	1836	46	level	level	NN
cord-034340-3ksfpaf7	1836	47	.	.	.
cord-034340-3ksfpaf7	1837	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1837	2	:	:	:
cord-034340-3ksfpaf7	1837	3	To	to	TO
cord-034340-3ksfpaf7	1837	4	describe	describe	VB
cord-034340-3ksfpaf7	1837	5	the	the	DT
cord-034340-3ksfpaf7	1837	6	case	case	NN
cord-034340-3ksfpaf7	1837	7	of	of	IN
cord-034340-3ksfpaf7	1837	8	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1837	9	Disease	Disease	NNP
cord-034340-3ksfpaf7	1837	10	complicated	complicate	VBN
cord-034340-3ksfpaf7	1837	11	by	by	IN
cord-034340-3ksfpaf7	1837	12	AKI	AKI	NNP
cord-034340-3ksfpaf7	1837	13	Methods	method	NNS
cord-034340-3ksfpaf7	1837	14	:	:	:
cord-034340-3ksfpaf7	1838	1	A	a	DT
cord-034340-3ksfpaf7	1838	2	5-year	5-year	CD
cord-034340-3ksfpaf7	1838	3	-	-	HYPH
cord-034340-3ksfpaf7	1838	4	old	old	JJ
cord-034340-3ksfpaf7	1838	5	female	female	NN
cord-034340-3ksfpaf7	1838	6	was	be	VBD
cord-034340-3ksfpaf7	1838	7	admitted	admit	VBN
cord-034340-3ksfpaf7	1838	8	to	to	IN
cord-034340-3ksfpaf7	1838	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1838	10	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1838	11	Unit	Unit	NNP
cord-034340-3ksfpaf7	1838	12	with	with	IN
cord-034340-3ksfpaf7	1838	13	persistent	persistent	JJ
cord-034340-3ksfpaf7	1838	14	fever	fever	NN
cord-034340-3ksfpaf7	1838	15	(	(	-LRB-
cord-034340-3ksfpaf7	1838	16	6	6	CD
cord-034340-3ksfpaf7	1838	17	days	day	NNS
cord-034340-3ksfpaf7	1838	18	)	)	-RRB-
cord-034340-3ksfpaf7	1838	19	,	,	,
cord-034340-3ksfpaf7	1838	20	widespread	widespread	JJ
cord-034340-3ksfpaf7	1838	21	polymorphous	polymorphous	JJ
cord-034340-3ksfpaf7	1838	22	exanthema	exanthema	NN
cord-034340-3ksfpaf7	1838	23	,	,	,
cord-034340-3ksfpaf7	1838	24	change	change	NN
cord-034340-3ksfpaf7	1838	25	in	in	IN
cord-034340-3ksfpaf7	1838	26	lips	lip	NNS
cord-034340-3ksfpaf7	1838	27	and	and	CC
cord-034340-3ksfpaf7	1838	28	in	in	IN
cord-034340-3ksfpaf7	1838	29	oral	oral	JJ
cord-034340-3ksfpaf7	1838	30	mucosa	mucosa	NN
cord-034340-3ksfpaf7	1838	31	.	.	.
cord-034340-3ksfpaf7	1839	1	Family	family	NN
cord-034340-3ksfpaf7	1839	2	history	history	NN
cord-034340-3ksfpaf7	1839	3	was	be	VBD
cord-034340-3ksfpaf7	1839	4	unremarkable	unremarkable	JJ
cord-034340-3ksfpaf7	1839	5	.	.	.
cord-034340-3ksfpaf7	1840	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1840	2	had	have	VBD
cord-034340-3ksfpaf7	1840	3	no	no	DT
cord-034340-3ksfpaf7	1840	4	chronic	chronic	JJ
cord-034340-3ksfpaf7	1840	5	underlying	underlie	VBG
cord-034340-3ksfpaf7	1840	6	disease	disease	NN
cord-034340-3ksfpaf7	1840	7	nor	nor	CC
cord-034340-3ksfpaf7	1840	8	history	history	NN
cord-034340-3ksfpaf7	1840	9	of	of	IN
cord-034340-3ksfpaf7	1840	10	previous	previous	JJ
cord-034340-3ksfpaf7	1840	11	hospitalization	hospitalization	NN
cord-034340-3ksfpaf7	1840	12	.	.	.
cord-034340-3ksfpaf7	1841	1	At	at	IN
cord-034340-3ksfpaf7	1841	2	admission	admission	NN
cord-034340-3ksfpaf7	1841	3	,	,	,
cord-034340-3ksfpaf7	1841	4	she	-PRON-	PRP
cord-034340-3ksfpaf7	1841	5	appeared	appear	VBD
cord-034340-3ksfpaf7	1841	6	stable	stable	JJ
cord-034340-3ksfpaf7	1841	7	.	.	.
cord-034340-3ksfpaf7	1842	1	Body	body	NN
cord-034340-3ksfpaf7	1842	2	temperature	temperature	NN
cord-034340-3ksfpaf7	1842	3	was	be	VBD
cord-034340-3ksfpaf7	1842	4	38.9	38.9	CD
cord-034340-3ksfpaf7	1842	5	°	°	NN
cord-034340-3ksfpaf7	1842	6	C	C	NNP
cord-034340-3ksfpaf7	1842	7	,	,	,
cord-034340-3ksfpaf7	1842	8	O2	o2	NN
cord-034340-3ksfpaf7	1842	9	saturation	saturation	NN
cord-034340-3ksfpaf7	1842	10	was	be	VBD
cord-034340-3ksfpaf7	1842	11	96	96	CD
cord-034340-3ksfpaf7	1842	12	%	%	NN
cord-034340-3ksfpaf7	1842	13	in	in	IN
cord-034340-3ksfpaf7	1842	14	ambient	ambient	JJ
cord-034340-3ksfpaf7	1842	15	area	area	NN
cord-034340-3ksfpaf7	1842	16	,	,	,
cord-034340-3ksfpaf7	1842	17	blood	blood	NN
cord-034340-3ksfpaf7	1842	18	pressure	pressure	NN
cord-034340-3ksfpaf7	1842	19	was	be	VBD
cord-034340-3ksfpaf7	1842	20	118/75	118/75	CD
cord-034340-3ksfpaf7	1842	21	mm	mm	NN
cord-034340-3ksfpaf7	1843	1	Hg	hg	NN
cord-034340-3ksfpaf7	1843	2	,	,	,
cord-034340-3ksfpaf7	1843	3	heart	heart	NN
cord-034340-3ksfpaf7	1843	4	rate	rate	NN
cord-034340-3ksfpaf7	1843	5	was	be	VBD
cord-034340-3ksfpaf7	1843	6	90	90	CD
cord-034340-3ksfpaf7	1843	7	bpm	bpm	NN
cord-034340-3ksfpaf7	1843	8	,	,	,
cord-034340-3ksfpaf7	1843	9	respiratory	respiratory	JJ
cord-034340-3ksfpaf7	1843	10	rate	rate	NN
cord-034340-3ksfpaf7	1843	11	was	be	VBD
cord-034340-3ksfpaf7	1843	12	21	21	CD
cord-034340-3ksfpaf7	1843	13	breaths	breath	NNS
cord-034340-3ksfpaf7	1843	14	per	per	IN
cord-034340-3ksfpaf7	1843	15	minute	minute	NN
cord-034340-3ksfpaf7	1843	16	.	.	.
cord-034340-3ksfpaf7	1844	1	On	on	IN
cord-034340-3ksfpaf7	1844	2	examination	examination	NN
cord-034340-3ksfpaf7	1844	3	she	-PRON-	PRP
cord-034340-3ksfpaf7	1844	4	presented	present	VBD
cord-034340-3ksfpaf7	1844	5	widespread	widespread	JJ
cord-034340-3ksfpaf7	1844	6	polymorphous	polymorphous	JJ
cord-034340-3ksfpaf7	1844	7	exanthema	exanthema	NN
cord-034340-3ksfpaf7	1844	8	,	,	,
cord-034340-3ksfpaf7	1844	9	changes	change	NNS
cord-034340-3ksfpaf7	1844	10	in	in	IN
cord-034340-3ksfpaf7	1844	11	lips	lip	NNS
cord-034340-3ksfpaf7	1844	12	and	and	CC
cord-034340-3ksfpaf7	1844	13	in	in	IN
cord-034340-3ksfpaf7	1844	14	oral	oral	JJ
cord-034340-3ksfpaf7	1844	15	mucosa	mucosa	JJ
cord-034340-3ksfpaf7	1844	16	,	,	,
cord-034340-3ksfpaf7	1844	17	cervical	cervical	JJ
cord-034340-3ksfpaf7	1844	18	lymphadenopathy	lymphadenopathy	JJ
cord-034340-3ksfpaf7	1844	19	and	and	CC
cord-034340-3ksfpaf7	1844	20	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	1844	21	conjunctival	conjunctival	NN
cord-034340-3ksfpaf7	1844	22	injection	injection	NN
cord-034340-3ksfpaf7	1844	23	.	.	.
cord-034340-3ksfpaf7	1845	1	Results	result	NNS
cord-034340-3ksfpaf7	1845	2	:	:	:
cord-034340-3ksfpaf7	1846	1	Exams	exam	NNS
cord-034340-3ksfpaf7	1846	2	revealed	reveal	VBD
cord-034340-3ksfpaf7	1846	3	:	:	:
cord-034340-3ksfpaf7	1846	4	white	white	JJ
cord-034340-3ksfpaf7	1846	5	blood	blood	NN
cord-034340-3ksfpaf7	1846	6	cells	cell	NNS
cord-034340-3ksfpaf7	1847	1	11980	11980	CD
cord-034340-3ksfpaf7	1847	2	/	/	SYM
cord-034340-3ksfpaf7	1847	3	μl	μl	NN
cord-034340-3ksfpaf7	1847	4	,	,	,
cord-034340-3ksfpaf7	1847	5	Hb	Hb	NNP
cord-034340-3ksfpaf7	1847	6	10.4	10.4	CD
cord-034340-3ksfpaf7	1847	7	g	g	NN
cord-034340-3ksfpaf7	1847	8	/	/	SYM
cord-034340-3ksfpaf7	1847	9	dL	dl	NN
cord-034340-3ksfpaf7	1847	10	,	,	,
cord-034340-3ksfpaf7	1847	11	platelets	platelet	NNS
cord-034340-3ksfpaf7	1848	1	389.000	389.000	CD
cord-034340-3ksfpaf7	1848	2	/	/	SYM
cord-034340-3ksfpaf7	1848	3	μl	μl	UH
cord-034340-3ksfpaf7	1848	4	,	,	,
cord-034340-3ksfpaf7	1848	5	albumin	albumin	NN
cord-034340-3ksfpaf7	1848	6	2.5	2.5	CD
cord-034340-3ksfpaf7	1848	7	g	g	NN
cord-034340-3ksfpaf7	1848	8	/	/	SYM
cord-034340-3ksfpaf7	1848	9	dL	dl	NN
cord-034340-3ksfpaf7	1848	10	,	,	,
cord-034340-3ksfpaf7	1848	11	serum	serum	NN
cord-034340-3ksfpaf7	1848	12	sodium	sodium	NN
cord-034340-3ksfpaf7	1848	13	126	126	CD
cord-034340-3ksfpaf7	1848	14	mEq	mEq	NNS
cord-034340-3ksfpaf7	1848	15	/	/	SYM
cord-034340-3ksfpaf7	1848	16	L	l	NN
cord-034340-3ksfpaf7	1848	17	,	,	,
cord-034340-3ksfpaf7	1848	18	serum	serum	NN
cord-034340-3ksfpaf7	1848	19	chloride	chloride	NN
cord-034340-3ksfpaf7	1848	20	90	90	CD
cord-034340-3ksfpaf7	1848	21	mEq	mEq	NNS
cord-034340-3ksfpaf7	1848	22	/	/	SYM
cord-034340-3ksfpaf7	1848	23	L.	L.	NNP
cord-034340-3ksfpaf7	1848	24	Transaminases	Transaminases	NNP
cord-034340-3ksfpaf7	1848	25	were	be	VBD
cord-034340-3ksfpaf7	1848	26	in	in	IN
cord-034340-3ksfpaf7	1848	27	normal	normal	JJ
cord-034340-3ksfpaf7	1848	28	range	range	NN
cord-034340-3ksfpaf7	1848	29	.	.	.
cord-034340-3ksfpaf7	1849	1	creatinine	creatinine	NN
cord-034340-3ksfpaf7	1849	2	was	be	VBD
cord-034340-3ksfpaf7	1849	3	1.5	1.5	CD
cord-034340-3ksfpaf7	1849	4	mg	mg	NNP
cord-034340-3ksfpaf7	1849	5	/	/	SYM
cord-034340-3ksfpaf7	1849	6	dL	dL	NNP
cord-034340-3ksfpaf7	1849	7	Disclosure	Disclosure	NNP
cord-034340-3ksfpaf7	1849	8	of	of	IN
cord-034340-3ksfpaf7	1849	9	Interest	Interest	NNP
cord-034340-3ksfpaf7	1850	1	None	none	NN
cord-034340-3ksfpaf7	1850	2	declared	declare	VBD
cord-034340-3ksfpaf7	1850	3	AB041	AB041	NNP
cord-034340-3ksfpaf7	1850	4	Paediatric	paediatric	JJ
cord-034340-3ksfpaf7	1850	5	extra	extra	JJ
cord-034340-3ksfpaf7	1850	6	-	-	JJ
cord-034340-3ksfpaf7	1850	7	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	1850	8	large	large	JJ
cord-034340-3ksfpaf7	1850	9	vessel	vessel	NN
cord-034340-3ksfpaf7	1850	10	arteritis	arteritis	NN
cord-034340-3ksfpaf7	1850	11	,	,	,
cord-034340-3ksfpaf7	1850	12	a	a	DT
cord-034340-3ksfpaf7	1850	13	forme	forme	FW
cord-034340-3ksfpaf7	1850	14	fruste	fruste	NN
cord-034340-3ksfpaf7	1850	15	of	of	IN
cord-034340-3ksfpaf7	1850	16	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1850	17	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	1850	18	's	's	POS
cord-034340-3ksfpaf7	1850	19	disease	disease	NN
cord-034340-3ksfpaf7	1850	20	?	?	.
cord-034340-3ksfpaf7	1851	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1851	2	presented	present	VBD
cord-034340-3ksfpaf7	1851	3	two	two	CD
cord-034340-3ksfpaf7	1851	4	siblings	sibling	NNS
cord-034340-3ksfpaf7	1851	5	from	from	IN
cord-034340-3ksfpaf7	1851	6	a	a	DT
cord-034340-3ksfpaf7	1851	7	consanguineous	consanguineous	JJ
cord-034340-3ksfpaf7	1851	8	marriage	marriage	NN
cord-034340-3ksfpaf7	1851	9	with	with	IN
cord-034340-3ksfpaf7	1851	10	different	different	JJ
cord-034340-3ksfpaf7	1851	11	clinical	clinical	JJ
cord-034340-3ksfpaf7	1851	12	presentations	presentation	NNS
cord-034340-3ksfpaf7	1851	13	of	of	IN
cord-034340-3ksfpaf7	1851	14	DADA2	DADA2	NNS
cord-034340-3ksfpaf7	1851	15	.	.	.
cord-034340-3ksfpaf7	1852	1	Further	further	RB
cord-034340-3ksfpaf7	1852	2	,	,	,
cord-034340-3ksfpaf7	1852	3	we	-PRON-	PRP
cord-034340-3ksfpaf7	1852	4	emphasize	emphasize	VBP
cord-034340-3ksfpaf7	1852	5	that	that	IN
cord-034340-3ksfpaf7	1852	6	genetic	genetic	JJ
cord-034340-3ksfpaf7	1852	7	testing	testing	NN
cord-034340-3ksfpaf7	1852	8	should	should	MD
cord-034340-3ksfpaf7	1852	9	be	be	VB
cord-034340-3ksfpaf7	1852	10	repeated	repeat	VBN
cord-034340-3ksfpaf7	1852	11	in	in	IN
cord-034340-3ksfpaf7	1852	12	the	the	DT
cord-034340-3ksfpaf7	1852	13	presence	presence	NN
cord-034340-3ksfpaf7	1852	14	of	of	IN
cord-034340-3ksfpaf7	1852	15	clinical	clinical	JJ
cord-034340-3ksfpaf7	1852	16	suspicion	suspicion	NN
cord-034340-3ksfpaf7	1852	17	.	.	.
cord-034340-3ksfpaf7	1853	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1853	2	:	:	:
cord-034340-3ksfpaf7	1854	1	There	there	EX
cord-034340-3ksfpaf7	1854	2	are	be	VBP
cord-034340-3ksfpaf7	1854	3	several	several	JJ
cord-034340-3ksfpaf7	1854	4	scoring	score	VBG
cord-034340-3ksfpaf7	1854	5	systems	system	NNS
cord-034340-3ksfpaf7	1854	6	developed	develop	VBN
cord-034340-3ksfpaf7	1854	7	in	in	IN
cord-034340-3ksfpaf7	1854	8	Japan	Japan	NNP
cord-034340-3ksfpaf7	1854	9	that	that	WDT
cord-034340-3ksfpaf7	1854	10	are	be	VBP
cord-034340-3ksfpaf7	1854	11	clinically	clinically	RB
cord-034340-3ksfpaf7	1854	12	used	use	VBN
cord-034340-3ksfpaf7	1854	13	to	to	TO
cord-034340-3ksfpaf7	1854	14	stratify	stratify	VB
cord-034340-3ksfpaf7	1854	15	high	high	JJ
cord-034340-3ksfpaf7	1854	16	risk	risk	NN
cord-034340-3ksfpaf7	1854	17	KD	KD	NNP
cord-034340-3ksfpaf7	1854	18	patients	patient	NNS
cord-034340-3ksfpaf7	1854	19	and	and	CC
cord-034340-3ksfpaf7	1854	20	thus	thus	RB
cord-034340-3ksfpaf7	1854	21	identify	identify	VB
cord-034340-3ksfpaf7	1854	22	the	the	DT
cord-034340-3ksfpaf7	1854	23	ones	one	NNS
cord-034340-3ksfpaf7	1854	24	that	that	WDT
cord-034340-3ksfpaf7	1854	25	may	may	MD
cord-034340-3ksfpaf7	1854	26	benefit	benefit	VB
cord-034340-3ksfpaf7	1854	27	from	from	IN
cord-034340-3ksfpaf7	1854	28	early	early	JJ
cord-034340-3ksfpaf7	1854	29	adjunctive	adjunctive	JJ
cord-034340-3ksfpaf7	1854	30	therapy	therapy	NN
cord-034340-3ksfpaf7	1854	31	.	.	.
cord-034340-3ksfpaf7	1855	1	There	there	EX
cord-034340-3ksfpaf7	1855	2	are	be	VBP
cord-034340-3ksfpaf7	1855	3	increasing	increase	VBG
cord-034340-3ksfpaf7	1855	4	reports	report	NNS
cord-034340-3ksfpaf7	1855	5	from	from	IN
cord-034340-3ksfpaf7	1855	6	all	all	RB
cord-034340-3ksfpaf7	1855	7	over	over	IN
cord-034340-3ksfpaf7	1855	8	the	the	DT
cord-034340-3ksfpaf7	1855	9	world	world	NN
cord-034340-3ksfpaf7	1855	10	on	on	IN
cord-034340-3ksfpaf7	1855	11	poor	poor	JJ
cord-034340-3ksfpaf7	1855	12	performance	performance	NN
cord-034340-3ksfpaf7	1855	13	of	of	IN
cord-034340-3ksfpaf7	1855	14	these	these	DT
cord-034340-3ksfpaf7	1855	15	scores	score	NNS
cord-034340-3ksfpaf7	1855	16	in	in	IN
cord-034340-3ksfpaf7	1855	17	other	other	JJ
cord-034340-3ksfpaf7	1855	18	ethnic	ethnic	JJ
cord-034340-3ksfpaf7	1855	19	populations	population	NNS
cord-034340-3ksfpaf7	1855	20	.	.	.
cord-034340-3ksfpaf7	1856	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1856	2	:	:	:
cord-034340-3ksfpaf7	1857	1	The	the	DT
cord-034340-3ksfpaf7	1857	2	aim	aim	NN
cord-034340-3ksfpaf7	1857	3	of	of	IN
cord-034340-3ksfpaf7	1857	4	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1857	5	study	study	NN
cord-034340-3ksfpaf7	1857	6	was	be	VBD
cord-034340-3ksfpaf7	1857	7	to	to	TO
cord-034340-3ksfpaf7	1857	8	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1857	9	the	the	DT
cord-034340-3ksfpaf7	1857	10	Kobayashi	Kobayashi	NNP
cord-034340-3ksfpaf7	1857	11	,	,	,
cord-034340-3ksfpaf7	1857	12	Egami	Egami	NNP
cord-034340-3ksfpaf7	1857	13	,	,	,
cord-034340-3ksfpaf7	1857	14	Sano	Sano	NNP
cord-034340-3ksfpaf7	1857	15	and	and	CC
cord-034340-3ksfpaf7	1857	16	Kawamura	Kawamura	NNP
cord-034340-3ksfpaf7	1857	17	scores	score	NNS
cord-034340-3ksfpaf7	1857	18	in	in	IN
cord-034340-3ksfpaf7	1857	19	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1857	20	population	population	NN
cord-034340-3ksfpaf7	1857	21	which	which	WDT
cord-034340-3ksfpaf7	1857	22	is	be	VBZ
cord-034340-3ksfpaf7	1857	23	homogenous	homogenous	JJ
cord-034340-3ksfpaf7	1857	24	Caucasian	Caucasian	NNP
cord-034340-3ksfpaf7	1857	25	.	.	.
cord-034340-3ksfpaf7	1858	1	Methods	method	NNS
cord-034340-3ksfpaf7	1858	2	:	:	:
cord-034340-3ksfpaf7	1859	1	Hospital	hospital	NN
cord-034340-3ksfpaf7	1859	2	database	database	NN
cord-034340-3ksfpaf7	1859	3	was	be	VBD
cord-034340-3ksfpaf7	1859	4	retrospectively	retrospectively	RB
cord-034340-3ksfpaf7	1859	5	searched	search	VBN
cord-034340-3ksfpaf7	1859	6	for	for	IN
cord-034340-3ksfpaf7	1859	7	code	code	NN
cord-034340-3ksfpaf7	1859	8	M30.3	M30.3	NNP
cord-034340-3ksfpaf7	1859	9	of	of	IN
cord-034340-3ksfpaf7	1859	10	the	the	DT
cord-034340-3ksfpaf7	1859	11	International	International	NNP
cord-034340-3ksfpaf7	1859	12	Classification	Classification	NNP
cord-034340-3ksfpaf7	1859	13	of	of	IN
cord-034340-3ksfpaf7	1859	14	Diseases	Diseases	NNPS
cord-034340-3ksfpaf7	1859	15	,	,	,
cord-034340-3ksfpaf7	1859	16	10th	10th	JJ
cord-034340-3ksfpaf7	1859	17	Revision	revision	NN
cord-034340-3ksfpaf7	1859	18	,	,	,
cord-034340-3ksfpaf7	1859	19	Clinical	Clinical	NNP
cord-034340-3ksfpaf7	1859	20	Modification	Modification	NNP
cord-034340-3ksfpaf7	1859	21	Code	Code	NNP
cord-034340-3ksfpaf7	1859	22	:	:	:
cord-034340-3ksfpaf7	1860	1	Mucocutaneous	mucocutaneous	JJ
cord-034340-3ksfpaf7	1860	2	lymph	lymph	NN
cord-034340-3ksfpaf7	1860	3	node	node	NN
cord-034340-3ksfpaf7	1860	4	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1860	5	[	[	-LRB-
cord-034340-3ksfpaf7	1860	6	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1860	7	]	]	-RRB-
cord-034340-3ksfpaf7	1860	8	,	,	,
cord-034340-3ksfpaf7	1860	9	over	over	IN
cord-034340-3ksfpaf7	1860	10	the	the	DT
cord-034340-3ksfpaf7	1860	11	period	period	NN
cord-034340-3ksfpaf7	1860	12	from	from	IN
cord-034340-3ksfpaf7	1860	13	January	January	NNP
cord-034340-3ksfpaf7	1860	14	2006	2006	CD
cord-034340-3ksfpaf7	1860	15	to	to	IN
cord-034340-3ksfpaf7	1860	16	December	December	NNP
cord-034340-3ksfpaf7	1860	17	2019	2019	CD
cord-034340-3ksfpaf7	1860	18	.	.	.
cord-034340-3ksfpaf7	1861	1	All	all	DT
cord-034340-3ksfpaf7	1861	2	patients	patient	NNS
cord-034340-3ksfpaf7	1861	3	who	who	WP
cord-034340-3ksfpaf7	1861	4	were	be	VBD
cord-034340-3ksfpaf7	1861	5	seen	see	VBN
cord-034340-3ksfpaf7	1861	6	in	in	IN
cord-034340-3ksfpaf7	1861	7	this	this	DT
cord-034340-3ksfpaf7	1861	8	period	period	NN
cord-034340-3ksfpaf7	1861	9	for	for	IN
cord-034340-3ksfpaf7	1861	10	the	the	DT
cord-034340-3ksfpaf7	1861	11	first	first	JJ
cord-034340-3ksfpaf7	1861	12	time	time	NN
cord-034340-3ksfpaf7	1861	13	for	for	IN
cord-034340-3ksfpaf7	1861	14	complete	complete	JJ
cord-034340-3ksfpaf7	1861	15	or	or	CC
cord-034340-3ksfpaf7	1861	16	incomplete	incomplete	JJ
cord-034340-3ksfpaf7	1861	17	Kawasaki	Kawasaki	NNP
cord-034340-3ksfpaf7	1861	18	disease	disease	NN
cord-034340-3ksfpaf7	1861	19	,	,	,
cord-034340-3ksfpaf7	1861	20	as	as	IN
cord-034340-3ksfpaf7	1861	21	defined	define	VBN
cord-034340-3ksfpaf7	1861	22	by	by	IN
cord-034340-3ksfpaf7	1861	23	the	the	DT
cord-034340-3ksfpaf7	1861	24	American	American	NNP
cord-034340-3ksfpaf7	1861	25	Heart	Heart	NNP
cord-034340-3ksfpaf7	1861	26	Association	Association	NNP
cord-034340-3ksfpaf7	1861	27	,	,	,
cord-034340-3ksfpaf7	1861	28	were	be	VBD
cord-034340-3ksfpaf7	1861	29	included	include	VBN
cord-034340-3ksfpaf7	1861	30	.	.	.
cord-034340-3ksfpaf7	1862	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1862	2	applied	apply	VBD
cord-034340-3ksfpaf7	1862	3	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1862	4	resistance	resistance	NN
cord-034340-3ksfpaf7	1862	5	prediction	prediction	NN
cord-034340-3ksfpaf7	1862	6	scores	score	NNS
cord-034340-3ksfpaf7	1862	7	(	(	-LRB-
cord-034340-3ksfpaf7	1862	8	Kobayashi	Kobayashi	NNP
cord-034340-3ksfpaf7	1862	9	,	,	,
cord-034340-3ksfpaf7	1862	10	Sano	Sano	NNP
cord-034340-3ksfpaf7	1862	11	,	,	,
cord-034340-3ksfpaf7	1862	12	Egami	Egami	NNP
cord-034340-3ksfpaf7	1862	13	and	and	CC
cord-034340-3ksfpaf7	1862	14	Kawamura	Kawamura	NNP
cord-034340-3ksfpaf7	1862	15	scores	score	NNS
cord-034340-3ksfpaf7	1862	16	)	)	-RRB-
cord-034340-3ksfpaf7	1862	17	to	to	IN
cord-034340-3ksfpaf7	1862	18	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1862	19	cohort	cohort	NN
cord-034340-3ksfpaf7	1862	20	.	.	.
cord-034340-3ksfpaf7	1863	1	Only	only	RB
cord-034340-3ksfpaf7	1863	2	patients	patient	NNS
cord-034340-3ksfpaf7	1863	3	who	who	WP
cord-034340-3ksfpaf7	1863	4	received	receive	VBD
cord-034340-3ksfpaf7	1863	5	2g/	2g/	CD
cord-034340-3ksfpaf7	1863	6	kg	kg	NN
cord-034340-3ksfpaf7	1863	7	IVIG	ivig	NN
cord-034340-3ksfpaf7	1863	8	within	within	IN
cord-034340-3ksfpaf7	1863	9	the	the	DT
cord-034340-3ksfpaf7	1863	10	first	first	JJ
cord-034340-3ksfpaf7	1863	11	10	10	CD
cord-034340-3ksfpaf7	1863	12	days	day	NNS
cord-034340-3ksfpaf7	1863	13	of	of	IN
cord-034340-3ksfpaf7	1863	14	the	the	DT
cord-034340-3ksfpaf7	1863	15	disease	disease	NN
cord-034340-3ksfpaf7	1863	16	were	be	VBD
cord-034340-3ksfpaf7	1863	17	included	include	VBN
cord-034340-3ksfpaf7	1863	18	in	in	IN
cord-034340-3ksfpaf7	1863	19	this	this	DT
cord-034340-3ksfpaf7	1863	20	analysis	analysis	NN
cord-034340-3ksfpaf7	1863	21	.	.	.
cord-034340-3ksfpaf7	1864	1	The	the	DT
cord-034340-3ksfpaf7	1864	2	scores	score	NNS
cord-034340-3ksfpaf7	1864	3	of	of	IN
cord-034340-3ksfpaf7	1864	4	prediction	prediction	NN
cord-034340-3ksfpaf7	1864	5	models	model	NNS
cord-034340-3ksfpaf7	1864	6	were	be	VBD
cord-034340-3ksfpaf7	1864	7	calculated	calculate	VBN
cord-034340-3ksfpaf7	1864	8	for	for	IN
cord-034340-3ksfpaf7	1864	9	each	each	DT
cord-034340-3ksfpaf7	1864	10	patient	patient	NN
cord-034340-3ksfpaf7	1864	11	and	and	CC
cord-034340-3ksfpaf7	1864	12	patients	patient	NNS
cord-034340-3ksfpaf7	1864	13	were	be	VBD
cord-034340-3ksfpaf7	1864	14	assigned	assign	VBN
cord-034340-3ksfpaf7	1864	15	to	to	IN
cord-034340-3ksfpaf7	1864	16	high	high	JJ
cord-034340-3ksfpaf7	1864	17	-	-	HYPH
cord-034340-3ksfpaf7	1864	18	or	or	CC
cord-034340-3ksfpaf7	1864	19	low	low	JJ
cord-034340-3ksfpaf7	1864	20	-	-	HYPH
cord-034340-3ksfpaf7	1864	21	risk	risk	NN
cord-034340-3ksfpaf7	1864	22	group	group	NN
cord-034340-3ksfpaf7	1864	23	accordingly	accordingly	RB
cord-034340-3ksfpaf7	1864	24	.	.	.
cord-034340-3ksfpaf7	1865	1	Results	result	NNS
cord-034340-3ksfpaf7	1865	2	:	:	:
cord-034340-3ksfpaf7	1866	1	During	during	IN
cord-034340-3ksfpaf7	1866	2	the	the	DT
cord-034340-3ksfpaf7	1866	3	study	study	NN
cord-034340-3ksfpaf7	1866	4	period	period	NN
cord-034340-3ksfpaf7	1866	5	a	a	DT
cord-034340-3ksfpaf7	1866	6	total	total	NN
cord-034340-3ksfpaf7	1866	7	of	of	IN
cord-034340-3ksfpaf7	1866	8	169	169	CD
cord-034340-3ksfpaf7	1866	9	children	child	NNS
cord-034340-3ksfpaf7	1866	10	were	be	VBD
cord-034340-3ksfpaf7	1866	11	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1866	12	with	with	IN
cord-034340-3ksfpaf7	1866	13	KD	KD	NNP
cord-034340-3ksfpaf7	1866	14	(	(	-LRB-
cord-034340-3ksfpaf7	1866	15	61.5	61.5	CD
cord-034340-3ksfpaf7	1866	16	%	%	NN
cord-034340-3ksfpaf7	1866	17	males	male	NNS
cord-034340-3ksfpaf7	1866	18	,	,	,
cord-034340-3ksfpaf7	1866	19	median	median	JJ
cord-034340-3ksfpaf7	1866	20	age	age	NN
cord-034340-3ksfpaf7	1866	21	3.28	3.28	CD
cord-034340-3ksfpaf7	1866	22	years	year	NNS
cord-034340-3ksfpaf7	1866	23	)	)	-RRB-
cord-034340-3ksfpaf7	1866	24	.	.	.
cord-034340-3ksfpaf7	1867	1	All	all	DT
cord-034340-3ksfpaf7	1867	2	of	of	IN
cord-034340-3ksfpaf7	1867	3	them	-PRON-	PRP
cord-034340-3ksfpaf7	1867	4	were	be	VBD
cord-034340-3ksfpaf7	1867	5	Caucasian	caucasian	JJ
cord-034340-3ksfpaf7	1867	6	except	except	IN
cord-034340-3ksfpaf7	1867	7	one	one	CD
cord-034340-3ksfpaf7	1867	8	child	child	NN
cord-034340-3ksfpaf7	1867	9	who	who	WP
cord-034340-3ksfpaf7	1867	10	was	be	VBD
cord-034340-3ksfpaf7	1867	11	biracial	biracial	JJ
cord-034340-3ksfpaf7	1867	12	(	(	-LRB-
cord-034340-3ksfpaf7	1867	13	Caucasian	caucasian	JJ
cord-034340-3ksfpaf7	1867	14	and	and	CC
cord-034340-3ksfpaf7	1867	15	African	african	JJ
cord-034340-3ksfpaf7	1867	16	American	American	NNP
cord-034340-3ksfpaf7	1867	17	)	)	-RRB-
cord-034340-3ksfpaf7	1867	18	.	.	.
cord-034340-3ksfpaf7	1868	1	Among	among	IN
cord-034340-3ksfpaf7	1868	2	them	-PRON-	PRP
cord-034340-3ksfpaf7	1868	3	,	,	,
cord-034340-3ksfpaf7	1868	4	158	158	CD
cord-034340-3ksfpaf7	1868	5	children	child	NNS
cord-034340-3ksfpaf7	1868	6	were	be	VBD
cord-034340-3ksfpaf7	1868	7	hospitalized	hospitalize	VBN
cord-034340-3ksfpaf7	1868	8	in	in	IN
cord-034340-3ksfpaf7	1868	9	the	the	DT
cord-034340-3ksfpaf7	1868	10	acute	acute	JJ
cord-034340-3ksfpaf7	1868	11	phase	phase	NN
cord-034340-3ksfpaf7	1868	12	of	of	IN
cord-034340-3ksfpaf7	1868	13	the	the	DT
cord-034340-3ksfpaf7	1868	14	disease	disease	NN
cord-034340-3ksfpaf7	1868	15	and	and	CC
cord-034340-3ksfpaf7	1868	16	11	11	CD
cord-034340-3ksfpaf7	1868	17	children	child	NNS
cord-034340-3ksfpaf7	1868	18	were	be	VBD
cord-034340-3ksfpaf7	1868	19	seen	see	VBN
cord-034340-3ksfpaf7	1868	20	in	in	IN
cord-034340-3ksfpaf7	1868	21	the	the	DT
cord-034340-3ksfpaf7	1868	22	subacute	subacute	JJ
cord-034340-3ksfpaf7	1868	23	phase	phase	NN
cord-034340-3ksfpaf7	1868	24	of	of	IN
cord-034340-3ksfpaf7	1868	25	the	the	DT
cord-034340-3ksfpaf7	1868	26	disease	disease	NN
cord-034340-3ksfpaf7	1868	27	.	.	.
cord-034340-3ksfpaf7	1869	1	151	151	CD
cord-034340-3ksfpaf7	1869	2	children	child	NNS
cord-034340-3ksfpaf7	1869	3	were	be	VBD
cord-034340-3ksfpaf7	1869	4	followed	follow	VBN
cord-034340-3ksfpaf7	1869	5	-	-	HYPH
cord-034340-3ksfpaf7	1869	6	up	up	NN
cord-034340-3ksfpaf7	1869	7	for	for	IN
cord-034340-3ksfpaf7	1869	8	at	at	RB
cord-034340-3ksfpaf7	1869	9	least	least	RBS
cord-034340-3ksfpaf7	1869	10	one	one	CD
cord-034340-3ksfpaf7	1869	11	year	year	NN
cord-034340-3ksfpaf7	1869	12	to	to	TO
cord-034340-3ksfpaf7	1869	13	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1869	14	persistent	persistent	JJ
cord-034340-3ksfpaf7	1869	15	coronary	coronary	JJ
cord-034340-3ksfpaf7	1869	16	artery	artery	NN
cord-034340-3ksfpaf7	1869	17	aneurysms	aneurysm	NNS
cord-034340-3ksfpaf7	1869	18	(	(	-LRB-
cord-034340-3ksfpaf7	1869	19	CAA	CAA	NNP
cord-034340-3ksfpaf7	1869	20	)	)	-RRB-
cord-034340-3ksfpaf7	1869	21	,	,	,
cord-034340-3ksfpaf7	1869	22	which	which	WDT
cord-034340-3ksfpaf7	1869	23	were	be	VBD
cord-034340-3ksfpaf7	1869	24	observed	observe	VBN
cord-034340-3ksfpaf7	1869	25	in	in	IN
cord-034340-3ksfpaf7	1869	26	8	8	CD
cord-034340-3ksfpaf7	1869	27	(	(	-LRB-
cord-034340-3ksfpaf7	1869	28	5.3	5.3	CD
cord-034340-3ksfpaf7	1869	29	%	%	NN
cord-034340-3ksfpaf7	1869	30	)	)	-RRB-
cord-034340-3ksfpaf7	1869	31	patients	patient	NNS
cord-034340-3ksfpaf7	1869	32	.	.	.
cord-034340-3ksfpaf7	1870	1	Among	among	IN
cord-034340-3ksfpaf7	1870	2	them	-PRON-	PRP
cord-034340-3ksfpaf7	1870	3	,	,	,
cord-034340-3ksfpaf7	1870	4	2	2	CD
cord-034340-3ksfpaf7	1870	5	were	be	VBD
cord-034340-3ksfpaf7	1870	6	not	not	RB
cord-034340-3ksfpaf7	1870	7	treated	treat	VBN
cord-034340-3ksfpaf7	1870	8	with	with	IN
cord-034340-3ksfpaf7	1870	9	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1870	10	and	and	CC
cord-034340-3ksfpaf7	1870	11	2	2	CD
cord-034340-3ksfpaf7	1870	12	received	receive	VBD
cord-034340-3ksfpaf7	1870	13	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1870	14	after	after	IN
cord-034340-3ksfpaf7	1870	15	10	10	CD
cord-034340-3ksfpaf7	1870	16	days	day	NNS
cord-034340-3ksfpaf7	1870	17	of	of	IN
cord-034340-3ksfpaf7	1870	18	illness	illness	NN
cord-034340-3ksfpaf7	1870	19	.	.	.
cord-034340-3ksfpaf7	1871	1	125	125	CD
cord-034340-3ksfpaf7	1871	2	patients	patient	NNS
cord-034340-3ksfpaf7	1871	3	were	be	VBD
cord-034340-3ksfpaf7	1871	4	treated	treat	VBN
cord-034340-3ksfpaf7	1871	5	with	with	IN
cord-034340-3ksfpaf7	1871	6	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1871	7	within	within	IN
cord-034340-3ksfpaf7	1871	8	first	first	JJ
cord-034340-3ksfpaf7	1871	9	10	10	CD
cord-034340-3ksfpaf7	1871	10	days	day	NNS
cord-034340-3ksfpaf7	1871	11	of	of	IN
cord-034340-3ksfpaf7	1871	12	illness	illness	NN
cord-034340-3ksfpaf7	1871	13	and	and	CC
cord-034340-3ksfpaf7	1871	14	were	be	VBD
cord-034340-3ksfpaf7	1871	15	included	include	VBN
cord-034340-3ksfpaf7	1871	16	in	in	IN
cord-034340-3ksfpaf7	1871	17	the	the	DT
cord-034340-3ksfpaf7	1871	18	calculation	calculation	NN
cord-034340-3ksfpaf7	1871	19	of	of	IN
cord-034340-3ksfpaf7	1871	20	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1871	21	resistance	resistance	NN
cord-034340-3ksfpaf7	1871	22	prediction	prediction	NN
cord-034340-3ksfpaf7	1871	23	scores	score	NNS
cord-034340-3ksfpaf7	1871	24	.	.	.
cord-034340-3ksfpaf7	1872	1	24	24	CD
cord-034340-3ksfpaf7	1872	2	(	(	-LRB-
cord-034340-3ksfpaf7	1872	3	19.2	19.2	CD
cord-034340-3ksfpaf7	1872	4	%	%	NN
cord-034340-3ksfpaf7	1872	5	)	)	-RRB-
cord-034340-3ksfpaf7	1872	6	were	be	VBD
cord-034340-3ksfpaf7	1872	7	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1872	8	resistant	resistant	JJ
cord-034340-3ksfpaf7	1872	9	.	.	.
cord-034340-3ksfpaf7	1873	1	Sensitivity	sensitivity	NN
cord-034340-3ksfpaf7	1873	2	of	of	IN
cord-034340-3ksfpaf7	1873	3	Kobayashi	Kobayashi	NNP
cord-034340-3ksfpaf7	1873	4	,	,	,
cord-034340-3ksfpaf7	1873	5	Sano	Sano	NNP
cord-034340-3ksfpaf7	1873	6	,	,	,
cord-034340-3ksfpaf7	1873	7	Egami	Egami	NNP
cord-034340-3ksfpaf7	1873	8	and	and	CC
cord-034340-3ksfpaf7	1873	9	Kawamura	Kawamura	NNP
cord-034340-3ksfpaf7	1873	10	scores	score	NNS
cord-034340-3ksfpaf7	1873	11	were	be	VBD
cord-034340-3ksfpaf7	1873	12	0.53	0.53	CD
cord-034340-3ksfpaf7	1873	13	,	,	,
cord-034340-3ksfpaf7	1873	14	0.47	0.47	CD
cord-034340-3ksfpaf7	1873	15	,	,	,
cord-034340-3ksfpaf7	1873	16	0.61and	0.61and	CD
cord-034340-3ksfpaf7	1873	17	0.58	0.58	CD
cord-034340-3ksfpaf7	1873	18	,	,	,
cord-034340-3ksfpaf7	1873	19	respectively	respectively	RB
cord-034340-3ksfpaf7	1873	20	.	.	.
cord-034340-3ksfpaf7	1874	1	Specificity	specificity	NN
cord-034340-3ksfpaf7	1874	2	of	of	IN
cord-034340-3ksfpaf7	1874	3	those	those	DT
cord-034340-3ksfpaf7	1874	4	scores	score	NNS
cord-034340-3ksfpaf7	1874	5	were	be	VBD
cord-034340-3ksfpaf7	1874	6	0.77	0.77	CD
cord-034340-3ksfpaf7	1874	7	,	,	,
cord-034340-3ksfpaf7	1874	8	0.87	0.87	CD
cord-034340-3ksfpaf7	1874	9	,	,	,
cord-034340-3ksfpaf7	1874	10	0.75	0.75	CD
cord-034340-3ksfpaf7	1874	11	and0.58	and0.58	NNP
cord-034340-3ksfpaf7	1874	12	,	,	,
cord-034340-3ksfpaf7	1874	13	respectively	respectively	RB
cord-034340-3ksfpaf7	1874	14	.	.	.
cord-034340-3ksfpaf7	1875	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1875	2	found	find	VBD
cord-034340-3ksfpaf7	1875	3	no	no	DT
cord-034340-3ksfpaf7	1875	4	difference	difference	NN
cord-034340-3ksfpaf7	1875	5	in	in	IN
cord-034340-3ksfpaf7	1875	6	demographic	demographic	JJ
cord-034340-3ksfpaf7	1875	7	or	or	CC
cord-034340-3ksfpaf7	1875	8	clinical	clinical	JJ
cord-034340-3ksfpaf7	1875	9	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	1875	10	between	between	IN
cord-034340-3ksfpaf7	1875	11	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1875	12	resistant	resistant	JJ
cord-034340-3ksfpaf7	1875	13	and	and	CC
cord-034340-3ksfpaf7	1875	14	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1875	15	responsive	responsive	JJ
cord-034340-3ksfpaf7	1875	16	patients	patient	NNS
cord-034340-3ksfpaf7	1875	17	.	.	.
cord-034340-3ksfpaf7	1876	1	Patients	patient	NNS
cord-034340-3ksfpaf7	1876	2	with	with	IN
cord-034340-3ksfpaf7	1876	3	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	1876	4	resistance	resistance	NN
cord-034340-3ksfpaf7	1876	5	had	have	VBD
cord-034340-3ksfpaf7	1876	6	significantly	significantly	RB
cord-034340-3ksfpaf7	1876	7	higher	high	JJR
cord-034340-3ksfpaf7	1876	8	ALT	alt	NN
cord-034340-3ksfpaf7	1876	9	(	(	-LRB-
cord-034340-3ksfpaf7	1876	10	p	p	NN
cord-034340-3ksfpaf7	1876	11	=	=	SYM
cord-034340-3ksfpaf7	1876	12	0.025	0.025	CD
cord-034340-3ksfpaf7	1876	13	)	)	-RRB-
cord-034340-3ksfpaf7	1876	14	,	,	,
cord-034340-3ksfpaf7	1876	15	neutrophil	neutrophil	NN
cord-034340-3ksfpaf7	1876	16	-	-	HYPH
cord-034340-3ksfpaf7	1876	17	to	to	IN
cord-034340-3ksfpaf7	1876	18	-	-	HYPH
cord-034340-3ksfpaf7	1876	19	lymphocyte	lymphocyte	NN
cord-034340-3ksfpaf7	1876	20	ratio	ratio	NN
cord-034340-3ksfpaf7	1876	21	(	(	-LRB-
cord-034340-3ksfpaf7	1876	22	p	p	NN
cord-034340-3ksfpaf7	1876	23	=	=	SYM
cord-034340-3ksfpaf7	1876	24	0.036	0.036	CD
cord-034340-3ksfpaf7	1876	25	)	)	-RRB-
cord-034340-3ksfpaf7	1876	26	and	and	CC
cord-034340-3ksfpaf7	1876	27	lower	low	JJR
cord-034340-3ksfpaf7	1876	28	serum	serum	NN
cord-034340-3ksfpaf7	1876	29	sodium	sodium	NN
cord-034340-3ksfpaf7	1876	30	(	(	-LRB-
cord-034340-3ksfpaf7	1876	31	p	p	NN
cord-034340-3ksfpaf7	1876	32	=	=	SYM
cord-034340-3ksfpaf7	1876	33	0.009	0.009	CD
cord-034340-3ksfpaf7	1876	34	)	)	-RRB-
cord-034340-3ksfpaf7	1876	35	.	.	.
cord-034340-3ksfpaf7	1877	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1877	2	:	:	:
cord-034340-3ksfpaf7	1878	1	By	by	IN
cord-034340-3ksfpaf7	1878	2	applying	apply	VBG
cord-034340-3ksfpaf7	1878	3	the	the	DT
cord-034340-3ksfpaf7	1878	4	Japanese	japanese	JJ
cord-034340-3ksfpaf7	1878	5	scores	score	NNS
cord-034340-3ksfpaf7	1878	6	to	to	IN
cord-034340-3ksfpaf7	1878	7	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1878	8	population	population	NN
cord-034340-3ksfpaf7	1878	9	,	,	,
cord-034340-3ksfpaf7	1878	10	we	-PRON-	PRP
cord-034340-3ksfpaf7	1878	11	were	be	VBD
cord-034340-3ksfpaf7	1878	12	able	able	JJ
cord-034340-3ksfpaf7	1878	13	to	to	TO
cord-034340-3ksfpaf7	1878	14	identify	identify	VB
cord-034340-3ksfpaf7	1878	15	most	most	JJS
cord-034340-3ksfpaf7	1878	16	of	of	IN
cord-034340-3ksfpaf7	1878	17	the	the	DT
cord-034340-3ksfpaf7	1878	18	low	low	JJ
cord-034340-3ksfpaf7	1878	19	-	-	HYPH
cord-034340-3ksfpaf7	1878	20	risk	risk	NN
cord-034340-3ksfpaf7	1878	21	,	,	,
cord-034340-3ksfpaf7	1878	22	but	but	CC
cord-034340-3ksfpaf7	1878	23	missed	miss	VBD
cord-034340-3ksfpaf7	1878	24	many	many	JJ
cord-034340-3ksfpaf7	1878	25	of	of	IN
cord-034340-3ksfpaf7	1878	26	the	the	DT
cord-034340-3ksfpaf7	1878	27	high	high	JJ
cord-034340-3ksfpaf7	1878	28	-	-	HYPH
cord-034340-3ksfpaf7	1878	29	risk	risk	NN
cord-034340-3ksfpaf7	1878	30	patients	patient	NNS
cord-034340-3ksfpaf7	1878	31	.	.	.
cord-034340-3ksfpaf7	1879	1	Our	-PRON-	PRP$
cord-034340-3ksfpaf7	1879	2	results	result	NNS
cord-034340-3ksfpaf7	1879	3	are	be	VBP
cord-034340-3ksfpaf7	1879	4	consistent	consistent	JJ
cord-034340-3ksfpaf7	1879	5	with	with	IN
cord-034340-3ksfpaf7	1879	6	Caucasi	Caucasi	NNP
cord-034340-3ksfpaf7	1879	7	n	n	NNP
cord-034340-3ksfpaf7	1879	8	based	base	VBD
cord-034340-3ksfpaf7	1879	9	population	population	NN
cord-034340-3ksfpaf7	1879	10	studies	study	NNS
cord-034340-3ksfpaf7	1879	11	available	available	JJ
cord-034340-3ksfpaf7	1879	12	to	to	IN
cord-034340-3ksfpaf7	1879	13	date	date	NN
cord-034340-3ksfpaf7	1879	14	.	.	.
cord-034340-3ksfpaf7	1880	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1880	2	:	:	:
cord-034340-3ksfpaf7	1881	1	Varicella	Varicella	NNP
cord-034340-3ksfpaf7	1881	2	zoster	zoster	NN
cord-034340-3ksfpaf7	1881	3	virus	virus	NN
cord-034340-3ksfpaf7	1881	4	(	(	-LRB-
cord-034340-3ksfpaf7	1881	5	VZV	VZV	NNP
cord-034340-3ksfpaf7	1881	6	)	)	-RRB-
cord-034340-3ksfpaf7	1881	7	related	relate	VBD
cord-034340-3ksfpaf7	1881	8	arterial	arterial	JJ
cord-034340-3ksfpaf7	1881	9	ischemic	ischemic	JJ
cord-034340-3ksfpaf7	1881	10	stroke	stroke	NN
cord-034340-3ksfpaf7	1881	11	(	(	-LRB-
cord-034340-3ksfpaf7	1881	12	AIS	AIS	NNP
cord-034340-3ksfpaf7	1881	13	)	)	-RRB-
cord-034340-3ksfpaf7	1881	14	has	have	VBZ
cord-034340-3ksfpaf7	1881	15	been	be	VBN
cord-034340-3ksfpaf7	1881	16	described	describe	VBN
cord-034340-3ksfpaf7	1881	17	in	in	IN
cord-034340-3ksfpaf7	1881	18	literature	literature	NN
cord-034340-3ksfpaf7	1881	19	in	in	IN
cord-034340-3ksfpaf7	1881	20	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1881	21	age	age	NN
cord-034340-3ksfpaf7	1881	22	.	.	.
cord-034340-3ksfpaf7	1882	1	However	however	RB
cord-034340-3ksfpaf7	1882	2	,	,	,
cord-034340-3ksfpaf7	1882	3	the	the	DT
cord-034340-3ksfpaf7	1882	4	long	long	JJ
cord-034340-3ksfpaf7	1882	5	-	-	HYPH
cord-034340-3ksfpaf7	1882	6	term	term	NN
cord-034340-3ksfpaf7	1882	7	course	course	NN
cord-034340-3ksfpaf7	1882	8	of	of	IN
cord-034340-3ksfpaf7	1882	9	post	post	JJ
cord-034340-3ksfpaf7	1882	10	-	-	JJ
cord-034340-3ksfpaf7	1882	11	VZV	vzv	JJ
cord-034340-3ksfpaf7	1882	12	vasculopathy	vasculopathy	NNP
cord-034340-3ksfpaf7	1882	13	need	need	VBP
cord-034340-3ksfpaf7	1882	14	to	to	TO
cord-034340-3ksfpaf7	1882	15	be	be	VB
cord-034340-3ksfpaf7	1882	16	inquired	inquire	VBN
cord-034340-3ksfpaf7	1882	17	:	:	:
cord-034340-3ksfpaf7	1882	18	clear	clear	JJ
cord-034340-3ksfpaf7	1882	19	information	information	NN
cord-034340-3ksfpaf7	1882	20	about	about	IN
cord-034340-3ksfpaf7	1882	21	prevalence	prevalence	NN
cord-034340-3ksfpaf7	1882	22	of	of	IN
cord-034340-3ksfpaf7	1882	23	recurrence	recurrence	NN
cord-034340-3ksfpaf7	1882	24	and	and	CC
cord-034340-3ksfpaf7	1882	25	severity	severity	NN
cord-034340-3ksfpaf7	1882	26	of	of	IN
cord-034340-3ksfpaf7	1882	27	clinical	clinical	JJ
cord-034340-3ksfpaf7	1882	28	outcome	outcome	NN
cord-034340-3ksfpaf7	1882	29	are	be	VBP
cord-034340-3ksfpaf7	1882	30	lacking	lack	VBG
cord-034340-3ksfpaf7	1882	31	,	,	,
cord-034340-3ksfpaf7	1882	32	even	even	RB
cord-034340-3ksfpaf7	1882	33	if	if	IN
cord-034340-3ksfpaf7	1882	34	a	a	DT
cord-034340-3ksfpaf7	1882	35	favorable	favorable	JJ
cord-034340-3ksfpaf7	1882	36	evolution	evolution	NN
cord-034340-3ksfpaf7	1882	37	was	be	VBD
cord-034340-3ksfpaf7	1882	38	initially	initially	RB
cord-034340-3ksfpaf7	1882	39	described	describe	VBN
cord-034340-3ksfpaf7	1882	40	,	,	,
cord-034340-3ksfpaf7	1882	41	and	and	CC
cord-034340-3ksfpaf7	1882	42	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	1882	43	protocols	protocol	NNS
cord-034340-3ksfpaf7	1882	44	are	be	VBP
cord-034340-3ksfpaf7	1882	45	not	not	RB
cord-034340-3ksfpaf7	1882	46	currently	currently	RB
cord-034340-3ksfpaf7	1882	47	standardized	standardize	VBN
cord-034340-3ksfpaf7	1882	48	.	.	.
cord-034340-3ksfpaf7	1883	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1883	2	:	:	:
cord-034340-3ksfpaf7	1883	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1883	4	aimed	aim	VBD
cord-034340-3ksfpaf7	1883	5	to	to	TO
cord-034340-3ksfpaf7	1883	6	describe	describe	VB
cord-034340-3ksfpaf7	1883	7	the	the	DT
cord-034340-3ksfpaf7	1883	8	clinical	clinical	JJ
cord-034340-3ksfpaf7	1883	9	,	,	,
cord-034340-3ksfpaf7	1883	10	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1883	11	and	and	CC
cord-034340-3ksfpaf7	1883	12	neuroradiologic	neuroradiologic	JJ
cord-034340-3ksfpaf7	1883	13	features	feature	NNS
cord-034340-3ksfpaf7	1883	14	of	of	IN
cord-034340-3ksfpaf7	1883	15	children	child	NNS
cord-034340-3ksfpaf7	1883	16	affected	affect	VBN
cord-034340-3ksfpaf7	1883	17	by	by	IN
cord-034340-3ksfpaf7	1883	18	AIS	AIS	NNP
cord-034340-3ksfpaf7	1883	19	due	due	IN
cord-034340-3ksfpaf7	1883	20	to	to	IN
cord-034340-3ksfpaf7	1883	21	post	post	JJ
cord-034340-3ksfpaf7	1883	22	-	-	JJ
cord-034340-3ksfpaf7	1883	23	VZV	VZV	NNP
cord-034340-3ksfpaf7	1883	24	referred	refer	VBD
cord-034340-3ksfpaf7	1883	25	to	to	IN
cord-034340-3ksfpaf7	1883	26	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1883	27	Institute	Institute	NNP
cord-034340-3ksfpaf7	1883	28	and	and	CC
cord-034340-3ksfpaf7	1883	29	to	to	TO
cord-034340-3ksfpaf7	1883	30	present	present	VB
cord-034340-3ksfpaf7	1883	31	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1883	32	experience	experience	NN
cord-034340-3ksfpaf7	1883	33	in	in	IN
cord-034340-3ksfpaf7	1883	34	their	-PRON-	PRP$
cord-034340-3ksfpaf7	1883	35	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	1883	36	management	management	NN
cord-034340-3ksfpaf7	1883	37	.	.	.
cord-034340-3ksfpaf7	1884	1	Methods	method	NNS
cord-034340-3ksfpaf7	1884	2	:	:	:
cord-034340-3ksfpaf7	1884	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1884	4	selected	select	VBD
cord-034340-3ksfpaf7	1884	5	22	22	CD
cord-034340-3ksfpaf7	1884	6	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1884	7	patients	patient	NNS
cord-034340-3ksfpaf7	1884	8	(	(	-LRB-
cord-034340-3ksfpaf7	1884	9	6	6	CD
cord-034340-3ksfpaf7	1884	10	females	female	NNS
cord-034340-3ksfpaf7	1884	11	)	)	-RRB-
cord-034340-3ksfpaf7	1884	12	with	with	IN
cord-034340-3ksfpaf7	1884	13	AIS	AIS	NNP
cord-034340-3ksfpaf7	1884	14	and	and	CC
cord-034340-3ksfpaf7	1884	15	a	a	DT
cord-034340-3ksfpaf7	1884	16	CNS	CNS	NNP
cord-034340-3ksfpaf7	1884	17	confirmed	confirm	VBD
cord-034340-3ksfpaf7	1884	18	VZV	VZV	NNP
cord-034340-3ksfpaf7	1884	19	reactivation	reactivation	NN
cord-034340-3ksfpaf7	1884	20	and/or	and/or	CC
cord-034340-3ksfpaf7	1884	21	with	with	IN
cord-034340-3ksfpaf7	1884	22	a	a	DT
cord-034340-3ksfpaf7	1884	23	VZV	VZV	NNP
cord-034340-3ksfpaf7	1884	24	history	history	NN
cord-034340-3ksfpaf7	1884	25	in	in	IN
cord-034340-3ksfpaf7	1884	26	the	the	DT
cord-034340-3ksfpaf7	1884	27	previous	previous	JJ
cord-034340-3ksfpaf7	1884	28	12	12	CD
cord-034340-3ksfpaf7	1884	29	months	month	NNS
cord-034340-3ksfpaf7	1884	30	.	.	.
cord-034340-3ksfpaf7	1885	1	Other	other	JJ
cord-034340-3ksfpaf7	1885	2	causes	cause	NNS
cord-034340-3ksfpaf7	1885	3	of	of	IN
cord-034340-3ksfpaf7	1885	4	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1885	5	stroke	stroke	NN
cord-034340-3ksfpaf7	1885	6	(	(	-LRB-
cord-034340-3ksfpaf7	1885	7	systemic	systemic	JJ
cord-034340-3ksfpaf7	1885	8	disease	disease	NN
cord-034340-3ksfpaf7	1885	9	,	,	,
cord-034340-3ksfpaf7	1885	10	cardiac	cardiac	JJ
cord-034340-3ksfpaf7	1885	11	disease	disease	NN
cord-034340-3ksfpaf7	1885	12	,	,	,
cord-034340-3ksfpaf7	1885	13	trauma	trauma	NN
cord-034340-3ksfpaf7	1885	14	,	,	,
cord-034340-3ksfpaf7	1885	15	major	major	JJ
cord-034340-3ksfpaf7	1885	16	thrombophilia	thrombophilia	NNP
cord-034340-3ksfpaf7	1885	17	)	)	-RRB-
cord-034340-3ksfpaf7	1885	18	were	be	VBD
cord-034340-3ksfpaf7	1885	19	excluded	exclude	VBN
cord-034340-3ksfpaf7	1885	20	.	.	.
cord-034340-3ksfpaf7	1886	1	Clinical	clinical	JJ
cord-034340-3ksfpaf7	1886	2	,	,	,
cord-034340-3ksfpaf7	1886	3	neuroimaging	neuroimaging	NN
cord-034340-3ksfpaf7	1886	4	,	,	,
cord-034340-3ksfpaf7	1886	5	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1886	6	and	and	CC
cord-034340-3ksfpaf7	1886	7	treatment	treatment	NN
cord-034340-3ksfpaf7	1886	8	data	datum	NNS
cord-034340-3ksfpaf7	1886	9	were	be	VBD
cord-034340-3ksfpaf7	1886	10	reviewed	review	VBN
cord-034340-3ksfpaf7	1886	11	,	,	,
cord-034340-3ksfpaf7	1886	12	focusing	focus	VBG
cord-034340-3ksfpaf7	1886	13	on	on	IN
cord-034340-3ksfpaf7	1886	14	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	1886	15	score	score	NN
cord-034340-3ksfpaf7	1886	16	outcome	outcome	NN
cord-034340-3ksfpaf7	1886	17	measure	measure	NN
cord-034340-3ksfpaf7	1886	18	(	(	-LRB-
cord-034340-3ksfpaf7	1886	19	PSOM	PSOM	NNP
cord-034340-3ksfpaf7	1886	20	)	)	-RRB-
cord-034340-3ksfpaf7	1886	21	and	and	CC
cord-034340-3ksfpaf7	1886	22	executive	executive	JJ
cord-034340-3ksfpaf7	1886	23	functions	function	NNS
cord-034340-3ksfpaf7	1886	24	final	final	JJ
cord-034340-3ksfpaf7	1886	25	outcome	outcome	NN
cord-034340-3ksfpaf7	1886	26	.	.	.
cord-034340-3ksfpaf7	1887	1	Results	result	NNS
cord-034340-3ksfpaf7	1887	2	:	:	:
cord-034340-3ksfpaf7	1888	1	Average	average	JJ
cord-034340-3ksfpaf7	1888	2	age	age	NN
cord-034340-3ksfpaf7	1888	3	of	of	IN
cord-034340-3ksfpaf7	1888	4	AIS	AIS	NNP
cord-034340-3ksfpaf7	1888	5	onset	onset	NN
cord-034340-3ksfpaf7	1888	6	,	,	,
cord-034340-3ksfpaf7	1888	7	VZV	VZV	NNP
cord-034340-3ksfpaf7	1888	8	primary	primary	JJ
cord-034340-3ksfpaf7	1888	9	infection	infection	NN
cord-034340-3ksfpaf7	1888	10	and	and	CC
cord-034340-3ksfpaf7	1888	11	interval	interval	NN
cord-034340-3ksfpaf7	1888	12	between	between	IN
cord-034340-3ksfpaf7	1888	13	infection	infection	NN
cord-034340-3ksfpaf7	1888	14	and	and	CC
cord-034340-3ksfpaf7	1888	15	AIS	AIS	NNP
cord-034340-3ksfpaf7	1888	16	were	be	VBD
cord-034340-3ksfpaf7	1888	17	:	:	:
cord-034340-3ksfpaf7	1888	18	4	4	CD
cord-034340-3ksfpaf7	1888	19	years	year	NNS
cord-034340-3ksfpaf7	1888	20	10mo	10mo	NNP
cord-034340-3ksfpaf7	1889	1	(	(	-LRB-
cord-034340-3ksfpaf7	1889	2	range	range	NN
cord-034340-3ksfpaf7	1889	3	:	:	:
cord-034340-3ksfpaf7	1889	4	1	1	CD
cord-034340-3ksfpaf7	1889	5	year	year	NN
cord-034340-3ksfpaf7	1889	6	and	and	CC
cord-034340-3ksfpaf7	1889	7	8	8	CD
cord-034340-3ksfpaf7	1889	8	mo-9	mo-9	NN
cord-034340-3ksfpaf7	1889	9	years	year	NNS
cord-034340-3ksfpaf7	1889	10	and	and	CC
cord-034340-3ksfpaf7	1889	11	11	11	CD
cord-034340-3ksfpaf7	1889	12	months	month	NNS
cord-034340-3ksfpaf7	1889	13	)	)	-RRB-
cord-034340-3ksfpaf7	1889	14	,	,	,
cord-034340-3ksfpaf7	1889	15	4	4	CD
cord-034340-3ksfpaf7	1889	16	years	year	NNS
cord-034340-3ksfpaf7	1889	17	and	and	CC
cord-034340-3ksfpaf7	1889	18	5	5	CD
cord-034340-3ksfpaf7	1889	19	months	month	NNS
cord-034340-3ksfpaf7	1889	20	(	(	-LRB-
cord-034340-3ksfpaf7	1889	21	range	range	VBP
cord-034340-3ksfpaf7	1889	22	8	8	CD
cord-034340-3ksfpaf7	1889	23	months-9.4	months-9.4	NNP
cord-034340-3ksfpaf7	1889	24	years	year	NNS
cord-034340-3ksfpaf7	1889	25	)	)	-RRB-
cord-034340-3ksfpaf7	1889	26	,	,	,
cord-034340-3ksfpaf7	1889	27	and	and	CC
cord-034340-3ksfpaf7	1889	28	7	7	CD
cord-034340-3ksfpaf7	1889	29	months	month	NNS
cord-034340-3ksfpaf7	1889	30	(	(	-LRB-
cord-034340-3ksfpaf7	1889	31	range	range	VBP
cord-034340-3ksfpaf7	1889	32	10days-34	10days-34	NNP
cord-034340-3ksfpaf7	1889	33	months	month	NNS
cord-034340-3ksfpaf7	1889	34	)	)	-RRB-
cord-034340-3ksfpaf7	1889	35	,	,	,
cord-034340-3ksfpaf7	1889	36	respectively	respectively	RB
cord-034340-3ksfpaf7	1889	37	.	.	.
cord-034340-3ksfpaf7	1890	1	The	the	DT
cord-034340-3ksfpaf7	1890	2	AIS	AIS	NNP
cord-034340-3ksfpaf7	1890	3	involved	involve	VBD
cord-034340-3ksfpaf7	1890	4	the	the	DT
cord-034340-3ksfpaf7	1890	5	nucleo	nucleo	JJ
cord-034340-3ksfpaf7	1890	6	-	-	JJ
cord-034340-3ksfpaf7	1890	7	capsular	capsular	JJ
cord-034340-3ksfpaf7	1890	8	region	region	NN
cord-034340-3ksfpaf7	1890	9	in	in	IN
cord-034340-3ksfpaf7	1890	10	18	18	CD
cord-034340-3ksfpaf7	1890	11	cases	case	NNS
cord-034340-3ksfpaf7	1890	12	,	,	,
cord-034340-3ksfpaf7	1890	13	the	the	DT
cord-034340-3ksfpaf7	1890	14	cerebral	cerebral	JJ
cord-034340-3ksfpaf7	1890	15	cortex	cortex	NN
cord-034340-3ksfpaf7	1890	16	in	in	IN
cord-034340-3ksfpaf7	1890	17	9	9	CD
cord-034340-3ksfpaf7	1890	18	cases	case	NNS
cord-034340-3ksfpaf7	1890	19	,	,	,
cord-034340-3ksfpaf7	1890	20	the	the	DT
cord-034340-3ksfpaf7	1890	21	thalamus	thalamus	NN
cord-034340-3ksfpaf7	1890	22	in	in	IN
cord-034340-3ksfpaf7	1890	23	4	4	CD
cord-034340-3ksfpaf7	1890	24	cases	case	NNS
cord-034340-3ksfpaf7	1890	25	,	,	,
cord-034340-3ksfpaf7	1890	26	and	and	CC
cord-034340-3ksfpaf7	1890	27	the	the	DT
cord-034340-3ksfpaf7	1890	28	pons	pon	NNS
cord-034340-3ksfpaf7	1890	29	in	in	IN
cord-034340-3ksfpaf7	1890	30	3	3	CD
cord-034340-3ksfpaf7	1890	31	subjects	subject	NNS
cord-034340-3ksfpaf7	1890	32	.	.	.
cord-034340-3ksfpaf7	1891	1	Seventeen	seventeen	CD
cord-034340-3ksfpaf7	1891	2	patients	patient	NNS
cord-034340-3ksfpaf7	1891	3	had	have	VBD
cord-034340-3ksfpaf7	1891	4	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1891	5	focal	focal	JJ
cord-034340-3ksfpaf7	1891	6	cerebral	cerebral	JJ
cord-034340-3ksfpaf7	1891	7	arteriopathy	arteriopathy	NN
cord-034340-3ksfpaf7	1891	8	(	(	-LRB-
cord-034340-3ksfpaf7	1891	9	iFCA	iFCA	NNP
cord-034340-3ksfpaf7	1891	10	)	)	-RRB-
cord-034340-3ksfpaf7	1891	11	.	.	.
cord-034340-3ksfpaf7	1892	1	Virological	virological	JJ
cord-034340-3ksfpaf7	1892	2	confirmation	confirmation	NN
cord-034340-3ksfpaf7	1892	3	(	(	-LRB-
cord-034340-3ksfpaf7	1892	4	VZV	VZV	NNP
cord-034340-3ksfpaf7	1892	5	-	-	HYPH
cord-034340-3ksfpaf7	1892	6	DNA	DNA	NNP
cord-034340-3ksfpaf7	1892	7	or	or	CC
cord-034340-3ksfpaf7	1892	8	anti	anti	JJ
cord-034340-3ksfpaf7	1892	9	-	-	JJ
cord-034340-3ksfpaf7	1892	10	VZV	vzv	JJ
cord-034340-3ksfpaf7	1892	11	IgG	igg	NN
cord-034340-3ksfpaf7	1892	12	in	in	IN
cord-034340-3ksfpaf7	1892	13	the	the	DT
cord-034340-3ksfpaf7	1892	14	cerebrospinal	cerebrospinal	JJ
cord-034340-3ksfpaf7	1892	15	fluid	fluid	NN
cord-034340-3ksfpaf7	1892	16	)	)	-RRB-
cord-034340-3ksfpaf7	1892	17	was	be	VBD
cord-034340-3ksfpaf7	1892	18	obtained	obtain	VBN
cord-034340-3ksfpaf7	1892	19	in	in	IN
cord-034340-3ksfpaf7	1892	20	11	11	CD
cord-034340-3ksfpaf7	1892	21	patients	patient	NNS
cord-034340-3ksfpaf7	1892	22	.	.	.
cord-034340-3ksfpaf7	1893	1	Three	three	CD
cord-034340-3ksfpaf7	1893	2	patients	patient	NNS
cord-034340-3ksfpaf7	1893	3	were	be	VBD
cord-034340-3ksfpaf7	1893	4	treated	treat	VBN
cord-034340-3ksfpaf7	1893	5	with	with	IN
cord-034340-3ksfpaf7	1893	6	trombectomy	trombectomy	NN
cord-034340-3ksfpaf7	1893	7	and	and	CC
cord-034340-3ksfpaf7	1893	8	one	one	CD
cord-034340-3ksfpaf7	1893	9	with	with	IN
cord-034340-3ksfpaf7	1893	10	rTPA	rTPA	NNP
cord-034340-3ksfpaf7	1893	11	.	.	.
cord-034340-3ksfpaf7	1894	1	Thirteen	thirteen	CD
cord-034340-3ksfpaf7	1894	2	patients	patient	NNS
cord-034340-3ksfpaf7	1894	3	were	be	VBD
cord-034340-3ksfpaf7	1894	4	treated	treat	VBN
cord-034340-3ksfpaf7	1894	5	with	with	IN
cord-034340-3ksfpaf7	1894	6	antiviral	antiviral	JJ
cord-034340-3ksfpaf7	1894	7	agents	agent	NNS
cord-034340-3ksfpaf7	1894	8	associated	associate	VBN
cord-034340-3ksfpaf7	1894	9	with	with	IN
cord-034340-3ksfpaf7	1894	10	steroids	steroid	NNS
cord-034340-3ksfpaf7	1894	11	in	in	IN
cord-034340-3ksfpaf7	1894	12	8	8	CD
cord-034340-3ksfpaf7	1894	13	cases	case	NNS
cord-034340-3ksfpaf7	1894	14	,	,	,
cord-034340-3ksfpaf7	1894	15	with	with	IN
cord-034340-3ksfpaf7	1894	16	different	different	JJ
cord-034340-3ksfpaf7	1894	17	administration	administration	NN
cord-034340-3ksfpaf7	1894	18	schedules	schedule	NNS
cord-034340-3ksfpaf7	1894	19	.	.	.
cord-034340-3ksfpaf7	1895	1	Only	only	RB
cord-034340-3ksfpaf7	1895	2	in	in	IN
cord-034340-3ksfpaf7	1895	3	one	one	CD
cord-034340-3ksfpaf7	1895	4	case	case	NN
cord-034340-3ksfpaf7	1895	5	steroid	steroid	NN
cord-034340-3ksfpaf7	1895	6	treatment	treatment	NN
cord-034340-3ksfpaf7	1895	7	was	be	VBD
cord-034340-3ksfpaf7	1895	8	given	give	VBN
cord-034340-3ksfpaf7	1895	9	without	without	IN
cord-034340-3ksfpaf7	1895	10	association	association	NN
cord-034340-3ksfpaf7	1895	11	with	with	IN
cord-034340-3ksfpaf7	1895	12	antiviral	antiviral	JJ
cord-034340-3ksfpaf7	1895	13	agents	agent	NNS
cord-034340-3ksfpaf7	1895	14	.	.	.
cord-034340-3ksfpaf7	1896	1	One	one	CD
cord-034340-3ksfpaf7	1896	2	patient	patient	NN
cord-034340-3ksfpaf7	1896	3	received	receive	VBD
cord-034340-3ksfpaf7	1896	4	a	a	DT
cord-034340-3ksfpaf7	1896	5	short	short	JJ
cord-034340-3ksfpaf7	1896	6	course	course	NN
cord-034340-3ksfpaf7	1896	7	of	of	IN
cord-034340-3ksfpaf7	1896	8	steroid	steroid	NN
cord-034340-3ksfpaf7	1896	9	and	and	CC
cord-034340-3ksfpaf7	1896	10	antiviral	antiviral	JJ
cord-034340-3ksfpaf7	1896	11	treatment	treatment	NN
cord-034340-3ksfpaf7	1896	12	at	at	IN
cord-034340-3ksfpaf7	1896	13	the	the	DT
cord-034340-3ksfpaf7	1896	14	time	time	NN
cord-034340-3ksfpaf7	1896	15	of	of	IN
cord-034340-3ksfpaf7	1896	16	the	the	DT
cord-034340-3ksfpaf7	1896	17	stroke	stroke	NN
cord-034340-3ksfpaf7	1896	18	and	and	CC
cord-034340-3ksfpaf7	1896	19	then	then	RB
cord-034340-3ksfpaf7	1896	20	a	a	DT
cord-034340-3ksfpaf7	1896	21	more	more	RBR
cord-034340-3ksfpaf7	1896	22	prolonged	prolonged	JJ
cord-034340-3ksfpaf7	1896	23	course	course	NN
cord-034340-3ksfpaf7	1896	24	after	after	IN
cord-034340-3ksfpaf7	1896	25	six	six	CD
cord-034340-3ksfpaf7	1896	26	months	month	NNS
cord-034340-3ksfpaf7	1896	27	at	at	IN
cord-034340-3ksfpaf7	1896	28	the	the	DT
cord-034340-3ksfpaf7	1896	29	time	time	NN
cord-034340-3ksfpaf7	1896	30	of	of	IN
cord-034340-3ksfpaf7	1896	31	the	the	DT
cord-034340-3ksfpaf7	1896	32	virological	virological	JJ
cord-034340-3ksfpaf7	1896	33	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1896	34	.	.	.
cord-034340-3ksfpaf7	1897	1	Prophylactic	prophylactic	JJ
cord-034340-3ksfpaf7	1897	2	antiaggregants	antiaggregant	NNS
cord-034340-3ksfpaf7	1897	3	were	be	VBD
cord-034340-3ksfpaf7	1897	4	administered	administer	VBN
cord-034340-3ksfpaf7	1897	5	to	to	IN
cord-034340-3ksfpaf7	1897	6	all	all	DT
cord-034340-3ksfpaf7	1897	7	patients	patient	NNS
cord-034340-3ksfpaf7	1897	8	.	.	.
cord-034340-3ksfpaf7	1898	1	Mean	mean	JJ
cord-034340-3ksfpaf7	1898	2	follow	follow	NN
cord-034340-3ksfpaf7	1898	3	-	-	HYPH
cord-034340-3ksfpaf7	1898	4	up	up	NN
cord-034340-3ksfpaf7	1898	5	was	be	VBD
cord-034340-3ksfpaf7	1898	6	2	2	CD
cord-034340-3ksfpaf7	1898	7	years	year	NNS
cord-034340-3ksfpaf7	1898	8	and	and	CC
cord-034340-3ksfpaf7	1898	9	5	5	CD
cord-034340-3ksfpaf7	1898	10	months	month	NNS
cord-034340-3ksfpaf7	1899	1	(	(	-LRB-
cord-034340-3ksfpaf7	1899	2	range	range	NNP
cord-034340-3ksfpaf7	1899	3	6	6	CD
cord-034340-3ksfpaf7	1899	4	mo	mo	NN
cord-034340-3ksfpaf7	1899	5	-10	-10	IN
cord-034340-3ksfpaf7	1899	6	years	year	NNS
cord-034340-3ksfpaf7	1899	7	)	)	-RRB-
cord-034340-3ksfpaf7	1899	8	;	;	:
cord-034340-3ksfpaf7	1899	9	iFCA	iFCA	NNP
cord-034340-3ksfpaf7	1899	10	was	be	VBD
cord-034340-3ksfpaf7	1899	11	persistent	persistent	JJ
cord-034340-3ksfpaf7	1899	12	in	in	IN
cord-034340-3ksfpaf7	1899	13	12	12	CD
cord-034340-3ksfpaf7	1899	14	cases	case	NNS
cord-034340-3ksfpaf7	1899	15	and	and	CC
cord-034340-3ksfpaf7	1899	16	transient	transient	JJ
cord-034340-3ksfpaf7	1899	17	in	in	IN
cord-034340-3ksfpaf7	1899	18	5	5	CD
cord-034340-3ksfpaf7	1899	19	subjects	subject	NNS
cord-034340-3ksfpaf7	1899	20	.	.	.
cord-034340-3ksfpaf7	1900	1	Four	four	CD
cord-034340-3ksfpaf7	1900	2	patients	patient	NNS
cord-034340-3ksfpaf7	1900	3	presented	present	VBD
cord-034340-3ksfpaf7	1900	4	a	a	DT
cord-034340-3ksfpaf7	1900	5	recurrence	recurrence	NN
cord-034340-3ksfpaf7	1900	6	of	of	IN
cord-034340-3ksfpaf7	1900	7	post	post	NN
cord-034340-3ksfpaf7	1900	8	VZV	VZV	NNP
cord-034340-3ksfpaf7	1900	9	arteriopathy	arteriopathy	NNP
cord-034340-3ksfpaf7	1900	10	,	,	,
cord-034340-3ksfpaf7	1900	11	two	two	CD
cord-034340-3ksfpaf7	1900	12	of	of	IN
cord-034340-3ksfpaf7	1900	13	them	-PRON-	PRP
cord-034340-3ksfpaf7	1900	14	presenting	present	VBG
cord-034340-3ksfpaf7	1900	15	new	new	JJ
cord-034340-3ksfpaf7	1900	16	stroke	stroke	NN
cord-034340-3ksfpaf7	1900	17	events	event	NNS
cord-034340-3ksfpaf7	1900	18	.	.	.
cord-034340-3ksfpaf7	1901	1	Twelve	twelve	CD
cord-034340-3ksfpaf7	1901	2	patients	patient	NNS
cord-034340-3ksfpaf7	1901	3	presented	present	VBD
cord-034340-3ksfpaf7	1901	4	a	a	DT
cord-034340-3ksfpaf7	1901	5	variable	variable	JJ
cord-034340-3ksfpaf7	1901	6	motor	motor	NN
cord-034340-3ksfpaf7	1901	7	deficit	deficit	NN
cord-034340-3ksfpaf7	1901	8	at	at	IN
cord-034340-3ksfpaf7	1901	9	last	last	JJ
cord-034340-3ksfpaf7	1901	10	follow	follow	VB
cord-034340-3ksfpaf7	1901	11	up	up	RP
cord-034340-3ksfpaf7	1901	12	.	.	.
cord-034340-3ksfpaf7	1902	1	The	the	DT
cord-034340-3ksfpaf7	1902	2	mean	mean	NN
cord-034340-3ksfpaf7	1902	3	PSOM	PSOM	NNP
cord-034340-3ksfpaf7	1902	4	score	score	NN
cord-034340-3ksfpaf7	1902	5	of	of	IN
cord-034340-3ksfpaf7	1902	6	the	the	DT
cord-034340-3ksfpaf7	1902	7	cohort	cohort	NN
cord-034340-3ksfpaf7	1902	8	at	at	IN
cord-034340-3ksfpaf7	1902	9	the	the	DT
cord-034340-3ksfpaf7	1902	10	last	last	JJ
cord-034340-3ksfpaf7	1902	11	visit	visit	NN
cord-034340-3ksfpaf7	1902	12	was	be	VBD
cord-034340-3ksfpaf7	1902	13	1	1	CD
cord-034340-3ksfpaf7	1903	1	(	(	-LRB-
cord-034340-3ksfpaf7	1903	2	range	range	NN
cord-034340-3ksfpaf7	1903	3	0	0	CD
cord-034340-3ksfpaf7	1903	4	-	-	SYM
cord-034340-3ksfpaf7	1903	5	2	2	CD
cord-034340-3ksfpaf7	1903	6	)	)	-RRB-
cord-034340-3ksfpaf7	1903	7	.	.	.
cord-034340-3ksfpaf7	1904	1	Executive	executive	NN
cord-034340-3ksfpaf7	1904	2	functions	function	NNS
cord-034340-3ksfpaf7	1904	3	were	be	VBD
cord-034340-3ksfpaf7	1904	4	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	1904	5	at	at	IN
cord-034340-3ksfpaf7	1904	6	last	last	JJ
cord-034340-3ksfpaf7	1904	7	follow	follow	VB
cord-034340-3ksfpaf7	1904	8	up	up	RP
cord-034340-3ksfpaf7	1904	9	in	in	IN
cord-034340-3ksfpaf7	1904	10	twelve	twelve	CD
cord-034340-3ksfpaf7	1904	11	patients	patient	NNS
cord-034340-3ksfpaf7	1904	12	,	,	,
cord-034340-3ksfpaf7	1904	13	showing	show	VBG
cord-034340-3ksfpaf7	1904	14	no	no	DT
cord-034340-3ksfpaf7	1904	15	deficit	deficit	NN
cord-034340-3ksfpaf7	1904	16	in	in	IN
cord-034340-3ksfpaf7	1904	17	seven	seven	CD
cord-034340-3ksfpaf7	1904	18	patients	patient	NNS
cord-034340-3ksfpaf7	1904	19	,	,	,
cord-034340-3ksfpaf7	1904	20	a	a	DT
cord-034340-3ksfpaf7	1904	21	mild	mild	JJ
cord-034340-3ksfpaf7	1904	22	deficit	deficit	NN
cord-034340-3ksfpaf7	1904	23	in	in	IN
cord-034340-3ksfpaf7	1904	24	two	two	CD
cord-034340-3ksfpaf7	1904	25	patients	patient	NNS
cord-034340-3ksfpaf7	1904	26	and	and	CC
cord-034340-3ksfpaf7	1904	27	a	a	DT
cord-034340-3ksfpaf7	1904	28	severe	severe	JJ
cord-034340-3ksfpaf7	1904	29	deficit	deficit	NN
cord-034340-3ksfpaf7	1904	30	in	in	IN
cord-034340-3ksfpaf7	1904	31	the	the	DT
cord-034340-3ksfpaf7	1904	32	last	last	JJ
cord-034340-3ksfpaf7	1904	33	three	three	CD
cord-034340-3ksfpaf7	1904	34	.	.	.
cord-034340-3ksfpaf7	1905	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1905	2	:	:	:
cord-034340-3ksfpaf7	1906	1	Albeit	albeit	IN
cord-034340-3ksfpaf7	1906	2	a	a	DT
cord-034340-3ksfpaf7	1906	3	favourable	favourable	JJ
cord-034340-3ksfpaf7	1906	4	evolution	evolution	NN
cord-034340-3ksfpaf7	1906	5	was	be	VBD
cord-034340-3ksfpaf7	1906	6	initially	initially	RB
cord-034340-3ksfpaf7	1906	7	described	describe	VBN
cord-034340-3ksfpaf7	1906	8	,	,	,
cord-034340-3ksfpaf7	1906	9	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1906	10	experience	experience	NN
cord-034340-3ksfpaf7	1906	11	suggests	suggest	VBZ
cord-034340-3ksfpaf7	1906	12	that	that	IN
cord-034340-3ksfpaf7	1906	13	VZV	VZV	NNP
cord-034340-3ksfpaf7	1906	14	-	-	HYPH
cord-034340-3ksfpaf7	1906	15	related	relate	VBN
cord-034340-3ksfpaf7	1906	16	AIS	AIS	NNP
cord-034340-3ksfpaf7	1906	17	may	may	MD
cord-034340-3ksfpaf7	1906	18	result	result	VB
cord-034340-3ksfpaf7	1906	19	in	in	IN
cord-034340-3ksfpaf7	1906	20	persistent	persistent	JJ
cord-034340-3ksfpaf7	1906	21	FCA	FCA	NNP
cord-034340-3ksfpaf7	1906	22	and	and	CC
cord-034340-3ksfpaf7	1906	23	significant	significant	JJ
cord-034340-3ksfpaf7	1906	24	neurological	neurological	JJ
cord-034340-3ksfpaf7	1906	25	impairment	impairment	NN
cord-034340-3ksfpaf7	1906	26	in	in	IN
cord-034340-3ksfpaf7	1906	27	the	the	DT
cord-034340-3ksfpaf7	1906	28	majority	majority	NN
cord-034340-3ksfpaf7	1906	29	of	of	IN
cord-034340-3ksfpaf7	1906	30	cases	case	NNS
cord-034340-3ksfpaf7	1906	31	.	.	.
cord-034340-3ksfpaf7	1907	1	Therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	1907	2	approach	approach	NN
cord-034340-3ksfpaf7	1907	3	,	,	,
cord-034340-3ksfpaf7	1907	4	particularly	particularly	RB
cord-034340-3ksfpaf7	1907	5	involving	involve	VBG
cord-034340-3ksfpaf7	1907	6	steroid	steroid	NN
cord-034340-3ksfpaf7	1907	7	administration	administration	NN
cord-034340-3ksfpaf7	1907	8	,	,	,
cord-034340-3ksfpaf7	1907	9	still	still	RB
cord-034340-3ksfpaf7	1907	10	need	need	VBP
cord-034340-3ksfpaf7	1907	11	to	to	TO
cord-034340-3ksfpaf7	1907	12	be	be	VB
cord-034340-3ksfpaf7	1907	13	validated	validate	VBN
cord-034340-3ksfpaf7	1907	14	.	.	.
cord-034340-3ksfpaf7	1908	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1908	2	:	:	:
cord-034340-3ksfpaf7	1908	3	IgA	IgA	NNP
cord-034340-3ksfpaf7	1908	4	vasculitis/	vasculitis/	CD
cord-034340-3ksfpaf7	1909	1	Henoch	Henoch	NNP
cord-034340-3ksfpaf7	1909	2	Schönlein	Schönlein	NNP
cord-034340-3ksfpaf7	1909	3	Purpura	Purpura	NNP
cord-034340-3ksfpaf7	1910	1	(	(	-LRB-
cord-034340-3ksfpaf7	1910	2	IgAV	IgAV	NNP
cord-034340-3ksfpaf7	1910	3	/	/	SYM
cord-034340-3ksfpaf7	1910	4	HSP	HSP	NNP
cord-034340-3ksfpaf7	1910	5	)	)	-RRB-
cord-034340-3ksfpaf7	1910	6	is	be	VBZ
cord-034340-3ksfpaf7	1910	7	the	the	DT
cord-034340-3ksfpaf7	1910	8	most	most	RBS
cord-034340-3ksfpaf7	1910	9	common	common	JJ
cord-034340-3ksfpaf7	1910	10	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1910	11	of	of	IN
cord-034340-3ksfpaf7	1910	12	childhood	childhood	NN
cord-034340-3ksfpaf7	1910	13	and	and	CC
cord-034340-3ksfpaf7	1910	14	renal	renal	JJ
cord-034340-3ksfpaf7	1910	15	involvement	involvement	NN
cord-034340-3ksfpaf7	1910	16	is	be	VBZ
cord-034340-3ksfpaf7	1910	17	the	the	DT
cord-034340-3ksfpaf7	1910	18	most	most	RBS
cord-034340-3ksfpaf7	1910	19	serious	serious	JJ
cord-034340-3ksfpaf7	1910	20	long	long	JJ
cord-034340-3ksfpaf7	1910	21	-	-	HYPH
cord-034340-3ksfpaf7	1910	22	term	term	NN
cord-034340-3ksfpaf7	1910	23	complication	complication	NN
cord-034340-3ksfpaf7	1910	24	.	.	.
cord-034340-3ksfpaf7	1911	1	A	a	DT
cord-034340-3ksfpaf7	1911	2	better	well	JJR
cord-034340-3ksfpaf7	1911	3	understanding	understanding	NN
cord-034340-3ksfpaf7	1911	4	of	of	IN
cord-034340-3ksfpaf7	1911	5	the	the	DT
cord-034340-3ksfpaf7	1911	6	pathophysiology	pathophysiology	NN
cord-034340-3ksfpaf7	1911	7	of	of	IN
cord-034340-3ksfpaf7	1911	8	the	the	DT
cord-034340-3ksfpaf7	1911	9	progression	progression	NN
cord-034340-3ksfpaf7	1911	10	to	to	IN
cord-034340-3ksfpaf7	1911	11	kidney	kidney	NN
cord-034340-3ksfpaf7	1911	12	disease	disease	NN
cord-034340-3ksfpaf7	1911	13	is	be	VBZ
cord-034340-3ksfpaf7	1911	14	required	require	VBN
cord-034340-3ksfpaf7	1911	15	for	for	IN
cord-034340-3ksfpaf7	1911	16	better	well	JJR
cord-034340-3ksfpaf7	1911	17	treatment	treatment	NN
cord-034340-3ksfpaf7	1911	18	to	to	TO
cord-034340-3ksfpaf7	1911	19	be	be	VB
cord-034340-3ksfpaf7	1911	20	achieved	achieve	VBN
cord-034340-3ksfpaf7	1911	21	and	and	CC
cord-034340-3ksfpaf7	1911	22	current	current	JJ
cord-034340-3ksfpaf7	1911	23	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	1911	24	of	of	IN
cord-034340-3ksfpaf7	1911	25	Ig	Ig	NNP
cord-034340-3ksfpaf7	1911	26	A	a	DT
cord-034340-3ksfpaf7	1911	27	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	1911	28	with	with	IN
cord-034340-3ksfpaf7	1911	29	nephritis	nephritis	NN
cord-034340-3ksfpaf7	1911	30	(	(	-LRB-
cord-034340-3ksfpaf7	1911	31	IgAVN	IgAVN	NNP
cord-034340-3ksfpaf7	1911	32	)	)	-RRB-
cord-034340-3ksfpaf7	1911	33	lack	lack	VBP
cord-034340-3ksfpaf7	1911	34	the	the	DT
cord-034340-3ksfpaf7	1911	35	predictive	predictive	JJ
cord-034340-3ksfpaf7	1911	36	value	value	NN
cord-034340-3ksfpaf7	1911	37	.	.	.
cord-034340-3ksfpaf7	1912	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1912	2	:	:	:
cord-034340-3ksfpaf7	1912	3	In	in	IN
cord-034340-3ksfpaf7	1912	4	this	this	DT
cord-034340-3ksfpaf7	1912	5	study	study	NN
cord-034340-3ksfpaf7	1912	6	,	,	,
cord-034340-3ksfpaf7	1912	7	an	an	DT
cord-034340-3ksfpaf7	1912	8	untargeted	untargeted	JJ
cord-034340-3ksfpaf7	1912	9	metabolomics	metabolomic	NNS
cord-034340-3ksfpaf7	1912	10	approach	approach	NN
cord-034340-3ksfpaf7	1912	11	was	be	VBD
cord-034340-3ksfpaf7	1912	12	performed	perform	VBN
cord-034340-3ksfpaf7	1912	13	to	to	TO
cord-034340-3ksfpaf7	1912	14	reveal	reveal	VB
cord-034340-3ksfpaf7	1912	15	the	the	DT
cord-034340-3ksfpaf7	1912	16	underlying	underlying	JJ
cord-034340-3ksfpaf7	1912	17	molecular	molecular	JJ
cord-034340-3ksfpaf7	1912	18	mechanism	mechanism	NN
cord-034340-3ksfpaf7	1912	19	of	of	IN
cord-034340-3ksfpaf7	1912	20	disease	disease	NN
cord-034340-3ksfpaf7	1912	21	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	1912	22	and	and	CC
cord-034340-3ksfpaf7	1912	23	to	to	TO
cord-034340-3ksfpaf7	1912	24	find	find	VB
cord-034340-3ksfpaf7	1912	25	potential	potential	JJ
cord-034340-3ksfpaf7	1912	26	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	1912	27	of	of	IN
cord-034340-3ksfpaf7	1912	28	plasma	plasma	NN
cord-034340-3ksfpaf7	1912	29	samples	sample	NNS
cord-034340-3ksfpaf7	1912	30	from	from	IN
cord-034340-3ksfpaf7	1912	31	patients	patient	NNS
cord-034340-3ksfpaf7	1912	32	with	with	IN
cord-034340-3ksfpaf7	1912	33	IgAV	IgAV	NNP
cord-034340-3ksfpaf7	1912	34	and	and	CC
cord-034340-3ksfpaf7	1912	35	IgAVN.Methods	igavn.method	NNS
cord-034340-3ksfpaf7	1912	36	:	:	:
cord-034340-3ksfpaf7	1912	37	IgAV	IgAV	NNP
cord-034340-3ksfpaf7	1912	38	was	be	VBD
cord-034340-3ksfpaf7	1912	39	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	1912	40	according	accord	VBG
cord-034340-3ksfpaf7	1912	41	to	to	IN
cord-034340-3ksfpaf7	1912	42	the	the	DT
cord-034340-3ksfpaf7	1912	43	Ankara	Ankara	NNP
cord-034340-3ksfpaf7	1912	44	criteria	criterion	NNS
cord-034340-3ksfpaf7	1912	45	in	in	IN
cord-034340-3ksfpaf7	1912	46	2008	2008	CD
cord-034340-3ksfpaf7	1912	47	(	(	-LRB-
cord-034340-3ksfpaf7	1912	48	1	1	CD
cord-034340-3ksfpaf7	1912	49	)	)	-RRB-
cord-034340-3ksfpaf7	1912	50	.	.	.
cord-034340-3ksfpaf7	1913	1	Forty	forty	CD
cord-034340-3ksfpaf7	1913	2	-	-	HYPH
cord-034340-3ksfpaf7	1913	3	five	five	CD
cord-034340-3ksfpaf7	1913	4	patients	patient	NNS
cord-034340-3ksfpaf7	1913	5	,	,	,
cord-034340-3ksfpaf7	1913	6	including	include	VBG
cord-034340-3ksfpaf7	1913	7	39	39	CD
cord-034340-3ksfpaf7	1913	8	active	active	JJ
cord-034340-3ksfpaf7	1913	9	IgAV	IgAV	NNP
cord-034340-3ksfpaf7	1913	10	patients	patient	NNS
cord-034340-3ksfpaf7	1913	11	(	(	-LRB-
cord-034340-3ksfpaf7	1913	12	H	H	NNP
cord-034340-3ksfpaf7	1913	13	)	)	-RRB-
cord-034340-3ksfpaf7	1913	14	,	,	,
cord-034340-3ksfpaf7	1913	15	6	6	CD
cord-034340-3ksfpaf7	1913	16	IgAVN	IgAVN	NNP
cord-034340-3ksfpaf7	1913	17	(	(	-LRB-
cord-034340-3ksfpaf7	1913	18	N	N	NNP
cord-034340-3ksfpaf7	1913	19	)	)	-RRB-
cord-034340-3ksfpaf7	1913	20	,	,	,
cord-034340-3ksfpaf7	1913	21	and	and	CC
cord-034340-3ksfpaf7	1913	22	6	6	CD
cord-034340-3ksfpaf7	1913	23	age	age	NN
cord-034340-3ksfpaf7	1913	24	-	-	HYPH
cord-034340-3ksfpaf7	1913	25	and	and	CC
cord-034340-3ksfpaf7	1913	26	gender	gender	NN
cord-034340-3ksfpaf7	1913	27	-	-	HYPH
cord-034340-3ksfpaf7	1913	28	matched	match	VBN
cord-034340-3ksfpaf7	1913	29	healthy	healthy	JJ
cord-034340-3ksfpaf7	1913	30	controls	control	NNS
cord-034340-3ksfpaf7	1913	31	(	(	-LRB-
cord-034340-3ksfpaf7	1913	32	C	C	NNP
cord-034340-3ksfpaf7	1913	33	)	)	-RRB-
cord-034340-3ksfpaf7	1913	34	,	,	,
cord-034340-3ksfpaf7	1913	35	were	be	VBD
cord-034340-3ksfpaf7	1913	36	enrolled	enrol	VBN
cord-034340-3ksfpaf7	1913	37	in	in	IN
cord-034340-3ksfpaf7	1913	38	the	the	DT
cord-034340-3ksfpaf7	1913	39	study	study	NN
cord-034340-3ksfpaf7	1913	40	.	.	.
cord-034340-3ksfpaf7	1914	1	Plasma	plasma	NN
cord-034340-3ksfpaf7	1914	2	samples	sample	NNS
cord-034340-3ksfpaf7	1914	3	from	from	IN
cord-034340-3ksfpaf7	1914	4	subjects	subject	NNS
cord-034340-3ksfpaf7	1914	5	were	be	VBD
cord-034340-3ksfpaf7	1914	6	collected	collect	VBN
cord-034340-3ksfpaf7	1914	7	on	on	IN
cord-034340-3ksfpaf7	1914	8	the	the	DT
cord-034340-3ksfpaf7	1914	9	same	same	JJ
cord-034340-3ksfpaf7	1914	10	day	day	NN
cord-034340-3ksfpaf7	1914	11	of	of	IN
cord-034340-3ksfpaf7	1914	12	IgAV(HSP	IgAV(HSP	NNP
cord-034340-3ksfpaf7	1914	13	)	)	-RRB-
cord-034340-3ksfpaf7	1914	14	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1914	15	and	and	CC
cord-034340-3ksfpaf7	1914	16	before	before	IN
cord-034340-3ksfpaf7	1914	17	steroid	steroid	NN
cord-034340-3ksfpaf7	1914	18	or	or	CC
cord-034340-3ksfpaf7	1914	19	other	other	JJ
cord-034340-3ksfpaf7	1914	20	immunosuppressive	immunosuppressive	JJ
cord-034340-3ksfpaf7	1914	21	treatment	treatment	NN
cord-034340-3ksfpaf7	1914	22	initiated	initiate	VBN
cord-034340-3ksfpaf7	1914	23	.	.	.
cord-034340-3ksfpaf7	1915	1	This	this	DT
cord-034340-3ksfpaf7	1915	2	study	study	NN
cord-034340-3ksfpaf7	1915	3	has	have	VBZ
cord-034340-3ksfpaf7	1915	4	utilized	utilize	VBN
cord-034340-3ksfpaf7	1915	5	liquid	liquid	JJ
cord-034340-3ksfpaf7	1915	6	chromatography	chromatography	NN
cord-034340-3ksfpaf7	1915	7	-	-	HYPH
cord-034340-3ksfpaf7	1915	8	mass	mass	NN
cord-034340-3ksfpaf7	1915	9	spectrometry	spectrometry	NN
cord-034340-3ksfpaf7	1915	10	(	(	-LRB-
cord-034340-3ksfpaf7	1915	11	LC	LC	NNP
cord-034340-3ksfpaf7	1915	12	-	-	HYPH
cord-034340-3ksfpaf7	1915	13	MS/	MS/	NNP
cord-034340-3ksfpaf7	1915	14	Q	Q	NNP
cord-034340-3ksfpaf7	1915	15	-	-	HYPH
cord-034340-3ksfpaf7	1915	16	TOF	TOF	NNP
cord-034340-3ksfpaf7	1915	17	)	)	-RRB-
cord-034340-3ksfpaf7	1915	18	to	to	TO
cord-034340-3ksfpaf7	1915	19	investigate	investigate	VB
cord-034340-3ksfpaf7	1915	20	the	the	DT
cord-034340-3ksfpaf7	1915	21	alterations	alteration	NNS
cord-034340-3ksfpaf7	1915	22	in	in	IN
cord-034340-3ksfpaf7	1915	23	plasma	plasma	NN
cord-034340-3ksfpaf7	1915	24	metabolomic	metabolomic	NN
cord-034340-3ksfpaf7	1915	25	profiles	profile	NNS
cord-034340-3ksfpaf7	1915	26	.	.	.
cord-034340-3ksfpaf7	1916	1	Three	three	CD
cord-034340-3ksfpaf7	1916	2	separate	separate	JJ
cord-034340-3ksfpaf7	1916	3	pools	pool	NNS
cord-034340-3ksfpaf7	1916	4	,	,	,
cord-034340-3ksfpaf7	1916	5	health	health	NN
cord-034340-3ksfpaf7	1916	6	controls	control	NNS
cord-034340-3ksfpaf7	1916	7	,	,	,
cord-034340-3ksfpaf7	1916	8	active	active	JJ
cord-034340-3ksfpaf7	1916	9	IgAV	IgAV	NNP
cord-034340-3ksfpaf7	1916	10	,	,	,
cord-034340-3ksfpaf7	1916	11	and	and	CC
cord-034340-3ksfpaf7	1916	12	IgAVN	IgAVN	NNP
cord-034340-3ksfpaf7	1916	13	were	be	VBD
cord-034340-3ksfpaf7	1916	14	created	create	VBN
cord-034340-3ksfpaf7	1916	15	.	.	.
cord-034340-3ksfpaf7	1917	1	Peak	peak	NN
cord-034340-3ksfpaf7	1917	2	picking	picking	NN
cord-034340-3ksfpaf7	1917	3	,	,	,
cord-034340-3ksfpaf7	1917	4	grouping	grouping	NN
cord-034340-3ksfpaf7	1917	5	,	,	,
cord-034340-3ksfpaf7	1917	6	and	and	CC
cord-034340-3ksfpaf7	1917	7	comparison	comparison	NN
cord-034340-3ksfpaf7	1917	8	parts	part	NNS
cord-034340-3ksfpaf7	1917	9	were	be	VBD
cord-034340-3ksfpaf7	1917	10	performed	perform	VBN
cord-034340-3ksfpaf7	1917	11	(	(	-LRB-
cord-034340-3ksfpaf7	1917	12	metabolite	metabolite	NN
cord-034340-3ksfpaf7	1917	13	profiling	profiling	NN
cord-034340-3ksfpaf7	1917	14	)	)	-RRB-
cord-034340-3ksfpaf7	1918	1	via	via	IN
cord-034340-3ksfpaf7	1918	2	XCMS	XCMS	NNP
cord-034340-3ksfpaf7	1918	3	(	(	-LRB-
cord-034340-3ksfpaf7	1918	4	https://xcmsonline.scripps.edu/	https://xcmsonline.scripps.edu/	ADD
cord-034340-3ksfpaf7	1918	5	)	)	-RRB-
cord-034340-3ksfpaf7	1918	6	software	software	NN
cord-034340-3ksfpaf7	1918	7	.	.	.
cord-034340-3ksfpaf7	1919	1	Results	result	NNS
cord-034340-3ksfpaf7	1919	2	:	:	:
cord-034340-3ksfpaf7	1920	1	Totally	totally	RB
cord-034340-3ksfpaf7	1920	2	2618	2618	CD
cord-034340-3ksfpaf7	1920	3	peaks	peak	NNS
cord-034340-3ksfpaf7	1920	4	were	be	VBD
cord-034340-3ksfpaf7	1920	5	detected	detect	VBN
cord-034340-3ksfpaf7	1920	6	for	for	IN
cord-034340-3ksfpaf7	1920	7	group	group	NN
cord-034340-3ksfpaf7	1920	8	H	H	NNP
cord-034340-3ksfpaf7	1920	9	,	,	,
cord-034340-3ksfpaf7	1920	10	N	N	NNP
cord-034340-3ksfpaf7	1920	11	and	and	CC
cord-034340-3ksfpaf7	1920	12	C.	C.	NNP
cord-034340-3ksfpaf7	1921	1	Among	among	IN
cord-034340-3ksfpaf7	1921	2	them	-PRON-	PRP
cord-034340-3ksfpaf7	1921	3	355	355	CD
cord-034340-3ksfpaf7	1921	4	peaks	peak	NNS
cord-034340-3ksfpaf7	1921	5	were	be	VBD
cord-034340-3ksfpaf7	1921	6	found	find	VBN
cord-034340-3ksfpaf7	1921	7	to	to	TO
cord-034340-3ksfpaf7	1921	8	be	be	VB
cord-034340-3ksfpaf7	1921	9	statistically	statistically	RB
cord-034340-3ksfpaf7	1921	10	significant	significant	JJ
cord-034340-3ksfpaf7	1921	11	and	and	CC
cord-034340-3ksfpaf7	1921	12	reliable	reliable	JJ
cord-034340-3ksfpaf7	1922	1	(	(	-LRB-
cord-034340-3ksfpaf7	1922	2	p	p	NN
cord-034340-3ksfpaf7	1922	3	<	<	XX
cord-034340-3ksfpaf7	1922	4	0.05	0.05	CD
cord-034340-3ksfpaf7	1922	5	)	)	-RRB-
cord-034340-3ksfpaf7	1922	6	and	and	CC
cord-034340-3ksfpaf7	1922	7	155	155	CD
cord-034340-3ksfpaf7	1922	8	of	of	IN
cord-034340-3ksfpaf7	1922	9	these	these	DT
cord-034340-3ksfpaf7	1922	10	peaks	peak	NNS
cord-034340-3ksfpaf7	1922	11	were	be	VBD
cord-034340-3ksfpaf7	1922	12	found	find	VBN
cord-034340-3ksfpaf7	1922	13	to	to	TO
cord-034340-3ksfpaf7	1922	14	be	be	VB
cord-034340-3ksfpaf7	1922	15	changed	change	VBN
cord-034340-3ksfpaf7	1922	16	(	(	-LRB-
cord-034340-3ksfpaf7	1922	17	fold	fold	JJ
cord-034340-3ksfpaf7	1922	18	change	change	NN
cord-034340-3ksfpaf7	1922	19	>	>	XX
cord-034340-3ksfpaf7	1922	20	1.5	1.5	CD
cord-034340-3ksfpaf7	1922	21	)	)	-RRB-
cord-034340-3ksfpaf7	1922	22	between	between	IN
cord-034340-3ksfpaf7	1922	23	the	the	DT
cord-034340-3ksfpaf7	1922	24	groups	group	NNS
cord-034340-3ksfpaf7	1922	25	C	C	NNP
cord-034340-3ksfpaf7	1922	26	and	and	CC
cord-034340-3ksfpaf7	1922	27	H.	h.	NN
cord-034340-3ksfpaf7	1923	1	On	on	IN
cord-034340-3ksfpaf7	1923	2	the	the	DT
cord-034340-3ksfpaf7	1923	3	other	other	JJ
cord-034340-3ksfpaf7	1923	4	hand	hand	NN
cord-034340-3ksfpaf7	1923	5	,	,	,
cord-034340-3ksfpaf7	1923	6	66	66	CD
cord-034340-3ksfpaf7	1923	7	peaks	peak	NNS
cord-034340-3ksfpaf7	1923	8	were	be	VBD
cord-034340-3ksfpaf7	1923	9	found	find	VBN
cord-034340-3ksfpaf7	1923	10	to	to	TO
cord-034340-3ksfpaf7	1923	11	be	be	VB
cord-034340-3ksfpaf7	1923	12	changed	change	VBN
cord-034340-3ksfpaf7	1923	13	(	(	-LRB-
cord-034340-3ksfpaf7	1923	14	fold	fold	JJ
cord-034340-3ksfpaf7	1923	15	change	change	NN
cord-034340-3ksfpaf7	1923	16	>	>	XX
cord-034340-3ksfpaf7	1923	17	1.5	1.5	CD
cord-034340-3ksfpaf7	1923	18	)	)	-RRB-
cord-034340-3ksfpaf7	1923	19	between	between	IN
cord-034340-3ksfpaf7	1923	20	the	the	DT
cord-034340-3ksfpaf7	1923	21	groups	group	NNS
cord-034340-3ksfpaf7	1923	22	H	h	NN
cord-034340-3ksfpaf7	1923	23	and	and	CC
cord-034340-3ksfpaf7	1923	24	N.	n.	NN
cord-034340-3ksfpaf7	1924	1	The	the	DT
cord-034340-3ksfpaf7	1924	2	number	number	NN
cord-034340-3ksfpaf7	1924	3	of	of	IN
cord-034340-3ksfpaf7	1924	4	the	the	DT
cord-034340-3ksfpaf7	1924	5	peaks	peak	NNS
cord-034340-3ksfpaf7	1924	6	on	on	IN
cord-034340-3ksfpaf7	1924	7	the	the	DT
cord-034340-3ksfpaf7	1924	8	intersection	intersection	NN
cord-034340-3ksfpaf7	1924	9	of	of	IN
cord-034340-3ksfpaf7	1924	10	the	the	DT
cord-034340-3ksfpaf7	1924	11	peaks	peak	NNS
cord-034340-3ksfpaf7	1924	12	found	find	VBN
cord-034340-3ksfpaf7	1924	13	to	to	TO
cord-034340-3ksfpaf7	1924	14	be	be	VB
cord-034340-3ksfpaf7	1924	15	changed	change	VBN
cord-034340-3ksfpaf7	1924	16	between	between	IN
cord-034340-3ksfpaf7	1924	17	the	the	DT
cord-034340-3ksfpaf7	1924	18	groups	group	NNS
cord-034340-3ksfpaf7	1924	19	(	(	-LRB-
cord-034340-3ksfpaf7	1924	20	C	C	NNP
cord-034340-3ksfpaf7	1924	21	and	and	CC
cord-034340-3ksfpaf7	1924	22	H	H	NNP
cord-034340-3ksfpaf7	1924	23	)	)	-RRB-
cord-034340-3ksfpaf7	1924	24	and	and	CC
cord-034340-3ksfpaf7	1924	25	(	(	-LRB-
cord-034340-3ksfpaf7	1924	26	H	H	NNP
cord-034340-3ksfpaf7	1924	27	and	and	CC
cord-034340-3ksfpaf7	1924	28	N	N	NNP
cord-034340-3ksfpaf7	1924	29	)	)	-RRB-
cord-034340-3ksfpaf7	1924	30	was	be	VBD
cord-034340-3ksfpaf7	1924	31	39	39	CD
cord-034340-3ksfpaf7	1924	32	.	.	.
cord-034340-3ksfpaf7	1925	1	Based	base	VBN
cord-034340-3ksfpaf7	1925	2	on	on	IN
cord-034340-3ksfpaf7	1925	3	putative	putative	JJ
cord-034340-3ksfpaf7	1925	4	identification	identification	NN
cord-034340-3ksfpaf7	1925	5	results	result	NNS
cord-034340-3ksfpaf7	1925	6	,	,	,
cord-034340-3ksfpaf7	1925	7	15	15	CD
cord-034340-3ksfpaf7	1925	8	peaks	peak	NNS
cord-034340-3ksfpaf7	1925	9	were	be	VBD
cord-034340-3ksfpaf7	1925	10	matched	match	VBN
cord-034340-3ksfpaf7	1925	11	with	with	IN
cord-034340-3ksfpaf7	1925	12	11	11	CD
cord-034340-3ksfpaf7	1925	13	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	1925	14	.	.	.
cord-034340-3ksfpaf7	1926	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1926	2	found	find	VBD
cord-034340-3ksfpaf7	1926	3	an	an	DT
cord-034340-3ksfpaf7	1926	4	up	up	RB
cord-034340-3ksfpaf7	1926	5	-	-	HYPH
cord-034340-3ksfpaf7	1926	6	regulated	regulated	JJ
cord-034340-3ksfpaf7	1926	7	level	level	NN
cord-034340-3ksfpaf7	1926	8	of	of	IN
cord-034340-3ksfpaf7	1926	9	DHAP(18:0	dhap(18:0	NN
cord-034340-3ksfpaf7	1926	10	)	)	-RRB-
cord-034340-3ksfpaf7	1926	11	,	,	,
cord-034340-3ksfpaf7	1926	12	prostaglandin	prostaglandin	NN
cord-034340-3ksfpaf7	1926	13	D2	d2	NN
cord-034340-3ksfpaf7	1926	14	/	/	,
cord-034340-3ksfpaf7	1926	15	I2	I2	NNP
cord-034340-3ksfpaf7	1926	16	,	,	,
cord-034340-3ksfpaf7	1926	17	5methyltetrahydrofolic	5methyltetrahydrofolic	CD
cord-034340-3ksfpaf7	1926	18	acid	acid	NN
cord-034340-3ksfpaf7	1926	19	,	,	,
cord-034340-3ksfpaf7	1926	20	porphobilinogen	porphobilinogen	NNP
cord-034340-3ksfpaf7	1926	21	and	and	CC
cord-034340-3ksfpaf7	1926	22	N	N	NNP
cord-034340-3ksfpaf7	1926	23	-	-	HYPH
cord-034340-3ksfpaf7	1926	24	Acetyl-4-O	acetyl-4-o	VB
cord-034340-3ksfpaf7	1926	25	-	-	HYPH
cord-034340-3ksfpaf7	1926	26	acetylneuraminic	acetylneuraminic	NNP
cord-034340-3ksfpaf7	1926	27	acid	acid	NN
cord-034340-3ksfpaf7	1926	28	/	/	SYM
cord-034340-3ksfpaf7	1926	29	N	N	NNP
cord-034340-3ksfpaf7	1926	30	-	-	HYPH
cord-034340-3ksfpaf7	1926	31	Acetyl-7-O	Acetyl-7-O	NNP
cord-034340-3ksfpaf7	1926	32	-	-	HYPH
cord-034340-3ksfpaf7	1926	33	acetylneuraminic	acetylneuraminic	NNP
cord-034340-3ksfpaf7	1926	34	acid	acid	NN
cord-034340-3ksfpaf7	1926	35	,	,	,
cord-034340-3ksfpaf7	1927	1	5-Aminopentanamide	5-aminopentanamide	CD
cord-034340-3ksfpaf7	1927	2	/5-Aminopentanoic	/5-aminopentanoic	NN
cord-034340-3ksfpaf7	1927	3	acid	acid	NN
cord-034340-3ksfpaf7	1927	4	,	,	,
cord-034340-3ksfpaf7	1927	5	Glycocholic	Glycocholic	NNP
cord-034340-3ksfpaf7	1927	6	acid	acid	NN
cord-034340-3ksfpaf7	1927	7	,	,	,
cord-034340-3ksfpaf7	1927	8	Saccharopine	Saccharopine	NNP
cord-034340-3ksfpaf7	1927	9	,	,	,
cord-034340-3ksfpaf7	1927	10	N2-Succinyl	N2-Succinyl	NNP
cord-034340-3ksfpaf7	1927	11	-	-	HYPH
cord-034340-3ksfpaf7	1927	12	L	l	NN
cord-034340-3ksfpaf7	1927	13	-	-	HYPH
cord-034340-3ksfpaf7	1927	14	ornithine	ornithine	NN
cord-034340-3ksfpaf7	1927	15	,	,	,
cord-034340-3ksfpaf7	1927	16	gamma	gamma	NN
cord-034340-3ksfpaf7	1927	17	Tocopherol	tocopherol	NN
cord-034340-3ksfpaf7	1927	18	,	,	,
cord-034340-3ksfpaf7	1927	19	and	and	CC
cord-034340-3ksfpaf7	1927	20	Galactosylsphingosine	Galactosylsphingosine	NNP
cord-034340-3ksfpaf7	1927	21	/Glucosylsphingosine	/Glucosylsphingosine	,
cord-034340-3ksfpaf7	1927	22	in	in	IN
cord-034340-3ksfpaf7	1927	23	IgAV	IgAV	NNP
cord-034340-3ksfpaf7	1927	24	patients	patient	NNS
cord-034340-3ksfpaf7	1927	25	.	.	.
cord-034340-3ksfpaf7	1928	1	In	in	IN
cord-034340-3ksfpaf7	1928	2	conclusion	conclusion	NN
cord-034340-3ksfpaf7	1928	3	,	,	,
cord-034340-3ksfpaf7	1928	4	we	-PRON-	PRP
cord-034340-3ksfpaf7	1928	5	have	have	VBP
cord-034340-3ksfpaf7	1928	6	identified	identify	VBN
cord-034340-3ksfpaf7	1928	7	a	a	DT
cord-034340-3ksfpaf7	1928	8	number	number	NN
cord-034340-3ksfpaf7	1928	9	of	of	IN
cord-034340-3ksfpaf7	1928	10	metabolites	metabolite	NNS
cord-034340-3ksfpaf7	1928	11	that	that	WDT
cord-034340-3ksfpaf7	1928	12	may	may	MD
cord-034340-3ksfpaf7	1928	13	be	be	VB
cord-034340-3ksfpaf7	1928	14	associated	associate	VBN
cord-034340-3ksfpaf7	1928	15	with	with	IN
cord-034340-3ksfpaf7	1928	16	the	the	DT
cord-034340-3ksfpaf7	1928	17	pathogenesis	pathogenesis	NN
cord-034340-3ksfpaf7	1928	18	of	of	IN
cord-034340-3ksfpaf7	1928	19	IgAV	IgAV	NNP
cord-034340-3ksfpaf7	1928	20	.	.	.
cord-034340-3ksfpaf7	1929	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	1929	2	also	also	RB
cord-034340-3ksfpaf7	1929	3	suggest	suggest	VBP
cord-034340-3ksfpaf7	1929	4	that	that	IN
cord-034340-3ksfpaf7	1929	5	DHAP	DHAP	NNP
cord-034340-3ksfpaf7	1929	6	(	(	-LRB-
cord-034340-3ksfpaf7	1929	7	18:0	18:0	CD
cord-034340-3ksfpaf7	1929	8	)	)	-RRB-
cord-034340-3ksfpaf7	1929	9	,	,	,
cord-034340-3ksfpaf7	1929	10	prostaglandin	prostaglandin	NN
cord-034340-3ksfpaf7	1929	11	D2	d2	NN
cord-034340-3ksfpaf7	1929	12	/	/	,
cord-034340-3ksfpaf7	1929	13	I2	I2	NNP
cord-034340-3ksfpaf7	1929	14	,	,	,
cord-034340-3ksfpaf7	1929	15	porphobilinogen	porphobilinogen	NNP
cord-034340-3ksfpaf7	1929	16	,	,	,
cord-034340-3ksfpaf7	1929	17	5-methyltetrahydrofolic	5-methyltetrahydrofolic	CD
cord-034340-3ksfpaf7	1929	18	acid	acid	NN
cord-034340-3ksfpaf7	1929	19	and	and	CC
cord-034340-3ksfpaf7	1929	20	N	N	NNP
cord-034340-3ksfpaf7	1929	21	-	-	HYPH
cord-034340-3ksfpaf7	1929	22	Acetyl-4-Oacetylneuraminic	Acetyl-4-Oacetylneuraminic	NNP
cord-034340-3ksfpaf7	1929	23	acid	acid	NN
cord-034340-3ksfpaf7	1929	24	/	/	SYM
cord-034340-3ksfpaf7	1929	25	N	N	NNP
cord-034340-3ksfpaf7	1929	26	-	-	HYPH
cord-034340-3ksfpaf7	1929	27	Acetyl-7-O	Acetyl-7-O	NNP
cord-034340-3ksfpaf7	1930	1	-acetylneuraminic	-acetylneuraminic	JJ
cord-034340-3ksfpaf7	1930	2	acid	acid	NN
cord-034340-3ksfpaf7	1930	3	may	may	MD
cord-034340-3ksfpaf7	1930	4	serve	serve	VB
cord-034340-3ksfpaf7	1930	5	as	as	IN
cord-034340-3ksfpaf7	1930	6	biomarkers	biomarker	NNS
cord-034340-3ksfpaf7	1930	7	for	for	IN
cord-034340-3ksfpaf7	1930	8	predicting	predict	VBG
cord-034340-3ksfpaf7	1930	9	kidney	kidney	NN
cord-034340-3ksfpaf7	1930	10	disease	disease	NN
cord-034340-3ksfpaf7	1930	11	since	since	IN
cord-034340-3ksfpaf7	1930	12	they	-PRON-	PRP
cord-034340-3ksfpaf7	1930	13	were	be	VBD
cord-034340-3ksfpaf7	1930	14	increased	increase	VBN
cord-034340-3ksfpaf7	1930	15	only	only	RB
cord-034340-3ksfpaf7	1930	16	in	in	IN
cord-034340-3ksfpaf7	1930	17	the	the	DT
cord-034340-3ksfpaf7	1930	18	patients	patient	NNS
cord-034340-3ksfpaf7	1930	19	who	who	WP
cord-034340-3ksfpaf7	1930	20	developed	develop	VBD
cord-034340-3ksfpaf7	1930	21	renal	renal	JJ
cord-034340-3ksfpaf7	1930	22	involvement	involvement	NN
cord-034340-3ksfpaf7	1930	23	at	at	IN
cord-034340-3ksfpaf7	1930	24	follow	follow	NN
cord-034340-3ksfpaf7	1930	25	-	-	HYPH
cord-034340-3ksfpaf7	1930	26	up	up	NN
cord-034340-3ksfpaf7	1930	27	.	.	.
cord-034340-3ksfpaf7	1931	1	Children	child	NNS
cord-034340-3ksfpaf7	1931	2	were	be	VBD
cord-034340-3ksfpaf7	1931	3	divided	divide	VBN
cord-034340-3ksfpaf7	1931	4	into	into	IN
cord-034340-3ksfpaf7	1931	5	four	four	CD
cord-034340-3ksfpaf7	1931	6	groups	group	NNS
cord-034340-3ksfpaf7	1931	7	:	:	:
cord-034340-3ksfpaf7	1931	8	those	those	DT
cord-034340-3ksfpaf7	1931	9	with	with	IN
cord-034340-3ksfpaf7	1931	10	JIA	JIA	NNP
cord-034340-3ksfpaf7	1931	11	who	who	WP
cord-034340-3ksfpaf7	1931	12	did	do	VBD
cord-034340-3ksfpaf7	1931	13	n't	not	RB
cord-034340-3ksfpaf7	1931	14	receive	receive	VB
cord-034340-3ksfpaf7	1931	15	MTX	MTX	NNP
cord-034340-3ksfpaf7	1931	16	yet	yet	RB
cord-034340-3ksfpaf7	1931	17	(	(	-LRB-
cord-034340-3ksfpaf7	1931	18	group	group	NN
cord-034340-3ksfpaf7	1931	19	1	1	CD
cord-034340-3ksfpaf7	1931	20	)	)	-RRB-
cord-034340-3ksfpaf7	1931	21	;	;	:
cord-034340-3ksfpaf7	1931	22	those	those	DT
cord-034340-3ksfpaf7	1931	23	who	who	WP
cord-034340-3ksfpaf7	1931	24	received	receive	VBD
cord-034340-3ksfpaf7	1931	25	MTX	MTX	NNP
cord-034340-3ksfpaf7	1931	26	less	less	JJR
cord-034340-3ksfpaf7	1931	27	than	than	IN
cord-034340-3ksfpaf7	1931	28	one	one	CD
cord-034340-3ksfpaf7	1931	29	gram	gram	NN
cord-034340-3ksfpaf7	1931	30	during	during	IN
cord-034340-3ksfpaf7	1931	31	whole	whole	JJ
cord-034340-3ksfpaf7	1931	32	treatment	treatment	NN
cord-034340-3ksfpaf7	1931	33	(	(	-LRB-
cord-034340-3ksfpaf7	1931	34	group	group	NN
cord-034340-3ksfpaf7	1931	35	2	2	CD
cord-034340-3ksfpaf7	1931	36	)	)	-RRB-
cord-034340-3ksfpaf7	1931	37	;	;	:
cord-034340-3ksfpaf7	1931	38	those	those	DT
cord-034340-3ksfpaf7	1931	39	who	who	WP
cord-034340-3ksfpaf7	1931	40	received	receive	VBD
cord-034340-3ksfpaf7	1931	41	MTX	MTX	NNP
cord-034340-3ksfpaf7	1931	42	from	from	IN
cord-034340-3ksfpaf7	1931	43	1	1	CD
cord-034340-3ksfpaf7	1931	44	to	to	IN
cord-034340-3ksfpaf7	1931	45	3	3	CD
cord-034340-3ksfpaf7	1931	46	grams	gram	NNS
cord-034340-3ksfpaf7	1931	47	(	(	-LRB-
cord-034340-3ksfpaf7	1931	48	group	group	NN
cord-034340-3ksfpaf7	1931	49	3	3	CD
cord-034340-3ksfpaf7	1931	50	)	)	-RRB-
cord-034340-3ksfpaf7	1931	51	;	;	:
cord-034340-3ksfpaf7	1931	52	children	child	NNS
cord-034340-3ksfpaf7	1931	53	,	,	,
cord-034340-3ksfpaf7	1931	54	received	receive	VBD
cord-034340-3ksfpaf7	1931	55	more	more	JJR
cord-034340-3ksfpaf7	1931	56	than	than	IN
cord-034340-3ksfpaf7	1931	57	3	3	CD
cord-034340-3ksfpaf7	1931	58	grams	gram	NNS
cord-034340-3ksfpaf7	1931	59	of	of	IN
cord-034340-3ksfpaf7	1931	60	MTX	MTX	NNP
cord-034340-3ksfpaf7	1931	61	(	(	-LRB-
cord-034340-3ksfpaf7	1931	62	group	group	NN
cord-034340-3ksfpaf7	1931	63	4	4	CD
cord-034340-3ksfpaf7	1931	64	)	)	-RRB-
cord-034340-3ksfpaf7	1931	65	.	.	.
cord-034340-3ksfpaf7	1932	1	The	the	DT
cord-034340-3ksfpaf7	1932	2	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1932	3	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1932	4	process	process	NN
cord-034340-3ksfpaf7	1932	5	in	in	IN
cord-034340-3ksfpaf7	1932	6	JIA	JIA	NNP
cord-034340-3ksfpaf7	1932	7	can	can	MD
cord-034340-3ksfpaf7	1932	8	cause	cause	VB
cord-034340-3ksfpaf7	1932	9	formation	formation	NN
cord-034340-3ksfpaf7	1932	10	of	of	IN
cord-034340-3ksfpaf7	1932	11	pathological	pathological	JJ
cord-034340-3ksfpaf7	1932	12	changes	change	NNS
cord-034340-3ksfpaf7	1932	13	in	in	IN
cord-034340-3ksfpaf7	1932	14	the	the	DT
cord-034340-3ksfpaf7	1932	15	liver	liver	NN
cord-034340-3ksfpaf7	1932	16	,	,	,
cord-034340-3ksfpaf7	1932	17	even	even	RB
cord-034340-3ksfpaf7	1932	18	before	before	IN
cord-034340-3ksfpaf7	1932	19	the	the	DT
cord-034340-3ksfpaf7	1932	20	start	start	NN
cord-034340-3ksfpaf7	1932	21	of	of	IN
cord-034340-3ksfpaf7	1932	22	treatment	treatment	NN
cord-034340-3ksfpaf7	1932	23	.	.	.
cord-034340-3ksfpaf7	1933	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	1933	2	is	be	VBZ
cord-034340-3ksfpaf7	1933	3	confirmed	confirm	VBN
cord-034340-3ksfpaf7	1933	4	by	by	IN
cord-034340-3ksfpaf7	1933	5	a	a	DT
cord-034340-3ksfpaf7	1933	6	statistically	statistically	RB
cord-034340-3ksfpaf7	1933	7	significant	significant	JJ
cord-034340-3ksfpaf7	1933	8	correlation	correlation	NN
cord-034340-3ksfpaf7	1933	9	of	of	IN
cord-034340-3ksfpaf7	1933	10	BFGF	BFGF	NNP
cord-034340-3ksfpaf7	1933	11	level	level	NN
cord-034340-3ksfpaf7	1933	12	in	in	IN
cord-034340-3ksfpaf7	1933	13	1st	1st	JJ
cord-034340-3ksfpaf7	1933	14	group	group	NN
cord-034340-3ksfpaf7	1933	15	with	with	IN
cord-034340-3ksfpaf7	1933	16	liver	liver	NN
cord-034340-3ksfpaf7	1933	17	steatosis	steatosis	NN
cord-034340-3ksfpaf7	1933	18	according	accord	VBG
cord-034340-3ksfpaf7	1933	19	to	to	IN
cord-034340-3ksfpaf7	1933	20	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	1933	21	examination	examination	NN
cord-034340-3ksfpaf7	1933	22	(	(	-LRB-
cord-034340-3ksfpaf7	1933	23	r	r	NN
cord-034340-3ksfpaf7	1933	24	=	=	SYM
cord-034340-3ksfpaf7	1933	25	0.8	0.8	CD
cord-034340-3ksfpaf7	1933	26	)	)	-RRB-
cord-034340-3ksfpaf7	1933	27	and	and	CC
cord-034340-3ksfpaf7	1933	28	the	the	DT
cord-034340-3ksfpaf7	1933	29	level	level	NN
cord-034340-3ksfpaf7	1933	30	of	of	IN
cord-034340-3ksfpaf7	1933	31	C	c	NN
cord-034340-3ksfpaf7	1933	32	-	-	HYPH
cord-034340-3ksfpaf7	1933	33	reactive	reactive	JJ
cord-034340-3ksfpaf7	1933	34	protein	protein	NN
cord-034340-3ksfpaf7	1933	35	(	(	-LRB-
cord-034340-3ksfpaf7	1933	36	r	r	NN
cord-034340-3ksfpaf7	1933	37	=	=	NN
cord-034340-3ksfpaf7	1933	38	0.7	0.7	CD
cord-034340-3ksfpaf7	1933	39	)	)	-RRB-
cord-034340-3ksfpaf7	1933	40	.	.	.
cord-034340-3ksfpaf7	1934	1	This	this	DT
cord-034340-3ksfpaf7	1934	2	indicates	indicate	VBZ
cord-034340-3ksfpaf7	1934	3	a	a	DT
cord-034340-3ksfpaf7	1934	4	close	close	JJ
cord-034340-3ksfpaf7	1934	5	relationship	relationship	NN
cord-034340-3ksfpaf7	1934	6	between	between	IN
cord-034340-3ksfpaf7	1934	7	the	the	DT
cord-034340-3ksfpaf7	1934	8	intensity	intensity	NN
cord-034340-3ksfpaf7	1934	9	of	of	IN
cord-034340-3ksfpaf7	1934	10	the	the	DT
cord-034340-3ksfpaf7	1934	11	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1934	12	process	process	NN
cord-034340-3ksfpaf7	1934	13	and	and	CC
cord-034340-3ksfpaf7	1934	14	collagen	collagen	NN
cord-034340-3ksfpaf7	1934	15	synthesis	synthesis	NN
cord-034340-3ksfpaf7	1934	16	activation	activation	NN
cord-034340-3ksfpaf7	1934	17	,	,	,
cord-034340-3ksfpaf7	1934	18	which	which	WDT
cord-034340-3ksfpaf7	1934	19	can	can	MD
cord-034340-3ksfpaf7	1934	20	further	further	RB
cord-034340-3ksfpaf7	1934	21	provoke	provoke	VB
cord-034340-3ksfpaf7	1934	22	liver	liver	NN
cord-034340-3ksfpaf7	1934	23	fibrosis	fibrosis	NN
cord-034340-3ksfpaf7	1934	24	.	.	.
cord-034340-3ksfpaf7	1935	1	Alterative	alterative	JJ
cord-034340-3ksfpaf7	1935	2	processes	process	NNS
cord-034340-3ksfpaf7	1935	3	in	in	IN
cord-034340-3ksfpaf7	1935	4	the	the	DT
cord-034340-3ksfpaf7	1935	5	liver	liver	NN
cord-034340-3ksfpaf7	1935	6	associated	associate	VBN
cord-034340-3ksfpaf7	1935	7	with	with	IN
cord-034340-3ksfpaf7	1935	8	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1935	9	inflammation	inflammation	NN
cord-034340-3ksfpaf7	1935	10	,	,	,
cord-034340-3ksfpaf7	1935	11	as	as	IN
cord-034340-3ksfpaf7	1935	12	evidenced	evidence	VBN
cord-034340-3ksfpaf7	1935	13	by	by	IN
cord-034340-3ksfpaf7	1935	14	the	the	DT
cord-034340-3ksfpaf7	1935	15	presence	presence	NN
cord-034340-3ksfpaf7	1935	16	of	of	IN
cord-034340-3ksfpaf7	1935	17	a	a	DT
cord-034340-3ksfpaf7	1935	18	positive	positive	JJ
cord-034340-3ksfpaf7	1935	19	correlation	correlation	NN
cord-034340-3ksfpaf7	1935	20	between	between	IN
cord-034340-3ksfpaf7	1935	21	the	the	DT
cord-034340-3ksfpaf7	1935	22	level	level	NN
cord-034340-3ksfpaf7	1935	23	of	of	IN
cord-034340-3ksfpaf7	1935	24	ALT	ALT	NNP
cord-034340-3ksfpaf7	1935	25	and	and	CC
cord-034340-3ksfpaf7	1935	26	BFGF	BFGF	NNP
cord-034340-3ksfpaf7	1935	27	(	(	-LRB-
cord-034340-3ksfpaf7	1935	28	r	r	NN
cord-034340-3ksfpaf7	1935	29	=	=	SYM
cord-034340-3ksfpaf7	1935	30	0.5	0.5	CD
cord-034340-3ksfpaf7	1935	31	)	)	-RRB-
cord-034340-3ksfpaf7	1935	32	.	.	.
cord-034340-3ksfpaf7	1936	1	Upon	upon	IN
cord-034340-3ksfpaf7	1936	2	reaching	reach	VBG
cord-034340-3ksfpaf7	1936	3	MTX	MTX	NNP
cord-034340-3ksfpaf7	1936	4	dose	dose	NN
cord-034340-3ksfpaf7	1936	5	1	1	CD
cord-034340-3ksfpaf7	1936	6	gram	gram	NN
cord-034340-3ksfpaf7	1936	7	and	and	CC
cord-034340-3ksfpaf7	1936	8	3	3	CD
cord-034340-3ksfpaf7	1936	9	grams	gram	NNS
cord-034340-3ksfpaf7	1936	10	,	,	,
cord-034340-3ksfpaf7	1936	11	it	-PRON-	PRP
cord-034340-3ksfpaf7	1936	12	is	be	VBZ
cord-034340-3ksfpaf7	1936	13	possible	possible	JJ
cord-034340-3ksfpaf7	1936	14	that	that	IN
cord-034340-3ksfpaf7	1936	15	compensatory	compensatory	JJ
cord-034340-3ksfpaf7	1936	16	processes	process	NNS
cord-034340-3ksfpaf7	1936	17	in	in	IN
cord-034340-3ksfpaf7	1936	18	the	the	DT
cord-034340-3ksfpaf7	1936	19	liver	liver	NN
cord-034340-3ksfpaf7	1936	20	are	be	VBP
cord-034340-3ksfpaf7	1936	21	triggered	trigger	VBN
cord-034340-3ksfpaf7	1936	22	,	,	,
cord-034340-3ksfpaf7	1936	23	as	as	IN
cord-034340-3ksfpaf7	1936	24	evidenced	evidence	VBN
cord-034340-3ksfpaf7	1936	25	by	by	IN
cord-034340-3ksfpaf7	1936	26	the	the	DT
cord-034340-3ksfpaf7	1936	27	negative	negative	JJ
cord-034340-3ksfpaf7	1936	28	correlation	correlation	NN
cord-034340-3ksfpaf7	1936	29	between	between	IN
cord-034340-3ksfpaf7	1936	30	the	the	DT
cord-034340-3ksfpaf7	1936	31	content	content	NN
cord-034340-3ksfpaf7	1936	32	of	of	IN
cord-034340-3ksfpaf7	1936	33	BFGF	BFGF	NNP
cord-034340-3ksfpaf7	1936	34	and	and	CC
cord-034340-3ksfpaf7	1936	35	HGF	HGF	NNP
cord-034340-3ksfpaf7	1937	1	(	(	-LRB-
cord-034340-3ksfpaf7	1937	2	r	r	NN
cord-034340-3ksfpaf7	1938	1	=	=	SYM
cord-034340-3ksfpaf7	1938	2	-0.6).Conclusion	-0.6).conclusion	NN
cord-034340-3ksfpaf7	1938	3	:	:	:
cord-034340-3ksfpaf7	1939	1	The	the	DT
cord-034340-3ksfpaf7	1939	2	use	use	NN
cord-034340-3ksfpaf7	1939	3	of	of	IN
cord-034340-3ksfpaf7	1939	4	modern	modern	JJ
cord-034340-3ksfpaf7	1939	5	markers	marker	NNS
cord-034340-3ksfpaf7	1939	6	with	with	IN
cord-034340-3ksfpaf7	1939	7	routine	routine	JJ
cord-034340-3ksfpaf7	1939	8	laboratory	laboratory	NN
cord-034340-3ksfpaf7	1939	9	and	and	CC
cord-034340-3ksfpaf7	1939	10	instrumental	instrumental	JJ
cord-034340-3ksfpaf7	1939	11	studies	study	NNS
cord-034340-3ksfpaf7	1939	12	is	be	VBZ
cord-034340-3ksfpaf7	1939	13	appropriate	appropriate	JJ
cord-034340-3ksfpaf7	1939	14	for	for	IN
cord-034340-3ksfpaf7	1939	15	the	the	DT
cord-034340-3ksfpaf7	1939	16	timely	timely	JJ
cord-034340-3ksfpaf7	1939	17	determination	determination	NN
cord-034340-3ksfpaf7	1939	18	of	of	IN
cord-034340-3ksfpaf7	1939	19	the	the	DT
cord-034340-3ksfpaf7	1939	20	risks	risk	NNS
cord-034340-3ksfpaf7	1939	21	of	of	IN
cord-034340-3ksfpaf7	1939	22	developing	develop	VBG
cord-034340-3ksfpaf7	1939	23	irreversible	irreversible	JJ
cord-034340-3ksfpaf7	1939	24	pathological	pathological	JJ
cord-034340-3ksfpaf7	1939	25	changes	change	NNS
cord-034340-3ksfpaf7	1939	26	in	in	IN
cord-034340-3ksfpaf7	1939	27	the	the	DT
cord-034340-3ksfpaf7	1939	28	liver	liver	NN
cord-034340-3ksfpaf7	1939	29	during	during	IN
cord-034340-3ksfpaf7	1939	30	JIA	JIA	NNP
cord-034340-3ksfpaf7	1939	31	treatment	treatment	NN
cord-034340-3ksfpaf7	1939	32	with	with	IN
cord-034340-3ksfpaf7	1939	33	MTX	MTX	NNP
cord-034340-3ksfpaf7	1939	34	.	.	.
cord-034340-3ksfpaf7	1940	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1940	2	:	:	:
cord-034340-3ksfpaf7	1941	1	The	the	DT
cord-034340-3ksfpaf7	1941	2	aim	aim	NN
cord-034340-3ksfpaf7	1941	3	of	of	IN
cord-034340-3ksfpaf7	1941	4	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1941	5	study	study	NN
cord-034340-3ksfpaf7	1941	6	is	be	VBZ
cord-034340-3ksfpaf7	1941	7	to	to	TO
cord-034340-3ksfpaf7	1941	8	evaluate	evaluate	VB
cord-034340-3ksfpaf7	1941	9	the	the	DT
cord-034340-3ksfpaf7	1941	10	efficacy	efficacy	NN
cord-034340-3ksfpaf7	1941	11	of	of	IN
cord-034340-3ksfpaf7	1941	12	(	(	-LRB-
cord-034340-3ksfpaf7	1941	13	IAG	IAG	NNP
cord-034340-3ksfpaf7	1941	14	)	)	-RRB-
cord-034340-3ksfpaf7	1941	15	injections	injection	NNS
cord-034340-3ksfpaf7	1941	16	in	in	IN
cord-034340-3ksfpaf7	1941	17	hip	hip	NN
cord-034340-3ksfpaf7	1941	18	in	in	IN
cord-034340-3ksfpaf7	1941	19	children	child	NNS
cord-034340-3ksfpaf7	1941	20	with	with	IN
cord-034340-3ksfpaf7	1941	21	(	(	-LRB-
cord-034340-3ksfpaf7	1941	22	JIA	JIA	NNP
cord-034340-3ksfpaf7	1941	23	)	)	-RRB-
cord-034340-3ksfpaf7	1941	24	and	and	CC
cord-034340-3ksfpaf7	1941	25	to	to	TO
cord-034340-3ksfpaf7	1941	26	assess	assess	VB
cord-034340-3ksfpaf7	1941	27	the	the	DT
cord-034340-3ksfpaf7	1941	28	factors	factor	NNS
cord-034340-3ksfpaf7	1941	29	predicting	predict	VBG
cord-034340-3ksfpaf7	1941	30	the	the	DT
cord-034340-3ksfpaf7	1941	31	improvement	improvement	NN
cord-034340-3ksfpaf7	1941	32	of	of	IN
cord-034340-3ksfpaf7	1941	33	this	this	DT
cord-034340-3ksfpaf7	1941	34	management	management	NN
cord-034340-3ksfpaf7	1941	35	.	.	.
cord-034340-3ksfpaf7	1942	1	Methods	method	NNS
cord-034340-3ksfpaf7	1942	2	:	:	:
cord-034340-3ksfpaf7	1942	3	This	this	DT
cord-034340-3ksfpaf7	1942	4	is	be	VBZ
cord-034340-3ksfpaf7	1942	5	a	a	DT
cord-034340-3ksfpaf7	1942	6	retrospective	retrospective	JJ
cord-034340-3ksfpaf7	1942	7	study	study	NN
cord-034340-3ksfpaf7	1942	8	,	,	,
cord-034340-3ksfpaf7	1942	9	between	between	IN
cord-034340-3ksfpaf7	1942	10	2006	2006	CD
cord-034340-3ksfpaf7	1942	11	and	and	CC
cord-034340-3ksfpaf7	1942	12	2009	2009	CD
cord-034340-3ksfpaf7	1942	13	,	,	,
cord-034340-3ksfpaf7	1942	14	including	include	VBG
cord-034340-3ksfpaf7	1942	15	patients	patient	NNS
cord-034340-3ksfpaf7	1942	16	with	with	IN
cord-034340-3ksfpaf7	1942	17	JIA	JIA	NNP
cord-034340-3ksfpaf7	1942	18	diagnosed	diagnose	VBD
cord-034340-3ksfpaf7	1942	19	according	accord	VBG
cord-034340-3ksfpaf7	1942	20	to	to	IN
cord-034340-3ksfpaf7	1942	21	the	the	DT
cord-034340-3ksfpaf7	1942	22	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	1942	23	criteria	criterion	NNS
cord-034340-3ksfpaf7	1942	24	.	.	.
cord-034340-3ksfpaf7	1943	1	The	the	DT
cord-034340-3ksfpaf7	1943	2	socio	socio	JJ
cord-034340-3ksfpaf7	1943	3	-	-	HYPH
cord-034340-3ksfpaf7	1943	4	demographic	demographic	JJ
cord-034340-3ksfpaf7	1943	5	data	datum	NNS
cord-034340-3ksfpaf7	1943	6	were	be	VBD
cord-034340-3ksfpaf7	1943	7	collected	collect	VBN
cord-034340-3ksfpaf7	1943	8	as	as	RB
cord-034340-3ksfpaf7	1943	9	well	well	RB
cord-034340-3ksfpaf7	1943	10	as	as	IN
cord-034340-3ksfpaf7	1943	11	the	the	DT
cord-034340-3ksfpaf7	1943	12	parameters	parameter	NNS
cord-034340-3ksfpaf7	1943	13	of	of	IN
cord-034340-3ksfpaf7	1943	14	the	the	DT
cord-034340-3ksfpaf7	1943	15	disease	disease	NN
cord-034340-3ksfpaf7	1943	16	.	.	.
cord-034340-3ksfpaf7	1944	1	The	the	DT
cord-034340-3ksfpaf7	1944	2	activity	activity	NN
cord-034340-3ksfpaf7	1944	3	was	be	VBD
cord-034340-3ksfpaf7	1944	4	evaluated	evaluate	VBN
cord-034340-3ksfpaf7	1944	5	by	by	IN
cord-034340-3ksfpaf7	1944	6	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	1944	7	.	.	.
cord-034340-3ksfpaf7	1945	1	The	the	DT
cord-034340-3ksfpaf7	1945	2	functional	functional	JJ
cord-034340-3ksfpaf7	1945	3	impact	impact	NN
cord-034340-3ksfpaf7	1945	4	was	be	VBD
cord-034340-3ksfpaf7	1945	5	assessed	assess	VBN
cord-034340-3ksfpaf7	1945	6	by	by	IN
cord-034340-3ksfpaf7	1945	7	the	the	DT
cord-034340-3ksfpaf7	1945	8	Lequesne	lequesne	JJ
cord-034340-3ksfpaf7	1945	9	score	score	NN
cord-034340-3ksfpaf7	1945	10	.	.	.
cord-034340-3ksfpaf7	1946	1	The	the	DT
cord-034340-3ksfpaf7	1946	2	treatments	treatment	NNS
cord-034340-3ksfpaf7	1946	3	taken	take	VBN
cord-034340-3ksfpaf7	1946	4	have	have	VBP
cord-034340-3ksfpaf7	1946	5	been	be	VBN
cord-034340-3ksfpaf7	1946	6	specified	specify	VBN
cord-034340-3ksfpaf7	1946	7	as	as	RB
cord-034340-3ksfpaf7	1946	8	well	well	RB
cord-034340-3ksfpaf7	1946	9	as	as	IN
cord-034340-3ksfpaf7	1946	10	the	the	DT
cord-034340-3ksfpaf7	1946	11	infiltrations	infiltration	NNS
cord-034340-3ksfpaf7	1946	12	received	receive	VBD
cord-034340-3ksfpaf7	1946	13	.	.	.
cord-034340-3ksfpaf7	1947	1	The	the	DT
cord-034340-3ksfpaf7	1947	2	improvement	improvement	NN
cord-034340-3ksfpaf7	1947	3	after	after	IN
cord-034340-3ksfpaf7	1947	4	infiltration	infiltration	NN
cord-034340-3ksfpaf7	1947	5	was	be	VBD
cord-034340-3ksfpaf7	1947	6	assessed	assess	VBN
cord-034340-3ksfpaf7	1947	7	by	by	IN
cord-034340-3ksfpaf7	1947	8	JADAS	JADAS	NNP
cord-034340-3ksfpaf7	1947	9	and	and	CC
cord-034340-3ksfpaf7	1947	10	Lequesne	Lequesne	NNP
cord-034340-3ksfpaf7	1947	11	score	score	NN
cord-034340-3ksfpaf7	1947	12	.	.	.
cord-034340-3ksfpaf7	1948	1	Results	result	NNS
cord-034340-3ksfpaf7	1948	2	:	:	:
cord-034340-3ksfpaf7	1949	1	Fourteen	fourteen	CD
cord-034340-3ksfpaf7	1949	2	patients	patient	NNS
cord-034340-3ksfpaf7	1949	3	were	be	VBD
cord-034340-3ksfpaf7	1949	4	included	include	VBN
cord-034340-3ksfpaf7	1949	5	,	,	,
cord-034340-3ksfpaf7	1949	6	with	with	IN
cord-034340-3ksfpaf7	1949	7	mean	mean	JJ
cord-034340-3ksfpaf7	1949	8	age	age	NN
cord-034340-3ksfpaf7	1949	9	17.21	17.21	CD
cord-034340-3ksfpaf7	1949	10	+6.8	+6.8	XX
cord-034340-3ksfpaf7	1949	11	.	.	.
cord-034340-3ksfpaf7	1950	1	The	the	DT
cord-034340-3ksfpaf7	1950	2	mean	mean	JJ
cord-034340-3ksfpaf7	1950	3	age	age	NN
cord-034340-3ksfpaf7	1950	4	at	at	IN
cord-034340-3ksfpaf7	1950	5	the	the	DT
cord-034340-3ksfpaf7	1950	6	onset	onset	NN
cord-034340-3ksfpaf7	1950	7	of	of	IN
cord-034340-3ksfpaf7	1950	8	symptoms	symptom	NNS
cord-034340-3ksfpaf7	1950	9	was	be	VBD
cord-034340-3ksfpaf7	1950	10	11	11	CD
cord-034340-3ksfpaf7	1950	11	+0.5	+0.5	NFP
cord-034340-3ksfpaf7	1950	12	[	[	-LRB-
cord-034340-3ksfpaf7	1950	13	3	3	CD
cord-034340-3ksfpaf7	1950	14	]	]	-RRB-
cord-034340-3ksfpaf7	1950	15	[	[	-LRB-
cord-034340-3ksfpaf7	1950	16	4	4	CD
cord-034340-3ksfpaf7	1950	17	]	]	-RRB-
cord-034340-3ksfpaf7	1950	18	[	[	-LRB-
cord-034340-3ksfpaf7	1950	19	5	5	CD
cord-034340-3ksfpaf7	1950	20	]	]	-RRB-
cord-034340-3ksfpaf7	1950	21	[	[	-LRB-
cord-034340-3ksfpaf7	1950	22	6	6	CD
cord-034340-3ksfpaf7	1950	23	]	]	-RRB-
cord-034340-3ksfpaf7	1950	24	[	[	-LRB-
cord-034340-3ksfpaf7	1950	25	7	7	CD
cord-034340-3ksfpaf7	1950	26	]	]	-RRB-
cord-034340-3ksfpaf7	1950	27	[	[	-LRB-
cord-034340-3ksfpaf7	1950	28	8	8	CD
cord-034340-3ksfpaf7	1950	29	]	]	-RRB-
cord-034340-3ksfpaf7	1950	30	[	[	-LRB-
cord-034340-3ksfpaf7	1950	31	9	9	CD
cord-034340-3ksfpaf7	1950	32	]	]	-RRB-
cord-034340-3ksfpaf7	1950	33	[	[	-LRB-
cord-034340-3ksfpaf7	1950	34	10	10	CD
cord-034340-3ksfpaf7	1950	35	]	]	-RRB-
cord-034340-3ksfpaf7	1950	36	[	[	-LRB-
cord-034340-3ksfpaf7	1950	37	11	11	CD
cord-034340-3ksfpaf7	1950	38	]	]	-RRB-
cord-034340-3ksfpaf7	1950	39	[	[	-LRB-
cord-034340-3ksfpaf7	1950	40	12	12	CD
cord-034340-3ksfpaf7	1950	41	]	]	-RRB-
cord-034340-3ksfpaf7	1950	42	[	[	-LRB-
cord-034340-3ksfpaf7	1950	43	13	13	CD
cord-034340-3ksfpaf7	1950	44	]	]	-RRB-
cord-034340-3ksfpaf7	1950	45	[	[	-LRB-
cord-034340-3ksfpaf7	1950	46	14	14	CD
cord-034340-3ksfpaf7	1950	47	]	]	-RRB-
cord-034340-3ksfpaf7	1950	48	[	[	-LRB-
cord-034340-3ksfpaf7	1950	49	15	15	CD
cord-034340-3ksfpaf7	1950	50	]	]	-RRB-
cord-034340-3ksfpaf7	1950	51	.	.	.
cord-034340-3ksfpaf7	1951	1	Subtypes	subtype	NNS
cord-034340-3ksfpaf7	1951	2	of	of	IN
cord-034340-3ksfpaf7	1951	3	JIA	JIA	NNP
cord-034340-3ksfpaf7	1951	4	according	accord	VBG
cord-034340-3ksfpaf7	1951	5	to	to	IN
cord-034340-3ksfpaf7	1951	6	The	the	DT
cord-034340-3ksfpaf7	1951	7	ILAR	ILAR	NNP
cord-034340-3ksfpaf7	1951	8	were	be	VBD
cord-034340-3ksfpaf7	1951	9	:	:	:
cord-034340-3ksfpaf7	1951	10	enthesitis	enthesitis	NN
cord-034340-3ksfpaf7	1951	11	-	-	HYPH
cord-034340-3ksfpaf7	1951	12	related	relate	VBN
cord-034340-3ksfpaf7	1951	13	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1951	14	in	in	IN
cord-034340-3ksfpaf7	1951	15	7	7	CD
cord-034340-3ksfpaf7	1951	16	cases	case	NNS
cord-034340-3ksfpaf7	1951	17	,	,	,
cord-034340-3ksfpaf7	1951	18	seropositive	seropositive	JJ
cord-034340-3ksfpaf7	1951	19	polyarticular	polyarticular	JJ
cord-034340-3ksfpaf7	1951	20	JIA	JIA	NNP
cord-034340-3ksfpaf7	1951	21	in	in	IN
cord-034340-3ksfpaf7	1951	22	2	2	CD
cord-034340-3ksfpaf7	1951	23	cases	case	NNS
cord-034340-3ksfpaf7	1951	24	,	,	,
cord-034340-3ksfpaf7	1951	25	seronegative	seronegative	JJ
cord-034340-3ksfpaf7	1951	26	polyarticular	polyarticular	JJ
cord-034340-3ksfpaf7	1951	27	JIA	JIA	NNP
cord-034340-3ksfpaf7	1951	28	in	in	IN
cord-034340-3ksfpaf7	1951	29	2	2	CD
cord-034340-3ksfpaf7	1951	30	cases	case	NNS
cord-034340-3ksfpaf7	1951	31	,	,	,
cord-034340-3ksfpaf7	1951	32	oligoarticular	oligoarticular	NNP
cord-034340-3ksfpaf7	1951	33	JIA	JIA	NNP
cord-034340-3ksfpaf7	1951	34	in	in	IN
cord-034340-3ksfpaf7	1951	35	2	2	CD
cord-034340-3ksfpaf7	1951	36	cases	case	NNS
cord-034340-3ksfpaf7	1951	37	and	and	CC
cord-034340-3ksfpaf7	1951	38	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1951	39	psoriatic	psoriatic	JJ
cord-034340-3ksfpaf7	1951	40	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1951	41	in	in	IN
cord-034340-3ksfpaf7	1951	42	one	one	CD
cord-034340-3ksfpaf7	1951	43	case	case	NN
cord-034340-3ksfpaf7	1951	44	.	.	.
cord-034340-3ksfpaf7	1952	1	All	all	PDT
cord-034340-3ksfpaf7	1952	2	the	the	DT
cord-034340-3ksfpaf7	1952	3	patients	patient	NNS
cord-034340-3ksfpaf7	1952	4	had	have	VBD
cord-034340-3ksfpaf7	1952	5	hip	hip	NN
cord-034340-3ksfpaf7	1952	6	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1952	7	,	,	,
cord-034340-3ksfpaf7	1952	8	inaugural	inaugural	JJ
cord-034340-3ksfpaf7	1952	9	in	in	IN
cord-034340-3ksfpaf7	1952	10	90	90	CD
cord-034340-3ksfpaf7	1952	11	%	%	NN
cord-034340-3ksfpaf7	1952	12	of	of	IN
cord-034340-3ksfpaf7	1952	13	the	the	DT
cord-034340-3ksfpaf7	1952	14	cases	case	NNS
cord-034340-3ksfpaf7	1952	15	.	.	.
cord-034340-3ksfpaf7	1953	1	Of	of	IN
cord-034340-3ksfpaf7	1953	2	these	these	DT
cord-034340-3ksfpaf7	1953	3	,	,	,
cord-034340-3ksfpaf7	1953	4	92.8	92.8	CD
cord-034340-3ksfpaf7	1953	5	%	%	NN
cord-034340-3ksfpaf7	1953	6	had	have	VBD
cord-034340-3ksfpaf7	1953	7	a	a	DT
cord-034340-3ksfpaf7	1953	8	flexion	flexion	JJ
cord-034340-3ksfpaf7	1953	9	deformity	deformity	NN
cord-034340-3ksfpaf7	1953	10	and	and	CC
cord-034340-3ksfpaf7	1953	11	lower	low	JJR
cord-034340-3ksfpaf7	1953	12	limb	limb	NN
cord-034340-3ksfpaf7	1953	13	inequality	inequality	NN
cord-034340-3ksfpaf7	1953	14	.	.	.
cord-034340-3ksfpaf7	1954	1	The	the	DT
cord-034340-3ksfpaf7	1954	2	average	average	JJ
cord-034340-3ksfpaf7	1954	3	Lequesne	lequesne	JJ
cord-034340-3ksfpaf7	1954	4	index	index	NN
cord-034340-3ksfpaf7	1954	5	was	be	VBD
cord-034340-3ksfpaf7	1954	6	8.5	8.5	CD
cord-034340-3ksfpaf7	1954	7	+4.6	+4.6	NNS
cord-034340-3ksfpaf7	1954	8	.	.	.
cord-034340-3ksfpaf7	1955	1	The	the	DT
cord-034340-3ksfpaf7	1955	2	treatments	treatment	NNS
cord-034340-3ksfpaf7	1955	3	taken	take	VBN
cord-034340-3ksfpaf7	1955	4	were	be	VBD
cord-034340-3ksfpaf7	1955	5	Methotrexate	Methotrexate	NNP
cord-034340-3ksfpaf7	1955	6	in	in	IN
cord-034340-3ksfpaf7	1955	7	57.14	57.14	CD
cord-034340-3ksfpaf7	1955	8	%	%	NN
cord-034340-3ksfpaf7	1955	9	of	of	IN
cord-034340-3ksfpaf7	1955	10	the	the	DT
cord-034340-3ksfpaf7	1955	11	cases	case	NNS
cord-034340-3ksfpaf7	1955	12	,	,	,
cord-034340-3ksfpaf7	1955	13	Sulfasalazine	Sulfasalazine	NNP
cord-034340-3ksfpaf7	1955	14	in	in	IN
cord-034340-3ksfpaf7	1955	15	14.28	14.28	CD
cord-034340-3ksfpaf7	1955	16	%	%	NN
cord-034340-3ksfpaf7	1955	17	of	of	IN
cord-034340-3ksfpaf7	1955	18	the	the	DT
cord-034340-3ksfpaf7	1955	19	cases	case	NNS
cord-034340-3ksfpaf7	1955	20	,	,	,
cord-034340-3ksfpaf7	1955	21	and	and	CC
cord-034340-3ksfpaf7	1955	22	the	the	DT
cord-034340-3ksfpaf7	1955	23	combination	combination	NN
cord-034340-3ksfpaf7	1955	24	of	of	IN
cord-034340-3ksfpaf7	1955	25	the	the	DT
cord-034340-3ksfpaf7	1955	26	two	two	CD
cord-034340-3ksfpaf7	1955	27	in	in	IN
cord-034340-3ksfpaf7	1955	28	21.4	21.4	CD
cord-034340-3ksfpaf7	1955	29	%	%	NN
cord-034340-3ksfpaf7	1955	30	of	of	IN
cord-034340-3ksfpaf7	1955	31	the	the	DT
cord-034340-3ksfpaf7	1955	32	cases	case	NNS
cord-034340-3ksfpaf7	1955	33	.	.	.
cord-034340-3ksfpaf7	1956	1	Eleven	eleven	CD
cord-034340-3ksfpaf7	1956	2	patients	patient	NNS
cord-034340-3ksfpaf7	1956	3	underwent	undergo	VBD
cord-034340-3ksfpaf7	1956	4	hip	hip	NN
cord-034340-3ksfpaf7	1956	5	infiltration	infiltration	NN
cord-034340-3ksfpaf7	1956	6	,	,	,
cord-034340-3ksfpaf7	1956	7	and	and	CC
cord-034340-3ksfpaf7	1956	8	three	three	CD
cord-034340-3ksfpaf7	1956	9	of	of	IN
cord-034340-3ksfpaf7	1956	10	them	-PRON-	PRP
cord-034340-3ksfpaf7	1956	11	required	require	VBD
cord-034340-3ksfpaf7	1956	12	more	more	JJR
cord-034340-3ksfpaf7	1956	13	than	than	IN
cord-034340-3ksfpaf7	1956	14	one	one	CD
cord-034340-3ksfpaf7	1956	15	.	.	.
cord-034340-3ksfpaf7	1957	1	Eighty	eighty	CD
cord-034340-3ksfpaf7	1957	2	one	one	CD
cord-034340-3ksfpaf7	1957	3	percent	percent	NN
cord-034340-3ksfpaf7	1957	4	improved	improve	VBN
cord-034340-3ksfpaf7	1957	5	thereafter	thereafter	RB
cord-034340-3ksfpaf7	1957	6	.	.	.
cord-034340-3ksfpaf7	1958	1	The	the	DT
cord-034340-3ksfpaf7	1958	2	number	number	NN
cord-034340-3ksfpaf7	1958	3	of	of	IN
cord-034340-3ksfpaf7	1958	4	infiltrations	infiltration	NNS
cord-034340-3ksfpaf7	1958	5	was	be	VBD
cord-034340-3ksfpaf7	1958	6	not	not	RB
cord-034340-3ksfpaf7	1958	7	statistically	statistically	RB
cord-034340-3ksfpaf7	1958	8	associated	associate	VBN
cord-034340-3ksfpaf7	1958	9	with	with	IN
cord-034340-3ksfpaf7	1958	10	the	the	DT
cord-034340-3ksfpaf7	1958	11	Lequesne	lequesne	JJ
cord-034340-3ksfpaf7	1958	12	index	index	NN
cord-034340-3ksfpaf7	1958	13	(	(	-LRB-
cord-034340-3ksfpaf7	1958	14	p	p	NN
cord-034340-3ksfpaf7	1958	15	=	=	SYM
cord-034340-3ksfpaf7	1958	16	0.069	0.069	CD
cord-034340-3ksfpaf7	1958	17	)	)	-RRB-
cord-034340-3ksfpaf7	1958	18	.	.	.
cord-034340-3ksfpaf7	1959	1	Improvement	improvement	NN
cord-034340-3ksfpaf7	1959	2	after	after	IN
cord-034340-3ksfpaf7	1959	3	infiltration	infiltration	NN
cord-034340-3ksfpaf7	1959	4	was	be	VBD
cord-034340-3ksfpaf7	1959	5	negatively	negatively	RB
cord-034340-3ksfpaf7	1959	6	associated	associate	VBN
cord-034340-3ksfpaf7	1959	7	with	with	IN
cord-034340-3ksfpaf7	1959	8	the	the	DT
cord-034340-3ksfpaf7	1959	9	prior	prior	JJ
cord-034340-3ksfpaf7	1959	10	existence	existence	NN
cord-034340-3ksfpaf7	1959	11	of	of	IN
cord-034340-3ksfpaf7	1959	12	an	an	DT
cord-034340-3ksfpaf7	1959	13	inequality	inequality	NN
cord-034340-3ksfpaf7	1959	14	of	of	IN
cord-034340-3ksfpaf7	1959	15	the	the	DT
cord-034340-3ksfpaf7	1959	16	lower	low	JJR
cord-034340-3ksfpaf7	1959	17	limbs	limb	NNS
cord-034340-3ksfpaf7	1959	18	(	(	-LRB-
cord-034340-3ksfpaf7	1959	19	p	p	NN
cord-034340-3ksfpaf7	1959	20	=	=	SYM
cord-034340-3ksfpaf7	1959	21	0.04	0.04	CD
cord-034340-3ksfpaf7	1959	22	)	)	-RRB-
cord-034340-3ksfpaf7	1959	23	.	.	.
cord-034340-3ksfpaf7	1960	1	The	the	DT
cord-034340-3ksfpaf7	1960	2	existence	existence	NN
cord-034340-3ksfpaf7	1960	3	of	of	IN
cord-034340-3ksfpaf7	1960	4	a	a	DT
cord-034340-3ksfpaf7	1960	5	flexion	flexion	JJ
cord-034340-3ksfpaf7	1960	6	deformity	deformity	NN
cord-034340-3ksfpaf7	1960	7	was	be	VBD
cord-034340-3ksfpaf7	1960	8	not	not	RB
cord-034340-3ksfpaf7	1960	9	associated	associate	VBN
cord-034340-3ksfpaf7	1960	10	with	with	IN
cord-034340-3ksfpaf7	1960	11	good	good	JJ
cord-034340-3ksfpaf7	1960	12	results	result	NNS
cord-034340-3ksfpaf7	1960	13	after	after	IN
cord-034340-3ksfpaf7	1960	14	infiltration	infiltration	NN
cord-034340-3ksfpaf7	1960	15	(	(	-LRB-
cord-034340-3ksfpaf7	1960	16	p	p	NN
cord-034340-3ksfpaf7	1960	17	=	=	SYM
cord-034340-3ksfpaf7	1960	18	0.476	0.476	CD
cord-034340-3ksfpaf7	1960	19	,	,	,
cord-034340-3ksfpaf7	1960	20	r=-0,624	r=-0,624	NNP
cord-034340-3ksfpaf7	1960	21	)	)	-RRB-
cord-034340-3ksfpaf7	1960	22	.	.	.
cord-034340-3ksfpaf7	1961	1	Ten	ten	CD
cord-034340-3ksfpaf7	1961	2	patients	patient	NNS
cord-034340-3ksfpaf7	1961	3	(	(	-LRB-
cord-034340-3ksfpaf7	1961	4	90	90	CD
cord-034340-3ksfpaf7	1961	5	%	%	NN
cord-034340-3ksfpaf7	1961	6	)	)	-RRB-
cord-034340-3ksfpaf7	1961	7	among	among	IN
cord-034340-3ksfpaf7	1961	8	those	those	DT
cord-034340-3ksfpaf7	1961	9	who	who	WP
cord-034340-3ksfpaf7	1961	10	had	have	VBD
cord-034340-3ksfpaf7	1961	11	an	an	DT
cord-034340-3ksfpaf7	1961	12	infiltration	infiltration	NN
cord-034340-3ksfpaf7	1961	13	did	do	VBD
cord-034340-3ksfpaf7	1961	14	not	not	RB
cord-034340-3ksfpaf7	1961	15	have	have	VB
cord-034340-3ksfpaf7	1961	16	to	to	TO
cord-034340-3ksfpaf7	1961	17	resort	resort	VB
cord-034340-3ksfpaf7	1961	18	to	to	IN
cord-034340-3ksfpaf7	1961	19	surgery	surgery	NN
cord-034340-3ksfpaf7	1961	20	.	.	.
cord-034340-3ksfpaf7	1962	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1962	2	:	:	:
cord-034340-3ksfpaf7	1963	1	IAG	IAG	NNP
cord-034340-3ksfpaf7	1963	2	injection	injection	NN
cord-034340-3ksfpaf7	1963	3	is	be	VBZ
cord-034340-3ksfpaf7	1963	4	an	an	DT
cord-034340-3ksfpaf7	1963	5	adjunct	adjunct	JJ
cord-034340-3ksfpaf7	1963	6	therapy	therapy	NN
cord-034340-3ksfpaf7	1963	7	in	in	IN
cord-034340-3ksfpaf7	1963	8	AJI	AJI	NNP
cord-034340-3ksfpaf7	1963	9	with	with	IN
cord-034340-3ksfpaf7	1963	10	hip	hip	NN
cord-034340-3ksfpaf7	1963	11	involvement	involvement	NN
cord-034340-3ksfpaf7	1963	12	offering	offer	VBG
cord-034340-3ksfpaf7	1963	13	a	a	DT
cord-034340-3ksfpaf7	1963	14	good	good	JJ
cord-034340-3ksfpaf7	1963	15	results	result	NNS
cord-034340-3ksfpaf7	1963	16	and	and	CC
cord-034340-3ksfpaf7	1963	17	delay	delay	NN
cord-034340-3ksfpaf7	1963	18	surgery	surgery	NN
cord-034340-3ksfpaf7	1963	19	in	in	IN
cord-034340-3ksfpaf7	1963	20	the	the	DT
cord-034340-3ksfpaf7	1963	21	majority	majority	NN
cord-034340-3ksfpaf7	1963	22	of	of	IN
cord-034340-3ksfpaf7	1963	23	cases	case	NNS
cord-034340-3ksfpaf7	1963	24	.	.	.
cord-034340-3ksfpaf7	1964	1	The	the	DT
cord-034340-3ksfpaf7	1964	2	presence	presence	NN
cord-034340-3ksfpaf7	1964	3	of	of	IN
cord-034340-3ksfpaf7	1964	4	lower	low	JJR
cord-034340-3ksfpaf7	1964	5	limb	limb	NN
cord-034340-3ksfpaf7	1964	6	inequality	inequality	NN
cord-034340-3ksfpaf7	1964	7	is	be	VBZ
cord-034340-3ksfpaf7	1964	8	associated	associate	VBN
cord-034340-3ksfpaf7	1964	9	with	with	IN
cord-034340-3ksfpaf7	1964	10	less	less	JJR
cord-034340-3ksfpaf7	1964	11	improvement	improvement	NN
cord-034340-3ksfpaf7	1964	12	of	of	IN
cord-034340-3ksfpaf7	1964	13	IAG	IAG	NNP
cord-034340-3ksfpaf7	1964	14	.	.	.
cord-034340-3ksfpaf7	1965	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	1965	2	:	:	:
cord-034340-3ksfpaf7	1966	1	Synovial	synovial	JJ
cord-034340-3ksfpaf7	1966	2	rice	rice	NN
cord-034340-3ksfpaf7	1966	3	bodies	body	NNS
cord-034340-3ksfpaf7	1966	4	are	be	VBP
cord-034340-3ksfpaf7	1966	5	rarely	rarely	RB
cord-034340-3ksfpaf7	1966	6	described	describe	VBN
cord-034340-3ksfpaf7	1966	7	in	in	IN
cord-034340-3ksfpaf7	1966	8	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1966	9	idiopathic	idiopathic	JJ
cord-034340-3ksfpaf7	1966	10	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1966	11	,	,	,
cord-034340-3ksfpaf7	1966	12	even	even	RB
cord-034340-3ksfpaf7	1966	13	less	less	RBR
cord-034340-3ksfpaf7	1966	14	at	at	IN
cord-034340-3ksfpaf7	1966	15	disease	disease	NN
cord-034340-3ksfpaf7	1966	16	onset	onset	NN
cord-034340-3ksfpaf7	1966	17	.	.	.
cord-034340-3ksfpaf7	1967	1	Their	-PRON-	PRP$
cord-034340-3ksfpaf7	1967	2	presence	presence	NN
cord-034340-3ksfpaf7	1967	3	has	have	VBZ
cord-034340-3ksfpaf7	1967	4	not	not	RB
cord-034340-3ksfpaf7	1967	5	been	be	VBN
cord-034340-3ksfpaf7	1967	6	associated	associate	VBN
cord-034340-3ksfpaf7	1967	7	to	to	IN
cord-034340-3ksfpaf7	1967	8	a	a	DT
cord-034340-3ksfpaf7	1967	9	worse	bad	JJR
cord-034340-3ksfpaf7	1967	10	disease	disease	NN
cord-034340-3ksfpaf7	1967	11	prognosis	prognosis	NN
cord-034340-3ksfpaf7	1967	12	or	or	CC
cord-034340-3ksfpaf7	1967	13	joint	joint	JJ
cord-034340-3ksfpaf7	1967	14	outcome	outcome	NN
cord-034340-3ksfpaf7	1967	15	but	but	CC
cord-034340-3ksfpaf7	1967	16	awareness	awareness	NN
cord-034340-3ksfpaf7	1967	17	of	of	IN
cord-034340-3ksfpaf7	1967	18	the	the	DT
cord-034340-3ksfpaf7	1967	19	existence	existence	NN
cord-034340-3ksfpaf7	1967	20	of	of	IN
cord-034340-3ksfpaf7	1967	21	this	this	DT
cord-034340-3ksfpaf7	1967	22	particular	particular	JJ
cord-034340-3ksfpaf7	1967	23	form	form	NN
cord-034340-3ksfpaf7	1967	24	of	of	IN
cord-034340-3ksfpaf7	1967	25	intraarticular	intraarticular	JJ
cord-034340-3ksfpaf7	1967	26	loose	loose	JJ
cord-034340-3ksfpaf7	1967	27	bodies	body	NNS
cord-034340-3ksfpaf7	1967	28	may	may	MD
cord-034340-3ksfpaf7	1967	29	encourage	encourage	VB
cord-034340-3ksfpaf7	1967	30	the	the	DT
cord-034340-3ksfpaf7	1967	31	clinician	clinician	NN
cord-034340-3ksfpaf7	1967	32	to	to	TO
cord-034340-3ksfpaf7	1967	33	use	use	VB
cord-034340-3ksfpaf7	1967	34	lower	low	JJR
cord-034340-3ksfpaf7	1967	35	gauge	gauge	NN
cord-034340-3ksfpaf7	1967	36	needle	needle	NN
cord-034340-3ksfpaf7	1967	37	during	during	IN
cord-034340-3ksfpaf7	1967	38	arthrocentesis	arthrocentesis	NN
cord-034340-3ksfpaf7	1967	39	procedure	procedure	NN
cord-034340-3ksfpaf7	1967	40	;	;	:
cord-034340-3ksfpaf7	1967	41	this	this	DT
cord-034340-3ksfpaf7	1967	42	can	can	MD
cord-034340-3ksfpaf7	1967	43	prevent	prevent	VB
cord-034340-3ksfpaf7	1967	44	arthroscopy	arthroscopy	NN
cord-034340-3ksfpaf7	1967	45	,	,	,
cord-034340-3ksfpaf7	1967	46	as	as	IN
cord-034340-3ksfpaf7	1967	47	occurred	occur	VBD
cord-034340-3ksfpaf7	1967	48	in	in	IN
cord-034340-3ksfpaf7	1967	49	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1967	50	case	case	NN
cord-034340-3ksfpaf7	1967	51	1	1	CD
cord-034340-3ksfpaf7	1967	52	.	.	.
cord-034340-3ksfpaf7	1968	1	Arthroscopy	Arthroscopy	NNP
cord-034340-3ksfpaf7	1968	2	may	may	MD
cord-034340-3ksfpaf7	1968	3	be	be	VB
cord-034340-3ksfpaf7	1968	4	necessary	necessary	JJ
cord-034340-3ksfpaf7	1968	5	in	in	IN
cord-034340-3ksfpaf7	1968	6	some	some	DT
cord-034340-3ksfpaf7	1968	7	cases	case	NNS
cord-034340-3ksfpaf7	1968	8	to	to	TO
cord-034340-3ksfpaf7	1968	9	achieve	achieve	VB
cord-034340-3ksfpaf7	1968	10	full	full	JJ
cord-034340-3ksfpaf7	1968	11	drainage	drainage	NN
cord-034340-3ksfpaf7	1968	12	of	of	IN
cord-034340-3ksfpaf7	1968	13	the	the	DT
cord-034340-3ksfpaf7	1968	14	joint	joint	NN
cord-034340-3ksfpaf7	1968	15	.	.	.
cord-034340-3ksfpaf7	1969	1	In	in	IN
cord-034340-3ksfpaf7	1969	2	our	-PRON-	PRP$
cord-034340-3ksfpaf7	1969	3	series	series	NN
cord-034340-3ksfpaf7	1969	4	the	the	DT
cord-034340-3ksfpaf7	1969	5	duration	duration	NN
cord-034340-3ksfpaf7	1969	6	of	of	IN
cord-034340-3ksfpaf7	1969	7	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1969	8	correlated	correlate	VBN
cord-034340-3ksfpaf7	1969	9	with	with	IN
cord-034340-3ksfpaf7	1969	10	the	the	DT
cord-034340-3ksfpaf7	1969	11	size	size	NN
cord-034340-3ksfpaf7	1969	12	of	of	IN
cord-034340-3ksfpaf7	1969	13	rice	rice	NN
cord-034340-3ksfpaf7	1969	14	bodies	body	NNS
cord-034340-3ksfpaf7	1969	15	and	and	CC
cord-034340-3ksfpaf7	1969	16	the	the	DT
cord-034340-3ksfpaf7	1969	17	number	number	NN
cord-034340-3ksfpaf7	1969	18	and	and	CC
cord-034340-3ksfpaf7	1969	19	agressiveness	agressiveness	NN
cord-034340-3ksfpaf7	1969	20	of	of	IN
cord-034340-3ksfpaf7	1969	21	procedures	procedure	NNS
cord-034340-3ksfpaf7	1969	22	needed	need	VBN
cord-034340-3ksfpaf7	1969	23	to	to	TO
cord-034340-3ksfpaf7	1969	24	evacuate	evacuate	VB
cord-034340-3ksfpaf7	1969	25	them	-PRON-	PRP
cord-034340-3ksfpaf7	1969	26	.	.	.
cord-034340-3ksfpaf7	1970	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	1970	2	:	:	:
cord-034340-3ksfpaf7	1970	3	We	-PRON-	PRP
cord-034340-3ksfpaf7	1970	4	described	describe	VBD
cord-034340-3ksfpaf7	1970	5	a	a	DT
cord-034340-3ksfpaf7	1970	6	case	case	NN
cord-034340-3ksfpaf7	1970	7	of	of	IN
cord-034340-3ksfpaf7	1970	8	liver	liver	NN
cord-034340-3ksfpaf7	1970	9	involvement	involvement	NN
cord-034340-3ksfpaf7	1970	10	in	in	IN
cord-034340-3ksfpaf7	1970	11	SLE	SLE	NNP
cord-034340-3ksfpaf7	1970	12	presenting	present	VBG
cord-034340-3ksfpaf7	1970	13	with	with	IN
cord-034340-3ksfpaf7	1970	14	emphasis	emphasis	NN
cord-034340-3ksfpaf7	1970	15	on	on	IN
cord-034340-3ksfpaf7	1970	16	the	the	DT
cord-034340-3ksfpaf7	1970	17	differential	differential	JJ
cord-034340-3ksfpaf7	1970	18	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1970	19	with	with	IN
cord-034340-3ksfpaf7	1970	20	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1970	21	hepatitis	hepatitis	NNP
cord-034340-3ksfpaf7	1970	22	.	.	.
cord-034340-3ksfpaf7	1971	1	Methods	method	NNS
cord-034340-3ksfpaf7	1971	2	:	:	:
cord-034340-3ksfpaf7	1972	1	case	case	NNP
cord-034340-3ksfpaf7	1972	2	report	report	NN
cord-034340-3ksfpaf7	1972	3	study	study	NN
cord-034340-3ksfpaf7	1972	4	Results	result	NNS
cord-034340-3ksfpaf7	1972	5	:	:	:
cord-034340-3ksfpaf7	1973	1	:	:	:
cord-034340-3ksfpaf7	1973	2	An	an	DT
cord-034340-3ksfpaf7	1973	3	8-year	8-year	JJ
cord-034340-3ksfpaf7	1973	4	-	-	HYPH
cord-034340-3ksfpaf7	1973	5	old	old	JJ
cord-034340-3ksfpaf7	1973	6	female	female	JJ
cord-034340-3ksfpaf7	1973	7	patient	patient	NN
cord-034340-3ksfpaf7	1973	8	was	be	VBD
cord-034340-3ksfpaf7	1973	9	referred	refer	VBN
cord-034340-3ksfpaf7	1973	10	to	to	IN
cord-034340-3ksfpaf7	1973	11	the	the	DT
cord-034340-3ksfpaf7	1973	12	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1973	13	clinic	clinic	NN
cord-034340-3ksfpaf7	1973	14	with	with	IN
cord-034340-3ksfpaf7	1973	15	complaints	complaint	NNS
cord-034340-3ksfpaf7	1973	16	icteric	icteric	JJ
cord-034340-3ksfpaf7	1973	17	sclera	sclera	NN
cord-034340-3ksfpaf7	1973	18	for	for	IN
cord-034340-3ksfpaf7	1973	19	10	10	CD
cord-034340-3ksfpaf7	1973	20	months	month	NNS
cord-034340-3ksfpaf7	1973	21	anorexia	anorexia	NN
cord-034340-3ksfpaf7	1973	22	,	,	,
cord-034340-3ksfpaf7	1973	23	malaise	malaise	NN
cord-034340-3ksfpaf7	1973	24	,	,	,
cord-034340-3ksfpaf7	1973	25	pain	pain	NN
cord-034340-3ksfpaf7	1973	26	in	in	IN
cord-034340-3ksfpaf7	1973	27	the	the	DT
cord-034340-3ksfpaf7	1973	28	both	both	DT
cord-034340-3ksfpaf7	1973	29	knees	knee	NNS
cord-034340-3ksfpaf7	1973	30	,	,	,
cord-034340-3ksfpaf7	1973	31	ankles	ankle	NNS
cord-034340-3ksfpaf7	1973	32	joints	joint	NNS
cord-034340-3ksfpaf7	1973	33	and	and	CC
cord-034340-3ksfpaf7	1973	34	both	both	DT
cord-034340-3ksfpaf7	1973	35	wrists	wrist	NNS
cord-034340-3ksfpaf7	1973	36	accompanied	accompany	VBN
cord-034340-3ksfpaf7	1973	37	by	by	IN
cord-034340-3ksfpaf7	1973	38	swelling	swell	VBG
cord-034340-3ksfpaf7	1973	39	,	,	,
cord-034340-3ksfpaf7	1973	40	and	and	CC
cord-034340-3ksfpaf7	1973	41	remarkable	remarkable	JJ
cord-034340-3ksfpaf7	1973	42	motion	motion	NN
cord-034340-3ksfpaf7	1973	43	limitations	limitation	NNS
cord-034340-3ksfpaf7	1973	44	.	.	.
cord-034340-3ksfpaf7	1974	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	1974	2	revealed	reveal	VBD
cord-034340-3ksfpaf7	1974	3	T	T	NNP
cord-034340-3ksfpaf7	1974	4	bilirubin	bilirubin	NN
cord-034340-3ksfpaf7	1974	5	4.9	4.9	CD
cord-034340-3ksfpaf7	1974	6	mainly	mainly	RB
cord-034340-3ksfpaf7	1974	7	direct	direct	VBP
cord-034340-3ksfpaf7	1974	8	3.9	3.9	CD
cord-034340-3ksfpaf7	1974	9	with	with	IN
cord-034340-3ksfpaf7	1974	10	elevated	elevated	JJ
cord-034340-3ksfpaf7	1974	11	liver	liver	NN
cord-034340-3ksfpaf7	1974	12	enzymes	enzyme	NNS
cord-034340-3ksfpaf7	1974	13	GOT	get	VBD
cord-034340-3ksfpaf7	1974	14	401	401	CD
cord-034340-3ksfpaf7	1974	15	,	,	,
cord-034340-3ksfpaf7	1974	16	GPT	GPT	NNP
cord-034340-3ksfpaf7	1974	17	189	189	CD
cord-034340-3ksfpaf7	1974	18	,	,	,
cord-034340-3ksfpaf7	1974	19	ALKP	ALKP	NNP
cord-034340-3ksfpaf7	1974	20	520	520	CD
cord-034340-3ksfpaf7	1974	21	,	,	,
cord-034340-3ksfpaf7	1974	22	high	high	JJ
cord-034340-3ksfpaf7	1974	23	Glutamyl	Glutamyl	NNP
cord-034340-3ksfpaf7	1974	24	transpeptidase	transpeptidase	NN
cord-034340-3ksfpaf7	1975	1	56U\L	56u\l	CD
cord-034340-3ksfpaf7	1976	1	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1976	2	WBC	WBC	NNP
cord-034340-3ksfpaf7	1976	3	7.4	7.4	CD
cord-034340-3ksfpaf7	1976	4	HGB	HGB	NNP
cord-034340-3ksfpaf7	1976	5	10	10	CD
cord-034340-3ksfpaf7	1976	6	,	,	,
cord-034340-3ksfpaf7	1976	7	PTL	PTL	NNP
cord-034340-3ksfpaf7	1976	8	317	317	CD
cord-034340-3ksfpaf7	1976	9	,	,	,
cord-034340-3ksfpaf7	1976	10	except	except	IN
cord-034340-3ksfpaf7	1976	11	very	very	RB
cord-034340-3ksfpaf7	1976	12	high	high	JJ
cord-034340-3ksfpaf7	1976	13	ESR	ESR	NNP
cord-034340-3ksfpaf7	1976	14	105ml\hr	105ml\hr	CD
cord-034340-3ksfpaf7	1977	1	,	,	,
cord-034340-3ksfpaf7	1977	2	CRP	CRP	NNP
cord-034340-3ksfpaf7	1977	3	was	be	VBD
cord-034340-3ksfpaf7	1977	4	positive	positive	JJ
cord-034340-3ksfpaf7	1977	5	190mg\dl	190mg\dl	CD
cord-034340-3ksfpaf7	1977	6	,	,	,
cord-034340-3ksfpaf7	1977	7	viral	viral	JJ
cord-034340-3ksfpaf7	1977	8	screen	screen	NN
cord-034340-3ksfpaf7	1977	9	(	(	-LRB-
cord-034340-3ksfpaf7	1977	10	HCV	HCV	NNP
cord-034340-3ksfpaf7	1977	11	,	,	,
cord-034340-3ksfpaf7	1977	12	HBSAg	HBSAg	NNP
cord-034340-3ksfpaf7	1977	13	,	,	,
cord-034340-3ksfpaf7	1977	14	HIV	HIV	NNP
cord-034340-3ksfpaf7	1977	15	)	)	-RRB-
cord-034340-3ksfpaf7	1977	16	was	be	VBD
cord-034340-3ksfpaf7	1977	17	normal	normal	JJ
cord-034340-3ksfpaf7	1977	18	,	,	,
cord-034340-3ksfpaf7	1977	19	serology	serology	NN
cord-034340-3ksfpaf7	1977	20	tests	test	NNS
cord-034340-3ksfpaf7	1978	1	ANA	ANA	NNP
cord-034340-3ksfpaf7	1978	2	was	be	VBD
cord-034340-3ksfpaf7	1978	3	positive	positive	JJ
cord-034340-3ksfpaf7	1978	4	with	with	IN
cord-034340-3ksfpaf7	1978	5	high	high	JJ
cord-034340-3ksfpaf7	1978	6	titer	titer	NN
cord-034340-3ksfpaf7	1978	7	1280	1280	CD
cord-034340-3ksfpaf7	1978	8	,	,	,
cord-034340-3ksfpaf7	1978	9	anti	anti	JJ
cord-034340-3ksfpaf7	1978	10	ds	ds	NNP
cord-034340-3ksfpaf7	1978	11	-	-	HYPH
cord-034340-3ksfpaf7	1978	12	DNA	DNA	NNP
cord-034340-3ksfpaf7	1978	13	AB	AB	NNP
cord-034340-3ksfpaf7	1978	14	was	be	VBD
cord-034340-3ksfpaf7	1978	15	positive	positive	JJ
cord-034340-3ksfpaf7	1978	16	320	320	CD
cord-034340-3ksfpaf7	1978	17	,	,	,
cord-034340-3ksfpaf7	1978	18	anti	anti	JJ
cord-034340-3ksfpaf7	1978	19	-	-	NNP
cord-034340-3ksfpaf7	1978	20	Sm	Sm	NNP
cord-034340-3ksfpaf7	1978	21	was	be	VBD
cord-034340-3ksfpaf7	1978	22	negative	negative	JJ
cord-034340-3ksfpaf7	1978	23	,	,	,
cord-034340-3ksfpaf7	1978	24	ANTI	ANTI	NNP
cord-034340-3ksfpaf7	1978	25	LKM1	LKM1	NNP
cord-034340-3ksfpaf7	1978	26	antibodies	antibody	NNS
cord-034340-3ksfpaf7	1978	27	negative	negative	JJ
cord-034340-3ksfpaf7	1978	28	,	,	,
cord-034340-3ksfpaf7	1978	29	anti	anti	JJ
cord-034340-3ksfpaf7	1978	30	smooth	smooth	JJ
cord-034340-3ksfpaf7	1978	31	muscle	muscle	NN
cord-034340-3ksfpaf7	1978	32	AB	ab	NN
cord-034340-3ksfpaf7	1978	33	negative	negative	JJ
cord-034340-3ksfpaf7	1978	34	soluble	soluble	JJ
cord-034340-3ksfpaf7	1978	35	liver	liver	NN
cord-034340-3ksfpaf7	1978	36	antigen	antigen	NN
cord-034340-3ksfpaf7	1978	37	were	be	VBD
cord-034340-3ksfpaf7	1978	38	negative	negative	JJ
cord-034340-3ksfpaf7	1978	39	,	,	,
cord-034340-3ksfpaf7	1978	40	antimitohondrial	antimitohondrial	JJ
cord-034340-3ksfpaf7	1978	41	AB	AB	NNP
cord-034340-3ksfpaf7	1978	42	(	(	-LRB-
cord-034340-3ksfpaf7	1978	43	M1,M2,M3	M1,M2,M3	NNP
cord-034340-3ksfpaf7	1978	44	)	)	-RRB-
cord-034340-3ksfpaf7	1978	45	.	.	.
cord-034340-3ksfpaf7	1979	1	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	1979	2	abdomen	abdomen	NN
cord-034340-3ksfpaf7	1979	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1979	4	mild	mild	JJ
cord-034340-3ksfpaf7	1979	5	enlarged	enlarged	JJ
cord-034340-3ksfpaf7	1979	6	spleen	spleen	NNS
cord-034340-3ksfpaf7	1979	7	,	,	,
cord-034340-3ksfpaf7	1979	8	abnormal	abnormal	JJ
cord-034340-3ksfpaf7	1979	9	diffused	diffuse	VBN
cord-034340-3ksfpaf7	1979	10	increased	increase	VBN
cord-034340-3ksfpaf7	1979	11	liver	liver	NN
cord-034340-3ksfpaf7	1979	12	echogenicity	echogenicity	NN
cord-034340-3ksfpaf7	1979	13	with	with	IN
cord-034340-3ksfpaf7	1979	14	early	early	JJ
cord-034340-3ksfpaf7	1979	15	stage	stage	NN
cord-034340-3ksfpaf7	1979	16	of	of	IN
cord-034340-3ksfpaf7	1979	17	liver	liver	NN
cord-034340-3ksfpaf7	1979	18	cirrhosis	cirrhosis	NN
cord-034340-3ksfpaf7	1979	19	treated	treat	VBD
cord-034340-3ksfpaf7	1979	20	her	-PRON-	PRP
cord-034340-3ksfpaf7	1979	21	by	by	IN
cord-034340-3ksfpaf7	1979	22	fresh	fresh	JJ
cord-034340-3ksfpaf7	1979	23	frozen	frozen	JJ
cord-034340-3ksfpaf7	1979	24	plasma	plasma	NN
cord-034340-3ksfpaf7	1979	25	5	5	CD
cord-034340-3ksfpaf7	1979	26	times	time	NNS
cord-034340-3ksfpaf7	1979	27	,	,	,
cord-034340-3ksfpaf7	1979	28	ViT	ViT	NNP
cord-034340-3ksfpaf7	1979	29	k	k	NNP
cord-034340-3ksfpaf7	1980	1	10	10	CD
cord-034340-3ksfpaf7	1980	2	mg	mg	NNP
cord-034340-3ksfpaf7	1980	3	once\	once\	DT
cord-034340-3ksfpaf7	1980	4	day	day	NN
cord-034340-3ksfpaf7	1980	5	then	then	RB
cord-034340-3ksfpaf7	1980	6	was	be	VBD
cord-034340-3ksfpaf7	1980	7	referred	refer	VBN
cord-034340-3ksfpaf7	1980	8	to	to	IN
cord-034340-3ksfpaf7	1980	9	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	1980	10	clinic	clinic	NN
cord-034340-3ksfpaf7	1980	11	regarding	regard	VBG
cord-034340-3ksfpaf7	1980	12	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1980	13	serology	serology	NN
cord-034340-3ksfpaf7	1980	14	tests	test	NNS
cord-034340-3ksfpaf7	1980	15	&	&	CC
cord-034340-3ksfpaf7	1980	16	developed	develop	VBD
cord-034340-3ksfpaf7	1980	17	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1980	18	of	of	IN
cord-034340-3ksfpaf7	1980	19	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1980	20	joints	joint	NNS
cord-034340-3ksfpaf7	1980	21	suspected	suspect	VBN
cord-034340-3ksfpaf7	1980	22	PSLE	PSLE	NNP
cord-034340-3ksfpaf7	1980	23	!	!	.
cord-034340-3ksfpaf7	1981	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	1981	2	was	be	VBD
cord-034340-3ksfpaf7	1981	3	performed	perform	VBN
cord-034340-3ksfpaf7	1981	4	liver	liver	NN
cord-034340-3ksfpaf7	1981	5	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1981	6	showed	show	VBD
cord-034340-3ksfpaf7	1981	7	lesions	lesion	NNS
cord-034340-3ksfpaf7	1981	8	necrotic	necrotic	JJ
cord-034340-3ksfpaf7	1981	9	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	1981	10	portal	portal	NN
cord-034340-3ksfpaf7	1981	11	and	and	CC
cord-034340-3ksfpaf7	1981	12	lobular	lobular	NNP
cord-034340-3ksfpaf7	1981	13	severe	severe	JJ
cord-034340-3ksfpaf7	1981	14	in	in	IN
cord-034340-3ksfpaf7	1981	15	eosinophilic	eosinophilic	JJ
cord-034340-3ksfpaf7	1981	16	polynuclear	polynuclear	NN
cord-034340-3ksfpaf7	1981	17	with	with	IN
cord-034340-3ksfpaf7	1981	18	cirrhosis	cirrhosis	NN
cord-034340-3ksfpaf7	1981	19	evoking	evoke	VBG
cord-034340-3ksfpaf7	1981	20	a	a	DT
cord-034340-3ksfpaf7	1981	21	syndrome	syndrome	NN
cord-034340-3ksfpaf7	1981	22	of	of	IN
cord-034340-3ksfpaf7	1981	23	overlap	overlap	NN
cord-034340-3ksfpaf7	1981	24	associating	associate	VBG
cord-034340-3ksfpaf7	1981	25	a	a	DT
cord-034340-3ksfpaf7	1981	26	primary	primary	JJ
cord-034340-3ksfpaf7	1981	27	biliary	biliary	JJ
cord-034340-3ksfpaf7	1981	28	cirrhosis	cirrhosis	NN
cord-034340-3ksfpaf7	1981	29	and	and	CC
cord-034340-3ksfpaf7	1981	30	an	an	DT
cord-034340-3ksfpaf7	1981	31	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1981	32	hepatitis	hepatitis	NN
cord-034340-3ksfpaf7	1981	33	.	.	.
cord-034340-3ksfpaf7	1982	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	1982	2	data	datum	NNS
cord-034340-3ksfpaf7	1982	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1982	4	liver	liver	NN
cord-034340-3ksfpaf7	1982	5	dysfunction	dysfunction	NN
cord-034340-3ksfpaf7	1982	6	and	and	CC
cord-034340-3ksfpaf7	1982	7	liver	liver	NN
cord-034340-3ksfpaf7	1982	8	biopsy	biopsy	NN
cord-034340-3ksfpaf7	1983	1	Suggesting	suggest	VBG
cord-034340-3ksfpaf7	1983	2	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1983	3	hepatitis	hepatitis	NN
cord-034340-3ksfpaf7	1983	4	,	,	,
cord-034340-3ksfpaf7	1983	5	and	and	CC
cord-034340-3ksfpaf7	1984	1	she	-PRON-	PRP
cord-034340-3ksfpaf7	1984	2	underwent	undergo	VBD
cord-034340-3ksfpaf7	1984	3	treatment	treatment	NN
cord-034340-3ksfpaf7	1984	4	for	for	IN
cord-034340-3ksfpaf7	1984	5	hepatitis	hepatitis	NN
cord-034340-3ksfpaf7	1984	6	(	(	-LRB-
cord-034340-3ksfpaf7	1984	7	prednisolone	prednisolone	NN
cord-034340-3ksfpaf7	1984	8	with	with	IN
cord-034340-3ksfpaf7	1984	9	azathioprine	azathioprine	NNP
cord-034340-3ksfpaf7	1984	10	)	)	-RRB-
cord-034340-3ksfpaf7	1984	11	,	,	,
cord-034340-3ksfpaf7	1984	12	Urosdoxycholic	urosdoxycholic	JJ
cord-034340-3ksfpaf7	1984	13	acid	acid	NN
cord-034340-3ksfpaf7	1984	14	with	with	IN
cord-034340-3ksfpaf7	1984	15	fat	fat	NN
cord-034340-3ksfpaf7	1984	16	-	-	HYPH
cord-034340-3ksfpaf7	1984	17	soluble	soluble	JJ
cord-034340-3ksfpaf7	1984	18	vitamins	vitamin	NNS
cord-034340-3ksfpaf7	1984	19	K	K	NNP
cord-034340-3ksfpaf7	1984	20	,	,	,
cord-034340-3ksfpaf7	1984	21	D&A	D&A	NNP
cord-034340-3ksfpaf7	1984	22	,	,	,
cord-034340-3ksfpaf7	1984	23	E.	E.	NNP
cord-034340-3ksfpaf7	1985	1	However	however	RB
cord-034340-3ksfpaf7	1985	2	,	,	,
cord-034340-3ksfpaf7	1985	3	with	with	IN
cord-034340-3ksfpaf7	1985	4	the	the	DT
cord-034340-3ksfpaf7	1985	5	elimination	elimination	NN
cord-034340-3ksfpaf7	1985	6	of	of	IN
cord-034340-3ksfpaf7	1985	7	jaundice	jaundice	NN
cord-034340-3ksfpaf7	1985	8	and	and	CC
cord-034340-3ksfpaf7	1985	9	decreased	decrease	VBD
cord-034340-3ksfpaf7	1985	10	hepatic	hepatic	JJ
cord-034340-3ksfpaf7	1985	11	enzyme	enzyme	NN
cord-034340-3ksfpaf7	1985	12	levels	level	NNS
cord-034340-3ksfpaf7	1985	13	,	,	,
cord-034340-3ksfpaf7	1985	14	the	the	DT
cord-034340-3ksfpaf7	1985	15	prednisolone	prednisolone	NN
cord-034340-3ksfpaf7	1985	16	dose	dose	NN
cord-034340-3ksfpaf7	1985	17	was	be	VBD
cord-034340-3ksfpaf7	1985	18	tapered	taper	VBN
cord-034340-3ksfpaf7	1985	19	within	within	IN
cord-034340-3ksfpaf7	1985	20	2	2	CD
cord-034340-3ksfpaf7	1985	21	months	month	NNS
cord-034340-3ksfpaf7	1985	22	and	and	CC
cord-034340-3ksfpaf7	1985	23	stopped	stop	VBD
cord-034340-3ksfpaf7	1985	24	before	before	IN
cord-034340-3ksfpaf7	1985	25	they	-PRON-	PRP
cord-034340-3ksfpaf7	1985	26	were	be	VBD
cord-034340-3ksfpaf7	1985	27	referred	refer	VBN
cord-034340-3ksfpaf7	1985	28	to	to	IN
cord-034340-3ksfpaf7	1985	29	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	1985	30	clinic	clinic	NN
cord-034340-3ksfpaf7	1985	31	.	.	.
cord-034340-3ksfpaf7	1986	1	On	on	IN
cord-034340-3ksfpaf7	1986	2	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1986	3	review	review	NN
cord-034340-3ksfpaf7	1986	4	of	of	IN
cord-034340-3ksfpaf7	1986	5	systems	system	NNS
cord-034340-3ksfpaf7	1986	6	,	,	,
cord-034340-3ksfpaf7	1986	7	she	-PRON-	PRP
cord-034340-3ksfpaf7	1986	8	has	have	VBZ
cord-034340-3ksfpaf7	1986	9	malar	malar	NNP
cord-034340-3ksfpaf7	1986	10	rash	rash	NNP
cord-034340-3ksfpaf7	1986	11	,	,	,
cord-034340-3ksfpaf7	1986	12	generalized	generalize	VBN
cord-034340-3ksfpaf7	1986	13	fatigability	fatigability	NN
cord-034340-3ksfpaf7	1986	14	.	.	.
cord-034340-3ksfpaf7	1987	1	On	on	IN
cord-034340-3ksfpaf7	1987	2	physical	physical	JJ
cord-034340-3ksfpaf7	1987	3	examination	examination	NN
cord-034340-3ksfpaf7	1987	4	,	,	,
cord-034340-3ksfpaf7	1987	5	we	-PRON-	PRP
cord-034340-3ksfpaf7	1987	6	found	find	VBD
cord-034340-3ksfpaf7	1987	7	malar	malar	NNP
cord-034340-3ksfpaf7	1987	8	rash	rash	NNP
cord-034340-3ksfpaf7	1987	9	,	,	,
cord-034340-3ksfpaf7	1987	10	levidoreticularis	levidoreticularis	NNP
cord-034340-3ksfpaf7	1987	11	of	of	IN
cord-034340-3ksfpaf7	1987	12	her	-PRON-	PRP$
cord-034340-3ksfpaf7	1987	13	skin	skin	NN
cord-034340-3ksfpaf7	1987	14	,	,	,
cord-034340-3ksfpaf7	1987	15	swelling	swelling	NN
cord-034340-3ksfpaf7	1987	16	and	and	CC
cord-034340-3ksfpaf7	1987	17	limitation	limitation	NN
cord-034340-3ksfpaf7	1987	18	of	of	IN
cord-034340-3ksfpaf7	1987	19	movement	movement	NN
cord-034340-3ksfpaf7	1987	20	in	in	IN
cord-034340-3ksfpaf7	1987	21	the	the	DT
cord-034340-3ksfpaf7	1987	22	knees	knee	NNS
cord-034340-3ksfpaf7	1987	23	,	,	,
cord-034340-3ksfpaf7	1987	24	ankles	ankle	NNS
cord-034340-3ksfpaf7	1987	25	,	,	,
cord-034340-3ksfpaf7	1987	26	wrists	wrist	VBZ
cord-034340-3ksfpaf7	1987	27	joints	joint	NNS
cord-034340-3ksfpaf7	1987	28	.	.	.
cord-034340-3ksfpaf7	1988	1	There	there	EX
cord-034340-3ksfpaf7	1988	2	was	be	VBD
cord-034340-3ksfpaf7	1988	3	hepatosplenomegaly	hepatosplenomegaly	NNS
cord-034340-3ksfpaf7	1988	4	.	.	.
cord-034340-3ksfpaf7	1989	1	Laboratory	laboratory	NN
cord-034340-3ksfpaf7	1989	2	data	datum	NNS
cord-034340-3ksfpaf7	1989	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	1989	4	liver	liver	NN
cord-034340-3ksfpaf7	1989	5	treatment	treatment	NN
cord-034340-3ksfpaf7	1989	6	for	for	IN
cord-034340-3ksfpaf7	1989	7	hepatitis	hepatitis	NN
cord-034340-3ksfpaf7	1989	8	,	,	,
cord-034340-3ksfpaf7	1989	9	ANA	ANA	NNP
cord-034340-3ksfpaf7	1989	10	still	still	RB
cord-034340-3ksfpaf7	1989	11	high	high	JJ
cord-034340-3ksfpaf7	1989	12	titer	titer	NN
cord-034340-3ksfpaf7	1989	13	1:1280	1:1280	CD
cord-034340-3ksfpaf7	1989	14	,	,	,
cord-034340-3ksfpaf7	1989	15	Antids	Antids	NNP
cord-034340-3ksfpaf7	1989	16	DAN	DAN	NNP
cord-034340-3ksfpaf7	1989	17	positive	positive	JJ
cord-034340-3ksfpaf7	1989	18	with	with	IN
cord-034340-3ksfpaf7	1989	19	titer	titer	NN
cord-034340-3ksfpaf7	1989	20	307	307	CD
cord-034340-3ksfpaf7	1990	1	IU\ml	iu\ml	RB
cord-034340-3ksfpaf7	1990	2	,	,	,
cord-034340-3ksfpaf7	1990	3	antiSMA	antiSMA	NNP
cord-034340-3ksfpaf7	1990	4	was	be	VBD
cord-034340-3ksfpaf7	1990	5	negative	negative	JJ
cord-034340-3ksfpaf7	1990	6	.WBC	.WBC	.
cord-034340-3ksfpaf7	1991	1	4.5	4.5	CD
cord-034340-3ksfpaf7	1991	2	,	,	,
cord-034340-3ksfpaf7	1991	3	HGB	HGB	NNP
cord-034340-3ksfpaf7	1991	4	11.8	11.8	CD
cord-034340-3ksfpaf7	1991	5	,	,	,
cord-034340-3ksfpaf7	1991	6	PLT	PLT	NNP
cord-034340-3ksfpaf7	1991	7	268	268	CD
cord-034340-3ksfpaf7	1991	8	,	,	,
cord-034340-3ksfpaf7	1991	9	ESR	ESR	NNP
cord-034340-3ksfpaf7	1991	10	68ml\hr	68ml\hr	NNP
cord-034340-3ksfpaf7	1991	11	,	,	,
cord-034340-3ksfpaf7	1991	12	Her	-PRON-	PRP$
cord-034340-3ksfpaf7	1991	13	ultrasound	ultrasound	NN
cord-034340-3ksfpaf7	1991	14	abdomen	abdomen	NN
cord-034340-3ksfpaf7	1991	15	:	:	:
cord-034340-3ksfpaf7	1991	16	revealed	reveal	VBD
cord-034340-3ksfpaf7	1991	17	slightly	slightly	RB
cord-034340-3ksfpaf7	1991	18	heterogeneous	heterogeneous	JJ
cord-034340-3ksfpaf7	1991	19	liver	liver	NN
cord-034340-3ksfpaf7	1991	20	with	with	IN
cord-034340-3ksfpaf7	1991	21	coarse	coarse	JJ
cord-034340-3ksfpaf7	1991	22	echotexture	echotexture	NN
cord-034340-3ksfpaf7	1991	23	without	without	IN
cord-034340-3ksfpaf7	1991	24	focal	focal	JJ
cord-034340-3ksfpaf7	1991	25	lesion	lesion	NN
cord-034340-3ksfpaf7	1991	26	with	with	IN
cord-034340-3ksfpaf7	1991	27	liver	liver	NN
cord-034340-3ksfpaf7	1991	28	span	span	NNP
cord-034340-3ksfpaf7	1991	29	14	14	CD
cord-034340-3ksfpaf7	1991	30	cm	cm	NNS
cord-034340-3ksfpaf7	1991	31	.	.	.
cord-034340-3ksfpaf7	1992	1	These	these	DT
cord-034340-3ksfpaf7	1992	2	paraclinical	paraclinical	JJ
cord-034340-3ksfpaf7	1992	3	results	result	VBZ
cord-034340-3ksfpaf7	1992	4	together	together	RB
cord-034340-3ksfpaf7	1992	5	with	with	IN
cord-034340-3ksfpaf7	1992	6	the	the	DT
cord-034340-3ksfpaf7	1992	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	1992	8	findings	finding	NNS
cord-034340-3ksfpaf7	1992	9	strongly	strongly	RB
cord-034340-3ksfpaf7	1992	10	suggested	suggest	VBD
cord-034340-3ksfpaf7	1992	11	systemic	systemic	JJ
cord-034340-3ksfpaf7	1992	12	lupus	lupus	NN
cord-034340-3ksfpaf7	1992	13	erythematosus	erythematosus	NN
cord-034340-3ksfpaf7	1992	14	(	(	-LRB-
cord-034340-3ksfpaf7	1992	15	SLE	SLE	NNP
cord-034340-3ksfpaf7	1992	16	)	)	-RRB-
cord-034340-3ksfpaf7	1992	17	as	as	IN
cord-034340-3ksfpaf7	1992	18	the	the	DT
cord-034340-3ksfpaf7	1992	19	definitive	definitive	JJ
cord-034340-3ksfpaf7	1992	20	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1992	21	.	.	.
cord-034340-3ksfpaf7	1993	1	Indeed	indeed	RB
cord-034340-3ksfpaf7	1993	2	,	,	,
cord-034340-3ksfpaf7	1993	3	in	in	IN
cord-034340-3ksfpaf7	1993	4	this	this	DT
cord-034340-3ksfpaf7	1993	5	case	case	NN
cord-034340-3ksfpaf7	1993	6	,	,	,
cord-034340-3ksfpaf7	1993	7	AIH	AIH	NNP
cord-034340-3ksfpaf7	1993	8	was	be	VBD
cord-034340-3ksfpaf7	1993	9	associated	associate	VBN
cord-034340-3ksfpaf7	1993	10	with	with	IN
cord-034340-3ksfpaf7	1993	11	SLE	SLE	NNP
cord-034340-3ksfpaf7	1993	12	,	,	,
cord-034340-3ksfpaf7	1993	13	prednisolone	prednisolone	NN
cord-034340-3ksfpaf7	1993	14	orally	orally	RB
cord-034340-3ksfpaf7	1993	15	for	for	IN
cord-034340-3ksfpaf7	1993	16	2	2	CD
cord-034340-3ksfpaf7	1993	17	months	month	NNS
cord-034340-3ksfpaf7	1993	18	,	,	,
cord-034340-3ksfpaf7	1993	19	after	after	IN
cord-034340-3ksfpaf7	1993	20	that	that	DT
cord-034340-3ksfpaf7	1993	21	dose	dose	NN
cord-034340-3ksfpaf7	1993	22	was	be	VBD
cord-034340-3ksfpaf7	1993	23	tapered	taper	VBN
cord-034340-3ksfpaf7	1993	24	and	and	CC
cord-034340-3ksfpaf7	1993	25	continued	continue	VBD
cord-034340-3ksfpaf7	1993	26	,	,	,
cord-034340-3ksfpaf7	1993	27	rapid	rapid	JJ
cord-034340-3ksfpaf7	1993	28	clinical	clinical	JJ
cord-034340-3ksfpaf7	1993	29	improvement	improvement	NN
cord-034340-3ksfpaf7	1993	30	in	in	IN
cord-034340-3ksfpaf7	1993	31	arthritis	arthritis	NN
cord-034340-3ksfpaf7	1993	32	,	,	,
cord-034340-3ksfpaf7	1993	33	malaise	malaise	NN
cord-034340-3ksfpaf7	1993	34	,	,	,
cord-034340-3ksfpaf7	1993	35	and	and	CC
cord-034340-3ksfpaf7	1993	36	general	general	JJ
cord-034340-3ksfpaf7	1993	37	condition	condition	NN
cord-034340-3ksfpaf7	1993	38	.	.	.
cord-034340-3ksfpaf7	1994	1	Azathioprine	Azathioprine	NNP
cord-034340-3ksfpaf7	1994	2	was	be	VBD
cord-034340-3ksfpaf7	1994	3	continued	continue	VBN
cord-034340-3ksfpaf7	1994	4	.	.	.
cord-034340-3ksfpaf7	1995	1	In	in	IN
cord-034340-3ksfpaf7	1995	2	addition	addition	NN
cord-034340-3ksfpaf7	1995	3	,	,	,
cord-034340-3ksfpaf7	1995	4	daily	daily	JJ
cord-034340-3ksfpaf7	1995	5	hydroxycholoquine	hydroxycholoquine	NN
cord-034340-3ksfpaf7	1995	6	sulfate	sulfate	NN
cord-034340-3ksfpaf7	1995	7	Overlapping	Overlapping	NNP
cord-034340-3ksfpaf7	1995	8	of	of	IN
cord-034340-3ksfpaf7	1995	9	SLE	SLE	NNP
cord-034340-3ksfpaf7	1995	10	and	and	CC
cord-034340-3ksfpaf7	1995	11	AIH	AIH	NNP
cord-034340-3ksfpaf7	1995	12	should	should	MD
cord-034340-3ksfpaf7	1995	13	be	be	VB
cord-034340-3ksfpaf7	1995	14	suspected	suspect	VBN
cord-034340-3ksfpaf7	1995	15	when	when	WRB
cord-034340-3ksfpaf7	1995	16	AIH	AIH	NNP
cord-034340-3ksfpaf7	1995	17	patients	patient	NNS
cord-034340-3ksfpaf7	1995	18	present	present	JJ
cord-034340-3ksfpaf7	1995	19	with	with	IN
cord-034340-3ksfpaf7	1995	20	a	a	DT
cord-034340-3ksfpaf7	1995	21	malar	malar	JJ
cord-034340-3ksfpaf7	1995	22	or	or	CC
cord-034340-3ksfpaf7	1995	23	other	other	JJ
cord-034340-3ksfpaf7	1995	24	skin	skin	NN
cord-034340-3ksfpaf7	1995	25	rash	rash	NN
cord-034340-3ksfpaf7	1995	26	.	.	.
cord-034340-3ksfpaf7	1996	1	The	the	DT
cord-034340-3ksfpaf7	1996	2	prompt	prompt	JJ
cord-034340-3ksfpaf7	1996	3	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1996	4	and	and	CC
cord-034340-3ksfpaf7	1996	5	adjustment	adjustment	NN
cord-034340-3ksfpaf7	1996	6	of	of	IN
cord-034340-3ksfpaf7	1996	7	further	further	JJ
cord-034340-3ksfpaf7	1996	8	treatment	treatment	NN
cord-034340-3ksfpaf7	1996	9	plans	plan	NNS
cord-034340-3ksfpaf7	1996	10	can	can	MD
cord-034340-3ksfpaf7	1996	11	improve	improve	VB
cord-034340-3ksfpaf7	1996	12	disease	disease	NN
cord-034340-3ksfpaf7	1996	13	outcomes	outcome	NNS
cord-034340-3ksfpaf7	1996	14	and	and	CC
cord-034340-3ksfpaf7	1996	15	prevent	prevent	VBP
cord-034340-3ksfpaf7	1996	16	liver	liver	NN
cord-034340-3ksfpaf7	1996	17	disease	disease	NN
cord-034340-3ksfpaf7	1996	18	progression	progression	NN
cord-034340-3ksfpaf7	1996	19	.	.	.
cord-034340-3ksfpaf7	1997	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	1997	2	:	:	:
cord-034340-3ksfpaf7	1998	1	Juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1998	2	systemic	systemic	JJ
cord-034340-3ksfpaf7	1998	3	lupus	lupus	NN
cord-034340-3ksfpaf7	1998	4	erythematosus	erythematosus	NN
cord-034340-3ksfpaf7	1998	5	(	(	-LRB-
cord-034340-3ksfpaf7	1998	6	SLE	SLE	NNP
cord-034340-3ksfpaf7	1998	7	)	)	-RRB-
cord-034340-3ksfpaf7	1998	8	is	be	VBZ
cord-034340-3ksfpaf7	1998	9	a	a	DT
cord-034340-3ksfpaf7	1998	10	chronic	chronic	JJ
cord-034340-3ksfpaf7	1998	11	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	1998	12	disease	disease	NN
cord-034340-3ksfpaf7	1998	13	characterized	characterize	VBN
cord-034340-3ksfpaf7	1998	14	by	by	IN
cord-034340-3ksfpaf7	1998	15	multi	multi	JJ
cord-034340-3ksfpaf7	1998	16	-	-	JJ
cord-034340-3ksfpaf7	1998	17	visceral	visceral	JJ
cord-034340-3ksfpaf7	1998	18	involvement	involvement	NN
cord-034340-3ksfpaf7	1998	19	with	with	IN
cord-034340-3ksfpaf7	1998	20	an	an	DT
cord-034340-3ksfpaf7	1998	21	unpredictable	unpredictable	JJ
cord-034340-3ksfpaf7	1998	22	prognosis	prognosis	NN
cord-034340-3ksfpaf7	1998	23	.	.	.
cord-034340-3ksfpaf7	1999	1	The	the	DT
cord-034340-3ksfpaf7	1999	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	1999	3	is	be	VBZ
cord-034340-3ksfpaf7	1999	4	usually	usually	RB
cord-034340-3ksfpaf7	1999	5	made	make	VBN
cord-034340-3ksfpaf7	1999	6	in	in	IN
cord-034340-3ksfpaf7	1999	7	young	young	JJ
cord-034340-3ksfpaf7	1999	8	women	woman	NNS
cord-034340-3ksfpaf7	1999	9	aged	age	VBN
cord-034340-3ksfpaf7	1999	10	between	between	IN
cord-034340-3ksfpaf7	1999	11	20	20	CD
cord-034340-3ksfpaf7	1999	12	to	to	IN
cord-034340-3ksfpaf7	1999	13	40years	40years	CD
cord-034340-3ksfpaf7	1999	14	,	,	,
cord-034340-3ksfpaf7	1999	15	however	however	RB
cord-034340-3ksfpaf7	1999	16	,	,	,
cord-034340-3ksfpaf7	1999	17	it	-PRON-	PRP
cord-034340-3ksfpaf7	1999	18	can	can	MD
cord-034340-3ksfpaf7	1999	19	affect	affect	VB
cord-034340-3ksfpaf7	1999	20	people	people	NNS
cord-034340-3ksfpaf7	1999	21	at	at	IN
cord-034340-3ksfpaf7	1999	22	any	any	DT
cord-034340-3ksfpaf7	1999	23	age	age	NN
cord-034340-3ksfpaf7	1999	24	and	and	CC
cord-034340-3ksfpaf7	1999	25	it	-PRON-	PRP
cord-034340-3ksfpaf7	1999	26	is	be	VBZ
cord-034340-3ksfpaf7	1999	27	classified	classify	VBN
cord-034340-3ksfpaf7	1999	28	as	as	IN
cord-034340-3ksfpaf7	1999	29	a	a	DT
cord-034340-3ksfpaf7	1999	30	juvenile	juvenile	JJ
cord-034340-3ksfpaf7	1999	31	illness	illness	NN
cord-034340-3ksfpaf7	1999	32	when	when	WRB
cord-034340-3ksfpaf7	1999	33	it	-PRON-	PRP
cord-034340-3ksfpaf7	1999	34	starts	start	VBZ
cord-034340-3ksfpaf7	1999	35	before	before	IN
cord-034340-3ksfpaf7	1999	36	the	the	DT
cord-034340-3ksfpaf7	1999	37	age	age	NN
cord-034340-3ksfpaf7	1999	38	of	of	IN
cord-034340-3ksfpaf7	1999	39	16	16	CD
cord-034340-3ksfpaf7	1999	40	.	.	.
cord-034340-3ksfpaf7	2000	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	2000	2	:	:	:
cord-034340-3ksfpaf7	2001	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	2001	2	are	be	VBP
cord-034340-3ksfpaf7	2001	3	reporting	report	VBG
cord-034340-3ksfpaf7	2001	4	the	the	DT
cord-034340-3ksfpaf7	2001	5	epidemical	epidemical	JJ
cord-034340-3ksfpaf7	2001	6	,	,	,
cord-034340-3ksfpaf7	2001	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	2001	8	,	,	,
cord-034340-3ksfpaf7	2001	9	therapeutical	therapeutical	JJ
cord-034340-3ksfpaf7	2001	10	and	and	CC
cord-034340-3ksfpaf7	2001	11	evolutional	evolutional	JJ
cord-034340-3ksfpaf7	2001	12	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	2001	13	of	of	IN
cord-034340-3ksfpaf7	2001	14	a	a	DT
cord-034340-3ksfpaf7	2001	15	series	series	NN
cord-034340-3ksfpaf7	2001	16	done	do	VBN
cord-034340-3ksfpaf7	2001	17	in	in	IN
cord-034340-3ksfpaf7	2001	18	the	the	DT
cord-034340-3ksfpaf7	2001	19	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	2001	20	Pole	Pole	NNP
cord-034340-3ksfpaf7	2001	21	in	in	IN
cord-034340-3ksfpaf7	2001	22	setif	setif	NN
cord-034340-3ksfpaf7	2001	23	with	with	IN
cord-034340-3ksfpaf7	2001	24	13	13	CD
cord-034340-3ksfpaf7	2001	25	girls	girl	NNS
cord-034340-3ksfpaf7	2001	26	and	and	CC
cord-034340-3ksfpaf7	2001	27	1	1	CD
cord-034340-3ksfpaf7	2001	28	boy	boy	NN
cord-034340-3ksfpaf7	2001	29	.	.	.
cord-034340-3ksfpaf7	2002	1	Methods	method	NNS
cord-034340-3ksfpaf7	2002	2	:	:	:
cord-034340-3ksfpaf7	2003	1	The	the	DT
cord-034340-3ksfpaf7	2003	2	average	average	JJ
cord-034340-3ksfpaf7	2003	3	age	age	NN
cord-034340-3ksfpaf7	2003	4	of	of	IN
cord-034340-3ksfpaf7	2003	5	onset	onset	NN
cord-034340-3ksfpaf7	2003	6	is	be	VBZ
cord-034340-3ksfpaf7	2003	7	13	13	CD
cord-034340-3ksfpaf7	2003	8	years	year	NNS
cord-034340-3ksfpaf7	2003	9	.	.	.
cord-034340-3ksfpaf7	2004	1	The	the	DT
cord-034340-3ksfpaf7	2004	2	average	average	JJ
cord-034340-3ksfpaf7	2004	3	time	time	NN
cord-034340-3ksfpaf7	2004	4	limits	limit	NNS
cord-034340-3ksfpaf7	2004	5	of	of	IN
cord-034340-3ksfpaf7	2004	6	the	the	DT
cord-034340-3ksfpaf7	2004	7	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	2004	8	is	be	VBZ
cord-034340-3ksfpaf7	2004	9	7	7	CD
cord-034340-3ksfpaf7	2004	10	months	month	NNS
cord-034340-3ksfpaf7	2004	11	.	.	.
cord-034340-3ksfpaf7	2005	1	The	the	DT
cord-034340-3ksfpaf7	2005	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	2005	3	features	feature	NNS
cord-034340-3ksfpaf7	2005	4	is	be	VBZ
cord-034340-3ksfpaf7	2005	5	done	do	VBN
cord-034340-3ksfpaf7	2005	6	with	with	IN
cord-034340-3ksfpaf7	2005	7	cutaneous	cutaneous	JJ
cord-034340-3ksfpaf7	2005	8	,	,	,
cord-034340-3ksfpaf7	2005	9	articular	articular	JJ
cord-034340-3ksfpaf7	2005	10	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	2005	11	and	and	CC
cord-034340-3ksfpaf7	2005	12	fever	fever	NN
cord-034340-3ksfpaf7	2005	13	respectively	respectively	RB
cord-034340-3ksfpaf7	2005	14	in	in	IN
cord-034340-3ksfpaf7	2005	15	100	100	CD
cord-034340-3ksfpaf7	2005	16	%	%	NN
cord-034340-3ksfpaf7	2005	17	71	71	CD
cord-034340-3ksfpaf7	2005	18	%	%	NN
cord-034340-3ksfpaf7	2005	19	and	and	CC
cord-034340-3ksfpaf7	2005	20	57	57	CD
cord-034340-3ksfpaf7	2005	21	%	%	NN
cord-034340-3ksfpaf7	2005	22	of	of	IN
cord-034340-3ksfpaf7	2005	23	the	the	DT
cord-034340-3ksfpaf7	2005	24	cases	case	NNS
cord-034340-3ksfpaf7	2005	25	,	,	,
cord-034340-3ksfpaf7	2005	26	followed	follow	VBN
cord-034340-3ksfpaf7	2005	27	by	by	IN
cord-034340-3ksfpaf7	2005	28	kidney	kidney	NN
cord-034340-3ksfpaf7	2005	29	damage	damage	NN
cord-034340-3ksfpaf7	2005	30	in	in	IN
cord-034340-3ksfpaf7	2005	31	42	42	CD
cord-034340-3ksfpaf7	2005	32	%	%	NN
cord-034340-3ksfpaf7	2005	33	of	of	IN
cord-034340-3ksfpaf7	2005	34	the	the	DT
cord-034340-3ksfpaf7	2005	35	cases	case	NNS
cord-034340-3ksfpaf7	2005	36	,	,	,
cord-034340-3ksfpaf7	2005	37	the	the	DT
cord-034340-3ksfpaf7	2005	38	cardiac	cardiac	NN
cord-034340-3ksfpaf7	2005	39	,	,	,
cord-034340-3ksfpaf7	2005	40	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	2005	41	and	and	CC
cord-034340-3ksfpaf7	2005	42	ophthalmological	ophthalmological	JJ
cord-034340-3ksfpaf7	2005	43	participations	participation	NNS
cord-034340-3ksfpaf7	2005	44	are	be	VBP
cord-034340-3ksfpaf7	2005	45	reported	report	VBN
cord-034340-3ksfpaf7	2005	46	with	with	IN
cord-034340-3ksfpaf7	2005	47	low	low	JJ
cord-034340-3ksfpaf7	2005	48	percentage	percentage	NN
cord-034340-3ksfpaf7	2005	49	.	.	.
cord-034340-3ksfpaf7	2006	1	Haematological	Haematological	NNP
cord-034340-3ksfpaf7	2006	2	involvement	involvement	NN
cord-034340-3ksfpaf7	2006	3	was	be	VBD
cord-034340-3ksfpaf7	2006	4	detected	detect	VBN
cord-034340-3ksfpaf7	2006	5	in	in	IN
cord-034340-3ksfpaf7	2006	6	85	85	CD
cord-034340-3ksfpaf7	2006	7	%	%	NN
cord-034340-3ksfpaf7	2006	8	of	of	IN
cord-034340-3ksfpaf7	2006	9	the	the	DT
cord-034340-3ksfpaf7	2006	10	patients	patient	NNS
cord-034340-3ksfpaf7	2006	11	and	and	CC
cord-034340-3ksfpaf7	2006	12	the	the	DT
cord-034340-3ksfpaf7	2006	13	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	2006	14	syndrome	syndrome	NN
cord-034340-3ksfpaf7	2006	15	was	be	VBD
cord-034340-3ksfpaf7	2006	16	almost	almost	RB
cord-034340-3ksfpaf7	2006	17	constant	constant	JJ
cord-034340-3ksfpaf7	2006	18	.	.	.
cord-034340-3ksfpaf7	2007	1	A	a	DT
cord-034340-3ksfpaf7	2007	2	positive	positive	JJ
cord-034340-3ksfpaf7	2007	3	titer	titer	NN
cord-034340-3ksfpaf7	2007	4	of	of	IN
cord-034340-3ksfpaf7	2007	5	anti	anti	JJ
cord-034340-3ksfpaf7	2007	6	-	-	JJ
cord-034340-3ksfpaf7	2007	7	nuclear	nuclear	JJ
cord-034340-3ksfpaf7	2007	8	antibodies	antibody	NNS
cord-034340-3ksfpaf7	2007	9	and	and	CC
cord-034340-3ksfpaf7	2007	10	anti	anti	JJ
cord-034340-3ksfpaf7	2007	11	-	-	JJ
cord-034340-3ksfpaf7	2007	12	DNA	DNA	NNP
cord-034340-3ksfpaf7	2007	13	is	be	VBZ
cord-034340-3ksfpaf7	2007	14	objectified	objectify	VBN
cord-034340-3ksfpaf7	2007	15	,	,	,
cord-034340-3ksfpaf7	2007	16	as	as	RB
cord-034340-3ksfpaf7	2007	17	well	well	RB
cord-034340-3ksfpaf7	2007	18	as	as	IN
cord-034340-3ksfpaf7	2007	19	a	a	DT
cord-034340-3ksfpaf7	2007	20	reduction	reduction	NN
cord-034340-3ksfpaf7	2007	21	in	in	IN
cord-034340-3ksfpaf7	2007	22	the	the	DT
cord-034340-3ksfpaf7	2007	23	complement	complement	NN
cord-034340-3ksfpaf7	2007	24	rate	rate	NN
cord-034340-3ksfpaf7	2007	25	.	.	.
cord-034340-3ksfpaf7	2008	1	Antibodies	antibody	NNS
cord-034340-3ksfpaf7	2008	2	anti	anti	JJ
cord-034340-3ksfpaf7	2008	3	GP	GP	NNP
cord-034340-3ksfpaf7	2008	4	2	2	CD
cord-034340-3ksfpaf7	2008	5	and	and	CC
cord-034340-3ksfpaf7	2009	1	anti	anti	JJ
cord-034340-3ksfpaf7	2009	2	cardiolopine	cardiolopine	NNP
cord-034340-3ksfpaf7	2009	3	are	be	VBP
cord-034340-3ksfpaf7	2009	4	positive	positive	JJ
cord-034340-3ksfpaf7	2009	5	in	in	IN
cord-034340-3ksfpaf7	2009	6	57	57	CD
cord-034340-3ksfpaf7	2009	7	%	%	NN
cord-034340-3ksfpaf7	2009	8	of	of	IN
cord-034340-3ksfpaf7	2009	9	cases	case	NNS
cord-034340-3ksfpaf7	2009	10	.	.	.
cord-034340-3ksfpaf7	2010	1	Kidney	kidney	NN
cord-034340-3ksfpaf7	2010	2	damage	damage	NN
cord-034340-3ksfpaf7	2010	3	was	be	VBD
cord-034340-3ksfpaf7	2010	4	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	2010	5	in	in	IN
cord-034340-3ksfpaf7	2010	6	42	42	CD
cord-034340-3ksfpaf7	2010	7	%	%	NN
cord-034340-3ksfpaf7	2010	8	of	of	IN
cord-034340-3ksfpaf7	2010	9	the	the	DT
cord-034340-3ksfpaf7	2010	10	cases	case	NNS
cord-034340-3ksfpaf7	2010	11	,	,	,
cord-034340-3ksfpaf7	2010	12	and	and	CC
cord-034340-3ksfpaf7	2010	13	only	only	RB
cord-034340-3ksfpaf7	2010	14	one	one	CD
cord-034340-3ksfpaf7	2010	15	case	case	NN
cord-034340-3ksfpaf7	2010	16	of	of	IN
cord-034340-3ksfpaf7	2010	17	overlap	overlap	NN
cord-034340-3ksfpaf7	2010	18	syndrome	syndrome	NN
cord-034340-3ksfpaf7	2010	19	with	with	IN
cord-034340-3ksfpaf7	2010	20	dermatomyosits	dermatomyosit	NNS
cord-034340-3ksfpaf7	2010	21	was	be	VBD
cord-034340-3ksfpaf7	2010	22	reported	report	VBN
cord-034340-3ksfpaf7	2010	23	.	.	.
cord-034340-3ksfpaf7	2011	1	Concerning	concern	VBG
cord-034340-3ksfpaf7	2011	2	the	the	DT
cord-034340-3ksfpaf7	2011	3	neurological	neurological	JJ
cord-034340-3ksfpaf7	2011	4	form	form	NN
cord-034340-3ksfpaf7	2011	5	it	-PRON-	PRP
cord-034340-3ksfpaf7	2011	6	was	be	VBD
cord-034340-3ksfpaf7	2011	7	present	present	JJ
cord-034340-3ksfpaf7	2011	8	in	in	IN
cord-034340-3ksfpaf7	2011	9	only	only	RB
cord-034340-3ksfpaf7	2011	10	one	one	CD
cord-034340-3ksfpaf7	2011	11	addolecent	addolecent	NN
cord-034340-3ksfpaf7	2011	12	girl	girl	NN
cord-034340-3ksfpaf7	2011	13	,	,	,
cord-034340-3ksfpaf7	2011	14	and	and	CC
cord-034340-3ksfpaf7	2011	15	only	only	RB
cord-034340-3ksfpaf7	2011	16	one	one	CD
cord-034340-3ksfpaf7	2011	17	case	case	NN
cord-034340-3ksfpaf7	2011	18	of	of	IN
cord-034340-3ksfpaf7	2011	19	familial	familial	JJ
cord-034340-3ksfpaf7	2011	20	lupus	lupus	NN
cord-034340-3ksfpaf7	2011	21	.	.	.
cord-034340-3ksfpaf7	2012	1	Results	result	NNS
cord-034340-3ksfpaf7	2012	2	:	:	:
cord-034340-3ksfpaf7	2013	1	The	the	DT
cord-034340-3ksfpaf7	2013	2	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	2013	3	is	be	VBZ
cord-034340-3ksfpaf7	2013	4	based	base	VBN
cord-034340-3ksfpaf7	2013	5	on	on	IN
cord-034340-3ksfpaf7	2013	6	the	the	DT
cord-034340-3ksfpaf7	2013	7	classification	classification	NN
cord-034340-3ksfpaf7	2013	8	of	of	IN
cord-034340-3ksfpaf7	2013	9	the	the	DT
cord-034340-3ksfpaf7	2013	10	American	American	NNP
cord-034340-3ksfpaf7	2013	11	College	College	NNP
cord-034340-3ksfpaf7	2013	12	of	of	IN
cord-034340-3ksfpaf7	2013	13	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	2013	14	(	(	-LRB-
cord-034340-3ksfpaf7	2013	15	ACR	ACR	NNP
cord-034340-3ksfpaf7	2013	16	)	)	-RRB-
cord-034340-3ksfpaf7	2013	17	1982	1982	CD
cord-034340-3ksfpaf7	2013	18	revised	revise	VBD
cord-034340-3ksfpaf7	2013	19	on	on	IN
cord-034340-3ksfpaf7	2013	20	1997	1997	CD
cord-034340-3ksfpaf7	2013	21	and	and	CC
cord-034340-3ksfpaf7	2013	22	the	the	DT
cord-034340-3ksfpaf7	2013	23	new	new	JJ
cord-034340-3ksfpaf7	2013	24	criteria	criterion	NNS
cord-034340-3ksfpaf7	2013	25	SLICC"Systemic	SLICC"Systemic	NNP
cord-034340-3ksfpaf7	2013	26	Lupus	Lupus	NNP
cord-034340-3ksfpaf7	2013	27	International	International	NNP
cord-034340-3ksfpaf7	2013	28	Collaborating	Collaborating	NNP
cord-034340-3ksfpaf7	2013	29	Clinics	Clinics	NNPS
cord-034340-3ksfpaf7	2013	30	"	"	''
cord-034340-3ksfpaf7	2013	31	.	.	.
cord-034340-3ksfpaf7	2014	1	The	the	DT
cord-034340-3ksfpaf7	2014	2	clinical	clinical	JJ
cord-034340-3ksfpaf7	2014	3	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	2014	4	of	of	IN
cord-034340-3ksfpaf7	2014	5	our	-PRON-	PRP$
cord-034340-3ksfpaf7	2014	6	series	series	NN
cord-034340-3ksfpaf7	2014	7	relies	rely	VBZ
cord-034340-3ksfpaf7	2014	8	on	on	IN
cord-034340-3ksfpaf7	2014	9	global	global	JJ
cord-034340-3ksfpaf7	2014	10	data	datum	NNS
cord-034340-3ksfpaf7	2014	11	of	of	IN
cord-034340-3ksfpaf7	2014	12	literature	literature	NN
cord-034340-3ksfpaf7	2014	13	with	with	IN
cord-034340-3ksfpaf7	2014	14	the	the	DT
cord-034340-3ksfpaf7	2014	15	Predominance	predominance	NN
cord-034340-3ksfpaf7	2014	16	of	of	IN
cord-034340-3ksfpaf7	2014	17	Cutaneous	cutaneous	JJ
cord-034340-3ksfpaf7	2014	18	and	and	CC
cord-034340-3ksfpaf7	2014	19	articular	articular	JJ
cord-034340-3ksfpaf7	2014	20	involvement	involvement	NN
cord-034340-3ksfpaf7	2014	21	.	.	.
cord-034340-3ksfpaf7	2015	1	with	with	IN
cord-034340-3ksfpaf7	2015	2	however	however	RB
cord-034340-3ksfpaf7	2015	3	some	some	DT
cord-034340-3ksfpaf7	2015	4	specific	specific	JJ
cord-034340-3ksfpaf7	2015	5	characteristics	characteristic	NNS
cord-034340-3ksfpaf7	2015	6	which	which	WDT
cord-034340-3ksfpaf7	2015	7	are	be	VBP
cord-034340-3ksfpaf7	2015	8	individualized	individualize	VBN
cord-034340-3ksfpaf7	2015	9	by	by	IN
cord-034340-3ksfpaf7	2015	10	a	a	DT
cord-034340-3ksfpaf7	2015	11	more	more	RBR
cord-034340-3ksfpaf7	2015	12	advanced	advanced	JJ
cord-034340-3ksfpaf7	2015	13	age	age	NN
cord-034340-3ksfpaf7	2015	14	of	of	IN
cord-034340-3ksfpaf7	2015	15	onset	onset	NN
cord-034340-3ksfpaf7	2015	16	,	,	,
cord-034340-3ksfpaf7	2015	17	13	13	CD
cord-034340-3ksfpaf7	2015	18	years	year	NNS
cord-034340-3ksfpaf7	2015	19	on	on	IN
cord-034340-3ksfpaf7	2015	20	average	average	JJ
cord-034340-3ksfpaf7	2015	21	in	in	IN
cord-034340-3ksfpaf7	2015	22	our	-PRON-	PRP$
cord-034340-3ksfpaf7	2015	23	study	study	NN
cord-034340-3ksfpaf7	2015	24	versus	versus	IN
cord-034340-3ksfpaf7	2015	25	10	10	CD
cord-034340-3ksfpaf7	2015	26	years	year	NNS
cord-034340-3ksfpaf7	2015	27	and	and	CC
cord-034340-3ksfpaf7	2015	28	12	12	CD
cord-034340-3ksfpaf7	2015	29	years	year	NNS
cord-034340-3ksfpaf7	2015	30	,	,	,
cord-034340-3ksfpaf7	2015	31	the	the	DT
cord-034340-3ksfpaf7	2015	32	rarity	rarity	NN
cord-034340-3ksfpaf7	2015	33	of	of	IN
cord-034340-3ksfpaf7	2015	34	familial	familial	JJ
cord-034340-3ksfpaf7	2015	35	forms	form	NNS
cord-034340-3ksfpaf7	2015	36	(	(	-LRB-
cord-034340-3ksfpaf7	2015	37	1	1	CD
cord-034340-3ksfpaf7	2015	38	case	case	NN
cord-034340-3ksfpaf7	2015	39	)	)	-RRB-
cord-034340-3ksfpaf7	2015	40	,	,	,
cord-034340-3ksfpaf7	2015	41	a	a	DT
cord-034340-3ksfpaf7	2015	42	lower	low	JJR
cord-034340-3ksfpaf7	2015	43	percentage	percentage	NN
cord-034340-3ksfpaf7	2015	44	of	of	IN
cord-034340-3ksfpaf7	2015	45	kidney	kidney	NN
cord-034340-3ksfpaf7	2015	46	damage	damage	NN
cord-034340-3ksfpaf7	2015	47	(	(	-LRB-
cord-034340-3ksfpaf7	2015	48	42	42	CD
cord-034340-3ksfpaf7	2015	49	%	%	NN
cord-034340-3ksfpaf7	2015	50	versus	versus	IN
cord-034340-3ksfpaf7	2015	51	63	63	CD
cord-034340-3ksfpaf7	2015	52	%	%	NN
cord-034340-3ksfpaf7	2015	53	and	and	CC
cord-034340-3ksfpaf7	2015	54	80%).The	80%).the	CD
cord-034340-3ksfpaf7	2015	55	therapeutic	therapeutic	JJ
cord-034340-3ksfpaf7	2015	56	management	management	NN
cord-034340-3ksfpaf7	2015	57	was	be	VBD
cord-034340-3ksfpaf7	2015	58	based	base	VBN
cord-034340-3ksfpaf7	2015	59	on	on	IN
cord-034340-3ksfpaf7	2015	60	corticosteroid	corticosteroid	NN
cord-034340-3ksfpaf7	2015	61	therapy	therapy	NN
cord-034340-3ksfpaf7	2015	62	and	and	CC
cord-034340-3ksfpaf7	2015	63	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-034340-3ksfpaf7	2015	64	in	in	IN
cord-034340-3ksfpaf7	2015	65	the	the	DT
cord-034340-3ksfpaf7	2015	66	majority	majority	NN
cord-034340-3ksfpaf7	2015	67	of	of	IN
cord-034340-3ksfpaf7	2015	68	cases	case	NNS
cord-034340-3ksfpaf7	2015	69	,	,	,
cord-034340-3ksfpaf7	2015	70	the	the	DT
cord-034340-3ksfpaf7	2015	71	use	use	NN
cord-034340-3ksfpaf7	2015	72	of	of	IN
cord-034340-3ksfpaf7	2015	73	immunosuppressants	immunosuppressant	NNS
cord-034340-3ksfpaf7	2015	74	has	have	VBZ
cord-034340-3ksfpaf7	2015	75	been	be	VBN
cord-034340-3ksfpaf7	2015	76	reserved	reserve	VBN
cord-034340-3ksfpaf7	2015	77	for	for	IN
cord-034340-3ksfpaf7	2015	78	severe	severe	JJ
cord-034340-3ksfpaf7	2015	79	forms	form	NNS
cord-034340-3ksfpaf7	2015	80	.	.	.
cord-034340-3ksfpaf7	2016	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	2016	2	:	:	:
cord-034340-3ksfpaf7	2017	1	Lupus	lupus	NN
cord-034340-3ksfpaf7	2017	2	is	be	VBZ
cord-034340-3ksfpaf7	2017	3	an	an	DT
cord-034340-3ksfpaf7	2017	4	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	2017	5	disease	disease	NN
cord-034340-3ksfpaf7	2017	6	with	with	IN
cord-034340-3ksfpaf7	2017	7	protean	protean	JJ
cord-034340-3ksfpaf7	2017	8	clinical	clinical	JJ
cord-034340-3ksfpaf7	2017	9	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	2017	10	,	,	,
cord-034340-3ksfpaf7	2018	1	the	the	DT
cord-034340-3ksfpaf7	2018	2	prognosis	prognosis	NN
cord-034340-3ksfpaf7	2018	3	of	of	IN
cord-034340-3ksfpaf7	2018	4	which	which	WDT
cord-034340-3ksfpaf7	2018	5	is	be	VBZ
cord-034340-3ksfpaf7	2018	6	dominated	dominate	VBN
cord-034340-3ksfpaf7	2018	7	by	by	IN
cord-034340-3ksfpaf7	2018	8	renal	renal	JJ
cord-034340-3ksfpaf7	2018	9	,	,	,
cord-034340-3ksfpaf7	2018	10	neurological	neurological	JJ
cord-034340-3ksfpaf7	2018	11	and	and	CC
cord-034340-3ksfpaf7	2018	12	thrombotic	thrombotic	JJ
cord-034340-3ksfpaf7	2018	13	disorders	disorder	NNS
cord-034340-3ksfpaf7	2018	14	.	.	.
cord-034340-3ksfpaf7	2019	1	Cortisonic	Cortisonic	NNP
cord-034340-3ksfpaf7	2019	2	treatments	treatment	NNS
cord-034340-3ksfpaf7	2019	3	and	and	CC
cord-034340-3ksfpaf7	2019	4	immunosuppressants	immunosuppressant	NNS
cord-034340-3ksfpaf7	2019	5	have	have	VBP
cord-034340-3ksfpaf7	2019	6	significantly	significantly	RB
cord-034340-3ksfpaf7	2019	7	improved	improve	VBN
cord-034340-3ksfpaf7	2019	8	the	the	DT
cord-034340-3ksfpaf7	2019	9	prognosis	prognosis	NN
cord-034340-3ksfpaf7	2019	10	for	for	IN
cord-034340-3ksfpaf7	2019	11	life	life	NN
cord-034340-3ksfpaf7	2019	12	.	.	.
cord-034340-3ksfpaf7	2020	1	Trial	trial	NN
cord-034340-3ksfpaf7	2020	2	registration	registration	NN
cord-034340-3ksfpaf7	2020	3	identifying	identify	VBG
cord-034340-3ksfpaf7	2020	4	number	number	NN
cord-034340-3ksfpaf7	2020	5	:	:	:
cord-034340-3ksfpaf7	2020	6	Lupus	lupus	NN
cord-034340-3ksfpaf7	2020	7	is	be	VBZ
cord-034340-3ksfpaf7	2020	8	an	an	DT
cord-034340-3ksfpaf7	2020	9	autoimmune	autoimmune	JJ
cord-034340-3ksfpaf7	2020	10	disease	disease	NN
cord-034340-3ksfpaf7	2020	11	with	with	IN
cord-034340-3ksfpaf7	2020	12	protean	protean	JJ
cord-034340-3ksfpaf7	2020	13	clinical	clinical	JJ
cord-034340-3ksfpaf7	2020	14	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	2020	15	,	,	,
cord-034340-3ksfpaf7	2021	1	the	the	DT
cord-034340-3ksfpaf7	2021	2	prognosis	prognosis	NN
cord-034340-3ksfpaf7	2021	3	of	of	IN
cord-034340-3ksfpaf7	2021	4	which	which	WDT
cord-034340-3ksfpaf7	2021	5	is	be	VBZ
cord-034340-3ksfpaf7	2021	6	dominated	dominate	VBN
cord-034340-3ksfpaf7	2021	7	by	by	IN
cord-034340-3ksfpaf7	2021	8	renal	renal	JJ
cord-034340-3ksfpaf7	2021	9	,	,	,
cord-034340-3ksfpaf7	2021	10	neurological	neurological	JJ
cord-034340-3ksfpaf7	2021	11	and	and	CC
cord-034340-3ksfpaf7	2021	12	thrombotic	thrombotic	JJ
cord-034340-3ksfpaf7	2021	13	disorders	disorder	NNS
cord-034340-3ksfpaf7	2021	14	.	.	.
cord-034340-3ksfpaf7	2022	1	Cortisonic	Cortisonic	NNP
cord-034340-3ksfpaf7	2022	2	treatments	treatment	NNS
cord-034340-3ksfpaf7	2022	3	and	and	CC
cord-034340-3ksfpaf7	2022	4	immunosuppressants	immunosuppressant	NNS
cord-034340-3ksfpaf7	2022	5	have	have	VBP
cord-034340-3ksfpaf7	2022	6	significantly	significantly	RB
cord-034340-3ksfpaf7	2022	7	improved	improve	VBN
cord-034340-3ksfpaf7	2022	8	the	the	DT
cord-034340-3ksfpaf7	2022	9	prognosis	prognosis	NN
cord-034340-3ksfpaf7	2022	10	for	for	IN
cord-034340-3ksfpaf7	2022	11	life	life	NN
cord-034340-3ksfpaf7	2022	12	.	.	.
cord-034340-3ksfpaf7	2023	1	onset	onset	NN
cord-034340-3ksfpaf7	2023	2	of	of	IN
cord-034340-3ksfpaf7	2023	3	inactive	inactive	JJ
cord-034340-3ksfpaf7	2023	4	and	and	CC
cord-034340-3ksfpaf7	2023	5	active	active	JJ
cord-034340-3ksfpaf7	2023	6	oligo	oligo	NN
cord-034340-3ksfpaf7	2023	7	-	-	HYPH
cord-034340-3ksfpaf7	2023	8	JA	JA	NNP
cord-034340-3ksfpaf7	2023	9	were	be	VBD
cord-034340-3ksfpaf7	2023	10	not	not	RB
cord-034340-3ksfpaf7	2023	11	significantly	significantly	RB
cord-034340-3ksfpaf7	2023	12	differ	differ	VB
cord-034340-3ksfpaf7	2023	13	.	.	.
cord-034340-3ksfpaf7	2024	1	The	the	DT
cord-034340-3ksfpaf7	2024	2	analysis	analysis	NN
cord-034340-3ksfpaf7	2024	3	revealed	reveal	VBD
cord-034340-3ksfpaf7	2024	4	a	a	DT
cord-034340-3ksfpaf7	2024	5	correlation	correlation	NN
cord-034340-3ksfpaf7	2024	6	between	between	IN
cord-034340-3ksfpaf7	2024	7	a	a	DT
cord-034340-3ksfpaf7	2024	8	short	short	JJ
cord-034340-3ksfpaf7	2024	9	phase	phase	NN
cord-034340-3ksfpaf7	2024	10	of	of	IN
cord-034340-3ksfpaf7	2024	11	beneficial	beneficial	JJ
cord-034340-3ksfpaf7	2024	12	effect	effect	NN
cord-034340-3ksfpaf7	2024	13	after	after	IN
cord-034340-3ksfpaf7	2024	14	is	be	VBZ
cord-034340-3ksfpaf7	2024	15	-	-	:
cord-034340-3ksfpaf7	2024	16	IAI	IAI	NNP
cord-034340-3ksfpaf7	2024	17	of	of	IN
cord-034340-3ksfpaf7	2024	18	TA	TA	NNP
cord-034340-3ksfpaf7	2024	19	and	and	CC
cord-034340-3ksfpaf7	2024	20	risk	risk	NN
cord-034340-3ksfpaf7	2024	21	of	of	IN
cord-034340-3ksfpaf7	2024	22	activity	activity	NN
cord-034340-3ksfpaf7	2024	23	disease	disease	NN
cord-034340-3ksfpaf7	2024	24	(	(	-LRB-
cord-034340-3ksfpaf7	2024	25	with	with	IN
cord-034340-3ksfpaf7	2024	26	an	an	DT
cord-034340-3ksfpaf7	2024	27	inactive	inactive	JJ
cord-034340-3ksfpaf7	2024	28	phase	phase	NN
cord-034340-3ksfpaf7	2024	29	of	of	IN
cord-034340-3ksfpaf7	2024	30	arthritis	arthritis	NN
cord-034340-3ksfpaf7	2024	31	less	less	JJR
cord-034340-3ksfpaf7	2024	32	than	than	IN
cord-034340-3ksfpaf7	2024	33	3	3	CD
cord-034340-3ksfpaf7	2024	34	months	month	NNS
cord-034340-3ksfpaf7	2024	35	,	,	,
cord-034340-3ksfpaf7	2024	36	the	the	DT
cord-034340-3ksfpaf7	2024	37	risk	risk	NN
cord-034340-3ksfpaf7	2024	38	activity	activity	NN
cord-034340-3ksfpaf7	2024	39	was	be	VBD
cord-034340-3ksfpaf7	2024	40	OR	or	CC
cord-034340-3ksfpaf7	2024	41	=	=	NFP
cord-034340-3ksfpaf7	2025	1	2.09	2.09	CD
cord-034340-3ksfpaf7	2025	2	,	,	,
cord-034340-3ksfpaf7	2025	3	p	p	NN
cord-034340-3ksfpaf7	2025	4	<	<	XX
cord-034340-3ksfpaf7	2025	5	0.001	0.001	XX
cord-034340-3ksfpaf7	2025	6	;	;	:
cord-034340-3ksfpaf7	2025	7	with	with	IN
cord-034340-3ksfpaf7	2025	8	an	an	DT
cord-034340-3ksfpaf7	2025	9	inactive	inactive	JJ
cord-034340-3ksfpaf7	2025	10	phase	phase	NN
cord-034340-3ksfpaf7	2025	11	less	less	JJR
cord-034340-3ksfpaf7	2025	12	than	than	IN
cord-034340-3ksfpaf7	2025	13	2	2	CD
cord-034340-3ksfpaf7	2025	14	months	month	NNS
cord-034340-3ksfpaf7	2025	15	-OR	-or	RB
cord-034340-3ksfpaf7	2025	16	=	=	SYM
cord-034340-3ksfpaf7	2025	17	8.9	8.9	CD
cord-034340-3ksfpaf7	2025	18	,	,	,
cord-034340-3ksfpaf7	2025	19	p	p	NN
cord-034340-3ksfpaf7	2025	20	<	<	XX
cord-034340-3ksfpaf7	2025	21	0.001	0.001	CD
cord-034340-3ksfpaf7	2025	22	)	)	-RRB-
cord-034340-3ksfpaf7	2025	23	.	.	.
cord-034340-3ksfpaf7	2026	1	RTX	RTX	NNP
cord-034340-3ksfpaf7	2026	2	was	be	VBD
cord-034340-3ksfpaf7	2026	3	administered	administer	VBN
cord-034340-3ksfpaf7	2026	4	to	to	IN
cord-034340-3ksfpaf7	2026	5	patients	patient	NNS
cord-034340-3ksfpaf7	2026	6	who	who	WP
cord-034340-3ksfpaf7	2026	7	had	have	VBD
cord-034340-3ksfpaf7	2026	8	received	receive	VBN
cord-034340-3ksfpaf7	2026	9	high	high	JJ
cord-034340-3ksfpaf7	2026	10	-	-	HYPH
cord-034340-3ksfpaf7	2026	11	dose	dose	NN
cord-034340-3ksfpaf7	2026	12	CS	cs	NN
cord-034340-3ksfpaf7	2026	13	with	with	IN
cord-034340-3ksfpaf7	2026	14	2	2	CD
cord-034340-3ksfpaf7	2026	15	-	-	SYM
cord-034340-3ksfpaf7	2026	16	3	3	CD
cord-034340-3ksfpaf7	2026	17	DMARDS	DMARDS	NNP
cord-034340-3ksfpaf7	2026	18	;	;	:
cord-034340-3ksfpaf7	2026	19	in	in	IN
cord-034340-3ksfpaf7	2026	20	all	all	DT
cord-034340-3ksfpaf7	2026	21	cases	case	NNS
cord-034340-3ksfpaf7	2026	22	combined	combine	VBN
cord-034340-3ksfpaf7	2026	23	pulse	pulse	NN
cord-034340-3ksfpaf7	2026	24	therapy	therapy	NN
cord-034340-3ksfpaf7	2026	25	CS	CS	NNP
cord-034340-3ksfpaf7	2026	26	№	№	NNP
cord-034340-3ksfpaf7	2026	27	2	2	CD
cord-034340-3ksfpaf7	2026	28	-	-	SYM
cord-034340-3ksfpaf7	2026	29	10	10	CD
cord-034340-3ksfpaf7	2026	30	was	be	VBD
cord-034340-3ksfpaf7	2026	31	preliminarily	preliminarily	RB
cord-034340-3ksfpaf7	2026	32	used	use	VBN
cord-034340-3ksfpaf7	2026	33	.	.	.
cord-034340-3ksfpaf7	2027	1	RTX	RTX	NNP
cord-034340-3ksfpaf7	2027	2	500	500	CD
cord-034340-3ksfpaf7	2027	3	mg	mg	NN
cord-034340-3ksfpaf7	2028	1	№	№	NNP
cord-034340-3ksfpaf7	2028	2	2	2	CD
cord-034340-3ksfpaf7	2028	3	was	be	VBD
cord-034340-3ksfpaf7	2028	4	applied	apply	VBN
cord-034340-3ksfpaf7	2028	5	after	after	IN
cord-034340-3ksfpaf7	2028	6	6mo-2y	6mo-2y	CD
cord-034340-3ksfpaf7	2028	7	from	from	IN
cord-034340-3ksfpaf7	2028	8	the	the	DT
cord-034340-3ksfpaf7	2028	9	debut	debut	NN
cord-034340-3ksfpaf7	2028	10	of	of	IN
cord-034340-3ksfpaf7	2028	11	the	the	DT
cord-034340-3ksfpaf7	2028	12	disease	disease	NN
cord-034340-3ksfpaf7	2028	13	.	.	.
cord-034340-3ksfpaf7	2029	1	In	in	IN
cord-034340-3ksfpaf7	2029	2	all	all	DT
cord-034340-3ksfpaf7	2029	3	5	5	CD
cord-034340-3ksfpaf7	2029	4	cases	case	NNS
cord-034340-3ksfpaf7	2029	5	,	,	,
cord-034340-3ksfpaf7	2029	6	its	-PRON-	PRP$
cord-034340-3ksfpaf7	2029	7	use	use	NN
cord-034340-3ksfpaf7	2029	8	led	lead	VBD
cord-034340-3ksfpaf7	2029	9	to	to	IN
cord-034340-3ksfpaf7	2029	10	clinical	clinical	JJ
cord-034340-3ksfpaf7	2029	11	improvement	improvement	NN
cord-034340-3ksfpaf7	2029	12	after	after	IN
cord-034340-3ksfpaf7	2029	13	1	1	CD
cord-034340-3ksfpaf7	2029	14	-	-	SYM
cord-034340-3ksfpaf7	2029	15	5	5	CD
cord-034340-3ksfpaf7	2029	16	mo	mo	NN
cord-034340-3ksfpaf7	2029	17	with	with	IN
cord-034340-3ksfpaf7	2029	18	normalization	normalization	NN
cord-034340-3ksfpaf7	2029	19	of	of	IN
cord-034340-3ksfpaf7	2029	20	laboratory	laboratory	NN
cord-034340-3ksfpaf7	2029	21	activity	activity	NN
cord-034340-3ksfpaf7	2029	22	indicators	indicator	NNS
cord-034340-3ksfpaf7	2029	23	,	,	,
cord-034340-3ksfpaf7	2029	24	in	in	IN
cord-034340-3ksfpaf7	2029	25	4	4	CD
cord-034340-3ksfpaf7	2029	26	cases	case	NNS
cord-034340-3ksfpaf7	2029	27	a	a	DT
cord-034340-3ksfpaf7	2029	28	decrease	decrease	NN
cord-034340-3ksfpaf7	2029	29	in	in	IN
cord-034340-3ksfpaf7	2029	30	the	the	DT
cord-034340-3ksfpaf7	2029	31	level	level	NN
cord-034340-3ksfpaf7	2029	32	of	of	IN
cord-034340-3ksfpaf7	2029	33	B	b	NN
cord-034340-3ksfpaf7	2029	34	cells	cell	NNS
cord-034340-3ksfpaf7	2029	35	to	to	IN
cord-034340-3ksfpaf7	2029	36	0	0	CD
cord-034340-3ksfpaf7	2029	37	-	-	HYPH
cord-034340-3ksfpaf7	2029	38	0.56	0.56	CD
cord-034340-3ksfpaf7	2029	39	in	in	IN
cord-034340-3ksfpaf7	2029	40	μl	μl	NN
cord-034340-3ksfpaf7	2029	41	was	be	VBD
cord-034340-3ksfpaf7	2029	42	noted	note	VBN
cord-034340-3ksfpaf7	2029	43	(	(	-LRB-
cord-034340-3ksfpaf7	2029	44	3	3	CD
cord-034340-3ksfpaf7	2029	45	with	with	IN
cord-034340-3ksfpaf7	2029	46	agammaglobulinemia	agammaglobulinemia	NN
cord-034340-3ksfpaf7	2029	47	)	)	-RRB-
cord-034340-3ksfpaf7	2029	48	.	.	.
cord-034340-3ksfpaf7	2030	1	After	after	IN
cord-034340-3ksfpaf7	2030	2	2	2	CD
cord-034340-3ksfpaf7	2030	3	months	month	NNS
cord-034340-3ksfpaf7	2030	4	3	3	CD
cord-034340-3ksfpaf7	2030	5	patients	patient	NNS
cord-034340-3ksfpaf7	2030	6	had	have	VBD
cord-034340-3ksfpaf7	2030	7	severe	severe	JJ
cord-034340-3ksfpaf7	2030	8	infectious	infectious	JJ
cord-034340-3ksfpaf7	2030	9	complications	complication	NNS
cord-034340-3ksfpaf7	2030	10	,	,	,
cord-034340-3ksfpaf7	2030	11	2	2	CD
cord-034340-3ksfpaf7	2030	12	of	of	IN
cord-034340-3ksfpaf7	2030	13	them	-PRON-	PRP
cord-034340-3ksfpaf7	2030	14	ended	end	VBD
cord-034340-3ksfpaf7	2030	15	fatally	fatally	RB
cord-034340-3ksfpaf7	2030	16	.	.	.
cord-034340-3ksfpaf7	2031	1	2	2	LS
cord-034340-3ksfpaf7	2032	1	another	another	DT
cord-034340-3ksfpaf7	2032	2	patients	patient	NNS
cord-034340-3ksfpaf7	2032	3	had	have	VBD
cord-034340-3ksfpaf7	2032	4	a	a	DT
cord-034340-3ksfpaf7	2032	5	second	second	JJ
cord-034340-3ksfpaf7	2032	6	stroke	stroke	NN
cord-034340-3ksfpaf7	2032	7	.	.	.
cord-034340-3ksfpaf7	2033	1	The	the	DT
cord-034340-3ksfpaf7	2033	2	1st	1st	JJ
cord-034340-3ksfpaf7	2033	3	patient	patient	NN
cord-034340-3ksfpaf7	2033	4	survived	survive	VBD
cord-034340-3ksfpaf7	2033	5	,	,	,
cord-034340-3ksfpaf7	2033	6	had	have	VBD
cord-034340-3ksfpaf7	2033	7	a	a	DT
cord-034340-3ksfpaf7	2033	8	kidney	kidney	NN
cord-034340-3ksfpaf7	2033	9	allotransplantation	allotransplantation	NN
cord-034340-3ksfpaf7	2033	10	,	,	,
cord-034340-3ksfpaf7	2033	11	there	there	EX
cord-034340-3ksfpaf7	2033	12	is	be	VBZ
cord-034340-3ksfpaf7	2033	13	no	no	DT
cord-034340-3ksfpaf7	2033	14	disease	disease	NN
cord-034340-3ksfpaf7	2033	15	activity	activity	NN
cord-034340-3ksfpaf7	2033	16	.	.	.
cord-034340-3ksfpaf7	2034	1	The	the	DT
cord-034340-3ksfpaf7	2034	2	2nd	2nd	JJ
cord-034340-3ksfpaf7	2034	3	patient	patient	NN
cord-034340-3ksfpaf7	2034	4	,	,	,
cord-034340-3ksfpaf7	2034	5	in	in	IN
cord-034340-3ksfpaf7	2034	6	connection	connection	NN
cord-034340-3ksfpaf7	2034	7	with	with	IN
cord-034340-3ksfpaf7	2034	8	the	the	DT
cord-034340-3ksfpaf7	2034	9	development	development	NN
cord-034340-3ksfpaf7	2034	10	of	of	IN
cord-034340-3ksfpaf7	2034	11	the	the	DT
cord-034340-3ksfpaf7	2034	12	demyelinating	demyelinating	JJ
cord-034340-3ksfpaf7	2034	13	process	process	NN
cord-034340-3ksfpaf7	2034	14	of	of	IN
cord-034340-3ksfpaf7	2034	15	CNS	CNS	NNP
cord-034340-3ksfpaf7	2034	16	,	,	,
cord-034340-3ksfpaf7	2034	17	attempted	attempt	VBD
cord-034340-3ksfpaf7	2034	18	to	to	TO
cord-034340-3ksfpaf7	2034	19	continue	continue	VB
cord-034340-3ksfpaf7	2034	20	therapy	therapy	NN
cord-034340-3ksfpaf7	2034	21	using	use	VBG
cord-034340-3ksfpaf7	2034	22	golimumab	golimumab	NNS
cord-034340-3ksfpaf7	2034	23	with	with	IN
cord-034340-3ksfpaf7	2034	24	IVIG	IVIG	NNP
cord-034340-3ksfpaf7	2034	25	.	.	.
cord-034340-3ksfpaf7	2035	1	It	-PRON-	PRP
cord-034340-3ksfpaf7	2035	2	led	lead	VBD
cord-034340-3ksfpaf7	2035	3	to	to	IN
cord-034340-3ksfpaf7	2035	4	an	an	DT
cord-034340-3ksfpaf7	2035	5	increase	increase	NN
cord-034340-3ksfpaf7	2035	6	in	in	IN
cord-034340-3ksfpaf7	2035	7	the	the	DT
cord-034340-3ksfpaf7	2035	8	infectious	infectious	JJ
cord-034340-3ksfpaf7	2035	9	syndrome	syndrome	NN
cord-034340-3ksfpaf7	2035	10	,	,	,
cord-034340-3ksfpaf7	2035	11	therefore	therefore	RB
cord-034340-3ksfpaf7	2035	12	,	,	,
cord-034340-3ksfpaf7	2035	13	we	-PRON-	PRP
cord-034340-3ksfpaf7	2035	14	decided	decide	VBD
cord-034340-3ksfpaf7	2035	15	to	to	TO
cord-034340-3ksfpaf7	2035	16	refrain	refrain	VB
cord-034340-3ksfpaf7	2035	17	from	from	IN
cord-034340-3ksfpaf7	2035	18	continuing	continue	VBG
cord-034340-3ksfpaf7	2035	19	with	with	IN
cord-034340-3ksfpaf7	2035	20	iTNF	iTNF	NNP
cord-034340-3ksfpaf7	2035	21	as	as	RB
cord-034340-3ksfpaf7	2035	22	well	well	RB
cord-034340-3ksfpaf7	2035	23	.	.	.
cord-034340-3ksfpaf7	2036	1	The	the	DT
cord-034340-3ksfpaf7	2036	2	patient	patient	NN
cord-034340-3ksfpaf7	2036	3	died	die	VBD
cord-034340-3ksfpaf7	2036	4	after	after	IN
cord-034340-3ksfpaf7	2036	5	2	2	CD
cord-034340-3ksfpaf7	2036	6	years	year	NNS
cord-034340-3ksfpaf7	2036	7	from	from	IN
cord-034340-3ksfpaf7	2036	8	the	the	DT
cord-034340-3ksfpaf7	2036	9	administration	administration	NN
cord-034340-3ksfpaf7	2036	10	of	of	IN
cord-034340-3ksfpaf7	2036	11	RTX	RTX	NNP
cord-034340-3ksfpaf7	2036	12	due	due	IN
cord-034340-3ksfpaf7	2036	13	to	to	IN
cord-034340-3ksfpaf7	2036	14	the	the	DT
cord-034340-3ksfpaf7	2036	15	progression	progression	NN
cord-034340-3ksfpaf7	2036	16	of	of	IN
cord-034340-3ksfpaf7	2036	17	neurological	neurological	JJ
cord-034340-3ksfpaf7	2036	18	disorders	disorder	NNS
cord-034340-3ksfpaf7	2036	19	.	.	.
cord-034340-3ksfpaf7	2037	1	2	2	CD
cord-034340-3ksfpaf7	2037	2	cases	case	NNS
cord-034340-3ksfpaf7	2037	3	with	with	IN
cord-034340-3ksfpaf7	2037	4	auto	auto	NN
cord-034340-3ksfpaf7	2037	5	-	-	HYPH
cord-034340-3ksfpaf7	2037	6	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	2037	7	syndromes	syndrome	NNS
cord-034340-3ksfpaf7	2037	8	were	be	VBD
cord-034340-3ksfpaf7	2037	9	:	:	:
cord-034340-3ksfpaf7	2037	10	chronic	chronic	JJ
cord-034340-3ksfpaf7	2037	11	infantile	infantile	JJ
cord-034340-3ksfpaf7	2037	12	neurologic	neurologic	JJ
cord-034340-3ksfpaf7	2037	13	cutaneous	cutaneous	JJ
cord-034340-3ksfpaf7	2037	14	and	and	CC
cord-034340-3ksfpaf7	2037	15	articular	articular	JJ
cord-034340-3ksfpaf7	2037	16	syndrome	syndrome	NN
cord-034340-3ksfpaf7	2037	17	received	receive	VBD
cord-034340-3ksfpaf7	2037	18	TCZ	TCZ	NNP
cord-034340-3ksfpaf7	2037	19	;	;	:
cord-034340-3ksfpaf7	2037	20	it	-PRON-	PRP
cord-034340-3ksfpaf7	2037	21	was	be	VBD
cord-034340-3ksfpaf7	2037	22	unsuccessful	unsuccessful	JJ
cord-034340-3ksfpaf7	2038	1	(	(	-LRB-
cord-034340-3ksfpaf7	2038	2	hyperthermia	hyperthermia	NN
cord-034340-3ksfpaf7	2038	3	and	and	CC
cord-034340-3ksfpaf7	2038	4	rash	rash	NN
cord-034340-3ksfpaf7	2038	5	persisted	persist	VBD
cord-034340-3ksfpaf7	2038	6	,	,	,
cord-034340-3ksfpaf7	2038	7	eye	eye	NN
cord-034340-3ksfpaf7	2038	8	lesions	lesion	NNS
cord-034340-3ksfpaf7	2038	9	progressed	progress	VBD
cord-034340-3ksfpaf7	2038	10	,	,	,
cord-034340-3ksfpaf7	2038	11	there	there	EX
cord-034340-3ksfpaf7	2038	12	were	be	VBD
cord-034340-3ksfpaf7	2038	13	no	no	DT
cord-034340-3ksfpaf7	2038	14	increase	increase	NN
cord-034340-3ksfpaf7	2038	15	in	in	IN
cord-034340-3ksfpaf7	2038	16	height	height	NN
cord-034340-3ksfpaf7	2038	17	)	)	-RRB-
cord-034340-3ksfpaf7	2038	18	,	,	,
cord-034340-3ksfpaf7	2038	19	later	later	RB
cord-034340-3ksfpaf7	2038	20	switched	switch	VBD
cord-034340-3ksfpaf7	2038	21	to	to	IN
cord-034340-3ksfpaf7	2038	22	anakinra	anakinra	NNP
cord-034340-3ksfpaf7	2038	23	.	.	.
cord-034340-3ksfpaf7	2039	1	Family	family	NN
cord-034340-3ksfpaf7	2039	2	mediterranean	mediterranean	NNP
cord-034340-3ksfpaf7	2039	3	fever	fever	NN
cord-034340-3ksfpaf7	2039	4	,	,	,
cord-034340-3ksfpaf7	2039	5	received	receive	VBD
cord-034340-3ksfpaf7	2039	6	adalimumab	adalimumab	NNS
cord-034340-3ksfpaf7	2039	7	(	(	-LRB-
cord-034340-3ksfpaf7	2039	8	ADA	ADA	NNP
cord-034340-3ksfpaf7	2039	9	)	)	-RRB-
cord-034340-3ksfpaf7	2039	10	.	.	.
cord-034340-3ksfpaf7	2040	1	The	the	DT
cord-034340-3ksfpaf7	2040	2	1-year	1-year	CD
cord-034340-3ksfpaf7	2040	3	-	-	HYPH
cord-034340-3ksfpaf7	2040	4	course	course	NN
cord-034340-3ksfpaf7	2040	5	of	of	IN
cord-034340-3ksfpaf7	2040	6	ADA	ADA	NNP
cord-034340-3ksfpaf7	2040	7	leaded	leaded	JJ
cord-034340-3ksfpaf7	2040	8	to	to	IN
cord-034340-3ksfpaf7	2040	9	the	the	DT
cord-034340-3ksfpaf7	2040	10	disappearance	disappearance	NN
cord-034340-3ksfpaf7	2040	11	of	of	IN
cord-034340-3ksfpaf7	2040	12	articular	articular	JJ
cord-034340-3ksfpaf7	2040	13	and	and	CC
cord-034340-3ksfpaf7	2040	14	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	2040	15	syndrome	syndrome	NN
cord-034340-3ksfpaf7	2040	16	while	while	IN
cord-034340-3ksfpaf7	2040	17	maintaining	maintain	VBG
cord-034340-3ksfpaf7	2040	18	persistent	persistent	JJ
cord-034340-3ksfpaf7	2040	19	increased	increase	VBN
cord-034340-3ksfpaf7	2040	20	levels	level	NNS
cord-034340-3ksfpaf7	2040	21	of	of	IN
cord-034340-3ksfpaf7	2040	22	ESR	ESR	NNP
cord-034340-3ksfpaf7	2040	23	and	and	CC
cord-034340-3ksfpaf7	2040	24	CRP	CRP	NNP
cord-034340-3ksfpaf7	2040	25	and	and	CC
cord-034340-3ksfpaf7	2040	26	periodic	periodic	JJ
cord-034340-3ksfpaf7	2040	27	fever	fever	NN
cord-034340-3ksfpaf7	2040	28	.	.	.
cord-034340-3ksfpaf7	2041	1	The	the	DT
cord-034340-3ksfpaf7	2041	2	use	use	NN
cord-034340-3ksfpaf7	2041	3	of	of	IN
cord-034340-3ksfpaf7	2041	4	TCZ	TCZ	NNP
cord-034340-3ksfpaf7	2041	5	in	in	IN
cord-034340-3ksfpaf7	2041	6	2	2	CD
cord-034340-3ksfpaf7	2041	7	patients	patient	NNS
cord-034340-3ksfpaf7	2041	8	with	with	IN
cord-034340-3ksfpaf7	2041	9	SSD	SSD	NNP
cord-034340-3ksfpaf7	2041	10	was	be	VBD
cord-034340-3ksfpaf7	2041	11	more	more	RBR
cord-034340-3ksfpaf7	2041	12	successful	successful	JJ
cord-034340-3ksfpaf7	2041	13	.	.	.
cord-034340-3ksfpaf7	2042	1	The	the	DT
cord-034340-3ksfpaf7	2042	2	first	first	JJ
cord-034340-3ksfpaf7	2042	3	patient	patient	NN
cord-034340-3ksfpaf7	2042	4	received	receive	VBD
cord-034340-3ksfpaf7	2042	5	it	-PRON-	PRP
cord-034340-3ksfpaf7	2042	6	subcutaneously	subcutaneously	RB
cord-034340-3ksfpaf7	2042	7	for	for	IN
cord-034340-3ksfpaf7	2042	8	1	1	CD
cord-034340-3ksfpaf7	2042	9	year	year	NN
cord-034340-3ksfpaf7	2042	10	,	,	,
cord-034340-3ksfpaf7	2042	11	CS&DMARDs	CS&DMARDs	NNP
cord-034340-3ksfpaf7	2042	12	(	(	-LRB-
cord-034340-3ksfpaf7	2042	13	3	3	CD
cord-034340-3ksfpaf7	2042	14	were	be	VBD
cord-034340-3ksfpaf7	2042	15	used	use	VBN
cord-034340-3ksfpaf7	2042	16	)	)	-RRB-
cord-034340-3ksfpaf7	2042	17	had	have	VBD
cord-034340-3ksfpaf7	2042	18	already	already	RB
cord-034340-3ksfpaf7	2042	19	been	be	VBN
cord-034340-3ksfpaf7	2042	20	canceled	cancel	VBN
cord-034340-3ksfpaf7	2042	21	,	,	,
cord-034340-3ksfpaf7	2042	22	lung	lung	NN
cord-034340-3ksfpaf7	2042	23	and	and	CC
cord-034340-3ksfpaf7	2042	24	kidney	kidney	NN
cord-034340-3ksfpaf7	2042	25	lesions	lesion	NNS
cord-034340-3ksfpaf7	2042	26	were	be	VBD
cord-034340-3ksfpaf7	2042	27	contained	contain	VBN
cord-034340-3ksfpaf7	2042	28	,	,	,
cord-034340-3ksfpaf7	2042	29	blood	blood	NN
cord-034340-3ksfpaf7	2042	30	pressure	pressure	NN
cord-034340-3ksfpaf7	2042	31	normalized	normalize	VBN
cord-034340-3ksfpaf7	2042	32	,	,	,
cord-034340-3ksfpaf7	2042	33	EScSG	EScSG	NNP
cord-034340-3ksfpaf7	2042	34	-	-	HYPH
cord-034340-3ksfpaf7	2042	35	AI	AI	NNP
cord-034340-3ksfpaf7	2042	36	decreased	decrease	VBD
cord-034340-3ksfpaf7	2042	37	from	from	IN
cord-034340-3ksfpaf7	2042	38	7	7	CD
cord-034340-3ksfpaf7	2042	39	to	to	IN
cord-034340-3ksfpaf7	2042	40	1	1	CD
cord-034340-3ksfpaf7	2042	41	,	,	,
cord-034340-3ksfpaf7	2042	42	MRSS	mrs	NNS
cord-034340-3ksfpaf7	2042	43	decreased	decrease	VBD
cord-034340-3ksfpaf7	2042	44	from	from	IN
cord-034340-3ksfpaf7	2042	45	18	18	CD
cord-034340-3ksfpaf7	2042	46	to	to	IN
cord-034340-3ksfpaf7	2042	47	14	14	CD
cord-034340-3ksfpaf7	2042	48	.	.	.
cord-034340-3ksfpaf7	2043	1	In	in	IN
cord-034340-3ksfpaf7	2043	2	the	the	DT
cord-034340-3ksfpaf7	2043	3	second	second	JJ
cord-034340-3ksfpaf7	2043	4	case	case	NN
cord-034340-3ksfpaf7	2043	5	,	,	,
cord-034340-3ksfpaf7	2043	6	the	the	DT
cord-034340-3ksfpaf7	2043	7	patient	patient	NN
cord-034340-3ksfpaf7	2043	8	received	receive	VBD
cord-034340-3ksfpaf7	2043	9	TCZ	TCZ	NNP
cord-034340-3ksfpaf7	2043	10	for	for	IN
cord-034340-3ksfpaf7	2043	11	6	6	CD
cord-034340-3ksfpaf7	2043	12	months	month	NNS
cord-034340-3ksfpaf7	2043	13	i	i	PRP
cord-034340-3ksfpaf7	2043	14	/	/	SYM
cord-034340-3ksfpaf7	2043	15	v	v	NN
cord-034340-3ksfpaf7	2043	16	,	,	,
cord-034340-3ksfpaf7	2043	17	decrease	decrease	NN
cord-034340-3ksfpaf7	2043	18	of	of	IN
cord-034340-3ksfpaf7	2043	19	EScSG	escsg	NN
cord-034340-3ksfpaf7	2043	20	-	-	HYPH
cord-034340-3ksfpaf7	2043	21	AI	AI	NNP
cord-034340-3ksfpaf7	2043	22	6.5	6.5	CD
cord-034340-3ksfpaf7	2043	23	to	to	IN
cord-034340-3ksfpaf7	2043	24	1	1	CD
cord-034340-3ksfpaf7	2043	25	,	,	,
cord-034340-3ksfpaf7	2043	26	MRSS	MRSS	NNP
cord-034340-3ksfpaf7	2043	27	33	33	CD
cord-034340-3ksfpaf7	2043	28	to	to	TO
cord-034340-3ksfpaf7	2043	29	21	21	CD
cord-034340-3ksfpaf7	2043	30	were	be	VBD
cord-034340-3ksfpaf7	2043	31	noted	note	VBN
cord-034340-3ksfpaf7	2043	32	,	,	,
cord-034340-3ksfpaf7	2043	33	the	the	DT
cord-034340-3ksfpaf7	2043	34	dose	dose	NN
cord-034340-3ksfpaf7	2043	35	of	of	IN
cord-034340-3ksfpaf7	2043	36	CS	CS	NNP
cord-034340-3ksfpaf7	2043	37	was	be	VBD
cord-034340-3ksfpaf7	2043	38	halved	halve	VBN
cord-034340-3ksfpaf7	2043	39	,	,	,
cord-034340-3ksfpaf7	2043	40	he	-PRON-	PRP
cord-034340-3ksfpaf7	2043	41	also	also	RB
cord-034340-3ksfpaf7	2043	42	continued	continue	VBD
cord-034340-3ksfpaf7	2043	43	treatment	treatment	NN
cord-034340-3ksfpaf7	2043	44	with	with	IN
cord-034340-3ksfpaf7	2043	45	cyclophosphamide	cyclophosphamide	NN
cord-034340-3ksfpaf7	2043	46	.	.	.
cord-034340-3ksfpaf7	2044	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	2044	2	introduce	introduce	VBP
cord-034340-3ksfpaf7	2044	3	a	a	DT
cord-034340-3ksfpaf7	2044	4	13-year	13-year	JJ
cord-034340-3ksfpaf7	2044	5	-	-	HYPH
cord-034340-3ksfpaf7	2044	6	old	old	JJ
cord-034340-3ksfpaf7	2044	7	girl	girl	NN
cord-034340-3ksfpaf7	2044	8	patient	patient	NN
cord-034340-3ksfpaf7	2044	9	who	who	WP
cord-034340-3ksfpaf7	2044	10	has	have	VBZ
cord-034340-3ksfpaf7	2044	11	been	be	VBN
cord-034340-3ksfpaf7	2044	12	admitted	admit	VBN
cord-034340-3ksfpaf7	2044	13	to	to	IN
cord-034340-3ksfpaf7	2044	14	our	-PRON-	PRP$
cord-034340-3ksfpaf7	2044	15	clinic	clinic	NN
cord-034340-3ksfpaf7	2044	16	with	with	IN
cord-034340-3ksfpaf7	2044	17	suspicion	suspicion	NN
cord-034340-3ksfpaf7	2044	18	of	of	IN
cord-034340-3ksfpaf7	2044	19	an	an	DT
cord-034340-3ksfpaf7	2044	20	erythema	erythema	NN
cord-034340-3ksfpaf7	2044	21	nodosum	nodosum	NN
cord-034340-3ksfpaf7	2044	22	.	.	.
cord-034340-3ksfpaf7	2045	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	2045	2	had	have	VBD
cord-034340-3ksfpaf7	2045	3	painful	painful	JJ
cord-034340-3ksfpaf7	2045	4	subcutaneous	subcutaneous	JJ
cord-034340-3ksfpaf7	2045	5	nodules	nodule	NNS
cord-034340-3ksfpaf7	2045	6	for	for	IN
cord-034340-3ksfpaf7	2045	7	4	4	CD
cord-034340-3ksfpaf7	2045	8	weeks	week	NNS
cord-034340-3ksfpaf7	2045	9	,	,	,
cord-034340-3ksfpaf7	2045	10	especially	especially	RB
cord-034340-3ksfpaf7	2045	11	on	on	IN
cord-034340-3ksfpaf7	2045	12	the	the	DT
cord-034340-3ksfpaf7	2045	13	lower	low	JJR
cord-034340-3ksfpaf7	2045	14	extremities	extremity	NNS
cord-034340-3ksfpaf7	2045	15	and	and	CC
cord-034340-3ksfpaf7	2045	16	her	-PRON-	PRP$
cord-034340-3ksfpaf7	2045	17	face	face	NN
cord-034340-3ksfpaf7	2045	18	.	.	.
cord-034340-3ksfpaf7	2046	1	Macroscopically	macroscopically	RB
cord-034340-3ksfpaf7	2046	2	,	,	,
cord-034340-3ksfpaf7	2046	3	central	central	JJ
cord-034340-3ksfpaf7	2046	4	necrotizing	necrotize	VBG
cord-034340-3ksfpaf7	2046	5	skin	skin	NN
cord-034340-3ksfpaf7	2046	6	rashes	rash	NNS
cord-034340-3ksfpaf7	2046	7	could	could	MD
cord-034340-3ksfpaf7	2046	8	be	be	VB
cord-034340-3ksfpaf7	2046	9	seen	see	VBN
cord-034340-3ksfpaf7	2046	10	.	.	.
cord-034340-3ksfpaf7	2047	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	2047	2	had	have	VBD
cord-034340-3ksfpaf7	2047	3	frank	frank	JJ
cord-034340-3ksfpaf7	2047	4	arthritis	arthritis	NN
cord-034340-3ksfpaf7	2047	5	of	of	IN
cord-034340-3ksfpaf7	2047	6	both	both	CC
cord-034340-3ksfpaf7	2047	7	knee	knee	NN
cord-034340-3ksfpaf7	2047	8	and	and	CC
cord-034340-3ksfpaf7	2047	9	ankle	ankle	NN
cord-034340-3ksfpaf7	2047	10	joints	joint	NNS
cord-034340-3ksfpaf7	2047	11	.	.	.
cord-034340-3ksfpaf7	2048	1	The	the	DT
cord-034340-3ksfpaf7	2048	2	comprehensive	comprehensive	JJ
cord-034340-3ksfpaf7	2048	3	serological	serological	JJ
cord-034340-3ksfpaf7	2048	4	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	2048	5	(	(	-LRB-
cord-034340-3ksfpaf7	2048	6	including	include	VBG
cord-034340-3ksfpaf7	2048	7	hepatitis	hepatitis	NN
cord-034340-3ksfpaf7	2048	8	serology	serology	NN
cord-034340-3ksfpaf7	2048	9	and	and	CC
cord-034340-3ksfpaf7	2048	10	anti	anti	JJ
cord-034340-3ksfpaf7	2048	11	-	-	JJ
cord-034340-3ksfpaf7	2048	12	streptolysin	streptolysin	JJ
cord-034340-3ksfpaf7	2048	13	titer	titer	NN
cord-034340-3ksfpaf7	2048	14	)	)	-RRB-
cord-034340-3ksfpaf7	2048	15	were	be	VBD
cord-034340-3ksfpaf7	2048	16	normal	normal	JJ
cord-034340-3ksfpaf7	2048	17	except	except	IN
cord-034340-3ksfpaf7	2048	18	for	for	IN
cord-034340-3ksfpaf7	2048	19	a	a	DT
cord-034340-3ksfpaf7	2048	20	slight	slight	JJ
cord-034340-3ksfpaf7	2048	21	increase	increase	NN
cord-034340-3ksfpaf7	2048	22	in	in	IN
cord-034340-3ksfpaf7	2048	23	CRP	CRP	NNP
cord-034340-3ksfpaf7	2048	24	0,9	0,9	CD
cord-034340-3ksfpaf7	2048	25	mg	mg	NNP
cord-034340-3ksfpaf7	2048	26	/	/	SYM
cord-034340-3ksfpaf7	2048	27	dl	dl	NNP
cord-034340-3ksfpaf7	2048	28	and	and	CC
cord-034340-3ksfpaf7	2048	29	ESR	ESR	NNP
cord-034340-3ksfpaf7	2048	30	36	36	CD
cord-034340-3ksfpaf7	2048	31	mm	mm	NNP
cord-034340-3ksfpaf7	2048	32	/	/	SYM
cord-034340-3ksfpaf7	2048	33	h	h	NN
cord-034340-3ksfpaf7	2048	34	.	.	.
cord-034340-3ksfpaf7	2049	1	The	the	DT
cord-034340-3ksfpaf7	2049	2	patient	patient	NN
cord-034340-3ksfpaf7	2049	3	also	also	RB
cord-034340-3ksfpaf7	2049	4	complained	complain	VBD
cord-034340-3ksfpaf7	2049	5	of	of	IN
cord-034340-3ksfpaf7	2049	6	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	2049	7	pain	pain	NN
cord-034340-3ksfpaf7	2049	8	and	and	CC
cord-034340-3ksfpaf7	2049	9	bloody	bloody	JJ
cord-034340-3ksfpaf7	2049	10	stools	stool	NNS
cord-034340-3ksfpaf7	2049	11	.	.	.
cord-034340-3ksfpaf7	2050	1	Calprotectin	Calprotectin	NNP
cord-034340-3ksfpaf7	2050	2	was	be	VBD
cord-034340-3ksfpaf7	2050	3	3613	3613	CD
cord-034340-3ksfpaf7	2050	4	μg	μg	NNP
cord-034340-3ksfpaf7	2050	5	/	/	SYM
cord-034340-3ksfpaf7	2050	6	g	g	NN
cord-034340-3ksfpaf7	2050	7	.	.	.
cord-034340-3ksfpaf7	2051	1	A	a	DT
cord-034340-3ksfpaf7	2051	2	Gastro	gastro	JJ
cord-034340-3ksfpaf7	2051	3	-	-	HYPH
cord-034340-3ksfpaf7	2051	4	coloscopy	coloscopy	NNP
cord-034340-3ksfpaf7	2051	5	revealed	reveal	VBD
cord-034340-3ksfpaf7	2051	6	a	a	DT
cord-034340-3ksfpaf7	2051	7	small	small	JJ
cord-034340-3ksfpaf7	2051	8	mariske	mariske	NN
cord-034340-3ksfpaf7	2051	9	and	and	CC
cord-034340-3ksfpaf7	2051	10	a	a	DT
cord-034340-3ksfpaf7	2051	11	minimal	minimal	JJ
cord-034340-3ksfpaf7	2051	12	inflammation	inflammation	NN
cord-034340-3ksfpaf7	2051	13	of	of	IN
cord-034340-3ksfpaf7	2051	14	the	the	DT
cord-034340-3ksfpaf7	2051	15	Ileocecal	Ileocecal	NNP
cord-034340-3ksfpaf7	2051	16	valve	valve	NN
cord-034340-3ksfpaf7	2051	17	,	,	,
cord-034340-3ksfpaf7	2051	18	without	without	IN
cord-034340-3ksfpaf7	2051	19	signs	sign	NNS
cord-034340-3ksfpaf7	2051	20	of	of	IN
cord-034340-3ksfpaf7	2051	21	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	2051	22	or	or	CC
cord-034340-3ksfpaf7	2051	23	chronic	chronic	JJ
cord-034340-3ksfpaf7	2051	24	bowel	bowel	NN
cord-034340-3ksfpaf7	2051	25	disease	disease	NN
cord-034340-3ksfpaf7	2051	26	.	.	.
cord-034340-3ksfpaf7	2052	1	A	a	DT
cord-034340-3ksfpaf7	2052	2	skin	skin	NN
cord-034340-3ksfpaf7	2052	3	biopsy	biopsy	NN
cord-034340-3ksfpaf7	2052	4	revealed	reveal	VBD
cord-034340-3ksfpaf7	2052	5	leukocytoclastic	leukocytoclastic	JJ
cord-034340-3ksfpaf7	2052	6	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	2052	7	of	of	IN
cord-034340-3ksfpaf7	2052	8	the	the	DT
cord-034340-3ksfpaf7	2052	9	small	small	JJ
cord-034340-3ksfpaf7	2052	10	arteries	artery	NNS
cord-034340-3ksfpaf7	2052	11	.	.	.
cord-034340-3ksfpaf7	2053	1	Angiography	angiography	NN
cord-034340-3ksfpaf7	2053	2	of	of	IN
cord-034340-3ksfpaf7	2053	3	the	the	DT
cord-034340-3ksfpaf7	2053	4	intestinal	intestinal	JJ
cord-034340-3ksfpaf7	2053	5	arteries	artery	NNS
cord-034340-3ksfpaf7	2053	6	was	be	VBD
cord-034340-3ksfpaf7	2053	7	rejected	reject	VBN
cord-034340-3ksfpaf7	2053	8	by	by	IN
cord-034340-3ksfpaf7	2053	9	the	the	DT
cord-034340-3ksfpaf7	2053	10	family	family	NN
cord-034340-3ksfpaf7	2053	11	.	.	.
cord-034340-3ksfpaf7	2054	1	Initially	initially	RB
cord-034340-3ksfpaf7	2054	2	we	-PRON-	PRP
cord-034340-3ksfpaf7	2054	3	started	start	VBD
cord-034340-3ksfpaf7	2054	4	a	a	DT
cord-034340-3ksfpaf7	2054	5	treatment	treatment	NN
cord-034340-3ksfpaf7	2054	6	with	with	IN
cord-034340-3ksfpaf7	2054	7	methylprednisolone	methylprednisolone	NN
cord-034340-3ksfpaf7	2054	8	pulses	pulse	NNS
cord-034340-3ksfpaf7	2054	9	followed	follow	VBN
cord-034340-3ksfpaf7	2054	10	by	by	IN
cord-034340-3ksfpaf7	2054	11	oral	oral	JJ
cord-034340-3ksfpaf7	2054	12	prednisolone	prednisolone	NN
cord-034340-3ksfpaf7	2054	13	.	.	.
cord-034340-3ksfpaf7	2055	1	The	the	DT
cord-034340-3ksfpaf7	2055	2	patient	patient	NN
cord-034340-3ksfpaf7	2055	3	showed	show	VBD
cord-034340-3ksfpaf7	2055	4	a	a	DT
cord-034340-3ksfpaf7	2055	5	very	very	RB
cord-034340-3ksfpaf7	2055	6	good	good	JJ
cord-034340-3ksfpaf7	2055	7	response	response	NN
cord-034340-3ksfpaf7	2055	8	with	with	IN
cord-034340-3ksfpaf7	2055	9	quick	quick	JJ
cord-034340-3ksfpaf7	2055	10	resolution	resolution	NN
cord-034340-3ksfpaf7	2055	11	of	of	IN
cord-034340-3ksfpaf7	2055	12	the	the	DT
cord-034340-3ksfpaf7	2055	13	skin	skin	NN
cord-034340-3ksfpaf7	2055	14	symptoms	symptom	NNS
cord-034340-3ksfpaf7	2055	15	and	and	CC
cord-034340-3ksfpaf7	2055	16	abdominal	abdominal	JJ
cord-034340-3ksfpaf7	2055	17	pain	pain	NN
cord-034340-3ksfpaf7	2055	18	.	.	.
cord-034340-3ksfpaf7	2056	1	The	the	DT
cord-034340-3ksfpaf7	2056	2	medication	medication	NN
cord-034340-3ksfpaf7	2056	3	could	could	MD
cord-034340-3ksfpaf7	2056	4	be	be	VB
cord-034340-3ksfpaf7	2056	5	quickly	quickly	RB
cord-034340-3ksfpaf7	2056	6	tapered	taper	VBN
cord-034340-3ksfpaf7	2056	7	and	and	CC
cord-034340-3ksfpaf7	2056	8	discontinued	discontinue	VBD
cord-034340-3ksfpaf7	2056	9	at	at	IN
cord-034340-3ksfpaf7	2056	10	full	full	JJ
cord-034340-3ksfpaf7	2056	11	remission	remission	NN
cord-034340-3ksfpaf7	2056	12	after	after	IN
cord-034340-3ksfpaf7	2056	13	one	one	CD
cord-034340-3ksfpaf7	2056	14	month	month	NN
cord-034340-3ksfpaf7	2056	15	Results	result	NNS
cord-034340-3ksfpaf7	2056	16	:	:	:
cord-034340-3ksfpaf7	2056	17	PAN	PAN	NNP
cord-034340-3ksfpaf7	2056	18	is	be	VBZ
cord-034340-3ksfpaf7	2056	19	classified	classify	VBN
cord-034340-3ksfpaf7	2056	20	as	as	IN
cord-034340-3ksfpaf7	2056	21	a	a	DT
cord-034340-3ksfpaf7	2056	22	cutaneous	cutaneous	JJ
cord-034340-3ksfpaf7	2056	23	PAN	PAN	NNP
cord-034340-3ksfpaf7	2056	24	(	(	-LRB-
cord-034340-3ksfpaf7	2056	25	cPAN	cPAN	NNP
cord-034340-3ksfpaf7	2056	26	)	)	-RRB-
cord-034340-3ksfpaf7	2056	27	when	when	WRB
cord-034340-3ksfpaf7	2056	28	there	there	EX
cord-034340-3ksfpaf7	2056	29	are	be	VBP
cord-034340-3ksfpaf7	2056	30	exclusive	exclusive	JJ
cord-034340-3ksfpaf7	2056	31	skin	skin	NN
cord-034340-3ksfpaf7	2056	32	manifestations	manifestation	NNS
cord-034340-3ksfpaf7	2056	33	,	,	,
cord-034340-3ksfpaf7	2056	34	besides	besides	IN
cord-034340-3ksfpaf7	2056	35	arthralgia	arthralgia	NNP
cord-034340-3ksfpaf7	2056	36	or	or	CC
cord-034340-3ksfpaf7	2056	37	arthritis	arthritis	NN
cord-034340-3ksfpaf7	2056	38	.	.	.
cord-034340-3ksfpaf7	2057	1	A	a	DT
cord-034340-3ksfpaf7	2057	2	systemic	systemic	JJ
cord-034340-3ksfpaf7	2057	3	PAN	pan	NN
cord-034340-3ksfpaf7	2057	4	must	must	MD
cord-034340-3ksfpaf7	2057	5	be	be	VB
cord-034340-3ksfpaf7	2057	6	diagnosed	diagnose	VBN
cord-034340-3ksfpaf7	2057	7	with	with	IN
cord-034340-3ksfpaf7	2057	8	the	the	DT
cord-034340-3ksfpaf7	2057	9	involvement	involvement	NN
cord-034340-3ksfpaf7	2057	10	of	of	IN
cord-034340-3ksfpaf7	2057	11	internal	internal	JJ
cord-034340-3ksfpaf7	2057	12	organs	organ	NNS
cord-034340-3ksfpaf7	2057	13	.	.	.
cord-034340-3ksfpaf7	2058	1	However	however	RB
cord-034340-3ksfpaf7	2058	2	,	,	,
cord-034340-3ksfpaf7	2058	3	cutaneous	cutaneous	JJ
cord-034340-3ksfpaf7	2058	4	PAN	PAN	NNP
cord-034340-3ksfpaf7	2058	5	may	may	MD
cord-034340-3ksfpaf7	2058	6	evolve	evolve	VB
cord-034340-3ksfpaf7	2058	7	into	into	IN
cord-034340-3ksfpaf7	2058	8	systemic	systemic	JJ
cord-034340-3ksfpaf7	2058	9	PAN	pan	NN
cord-034340-3ksfpaf7	2058	10	.	.	.
cord-034340-3ksfpaf7	2059	1	In	in	IN
cord-034340-3ksfpaf7	2059	2	our	-PRON-	PRP$
cord-034340-3ksfpaf7	2059	3	patient	patient	NN
cord-034340-3ksfpaf7	2059	4	,	,	,
cord-034340-3ksfpaf7	2059	5	the	the	DT
cord-034340-3ksfpaf7	2059	6	skin	skin	NN
cord-034340-3ksfpaf7	2059	7	and	and	CC
cord-034340-3ksfpaf7	2059	8	joints	joint	NNS
cord-034340-3ksfpaf7	2059	9	were	be	VBD
cord-034340-3ksfpaf7	2059	10	primarily	primarily	RB
cord-034340-3ksfpaf7	2059	11	affected	affect	VBN
cord-034340-3ksfpaf7	2059	12	.	.	.
cord-034340-3ksfpaf7	2060	1	If	if	IN
cord-034340-3ksfpaf7	2060	2	the	the	DT
cord-034340-3ksfpaf7	2060	3	existing	exist	VBG
cord-034340-3ksfpaf7	2060	4	gastrointestinal	gastrointestinal	JJ
cord-034340-3ksfpaf7	2060	5	complaints	complaint	NNS
cord-034340-3ksfpaf7	2060	6	are	be	VBP
cord-034340-3ksfpaf7	2060	7	part	part	NN
cord-034340-3ksfpaf7	2060	8	of	of	IN
cord-034340-3ksfpaf7	2060	9	a	a	DT
cord-034340-3ksfpaf7	2060	10	systemic	systemic	JJ
cord-034340-3ksfpaf7	2060	11	PAN	pan	NN
cord-034340-3ksfpaf7	2060	12	or	or	CC
cord-034340-3ksfpaf7	2060	13	chronic	chronic	JJ
cord-034340-3ksfpaf7	2060	14	bowel	bowel	NN
cord-034340-3ksfpaf7	2060	15	disease	disease	NN
cord-034340-3ksfpaf7	2060	16	could	could	MD
cord-034340-3ksfpaf7	2060	17	not	not	RB
cord-034340-3ksfpaf7	2060	18	be	be	VB
cord-034340-3ksfpaf7	2060	19	cleared	clear	VBN
cord-034340-3ksfpaf7	2060	20	yet	yet	RB
cord-034340-3ksfpaf7	2060	21	,	,	,
cord-034340-3ksfpaf7	2060	22	due	due	IN
cord-034340-3ksfpaf7	2060	23	to	to	IN
cord-034340-3ksfpaf7	2060	24	refusal	refusal	NN
cord-034340-3ksfpaf7	2060	25	of	of	IN
cord-034340-3ksfpaf7	2060	26	further	further	JJ
cord-034340-3ksfpaf7	2060	27	investigations	investigation	NNS
cord-034340-3ksfpaf7	2060	28	.	.	.
cord-034340-3ksfpaf7	2061	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	2061	2	:	:	:
cord-034340-3ksfpaf7	2061	3	cPAN	cPAN	NNP
cord-034340-3ksfpaf7	2061	4	must	must	MD
cord-034340-3ksfpaf7	2061	5	be	be	VB
cord-034340-3ksfpaf7	2061	6	considered	consider	VBN
cord-034340-3ksfpaf7	2061	7	as	as	IN
cord-034340-3ksfpaf7	2061	8	a	a	DT
cord-034340-3ksfpaf7	2061	9	suspected	suspect	VBN
cord-034340-3ksfpaf7	2061	10	diagnosis	diagnosis	NN
cord-034340-3ksfpaf7	2061	11	in	in	IN
cord-034340-3ksfpaf7	2061	12	patients	patient	NNS
cord-034340-3ksfpaf7	2061	13	with	with	IN
cord-034340-3ksfpaf7	2061	14	necrotizing	necrotize	VBG
cord-034340-3ksfpaf7	2061	15	skin	skin	NN
cord-034340-3ksfpaf7	2061	16	nodules	nodule	NNS
cord-034340-3ksfpaf7	2061	17	.	.	.
cord-034340-3ksfpaf7	2062	1	As	as	IN
cord-034340-3ksfpaf7	2062	2	transition	transition	NN
cord-034340-3ksfpaf7	2062	3	of	of	IN
cord-034340-3ksfpaf7	2062	4	the	the	DT
cord-034340-3ksfpaf7	2062	5	cutaneous	cutaneous	JJ
cord-034340-3ksfpaf7	2062	6	into	into	IN
cord-034340-3ksfpaf7	2062	7	the	the	DT
cord-034340-3ksfpaf7	2062	8	systemic	systemic	JJ
cord-034340-3ksfpaf7	2062	9	form	form	NN
cord-034340-3ksfpaf7	2062	10	can	can	MD
cord-034340-3ksfpaf7	2062	11	not	not	RB
cord-034340-3ksfpaf7	2062	12	be	be	VB
cord-034340-3ksfpaf7	2062	13	predicted	predict	VBN
cord-034340-3ksfpaf7	2062	14	regular	regular	JJ
cord-034340-3ksfpaf7	2062	15	monitoring	monitoring	NN
cord-034340-3ksfpaf7	2062	16	is	be	VBZ
cord-034340-3ksfpaf7	2062	17	mandatory	mandatory	JJ
cord-034340-3ksfpaf7	2062	18	.	.	.
cord-034340-3ksfpaf7	2063	1	Introduction	introduction	NN
cord-034340-3ksfpaf7	2063	2	:	:	:
cord-034340-3ksfpaf7	2064	1	Prevalence	prevalence	NN
cord-034340-3ksfpaf7	2064	2	of	of	IN
cord-034340-3ksfpaf7	2064	3	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	2064	4	's	's	POS
cord-034340-3ksfpaf7	2064	5	disease	disease	NN
cord-034340-3ksfpaf7	2064	6	in	in	IN
cord-034340-3ksfpaf7	2064	7	children	child	NNS
cord-034340-3ksfpaf7	2064	8	is	be	VBZ
cord-034340-3ksfpaf7	2064	9	not	not	RB
cord-034340-3ksfpaf7	2064	10	known	know	VBN
cord-034340-3ksfpaf7	2064	11	,	,	,
cord-034340-3ksfpaf7	2064	12	but	but	CC
cord-034340-3ksfpaf7	2064	13	is	be	VBZ
cord-034340-3ksfpaf7	2064	14	probably	probably	RB
cord-034340-3ksfpaf7	2064	15	very	very	RB
cord-034340-3ksfpaf7	2064	16	low	low	JJ
cord-034340-3ksfpaf7	2064	17	.	.	.
cord-034340-3ksfpaf7	2065	1	Extra	extra	JJ
cord-034340-3ksfpaf7	2065	2	-	-	JJ
cord-034340-3ksfpaf7	2065	3	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	2065	4	large	large	JJ
cord-034340-3ksfpaf7	2065	5	vessel	vessel	NN
cord-034340-3ksfpaf7	2065	6	arteritis	arteritis	NN
cord-034340-3ksfpaf7	2065	7	in	in	IN
cord-034340-3ksfpaf7	2065	8	these	these	DT
cord-034340-3ksfpaf7	2065	9	cases	case	NNS
cord-034340-3ksfpaf7	2065	10	is	be	VBZ
cord-034340-3ksfpaf7	2065	11	even	even	RB
cord-034340-3ksfpaf7	2065	12	rarer	rare	JJR
cord-034340-3ksfpaf7	2065	13	as	as	IN
cord-034340-3ksfpaf7	2065	14	a	a	DT
cord-034340-3ksfpaf7	2065	15	presenting	present	VBG
cord-034340-3ksfpaf7	2065	16	manifestation	manifestation	NN
cord-034340-3ksfpaf7	2065	17	.	.	.
cord-034340-3ksfpaf7	2066	1	Objectives	objective	NNS
cord-034340-3ksfpaf7	2066	2	:	:	:
cord-034340-3ksfpaf7	2066	3	To	to	TO
cord-034340-3ksfpaf7	2066	4	report	report	VB
cord-034340-3ksfpaf7	2066	5	two	two	CD
cord-034340-3ksfpaf7	2066	6	cases	case	NNS
cord-034340-3ksfpaf7	2066	7	of	of	IN
cord-034340-3ksfpaf7	2066	8	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	2066	9	extrapulmonary	extrapulmonary	JJ
cord-034340-3ksfpaf7	2066	10	large	large	JJ
cord-034340-3ksfpaf7	2066	11	vessel	vessel	NN
cord-034340-3ksfpaf7	2066	12	arteritis	arteritis	NN
cord-034340-3ksfpaf7	2066	13	with	with	IN
cord-034340-3ksfpaf7	2066	14	a	a	DT
cord-034340-3ksfpaf7	2066	15	'	'	``
cord-034340-3ksfpaf7	2066	16	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	2066	17	like	like	IN
cord-034340-3ksfpaf7	2066	18	disease	disease	NN
cord-034340-3ksfpaf7	2066	19	'	'	''
cord-034340-3ksfpaf7	2066	20	.	.	.
cord-034340-3ksfpaf7	2067	1	Methods	method	NNS
cord-034340-3ksfpaf7	2067	2	:	:	:
cord-034340-3ksfpaf7	2068	1	We	-PRON-	PRP
cord-034340-3ksfpaf7	2068	2	present	present	VBP
cord-034340-3ksfpaf7	2068	3	case	case	NN
cord-034340-3ksfpaf7	2068	4	reports	report	NNS
cord-034340-3ksfpaf7	2068	5	of	of	IN
cord-034340-3ksfpaf7	2068	6	two	two	CD
cord-034340-3ksfpaf7	2068	7	cases	case	NNS
cord-034340-3ksfpaf7	2068	8	who	who	WP
cord-034340-3ksfpaf7	2068	9	presented	present	VBD
cord-034340-3ksfpaf7	2068	10	to	to	IN
cord-034340-3ksfpaf7	2068	11	paediatric	paediatric	JJ
cord-034340-3ksfpaf7	2068	12	rheumatology	rheumatology	NN
cord-034340-3ksfpaf7	2068	13	OPD	OPD	NNP
cord-034340-3ksfpaf7	2068	14	to	to	IN
cord-034340-3ksfpaf7	2068	15	our	-PRON-	PRP$
cord-034340-3ksfpaf7	2068	16	department	department	NN
cord-034340-3ksfpaf7	2068	17	.	.	.
cord-034340-3ksfpaf7	2069	1	Ms.	Ms.	NNP
cord-034340-3ksfpaf7	2069	2	F	F	NNP
cord-034340-3ksfpaf7	2069	3	,	,	,
cord-034340-3ksfpaf7	2069	4	a	a	DT
cord-034340-3ksfpaf7	2069	5	16	16	CD
cord-034340-3ksfpaf7	2069	6	year	year	NN
cord-034340-3ksfpaf7	2069	7	old	old	JJ
cord-034340-3ksfpaf7	2069	8	girl	girl	NN
cord-034340-3ksfpaf7	2069	9	was	be	VBD
cord-034340-3ksfpaf7	2069	10	referred	refer	VBN
cord-034340-3ksfpaf7	2069	11	to	to	IN
cord-034340-3ksfpaf7	2069	12	us	-PRON-	PRP
cord-034340-3ksfpaf7	2069	13	with	with	IN
cord-034340-3ksfpaf7	2069	14	history	history	NN
cord-034340-3ksfpaf7	2069	15	of	of	IN
cord-034340-3ksfpaf7	2069	16	short	short	JJ
cord-034340-3ksfpaf7	2069	17	duration	duration	NN
cord-034340-3ksfpaf7	2069	18	of	of	IN
cord-034340-3ksfpaf7	2069	19	fever	fever	NN
cord-034340-3ksfpaf7	2069	20	,	,	,
cord-034340-3ksfpaf7	2069	21	generalized	generalize	VBN
cord-034340-3ksfpaf7	2069	22	lymphadenopathy	lymphadenopathy	NNP
cord-034340-3ksfpaf7	2069	23	,	,	,
cord-034340-3ksfpaf7	2069	24	neutrophilic	neutrophilic	NNP
cord-034340-3ksfpaf7	2069	25	leucocytosis	leucocytosis	NNP
cord-034340-3ksfpaf7	2069	26	,	,	,
cord-034340-3ksfpaf7	2069	27	thrombocytosis	thrombocytosis	NNP
cord-034340-3ksfpaf7	2069	28	,	,	,
cord-034340-3ksfpaf7	2069	29	hyperglobulinemia	hyperglobulinemia	NNP
cord-034340-3ksfpaf7	2069	30	and	and	CC
cord-034340-3ksfpaf7	2069	31	high	high	JJ
cord-034340-3ksfpaf7	2069	32	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	2069	33	markers	marker	NNS
cord-034340-3ksfpaf7	2069	34	.	.	.
cord-034340-3ksfpaf7	2070	1	On	on	IN
cord-034340-3ksfpaf7	2070	2	detailed	detailed	JJ
cord-034340-3ksfpaf7	2070	3	history	history	NN
cord-034340-3ksfpaf7	2070	4	and	and	CC
cord-034340-3ksfpaf7	2070	5	examination	examination	NN
cord-034340-3ksfpaf7	2070	6	she	-PRON-	PRP
cord-034340-3ksfpaf7	2070	7	was	be	VBD
cord-034340-3ksfpaf7	2070	8	found	find	VBN
cord-034340-3ksfpaf7	2070	9	to	to	TO
cord-034340-3ksfpaf7	2070	10	have	have	VB
cord-034340-3ksfpaf7	2070	11	a	a	DT
cord-034340-3ksfpaf7	2070	12	healed	heal	VBN
cord-034340-3ksfpaf7	2070	13	palatal	palatal	JJ
cord-034340-3ksfpaf7	2070	14	ulcer	ulcer	NN
cord-034340-3ksfpaf7	2070	15	and	and	CC
cord-034340-3ksfpaf7	2070	16	her	-PRON-	PRP$
cord-034340-3ksfpaf7	2070	17	maternal	maternal	JJ
cord-034340-3ksfpaf7	2070	18	aunt	aunt	NN
cord-034340-3ksfpaf7	2070	19	was	be	VBD
cord-034340-3ksfpaf7	2070	20	found	find	VBN
cord-034340-3ksfpaf7	2070	21	to	to	TO
cord-034340-3ksfpaf7	2070	22	have	have	VB
cord-034340-3ksfpaf7	2070	23	a	a	DT
cord-034340-3ksfpaf7	2070	24	history	history	NN
cord-034340-3ksfpaf7	2070	25	of	of	IN
cord-034340-3ksfpaf7	2070	26	recurrent	recurrent	JJ
cord-034340-3ksfpaf7	2070	27	oral	oral	JJ
cord-034340-3ksfpaf7	2070	28	ulcer	ulcer	NN
cord-034340-3ksfpaf7	2070	29	,	,	,
cord-034340-3ksfpaf7	2070	30	genital	genital	JJ
cord-034340-3ksfpaf7	2070	31	ulcer	ulcer	NN
cord-034340-3ksfpaf7	2070	32	and	and	CC
cord-034340-3ksfpaf7	2070	33	enthesitis	enthesitis	NN
cord-034340-3ksfpaf7	2070	34	.	.	.
cord-034340-3ksfpaf7	2071	1	Patient	Patient	NNP
cord-034340-3ksfpaf7	2071	2	's	's	POS
cord-034340-3ksfpaf7	2071	3	Montoux	Montoux	NNP
cord-034340-3ksfpaf7	2071	4	test	test	NN
cord-034340-3ksfpaf7	2071	5	was	be	VBD
cord-034340-3ksfpaf7	2071	6	positive	positive	JJ
cord-034340-3ksfpaf7	2071	7	but	but	CC
cord-034340-3ksfpaf7	2071	8	the	the	DT
cord-034340-3ksfpaf7	2071	9	gene	gene	NN
cord-034340-3ksfpaf7	2071	10	expert	expert	NN
cord-034340-3ksfpaf7	2071	11	for	for	IN
cord-034340-3ksfpaf7	2071	12	MTB	MTB	NNP
cord-034340-3ksfpaf7	2071	13	was	be	VBD
cord-034340-3ksfpaf7	2071	14	negative	negative	JJ
cord-034340-3ksfpaf7	2071	15	.	.	.
cord-034340-3ksfpaf7	2072	1	MD	MD	NNP
cord-034340-3ksfpaf7	2072	2	-	-	HYPH
cord-034340-3ksfpaf7	2072	3	CT	CT	NNP
cord-034340-3ksfpaf7	2072	4	showed	show	VBD
cord-034340-3ksfpaf7	2072	5	a	a	DT
cord-034340-3ksfpaf7	2072	6	circumferential	circumferential	JJ
cord-034340-3ksfpaf7	2072	7	thickening	thickening	NN
cord-034340-3ksfpaf7	2072	8	of	of	IN
cord-034340-3ksfpaf7	2072	9	aorta	aorta	NN
cord-034340-3ksfpaf7	2072	10	,	,	,
cord-034340-3ksfpaf7	2072	11	subclavian	subclavian	JJ
cord-034340-3ksfpaf7	2072	12	and	and	CC
cord-034340-3ksfpaf7	2072	13	bilateral	bilateral	JJ
cord-034340-3ksfpaf7	2072	14	renal	renal	JJ
cord-034340-3ksfpaf7	2072	15	artery	artery	NN
cord-034340-3ksfpaf7	2072	16	with	with	IN
cord-034340-3ksfpaf7	2072	17	stenosis	stenosis	NN
cord-034340-3ksfpaf7	2072	18	at	at	IN
cord-034340-3ksfpaf7	2072	19	origin	origin	NN
cord-034340-3ksfpaf7	2072	20	of	of	IN
cord-034340-3ksfpaf7	2072	21	both	both	DT
cord-034340-3ksfpaf7	2072	22	renal	renal	JJ
cord-034340-3ksfpaf7	2072	23	arteries	artery	NNS
cord-034340-3ksfpaf7	2072	24	indicating	indicate	VBG
cord-034340-3ksfpaf7	2072	25	a	a	DT
cord-034340-3ksfpaf7	2072	26	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	2072	27	.	.	.
cord-034340-3ksfpaf7	2073	1	Few	few	JJ
cord-034340-3ksfpaf7	2073	2	necrotic	necrotic	JJ
cord-034340-3ksfpaf7	2073	3	nodes	node	NNS
cord-034340-3ksfpaf7	2073	4	were	be	VBD
cord-034340-3ksfpaf7	2073	5	also	also	RB
cord-034340-3ksfpaf7	2073	6	noted	note	VBN
cord-034340-3ksfpaf7	2073	7	in	in	IN
cord-034340-3ksfpaf7	2073	8	lungs	lung	NNS
cord-034340-3ksfpaf7	2073	9	.	.	.
cord-034340-3ksfpaf7	2074	1	Lymph	lymph	NN
cord-034340-3ksfpaf7	2074	2	node	node	NN
cord-034340-3ksfpaf7	2074	3	biopsy	biopsy	NN
cord-034340-3ksfpaf7	2074	4	suggested	suggest	VBD
cord-034340-3ksfpaf7	2074	5	a	a	DT
cord-034340-3ksfpaf7	2074	6	reactive	reactive	JJ
cord-034340-3ksfpaf7	2074	7	hyperplasia	hyperplasia	NN
cord-034340-3ksfpaf7	2074	8	.	.	.
cord-034340-3ksfpaf7	2075	1	Tissue	tissue	NN
cord-034340-3ksfpaf7	2075	2	typing	typing	NN
cord-034340-3ksfpaf7	2075	3	showed	show	VBD
cord-034340-3ksfpaf7	2075	4	presence	presence	NN
cord-034340-3ksfpaf7	2075	5	of	of	IN
cord-034340-3ksfpaf7	2075	6	HLA	HLA	NNP
cord-034340-3ksfpaf7	2075	7	B	B	NNP
cord-034340-3ksfpaf7	2075	8	44	44	CD
cord-034340-3ksfpaf7	2075	9	,	,	,
cord-034340-3ksfpaf7	2075	10	B	B	NNP
cord-034340-3ksfpaf7	2075	11	51	51	CD
cord-034340-3ksfpaf7	2075	12	.	.	.
cord-034340-3ksfpaf7	2076	1	She	-PRON-	PRP
cord-034340-3ksfpaf7	2076	2	improved	improve	VBD
cord-034340-3ksfpaf7	2076	3	clinically	clinically	RB
cord-034340-3ksfpaf7	2076	4	with	with	IN
cord-034340-3ksfpaf7	2076	5	oral	oral	JJ
cord-034340-3ksfpaf7	2076	6	Prednisolone	Prednisolone	NNP
cord-034340-3ksfpaf7	2076	7	and	and	CC
cord-034340-3ksfpaf7	2076	8	Mycophenolate	Mycophenolate	NNP
cord-034340-3ksfpaf7	2076	9	Mofetil	Mofetil	NNP
cord-034340-3ksfpaf7	2076	10	and	and	CC
cord-034340-3ksfpaf7	2076	11	had	have	VBD
cord-034340-3ksfpaf7	2076	12	no	no	DT
cord-034340-3ksfpaf7	2076	13	recurrence	recurrence	NN
cord-034340-3ksfpaf7	2076	14	till	till	IN
cord-034340-3ksfpaf7	2076	15	her	-PRON-	PRP$
cord-034340-3ksfpaf7	2076	16	recent	recent	JJ
cord-034340-3ksfpaf7	2076	17	follow	follow	VB
cord-034340-3ksfpaf7	2076	18	up	up	RP
cord-034340-3ksfpaf7	2076	19	visit	visit	NN
cord-034340-3ksfpaf7	2076	20	.	.	.
cord-034340-3ksfpaf7	2077	1	Second	second	JJ
cord-034340-3ksfpaf7	2077	2	case	case	NN
cord-034340-3ksfpaf7	2077	3	,	,	,
cord-034340-3ksfpaf7	2077	4	master	master	NN
cord-034340-3ksfpaf7	2077	5	FKN	FKN	NNP
cord-034340-3ksfpaf7	2077	6	an	an	DT
cord-034340-3ksfpaf7	2077	7	11	11	CD
cord-034340-3ksfpaf7	2077	8	year	year	NN
cord-034340-3ksfpaf7	2077	9	old	old	JJ
cord-034340-3ksfpaf7	2077	10	child	child	NN
cord-034340-3ksfpaf7	2077	11	was	be	VBD
cord-034340-3ksfpaf7	2077	12	referred	refer	VBN
cord-034340-3ksfpaf7	2077	13	to	to	IN
cord-034340-3ksfpaf7	2077	14	us	-PRON-	PRP
cord-034340-3ksfpaf7	2077	15	with	with	IN
cord-034340-3ksfpaf7	2077	16	a	a	DT
cord-034340-3ksfpaf7	2077	17	background	background	NN
cord-034340-3ksfpaf7	2077	18	of	of	IN
cord-034340-3ksfpaf7	2077	19	2	2	CD
cord-034340-3ksfpaf7	2077	20	week	week	NN
cord-034340-3ksfpaf7	2077	21	history	history	NN
cord-034340-3ksfpaf7	2077	22	of	of	IN
cord-034340-3ksfpaf7	2077	23	fever	fever	NN
cord-034340-3ksfpaf7	2077	24	,	,	,
cord-034340-3ksfpaf7	2077	25	non	non	JJ
cord-034340-3ksfpaf7	2077	26	migratory	migratory	JJ
cord-034340-3ksfpaf7	2077	27	arthritis	arthritis	NN
cord-034340-3ksfpaf7	2077	28	,	,	,
cord-034340-3ksfpaf7	2077	29	raised	raise	VBD
cord-034340-3ksfpaf7	2077	30	inflammatory	inflammatory	JJ
cord-034340-3ksfpaf7	2077	31	markers	marker	NNS
cord-034340-3ksfpaf7	2077	32	and	and	CC
cord-034340-3ksfpaf7	2077	33	a	a	DT
cord-034340-3ksfpaf7	2077	34	symptomatic	symptomatic	JJ
cord-034340-3ksfpaf7	2077	35	severe	severe	JJ
cord-034340-3ksfpaf7	2077	36	aortic	aortic	JJ
cord-034340-3ksfpaf7	2077	37	regurgitation	regurgitation	NN
cord-034340-3ksfpaf7	2077	38	with	with	IN
cord-034340-3ksfpaf7	2077	39	pandiastolic	pandiastolic	NNP
cord-034340-3ksfpaf7	2077	40	flow	flow	NN
cord-034340-3ksfpaf7	2077	41	reversal	reversal	NN
cord-034340-3ksfpaf7	2077	42	on	on	IN
cord-034340-3ksfpaf7	2077	43	2D	2D	NNP
cord-034340-3ksfpaf7	2077	44	echo	echo	NN
cord-034340-3ksfpaf7	2077	45	.	.	.
cord-034340-3ksfpaf7	2078	1	His	-PRON-	PRP$
cord-034340-3ksfpaf7	2078	2	evaluation	evaluation	NN
cord-034340-3ksfpaf7	2078	3	showed	show	VBD
cord-034340-3ksfpaf7	2078	4	negative	negative	JJ
cord-034340-3ksfpaf7	2078	5	Montoux	Montoux	NNP
cord-034340-3ksfpaf7	2078	6	,	,	,
cord-034340-3ksfpaf7	2078	7	normal	normal	JJ
cord-034340-3ksfpaf7	2078	8	IGG4	IGG4	NNP
cord-034340-3ksfpaf7	2078	9	levels	level	NNS
cord-034340-3ksfpaf7	2078	10	and	and	CC
cord-034340-3ksfpaf7	2078	11	HLA	HLA	NNP
cord-034340-3ksfpaf7	2078	12	B35	B35	NNP
cord-034340-3ksfpaf7	2078	13	B	B	NNP
cord-034340-3ksfpaf7	2078	14	51	51	CD
cord-034340-3ksfpaf7	2078	15	on	on	IN
cord-034340-3ksfpaf7	2078	16	tissue	tissue	NN
cord-034340-3ksfpaf7	2078	17	typing	typing	NN
cord-034340-3ksfpaf7	2078	18	.	.	.
cord-034340-3ksfpaf7	2079	1	His	-PRON-	PRP$
cord-034340-3ksfpaf7	2079	2	aortic	aortic	JJ
cord-034340-3ksfpaf7	2079	3	wall	wall	NN
cord-034340-3ksfpaf7	2079	4	thickness	thickness	NN
cord-034340-3ksfpaf7	2079	5	resolved	resolve	VBN
cord-034340-3ksfpaf7	2079	6	with	with	IN
cord-034340-3ksfpaf7	2079	7	1	1	CD
cord-034340-3ksfpaf7	2079	8	mg	mg	NNP
cord-034340-3ksfpaf7	2079	9	/	/	SYM
cord-034340-3ksfpaf7	2079	10	kg	kg	CD
cord-034340-3ksfpaf7	2079	11	oral	oral	JJ
cord-034340-3ksfpaf7	2079	12	Prednisolone	Prednisolone	NNP
cord-034340-3ksfpaf7	2079	13	and	and	CC
cord-034340-3ksfpaf7	2079	14	Mycofenolate	Mycofenolate	NNP
cord-034340-3ksfpaf7	2079	15	mofetil	mofetil	NNP
cord-034340-3ksfpaf7	2079	16	.	.	.
cord-034340-3ksfpaf7	2080	1	Results	result	NNS
cord-034340-3ksfpaf7	2080	2	:	:	:
cord-034340-3ksfpaf7	2081	1	Both	both	CC
cord-034340-3ksfpaf7	2081	2	these	these	DT
cord-034340-3ksfpaf7	2081	3	cases	case	NNS
cord-034340-3ksfpaf7	2081	4	have	have	VBP
cord-034340-3ksfpaf7	2081	5	features	feature	NNS
cord-034340-3ksfpaf7	2081	6	similar	similar	JJ
cord-034340-3ksfpaf7	2081	7	to	to	IN
cord-034340-3ksfpaf7	2081	8	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	2081	9	's	's	POS
cord-034340-3ksfpaf7	2081	10	disease	disease	NN
cord-034340-3ksfpaf7	2081	11	.	.	.
cord-034340-3ksfpaf7	2082	1	These	these	DT
cord-034340-3ksfpaf7	2082	2	cases	case	NNS
cord-034340-3ksfpaf7	2082	3	do	do	VBP
cord-034340-3ksfpaf7	2082	4	not	not	RB
cord-034340-3ksfpaf7	2082	5	fulfil	fulfil	VB
cord-034340-3ksfpaf7	2082	6	ISG	ISG	NNP
cord-034340-3ksfpaf7	2082	7	,	,	,
cord-034340-3ksfpaf7	2082	8	ICBD	icbd	CD
cord-034340-3ksfpaf7	2082	9	2014	2014	CD
cord-034340-3ksfpaf7	2082	10	or	or	CC
cord-034340-3ksfpaf7	2082	11	ICBD	icbd	CD
cord-034340-3ksfpaf7	2082	12	criteria	criterion	NNS
cord-034340-3ksfpaf7	2082	13	for	for	IN
cord-034340-3ksfpaf7	2082	14	pediatric	pediatric	JJ
cord-034340-3ksfpaf7	2082	15	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	2082	16	's	's	POS
cord-034340-3ksfpaf7	2082	17	disease	disease	NN
cord-034340-3ksfpaf7	2082	18	.	.	.
cord-034340-3ksfpaf7	2083	1	However	however	RB
cord-034340-3ksfpaf7	2083	2	,	,	,
cord-034340-3ksfpaf7	2083	3	the	the	DT
cord-034340-3ksfpaf7	2083	4	aortitis	aortitis	NN
cord-034340-3ksfpaf7	2083	5	and	and	CC
cord-034340-3ksfpaf7	2083	6	other	other	JJ
cord-034340-3ksfpaf7	2083	7	clinical	clinical	JJ
cord-034340-3ksfpaf7	2083	8	features	feature	NNS
cord-034340-3ksfpaf7	2083	9	responded	respond	VBD
cord-034340-3ksfpaf7	2083	10	well	well	RB
cord-034340-3ksfpaf7	2083	11	to	to	IN
cord-034340-3ksfpaf7	2083	12	the	the	DT
cord-034340-3ksfpaf7	2083	13	treatment	treatment	NN
cord-034340-3ksfpaf7	2083	14	in	in	IN
cord-034340-3ksfpaf7	2083	15	both	both	DT
cord-034340-3ksfpaf7	2083	16	cases	case	NNS
cord-034340-3ksfpaf7	2083	17	.	.	.
cord-034340-3ksfpaf7	2084	1	Conclusion	conclusion	NN
cord-034340-3ksfpaf7	2084	2	:	:	:
cord-034340-3ksfpaf7	2084	3	Paediatric	paediatric	JJ
cord-034340-3ksfpaf7	2084	4	case	case	NN
cord-034340-3ksfpaf7	2084	5	with	with	IN
cord-034340-3ksfpaf7	2084	6	extra	extra	JJ
cord-034340-3ksfpaf7	2084	7	-	-	JJ
cord-034340-3ksfpaf7	2084	8	pulmonary	pulmonary	JJ
cord-034340-3ksfpaf7	2084	9	Large	large	JJ
cord-034340-3ksfpaf7	2084	10	vessel	vessel	NN
cord-034340-3ksfpaf7	2084	11	arteritis	arteritis	NN
cord-034340-3ksfpaf7	2084	12	that	that	WDT
cord-034340-3ksfpaf7	2084	13	do	do	VBP
cord-034340-3ksfpaf7	2084	14	not	not	RB
cord-034340-3ksfpaf7	2084	15	meet	meet	VB
cord-034340-3ksfpaf7	2084	16	criteria	criterion	NNS
cord-034340-3ksfpaf7	2084	17	for	for	IN
cord-034340-3ksfpaf7	2084	18	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	2084	19	's	's	POS
cord-034340-3ksfpaf7	2084	20	disease	disease	NN
cord-034340-3ksfpaf7	2084	21	but	but	CC
cord-034340-3ksfpaf7	2084	22	have	have	VBP
cord-034340-3ksfpaf7	2084	23	specific	specific	JJ
cord-034340-3ksfpaf7	2084	24	clinical	clinical	JJ
cord-034340-3ksfpaf7	2084	25	or	or	CC
cord-034340-3ksfpaf7	2084	26	laboratory	laboratory	NN
cord-034340-3ksfpaf7	2084	27	features	feature	NNS
cord-034340-3ksfpaf7	2084	28	do	do	VBP
cord-034340-3ksfpaf7	2084	29	respond	respond	VB
cord-034340-3ksfpaf7	2084	30	well	well	RB
cord-034340-3ksfpaf7	2084	31	to	to	IN
cord-034340-3ksfpaf7	2084	32	immunosuppression	immunosuppression	NN
cord-034340-3ksfpaf7	2084	33	.	.	.
cord-034340-3ksfpaf7	2085	1	Therefore	therefore	RB
cord-034340-3ksfpaf7	2085	2	,	,	,
cord-034340-3ksfpaf7	2085	3	after	after	IN
cord-034340-3ksfpaf7	2085	4	ruling	rule	VBG
cord-034340-3ksfpaf7	2085	5	out	out	RP
cord-034340-3ksfpaf7	2085	6	other	other	JJ
cord-034340-3ksfpaf7	2085	7	causes	cause	NNS
cord-034340-3ksfpaf7	2085	8	of	of	IN
cord-034340-3ksfpaf7	2085	9	the	the	DT
cord-034340-3ksfpaf7	2085	10	large	large	JJ
cord-034340-3ksfpaf7	2085	11	vessel	vessel	NN
cord-034340-3ksfpaf7	2085	12	vasculitis	vasculitis	NN
cord-034340-3ksfpaf7	2085	13	,	,	,
cord-034340-3ksfpaf7	2085	14	a	a	DT
cord-034340-3ksfpaf7	2085	15	possibility	possibility	NN
cord-034340-3ksfpaf7	2085	16	of	of	IN
cord-034340-3ksfpaf7	2085	17	form	form	NN
cord-034340-3ksfpaf7	2085	18	fruste	fruste	NN
cord-034340-3ksfpaf7	2085	19	of	of	IN
cord-034340-3ksfpaf7	2085	20	Behcet	Behcet	NNP
cord-034340-3ksfpaf7	2085	21	's	's	POS
cord-034340-3ksfpaf7	2085	22	disease	disease	NN
cord-034340-3ksfpaf7	2085	23	should	should	MD
cord-034340-3ksfpaf7	2085	24	be	be	VB
cord-034340-3ksfpaf7	2085	25	under	under	IN
cord-034340-3ksfpaf7	2085	26	consideration	consideration	NN
cord-034340-3ksfpaf7	2085	27	.	.	.
cord-034340-3ksfpaf7	2086	1	Publisher	publisher	NN
cord-034340-3ksfpaf7	2086	2	's	's	POS
cord-034340-3ksfpaf7	2086	3	Note	Note	NNP
cord-034340-3ksfpaf7	2086	4	Springer	Springer	NNP
cord-034340-3ksfpaf7	2086	5	Nature	Nature	NNP
cord-034340-3ksfpaf7	2086	6	remains	remain	VBZ
cord-034340-3ksfpaf7	2086	7	neutral	neutral	JJ
cord-034340-3ksfpaf7	2086	8	with	with	IN
cord-034340-3ksfpaf7	2086	9	regard	regard	NN
cord-034340-3ksfpaf7	2086	10	to	to	IN
cord-034340-3ksfpaf7	2086	11	jurisdictional	jurisdictional	JJ
cord-034340-3ksfpaf7	2086	12	claims	claim	NNS
cord-034340-3ksfpaf7	2086	13	in	in	IN
cord-034340-3ksfpaf7	2086	14	published	publish	VBN
cord-034340-3ksfpaf7	2086	15	maps	map	NNS
cord-034340-3ksfpaf7	2086	16	and	and	CC
cord-034340-3ksfpaf7	2086	17	institutional	institutional	JJ
cord-034340-3ksfpaf7	2086	18	affiliations	affiliation	NNS
cord-034340-3ksfpaf7	2086	19	.	.	.
cord-034340-3ksfpaf7	2087	1	These	these	DT
cord-034340-3ksfpaf7	2087	2	abstracts	abstract	NNS
cord-034340-3ksfpaf7	2087	3	have	have	VBP
cord-034340-3ksfpaf7	2087	4	been	be	VBN
cord-034340-3ksfpaf7	2087	5	published	publish	VBN
cord-034340-3ksfpaf7	2087	6	as	as	IN
cord-034340-3ksfpaf7	2087	7	part	part	NN
cord-034340-3ksfpaf7	2087	8	of	of	IN
cord-034340-3ksfpaf7	2087	9	Pediatric	Pediatric	NNP
cord-034340-3ksfpaf7	2087	10	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	2087	11	,	,	,
cord-034340-3ksfpaf7	2087	12	Volume	volume	NN
cord-034340-3ksfpaf7	2087	13	18	18	CD
cord-034340-3ksfpaf7	2087	14	,	,	,
cord-034340-3ksfpaf7	2087	15	Supplement	Supplement	NNP
cord-034340-3ksfpaf7	2087	16	2	2	CD
cord-034340-3ksfpaf7	2087	17	,	,	,
cord-034340-3ksfpaf7	2087	18	2020	2020	CD
cord-034340-3ksfpaf7	2087	19	:	:	:
cord-034340-3ksfpaf7	2088	1	Proceedings	proceeding	NNS
cord-034340-3ksfpaf7	2088	2	of	of	IN
cord-034340-3ksfpaf7	2088	3	the	the	DT
cord-034340-3ksfpaf7	2088	4	26th	26th	JJ
cord-034340-3ksfpaf7	2088	5	European	European	NNP
cord-034340-3ksfpaf7	2088	6	Paediatric	Paediatric	NNP
cord-034340-3ksfpaf7	2088	7	Rheumatology	Rheumatology	NNP
cord-034340-3ksfpaf7	2088	8	Congress	Congress	NNP
cord-034340-3ksfpaf7	2088	9	(	(	-LRB-
cord-034340-3ksfpaf7	2088	10	PReS	PReS	NNP
cord-034340-3ksfpaf7	2088	11	2020	2020	CD
cord-034340-3ksfpaf7	2088	12	)	)	-RRB-
cord-034340-3ksfpaf7	2088	13	.	.	.
cord-034340-3ksfpaf7	2089	1	The	the	DT
cord-034340-3ksfpaf7	2089	2	full	full	JJ
cord-034340-3ksfpaf7	2089	3	contents	content	NNS
cord-034340-3ksfpaf7	2089	4	of	of	IN
cord-034340-3ksfpaf7	2089	5	the	the	DT
cord-034340-3ksfpaf7	2089	6	supplement	supplement	NN
cord-034340-3ksfpaf7	2089	7	are	be	VBP
cord-034340-3ksfpaf7	2089	8	available	available	JJ
cord-034340-3ksfpaf7	2089	9	at	at	IN
cord-034340-3ksfpaf7	2089	10	https://ped	https://pe	VBN
cord-034340-3ksfpaf7	2089	11	-	-	HYPH
cord-034340-3ksfpaf7	2089	12	rheum	rheum	NN
cord-034340-3ksfpaf7	2089	13	.	.	.
cord-034340-3ksfpaf7	2090	1	biomedcentral.com/articles/supplements/volume-18-supplement-2	biomedcentral.com/articles/supplements/volume-18-supplement-2	NNP
cord-034340-3ksfpaf7	2090	2	.	.	.
cord-034340-3ksfpaf7	2091	1	Please	please	UH
cord-034340-3ksfpaf7	2091	2	note	note	VB
cord-034340-3ksfpaf7	2091	3	that	that	IN
cord-034340-3ksfpaf7	2091	4	this	this	DT
cord-034340-3ksfpaf7	2091	5	is	be	VBZ
cord-034340-3ksfpaf7	2091	6	part	part	NN
cord-034340-3ksfpaf7	2091	7	2	2	CD
cord-034340-3ksfpaf7	2091	8	of	of	IN
cord-034340-3ksfpaf7	2091	9	2	2	CD
cord-034340-3ksfpaf7	2091	10	.	.	.